PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	BISTER, K; TRACHMANN, C; JANSEN, HW; SCHROEER, B; PATSCHINSKY, T				BISTER, K; TRACHMANN, C; JANSEN, HW; SCHROEER, B; PATSCHINSKY, T			STRUCTURE OF MUTANT AND WILD-TYPE MC29 V-MYC ALLELES AND BIOCHEMICAL-PROPERTIES OF THEIR PROTEIN PRODUCTS	ONCOGENE			English	Article											BISTER, K (corresponding author), MAX PLANCK INST MOLEC GENET,OTTO WARBURG LAB,D-1000 BERLIN 33,FED REP GER.		Bister, Klaus/AFA-9400-2022	Bister, Klaus/0000-0001-6545-5653				ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; BAYDOUN H, 1981, PROTEIN PHOSPHORYLAT, P1095; BISTER K, 1983, J VIROL, V46, P337, DOI 10.1128/JVI.46.2.337-346.1983; Bister K., 1984, Mechanisms of viral leukaemogenesis, P38; BISTER K, 1986, ADV CANCER RES, V47, P99, DOI 10.1016/S0065-230X(08)60199-2; BISTER K, 1977, VIROLOGY, V82, P431, DOI 10.1016/0042-6822(77)90017-4; BISTER K, 1980, J VIROL, V36, P617, DOI 10.1128/JVI.36.2.617-621.1980; BISTER K, 1982, J VIROL, V41, P754, DOI 10.1128/JVI.41.3.754-766.1982; BISTER K, 1986, ADV VIRAL ONCOL, V6, P45; BUNTE T, 1983, EMBO J, V2, P1087, DOI 10.1002/j.1460-2075.1983.tb01550.x; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DONNER P, 1983, P NATL ACAD SCI-BIOL, V80, P2861, DOI 10.1073/pnas.80.10.2861; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; ENRIETTO PJ, 1983, VIROLOGY, V124, P164, DOI 10.1016/0042-6822(83)90300-8; ENRIETTO PJ, 1982, J VIROL, V44, P711, DOI 10.1128/JVI.44.2.711-715.1982; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JANSEN HW, 1985, VIROLOGY, V142, P248, DOI 10.1016/0042-6822(85)90333-2; JANSEN HW, 1983, J VIROL, V48, P61, DOI 10.1128/JVI.48.1.61-73.1983; JANSEN HW, 1983, EMBO J, V2, P1969, DOI 10.1002/j.1460-2075.1983.tb01686.x; JANSEN HW, 1984, NATURE, V307, P281, DOI 10.1038/307281a0; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; KONIGSBERG WH, 1977, PROTEINS, V3, P1; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAUTENBERGER JA, 1981, P NATL ACAD SCI-BIOL, V78, P1518, DOI 10.1073/pnas.78.3.1518; PATSCHINSKY T, 1986, J VIROL, V59, P341, DOI 10.1128/JVI.59.2.341-353.1986; PATSCHINSKY T, 1984, VIROLOGY, V136, P348, DOI 10.1016/0042-6822(84)90171-5; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; RAMSAY G, 1982, EMBO J, V1, P1111, DOI 10.1002/j.1460-2075.1982.tb01305.x; RAMSAY GM, 1982, J VIROL, V41, P745, DOI 10.1128/JVI.41.3.745-753.1982; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; SHAW J, 1985, J VIROL, V56, P943, DOI 10.1128/JVI.56.3.943-950.1985; TUAZON PT, 1979, EUR J BIOCHEM, V94, P497, DOI 10.1111/j.1432-1033.1979.tb12918.x; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WALTHER N, 1986, VIROLOGY, V154, P219, DOI 10.1016/0042-6822(86)90444-7; WALTHER N, 1985, J VIROL, V54, P576, DOI 10.1128/JVI.54.2.576-585.1985; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448	44	37	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					97	109						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	3438084				2022-12-17	WOS:A1987J635200002
J	Tang, L; Xiong, W; Zhang, LS; Wang, D; Wang, Y; Wu, YF; Wei, F; Mo, YZ; Hou, XC; Shi, L; Xiong, F; Zhang, SS; Gong, ZJ; Liao, QJ; Xiang, B; Zhang, WL; Zhou, M; Li, XL; Li, GY; Guo, C; Zeng, ZY				Tang, Le; Xiong, Wei; Zhang, Lishen; Wang, Dan; Wang, Yian; Wu, Yingfen; Wei, Fang; Mo, Yongzhen; Hou, Xiangchan; Shi, Lei; Xiong, Fang; Zhang, Shanshan; Gong, Zhaojian; Liao, Qianjin; Xiang, Bo; Zhang, Wenling; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Guo, Can; Zeng, Zhaoyang			circSETD3 regulates MAPRE1 through miR-615-5p and miR-1538 sponges to promote migration and invasion in nasopharyngeal carcinoma	ONCOGENE			English	Article							CELL-PROLIFERATION; CIRCULAR RNAS; CANCER; EB1; GROWTH; ACTS; EXPRESSION; BIOMARKER; DYNAMICS; CIRCRNAS	Circular RNAs (circRNAs) play an essential role in tumorigenesis and development. However, they have rarely been investigated in nasopharyngeal carcinoma (NPC). This study aimed to investigate the role of circRNA in the invasion and metastasis of NPC. We screened and verified the high expression of circSETD3 in NPC cell lines using RNA sequencing (RNA-Seq) and verified the results of NPC biopsy samples using real-time quantitative polymerase chain reaction (qRT-PCR) and in situ hybridization (ISH). In vivo and in vitro experiments indicated that circSETD3 could promote NPC cell invasion and migration. We compared the proteomic data of NPC cells before and after the overexpression or knockdown of circSETD3 in combination with bioinformatics prediction and experimental verification. It was found that circSETD3 competitively adsorbs to miR-615-5p and miR-1538 and negates their inhibitory effect on MAPRE1 mRNA, thereby upregulating the expression of MAPRE1. The upregulated MAPRE1 then inhibits the acetylation of alpha-tubulin, promotes the dynamic assembly of microtubules, and enhances the invasion and migration capabilities of NPC cells. The results of this study suggest that circSETD3 is a novel molecular marker and a potential target for NPC diagnosis and treatment.	[Tang, Le; Xiong, Wei; Liao, Qianjin; Xiang, Bo; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Zeng, Zhaoyang] Cent South Univ, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China; [Tang, Le; Xiong, Wei; Liao, Qianjin; Xiang, Bo; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Zeng, Zhaoyang] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China; [Tang, Le; Xiong, Wei; Zhang, Lishen; Wang, Dan; Wang, Yian; Wu, Yingfen; Wei, Fang; Mo, Yongzhen; Hou, Xiangchan; Xiang, Bo; Zhang, Wenling; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Guo, Can; Zeng, Zhaoyang] Cent South Univ, Chinese Minist Educ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China; [Tang, Le; Xiong, Wei; Xiang, Bo; Zhang, Wenling; Zhou, Ming; Li, Xiaoling; Li, Guiyuan; Zeng, Zhaoyang] Cent South Univ, Xiangya Hosp 3, Dis Genome Res Ctr, Hunan Key Lab Nonresolving Inflammat & Canc, Changsha, Hunan, Peoples R China; [Shi, Lei; Gong, Zhaojian] Cent South Univ, Xiangya Hosp 2, Dept Oral & Maxillofacial Surg, Changsha, Hunan, Peoples R China; [Xiong, Fang; Zhang, Shanshan] Cent South Univ, Xiangya Hosp, Dept Stomatol, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University	Zeng, ZY (corresponding author), Cent South Univ, Hunan Canc Hosp, NHC Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Chinese Minist Educ, Canc Res Inst, Key Lab Carcinogenesis & Canc Invas, Changsha, Hunan, Peoples R China.; Zeng, ZY (corresponding author), Cent South Univ, Xiangya Hosp 3, Dis Genome Res Ctr, Hunan Key Lab Nonresolving Inflammat & Canc, Changsha, Hunan, Peoples R China.	zengzhaoyang@csu.edu.cn	li, xiaofeng/GXF-9442-2022; li, xiao/GSN-6181-2022		National Natural Science Foundation of China [81672683, 81702907, 81772901, 81772928, 81803025, 81972776, 82072374]; Natural Science Foundation of Hunan Province [2018JJ3704, 2018JJ3815, 2018SK21210, 2018SK21211, 2019JJ50872, 2019JJ50778, 2020JJ4125]; Fundamental Research Funds for the Central South University [2019zzts712, 2019zzts727]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Fundamental Research Funds for the Central South University	This work was supported by grants from the National Natural Science Foundation of China (81672683, 81702907, 81772901, 81772928, 81803025, 81972776 and 82072374), the Natural Science Foundation of Hunan Province (2018JJ3704, 2018JJ3815, 2018SK21210, 2018SK21211, 2019JJ50872, 2019JJ50778 and 2020JJ4125), and the Fundamental Research Funds for the Central South University (2019zzts712 and 2019zzts727).	Bai YX, 2019, EBIOMEDICINE, V42, P311, DOI 10.1016/j.ebiom.2019.03.045; Berges R, 2016, MOL CANCER THER, V15, P2740, DOI 10.1158/1535-7163.MCT-16-0252; Bo H, 2019, ONCOL REP, V41, P2431, DOI 10.3892/or.2019.7027; Bo H, 2018, J CANCER, V9, P4677, DOI 10.7150/jca.26461; Chen LJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0943-0; Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32; Chen NF, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1594-y; Cheng HP, 2017, ONCOL RES, V25, P587, DOI 10.3727/096504016X14761811155298; Das M, 2018, RNA BIOL, V15, P214, DOI 10.1080/15476286.2017.1397261; Deng XY, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0428-0; Dong X, 2010, J PATHOL, V220, P361, DOI 10.1002/path.2662; Fan CM, 2019, CANCER SCI, V110, P2180, DOI 10.1111/cas.14034; Fan CM, 2021, CANCER LETT, V496, P41, DOI 10.1016/j.canlet.2020.09.006; Fan CM, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07408-w; Fan CM, 2021, SCI CHINA LIFE SCI, V64, P534, DOI 10.1007/s11427-019-1735-4; Fan CM, 2019, J CANCER, V10, P3926, DOI 10.7150/jca.31345; Fan CM, 2019, CARCINOGENESIS, V40, P380, DOI 10.1093/carcin/bgy143; Fan CM, 2018, J CANCER, V9, P2852, DOI 10.7150/jca.25460; Fukushima N, 2009, J NEUROCHEM, V109, P683, DOI 10.1111/j.1471-4159.2009.06013.x; Gao W, 2015, ONCOGENE, V34, P1629, DOI 10.1038/onc.2014.101; Gao Y, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-014-0571-3; Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020; Han Y, 2020, LIFE SCI, V241, DOI 10.1016/j.lfs.2019.117140; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hauptmann J, 2013, DEV CELL, V25, P553, DOI 10.1016/j.devcel.2013.06.009; He RF, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0614-1; He Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0265-y; Huang GL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131225; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Jaulin F, 2010, J CELL BIOL, V190, P443, DOI 10.1083/jcb.201006044; Jayatilaka H, 2018, FASEB J, V32, P1207, DOI 10.1096/fj.201700444RR; Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890; Jiang XJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01709-5; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Jin K, 2019, CELL MOL LIFE SCI, V76, P4275, DOI 10.1007/s00018-019-03222-1; Kong Z, 2017, BIOCHEM BIOPH RES CO, V493, P1217, DOI 10.1016/j.bbrc.2017.07.162; Li F, 2015, ONCOTARGET, V6, P6001, DOI 10.18632/oncotarget.3469; Li HB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6017-2; Li N, 2011, P NATL ACAD SCI USA, V108, P12851, DOI 10.1073/pnas.1017372108; Li PC, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12165; Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581; Lian Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0918-9; Liu M, 2009, MOL CARCINOGEN, V48, P212, DOI 10.1002/mc.20471; Liu Y, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1894-5; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Mo YZ, 2019, J CANCER, V10, P3789, DOI 10.7150/jca.31166; Mo YZ, 2019, J CANCER, V10, P2342, DOI 10.7150/jca.30454; Peng M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1055-6; Rodrigues-Ferreira S, 2019, BREAST CANCER RES TR, V173, P573, DOI 10.1007/s10549-018-5026-1; Serre L, 2019, J MOL BIOL, V431, P1993, DOI 10.1016/j.jmb.2019.03.028; Shan B, 2008, J BIOL CHEM, V283, P21065, DOI 10.1074/jbc.M802786200; Sugihara Y, 2012, J PROTEOMICS, V75, P5342, DOI 10.1016/j.jprot.2012.06.013; Taguchi A, 2015, CANCER PREV RES, V8, P1112, DOI 10.1158/1940-6207.CAPR-15-0077; Tang L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0758-7; Tang T, 2020, MOL ONCOL, V14, P2251, DOI 10.1002/1878-0261.12703; Tang YY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0825-x; Tu CF, 2018, CARCINOGENESIS, V39, P1517, DOI 10.1093/carcin/bgy108; Tufo G, 2014, CELL DEATH DIFFER, V21, P685, DOI 10.1038/cdd.2013.193; van Haren J, 2018, NAT CELL BIOL, V20, P252, DOI 10.1038/s41556-017-0028-5; Wan L, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1579490; Wang D, 2020, FASEB J, V34, P8012, DOI 10.1096/fj.202000039RR; Wang D, 2020, CELL MOL LIFE SCI, V77, P2949, DOI 10.1007/s00018-020-03469-z; Wang JJ, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22379; Wang YH, 2005, ONCOGENE, V24, P6637, DOI 10.1038/sj.onc.1208819; Wang YA, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0913-y; Wang YM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0598-7; Wei F, 2021, CELL MOL LIFE SCI, V78, P173, DOI 10.1007/s00018-020-03581-0; Wei F, 2019, J CANCER, V10, P1145, DOI 10.7150/jca.29049; Wei F, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0409-0; Wei F, 2018, BRIT J CANCER, V118, P233, DOI 10.1038/bjc.2017.385; Wieczorek M, 2015, NAT CELL BIOL, V17, P907, DOI 10.1038/ncb3188; Wu CC, 2019, SCI CHINA LIFE SCI, V62, P640, DOI 10.1007/s11427-018-9461-5; Wu P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1147-3; Wu YF, 2020, FASEB J, V34, P16205, DOI 10.1096/fj.202001508R; Wu YF, 2019, J CANCER, V10, P2185, DOI 10.7150/jca.30222; Wu YZ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1007-1; Xiao L, 2019, CARCINOGENESIS, V40, P819, DOI 10.1093/carcin/bgz095; Xiong F, 2019, CHINESE MED J-PEKING, V132, P749, DOI 10.1097/CM9.0000000000000132; Xu LL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1041-2; Yang CD, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0771-7; Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012; Zeng ZY, 2011, SCI CHINA LIFE SCI, V54, P966, DOI 10.1007/s11427-011-4223-5; Zhao J, 2020, CANCER LETT, V477, P131, DOI 10.1016/j.canlet.2020.02.010; Zhong YX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0827-8; Zhou RY, 2018, CANCER LETT, V425, P134, DOI 10.1016/j.canlet.2018.03.035; Zhu KJ, 2020, CANCER LETT, V492, P11, DOI 10.1016/j.canlet.2020.07.028	86	36	37	3	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					307	321		10.1038/s41388-020-01531-5	http://dx.doi.org/10.1038/s41388-020-01531-5		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33122825				2022-12-17	WOS:000582827800002
J	Zhai, SY; Xu, ZW; Xie, JJ; Zhang, J; Wang, XJ; Peng, CH; Li, HW; Chen, H; Shen, BY; Deng, XX				Zhai, Shuyu; Xu, Zhiwei; Xie, Junjie; Zhang, Jun; Wang, Xinjing; Peng, Chenghong; Li, Hongwei; Chen, Hao; Shen, Baiyong; Deng, Xiaxing			Epigenetic silencing of LncRNA LINC00261 promotes c-myc-mediated aerobic glycolysis by regulating miR-222-3p/HIPK2/ERK axis and sequestering IGF2BP1	ONCOGENE			English	Article							LONG NONCODING RNAS; SIGNALING PATHWAY; PANCREATIC-CANCER; METHYLATION; HIPK2	Long noncoding RNAs have been identified as key regulators in the progression of various cancers. LINC00261 has been reported as a tumor suppressor in multiple cancers. However, its function and underlying mechanisms in pancreatic cancer remain largely unclear. Quantitative real-time PCR was performed to detect RNA expression. In situ hybridization was used to discover the subcellular location. The direct binding of LINC00261 to miR-222-3p was verified using a dual-luciferase reporter assay and RNA immunoprecipitation. LINC00261-binding proteins were detected using an RNA pulldown assay. LINC00261 was downregulated in pancreatic cancer tissues and cell lines. Its reduced expression was correlated with advanced pathological stage and poor prognosis. Forced expression of LINC00261 suppressed pancreatic cancer glycolysis and proliferation and induced cell cycle arrest and apoptosis. Mechanistically, downregulation of LINC00261 was caused by hypermethylation of the CpG island in the promoter region and EZH2-mediated histone H3 lysine 27 trimethylation. Moreover, LINC00261 exerted its biological function by binding to miR-222-3p to activate the HIPK2/ERK/c-myc pathway. In addition, LINC00261 could also reduce c-myc expression by sequestering IGF2BP1. Our study suggests that LINC00261 functions as a tumor suppressor in pancreatic cancer and identifies novel epigenetic and posttranscriptional regulatory mechanisms of LINC00261, which contribute to the targeted therapy of pancreatic cancer.	[Zhai, Shuyu; Xu, Zhiwei; Xie, Junjie; Zhang, Jun; Wang, Xinjing; Peng, Chenghong; Li, Hongwei; Chen, Hao; Shen, Baiyong; Deng, Xiaxing] Shanghai Jiao Tong Univ, Ruijin Hosp, Res Inst Pancreat Dis, Dept Gen Surg,Pancreat Dis Ctr,Sch Med, Shanghai, Peoples R China; [Zhai, Shuyu; Xu, Zhiwei; Xie, Junjie; Zhang, Jun; Wang, Xinjing; Peng, Chenghong; Li, Hongwei; Chen, Hao; Shen, Baiyong; Deng, Xiaxing] Shanghai Jiao Tong Univ, Sch Med, Res Inst Pancreat Dis, Shanghai, Peoples R China; [Zhai, Shuyu; Xu, Zhiwei; Xie, Junjie; Zhang, Jun; Wang, Xinjing; Peng, Chenghong; Li, Hongwei; Chen, Hao; Shen, Baiyong; Deng, Xiaxing] Shanghai Jiao Tong Univ, Inst Translat Med, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, H; Shen, BY; Deng, XX (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Res Inst Pancreat Dis, Dept Gen Surg,Pancreat Dis Ctr,Sch Med, Shanghai, Peoples R China.; Chen, H; Shen, BY; Deng, XX (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Res Inst Pancreat Dis, Shanghai, Peoples R China.; Chen, H; Shen, BY; Deng, XX (corresponding author), Shanghai Jiao Tong Univ, Inst Translat Med, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China.	haochendr@126.com; shenby@shsmu.edu.cn; dxx10716@rjh.com.cn		Peng, Chenghong/0000-0002-5573-7873				Amin V, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7370; Black JC, 2012, MOL CELL, V48, P491, DOI 10.1016/j.molcel.2012.11.006; Chen TX, 2020, ONCOL REP, V43, P930, DOI 10.3892/or.2020.7480; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Chiorean EG, 2015, DRUG DES DEV THER, V9, P3529, DOI 10.2147/DDDT.S60328; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Gits CMM, 2013, BRIT J CANCER, V109, P1625, DOI 10.1038/bjc.2013.483; Guo CX, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01332-6; Guo JP, 2018, ONCOTARGETS THER, V11, P8643, DOI 10.2147/OTT.S175745; He J, 2019, CANCER LETT, V450, P98, DOI 10.1016/j.canlet.2019.02.033; Hofmann TG, 2013, BIOESSAYS, V35, P55, DOI 10.1002/bies.201200060; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Huang XW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0628-y; Ihle MA, 2015, MOL ONCOL, V9, P1421, DOI 10.1016/j.molonc.2015.03.013; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Klutstein M, 2016, CANCER RES, V76, P3446, DOI 10.1158/0008-5472.CAN-15-3278; Luo H, 2015, BRAIN, V138, P3654, DOI 10.1093/brain/awv287; Muller S, 2018, NUCLEIC ACIDS RES, V46, P6285, DOI 10.1093/nar/gky229; MULLER S, 2015, MOL CANCER, V14; Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006; Qin Y, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12603; Rashid F, 2016, GENOM PROTEOM BIOINF, V14, P73, DOI 10.1016/j.gpb.2016.03.005; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Saul VV, 2013, J MOL MED, V91, P1051, DOI 10.1007/s00109-013-1042-0; Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Shi HL, 2019, MOL CELL, V74, P640, DOI 10.1016/j.molcel.2019.04.025; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Sun SS, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819892256; Wang X, 2020, ARCH BIOCHEM BIOPHYS, V689, DOI 10.1016/j.abb.2020.108469; Wapinski O, 2011, TRENDS CELL BIOL, V21, P354, DOI 10.1016/j.tcb.2011.04.001; Yan DS, 2019, J CELL PHYSIOL, V234, P22648, DOI 10.1002/jcp.28831; Yang HJ, 2019, BIOCHIMIE, V165, P9, DOI 10.1016/j.biochi.2019.06.012; Yu YC, 2017, J CELL MOL MED, V21, P955, DOI 10.1111/jcmm.13035; Zeng LP, 2016, J CELL MOL MED, V20, P559, DOI 10.1111/jcmm.12760; Zhang BG, 2018, AM J TRANSL RES, V10, P2648; Zhu S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15403-9	37	36	37	3	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					277	291		10.1038/s41388-020-01525-3	http://dx.doi.org/10.1038/s41388-020-01525-3		OCT 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33122827	Green Published, hybrid			2022-12-17	WOS:000582827800004
J	Ramirez-Moya, J; Baker, AR; Slack, FJ; Santisteban, P				Ramirez-Moya, Julia; Baker, Allison R.; Slack, Frank J.; Santisteban, Pilar			ADAR1-mediated RNA editing is a novel oncogenic process in thyroid cancer and regulates miR-200 activity	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; E-CADHERIN; ADAR1 PROMOTES; ZEB1; MICRORNAS; FAMILY; PHENOTYPE; CELLS; PATHOGENESIS; METASTASIS	Adenosine deaminases acting on RNA (ADARs) convert adenosine to inosine in double-stranded RNA. A-to-I editing of RNA is a widespread posttranscriptional process that has recently emerged as an important mechanism in cancer biology. A-to-I editing levels are high in several human cancers, including thyroid cancer, but ADAR1 editase-dependent mechanisms governing thyroid cancer progression are unexplored. To address the importance of RNA A-to-I editing in thyroid cancer, we examined the role of ADAR1. Loss-of-function analysis showed that ADAR1 suppression profoundly repressed proliferation, invasion, and migration in thyroid tumor cell models. These observations were validated in an in vivo xenograft model, which showed that ADAR1-silenced cells had a diminished ability to form tumors. RNA editing of miRNAs has the potential to markedly alter target recognition. According to TCGA data, the tumor suppressor miR-200b is overedited in thyroid tumors, and its levels of editing correlate with a worse progression-free survival and disease stage. We confirmed miR-200b overediting in thyroid tumors and we showed that edited miR-200b has weakened activity against its target gene ZEB1 in thyroid cancer cells, likely explaining the reduced aggressiveness of ADAR1-silenced cells. We also found that RAS, but not BRAF, modulates ADAR1 levels, an effect mediated predominantly by PI3K and in part by MAPK. Lastly, pharmacological inhibition of ADAR1 activity with the editing inhibitor 8-azaadenosine reduced cancer cell aggressiveness. Overall, our data implicate ADAR1-mediated A-to-I editing as an important pathway in thyroid cancer progression, and highlight RNA editing as a potential therapeutic target in thyroid cancer.	[Ramirez-Moya, Julia; Santisteban, Pilar] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Ramirez-Moya, Julia; Santisteban, Pilar] Univ Autonoma Madrid, Consejo Super Invest Cient, Madrid, Spain; [Ramirez-Moya, Julia; Baker, Allison R.; Slack, Frank J.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Pathol, Harvard Med Sch Initiat RNA Med, Boston, MA 02115 USA; [Ramirez-Moya, Julia; Santisteban, Pilar] Inst Salud Carlos III ISCII, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC	Santisteban, P (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Madrid, Spain.; Santisteban, P (corresponding author), Univ Autonoma Madrid, Consejo Super Invest Cient, Madrid, Spain.; Santisteban, P (corresponding author), Inst Salud Carlos III ISCII, Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain.	psantisteban@iib.uam.es	Ramírez-Moya, Julia/B-9104-2018	Ramírez-Moya, Julia/0000-0002-2458-2186; Slack, Frank/0000-0001-8263-0409; Baker, Allison/0000-0003-2030-7379	Ministerio de Ciencia e Innovacion (MICIN), Spain [SAF2016-75531-R]; Comunidad de Madrid [B2017/BMD-3724]; Fundacion Espanola contra el Cancer (AECC) [GCB14142311CRES]; Ludwig Center at Harvard; MECD (Spain); Fondo Europeo de Desarrollo Regional FEDER	Ministerio de Ciencia e Innovacion (MICIN), Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Comunidad de Madrid(Comunidad de Madrid); Fundacion Espanola contra el Cancer (AECC); Ludwig Center at Harvard; MECD (Spain)(Spanish Government); Fondo Europeo de Desarrollo Regional FEDER(European CommissionSpanish Government)	This work was supported by grants SAF2016-75531-R from Ministerio de Ciencia e Innovacion (MICIN), Spain, Fondo Europeo de Desarrollo Regional FEDER, B2017/BMD-3724 from Comunidad de Madrid, and GCB14142311CRES from Fundacion Espanola contra el Cancer (AECC) (To PS), and by the Ludwig Center at Harvard (To FJS). JR-M hold a FPU fellowship from MECD (Spain).	Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050; Antoni D, 2015, INT J MOL SCI, V16, P5517, DOI 10.3390/ijms16035517; Bass BL, 2002, ANNU REV BIOCHEM, V71, P817, DOI 10.1146/annurev.biochem.71.110601.135501; Baysal BE, 2017, CANCER RES, V77, P3733, DOI 10.1158/0008-5472.CAN-17-0520; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Butz Henriett, 2019, EJIFCC, V30, P146; Cho CJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040799; Crews LA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0370-3; Feng B, 2012, BIOMED PHARMACOTHER, V66, P397, DOI 10.1016/j.biopha.2012.06.002; Feng XL, 2014, CANCER LETT, V344, P166, DOI 10.1016/j.canlet.2013.11.004; Fritzell K, 2018, SEMIN CELL DEV BIOL, V79, P123, DOI 10.1016/j.semcdb.2017.11.018; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; Gannon HS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07824-4; Gregory PA, 2008, CELL CYCLE, V7, P3112, DOI 10.4161/cc.7.20.6851; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Han L, 2015, CANCER CELL, V28, DOI 10.1016/j.ccell.2015.08.013; Ishizuka JJ, 2019, NATURE, V565, P43, DOI 10.1038/s41586-018-0768-9; Jia BQ, 2012, MOL CELL BIOCHEM, V366, P223, DOI 10.1007/s11010-012-1299-6; Jiang QF, 2013, P NATL ACAD SCI USA, V110, P1041, DOI 10.1073/pnas.1213021110; Keegan LP, 2001, NAT REV GENET, V2, P869, DOI 10.1038/35098584; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; Lehmann KA, 1999, J MOL BIOL, V291, P1, DOI 10.1006/jmbi.1999.2914; Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719; Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932; Liu HY, 2019, NAT MED, V25, P95, DOI 10.1038/s41591-018-0302-5; Liu X, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1300-2; Mitsutake N, 2005, CANCER RES, V65, P2465, DOI 10.1158/0008-5472.CAN-04-3314; Montemayor-Garcia C, 2013, ENDOCR PATHOL, V24, P206, DOI 10.1007/s12022-013-9272-9; Nemlich Y, 2013, J CLIN INVEST, V123, P2703, DOI 10.1172/JCI62980; Nishikura K, 2016, NAT REV MOL CELL BIO, V17, P83, DOI 10.1038/nrm.2015.4; Pallante P, 2014, NAT REV ENDOCRINOL, V10, P88, DOI 10.1038/nrendo.2013.223; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Paterson EL, 2008, THESCIENTIFICWORLDJO, V8, P901, DOI 10.1100/tsw.2008.115; Paz-Yaacov N, 2015, CELL REP, V13, P267, DOI 10.1016/j.celrep.2015.08.080; Qi LH, 2014, CANCER RES, V74, P1301, DOI 10.1158/0008-5472.CAN-13-3485; Qin YR, 2014, CANCER RES, V74, P840, DOI 10.1158/0008-5472.CAN-13-2545; Ramirez-Moya J, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00430; Ramirez-Moya J, 2019, ONCOGENE, V38, P5486, DOI 10.1038/s41388-019-0804-8; Ramirez-Moya J, 2018, ONCOGENE, V37, P3369, DOI 10.1038/s41388-017-0088-9; Riesco-Eizaguirre G, 2015, CANCER RES, V75, P4119, DOI 10.1158/0008-5472.CAN-14-3547; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Sastre-Perona A, 2016, ONCOTARGET, V7, P49435, DOI 10.18632/oncotarget.10356; Shen AD, 2012, J SURG ONCOL, V105, P830, DOI 10.1002/jso.23012; Shirokawa JM, 2000, MOL ENDOCRINOL, V14, P1725, DOI 10.1210/me.14.11.1725; Shoshan E, 2015, NAT CELL BIOL, V17, P311, DOI 10.1038/ncb3110; Song C, 2016, GENES-BASEL, V7, DOI 10.3390/genes7120129; SPREMULLI EN, 1983, J NATL CANCER I, V70, P499; Wahlstedt H, 2009, GENOME RES, V19, P978, DOI 10.1101/gr.089409.108; Walkley CR, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1347-3; Wang HF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-282; Wang YM, 2017, GENOME RES, V27, P1112, DOI 10.1101/gr.219741.116; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Xu L., 2018, SUSTAINABILITY, V10, P1, DOI [10.3390/su10020001, DOI 10.3390/genes10010012]; Zaballos MA, 2017, J ENDOCRINOL, V235, pR43, DOI 10.1530/JOE-17-0266; Zhang BH, 2007, DEV BIOL, V302, P1, DOI 10.1016/j.ydbio.2006.08.028; Zhang JX, 2013, MOL BIOL REP, V40, P949, DOI 10.1007/s11033-012-2136-4; Zhang PJ, 2015, CELL CYCLE, V14, P481, DOI 10.1080/15384101.2015.1006048; Zhang XP, 2019, INT J NONLIN SCI NUM, V20, P1, DOI 10.1515/ijnsns-2017-0166; Zhang YC, 2016, INT J FUTUR GENER CO, V9, P1, DOI 10.14257/ijfgcn.2016.9.10.01; Zipeto MA, 2016, CELL STEM CELL, V19, P177, DOI 10.1016/j.stem.2016.05.004	61	36	37	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3738	3753		10.1038/s41388-020-1248-x	http://dx.doi.org/10.1038/s41388-020-1248-x		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32157211	Green Published, hybrid			2022-12-17	WOS:000518886000002
J	Yu, XF; Wang, RK; Zhang, YN; Zhou, L; Wang, W; Liu, HD; Li, W				Yu, Xinfang; Wang, Ruike; Zhang, Yangnan; Zhou, Li; Wang, Wei; Liu, Haidan; Li, Wei			Skp2-mediated ubiquitination and mitochondrial localization of Akt drive tumor growth and chemoresistance to cisplatin	ONCOGENE			English	Article							SENSITIZES NASOPHARYNGEAL CARCINOMA; POOR-PROGNOSIS; CANCER CELLS; SKP2; ACTIVATION; GLYCOLYSIS; LUNG; DEGRADATION; CONTRIBUTES; RESISTANCE	The E3 ligase S-phase kinase-associated protein 2(Skp2) is overexpressed in human cancers and correlated with poor prognosis, but its contributions to tumorigenesis and chemoresistance in nasopharyngeal carcinoma (NPC) are not evident. Herein we show that Skp2 is highly expressed in NPC tumor tissues and cell lines. Knockdown of Skp2 suppresses tumor cell growth, colony formation, glycolysis, and in vivo tumor growth. Skp2 promotes Akt K63-mediated ubiquitination and activation, which is required for EGF-induced Akt mitochondrial localization. Importantly, K63-linked ubiquitination enhances the interaction between Akt and HK2 and eventually increases HK2 phosphorylation on Thr473 and mitochondrial localization. Overexpression of Skp2 impaired the intrinsic apoptotic pathway and confers cisplatin resistance. Moreover, ectopic expression of Myr-Akt1 or phosphomimetic HK2-T473D rescued cisplatin-induced tumor suppression in Skp2 knockdown stable cells. Also, depletion of Akt ubiquitination enhances the antitumor efficacy of cisplatin in vitro and in vivo. Finally, we demonstrated that Skp2 is positively correlated with p-Akt and HK2 in NPC tumor tissues. This study highlights the clinical value of Skp2 targeting in NPC treatment.	[Yu, Xinfang; Liu, Haidan] Cent S Univ, Dept Cardiovasc Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China; [Yu, Xinfang; Liu, Haidan] Cent S Univ, Clin Ctr Gene Diag & Therapy, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China; [Yu, Xinfang] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA; [Wang, Ruike; Zhang, Yangnan] Cent S Univ, Xiangya Sch Med, Changsha 410000, Hunan, Peoples R China; [Zhou, Li] Cent S Univ, Dept Pathol, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Wang, Wei; Li, Wei] Cent S Univ, Dept Radiol, Xiangya Hosp 3, Changsha 410000, Hunan, Peoples R China	Central South University; Central South University; Cleveland Clinic Foundation; Central South University; Central South University; Central South University	Liu, HD (corresponding author), Cent S Univ, Dept Cardiovasc Surg, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.; Liu, HD (corresponding author), Cent S Univ, Clin Ctr Gene Diag & Therapy, Xiangya Hosp 2, Changsha 410011, Hunan, Peoples R China.; Wang, W; Li, W (corresponding author), Cent S Univ, Dept Radiol, Xiangya Hosp 3, Changsha 410000, Hunan, Peoples R China.	cjr.wangwei@vip.163.com; haidanliu@csu.edu.cn; weililx@csu.edu.cn			National Natural Science Foundation of China [81572280, 81502121, 81401548]; Natural Science Foundation of Hunan Province [2018JJ3787, 2019JJ40420]; New Xiangya Talent Project of the Third Xiangya Hospital of Central South University [JY2015011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); New Xiangya Talent Project of the Third Xiangya Hospital of Central South University	This work was supported by the National Natural Science Foundation of China (Nos. 81572280, 81502121, and 81401548), the Natural Science Foundation of Hunan Province (2018JJ3787 and 2019JJ40420), and the New Xiangya Talent Project of the Third Xiangya Hospital of Central South University (No. JY2015011).	Bhattacharyya T, 2018, J ONCOL, V2018, DOI 10.1155/2018/3725837; Bijur GN, 2003, J NEUROCHEM, V87, P1427, DOI 10.1046/j.1471-4159.2003.02113.x; Bissey PA, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0050-x; Byun WS, 2018, BIOCHEM PHARMACOL, V158, P84, DOI 10.1016/j.bcp.2018.10.002; Chae YC, 2016, CANCER CELL, V30, P257, DOI 10.1016/j.ccell.2016.07.004; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chen D, 2011, CURR CANCER DRUG TAR, V11, P239, DOI 10.2174/156800911794519752; Cheng CY, 2018, BIOMED PHARMACOTHER, V108, P194, DOI 10.1016/j.biopha.2018.09.031; Fan L, 2018, INT J MOL MED, V42, P2247, DOI 10.3892/ijmm.2018.3778; Feng SY, 2017, CELL CYCLE, V16, P869, DOI 10.1080/15384101.2017.1308617; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Fu HC, 2016, ONCOTARGET, V7, P44047, DOI 10.18632/oncotarget.10057; Gallo LH, 2017, CELL CYCLE, V16, P634, DOI 10.1080/15384101.2017.1288326; Gao W, 2017, CANCER MED-US, V6, P439, DOI 10.1002/cam4.982; Ghosh JC, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju502; Katano A, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010502; Kuang CM, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.271; Lam W K Jacky, 2018, F1000Res, V7, DOI 10.12688/f1000research.15066.1; Lee AWM, 2015, J CLIN ONCOL, V33, P3356, DOI 10.1200/JCO.2015.60.9347; Lee AWM, 2005, J CLIN ONCOL, V23, P6966, DOI 10.1200/JCO.2004.00.7542; Lee SW, 2015, MOL CELL, V57, P1022, DOI 10.1016/j.molcel.2015.01.015; Lee VH, 2018, J ONCOL PRACT, V14, P594, DOI 10.1200/JOP.18.00219; Li SN, 2017, BRIT J CANCER, V117, P1518, DOI 10.1038/bjc.2017.323; Li S, 2017, CELL CYCLE, V16, P1601, DOI 10.1080/15384101.2017.1356508; Li W, 2018, J CELL MOL MED, V22, P6213, DOI 10.1111/jcmm.13908; Li W, 2018, CELL SIGNAL, V50, P131, DOI 10.1016/j.cellsig.2018.07.001; Li W, 2017, ONCOTARGET, V8, P32586, DOI 10.18632/oncotarget.15937; Li W, 2013, CANCER RES, V73, P6938, DOI 10.1158/0008-5472.CAN-13-0913; Liu F, 2018, CANCER BIOL THER, V19, P534, DOI 10.1080/15384047.2018.1450119; Liu HD, 2016, ONCOTARGET, V7, P56338, DOI 10.18632/oncotarget.10841; Mair R, 2018, CANCER RES, V78, P5408, DOI 10.1158/0008-5472.CAN-18-0759; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Roberts DJ, 2013, J BIOL CHEM, V288, P23798, DOI 10.1074/jbc.M113.482026; Ruan D, 2017, ONCOGENE, V36, P4299, DOI 10.1038/onc.2017.64; Shi C, 2018, ONCOGENE, V37, P3260, DOI 10.1038/s41388-018-0217-0; Shuang H, 2019, CLIN TRANSL ONCOL, V21, P213, DOI 10.1007/s12094-018-1911-7; Su CC, 2012, AM J PHYSIOL-HEART C, V302, pH716, DOI 10.1152/ajpheart.00455.2011; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Tian YF, 2013, TUMOR BIOL, V34, P1107, DOI 10.1007/s13277-013-0652-z; Timmerbeul I, 2006, P NATL ACAD SCI USA, V103, P14009, DOI 10.1073/pnas.0606316103; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Wang J, 2014, ONCOTARGET, V5, P5591, DOI 10.18632/oncotarget.2149; Wang ZW, 2012, FRONT ONCOL, V1, DOI [10.3389/fonc.2011.00057, 10.3389/fonc.2012.00201]; Wu J, 2012, MOL CELL, V46, P351, DOI 10.1016/j.molcel.2012.02.018; Xiao L, 2014, ONCOGENE, V33, P4568, DOI 10.1038/onc.2014.32; Xie P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.195; Yang TT, 2018, ONCOGENE, V37, P5997, DOI 10.1038/s41388-018-0386-x; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yao F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04620-y; Yu XF, 2017, MOL CARCINOGEN, V56, P1414, DOI 10.1002/mc.22602; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang XY, 2018, INT J BIOCHEM CELL B, V95, P9, DOI 10.1016/j.biocel.2017.12.010; Zhao HL, 2013, CANCER CELL, V24, P645, DOI 10.1016/j.ccr.2013.09.021; Zhen Y, 2017, ONCOGENE, V36, P275, DOI 10.1038/onc.2016.201	57	36	39	5	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2019	38	50					7457	7472		10.1038/s41388-019-0955-7	http://dx.doi.org/10.1038/s41388-019-0955-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JV7GY	31435020				2022-12-17	WOS:000502530500002
J	Zeng, YT; Liu, XF; Yang, WT; Zheng, PS				Zeng, Yu-Ting; Liu, Xiao-Fang; Yang, Wen-Ting; Zheng, Peng-Sheng			REX1 promotes EMT-induced cell metastasis by activating the JAK2/STAT3-signaling pathway by targeting SOCS1 in cervical cancer	ONCOGENE			English	Article							SIGNAL TRANSDUCER; DNA METHYLATION; GENE-EXPRESSION; YY1; PROTEIN; MARKER; CLASSIFICATION; ASSOCIATION; SUPPRESSOR; CARCINOMA	ZFP42 zinc finger protein (REX1), a pluripotency marker in mouse pluripotent stem cells, has been identified as a tumor suppressor in several human cancers. However, the function of REX1 in cervical cancer remains unknown. Both IHC and western blot assays demonstrated that the expression of REX1 protein in cervical cancer tissue was much higher than that in normal cervical tissue. A xenograft assay showed that REX1 overexpression in SiHa and HeLa cells facilitated distant metastasis but did not significantly affect tumor formation in vivo. In addition, in vitro cell migration and invasion capabilities were also promoted by REX1. Mechanistically, REX1 overexpression induced epithelial-to-mesenchymal transition (EMT) by upregulating VIMENTIN and downregulating E-CADHERIN. Furthermore, the JAK2/STAT3-signaling pathway was activated in REX1-overexpressing cells, which also exhibited increased levels of p-STAT3 and p-JAK2, as well as downregulated expression of SOCS1, which is an inhibitor of the JAK2/STAT3-signaling pathway, at both the transcriptional and translational levels. A dual-luciferase reporter assay and qChIP assays confirmed that REX1 trans-suppressed the expression of SOCS1 by binding to two specific regions of the SOCS1 promoter. Therefore, all our data suggest that REX1 overexpression could play a crucial role in the metastasis and invasion of cervical cancer by upregulating the activity of the JAK2/STAT3 pathway by trans-suppressing SOCS1 expression.	[Zeng, Yu-Ting; Yang, Wen-Ting; Zheng, Peng-Sheng] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710061, Shaanxi, Peoples R China; [Liu, Xiao-Fang; Zheng, Peng-Sheng] Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Stem Cell Res, Xian 710061, Shaanxi, Peoples R China	Xi'an Jiaotong University; Ministry of Education, China	Yang, WT; Zheng, PS (corresponding author), Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Reprod Med, Xian 710061, Shaanxi, Peoples R China.; Zheng, PS (corresponding author), Minist Educ Peoples Republ China, Key Lab Environm & Genes Related Dis, Sect Canc Stem Cell Res, Xian 710061, Shaanxi, Peoples R China.	04203031@stu.xjtu.edu.cn; zpsheng@mail.xjtu.edu.cn			National Natural Science Foundation of China [81802946, 81472728, 81672910]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by a to grant Dr XiaoFang Liu from the National Natural Science Foundation of China (No. 81802946) and Prof. Peng-Sheng Zheng from the National Natural Science Foundation of China (Nos. 81472728 and 81672910).	Anzai E, 2017, BIOL PHARM BULL, V40, P1483, DOI 10.1248/bpb.b17-00307; Aoyama T, 2010, J BIOL CHEM, V285, P29842, DOI 10.1074/jbc.M110.116319; Arai E, 2012, CARCINOGENESIS, V33, P1487, DOI 10.1093/carcin/bgs177; Astudillo H, 2004, J CLIN ONCOL, V22, p466S; Berkopec A, 2007, J DISCRET ALGORITHMS, V5, P341, DOI 10.1016/j.jda.2006.01.001; Boxberg M, 2019, AM J SURG PATHOL, V43, P303, DOI 10.1097/PAS.0000000000001178; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brivanlou AH, 2003, SCIENCE, V300, P913, DOI 10.1126/science.1082940; Chan EM, 2009, NAT BIOTECHNOL, V27, P1033, DOI 10.1038/nbt.1580; Chen Q, 2016, ONCOTARGET, V7, P36115, DOI 10.18632/oncotarget.8741; Cui N, 2016, ONCOTARGET, V7, P26152, DOI 10.18632/oncotarget.8434; Cui Y, 2016, ONCOL REP, V36, P108, DOI 10.3892/or.2016.4822; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; Do Kim J, 2009, NUCLEIC ACIDS RES, V37, P5656, DOI 10.1093/nar/gkp613; Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027; Garcia-Tunon I, 2011, STEM CELL RES, V7, P1, DOI 10.1016/j.scr.2011.02.005; Henderson JK, 2002, STEM CELLS, V20, P329, DOI 10.1634/stemcells.20-4-329; Huang SY, 2007, CLIN CANCER RES, V13, P1362, DOI 10.1158/1078-0432.CCR-06-2313; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Karpathiou G, 2019, HEAD NECK-J SCI SPEC, V41, P1918, DOI 10.1002/hed.25629; Kim BS, 2011, HUM GENE THER, V22, P1551, DOI 10.1089/hum.2011.096; Kim MH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123133; Kumar L, 2007, BIOINFORMATION, V2, P5, DOI 10.6026/97320630002005; Lee MY, 2010, J CELL PHYSIOL, V224, P17, DOI 10.1002/jcp.22071; Liu XF, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0359-6; Mongan NP, 2006, MOL CARCINOGEN, V45, P887, DOI 10.1002/mc.20186; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Oka D, 2009, CANCER-AM CANCER SOC, V115, P3412, DOI 10.1002/cncr.24394; Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934; Palko L, 2004, J CELL SCI, V117, P465, DOI 10.1242/jcs.00870; Qin HW, 2012, P NATL ACAD SCI USA, V109, P5004, DOI 10.1073/pnas.1117218109; Qureshi R, 2015, CANCER LETT, V356, P321, DOI 10.1016/j.canlet.2014.09.021; Raman JD, 2006, CARCINOGENESIS, V27, P499, DOI 10.1093/carcin/bgi299; Rizvi MMA, 2011, J CANCER RES CLIN, V137, P1255, DOI 10.1007/s00432-011-0994-0; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sobti RC, 2011, CELL ONCOL, V34, P533, DOI 10.1007/s13402-011-0056-2; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takemoto S, 2009, BRIT J CANCER, V101, P967, DOI 10.1038/sj.bjc.6605212; Tarazona S, 2011, GENOME RES, V21, P2213, DOI 10.1101/gr.124321.111; Tewari KS, 2014, NEW ENGL J MED, V370, P734, DOI 10.1056/NEJMoa1309748; Thomas MJ, 1999, GENE, V236, P197, DOI 10.1016/S0378-1119(99)00261-9; Toyooka Y, 2008, DEVELOPMENT, V135, P909, DOI 10.1242/dev.017400; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wang HY, 2015, ONCOTARGET, V6, P20711, DOI 10.18632/oncotarget.4133; Wu YZ, 2004, ONCOGENE, V23, P168, DOI 10.1038/sj.onc.1207003; Yang WT, 2012, CANCER-AM CANCER SOC, V118, P3691, DOI 10.1002/cncr.26698; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zhang JJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-130; Zhao GW, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0177-y; Zhou XC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0911-3	52	36	38	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2019	38	43					6940	6957		10.1038/s41388-019-0906-3	http://dx.doi.org/10.1038/s41388-019-0906-3			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JH4GX	31409905	hybrid			2022-12-17	WOS:000492728000005
J	Gobbi, G; Donati, B; Do Valle, IF; Reggiani, F; Torricelli, F; Remondini, D; Castellani, G; Ambrosetti, DC; Ciarrocchi, A; Sancisi, V				Gobbi, Giulia; Donati, Benedetta; Do Valle, Italo Faria; Reggiani, Francesca; Torricelli, Federica; Remondini, Daniel; Castellani, Gastone; Ambrosetti, Davide Carlo; Ciarrocchi, Alessia; Sancisi, Valentina			The Hippo pathway modulates resistance to BET proteins inhibitors in lung cancer cells	ONCOGENE			English	Article							DOSE-ESCALATION; TAZ; BRD4; YAP; SENSITIVITY; EXPRESSION; OVEREXPRESSION; TUMORIGENESIS; PROGRESSION; SUPPRESSES	Inhibitors of BET proteins (BETi) are anti-cancer drugs that have shown efficacy in pre-clinical settings and are currently in clinical trials for different types of cancer, including non-small cell lung cancer (NSCLC). Currently, no predictive biomarker is available to identify patients that may benefit from this treatment. To uncover the mechanisms of resistance to BETi, we performed a genome-scale CRISPR/Cas9 screening in lung cancer cells. We identified three Hippo pathway genes, LATS2, TAOK1, and NF2, as key determinants for sensitivity to BETi. The knockout of these genes induces resistance to BETi, by promoting TAZ nuclear localization and transcriptional activity. Conversely, TAZ expression promotes resistance to these drugs. We also showed that TAZ, YAP, and their partner TEAD are direct targets of BRD4 and that treatment with BETi downregulates their expression. Noticeably, molecular alterations in one or more of these genes are present in a large fraction of NSCLC patients and TAZ amplification or overexpression correlates with a worse outcome in lung adenocarcinoma. Our data define the central role of Hippo pathway in mediating resistance to BETi and provide a rationale for using BETi to counter-act YAP/TAZ-mediated pro-oncogenic activity.	[Gobbi, Giulia; Donati, Benedetta; Reggiani, Francesca; Torricelli, Federica; Ciarrocchi, Alessia; Sancisi, Valentina] Azienda USL Reggio Emilia IRCCS, Lab Translat Res, Reggio Emilia, Italy; [Do Valle, Italo Faria] Northeastern Univ, Dept Phys, Ctr Complex Network Res, Boston, MA 02115 USA; [Remondini, Daniel; Castellani, Gastone] Univ Bologna, Dept Phys & Astron, Bologna, Italy; [Ambrosetti, Davide Carlo] Univ Bologna, Dept Pharm & Biotechnol FaBit, Bologna, Italy	Northeastern University; University of Bologna; University of Bologna	Sancisi, V (corresponding author), Azienda USL Reggio Emilia IRCCS, Lab Translat Res, Reggio Emilia, Italy.	valentina.sancisi@ausl.re.it	Remondini, Daniel/ABA-9971-2020; Gobbi, Giulia/AAB-6104-2019; REGGIANI, FRANCESCA/K-1082-2018; Ciarrocchi, Alessia/AAA-1130-2019; dovalle, italo/AAH-2621-2020; Donati, Benedetta/AAA-7779-2022; Donati, Benedetta/H-7741-2018; torricelli, federica/H-7734-2018; Sancisi, Valentina/H-6701-2018	Gobbi, Giulia/0000-0002-4746-967X; REGGIANI, FRANCESCA/0000-0002-4090-8908; Ciarrocchi, Alessia/0000-0002-5541-2075; Donati, Benedetta/0000-0002-9163-8194; Donati, Benedetta/0000-0002-9163-8194; torricelli, federica/0000-0003-1954-5695; Sancisi, Valentina/0000-0003-4357-1228				Amorim S, 2016, LANCET HAEMATOL, V3, pE196, DOI 10.1016/S2352-3026(16)00021-1; Bartucci M, 2015, ONCOGENE, V34, P681, DOI 10.1038/onc.2014.5; Basu-Roy U, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7411; Berthon C, 2016, LANCET HAEMATOL, V3, pE186, DOI 10.1016/S2352-3026(15)00247-1; Boggiano JC, 2011, DEV CELL, V21, P888, DOI 10.1016/j.devcel.2011.08.028; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Cheng HY, 2016, ONCOTARGET, V7, P28976, DOI 10.18632/oncotarget.6721; Dai XP, 2017, NAT MED, V23, DOI 10.1038/nm.4378; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Gao ZY, 2018, CANCER BIOL THER, V19, P407, DOI 10.1080/15384047.2018.1423923; Ghiso E, 2017, NEOPLASIA, V19, P1012, DOI 10.1016/j.neo.2017.10.003; Gugnoni M, 2017, ONCOGENE, V36, P667, DOI 10.1038/onc.2016.237; Gujral TS, 2017, P NATL ACAD SCI USA, V114, pE3729, DOI 10.1073/pnas.1703096114; Janouskova H, 2017, MOL CELL PROTEOMICS, V16, pS68; Kanno T, 2014, NAT STRUCT MOL BIOL, V21, P1047, DOI 10.1038/nsmb.2912; Kawano S, 2015, J BIOCHEM, V158, P413, DOI 10.1093/jb/mvv051; Klingbeil O, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.271; Lau AN, 2014, EMBO J, V33, P468, DOI 10.1002/embj.201386082; Li W, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0843-6; Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218; Lockwood WW, 2012, P NATL ACAD SCI USA, V109, P19408, DOI 10.1073/pnas.1216363109; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Manzotti G, 2019, CANCERS, V11, DOI 10.3390/cancers11030304; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Sancisi V, 2017, NUCLEIC ACIDS RES, V45, P11249, DOI 10.1093/nar/gkx802; Sancisi V, 2015, CANCER RES, V75, P1868, DOI 10.1158/0008-5472.CAN-14-2087; Sancisi V, 2012, J CLIN ENDOCR METAB, V97, pE2006, DOI 10.1210/jc.2012-1903; Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047; Shalem O, 2015, NAT REV GENET, V16, P299, DOI 10.1038/nrg3899; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904; Stein C, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005465; Varelas X, 2014, DEVELOPMENT, V141, P1614, DOI 10.1242/dev.102376; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Xie M, 2012, J THORAC ONCOL, V7, P799, DOI 10.1097/JTO.0b013e318248240b; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Yin F, 2013, CELL, V154, P1342, DOI 10.1016/j.cell.2013.08.025; Zaman A, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.05.02; Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8; Zanconato F, 2015, NAT CELL BIOL, V17, P1218, DOI 10.1038/ncb3216; Zhang PZ, 2017, NAT MED, V23, P1055, DOI 10.1038/nm.4379; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao Y, 2016, CELL REP, V16, P2003, DOI 10.1016/j.celrep.2016.07.032	50	36	36	3	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2019	38	42					6801	6817		10.1038/s41388-019-0924-1	http://dx.doi.org/10.1038/s41388-019-0924-1			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JE5UU	31406246				2022-12-17	WOS:000490758200001
J	Feng, DF; Qin, B; Pal, K; Sun, L; Dutta, S; Dong, HD; Liu, X; Mukhopadhyay, D; Huang, SB; Sinicrope, FA				Feng, Daofu; Qin, Bo; Pal, Krishnendu; Sun, Lei; Dutta, Shamit; Dong, Haidong; Liu, Xin; Mukhopadhyay, Debabrata; Huang, Shengbing; Sinicrope, Frank A.			BRAF(V600E)-induced, tumor intrinsic PD-L1 can regulate chemotherapy-induced apoptosis in human colon cancer cells and in tumor xenografts	ONCOGENE			English	Article							B7-H1 PD-L1; EXPRESSION; MEK; ACTIVATION; BLOCKADE; PROTEIN; RESISTANCE; RECEPTOR; MUTATION; CASCADE	Programmed death ligand 1 (PD-L1) is an immune checkpoint protein; however, emerging data suggest that tumor cell PD-L1 may regulate immune-independent and intrinsic cellular functions. We demonstrate regulation of PD-L1 by oncogenic BRAF(V600E) and investigated its ability to influence apoptotic susceptibility in colorectal cancer (CRC) cells. Endogenous or exogenous mutant vs. wild-type BRAF were shown to increase PD-L1 messenger RNA (mRNA) and protein expression that was attenuated by MEK (mitogen-activated protein kinase/extracellular signal-regulated kinase) inhibition or c-JUN and YAP knockdown. Deletion of PD-L1 reduced tumor cell growth in vitro and in vivo. Loss of PD-L1 was also shown to attenuate DNA damage and apoptosis induced by diverse anti-cancer drugs that could be reversed by restoration of wild-type PD-L1, but not mutants with deletion of its extra- or intracellular domain. The effect of PD-L1 on chemosensitivity was confirmed in MC38 murine tumor xenografts generated from PD-L1-knockout vs. parental cells. Deletion of PD-L1 suppressed BH3-only BIM and BIK proteins that could be restored by re-expression of PD-L1; re-introduction of BIM enhanced apoptosis. PD-L1 expression was significantly increased in BRAF(V600E) human colon cancers, and patients whose tumors had high vs. low PD-L1 had significantly better survival. In summary, BRAF(V600E) can transcriptionally upregulate PD-L1 expression that was shown to induce BIM and BIK to enhance chemotherapy-induced apoptosis. These data indicate an intrinsic, non-immune function of PD-L1, and suggest the potential for tumor cell PD-L1 as a predictive biomarker.	[Feng, Daofu; Qin, Bo; Sun, Lei; Huang, Shengbing; Sinicrope, Frank A.] Gastrointestinal Res Unit, Rochester, MN 55905 USA; [Pal, Krishnendu; Dutta, Shamit; Mukhopadhyay, Debabrata] Mayo Clin, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA; [Dong, Haidong; Liu, Xin] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Dept Med, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Dept Oncol, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Mayo Clin, Rochester, MN 55905 USA; [Sinicrope, Frank A.] Mayo Comprehens Canc Ctr, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Sinicrope, FA (corresponding author), Gastrointestinal Res Unit, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Dept Med, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Dept Oncol, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Mayo Clin, Rochester, MN 55905 USA.; Sinicrope, FA (corresponding author), Mayo Comprehens Canc Ctr, Rochester, MN 55905 USA.	sinicrope.frank@mayo.edu		Pal, Krishnendu/0000-0002-4006-213X	NCI R01 [CA210509-01A1]; Scientific Research Training Program for Young Talents of Tianjin Medical University General Hospital, PRC; Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; NATIONAL CANCER INSTITUTE [R01CA210509] Funding Source: NIH RePORTER	NCI R01(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Scientific Research Training Program for Young Talents of Tianjin Medical University General Hospital, PRC; Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported, in part, by NCI R01 (CA210509-01A1) to F.A.S. D.F. was supported by the Scientific Research Training Program for Young Talents of Tianjin Medical University General Hospital, PRC; current address is Department of General Surgery, Tianjin Medical University General Hospital, Tianjin, China. L.S. is supported by the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. The authors' express their gratitude to Mr. Matthew A. Bockol for downloading TCGA data.	Adams JM, 2018, CELL DEATH DIFFER, V25, P27, DOI 10.1038/cdd.2017.161; Atefi M, 2014, CLIN CANCER RES, V20, P3446, DOI 10.1158/1078-0432.CCR-13-2797; Audrito V, 2017, ONCOTARGET, V8, P15894, DOI 10.18632/oncotarget.15213; Azuma T, 2008, BLOOD, V111, P3635, DOI 10.1182/blood-2007-11-123141; Bae SU, 2018, ONCOL LETT, V16, P5214, DOI 10.3892/ol.2018.9264; Baeten JM, 2016, NEW ENGL J MED, V375, P2121, DOI 10.1056/NEJMoa1506110; Bhalla S, 2011, BLOOD, V118, P1052, DOI 10.1182/blood-2011-03-340109; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Clark CA, 2016, CANCER RES, V76, P6964, DOI 10.1158/0008-5472.CAN-16-0258; Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; Droeser RA, 2013, EUR J CANCER, V49, P2233, DOI 10.1016/j.ejca.2013.02.015; Ghebeh H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2605; Guzman C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092444; Hamanishi J, 2016, INT J CLIN ONCOL, V21, P462, DOI 10.1007/s10147-016-0959-z; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hersey P, 2013, CLIN CANCER RES, V19, P514, DOI 10.1158/1078-0432.CCR-12-3312; Kawakami H, 2016, MOL CANCER THER, V15, P3015, DOI 10.1158/1535-7163.MCT-16-0017; Kim MH, 2018, CANCER IMMUNOL RES, V6, P255, DOI 10.1158/2326-6066.CIR-17-0320; King AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062613; Kleffel S, 2015, CELL, V162, P1242, DOI 10.1016/j.cell.2015.08.052; Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497; Le DT, 2017, CANCER IMMUNOL RES, V5, P942, DOI 10.1158/2326-6066.CIR-17-0375; Lee BS, 2017, BIOCHEM BIOPH RES CO, V491, P493, DOI 10.1016/j.bbrc.2017.07.007; Li YQ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0539-x; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Liu J, 2018, ONCOL LETT, V15, P3321, DOI 10.3892/ol.2017.7682; Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125; Luo H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.3; Merino D, 2009, J CELL BIOL, V186, P355, DOI 10.1083/jcb.200905153; Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275; Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Orzechowski A, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-5026; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Phipps AI, 2015, CANCER EPIDEM BIOMAR, V24, P1046, DOI 10.1158/1055-9965.EPI-15-0204; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; Song MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055761; Sznol M, 2013, CLIN CANCER RES, V19, P5542, DOI 10.1158/1078-0432.CCR-13-2234; Taieb J, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw272; Tang HD, 2018, J CLIN INVEST, V128, P580, DOI 10.1172/JCI96061; Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689; Topalian SL, 2012, CURR OPIN IMMUNOL, V24, P207, DOI 10.1016/j.coi.2011.12.009; Tu XY, 2019, MOL CELL, V74, P1215, DOI 10.1016/j.molcel.2019.04.005; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; YAN F, 2016, PLOS ONE, V11, DOI DOI 10.1371/JOURNAL.PONE.0156889; Yang SM, 2018, INT J MOL MED, V42, P3477, DOI 10.3892/ijmm.2018.3890; Zaanan A, 2015, J BIOL CHEM, V290, P23838, DOI 10.1074/jbc.M115.657833; Zhang P, 2018, MOL CANCER RES, V16, P378, DOI 10.1158/1541-7786.MCR-17-0404; Zhang XH, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.37	54	36	41	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6752	6766		10.1038/s41388-019-0919-y	http://dx.doi.org/10.1038/s41388-019-0919-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31406255	Green Accepted			2022-12-17	WOS:000489552900003
J	Zhong, Z; Sepramaniam, S; Chew, XH; Wood, K; Lee, MA; Madan, B; Virshup, DM				Zhong, Zheng; Sepramaniam, Sugunavathi; Chew, Xin Hui; Wood, Kris; Lee, May Ann; Madan, Babita; Virshup, David M.			PORCN inhibition synergizes with PI3K/mTOR inhibition in Wnt-addicted cancers	ONCOGENE			English	Article							ADVANCED PANCREATIC-CANCER; IN-VIVO; C-MYC; GEMCITABINE; PHOSPHORYLATION; REVEALS; PATHWAY; PROTEIN; TRIAL; DEPENDENCIES	Pancreatic cancer (pancreatic ductal adenocarcinoma, PDAC) is aggressive and lethal. Although there is an urgent need for effective therapeutics in treating pancreatic cancer, none of the targeted therapies tested in clinical trials to date significantly improve its outcome. PORCN inhibitors show efficacy in preclinical models of Wnt-addicted cancers, including RNF43-mutant pancreatic cancers and have advanced to clinical trials. In this study, we aimed to develop drug combination strategies to further enhance the therapeutic efficacy of the PORCN inhibitor ETC-159. To identify additional druggable vulnerabilities in Wnt-driven pancreatic cancers, we performed an in vivo CRISPR loss-of-function screen. CTNNB1, KRAS, and MYC were reidentified as key oncogenic drivers. Notably, glucose metabolism pathway genes were important in vivo but less so in vitro. Knockout of multiple genes regulating PI3K/mTOR signaling impacted the growth of Wnt-driven pancreatic cancer cells in vivo. Importantly, multiple PI3K/mTOR pathway inhibitors in combination with ETC-159 synergistically suppressed the growth of multiple Wnt-addicted cancer cell lines in soft agar. Furthermore, the combination of the PORCN inhibitor ETC-159 and the pan-PI3K inhibitor GDC-0941 potently suppressed the in vivo growth of RNF43-mutant pancreatic cancer xenografts. This was largely due to enhanced suppressive effects on both cell proliferation and glucose metabolism. These findings demonstrate that dual PORCN and PI3K/mTOR inhibition is a potential strategy for treating Wnt-driven pancreatic cancers.	[Zhong, Zheng; Madan, Babita; Virshup, David M.] Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore; [Zhong, Zheng] Natl Univ Singapore, Dept Physiol, Singapore, Singapore; [Sepramaniam, Sugunavathi; Chew, Xin Hui; Lee, May Ann] ASTAR, Biopolis, Expt Therapeut Ctr, Singapore, Singapore; [Wood, Kris] Duke Univ, Dept Pharmacol & Canc Biol, Durham, NC USA; [Virshup, David M.] Duke Univ, Dept Pediat, Durham, NC 27706 USA	National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Experimental Drug Development Centre (EDDC); Experimental Therapeutics Centre; Duke University; Duke University	Madan, B; Virshup, DM (corresponding author), Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore, Singapore.; Virshup, DM (corresponding author), Duke Univ, Dept Pediat, Durham, NC 27706 USA.	babita.madan@duke-nus.edu.sg; david.virshup@duke-nus.edu.sg	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; Zhong, Zheng/0000-0003-1614-7798; Wood, Kris/0000-0002-5887-2253	National Research Foundation Singapore; Singapore Ministry of Health's National Medical Research Council Open Fund-Independent Research Grant	National Research Foundation Singapore(National Research Foundation, Singapore); Singapore Ministry of Health's National Medical Research Council Open Fund-Independent Research Grant(Ministry of Health-SingaporeNational Medical Research Council, Singapore)	This study is supported in part by the National Research Foundation Singapore and administered by the Singapore Ministry of Health's National Medical Research Council under the STAR Award Program to DMV. BM acknowledges the support of the Singapore Ministry of Health's National Medical Research Council Open Fund-Independent Research Grant. We gratefully acknowledge the assistance from Yun Ka Wong and other members of both the Virshup lab and the Experimental Therapeutics Centre. We thank Prof. Stuart Cook and Edmund Pua for help with the MiSeq; Muhammad Idris Bin Kachi Mydin for help with bioinformatic analysis; Duke-NUS Metabolomics Facility, Dr. Jianhong Ching, and Dr. Zing Tan for help with the glucose metabolite quantification, and Profs. Shazib Pervaiz and Patrick Tan for useful suggestions on this study. Figure 1a was adapted from Servier Medical Art, licensed under a Creative Commons Attribution 3.0 Unported License (https://smart.servier.com).	Anderson GR, 2017, CELL REP, V20, P999, DOI 10.1016/j.celrep.2017.07.006; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; Cancer Genome Atlas Research Network. Electronic address: andrew_aguirre@dfci.harvard.edu, 2017, Cancer Cell, V32, P185, DOI 10.1016/j.ccell.2017.07.007; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chung V, 2017, JAMA ONCOL, V3, P516, DOI 10.1001/jamaoncol.2016.5383; Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Hammel P, 2016, JAMA-J AM MED ASSOC, V315, P1844, DOI 10.1001/jama.2016.4324; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Infante JR, 2014, EUR J CANCER, V50, P2072, DOI 10.1016/j.ejca.2014.04.024; Janda CY, 2012, SCIENCE, V337, P59, DOI 10.1126/science.1222879; Janku F, 2015, MOL CANCER THER, V14, pC45, DOI DOI 10.1158/1535-7163.TARG-15-C45; Javle MM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-368; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Ko AH, 2016, CLIN CANCER RES, V22, P61, DOI 10.1158/1078-0432.CCR-15-0979; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4; Lin RT, 2015, NAT CELL BIOL, V17, P1484, DOI 10.1038/ncb3255; Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280; Madan B, 2018, J CLIN INVEST, V128, P5620, DOI 10.1172/JCI122383; Madan B, 2018, BONE RES, V6, DOI 10.1038/s41413-018-0017-8; Madan B, 2016, ONCOTARGET, V7, P12386, DOI 10.18632/oncotarget.7157; McDonald ER, 2017, CELL, V170, P577, DOI 10.1016/j.cell.2017.07.005; Miller TE, 2017, NATURE, V547, P355, DOI 10.1038/nature23000; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Muir A, 2018, SCIENCE, V360, P962, DOI 10.1126/science.aar5986; Najdi R, 2012, DIFFERENTIATION, V84, P203, DOI 10.1016/j.diff.2012.06.004; Ng M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2584; Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622; Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598; Picco G, 2017, EMBO MOL MED, V9, P293, DOI 10.15252/emmm.201606773; Possik PA, 2014, CELL REP, V9, P1375, DOI 10.1016/j.celrep.2014.10.024; Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Schmid P, 2016, J CLIN ONCOL, V34, P1987, DOI 10.1200/JCO.2015.63.9179; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003; Van Cutsem E, 2017, J CLIN ONCOL, V33, P344; Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169; Wall M, 2008, BLOOD, V112, P2305, DOI 10.1182/blood-2007-09-111856; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Ward PS, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a006783; Whittaker SR, 2004, CANCER RES, V64, P262, DOI 10.1158/0008-5472.CAN-03-0110; Wolpin BM, 2009, J CLIN ONCOL, V27, P193, DOI 10.1200/JCO.2008.18.9514; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Zhang L, 2014, J BIOL CHEM, V289, P24863, DOI 10.1074/jbc.M114.586818	53	36	36	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2019	38	40					6662	6677		10.1038/s41388-019-0908-1	http://dx.doi.org/10.1038/s41388-019-0908-1			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC0EY	31391551	hybrid			2022-12-17	WOS:000488953500002
J	Cordero, A; Kanojia, D; Miska, J; Panek, WK; Xiao, AN; Han, Y; Bonamici, N; Zhou, WD; Xiaol, T; Wu, MJ; Ahmed, AU; Lesniak, MS				Cordero, Alex; Kanojia, Deepak; Miska, Jason; Panek, Wojciech K.; Xiao, Annie; Han, Yu; Bonamici, Nicolas; Zhou, Weidong; Xiaol, Ting; Wu, Meijing; Ahmed, Atique U.; Lesniak, Maciej S.			FABP7 is a key metabolic regulator in HER2+breast cancer brain metastasis	ONCOGENE			English	Article							ACID-BINDING PROTEIN; HUMAN-BREAST-CANCER; POOR-PROGNOSIS; SURVIVAL; EXPRESSION; TUMOR; HYPOXIA; CELLS; GENE; OXIDATION	Overexpression of human epidermal growth factor receptor 2 (HER2) in breast cancer patients is associated with increased incidence of breast cancer brain metastases (BCBM), but the mechanisms underlying this phenomenon remain unclear. Here, to identify brain-predominant genes critical for the establishment of BCBM, we conducted an in silico screening analysis and identified that increased levels of fatty acid-binding protein 7 (FABP7) correlate with a lower survival and higher incidence of brain metastases in breast cancer patients. We validated these findings using HER2+ BCBM cells compared with parental breast cancer cells. Importantly, through knockdown and overexpression assays, we characterized the role of FABP7 in the BCBM process in vitro and in vivo. Our results uncover a key role of FABP7 in metabolic reprogramming of HER2 + breast cancer cells, supporting a glycolytic phenotype and storage of lipid droplets that enable their adaptation and survival in the brain microenvironment. In addition, FABP7 is shown to be required for upregulation of key metastatic genes and pathways, such as integrins-Src and VEGFA, and for the growth of HER2+ breast cancer cells in the brain microenvironment in vivo. Together, our results support FABP7 as a potential target for the treatment of HER2+ BCBM.	[Cordero, Alex; Kanojia, Deepak; Miska, Jason; Panek, Wojciech K.; Xiao, Annie; Han, Yu; Bonamici, Nicolas; Xiaol, Ting; Wu, Meijing; Ahmed, Atique U.; Lesniak, Maciej S.] Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA; [Zhou, Weidong] George Mason Univ, Ctr Appl Prot & Mol Med, Manassas, VA 20110 USA	Northwestern University; Feinberg School of Medicine; George Mason University	Lesniak, MS (corresponding author), Northwestern Univ, Dept Neurol Surg, Feinberg Sch Med, Chicago, IL 60611 USA.	maciej.lesniak@northwestern.edu	Casanovas, Alex Cordero/AAA-8157-2020; Kanojia, Deepak/G-5120-2014	Kanojia, Deepak/0000-0003-4295-4972; Panek, Wojciech Krzysztof/0000-0002-5667-5715; Cordero Casanovas, Alejandro/0000-0002-2224-7122	NIH [R35CA197725, R01NS87990, R01NS093903, 1R01NS096376-01A1]; NATIONAL CANCER INSTITUTE [R35CA197725, P50CA221747] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS087990, R01NS096376, R01NS093903] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We would like to thank Dr Katarzyna C. Pituch and Dr Diana Saleiro for helpful discussions during the preparation of this paper; Paul Joseph Mehl, Aurora Lopez-Rosas, and Northwestern University animal facility for their technical assistance. This work was supported by NIH grants R35CA197725, R01NS87990, R01NS093903 (MSL), and 1R01NS096376-01A1 (AUA).	Anthony TE, 2005, GENE DEV, V19, P1028, DOI 10.1101/gad.1302105; Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49; Bennett V, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003012; Bensaad K, 2014, CELL REP, V9, P349, DOI 10.1016/j.celrep.2014.08.056; Blackwell KL, 2012, J CLIN ONCOL, V30, P2585, DOI 10.1200/JCO.2011.35.6725; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Camarda R, 2016, NAT MED, V22, P427, DOI 10.1038/nm.4055; Cheng C, 2012, CELL ONCOL, V35, P217, DOI 10.1007/s13402-012-0081-9; Chlenski A, 2000, BBA-GENE STRUCT EXPR, V1493, P319, DOI 10.1016/S0167-4781(00)00185-8; Chua J, 2009, P NATL ACAD SCI USA, V106, P20770, DOI 10.1073/pnas.0909812106; Ciminera AK, 2017, CLIN EXP METASTAS, V34, P401, DOI 10.1007/s10585-017-9864-8; DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200; Desai S, 2014, ONCOTARGET, V5, P8202, DOI 10.18632/oncotarget.1159; Dong GC, 2016, ONCOL LETT, V11, P1980, DOI 10.3892/ol.2016.4168; Emi Y, 2002, SURGERY, V131, pS217, DOI 10.1067/msy.2002.119580; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Feng YX, 2018, GENES DIS, V5, P77, DOI 10.1016/j.gendis.2018.05.001; Gajria D, 2011, EXPERT REV ANTICANC, V11, P263, DOI 10.1586/ERA.10.226; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gilkes DM, 2013, J BIOL CHEM, V288, P10819, DOI 10.1074/jbc.M112.442939; Guaita-Esteruelas S, 2018, MOL CELL ENDOCRINOL, V462, P107, DOI 10.1016/j.mce.2017.02.002; Han TY, 2013, CELL ADHES MIGR, V7, P395, DOI 10.4161/cam.26345; Hao JQ, 2018, CELL METAB, V28, P689, DOI 10.1016/j.cmet.2018.07.006; Hao JQ, 2018, CANCER RES, V78, P2343, DOI 10.1158/0008-5472.CAN-17-2465; Haunerland NH, 2004, PROG LIPID RES, V43, P328, DOI 10.1016/j.plipres.2004.05.001; Kaloshi G, 2007, J NEURO-ONCOL, V84, P245, DOI 10.1007/s11060-007-9377-4; Kanojia D, 2015, STEM CELLS, V33, P2985, DOI 10.1002/stem.2109; Kanojia D, 2015, MOL CANCER THER, V14, P1152, DOI 10.1158/1535-7163.MCT-14-0950; Kim HM, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0354-3; Kodack DP, 2015, CANCER CELL, V27, P163, DOI 10.1016/j.ccell.2015.01.001; Koizume S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091430; Krakhmal NV, 2015, ACTA NATURAE, V7, P17, DOI 10.32607/20758251-2015-7-2-17-28; LaGory EL, 2016, NAT CELL BIOL, V18, P356, DOI 10.1038/ncb3330; Lamborn KR, 2004, NEURO-ONCOLOGY, V6, P227, DOI 10.1215/S1152851703000620; Leyland-Jones B, 2009, J CLIN ONCOL, V27, P5278, DOI 10.1200/JCO.2008.19.8481; Liang Y, 2005, P NATL ACAD SCI USA, V102, P5814, DOI 10.1073/pnas.0402870102; Listenberger Laura L, 2016, Curr Protoc Cell Biol, V71, DOI 10.1002/cpcb.7; Liu Katy C, 2012, Bioarchitecture, V2, P158, DOI 10.4161/bioa.21791; Liu RZ, 2012, J PATHOL, V228, P310, DOI 10.1002/path.4001; Martin TA, 2004, EUR J CANCER, V40, P2717, DOI 10.1016/j.ejca.2004.08.008; Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005; Miska J, 2019, CELL REP, V27, P226, DOI 10.1016/j.celrep.2019.03.029; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413; Marie SKN, 2011, CLINICS, V66, P33, DOI 10.1590/S1807-59322011001300005; Neman J, 2014, P NATL ACAD SCI USA, V111, P984, DOI 10.1073/pnas.1322098111; Nguyen A, 2016, J CLIN INVEST, V126, P681, DOI 10.1172/JCI83587; Park JH, 2016, CELL REP, V14, P2154, DOI 10.1016/j.celrep.2016.02.004; Pascual G, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032920; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pelletier M, 2014, METHOD ENZYMOL, V542, P125, DOI 10.1016/B978-0-12-416618-9.00007-8; Reily C, 2013, REDOX BIOL, V1, P86, DOI 10.1016/j.redox.2012.11.009; Seliger B, 2005, PROTEOMICS, V5, P2631, DOI 10.1002/pmic.200401264; Seyfried TN, 2011, BBA-BIOENERGETICS, V1807, P577, DOI 10.1016/j.bbabio.2010.08.009; Sihto H, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2944; Sjobakk TE, 2013, INT J MOL SCI, V14, P2104, DOI 10.3390/ijms14012104; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Slipicevic A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-276; Stivarou T, 2015, CANCERS, V7, P238, DOI 10.3390/cancers7010238; Storch J, 2008, ANNU REV NUTR, V28, P73, DOI 10.1146/annurev.nutr.27.061406.093710; Talasila KM, 2017, NEURO-ONCOLOGY, V19, P383, DOI 10.1093/neuonc/now175; Tang ZY, 2016, ONCOTARGET, V7, P46253, DOI 10.18632/oncotarget.10086; Thakur R, 2015, SCI REP-UK, V5, DOI 10.1038/srep10194; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Valiente M, 2014, CELL, V156, P1002, DOI 10.1016/j.cell.2014.01.040; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Wang TY, 2018, CELL METAB, V27, P1357, DOI 10.1016/j.cmet.2018.04.018; Zhang SY, 2013, CANCER RES, V73, P5764, DOI 10.1158/0008-5472.CAN-12-1803; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhang YW, 2014, CANCER RES, V74, P2986, DOI 10.1158/0008-5472.CAN-13-2689; Zhou YQ, 2017, ONCOTARGET, V8, P35877, DOI 10.18632/oncotarget.16270	72	36	36	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2019	38	37					6445	6460		10.1038/s41388-019-0893-4	http://dx.doi.org/10.1038/s41388-019-0893-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IX6FR	31324889	Green Accepted			2022-12-17	WOS:000485778800004
J	Sicari, D; Fantuz, M; Bellazzo, A; Valentino, E; Apollonio, M; Pontisso, I; Di Cristino, F; Dal Ferro, M; Bicciato, S; Del Salf, G; Collavin, L				Sicari, Dania; Fantuz, Marco; Bellazzo, Arianna; Valentino, Elena; Apollonio, Mattia; Pontisso, Ilaria; Di Cristino, Francesca; Dal Ferro, Marco; Bicciato, Silvio; Del Salf, Giannino; Collavin, Licio			Mutant p53 improves cancer cells' resistance to endoplasmic reticulum stress by sustaining activation of the UPR regulator ATF6	ONCOGENE			English	Article							TRANSMEMBRANE PROTEIN; SURVIVAL; ER; TRANSLATION; PROTEOLYSIS; METASTASIS; APOPTOSIS	Missense mutations in the TP53 gene are frequent in human cancers, giving rise to mutant p53 proteins that can acquire oncogenic properties. Gain of function mutant p53 proteins can enhance tumour aggressiveness by promoting cell invasion, metastasis and chemoresistance. Accumulating evidences indicate that mutant p53 proteins can also modulate cell homeostatic processes, suggesting that missense p53 mutation may increase resistance of tumour cells to intrinsic and extrinsic cancer-related stress conditions, thus offering a selective advantage. Here we provide evidence that mutant p53 proteins can modulate the Unfolded Protein Response (UPR) to increase cell survival upon Endoplasmic Reticulum (ER) stress, a condition to which cancer cells are exposed during tumour formation and progression, as well as during therapy. Mechanistically, this action of mutant p53 is due to enhanced activation of the pro-survival UPR effector ATF6, coordinated with inhibition of the pro-apoptotic UPR effectors JNK and CHOP. In a triple-negative breast cancer cell model with missense TP53 mutation, we found that ATF6 activity is necessary for viability and invasion phenotypes. Together, these findings suggest that ATF6 inhibitors might be combined with mutant p53-targeting drugs to specifically sensitise cancer cells to endogenous or chemotherapy-induced ER stress.	[Sicari, Dania; Fantuz, Marco; Bellazzo, Arianna; Valentino, Elena; Apollonio, Mattia; Pontisso, Ilaria; Di Cristino, Francesca; Del Salf, Giannino; Collavin, Licio] Natl Lab CIB LNCIB, Area Sci Pk, I-34149 Trieste, Italy; [Sicari, Dania; Fantuz, Marco; Bellazzo, Arianna; Valentino, Elena; Apollonio, Mattia; Pontisso, Ilaria; Di Cristino, Francesca; Dal Ferro, Marco; Del Salf, Giannino; Collavin, Licio] Univ Trieste, Dept Life Sci, I-34127 Trieste, Italy; [Fantuz, Marco] Int Sch Adv Studies SISSA, Trieste, Italy; [Bicciato, Silvio] Univ Modena & Reggio Emilia, Dept Life Sci, I-41100 Modena, Italy; [Del Salf, Giannino] FIRC Inst Mol Oncol, IFOM, Trieste, Italy	University of Trieste; International School for Advanced Studies (SISSA); Universita di Modena e Reggio Emilia; IFOM - FIRC Institute of Molecular Oncology	Del Salf, G; Collavin, L (corresponding author), Natl Lab CIB LNCIB, Area Sci Pk, I-34149 Trieste, Italy.; Del Salf, G; Collavin, L (corresponding author), Univ Trieste, Dept Life Sci, I-34127 Trieste, Italy.; Del Salf, G (corresponding author), FIRC Inst Mol Oncol, IFOM, Trieste, Italy.	giannino.delsal@Lncib.it; collavin@Lncib.it	Collavin, Licio/A-5312-2010; Bicciato, Silvio/C-9825-2009	Collavin, Licio/0000-0001-6815-5381; Bicciato, Silvio/0000-0002-1944-7078; Fantuz, Marco/0000-0001-7758-3660; Pontisso, Ilaria/0000-0002-4167-6539; Sicari, Daria/0000-0003-3847-129X	AIRC (Italian Association for Cancer Research) Investigator Grant [IG 14173]; AIRC Special Program Molecular Clinical Oncology "5 per mille" [10016]; Regione FVG [LR 17/2014]; FIRC (Fondazione Italiana Ricerca sul Cancro); Fondazione Umberto Veronesi postdoctoral fellowship; FIRC	AIRC (Italian Association for Cancer Research) Investigator Grant(Fondazione AIRC per la ricerca sul cancro); AIRC Special Program Molecular Clinical Oncology "5 per mille"(Fondazione AIRC per la ricerca sul cancro); Regione FVG(Regione Friuli Venezia Giulia); FIRC (Fondazione Italiana Ricerca sul Cancro)(Fondazione AIRC per la ricerca sul cancro); Fondazione Umberto Veronesi postdoctoral fellowship(Fondazione Umberto Veronesi); FIRC(Fondazione AIRC per la ricerca sul cancro)	We thank Giada Pastore (LNCIB, Trieste) for assistance with tissue culture. We thank Ciara Gallagher and Peter Walter (UCSF, USA) for kindly providing Ceapin-A7. We thank all people from LNCIB (Trieste) for advice and discussion. This work was funded by AIRC (Italian Association for Cancer Research) Investigator Grant (IG 14173) to LC, and AIRC Special Program Molecular Clinical Oncology "5 per mille" (Grant no. 10016) to GDS. This work was also funded by Regione FVG (LR 17/2014; project acronym RIFT) to GDS. AB was supported by a "G. Lucatello e G. Mazzega" postdoctoral fellowship from FIRC (Fondazione Italiana Ricerca sul Cancro), and by a Fondazione Umberto Veronesi postdoctoral fellowship. MF was supported by a "L. Fontana and M. Lionello" fellowship from FIRC. EV was supported by a "G. Lucatello e G. Mazzega" postdoctoral fellowship from FIRC.	Adachi Y, 2008, CELL STRUCT FUNCT, V33, P75, DOI 10.1247/csf.07044; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bourougaa K, 2010, MOL CELL, V38, P78, DOI 10.1016/j.molcel.2010.01.041; Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Clarke HJ, 2014, CANCER CELL, V25, P563, DOI 10.1016/j.ccr.2014.03.015; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Cunha DA, 2012, DIABETES, V61, P2763, DOI 10.2337/db12-0123; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Gallagher CM, 2016, ELIFE, V5, DOI 10.7554/eLife.11880; Guan M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09698; Guan M, 2011, CLIN CANCER RES, V17, P1796, DOI 10.1158/1078-0432.CCR-10-3216; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Ingallina E, 2018, NAT CELL BIOL, V20, P28, DOI 10.1038/s41556-017-0009-8; Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185; Li C, 2018, EXP CELL RES, V367, P170, DOI 10.1016/j.yexcr.2018.03.033; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052; Mantovani F, 2019, CELL DEATH DIFFER, V26, P199, DOI 10.1038/s41418-018-0246-9; Montibeller L, 2018, CELL STRESS CHAPERON, V23, P897, DOI 10.1007/s12192-018-0897-y; Namba T, 2015, ONCOTARGET, V6, P19990, DOI 10.18632/oncotarget.4598; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Prischi F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4554; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151; Schewe DM, 2008, P NATL ACAD SCI USA, V105, P10519, DOI 10.1073/pnas.0800939105; Senft D, 2016, TRENDS CANCER, V2, P429, DOI 10.1016/j.trecan.2016.06.004; Silwal-Pandit L, 2014, CLIN CANCER RES, V20, P3569, DOI 10.1158/1078-0432.CCR-13-2943; Tay KH, 2014, CELL SIGNAL, V26, P287, DOI 10.1016/j.cellsig.2013.11.008; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007; Vogiatzi F, 2016, P NATL ACAD SCI USA, V113, pE8433, DOI 10.1073/pnas.1612711114; Walerych D, 2016, NAT CELL BIOL, V18, P897, DOI 10.1038/ncb3380; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang M, 2014, NAT REV CANCER, V14, P581, DOI 10.1038/nrc3800; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wu J, 2007, DEV CELL, V13, P351, DOI 10.1016/j.devcel.2007.07.005; Yao XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125634; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Zeng LF, 2004, EMBO J, V23, P950, DOI 10.1038/sj.emboj.7600106	42	36	36	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2019	38	34					6184	6195		10.1038/s41388-019-0878-3	http://dx.doi.org/10.1038/s41388-019-0878-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IS5RM	31312025	Green Submitted			2022-12-17	WOS:000482210100003
J	Wang, Y; Xie, BH; Lin, WH; Huang, YH; Ni, JY; Hu, J; Cui, W; Zhou, J; Shen, L; Xu, LF; Lian, F; Li, HP				Wang, Yu; Xie, Bin-hui; Lin, Wei-hao; Huang, Yong-hui; Ni, Jia-yan; Hu, Jie; Cui, Wei; Zhou, Jun; Shen, Long; Xu, Lin-feng; Lian, Fan; Li, He-ping			Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-3; MATRIX METALLOPROTEINASES; CELL-PROLIFERATION; LYSINE METHYLATION; EARLY-DIAGNOSIS; POOR-PROGNOSIS; RISK-FACTORS; CANCER; OVEREXPRESSION; EXPRESSION	SMYD3, a member that belongs to the SET and MYND-domain (SMYD) family, has also been proven to largely participate in gene transcription regulation and progression of several human cancers as a histone lysine methyltransferase. However, the role and significance of SMYD3 in both the clinic and progression of hepatocellular carcinoma (HCC) remain unclear. Herein, we find that SMYD3 is increased in cirrhotic livers, and strikingly upregulated in hepatocellular carcinoma (HCC) tissues and cell lines. Subsequent analyses suggest that high expression level of SMYD3 significantly correlates with the malignant characteristics of HCC, and predicts poor prognosis in patients. Our results show that overexpression of SMYD3 increases, while silencing of SMYD3 inhibits, cell proliferation, invasiveness and tumorigenicity both in vitro and in vivo. SMYD3 also promotes intrahepatic metastasis of HCC cells. For the mechanisms, we identify that SMYD3 bound to CDK2 and MMP2 promoter and increased H3K4me3 modification at the corresponding promoters to promote gene transcription. Importantly, pharmacological targeting of SMYD3 with BCI-121 inhibitor effectively repressed the tumorigenicity of HCC cells. Finally, our results show that gene locus amplification is a cause for SMYD3 overexpression in HCC. These findings not only uncover that SMYD3 overexpression promotes the tumorigenicity and intrahepatic metastasis of HCC cell via upregulation of CDK2 and MMP2, but also suggest SMYD3 could be a practical prognosis marker or therapeutic target against the disease.	[Wang, Yu; Cui, Wei; Shen, Long] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Intervent Oncol, Guangzhou 510080, Guangdong, Peoples R China; [Xie, Bin-hui] Gannan Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Ganzhou 341000, Peoples R China; [Lin, Wei-hao] Sun Yat Sen Univ, Dept Thyroid & Breast Surg, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Huang, Yong-hui] Sun Yat Sen Univ, Dept Intervent Radiol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Ni, Jia-yan; Xu, Lin-feng] Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Dept Intervent Radiol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China; [Hu, Jie; Li, He-ping] Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China; [Zhou, Jun; Lian, Fan] Sun Yat Sen Univ, Dept Rheumatol & Clin Immunol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China	Sun Yat Sen University; Gannan Medical University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Xu, LF (corresponding author), Sun Yat Sen Univ, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Dept Intervent Radiol, Sun Yat Sen Mem Hosp, Guangzhou 510120, Guangdong, Peoples R China.; Li, HP (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.; Lian, F (corresponding author), Sun Yat Sen Univ, Dept Rheumatol & Clin Immunol, Affiliated Hosp 1, Guangzhou 510080, Guangdong, Peoples R China.	xulf1@21cn.com; lianfan_1@hotmail.com; drliheping@163.com		Huang, Yonghui/0000-0001-5921-583X	Natural Science Foundation of China [30600156, 30970837, 81101135, 81102270, 81602701, 81760496]; Natural Science Foundation of Guangdong Province [2014A030313053, 2016A030313278, 2016A030313365, 2017A030313547]; Science and Technology Projects Foundation of Guangdong Province [2015A070710006, 2016A020215053]; Science and Technology Projects Foundation of Guangzhou City [201507020037, 201607010260]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Science and Technology Projects Foundation of Guangdong Province; Science and Technology Projects Foundation of Guangzhou City	This study was supported by the grants including Natural Science Foundation of China (No. 30600156; 30970837; 81101135; 81102270; 81602701, 81760496), Natural Science Foundation of Guangdong Province (No. 2014A030313053; 2016A030313278; 2016A030313365; 2017A030313547), Science and Technology Projects Foundation of Guangdong Province (No. 2015A070710006; 2016A020215053), and Science and Technology Projects Foundation of Guangzhou City (No. 201507020037; 201607010260).	Chen LB, 2007, WORLD J GASTROENTERO, V13, P5718, DOI 10.3748/wjg.v13.i43.5718; Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052; Dai B, 2015, ONCOL REP, V34, P2722, DOI 10.3892/or.2015.4239; Della Corte C, 2016, LIVER INT, V36, P166, DOI 10.1111/liv.12965; Dong SW, 2014, ONCOL REP, V32, P1064, DOI 10.3892/or.2014.3307; Duarte S, 2015, MATRIX BIOL, V44-46, P147, DOI 10.1016/j.matbio.2015.01.004; Farinati F, 2006, AM J GASTROENTEROL, V101, P524, DOI 10.1111/j.1572-0241.2006.00443.x; Foreman KW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022290; Forner A, 2012, LANCET, V379, P1245, DOI 10.1016/S0140-6736(11)61347-0; Furuta M, 2017, J HEPATOL, V66, P363, DOI 10.1016/j.jhep.2016.09.021; Giannandrea M, 2014, DIS MODEL MECH, V7, P193, DOI 10.1242/dmm.012062; Greer EL, 2012, NAT REV GENET, V13, P343, DOI 10.1038/nrg3173; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x; Hao SH, 2017, J GASTROINTEST SURG, V21, P312, DOI 10.1007/s11605-016-3311-z; He CC, 2012, HUM PATHOL, V43, P1425, DOI 10.1016/j.humpath.2011.11.003; Hu LP, 2009, CANCER RES, V69, P4067, DOI 10.1158/0008-5472.CAN-08-4097; Huang L, 2017, AM J TRANSL RES, V9, P1; Imamura H, 2003, J HEPATOL, V38, P200, DOI 10.1016/S0168-8278(02)00360-4; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485; Komatsu S, 2015, BRIT J CANCER, V112, P357, DOI 10.1038/bjc.2014.543; Kunizaki M, 2007, CANCER RES, V67, P10759, DOI 10.1158/0008-5472.CAN-07-1132; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126; Liu C, 2013, JNCI-J NATL CANCER I, V105, P1719, DOI 10.1093/jnci/djt304; Liu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052703; Liu Y, 2015, TUMOR BIOL, V36, P4377, DOI 10.1007/s13277-015-3077-z; Liu Y, 2015, TUMOR BIOL, V36, P2685, DOI 10.1007/s13277-014-2891-z; Ma WJ, 2013, WORLD J SURG ONCOL, V11, DOI 10.1186/1477-7819-11-212; Mazur PK, 2014, NATURE, V510, P283, DOI 10.1038/nature13320; Notarpaolo A, 2017, J HEPATOL, V66, P552, DOI 10.1016/j.jhep.2016.10.038; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Peserico A, 2015, J CELL PHYSIOL, V230, P2447, DOI 10.1002/jcp.24975; Raje N, 2005, BLOOD, V106, P1042, DOI 10.1182/blood-2005-01-0320; Ren TN, 2011, MED ONCOL, V28, pS91, DOI 10.1007/s12032-010-9718-6; Sarris ME, 2016, CANCER CELL, V29, P354, DOI 10.1016/j.ccell.2016.01.013; Sims RJ, 2003, TRENDS GENET, V19, P629, DOI 10.1016/j.tig.2003.09.007; Stender JD, 2012, MOL CELL, V48, P28, DOI 10.1016/j.molcel.2012.07.020; Tan XG, 2006, P NATL ACAD SCI USA, V103, P7935, DOI 10.1073/pnas.0602555103; Thomenius MJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197372; Tracy CM, 2018, CURR OPIN PHYSIOL, V1, P140, DOI 10.1016/j.cophys.2017.10.001; Tsuchiya N, 2015, WORLD J GASTROENTERO, V21, P10573, DOI 10.3748/wjg.v21.i37.10573; Van Aller GS, 2012, EPIGENETICS-US, V7, P340, DOI 10.4161/epi.19506; Venkatesh HS, 2017, NATURE, V549, P533, DOI 10.1038/nature24014; Wang L, 2017, J GASTRIC CANCER, V17, P295, DOI 10.5230/jgc.2017.17.e33; Xu ST, 2011, J MOL CELL BIOL, V3, P293, DOI 10.1093/jmcb/mjr015; Zhang XD, 2018, NUCLEIC ACIDS RES, V46, P1793, DOI 10.1093/nar/gkx1259; Zou JN, 2009, CANCER LETT, V280, P78, DOI 10.1016/j.canlet.2009.02.015	49	36	38	4	23	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					4948	4961		10.1038/s41388-019-0766-x	http://dx.doi.org/10.1038/s41388-019-0766-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30842588				2022-12-17	WOS:000472145900005
J	Alessandrini, F; Menotti, L; Avitabile, E; Appolloni, I; Ceresa, D; Marubbi, D; Campadelli-Fiume, G; Malatesta, P				Alessandrini, Francesco; Menotti, Laura; Avitabile, Elisa; Appolloni, Irene; Ceresa, Davide; Marubbi, Daniela; Campadelli-Fiume, Gabriella; Malatesta, Paolo			Eradication of glioblastoma by immuno-virotherapy with a retargeted oncolytic HSV in a preclinical model	ONCOGENE			English	Article							HERPES-SIMPLEX-VIRUS; PHASE-I; EXPRESSING IL-12; VIRAL THERAPY; STEM-CELLS; GLIOMA; GROWTH; MUTANT; EFFICACY; TUMOR	Oncolytic herpes simplex viruses are proving to be effective in clinical trials against a number of cancers. Here, R-115, an oncolytic herpes simplex virus retargeted to human erbB-2, fully virulent in its target cells, and armed with murine interleukin-12 was evaluated in a murine model of glioblastoma. We show that a single R-115 injection in established tumors resulted, in about 30% of animals, in the complete eradication of the tumor, otherwise invariably lethal. The treatment also induced a significant improvement in the overall median survival time of mice and a resistance to recurrence from the same neoplasia. Such a high degree of protection was unprecedented; it was not observed before following treatments with the commonly used, mutated/attenuated oncolytic viruses. This is the first study providing the evidence of benefits offered by a fully virulent, retargeted, and armed herpes simplex virus in the treatment of glioblastoma and paves the way for clinical translation.	[Alessandrini, Francesco; Appolloni, Irene; Ceresa, Davide; Marubbi, Daniela; Malatesta, Paolo] Univ Genoa, Dept Expt Med, Genoa, Italy; [Menotti, Laura; Avitabile, Elisa] Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy; [Marubbi, Daniela; Malatesta, Paolo] Osped Policlin San Martino, IRCCS Oncol, Genoa, Italy; [Campadelli-Fiume, Gabriella] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy	University of Genoa; University of Bologna; University of Bologna	Malatesta, P (corresponding author), Univ Genoa, Dept Expt Med, Genoa, Italy.; Malatesta, P (corresponding author), Osped Policlin San Martino, IRCCS Oncol, Genoa, Italy.	paolo.malatesta@unige.it	Ceresa, Davide/AAB-8518-2019; Appolloni, Irene/AAC-1629-2019; Malatesta, Paolo/J-3570-2012	Malatesta, Paolo/0000-0003-3045-3361; Alessandrini, Francesco/0000-0002-8450-848X; MENOTTI, LAURA/0000-0003-3277-5399; AVITABILE, ELISA/0000-0003-0328-2544	European Research Council (ERC) [340060]; Compagnia di San Paolo, Turin, Italy [2015.9834]; RFO (University of Bologna)	European Research Council (ERC)(European Research Council (ERC)); Compagnia di San Paolo, Turin, Italy(Compagnia di San Paolo); RFO (University of Bologna)	This work was supported by European Research Council (ERC) advanced grant number 340060 to GCF and PM; by Compagnia di San Paolo, Turin, Italy (grant no 2015.9834) "Terapie innovative per il glioblastoma" to PM; by RFO (University of Bologna) to LM and EA. We would like to thank Dr. Antonio Daga for providing human glioma-initiating cells.	Ahmed N, 2010, CLIN CANCER RES, V16, P474, DOI 10.1158/1078-0432.CCR-09-1322; Alessandrini F, 2016, J CANCER, V7, P1791, DOI 10.7150/jca.15564; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Appolloni I, 2019, CANCER LETT, V442, P213, DOI 10.1016/j.canlet.2018.10.006; Banelli B, 2015, CELL CYCLE, V14, P3418, DOI 10.1080/15384101.2015.1090063; BYSTRYN JC, 1978, J IMMUNOL, V120, P96; Campadelli-Fiume G, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8030063; Campadelli-Fiume G, 2011, REV MED VIROL, V21, P213, DOI 10.1002/rmv.691; Cheema TA, 2013, P NATL ACAD SCI USA, V110, P12006, DOI 10.1073/pnas.1307935110; Cody JJ, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/628697; Coffin RS, 2015, CURR OPIN VIROL, V13, P93, DOI 10.1016/j.coviro.2015.06.005; Delman KA, 2000, HUM GENE THER, V11, P2465, DOI 10.1089/10430340050207957; Dobin Alexander, 2015, Curr Protoc Bioinformatics, V51, DOI 10.1002/0471250953.bi1114s51; Duhem-Tonnelle V, 2010, J NEUROPATH EXP NEUR, V69, P606, DOI 10.1097/NEN.0b013e3181e00579; Edelstein Arthur, 2010, Curr Protoc Mol Biol, VChapter 14, DOI 10.1002/0471142727.mb1420s92; Favaro R, 2014, CANCER RES, V74, P1833, DOI 10.1158/0008-5472.CAN-13-1942; Gambini E, 2012, MOL THER, V20, P994, DOI 10.1038/mt.2012.22; Gulati S, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-18; Guo HY, 2015, MED MICROBIOL IMMUN, V204, P439, DOI 10.1007/s00430-015-0410-5; Hausler SFM, 2011, CANCER IMMUNOL IMMUN, V60, P1405, DOI 10.1007/s00262-011-1040-4; Hellums EK, 2005, NEURO-ONCOLOGY, V7, P213, DOI 10.1215/S1152851705000074; HIESIGER EM, 1993, J NEURO-ONCOL, V16, P93, DOI 10.1007/BF01324695; Hunter WD, 1999, J VIROL, V73, P6319, DOI 10.1128/JVI.73.8.6319-6326.1999; Kambara H, 2005, CANCER RES, V65, P2832, DOI 10.1158/0008-5472.CAN-04-3227; Kemeny N, 2006, HUM GENE THER, V17, P1214, DOI 10.1089/hum.2006.17.1214; Kimata H, 2006, ANN SURG ONCOL, V13, P1078, DOI 10.1245/ASO.2006.08.035; Korn T, 2017, NAT REV IMMUNOL, V17, P179, DOI 10.1038/nri.2016.144; Lambright ES, 2000, MOL THER, V2, P387, DOI 10.1006/mthe.2000.0133; Leoni V, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007209; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Liu BL, 2003, GENE THER, V10, P292, DOI 10.1038/sj.gt.3301885; Louis DN., 2016, WHO CLASSIFICATION T; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332; Menotti L, 2008, J VIROL, V82, P10153, DOI 10.1128/JVI.01133-08; Menotti L, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10070352; Mineo JF, 2007, J NEURO-ONCOL, V85, P281, DOI 10.1007/s11060-007-9424-1; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111, DOI 10.1016/S0065-2776(08)60652-5; Nabika Shinya, 2010, Hiroshima Journal of Medical Sciences, V59, P65; Nakao A, 2011, CANCER GENE THER, V18, P167, DOI 10.1038/cgt.2010.65; Parker JN, 2000, P NATL ACAD SCI USA, V97, P2208, DOI 10.1073/pnas.040557897; Patel DM, 2016, HUM GENE THER CL DEV, V27, P69, DOI 10.1089/humc.2016.031; Pritchard CC, 2001, P NATL ACAD SCI USA, V98, P13266, DOI 10.1073/pnas.221465998; R Core Team, 2017, R LANG ENV STAT COMP; Reisoli E, 2012, CANCER GENE THER, V19, P788, DOI 10.1038/cgt.2012.62; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Thomas ED, 2016, J OVARIAN RES, V9, DOI 10.1186/s13048-016-0282-3; Toda M, 1998, J IMMUNOL, V160, P4457; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Uchida H, 2013, MOL THER, V21, P561, DOI 10.1038/mt.2012.211; Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419; van der Woude LL, 2017, TRENDS CANCER, V3, P797, DOI 10.1016/j.trecan.2017.09.006; Veinalde R, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1285992	58	36	36	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2019	38	23					4467	4479		10.1038/s41388-019-0737-2	http://dx.doi.org/10.1038/s41388-019-0737-2			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IB4KM	30755732	Green Submitted			2022-12-17	WOS:000470240300003
J	Hepburn, AC; Steele, RE; Veeratterapillay, R; Wilson, L; Kounatidou, EE; Barnard, A; Berry, P; Cassidy, JR; Moad, M; El-Sherif, A; Gaughan, L; Mills, IG; Robson, CN; Heer, R				Hepburn, A. C.; Steele, R. E.; Veeratterapillay, R.; Wilson, L.; Kounatidou, E. E.; Barnard, A.; Berry, P.; Cassidy, J. R.; Moad, M.; El-Sherif, A.; Gaughan, L.; Mills, I. G.; Robson, C. N.; Heer, R.			The induction of core pluripotency master regulators in cancers defines poor clinical outcomes and treatment resistance	ONCOGENE			English	Article							ANDROGEN-RECEPTOR; PROSTATE-CANCER; STEM-CELLS; MESENCHYMAL TRANSITION; SERUM TRIIODOTHYRONINE; THYROID-HORMONE; TUMOR-GROWTH; METASTASIS; PLASTICITY; DIFFERENTIATION	Stem cell characteristics have been associated with treatment resistance and poor prognosis across many cancer types. The ability to induce and regulate the pathways that sustain these characteristic hallmarks of lethal cancers in a novel in vitro model would greatly enhance our understanding of cancer progression and treatment resistance. In this work, we present such a model, based simply on applying standard pluripotency/embryonic stem cell media alone. Core pluripotency stem cell master regulators (OCT4, SOX2 and NANOG) along with epithelial-mesenchymal transition (EMT) markers (Snail, Slug, vimentin and N-cadherin) were induced in human prostate, breast, lung, bladder, colorectal, and renal cancer cells. RNA sequencing revealed pathways activated by pluripotency inducing culture that were shared across all cancers examined. These pathways highlight a potential core mechanism of treatment resistance. With a focus on prostate cancer, the culture-based induction of core pluripotent stem cell regulators was shown to promote survival in castrate conditions-mimicking first line treatment resistance with hormonal therapies. This acquired phenotype was shown to be mediated through the upregulation of iodothyronine deiodinase DIO2, a critical modulator of the thyroid hormone signalling pathway. Subsequent inhibition of DIO2 was shown to supress expression of prostate specific antigen, the cardinal clinical biomarker of prostate cancer progression and highlighted a novel target for clinical translation in this otherwise fatal disease. This study identifies a new and widely accessible simple preclinical model to recreate and explore underpinning pathways of lethal disease and treatment resistance.	[Hepburn, A. C.; Wilson, L.; Kounatidou, E. E.; Barnard, A.; Berry, P.; Cassidy, J. R.; Moad, M.; Gaughan, L.; Robson, C. N.; Heer, R.] Newcastle Univ, Northern Inst Canc Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; [Steele, R. E.; Mills, I. G.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Prostate Canc UK Movember Ctr Excellence Prostate, Belfast BT9 7AE, Antrim, North Ireland; [Veeratterapillay, R.; Heer, R.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Urol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England; [El-Sherif, A.] Newcastle Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Dept Pathol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Mills, I. G.] Univ Oxford, Nuffield Dept Surg Sci, Oxford OX3 9DU, England	Newcastle University - UK; Queens University Belfast; Newcastle Freeman Hospital; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; University of Oxford	Hepburn, AC; Robson, CN; Heer, R (corresponding author), Newcastle Univ, Northern Inst Canc Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; Heer, R (corresponding author), Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Urol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England.	anastasia.hepburn@newcastle.ac.uk; c.n.robson@newcastle.ac.uk; rakesh.heer@newcastle.ac.uk	Mills, Ian/AAK-9292-2020	Mills, Ian/0000-0001-5347-5083	Prostate Cancer UK [PG12-24]; Cancer Research UK ECMC [C9380/A25138]; European Union [721746]	Prostate Cancer UK; Cancer Research UK ECMC; European Union(European Commission)	We are grateful for financial support by Prostate Cancer UK (PG12-24) and Cancer Research UK ECMC (C9380/A25138). This project also received funding from the European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant agreement No721746.	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Agudo J, 2018, IMMUNITY, V48, P271, DOI 10.1016/j.immuni.2018.02.001; Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012; Baccelli I, 2013, NAT BIOTECHNOL, V31, P539, DOI 10.1038/nbt.2576; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bishop JL, 2017, CANCER DISCOV, V7, P54, DOI 10.1158/2159-8290.CD-15-1263; Bluemn EG, 2017, CANCER CELL, V32, P474, DOI 10.1016/j.ccell.2017.09.003; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Fagnocchi L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11903; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gao D, 2014, CELL, V159, P176, DOI 10.1016/j.cell.2014.08.016; Glinsky GV, 2008, J CLIN ONCOL, V26, P2846, DOI 10.1200/JCO.2008.17.0266; Grillet F, 2017, GUT, V66, P1802, DOI 10.1136/gutjnl-2016-311447; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Harner-Foreman N, 2017, SCI REP-UK, V7, DOI 10.1038/srep40633; Hassan KA, 2009, CLIN CANCER RES, V15, P6386, DOI 10.1158/1078-0432.CCR-09-1105; Hepburn AC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050690; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jeter CR, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.41; Jeter CR, 2015, STEM CELLS, V33, P2381, DOI 10.1002/stem.2007; Khan A, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1708-7; Kolijn K, 2018, CANCER RES, V78, P4671, DOI 10.1158/0008-5472.CAN-17-3752; Korpal M, 2013, CANCER DISCOV, V3, P1030, DOI 10.1158/2159-8290.CD-13-0142; Krebs AM, 2017, NAT CELL BIOL, V19, P518, DOI 10.1038/ncb3513; Kregel S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053701; Lehrer S, 2001, PROSTATE CANCER P D, V4, P232, DOI 10.1038/sj.pcan.4500542; Lehrer S, 2002, J UROLOGY, V168, P2431, DOI 10.1016/S0022-5347(05)64161-4; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li P, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-55; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Malinowska K, 2009, PROSTATE, V69, P1109, DOI 10.1002/pros.20956; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marinho PA, 2015, SCI REP-UK, V5, DOI 10.1038/srep09834; Mathieu J, 2011, CANCER RES, V71, P4640, DOI 10.1158/0008-5472.CAN-10-3320; Moad M, 2013, EUR UROL, V64, P753, DOI 10.1016/j.eururo.2013.03.054; Moeller LC, 2013, ENDOCR-RELAT CANCER, V20, pR19, DOI 10.1530/ERC-12-0219; Mondul AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047730; Mu P, 2017, SCIENCE, V355, P84, DOI 10.1126/science.aah4307; Mukherjee R, 2011, BRIT J CANCER, V104, P1920, DOI 10.1038/bjc.2011.163; Murgai M, 2017, NAT MED, V23, P1176, DOI 10.1038/nm.4400; Navone NM, 2018, PROSTATE, V78, P1262, DOI 10.1002/pros.23701; PASCUAL A, 1987, ENDOCRINOLOGY, V120, P1089, DOI 10.1210/endo-120-3-1089; Poli V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03264-2; Rosene ML, 2010, ENDOCRINOLOGY, V151, P5961, DOI 10.1210/en.2010-0553; Schmidinger M, 2011, CANCER-AM CANCER SOC, V117, P534, DOI 10.1002/cncr.25422; Schoenhals M, 2009, BIOCHEM BIOPH RES CO, V383, P157, DOI 10.1016/j.bbrc.2009.02.156; Sedelaar JPM, 2009, PROSTATE, V69, P1724, DOI 10.1002/pros.21028; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Theodossiou C, 2000, AM J MED SCI, V319, P96, DOI 10.1097/00000441-200002000-00005; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Tran HD, 2014, CANCER RES, V74, P6330, DOI 10.1158/0008-5472.CAN-14-0923; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Williamson SC, 2013, BRIT J CANCER, V109, P950, DOI 10.1038/bjc.2013.399; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	60	36	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4412	4424		10.1038/s41388-019-0712-y	http://dx.doi.org/10.1038/s41388-019-0712-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30742096	Green Published, hybrid, Green Accepted			2022-12-17	WOS:000469339100015
J	Liu, Y; Long, YH; Wang, SQ; Zhang, YY; Li, YF; Mi, JS; Yu, CH; Li, DY; Zhang, JH; Zhang, XJ				Liu, Yan; Long, Yue-Hong; Wang, Shu-Qing; Zhang, Yuan-Yue; Li, Yu-Feng; Mi, Jiang-Sheng; Yu, Cheng-Hua; Li, De-Yan; Zhang, Jing-Hua; Zhang, Xiao-Jun			JMJD6 regulates histone H2A.X phosphorylation and promotes autophagy in triple-negative breast cancer cells via a novel tyrosine kinase activity	ONCOGENE			English	Article							IN-VIVO; PROTEIN; INHIBITOR; TRANSCRIPTION; COMPLEXES; ACTIVATOR; RECEPTOR; BINDING; DAMAGE	Overexpression of Jumonji domain-containing 6 (JMJD6) has been reported to be associated with more aggressive breast cancer characteristics. However, the precise role of JMJD6 in breast cancer development remains unclear. Here, we demonstrate that JMJD6 has intrinsic tyrosine kinase activity and can utilize ATP and GTP as phosphate donors to phosphorylate Y39 of histone H2A.X (H2A.X-Y39ph). High JMJD6 levels promoted autophagy in triple negative breast cancer (TNBC) cells by regulating the expression of autophagy-related genes. The JMJD6-H2A.X-Y39ph axis promoted TNBC cell growth via the autophagy pathway. We show that combined inhibition of JMJD6 kinase activity and autophagy efficiently decreases TNBC growth. Together, these findings suggest an effective strategy for TNBC treatment.	[Liu, Yan; Long, Yue-Hong; Zhang, Yuan-Yue] North China Univ Sci & Technol, Coll Life Sci, Tangshan, Peoples R China; [Liu, Yan; Zhang, Yuan-Yue; Li, Yu-Feng; Zhang, Jing-Hua] Tangshan Peoples Hosp, Inst Canc, Tangshan, Peoples R China; [Wang, Shu-Qing] Hosp North China Univ Sci & Technol, Tangshan, Peoples R China; [Mi, Jiang-Sheng; Yu, Cheng-Hua; Li, De-Yan; Zhang, Xiao-Jun] Peoples Hosp Zunhua, Zunhua, Peoples R China	North China University of Science & Technology	Zhang, JH (corresponding author), Tangshan Peoples Hosp, Inst Canc, Tangshan, Peoples R China.; Wang, SQ (corresponding author), Hosp North China Univ Sci & Technol, Tangshan, Peoples R China.; Zhang, XJ (corresponding author), Peoples Hosp Zunhua, Zunhua, Peoples R China.	044a141211@ncst.edu.cn; jhzhang_te@163.com; tech_ol@foxmail.com	zhang, jin/GXV-9154-2022		National Natural Science Foundation of China [81772834, 81302324, 81301779]; Science Fund for Distinguished Young Scholars of North China University of Science and Technology [JQ201704]; Scientific Research Matching Funds of North China University of Science and Technology; scientific research funds of Tangshan People's Hospital; Doctoral Research Project of North China University of Science and Technology	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Fund for Distinguished Young Scholars of North China University of Science and Technology; Scientific Research Matching Funds of North China University of Science and Technology; scientific research funds of Tangshan People's Hospital; Doctoral Research Project of North China University of Science and Technology	This work was primarily supported by the National Natural Science Foundation of China (grant numbers 81772834, 81302324, 81301779). Other support include: Science Fund for Distinguished Young Scholars of North China University of Science and Technology (JQ201704); Doctoral Research Project of North China University of Science and Technology. This work was also supported by the Scientific Research Matching Funds of North China University of Science and Technology and scientific research funds of Tangshan People's Hospital.	Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Aprelikova O, 2016, CLIN EPIGENETICS, V8, DOI 10.1186/s13148-016-0205-6; BELLARD M, 1989, METHOD ENZYMOL, V170, P317; Bellodi C, 2009, J CLIN INVEST, V119, P1109, DOI 10.1172/JCI35660; Chang BS, 2007, SCIENCE, V318, P444, DOI 10.1126/science.1145801; Cheng AW, 2013, CELL RES, V23, P1163, DOI 10.1038/cr.2013.122; Chittaranjan S, 2014, CLIN CANCER RES, V20, P3159, DOI 10.1158/1078-0432.CCR-13-2060; Cikala M, 2004, BMC CELL BIOL, V5, DOI 10.1186/1471-2121-5-26; Cook PJ, 2009, NATURE, V458, P591, DOI 10.1038/nature07849; Dragowska WH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076503; Druzinec D, 2013, ADV BIOCHEM ENG BIOT, V136, P65, DOI 10.1007/10_2013_205; Hahn P, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-293; HATHAWAY GM, 1983, METHOD ENZYMOL, V99, P317, DOI 10.1016/0076-6879(83)99067-5; Kung Hsing-Jien, 2011, Hormones & Cancer, V2, P38, DOI 10.1007/s12672-010-0053-3; Lee YF, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3200; Lefort S, 2014, AUTOPHAGY, V10, P2122, DOI 10.4161/15548627.2014.981788; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Liang DH, 2016, CANCER LETT, V376, P249, DOI 10.1016/j.canlet.2016.04.002; Liu X, 2010, J BIOL CHEM, V285, P9729, DOI 10.1074/jbc.M109.073452; Liu Y, 2016, FEBS J, V283, P4462, DOI 10.1111/febs.13951; Liu Y, 2012, J BIOL CHEM, V287, P41469, DOI 10.1074/jbc.M112.367847; Lowary PT, 1998, J MOL BIOL, V276, P19, DOI 10.1006/jmbi.1997.1494; Luger K, 1999, METHOD ENZYMOL, V304, P3; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Miller TE, 2017, NATURE, V547, P355, DOI 10.1038/nature23000; Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583; Pattingre S, 2004, METHOD ENZYMOL, V390, P17; Poulard C, 2016, ONCOTARGET, V7, P67532, DOI 10.18632/oncotarget.11376; Poulard C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126181; Quack I, 2006, P NATL ACAD SCI USA, V103, P14110, DOI 10.1073/pnas.0602587103; Rao R, 2012, MOL CANCER THER, V11, P973, DOI 10.1158/1535-7163.MCT-11-0979; Rio DC., 2013, COLD SPRING HARB PRO, V2013; RUBIN CS, 1975, ANNU REV BIOCHEM, V44, P831, DOI 10.1146/annurev.bi.44.070175.004151; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Steger DJ, 1998, P NATL ACAD SCI USA, V95, P12924, DOI 10.1073/pnas.95.22.12924; Thomas S, 2012, CANCER LETT, V325, P63, DOI 10.1016/j.canlet.2012.05.030; Tsai A, 2006, NAT PROTOC, V1, P2820, DOI 10.1038/nprot.2006.371; Vangimalla SS, 2017, BIOMOLECULES, V7, DOI 10.3390/biom7020041; Wang F, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001819; Webby CJ, 2009, SCIENCE, V325, P90, DOI 10.1126/science.1175865; Wolf A, 2013, BIOCHEM J, V453, P357, DOI 10.1042/BJ20130529; Wu T, 2014, CELL STEM CELL, V15, P281, DOI 10.1016/j.stem.2014.06.004; Xiao A, 2009, NATURE, V457, P57, DOI 10.1038/nature07668; Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032	46	36	37	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					980	997		10.1038/s41388-018-0466-y	http://dx.doi.org/10.1038/s41388-018-0466-y			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30185813				2022-12-17	WOS:000458624900005
J	Goroshchuk, O; Kolosenko, I; Vidarsdottir, L; Azimi, A; Palm-Apergi, C				Goroshchuk, Oksana; Kolosenko, Iryna; Vidarsdottir, Linda; Azimi, Alireza; Palm-Apergi, Caroline			Polo-like kinases and acute leukemia	ONCOGENE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; INHIBITOR BI 2536; BOX DOMAIN; IN-VITRO; ANTITUMOR-ACTIVITY; TARGETING PLK1; RNAI PRODRUGS; AML PATIENTS; CANCER	Acute leukemia is a common malignancy among children and adults worldwide and many patients suffer from chronic health issues using current therapeutic approaches. Therefore, there is a great need for the development of novel and more specific therapies with fewer side effects. The family of Polo-like kinases (Plks) is a group of five serine/threonine kinases that play an important role in cell cycle regulation and are critical targets for therapeutic invention. Plk1 and Plk4 are novel targets for cancer therapy as leukemic cells often express higher levels than normal cells. In contrast, Plk2 and Plk3 are considered to be tumor suppressors. Several small molecule inhibitors have been developed for targeting Plk1 inhibition. Despite reaching phase III clinical trials, one of the ATP-competitive Plk1 inhibitor, volasertib, did not induce an objective clinical response and even caused lethal side effects in some patients. In order to improve the specificity of the Plk1 inhibitors and reduce off-target side effects, novel RNA interference (RNAi)-based therapies have been developed. In this review, we summarize the mechanisms of action of the Plk family members in acute leukemia, describe preclinical studies and clinical trials involving Plk-targeting drugs and discuss novel approaches in Plk targeting.	[Goroshchuk, Oksana; Kolosenko, Iryna; Vidarsdottir, Linda; Azimi, Alireza; Palm-Apergi, Caroline] Karolinska Inst, Dept Lab Med, Clin Res Ctr, Stockholm, Sweden	Karolinska Institutet	Palm-Apergi, C (corresponding author), Karolinska Inst, Dept Lab Med, Clin Res Ctr, Stockholm, Sweden.	caroline.palm.apergi@ki.se		Palm Apergi, Caroline/0000-0003-2236-2099; Azimi, Alireza/0000-0002-7398-5643; Goroshchuk, Oksana/0000-0002-1585-1962; Vidarsdottir, Linda/0000-0003-3082-1320	Swedish Foundation for Strategic Research; Swedish Childhood Cancer Foundation	Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Childhood Cancer Foundation(European Commission)	This study was supported by the Swedish Foundation for Strategic Research (C.P.A.) and the Swedish Childhood Cancer Foundation (C.P.A.).	Abbou S, 2016, ANTICANCER RES, V36, P599; [Anonymous], 2008, WHO CLASSIFICATION T, V4th; [Anonymous], 2017, EU CLIN TRIALS REGIS, P1; Archambault V, 2017, CELL CYCLE, V16, P1220, DOI 10.1080/15384101.2017.1325043; Armstrong GT, 2014, J CLIN ONCOL, V32, P1218, DOI 10.1200/JCO.2013.51.1055; Bahassi EM, 2006, MUTAT RES-FUND MOL M, V596, P166, DOI 10.1016/j.mrfmmm.2005.12.002; Bassan R, 2011, J CLIN ONCOL, V29, P532, DOI 10.1200/JCO.2010.30.1382; Benetatos L, 2011, ANN HEMATOL, V90, P1037, DOI 10.1007/s00277-011-1193-4; Bin OY, 1997, J BIOL CHEM, V272, P28646, DOI 10.1074/jbc.272.45.28646; Burns TF, 2003, MOL CELL BIOL, V23, P5556, DOI 10.1128/MCB.23.16.5556-5571.2003; Casolaro A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058424; Chang JE, 2010, LEUKEMIA LYMPHOMA, V49, P2298; Cheng KY, 2003, EMBO J, V22, P5757, DOI 10.1093/emboj/cdg558; Cizmecioglu O, 2008, CELL CYCLE, V7, P3548, DOI 10.4161/cc.7.22.7071; Dasmahapatra G, 2013, CLIN CANCER RES, V19, P404, DOI 10.1158/1078-0432.CCR-12-2799; de Carcer G, 2011, CELL CYCLE, V10, P2255, DOI 10.4161/cc.10.14.16494; de Carcer G, 2011, MOL CELL BIOL, V31, P1225, DOI 10.1128/MCB.00607-10; De Kouchkovsky I, 2016, BLOOD CANCER J, V6, DOI 10.1038/bcj.2016.50; de Viron E, 2009, BRIT J HAEMATOL, V147, P641, DOI 10.1111/j.1365-2141.2009.07900.x; Dinner S, 2016, J CELL BIOCHEM, V117, P1745, DOI 10.1002/jcb.25559; Dohner H, 2014, BLOOD, V124, P1426, DOI 10.1182/blood-2014-03-560557; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; Elia AEH, 2003, CELL, V115, P83, DOI 10.1016/S0092-8674(03)00725-6; Ferlay J, 2013, IARC CANCERBASE, P11; Fey MF, 2013, ANN ONCOL, V24, P138, DOI 10.1093/annonc/mdt320; Fournier M, 2017, MOL CELL ONCOL, V4, DOI 10.1080/23723556.2016.1270391; Girardi T, 2017, BLOOD, V129, P1113, DOI 10.1182/blood-2016-10-706465; Gjertsen BT, 2015, LEUKEMIA, V29, P11, DOI 10.1038/leu.2014.222; Gorlick R, 2014, PEDIATR BLOOD CANCER, V61, P158, DOI 10.1002/pbc.24616; Gustafsson G., 2013, CHILD CANC INCID SUR, V1984-2010, P1; Hartsink-Segers SA, 2013, HAEMATOLOGICA, V98, P1539, DOI 10.3324/haematol.2013.084434; Hoelzer D, 2016, ANN ONCOL, V27, pv69, DOI 10.1093/annonc/mdw025; HOLTRICH U, 1994, P NATL ACAD SCI USA, V91, P1736, DOI 10.1073/pnas.91.5.1736; Hu CK, 2012, MOL BIOL CELL, V23, P2702, DOI 10.1091/mbc.E12-01-0058; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Ikezoe T, 2009, LEUKEMIA, V23, P1564, DOI 10.1038/leu.2009.94; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kanasty R, 2013, NAT MATER, V12, P967, DOI [10.1038/NMAT3765, 10.1038/nmat3765]; Kannan S, 2013, BLOOD, V122, DOI 10.1182/blood.V122.21.2912.2912; Kantarjian HM, 2000, J CLIN ONCOL, V18, P547, DOI 10.1200/JCO.2000.18.3.547; Kazazian K, 2017, CANCER RES, V77, P434, DOI 10.1158/0008-5472.CAN-16-2060; Kim MS, 2013, MOL CELLS, V36, P177, DOI 10.1007/s10059-013-0061-6; Kim SM, 2014, AMINO ACIDS, V46, P2595, DOI 10.1007/s00726-014-1798-8; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Kolosenko I, 2017, J CONTROL RELEASE, V261, P199, DOI 10.1016/j.jconrel.2017.07.002; Lee KS, 2015, TRENDS PHARMACOL SCI, V36, P858, DOI 10.1016/j.tips.2015.08.013; Li L, 2009, ACTA PHARMACOL SIN, V30, P1443, DOI 10.1038/aps.2009.141; Li S, 2018, MEDICINE, V97, P1; Li ZH, 2016, J CANCER, V7, P1125, DOI 10.7150/jca.14307; Lindon C, 2004, J CELL BIOL, V164, P233, DOI 10.1083/jcb.200309035; Liu D, 2012, J CELL BIOL, V198, P491, DOI 10.1083/jcb.201205090; Maniswami RR, 2018, EXPERT OPIN THER TAR, V22, P59, DOI 10.1080/14728222.2018.1410140; Marina M, 2014, FRONT BIOSCI-LANDMRK, V19, P352, DOI 10.2741/4212; Mason JM, 2014, CANCER CELL, V26, P163, DOI 10.1016/j.ccr.2014.05.006; McArthur K, 2017, ONCOTARGE; Meade BR, 2014, NAT BIOTECHNOL, V32, P1256, DOI 10.1038/nbt.3078; Metayer C, 2013, CANCER EPIDEMIOL, V37, P336, DOI 10.1016/j.canep.2012.12.011; Mross K, 2012, BRIT J CANCER, V107, P280, DOI 10.1038/bjc.2012.257; Muller-Tidow C, 2013, BRIT J HAEMATOL, V163, P214, DOI 10.1111/bjh.12518; Munch C, 2015, LEUKEMIA RES, V39, P462, DOI 10.1016/j.leukres.2015.01.007; NCNN Clinical Practice Guidelines in Oncology, 2015, NED TIJDSCHR TANDHEE, V109, P463; Nielsen SN, 2017, PEDIAT BLOOD CANC, V64, P1; Normandin K, 2016, SCI REP-UK, V6, DOI 10.1038/srep37581; Oliveira JC, 2014, PEDIATR BLOOD CANCER, V61, P1227, DOI 10.1002/pbc.24978; Olmos D, 2011, CLIN CANCER RES, V17, P3420, DOI 10.1158/1078-0432.CCR-10-2946; Osca-Gelis G, 2013, HAEMATOLOGICA, V98, pE95, DOI 10.3324/haematol.2013.084061; Pritchard-Jones K, 2014, CANCER-AM CANCER SOC, V120, P2388, DOI 10.1002/cncr.28745; Raab M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1395; Reaman Gregory H, 2011, PRACTICAL HDB, P336; Reindl W, 2009, CHEMBIOCHEM, V10, P1145, DOI 10.1002/cbic.200900059; Renner AG, 2009, BLOOD, V114, P659, DOI 10.1182/blood-2008-12-195867; Rudolph D, 2009, CLIN CANCER RES, V15, P3094, DOI 10.1158/1078-0432.CCR-08-2445; Sang MX, 2009, GENES CELLS, V14, P775, DOI 10.1111/j.1365-2443.2009.01309.x; Scharow A, 2016, CHEMBIOCHEM, V17, P759, DOI 10.1002/cbic.201500535; SIMMONS DL, 1992, MOL CELL BIOL, V12, P4164, DOI 10.1128/MCB.12.9.4164; Sobin L, 2000, INT CLASSIFICATION D; Spaniol K, 2011, ANTI-CANCER DRUG, V22, P531, DOI 10.1097/CAD.0b013e3283454526; Sparta AM, 2014, CELL CYCLE, V13, P2237, DOI 10.4161/cc.29267; Steegmaier M, 2007, CURR BIOL, V17, P316, DOI 10.1016/j.cub.2006.12.037; Syed N, 2006, BLOOD, V107, P250, DOI 10.1182/blood-2005-03-1194; Takai N, 2005, ONCOGENE, V24, P287, DOI 10.1038/sj.onc.1208272; Talati C, 2016, CRIT REV ONCOL HEMAT, V98, P200, DOI 10.1016/j.critrevonc.2015.10.013; Tao YF, 2017, ONCOL REP, V37, P1419, DOI 10.3892/or.2017.5417; Thomas DA, 1999, CANCER-AM CANCER SOC, V86, P1216, DOI 10.1002/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O; Tontsch-Grunt U, 2018, CANCER LETT, V421, P112, DOI 10.1016/j.canlet.2018.02.018; Valsasina B, 2012, MOL CANCER THER, V11, P1006, DOI 10.1158/1535-7163.MCT-11-0765; Wang NN, 2015, INT J MOL SCI, V16, P1266, DOI 10.3390/ijms16011266; Ward A, 2015, LEUKEMIA LYMPHOMA, V56, P2123, DOI 10.3109/10428194.2014.971407; Zitouni S, 2014, NAT REV MOL CELL BIO, V15, P433, DOI 10.1038/nrm3819; Zwaan CM, 2015, J CLIN ONCOL, V33, P2949, DOI 10.1200/JCO.2015.62.8289	90	36	37	6	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2019	38	1					1	16		10.1038/s41388-018-0443-5	http://dx.doi.org/10.1038/s41388-018-0443-5			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG2EL	30104712				2022-12-17	WOS:000454775900001
J	Huang, XJ; Xie, XH; Liu, P; Yang, L; Chen, B; Song, CL; Tang, HL; Xie, XM				Huang, Xiaojia; Xie, Xinhua; Liu, Peng; Yang, Lu; Chen, Bo; Song, Cailu; Tang, Hailin; Xie, Xiaoming			Adam12 and Inc015192 act as ceRNAs in breast cancer by regulating miR-34a	ONCOGENE			English	Article							LONG NONCODING RNA; FEEDBACK LOOP; METASTASIS; EXPRESSION; INVASION; CELLS; MICRORNAS; EMT	Long non-coding RNAs (lncRNAs) are reported to play vital roles in the progress of multiple cancers. However, the functions of lncRNAs in breast cancer remain to be discovered. We performed microarrays to identify the differentially expressed mRNAs and lncRNAs in breast tissues with or without miR-34a knockout. To explore the functions of the differentially expressed mRNA and lncRNA in breast cancer, we conducted a series of experiments. We found that Adam12 and lnc015192 were significantly upregulated in miR-34a knockout breast tissues. Knockdown of Adam12 and lnc015192 inhibited breast cancer cell migration, invasion, and epithelial-mesenchymal transition (EMT). Further experiments revealed that lnc015192 regulated Adam12 expression by functioning as a competing endogenous RNA (ceRNA) for miR-34a. In summary, our study demonstrate that Adam12 and lnc015192 promote breast cancer metastasis partly by sponging miR-34a through the ceRNA mechanism.	[Huang, Xiaojia; Xie, Xinhua; Liu, Peng; Yang, Lu; Chen, Bo; Song, Cailu; Tang, Hailin; Xie, Xiaoming] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University	Tang, HL; Xie, XM (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Breast Oncol, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.	tanghl@sysucc.org.cn; xiexm@sysucc.org.cn	Chen, Bo/GRS-7546-2022		National Natural Science Foundation of China [81672598, 81772961]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by funds from the National Natural Science Foundation of China (81672598 and 81772961).	Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012; Bouchie A, 2013, NAT BIOTECHNOL, V31, P577, DOI 10.1038/nbt0713-577; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Concepcion CP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002797; Dong R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.143; Duffy MJ, 2009, CLIN CANCER RES, V15, P1140, DOI 10.1158/1078-0432.CCR-08-1585; Eckert MA, 2017, J CELL SCI, V130, P2036, DOI 10.1242/jcs.198200; Frohlich C, 2006, CLIN CANCER RES, V12, P7359, DOI 10.1158/1078-0432.CCR-06-1066; Grelet S, 2017, NAT CELL BIOL, V19, P1105, DOI 10.1038/ncb3595; Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981; Jang E, 2016, BIOMATERIALS, V105, P12, DOI 10.1016/j.biomaterials.2016.07.036; Kallen AN, 2013, MOL CELL, V52, P101, DOI 10.1016/j.molcel.2013.08.027; Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166; Kong L, 2007, NUCLEIC ACIDS RES, V35, pW345, DOI 10.1093/nar/gkm391; Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Li LS, 2013, CLIN EXP MED, V13, P109, DOI 10.1007/s10238-012-0186-5; Li LS, 2012, MOL THER, V20, P2326, DOI 10.1038/mt.2012.201; Ling H, 2013, NAT REV DRUG DISCOV, V12, P847, DOI 10.1038/nrd4140; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu LF, 2017, ONCOTARGET, V8, P31386, DOI 10.18632/oncotarget.15607; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Rao VH, 2012, ONCOGENE, V31, P2888, DOI 10.1038/onc.2011.460; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Song YX, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00304-1; Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986; Wang JW, 2016, INT J CANCER, V139, P1327, DOI 10.1002/ijc.30173; Wang L, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt006; Wang LH, 2016, ELIFE, V5, DOI 10.7554/eLife.14620; Wiggins JF, 2010, CANCER RES, V70, P5923, DOI 10.1158/0008-5472.CAN-10-0655; Xiao XS, 2016, SCI REP-UK, V6, DOI 10.1038/srep21735; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Zhu M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14718	34	36	36	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6316	6326		10.1038/s41388-018-0410-1	http://dx.doi.org/10.1038/s41388-018-0410-1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30042416				2022-12-17	WOS:000452384400003
J	Liu, H; Chen, W; Zhi, X; Chen, EJ; Wei, T; Zhang, J; Shen, J; Hu, LQ; Zhao, B; Feng, XH; Bai, XL; Liang, TB				Liu, Hao; Chen, Wei; Zhi, Xiao; Chen, En-Jiang; Wei, Tao; Zhang, Jian; Shen, Jian; Hu, Li-Qiang; Zhao, Bin; Feng, Xin-Hua; Bai, Xue-Li; Liang, Ting-Bo			Tumor-derived exosomes promote tumor self-seeding in hepatocellular carcinoma by transferring miRNA-25-5p to enhance cell motility	ONCOGENE			English	Article							CANCER-CELLS; METASTASIS; RESISTANCE; MIGRATION; PROTEINS; VESICLES; INVASION; DENSIN-180; MICRORNAS; APOPTOSIS	Tumor self-seeding occurs when circulating malignant cells reinfiltrate the original tumor. The process may breed more aggressive tumor cells, which may contribute to cancer progression. In this study, we observed tumor self-seeding in mouse xenograft models of hepatocellular carcinoma (HCC) for the first time. We confirmed that circulating tumor cell uptake of tumor-derived exosomes, which are increasingly recognized as key instigators of cancer progression by facilitating cell-cell communication, promoted tumor self-seeding by enhancing the invasive and migration capability of recipient HCC cells. Horizontal transfer of exosomal microRNA-25-5p to anoikis-resistant HCC cells significantly enhanced their migratory and invasive abilities, whereas inhibiting microRNA-25-5p alleviated these effects. Our experiments delineate an exosome-based novel pathway employed by functional microRNA from the original tumor cells that can influence the biological fate of circulating tumor cells.	[Liu, Hao; Chen, Wei; Zhi, Xiao; Chen, En-Jiang; Wei, Tao; Zhang, Jian; Shen, Jian; Hu, Li-Qiang; Bai, Xue-Li; Liang, Ting-Bo] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Zhejiang, Peoples R China; [Liu, Hao; Chen, Wei; Zhi, Xiao; Chen, En-Jiang; Wei, Tao; Zhang, Jian; Shen, Jian; Hu, Li-Qiang; Bai, Xue-Li; Liang, Ting-Bo] Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Zhejiang, Peoples R China; [Zhao, Bin; Feng, Xin-Hua] Zhejiang Univ, Life Sci Inst, Hangzhou, Zhejiang, Peoples R China; [Zhao, Bin; Feng, Xin-Hua] Zhejiang Univ, Innovat Ctr Cell Signaling Network, Hangzhou, Zhejiang, Peoples R China	Zhejiang University; Zhejiang University; Zhejiang University	Liang, TB (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Zhejiang, Peoples R China.; Liang, TB (corresponding author), Zhejiang Prov Key Lab Pancreat Dis, Hangzhou, Zhejiang, Peoples R China.	liangtingbo@zju.edu.cn	Chen, Wei/X-6211-2019		National Natural Science Foundation of China [81472212]; 973 Program of China [2014CB542101]; Key Program of Medical Scientific Research Foundation of Zhejiang Province, China [WKJ-ZJ-1410]; Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China [2014ZZ007]; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 973 Program of China(National Basic Research Program of China); Key Program of Medical Scientific Research Foundation of Zhejiang Province, China; Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China; Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents	This work was supported by the National Natural Science Foundation of China (No. 81472212), 973 Program of China (No. 2014CB542101), Key Program of Medical Scientific Research Foundation of Zhejiang Province, China (No. WKJ-ZJ-1410), Key Program of Administration of Traditional Chinese Medicine of Zhejiang Province, China (No. 2014ZZ007) and Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents.	Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Atay S, 2014, P NATL ACAD SCI USA, V111, P711, DOI 10.1073/pnas.1310501111; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Dondossola E, 2012, CANCER RES, V72, P449, DOI 10.1158/0008-5472.CAN-11-2944; Ekstrom EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Harris DA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117495; Hedlund M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016899; Heikkila E, 2007, MOL CELL BIOCHEM, V305, P9, DOI 10.1007/s11010-007-9522-6; Hendrix A, 2010, CANCER RES, V70, P9533, DOI 10.1158/0008-5472.CAN-10-3248; Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756; Izawa I, 2002, J BIOL CHEM, V277, P5345, DOI 10.1074/jbc.M110052200; Janikashvili N, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/430394; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kosaka N, 2010, J BIOL CHEM, V285, P17442, DOI 10.1074/jbc.M110.107821; Li BS, 2015, ONCOGENE, V34, P2556, DOI 10.1038/onc.2014.214; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Lv MM, 2014, TUMOR BIOL, V35, P10773, DOI 10.1007/s13277-014-2377-z; Maluccio M, 2012, CA-CANCER J CLIN, V62, P394, DOI 10.3322/caac.21161; McKenzie AJ, 2016, CELL REP, V15, P978, DOI 10.1016/j.celrep.2016.03.085; Meister G, 2013, NAT REV GENET, V14, P447, DOI 10.1038/nrg3462; Melo SA, 2014, CANCER CELL, V26, P707, DOI 10.1016/j.ccell.2014.09.005; Mineo M, 2012, ANGIOGENESIS, V15, P33, DOI 10.1007/s10456-011-9241-1; PAGET S, 1989, CANCER METAST REV, V8, P98; Park JE, 2010, MOL CELL PROTEOMICS, V9, P1085, DOI 10.1074/mcp.M900381-MCP200; Razumilava N, 2012, HEPATOLOGY, V55, P465, DOI 10.1002/hep.24698; Robison AJ, 2005, J BIOL CHEM, V280, P35329, DOI 10.1074/jbc.M502191200; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Wang CR, 2015, ONCOTARGET, V6, P36231, DOI 10.18632/oncotarget.4740; Zhang HY, 2012, ONCOL REP, V27, P594, DOI 10.3892/or.2011.1530; Zhang Y, 2013, J CANCER RES CLIN, V140, P329; Zhang YN, 2006, J BIOL CHEM, V281, P22299, DOI 10.1074/jbc.M602902200; Zhang ZY, 2008, CANCER LETT, V267, P106, DOI 10.1016/j.canlet.2008.03.010; Zhou HL, 2014, RNA, V20, P1431, DOI 10.1261/rna.045757.114; Zhou WY, 2014, CANCER CELL, V25, P501, DOI 10.1016/j.ccr.2014.03.007	37	36	38	2	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 6	2018	37	36					4964	4978		10.1038/s41388-018-0309-x	http://dx.doi.org/10.1038/s41388-018-0309-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GS6QR	29786077				2022-12-17	WOS:000443823600005
J	Gates, LA; Gu, GW; Chen, Y; Rohira, AD; Lei, JT; Hamilton, RA; Yu, Y; Lonard, DM; Wang, J; Wang, SP; Edwards, DG; Lavere, PF; Shao, JY; Yi, P; Jain, A; Jung, SY; Malovannaya, A; Li, SQ; Shao, JY; Roeder, RG; Ellis, MJ; Qin, J; Fuqua, SAW; O'Malley, BW; Foulds, CE				Gates, Leah A.; Gu, Guowei; Chen, Yue; Rohira, Aarti D.; Lei, Jonathan T.; Hamilton, Ross A.; Yu, Yang; Lonard, David M.; Wang, Jin; Wang, Shu-Ping; Edwards, David G.; Lavere, Philip F.; Shao, Jiangyong; Yi, Ping; Jain, Antrix; Jung, Sung Yun; Malovannaya, Anna; Li, Shunqiang; Shao, Jieya; Roeder, Robert G.; Ellis, Matthew J.; Qin, Jun; Fuqua, Suzanne A. W.; O'Malley, Bert W.; Foulds, Charles E.			Proteomic profiling identifies key coactivators utilized by mutant ER alpha proteins as potential new therapeutic targets	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; ESR1 MUTATIONS; ENDOCRINE RESISTANCE; GENETIC SCREENS; PROTEASOME; RECRUITMENT; INHIBITOR; REVEALS; DNA	Approximately 75% of breast cancers are estrogen receptor alpha (ER alpha)-positive and are treatable with endocrine therapies, but often patients develop lethal resistant disease. Frequent mutations (10-40%) in the ligand-binding domain (LBD) codons in the gene encoding ER alpha (ESR1) have been identified, resulting in ligand-independent, constitutively active receptors. In addition, ESR1 chromosomal translocations can occur, resulting in fusion proteins that lack the LBD and are entirely unresponsive to all endocrine treatments. Thus, identifying coactivators that bind to these mutant ERa proteins may offer new therapeutic targets for endocrine-resistant cancer. To define coactivator candidate targets, a proteomics approach was performed profiling proteins recruited to the two most common ER alpha LBD mutants, Y537S and D538G, and an ESR1-YAP1 fusion protein. These mutants displayed enhanced coactivator interactions as compared to unliganded wild-type ER alpha. Inhibition of these coactivators decreased the ability of ESR1 mutants to activate transcription and promote breast cancer growth in vitro and in vivo. Thus, we have identified specific coactivators that may be useful as targets for endocrine-resistant breast cancers.	[Gates, Leah A.; Gu, Guowei; Rohira, Aarti D.; Hamilton, Ross A.; Yu, Yang; Lonard, David M.; Wang, Jin; Lavere, Philip F.; Shao, Jiangyong; Yi, Ping; Jain, Antrix; Malovannaya, Anna; Qin, Jun; O'Malley, Bert W.; Foulds, Charles E.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Gates, Leah A.] Rockefeller Univ, Lab Chromatin Biol & Epigenet, New York, NY 10065 USA; [Gu, Guowei; Lei, Jonathan T.; Edwards, David G.; Ellis, Matthew J.; Fuqua, Suzanne A. W.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Chen, Yue] Adrienne Helis Malvin Med Res Fdn, New Orleans, LA 70130 USA; [Lei, Jonathan T.; Ellis, Matthew J.] Baylor Coll Med, Interdept Grad Program Translat Biol & Mol Med, Houston, TX 77030 USA; [Wang, Jin] Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; [Wang, Jin] Baylor Coll Med, Ctr Drug Discovery, Houston, TX 77030 USA; [Wang, Shu-Ping; Roeder, Robert G.] Rockefeller Univ, Lab Biochem & Mol Biol, New York, NY 10065 USA; [Jung, Sung Yun; Malovannaya, Anna; Qin, Jun] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Li, Shunqiang; Shao, Jieya] Washington Univ, Sch Med, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA; [Ellis, Matthew J.; Fuqua, Suzanne A. W.; O'Malley, Bert W.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Foulds, Charles E.] Baylor Coll Med, Ctr Precis Environm Hlth, Houston, TX 77030 USA	Baylor College of Medicine; Rockefeller University; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Rockefeller University; Baylor College of Medicine; Washington University (WUSTL); Baylor College of Medicine; Baylor College of Medicine	Foulds, CE (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.; Foulds, CE (corresponding author), Baylor Coll Med, Ctr Precis Environm Hlth, Houston, TX 77030 USA.	foulds@bcm.edu	Jain, Antrix/AEB-7319-2022; Wang, Jin/AAC-7292-2019; Wang, Shu-Ping/S-4379-2018	Jain, Antrix/0000-0002-2815-3645; Wang, Jin/0000-0003-3625-7919; Wang, Shu-Ping/0000-0002-5895-1269; Lei, Jonathan/0000-0002-0209-8051; Jung, Sung Yun/0000-0003-1521-7977; Malovannaya, Anna/0000-0003-2953-6485	NCI [P30 CA125123]; CPRIT [RP170005, RP150578, RR140033, RP150440, RP120732-P2, RP110784]; NIH [DK56338, CA125123, R01 HD008188, R01 HD007857, R01 CA207270, R01 CA072038, R01 GM115622, R01 CA207701, R21 CA213535, R01 DK071900, R01 CA178765, 1F31CA210385-01, T32 GM088129]; Susan G. Komen Foundation [PG12220321, CCR14300139]; Breast Cancer Research Foundation [17-055]; DOD [W81XWH-13-1-0285, W81XWH-16-1-0539]; Human Frontier Science Program Fellowship [LT000538/2011-L]; McNair Medical Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD007857, R01HD008188] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [F31CA210385, R01CA207701, R21CA213535, R01CA178765, R01CA072038, R01CA207270, P30CA125123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071900, P30DK056338] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM088129, R01GM115622] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CPRIT; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G. Komen Foundation(Susan G. Komen Breast Cancer Foundation); Breast Cancer Research Foundation; DOD(United States Department of Defense); Human Frontier Science Program Fellowship(Human Frontier Science Program); McNair Medical Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the following BCM cores (Tissue Culture, Monoclonal Antibody/Recombinant Protein and Mass Spectrometry Proteomics (funded by NCI P30 CA125123 and CPRIT RP170005), Gene Vector, Integrated Microscopy (funded by NIH (DK56338 and CA125123) and CPRIT (RP150578))), David Bader, Doug Chan, and Rainer Lanz. We acknowledge the joint participation with the Adrienne Helis Malvin Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with BCM and the Cancer Program. This work was supported by the NIH ((R01 HD008188 and R01 HD007857 to B.W.O.), (R01 CA207270 and R01 CA072038 to S.A.W.F), (R01 GM115622, R01 CA207701, and R21 CA213535 to J.W.), (R01 DK071900 and R01 CA178765 to R.G.R.), (1F31CA210385-01 to L.A.G.), and (T32 GM088129 to J.T.L.)), CPRIT ((RR140033 to M.J.E), (RP150440 and RP120732-P2 to S.A.W.F.), and (RP110784 to J.Q.)), Susan G. Komen Foundation ((PG12220321 to M.J.E.) and (CCR14300139 to Jieya Shao)), Breast Cancer Research Foundation (17-055 to S.A.W.F.), DOD ((W81XWH-13-1-0285 to B.W.O.) and (W81XWH-16-1-0539 to M.J.E.)), the Human Frontier Science Program Fellowship (LT000538/2011-L to S.P.W.), and the McNair Medical Foundation (M.J.E.).	Abmayr Susan M, 2006, Curr Protoc Pharmacol, VChapter 12, DOI [10.1002/0471142727.mb1201s75, 10.1002/0471141755.ph1203s35]; Alluri PG, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-2156; Boney-Montoya J, 2010, MOL ENDOCRINOL, V24, P346, DOI 10.1210/me.2009-0429; Bossi D, 2016, CANCER DISCOV, V6, P650, DOI 10.1158/2159-8290.CD-15-1200; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chandarlapaty S, 2016, JAMA ONCOL, V2, P1310, DOI 10.1001/jamaoncol.2016.1279; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Ciruelos E, 2014, BREAST, V23, P201, DOI 10.1016/j.breast.2014.01.016; Clatot F, 2016, ONCOTARGET, V7, P74448, DOI 10.18632/oncotarget.12950; Dawkins JBN, 2016, CANCER RES, V76, P4861, DOI 10.1158/0008-5472.CAN-16-0481; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Fanning Sean W, 2016, Elife, V5, DOI 10.7554/eLife.12792; Foulds CE, 2013, MOL CELL, V51, P185, DOI 10.1016/j.molcel.2013.06.007; Foulds Charles E, 2010, Mol Endocrinol, V24, P1090, DOI 10.1210/me.2009-0427; Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061; Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI [10.1126/scitranslmed.aab0021, 10.1126/scitranslmed.aac7551]; Gelsomino L, 2016, BREAST CANCER RES TR, V157, P253, DOI 10.1007/s10549-016-3829-5; Gu GW, 2015, BREAST CANCER RES TR, V150, P535, DOI 10.1007/s10549-015-3354-y; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Harrod A, 2017, ONCOGENE, V36, P2286, DOI 10.1038/onc.2016.382; Hartmaier RJ, 2018, ANN ONCOL, V29, P872, DOI 10.1093/annonc/mdy025; Jeong KW, 2012, MOL ENDOCRINOL, V26, P955, DOI 10.1210/me.2012-1066; Jeselsohn R, 2018, CANCER CELL, V33, P173, DOI 10.1016/j.ccell.2018.01.004; Jeselsohn R, 2014, CLIN CANCER RES, V20, P1757, DOI 10.1158/1078-0432.CCR-13-2332; Johnson AB, 2012, MOL CELL ENDOCRINOL, V348, P430, DOI 10.1016/j.mce.2011.04.021; Joseph JD, 2016, ELIFE, V5, DOI 10.7554/eLife.15828; Jozwik KM, 2016, CELL REP, V17, P2715, DOI 10.1016/j.celrep.2016.11.028; Kinyamu HK, 2008, MOL CARCINOGEN, V47, P845, DOI 10.1002/mc.20440; Lake MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044160; Lazennec G, 1997, MOL ENDOCRINOL, V11, P1375, DOI 10.1210/me.11.9.1375; Li SQ, 2013, CELL REP, V4, P1116, DOI 10.1016/j.celrep.2013.08.022; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Long WW, 2012, J CLIN INVEST, V122, P1869, DOI 10.1172/JCI61492; Mao CJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep34753; Massarweh S, 2007, CLIN CANCER RES, V13, P1950, DOI 10.1158/1078-0432.CCR-06-2540; Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Mo R, 2006, J BIOL CHEM, V281, P15714, DOI 10.1074/jbc.M513245200; Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917; Powers GL, 2010, ONCOGENE, V29, P1509, DOI 10.1038/onc.2009.434; Prenzel T, 2011, CANCER RES, V71, P5739, DOI 10.1158/0008-5472.CAN-11-1896; Raj GV, 2017, ELIFE, V6, DOI 10.7554/eLife.26857; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823; Scott GK, 2017, ONCOTARGET, V8, P83432, DOI 10.18632/oncotarget.12735; Shi L, 2011, P NATL ACAD SCI USA, V108, P7541, DOI 10.1073/pnas.1017374108; Song XZ, 2016, P NATL ACAD SCI USA, V113, P4970, DOI 10.1073/pnas.1604274113; Spoerke JM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11579; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Symmans WF, 2010, J CLIN ONCOL, V28, P4111, DOI 10.1200/JCO.2010.28.4273; Thaler S, 2015, INT J CANCER, V137, P686, DOI 10.1002/ijc.29404; Toska E, 2017, SCIENCE, V355, P1324, DOI 10.1126/science.aah6893; Toy W, 2017, CANCER DISCOV, V7, P277, DOI 10.1158/2159-8290.CD-15-1523; Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822; Van Asten K, 2014, ENDOCR-RELAT CANCER, V21, pR31, DOI 10.1530/ERC-13-0269; Wang SP, 2017, MOL CELL, V67, P308, DOI 10.1016/j.molcel.2017.06.028; Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981; Wardell SE, 2015, CLIN CANCER RES, V21, P5121, DOI 10.1158/1078-0432.CCR-15-0360; Weir HM, 2016, CANCER RES, V76, P3307, DOI 10.1158/0008-5472.CAN-15-2357; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; Wierer M, 2013, CELL REP, V3, P2021, DOI 10.1016/j.celrep.2013.05.024; Zhang JY, 2015, NAT MED, V21, P1190, DOI 10.1038/nm.3940; Zhang QX, 1997, CANCER RES, V57, P1244; Zhao YC, 2017, CANCER RES, V77, P5602, DOI 10.1158/0008-5472.CAN-17-1265	66	36	36	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 16	2018	37	33					4581	4598		10.1038/s41388-018-0284-2	http://dx.doi.org/10.1038/s41388-018-0284-2			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GQ5OV	29748621	Green Published, hybrid			2022-12-17	WOS:000441736700007
J	Liu, JY; Zeng, QH; Cao, PG; Xie, D; Yang, F; He, LY; Dai, YB; Li, JJ; Liu, XM; Zeng, HL; Fan, XJ; Liu, L; Zhu, YX; Gong, L; Cheng, Y; Zhou, JD; Hu, J; Bo, H; Xu, ZZ; Cao, K				Liu, J. Y.; Zeng, Q. H.; Cao, P. G.; Xie, D.; Yang, F.; He, L. Y.; Dai, Y. B.; Li, J. J.; Liu, X. M.; Zeng, H. L.; Fan, X. J.; Liu, L.; Zhu, Y. X.; Gong, L.; Cheng, Y.; Zhou, J. D.; Hu, J.; Bo, H.; Xu, Z. Z.; Cao, K.			SPAG5 promotes proliferation and suppresses apoptosis in bladder urothelial carcinoma by upregulating Wnt3 via activating the AKT/mTOR pathway and predicts poorer survival	ONCOGENE			English	Article							RADICAL CYSTECTOMY; SIGNALING PATHWAY; EAU GUIDELINES; CANCER; CHEMOTHERAPY; EXPRESSION; ASTRIN; PROGRESSION; RECURRENCE; PROTEINS	Sperm-associated antigen 5 (SPAG5) is involved in various biological processes. However, the roles of SPAG5 in bladder urothelial carcinoma (BUC) are unknown. This study showed that upregulation of SPAG5 was detected frequently in primary BUC tissues, and was associated with significantly worse survival among the 112 patients that underwent radical cystectomy (RC). Up and downregulating the expression of SPAG5 enhanced or inhibited, respectively, the proliferation of BUC cells in vitro and in vivo, and suppressed or enhanced, respectively, apoptosis in vitro and in vivo. Moreover, SPAG5 increased the resistance of BUC cells to chemotherapy-induced apoptosis. Mechanistic investigations showed that SPAG5 promotes proliferation and suppresses apoptosis in BUC at least partially via upregulating Wnt3 through activating the AKT/mTOR signaling pathway. The importance of the SPAG5/AKT-mTOR/Wnt3 axis identified in BUC cell models was confirmed via immunohistochemical analysis of a cohort of human BUC specimens that underwent RC. Collectively, our data suggested that in patients with BUC who underwent RC, high SPAG5 expression is associated with poor survival. In addition, targeting SPAG5 might represent a novel therapeutic strategy to improve the survival of patients with BUC.	[Liu, J. Y.; He, L. Y.; Dai, Y. B.] Cent South Univ, Xiangya Hosp 3, Dept Urol, Changsha, Hunan, Peoples R China; [Liu, J. Y.; He, L. Y.; Dai, Y. B.] Cent South Univ, Inst Prostate Dis, Changsha, Hunan, Peoples R China; [Zeng, Q. H.] Cent South Univ, Xiangya Hosp 3, Dept Dermatol, Changsha, Hunan, Peoples R China; [Cao, P. G.; Zhu, Y. X.; Gong, L.; Cao, K.] Cent South Univ, Xiangya Hosp 3, Dept Onol, Changsha, Hunan, Peoples R China; [Xie, D.] Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Guangdong, Peoples R China; [Xie, D.] State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China; [Yang, F.] Cent South Univ, Sch Publ Hlth, Changsha, Hunan, Peoples R China; [Li, J. J.; Zhou, J. D.] Cent South Univ, Xiangya Hosp 3, Dept Plast Surg, Changsha, Hunan, Peoples R China; [Liu, X. M.] Cent South Univ, Xiangya Hosp 3, Dept Gastroenterol, Changsha, Hunan, Peoples R China; [Zeng, H. L.] Hunan Key Lab Pharmacodynam & Safety Evaluat New, Changsha, Hunan, Peoples R China; [Fan, X. J.] Cent South Univ, Xiangya Hosp 3, Res Serv Off, Changsha, Hunan, Peoples R China; [Liu, L.] Cent South Univ, Xiangya Hosp 3, Outpatient Serv Off, Changsha, Hunan, Peoples R China; [Cheng, Y.] Cent South Univ, Sch Pharmaceut Sci, Dept Pharmacol, Changsha, Hunan, Peoples R China; [Hu, J.] Hunan Canc Hosp, Dept Tissue Bank, Changsha, Hunan, Peoples R China; [Bo, H.] Cent South Univ, Inst Reprod & Stem Cell Engn, Changsha, Hunan, Peoples R China; [Xu, Z. Z.] Hunan Canc Hosp, Dept Urol, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; Sun Yat Sen University; State Key Lab Oncology South China; Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Central South University	Cao, K (corresponding author), Cent South Univ, Xiangya Hosp 3, Dept Onol, Changsha, Hunan, Peoples R China.	CSUcaoke@163.com			Natural Science Foundation of China [81301688, 81572965, 81572689]; Innovation-Driven Project of Central South University [2017CX012]; "125 Talent Project" of the Third Xiangya Hospital of Central South University; "New Xiangya Talent Project" of the Third Xiangya Hospital of Central South University; New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University [JY201615]; Scientific Projects of Health and Family Planning Commision of Hunan Province [B2017034]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation-Driven Project of Central South University; "125 Talent Project" of the Third Xiangya Hospital of Central South University; "New Xiangya Talent Project" of the Third Xiangya Hospital of Central South University; New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University; Scientific Projects of Health and Family Planning Commision of Hunan Province	This work was supported by the Natural Science Foundation of China (Grant nos. 81301688, 81572965, and 81572689), the Innovation-Driven Project of Central South University (Grant no. 2017CX012), the "125 Talent Project" and "New Xiangya Talent Project" of the Third Xiangya Hospital of Central South University, the New Xiangya Talent Projects of the Third Xiangya Hospital of Central South University (Grant no. JY201615), and the Scientific Projects of Health and Family Planning Commision of Hunan Province (Grant no. B2017034).	Abdel-Fatah TMA, 2016, LANCET ONCOL, V17, P1004, DOI 10.1016/S1470-2045(16)00174-1; Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419; Babjuk M, 2017, EUR UROL, V71, P447, DOI 10.1016/j.eururo.2016.05.041; Bengochea A, 2008, BRIT J CANCER, V99, P143, DOI 10.1038/sj.bjc.6604422; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Buechler S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-243; Chang MS, 2001, BIOCHEM BIOPH RES CO, V287, P116, DOI 10.1006/bbrc.2001.5554; Chen WJ, 2017, ONCOTARGET, V8, P61282, DOI 10.18632/oncotarget.18058; Cornen S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0081843; Diamandis M, 2010, MOL CANCER RES, V8, P1175, DOI 10.1158/1541-7786.MCR-10-0264; Easton JB, 2006, ONCOGENE, V25, P6436, DOI 10.1038/sj.onc.1209886; Gao C, 2010, NAT CELL BIOL, V12, P781, DOI 10.1038/ncb2082; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Johansson I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078299; Kaufman DS, 2009, LANCET, V374, P239, DOI 10.1016/S0140-6736(09)60491-8; Kim M, 2008, J HEPATOL, V48, P780, DOI 10.1016/j.jhep.2007.12.020; Kim SE, 2007, CELL SIGNAL, V19, P511, DOI 10.1016/j.cellsig.2006.08.008; Leow JJ, 2014, EUR UROL, V66, P42, DOI 10.1016/j.eururo.2013.08.033; Liu PP, 2014, CELL DEATH DIFFER, V21, P124, DOI 10.1038/cdd.2013.131; Lotan Y, 2005, J CLIN ONCOL, V23, P6533, DOI 10.1200/JCO.2005.05.516; Lotan Y, 2013, EUR UROL, V64, P465, DOI 10.1016/j.eururo.2013.03.043; Mack GJ, 2001, P NATL ACAD SCI USA, V98, P14434, DOI 10.1073/pnas.261371298; Manning AL, 2010, EMBO J, V29, P3531, DOI 10.1038/emboj.2010.230; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Peng Y, 2014, CELL SIGNAL, V26, P2782, DOI 10.1016/j.cellsig.2014.08.021; Poppova L, 2016, BRIT J HAEMATOL, V175, P851, DOI 10.1111/bjh.14312; Samarin J, 2016, HEPATOLOGY, V63, P813, DOI 10.1002/hep.28357; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Siu MK, 2015, ONCOGENE, V34, P4767, DOI 10.1038/onc.2014.414; Slomovitz BM, 2012, CLIN CANCER RES, V18, P5856, DOI 10.1158/1078-0432.CCR-12-0662; Steele LP, 2006, CELL DEATH DIFFER, V13, P1564, DOI 10.1038/sj.cdd.4401846; Stein JP, 2001, J CLIN ONCOL, V19, P666, DOI 10.1200/JCO.2001.19.3.666; Sternberg CN, 2015, LANCET ONCOL, V16, P76, DOI 10.1016/S1470-2045(14)71160-X; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Thedieck K, 2013, CELL, V154, P859, DOI 10.1016/j.cell.2013.07.031; Valk K, 2010, ONCOLOGY-BASEL, V79, P283, DOI 10.1159/000322116; Witjes JA, 2017, EUR UROL, V71, P462, DOI 10.1016/j.eururo.2016.06.020; Yuan LJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.222	38	36	37	3	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					3937	3952		10.1038/s41388-018-0223-2	http://dx.doi.org/10.1038/s41388-018-0223-2			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29662193				2022-12-17	WOS:000439101300003
J	Zhang, YQ; Wang, SY; Kang, W; Liu, CX; Dong, YJ; Ren, FL; Wang, YY; Zhang, JL; Wang, GP; To, KF; Zhang, XJ; Sung, JY; Chang, ZJ; Yu, J				Zhang, Yanquan; Wang, Shiyan; Kang, Wei; Liu, Chunxiao; Dong, Yujuan; Ren, Fangli; Wang, Yinyin; Zhang, Jinglin; Wang, Guoping; To, Ka Fai; Zhang, Xueji; Sung, Joseph J. Y.; Chang, Zhijie; Yu, Jun			CREPT facilitates colorectal cancer growth through inducing Wnt/beta-catenin pathway by enhancing p300-mediated beta-catenin acetylation	ONCOGENE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; PROMOTES TUMOR-GROWTH; C-TERMINAL DOMAIN; TRANSCRIPTIONAL COACTIVATOR; CHROMOSOMAL GAINS; GENE-EXPRESSION; POOR-PROGNOSIS; CELL-CYCLE; PROGRESSION; P300/CBP	Using whole genome sequencing, we identified gene amplification of CREPT in colorectal cancer (CRC). In this study, we aim to clarify its clinical significance, biological effects, and mechanism in CRC. CREPT was upregulated in CRC cell lines and in 47.37% (72/152) of primary CRC tumors. Amplification of CREPT was detected in 48.28% (56/116) of primary CRC tumors, which was positively correlated with its overexpression (P < 0.001). Multivariate analysis showed that CRC patients with CREPT protein overexpression were significantly associated with poor disease-free survival (P < 0.05). CREPT significantly accelerated CRC cell proliferation and metastasis both in vitro and in vivo. RNA-sequencing (seq) analysis uncovered that the tumor-promoting effect by CREPT was attributed to enhancing Wnt/beta-catenin signaling. Using co-immunoprecipitation coupled with mass spectroscopy, we identified p300 protein was a novel CREPT interacting partner. CREPT greatly increased the interaction between p300 and beta-catenin, thus promoting p300-mediated beta-catenin acetylation and stabilization. Moreover, CREPT cooperated with p300, leading to elevated active histone acetylation markers H3K27ac and H4Ac and decreased repressive histone marker H3K9me3 at the promoters of Wnt downstream targets. In summary, CREPT plays a pivotal oncogenic role in colorectal carcinogenesis through promoting Wnt/beta-catenin pathway via cooperating with p300. CREPT may serve as a prognostic biomarker of patients with CRC.	[Zhang, Yanquan; Wang, Shiyan; Dong, Yujuan; Wang, Guoping; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Sha Tin, Hong Kong, Peoples R China; [Zhang, Yanquan; Wang, Shiyan; Dong, Yujuan; Wang, Guoping; Sung, Joseph J. Y.; Yu, Jun] Chinese Univ Hong Kong, Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Sha Tin, Hong Kong, Peoples R China; [Zhang, Yanquan; Liu, Chunxiao; Ren, Fangli; Wang, Yinyin; Chang, Zhijie] Tsinghua Univ, Sch Med, Beijing, Peoples R China; [Zhang, Yanquan; Liu, Chunxiao; Ren, Fangli; Wang, Yinyin; Chang, Zhijie] Tsinghua Univ, Sch Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing, Peoples R China; [Wang, Shiyan; Zhang, Xueji] Univ Sci & Technol Beijing, Sch Chem & Biol Engn, Res Ctr Bioengn & Sensing Technol, Beijing, Peoples R China; [Kang, Wei; Zhang, Jinglin; To, Ka Fai] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Sha Tin, Hong Kong, Peoples R China; [Dong, Yujuan] Chinese Univ Hong Kong, Dept Surg, Sha Tin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Tsinghua University; Tsinghua University; University of Science & Technology Beijing; Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Sha Tin, Hong Kong, Peoples R China.; Yu, J (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Li Ka Shing Inst Hlth Sci, Dept Med & Therapeut,State Key Lab Digest Dis, Sha Tin, Hong Kong, Peoples R China.; Chang, ZJ (corresponding author), Tsinghua Univ, Sch Med, Beijing, Peoples R China.; Chang, ZJ (corresponding author), Tsinghua Univ, Sch Life Sci, State Key Lab Biomembrane & Membrane Biotechnol, Beijing, Peoples R China.	zhijiec@tsinghua.edu.cn; junyu@cuhk.edu.hk	Yu, Jun/D-8569-2015; zhang, xueji/B-1904-2010; Zhang, Yanquan/D-5615-2017; KANG, Wei/C-5451-2016; zhang, xueji/ABE-6497-2020; Sung, Joseph J. Y./R-3203-2018; Dong, Yujuan/AAS-3467-2021; Wang, Yin/HCI-9352-2022; Chang, Zhijie/AAH-8109-2019	Yu, Jun/0000-0001-5008-2153; Zhang, Yanquan/0000-0003-3527-9972; KANG, Wei/0000-0002-4651-677X; zhang, xueji/0000-0002-0035-3821; Sung, Joseph J. Y./0000-0003-3125-5199; ZHANG, Jingwan/0000-0002-0344-3398; Chang, Zhijie/0000-0003-1567-3227	National Natural Science Foundation [81301775, 81230044, 81572728]; RGC-GRF Hong Kong [14106415, 14111216, 14163817]; 135 program project [2016YFC1303200]; National Key Research and Development Program [2016YFA0500301]; Shenzhen Virtual University Park Support Scheme	National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); RGC-GRF Hong Kong(Hong Kong Research Grants Council); 135 program project; National Key Research and Development Program; Shenzhen Virtual University Park Support Scheme	This project was supported by the National Natural Science Foundation (81301775, 81230044, 81572728), RGC-GRF Hong Kong (14106415, 14111216, 14163817), 135 program project (2016YFC1303200), National Key Research and Development Program (2016YFA0500301); Shenzhen Virtual University Park Support Scheme to CUHK Shenzhen Research Institute.	Carvalho B, 2009, GUT, V58, P79, DOI 10.1136/gut.2007.143065; Chan HM, 2001, J CELL SCI, V114, P2363; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Dancy BM, 2015, CHEM REV, V115, P2419, DOI 10.1021/cr500452k; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Ge XJ, 2009, MOL BIOL CELL, V20, P419, DOI 10.1091/mbc.E08-08-0792; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Jung HM, 2009, J CELL BIOCHEM, V106, P703, DOI 10.1002/jcb.22063; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Lu DD, 2012, CANCER CELL, V21, P92, DOI 10.1016/j.ccr.2011.12.016; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Ma JT, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174309; Meijer GA, 1998, J CLIN PATHOL, V51, P901, DOI 10.1136/jcp.51.12.901; Mosimann C, 2009, NAT REV MOL CELL BIO, V10, P276, DOI 10.1038/nrm2654; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Ni ZY, 2014, NAT STRUCT MOL BIOL, V21, P686, DOI 10.1038/nsmb.2853; Ni ZY, 2011, TRANSCR-AUSTIN, V2, P237, DOI 10.4161/trns.2.5.17803; Ren Fangli, 2014, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, V33, P401, DOI 10.1089/mab.2014.0043; Ried T, 1996, GENE CHROMOSOME CANC, V15, P234, DOI 10.1002/(SICI)1098-2264(199604)15:4<234::AID-GCC5>3.0.CO;2-2; Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052; She YG, 2014, INT J CLIN EXP PATHO, V7, P6596; Sun W, 2017, HEPATOLOGY, DOI [10.1002/hep.29750, DOI 10.1002/HEP.29750.]; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150; Wang S, 2015, ONCOGENE, V34, P2575, DOI 10.1038/onc.2014.201; Wang Y, 2014, ONCOL REP, V31, P1389, DOI 10.3892/or.2014.2990; Wolf D, 2002, J BIOL CHEM, V277, P25562, DOI 10.1074/jbc.M201196200; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Xie T, 2012, PLOS ONE, V7; Xu LX, 2016, GUT, V65, P635, DOI 10.1136/gutjnl-2014-308257; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zhang JW, 2016, GUT, V65, P1482, DOI 10.1136/gutjnl-2014-308614; Zhang YQ, 2014, J BIOL CHEM, V289, P22589, DOI 10.1074/jbc.M114.560979; Zheng GX, 2016, BIOCHEM BIOPH RES CO, V480, P436, DOI 10.1016/j.bbrc.2016.10.067	41	36	39	3	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3485	3500		10.1038/s41388-018-0161-z	http://dx.doi.org/10.1038/s41388-018-0161-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563608	hybrid, Green Published			2022-12-17	WOS:000436412500002
J	Shen, LL; Qu, X; Li, HC; Xu, CS; Wei, MY; Wang, QH; Ru, Y; Liu, B; Xu, YQ; Li, K; Hu, JB; Wang, LF; Ma, YZ; Li, MY; Lai, XF; Gao, L; Wu, KC; Yao, LB; Zheng, JY; Zhang, J				Shen, Liangliang; Qu, Xuan; Li, Huichen; Xu, Chunsheng; Wei, Mengying; Wang, Qinhao; Ru, Yi; Liu, Bei; Xu, Yuqiao; Li, Kai; Hu, Junbi; Wang, Lifeng; Ma, Yongzheng; Li, Mengyang; Lai, Xiaofeng; Gao, Lei; Wu, Kaichun; Yao, Libo; Zheng, Jianyong; Zhang, Jian			NDRG2 facilitates colorectal cancer differentiation through the regulation of Skp2-p21/p27 axis	ONCOGENE			English	Article							BETA-CATENIN; CELL-CYCLE; TUMOR-SUPPRESSOR; COLON-CARCINOMA; C-MYC; UBIQUITIN LIGASES; BREAST-CANCER; EXPRESSION; SKP2; PATHWAY	Poorly differentiated colorectal cancers (CRCs) are more aggressive and lack targeted therapies. We and others previously reported the predominant role of tumor-suppressor NDRG2 in promoting CRC differentiation, but the underlying mechanism is largely unknown. Herein, we demonstrate that NDRG2 induction of CRC cell differentiation is dependent on the repression of E3 ligase Skp2 activity. In patients and Ndrg2 knockout mice, NDRG2 and Skp2 are negatively correlated and associated with cell differentiation stage. Further, NDRG2 suppression of Skp2 contributes to the inductions and stabilizations of p21 and p27, which are Skp2 target proteins for degradation. The reduction of either p21 or p27 levels by shRNA can decrease NDRG2-induced AKP activity and resume cell growth inhibition, thus both p21 and p27 are required for NDRG2 effect on the promotion of cell differentiation in CRCs. The mechanistic study shows that NDRG2 suppresses beta-catenin nuclear translocation and decreases the occupancy of beta-catenin/TCF complex on Skp2 promoter, potentially through dephosphorylating GSK-3 beta. By subjecting a series of NDRG2 deletion mutants to Skp2 expression, the loss of NH2-terminal domain can completely abolish NDRG2-dependent differentiation induction. Supporting the biological significance of the reciprocal relationship between NDRG2 and Skp2, an NDRG2(low)/Skp2(high) gene expression signature correlates with poor CRC patient outcome and could be considered as a diagnostic marker of CRCs.	[Shen, Liangliang; Li, Huichen; Wei, Mengying; Wang, Qinhao; Ru, Yi; Wang, Lifeng; Ma, Yongzheng; Li, Mengyang; Lai, Xiaofeng; Yao, Libo; Zhang, Jian] Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Qu, Xuan] Shaanxi Univ Chinese Med, Xianyang, Peoples R China; [Xu, Chunsheng] 537 Hosp PLA, Dept Gen Surg, Baoji, Peoples R China; [Liu, Bei] Fourth Mil Med Univ, Tangdu Hosp, Dept Neurosurg, Xian, Shaanxi, Peoples R China; [Liu, Bei] Fourth Mil Med Univ, Tangdu Hosp, Inst Funct Brain Disorders, Xian, Shaanxi, Peoples R China; [Xu, Yuqiao] Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Xu, Yuqiao] Fourth Mil Med Univ, Xijing Hosp, Dept Pathol, Xian, Shaanxi, Peoples R China; [Li, Kai] Gen Hosp Xinjiang Mil Command, Dept Clin Lab, Xinjiang, Peoples R China; [Hu, Junbi] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Gastroenterol, Xian, Shaanxi, Peoples R China; [Gao, Lei] Wuhan Gen Hosp Guangzhou Mil Reg, Dept Urol, Wuhan, Hubei, Peoples R China; [Wu, Kaichun] Fourth Mil Med Univ, Natl Clin Res Ctr Digest Dis, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China; [Wu, Kaichun] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian, Shaanxi, Peoples R China; [Zheng, Jianyong] Fourth Mil Med Univ, Xijing Hosp, Dept Gastrointestinal Surg, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China	Air Force Military Medical University; Shaanxi University of Chinese Medicine; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University; Xi'an Jiaotong University; Air Force Military Medical University; Air Force Military Medical University; Air Force Military Medical University	Shen, LL; Zhang, J (corresponding author), Fourth Mil Med Univ, Dept Biochem & Mol Biol, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China.; Zheng, JY (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Gastrointestinal Surg, State Key Lab Canc Biol, Xian, Shaanxi, Peoples R China.	bioliangshen@fmmu.edu.cn; zhjy68@163.com; biozhangj@fmmu.edu.cn		Li, Mengyang/0000-0001-8973-0445	National Natural Science Foundation of China [31401161, 81230043, 31571437, 81502370, 81401069, 81770523, 81502210]; Founds for Creative Research Groups of China [81421003]; State Key Laboratory of Cancer Biology Project [CBSKL2017Z11]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Founds for Creative Research Groups of China; State Key Laboratory of Cancer Biology Project	This work was financially sponsored by grants from the National Natural Science Foundation of China (no. 31401161; no. 81230043; no. 31571437; no. 81502370; no. 81401069; no. 81770523; and no. 81502210), the Founds for Creative Research Groups of China (no. 81421003), and the State Key Laboratory of Cancer Biology Project (CBSKL2017Z11).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chen J, 1996, ONCOGENE, V13, P1395; Chu D, 2011, MOL CANCER THER, V10, P47, DOI 10.1158/1535-7163.MCT-10-0614; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Deng YC, 2003, INT J CANCER, V106, P342, DOI 10.1002/ijc.11228; Derwinger K, 2010, ACTA ONCOL, V49, P57, DOI 10.3109/02841860903334411; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Gao DM, 2009, NAT CELL BIOL, V11, P397, DOI 10.1038/ncb1847; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Guo YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077305; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Kang K, 2015, BIOCHEM BIOPH RES CO, V468, P611, DOI 10.1016/j.bbrc.2015.10.167; Kim SJ, 2014, CELL DEATH DIFFER, V21, P1769, DOI 10.1038/cdd.2014.88; Kim YJ, 2013, ONCOL REP, V30, P1890, DOI 10.3892/or.2013.2642; Kim YJ, 2009, CARCINOGENESIS, V30, P598, DOI 10.1093/carcin/bgp047; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Li X, 2007, CANCER RES, V67, P8716, DOI 10.1158/0008-5472.CAN-06-3731; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Lorentzen A, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-192; Marikawa Y, 1998, MECH DEVELOP, V77, P75, DOI 10.1016/S0925-4773(98)00134-8; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nakahata S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4393; Nakayama KI, 2005, SEMIN CELL DEV BIOL, V16, P323, DOI 10.1016/j.semcdb.2005.02.010; Ng RCL, 2014, CELL DEATH DIFFER, V21, P978, DOI 10.1038/cdd.2014.20; Pfeuty B, 2008, CELL CYCLE, V7, P3246, DOI 10.4161/cc.7.20.6853; PONCECASTANEDA MV, 1995, CANCER RES, V55, P1211; Qu X, 2014, J INVEST DERMATOL, V134, P159, DOI 10.1038/jid.2013.281; Shapira M, 2005, CANCER-AM CANCER SOC, V103, P1336, DOI 10.1002/cncr.20917; Shen L, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2013.48; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Shiohara M, 1997, LEUKEMIA LYMPHOMA, V26, P35, DOI 10.3109/10428199709109155; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tian YF, 2013, TUMOR BIOL, V34, P1107, DOI 10.1007/s13277-013-0652-z; Xu XY, 2015, ONCOTARGET, V6, P26161, DOI 10.18632/oncotarget.4544; Yao LB, 2008, ACTA BIOCH BIOPH SIN, V40, P625, DOI 10.1111/j.1745-7270.2008.00434.x; Zhang J, 2006, J BIOL CHEM, V281, P39159, DOI 10.1074/jbc.M605820200	41	36	36	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1759	1774		10.1038/s41388-017-0118-7	http://dx.doi.org/10.1038/s41388-017-0118-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29343851	Green Published, hybrid			2022-12-17	WOS:000428632600006
J	Chen, G; Zhang, B; Xu, H; Sun, Y; Shi, Y; Luo, Y; Jia, H; Wang, F				Chen, G.; Zhang, B.; Xu, H.; Sun, Y.; Shi, Y.; Luo, Y.; Jia, H.; Wang, F.			Suppression of Sirt1 sensitizes lung cancer cells to WEE1 inhibitor MK-1775-induced DNA damage and apoptosis	ONCOGENE			English	Article							STRAND BREAK REPAIR; MITOTIC CATASTROPHE; LYSINE ACETYLATION; ANTITUMOR-ACTIVITY; S-PHASE; KINASE; MK-1775; AZD1775; CYCLE; CHK1	Lung cancer treatment remains a challenge for clinical practice and new therapeutic approaches are urgently needed. Loss of functional WEE1 kinase causes DNA replication stress, DNA damage and unscheduled mitotic entry due to elevated CDK activity. The selective WEE1 inhibitor MK-1775 synergize with DNA-damaging agent to inhibit cancer cell growth. Here we report that inhibition of Sirt1 deacetylase through small interfering RNA or selective inhibitor Ex527 greatly enhances MK-1775-induced growth inhibition and apoptosis in human lung cancer cells. We further demonstrate that Sirt1 interacts and deacetylates homologous recombination (HR) repair machinery proteins, including NBS1 and Rad51. Inhibition of Sirt1 impairs HR repair activity, which causes unrepairable damage when combining MK-1775 and Ex527. Meanwhile, combination of MK-1775 and Ex527 induces cooperative antitumor activity in lung cancer xenograft model in vivo. Thus, our study provides a novel therapeutic strategy to optimize MK-1775 treatment efficiency in lung cancers.	[Chen, G.; Xu, H.; Sun, Y.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA; [Zhang, B.] Xi An Jiao Tong Univ, Dept Physiol & Pathophysiol, Sch Med, Xian, Shaanxi, Peoples R China; [Shi, Y.; Wang, F.] Xidian Univ, Sch Life Sci & Technol, Engn Res Ctr Mol & Neuro Imaging, Minist Educ, Xian, Shaanxi, Peoples R China; [Luo, Y.] Second Mil Med Univ, Changhai Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Jia, H.] Agr Univ Hebei, Dept Bioengn, Coll Food Sci & Technol, Baoding, Peoples R China	Emory University; Xi'an Jiaotong University; Xidian University; Naval Medical University; Hebei Agricultural University	Chen, G (corresponding author), Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA 30322 USA.; Wang, F (corresponding author), Xidian Univ, Sch Life Sci & Technol, Engn Res Ctr Mol & Neuro Imaging, Minist Educ, Xian, Shaanxi, Peoples R China.	guo.chen84@outlook.com; fwang@xidian.edu.cn	Chen, Guo/HGE-9902-2022; Xu, Haidong/Q-1095-2019; Sun, Youwei/I-1265-2018; Wang, Fu/S-7955-2017	Chen, Guo/0000-0001-8886-1873; Wang, Fu/0000-0001-9222-0833; Zhang, Beilei/0000-0003-1384-0175	National Natural Science Foundation of China [81772010, 81571721, 81301214]; National Basic Research and Development Program of China (973 Program) [2013CB733803]; Natural Science Basis Research Plan in Shaanxi Province of China [2016JM8016, 2013JQ4040]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research and Development Program of China (973 Program)(National Basic Research Program of China); Natural Science Basis Research Plan in Shaanxi Province of China	This work was supported by National Natural Science Foundation of China (No. 81772010, 81571721 and 81301214), The National Basic Research and Development Program of China (973 Program; No. 2013CB733803) and Natural Science Basis Research Plan in Shaanxi Province of China (Program No. 2016JM8016 and 2013JQ4040).	Aarts M, 2015, MOL CANCER THER, V14, P865, DOI 10.1158/1535-7163.MCT-14-0845; Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320; Beck H, 2010, J CELL BIOL, V188, P629, DOI 10.1083/jcb.200905059; Carrassa L, 2012, CELL CYCLE, V11, P2507, DOI 10.4161/cc.20899; Chaudhuri L, 2014, HAEMATOLOGICA, V99, P688, DOI 10.3324/haematol.2013.093187; Chen G, 2013, APPL MICROBIOL BIOT, V97, P4393, DOI 10.1007/s00253-012-4321-8; Chen G, 2012, INT J ONCOL, V40, P139, DOI 10.3892/ijo.2011.1210; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Chu WK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms6931; Do K, 2015, J CLIN ONCOL, V33, P3409, DOI 10.1200/JCO.2014.60.4009; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Guertin AD, 2013, MOL CANCER THER, V12, P1442, DOI 10.1158/1535-7163.MCT-13-0025; Hamer PCD, 2011, CLIN CANCER RES, V17, P4200, DOI 10.1158/1078-0432.CCR-10-2537; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Iorns E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005120; Jeggo PA, 2016, NAT REV CANCER, V16, P35, DOI 10.1038/nrc.2015.4; Jhuraney A, 2016, MOL CANCER THER, V15, P1669, DOI 10.1158/1535-7163.MCT-15-0182; Kreahling JM, 2012, MOL CANCER THER, V11, P174, DOI 10.1158/1535-7163.MCT-11-0529; KREAHLING JM, 2013, PLOS ONE, V8; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Leijen S, 2016, J CLIN ONCOL, V34, P4371, DOI 10.1200/JCO.2016.67.5991; Magnussen GI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038254; Mak JPY, 2014, ONCOTARGET, V5, P10546, DOI 10.18632/oncotarget.2508; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Masumoto H, 2005, NATURE, V436, P294, DOI 10.1038/nature03714; McCord RA, 2009, AGING-US, V1, P109, DOI 10.18632/aging.100011; Mir SE, 2010, CANCER CELL, V18, P244, DOI 10.1016/j.ccr.2010.08.011; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Osman AA, 2015, MOL CANCER THER, V14, P608, DOI 10.1158/1535-7163.MCT-14-0735-T; Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015; Tomimatsu N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4561; Vassilopoulos A, 2015, ONCOGENE, V34, P3023, DOI 10.1038/onc.2014.239; Wang G, 2015, CANCER LETT, V356, P656, DOI 10.1016/j.canlet.2014.10.015; Wang LK, 2012, NUCLEIC ACIDS RES, V40, pW376, DOI 10.1093/nar/gks437; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zhou L, 2015, LEUKEMIA, V29, P807, DOI 10.1038/leu.2014.296	40	36	38	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6863	6872		10.1038/onc.2017.297	http://dx.doi.org/10.1038/onc.2017.297			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28869605				2022-12-17	WOS:000418041800003
J	Guo, H; Zhu, Q; Yu, X; Merugu, SB; Mangukiya, HB; Smith, N; Li, Z; Zhang, B; Negi, H; Rong, R; Cheng, K; Wu, Z; Li, D				Guo, H.; Zhu, Q.; Yu, X.; Merugu, S. B.; Mangukiya, H. B.; Smith, N.; Li, Z.; Zhang, B.; Negi, H.; Rong, R.; Cheng, K.; Wu, Z.; Li, D.			Tumor-secreted anterior gradient-2 binds to VEGF and FGF2 and enhances their activities by promoting their homodimerization	ONCOGENE			English	Article							GROWTH-FACTOR; ANTIANGIOGENIC THERAPIES; MONOCLONAL-ANTIBODY; INTERSTITIAL FLUID; AGR2 EXPRESSION; ANGIOGENESIS; MICROENVIRONMENT; PATHWAYS; MECHANISMS; RESISTANCE	The importance of the tumor microenvironment in targeted anticancer therapies has been well recognized. Various protein factors participate in the cross-talk between tumor cells and non-malignant cells. Anterior gradient-2 (AGR2) is overexpressed in diverse human adenocarcinomas and it exists in both intracellular and extracellular spaces. Although intracellular AGR2 has been intensively investigated, the function of secreted AGR2, especially its exact mechanism of action is still poorly understood. Here we report that the secreted AGR2 promotes the angiogenesis and the invasion of vascular endothelial cells and fibroblasts by enhancing the activities of vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF2). Further study indicated that AGR2 directly binds to these extracellular signaling molecules, and enhances their homodimerization. The extracellular AGR2 activity can be blocked to reduce angiogenesis and inhibit tumor growth in vitro and in vivo by a monoclonal antibody targeting the AGR2 self-dimerization region, and combined treatment with bevacizumab produced maximum inhibition effect. In conclusion, our investigation reveals a mechanism that directly links the secreted AGR2 with extracellular signaling networks, and we propose that the secreted AGR2 is a blockable molecular target, which acts as a chaperon-like enhancer to VEGF and FGF2.	[Guo, H.; Zhu, Q.; Merugu, S. B.; Mangukiya, H. B.; Zhang, B.; Negi, H.; Rong, R.; Wu, Z.; Li, D.] Shanghai Jiao Tong Univ, Sch Pharm, 308-BLDG6,800 Dongchuan Rd, Shanghai 200240, Peoples R China; [Guo, H.; Zhu, Q.; Zhang, B.; Li, D.] Shanghai Jiao Tong Univ, Sch Pharm, Minist Educ, Engn Res Ctr Cell & Therapeut Antibody, Shanghai, Peoples R China; [Yu, X.] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Neurol, Shanghai, Peoples R China; [Smith, N.; Li, Z.] Univ Pittsburgh, Sch Med, Dept Mol Pharmacol & Chem Biol, Pittsburgh, PA USA; [Cheng, K.] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Resp Med, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Tongji University	Wu, Z; Li, D (corresponding author), Shanghai Jiao Tong Univ, Sch Pharm, 308-BLDG6,800 Dongchuan Rd, Shanghai 200240, Peoples R China.	wuzhenghua@sjtu.edu.cn; daweili@sjtu.edu.cn		Mangukiya, Hitesh/0000-0002-8460-4850	National Natural Science Foundation of China [81373319]; Shanghai Science and Technology Commission Foundation [14431903400]; Guangdong Major Science and Technology Projects Foundation [2012A080202014]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Commission Foundation; Guangdong Major Science and Technology Projects Foundation	This research was supported by National Natural Science Foundation of China No. 81373319; Shanghai Science and Technology Commission Foundation No. 14431903400; Guangdong Major Science and Technology Projects Foundation No. 2012A080202014.	Aberger F, 1998, MECH DEVELOP, V72, P115, DOI 10.1016/S0925-4773(98)00021-5; Abuharbeid S, 2006, INT J BIOCHEM CELL B, V38, P1463, DOI 10.1016/j.biocel.2005.10.017; Ahn SM, 2007, PROTEOM CLIN APPL, V1, P1004, DOI 10.1002/prca.200700217; Armes JE, 2013, PATHOLOGY, V45, P49, DOI 10.1097/PAT.0b013e32835bd561; Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392; Bamias A, 2012, CRIT REV ONCOL HEMAT, V84, P314, DOI 10.1016/j.critrevonc.2012.04.002; Brychtova V, 2015, SEMIN CANCER BIOL, V33, P16, DOI 10.1016/j.semcancer.2015.04.005; Brychtova V, 2011, CANCER LETT, V304, P1, DOI 10.1016/j.canlet.2010.12.023; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346; Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X; De Crescenzo G, 2006, J MOL BIOL, V355, P47, DOI 10.1016/j.jmb.2005.10.022; Edgell TA, 2010, CLIN SCI, V118, P717, DOI 10.1042/CS20090537; Fang H, 2013, CANCER RES, V73, P4965, DOI 10.1158/0008-5472.CAN-13-0661; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; Gavalas NG, 2013, INT J MOL SCI, V14, P15885, DOI 10.3390/ijms140815885; Gray TA, 2013, PROTEIN SCI, V22, P1266, DOI 10.1002/pro.2299; Hagedorn M, 2000, CRIT REV ONCOL HEMAT, V34, P89, DOI 10.1016/S1040-8428(00)00056-1; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Haslene-Hox H, 2014, BBA CLIN, V2, P18, DOI 10.1016/j.bbacli.2014.08.002; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Hong XY, 2013, CELL BIOCHEM BIOPHYS, V67, P1487, DOI 10.1007/s12013-013-9650-4; Hwang H, 2014, INTEGR BIOL-UK, V6, P267, DOI 10.1039/c3ib40183a; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Kim JY, 2015, J CONTROL RELEASE, V199, P122, DOI 10.1016/j.jconrel.2014.12.015; Kumar A, 2007, SCIENCE, V318, P772, DOI 10.1126/science.1147710; Li BH, 2013, CANCER RES, V73, P6471, DOI 10.1158/0008-5472.CAN-13-0657; Li DW, 2013, CANCER RES, V73, DOI 10.1158/1538-7445.AM2013-4320; Li ZQ, 2015, CANCER SCI, V106, P1041, DOI 10.1111/cas.12714; Lieu C, 2011, CLIN CANCER RES, V17, P6130, DOI 10.1158/1078-0432.CCR-11-0659; Moserle L, 2014, CANCER DISCOV, V4, P31, DOI 10.1158/2159-8290.CD-13-0199; Nadkarni NJ, 2013, CANCER LETT, V331, P99, DOI 10.1016/j.canlet.2012.12.016; Petrillo M, 2012, EXPERT OPIN INV DRUG, V21, P451, DOI 10.1517/13543784.2012.661715; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Ray Avijit, 2010, J Vis Exp, DOI 10.3791/1488; Rice GE, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-62; Schmitt J, 2012, CANCER TREAT REV, V38, P272, DOI 10.1016/j.ctrv.2011.06.004; Sounni NE, 2013, CLIN CHEM, V59, P85, DOI 10.1373/clinchem.2012.185363; Tassi E, 2001, J BIOL CHEM, V276, P40247, DOI 10.1074/jbc.M104933200; Teoh DGK, 2011, CANCER CONTROL, V18, P31, DOI 10.1177/107327481101800105; Tsuji T, 2015, CANCER RES, V75, P356, DOI 10.1158/0008-5472.CAN-14-1693; Wiggins HL, 2010, BIOTECHNIQUES, V48, P120, DOI 10.2144/000113353; Wiig H, 2003, AM J PHYSIOL-HEART C, V284, pH416, DOI 10.1152/ajpheart.00327.2002; Wu Zheng-Hua, 2010, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V26, P49; Xia Y, 2014, SCI REP UK, V4, P6031; Zhang X, 2008, ACTA PHARMACOL SIN, V29, P942, DOI 10.1111/j.1745-7254.2008.00830.x; Zweitzig DR, 2007, MOL CELL BIOCHEM, V306, P255, DOI 10.1007/s11010-007-9562-y	49	36	38	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 7	2017	36	36					5098	5109		10.1038/onc.2017.132	http://dx.doi.org/10.1038/onc.2017.132			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FF9XD	28481872				2022-12-17	WOS:000409371100002
J	Shi, Z; He, F; Chen, M; Hua, L; Wang, W; Jiao, S; Zhou, Z				Shi, Z.; He, F.; Chen, M.; Hua, L.; Wang, W.; Jiao, S.; Zhou, Z.			DNA-binding mechanism of the Hippo pathway transcription factor TEAD4	ONCOGENE			English	Article							ORGAN SIZE CONTROL; EMERGING ROLES; YAP; TEF-1; GENE; INSIGHTS; MOTIFS; DOMAIN; TAZ	TEA domain (TEAD) family transcription factors are key regulators in development, tissue homeostasis and cancer progression. TEAD4 acts as a critical downstream effector of the evolutionarily conserved Hippo signaling pathway. The well-studied oncogenic protein YAP forms a complex with TEAD4 to regulate gene transcription; so does the tumor suppressor VGLL4. Although it is known that TEAD proteins can bind promoter regions of target genes through the TEA domain, the specific and detailed mechanism of DNA recognition by the TEA domain remains partially understood. Here, we report the crystal structure of TEAD4 TEA domain in complex with a muscle-CAT DNA element. The structure revealed extensive interactions between the TEA domain and the DNA duplex involving both the major and minor grooves of DNA helix. The DNA recognition helix, a3 helix, determines the specificity of the TEA domain binding to DNA sequence. Structure-guided biochemical analysis identified two major binding sites on the interface of the TEA domain-DNA complex. Mutation of TEAD4 at either site substantially decreases its occupancy on the promoter region of target genes, and largely impaired YAP-induced TEAD4 transactivation and target gene transcription, leading to inhibition of growth and colony formation of gastric cancer cell HGC-27. Collectively, our work provides a structural basis for understanding the regulatory mechanism of TEAD-mediated gene transcription.	[Shi, Z.; He, F.; Chen, M.; Hua, L.; Wang, W.; Jiao, S.; Zhou, Z.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci,State Key Lab Cel, 320 Yue Yang Rd, Shanghai 200031, Peoples R China; [Zhou, Z.] ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; ShanghaiTech University	Zhou, Z (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci,State Key Lab Cel, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	zczhou@sibcb.ac.cn	Shi, Zhubing/F-9490-2010	Shi, Zhubing/0000-0002-9624-4960; He, Feng/0000-0002-6286-8134	Ministry of Science and Technology of China [2012CB910204]; National Natural Science Foundation of China [31270808, 31300734, 31470736, 31470868, 31600731, 91442125, 91542125]; Youth Innovation Promotion Association of Chinese Academy of Sciences; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences [2014KIP202]; Chinese Academy of Sciences [XDA12020342, XDB19020202]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Youth Innovation Promotion Association of Chinese Academy of Sciences; Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences(Knowledge Innovation Program of the Chinese Academy of SciencesChinese Academy of Sciences); Chinese Academy of Sciences(Chinese Academy of Sciences)	We thank the staff at beamline BL17U of Shanghai Synchrotron Radiation Facility (SSRF) for assistance with data collection. This work was supported by the 973 program of the Ministry of Science and Technology of China (2012CB910204), the National Natural Science Foundation of China (31270808, 31300734, 31470736, 31470868, 31600731, 91442125 and 91542125), the Youth Innovation Promotion Association of Chinese Academy of Sciences, the Knowledge Innovation Program of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences (2014KIP202), and the 'Strategic Priority Research Program' of the Chinese Academy of Sciences (XDA12020342 and XDB19020202).	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; ADRIANOPOULOS A, 1991, PLANT CELL, V3, P747, DOI 10.1105/tpc.3.8.747; Afonine PV, 2012, ACTA CRYSTALLOGR D, V68, P352, DOI 10.1107/S0907444912001308; Anbanandam A, 2006, P NATL ACAD SCI USA, V103, P17225, DOI 10.1073/pnas.0607171103; Aravind L, 2005, FEMS MICROBIOL REV, V29, P231, DOI 10.1016/j.fmrre.2004.12.008; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; Chan P, 2016, NAT CHEM BIOL, V12, P282, DOI [10.1038/NCHEMBIO.2036, 10.1038/nchembio.2036]; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Chen LM, 2010, GENE DEV, V24, P290, DOI 10.1101/gad.1865310; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493; Guo T, 2013, CELL RES, V23, P1201, DOI 10.1038/cr.2013.120; Jiao S, 2014, CANCER CELL, V25, P166, DOI 10.1016/j.ccr.2014.01.010; Koontz LM, 2013, DEV CELL, V25, P388, DOI 10.1016/j.devcel.2013.04.021; Lee DS, 2016, J MOL BIOL, V428, P2557, DOI 10.1016/j.jmb.2016.03.008; Li Z, 2010, GENE DEV, V24, P235, DOI 10.1101/gad.1865810; Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409; Maeda T, 2002, J BIOL CHEM, V277, P48889, DOI 10.1074/jbc.M206858200; MAR JH, 1988, P NATL ACAD SCI USA, V85, P6404, DOI 10.1073/pnas.85.17.6404; MAR JH, 1990, MOL CELL BIOL, V10, P4271, DOI 10.1128/MCB.10.8.4271; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Mo JS, 2015, NAT CELL BIOL, V17, P500, DOI 10.1038/ncb3111; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; NIKOVITS W, 1986, NUCLEIC ACIDS RES, V14, P3377, DOI 10.1093/nar/14.8.3377; Noland CL, 2016, STRUCTURE, V24, P179, DOI 10.1016/j.str.2015.11.005; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007; Pobbati AV, 2013, CANCER BIOL THER, V14, P390, DOI 10.4161/cbt.23788; Pobbati AV, 2012, STRUCTURE, V20, P1135, DOI 10.1016/j.str.2012.04.004; Shi ZB, 2015, ACTA BIOCH BIOPH SIN, V47, P29, DOI 10.1093/abbs/gmu107; Vaudin P, 1999, DEVELOPMENT, V126, P4807; Wang WQ, 2015, NAT CELL BIOL, V17, P490, DOI 10.1038/ncb3113; XIAO JH, 1987, EMBO J, V6, P3005, DOI 10.1002/j.1460-2075.1987.tb02606.x; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Zhang WJ, 2014, CELL RES, V24, P331, DOI 10.1038/cr.2014.10; Zhao B, 2011, NAT CELL BIOL, V13, P877, DOI 10.1038/ncb2303; Zhou YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010138	37	36	39	3	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4362	4369		10.1038/onc.2017.24	http://dx.doi.org/10.1038/onc.2017.24			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28368398				2022-12-17	WOS:000406360600012
J	Wang, T; Xu, X; Xu, Q; Ren, J; Shen, S; Fan, C; Hou, Y				Wang, T.; Xu, X.; Xu, Q.; Ren, J.; Shen, S.; Fan, C.; Hou, Y.			miR-19a promotes colitis-associated colorectal cancer by regulating tumor necrosis factor alpha-induced protein 3-NF-kappa B feedback loops	ONCOGENE			English	Article							NF-KAPPA-B; MOUSE MODEL; TNF-ALPHA; LINEAR POLYUBIQUITIN; DOWN-REGULATION; BREAST-CANCER; COLON-CANCER; A20; ACTIVATION; INHIBITION	Chronic inflammation is believed to have a crucial role in colon cancer development. MicroRNA (miRNA) deregulation is common in human colorectal cancers, but little is known regarding whether miRNA drives tumor progression by regulating inflammation. Here, we showed that miR-19a can promote colitis and colitis-associated colon cancer (CAC) development using a CAC mouse model and an acute colitis mouse model. Tumor necrosis factor-a (TNF-a) stimulation can increase miR-19a expression, and upregulated miR-19a can in turn activate nuclear factor (NF)-kappa B signaling and TNF-a production by targeting TNF alpha-induced protein 3 (TNFAIP3). miR-19a inhibition can also alleviate CAC in vivo. Moreover, the regulatory effects of miR-19a on TNFAIP3 and NF-kappa B signaling were confirmed using tumor samples from patients with colon cancer. These new findings demonstrate that miR-19a has a direct role in upregulating NF-kappa B signaling and that miR-19a has roles in inflammation and CAC.	[Wang, T.; Xu, Q.; Ren, J.; Shen, S.; Hou, Y.] Nanjing Univ, Sch Med, State Key Lab Pharmaceut Biotechnol, Div Immunol, Nanjing 210093, Jiangsu, Peoples R China; [Wang, T.; Shen, S.; Hou, Y.] Jiangsu Key Lab Mol Med, Nanjing, Jiangsu, Peoples R China; [Wang, T.] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Xu, X.; Fan, C.] Nanjing Univ, Sch Med, Jinling Hosp, Gen Surg, Nanjing 210093, Jiangsu, Peoples R China	Nanjing University; University of Texas System; UTMD Anderson Cancer Center; Nanjing University	Shen, S; Hou, Y (corresponding author), Nanjing Univ, Sch Med, State Key Lab Pharmaceut Biotechnol, Div Immunol, Nanjing 210093, Jiangsu, Peoples R China.; Fan, C (corresponding author), Nanjing Univ, Sch Med, Jinling Hosp, Gen Surg, Nanjing 210093, Jiangsu, Peoples R China.	shensn@nju.edu.cn; fancg2002@hotmail.com; yayihou@nju.edu.cn			National Natural Science Foundation of China [81572354, 81571800, 81371680]; Natural Science Foundation of Jiangsu Province [BK20161400]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province)	This work was partially supported by grants from the National Natural Science Foundation of China (81572354, 81571800, and 81371680) and Natural Science Foundation of Jiangsu Province (BK20161400).	Ahmed FE, 2014, EXPERT REV ANTICANC, V14, P463, DOI 10.1586/14737140.2014.869479; Bhaumik D, 2008, ONCOGENE, V27, P5643, DOI 10.1038/onc.2008.171; Bi LK, 2010, J BIOL CHEM, V285, P25969, DOI 10.1074/jbc.M110.131300; Burisch J, 2015, SCAND J GASTROENTERO, V50, P942, DOI 10.3109/00365521.2015.1014407; Cellura D, 2015, MOL CANCER RES, V13, P1095, DOI 10.1158/1541-7786.MCR-14-0466; Chen B, 2013, SCAND J GASTROENTERO, V48, P815, DOI 10.3109/00365521.2013.800991; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Fluckiger A, 2016, ONCOGENE, V35, P4611, DOI 10.1038/onc.2015.523; Gantier MP, 2012, NUCLEIC ACIDS RES, V40, P8048, DOI 10.1093/nar/gks521; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Guina T, 2015, ANN NY ACAD SCI, V1340, P95, DOI 10.1111/nyas.12734; Hamilton MP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3730; HAYASHITA Y, 2005, CANCER RES, V65, P9628, DOI [DOI 10.1158/0008-5472.CAN-05-2352, 10.1158/0008-5472.CAN-05-2352]; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Huang LL, 2015, SCI REP-UK, V5, DOI 10.1038/srep13350; Ishikawa TO, 2010, CARCINOGENESIS, V31, P729, DOI 10.1093/carcin/bgq002; Ito Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1315-9; Jiang H, 2014, AM J PATHOL, V184, P1355, DOI 10.1016/j.ajpath.2014.01.037; Jiang LL, 2012, J CLIN INVEST, V122, P33, DOI 10.1172/JCI58849; Jin LJ, 2014, BREAST CANCER RES TR, V146, P41, DOI 10.1007/s10549-014-2978-7; Jung SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3562; Kanaan Z, 2012, HUM MUTAT, V33, P551, DOI 10.1002/humu.22021; Kato M, 2009, NATURE, V459, P712, DOI 10.1038/nature07969; Kim SW, 2012, P NATL ACAD SCI USA, V109, P7865, DOI 10.1073/pnas.1200081109; Knudsen KN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140503; Landers CJ, 2002, GASTROENTEROLOGY, V123, P689, DOI 10.1053/gast.2002.35379; Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792; Liu KJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/867537; Liu M, 2011, INT J ONCOL, V38, P1013, DOI 10.3892/ijo.2011.924; Lu T, 2015, CANCER RES, V75, P3692, DOI 10.1158/0008-5472.CAN-15-1022; Ma HB, 2016, CANCER LETT, V376, P293, DOI 10.1016/j.canlet.2016.04.011; Mihailovich M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9725; Nakshatri H, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.569; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Shao L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062223; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Simpson LJ, 2014, NAT IMMUNOL, V15, P1162, DOI 10.1038/ni.3026; Skaug B, 2011, MOL CELL, V44, P559, DOI 10.1016/j.molcel.2011.09.015; Song LB, 2012, J CLIN INVEST, V122, P3563, DOI 10.1172/JCI62339; Su JL, 2010, CANCER RES, V70, P5096, DOI 10.1158/0008-5472.CAN-09-4148; Tokunaga F, 2012, EMBO J, V31, P3856, DOI 10.1038/emboj.2012.241; Verhelst K, 2012, EMBO J, V31, P3845, DOI 10.1038/emboj.2012.240; Vlantis K, 2011, J CLIN INVEST, V121, P2781, DOI 10.1172/JCI45349; Wang TT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043268; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wirtz S, 2007, NAT PROTOC, V2, P541, DOI 10.1038/nprot.2007.41; Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015; Zhang J, 2012, BRIT J CANCER, V107, P352, DOI 10.1038/bjc.2012.251; Zhu HQ, 2015, CARCINOGENESIS, V36, P1213, DOI 10.1093/carcin/bgv112	51	36	38	0	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2017	36	23					3240	3251		10.1038/onc.2016.468	http://dx.doi.org/10.1038/onc.2016.468			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW9WJ	27991929				2022-12-17	WOS:000402869800004
J	Hiraki, M; Maeda, T; Bouillez, A; Alam, M; Tagde, A; Hinohara, K; Suzuki, Y; Markert, T; Miyo, M; Komura, K; Ahmad, R; Rajabi, H; Kufe, D				Hiraki, M.; Maeda, T.; Bouillez, A.; Alam, M.; Tagde, A.; Hinohara, K.; Suzuki, Y.; Markert, T.; Miyo, M.; Komura, K.; Ahmad, R.; Rajabi, H.; Kufe, D.			MUC1-C activates BMI1 in human cancer cells	ONCOGENE			English	Article							POLYCOMB GROUP PROTEINS; EPITHELIAL-MESENCHYMAL TRANSITION; DNA-DAMAGE RESPONSE; STEM-CELLS; SELF-RENEWAL; TRANSCRIPTION FACTOR; H2A UBIQUITYLATION; SENESCENT CELLS; BETA-CATENIN; HISTONE H2A	B-cell-specific Moloney murine leukemia virus integration site 1 (BMI1) is a component of the polycomb repressive complex 1 (PRC1) complex that is overexpressed in breast and other cancers, and promotes self-renewal of cancer stem-like cells. The oncogenic mucin 1 (MUC1) C-terminal (MUC1-C) subunit is similarly overexpressed in human carcinoma cells and has been linked to their self-renewal. There is no known relationship between MUC1-C and BMI1 in cancer. The present studies demonstrate that MUC1-C drives BMI1 transcription by a MYC-dependent mechanism in breast and other cancer cells. In addition, we show that MUC1-C blocks miR-200c-mediated downregulation of BMI1 expression. The functional significance of this MUC1-C -> BMI1 pathway is supported by the demonstration that targeting MUC1-C suppresses BMI1-induced ubiquitylation of H2A and thereby derepresses homeobox HOXC5 and HOXC13 gene expression. Notably, our results further show that MUC1-C binds directly to BMI1 and promotes occupancy of BMI1 on the CDKN2A promoter. In concert with BMI1-induced repression of the p16(INK4a) tumor suppressor, we found that targeting MUC1-C is associated with induction of p16(INK4a) expression. In support of these results, analysis of three gene expresssion data sets demonstrated highly significant correlations between MUC1-C and BMI1 in breast cancers. These findings uncover a previously unrecognized role for MUC1-C in driving BMI1 expression and in directly interacting with this stem cell factor, linking MUC1-C with function of the PRC1 in epigenetic gene silencing.	[Hiraki, M.; Maeda, T.; Bouillez, A.; Alam, M.; Tagde, A.; Hinohara, K.; Suzuki, Y.; Markert, T.; Miyo, M.; Komura, K.; Ahmad, R.; Rajabi, H.; Kufe, D.] Harvard Med Sch, Dana Farber Canc Inst, Med Oncol, Boston, MA USA; [Suzuki, Y.] Osaka Police Hosp, Dept Gastroenterol Surg, Kitayama Cho 10-31 Tennoji, Osaka, Osaka 5430035, Japan; [Ahmad, R.] King Saud Univ, Coll Med, Riyadh, Saudi Arabia	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Osaka Police Hospital; King Saud University	Kufe, D (corresponding author), Dana Farber Canc Inst, Med Oncol, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu		Ahmad, Rehan/0000-0003-2612-2818	National Cancer Institute of the National Institutes of Health [CA97098, CA166480]; Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA097098, R01CA166480] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Lung Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants from the National Cancer Institute of the National Institutes of Health under award numbers CA97098 and CA166480 and by the Lung Cancer Research Foundation. The authors thank Dr Goberdhan P Dimri, Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington, DC for kindly providing the pGL-BMI1PrWT and pGL-BMI1PrMut reporter vectors.	Ahmad R, 2007, NAT CELL BIOL, V9, P1419, DOI 10.1038/ncb1661; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Alam M, MOL CANC RES; Alam M, 2015, MOL CANCER RES, V13, P449, DOI 10.1158/1541-7786.MCR-14-0363; Alam M, 2014, ONCOTARGET, V5, P2622, DOI 10.18632/oncotarget.1848; Alam M, 2013, J BIOL CHEM, V288, P30892, DOI 10.1074/jbc.M113.477158; Bouillez A, 2016, CANCER RES, V76, P1538, DOI 10.1158/0008-5472.CAN-15-1804; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Cao R, 2005, MOL CELL, V20, P845, DOI 10.1016/j.molcel.2005.12.002; Cho JH, 2013, J BIOL CHEM, V288, P3406, DOI 10.1074/jbc.M112.422931; Crea F, 2012, CRIT REV ONCOL HEMAT, V83, P184, DOI 10.1016/j.critrevonc.2011.10.007; de Napoles M, 2004, DEV CELL, V7, P663, DOI 10.1016/j.devcel.2004.10.005; Dimri M, 2016, ONCOTARGET, V7, P36220, DOI 10.18632/oncotarget.8811; Endoh M, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002774; Fleming A, 2004, CELL, V119, P449, DOI 10.1016/j.cell.2004.11.001; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Ginjala V, 2011, MOL CELL BIOL, V31, P1972, DOI 10.1128/MCB.00981-10; Hasegawa M, 2016, ONCOTARGET, V7, P11756, DOI 10.18632/oncotarget.7598; Hasegawa M, 2015, CLIN CANCER RES, V21, P2338, DOI 10.1158/1078-0432.CCR-14-3000; Hiraki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep26643; Hiraki M, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.5; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Huang R, 2011, FASEB J, V25, P4138, DOI 10.1096/fj.11-185033; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kazanets A, 2016, BBA-REV CANCER, V1865, P275, DOI 10.1016/j.bbcan.2016.04.001; Kharbanda A, 2014, CLIN CANCER RES, V20, P5423, DOI 10.1158/1078-0432.CCR-13-3168; Kharbanda A, 2014, ONCOTARGET, V5, P8893, DOI 10.18632/oncotarget.2360; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; KUFE D, 2009, CANCER BIOL THER, V8, P1201; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lin XZ, 2015, BIOMOLECULES, V5, P3396, DOI 10.3390/biom5043396; Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040; Mallo M, 2013, DEVELOPMENT, V140, P3951, DOI 10.1242/dev.068346; Meng S, 2010, J BIOL CHEM, V285, P33219, DOI 10.1074/jbc.M110.133686; Nacerddine K, 2012, J CLIN INVEST, V122, P1920, DOI 10.1172/JCI57477; Ohtsubo M, 2008, P NATL ACAD SCI USA, V105, P10396, DOI 10.1073/pnas.0800672105; Park IK, 2004, J CLIN INVEST, V113, P175, DOI 10.1172/JCI200420800; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Raina D, 2014, ONCOGENE, V33, P3422, DOI 10.1038/onc.2013.308; Raina D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135156; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Rajabi H, 2016, ONCOGENE, V35, P6439, DOI 10.1038/onc.2016.180; Rajabi H, 2014, ONCOGENE, V33, P1680, DOI 10.1038/onc.2013.114; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Richly H, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.84; Rizo A, 2009, BLOOD, V114, P1498, DOI 10.1182/blood-2009-03-209734; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Tagde A, 2016, ONCOTARGET, V7, P38974, DOI 10.18632/oncotarget.9777; Tagde A, 2016, BLOOD, V127, P2587, DOI 10.1182/blood-2015-07-659151; Takahashi H, 2015, ONCOGENE, V34, P5187, DOI 10.1038/onc.2014.442; Tam WL, 2013, NAT MED, V19, P1438, DOI 10.1038/nm.3336; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Wang YY, 2012, WORLD J SURG, V36, P1189, DOI 10.1007/s00268-012-1514-3; Wei JH, 2006, J BIOL CHEM, V281, P22537, DOI 10.1074/jbc.M600826200; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099	63	36	36	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2017	36	20					2791	2801		10.1038/onc.2016.439	http://dx.doi.org/10.1038/onc.2016.439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV3ZM	27893710	Green Accepted, Green Submitted			2022-12-17	WOS:000401697800002
J	Blomme, A; Costanza, B; de Tullio, P; Thiry, M; Van Simaeys, G; Boutry, S; Doumont, G; Di Valentin, E; Hirano, T; Yokobori, T; Gofflot, S; Peulen, O; Bellahcene, A; Sherer, F; Le Goff, C; Cavalier, E; Mouithys-Mickalad, A; Jouret, F; Cusumano, PG; Lifrange, E; Muller, RN; Goldman, S; Delvenne, P; De Pauw, E; Nishiyama, M; Castronovo, V; Turtoi, A				Blomme, A.; Costanza, B.; de Tullio, P.; Thiry, M.; Van Simaeys, G.; Boutry, S.; Doumont, G.; Di Valentin, E.; Hirano, T.; Yokobori, T.; Gofflot, S.; Peulen, O.; Bellahcene, A.; Sherer, F.; Le Goff, C.; Cavalier, E.; Mouithys-Mickalad, A.; Jouret, F.; Cusumano, P. G.; Lifrange, E.; Muller, R. N.; Goldman, S.; Delvenne, P.; De Pauw, E.; Nishiyama, M.; Castronovo, V.; Turtoi, A.			Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer	ONCOGENE			English	Article							TRAFFICKING; ENDOCYTOSIS; ENDOSOME; PROTEINS; CAVEOLAE; REVEALS; BIOLOGY; GROWTH; CELLS	Myoferlin is a multiple C2-domain-containing protein that regulates membrane repair, tyrosine kinase receptor function and endocytosis in myoblasts and endothelial cells. Recently it has been reported as overexpressed in several cancers and shown to contribute to proliferation, migration and invasion of cancer cells. We have previously demonstrated that myoferlin regulates epidermal growth factor receptor activity in breast cancer. In the current study, we report a consistent overexpression of myoferlin in triple-negative breast cancer cells (TNBC) over cells originating from other breast cancer subtypes. Using a combination of proteomics, metabolomics and electron microscopy, we demonstrate that myoferlin depletion results in marked alteration of endosomal system and metabolism. Mechanistically, myoferlin depletion caused impaired vesicle traffic that led to a misbalance of saturated/unsaturated fatty acids. This provoked mitochondrial dysfunction in TNBC cells. As a consequence of the major metabolic stress, TNBC cells rapidly triggered AMP activated protein kinase-mediated metabolic reprogramming to glycolysis. This reduced their ability to balance between oxidative phosphorylation and glycolysis, rendering TNBC cells metabolically inflexible, and more sensitive to metabolic drug targeting in vitro. In line with this, our in vivo findings demonstrated a significantly reduced capacity of myoferlin-deficient TNBC cells to metastasise to lungs. The significance of this observation was further supported by clinical data, showing that TNBC patients whose tumors overexpress myoferlin have worst distant metastasis-free and overall survivals. This novel insight into myoferlin function establishes an important link between vesicle traffic, cancer metabolism and progression, offering new diagnostic and therapeutic concepts to develop treatments for TNBC patients.	[Blomme, A.; Costanza, B.; Peulen, O.; Bellahcene, A.; Castronovo, V.; Turtoi, A.] Univ Liege, Metastasis Res Lab, GIGA Canc, Ave Hop 3,Tour Patho 4, B-4000 Liege, Belgium; [Costanza, B.; Yokobori, T.; Nishiyama, M.; Turtoi, A.] Gunma Univ, Dept Mol Pharmacol & Oncol, Grad Sch Med, Gunma, Japan; [de Tullio, P.] Univ Liege, CIRM, Liege, Belgium; [Thiry, M.] Univ Liege, Lab Cell Biol, Fac Sci, Liege, Belgium; [Van Simaeys, G.; Boutry, S.; Doumont, G.; Sherer, F.; Muller, R. N.; Goldman, S.] Ctr Microscopy & Mol Imaging, Charleroi, Belgium; [Van Simaeys, G.; Goldman, S.] Univ Libre Bruxelles, Dept Nucl Med, Hop Erasme, Brussels, Belgium; [Boutry, S.; Muller, R. N.] Univ Mons, Dept Gen Organ & Biomed Chem, NMR & Mol Imaging Lab, Mons, Belgium; [Di Valentin, E.] Univ Liege, GIGA Viral Vectors Platform, Liege, Belgium; [Hirano, T.] Gunma Univ, Dept Mol Pharmacol & Oncol, Grad Sch Med, Gunma, Japan; [Gofflot, S.] Univ Liege, BIOTHEQUE, Liege, Belgium; [Le Goff, C.; Cavalier, E.] Univ Liege, Univ Hosp, Dept Clin Chem, Liege, Belgium; [Mouithys-Mickalad, A.] Univ Liege, Ctr Oxygen Res & Dev, Liege, Belgium; [Jouret, F.] Univ Liege, GIGA Cardiovasc Sci, Liege, Belgium; [Cusumano, P. G.; Lifrange, E.] Univ Liege, Univ Hosp, Dept Senol, Liege, Belgium; [Delvenne, P.] Univ Liege, Univ Hosp, Dept Pathol, Liege, Belgium; [De Pauw, E.; Turtoi, A.] Univ Liege, Mass Spectrometry Lab, Liege, Belgium	University of Liege; Gunma University; University of Liege; University of Liege; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; Universite Libre de Bruxelles; Vrije Universiteit Brussel; University of Mons; University of Liege; Gunma University; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege	Turtoi, A (corresponding author), Univ Liege, Metastasis Res Lab, GIGA Canc, Ave Hop 3,Tour Patho 4, B-4000 Liege, Belgium.	a.turtoi@ulg.ac.be	Blomme, Arnaud/AGO-7915-2022; Costanza, Brunella/AAB-6354-2022; De Tullio, Pascal/ABE-5585-2021; Cavalier, Etienne/E-8661-2011; Van Simaeys, Gaetan/AAR-8082-2020; Blomme, Arnaud/AAM-1440-2020; Turtoi, Andrei/ABD-1271-2021; Peulen, Olivier/C-1250-2018	Blomme, Arnaud/0000-0003-4183-8726; Cavalier, Etienne/0000-0003-0947-2226; Van Simaeys, Gaetan/0000-0002-2678-542X; Turtoi, Andrei/0000-0003-3813-6635; Peulen, Olivier/0000-0002-6933-0134; De Pauw, Edwin/0000-0003-3475-1315; Costanza, Brunella/0000-0001-8279-805X; Di Valentin, Emmanuel/0000-0002-5287-7950	University of Liege (Concerted Research Action Program (IDEA project)); National Fund for Scientific Research (FNRS); Fonds Erasme; Convention de Recherche Association Vincotte Nuclear-AVN; Gunma University (GIAR Research Program for Omics-Based Medical Science); European Regional Development Fund; Wallonia (FEDER)	University of Liege (Concerted Research Action Program (IDEA project)); National Fund for Scientific Research (FNRS)(Fonds de la Recherche Scientifique - FNRS); Fonds Erasme; Convention de Recherche Association Vincotte Nuclear-AVN; Gunma University (GIAR Research Program for Omics-Based Medical Science); European Regional Development Fund(European Commission); Wallonia (FEDER)	We acknowledge the experimental support of Dr Chantal Humblet and Mrs Alice Marquet (GIGA-histology platform, ULg), Dr Sandra Ormenese (GIGA-imaging platform, ULg), Mr Vincent Hennequiere and Mrs Naima Maloujahmoum (Metastasis Research Laboratory) for experimental support. We are also thankful to the institutional Biobank of the University Hospital Liege for providing patient material. Mr Mathieu Roch (CMMI) is thanked for his help in tumor volume measurements on MR images. We are grateful to Mrs Marie-Aline Laute and Mr Nicolas Passon, the Cyclotron team (Erasme Hospital, Brussels, Belgium) and Dr. Bolag Altan (Gunma University) for technical assistance. The results shown in this work are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. This work was supported with grants from the University of Liege (Concerted Research Action Program (IDEA project)), National Fund for Scientific Research (FNRS), Fonds Erasme, Convention de Recherche Association Vincotte Nuclear-AVN and Gunma University (GIAR Research Program for Omics-Based Medical Science). Andrei Turtoi and Arnaud Blomme are post-doctoral research fellows (FNRS/Televie), Akeila Bellahcene and Pascal de Tullio are senior research associates (FNRS). The Center for Microscopy and Molecular Imaging (CMMI) as well as Gilles Doumont are supported by the European Regional Development Fund and Wallonia (FEDER). No funding bodies had any role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Aisen P, 2001, INT J BIOCHEM CELL B, V33, P940, DOI 10.1016/S1357-2725(01)00063-2; Antonescu CN, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016964; Bernatchez PN, 2007, J BIOL CHEM, V282, P30745, DOI 10.1074/jbc.M704798200; Bernatchez PN, 2009, AM J PHYSIOL-CELL PH, V297, pC484, DOI 10.1152/ajpcell.00498.2008; Chen JLY, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000293; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Doherty KR, 2008, J BIOL CHEM, V283, P20252, DOI 10.1074/jbc.M802306200; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; Fahmy K, 2016, INT J CANCER, V138, P652, DOI 10.1002/ijc.29820; Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564; Griguer CE, 2005, J NEURO-ONCOL, V74, P123, DOI 10.1007/s11060-004-6404-6; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hullin-Matsuda F, 2014, SEMIN CELL DEV BIOL, V31, P48, DOI 10.1016/j.semcdb.2014.04.010; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Jovic M, 2010, HISTOL HISTOPATHOL, V25, P99, DOI 10.14670/HH-25.99; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; Kiss AL, 2012, ADV EXP MED BIOL, V729, P14, DOI 10.1007/978-1-4614-1222-9_2; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Leung C, 2013, AM J PATHOL, V182, P1900, DOI 10.1016/j.ajpath.2013.01.041; Li RW, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0051897, 10.1371/journal.pone.0037127, 10.1371/journal.pone.0029392]; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Matheus N, 2014, PHYTOCHEM ANALYSIS, V25, P342, DOI 10.1002/pca.2498; Mayer IA, 2014, CLIN CANCER RES, V20, P782, DOI 10.1158/1078-0432.CCR-13-0583; Miccheli A, 2006, BIOCHIMIE, V88, P437, DOI 10.1016/j.biochi.2005.10.004; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; O'Toole SA, 2013, J CLIN PATHOL, V66, P530, DOI 10.1136/jclinpath-2012-201361; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Penzo D, 2002, BBA-BIOENERGETICS, V1555, P160, DOI 10.1016/S0005-2728(02)00272-4; Pilch PF, 2011, TRENDS ENDOCRIN MET, V22, P318, DOI 10.1016/j.tem.2011.04.001; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Rambold AS, 2015, DEV CELL, V32, P678, DOI 10.1016/j.devcel.2015.01.029; Sachen KL, 2012, BLOOD, V120, P4182, DOI 10.1182/blood-2012-05-427534; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Turtoi A, 2013, CANCER RES, V73, P5438, DOI 10.1158/0008-5472.CAN-13-1142; Turtoi A, 2011, J PROTEOME RES, V10, P4302, DOI 10.1021/pr200527z; Unger RH, 2010, BBA-MOL CELL BIOL L, V1801, P209, DOI 10.1016/j.bbalip.2009.10.006; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Volakis LI, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086110; Wang WS, 2013, J PROTEOMICS, V91, P453, DOI 10.1016/j.jprot.2013.06.032; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Youm YH, 2015, NAT MED, V21, P263, DOI 10.1038/nm.3804; Zheng J, 2012, ONCOL LETT, V4, P1151, DOI 10.3892/ol.2012.928	44	36	37	3	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2116	2130		10.1038/onc.2016.369	http://dx.doi.org/10.1038/onc.2016.369			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27775075				2022-12-17	WOS:000399782500008
J	Wang, D; Shi, W; Tang, Y; Liu, Y; He, K; Hu, Y; Li, J; Yang, Y; Song, J				Wang, D.; Shi, W.; Tang, Y.; Liu, Y.; He, K.; Hu, Y.; Li, J.; Yang, Y.; Song, J.			Prefoldin 1 promotes EMT and lung cancer progression by suppressing cyclin A expression	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; CELL-PROLIFERATION; CHAPERONE; PROTEIN; GROWTH; IDENTIFICATION; INHIBITION; TRANSCRIPTION; METASTASIS; COMPLEX	Prefoldin (PFDN) is a co-chaperone protein that is primarily known for its classic cytoplasmic functions in the folding of actin and tubulin monomers during cytoskeletal assembly. Here, we report a marked increase in prefoldin subunit 1 (PFDN1) levels during the transforming growth factor (TGF)-beta 1-mediated epithelial-mesenchymal transition (EMT) and in human lung tumor tissues. Interestingly, the nuclear localization of PFDN1 was also detected. These observations suggest that PFDN1 may be essential for important novel functions. Overexpression of PFDN1 induced EMT and cell invasion. In sharp contrast, knockdown of PFDN1 generated the opposite effects. Overexpression of PFDN1 was also found to induce lung tumor growth and metastasis. Further experiments showed that PFDN1 overexpression inhibits the expression of cyclin A. PFDN1 suppressed cyclin A expression by directly interacting with the cyclin A promoter at the transcriptional start site. Strikingly, cyclin A overexpression abolished the above PFDN1-mediated effects on the behavior of lung cancer cells, whereas cyclin A knockdown alone induced EMT and increased cell migration and invasion ability. This study reveals that the TGF-beta 1/ PFDN1/ cyclin A axis is essential for EMT induction and metastasis of lung cancer cells.	[Wang, D.; Shi, W.; Tang, Y.; Liu, Y.; He, K.; Hu, Y.; Li, J.; Yang, Y.; Song, J.] Chinese Acad Sci, Innovat Ctr Cell Signaling Network, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci,State Key Lab Cell Biol, 320 YueYang Rd, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Song, J (corresponding author), Chinese Acad Sci, Innovat Ctr Cell Signaling Network, Inst Biochem & Cell Biol, Shanghai Inst Biol Sci,State Key Lab Cell Biol, 320 YueYang Rd, Shanghai 200031, Peoples R China.	jgsong@sibcb.ac.cn			Natural Science Foundation of China [81472603]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the Natural Science Foundation of China (81472603). We thank Xinwang Yuan, Xiaojie Guo and Guoqing Cai for helpful discussion and technical assistance. We are especially grateful to Dr Lingling Chen for generous support to this work.	Adler JJ, 2013, P NATL ACAD SCI USA, V110, P17368, DOI 10.1073/pnas.1308236110; Alldinger I, 2005, PANCREATOLOGY, V5, P370, DOI 10.1159/000086537; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Arsic N, 2012, J CELL BIOL, V196, P147, DOI 10.1083/jcb.201102085; Asperger A, 2011, CANCER INVEST, V29, P272, DOI 10.3109/07357907.2010.550666; Barcellos KSA, 2013, J BIOL CHEM, V288, P2179, DOI 10.1074/jbc.M112.432716; Bendris N, 2014, CELL MOL LIFE SCI, V71, P4881, DOI 10.1007/s00018-014-1654-8; Cao S, 2008, J IMMUNOL, V181, P476, DOI 10.4049/jimmunol.181.1.476; Cheung CT, 2015, CARCINOGENESIS, V36, P914, DOI 10.1093/carcin/bgv069; Farooq M, 2013, ASIAN PAC J CANCER P, V14, P915, DOI 10.7314/APJCP.2013.14.2.915; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hu Y, 2013, CARCINOGENESIS, V34, P1764, DOI 10.1093/carcin/bgt132; Iijima M, 1996, ACTA MED OKAYAMA, V50, P73; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; Katsuno Y, 2013, CURR OPIN ONCOL, V25, P76, DOI 10.1097/CCO.0b013e32835b6371; Kim HRC, 1999, CANCER RES, V59, P4148; Kim SY, 2008, BMB REP, V41, P158, DOI 10.5483/BMBRep.2008.41.2.158; KUBOTA H, 1994, CURR BIOL, V4, P89, DOI 10.1016/S0960-9822(94)00024-2; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lopez V, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-182; Lundin VF, 2008, DEV BIOL, V313, P320, DOI 10.1016/j.ydbio.2007.10.022; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Ma XJ, 2015, CANCER RES, V75, P2822, DOI 10.1158/0008-5472.CAN-15-0125; Martin-Benito J, 2002, EMBO J, V21, P6377, DOI 10.1093/emboj/cdf640; Millan-Zambrano G, 2014, OPEN BIOL, V4, DOI 10.1098/rsob.140085; Millan-Zambrano G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003776; Miyoshi N, 2010, ANN SURG ONCOL, V17, P3030, DOI 10.1245/s10434-010-1138-5; Munnia A, 2001, ONCOGENE, V20, P4853, DOI 10.1038/sj.onc.1204650; Narita R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041891; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Ostrov DA, 2007, TISSUE ANTIGENS, V69, P181, DOI 10.1111/j.1399-0039.2006.00730.x; ROSENBERG AR, 1995, ONCOGENE, V10, P1501; Satou A, 2001, J BIOL CHEM, V276, P46562, DOI 10.1074/jbc.M104937200; Shi J, 2009, CANCER RES, V69, P7180, DOI 10.1158/0008-5472.CAN-08-4470; Shiota M, 2013, CANCER RES, V73, P3109, DOI 10.1158/0008-5472.CAN-12-3979; Shiota M, 2012, CANCER RES, V72, P5261, DOI 10.1158/0008-5472.CAN-12-0254; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Siegert R, 2000, CELL, V103, P621, DOI 10.1016/S0092-8674(00)00165-3; Tang YN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9230; Tang YN, 2011, CELL RES, V21, P316, DOI 10.1038/cr.2010.126; Tsuchiya H, 1996, CANCER RES, V56, P2881; Vainberg IE, 1998, CELL, V93, P863, DOI 10.1016/S0092-8674(00)81446-4; Wang D, 2014, INT J ONCOL, V44, P161, DOI 10.3892/ijo.2013.2170; Wang DM, 2010, BIOL CELL, V102, P1, DOI 10.1042/BC20090070; Whipple RA, 2010, CANCER RES, V70, P8127, DOI 10.1158/0008-5472.CAN-09-4613; Yang Y, 2006, ONCOGENE, V25, P7235, DOI 10.1038/sj.onc.1209712; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yin XF, 2013, CLIN CANCER RES, V19, P5686, DOI 10.1158/1078-0432.CCR-13-0405; Yuan XW, 2013, J BIOL CHEM, V288, P31206, DOI 10.1074/jbc.M113.480285; Zhang LA, 2010, FEBS LETT, V584, P4646, DOI 10.1016/j.febslet.2010.10.038; Zhu JQ, 2015, CANCER RES, V75, P1580, DOI 10.1158/0008-5472.CAN-14-1027	52	36	37	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					885	898		10.1038/onc.2016.257	http://dx.doi.org/10.1038/onc.2016.257			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27694898	Green Published, hybrid			2022-12-17	WOS:000394169100002
J	Jeong, M; Lee, EW; Seong, D; Seo, J; Kim, JH; Grootjans, S; Kim, SY; Vandenabeele, P; Song, J				Jeong, M.; Lee, E-W; Seong, D.; Seo, J.; Kim, J-H; Grootjans, S.; Kim, S-Y; Vandenabeele, P.; Song, J.			USP8 suppresses death receptor-mediated apoptosis by enhancing FLIPL stability	ONCOGENE			English	Article							FLICE-INHIBITORY PROTEIN; TUMOR-NECROSIS-FACTOR; CELL LUNG-CANCER; SIGNALING COMPLEX; C-FLIP; CASPASE-8 ACTIVATION; CFLIP ISOFORMS; TRAIL; DEGRADATION; PATHWAY	FLICE-like inhibitory protein (FLIP) is a critical regulator of death receptor-mediated apoptosis. Here, we found ubiquitin-specific peptidase 8 (USP8) to be a novel deubiquitylase of the long isoform of FLIP (FLIPL). USP8 directly deubiquitylates and stabilizes FLIPL, but not the short isoform. USP8 depletion induces FLIPL destabilization, promoting anti-Fas-, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- and tumor necrosis factor alpha-induced extrinsic apoptosis by facilitating death-inducing signaling complex or TNFR1 complex II formation, which results in the activation of caspase-8 and caspase-3. USP8 mRNA levels are elevated in melanoma and cervical cancers, and the protein levels of USP8 and FLIPL are positively correlated in these cancer cell lines. Xenograft analyses using ME-180 cervical cancer cells showed that USP8 depletion attenuated tumor growth upon TRAIL injection. Taken together, our data indicate that USP8 functions as a novel deubiquitylase of FLIPL and inhibits extrinsic apoptosis by stabilizing FLIPL.	[Jeong, M.; Lee, E-W; Seong, D.; Seo, J.; Kim, J-H; Song, J.] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Yonsei Ro 50, Seoul 120749, South Korea; [Grootjans, S.; Vandenabeele, P.] VIB, Inflammat Res Ctr, Zwijnaarde Ghent, Belgium; [Grootjans, S.; Vandenabeele, P.] Univ Ghent, Dept Biomed Mol Biol, Zwijnaarde Ghent, Belgium; [Kim, S-Y] Natl Canc Ctr, Canc Cell & Mol Biol Branch, Div Canc Biol, Res Inst, Goyang, South Korea	Yonsei University; Flanders Institute for Biotechnology (VIB); Ghent University; National Cancer Center - Korea (NCC)	Song, J (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biochem, Yonsei Ro 50, Seoul 120749, South Korea.	jso678@yonsei.ac.kr	Lee, Eun-Woo/AAP-9603-2020; Vandenabeele, Peter/C-8597-2009; Vandenabeele, Peter/AAD-5793-2022; Grootjans, Sasker/N-3262-2013	Vandenabeele, Peter/0000-0002-6669-8822; Grootjans, Sasker/0000-0002-8385-2545; Song, Jaewhan/0000-0001-8152-9210; Lee, Eun-Woo/0000-0002-5156-0003	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2015R1A3A2066581]; Ministry of Education [2012R1A6A3A04040105]	National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning; Ministry of Education	This work was supported by a grant from the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT and Future Planning (NRF-2015R1A3A2066581) (to J Song) and by the Ministry of Education (2012R1A6A3A04040105) (to E-WL).	Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Boatright KM, 2004, BIOCHEM J, V382, P651, DOI 10.1042/BJ20040809; Byun S, 2013, CLIN CANCER RES, V19, P3894, DOI 10.1158/1078-0432.CCR-12-3696; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Chanvorachote P, 2005, J BIOL CHEM, V280, P42044, DOI 10.1074/jbc.M510080200; den Hollander MW, 2013, CANCER LETT, V332, P194, DOI 10.1016/j.canlet.2012.04.007; Dickens LS, 2012, MOL CELL, V47, P291, DOI 10.1016/j.molcel.2012.05.004; Dillon CP, 2012, CELL REPORTS, V1, P401, DOI 10.1016/j.celrep.2012.03.010; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; French LE, 2003, CELL DEATH DIFFER, V10, P117, DOI 10.1038/sj.cdd.4401185; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Geserick P, 2009, J CELL BIOL, V187, P1037, DOI 10.1083/jcb.200904158; Goltsev YV, 1997, J BIOL CHEM, V272, P19641, DOI 10.1074/jbc.272.32.19641; Guedat P, 2007, BMC BIOCHEM, V8, DOI 10.1186/1471-2091-8-S1-S14; Hu SM, 1997, J BIOL CHEM, V272, P17255, DOI 10.1074/jbc.272.28.17255; Hughes MA, 2016, MOL CELL, V61, P834, DOI 10.1016/j.molcel.2016.02.023; Inohara N, 1997, P NATL ACAD SCI USA, V94, P10717, DOI 10.1073/pnas.94.20.10717; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Kaunisto A, 2009, CELL DEATH DIFFER, V16, P1215, DOI 10.1038/cdd.2009.35; Kavuri SM, 2011, J BIOL CHEM, V286, P16631, DOI 10.1074/jbc.M110.148585; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kreuz S, 2001, MOL CELL BIOL, V21, P3964, DOI 10.1128/MCB.21.12.3964-3973.2001; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lavrik I, 2005, J CELL SCI, V118, P265, DOI 10.1242/jcs.01610; Lee EW, 2015, CELL DEATH DIFFER, V22, P1463, DOI 10.1038/cdd.2014.234; Mahmood Z, 2010, EXP CELL RES, V316, P887, DOI 10.1016/j.yexcr.2009.12.011; Maksimovic-Ivanic D, 2012, IMMUNOL RES, V52, P157, DOI 10.1007/s12026-012-8284-8; Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200; Mizuno E, 2005, MOL BIOL CELL, V16, P5163, DOI 10.1091/mbc.E05-06-0560; Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241; Niendorf S, 2007, MOL CELL BIOL, V27, P5029, DOI 10.1128/MCB.01566-06; O'Donnell MA, 2011, NAT CELL BIOL, V13, P1437, DOI 10.1038/ncb2362; Oberst A, 2011, NATURE, V471, P363, DOI 10.1038/nature09852; Oh YM, 2014, SCI REP-UK, V4, DOI 10.1038/srep04980; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Panner A, 2010, CANCER RES, V70, P5046, DOI 10.1158/0008-5472.CAN-09-3979; Perez D, 2003, J VIROL, V77, P2651, DOI 10.1128/JVI.77.4.2651-2662.2003; Pop C, 2011, BIOCHEM J, V433, P447, DOI 10.1042/BJ20101738; Poukkula M, 2005, J BIOL CHEM, V280, P27345, DOI 10.1074/jbc.M504019200; Pyeon D, 2007, CANCER RES, V67, P4605, DOI 10.1158/0008-5472.CAN-06-3619; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Schleich K, 2012, MOL CELL, V47, P306, DOI 10.1016/j.molcel.2012.05.006; Schutze S, 2008, NAT REV MOL CELL BIO, V9, P655, DOI 10.1038/nrm2430; Shirley S, 2013, CANCER LETT, V332, P141, DOI 10.1016/j.canlet.2010.10.009; Shu HB, 1997, IMMUNITY, V6, P751, DOI 10.1016/S1074-7613(00)80450-1; Soria JC, 2011, J CLIN ONCOL, V29, P4442, DOI 10.1200/JCO.2011.37.2623; Soria JC, 2010, J CLIN ONCOL, V28, P1527, DOI 10.1200/JCO.2009.25.4847; Srinivasula SM, 1997, J BIOL CHEM, V272, P18542, DOI 10.1074/jbc.272.30.18542; Stuckey DW, 2013, TRENDS MOL MED, V19, P685, DOI 10.1016/j.molmed.2013.08.007; Symons A, 2006, TRENDS IMMUNOL, V27, P40, DOI 10.1016/j.it.2005.11.007; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Thome M, 2001, NAT REV IMMUNOL, V1, P50, DOI 10.1038/35095508; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Vandenabeele P, 2012, CELL DEATH DIFFER, V19, P1093, DOI 10.1038/cdd.2012.65; Varfolomeev EE, 2004, CELL, V116, P491, DOI 10.1016/S0092-8674(04)00166-7; Wajant H, 2003, ESSAYS BIOCHEM, V39, P53, DOI 10.1042/bse0390053; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Weinlich R, 2011, TRENDS CELL BIOL, V21, P630, DOI 10.1016/j.tcb.2011.09.002; Wilson NS, 2009, NAT IMMUNOL, V10, P348, DOI 10.1038/ni.1714; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9; Yerbes R, 2012, CELL DEATH DIFFER, V19, P1908, DOI 10.1038/cdd.2012.78; Yu JW, 2008, ONCOGENE, V27, P6216, DOI 10.1038/onc.2008.299	64	36	36	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 26	2017	36	4					458	470		10.1038/onc.2016.215	http://dx.doi.org/10.1038/onc.2016.215			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8II	27321185				2022-12-17	WOS:000394166700003
J	Fessler, E; Jansen, M; Melo, FDSE; Zhao, L; Prasetyanti, PR; Rodermond, H; Kandimalla, R; Linnekamp, JF; Franitza, M; van Hooff, SR; de Jong, JH; Oppeneer, SC; van Noesel, CJM; Dekker, E; Stassi, G; Wang, X; Medema, JP; Vermeulen, L				Fessler, E.; Jansen, M.; Melo, F. De Sousa E.; Zhao, L.; Prasetyanti, P. R.; Rodermond, H.; Kandimalla, R.; Linnekamp, J. F.; Franitza, M.; van Hooff, S. R.; de Jong, J. H.; Oppeneer, S. C.; van Noesel, C. J. M.; Dekker, E.; Stassi, G.; Wang, X.; Medema, J. P.; Vermeulen, L.			A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype	ONCOGENE			English	Article							MIR-200 FAMILY; ANALYSES IDENTIFY; POOR SURVIVAL; EXPRESSION; TRANSITION; METASTASIS; ZEB1; EMT; HETEROGENEITY; PHENOTYPE	Colorectal cancer (CRC) is a heterogeneous disease posing a challenge for accurate classification and treatment of this malignancy. There is no common genetic molecular feature that would allow for the identification of patients at risk for developing recurrences and thus selecting patients who would benefit from more stringent therapies still poses a major clinical challenge. Recently, an international multicenter consortium (CRC Subtyping Consortium) was established aiming at the classification of CRC patients in biologically homogeneous CRC subtypes. Four consensus molecular subtypes (CMSs) were identified, of which the mesenchymal CMS4 presented with worse prognosis signifying the importance of identifying these patients. Despite the large number of samples analyzed and their clear association with unifying biological programs and clinical features, single-driver mutations could not be identified and patients are heterogeneous with regard to currently used clinical markers. We therefore set out to define the regulatory mechanisms underlying the distinct gene expression profiles using a network-based approach involving multiple molecular modalities such as gene expression, methylation levels and microRNA (miR) expression. The miR-200 family presented as the most powerful determinant of CMS4-specific gene expression, tuning the majority of genes differentially expressed in the poor prognosis subtype, including genes associated with the epithelial-mesenchymal transition program. Furthermore, our data show that two epigenetic marks, namely the methylation of the two miR-200 promoter regions, can identify tumors belonging to the mesenchymal subtype and is predictive of disease-free survival in CRC patients. Importantly, epigenetic silencing of the miR-200 family is also detected in epithelial CRC cell lines that belong to the mesenchymal CMS. We thus show that determining regulatory networks is a powerful strategy to define drivers of distinct cancer subtypes, which possess the ability to identify subtype affiliation and to shed light on biological behavior.	[Fessler, E.; Melo, F. De Sousa E.; Prasetyanti, P. R.; Rodermond, H.; Kandimalla, R.; Linnekamp, J. F.; van Hooff, S. R.; de Jong, J. H.; Medema, J. P.; Vermeulen, L.] Univ Amsterdam, Lab Expt Oncol & Radiobiol LEXOR, Ctr Expt Mol Med, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Fessler, E.; Melo, F. De Sousa E.; Prasetyanti, P. R.; Rodermond, H.; Kandimalla, R.; Linnekamp, J. F.; van Hooff, S. R.; de Jong, J. H.; Medema, J. P.] Canc Genom Ctr, Utrecht, Netherlands; [Jansen, M.; van Noesel, C. J. M.] Univ Amsterdam, AMC, Dept Pathol, Amsterdam, Netherlands; [Zhao, L.; Wang, X.] City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China; [Franitza, M.] Univ Cologne, CCG, Cologne, Germany; [Franitza, M.] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany; [Oppeneer, S. C.; Dekker, E.] Univ Amsterdam, AMC, Dept Gastroenterol, Amsterdam, Netherlands; [Stassi, G.] Univ Palermo, Dept Surg & Oncol Sci, Cellular & Mol Pathophysiol Lab, Palermo, Italy; [Jansen, M.] Univ London, Barts Canc Inst, Ctr Tumour Biol, London, England; [Melo, F. De Sousa E.] Genentech Inc, Dept Mol Oncol, 460 Point San Bruno Blvd, San Francisco, CA 94080 USA	University of Amsterdam; Academic Medical Center Amsterdam; Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam; City University of Hong Kong; University of Cologne; University of Cologne; University of Amsterdam; Academic Medical Center Amsterdam; University of Palermo; University of London; Queen Mary University London; Roche Holding; Genentech	Medema, JP; Vermeulen, L (corresponding author), Univ Amsterdam, Lab Expt Oncol & Radiobiol LEXOR, Ctr Expt Mol Med, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.; Wang, X (corresponding author), City Univ Hong Kong, Dept Biomed Sci, Kowloon Tong, Hong Kong, Peoples R China.	xin.wang@cityu.edu.hk; j.p.medema@amc.nl; l.vermeulen@amc.nl	Vermeulen, Louis/B-7488-2008; Stassi, Giorgio/AAC-1175-2022; Wang, Xin/A-1130-2012; Kandimalla, Raju/C-1400-2016	Vermeulen, Louis/0000-0002-6066-789X; Wang, Xin/0000-0002-5122-2418; Dekker, Evelien/0000-0002-4363-0745; Zhao, Lan/0000-0003-2681-7695; Medema, Jan Paul/0000-0003-3045-2924; Kandimalla, Raju/0000-0002-0342-5229; Jansen, Marnix/0000-0003-0645-564X	AMC Graduate School PhD Scholarship; KWF [UvA2009-4416, UvA2012-5735, UVA2011-4969, UVA2014-7245]; MLDS focus project [FP13-07]; NWO gravitation; Worldwide Cancer Research [14-1164]; Maag Lever Darm Stichting [MLDS-CDG 14-03]; European Research Council [ERG-StG 638193]; CityU Start-up Grant for New Faculty [7200455]; Research Grants Council of Hong Kong SAR [9048033]	AMC Graduate School PhD Scholarship; KWF; MLDS focus project; NWO gravitation; Worldwide Cancer Research; Maag Lever Darm Stichting; European Research Council(European Research Council (ERC)European Commission); CityU Start-up Grant for New Faculty; Research Grants Council of Hong Kong SAR(Hong Kong Research Grants Council)	This work was supported by an AMC Graduate School PhD Scholarship (EF), KWF grants (UvA2009-4416 and UvA2012-5735) KWF/Alpe d'Huzes program CONNECTION, MLDS focus project FP13-07 and NWO gravitation (JPM), KWF grants (UVA2011-4969 and UVA2014-7245), Worldwide Cancer Research (14-1164), the Maag Lever Darm Stichting (MLDS-CDG 14-03) and the European Research Council (ERG-StG 638193) (LV), CityU Start-up Grant for New Faculty (7200455) and an early career scheme grant from the Research Grants Council of Hong Kong SAR (9048033) (XW).	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967; Hong FX, 2006, BIOINFORMATICS, V22, P2825, DOI 10.1093/bioinformatics/btl476; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Hur K, 2013, GUT, V62, P1315, DOI 10.1136/gutjnl-2011-301846; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224; Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Neves R., 2010, BMC RES NOTES, V3, P3, DOI DOI 10.1186/1756-0500-3-219; Nicoloso MS, 2009, NAT REV CANCER, V9, P293, DOI 10.1038/nrc2619; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Paterson EL, 2013, NEOPLASIA, V15, P180, DOI 10.1593/neo.121828; Prasetyanti PR, 2013, METHODS MOL BIOL, V1035, P247, DOI 10.1007/978-1-62703-508-8_21; Roepman P, 2014, INT J CANCER, V134, P552, DOI 10.1002/ijc.28387; Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175; Schlicker A, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-66; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shioiri M, 2006, BRIT J CANCER, V94, P1816, DOI 10.1038/sj.bjc.6603193; Song FJ, 2014, CLIN CANCER RES, V20, P878, DOI 10.1158/1078-0432.CCR-13-1844; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sugai T, 2006, J MOL DIAGN, V8, P193, DOI 10.2353/jmoldx.2006.050052; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tian Y, 2014, J BIOL CHEM, V289, P36101, DOI 10.1074/jbc.M114.598383; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wagner KW, 2007, NAT MED, V13, P1070, DOI 10.1038/nm1627; Wang X, 2013, INT J BIOCHEM CELL B, V45, P2574, DOI 10.1016/j.biocel.2013.08.014; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Yang D, 2013, CANCER CELL, V23, P186, DOI 10.1016/j.ccr.2012.12.020; Zhang HM, 2012, NUCLEIC ACIDS RES, V40, pD144, DOI 10.1093/nar/gkr965; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	49	36	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6026	6037		10.1038/onc.2016.134	http://dx.doi.org/10.1038/onc.2016.134			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27157610	Green Published, hybrid			2022-12-17	WOS:000388509400009
J	Li, X; Roife, D; Kang, Y; Dai, B; Pratt, M; Fleming, JB				Li, X.; Roife, D.; Kang, Y.; Dai, B.; Pratt, M.; Fleming, J. B.			Extracellular lumican augments cytotoxicity of chemotherapy in pancreatic ductal adenocarcinoma cells via autophagy inhibition	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; STELLATE CELLS; PHASE-III; CANCER; LOCALIZATION; GEMCITABINE; EXPRESSION; RESISTANCE; CARCINOMA; TARGET	Lumican, an extracellular matrix proteoglycan overexpressed by pancreatic stellate cells (PSCs) and pancreatic ductal adenocarcinoma cells (PDACs), drives the formation of a tumor-specific microenvironment. We recently showed that extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Here we investigated the role of extracellular lumican in chemotherapy-mediated cancer therapy. Lumican secretion was increased by chemotherapeutic agents in PDAC, and especially in PSCs, and appeared to be linked to the extent of cells' response to chemotherapy-induced growth inhibition. In multiple PDAC models, including cell lines, patient-derived xenografts and lumican knockout mice, lumican significantly increased antitumor effect of chemotherapy. This effect was associated with DNA damage, apoptosis and inhibition of cell viability, glucose consumption, lactate production and vascular endothelial growth factor secretion. In PDAC cells, chemotherapeutic agents triggered autophagosome formation and increased LC3 expression through the reactive oxygen species-mediated AMP-activated kinase (AMPK) signaling pathway. Inhibition of gemcitabine-induced autophagy in cancer cells by treatment with AMPK inhibitor compound C, lysosomal inhibitor chloroquine or autophagy inhibitor 3MA enhanced gemcitabine-induced apoptosis, suggesting that autophagy is a protective cellular response to gemcitabine treatment. Importantly, lumican dramatically decreased AMPK activity, inhibiting chemotherapy-induced autophagy in both in vitro and in vivo PDAC models. Co-treatment of PDAC cells with lumican and gemcitabine increased mitochondrial damage, reactive oxygen species (ROS) production and cytochrome c release, indicating that lumican-induced disruption of mitochondrial function may be the mechanism of sensitization to gemcitabine. Together, our findings demonstrate that extracellular lumican augments cytotoxicity of chemotherapy in PDAC cells through inhibition of chemotherapeutic agent-induced autophagy.	[Li, X.; Roife, D.; Kang, Y.; Dai, B.; Pratt, M.; Fleming, J. B.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,FCT17-5048, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fleming, JB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1515 Holcombe Blvd,FCT17-5048, Houston, TX 77030 USA.	jbflemin@mdanderson.org		Roife, David/0000-0001-9052-2248	Viragh Family Foundation; W. Smith Foundation; National Institutes of Health (NIH) [T32CA009599]	Viragh Family Foundation; W. Smith Foundation; National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants from the Viragh Family Foundation (to JF), the W. Smith Foundation (to JF) and National Institutes of Health (NIH) grant T32CA009599 (to DR).	Apte MV, 2004, PANCREAS, V29, P179, DOI 10.1097/00006676-200410000-00002; Baba H, 2001, JPN CIRC J, V65, P445, DOI 10.1253/jcj.65.445; Berlin JD, 2002, J CLIN ONCOL, V20, P3270, DOI 10.1200/JCO.2002.11.149; Bin-Umer MA, 2014, P NATL ACAD SCI USA, V111, P11798, DOI 10.1073/pnas.1403145111; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; Coulson-Thomas VJ, 2013, EXP CELL RES, V319, P967, DOI 10.1016/j.yexcr.2013.01.023; Erkan M, 2007, GASTROENTEROLOGY, V132, P1447, DOI 10.1053/j.gastro.2007.01.031; Erkan M, 2012, GUT, V61, P172, DOI 10.1136/gutjnl-2011-301220; Hamada S, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00331; Hardie DG, 2015, CURR OPIN CELL BIOL, V33, P1, DOI 10.1016/j.ceb.2014.09.004; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Herrmann R, 2007, J CLIN ONCOL, V25, P2212, DOI 10.1200/JCO.2006.09.0886; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Ishiwata T, 2007, ONCOL REP, V18, P537; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kim MP, 2012, ANN SURG ONCOL, V19, pS395, DOI 10.1245/s10434-011-1839-4; Kim MP, 2009, NAT PROTOC, V4, P1670, DOI 10.1038/nprot.2009.171; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156; Li XQ, 2015, ONCOTARGET, V6, P11507, DOI 10.18632/oncotarget.3432; Li XQ, 2014, CLIN CANCER RES, V20, P6529, DOI 10.1158/1078-0432.CCR-14-0970; Masamune A, 2013, PANCREATOLOGY, V13, P102, DOI 10.1016/j.pan.2012.12.058; Masamune A, 2009, J GASTROENTEROL, V44, P249, DOI 10.1007/s00535-009-0013-2; Maycotte P, 2011, CANCER BIOL THER, V11, P127, DOI 10.4161/cbt.11.2.14627; Nikitovic D, 2008, IUBMB LIFE, V60, P818, DOI 10.1002/iub.131; Ozdemir BC, 2014, CANCER CELL, V25, P719, DOI 10.1016/j.ccr.2014.04.005; Rehman G, 2014, ARCH PHARM, V347, P457, DOI 10.1002/ardp.201300402; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2009, ACTA PHYSIOL, V196, P65, DOI 10.1111/j.1748-1716.2009.01972.x; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Vonlaufen A, 2008, CANCER RES, V68, P2085, DOI 10.1158/0008-5472.CAN-07-2477; Zhu H, 2013, J BIOL CHEM, V288, P16495, DOI 10.1074/jbc.M112.443580	34	36	36	0	22	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4881	4890		10.1038/onc.2016.20	http://dx.doi.org/10.1038/onc.2016.20			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876211				2022-12-17	WOS:000383330700006
J	Mukherjee, S; Manna, A; Bhattacharjee, P; Mazumdar, M; Saha, S; Chakraborty, S; Guha, D; Adhikary, A; Jana, D; Gorain, M; Mukherjee, SA; Kundu, GC; Sarkar, DK; Das, T				Mukherjee, S.; Manna, A.; Bhattacharjee, P.; Mazumdar, M.; Saha, S.; Chakraborty, S.; Guha, D.; Adhikary, A.; Jana, D.; Gorain, M.; Mukherjee, S. A.; Kundu, G. C.; Sarkar, D. K.; Das, T.			Non-migratory tumorigenic intrinsic cancer stem cells ensure breast cancer metastasis by generation of CXCR4(+) migrating cancer stem cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CHEMOKINE RECEPTOR CXCR4; TUMOR-CELLS; CARCINOMA-CELLS; GROWTH; MICROENVIRONMENT; PERSPECTIVE; PROGRESSION; RESISTANCE; INHIBITION	Although the role of metastatic cancer stem cells (mCSCs) in tumor progression has been well documented, our study reveals a hitherto unidentified role of tumorigenic intrinsic CSCs (iCSCs) in breast cancer metastasis. We show that unlike highly migratory mCSCs residing in the breast tumor disseminating/peripheral regions, iCSCs populate the inner mass of the tumor and are nonmigratory. However iCSCs, via paracrine signaling, induce conversion of non-stem cancer cells to CSCs that (i) are identical to the previously reported mCSCs, and (ii) in contrast to iCSCs, express chemokine receptor, chemokine (C-X-C motif) receptor 4 (CXCR4), which is crucial for their metastatic potential. These mCSCs also demonstrate high in vivo tumorigenicity. Physical non-participation of iCSCs in metastasis is further validated in vivo, where only mCSCs are found to exist in the metastatic sites, lymph nodes and bone marrow, whereas the primary tumor retains both iCSCs and mCSCs. However, iCSCs ensure metastasis since their presence is crucial for deliverance of highly metastatic CXCR4(+) mCSCs to the migrating fraction of cells. Cumulatively, these results unveil a novel role of iCSCs in breast cancer metastasis as parental regulators of CXCR4(+) mCSCs, and highlight the therapeutic requisite of targeting iCSCs, but not CXCR4(+) mCSCs, to restrain breast cancer metastasis from the root by inhibiting the generation of mCSCs from iCSCs. Considering the pivotal role of iCSCs in tumor metastasis, the possibility of metastasis to be a 'stem cell phenomena' is suggested.	[Mukherjee, S.; Manna, A.; Bhattacharjee, P.; Mazumdar, M.; Saha, S.; Chakraborty, S.; Guha, D.; Adhikary, A.; Das, T.] Calcutta Improvement Trust Scheme VII M, Bose Inst, Div Mol Med, P-1-12, Kolkata, W Bengal, India; [Jana, D.; Sarkar, D. K.] SSKM Hosp, Dept Surg, Kolkata, India; [Gorain, M.; Kundu, G. C.] NCCS, Lab Tumor Biol Angiogenesis & Nanomed Res, NCCS Complex, Pune, Maharashtra, India; [Mukherjee, S. A.] Bankura Sammilani Med Coll, Dept Physiol, Kenduadihi, Bankura, India	Department of Science & Technology (India); Bose Institute; Institute of Post Graduate Medical Education & Research (IPGMER), Kolkata; Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Das, T (corresponding author), P 1 12 CIT Scheme VII M, Bose Inst, Div Mol Med, Kolkata 700054, India.	tanya@jcbose.ac.in	Gorain, Mahadeo/AED-4445-2022; Kundu, Gopal C./ABA-9897-2020; Bhattacharjee, Pushpak/AFV-4590-2022; Chakraborty, Samik/Q-1779-2018	Chakraborty, Samik/0000-0002-5232-0474	Council of Scientific and Industrial Research (CSIR), Government of India; Department of Science and Technology (DST), Government of India; Department of Biotechnology (DBT), Government of India	Council of Scientific and Industrial Research (CSIR), Government of India(Council of Scientific & Industrial Research (CSIR) - India); Department of Science and Technology (DST), Government of India(Department of Science & Technology (India)); Department of Biotechnology (DBT), Government of India(Department of Biotechnology (DBT) India)	We thank Gaurisankar Sa for his helpful discussions. Authors also acknowledge Uttam K. Ghosh and Ranjan Dutta for technical assistance. This work was supported by research grants from Council of Scientific and Industrial Research (CSIR), Department of Science and Technology (DST) and Department of Biotechnology (DBT), Government of India.	Ablett MP, 2014, ONCOTARGET, V5, P599, DOI 10.18632/oncotarget.1169; Adhikary A, 2014, J BIOL CHEM, V289, P25431, DOI 10.1074/jbc.M113.527267; Baccelli I, 2012, J CELL BIOL, V198, P281, DOI 10.1083/jcb.201202014; Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Burger JA, 2006, BLOOD, V107, P1761, DOI 10.1182/blood-2005-08-3182; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Chimal-Ramirez GK, 2013, J ONCOL, V2013, DOI 10.1155/2013/835956; Croker AK, 2008, J CELL MOL MED, V12, P374, DOI 10.1111/j.1582-4934.2007.00211.x; Currier N, 2005, TOXICOL PATHOL, V33, P726, DOI 10.1080/01926230500352226; Dick JE, 2009, NAT BIOTECHNOL, V27, P44, DOI 10.1038/nbt0109-44; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Fehm T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2349; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Hallab N, 2000, BIOMATERIALS, V21, P1301, DOI 10.1016/S0142-9612(99)00235-5; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hossain DMS, 2013, IMMUNITY, V39, P1057, DOI 10.1016/j.immuni.2013.11.005; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jinushi M, 2012, AM J CANCER RES, V2, P529; Lebret SC, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1656; Lorusso G, 2008, HISTOCHEM CELL BIOL, V130, P1091, DOI 10.1007/s00418-008-0530-8; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Mukherjee D, 2013, AM J CANCER RES, V3, P46; Mukherjee S, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt506; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Oskarsson T, 2014, CELL STEM CELL, V14, P306, DOI 10.1016/j.stem.2014.02.002; Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001; Park BH, 2013, J BIOL CHEM, V288, P28656, DOI 10.1074/jbc.M113.509505; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Rasanen K, 2012, CANCER DISCOV, V2, P775, DOI 10.1158/2159-8290.CD-12-0312; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Tam WL, 2013, CANCER CELL, V24, P347, DOI 10.1016/j.ccr.2013.08.005; Tamamura H, 2003, FEBS LETT, V550, P79, DOI 10.1016/S0014-5793(03)00824-X; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang XF, 2013, CANCER EPIDEMIOL, V37, P60, DOI 10.1016/j.canep.2012.07.007; Wei W, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-S1-S6; Wiedswang G, 2004, CLIN CANCER RES, V10, P5342, DOI 10.1158/1078-0432.CCR-04-0245; Yao XH, 2008, J PATHOL, V215, P369, DOI 10.1002/path.2356	45	36	36	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4937	4948		10.1038/onc.2016.26	http://dx.doi.org/10.1038/onc.2016.26			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26923331				2022-12-17	WOS:000383330700011
J	Zhao, JC; Fong, KW; Jin, HJ; Yang, YA; Kim, J; Yu, J				Zhao, J. C.; Fong, K-W; Jin, H-J; Yang, Y. A.; Kim, J.; Yu, J.			FOXA1 acts upstream of GATA2 and AR in hormonal regulation of gene expression	ONCOGENE			English	Article							TRANSCRIPTION FACTOR GATA-1; RESISTANT PROSTATE-CANCER; ANDROGEN RECEPTOR; BINDING; DIFFERENTIATION; RECRUITMENT; PROGRESSION; ENHANCERS; CHROMATIN; POLYCOMB	Hormonal regulation of gene expression by androgen receptor (AR) is tightly controlled by many transcriptional cofactors, including pioneer factors FOXA1 and GATA2, which, however, exhibit distinct expression patterns and functional roles in prostate cancer. Here, we examined how FOXA1, GATA2 and AR crosstalk and regulate hormone-dependent gene expression in prostate cancer cells. Chromatin immunoprecipitation sequencing analysis revealed that FOXA1 reprograms both AR and GATA2 cistrome by preferably recruiting them to FKHD-containing genomic sites. By contrast, GATA2 is unable to shift AR or FOXA1 to GATA motifs. Rather, GATA2 co-occupancy enhances AR and FOXA1 binding to nearby ARE and FKHD sites, respectively. Similarly, AR increases, but not reprograms, GATA2 and FOXA1 cistromes. Concordantly, GATA2 and AR strongly enhance the transcriptional program of each other, whereas FOXA1 regulates GATA2- and AR-mediated gene expression in a context-dependent manner due to its reprogramming effects. Taken together, our data delineated for the first time the distinct mechanisms by which GATA2 and FOXA1 regulate AR cistrome and suggest that FOXA1 acts upstream of GATA2 and AR in determining hormone-dependent gene expression in prostate cancer.	[Zhao, J. C.; Fong, K-W; Jin, H-J; Yang, Y. A.; Kim, J.; Yu, J.] Northwestern Univ, Dept Med, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA; [Yu, J.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Yu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Robert H Lurie Comprehens Canc Ctr,Dept Med, 303 E Super St Lurie 5-117, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu	Kim, Jung/Q-7801-2016	Kim, Jung/0000-0001-6274-2841; Jin, Hongjian/0000-0003-3833-7170; Yang, Angela/0000-0002-9868-7431; Fong, Ka-wing/0000-0001-6995-0264	Robert H Lurie Comprehensive Cancer Center [P30CA060553]; SPORE in Prostate Cancer [P50CA180995]; Research Scholar Award from American Cancer Society [RSG-12-085-01]; NIH Training Program in Oncogenesis and Developmental Biology [T32CA080621]; NIH/NCI training grant [T32CA009560]; Office of the Provost; Office for Research; Northwestern University Information Technology; NATIONAL CANCER INSTITUTE [T32CA080621, P50CA180995, P30CA060553, T32CA009560] Funding Source: NIH RePORTER	Robert H Lurie Comprehensive Cancer Center; SPORE in Prostate Cancer; Research Scholar Award from American Cancer Society; NIH Training Program in Oncogenesis and Developmental Biology; NIH/NCI training grant; Office of the Provost; Office for Research; Northwestern University Information Technology; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr John Crispino (Northwestern University) for critical reading of the manuscript. The project described was supported by the Robert H Lurie Comprehensive Cancer Center (P30CA060553), SPORE in Prostate Cancer (P50CA180995), and the Research Scholar Award RSG-12-085-01 (to JY) from the American Cancer Society. JK was supported in part by the NIH Training Program in Oncogenesis and Developmental Biology (T32CA080621), and YAY was supported in part by the NIH/NCI training grant T32CA009560. Computational analysis was supported by the computational resources and staff contributions provided for the Quest high performance computing facility at Northwestern University which is jointly supported by the Office of the Provost, the Office for Research, and Northwestern University Information Technology. Accession Numbers: New high-throughput data generated in this study has been deposited in GEO database under accession number GSE69045.	Andreu-Vieyra C, 2011, MOL CELL BIOL, V31, P4648, DOI 10.1128/MCB.05934-11; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bossard P, 1998, DEVELOPMENT, V125, P4909; Boyes J, 1998, J MOL BIOL, V279, P529, DOI 10.1006/jmbi.1998.1783; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Chen Y, 2013, NAT MED, V19, P1023, DOI 10.1038/nm.3216; Gao N, 2003, MOL ENDOCRINOL, V17, P1484, DOI 10.1210/me.2003-0020; Gerhardt J, 2012, AM J PATHOL, V180, P848, DOI 10.1016/j.ajpath.2011.10.021; Godoy P, 2014, BREAST CANCER-TOKYO, V21, P491, DOI 10.1007/s12282-012-0404-8; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; He B, 2014, P NATL ACAD SCI USA, V111, P18261, DOI 10.1073/pnas.1421415111; Jin HJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4972; Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Sahu B, 2011, EMBO J, V30, P3962, DOI 10.1038/emboj.2011.328; Sekiya T, 2009, GENE DEV, V23, P804, DOI 10.1101/gad.1775509; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Vidal SJ, 2015, CANCER CELL, V27, P223, DOI 10.1016/j.ccell.2014.11.013; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wu DY, 2014, NUCLEIC ACIDS RES, V42, P3607, DOI 10.1093/nar/gkt1382; Wu L, 2014, ONCOGENE, V33, P504, DOI 10.1038/onc.2012.602; Wu Q, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-3; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002; Zhang CP, 2011, CANCER RES, V71, P6738, DOI 10.1158/0008-5472.CAN-11-1882; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111	29	36	38	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4335	4344		10.1038/onc.2015.496	http://dx.doi.org/10.1038/onc.2015.496			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26751772	Green Accepted			2022-12-17	WOS:000382152100005
J	Trikha, P; Sharma, N; Pena, C; Reyes, A; Pecot, T; Khurshid, S; Rawahneh, M; Moffitt, J; Stephens, JA; Fernandez, SA; Ostrowski, MC; Leone, G				Trikha, P.; Sharma, N.; Pena, C.; Reyes, A.; Pecot, T.; Khurshid, S.; Rawahneh, M.; Moffitt, J.; Stephens, J. A.; Fernandez, S. A.; Ostrowski, M. C.; Leone, G.			E2f3 in tumor macrophages promotes lung metastasis	ONCOGENE			English	Article							TRANSCRIPTION FACTOR; CELL MIGRATION; BREAST-CANCER; LIN-35 RB; FACTOR-I; EXPRESSION; ANGIOGENESIS; INVASION; MICROENVIRONMENT; INFILTRATION	The Rb-E2F axis is an important pathway involved in cell-cycle control that is deregulated in a number of cancers. E2f transcription factors have distinct roles in the control of cell proliferation, cell survival and differentiation in a variety of tissues. We have previously shown that E2fs are important downstream targets of a CSF-1 signaling cascade involved in myeloid development. In cancer, tumor-associated macrophages (TAMs) are recruited to the tumor stroma in response to cytokines secreted by tumor cells, and are believed to facilitate tumor cell invasion and metastasis. Using the MMTV-Polyoma Middle T antigen (PyMT) mouse model of human ductal carcinoma, we show that the specific ablation of E2f3 in TAMs, but not in tumor epithelial cells, attenuates lung metastasis without affecting primary tumor growth. Histological analysis and gene expression profiling suggest that E2f3 does not impact the proliferation or survival of TAMs, but rather controls a novel gene expression signature associated with cytoskeleton rearrangements, cell migration and adhesion. This E2f3 TAM gene expression signature was sufficient to predict cancer recurrence and overall survival of estrogen receptor (ER)-positive breast cancer patients. Interestingly, we find that E2f3b but not E2f3a levels are elevated in TAMs from PyMT mammary glands relative to controls, suggesting a differential role for these isoforms in metastasis. In summary, these findings identify E2f3 as a key transcription factor in TAMs, which influences the tumor microenvironment and tumor cell metastasis.	[Trikha, P.; Sharma, N.; Pena, C.; Reyes, A.; Pecot, T.; Khurshid, S.; Rawahneh, M.; Moffitt, J.; Ostrowski, M. C.; Leone, G.] Ohio State Univ, Human Canc Genet Program, Columbus, OH 43210 USA; [Trikha, P.; Sharma, N.; Pena, C.; Reyes, A.; Pecot, T.; Khurshid, S.; Rawahneh, M.; Moffitt, J.; Ostrowski, M. C.; Leone, G.] Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Trikha, P.; Sharma, N.; Pena, C.; Reyes, A.; Pecot, T.; Khurshid, S.; Rawahneh, M.; Moffitt, J.; Ostrowski, M. C.; Leone, G.] Ohio State Univ, Coll Biol Sci, Dept Mol Genet, Columbus, OH 43210 USA; [Stephens, J. A.; Fernandez, S. A.] Ohio State Univ, Coll Med, Ctr Biostat, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Leone, G (corresponding author), Ohio State Univ, Dept Mol Virol, Human Canc Genet Program, Ctr Comprehens Canc, 460W 12th Ave, Columbus, OH 43210 USA.	Gustavo.Leone@osumc.edu	; Ostrowski, Michael/H-3108-2011	Khurshid, Safiya/0000-0003-1620-3091; Ostrowski, Michael/0000-0003-2948-6297; Pecot, Thierry/0000-0003-0772-9753	NIH [R01CA121275, R01CA098956, P01CA097189]; T32 fellowship [CA 106196-06]; NATIONAL CANCER INSTITUTE [T32CA106196, R01CA121275, R01CA098956, P01CA097189] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); T32 fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bryan Mcelwain for technical assistance with flow cytometry. This work was funded by NIH grants R01CA121275, R01CA098956 and P01CA097189 MC and GL to GL. PT and NS are recipients of the T32 fellowship (CA 106196-06).	Adams MR, 2000, MOL CELL BIOL, V20, P3633, DOI 10.1128/MCB.20.10.3633-3639.2000; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bosco EE, 2007, CELL CYCLE, V6, P667, DOI 10.4161/cc.6.6.3988; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396; Ceol CJ, 2001, MOL CELL, V7, P461, DOI 10.1016/S1097-2765(01)00194-0; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cooper CS, 2006, LUNG CANCER, V54, P155, DOI 10.1016/j.lungcan.2006.07.005; De Meyer T, 2009, J PATHOL, V217, P14, DOI 10.1002/path.2452; DeNardo DG, 2008, CANCER METAST REV, V27, P11, DOI 10.1007/s10555-007-9100-0; Diel Ingo J., 2000, Cancer, V88, P3080, DOI 10.1002/1097-0142(20000615)88:12+<3080::AID-CNCR27>3.0.CO;2-W; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Foster CS, 2004, ONCOGENE, V23, P5871, DOI 10.1038/sj.onc.1207800; Gauthier ML, 2007, CANCER CELL, V12, P479, DOI 10.1016/j.ccr.2007.10.017; Hurley PJ, 2012, P NATL ACAD SCI USA, V109, P14977, DOI 10.1073/pnas.1203525109; Jiang Z, 2010, J CLIN INVEST, V120, P3296, DOI 10.1172/JCI41490; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; KACINSKI BM, 1995, ANN MED, V27, P79, DOI 10.3109/07853899509031941; Kim BG, 2006, NATURE, V441, P1015, DOI 10.1038/nature04846; Leek RD, 1996, CANCER RES, V56, P4625; Leone G, 2000, MOL CELL BIOL, V20, P3626, DOI 10.1128/MCB.20.10.3626-3632.2000; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lujambio A, 2008, P NATL ACAD SCI USA, V105, P13556, DOI 10.1073/pnas.0803055105; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mundy GR, 1998, NEW ENGL J MED, V339, P398, DOI 10.1056/NEJM199808063390609; Myers TR, 2005, DEV CELL, V8, P117, DOI 10.1016/j.devcel.2004.11.015; Nasser MW, 2012, CANCER RES, V72, P604, DOI 10.1158/0008-5472.CAN-11-0669; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; O'Shaughnessy J, 2005, ONCOLOGIST, V10, P20, DOI 10.1634/theoncologist.10-90003-20; Olsson AY, 2007, ONCOGENE, V26, P1028, DOI 10.1038/sj.onc.1209854; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Reynolds LE, 2010, NATURE, V465, P813, DOI 10.1038/nature09106; Sangaletti S, 2003, J EXP MED, V198, P1475, DOI 10.1084/jem.20030202; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; Talmadge JE, 2007, CANCER METAST REV, V26, P373, DOI 10.1007/s10555-007-9072-0; Trikha P, 2011, J BIOL CHEM, V286, P4783, DOI 10.1074/jbc.M110.182733; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Van Nguyen A, 2002, DEV BIOL, V247, P11, DOI 10.1006/dbio.2002.0669; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wu L, 2013, ONCOGENE; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Yue W, 2009, CANCER RES, V69, P6339, DOI 10.1158/0008-5472.CAN-09-0398; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	50	36	41	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3636	3646		10.1038/onc.2015.429	http://dx.doi.org/10.1038/onc.2015.429			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26549026	Green Accepted			2022-12-17	WOS:000379622800003
J	Zhao, Y; Masiello, D; McMillian, M; Nguyen, C; Wu, Y; Melendez, E; Smbatyan, G; Kida, A; He, Y; Teo, JL; Kahn, M				Zhao, Y.; Masiello, D.; McMillian, M.; Nguyen, C.; Wu, Y.; Melendez, E.; Smbatyan, G.; Kida, A.; He, Y.; Teo, J-L; Kahn, M.			CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells	ONCOGENE			English	Article							CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; BETA-CATENIN; GENE-EXPRESSION; CANCER-CELLS; DIFFERENTIAL ROLES; KINASE INHIBITION; BINDING PROTEIN	CREB-binding protein (CBP) and p300 are highly homologous transcriptional coactivators with unique, non-redundant roles that bind a wide array of proteins, including catenins-beta and gamma. ICG-001 is a small-molecule inhibitor that specifically inhibits the CBP/catenin interaction. Importantly, ICG-001 does not inhibit the p300/catenin interaction. We demonstrate that specifically inhibiting the interaction between CBP and catenin with ICG-001 results in the differentiation of quiescent drug-resistant chronic myelogenous leukemia-initiating cells (CML LICs), thereby sensitizing them to BCR-ABL tyrosine kinase inhibitors, for example, Imatinib. Using ICG-001 in a NOD/SCID/IL2R gamma(-/-) mouse model of engrafted human chronic myelogenous leukemia, we now demonstrate the complete elimination of engrafted leukemia after only one course of combined chemotherapy. Combination-treated animals live as long as their non-engrafted littermates. Results from these studies demonstrate that specifically antagonizing the CBP/catenin interaction with ICG-001 can eliminate drug-resistant CML LICs without deleterious effects to the normal endogenous hematopoietic stem cell population.	[Zhao, Y.] Univ Southern Calif, Keck Sch Med, Dept Med, Los Angeles, CA USA; [Zhao, Y.; McMillian, M.; Nguyen, C.; Melendez, E.; Smbatyan, G.; Teo, J-L; Kahn, M.] Univ Southern Calif, Norris Comprehens Canc Ctr, 1450 Biggy St,NRT 4501, Los Angeles, CA 90033 USA; [Zhao, Y.; Masiello, D.; McMillian, M.; Nguyen, C.; Wu, Y.; Melendez, E.; Smbatyan, G.; Kida, A.; He, Y.; Teo, J-L; Kahn, M.] Univ Southern Calif, Keck Sch Med, Ctr Mol Pathways & Drug Discovery, Los Angeles, CA USA; [Kahn, M.] Univ Southern Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA USA; [Kahn, M.] Univ Southern Calif, Keck Sch Med, Dept Mol Pharmacol & Toxicol, Los Angeles, CA USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California; University of Southern California	Kahn, M (corresponding author), Univ Southern Calif, Norris Comprehens Canc Ctr, 1450 Biggy St,NRT 4501, Los Angeles, CA 90033 USA.	kahnm@usc.edu			USC Norris Comprehensive Cancer Center Support Grant [P30 CA014089]; NIH [1R01CA166161-01A1, 1R01 HL112638-01]; NATIONAL CANCER INSTITUTE [R01CA166161, P30CA014089] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL112638] Funding Source: NIH RePORTER	USC Norris Comprehensive Cancer Center Support Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Support from USC Norris Comprehensive Cancer Center Support Grant P30 CA014089, NIH 1R01CA166161-01A1 and NIH 1R01 HL112638-01 is gratefully acknowledged.	Banerjee ER, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033165; Bolton-Gillespie E, 2013, BLOOD, V121, P4175, DOI 10.1182/blood-2012-11-466938; Chan WI, 2011, MOL CELL BIOL, V31, P5046, DOI 10.1128/MCB.05830-11; el-Khoueiry A., 2013, J CLIN ONC ABSTR, V31, P2501, DOI DOI 10.1200/jco.2013.31.15_suppl.2501; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Gang EJ, 2014, ONCOGENE, V33, P2169, DOI 10.1038/onc.2013.169; Giles FJ, 2008, SEMIN ONCOL, V35, pS1, DOI 10.1053/j.seminoncol.2007.12.002; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Hao S, 2011, J AM SOC NEPHROL, V22, P1642, DOI 10.1681/ASN.2010101079; Haraguchi N, 2006, STEM CELLS, V24, P506, DOI 10.1634/stemcells.2005-0282; Hasegawa K, 2012, STEM CELL TRANSL MED, V1, P18, DOI 10.5966/sctm.2011-0033; He KJ, 2014, INT J CANCER, V134, P43, DOI 10.1002/ijc.28341; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Heidel FH, 2012, CELL STEM CELL, V10, P412, DOI 10.1016/j.stem.2012.02.017; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Jabbour EJ, 2013, CL LYMPH MYELOM LEUK, V13, P515, DOI 10.1016/j.clml.2013.03.018; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kahn M, 2011, FUTURE MED CHEM, V3, P1745, DOI [10.4155/FMC.11.126, 10.4155/fmc.11.126]; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim YM, 2011, CURR CANCER DRUG TAR, V11, P213, DOI 10.2174/156800911794328420; Konig H, 2008, LEUKEMIA, V22, P748, DOI 10.1038/sj.leu.2405086; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Lenz HJ, 2014, CANCER SCI, V105, P1087, DOI 10.1111/cas.12471; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Marson A, 2008, CELL STEM CELL, V3, P132, DOI 10.1016/j.stem.2008.06.019; Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746; Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104; Nicholson E, 2009, CLIN LYMPHOMA MYELOM, V9, pS376, DOI 10.3816/CLM.2009.s.037; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; Park E, 2011, BLOOD, V118, P2191, DOI 10.1182/blood-2011-04-351239; Pehlivan M, 2009, LEUKEMIA RES, V33, P1062, DOI 10.1016/j.leukres.2008.11.013; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Ramos YFM, 2010, NUCLEIC ACIDS RES, V38, P5396, DOI 10.1093/nar/gkq184; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rice KN, 2010, INT J HEMATOL, V91, P748, DOI 10.1007/s12185-010-0615-8; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Teo JL, 2005, P NATL ACAD SCI USA, V102, P12171, DOI 10.1073/pnas.0504600102; Velculescu VE, 1999, NAT GENET, V23, P387, DOI 10.1038/70487; Wend P, 2013, EMBO J, V32, P1977, DOI 10.1038/emboj.2013.127; Xia BF, 2012, BIOPHARM DRUG DISPOS, V33, P536, DOI 10.1002/bdd.1821; Yamada T, 2003, CANCER RES, V63, P895; Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032; Zemans RL, 2011, P NATL ACAD SCI USA, V108, P15990, DOI 10.1073/pnas.1110144108; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003	49	36	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3705	3717		10.1038/onc.2015.438	http://dx.doi.org/10.1038/onc.2015.438			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26657156	Green Accepted			2022-12-17	WOS:000379622800009
J	Mizutani, R; Imamachi, N; Suzuki, Y; Yoshida, H; Tochigi, N; Oonishi, T; Suzuki, Y; Akimitsu, N				Mizutani, R.; Imamachi, N.; Suzuki, Y.; Yoshida, H.; Tochigi, N.; Oonishi, T.; Suzuki, Y.; Akimitsu, N.			Oncofetal protein IGF2BP3 facilitates the activity of proto-oncogene protein eIF4E through the destabilization of EIF4E-BP2 mRNA	ONCOGENE			English	Article							BINDING PROTEINS; TRANSLATIONAL CONTROL; CANCER; GROWTH; EXPRESSION; PHOSPHORYLATION; PROLIFERATION; ACTIVATION; STABILITY; REGULONS	RNA-binding proteins (RBPs) have important roles in tumorigenesis. Although IGF2BP3, an evolutionally conserved RBP, has been reported as a useful diagnostic marker for various cancers and has been considered a regulator of tumorigenesis, little is known of the function of IGF2BP3 because of lack of information regarding IGF2BP3 target mRNAs. Here, we report the identification of IGF2BP3 target mRNAs and IGF2BP3 function in cancer proliferation. We identified mRNAs with altered expression in IGF2BP3-depleted cells by massive sequencing analysis and IGF2BP3-binding RNAs by immunoprecipitation of IGF2BP3 followed by massive sequencing analysis, resulting in the identification of 110 candidates that are negatively regulated by IGF2BP3. We found that IGF2BP3 destabilized EIF4E-BP2 and MEIS3 mRNAs. Co-immunoprecipitation analysis revealed the interaction between IGF2BP3 and ribonucleases such as XRN2 and exosome component. The retarded proliferation of IGF2BP3-depleted cells was partially rescued by the depletion of EIF4E-BP2, which negatively regulates eukaryotic translation initiation factor 4E (eIF4E), an activator of translation and a well-known proto-oncogene. Consistent with this observation, IGF2BP3 depletion reduced phosphorylated eIF4E, the active form, and translational efficiency of eIF4E target transcripts. Reduction of phosphorylated eIF4E by IGF2BP3 depletion was rescued by EIF4E-BP2 depletion. At last, we found an inverse correlation between the expression level of IGF2BP3 and EIF4E-BP2 in human lung adenocarcinoma tissues. Together, these results suggest that IGF2BP3 promotes eIF4E-mediated translational activation through the reduction of EIF4E-BP2 via mRNA degradation, leading to enhanced cell proliferation. This is the first report demonstrating that IGF2BP3 is an RNA-destabilizing factor. Notably, here we provide the first evidence for the functional linkage between two previously well-known cancer biomarkers, IGF2BP3 and eIF4E.	[Mizutani, R.; Imamachi, N.; Akimitsu, N.] Univ Tokyo, Isotope Sci Ctr, Tokyo, Japan; [Suzuki, Y.; Yoshida, H.; Tochigi, N.] Asahi Gen Hosp, Dept Pathol, Chiba, Japan; [Oonishi, T.] Med Consultat Off Inc, Yokohama, Kanagawa, Japan; [Suzuki, Y.] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol, Kashiwa, Chiba, Japan	University of Tokyo; University of Tokyo	Akimitsu, N (corresponding author), Univ Tokyo, Radioisotope Ctr, Bunkyo Ku, 2-11-16 Yayoi, Tokyo 1130032, Japan.	akimitsu@ric.u-tokyo.ac.jp		Imamachi, Naoto/0000-0002-3503-7589	Research Fellowship of the Japan Society for the Promotion of Science; Ministry of Education, Culture, Sports, Science and Technology of Japan; Funding Program for World-Leading Innovative R&D on Science and Technology of the Japan Society for the Promotion of Science	Research Fellowship of the Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Funding Program for World-Leading Innovative R&D on Science and Technology of the Japan Society for the Promotion of Science	We thank Dr Hiroki Kurihara, Dr Yukiko Kurihara, Dr Hiro-oki Iwakawa and Dr Yukihide Tomari (The University of Tokyo) for helpful supports and fruitful discussions. This work was financially supported by the Research Fellowship of the Japan Society for the Promotion of Science, Grant-in-Aid for Scientific Research, Grant-in-Aid for Scientific Research on Innovative Areas 'Functional machinery for noncoding RNAs' and 'Genome science' from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and The Funding Program for World-Leading Innovative R&D on Science and Technology of the Japan Society for the Promotion of Science.	Avdulov S, 2004, CANCER CELL, V5, P553, DOI 10.1016/j.ccr.2004.05.024; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bhardwaj A, 2013, NUCLEIC ACIDS RES, V41, P5062, DOI 10.1093/nar/gkt189; Bitterman PB, 2014, BIOCHIM BIOPHYS ACTA, V1849, P774; Blackinton JG, 2014, SEMIN CELL DEV BIOL, V34, P44, DOI 10.1016/j.semcdb.2014.05.014; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Cook KB, 2011, NUCLEIC ACIDS RES, V39, pD301, DOI 10.1093/nar/gkq1069; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Farina KL, 2003, J CELL BIOL, V160, P77, DOI 10.1083/jcb.200206003; Fedele M, 2010, MOL CELL ENDOCRINOL, V326, P19, DOI 10.1016/j.mce.2010.03.019; Findeis-Hosey JJ, 2010, HUM PATHOL, V41, P477, DOI 10.1016/j.humpath.2009.10.004; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Graff JR, 1997, BIOCHEM BIOPH RES CO, V240, P15, DOI 10.1006/bbrc.1997.7592; Hammerle M, 2013, HEPATOLOGY, V58, P1703, DOI 10.1002/hep.26537; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Huttelmaier S, 2005, NATURE, V438, P512, DOI 10.1038/nature04115; Hwang YS, 2012, CARCINOGENESIS, V33, P2135, DOI 10.1093/carcin/bgs258; Imamachi N, 2014, METHODS, V67, P55, DOI 10.1016/j.ymeth.2013.07.014; Jeng YM, 2008, HEPATOLOGY, V48, P1118, DOI 10.1002/hep.22459; Jonson L, 2014, CELL REP, V7, P539, DOI 10.1016/j.celrep.2014.03.015; Kanematsu S, 2014, GENE, V533, P520, DOI 10.1016/j.gene.2013.08.005; Keene JD, 2007, NAT REV GENET, V8, P533, DOI 10.1038/nrg2111; Kevil CG, 1996, INT J CANCER, V65, P785, DOI 10.1002/(SICI)1097-0215(19960315)65:6<785::AID-IJC14>3.0.CO;2-3; Kim YY, 2009, CANCER RES, V69, P8455, DOI 10.1158/0008-5472.CAN-09-1923; Liao BS, 2005, J BIOL CHEM, V280, P18517, DOI 10.1074/jbc.M500270200; Lukong KE, 2008, TRENDS GENET, V24, P416, DOI 10.1016/j.tig.2008.05.004; Martineau Y, 2013, ONCOGENE, V32, P671, DOI 10.1038/onc.2012.116; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Muller D, 2013, TRANSLATION, V1, DOI 10.4161/trla.25819; MuellerPillasch F, 1997, ONCOGENE, V14, P2729, DOI 10.1038/sj.onc.1201110; Mukherjee N, 2011, MOL CELL, V43, P327, DOI 10.1016/j.molcel.2011.06.007; Musunuru K, 2003, TRENDS CARDIOVAS MED, V13, P188, DOI 10.1016/S1050-1738(03)00075-6; Nathan CA, 1997, ONCOGENE, V15, P1087, DOI 10.1038/sj.onc.1201272; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Richter JD, 2005, NATURE, V433, P477, DOI 10.1038/nature03205; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Sonenberg N, 2007, MOL CELL, V28, P721, DOI 10.1016/j.molcel.2007.11.018; Stohr N, 2006, J CELL BIOL, V175, P527, DOI 10.1083/jcb.200608071; Sutandy FX, 2015, CRIT REV BIOTECHNOL, V20, P1; Suvasini R, 2011, J BIOL CHEM, V286, P25882, DOI 10.1074/jbc.M110.178012; Tani H, 2012, GENOME RES, V22, P947, DOI 10.1101/gr.130559.111; Topisirovic I, 2011, COLD SH Q B, V76, P355, DOI 10.1101/sqb.2011.76.010785; Vargas TR, 2014, ONCOGENE, V33, P2866, DOI 10.1038/onc.2013.252; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Wagner M, 2003, GASTROENTEROLOGY, V124, P1901, DOI 10.1016/S0016-5085(03)00402-5; Wei QZ, 2014, HUM PATHOL, V45, P2218, DOI 10.1016/j.humpath.2014.07.006; Weidensdorfer D, 2009, RNA, V15, P104, DOI 10.1261/rna.1175909; Yuan RH, 2009, ANN SURG ONCOL, V16, P1711, DOI 10.1245/s10434-009-0446-0; Zhao J, 2010, MOL CELL, V40, P939, DOI 10.1016/j.molcel.2010.12.011	49	36	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3495	3502		10.1038/onc.2015.410	http://dx.doi.org/10.1038/onc.2015.410			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26522719				2022-12-17	WOS:000379621500002
J	Yang, WH; Su, YH; Hsu, WH; Wang, CC; Arbiser, JL; Yang, MH				Yang, W-H; Su, Y-H; Hsu, W-H; Wang, C-C; Arbiser, J. L.; Yang, M-H			Imipramine blue halts head and neck cancer invasion through promoting F-box and leucine-rich repeat protein 14-mediated Twist1 degradation	ONCOGENE			English	Article							TREATMENT STRATEGIES; TRANSCRIPTION; ACTIVATION; TRANSITION; PLASTICITY; CELLS; MECHANISMS; METASTASES; CARCINOMA; SNAIL	The unique characteristic of head and neck squamous cell carcinoma (HNSCC) is that local invasion rather than distant metastasis is the major route for dissemination. Therefore, targeting the locally invasive cancer cells is more important than preventing systemic metastasis in HNSCC and other invasive-predominant cancers. We previously demonstrate a specific mechanism for HNSCC local invasion: the epithelial-mesenchymal transition (EMT) regulator Twist1 represses microRNA let-7i expression, leading to the activation of the small GTPase Rac1 and engendering the mesenchymal-mode movement in three-dimensional (3D) culture. However, targeting the EMT regulator is relatively difficult because of its transcription factor nature and the strategy for confining HNSCC invasion to facilitate local treatment is limited. Imipramine blue (IB) is a newly identified anti-invasive compound that effectively inhibits glioma invasion. Here we demonstrate that in HNSCC cells, a noncytotoxic dose of IB represses mesenchymal-mode migration in two-and-a-half-dimensional/3D culture system. IB suppresses EMT and stemness of HNSCC cells through inhibition of Twist1-mediated let-7i downregulation and Rac1 activation and the EMT signalling. Mechanistically, IB inhibits reactive oxygen species-induced nuclear factor-kappa B pathway activation. Importantly, IB promotes degradation of the EMT inducer Twist1 by enhancing F-box and leucine-rich repeat protein 14 (FBXL14)-mediated polyubiquitination of Twist1. Together, this study demonstrates the potent anti-invasion and EMT-inhibition effect of IB, suggesting the potential of IB in treating local invasion-predominant cancers.	[Yang, W-H; Su, Y-H; Hsu, W-H; Yang, M-H] Natl Yang Ming Univ, Inst Clin Med, 155,Sec 2,Li Nong St, Taipei 11221, Taiwan; [Wang, C-C] Taichung Vet Gen Hosp, Dept Otolaryngol Head & Neck Surg, Taichung, Taiwan; [Wang, C-C] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan; [Wang, C-C] Chung Shan Med Univ, Sch Speech Language Pathol & Audiol, Taichung 40201, Taiwan; [Arbiser, J. L.] Emory Sch Med, Dept Dermatol, Atlanta, GA USA; [Arbiser, J. L.] Atlanta Vet Adm Med Ctr, Atlanta, GA USA; [Yang, M-H] Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; [Yang, M-H] Natl Yang Ming Univ, Genome Res Ctr, Taipei 112, Taiwan; [Yang, M-H] Taipei Vet Gen Hosp, Div Hematol Oncol, Dept Med, Taipei, Taiwan	National Yang Ming Chiao Tung University; Taichung Veterans General Hospital; National Yang Ming Chiao Tung University; Chung Shan Medical University; Emory University; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Yang, MH (corresponding author), Natl Yang Ming Univ, Inst Clin Med, 155,Sec 2,Li Nong St, Taipei 11221, Taiwan.; Arbiser, JL (corresponding author), Emory Sch Med, Dept Dermatol, Atlanta, GA USA.; Arbiser, JL (corresponding author), Atlanta Vet Adm Med Ctr, Atlanta, GA USA.; Arbiser, JL (corresponding author), Winship Canc Inst, Dept Dermatol, Atlanta, GA USA.; Arbiser, JL (corresponding author), Emory Univ, Sch Med, Atlanta Vet Adm Hosp, WMB 5309,1639 Pierce Dr, Atlanta, GA 30322 USA.	jarbise@emory.edu; mhyang2@vghtpe.gov.tw	Yang, Muh-Hwa/AAE-4691-2020	Hsu, Wen-Hao/0000-0001-9050-8227; Su, Yen-Hao/0000-0001-8288-3772	Ministry of Science and Technology [103-2321-B-010-019, 103-2314-B-010-034, 103-2633-H-010-001, 103-2314-B-010-035]; Taipei Veterans General Hospital [V104-E8-001]; Ministry of Education, Aim for the Top University Plan; Ministry of Health and Welfare, Center of Excellence for Cancer Research [MOHW104-TDU-B-211-124-001]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047901] Funding Source: NIH RePORTER	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Taipei Veterans General Hospital(Taipei Veterans General Hospital); Ministry of Education, Aim for the Top University Plan(Ministry of Education, Taiwan); Ministry of Health and Welfare, Center of Excellence for Cancer Research; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Professor Victor M Diaz (Universitat Pompeu Fabra, Barcelona, Spain) for the generous gifts of pcDNA3-myc-FBXL14 and pcDNA3-FBXL14 Delta F plasmids. We thank Professor Kuo-Wei Chang (National Yang-Ming University, Taiwan) for providing OECM-1 cell line. This work was supported by Ministry of Science and Technology (103-2321-B-010-019, 103-2314-B-010-034, 103-2633-H-010-001, and 103-2314-B-010-035 to M-HY), Taipei Veterans General Hospital (V104-E8-001 to M-HY), a grant from Ministry of Education, Aim for the Top University Plan (to M-HY) and a grant from the Ministry of Health and Welfare, Center of Excellence for Cancer Research (MOHW104-TDU-B-211-124-001 to M-HY).	Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850; Carlsson SK, 2014, EMBO MOL MED, V6, P1359, DOI 10.15252/emmm.201302627; COGSWELL JP, 1994, J IMMUNOL, V153, P712; Di CH, 2010, ANTI-CANCER AGENT ME, V10, P543, DOI 10.2174/187152010793498618; Even-Ram S, 2005, CURR OPIN CELL BIOL, V17, P524, DOI 10.1016/j.ceb.2005.08.015; Forastiere AA, 2013, J CLIN ONCOL, V31, P845, DOI 10.1200/JCO.2012.43.6097; Friedl P, 2004, CURR OPIN CELL BIOL, V16, P14, DOI 10.1016/j.ceb.2003.11.001; Garavello W, 2006, ARCH OTOLARYNGOL, V132, P762, DOI 10.1001/archotol.132.7.762; Ho MS, 2006, J BIOMED SCI, V13, P181, DOI 10.1007/s11373-005-9058-2; Hsu DSS, 2014, CANCER CELL, V26, P534, DOI 10.1016/j.ccell.2014.09.002; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Lander R, 2011, J CELL BIOL, V194, P17, DOI 10.1083/jcb.201012085; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Lorch JH, 2011, LANCET ONCOL, V12, P153, DOI 10.1016/S1470-2045(10)70279-5; Madsen CD, 2010, DEV CELL, V19, P13, DOI 10.1016/j.devcel.2010.06.013; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Michael J Morgan, 2011, Cell Research, V21, P103; Munson JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003016; NEWTON HB, 1992, CANCER, V69, P2149, DOI 10.1002/1097-0142(19920415)69:8<2149::AID-CNCR2820690822>3.0.CO;2-G; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Pentenero M, 2005, HEAD NECK-J SCI SPEC, V27, P1080, DOI 10.1002/hed.20275; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Ravid T, 2008, NAT REV MOL CELL BIO, V9, P679, DOI 10.1038/nrm2468; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Sanz-Moreno V, 2010, CURR OPIN CELL BIOL, V22, P690, DOI 10.1016/j.ceb.2010.08.020; Slorach EM, 2011, GENE DEV, V25, P471, DOI 10.1101/gad.1998111; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang WH, 2013, BIOCHEM BIOPH RES CO, V433, P24, DOI 10.1016/j.bbrc.2013.02.076; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Zhong JT, 2013, DISCOV MED, V15, P7	35	36	36	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 5	2016	35	18					2287	2298		10.1038/onc.2015.291	http://dx.doi.org/10.1038/onc.2015.291			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GL	26257063	Green Accepted			2022-12-17	WOS:000376165000002
J	Zhu, J; Zhao, C; Zhuang, T; Jonsson, P; Sinha, I; Williams, C; Stromblad, S; Dahlman-Wright, K				Zhu, J.; Zhao, C.; Zhuang, T.; Jonsson, P.; Sinha, I.; Williams, C.; Stromblad, S.; Dahlman-Wright, K.			RING finger protein 31 promotes p53 degradation in breast cancer cells	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; UBIQUITIN LIGASE ACTIVITY; MDM2 ANTAGONIST NUTLIN-3; TRANSCRIPTIONAL REPRESSION; ONCOPROTEIN MDM2; E3; ACTIVATION; MUTATIONS; IDENTIFICATION; NEUROBLASTOMA	The atypical E3 ubiquitin ligase RNF31 is highly expressed in human breast cancer, the most frequent neoplastic lethality among women. Here, RNF31 depletion in breast cancer cells in combination with global gene expression profiling revealed p53 (TP53) signaling as a potential RNF31 target. Interestingly, RNF31 decreased p53 stability, whereas depletion of RNF31 in breast cancer cells caused cell cycle arrest and cisplatin-induced apoptosis in a p53-dependent manner. Furthermore, RNF31 associated with the p53/MDM2 complex and facilitated p53 polyubiquitination and degradation by stabilizing MDM2, suggesting a molecular mechanism by which RNF31 regulates cell death. Analysis of publically available clinical data sets displayed a negative correlation between RNF31 and p53 target genes, including IGFBP3 and BTG1, consistent with RNF31 regulating p53 function in vivo as well. Together, our findings suggest RNF31 as a potential therapeutic target to restore p53 function in breast cancer.	[Zhu, J.; Zhao, C.; Zhuang, T.; Sinha, I.; Stromblad, S.; Dahlman-Wright, K.] Karolinska Inst, Dept Biosci & Nutr, Stockholm, Sweden; [Jonsson, P.; Williams, C.] Univ Houston, Dept Biol & Biochem, Ctr Nucl Receptors & Cell Signaling, Houston, TX USA; [Williams, C.] Royal Inst Technol KTH, SciLifeLab, Dept Prote & Nanotechnol, Solna, Sweden; [Dahlman-Wright, K.] SciLifeLab, Sci Life Lab, Solna, Sweden	Karolinska Institutet; University of Houston System; University of Houston; Royal Institute of Technology; SciLifeLab; SciLifeLab	Dahlman-Wright, K (corresponding author), Karolinska Inst, Dept Biosci & Nutr, Novum, Halsovagen 7-9, SE-14183 Huddinge, Stockholmm, Sweden.	karin.dahlman-wright@ki.se	Williams, Cecilia/A-6677-2009; zhu, jian/D-7361-2017	Williams, Cecilia/0000-0002-0602-2062; zhu, jian/0000-0003-3596-4339; Zhuang, Ting/0000-0002-6308-1253; Stromblad, Staffan/0000-0002-1236-6339; Sinha, Indranil/0000-0002-2513-5927; Jonsson, Philip/0000-0002-1537-0624; zhu, jian/0000-0003-0171-4251	China Scholarship Council; Karolinska Institutet; Center for Innovative Medicine at Karolinska Institutet, Marie Curie Actions via the VINNOVA programme Mobility for Growth [GROWTH 291795]; Swedish Cancer Society; Swedish Research Council	China Scholarship Council(China Scholarship Council); Karolinska Institutet(Karolinska Institutet); Center for Innovative Medicine at Karolinska Institutet, Marie Curie Actions via the VINNOVA programme Mobility for Growth; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission)	We thank members of the KDW, SS and ET group members for sharing materials and for valuable discussions. We thank Marie Franzen for assisting with manuscript submission and Lars-Arne Haldosen for critical comments. This study was supported by scholarships from the China Scholarship Council, a PhD student grant (KID) from the Karolinska Institutet, funding from the Center for Innovative Medicine at Karolinska Institutet, Marie Curie Actions FP7-PEOPLE-2011-COFUND [GROWTH 291795] via the VINNOVA programme Mobility for Growth, the Swedish Cancer Society, the Swedish Research Council and the Karolinska Institutet.	Barnes DM, 1996, J MAMMARY GLAND BIOL, V1, P163, DOI 10.1007/BF02013640; Carvajal D, 2005, CANCER RES, V65, P1918, DOI 10.1158/0008-5472.CAN-04-3576; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Di Leo A, 2007, ANN ONCOL, V18, P997, DOI 10.1093/annonc/mdm075; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Ehrlund A, 2009, MOL CELL BIOL, V29, P2230, DOI 10.1128/MCB.00743-08; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Grumati P, 2014, CANCER DISCOV, V4, P394, DOI 10.1158/2159-8290.CD-14-0177; Gustafsson N, 2010, CANCER RES, V70, P1265, DOI 10.1158/0008-5472.CAN-09-2674; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Huang BY, 2009, AGING-US, V1, P845, DOI 10.18632/aging.100091; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jiang M, 2007, J BIOL CHEM, V282, P2636, DOI 10.1074/jbc.M606928200; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; MacKay C, 2014, CANCER RES, V74, P2246, DOI 10.1158/0008-5472.CAN-13-2131; Nie J, 2010, J BIOL CHEM, V285, P22816, DOI 10.1074/jbc.M110.126920; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Peirce SK, 2009, INT J ONCOL, V34, P1395, DOI 10.3892/ijo_00000267; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Sayeed A, 2007, CANCER RES, V67, P7746, DOI 10.1158/0008-5472.CAN-06-3724; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Smit JJ, 2012, EMBO J, V31, P3833, DOI 10.1038/emboj.2012.217; Tatematsu K, 2008, J BIOL CHEM, V283, P11575, DOI 10.1074/jbc.M706961200; Thompson HGR, 2004, EXP CELL RES, V295, P448, DOI 10.1016/j.yexcr.2004.01.019; Uji K, 2014, CANCER LETT, V342, P19, DOI 10.1016/j.canlet.2013.08.028; Van Maerken T, 2009, JNCI-J NATL CANCER I, V101, P1562, DOI 10.1093/jnci/djp355; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Wen W, 2014, ONCOGENE, V33, P421, DOI 10.1038/onc.2012.605; Williams C, 1998, CLIN CHEM, V44, P455; Yang YB, 2014, CANCER DISCOV, V4, P480, DOI 10.1158/2159-8290.CD-13-0915; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhao CY, 2007, CANCER RES, V67, P3955, DOI 10.1158/0008-5472.CAN-06-3505; Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573	41	36	38	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2016	35	15					1955	1964		10.1038/onc.2015.260	http://dx.doi.org/10.1038/onc.2015.260			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DJ2CC	26148235	hybrid, Green Published			2022-12-17	WOS:000374010300008
J	Bjork, JK; Akerfelt, M; Joutsen, J; Puustinen, MC; Cheng, F; Sistonen, L; Nees, M				Bjork, J. K.; Akerfelt, M.; Joutsen, J.; Puustinen, M. C.; Cheng, F.; Sistonen, L.; Nees, M.			Heat-shock factor 2 is a suppressor of prostate cancer invasion	ONCOGENE			English	Article							GENE-EXPRESSION PROFILES; METASTASIS SUPPRESSOR; CELL-CULTURE; IN-VITRO; STRESS; TRANSCRIPTION; PROGRESSION; HSF1; DIFFERENTIATION; CARCINOMAS	Heat-shock factors (HSFs) are key transcriptional regulators in cell survival. Although HSF1 has been identified as a driver of carcinogenesis, HSF2 has not been explored in malignancies. Here, we report that HSF2 suppresses tumor invasion of prostate cancer (PrCa). In three-dimensional organotypic cultures and the in vivo xenograft chorioallantoic membrane model HSF2 knockdown perturbs organoid differentiation and promotes invasiveness. Gene expression profiling together with functional studies demonstrated that the molecular mechanism underlying the effect on tumor progression originates from HSF2 steering the switch between acinar morphogenesis and invasion. This is achieved by the regulation of genes connected to, for example, GTPase activity, cell adhesion, extracellular matrix and actin cytoskeleton dynamics. Importantly, low HSF2 expression correlates with high Gleason score, metastasis and poor survival of PrCa patients, highlighting the clinical relevance of our findings. Finally, the study was expanded beyond PrCa, revealing that the expression of HSF2 is decreased in a wide range of cancer types. This study provides the first evidence for HSF2 acting as a suppressor of invasion in human malignancies.	[Bjork, J. K.; Akerfelt, M.; Joutsen, J.; Puustinen, M. C.; Cheng, F.; Sistonen, L.; Nees, M.] Univ Turku, Ctr Biotechnol, Tykistokatu 6, FIN-20520 Turku, Finland; [Bjork, J. K.; Akerfelt, M.; Joutsen, J.; Puustinen, M. C.; Cheng, F.; Sistonen, L.; Nees, M.] Abo Akad Univ, Tykistokatu 6, FIN-20520 Turku, Finland; [Bjork, J. K.; Akerfelt, M.] VTT Tech Res Ctr Finland, Med Biotechnol, Turku, Finland; [Joutsen, J.; Puustinen, M. C.; Cheng, F.; Sistonen, L.] Abo Akad Univ, Dept Biosci, FIN-20520 Turku, Finland	University of Turku; Abo Akademi University; VTT Technical Research Center Finland; Abo Akademi University	Sistonen, L; Nees, M (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6, FIN-20520 Turku, Finland.; Sistonen, L; Nees, M (corresponding author), Abo Akad Univ, Tykistokatu 6, FIN-20520 Turku, Finland.	lea.sistonen@abo.fi; matthias.nees@btk.fi	Nees, Matthias/W-6596-2018; Nees, Matthias/AAT-5577-2020	Nees, Matthias/0000-0002-9034-301X; Sistonen, Lea/0000-0003-1341-2867; Joutsen, Jenny/0000-0002-7868-556X; Akerfelt, Malin/0000-0003-4810-7862	Academy of Finland; IMI PREDECT consortium; Sigrid Juselius Foundation; Finnish Cancer Organizations; Abo Akademi University; Abo Akademi University Endowment Research Institute; Tor, Joe and Pentti Borg Foundation	Academy of Finland(Academy of Finland); IMI PREDECT consortium; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cancer Organizations; Abo Akademi University; Abo Akademi University Endowment Research Institute; Tor, Joe and Pentti Borg Foundation	We thank the members of our laboratories for invaluable comments. Vidal Fey, Samu V Himanen, Heidi Lustig, Satu Orasniemi, Pauliina Toivonen, and Johannes Virtanen are acknowledged for technical assistance and other contributions. The work was supported by The Academy of Finland (FC, JKB, LS, MN, MA), IMI PREDECT consortium (MN, MA), The Sigrid Juselius Foundation (LS), The Finnish Cancer Organizations (LS), Abo Akademi University (JKB, LS), Abo Akademi University Endowment Research Institute, and Tor, Joe and Pentti Borg Foundation (JKB).	Acloque H, 2008, EMBO REP, V9, P322, DOI 10.1038/embor.2008.30; Adib TR, 2004, BRIT J CANCER, V90, P686, DOI 10.1038/sj.bjc.6601603; Ahlskog JK, 2010, MOL CELL BIOL, V30, P5608, DOI 10.1128/MCB.01506-09; Akerfelt M, 2010, NAT REV MOL CELL BIO, V11, P545, DOI 10.1038/nrm2938; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bjork JK, 2010, FEBS J, V277, P4126, DOI 10.1111/j.1742-4658.2010.07828.x; Bjork JK, 2010, DEVELOPMENT, V137, P3177, DOI 10.1242/dev.050955; Burns-Cox N, 2001, J UROLOGY, V166, P1698, DOI 10.1016/S0022-5347(05)65656-X; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Choi YL, 2007, ONCOGENE, V26, P1245, DOI 10.1038/sj.onc.1209898; DAGG CP, 1956, CANCER RES, V16, P589; Dai C, 2007, CELL, V130, P1005, DOI 10.1016/j.cell.2007.07.020; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Durig J, 2007, LEUKEMIA, V21, P2153, DOI 10.1038/sj.leu.2404877; El Fatimy R, 2014, EMBO MOL MED, V6, P1043, DOI 10.15252/emmm.201303311; Elsing AN, 2014, J CELL BIOL, V206, P735, DOI 10.1083/jcb.201402002; Epstein JI, 2005, AM J SURG PATHOL, V29, P1228, DOI 10.1097/01.pas.0000173646.99337.b1; Estilo CL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-11; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Friedl P, 2009, NAT REV MOL CELL BIO, V10, P445, DOI 10.1038/nrm2720; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gutmann DH, 2002, CANCER RES, V62, P2085; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harma V, 2012, ONCOGENE, V31, P2075, DOI 10.1038/onc.2011.396; Harma V, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096426; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Haslinger C, 2004, J CLIN ONCOL, V22, P3937, DOI 10.1200/JCO.2004.12.133; Hulsen T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-488; Jin XJ, 2011, CELL METAB, V14, P91, DOI 10.1016/j.cmet.2011.03.025; Jones J, 2005, CLIN CANCER RES, V11, P5730, DOI 10.1158/1078-0432.CCR-04-2225; Kelly P, 2007, BIOCHEMISTRY-US, V46, P6677, DOI 10.1021/bi700235f; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kimchi ET, 2005, CANCER RES, V65, P3146, DOI 10.1158/0008-5472.CAN-04-2490; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Kogan I, 2006, CANCER RES, V66, P3531, DOI 10.1158/0008-5472.CAN-05-2183; Korkola JE, 2006, CANCER RES, V66, P820, DOI 10.1158/0008-5472.CAN-05-2445; Kunzi-Rapp K, 2001, J UROLOGY, V166, P1502, DOI 10.1016/S0022-5347(05)65820-X; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; Loison F, 2006, BIOCHEM J, V395, P223, DOI 10.1042/BJ20051190; Marino N, 2012, CANCER METAST REV, V31, P593, DOI 10.1007/s10555-012-9374-8; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; Massard C, 2011, CLIN CANCER RES, V17, P3876, DOI 10.1158/1078-0432.CCR-10-2815; Mendillo ML, 2012, CELL, V150, P549, DOI 10.1016/j.cell.2012.06.031; Min JN, 2007, ONCOGENE, V26, P5086, DOI 10.1038/sj.onc.1210317; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morin P, 2011, EUR J CELL BIOL, V90, P13, DOI 10.1016/j.ejcb.2010.09.009; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Ostling P, 2007, J BIOL CHEM, V282, P7077, DOI 10.1074/jbc.M607556200; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Parri M, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-23; Rasheed SAK, 2013, J BIOL CHEM, V288, P7986, DOI 10.1074/jbc.M112.437749; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Rossi A, 2014, J BIOL CHEM, V289, P12705, DOI 10.1074/jbc.M113.513242; Sabeh F, 2004, J CELL BIOL, V167, P769, DOI 10.1083/jcb.200408028; Sandqvist A, 2009, MOL BIOL CELL, V20, P1340, DOI 10.1091/mbc.E08-08-0864; Santagata S, 2013, SCIENCE, V341, P250, DOI 10.1126/science.1238303; Santagata S, 2011, P NATL ACAD SCI USA, V108, P18378, DOI 10.1073/pnas.1115031108; Scherz-Shouval R, 2014, CELL, V158, P564, DOI 10.1016/j.cell.2014.05.045; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Sinha S, 2008, CELL SIGNAL, V20, P1927, DOI 10.1016/j.cellsig.2008.05.002; Skotheim RI, 2005, CANCER RES, V65, P5588, DOI 10.1158/0008-5472.CAN-05-0153; Solimini NL, 2007, CELL, V130, P986, DOI 10.1016/j.cell.2007.09.007; STEEG PS, 1988, J NATL CANCER I, V80, P200, DOI 10.1093/jnci/80.3.200; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vihervaara A, 2013, P NATL ACAD SCI USA, V110, pE3388, DOI 10.1073/pnas.1305275110; Wang X, 2009, J ANDROL, V30, P259, DOI 10.2164/jandrol.108.006494; Welsh JB, 2001, P NATL ACAD SCI USA, V98, P1176, DOI 10.1073/pnas.98.3.1176; Yusenko MV, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-152	75	36	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 7	2016	35	14					1770	1784		10.1038/onc.2015.241	http://dx.doi.org/10.1038/onc.2015.241			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DI6LM	26119944	hybrid, Green Published			2022-12-17	WOS:000373610400004
J	Pan, D; Jiang, C; Ma, Z; Blonska, M; You, MJ; Lin, X				Pan, D.; Jiang, C.; Ma, Z.; Blonska, M.; You, M. J.; Lin, X.			MALT1 is required for EGFR-induced NF-kappa B activation and contributes to EGFR-driven lung cancer progression	ONCOGENE			English	Article							T-CELL-ACTIVATION; LYMPHOID-TISSUE; SIGNALING PATHWAYS; ABC-DLBCL; IN-VIVO; K-RAS; ADENOCARCINOMAS; PHOSPHORYLATION; LYMPHOCYTES; PARACASPASE	The transcription factor nuclear factor kappa B (NF-kappa B) has been implicated in having a crucial role in the tumorigenesis of many types of human cancers. Although epidermal growth factor receptor (EGFR) can directly activate NF-kappa B, the mechanism by which EGFR induces NF-kappa B activation and the role of NF-kappa B in EGFR-associated tumor progression is still not fully defined. Herein, we found that mucosa-associated lymphoid tissue 1 (MALT1) is involved in EGFR-induced NF-kappa B activation in cancer cells, and that MALT1 deficiency impaired EGFR-induced NF-kappa B activation. MALT1 mainly functions as a scaffold protein by recruiting E3 ligase TRAF6 to IKK complex to activate NF-kappa B in response to EGF stimulation. Functionally, MALT1 inhibition shows significant defects in EGFR-associated tumor malignancy, including cell migration, metastasis and anchorageindependent growth. To further access a physiological role of MALT1-dependent NF-kappa B activation in EGFR-driven tumor progression, we generated triple-transgenic mouse model (tetO-EGFR(L858R); CCSP-rtTA; Malt1(-/-)), in which mutant EGFR-driven lung cancer was developed in the absence of MALT1 expression. MALT1-deficient mice show significantly less lung tumor burden when compared with its heterozygous controls, suggesting that MALT1 is required for the progression of EGFR-induced lung cancer. Mechanistically, MALT1 deficiency abolished both NF-kappa B and STAT3 activation in vivo, which is a result of a defect of interleukin-6 production. In comparison, MALT1 deficiency does not affect tumor progression in a mouse model (LSL-K-ras(G12D); CCSP-Cre; Malt1(-/-)) in which lung cancer is induced by expressing a K-ras mutant. Thus, our study has provided the cellular and genetic evidence that suggests MALT1-dependent NF-kappa B activation is important in EGFR-associated solid-tumor progression.	[Pan, D.; Jiang, C.; Ma, Z.; Blonska, M.; Lin, X.] Univ Texas MD Anderson Canc Ctr, Ctr Inflammat & Canc, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Pan, D.; You, M. J.; Lin, X.] Univ Texas Houston, Grad Sch Biomed Sci, Canc Biol Program, Houston, TX USA; [You, M. J.] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Lin, X (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr Inflammat & Canc, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	xllin@mdanderson.org	Ma, Zhongliang/D-9490-2015; Blonska, Marzenna/U-7751-2019; Jiang, Changying/AAL-3711-2020	Ma, Zhongliang/0000-0002-4429-5213; Jiang, Changying/0000-0003-3778-4438; Blonska, Marzenna/0000-0001-5237-8732; Pan, Deng/0000-0002-6475-0463	Cancer Prevention Research Institute of Texas (CPRIT) [RP120316]; National Institutes of Health (NIH) [GM079451, GM065899]; NCI/NIH [R01 CA164346]; Developmental Research Awards in Leukemia SPORE [CA100632]; Center for Inflammation and Cancer; Center for Genetics and Genomics; IRG; Sister Institution Network fund of UT MD Anderson Cancer Center; Cancer Prevention Research Institute of Texas; NATIONAL CANCER INSTITUTE [R01CA164346, P30CA016672, P50CA100632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R56GM065899, R01GM065899, R01GM079451] Funding Source: NIH RePORTER	Cancer Prevention Research Institute of Texas (CPRIT); National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Developmental Research Awards in Leukemia SPORE; Center for Inflammation and Cancer; Center for Genetics and Genomics; IRG; Sister Institution Network fund of UT MD Anderson Cancer Center; Cancer Prevention Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Vishva Dixit (Genentech Corporation) for providing Malt1-deficient mice and Dr Francesco J DeMayo (Baylor College of Medicine) for providing CCSP-Cre mice and Dr Jeffrey Whitsett (Cincinnati Children's Hospital Medical Center) for providing CCSP-tTA mice. This work is partially supported by grants, RP120316 from Cancer Prevention Research Institute of Texas (CPRIT) to XL, GM079451 and GM065899 from National Institutes of Health (NIH) to XL and R01 CA164346 (NCI/NIH), Developmental Research Awards in Leukemia SPORE CA100632 to MJY, and Center for Inflammation and Cancer, Center for Genetics and Genomics, IRG, Sister Institution Network fund of UT MD Anderson Cancer Center, and Cancer Prevention Research Institute of Texas to MJY.	Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460; Blonska M, 2011, CELL RES, V21, P55, DOI 10.1038/cr.2010.182; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Fan Q. W., 2009, SCI SIGNAL, V2, pra4, DOI DOI 10.1126/SCISIGNAL.2000014; Ferch U, 2009, J EXP MED, V206, P2313, DOI 10.1084/jem.20091167; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; Fontan L, 2012, CANCER CELL, V22, P812, DOI 10.1016/j.ccr.2012.11.003; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007; Hailfinger S, 2011, P NATL ACAD SCI USA, V108, P14596, DOI 10.1073/pnas.1105020108; Hailfinger S, 2009, P NATL ACAD SCI USA, V106, P19946, DOI 10.1073/pnas.0907511106; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jiang T, 2011, CANCER RES, V71, P2183, DOI 10.1158/0008-5472.CAN-10-3626; Karin M, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000141; Li HG, 2008, GENESIS, V46, P300, DOI 10.1002/dvg.20396; Marion S, 2012, DEV CELL, V23, P954, DOI 10.1016/j.devcel.2012.09.021; Matsumoto R, 2005, IMMUNITY, V23, P575, DOI 10.1016/j.immuni.2005.10.007; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Morgan JA, 1999, CANCER RES, V59, P6205; Nagel D, 2012, CANCER CELL, V22, P825, DOI 10.1016/j.ccr.2012.11.002; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; Pan D, 2013, CANCER J, V19, P461, DOI 10.1097/PPO.0000000000000001; Politi K, 2006, GENE DEV, V20, P1496, DOI 10.1101/gad.1417406; Rebeaud F, 2008, NAT IMMUNOL, V9, P272, DOI 10.1038/ni1568; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; Ruefli-Brasse AA, 2003, SCIENCE, V302, P1581, DOI 10.1126/science.1090769; Ruland J, 2003, IMMUNITY, V19, P749, DOI 10.1016/S1074-7613(03)00293-0; Shambharkar PB, 2007, EMBO J, V26, P1794, DOI 10.1038/sj.emboj.7601622; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Sommer K, 2005, IMMUNITY, V23, P561, DOI 10.1016/j.immuni.2005.09.014; Songur N, 2004, TUMORI J, V90, P196, DOI 10.1177/030089160409000207; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Stewart JR, 2005, MOL CANCER THER, V4, P726, DOI 10.1158/1535-7163.MCT-05-0013; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Thome M, 2008, NAT REV IMMUNOL, V8, P495, DOI 10.1038/nri2338; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Yang WW, 2012, MOL CELL, V48, P771, DOI 10.1016/j.molcel.2012.09.028	43	36	40	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2016	35	7					919	928		10.1038/onc.2015.146	http://dx.doi.org/10.1038/onc.2015.146			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE0RO	25982276	Green Accepted			2022-12-17	WOS:000370332200012
J	Tian, H; Liu, J; Chen, J; Gatza, ML; Blobe, GC				Tian, H.; Liu, J.; Chen, J.; Gatza, M. L.; Blobe, G. C.			Fibulin-3 is a novel TGF-beta pathway inhibitor in the breast cancer microenvironment	ONCOGENE			English	Article							GROWTH-FACTOR-BETA; TUMOR MICROENVIRONMENT; PROMOTER METHYLATION; COLORECTAL-CANCER; DOWN-REGULATION; POOR-PROGNOSIS; STEM-CELLS; PROGRESSION; LUNG; METASTASIS	Transforming growth factor-beta (TGF-beta) is an important regulator of breast cancer progression. However, how the breast cancer microenvironment regulates TGF-beta signaling during breast cancer progression remains largely unknown. Here, we identified fibulin-3 as a secreted protein in the breast cancer microenvironment, which efficiently inhibits TGF-beta signaling in both breast cancer cells and endothelial cells. Mechanistically, fibulin-3 interacts with the type I TGF-beta receptor (T beta RI) to block TGF-beta induced complex formation of T beta RI with the type II TGF-beta receptor (T beta RII) and subsequent downstream TGF-beta signaling. Fibulin-3 expression decreases during breast cancer progression, with low fibulin-3 levels correlating with a poorer prognosis. Functionally, high fibulin-3 levels inhibited TGF-beta-induced epithelial-mesenchymal transition (EMT), migration, invasion and endothelial permeability, while loss of fibulin-3 expression/function promoted these TGF-beta-mediated effects. Further, restoring fibulin-3 expression in breast cancer cells inhibited TGF-beta signaling, breast cancer cell EMT, invasion and metastasis in vivo. These studies provide a novel mechanism for how TGF-beta signaling is regulated by the tumor microenvironment, and provide insight into targeting the TGF-beta signaling pathway in human breast cancer patients.	[Tian, H.; Chen, J.; Blobe, G. C.] Duke Univ, Med Ctr, Div Med Oncol, Dept Med, Durham, NC 27708 USA; [Liu, J.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27708 USA; [Liu, J.] Chinese Acad Sci, State Key Lab Phytochem & Plant Resources West Ch, Kunming Inst Bot, Kunming, Yunnan, Peoples R China; [Gatza, M. L.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Blobe, G. C.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27708 USA	Duke University; Duke University; Chinese Academy of Sciences; Kunming Institute of Botany, CAS; University of North Carolina; University of North Carolina Chapel Hill; Duke University	Blobe, GC (corresponding author), Duke Univ, Med Ctr, Dept Med Pharmacol & Canc Biol, B354 LSRC,Box 91004, Durham, NC 27708 USA.	gerard.blobe@duke.edu	Blobe, Gerard/AAJ-5945-2020; Wang, Limin/O-3724-2015	Blobe, Gerard/0000-0002-4274-8901; Gatza, Michael/0000-0001-6796-7791	Komen for the Cure [KG111383, SAC100002]; NIH/NCI [R01-135006, R01-136786]; NATIONAL CANCER INSTITUTE [R01CA136786, R01CA135006] Funding Source: NIH RePORTER	Komen for the Cure(Susan G. Komen Breast Cancer Foundation); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by Komen for the Cure Grants KG111383 (HT) and SAC100002 (GCB), NIH/NCI Grants R01-135006 (GCB), and R01-136786 (GCB). We thank Yi-Hong Zhou at University of California Irvine for the fibulin-3 pcDNA3.1 overexpression plasmid.	Allinen M, 2004, CANCER CELL, V6, P17, DOI 10.1016/j.ccr.2004.06.010; ANDRES JL, 1992, J BIOL CHEM, V267, P5927; Argraves WS, 2003, EMBO REP, V4, P1127, DOI 10.1038/sj.embor.7400033; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bierie B, 2009, CELL CYCLE, V8, P3319, DOI 10.4161/cc.8.20.9727; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Buck MB, 2006, ANN NY ACAD SCI, V1089, P119, DOI 10.1196/annals.1386.024; Camaj P, 2009, BIOL CHEM, V390, P1293, DOI 10.1515/BC.2009.140; Chang CF, 2007, FRONT BIOSCI-LANDMRK, V12, P4393, DOI 10.2741/2396; Chen XJ, 2014, CARCINOGENESIS, V35, P1707, DOI 10.1093/carcin/bgu023; Cho JA, 2012, INT J ONCOL, V40, P130, DOI 10.3892/ijo.2011.1193; Culig Z, 2011, BBA-MOL CELL RES, V1813, P308, DOI 10.1016/j.bbamcr.2010.12.010; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Drabsch Y, 2011, J MAMMARY GLAND BIOL, V16, P97, DOI 10.1007/s10911-011-9217-1; Gallagher WM, 2005, TRENDS MOL MED, V11, P336, DOI 10.1016/j.molmed.2005.06.001; Gao H, 2012, CELL, V150, P764, DOI 10.1016/j.cell.2012.06.035; Gold LI, 1999, CRIT REV ONCOGENESIS, V10, P303; Hanks BA, 2013, J CLIN INVEST, V123, P3925, DOI 10.1172/JCI65745; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hu B, 2012, CANCER RES, V72, P3873, DOI 10.1158/0008-5472.CAN-12-1060; Hwang CF, 2010, J PATHOL, V222, P367, DOI 10.1002/path.2776; Hynes NE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003186; Imamura T, 2012, BREAST CANCER-TOKYO, V19, P118, DOI 10.1007/s12282-011-0321-2; Kim EJ, 2012, INT J ONCOL, V40, P402, DOI 10.3892/ijo.2011.1191; Kim YJ, 2011, CLIN CANCER RES, V17, P4523, DOI 10.1158/1078-0432.CCR-10-2817; Kobayashi N, 2007, J BIOL CHEM, V282, P11805, DOI 10.1074/jbc.M611029200; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Laib AM, 2009, NAT PROTOC, V4, P1202, DOI 10.1038/nprot.2009.96; Lee JK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084256; Luo RZ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070511; Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moses H, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a003277; Muraoka-Cook RS, 2005, CLIN CANCER RES, V11, p937S; Nicolini A, 2006, CYTOKINE GROWTH F R, V17, P325, DOI 10.1016/j.cytogfr.2006.07.002; O'Brien K, 2013, EUR J CANCER, V49, P1845, DOI 10.1016/j.ejca.2013.01.017; Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912; Sadr-Nabavi A, 2009, INT J CANCER, V124, P1727, DOI 10.1002/ijc.24108; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Tong JD, 2011, NEOPLASMA, V58, P441, DOI 10.4149/neo_2011_05_441; Wang Z, 2012, PATHOL ONCOL RES, V18, P263, DOI 10.1007/s12253-011-9437-0; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Zu XY, 2012, CELL TISSUE RES, V347, P73, DOI 10.1007/s00441-011-1225-3	50	36	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2015	34	45					5635	5647		10.1038/onc.2015.13	http://dx.doi.org/10.1038/onc.2015.13			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CV9GA	25823021	Green Submitted, Green Accepted			2022-12-17	WOS:000364594300005
J	Fan, LC; Shiau, CW; Tai, WT; Hung, MH; Chu, PY; Hsieh, FS; Lin, H; Yu, HC; Chen, KF				Fan, L-C; Shiau, C-W; Tai, W-T; Hung, M-H; Chu, P-Y; Hsieh, F-S; Lin, H.; Yu, H-C; Chen, K-F			SHP-1 is a negative regulator of epithelial-mesenchymal transition in hepatocellular carcinoma	ONCOGENE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; GROWTH-FACTOR RECEPTOR; G-ALPHA-I; TGF-BETA; SIGNAL TRANSDUCER; STAT3 ACTIVATION; CELL-CYCLE; MECHANISMS; SORAFENIB; EXPRESSION	Epithelial-to-mesenchymal transition (EMT) is well known to involve in tumor invasion and metastasis. Src homology region 2 domain-containing phosphatase 1 (SHP-1) functions as a potent tumor suppressor and also acts as a negative regulator of p-STAT3(Tyr705) oncogenic signaling. However, little is known about the molecular mechanism(s) through which SHP-1 regulates EMT during hepatocellular carcinoma (HCC) progression. Here we first reported that endogenous SHP-1 protein levels were significantly downregulated in cells with mesenchymal characteristics and negatively correlated with p-STAT3(Tyr705) and vimentin but positively correlated with E-cadherin. SHP-1 overexpression abolished transforming growth factor-beta 1 (TGF-beta 1)-induced p-STAT3(Tyr705) and EMT, as well inhibited migration and invasion but further rescued by signal transducer and activator of transcription factor 3 (STAT3) overexpression. Depletion of SHP-1 could induce a more increase in TGF-beta 1-induced p-STAT3(Tyr-705) and EMT characteristics, further supporting the mechanism that suppression of TGF-beta 1-induced EMT is dependent on SHP-1-mediated STAT3 inactivation. Constitutively overexpressed SHP-1 tyrosine phosphatase activity by D61A-mutated SHP-1 markedly reduced TGF-beta 1-induced p-STAT3(Tyr705) and EMT features but was not altered by C453S catalytic-dead mutant SHP-1. Consequently, SHP-1 acted as a powerful suppressor in preventing EMT by exerting its tyrosine phosphatase activity that directly downregulated p-STAT3(Tyr705). Most notably, we discovered a novel SHP-1 agonist SC-43 better than sorafenib to exert more potent anti-EMT effects in vitro as well as anti-metastatic growth in vivo. In conclusion, SHP-1 is a potent suppressor of HCC EMT and metastasis, thus highlighting that SC-43-SHP-1 axis may serve as a potential therapeutic target that antagonized p-STAT3(Tyr705) and thereby prevented HCC EMT and metastasis.	[Fan, L-C; Tai, W-T; Hsieh, F-S; Lin, H.; Yu, H-C; Chen, K-F] Natl Taiwan Univ Hosp, Dept Med Res, Taipei 100, Taiwan; [Fan, L-C; Tai, W-T; Hsieh, F-S; Lin, H.; Yu, H-C; Chen, K-F] Natl Taiwan Univ Hosp, Natl Ctr Excellence Clin Trial & Res, Taipei 100, Taiwan; [Shiau, C-W] Natl Yang Ming Univ, Inst Biopharmaceut Sci, Taipei 112, Taiwan; [Hung, M-H] Taipei Vet Gen Hosp, Dept Med, Div Hematol & Oncol, Taipei, Taiwan; [Hung, M-H] Natl Yang Ming Univ, Sch Life Sci, Program Mol Med, Taipei 112, Taiwan; [Chu, P-Y] Show Chwan Mem Hosp, Dept Pathol, Changhua, Taiwan; [Chu, P-Y] Fu Jen Catholic Univ, Sch Med, New Taipei City, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; National Yang Ming Chiao Tung University; Show Chwan Memorial Hospital; Fu Jen Catholic University	Chen, KF (corresponding author), Natl Taiwan Univ Hosp, Dept Med Res, 7 Chung Shan South Rd, Taipei 100, Taiwan.	kfchen1970@ntu.edu.tw		Chen, Kuen-Feng/0000-0002-4686-7019; Chu, Pei-Yi/0000-0001-7336-2465	National Science Council [NSC 102-2325-B-002-031, NHRI-EX102-10246B]; National Health Research Institutes, Taiwan	National Science Council(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan)	This work was supported by grants NSC 102-2325-B-002-031 and NHRI-EX102-10246BI from the National Science Council and the National Health Research Institutes, Taiwan. For SHP-1 and E-cadherin, gene expression levels were assessed by using microarray data deposited in the Gene Expression Omnibus (GEO) database under accession no. GSE25097.	BANVILLE D, 1995, GENOMICS, V27, P165, DOI 10.1006/geno.1995.1020; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chen KF, 2012, EUR J MED CHEM, V55, P220, DOI 10.1016/j.ejmech.2012.07.023; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Garcia-Marcos M, 2009, P NATL ACAD SCI USA, V106, P3178, DOI 10.1073/pnas.0900294106; Ghosh P, 2010, MOL BIOL CELL, V21, P2338, DOI 10.1091/mbc.E10-01-0028; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4; Kang JH, 2008, CANCER LETT, V261, P84, DOI 10.1016/j.canlet.2007.11.006; Lee JH, 2014, CANCER LETT, V345, P140, DOI 10.1016/j.canlet.2013.12.008; Liu CY, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3457; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lopez-Ruiz P, 2011, ANTI-CANCER AGENT ME, V11, P89, DOI 10.2174/187152011794941154; Lu HS, 2014, TUMOR BIOL, V35, P9807, DOI 10.1007/s13277-014-2256-7; Luo F, 2013, TOXICOL APPL PHARM, V273, P27, DOI 10.1016/j.taap.2013.08.025; Mittal Y, 2011, J BIOL CHEM, V286, P32404, DOI 10.1074/jbc.M111.275685; MOK SC, 1995, GYNECOL ONCOL, V57, P299, DOI 10.1006/gyno.1995.1146; Oh J, 2004, CANCER RES, V64, P9062, DOI 10.1158/0008-5472.CAN-04-1981; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Rokavec M, 2014, J CLIN INVEST, V124, P1853, DOI 10.1172/JCI73531; Sainz-Perez A, 2008, J IMMUNOL, V181, P6051, DOI 10.4049/jimmunol.181.9.6051; Simpson D, 2008, DRUGS, V68, P251, DOI 10.2165/00003495-200868020-00007; Tai WT, 2014, HEPATOLOGY, V59, P190, DOI 10.1002/hep.26640; Tai WT, 2011, J HEPATOL, V55, P1041, DOI 10.1016/j.jhep.2011.06.005; Tsui HW, 2002, EUR J BIOCHEM, V269, P3057, DOI 10.1046/j.1432-1033.2002.02986.x; Wendt MK, 2009, FUTURE ONCOL, V5, P1145, DOI 10.2217/FON.09.90; Witkiewicz A, 2007, HUM PATHOL, V38, P462, DOI 10.1016/j.humpath.2006.09.012; Wu CY, 2003, J CELL BIOCHEM, V90, P1026, DOI 10.1002/jcb.10727; Wu CY, 2003, GENE, V306, P1, DOI 10.1016/S0378-1119(03)00400-1; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Yang YN, 2006, CANCER RES, V66, P8617, DOI 10.1158/0008-5472.CAN-06-1308; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang Zhuqing, 2013, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V27, P1265	34	36	38	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5252	5263		10.1038/onc.2014.445	http://dx.doi.org/10.1038/onc.2014.445			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25619838				2022-12-17	WOS:000362575400005
J	Klein, SR; Piya, S; Lu, Z; Xia, Y; Alonso, MM; White, EJ; Wei, J; Gomez-Manzano, C; Jiang, H; Fueyo, J				Klein, S. R.; Piya, S.; Lu, Z.; Xia, Y.; Alonso, M. M.; White, E. J.; Wei, J.; Gomez-Manzano, C.; Jiang, H.; Fueyo, J.			C-Jun N-terminal kinases are required for oncolytic adenovirus-mediated autophagy	ONCOGENE			English	Article							PATHWAY; PHOSPHORYLATION; VIRUS; ACTIVATION; INHIBITOR; APOPTOSIS; BECLIN-1; STRESS; CELLS; TSC2	Oncolytic adenoviruses, such as Delta-24-RGD (Delta 24RGD), are replication-competent viruses that are genetically engineered to induce selective cancer cell lysis. In cancer cells,Delta 24RGD induces massive autophagy, which is required for efficient cell lysis and adenoviral spread. Understanding the cellular mechanisms underlying the regulation of autophagy in cells treated with oncolytic adenoviruses may provide new avenues to improve the therapeutic effect. In this work, we showed that cancer cells infected with Delta 24RGDundergo autophagy despite the concurrent activation of the AKT/mTOR pathway. Moreover, adenovirus replication induced sustained activation of JNK proteins in vitro. ERK1/2 phosphorylation remained unchanged during adenoviral infection, suggesting specificity of JNK activation. Using genetic ablation and pharmacological inactivation of JNK, we unequivocally demonstrated that cells infected with Delta 24RGD required JNK activation. Thus, genetic co-ablation of JNK1 and JNK2 genes or inhibition of JNK kinase function rendered Delta 24RGD-treated cells resistant to autophagy. Accordingly, JNK activation induced phosphorylation of Bcl-2 and prevented the formation of Bcl-2/Beclin 1 autophagy suppressor complexes. Using an orthotopic model of human glioma xenograft, we showed that treatment with.24RGD induced phosphorylation and nuclear translocation of JNK, as well as phosphorylation of Bcl-2. Collectively, our data identified JNK proteins as an essential mechanistic link between Delta 24RGD infection and autophagy in cancer cells. Activation of JNK without inactivation of the AKT/mTOR pathway constitutes a distinct molecular signature of autophagy regulation that differentiates Delta 24RGD adenovirus from the mechanism used by other oncolytic viruses to induce autophagy and provides a new rationale for the combination of oncolytic viruses and chemotherapy.	[Klein, S. R.; Piya, S.; Lu, Z.; Xia, Y.; White, E. J.; Gomez-Manzano, C.; Jiang, H.; Fueyo, J.] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Klein, S. R.; Piya, S.; Gomez-Manzano, C.] Univ Texas Houston, Grad Sch Biomed Sci Houston, Canc Biol Program, Houston, TX USA; [Alonso, M. M.] Univ Hosp Navarra, Dept Med Oncol, Pamplona, Spain; [Wei, J.; Fueyo, J.] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurosurg, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Servicio Navarro de Salud - Osasunbidea; University of Navarra; University of Texas System; UTMD Anderson Cancer Center	Fueyo, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurooncol, S5-8316,Unit 1002,1515 Holcombe Blvd, Houston, TX 77030 USA.	jfueyo@mdanderson.org	Alonso, Marta M/AAI-9457-2020	Alonso, Marta M/0000-0002-7520-7351; Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133	NHI/NCI [P50CA127001, P30CA016672]; Marnie Rose Foundation; Will Power Foundation; Schissler Foundation; American Legion Auxiliary; NATIONAL CANCER INSTITUTE [P30CA016672, P50CA127001] Funding Source: NIH RePORTER	NHI/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Marnie Rose Foundation; Will Power Foundation; Schissler Foundation; American Legion Auxiliary; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Tamara Locke (Department of Scientific Publications, The University of Texas MD Anderson Cancer Center) for editorial assistance. This work was supported by grants from the NHI/NCI (P50CA127001; Cancer Center Support Grant P30CA016672-High Resolution Electron Microscopy and Research Animal Support Facilities), the Marnie Rose Foundation, the Will Power Foundation, the Schissler Foundation and the American Legion Auxiliary.	Alonso MM, 2008, MOL THER, V16, P487, DOI 10.1038/sj.mt.6300400; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bode AM, 2007, MOL CARCINOGEN, V46, P591, DOI 10.1002/mc.20348; Chen L, 2009, CANCER LETT, V284, P141, DOI 10.1016/j.canlet.2009.04.026; Dong XN, 2013, J INNATE IMMUN, V5, P480, DOI 10.1159/000346388; Eyre TA, 2014, BRIT J HAEMATOL, V166, P336, DOI 10.1111/bjh.12945; Fueyo J, 2000, ONCOGENE, V19, P2, DOI 10.1038/sj.onc.1203251; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Gingras AC, 2003, CURR TOP MICROBIOL, V279, P169; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; He B, 2006, CELL DEATH DIFFER, V13, P393, DOI 10.1038/sj.cdd.4401833; Hung CH, 2014, J VIROL, V88, P12133, DOI 10.1128/JVI.02033-14; Ingemarsdotter CK, 2010, ONCOGENE, V29, P6051, DOI 10.1038/onc.2010.335; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ito H, 2006, JNCI-J NATL CANCER I, V98, P625, DOI 10.1093/jnci/djj161; Jiang H, 2011, J VIROL, V85, P4720, DOI 10.1128/JVI.02032-10; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Kudchodkar SB, 2004, J VIROL, V78, P11030, DOI 10.1128/JVI.78.20.11030-11039.2004; Kumar SH, 2009, J VIROL, V83, P8565, DOI 10.1128/JVI.00603-09; Li XD, 2005, VIROLOGY, V333, P180, DOI 10.1016/j.virol.2005.01.002; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Liu TC, 2007, NAT CLIN PRACT ONCOL, V4, P101, DOI 10.1038/ncponc0736; Martin JH, 1996, MOL BRAIN RES, V35, P47, DOI 10.1016/0169-328X(95)00181-Q; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Oberstein A, 2007, J BIOL CHEM, V282, P13123, DOI 10.1074/jbc.M700492200; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Orvedahl A, 2008, AUTOPHAGY, V4, P280, DOI 10.4161/auto.5289; Orvedahl A, 2007, CELL HOST MICROBE, V1, P23, DOI 10.1016/j.chom.2006.12.001; Piya S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029467; Russell SJ, 2012, NAT BIOTECHNOL, V30, P658, DOI 10.1038/nbt.2287; Shelly S, 2009, IMMUNITY, V30, P588, DOI 10.1016/j.immuni.2009.02.009; Shertz CA, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002269; Wang JR, 2009, J BIOL CHEM, V284, P21412, DOI 10.1074/jbc.M109.026013; Wang W, 2014, MOL CANCER THER, V13, P1480, DOI 10.1158/1535-7163.MCT-13-0629; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Wileman T, 2006, SCIENCE, V312, P875, DOI 10.1126/science.1126766; Xu P, 2011, GENE DEV, V25, P310, DOI 10.1101/gad.1984311	42	36	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2015	34	41					5295	5301		10.1038/onc.2014.452	http://dx.doi.org/10.1038/onc.2014.452			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CT1QL	25619840	Green Accepted			2022-12-17	WOS:000362575400009
J	Musahl, AS; Huang, X; Rusakiewicz, S; Ntini, E; Marsico, A; Kroemer, G; Kepp, O; Orom, UA				Musahl, A-S; Huang, X.; Rusakiewicz, S.; Ntini, E.; Marsico, A.; Kroemer, G.; Kepp, O.; Orom, U. A.			A long non-coding RNA links calreticulin-mediated immunogenic cell removal to RB1 transcription	ONCOGENE			English	Article							BIDIRECTIONAL PROMOTERS; DIVERGENT TRANSCRIPTION; HUMAN GENOME; GENE-EXPRESSION; MAJOR SOURCE; CHROMATIN; REVEALS; ELEMENTS; CANCER; SITE	A subset of promoters bidirectionally expresses long non-coding RNAs (ncRNAs) of unknown function and protein-coding genes (PCGs) in parallel. Here, we define a set of 1107 highly conserved human bidirectional promoters that mediate the linked expression of long ncRNAs and PCGs. Depletion of the long ncRNA expressed from the RB1 promoter, ncRNA-RB1, reveals regulatory effects different from the RB1-controlled transcriptional program. ncRNA-RB1 positively regulates the expression of calreticulin (CALR) that in response to certain therapeutic interventions can translocate from the endoplasmic reticulum to the cell surface, hence activating anticancer immune responses. Knockdown of ncRNA-RB1 in tumor cells reduced expression of CALR, impaired the translocation of the protein to the cell surface upon treatment with anthracylines and consequently inhibited the cellular uptake by macrophages. In conclusion, co-transcription of ncRNA-RB1 and RB1 provides a positive link between the expression of the two tumor suppressors RB1 and the immune-relevant CALR protein. This regulatory interplay exemplifies disease-relevant co-regulation of two distinct gene products, in which loss of expression of one oncosuppressor protein entails the abolition of additional tumor-inhibitory mechanisms.	[Musahl, A-S; Ntini, E.; Orom, U. A.] Max Planck Inst Mol Genet, Noncoding RNA Res Grp, D-14195 Berlin, Germany; [Huang, X.; Kroemer, G.; Kepp, O.] INSERM, Cordeliers Res Canc, U1138, Team11,Equipe Labellisee Ligue Canc, Paris, France; [Huang, X.; Kroemer, G.; Kepp, O.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Huang, X.; Kroemer, G.; Kepp, O.] Gustave Roussy Comprehens Canc Ctr, Cell Biol & Metabol Platforms, Villejuif, France; [Rusakiewicz, S.] Gustave Roussy, Villejuif, France; [Rusakiewicz, S.] INSERM, U1015, CICBT507, Villejuif, France; [Marsico, A.] Max Planck Inst Mol Genet, Dept Computat Biol, D-14195 Berlin, Germany; [Marsico, A.] Max Planck Inst Mol Genet, RNA Bioinformat Grp, D-14195 Berlin, Germany; [Marsico, A.] Free Univ Berlin, Berlin, Germany; [Kroemer, G.] Univ Paris 06, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Max Planck Society; Max Planck Society; Free University of Berlin; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Orom, UA (corresponding author), Max Planck Inst Mol Genet, Warburg Labs, Ihnestr 63, D-14195 Berlin, Germany.	Oerom@molgen.mpg.de	Marsico, Annalisa/AFU-3262-2022; Kepp, Oliver/GPX-8627-2022; KROEMER, Guido/B-4263-2013; Kroemer, Guido/AAY-9859-2020; Kepp, Oliver/N-2763-2017; 黄, 星/AAB-2241-2019	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; 黄, 星/0000-0002-8886-2777; Ntini, Evgenia/0000-0002-4649-6051; Orom, Ulf/0000-0002-0643-0592	Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); European Commission (ArtForce); European Research Council (ERC); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); German Ministry of education and research through the Alexander von Humboldt Foundation Sofja Kovalevskaja Award	Ligue contre le Cancer (equipe labelisee)(Ligue nationale contre le cancer); Agence National de la Recherche (ANR)(French National Research Agency (ANR)); Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Canceropole Ile-de-France(Region Ile-de-France); AXA Chair for Longevity Research(AXA Research Fund); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation Bettencourt-Schueller; Fondation de France(Fondation de France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); European Research Council (ERC)(European Research Council (ERC)European Commission); LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); SIRIC Cancer Research and Personalized Medicine (CARPEM); Paris Alliance of Cancer Research Institutes (PACRI); German Ministry of education and research through the Alexander von Humboldt Foundation Sofja Kovalevskaja Award	Work in the laboratories of GK and OK are suppported by the Ligue contre le Cancer (equipe labelisee); Agence National de la Recherche (ANR); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; AXA Chair for Longevity Research; Institut National du Cancer (INCa); Fondation Bettencourt-Schueller; Fondation de France; Fondation pour la Recherche Medicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI). Work in the laboratory of UAO is supported by the German Ministry of education and research through the Alexander von Humboldt Foundation Sofja Kovalevskaja Award.	Adachi N, 2002, CELL, V109, P807, DOI 10.1016/S0092-8674(02)00758-4; Almada AE, 2013, NATURE, V499, P360, DOI 10.1038/nature12349; Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787; Bhatt DM, 2012, CELL, V150, P279, DOI 10.1016/j.cell.2012.05.043; Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Chao MP, 2012, NAT REV CANCER, V12, P58, DOI 10.1038/nrc3171; Chao MP, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001375; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Flynn RA, 2011, P NATL ACAD SCI USA, V108, P10460, DOI 10.1073/pnas.1106630108; Fruman DA, 2014, NAT REV DRUG DISCOV, V13, P140, DOI 10.1038/nrd4204; Gardai SJ, 2005, CELL, V123, P321, DOI 10.1016/j.cell.2005.08.032; GILL RM, 1994, CELL GROWTH DIFFER, V5, P467; Grote P, 2013, DEV CELL, V24, P206, DOI 10.1016/j.devcel.2012.12.012; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Harrow J, 2012, GENOME RES, V22, P1760, DOI 10.1101/gr.135350.111; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lenhard B, 2012, NAT REV GENET, V13, P233, DOI 10.1038/nrg3163; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Manning AL, 2011, TRENDS CELL BIOL, V21, P433, DOI 10.1016/j.tcb.2011.05.003; Marquardt S, 2014, CELL, V157, P1712, DOI 10.1016/j.cell.2014.04.036; Melo CA, 2013, MOL CELL, V49, P524, DOI 10.1016/j.molcel.2012.11.021; Michalak M, 2009, BIOCHEM J, V417, P651, DOI 10.1042/BJ20081847; Neil H, 2009, NATURE, V457, P1038, DOI 10.1038/nature07747; Ntini E, 2013, NAT STRUCT MOL BIOL, V20, P923, DOI 10.1038/nsmb.2640; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Orom UA, 2013, CELL, V154, P1190, DOI 10.1016/j.cell.2013.08.028; Orom UA, 2010, CELL, V143, P46, DOI 10.1016/j.cell.2010.09.001; Ozsolak F, 2007, NAT BIOTECHNOL, V25, P244, DOI 10.1038/nbt1279; Pandey RR, 2008, MOL CELL, V32, P232, DOI 10.1016/j.molcel.2008.08.022; Polson A, 2014, GENE, V538, P138, DOI 10.1016/j.gene.2013.12.046; Preker P, 2008, SCIENCE, V322, P1851, DOI 10.1126/science.1164096; Rhee HS, 2012, NATURE, V483, P295, DOI 10.1038/nature10799; Rinn JL, 2007, CELL, V129, P1311, DOI 10.1016/j.cell.2007.05.022; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAVOYSKY E, 1994, ONCOGENE, V9, P1839; Seila AC, 2008, SCIENCE, V322, P1849, DOI 10.1126/science.1162253; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Sigova AA, 2013, P NATL ACAD SCI USA, V110, P2876, DOI 10.1073/pnas.1221904110; Sowa Y, 1997, CANCER RES, V57, P3145; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Trimarchi T, 2014, CELL, V158, P593, DOI 10.1016/j.cell.2014.05.049; Uesaka M, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-35; Wakano C, 2012, BBA-GENE REGUL MECH, V1819, P688, DOI 10.1016/j.bbagrm.2012.02.006; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wu XB, 2013, CELL, V155, P990, DOI 10.1016/j.cell.2013.10.048; Yang MQ, 2007, PLOS COMPUT BIOL, V3, P733, DOI 10.1371/journal.pcbi.0030072; Zhang L, 2013, MOL CELL BIOCHEM, V382, P237, DOI 10.1007/s11010-013-1739-y; Zhao J, 2008, SCIENCE, V322, P750, DOI 10.1126/science.1163045	57	36	37	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	2015	34	39					5046	5054		10.1038/onc.2014.424	http://dx.doi.org/10.1038/onc.2014.424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CR9RC	25579178	Green Published			2022-12-17	WOS:000361693300005
J	Emelyanov, A; Bulavin, DV				Emelyanov, A.; Bulavin, D. V.			Wip1 phosphatase in breast cancer	ONCOGENE			English	Review							COMPARATIVE GENOMIC HYBRIDIZATION; MAMMARY EPITHELIAL-CELLS; DNA-DAMAGE RESPONSE; TUMOR-SUPPRESSOR ACTIVITY; GENE-EXPRESSION PATTERNS; IN-SITU HYBRIDIZATION; NF-KAPPA-B; PROGENITOR CELLS; COPY NUMBER; PROTEIN PHOSPHATASE	Understanding the factors contributing to tumor initiation, progression and evolution is of paramount significance. Among them, wild-type p53-induced phosphatase 1 (Wip1) is emerging as an important oncogene by virtue of its negative control on several key tumor suppressor pathways. Originally discovered as a p53-regulated gene, Wip1 has been subsequently found amplified and more recently mutated in a significant fraction of human cancers including breast tumors. Recent development in the field further uncovered the utility of anti-Wip1-directed therapies in delaying tumor onset or in reducing the tumor burden. Furthermore, Wip1 could be an important factor that contributes to tumor heterogeneity, suggesting that its inhibition may decrease the rate of cancer evolution. These effects depend on several signaling pathways modulated by Wip1 phosphatase in a spatial and temporal manner. In this review we discuss the recent development in understanding how Wip1 contributes to tumorigenesis with its relevance to breast cancer.	[Emelyanov, A.; Bulavin, D. V.] Univ Nice Sophia Antipolis, Ctr Antoine Lacassagne, CNRS, IRCAN,INSERM,U1081,UMR 7284, F-06189 Nice, France; [Bulavin, D. V.] Proteos, Inst Mol & Cell Biol, Singapore, Singapore	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Bulavin, DV (corresponding author), IRCAN, Nice, France.	Dmitry.Bulavin@unice.fr		Emelyanov, Alexander/0000-0002-8693-794X	Agency for Science, Technology and Research (Singapore); Foundation ARC (France)	Agency for Science, Technology and Research (Singapore)(Agency for Science Technology & Research (A*STAR)); Foundation ARC (France)	The research for DVB was supported by the Agency for Science, Technology and Research (Singapore) and for AE and DVB by the Foundation ARC (France).	Abraham SC, 2002, HUM PATHOL, V33, P39, DOI 10.1053/hupa.2002.30196; Al-Kuraya K, 2004, CANCER RES, V64, P8534, DOI 10.1158/0008-5472.CAN-04-1945; Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; Ali AY, 2012, ONCOGENE, V31, P2175, DOI 10.1038/onc.2011.399; Andersen CL, 2002, AM J PATHOL, V161, P73, DOI 10.1016/S0002-9440(10)64158-2; Andrulis IL, 1998, J CLIN ONCOL, V16, P1340, DOI 10.1200/JCO.1998.16.4.1340; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Axlund SD, 2012, MOL CELL ENDOCRINOL, V357, P71, DOI 10.1016/j.mce.2011.09.021; Barlund M, 2000, CANCER RES, V60, P5340; Belgnaoui SM, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-13; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Bilal E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038575; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Bransteitter R, 2009, CELL MOL LIFE SCI, V66, P3137, DOI 10.1007/s00018-009-0070-y; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Burns MB, 2013, NATURE, V494, P366, DOI 10.1038/nature11881; Buss MC, 2015, ONCOGENE, V34, P1126, DOI 10.1038/onc.2014.37; Carr JA, 2000, ARCH SURG-CHICAGO, V135, P1469, DOI 10.1001/archsurg.135.12.1469; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Cha H, 2010, CANCER RES, V70, P4112, DOI 10.1158/0008-5472.CAN-09-4244; Chen L, 2012, BREAST CANCER RES TR, V136, P129, DOI 10.1007/s10549-012-2246-7; Cheung AMY, 2004, CANCER RES, V64, P1959, DOI 10.1158/0008-5472.CAN-03-2270; Chew J, 2009, NAT CELL BIOL, V11, P659, DOI 10.1038/ncb1873; Clarke RB, 1997, CANCER RES, V57, P4987; Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187; Cooke SL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4644; Costello JF, 2000, NAT GENET, V24, P132, DOI 10.1038/72785; Courjal F, 1997, CANCER RES, V57, P4368; Cruickshanks HA, 2009, GENOMICS, V94, P397, DOI 10.1016/j.ygeno.2009.08.013; Curtin NJ, 2012, NAT REV CANCER, V12, P801, DOI 10.1038/nrc3399; Dawson SJ, 2013, EMBO J, V32, P617, DOI 10.1038/emboj.2013.19; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Dudgeon C, 2013, CELL CYCLE, V12, P2656, DOI 10.4161/cc.25694; Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925; Filipponi D, 2013, CANCER CELL, V24, P528, DOI 10.1016/j.ccr.2013.08.022; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Fuku T, 2007, PATHOL INT, V57, P566, DOI 10.1111/j.1440-1827.2007.02140.x; Gasior SL, 2006, J MOL BIOL, V357, P1383, DOI 10.1016/j.jmb.2006.01.089; Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205; Gilmartin AG, 2014, NAT CHEM BIOL, V10, P181, DOI [10.1038/NCHEMBIO.1427, 10.1038/nchembio.1427]; Goloudina AR, 2012, CELL CYCLE, V11, P1883, DOI 10.4161/cc.19901; Goloudina AR, 2012, P NATL ACAD SCI USA, V109, pE68, DOI 10.1073/pnas.1107017108; Guedj M, 2012, ONCOGENE, V31, P1196, DOI 10.1038/onc.2011.301; Hancks DC, 2012, CURR OPIN GENET DEV, V22, P191, DOI 10.1016/j.gde.2012.02.006; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hayes MJ, 2008, CLIN CANCER RES, V14, P4038, DOI 10.1158/1078-0432.CCR-07-4379; Helman E, 2014, GENOME RES, V24, P1053, DOI 10.1101/gr.163659.113; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Ho GH, 2001, BREAST CANCER RES TR, V65, P225, DOI 10.1023/A:1010686518990; Horlings HM, 2010, CLIN CANCER RES, V16, P651, DOI 10.1158/1078-0432.CCR-09-0709; Horseman ND, 2014, J MOL ENDOCRINOL, V52, pR95, DOI 10.1530/JME-13-0220; Hu Wenwei, 2010, Genes Cancer, V1, P360; Hyman E, 2002, CANCER RES, V62, P6240; Jackson SP, 2013, MOL CELL, V49, P795, DOI 10.1016/j.molcel.2013.01.017; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Jiao L, 2014, ANTICANCER RES, V34, P2919; Jonkers J, 2001, NAT GENET, V29, P418, DOI 10.1038/ng747; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kasahara K, 2002, CANCER GENET CYTOGEN, V137, P59, DOI 10.1016/S0165-4608(02)00552-6; KAZAZIAN HH, 1988, NATURE, V332, P164, DOI 10.1038/332164a0; Kelemen LE, 2009, CANCER EPIDEM BIOMAR, V18, P1864, DOI 10.1158/1055-9965.EPI-08-0486; Kleiblova P, 2013, J CELL BIOL, V201, P511, DOI 10.1083/jcb.201210031; Kong WH, 2009, CANCER BIOL THER, V8, P555, DOI 10.4161/cbt.8.6.7742; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lambros MB, 2010, MODERN PATHOL, V23, P1334, DOI 10.1038/modpathol.2010.121; Lamy PJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2824; Lee E, 2012, SCIENCE, V337, P967, DOI 10.1126/science.1222077; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Li GB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060775; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lonning PE, 2013, ONCOGENE, V32, P5315, DOI 10.1038/onc.2013.48; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Lowe JM, 2010, J BIOL CHEM, V285, P5249, DOI 10.1074/jbc.M109.034579; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2004, MOL CELL, V15, P621, DOI 10.1016/j.molcel.2004.08.007; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Ludwig T, 2001, ONCOGENE, V20, P3937, DOI 10.1038/sj.onc.1204512; Ma D, 2014, MOL MED REP, V10, P191, DOI 10.3892/mmr.2014.2165; Macurek L, 2010, ONCOGENE, V29, P2281, DOI 10.1038/onc.2009.501; Melchor L, 2005, CLIN CANCER RES, V11, P8577, DOI 10.1158/1078-0432.CCR-05-1278; Mendrzyk F, 2005, J CLIN ONCOL, V23, P8853, DOI 10.1200/JCO.2005.02.8589; MIKI Y, 1992, CANCER RES, V52, P643; Miyoshi K, 2001, J CELL BIOL, V155, P531, DOI 10.1083/jcb.200107065; Mizuno H, 2010, P NATL ACAD SCI USA, V107, P22745, DOI 10.1073/pnas.1017001108; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Monni O, 2001, P NATL ACAD SCI USA, V98, P5711, DOI 10.1073/pnas.091582298; Moon SH, 2010, J BIOL CHEM, V285, P12935, DOI 10.1074/jbc.M109.071696; Moore E, 1999, J PATHOL, V187, P403, DOI 10.1002/(SICI)1096-9896(199903)187:4<403::AID-PATH284>3.0.CO;2-J; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; Nan FF, 2012, J CANCER RES CLIN, V138, P1937, DOI 10.1007/s00432-012-1272-5; Natrajan R, 2010, BREAST CANCER RES TR, V121, P575, DOI 10.1007/s10549-009-0501-3; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Nguyen TA, 2010, DNA REPAIR, V9, P813, DOI 10.1016/j.dnarep.2010.04.005; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Oliva-Trastoy M, 2007, ONCOGENE, V26, P1449, DOI 10.1038/sj.onc.1209927; Orsetti B, 2004, CANCER RES, V64, P6453, DOI 10.1158/0008-5472.CAN-04-0756; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Parssinen J, 2007, BRIT J CANCER, V96, P1258, DOI 10.1038/sj.bjc.6603692; Parssinen J, 2008, CANCER GENET CYTOGEN, V182, P33, DOI 10.1016/j.cancergencyto.2007.12.013; Peng TS, 2014, EXP THER MED, V8, P430, DOI 10.3892/etm.2014.1762; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Polyak K, 2011, J CLIN INVEST, V121, P3786, DOI 10.1172/JCI60534; Raouf A, 2012, SEMIN CELL DEV BIOL, V23, P606, DOI 10.1016/j.semcdb.2012.04.009; Rauta J, 2006, BREAST CANCER RES TR, V95, P257, DOI 10.1007/s10549-005-9017-7; Rennstam K, 2003, CANCER RES, V63, P8861; Reynolds PA, 2006, J BIOL CHEM, V281, P24790, DOI 10.1074/jbc.M604175200; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Rodic N, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003402; Rosen Jeffrey M, 2003, Breast Dis, V18, P3; Roy S, 2013, P NATL ACAD SCI USA, V110, P4598, DOI 10.1073/pnas.1218682110; Roylance R, 1999, CANCER RES, V59, P1433; Ruark E, 2013, NATURE, V493, P406, DOI 10.1038/nature11725; Russo J, 2004, MATURITAS, V49, P2, DOI 10.1016/j.maturitas.2004.04.011; Saito-Ohara F, 2003, CANCER RES, V63, P1876; Sale S, 2013, NAT CELL BIOL, V15, P451, DOI 10.1038/ncb2725; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shaltiel IA, 2014, P NATL ACAD SCI USA, V111, P7313, DOI 10.1073/pnas.1322021111; Shehata M, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3334; Shimada M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00008; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Silwal-Pandit L, 2014, CLIN CANCER RES, V20, P3569, DOI 10.1158/1078-0432.CCR-13-2943; Sinclair CS, 2003, BREAST CANCER RES TR, V78, P313, DOI 10.1023/A:1023081624133; Smith HC, 2012, SEMIN CELL DEV BIOL, V23, P258, DOI 10.1016/j.semcdb.2011.10.004; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Spike Benjamin T, 2011, Genes Cancer, V2, P404, DOI 10.1177/1947601911410224; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Tao LW, 2014, STEM CELL REP, V2, P770, DOI 10.1016/j.stemcr.2014.04.004; Tarulli GA, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3381; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Ulrich HD, 2012, J CELL SCI, V125, P249, DOI 10.1242/jcs.091801; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Vogel C, 2012, NAT REV GENET, V13, P227, DOI 10.1038/nrg3185; Vogel C, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.59; Wagner KU, 2004, MOL CELL BIOL, V24, P5510, DOI 10.1128/MCB.24.12.5510-5520.2004; Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917; Yagi H, 2012, BIOORG MED CHEM LETT, V22, P729, DOI 10.1016/j.bmcl.2011.10.084; Yang DH, 2012, GLAND SURG, V1, P33, DOI [10.3978/j.issn.2227-684X.2012.04.07, 10.3978/j.issn.2227-684X.2012.04.01]; Yoda A, 2006, J BIOL CHEM, V281, P24847, DOI 10.1074/jbc.M600403200; Yu E, 2007, BREAST CANCER RES TR, V101, P269, DOI 10.1007/s10549-006-9304-y; Yu Q, 2014, DIAGN PATHOL, V9, DOI 10.1186/1746-1596-9-71; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhang LW, 2014, NAT GENET, V46, P726, DOI 10.1038/ng.2995; Zhang XN, 2010, CANCER RES, V70, P7176, DOI 10.1158/0008-5472.CAN-10-0697; Zhang XN, 2009, CANCER RES, V69, P7960, DOI 10.1158/0008-5472.CAN-09-0634; Zhu YH, 2014, J CLIN INVEST, V124, P3263, DOI 10.1172/JCI73015	169	36	38	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4429	4438		10.1038/onc.2014.375	http://dx.doi.org/10.1038/onc.2014.375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25381821				2022-12-17	WOS:000360189200002
J	Lopes, MH; Santos, TG; Rodrigues, BR; Queiroz-Hazarbassanov, N; Cunha, IW; Wasilewska-Sampaio, AP; Costa-Silva, B; Marchi, FA; Bleggi-Torres, LF; Sanematsu, PI; Suzuki, SH; Oba-Shinjo, SM; Marie, SKN; Toulmin, E; Hill, AF; Martins, VR				Lopes, M. H.; Santos, T. G.; Rodrigues, B. R.; Queiroz-Hazarbassanov, N.; Cunha, I. W.; Wasilewska-Sampaio, A. P.; Costa-Silva, B.; Marchi, F. A.; Bleggi-Torres, L. F.; Sanematsu, P. I.; Suzuki, S. H.; Oba-Shinjo, S. M.; Marie, S. K. N.; Toulmin, E.; Hill, A. F.; Martins, V. R.			Disruption of prion protein-HOP engagement impairs glioblastoma growth and cognitive decline and improves overall survival	ONCOGENE			English	Article							STRESS-INDUCIBLE PROTEIN-1; INDUCED PHOSPHOPROTEIN 1; CANCER-CELL-LINES; SIGNALING PATHWAYS; COLORECTAL-CANCER; PANCREATIC-CANCER; CLINICAL-TRIALS; BREAST-CANCER; BRAIN-TUMOR; PRO-PRION	Glioblastomas (GBMs) are resistant to current therapy protocols and identification of molecules that target these tumors is crucial. Interaction of secreted heat-shock protein 70 (Hsp70)-Hsp90-organizing protein (HOP) with cellular prion protein (PrPC) triggers a large number of trophic effects in the nervous system. We found that both PrPC and HOP are highly expressed in human GBM samples relative to non-tumoral tissue or astrocytoma grades I-III. High levels of PrPC and HOP were associated with greater GBM proliferation and lower patient survival. HOP-PrPC binding increased GBM proliferation in vitro via phosphatidylinositide 3-kinase and extracellular-signal-regulated kinase pathways, and a HOP peptide mimicking the PrPC binding site (HOP230-245) abrogates this effect. PrPC knockdown impaired tumor growth and increased survival of mice with tumors. In mice, intratumor delivery of HOP230-245 peptide impaired proliferation and promoted apoptosis of GBM cells. In addition, treatment with HOP230-245 peptide inhibited tumor growth, maintained cognitive performance and improved survival. Thus, together, the present results indicate that interfering with PrPC-HOP engagement is a promising approach for GBM therapy.	[Lopes, M. H.; Santos, T. G.; Rodrigues, B. R.; Queiroz-Hazarbassanov, N.; Wasilewska-Sampaio, A. P.; Costa-Silva, B.; Marchi, F. A.; Martins, V. R.] AC Camargo Canc Ctr, Int Res Ctr, BR-01508010 Sao Paulo, Brazil; [Lopes, M. H.] Univ Sao Paulo, Inst Biomed Sci, Dept Cell & Dev Biol, Sao Paulo, Brazil; [Lopes, M. H.; Santos, T. G.; Rodrigues, B. R.; Queiroz-Hazarbassanov, N.; Wasilewska-Sampaio, A. P.; Costa-Silva, B.; Marchi, F. A.; Martins, V. R.] CNPq MCT FAPESP, Nat Inst Translat Neurosci, Sao Paulo, Brazil; [Lopes, M. H.; Santos, T. G.; Rodrigues, B. R.; Queiroz-Hazarbassanov, N.; Wasilewska-Sampaio, A. P.; Costa-Silva, B.; Marchi, F. A.; Martins, V. R.] CNPq MCT FAPESP, Natl Inst Oncogen, Sao Paulo, Brazil; [Cunha, I. W.] AC Camargo Canc Ctr, Dept Pathol, BR-01508010 Sao Paulo, Brazil; [Marchi, F. A.] Univ Sao Paulo, Inst Math & Stat, Interinst Grad Program Bioinformat, Sao Paulo, Brazil; [Bleggi-Torres, L. F.] Univ Fed Parana, Dept Pathol, BR-80060000 Curitiba, Parana, Brazil; [Bleggi-Torres, L. F.] Pele Pequeno Principe Res Inst, Curitiba, Parana, Brazil; [Sanematsu, P. I.; Suzuki, S. H.] AC Camargo Canc Ctr, Dept Neurosurg, BR-01508010 Sao Paulo, Brazil; [Oba-Shinjo, S. M.; Marie, S. K. N.] Univ Sao Paulo, Sch Med, Dept Neurol, BR-05508 Sao Paulo, Brazil; [Toulmin, E.; Hill, A. F.] Univ Melbourne, Dept Biochem & Mol Biol, Mol Sci & Biotechnol Inst Bio21, Melbourne, Vic, Australia; [Martins, V. R.] Ludwig Inst Canc Res, Sao Paulo, Brazil	A.C.Camargo Cancer Center; Universidade de Sao Paulo; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP); A.C.Camargo Cancer Center; Universidade de Sao Paulo; Universidade Federal do Parana; Hospital Pequeno Principe; A.C.Camargo Cancer Center; Universidade de Sao Paulo; University of Melbourne; Ludwig Institute for Cancer Research	Martins, VR (corresponding author), AC Camargo Canc Ctr, Int Res Ctr, Rua Tagua 440, BR-01508010 Sao Paulo, Brazil.	vmartins@cipe.accamargo.org.br	Hill, Andrew F/B-4527-2009; Costa-Silva, Bruno/AAY-2266-2020; Hill, Andrew/GZL-4124-2022; Hill, Andrew F./AAH-2854-2020; Marie, Suely Kazue Nagahashi/D-1870-2012; dos Santos, Tiago Goss/A-1538-2019; Queiroz-Hazarbassanov, Nicolle/P-4333-2014; Marchi, Fabio A/N-9288-2018; Lopes, Marilene/GLV-4734-2022; Santos, Tiago Goss/AAQ-4272-2020; Oba-Shinjo, Sueli M./C-4017-2012; Queiroz-Hazarbassanov, Nicolle/Q-6901-2019; Martins, Vilma/N-5446-2019; Cunha, Isabela/H-3013-2012; Martins, Vilma R/E-2547-2012; Santos, Tiago/F-2387-2012; Marchi, Fabio Albuquerque/AAC-1380-2021	Hill, Andrew F/0000-0001-5581-2354; Hill, Andrew/0000-0001-5581-2354; Hill, Andrew F./0000-0001-5581-2354; Marie, Suely Kazue Nagahashi/0000-0003-4419-7928; dos Santos, Tiago Goss/0000-0001-6641-7413; Queiroz-Hazarbassanov, Nicolle/0000-0002-5692-0565; Marchi, Fabio A/0000-0001-5815-8423; Lopes, Marilene/0000-0003-2496-0674; Santos, Tiago Goss/0000-0001-6641-7413; Oba-Shinjo, Sueli M./0000-0002-1650-5973; Queiroz-Hazarbassanov, Nicolle/0000-0002-5692-0565; Cunha, Isabela/0000-0002-2029-5139; Martins, Vilma R/0000-0002-2909-8502; Santos, Tiago/0000-0001-6641-7413; Marchi, Fabio Albuquerque/0000-0001-5815-8423; Costa-Silva, Bruno/0000-0002-5932-6211	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo [FAPESP 09/14027-2, 07/08410-2, 04/12133-6]; Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq); FAPESP [2009/51653-9, 2009/51751-0, 2008/55381-0, 2010-13654-0, 2012/19019-0, 2010/20796-6]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	Fundacao de Amparo a Pesquisa do Estado de Sao Paulo(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP 09/14027-2, 07/08410-2 and 04/12133-6) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq). Fellowships from FAPESP (to TGS) (2009/51653-9), NGQ (2009/51751-0), BC-S (2008/55381-0), BRR (2010-13654-0, 2012/19019-0), APW-S (2010/20796-6), and from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) (to APW-S) are gratefully acknowledged. We are thankful for Maria Del Mar Inda and Severino da Silva Ferreira for technical assistance. Drs Maria Dirlei Begnami, Victor Piana de Andrade and Martin Roffe contributed with helpful discussions. We thank the AC Camargo Biobank for providing the astrocytoma samples used in this study.	Allhenn D, 2012, INT J PHARMACEUT, V436, P299, DOI 10.1016/j.ijpharm.2012.06.025; Alvarenga AW, 2013, J HISTOCHEM CYTOCHEM, V61, P272, DOI 10.1369/0022155413477661; Antonacopoulou AG, 2008, ANTICANCER RES, V28, P1221; Antonacopoulou AG, 2010, MOL CARCINOGEN, V49, P693, DOI 10.1002/mc.20642; Barbieri G, 2011, AUTOPHAGY, V7, P840, DOI 10.4161/auto.7.8.15615; Brown KR, 2009, BIOINFORMATICS, V25, P3327, DOI 10.1093/bioinformatics/btp595; Butowski N, 2012, CURR OPIN NEUROL, V25, P780, DOI 10.1097/WCO.0b013e328359b45e; Caine C, 2012, EXPERT REV ANTICANC, V12, P655, DOI [10.1586/era.12.34, 10.1586/ERA.12.34]; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Coltinho AS, 2007, NEUROBIOL DIS, V26, P282, DOI 10.1016/j.nbd.2007.01.005; Erlich RB, 2007, GLIA, V55, P1690, DOI 10.1002/glia.20579; Eustace BK, 2004, CELL CYCLE, V3, P1098; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gehring K, 2008, LANCET NEUROL, V7, P548, DOI 10.1016/S1474-4422(08)70111-X; Hajj GNM, 2013, CELL MOL LIFE SCI, V70, P3211, DOI 10.1007/s00018-013-1328-y; Horibe T, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-59; Horibe T, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-8; Jones TS, 2012, ONCOGENE, V31, P1995, DOI 10.1038/onc.2011.398; Joo KM, 2013, CELL REP, V3, P260, DOI 10.1016/j.celrep.2012.12.013; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kubota H, 2010, CELL STRESS CHAPERON, V15, P1003, DOI 10.1007/s12192-010-0211-0; Lal S, 2000, J NEUROSURG, V92, P326, DOI 10.3171/jns.2000.92.2.0326; Lee CT, 2012, EMBO J, V31, P1518, DOI 10.1038/emboj.2012.37; Li CY, 2010, J BIOL CHEM, V285, P30328, DOI 10.1074/jbc.M110.147413; Li CY, 2009, J CLIN INVEST, V119, P2725, DOI 10.1172/JCI39542; Li QQ, 2011, CANCER SCI, V102, P400, DOI 10.1111/j.1349-7006.2010.01811.x; Lima FRS, 2007, J NEUROCHEM, V103, P2164, DOI 10.1111/j.1471-4159.2007.04904.x; Linden R, 2008, PHYSIOL REV, V88, P673, DOI 10.1152/physrev.00007.2007; Lopes MH, 2005, J NEUROSCI, V25, P11330, DOI 10.1523/JNEUROSCI.2313-05.2005; Maciejewski A, 2013, BIOMOL NMR ASSIGN, V7, P305, DOI 10.1007/s12104-012-9433-7; Martins VR, 2010, CURR ISSUES MOL BIOL, V12, P63; Meslin F, 2007, ANN ONCOL, V18, P1793, DOI 10.1093/annonc/mdm406; Muller P, 2013, ONCOGENE, V32, P3101, DOI 10.1038/onc.2012.314; Ohgaki H, 2013, CLIN CANCER RES, V19, P764, DOI 10.1158/1078-0432.CCR-12-3002; Pan YL, 2006, FASEB J, V20, P1886, DOI 10.1096/fj.06-6138fje; Pimienta G, 2011, MOL PHARMACEUT, V8, P2252, DOI 10.1021/mp200346y; Quant EC, 2010, NEUROIMAG CLIN N AM, V20, P425, DOI 10.1016/j.nic.2010.04.007; Ruckova E, 2012, CELL MOL BIOL LETT, V17, P446, DOI 10.2478/s11658-012-0021-8; Santos TG, 2011, STEM CELLS, V29, P1126, DOI 10.1002/stem.664; Sims JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018848; Sun W, 2007, MOL CELL PROTEOMICS, V6, P1798, DOI 10.1074/mcp.M600449-MCP200; Sy MS, 2011, CANCER BIOMARK, V10, P251, DOI 10.3233/CBM-2012-0256; Tsai CL, 2012, CELL REP, V2, P283, DOI 10.1016/j.celrep.2012.07.002; Walsh N, 2011, CANCER LETT, V306, P180, DOI 10.1016/j.canlet.2011.03.004; Walsh N, 2009, PROTEOME SCI, V7, DOI 10.1186/1477-5956-7-3; Wang TH, 2010, MOL CELL PROTEOMICS, V9, P1873, DOI 10.1074/mcp.M110.000802; Wasilewska-Sampaio AP, 2013, PHYSL BEHAV C, V123C, P55; Weissert R, 1998, J CLIN INVEST, V102, P1265, DOI 10.1172/JCI3022; Westphal M, 2011, NAT REV NEUROSCI, V12, P495, DOI 10.1038/nrn3060; Willmer T, 2013, CANCER LETT, V328, P252, DOI 10.1016/j.canlet.2012.09.021; Yu GH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048146; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325; Zhuang DX, 2012, INT J CANCER, V130, P309, DOI 10.1002/ijc.25985	53	36	36	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	25					3305	3314		10.1038/onc.2014.261	http://dx.doi.org/10.1038/onc.2014.261			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CK9XH	25151961				2022-12-17	WOS:000356592300009
J	Rosario, CO; Kazazian, K; Zih, FSW; Brashavitskaya, O; Haffani, Y; Xu, RSZ; George, A; Dennis, JW; Swallow, CJ				Rosario, C. O.; Kazazian, K.; Zih, F. S. W.; Brashavitskaya, O.; Haffani, Y.; Xu, R. S. Z.; George, A.; Dennis, J. W.; Swallow, C. J.			A novel role for Plk4 in regulating cell spreading and motility	ONCOGENE			English	Article							POLO-LIKE KINASE; CENTRIOLE DUPLICATION; CENTROSOME DUPLICATION; CYTOKINESIS; EXPRESSION; PROTEIN; REVEALS; FAILURE; CANCER; SAK	Polo family kinase 4 (Plk4) is required for mitotic progression, and is haploinsufficient for tumor suppression and timely hepatocyte polarization in regenerating liver. At the same time, recent evidence suggests that Plk4 expression may have a role in clinical cancer progression, although the mechanisms are not clear. Here we identify a gene expression pattern predictive of reduced motility in Plk4(+/-) murine embryonic fibroblasts (MEFs) and validate this prediction with functional assays of cell spreading, migration and invasion. Increased Plk4 expression enhances cell spreading in Plk4(+/-) MEFs and migration in human embryonic kidney 293T cells, and increases invasion by DLD-1 colon cancer cells. Plk4 depletion impairs invasion of wild-type MEFs and suppresses invasion by MDA-MB231 breast cancer cells. Cytoskeletal reorganization and development of polarity are impaired in Plk4-deficient cells that have been stimulated to migrate. Endogenous Plk4 phosphorylated at the autophosphorylation site S305 localizes to the protrusions of motile cells, coincident with the RhoA GEF Ect2, GTP-bound RhoA and the RhoA effector mDia. Taken together, our findings reveal an unexpected activity of Plk4 that promotes cell migration and may underlie an association between increased Plk4 expression, cancer progression and death from metastasis in solid tumor patients.	[Rosario, C. O.; Kazazian, K.; Zih, F. S. W.; Brashavitskaya, O.; Haffani, Y.; Xu, R. S. Z.; George, A.; Dennis, J. W.; Swallow, C. J.] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada; [Rosario, C. O.; Brashavitskaya, O.; Dennis, J. W.; Swallow, C. J.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Kazazian, K.; Zih, F. S. W.; Swallow, C. J.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Kazazian, K.; Zih, F. S. W.; Xu, R. S. Z.; Swallow, C. J.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Dennis, J. W.] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Swallow, CJ (corresponding author), Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.	cswallow@mtsinai.on.ca	Dennis, James/E-7268-2013	Haffani, Yosr Z./0000-0003-2956-3651	CIHR; NCIC; Syd Cooper Program for the Prevention of Cancer Progression	CIHR(Canadian Institutes of Health Research (CIHR)); NCIC(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Syd Cooper Program for the Prevention of Cancer Progression	This work was supported by grants from CIHR (CJS) and NCIC (JWD), and from the Syd Cooper Program for the Prevention of Cancer Progression (CJS). We acknowledge Karina Pacholczyk, Peter E Wu and Kevin Yau for technical assistance, Judy Pawling for manuscript review, and Jayne Danska and Laurence Pelletier for helpful discussions.	Agarwal R, 2009, CLIN CANCER RES, V15, P3654, DOI 10.1158/1078-0432.CCR-08-3293; Bahtz R, 2012, J CELL SCI, V125, P486, DOI 10.1242/jcs.093930; Basu R, 2007, CURR OPIN CELL BIOL, V19, P88, DOI 10.1016/j.ceb.2006.12.012; Brownlee CW, 2011, J CELL BIOL, V195, P231, DOI 10.1083/jcb.201107086; Burkard ME, 2007, P NATL ACAD SCI USA, V104, P4383, DOI 10.1073/pnas.0701140104; Cizmecioglu O, 2010, J CELL BIOL, V191, P731, DOI 10.1083/jcb.201007107; Coelho PA, 2013, DEV CELL, V27, P586, DOI 10.1016/j.devcel.2013.09.029; Cunha-Ferreira I, 2013, CURR BIOL, V23, P2245, DOI 10.1016/j.cub.2013.09.037; Cunha-Ferreira I, 2009, CURR BIOL, V19, P43, DOI 10.1016/j.cub.2008.11.037; Dzhindzhev NS, 2010, NATURE, V467, P714, DOI 10.1038/nature09445; Finetti P, 2008, CANCER RES, V68, P767, DOI 10.1158/0008-5472.CAN-07-5516; Fischer M, 2014, NUCLEIC ACIDS RES, V42, P163, DOI 10.1093/nar/gkt849; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Glinsky GV, 2006, CELL CYCLE, V5, P1208, DOI 10.4161/cc.5.11.2796; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Goulimari P, 2005, J BIOL CHEM, V280, P42242, DOI 10.1074/jbc.M508690200; Guderian G, 2010, J CELL SCI, V123, P2163, DOI 10.1242/jcs.068502; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Hatch EM, 2010, J CELL BIOL, V191, P721, DOI 10.1083/jcb.201006049; Holland AJ, 2012, GENE DEV, V26, P2684, DOI 10.1101/gad.207027.112; Holland AJ, 2012, MOL BIOL CELL, V23, P1838, DOI 10.1091/mbc.E11-12-1043; Holland AJ, 2010, J CELL BIOL, V188, P191, DOI 10.1083/jcb.200911102; Hudson JW, 2001, CURR BIOL, V11, P441, DOI 10.1016/S0960-9822(01)00117-8; Johnson EF, 2007, BIOCHEMISTRY-US, V46, P9551, DOI 10.1021/bi7008745; Klebba JE, 2013, CURR BIOL, V23, P2255, DOI 10.1016/j.cub.2013.09.019; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Korzeniewski N, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-61; Laufer R, 2013, J MED CHEM, V56, P6069, DOI 10.1021/jm400380m; Leung GC, 2002, NAT STRUCT BIOL, V9, P719, DOI 10.1038/nsb848; Leung GC, 2007, FEBS LETT, V581, P77, DOI 10.1016/j.febslet.2006.11.080; Lim Y, 2008, J CELL BIOL, V180, P187, DOI 10.1083/jcb.200708194; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Macmillan JC, 2001, ANN SURG ONCOL, V8, P729, DOI 10.1245/aso.2001.8.9.729; Martindill DMJ, 2007, NAT CELL BIOL, V9, P1131, DOI 10.1038/ncb1633; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Moss DK, 2007, J CELL SCI, V120, P3064, DOI 10.1242/jcs.010322; Nakamura T, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2752; Nguyen TN, 2000, EXP CELL RES, V258, P171, DOI 10.1006/excr.2000.4929; Ohn T, 2010, WIRES RNA, V1, P486, DOI 10.1002/wrna.23; Park AYJ, 2009, J BIOL CHEM, V284, P9418, DOI 10.1074/jbc.M809040200; Petronczki M, 2007, DEV CELL, V12, P713, DOI 10.1016/j.devcel.2007.03.013; Przewloka MR, 2011, CURR BIOL, V21, P399, DOI 10.1016/j.cub.2011.02.005; Puklowski A, 2011, NAT CELL BIOL, V13, P1004, DOI 10.1038/ncb2282; Rogers GC, 2009, J CELL BIOL, V184, P225, DOI 10.1083/jcb.200808049; Rosario CO, 2010, P NATL ACAD SCI USA, V107, P6888, DOI 10.1073/pnas.0910941107; Rosario CO, 2010, EFFECTS POLO LIKE KI; Sillibourne JE, 2010, MOL BIOL CELL, V21, P547, DOI 10.1091/mbc.E09-06-0505; Slevin LK, 2012, STRUCTURE, V20, P1905, DOI 10.1016/j.str.2012.08.025; Small JV, 2002, NAT REV MOL CELL BIO, V3, P957, DOI 10.1038/nrm971; Swallow CJ, 2005, ONCOGENE, V24, P306, DOI 10.1038/sj.onc.1208275	51	36	37	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2015	34	26					3441	3451		10.1038/onc.2014.275	http://dx.doi.org/10.1038/onc.2014.275			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CL3SU	25174401				2022-12-17	WOS:000356871700009
J	Shimozato, O; Waraya, M; Nakashima, K; Souda, H; Takiguchi, N; Yamamoto, H; Takenobu, H; Uehara, H; Ikeda, E; Matsushita, S; Kubo, N; Nakagawara, A; Ozaki, T; Kamijo, T				Shimozato, O.; Waraya, M.; Nakashima, K.; Souda, H.; Takiguchi, N.; Yamamoto, H.; Takenobu, H.; Uehara, H.; Ikeda, E.; Matsushita, S.; Kubo, N.; Nakagawara, A.; Ozaki, T.; Kamijo, T.			Receptor-type protein tyrosine phosphatase. directly dephosphorylates CD133 and regulates downstream AKT activation	ONCOGENE			English	Article							CANCER STEM-CELLS; GROWTH-FACTOR RECEPTOR; R-PTP-KAPPA; BETA-CATENIN; HEMATOPOIETIC STEM; MARKER CD133; PATHWAY; EXPRESSION; PHOSPHORYLATION; DIFFERENTIATION	Although CD133 has been considered to be a molecular marker for cancer stem cells, its functional roles in tumorigenesis remain unclear. We here examined the molecular basis behind CD133-mediated signaling. Knockdown of CD133 resulted in the retardation of xenograft tumor growth of colon cancer-derived HT-29 and LoVo cells accompanied by hypophosphorylation of AKT, which diminished beta-catenin/T-cell factor-mediated CD44 expression. As tyrosine residues of CD133 at positions 828 and 852 were phosphorylated in HT-29 and SW480 cells, we further addressed the significance of this phosphorylation in the tumorigenesis of SW480 cells expressing mutant CD133, with substitution of these tyrosine residues by glutamate (CD133-EE) or phenylalanine (CD133-FF). Forced expression of CD133-EE promoted much more aggressive xenograft tumor growth relative to wild-type CD133-expressing cells accompanied by hyperphosphorylation of AKT; however, CD133-FF expression had negligible effects on AKT phosphorylation and xenograft tumor formation. Intriguingly, the tyrosine phosphorylation status of CD133 was closely linked to the growth of SW480-derived spheroids. Using yeast two-hybrid screening, we finally identified receptor-type protein tyrosine phosphatase. (PTPRK) as a binding partner of CD133. In vitro studies demonstrated that PTPRK associates with the carboxyl-terminal region of CD133 through its intracellular phosphatase domains and also catalyzes dephosphorylation of CD133 at tyrosine-828/tyrosine-852. Silencing of PTPRK elevated the tyrosine phosphorylation of CD133, whereas forced expression of PTPRK reduced its phosphorylation level markedly and abrogated CD133-mediated AKT phosphorylation. Endogenous CD133 expression was also closely associated with higher AKT phosphorylation in primary colon cancer cells, and ectopic expression of CD133 enhanced AKT phosphorylation. Furthermore, lower PTPRK expression significantly correlated with the poor prognosis of colon cancer patients with high expression of CD133. Thus, our present findings strongly indicate that the tyrosine phosphorylation of CD133, which is dephosphorylated by PTPRK, regulates AKT signaling and has a critical role in colon cancer progression.	[Shimozato, O.; Waraya, M.; Nakashima, K.; Takenobu, H.; Uehara, H.; Ikeda, E.; Kamijo, T.] Chiba Canc Ctr Res Inst, Div Biochem & Mol Carcinogenesis, Chiba, Japan; [Souda, H.; Takiguchi, N.; Yamamoto, H.] Chiba Canc Ctr Hosp, Dept Gastrointestinal Surg, Chiba, Japan; [Matsushita, S.; Kubo, N.; Ozaki, T.] Chiba Canc Ctr Res, Lab DNA Damage Signaling, Chiba, Japan; [Nakagawara, A.] Chiba Canc Ctr Res Inst, Div Biochem & Innovat Canc Therapeut, Chiba, Japan; [Kamijo, T.] Saitama Canc Ctr, Res Inst Clin Oncol, Saitama 3620806, Japan	Chiba Cancer Center; Chiba Cancer Center; Chiba Cancer Center; Chiba Cancer Center	Kamijo, T (corresponding author), Saitama Canc Ctr, Res Inst Clin Oncol, 818 Komuro, Saitama 3620806, Japan.	tkamijo@cancer-c.pref.saitama.jp		Takenobu, Hisanori/0000-0001-7355-1565	JSPS [21790397, 23591978, 24390269]; National Cancer Center Research and Development Fund [25-B-3]; Grants-in-Aid for Scientific Research [23591978, 15K08412] Funding Source: KAKEN	JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); National Cancer Center Research and Development Fund(National Cancer Center - Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Ms Kumiko Sakurai for technical assistance, Mr Daniel Mrozek (Medical English Service, Kyoto, Japan) for English editorial assistance and Dr Takafumi Nakamura (Graduate School of Medical Sciences, Tottori University Faculty of Medicine) for pHR lentiviral vectors. This work was supported in part by grants-in-aid from JSPS for Young Scientists (B) and for Scientific Research (C) (Grant numbers: 21790397 and 23591978, respectively), a grant-in-aid for Scientific Research (B) from JSPS (24390269) and a grant-in-aid from the National Cancer Center Research and Development Fund (25-B-3).	Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Anders L, 2006, MOL CELL BIOL, V26, P3917, DOI 10.1128/MCB.26.10.3917-3934.2006; Arora D, 2011, J BIOL CHEM, V286, P10918, DOI 10.1074/jbc.M110.205021; Artells R, 2010, EUR J CANCER, V46, P642, DOI 10.1016/j.ejca.2009.11.003; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Blaker H, 2008, GENE CHROMOSOME CANC, V47, P159, DOI 10.1002/gcc.20516; Boivin D, 2009, BIOCHEMISTRY-US, V48, P3998, DOI 10.1021/bi900159d; Bussolati B, 2005, AM J PATHOL, V166, P545, DOI 10.1016/S0002-9440(10)62276-6; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0021428, 10.1371/journal.pone.0017876, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0027333, 10.1371/journal.pone.0017844, 10.1371/journal.pone.0024144]; Chu P, 2009, INT J CANCER, V124, P1312, DOI 10.1002/ijc.24061; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Fan X, 2006, CANCER RES, V66, P7445, DOI 10.1158/0008-5472.CAN-06-0858; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Horst D, 2009, J PATHOL, V219, P427, DOI 10.1002/path.2597; Hu LM, 2000, CLIN CANCER RES, V6, P880; JIANG YP, 1993, MOL CELL BIOL, V13, P2942, DOI 10.1128/MCB.13.5.2942; Kojima M, 2008, CANCER SCI, V99, P1578, DOI 10.1111/j.1349-7006.2008.00849.x; Komatsu S, 2009, ONCOGENE, V28, P3631, DOI 10.1038/onc.2009.216; Kondo J, 2011, P NATL ACAD SCI USA, V108, P6235, DOI 10.1073/pnas.1015938108; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Kubo N, 2013, BIOCHEM BIOPH RES CO, V430, P1034, DOI 10.1016/j.bbrc.2012.11.121; Kurata K, 2008, ONCOGENE, V27, P741, DOI 10.1038/sj.onc.1210672; Lee A, 2005, NAT NEUROSCI, V8, P723, DOI 10.1038/nn1473; Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005; Ma S, 2008, ONCOGENE, V27, P1749, DOI 10.1038/sj.onc.1210811; Mak AB, 2012, CELL REP, V2, P951, DOI 10.1016/j.celrep.2012.09.016; Miki J, 2007, CANCER RES, V67, P3153, DOI 10.1158/0008-5472.CAN-06-4429; Miraglia S, 1997, BLOOD, V90, P5013, DOI 10.1182/blood.V90.12.5013.5013_5013_5021; Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283; Nikolova T, 2007, DIFFERENTIATION, V75, P100, DOI 10.1111/j.1432-0436.2006.00119.x; Novellino L, 2008, CELL SIGNAL, V20, P872, DOI 10.1016/j.cellsig.2007.12.024; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Ochiai H, 2010, ONCOGENE, V29, P2681, DOI 10.1038/onc.2010.22; Pardal R, 2003, NAT REV CANCER, V3, P895, DOI 10.1038/nrc1232; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Ricci-Vitiani L, 2010, FASEB J, V24, P4291, DOI 10.1096/fj.10-159970; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Starr TK, 2009, SCIENCE, V323, P1747, DOI 10.1126/science.1163040; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Takenobu H, 2011, ONCOGENE, V30, P97, DOI 10.1038/onc.2010.383; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Uddin S, 2006, BLOOD, V108, P4178, DOI 10.1182/blood-2006-04-016907; Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105; Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130; Wei YY, 2013, P NATL ACAD SCI USA, V110, P6829, DOI 10.1073/pnas.1217002110; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Xu YR, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.212597; Yang Y, 1997, GENE, V186, P77, DOI 10.1016/S0378-1119(96)00684-1; Yin AH, 1997, BLOOD, V90, P5002, DOI 10.1182/blood.V90.12.5002.5002_5002_5012; Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589	61	36	38	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1949	1960		10.1038/onc.2014.141	http://dx.doi.org/10.1038/onc.2014.141			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24882578				2022-12-17	WOS:000352725600009
J	Valdes-Mora, F; Clark, SJ				Valdes-Mora, F.; Clark, S. J.			Prostate cancer epigenetic biomarkers: next-generation technologies	ONCOGENE			English	Review							CPG ISLAND HYPERMETHYLATION; ANDROGEN RECEPTOR COACTIVATOR; POLYMERASE-CHAIN-REACTION; HISTONE VARIANT H2A.Z; DNA-BASED DETECTION; GENOMICS X PRIZE; HIGH-THROUGHPUT; METHYLATION ANALYSIS; MOLECULAR-DETECTION; PROGNOSTIC MARKERS	Cancer is caused by a combination of genetic alterations and gross changes to the epigenetic landscape that together result in aberrant cancer gene regulation. Therefore, we need to fully sequence both the cancer genome and the matching cancer epigenomes before we can fully integrate the suite of molecular mechanisms involved in initiation and progression of cancer. A further understanding of epigenetic aberrations has a great potential in the next era of molecular genomic pathology in cancer detection and treatment in all types of cancer, including prostate cancer. In this review, we discuss the most common epigenetic aberrations identified in prostate cancer with the biomarker potential. We also describe the innovative and current epigenomic technologies used for the identification of epigenetic-associated changes in prostate cancer and future translational applications in molecular pathology for cancer detection and prognosis.	[Valdes-Mora, F.; Clark, S. J.] Garvan Inst Med Res, Canc Res Div, Epigenet Lab, Canc Res Program, Sydney, NSW 2010, Australia; [Valdes-Mora, F.; Clark, S. J.] Garvan Inst Med Res, Kinghorn Canc Ctr, Sydney, NSW 2010, Australia; [Valdes-Mora, F.; Clark, S. J.] St Vincents Hosp, St Vincents Clin Sch, Darlinghurst, NSW 2010, Australia; [Valdes-Mora, F.; Clark, S. J.] Univ New S Wales, Darlinghurst, NSW, Australia	Garvan Institute of Medical Research; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Clark, SJ (corresponding author), Garvan Inst Med Res, Canc Res Div, Epigenet Lab, Canc Res Program, 384 Victoria Rd, Sydney, NSW 2010, Australia.	s.clark@garvan.org.au	Mora, Fatima Valdes/AAB-9728-2021; Clark, Susan J/U-7365-2019; Clark, Susan J/B-2272-2008	Mora, Fatima Valdes/0000-0001-7490-0114; Clark, Susan J/0000-0001-5925-5030; Clark, Susan J/0000-0001-5925-5030	Prostate Cancer Foundation of Australia (PCFA) Project Grant [PG 4310]	Prostate Cancer Foundation of Australia (PCFA) Project Grant	F.V.M. is a National Breast Cancer Foundation/Cure Cancer Australia Foundation Postdoctoral Training Fellow. S.J.C. is a National Health and Medical Research Council (NH&MRC) Senior Principal Research Fellow. This work was further supported by Prostate Cancer Foundation of Australia (PCFA) Project Grant (PG 4310) (to F.V.M and S.J.C).	Arand J, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002750; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Baden J, 2011, J UROLOGY, V186, P2101, DOI 10.1016/j.juro.2011.06.052; Bae Jae-Bum, 2013, Genomics & Informatics, V11, P7, DOI 10.5808/GI.2013.11.1.7; Banez LL, 2010, J UROLOGY, V184, P149, DOI 10.1016/j.juro.2010.03.012; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Bastian PJ, 2005, CLIN CANCER RES, V11, P4097, DOI 10.1158/1078-0432.CCR-04-1832; Bastian PJ, 2005, CLIN CANCER RES, V11, P4037, DOI 10.1158/1078-0432.CCR-04-2446; Behbahani TE, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-5; Beltran H, 2013, CLIN CANCER RES, V19, P517, DOI 10.1158/1078-0432.CCR-12-1452; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bert SA, 2013, CANCER CELL, V23, P9, DOI 10.1016/j.ccr.2012.11.006; Bhusari S, 2011, PROSTATE, V71, P1621, DOI 10.1002/pros.21379; Bianco-Miotto T, 2010, CANCER EPIDEM BIOMAR, V19, P2611, DOI 10.1158/1055-9965.EPI-10-0555; Bock C, 2010, NAT BIOTECHNOL, V28, P1106, DOI 10.1038/nbt.1681; Booth MJ, 2012, SCIENCE, V336, P934, DOI 10.1126/science.1220671; Brase JC, 2011, INT J CANCER, V128, P608, DOI 10.1002/ijc.25376; Brothman AR, 2005, CANCER GENET CYTOGEN, V156, P31, DOI 10.1016/j.cancergencyto.2004.04.004; Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595; Cairns P, 2001, CLIN CANCER RES, V7, P2727; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Cho NY, 2007, J PATHOL, V211, P269, DOI 10.1002/path.2106; Cho NY, 2009, VIRCHOWS ARCH, V454, P17, DOI 10.1007/s00428-008-0706-6; Chou R, 2011, ANN INTERN MED, V155, P762, DOI 10.7326/0003-4819-155-11-201112060-00375; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Clark SJ, 2006, NAT PROTOC, V1, P2353, DOI 10.1038/nprot.2006.324; Comuzzi B, 2004, J PATHOL, V204, P159, DOI 10.1002/path.1609; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Coolen MW, 2010, NAT CELL BIOL, V12, P235, DOI 10.1038/ncb2023; Cottrell S, 2007, J UROLOGY, V177, P1753, DOI 10.1016/j.juro.2007.01.010; de Matos LL, 2010, BIOMARK INSIGHTS, V5, P9; Dedeurwaerder S, 2011, EPIGENOMICS-UK, V3, P771, DOI [10.2217/EPI.11.105, 10.2217/epi.11.105]; Deligezer U, 2010, CLIN CHIM ACTA, V411, P1452, DOI 10.1016/j.cca.2010.05.040; Desai AN, 2012, CLIN GENET, V81, P503, DOI 10.1111/j.1399-0004.2012.01865.x; Devaney J, 2011, CANCER EPIDEM BIOMAR, V20, P148, DOI 10.1158/1055-9965.EPI-10-0719; Draisma G, 2009, JNCI-J NATL CANCER I, V101, P374, DOI 10.1093/jnci/djp001; Draker R, 2011, NUCLEIC ACIDS RES, V39, P3529, DOI 10.1093/nar/gkq1352; Dryhurst D, 2012, CANCER LETT, V315, P38, DOI 10.1016/j.canlet.2011.10.003; Ellinger J, 2008, UROLOGY, V71, P161, DOI 10.1016/j.urology.2007.09.056; Ellinger J, 2012, CANCER INVEST, V30, P92, DOI 10.3109/07357907.2011.636117; Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038; Enokida H, 2005, CLIN CANCER RES, V11, P6582, DOI 10.1158/1078-0432.CCR-05-0658; Fraga ME, 2002, BIOTECHNIQUES, V33, P632, DOI 10.2144/02333rv01; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Globisch D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015367; Goessl C, 2000, CANCER RES, V60, P5941; Goessl C, 2001, UROLOGY, V58, P335, DOI 10.1016/S0090-4295(01)01268-7; Gonzalgo ML, 2003, CLIN CANCER RES, V9, P2673; Gregory CW, 2001, CANCER RES, V61, P4315; Gu H, 2010, NAT METHODS, V7, P133, DOI 10.1038/nmeth.1414; Guil S, 2009, INT J BIOCHEM CELL B, V41, P87, DOI 10.1016/j.biocel.2008.09.005; Haffner MC, 2011, ONCOTARGET, V2, P627; Hagman Z, 2010, INT J CANCER, V127, P2768, DOI 10.1002/ijc.25269; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Harris RA, 2010, NAT BIOTECHNOL, V28, P1097, DOI 10.1038/nbt.1682; Heemers HV, 2007, CANCER RES, V67, P3422, DOI 10.1158/0008-5472.CAN-06-2836; Henrique R, 2007, CLIN CANCER RES, V13, P6122, DOI 10.1158/1078-0432.CCR-07-1042; Holdenrieder S, 2008, ANN NY ACAD SCI, V1137, P180, DOI 10.1196/annals.1448.012; Hoque MO, 2005, J CLIN ONCOL, V23, P6569, DOI 10.1200/JCO.2005.07.009; Hsu CH, 2012, CELL REP, V2, P568, DOI 10.1016/j.celrep.2012.08.030; Hua S, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.25; Hulf T, 2013, ONCOGENE, V32, P2891, DOI 10.1038/onc.2012.300; Iqbal K, 2011, P NATL ACAD SCI USA, V108, P3642, DOI 10.1073/pnas.1014033108; Irizarry RA, 2008, GENOME RES, V18, P780, DOI 10.1101/gr.7301508; Jarrard DF, 1995, CLIN CANCER RES, V1, P1471; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jeronimo C, 2002, UROLOGY, V60, P1131; Jeronimo C, 2011, EUR UROL, V60, P753, DOI 10.1016/j.eururo.2011.06.035; Jin SG, 2011, CANCER RES, V71, P7360, DOI 10.1158/0008-5472.CAN-11-2023; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kedes L, 2011, NAT GENET, V43, P1055, DOI 10.1038/ng.988; Kedes L, 2011, NAT GENET, V43, P175, DOI 10.1038/ng0311-175; Kim J, 2012, BBA-REV CANCER, V1825, P186, DOI 10.1016/j.bbcan.2011.12.003; Kim JH, 2011, GENOME RES, V21, P1028, DOI 10.1101/gr.119347.110; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Kobayashi Y, 2011, GENOME RES, V21, P1017, DOI 10.1101/gr.119487.110; Kriaucionis S, 2009, SCIENCE, V324, P929, DOI 10.1126/science.1169786; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Laitinen S, 2008, INT J CANCER, V122, P595, DOI 10.1002/ijc.23145; Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P533, DOI 10.1016/j.urolonc.2009.05.008; Li YW, 2012, EPIGENETICS-US, V7, P940, DOI 10.4161/epi.21236; Lin PC, 2013, NEOPLASIA, V15, P373, DOI 10.1593/neo.122146; Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514; Lorincz Attila T, 2011, Expert Opin Med Diagn, V5, P375; Martens-Uzunova ES, 2012, ONCOGENE, V31, P978, DOI 10.1038/onc.2011.304; Masser DR, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-33; Masson S, 2012, BJU INT, V110, P1110, DOI 10.1111/j.1464-410X.2012.11076.x; Meissner A, 2008, NATURE, V454, P766, DOI 10.1038/nature07107; Metzker Michael L, 2010, Nat Rev Genet, V11, P31, DOI 10.1038/nrg2626; Millar DS, 1999, ONCOGENE, V18, P1313, DOI 10.1038/sj.onc.1202415; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Nakayama M, 2004, J CELL BIOCHEM, V91, P540, DOI 10.1002/jcb.10740; Ngollo M, 2014, OMICS, V18, P207, DOI 10.1089/omi.2013.0117; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Ozsolak F, 2011, NAT REV GENET, V12, P87, DOI 10.1038/nrg2934; Pellakuru LG, 2012, AM J PATHOL, V181, P560, DOI 10.1016/j.ajpath.2012.04.021; Perez C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031605; Perkel J, 2013, BIOTECHNIQUES, V54, P71, DOI 10.2144/000113988; Prensner JR, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003180; Prensner JR, 2011, NAT BIOTECHNOL, V29, P742, DOI 10.1038/nbt.1914; Robinson MD, 2010, GENOME RES, V20, P1719, DOI 10.1101/gr.110601.110; Roupret M, 2007, CLIN CANCER RES, V13, P1720, DOI 10.1158/1078-0432.CCR-06-2467; Ruijter ET, 1996, J PATHOL, V180, P295; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Schaefer A, 2010, INT J CANCER, V126, P1166, DOI 10.1002/ijc.24827; Schwarzenbach H, 2011, NAT REV CANCER, V11, P426, DOI 10.1038/nrc3066; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Slupianek A, 2010, J CELL PHYSIOL, V224, P369, DOI 10.1002/jcp.22132; Song CX, 2011, NAT BIOTECHNOL, V29, P68, DOI 10.1038/nbt.1732; Sporn JC, 2009, ONCOGENE, V28, P3423, DOI 10.1038/onc.2009.26; Sporn JC, 2012, AM J PATHOL, V180, P2516, DOI 10.1016/j.ajpath.2012.02.027; Spruijt CG, 2013, CELL, V152, P1146, DOI 10.1016/j.cell.2013.02.004; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Talbert PB, 2010, NAT REV MOL CELL BIO, V11, P264, DOI 10.1038/nrm2861; Tomizawa S, 2011, DEVELOPMENT, V138, P811, DOI 10.1242/dev.061416; Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77; Tsai HC, 2011, CELL RES, V21, P502, DOI 10.1038/cr.2011.24; Valdes-Mora F, 2012, GENOME RES, V22, P307, DOI 10.1101/gr.118919.110; Van Neste L, 2012, PROSTATE, V72, P1248, DOI 10.1002/pros.22459; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vardabasso C, 2014, CELL MOL LIFE SCI, V71, P379, DOI 10.1007/s00018-013-1343-z; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Woodson K, 2006, EPIGENETICS-US, V1, P183, DOI 10.4161/epi.1.4.3530; Wossidlo M, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1240; Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang B, 2013, UROL ONCOL-SEMIN ORI, V31, P628, DOI 10.1016/j.urolonc.2011.05.009; Yang H, 2013, ONCOGENE, V32, P663, DOI 10.1038/onc.2012.67; Yavartanoo Maryam, 2013, Genomics & Informatics, V11, P2, DOI 10.5808/GI.2013.11.1.2; Yegnasubramanian S, 2004, CANCER RES, V64, P1975, DOI 10.1158/0008-5472.CAN-03-3972; Yegnasubramanian S, 2008, CANCER RES, V68, P8954, DOI 10.1158/0008-5472.CAN-07-6088; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yu M, 2012, CELL, V149, P1368, DOI 10.1016/j.cell.2012.04.027; Yu YP, 2005, CARCINOGENESIS, V26, P471, DOI 10.1093/carcin/bgh310; Ziller MJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002389	138	36	36	0	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1609	1618		10.1038/onc.2014.111	http://dx.doi.org/10.1038/onc.2014.111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24837368				2022-12-17	WOS:000351848400001
J	Yin, B; Ma, ZY; Zhou, ZW; Gao, WC; Du, ZG; Zhao, ZH; Li, QQ				Yin, B.; Ma, Z. Y.; Zhou, Z. W.; Gao, W. C.; Du, Z. G.; Zhao, Z. H.; Li, Q. Q.			The TrkB plus cancer stem cells contribute to post-chemotherapy recurrence of triple-negative breast cancers in an orthotopic mouse model	ONCOGENE			English	Article						cancer stem cells; brain-derived neurotrophic factor; TrkB; self-renewal; TNBC recurrence	EPITHELIAL-MESENCHYMAL TRANSITION; NEUROTROPHIC FACTOR; GENE-EXPRESSION; PROGRESSION; TARGETS; GROWTH	Cancer stem cells (CSCs) are believed to have a crucial role in triple-negative breast cancer (TNBC) recurrence. However, the exact mechanisms that are functionally critical in CSCs-mediated recurrence remain unclear. Here, we showed that CSCs derived from recurrent TNBCs are endowed with increased self-renewal capacity as compared with those from the matched primary lesions. Using patient-derived specimens, we demonstrated the existence of paracrine brain-derived neurotrophic factor (BDNF) signaling between differentiated recurrent TNBC cells and CSCs characterized by the expression of TrkB, the receptor of BDNF. We showed that paclitaxel induced BDNF expression and apoptosis simultaneously in a cell cycle-dependent manner. BDNF promotes the self-renewal potential of the TrkB + CSCs through induction of KLF4. The TrkB + CSCs represent a particular subset indispensable for TNBC relapse. In line with this, TrkB is proved to be a superior predictor for TNBC recurrence. Using a genetically engineered mouse model of TNBC, we observed that ablation of the TrkB + CSCs potentially prevents relapse of malignant tumors. Further preclinical investigation of this promising approach may lead to development of a novel therapeutic strategy to improve the devastating prognosis of TNBC patients.	[Yin, B.] Fudan Univ, HuaShan Hosp, Dept Radiol, Shanghai 200433, Peoples R China; [Ma, Z. Y.] Fudan Univ, HuaShan Hosp, Dept Gen Surg, Shanghai 200040, Peoples R China; [Zhou, Z. W.; Du, Z. G.] Fudan Univ, HuaShan Hosp, Dept Pathol, Shanghai 200040, Peoples R China; [Gao, W. C.] Second Mil Med Univ, ChangZheng Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Zhao, Z. H.; Li, Q. Q.] Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai 200040, Peoples R China	Fudan University; Fudan University; Fudan University; Naval Medical University; Fudan University	Li, QQ (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai 200040, Peoples R China.	061101040@fudan.edu.cn			National Nature Science Foundation of China [81000957]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was generously supported by grants from the National Nature Science Foundation of China (81000957).	Aid T, 2007, J NEUROSCI RES, V85, P525, DOI 10.1002/jnr.21139; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alfonso J, 2006, BIOL PSYCHIAT, V59, P244, DOI 10.1016/j.biopsych.2005.06.036; Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081; Howe LR, 2004, CANCER BIOL THER, V3, P36, DOI 10.4161/cbt.3.1.561; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Lee LF, 1998, J BIOL CHEM, V273, P28253, DOI 10.1074/jbc.273.43.28253; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Lorico A, 2011, J ONCOL, V2011, DOI 10.1155/2011/135039; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McDermott SP, 2010, MOL ONCOL, V4, P404, DOI 10.1016/j.molonc.2010.06.005; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Millar HJ, 2008, CANCER EPIDEM BIOMAR, V17, P2180, DOI 10.1158/1055-9965.EPI-07-2915; Nair A, 2007, NEUROPSYCHOPHARMACOL, V32, P1504, DOI 10.1038/sj.npp.1301276; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Sneddon JB, 2007, CELL STEM CELL, V1, P607, DOI 10.1016/j.stem.2007.11.009; Tang DG, 2012, CELL RES, V22, P457, DOI 10.1038/cr.2012.13; Thijssen VL, 2010, CANCER RES, V70, P6216, DOI 10.1158/0008-5472.CAN-09-4150; Uemura Y, 2006, INT J MOL MED, V18, P365; Vanhecke E, 2011, CLIN CANCER RES, V17, P1741, DOI 10.1158/1078-0432.CCR-10-1890; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wang ZW, 2010, CURR PROTEIN PEPT SC, V11, P398, DOI 10.2174/138920310791824039; Yang XM, 2012, INT J ONCOL, V41, P1541, DOI 10.3892/ijo.2012.1581; Yang ZJ, 2007, CANCER CELL, V11, P3, DOI 10.1016/j.ccr.2006.12.007	32	36	35	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					761	770		10.1038/onc.2014.8	http://dx.doi.org/10.1038/onc.2014.8			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24531713				2022-12-17	WOS:000348853800009
J	Ming, M; Soltani, K; Shea, CR; Li, X; He, YY				Ming, M.; Soltani, K.; Shea, C. R.; Li, X.; He, Y. Y.			Dual role of SIRT1 in UVB-induced skin tumorigenesis	ONCOGENE			English	Article						SIRT1; UVB; skin tumorigenesis; DNA repair; apoptosis	DNA-DAMAGE RESPONSE; CELL-SURVIVAL; CALORIE RESTRICTION; MAMMALIAN SIRTUINS; CANCER; MICE; P53; DEACETYLASE; PROTEIN; REPAIR	The protein deacetylase SIRT1 regulates various pathways in metabolism, aging and cancer. However, the role of SIRT1 in skin cancer remains unclear. Here, using mice with targeted deletions of SIRT1 in their epidermis in both resistant B6 and sensitive SKH1 hairless backgrounds, we show that the role of SIRT1 in skin cancer development induced by ultraviolet B (UVB) radiation is dependent on its gene dose. Keratinocyte-specific heterozygous deletion of SIRT1 promotes UVB-induced skin tumorigenesis, whereas homozygous deletion of SIRT1 suppresses skin tumor development but sensitizes the B6 mice to chronic solar injury. In mouse skin, SIRT1 is haploinsufficient for UVB-induced DNA damage repair and expression of xeroderma pigmentosum C (XPC), a protein critical for repairing UVB-induced DNA damage. As compared with normal human skin, downregulation of SIRT1 is in parallel with downregulation of XPC in human cutaneous squamous cell carcinoma at both the protein and mRNA levels. In contrast, homozygous SIRT1 deletion in mouse skin augments p53 acetylation and expression of its transcriptional target Noxa, and sensitizes the epidermis to UVB-induced apoptosis in vivo, while heterozygous SIRT1 deletion has no such effect. The gene dosage-dependent function of SIRT1 in DNA repair and cell survival is consistent with the dual roles of SIRT1 in UVB-induced skin tumorigenesis. Our results reveal the gene dosage-dependent in vivo functions of SIRT1 in skin tumorigenesis and may shed light on the role of SIRT1 in epithelial cancer induced by DNA damage.	[Ming, M.; Soltani, K.; Shea, C. R.; He, Y. Y.] Univ Chicago, Dermatol Sect, Dept Med, Chicago, IL 60637 USA; [Li, X.] NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC USA	University of Chicago; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	He, YY (corresponding author), Univ Chicago, Dermatol Sect, Dept Med, Chicago, IL 60637 USA.	yyhe@medicine.bsd.uchicago.edu	Shea, Christopher R./AAJ-7143-2021; Li, Xiaoling/A-2994-2015	Li, Xiaoling/0000-0001-5920-7784	NIH/NIEHS [ES016936]; American Cancer Society (ACS) [RSG-13-078-01]; University of Chicago Cancer Research Center [P30 CA014599]; CTSA [NIH UL1RR024999]; University of Chicago Friends of Dermatology Endowment Fund; NATIONAL CANCER INSTITUTE [P30CA014599] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024999] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016936] Funding Source: NIH RePORTER	NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); American Cancer Society (ACS)(American Cancer Society); University of Chicago Cancer Research Center; CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); University of Chicago Friends of Dermatology Endowment Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This work was supported by the NIH/NIEHS Grant ES016936 (to YYH), the American Cancer Society (ACS) Grant RSG-13-078-01 (to YYH), the University of Chicago Cancer Research Center (P30 CA014599), the CTSA (NIH UL1RR024999) and the University of Chicago Friends of Dermatology Endowment Fund. We thank Terri Li for Ki67 and TUNEL and XPC immunohistochemical analysis, and Dr Xiaobing Shi for kindly providing the WT and K382R mutant p53 plasmids.	Berg RJW, 1998, J INVEST DERMATOL, V110, P405, DOI 10.1111/j.1523-1747.1998.00173.x; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Boily G, 2009, ONCOGENE, V28, P2882, DOI 10.1038/onc.2009.147; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Cheo DL, 2000, CANCER RES, V60, P1580; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Fan W, MOL CELL, V39, P247; Fan W, 2010, MOL CELL, V39, P247, DOI 10.1016/j.molcel.2010.07.006; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Haigis MC, 2006, GENE DEV, V20, P2913, DOI 10.1101/gad.1467506; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Herranz D, 2013, ONCOGENE, V32, P4052, DOI 10.1038/onc.2012.407; Herranz D, 2010, NAT REV CANCER, V10, P819, DOI 10.1038/nrc2962; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Hida Y, 2007, ARCH DERMATOL RES, V299, P103, DOI 10.1007/s00403-006-0725-6; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Itoh T, 2004, P NATL ACAD SCI USA, V101, P2052, DOI 10.1073/pnas.0306551101; Jeong J, 2007, EXP MOL MED, V39, P8, DOI 10.1038/emm.2007.2; Kamel C, 2006, AGING CELL, V5, P81, DOI 10.1111/j.1474-9726.2006.00191.x; Li HZ, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1632; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Ming M, P NATL ACAD SCI US, V107, P22623; Ming M, 2010, P NATL ACAD SCI USA, V107, P22623, DOI 10.1073/pnas.1010377108; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Oka M, 2010, CARCINOGENESIS, V31, P1897, DOI 10.1093/carcin/bgq164; Powell MJ, 2011, CANCER RES, V71, P964, DOI 10.1158/0008-5472.CAN-10-3172; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Smith JS, 2002, TRENDS CELL BIOL, V12, P404, DOI 10.1016/S0962-8924(02)02342-5; Solomon JM, 2006, MOL CELL BIOL, V26, P28, DOI 10.1128/MCB.26.1.28-38.2006; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Sugasawa K, 2008, CARCINOGENESIS, V29, P455, DOI 10.1093/carcin/bgm282; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wu CL, 2013, ONCOGENE, V32, P2682, DOI 10.1038/onc.2012.279; Yuan Z, 2007, CELL CYCLE, V6, P2869, DOI 10.4161/cc.6.23.5026; Yuan Z, 2007, MOL CELL, V27, P149, DOI 10.1016/j.molcel.2007.05.029	45	36	36	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					281	287		10.1038/onc.2013.583	http://dx.doi.org/10.1038/onc.2013.583			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24441046	Green Accepted			2022-12-17	WOS:000348145500002
J	Sales, KU; Friis, S; Konkel, JE; Godiksen, S; Hatakeyama, M; Hansen, KK; Rogatto, SR; Szabo, R; Vogel, LK; Chen, W; Gutkind, JS; Bugge, TH				Sales, K. U.; Friis, S.; Konkel, J. E.; Godiksen, S.; Hatakeyama, M.; Hansen, K. K.; Rogatto, S. R.; Szabo, R.; Vogel, L. K.; Chen, W.; Gutkind, J. S.; Bugge, T. H.			Non-hematopoietic PAR-2 is essential for matriptase-driven pre-malignant progression and potentiation of ras-mediated squamous cell carcinogenesis	ONCOGENE			English	Article						epithelial carcinogenesis; inflammation; keratinocyte stem cells; pericellular proteolysis	PROTEINASE-ACTIVATED RECEPTOR-2; SERINE-PROTEASE MATRIPTASE; TISSUE MICROARRAY ANALYSIS; HUMAN KERATINOCYTES; CLINICOPATHOLOGICAL PARAMETERS; GENE-EXPRESSION; OVARIAN-CANCER; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; IN-VITRO	The membrane-anchored serine protease, matriptase, is consistently dysregulated in a range of human carcinomas, and high matriptase activity correlates with poor prognosis. Furthermore, matriptase is unique among tumor-associated proteases in that epithelial stem cell expression of the protease suffices to induce malignant transformation. Here, we use genetic epistasis analysis to identify proteinase-activated receptor (PAR)-2-dependent inflammatory signaling as an essential component of matriptase-mediated oncogenesis. In cell-based assays, matriptase was a potent activator of PAR-2, and PAR-2 activation by matriptase caused robust induction of nuclear factor (NF)kappa B through G alpha i. Importantly, genetic elimination of PAR-2 from mice completely prevented matriptase-induced pre-malignant progression, including inflammatory cytokine production, inflammatory cell recruitment, epidermal hyperplasia and dermal fibrosis. Selective ablation of PAR-2 from bone marrow-derived cells did not prevent matriptase-driven pre-malignant progression, indicating that matriptase activates keratinocyte stem cell PAR-2 to elicit its pro-inflammatory and pro-tumorigenic effects. When combined with previous studies, our data suggest that dual induction of PAR-2-NF kappa B inflammatory signaling and PI3K-Akt-mTor survival/proliferative signaling underlies the transforming potential of matriptase and may contribute to pro-tumorigenic signaling in human epithelial carcinogenesis.	[Sales, K. U.; Friis, S.; Konkel, J. E.; Godiksen, S.; Hansen, K. K.; Szabo, R.; Chen, W.; Gutkind, J. S.; Bugge, T. H.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; [Sales, K. U.] Natl Inst Dent & Craniofacial Res, Clin Res Core, NIH, Bethesda, MD 20892 USA; [Friis, S.; Godiksen, S.; Vogel, L. K.] Univ Copenhagen, Fac Hlth & Med Sci, Dept Cellular & Mol Med, Copenhagen, Denmark; [Godiksen, S.] Univ Copenhagen, Fac Sci, Dept Biol, Copenhagen, Denmark; [Hatakeyama, M.; Rogatto, S. R.] Sao Paulo State Univ UNESP, Fac Med, Dept Urol, Botucatu, SP, Brazil; [Hatakeyama, M.; Rogatto, S. R.] AC Camargo Canc Ctr, Sao Paulo, Brazil	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Copenhagen; University of Copenhagen; Universidade Estadual Paulista; A.C.Camargo Cancer Center	Bugge, TH (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Room 211, Bethesda, MD 20892 USA.	thomas.bugge@nih.gov	sales, katiuchia u/J-4880-2012; Gutkind, J. Silvio/J-1201-2016; Rogatto, Silvia R/E-6535-2012	Gutkind, J. Silvio/0000-0002-5150-4482; Vogel, Lotte K./0000-0001-9920-0982; sales, katiuchia/0000-0002-3768-5790; Rogatto, Silvia/0000-0003-4637-5687	NIDCR Intramural Research Program; Augustinus Foundation, Kobmand Kristian Kjaer og hustrus Foundation; Kjaer-Foundation; Dagmar Marshalls Foundation; Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Foundation; Grosserer Valdemar Foersom og Hustru Thyra Foersoms Foundation; Fabrikant Einar Willumsens Mindelegat; Sao Paulo Research Foundation (FAPESP); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000699, ZIADE000558, ZIADE000551] Funding Source: NIH RePORTER	NIDCR Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Augustinus Foundation, Kobmand Kristian Kjaer og hustrus Foundation; Kjaer-Foundation; Dagmar Marshalls Foundation; Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Foundation; Grosserer Valdemar Foersom og Hustru Thyra Foersoms Foundation; Fabrikant Einar Willumsens Mindelegat; Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Mary Jo Danton for critically reviewing this manuscript. Histology was performed by Histoserv, Germantown, MD, USA. We thank Dr Allessia Gallo, Shyh-Ing Jang, Colleen Doci, Patricia Pilla, Zhiyong Wang, Canstantinos Mikelis, Ramiro Iglesias-Bartolome and Morgan O'Hare for technical assistance. The study was supported by the NIDCR Intramural Research Program (THB, JSG, WC), the Augustinus Foundation, Kobmand Kristian Kjaer og hustrus Foundation, the Kjaer-Foundation, the Dagmar Marshalls Foundation, the Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Foundation, the Grosserer Valdemar Foersom og Hustru Thyra Foersoms Foundation and Fabrikant Einar Willumsens Mindelegat (SG and LKV), and the Sao Paulo Research Foundation (FAPESP) (MH, SRR).	Benaud C, 2002, J BIOL CHEM, V277, P10539, DOI 10.1074/jbc.M109064200; Bocheva G, 2009, J INVEST DERMATOL, V129, P1816, DOI 10.1038/jid.2008.449; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Buddenkotte J, 2005, J INVEST DERMATOL, V124, P38, DOI 10.1111/j.0022-202X.2004.23539.x; Bugge TH, 2009, J BIOL CHEM, V284, P23177, DOI 10.1074/jbc.R109.021006; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Camerer E, 1996, J BIOL CHEM, V271, P29034, DOI 10.1074/jbc.271.46.29034; Camerer E, 2002, J BIOL CHEM, V277, P16081, DOI 10.1074/jbc.M108555200; Camerer E, 2010, DEV CELL, V18, P25, DOI 10.1016/j.devcel.2009.11.014; Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355; Chokki M, 2004, AM J RESP CELL MOL, V30, P470, DOI 10.1165/rcmb.2003-0199OC; Coughlin SR, 2003, J CLIN INVEST, V111, P25, DOI 10.1172/JCI200317564; Frateschi S, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1162; Friis S, 2013, J BIOL CHEM, V288, P19028, DOI 10.1074/jbc.M113.469932; Hoang CD, 2004, CHEST, V125, P1843, DOI 10.1378/chest.125.5.1843; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; Jin JS, 2006, MODERN PATHOL, V19, P447, DOI 10.1038/modpathol.3800495; Jin JS, 2006, INT J SURG PATHOL, V14, P65, DOI 10.1177/106689690601400111; Johnson MD, 2003, EXPERT REV MOL DIAGN, V3, P331, DOI 10.1586/14737159.3.3.331; Kang JY, 2003, CANCER RES, V63, P1101; Kanke T, 2001, J BIOL CHEM, V276, P31657, DOI 10.1074/jbc.M100377200; Kaufmann R, 2009, CARCINOGENESIS, V30, P1487, DOI 10.1093/carcin/bgp153; LeBeau AM, 2013, P NATL ACAD SCI USA, V110, P93, DOI 10.1073/pnas.1218694110; Lee JW, 2005, HUM PATHOL, V36, P626, DOI 10.1016/j.humpath.2005.03.003; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; List K, 2006, AM J PATHOL, V168, P1513, DOI 10.2353/ajpath.2006.051071; List K, 2005, GENE DEV, V19, P1934, DOI 10.1101/gad.1300705; List K, 2009, FUTURE ONCOL, V5, P97, DOI 10.2217/14796694.5.1.97; Lopez-Otin C, 2010, NAT REV CANCER, V10, P278, DOI 10.1038/nrc2823; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Oberst M, 2001, AM J PATHOL, V158, P1301, DOI 10.1016/S0002-9440(10)64081-3; Oberst MD, 2002, CLIN CANCER RES, V8, P1101; Oikonomopoulou K, 2006, J BIOL CHEM, V281, P32095, DOI 10.1074/jbc.M513138200; Perez-Moreno M, 2006, CELL, V124, P631, DOI 10.1016/j.cell.2005.11.043; Ramsay AJ, 2008, J BIOL CHEM, V283, P12293, DOI 10.1074/jbc.M709493200; Rothmeier AS, SEMIN IMMUNOPATHOL, V34, P133; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; Schaffner F, 2008, SEMIN THROMB HEMOST, V34, P147, DOI 10.1055/s-2008-1079254; Schmidlin F, 2002, J IMMUNOL, V169, P5315, DOI 10.4049/jimmunol.169.9.5315; Scott G, 2004, J INVEST DERMATOL, V122, P1214, DOI 10.1111/j.0022-202X.2004.22516.x; Scott G, 2003, J INVEST DERMATOL, V121, P529, DOI 10.1046/j.1523-1747.2003.12427.x; Seitz I, 2007, ARTERIOSCL THROM VAS, V27, P769, DOI 10.1161/01.ATV.0000258862.61067.14; Szabo R, 2011, ONCOGENE, V30, P2003, DOI 10.1038/onc.2010.586; Szabo R, 2008, J BIOL CHEM, V283, P29495, DOI 10.1074/jbc.M801970200; Szabo R, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002937; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Tanimoto H, 2005, BRIT J CANCER, V92, P278, DOI 10.1038/sj.bjc.6602320; Vogel LK, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-176; Wakita H, 1997, P ASSOC AM PHYSICIAN, V109, P190; Wilson S, 2005, BIOCHEM J, V388, P967, DOI 10.1042/BJ20041066	51	36	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					288	298		10.1038/onc.2013.563	http://dx.doi.org/10.1038/onc.2013.563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24469043	Green Accepted			2022-12-17	WOS:000348145500003
J	Andrechek, ER				Andrechek, E. R.			HER2/Neu tumorigenesis and metastasis is regulated by E2F activator transcription factors	ONCOGENE			English	Article						MMTV-Neu; metastasis; E2F transcription factors; gene expression; signatures	HUMAN-BREAST-CANCER; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNALING PATHWAY; BINDING-SITES; NEU ONCOGENE; CYCLIN D1; PROLIFERATION; EXPRESSION; MICE; CARCINOMAS	HER2/Neu is amplified and overexpressed in a large proportion of human breast cancers, but the signaling pathways that contribute to tumor development and metastatic progression are not completely understood. Using gene expression data and pathway signatures, we predicted a role for activator E2F transcription factors in Neu-induced tumors. This was genetically tested by interbreeding Neu transgenics with knockouts of the three activator E2Fs. Loss of any E2F delayed Neu-induced tumor onset. E2F1 loss accelerated tumor growth, while E2F2 and E2F3 loss did not. Strikingly, it was observed that loss of E2F1 or E2F2 significantly reduced the metastatic capacity of the tumor and this was associated with a reduction in circulating tumor cells in the E2F2 knockout. Gene expression analysis between the tumors in the various E2F-mutant backgrounds revealed that there was extensive compensation by other E2F family members in the individual knockouts, underscoring the importance of the E2Fs in HER2/Neu-induced tumors. Extension to HER2-positive (HER2+) human breast cancer revealed a number of HER2+ subtypes based on E2F activity with differences in relapse-free survival times. Taken together, these data demonstrate that the E2F transcription factors are integral to HER2+ tumor development and progression.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA	Michigan State University	Andrechek, ER (corresponding author), Michigan State Univ, Dept Physiol, 2194 Biomed Phys Sci Bldg,567 Wilson Rd, E Lansing, MI 48824 USA.	andrech1@msu.edu		Andrechek, Eran/0000-0002-8680-3423	NCI [1R01CA160514]; NATIONAL CANCER INSTITUTE [R01CA160514] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	I thank Inez Yuwanita for providing a merged human breast cancer gene expression data set and Daniel Hollern for his cell signaling predictions from his mouse breast cancer gene expression database. I thank the members of my laboratory for numerous discussions and critical reading of the manuscript and Jordan Honeysett for technical support. This work was supported by a grant from the NCI (1R01CA160514).	Andrechek ER, 2008, DEVELOPMENT, V135, P2403, DOI 10.1242/dev.019018; Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Carvalho CM, 2008, J AM STAT ASSOC, V103, P1438, DOI 10.1198/016214508000000869; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DeGregori J, 2006, CURR MOL MED, V6, P739; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eceles SA, 2001, J MAMMARY GLAND BIOL, V6, P393, DOI 10.1023/A:1014730829872; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Fujiwara K, 2011, CANCER RES, V71, P1924, DOI 10.1158/0008-5472.CAN-10-2386; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Humbert PO, 2000, GENE DEV, V14, P690; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Leone G, 2001, MOL CELL, V8, P105, DOI 10.1016/S1097-2765(01)00275-1; Lin NU, 2007, CLIN CANCER RES, V13, P1648, DOI 10.1158/1078-0432.CCR-06-2478; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Murga M, 2001, IMMUNITY, V15, P959, DOI 10.1016/S1074-7613(01)00254-0; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Qin GJ, 2006, P NATL ACAD SCI USA, V103, P11015, DOI 10.1073/pnas.0509533103; Rabinovich A, 2008, GENOME RES, V18, P1763, DOI 10.1101/gr.080622.108; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; Sears RC, 2002, J BIOL CHEM, V277, P11617, DOI 10.1074/jbc.R100063200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tsai SY, 2008, NATURE, V454, P1137, DOI 10.1038/nature07066; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Ziebold U, 2003, MOL CELL BIOL, V23, P6542, DOI 10.1128/MCB.23.18.6542-6552.2003	36	36	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 8	2015	34	2					217	225		10.1038/onc.2013.540	http://dx.doi.org/10.1038/onc.2013.540			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AY8FS	24362522	Green Accepted			2022-12-17	WOS:000347790500009
J	Vanoirbeek, E; Eelen, G; Verlinden, L; Carmeliet, G; Mathieu, C; Bouillon, R; O'Connor, R; Xiao, G; Verstuyf, A				Vanoirbeek, E.; Eelen, G.; Verlinden, L.; Carmeliet, G.; Mathieu, C.; Bouillon, R.; O'Connor, R.; Xiao, G.; Verstuyf, A.			PDLIM2 expression is driven by vitamin D and is involved in the pro-adhesion, and anti-migration and -invasion activity of vitamin D	ONCOGENE			English	Article						PDLIM2; breast cancer; vitamin D; metastasis; DNA methylation	DOMAIN-CONTAINING PROTEIN-2; CANCER; CELLS; GENES; DNA; 1-ALPHA,25-DIHYDROXYVITAMIN-D-3; IDENTIFICATION; INHIBITION; REPRESSION; MECHANISM	1Alpha, 25-dihydroxyvitamin D-3[1,25(OH)(2)D-3], the biologically active form of vitamin D-3, is a pleiotropic hormone that exerts its effects on a wide range of tissues, resulting in different biological responses such as anticancer activity. It is the ligand of the vitamin D receptor (VDR), a nuclear receptor with transactivating capacity. We demonstrated in this study that 1,25(OH)(2)D-3 induces PDZ-LIM domain-containing protein 2 (PDLIM2) expression. PDLIM2 is an adaptor molecule that links different components of the cytoskeleton, and was recently shown to be repressed in human breast cancer cells by hypermethylation of regulatory promoter regions, leading to enhanced tumorigenicity. We demonstrated that PDLIM2 was a direct target gene of 1,25(OH)(2)D-3; its upregulation was VDR-dependent and a functional VDRE in the promoter was identified. Moreover, 1,25(OH)(2)D-3 induced demethylation of the PDLIM2 promoter, leading to enhanced transcription. Finally, PDLIM2 was found to be crucial for 1,25(OH)(2)D-3-induced cell adhesion and for mediating the ability of 1,25(OH)(2)D-3 to suppress cancer cell migration and invasion. This study provides mechanistic insights into the anticancer activities of 1,25(OH)(2)D-3 in human breast cancer cells.	[Vanoirbeek, E.; Eelen, G.; Verlinden, L.; Carmeliet, G.; Mathieu, C.; Bouillon, R.; Verstuyf, A.] Katholieke Univ Leuven, Lab Clin & Expt Endocrinol, Leuven, Belgium; [Eelen, G.] Katholieke Univ Leuven, VIB, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, Leuven, Belgium; [O'Connor, R.] Univ Coll, Dept Biochem, Cork, Ireland; [Xiao, G.] Univ Pittsburgh, Hillman Canc Ctr Res Pavil, Pittsburgh, PA USA	KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University College Cork; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Verstuyf, A (corresponding author), Afdeling Expt Geneeskunde Endocrinol, UZ Herestr 49,Bus 902,O&NI, B-3000 Louvain, Belgium.	mieke.verstuyf@med.kuleuven.be	O'Connor, Rosemary/B-7902-2014; mathieu, chantal/ABD-5505-2021	O'Connor, Rosemary/0000-0002-0687-3422; mathieu, chantal/0000-0002-4055-5233; Verlinden, Lieve/0000-0002-9621-3662; Verstuyf, Annemieke/0000-0003-3193-2698	University of Leuven [GOA/04/10]; Flanders Research Foundation (FWO) [G.0587.09, G.0859.11]; Stichting tegen Kanker [212-2008]	University of Leuven(KU Leuven); Flanders Research Foundation (FWO)(FWO); Stichting tegen Kanker	We thank Ine Beullens, Mark Van Camp, Suzanne Marcelis and Biauw Keng Tan for excellent technical assistance. This work was supported by grants from the University of Leuven (GOA/04/10), Flanders Research Foundation (FWO G.0587.09 and G.0859.11) and Stichting tegen Kanker (212-2008).	Buss F, 2002, TRAFFIC, V3, P851, DOI 10.1034/j.1600-0854.2002.31201.x; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t; Dalmay T, 2006, ONCOGENE, V25, P6170, DOI 10.1038/sj.onc.1209911; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; Doig CL, 2013, CARCINOGENESIS, V34, P248, DOI 10.1093/carcin/bgs331; Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004; Eelen G, 2007, CURR MED CHEM, V14, P1893; Eelen G, 2004, J BONE MINER RES, V19, P133, DOI 10.1359/JBMR.0301204; Estecio MRH, 2011, FEBS LETT, V585, P2078, DOI 10.1016/j.febslet.2010.12.001; Healy NC, 2009, J LEUKOCYTE BIOL, V85, P481, DOI 10.1189/jlb.0408238; Hsu JW, 2011, AM J PATHOL, V178, P872, DOI 10.1016/j.ajpath.2010.10.036; Ishteiwy RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052106; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Liu W, 2011, LAB INVEST, V91, P147, DOI 10.1038/labinvest.2010.144; Lopes N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-483; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; Luo W, 2010, CANCER RES, V70, P5953, DOI 10.1158/0008-5472.CAN-10-0617; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pereira F, 2012, CELL CYCLE, V11, P1081, DOI 10.4161/cc.11.6.19508; Qu ZX, 2010, CANCER RES, V70, P1766, DOI 10.1158/0008-5472.CAN-09-3263; Qu ZX, 2010, J BIOL CHEM, V285, P11786, DOI 10.1074/jbc.M109.086561; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Shah AK, 1999, BIOL CELL, V91, P131, DOI 10.1016/S0248-4900(99)80037-9; Torrado M, 2004, INVEST OPHTH VIS SCI, V45, P3955, DOI 10.1167/iovs.04-0721; Vanoirbeek E, 2009, ANTICANCER RES, V29, P3585; Verlinden L, 2005, J BIOL CHEM, V280, P37319, DOI 10.1074/jbc.M503587200; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Verstuyf A, 1998, J BONE MINER RES, V13, P549, DOI 10.1359/jbmr.1998.13.4.549; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wang WD, 2011, J INEQUAL APPL, DOI 10.1186/1029-242X-2011-6; Wang XN, 2009, CELL CYCLE, V8, P736, DOI 10.4161/cc.8.5.7870; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	36	36	37	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1904	1911		10.1038/onc.2013.123	http://dx.doi.org/10.1038/onc.2013.123			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23584482				2022-12-17	WOS:000334346300003
J	Zhao, H; Chen, MS; Lo, YH; Waltz, SE; Wang, J; Ho, PC; Vasiliauskas, J; Plattner, R; Wang, YL; Wang, SC				Zhao, H.; Chen, M-S; Lo, Y-H; Waltz, S. E.; Wang, J.; Ho, P-C; Vasiliauskas, J.; Plattner, R.; Wang, Y-L; Wang, S-C			The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer	ONCOGENE			English	Article						PCNA; Ron; receptor tyrosine kinase; tyrosine phosphorylation; Y211; c-Abl	GROWTH-FACTOR RECEPTOR; TERMINAL REPEATED DOMAIN; DAMAGE-INDUCED APOPTOSIS; NUCLEAR ANTIGEN PCNA; DNA MISMATCH REPAIR; RNA-POLYMERASE-II; TUMOR-FORMATION; PROTEIN; REPLICATION; FAMILY	Multiple growth pathways lead to enhanced proliferation in malignant cells. However, how the core machinery of DNA replication is regulated by growth signaling remains largely unclear. The sliding clamp proliferating cell nuclear antigen (PCNA) is an indispensable component of the DNA machinery responsible for replicating the genome and maintaining genomic integrity. We previously reported that epidermal growth factor receptor (EGFR) triggered tyrosine 211 (Y211) phosphorylation of PCNA, which in turn stabilized PCNA on chromatin to promote cell proliferation. Here we show that the phosphorylation can also be catalyzed by the non-receptor tyrosine kinase c-Abl. We further demonstrate that, in the absence of EGFR, signaling to PCNA can be attained through the activation of the Ron receptor tyrosine kinase and the downstream non-receptor tyrosine kinase c-Abl. We show that Ron and c-Abl form a complex, and that activation of Ron by its ligand, hepatocyte growth factor-like protein (HGFL), stimulates c-Abl kinase activity, which in turn directly phosphorylates PCNA at Y211 and leads to an increased level of chromatin-associated PCNA. Correspondingly, HGFL-induced Ron activation resulted in Y211 phosphorylation of PCNA while silencing of c-Abl blocked this effect. We show that c-Abl and Y211 phosphorylation of PCNA is an important axis downstream of Ron, which is required for cell proliferation. Treatment with a specific peptide that inhibits Y211 phosphorylation of PCNA or with the c-Abl pharmacological inhibitor imatinib suppressed HGFL-induced cell proliferation. Our findings identify the pathway of Ron-c-Abl-PCNA as a mechanism of oncogene-induced cell proliferation, with potentially important implications for development of combination therapy of breast cancer.	[Zhao, H.; Chen, M-S; Lo, Y-H; Waltz, S. E.; Ho, P-C; Vasiliauskas, J.; Wang, Y-L; Wang, S-C] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH 45267 USA; [Waltz, S. E.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA; [Wang, J.] Univ Cincinnati Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH USA; [Plattner, R.] Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, Lexington, KY USA	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; University of Kentucky	Wang, SC (corresponding author), Univ Cincinnati, Coll Med, Vontz Ctr, Dept Canc Biol, 3125 Eden Ave,PO 670521, Cincinnati, OH 45267 USA.	wangsc@ucmail.uc.edu	Wang, Shao-Chun/P-9904-2019	Wang, Shao-Chun/0000-0002-5477-1682; Waltz, Susan/0000-0003-3572-4642	Susan G Komen Breast Cancer Research Award [KG080540]; Department of Defense Prostate Cancer Research Program New Investigator Award [PC073951]; Center for Clinical and Translational Science and Training (CCTST) of University of Cincinnati and Cincinnati Children's Hospital; Elsa Pardee Foundation; VA Merit Award [1001BX000803, R01 CA125379, R01 CA116784]; PHS [P30 DK078392]; NATIONAL CANCER INSTITUTE [R01CA125379, R01CA116784, R01CA100002, T32CA117846] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000803] Funding Source: NIH RePORTER	Susan G Komen Breast Cancer Research Award(Susan G. Komen Breast Cancer Foundation); Department of Defense Prostate Cancer Research Program New Investigator Award(United States Department of Defense); Center for Clinical and Translational Science and Training (CCTST) of University of Cincinnati and Cincinnati Children's Hospital; Elsa Pardee Foundation; VA Merit Award(US Department of Veterans Affairs); PHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We thank Drs David Plas and Daniel Starczynowski for the help in discussion and reagents. We also like to thank Dr Belinda Peace and Glenn Doerman for assistance in editing the manuscript and preparing the graphics, and Jerylin Gray for technical assistance. This work was supported in part by the Susan G Komen Breast Cancer Research Award KG080540, the Department of Defense Prostate Cancer Research Program New Investigator Award PC073951, the Center for Clinical and Translational Science and Training (CCTST) of University of Cincinnati and Cincinnati Children's Hospital, and the Elsa Pardee Foundation (S-CW), the VA Merit Award 1001BX000803 and R01 CA125379 (SEW), and R01 CA116784 (RP). This project was also supported in part by PHS Grant P30 DK078392.	Agami R, 1999, NATURE, V399, P809; Andoniou CE, 1996, ONCOGENE, V12, P1981; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Baker MA, 2009, DEV BIOL, V333, P57, DOI 10.1016/j.ydbio.2009.06.022; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Baskaran R, 1999, CELL GROWTH DIFFER, V10, P387; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Essers J, 2005, MOL CELL BIOL, V25, P9350, DOI 10.1128/MCB.25.21.9350-9359.2005; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; FURUKAWA T, 1991, J SURG ONCOL, V48, P188, DOI 10.1002/jso.2930480310; Gong JG, 1999, NATURE, V399, P806; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Kim WJ, 2007, J BIOL CHEM, V282, P32021, DOI 10.1074/jbc.M701451200; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Lee WY, 2005, CLIN CANCER RES, V11, P2222, DOI 10.1158/1078-0432.CCR-04-1761; Lehmann AR, 2006, EXP CELL RES, V312, P2673, DOI 10.1016/j.yexcr.2006.06.010; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Leonis Mike A, 2007, Future Oncol, V3, P441, DOI 10.2217/14796694.3.4.441; Levav-Cohen Y, 2005, BIOCHEM BIOPH RES CO, V331, P737, DOI 10.1016/j.bbrc.2005.03.152; Lin J, 2008, ONCOGENE, V27, P4385, DOI 10.1038/onc.2008.86; Lin J, 2007, ONCOGENE, V26, P6989, DOI 10.1038/sj.onc.1210500; Lo YH, 2011, ANTICANCER RES, V31, P789; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; Matunis MJ, 2002, MOL CELL, V10, P441, DOI 10.1016/S1097-2765(02)00653-6; McClaine RJ, 2010, NEOPLASIA, V12, P650, DOI 10.1593/neo.10476; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Nehme A, 1997, CANCER RES, V57, P3253; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Plattner R, 2004, MOL CELL BIOL, V24, P2573, DOI 10.1128/mcb.24.6.2573-2583.2004; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shaul Y, 2005, CELL RES, V15, P33, DOI 10.1038/sj.cr.7290261; Sirvent A, 2007, ONCOGENE, V26, P7313, DOI 10.1038/sj.onc.1210543; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Srinivasan D, 2009, CELL SIGNAL, V21, P1143, DOI 10.1016/j.cellsig.2009.03.003; Stuart JR, 2006, J BIOL CHEM, V281, P31290, DOI 10.1074/jbc.M602389200; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Thobe MN, 2010, ONCOGENE, V29, P214, DOI 10.1038/onc.2009.331; Truong T, 2003, P NATL ACAD SCI USA, V100, P10281, DOI 10.1073/pnas.1635435100; Tsai KKC, 2003, CANCER RES, V63, P3418; Ulrich HD, 2004, CELL CYCLE, V3, P15; Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8; Wang JYJ, 2001, BIOCHEM SOC T, V29, P666, DOI 10.1042/0300-5127:0290666; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Yi W, 2006, CANCER RES, V66, P151, DOI 10.1158/0008-5472.CAN-05-3019; Yogalingam G, 2008, J BIOL CHEM, V283, P35941, DOI 10.1074/jbc.M804543200; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhao HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029416; Zhao HJ, 2011, MOL CANCER THER, V10, P29, DOI 10.1158/1535-7163.MCT-10-0778; Zhao HJ, 2011, MOL CARCINOGEN, V50, P383, DOI 10.1002/mc.20721; Zhao HJ, 2010, NEOPLASIA, V12, P214, DOI 10.1593/neo.91576; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	72	36	41	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1429	1437		10.1038/onc.2013.84	http://dx.doi.org/10.1038/onc.2013.84			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542172	Green Accepted			2022-12-17	WOS:000332943500010
J	Yu, Y; Zhang, D; Huang, H; Li, J; Zhang, M; Wan, Y; Gao, J; Huang, C				Yu, Y.; Zhang, D.; Huang, H.; Li, J.; Zhang, M.; Wan, Y.; Gao, J.; Huang, C.			NF-kappa B1 p50 promotes p53 protein translation through miR-190 downregulation of PHLPP1	ONCOGENE			English	Article						p50; p53 translation; miR-190; PHLPP1; Akt/S6 ribosomal protein	NF-KAPPA-B; TUMOR-SUPPRESSOR; CANCER CELLS; INDUCED APOPTOSIS; ARSENIC TRIOXIDE; AKT ACTIVATION; DNA-DAMAGE; GROWTH; DEGRADATION; INDUCTION	The biological function of NF-kappa B1 (p50) in the regulation of protein expression is far from well understood owing to the lack of a transcriptional domain. Here, we report a novel function of p50 in its regulation of p53 protein translation under stress conditions. We found that the deletion of p50 (p50-/-) impaired arsenite-induced p53 protein expression, which could be restored after reconstitutive expression of HA-p50 in p50-/- cells, p50-/- (Ad-HA-p50). Further studies indicated that the amounts of p53 mRNA, p53 promoter-driven transcription activity and p53 protein degradation were comparable between wild-type and p50-/- cells. Moreover, we found that p50 was crucial for Akt/S6 ribosomal protein activation via inhibition of the translation of the PH domain and leucine-rich repeat protein phosphatases 1 (PHLPP1), a phosphatase of Akt. Further studies showed that p50-mediated upregulation of miR-190 was responsible for the inhibition of PHLPP1 translation by targeting the 30-untranslated region of its mRNA. Collectively, we have identified a novel function of p50 in modulating p53 protein translation via regulation of the miR-190/PHLPP1/Akt-S6 ribosomal protein pathway.	[Yu, Y.; Zhang, D.; Huang, H.; Li, J.; Zhang, M.; Huang, C.] NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; [Yu, Y.; Wan, Y.] Wuhan Univ, Med Res Ctr, Oversea Lab, Wuhan 430072, Hubei, Peoples R China; [Huang, H.; Zhang, M.; Gao, J.; Huang, C.] Wenzhou Med Coll, Sch Life Sci, Zhejiang Prov Key Lab Technol & Applicat Model Or, Wenzhou, Zhejiang, Peoples R China	New York University; Wuhan University; Wenzhou Medical University	Huang, C (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu.huang@nyumc.org	Yu, Yonghui/AAZ-3746-2021; Yu, Yonghui/AAZ-4093-2021	Huang, Chuanshu/0000-0003-4133-5096	NIH/NCI [CA112557, NBRPC2012CB525004]; NIH/NIEHS [ES000260];  [NSFC81229002]; NATIONAL CANCER INSTITUTE [R01CA112557, P30CA016087, R01CA177665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Ms Nedda Tichi and Mr Andy Hu for their critical reading of this manuscript. We thank Dr Ping-Yee Law (Department of Pharmacology, University of Minnesota) for providing us with constructs of miR-190 and its control. We also thank Dr Fei Chen (Department of Pharmaceutical Sciences, Wayne State University) for providing us with the PHLPP1 3'-UTR luciferase reporter. This work was partially supported by grants from NSFC81229002, NIH/NCI CA112557, NBRPC2012CB525004 and NIH/NIEHS ES000260.	Beezhold K, 2011, TOXICOL SCI, V123, P411, DOI 10.1093/toxsci/kfr188; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bellodi C, 2010, EMBO J, V29, P1865, DOI 10.1038/emboj.2010.83; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BOSARI S, 1995, AM J PATHOL, V147, P790; Chen A, 2002, EUR J PHARMACOL, V448, P11, DOI 10.1016/S0014-2999(02)01901-5; Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990; Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014-5793(02)02292-5; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Fiaschi Tania, 2012, Int J Cell Biol, V2012, P762825, DOI 10.1155/2012/762825; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gebel TW, 1999, SCIENCE, V283, P1458; Guo W, 2011, CELL MOL LIFE SCI, V68, P475, DOI 10.1007/s00018-010-0459-7; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hinata N, 2003, UROL RES, V31, P387, DOI 10.1007/s00240-003-0355-9; Hutchinson JA, 2011, J BIOL CHEM, V286, P8688, DOI 10.1074/jbc.M110.141754; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Karawajew L, 2005, BLOOD, V105, P4767, DOI 10.1182/blood-2004-09-3428; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li JL, 2004, HYBRIDOMA HYBRIDOM, V23, P1, DOI 10.1089/153685904322771962; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Maillet A, 2012, ANTIOXID REDOX SIGN, V16, P1285, DOI 10.1089/ars.2011.4434; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; Quinn JE, 2003, CANCER RES, V63, P6221; Rossman TG, 2011, METALLOMICS, V3, P1135, DOI 10.1039/c1mt00074h; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Song L, 2006, J CELL BIOL, V175, P607, DOI 10.1083/jcb.200602149; Stahnke K, 2001, BLOOD, V98, P3066, DOI 10.1182/blood.V98.10.3066; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Teodoro JG, 2006, SCIENCE, V313, P968, DOI 10.1126/science.1126391; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020-06; Wang YJ, 2007, CELL RES, V17, P933, DOI 10.1038/cr.2007.89; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yan WS, 2011, J BIOL CHEM, V286, P17478, DOI 10.1074/jbc.M111.231639; Yang DQ, 2006, ONCOGENE, V25, P4613, DOI 10.1038/sj.onc.1209483; Yang X, 2003, CELL DEATH DIFFER, V10, P400, DOI 10.1038/cj.cdd.4401182; Yih LH, 2000, CANCER RES, V60, P6346; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Ying SY, 2004, GENE, V342, P25, DOI 10.1016/j.gene.2004.07.025; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu YH, 2009, CURR CANCER DRUG TAR, V9, P566, DOI 10.2174/156800909788486759; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424; Zheng H, 2010, J BIOL CHEM, V285, P21994, DOI 10.1074/jbc.M110.112607	53	36	37	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					996	1005		10.1038/onc.2013.8	http://dx.doi.org/10.1038/onc.2013.8			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23396362	Green Accepted			2022-12-17	WOS:000331933200007
J	Du, Y; Shen, J; Hsu, JL; Han, Z; Hsu, MC; Yang, CC; Kuo, HP; Wang, YN; Yamaguchi, H; Miller, SA; Hung, MC				Du, Y.; Shen, J.; Hsu, J. L.; Han, Z.; Hsu, M-C; Yang, C-C; Kuo, H-P; Wang, Y-N; Yamaguchi, H.; Miller, S. A.; Hung, M-C			Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking	ONCOGENE			English	Article						EGF receptor; Golgi and nuclear translocation; microtubules; syntaxin 6	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; MEMBRANE; LOCALIZATION; PROTEIN; PHOSPHORYLATION; EXPRESSION; TRANSPORT; ENDOCYTOSIS; MECHANISM	Receptor tyrosine kinases (RTKs) are cell surface receptors that initiate signal cascades in response to ligand stimulation. Abnormal expression and dysregulated intracellular trafficking of RTKs have been shown to be involved in tumorigenesis. Recent evidence shows that these cell surface receptors translocate from cell surface to different cellular compartments, including the Golgi, mitochondria, endoplasmic reticulum (ER) and the nucleus, to regulate physiological and pathological functions. Although some trafficking mechanisms have been resolved, the mechanism of intracellular trafficking from cell surface to the Golgi is not yet completely understood. Here we report a mechanism of Golgi translocation of epidermal growth factor receptor (EGFR) in which EGF-induced EGFR travels to the Golgi via microtubule-dependent movement by interacting with dynein and fuses with the Golgi through syntaxin 6-mediated membrane fusion. We also demonstrate that the microtubule-and syntaxin 6-mediated Golgi translocation of EGFR is necessary for its consequent nuclear translocation and nuclear functions. Thus, together with previous studies, the microtubule-and syntaxin 6-mediated trafficking pathway from cell surface to the Golgi, ER and the nucleus defines a comprehensive trafficking route for EGFR to travel from cell surface to the Golgi and the nucleus.	[Du, Y.; Shen, J.; Hsu, J. L.; Han, Z.; Hsu, M-C; Yang, C-C; Kuo, H-P; Wang, Y-N; Yamaguchi, H.; Miller, S. A.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Du, Y.; Shen, J.; Yang, C-C; Kuo, H-P; Hung, M-C] Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX USA; [Hsu, J. L.; Wang, Y-N; Hung, M-C] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Hsu, J. L.; Wang, Y-N; Hung, M-C] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Hsu, J. L.; Wang, Y-N; Hung, M-C] Asia Univ, Dept Biotechnol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	Hsu, MC/AAE-5310-2020; Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Du, Yi/0000-0002-3969-2652; Wang, Ying-Nai/0000-0002-5275-6729	National Institutes of Health [CA109311, CA099031]; Cancer Research Center of Excellence, Taiwan [D0H101-TD-C-111-005]; Private University Grant, Taiwan [NSC99-2632-B-039-001-MY3]; Program for Stem Cell and Regenerative Medicine Frontier Research, Taiwan [NSC100-2321-B-039-002]; International Research-Intensive Centers of Excellence in Taiwan, Taiwan [NSC101-2911-I-002-303]; University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; National Institutes of Health through MD Anderson's Cancer Center Support Grant; Center for Biological Pathways [CA016672]; Patel Memorial Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA109311, P01CA099031] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research Center of Excellence, Taiwan; Private University Grant, Taiwan; Program for Stem Cell and Regenerative Medicine Frontier Research, Taiwan; International Research-Intensive Centers of Excellence in Taiwan, Taiwan; University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; National Institutes of Health through MD Anderson's Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Biological Pathways; Patel Memorial Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr B Storrie (University of Arkansas for Medical Sciences) for providing the GalNac T2-GFP plasmid. This study was partially supported by the following grants: National Institutes of Health Grants CA109311 and CA099031 (to MC Hung); Cancer Research Center of Excellence (D0H101-TD-C-111-005, Taiwan); Private University Grant (NSC99-2632-B-039-001-MY3, Taiwan); Program for Stem Cell and Regenerative Medicine Frontier Research (NSC100-2321-B-039-002, Taiwan); International Research-Intensive Centers of Excellence in Taiwan (NSC101-2911-I-002-303, Taiwan); The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; National Institutes of Health through MD Anderson's Cancer Center Support Grant and the Center for Biological Pathways (CA016672); Patel Memorial Breast Cancer Research Fund.	Akgoz M, 2004, J BIOL CHEM, V279, P51541, DOI 10.1074/jbc.M410639200; Allan VJ, 1999, CURR OPIN CELL BIOL, V11, P476, DOI 10.1016/S0955-0674(99)80068-4; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Bryant DM, 2005, MOL BIOL CELL, V16, P14, DOI 10.1091/mbc.E04-09-0845; Cao XY, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-26; Carpenter G, 2009, EXP CELL RES, V315, P1556, DOI 10.1016/j.yexcr.2008.09.027; Caviston JP, 2006, TRENDS CELL BIOL, V16, P530, DOI 10.1016/j.tcb.2006.08.002; Chen DJ, 2007, CLIN CANCER RES, V13, P6555, DOI 10.1158/1078-0432.CCR-07-1610; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0021428, 10.1371/journal.pone.0017876, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0027333, 10.1371/journal.pone.0017844, 10.1371/journal.pone.0024144]; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Das AK, 2007, CANCER RES, V67, P5267, DOI 10.1158/0008-5472.CAN-07-0242; Demory ML, 2009, J BIOL CHEM, V284, P36592, DOI 10.1074/jbc.M109.000760; Deribe YL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000576; Dittmann K, 2010, STRAHLENTHER ONKOL, V186, P1, DOI 10.1007/s00066-009-2026-4; Klaus HD, 2008, INT J RADIAT ONCOL, V70, P203, DOI 10.1016/j.ijrobp.2007.08.065; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Fourest-Lieuvin A, 2006, MOL BIOL CELL, V17, P1041, DOI 10.1091/mbc.E05-07-0621; Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Heisler FF, 2011, NEURON, V70, P66, DOI 10.1016/j.neuron.2011.03.008; Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200; Hsu SC, 2009, AM J TRANSL RES, V1, P249; Huang WC, 2011, J BIOL CHEM, V286, P20558, DOI 10.1074/jbc.M111.240796; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Johannes L, 2008, CELL, V135, P1175, DOI 10.1016/j.cell.2008.12.009; Kabayama H, 2008, NEUROSCI LETT, V436, P340, DOI 10.1016/j.neulet.2008.03.061; KAMIO T, 1990, HUM PATHOL, V21, P277, DOI 10.1016/0046-8177(90)90227-V; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Li LY, 2011, CANCER RES, V71, P4269, DOI 10.1158/0008-5472.CAN-10-3504; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Martens S, 2008, NAT REV MOL CELL BIO, V9, P543, DOI 10.1038/nrm2417; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Mittar S, 2009, EXP CELL RES, V315, P877, DOI 10.1016/j.yexcr.2008.12.020; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Ookata K, 1997, BIOCHEMISTRY-US, V36, P15873, DOI 10.1021/bi971251w; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; ROBERTSON BJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P190, DOI 10.1016/0003-9861(92)90067-7; Sadowski L, 2009, EXP CELL RES, V315, P1601, DOI 10.1016/j.yexcr.2008.09.021; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Srinivasan R, 2000, CANCER RES, V60, P1483; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Wang YN, 2010, J BIOL CHEM, V285, P38720, DOI 10.1074/jbc.M110.158659; Wang YN, 2010, BIOCHEM BIOPH RES CO, V399, P498, DOI 10.1016/j.bbrc.2010.07.096; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yarden Y, 2007, CELL, V131, DOI 10.1016/j.cell.2007.11.013	60	36	38	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					756	770		10.1038/onc.2013.1	http://dx.doi.org/10.1038/onc.2013.1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23376851	Green Accepted			2022-12-17	WOS:000331129200010
J	Kamranvar, SA; Chen, X; Masucci, MG				Kamranvar, S. A.; Chen, X.; Masucci, M. G.			Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein-Barr virus	ONCOGENE			English	Article						EBV; telomere; telomerase; ALT; shelterin; TRF2	LYMPHOBLASTOID CELL-LINES; PROMOTES GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; CHROMOSOME ENDS; MAMMALIAN TELOMERES; PROTECTS TELOMERES; PML BODY; MAINTENANCE; TRF2; DAMAGE	Malignant cells achieve replicative immortality by two alternative mechanisms, a common one dependent on de novo synthesis of telomeric DNA by telomerase, and a rare one based on telomere recombination known as alternative lengthening of telomeres (ALT). Epstein-Barr virus (EBV) transforms human B-lymphocytes into lymphoblastoid cell lines with unlimited growth potential in vitro and in vivo. Here we show that newly EBV-infected cells exhibit multiple signs of telomere dysfunction, including the occurrence of extra-chromosomal telomeres, telomere fusion and telomere length heterogeneity, and undergo progressive increase in telomere length without a parallel increase in telomerase activity. This phenotype is accompanied by the accumulation of telomere-associated promyelocytic leukemia nuclear bodies and telomeric-sister chromatid exchange, suggesting that EBV infection promotes the activation of ALT. Newly infected cells also display a significant reduction of telomere-associated TRF2 and express low levels of TRF1, TRF2, POT1 and ATRX, pointing to telomere de-protection as an important correlate of ALT activation. Collectively, these findings highlight the involvement of recombination-dependent mechanisms for maintenance of telomere homeostasis in EBV-induced B-cell immortalization.	[Kamranvar, S. A.; Chen, X.; Masucci, M. G.] Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 285, S-17177 Stockholm, Sweden.	maria.masucci@ki.se	Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809; Chen, Xinsong/0000-0002-3214-9075	Swedish Cancer Society; Swedish Medical Research Council; Karolinska Institutet, Stockholm, Sweden; China Scholarship Council	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Karolinska Institutet, Stockholm, Sweden; China Scholarship Council(China Scholarship Council)	This study was supported by grants awarded by the Swedish Cancer Society, the Swedish Medical Research Council and the Karolinska Institutet, Stockholm, Sweden. XC was supported by a fellowship awarded by the China Scholarship Council.	Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182; Bechter OE, 2003, EMBO REP, V4, P1138, DOI 10.1038/sj.embor.7400027; Bellon M, 2008, JNCI-J NATL CANCER I, V100, P98, DOI 10.1093/jnci/djm269; BIRD AG, 1981, NATURE, V289, P300, DOI 10.1038/289300a0; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Cesare AJ, 2010, NAT REV GENET, V11, P319, DOI 10.1038/nrg2763; Chen F, 2005, INT J CANCER, V113, P284, DOI 10.1002/ijc.20594; Chung I, 2012, NUCLEUS-PHILA, V3, P263, DOI 10.4161/nucl.20326; De La Fuente R, 2011, REPRODUCTION, V142, P221, DOI 10.1530/REP-10-0380; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; Henson JD, 2010, FEBS LETT, V584, P3800, DOI 10.1016/j.febslet.2010.06.009; Henson JD, 2009, NAT BIOTECHNOL, V27, P1181, DOI 10.1038/nbt.1587; Hockemeyer D, 2005, EMBO J, V24, P2667, DOI 10.1038/sj.emboj.7600733; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Kamranvar SA, 2007, ONCOGENE, V26, P5115, DOI 10.1038/sj.onc.1210324; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kataoka H, 1997, DIFFERENTIATION, V62, P203; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Lacoste S, 2010, ONCOGENE, V29, P503, DOI 10.1038/onc.2009.359; Lenoir GM, 1985, IARC SCI PUBL, V60, P308; Lovejoy CA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002772; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; Mei YP, 2006, CANCER LETT, V232, P189, DOI 10.1016/j.canlet.2005.02.010; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; Nikitin PA, 2010, CELL HOST MICROBE, V8, P510, DOI 10.1016/j.chom.2010.11.004; O'Connor MS, 2006, P NATL ACAD SCI USA, V103, P11874, DOI 10.1073/pnas.0605303103; Opresko PL, 2005, NUCLEIC ACIDS RES, V33, P1230, DOI 10.1093/nar/gki273; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Parish CR, 2009, CURRENT PROT IMMUNOL, V84; PURTILO DT, 1992, LAB INVEST, V67, P5; Ritchie K, 2008, J CELL BIOL, V180, P315, DOI 10.1083/jcb.200706083; Royle NJ, 2008, CYTOGENET GENOME RES, V122, P281, DOI 10.1159/000167814; Sfeir A, 2010, SCIENCE, V327, P1657, DOI 10.1126/science.1185100; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sugimoto M, 1999, MECH AGEING DEV, V107, P51, DOI 10.1016/S0047-6374(98)00131-6; Sugimoto M, 2004, CANCER RES, V64, P3361, DOI 10.1158/0008-5472.CAN-04-0079; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Terrin L, 2008, J VIROL, V82, P10175, DOI 10.1128/JVI.00321-08; TORSTEINSDOTTIR S, 1991, CELL IMMUNOL, V137, P501, DOI 10.1016/0008-8749(91)90097-U; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Von Zglinicki T, 2000, ANN NY ACAD SCI, V908, P99, DOI 10.1111/j.1749-6632.2000.tb06639.x; Walker JR, 2012, MECH AGEING DEV, V133, P421, DOI 10.1016/j.mad.2012.05.002; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Xia T, 2008, CANCER RES, V68, P1436, DOI 10.1158/0008-5472.CAN-07-5126; Yang J, 2004, J EXP CLIN CANC RES, V23, P495; Yeager TR, 1999, CANCER RES, V59, P4175; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556	63	36	38	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5522	5530		10.1038/onc.2013.189	http://dx.doi.org/10.1038/onc.2013.189			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23708666	hybrid, Green Published			2022-12-17	WOS:000328276400003
J	Gordon, LK; Kiyohara, M; Fu, M; Braun, J; Dhawan, P; Chan, A; Goodglick, L; Wadehra, M				Gordon, L. K.; Kiyohara, M.; Fu, M.; Braun, J.; Dhawan, P.; Chan, A.; Goodglick, L.; Wadehra, M.			EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF	ONCOGENE			English	Article						EMP2; VEGF; neoangiogenesis	EPITHELIAL MEMBRANE PROTEIN-2; ENDOTHELIAL GROWTH-FACTOR; COLLAGEN GEL CONTRACTION; TUMOR ANGIOGENESIS; SPLICE VARIANTS; EXPRESSION; TARGET; GLIOBLASTOMA; INHIBITION; RECEPTOR	Understanding tumor-induced angiogenesis is a challenging problem with important consequences for the diagnosis and treatment of cancer. In this study, we define a novel function for epithelial membrane protein-2 (EMP2) in the control of angiogenesis. EMP2 functions as an oncogene in endometrial cancer, and its expression has been linked to decreased survival. Using endometrial cancer xenografts, modulation of EMP2 expression resulted in profound changes to the tumor microvasculature. Under hypoxic conditions, upregulation of EMP2 promoted vascular endothelial growth factors (VEGF) expression through a HIF-1 alpha-dependent pathway and resulted in successful capillary-like tube formation. In contrast, reduction of EMP2 correlated with reduced HIF-1 alpha and VEGF expression with the net consequence of poorly vascularized tumors in vivo. We have previously shown that targeting of EMP2 using diabodies in endometrial cancer resulted in a reduction of tumor load, and since then we have constructed a fully human EMP2 IgG1. Treatment of endometrial cancer cells with EMP2-IgG1 reduced tumor load with a significant improvement in survival. These results support the role of EMP2 in the control of the tumor microenvironment and confirm the cytotoxic effects observed by EMP2 treatment in vivo.	[Gordon, L. K.; Chan, A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA; [Kiyohara, M.; Fu, M.; Braun, J.; Chan, A.; Goodglick, L.; Wadehra, M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Braun, J.; Goodglick, L.; Wadehra, M.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Dhawan, P.] Harbor UCLA Med Ctr, Dept Surg, Torrance, CA 90509 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Wadehra, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.	mwadehra@mednet.ucla.edu		Braun, Jonathan/0000-0003-1646-2974	Early Detection Research Network NCI [CA-86366]; NIH [CA16042, CA131756, CA163971]; Stein Oppenheimer Award; Richard and Barbara Braun fund; NATIONAL CANCER INSTITUTE [U24CA086366, R01CA163971, P30CA016042, R21CA131756] Funding Source: NIH RePORTER	Early Detection Research Network NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stein Oppenheimer Award; Richard and Barbara Braun fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Heather Christofk and her laboratory for use of the hypoxic chamber, and thankful to Dr Judith Berliner and Dr Sangderk Lee for providing HAEC cells. This work was generously supported by the Early Detection Research Network NCI CA-86366 (LG), NIH grants CA16042 (JB), CA131756 (MW), CA163971 (MW), the Stein Oppenheimer Award (MW) and Richard and Barbara Braun fund.	Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Bates DO, 2006, CLIN SCI, V110, P575, DOI 10.1042/CS20050292; Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3; de Oliveira RL, 2011, MOL ASPECTS MED, V32, P71, DOI 10.1016/j.mam.2011.04.001; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Fu MY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019945; Fu MY, 2010, CLIN CANCER RES, V16, P3954, DOI 10.1158/1078-0432.CCR-10-0368; Habeeb O, 2010, CANCER-AM CANCER SOC, V116, P4718, DOI 10.1002/cncr.25259; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Kadenhe-Chiweshe A, 2008, MOL CANCER RES, V6, P1, DOI 10.1158/1541-7786.MCR-07-0101; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kilarski WW, 2009, NAT MED, V15, P657, DOI 10.1038/nm.1985; Lu KV, 2009, CANCER RES, V69, P6889, DOI 10.1158/0008-5472.CAN-09-0347; Mahimainathan L, 2005, AM J PHYSIOL-RENAL, V289, pF72, DOI 10.1152/ajprenal.00277.2004; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Merdzhanova G, 2010, ONCOGENE, V29, P5392, DOI 10.1038/onc.2010.281; Morales SA, 2007, EXP EYE RES, V85, P790, DOI 10.1016/j.exer.2007.08.014; Morales SA, 2009, INVEST OPHTH VIS SCI, V50, P4949, DOI 10.1167/iovs.08-3315; Morales SA, 2009, INVEST OPHTH VIS SCI, V50, P462, DOI 10.1167/iovs.07-1598; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Robinson CJ, 2001, J CELL SCI, V114, P853; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Seton-Rogers S, 2011, NAT REV CANCER, V11, P391, DOI 10.1038/nrc3074; Shimazaki K, 2008, CLIN CANCER RES, V14, P7367, DOI 10.1158/1078-0432.CCR-08-1016; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Travasso RDM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019989; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wadehra M, 2006, DEV BIOL, V292, P430, DOI 10.1016/j.ydbio.2006.01.015; Wadehra M, 2005, DEV BIOL, V287, P336, DOI 10.1016/j.ydbio.2005.09.003; Wadehra M, 2002, BIOTECHNIQUES, V32, P242, DOI 10.2144/02322bm02; Wadehra M, 2002, J BIOL CHEM, V277, P41094, DOI 10.1074/jbc.M206868200; Wadehra M, 2006, CANCER-AM CANCER SOC, V107, P90, DOI 10.1002/cncr.21957; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482	43	36	42	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5369	5376		10.1038/onc.2012.622	http://dx.doi.org/10.1038/onc.2012.622			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23334331	Green Published, hybrid			2022-12-17	WOS:000326922400007
J	Sudol, M				Sudol, M.			YAP1 oncogene and its eight isoforms	ONCOGENE			English	Letter									[Sudol, M.] Weis Ctr Res, Geisinger Clin, Lab Signal Transduct & Prote Profiling, Danville, PA 17822 USA; [Sudol, M.] Mt Sinai Sch Med, Dept Med, New York, NY USA	Icahn School of Medicine at Mount Sinai	Sudol, M (corresponding author), Weis Ctr Res, Geisinger Clin, Lab Signal Transduct & Prote Profiling, Danville, PA 17822 USA.	msudol1@geisinger.edu						Ehsanian R, 2010, ONCOGENE, V29, P6160, DOI 10.1038/onc.2010.339; Fernandez A, 2012, ONCOGENE, V31, P1923, DOI 10.1038/onc.2011.379; Gaffney CJ, 2012, GENE, V509, P215, DOI 10.1016/j.gene.2012.08.025; Liu X, 2013, ONCOGENE, V32, P1266, DOI 10.1038/onc.2012.147; Oka T, 2012, ONCOGENE, V31, P128, DOI 10.1038/onc.2011.216	5	36	37	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3922	3922		10.1038/onc.2012.520	http://dx.doi.org/10.1038/onc.2012.520			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	23160371				2022-12-17	WOS:000323210200015
J	Borovski, T; Beke, P; van Tellingen, O; Rodermond, HM; Verhoeff, JJ; Lascano, V; Daalhuisen, JB; Medema, JP; Sprick, MR				Borovski, T.; Beke, P.; van Tellingen, O.; Rodermond, H. M.; Verhoeff, J. J.; Lascano, V.; Daalhuisen, J. B.; Medema, J. P.; Sprick, M. R.			Therapy-resistant tumor microvascular endothelial cells contribute to treatment failure in glioblastoma multiforme	ONCOGENE			English	Article						glioblastoma multiforme; cancer stem cells; tumor microvasculature; tumor microenvironment; therapy resistance; senescence	STEM-LIKE CELLS; SENESCENCE; CANCER; ANGIOGENESIS; RADIOTHERAPY; TEMOZOLOMIDE; PHENOTYPE; GROWTH	Glioblastoma multiforme (GBM) is a devastating disease with high mortality and poor prognosis. Cancer stem cells (CSCs) have recently been defined as a fraction of tumor cells highly resistant to therapy and subsequently considered to be responsible for tumor recurrence. These cells have been characterized in GBM and suggested to reside in and be supported by the tumor microvascular niche. Here we evaluated the response of tumor microvascular endothelial cells (tMVECs) to radio-and chemotherapy, and analyzed how this affects their interaction with CSCs. Our data demonstrate that tMVECs exhibit extreme resistance to both therapies, with the main response to irradiation being senescence. Importantly, senescent tMVECs can be detected in human GBM samples as well as in mice upon irradiation. Even though permanently arrested, they are still viable and able to support CSC growth with the same efficacy as non-senescent tMVECs. Intriguingly, GBM CSCs themselves are capable of differentiating into cells with similar features as tMVECs that subsequently undergo senescence when exposed to radiation. This indicates that endothelial-like cells are therapy resistant and, more importantly, support expansion of GBM cells. Oncogene (2013) 32, 1539-1548; doi:10.1038/onc.2012.172; published online 21 May 2012	[Borovski, T.; Beke, P.; Rodermond, H. M.; Lascano, V.; Daalhuisen, J. B.; Medema, J. P.] Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol LEXOR, Amsterdam, Netherlands; [van Tellingen, O.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Clin Chem Preclin Pharmacol, Amsterdam, Netherlands; [Verhoeff, J. J.] Univ Amsterdam, Acad Med Ctr, Dept Radiat Oncol, NL-1105 AZ Amsterdam, Netherlands; [Sprick, M. R.] Deutsch Krebsforschungszentrum DKFZ, Heidelberg, Germany; [Sprick, M. R.] HISTEM gGmbH, Heidelberg, Germany	Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Helmholtz Association; German Cancer Research Center (DKFZ)	Medema, JP (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Expt Mol Med, Lab Expt Oncol & Radiobiol LEXOR, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	J.P.Medema@amc.uva.nl	Sprick, Martin R./I-7995-2019; Sprick, Martin R./A-8611-2008	Sprick, Martin R./0000-0001-9691-7574; Sprick, Martin R./0000-0001-9691-7574; Verhoeff, Joost J.C./0000-0001-9673-0793; Medema, Jan Paul/0000-0003-3045-2924	VICI grant (NWO); KWF grant [2009-4416]; EMBO Long-Term Fellowship [ALTF 1063-2005]	VICI grant (NWO); KWF grant; EMBO Long-Term Fellowship(European Molecular Biology Organization (EMBO))	We thank Jan-Jacob Sonke and Alessia Gasparini for setting up the irradiation machine for irradiating mice, Dr E Aronica for helping with preparation of GBM samples and Dr Louis Vermeulen for helpful discussions and critical reading of the manuscript. Jan Paul Medema is supported by a VICI grant (NWO) and a KWF grant (2009-4416); Martin R Sprick was partially funded by an EMBO Long-Term Fellowship (ALTF 1063-2005).	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao SD, 2006, CANCER RES, V66, P7843, DOI 10.1158/0008-5472.CAN-06-1010; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Borovski T, 2009, INT J CANCER, V125, P1222, DOI 10.1002/ijc.24408; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Charalambous C, 2007, EXP CELL RES, V313, P1192, DOI 10.1016/j.yexcr.2006.12.027; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Clarke Michael F, 2006, Cancer Res, V66, P9339, DOI 10.1158/0008-5472.CAN-06-3126; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Dickson PV, 2007, CLIN CANCER RES, V13, P3942, DOI 10.1158/1078-0432.CCR-07-0278; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Giese A, 2003, J CLIN ONCOL, V21, P1624, DOI 10.1200/JCO.2003.05.063; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Igrashi K, 2007, EXP CELL RES, V313, P3326, DOI 10.1016/j.yexcr.2007.06.001; Jain RK, 2007, NAT REV NEUROSCI, V8, P610, DOI 10.1038/nrn2175; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Verhoeff JJC, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-444; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624	27	36	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 21	2013	32	12					1539	1548		10.1038/onc.2012.172	http://dx.doi.org/10.1038/onc.2012.172			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22614016				2022-12-17	WOS:000316456000007
J	Maslov, AY; Lee, M; Gundry, M; Gravina, S; Strogonova, N; Tazearslan, C; Bendebury, A; Suh, Y; Vijg, J				Maslov, A. Y.; Lee, M.; Gundry, M.; Gravina, S.; Strogonova, N.; Tazearslan, C.; Bendebury, A.; Suh, Y.; Vijg, J.			5-Aza-2 '-deoxycytidine-induced genome rearrangements are mediated by DNMT1	ONCOGENE			English	Article						DNA methylation; 5-aza-2 '-deoxycytidine; mutations; genome rearrangements; DNMT1	BASE EXCISION-REPAIR; DNA METHYLTRANSFERASE; MASS-SPECTROMETRY; CANCER-CELLS; POLY(ADP-RIBOSE) POLYMERASE; MYELODYSPLASTIC SYNDROME; MAMMALIAN-CELLS; IN-VIVO; DEMETHYLATION; METHYLATION	Observations that genome-wide DNA hypomethylation induces genome instability and tumors in animals caution against the indiscriminate use of demethylating agents, such as 5-aza-2'-deoxycytidine (5-Aza-dC). Using primary mouse embryonic fibroblasts harboring a lacZ mutational reporter construct that allows the quantification and characterization of a wide range of mutational events, we found that, in addition to demethylation, treatment with 5-Aza-dC induces gamma-H2AX expression, a marker for DNA breaks, and both point mutations and genome rearrangements. To gain insight into the source of these mutations, we first tested the hypothesis that the mutagenic effect of 5-Aza-dC may be directly mediated through the DNA methyltransferase 1 (DNMT1) covalently trapped in 5-Aza-dC-substituted DNA. Knockdown of DNMT1 resulted in increased resistance to the cytostatic effects of 5-Aza-dC, delayed onset of g-H2AX expression and a significant reduction in the frequency of genome rearrangements. There was no effect on the 5-Aza-dC-induced point mutations. An alternative mechanism for 5-Aza-dC-induced demethylation and genome rearrangements via activation-induced cytidine deaminase (AID) followed by base excision repair (BER) was found not to be involved. That is, 5-Aza-dC treatment did not significantly induce AID expression and inhibition of BER did not reduce the frequency of genome rearrangements. Thus, our results indicate that the formation of DNMT1 adducts is the prevalent mechanism of 5-Aza-dC-induced genome rearrangements, although hypomethylation per se may still contribute. As the therapeutic effects of 5-Aza-dC greatly depend on the presence of DNMT1, the expression level of DNA methyltransferases in tumors may serve as a prognostic factor for the efficacy of 5-Aza-dC treatment. Oncogene (2012) 31, 5172--5179; doi:10.1038/onc.2012.9; published online 20 February 2012	[Maslov, A. Y.; Lee, M.; Gundry, M.; Gravina, S.; Strogonova, N.; Tazearslan, C.; Bendebury, A.; Suh, Y.; Vijg, J.] Albert Einstein Coll Med, Dept Genet, Bronx, NY 10461 USA; [Suh, Y.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Suh, Y.] Guangdong Med Coll, Inst Aging Res, Dongguan, Peoples R China	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Guangdong Medical University	Maslov, AY (corresponding author), Albert Einstein Coll Med, Dept Genet, 1301 Morris Pk Ave, Bronx, NY 10461 USA.	alex.maslov@einstein.yu.edu; yousin.suh@einstein.yu.edu; jan.vijg@einstein.yu.edu	Gundry, Michael/AAE-7670-2020; Maslov, Alexander/AAH-3788-2019	Gundry, Michael/0000-0003-3654-1741; 	NIH [P01 AG017242, R01 AG024391]; Ellison/AFAR; NATIONAL INSTITUTE ON AGING [R01AG024391, P01AG017242] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ellison/AFAR; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by NIH Grant P01 AG017242 to JV and YS; R01 AG024391 to YS. CT is a recipient of Ellison/AFAR postdoctoral fellowship.	Allinson SL, 2003, ACTA BIOCHIM POL, V50, P169; AMACHER DE, 1987, MUTAT RES, V176, P123, DOI 10.1016/0027-5107(87)90259-4; Bhutani N, 2011, CELL, V146, P866, DOI 10.1016/j.cell.2011.08.042; BOERRIGTER METI, 1995, NATURE, V377, P657, DOI 10.1038/377657a0; CHABOT GG, 1983, BIOCHEM PHARMACOL, V32, P1327, DOI 10.1016/0006-2952(83)90293-9; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Coolen MW, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkm662; Daskalakis M, 2002, BLOOD, V100, P2957, DOI 10.1182/blood.V100.8.2957; Dolle MET, 2002, GENOME RES, V12, P1732, DOI 10.1101/gr.125502; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Fandy TE, 2009, CURR MED CHEM, V16, P2075, DOI 10.2174/092986709788612738; Ferguson AT, 1997, J BIOL CHEM, V272, P32260, DOI 10.1074/jbc.272.51.32260; Fisher AEO, 2007, MOL CELL BIOL, V27, P5597, DOI 10.1128/MCB.02248-06; Fritz EL, 2010, GENE DEV, V24, P2107, DOI 10.1101/gad.1963010; Garcia Ana Maria, 2007, Methods Mol Biol, V371, P267; Hernandez R, 1997, CYTOGENET CELL GENET, V76, P196, DOI 10.1159/000134548; Hoglund A, 2009, BLOOD, V113, P4281, DOI 10.1182/blood-2008-10-183475; JacksonGrusby L, 1997, P NATL ACAD SCI USA, V94, P4681, DOI 10.1073/pnas.94.9.4681; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Karpf AR, 2001, MOL PHARMACOL, V59, P751, DOI 10.1124/mol.59.4.751; Kelecsenyi Z, 2000, MUTAGENESIS, V15, P25, DOI 10.1093/mutage/15.1.25; Kuo HK, 2007, CANCER RES, V67, P8248, DOI 10.1158/0008-5472.CAN-07-1038; LANDOLPH JR, 1982, CANCER RES, V42, P817; Langer F, 2005, LEUKEMIA RES, V29, P325, DOI 10.1016/j.leukres.2004.08.004; Larijani M, 2005, MOL IMMUNOL, V42, P599, DOI 10.1016/j.molimm.2004.09.007; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Masaoka A, 2009, DNA REPAIR, V8, P1290, DOI 10.1016/j.dnarep.2009.08.004; Nakano T, 2009, J BIOL CHEM, V284, P27065, DOI 10.1074/jbc.M109.019174; Obeid S, 2010, EMBO J, V29, P1738, DOI 10.1038/emboj.2010.64; Palii SS, 2008, MOL CELL BIOL, V28, P752, DOI 10.1128/MCB.01799-07; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogstad DK, 2009, CHEM RES TOXICOL, V22, P1194, DOI 10.1021/tx900131u; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Sampath D, 2003, ONCOGENE, V22, P9063, DOI 10.1038/sj.onc.1207229; Sandhu SK, 2010, EUR J CANCER, V46, P9, DOI 10.1016/j.ejca.2009.10.021; Sczepanski JT, 2010, P NATL ACAD SCI USA, V107, P22475, DOI 10.1073/pnas.1012860108; Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211; Stavnezer J, 2008, ANNU REV IMMUNOL, V26, P261, DOI 10.1146/annurev.immunol.26.021607.090248; Vodenicharov MD, 2000, NUCLEIC ACIDS RES, V28, P3887, DOI 10.1093/nar/28.20.3887; ZIMMERMANN FK, 1984, MUTAT RES, V139, P21, DOI 10.1016/0165-7992(84)90116-7	42	36	39	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC	2012	31	50					5172	5179		10.1038/onc.2012.9	http://dx.doi.org/10.1038/onc.2012.9			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055WY	22349820	Green Accepted			2022-12-17	WOS:000312449800006
J	Manser, C; Guillot, F; Vagnoni, A; Davies, J; Lau, KF; McLoughlin, DM; De Vos, KJ; Miller, CCJ				Manser, C.; Guillot, F.; Vagnoni, A.; Davies, J.; Lau, K-F; McLoughlin, D. M.; De Vos, K. J.; Miller, C. C. J.			Lemur tyrosine kinase-2 signalling regulates kinesin-1 light chain-2 phosphorylation and binding of Smad2 cargo	ONCOGENE			English	Article						glycogen synthase kinase-3 beta; protein phosphatase-1C; transforming growth factor-beta; amyotrophic lateral sclerosis; Alzheimer's disease; axonal transport	GLYCOGEN-SYNTHASE KINASE-3-BETA; PROTEIN PHOSPHATASE-1; TGF-BETA; MYOSIN-VI; GENE-EXPRESSION; IDENTIFICATION; INACTIVATION; INHIBITOR; TRANSPORT; BRAIN	A recent genome-wide association study identified the gene encoding lemur tyrosine kinase-2 (LMTK2) as a susceptibility gene for prostate cancer. The identified genetic alteration is within intron 9, but the mechanisms by which LMTK2 may impact upon prostate cancer are not clear because the functions of LMTK2 are poorly understood. Here, we show that LMTK2 regulates a known pathway that controls phosphorylation of kinesin-1 light chain-2 (KLC2) by glycogen synthase kinase-3 beta (GSK3b). KLC2 phosphorylation by GSK3 beta induces the release of cargo from KLC2. LMTK2 signals via protein phosphatase-1C (PP1C) to increase inhibitory phosphorylation of GSK3 beta on serine-9 that reduces KLC2 phosphorylation and promotes binding of the known KLC2 cargo Smad2. Smad2 signals to the nucleus in response to transforming growth factor-beta (TGF beta) receptor stimulation and transport of Smad2 by kinesin-1 is required for this signalling. We show that small interfering RNA loss of LMTK2 not only reduces binding of Smad2 to KLC2, but also inhibits TGF beta-induced Smad2 signalling. Thus, LMTK2 may regulate the activity of kinesin-1 motor function and Smad2 signalling. Oncogene (2012) 31, 2773-2782; doi: 10.1038/onc.2011.437; published online 26 September 2011	[Manser, C.; Guillot, F.; Vagnoni, A.; Davies, J.; Lau, K-F; McLoughlin, D. M.; De Vos, K. J.; Miller, C. C. J.] Kings Coll London, Dept Neurosci P037, MRC Ctr Neurodegenerat Res, Inst Psychiat, London SE5 8AF, England; [Lau, K-F] Chinese Univ Hong Kong, Dept Biochem, Shatin, Hong Kong, Peoples R China; [McLoughlin, D. M.] St Patricks Hosp, Trinity Coll Inst Neurosci, Dept Psychiat, Dublin, Ireland	University of London; King's College London; Chinese University of Hong Kong; Trinity College Dublin	Miller, CCJ (corresponding author), Kings Coll London, Dept Neurosci P037, MRC Ctr Neurodegenerat Res, Inst Psychiat, De Crespigny Pk,Denmark Hill, London SE5 8AF, England.	chris.miller@kcl.ac.uk	Miller, Christopher/H-5733-2012; De Vos, Kurt/D-8380-2011	De Vos, Kurt/0000-0003-2161-6309; Miller, Christopher/0000-0002-5130-1845; , Florence/0000-0002-8491-4269; Lau, Kwok-Fai/0000-0002-0193-1152; Vagnoni, Alessio/0000-0003-2947-9193; McLoughlin, Declan/0000-0003-4574-2799	Wellcome Trust; MRC; MNDA; BBSRC; MRC [G0501573] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C506913/1] Funding Source: researchfish; Medical Research Council [G0501573] Funding Source: researchfish	Wellcome Trust(Wellcome TrustEuropean Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MNDA; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by grants from the Wellcome Trust, MRC, MNDA and BBSRC. We thank Caroline Hill (Cancer Research UK London Research Institute) for EGFP-Smad2 plasmid, Peter ten Dijke (Leiden University Medical Centre) for Smad2 reporter plasmids, Folma Buss (University of Cambridge UK) for LMTK2 antibody and Manuel Mayr (KCL London) for assistance with analyses of Pro-Q labelling.	Bajaj NPS, 1999, PROG NEURO-PSYCHOPH, V23, P833, DOI 10.1016/S0278-5846(99)00044-5; Batut J, 2007, DEV CELL, V12, P261, DOI 10.1016/j.devcel.2007.01.010; Bhat R, 2003, J BIOL CHEM, V278, P45937, DOI 10.1074/jbc.M306268200; Chibalina MV, 2007, J CELL SCI, V120, P4278, DOI 10.1242/jcs.014217; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; De Vos KJ, 2008, ANNU REV NEUROSCI, V31, P151, DOI 10.1146/annurev.neuro.31.061307.090711; DeBoer SR, 2008, BIOCHEMISTRY-US, V47, P4535, DOI 10.1021/bi702445j; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Eeles RA, 2008, NAT GENET, V40, P316, DOI 10.1038/ng.90; FitzGerald LM, 2009, CLIN CANCER RES, V15, P3231, DOI 10.1158/1078-0432.CCR-08-2190; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guidato S, 1998, J NEUROCHEM, V70, P335; Guo CY, 2002, J BIOL CHEM, V277, P41756, DOI 10.1074/jbc.M207519200; Harries LW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-315; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hernandez F, 2010, MOL CELL BIOCHEM, V344, P211, DOI 10.1007/s11010-010-0544-0; Hill CS, 2009, CELL RES, V19, P36, DOI 10.1038/cr.2008.325; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Inoue T, 2008, GENES CELLS, V13, P483, DOI 10.1111/j.1365-2443.2008.01184.x; Katsuno M, 2011, Curr Mol Med, V11, P48, DOI 10.2174/156652411794474356; Kawa S, 2004, GENES CELLS, V9, P219, DOI 10.1111/j.1356-9597.2004.00714.x; Kawa S, 2006, P NATL ACAD SCI USA, V103, P19344, DOI 10.1073/pnas.0603603103; Kesavapany S, 2003, J NEUROSCI, V23, P4975; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P2168, DOI 10.1073/pnas.94.6.2168; Lau KF, 2008, J BIOL CHEM, V283, P34728, DOI 10.1074/jbc.M801874200; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Li T, 2007, J BIOL CHEM, V282, P6619, DOI 10.1074/jbc.M606347200; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; Martin K, 2003, PROTEOMICS, V3, P1244, DOI 10.1002/pmic.200300445; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; McLoughlin DM, 1996, FEBS LETT, V397, P197; Mitsuhashi S, 2003, J BIOL CHEM, V278, P82, DOI 10.1074/jbc.M208888200; Mitsuhashi S, 2001, BIOCHEM BIOPH RES CO, V287, P328, DOI 10.1006/bbrc.2001.5596; Morfini G, 2002, EMBO J, V21, P281, DOI 10.1093/emboj/21.3.281; Morfini G, 2004, EMBO J, V23, P2235, DOI 10.1038/sj.emboj.7600237; Murakami M, 2009, GENES CELLS, V14, P469, DOI 10.1111/j.1365-2443.2009.01283.x; Noda D, 2006, ONCOGENE, V25, P5591, DOI 10.1038/sj.onc.1209571; Puri C, 2010, ONCOGENE, V29, P188, DOI 10.1038/onc.2009.328; Rahman A, 1998, J BIOL CHEM, V273, P15395, DOI 10.1074/jbc.273.25.15395; Rahman-Roblick R, 2008, ONCOGENE, V27, P4854, DOI 10.1038/onc.2008.124; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Ross S, 2008, INT J BIOCHEM CELL B, V40, P383, DOI 10.1016/j.biocel.2007.09.006; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Su AI, 2001, CANCER RES, V61, P7388; Su SC, 2011, ANNU REV CE IN PRESS; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tomomura M, 2007, NEUROSCIENCE, V148, P510, DOI 10.1016/j.neuroscience.2007.05.048; Town T, 2008, NAT MED, V14, P681, DOI 10.1038/nm1781; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Vagnoni A, 2011, J CELL SCI, V124, P1032, DOI 10.1242/jcs.075168; Wang H, 2002, J BIOL CHEM, V277, P49605, DOI 10.1074/jbc.M209335200; Wang H, 2006, MOL CELL PROTEOMICS, V5, P2124, DOI 10.1074/mcp.M600188-MCP200; Waters KM, 2009, CANCER EPIDEM BIOMAR, V18, P1285, DOI 10.1158/1055-9965.EPI-08-1142; Wozniak MJ, 2006, EMBO J, V25, P5457, DOI 10.1038/sj.emboj.7601427; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3	59	36	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2012	31	22					2773	2782		10.1038/onc.2011.437	http://dx.doi.org/10.1038/onc.2011.437			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	952DB	21996745	Green Accepted, Green Published			2022-12-17	WOS:000304769000007
J	Joha, S; Nugues, AL; Hetuin, D; Berthon, C; Dezitter, X; Dauphin, V; Mahon, FX; Roche-Lestienne, C; Preudhomme, C; Quesnel, B; Idziorek, T				Joha, S.; Nugues, A-L; Hetuin, D.; Berthon, C.; Dezitter, X.; Dauphin, V.; Mahon, F-X; Roche-Lestienne, C.; Preudhomme, C.; Quesnel, B.; Idziorek, T.			GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells	ONCOGENE			English	Article						GILZ; imatinib; dasatinib; BCR-ABL; mTORC2; AKT	PROTECTS T-LYMPHOCYTES; LEUCINE-ZIPPER GILZ; DORMANT TUMOR-CELLS; BCR-ABL; GLUCOCORTICOID-RECEPTOR; MAMMALIAN TARGET; INDUCE APOPTOSIS; LEUKEMIC-CELLS; TOR COMPLEX-2; RAPAMYCIN	The malignant phenotype of chronic myeloid leukemia (CML) is due to the abnormal tyrosine kinase activity of the BCR-ABL oncoprotein, which signals several downstream cell survival pathways, including phosphoinositide 3-kinase/AKT, signal transducer and activator of transcription 5 and extracellular signal-regulated kinase 1/2. In patients with CML, tyrosine kinase inhibitors (TKIs) are used to suppress the BCR-ABL tyrosine kinase, resulting in impressive response rates. However, resistance can occur, especially in acute-phase CML, through various mechanisms. Here, we show that the glucocorticoid-induced leucine zipper protein (GILZ) modulates imatinib and dasatinib resistance and suppresses tumor growth by inactivating the mammalian target of rapamycin complex-2 (mTORC2)/AKT signaling pathway. In mouse and human models, GILZ binds to mTORC2, but not to mTORC1, inhibiting phosphorylation of AKT (at Ser473) and activating FoxO3a-mediated transcription of the pro-apoptotic protein Bim; these results demonstrate that GILZ is a key inhibitor of the mTORC2 pathway. Furthermore, CD34(+) stem cells isolated from relapsing CML patients underwent apoptosis and showed inhibition of mTORC2 after incubation with glucocorticoids and imatinib. Our findings provide new mechanistic insights into the role of mTORC2 in BCR-ABL(+) cells and indicate that regulation by GILZ may influence TKI sensitivity. Oncogene (2012) 31, 1419-1430; doi:10.1038/onc.2011.328; published online 1 August 2011	[Quesnel, B.] CHU Lille, Serv Malad Sang, F-59037 Lille, France; [Joha, S.; Nugues, A-L; Hetuin, D.; Berthon, C.; Dezitter, X.; Dauphin, V.; Roche-Lestienne, C.; Preudhomme, C.; Quesnel, B.; Idziorek, T.] Univ Lille Nord de France, INSERM, U837, Inst Rech Canc Lille, Lille, France; [Mahon, F-X] Univ Victor Segalen, INSERM, U876, Bordeaux, France	Universite de Lille - ISITE; CHU Lille; Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Quesnel, B (corresponding author), CHU Lille, Serv Malad Sang, Rue Polonovski, F-59037 Lille, France.	brunoquesnel@hotmail.com	Quesnel, Bruno/D-5533-2018; Preudhomme, Claude/T-8553-2018; Dezitter, Xavier/H-6923-2018	Quesnel, Bruno/0000-0002-6563-2709; Preudhomme, Claude/0000-0002-1267-9546; Dezitter, Xavier/0000-0001-6932-6947; Roche-Lestienne, Catherine/0000-0002-7998-3817	Ligue Nationale Contre le Cancer (Equipe labellisee); Fondation de France; Institut National du Cancer; Ministere des Relations Exterieures; Institut de Recherche sur le Cancer de Lille; Region Nord Pas de Calais	Ligue Nationale Contre le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); Fondation de France(Fondation de France); Institut National du Cancer(Institut National du Cancer (INCA) France); Ministere des Relations Exterieures; Institut de Recherche sur le Cancer de Lille; Region Nord Pas de Calais(Region Hauts-de-France)	We are grateful to Professor Carlo Riccardi (University of Perugia, Perugia, Italy) for providing the mouse GILZ antibodies and plasmids and to Professor Michael Hall (Biozentrum, University of Basel, Basel, Switzerland) for providing the mouse Rictor plasmid. This work was supported by the Ligue Nationale Contre le Cancer (Equipe labellisee), the Fondation de France, Region Nord Pas de Calais and the Institut National du Cancer (project IMMUDORM). SJ was supported by the Ministere des Relations Exterieures and Institut de Recherche sur le Cancer de Lille.	Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Asselin-Labat ML, 2004, BLOOD, V104, P215, DOI 10.1182/blood-2003-12-4295; Ayroldi E, 2002, MOL CELL BIOL, V22, P7929, DOI 10.1128/MCB.22.22.7929-7941.2002; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Ayroldi E, 2007, J CLIN INVEST, V117, P1605, DOI 10.1172/JCI30724; Ayroldi E, 2009, FASEB J, V23, P3649, DOI 10.1096/fj.09-134684; Berrebi D, 2003, BLOOD, V101, P729, DOI 10.1182/blood-2002-02-0538; Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107; Cohen N, 2006, BLOOD, V107, P2037, DOI 10.1182/blood-2005-07-2760; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; Dayyani F, 2003, J LEUKOCYTE BIOL, V74, P33, DOI 10.1189/jlb.1202612; deJong R, 1997, ONCOGENE, V14, P507, DOI 10.1038/sj.onc.1200885; Delfino DV, 2011, CELL DEATH DIFFER, V18, P183, DOI 10.1038/cdd.2010.86; Delfino DV, 2004, BLOOD, V104, P4134, DOI 10.1182/blood-2004-03-0920; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Grugan KD, 2008, J STEROID BIOCHEM, V110, P244, DOI 10.1016/j.jsbmb.2007.11.003; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Hicsonmez G, 2006, LEUKEMIA RES, V30, P60, DOI 10.1016/j.leukres.2005.05.015; Hietakangas V, 2007, GENE DEV, V21, P632, DOI 10.1101/gad.416307; IHLE JN, 1985, CONTEMP TOP MOLEC IM, V10, P93; Ikenoue T, 2009, METHOD ENZYMOL, V452, P165, DOI 10.1016/S0076-6879(08)03611-2; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Kawauchi K, 2003, BLOOD CELL MOL DIS, V31, P11, DOI 10.1016/S1079-9796(03)00070-6; Kharas MG, 2008, J CLIN INVEST, V118, P3038, DOI 10.1172/JCI33337; Kolbus A, 2003, BLOOD, V102, P3136, DOI 10.1182/blood-2003-03-0923; Liu J, 2008, LEUKEMIA, V22, P791, DOI 10.1038/leu.2008.3; Ly C, 2003, CANCER RES, V63, P5716; Mancini M, 2010, J CELL BIOCHEM, V109, P320, DOI 10.1002/jcb.22380; Martin J, 2008, BIOCHEM BIOPH RES CO, V372, P578, DOI 10.1016/j.bbrc.2008.05.086; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Miyoshi H, 1997, LEUKEMIA RES, V21, P45, DOI 10.1016/S0145-2126(96)00089-6; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Perez SA, 2005, BLOOD, V106, P158, DOI 10.1182/blood-2004-08-3232; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Pocaly M, 2008, PROTEOMICS, V8, P2394, DOI 10.1002/pmic.200701035; Polak P, 2006, DEV CELL, V11, P433, DOI 10.1016/j.devcel.2006.09.005; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Saudemont A, 2005, BLOOD, V105, P2428, DOI 10.1182/blood-2004-09-3458; Saudemont A, 2004, BLOOD, V104, P2124, DOI 10.1182/blood-2004-01-0064; Saudemont A, 2007, CANCER RES, V67, P4491, DOI 10.1158/0008-5472.CAN-06-1627; Schmidt M, 2001, J IMMUNOL, V166, P1344, DOI 10.4049/jimmunol.166.2.1344; Sharma SV, 2006, CANCER CELL, V10, P425, DOI 10.1016/j.ccr.2006.09.014; Steelman LS, 2008, LEUKEMIA, V22, P686, DOI 10.1038/leu.2008.26; Toker A, 2006, CANCER RES, V66, P3963, DOI 10.1158/0008-5472.CAN-06-0743; Vakana E, 2010, AUTOPHAGY, V6, P966, DOI 10.1073/pnas.1005114107; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; Wang SW, 2005, APOPTOSIS, V10, P341, DOI 10.1007/s10495-005-0808-4; Yu CR, 2002, CANCER RES, V62, P188; Zeng ZH, 2007, BLOOD, V109, P3509, DOI 10.1182/blood-2006-06-030833	54	36	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	11					1419	1430		10.1038/onc.2011.328	http://dx.doi.org/10.1038/onc.2011.328			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21804606	Green Published, hybrid			2022-12-17	WOS:000301780000009
J	Richards, JS; Fan, HY; Liu, Z; Tsoi, M; Lague, MN; Boyer, A; Boerboom, D				Richards, J. S.; Fan, H-Y; Liu, Z.; Tsoi, M.; Lague, M-N; Boyer, A.; Boerboom, D.			Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis	ONCOGENE			English	Article						CTNNB1; KRAS; PTEN; granulosa cell tumor; ovary; testis	BETA-CATENIN EXPRESSION; GROWTH-FACTOR NETWORK; TRANSCRIPTION FACTOR; CUMULUS CELLS; FOLLICLE DEVELOPMENT; TARGETED DISRUPTION; SIGNALING PATHWAY; FACTOR FOXL2; GERM-CELLS; PROLIFERATION	WNT, RAS or phosphoinositide 3-kinase signaling pathways control specific stages of ovarian follicular development. To analyze the functional interactions of these pathways in granulosa cells during follicular development in vivo, we generated specific mutant mouse models. Stable activation of the WNT signaling effector beta-catenin (CTNNB1) in granulosa cells results in the formation of premalignant lesions that develop into granulosa cell tumors (GCTs) spontaneously later in life or following targeted deletion of the tumor suppressor gene Pten. Conversely, expression of oncogenic KRAS(G12D) dramatically arrests proliferation, differentiation and apoptosis in granulosa cells, and consequently, small abnormal follicle-like structures devoid of oocytes accumulate in the ovary. Because of the potent anti-proliferative effects of KRAS(G12D) in granulosa cells, we sought to determine whether KRAS(G12D) would block precancerous lesion and tumor formation in follicles of the CTNNB1-mutant mice. Unexpectedly, transgenic Ctnnb1;Kras-mutant mice exhibited increased GC proliferation, decreased apoptosis and impaired differentiation and developed early-onset GCTs leading to premature death in a manner similar to the Ctnnb1; Pten-mutant mice. Microarray and reverse transcription-PCR analyses revealed that gene regulatory processes induced by CTNNB1 were mostly enhanced by either KRAS activation or Pten loss in remarkably similar patterns and degree. The concomitant activation of CTNNB1 and KRAS in Sertoli cells also caused testicular granulosa cell tumors that showed gene expression patterns that partially overlapped those observed in GCTs of the ovary. Although the mutations analyzed herein have not yet been linked to adult GCTs in humans, they may be related to juvenile GCTs or to tumors in other tissues where CTNNB1 is mutated. Importantly, the results provide strong evidence that CTNNB1 is the driver in these contexts and that KRAS(G12D) and Pten loss promote the program set in motion by the CTNNB1. Oncogene (2012) 31, 1504-1520; doi:10.1038/onc.2011.341; published online 22 August 2011	[Richards, J. S.; Fan, H-Y; Liu, Z.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Tsoi, M.; Lague, M-N; Boyer, A.; Boerboom, D.] Univ Montreal, Ctr Rech Reprod Anim, Dept Biomed Vet, St Hyacinthe, PQ, Canada	Baylor College of Medicine; Universite de Montreal	Richards, JS (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	joanner@bcm.edu			Eunice Kennedy Shriver NICHD/NIH [U54-(HD07945)]; Canadian Institutes of Health Research; National Sciences and Engineering Research Council; Eunice Kennedy Shriver NICHD/NIH (SCCPIR) [U54-HD29034];  [NIH-HD-16229]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD016229, U54HD007495] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016272, R56HD016229, R37HD016229, F32HD007945] Funding Source: NIH RePORTER	Eunice Kennedy Shriver NICHD/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Sciences and Engineering Research Council(Natural Sciences and Engineering Research Council of Canada (NSERC)); Eunice Kennedy Shriver NICHD/NIH (SCCPIR)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))	We thank the Microarray Core Facility at Baylor College of Medicine (Lisa K White, director) for performing the microarray analyses. Supported, in part, by NIH-HD-16229 and the Eunice Kennedy Shriver NICHD/NIH cooperative agreement (U54-(HD07945)) as part of the Specialized Cooperative Centers Program in Reproduction and Infertility Research (JSR), an operating grant from the Canadian Institutes of Health Research (DB) and a Discovery Grant from the National Sciences and Engineering Research Council (DB). We also acknowledge that hormone assays were done by The University of Virginia Research in Reproduction Ligand Assay and Analysis Core supported by the Eunice Kennedy Shriver NICHD/NIH (SCCPIR) grant U54-HD29034.	Ashkenazi H, 2005, ENDOCRINOLOGY, V146, P77, DOI 10.1210/en.2004-0588; Boerboom D, 2006, CANCER RES, V66, P1964, DOI 10.1158/0008-5472.CAN-05-3493; Boerboom D, 2005, CANCER RES, V65, P9206, DOI 10.1158/0008-5472.CAN-05-1024; Boyer A, 2008, BIOL REPROD, V79, P475, DOI 10.1095/biolreprod.108.068627; Boyer A, 2010, FASEB J, V24, P3010, DOI 10.1096/fj.09-145789; Boyer A, 2010, TRENDS ENDOCRIN MET, V21, P25, DOI 10.1016/j.tem.2009.08.005; Boyer A, 2009, CARCINOGENESIS, V30, P869, DOI 10.1093/carcin/bgp051; Breloer M, 2008, TRENDS IMMUNOL, V29, P186, DOI 10.1016/j.it.2008.01.009; Broad KD, 2009, DEV NEUROBIOL, V69, P314, DOI 10.1002/dneu.20702; Chi P, 2010, NATURE, V467, P849, DOI 10.1038/nature09409; Conti M, 2006, MOL ENDOCRINOL, V20, P715, DOI 10.1210/me.2005-0185; DILWORTH JP, 1991, UROLOGY, V37, P399, DOI 10.1016/0090-4295(91)80100-L; Drews-Elger K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005245; Edson MA, 2010, MOL ENDOCRINOL, V24, P1251, DOI 10.1210/me.2009-0461; Garcia-Ortiz JE, 2009, BMC DEV BIOL, V9, DOI 10.1186/1471-213X-9-36; Eo J, 2008, J ENDOCRINOL, V198, P281, DOI 10.1677/JOE-08-0142; Fan HY, 2008, MOL ENDOCRINOL, V22, P2128, DOI 10.1210/me.2008-0095; Fan HY, 2008, DEVELOPMENT, V135, P2127, DOI 10.1242/dev.020560; Fan HY, 2010, MOL ENDOCRINOL, V24, P286, DOI 10.1210/me.2009-0251; Fan HY, 2009, CANCER RES, V69, P6463, DOI 10.1158/0008-5472.CAN-08-3363; Fan HY, 2009, SCIENCE, V324, P938, DOI 10.1126/science.1171396; Fellenberg J, 2010, INT J CANCER, V127, P1804, DOI 10.1002/ijc.25205; Fleming NI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014389; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; Harper K, 2010, CANCER RES, V70, P4634, DOI 10.1158/0008-5472.CAN-09-3813; Heinrich MC, 2010, NATURE, V467, P796, DOI 10.1038/467796a; Hernandez-Gonzalez I, 2006, MOL ENDOCRINOL, V20, P1300, DOI 10.1210/me.2005-0420; Hsieh M, 2005, TRENDS ENDOCRIN MET, V16, P320, DOI 10.1016/j.tem.2005.07.005; Hsieh M, 2007, MOL CELL BIOL, V27, P1914, DOI 10.1128/MCB.01919-06; Hussain S, 2010, LEUKEMIA, V24, P1641, DOI 10.1038/leu.2010.138; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jamieson S, 2010, MODERN PATHOL, V23, P1477, DOI 10.1038/modpathol.2010.145; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Jane-Valbuena J, 2010, CANCER RES, V70, P2075, DOI 10.1158/0008-5472.CAN-09-3092; Jiang XL, 2010, J BIOL CHEM, V285, P8472, DOI 10.1074/jbc.M109.069450; Jin TR, 2008, CELL SIGNAL, V20, P1697, DOI 10.1016/j.cellsig.2008.04.014; Jubb I, 1993, PATHOLOGY DOMESTIC A; KALFA N, 2008, SEX DEV, V2, P142; Kim JH, 2011, ONCOGENE, V30, P1653, DOI 10.1038/onc.2010.541; Kobel M, 2009, CANCER RES, V69, P9160, DOI 10.1158/0008-5472.CAN-09-2669; Lague MN, 2008, CARCINOGENESIS, V29, P2062, DOI 10.1093/carcin/bgn186; Lee K, 2005, BIOCHEM BIOPH RES CO, V336, P876, DOI 10.1016/j.bbrc.2005.08.184; Li G, 2002, DEVELOPMENT, V129, P4159; Liu ZL, 2010, MOL ENDOCRINOL, V24, P1794, DOI 10.1210/me.2010-0086; Liu ZL, 2009, MOL ENDOCRINOL, V23, P649, DOI 10.1210/me.2008-0412; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; Moumne L, 2008, MOL CELL ENDOCRINOL, V282, P2, DOI 10.1016/j.mce.2007.11.006; Ottolenghi C, 2007, HUM MOL GENET, V16, P2795, DOI 10.1093/hmg/ddm235; Pangas SA, 2008, MOL CELL BIOL, V28, P248, DOI 10.1128/MCB.01404-07; Parakh TN, 2006, P NATL ACAD SCI USA, V103, P12435, DOI 10.1073/pnas.0603006103; Park, 2004, SCIENCE, V290, P395; Pisarska MD, 2011, ENDOCRINOLOGY, V152, P1199, DOI 10.1210/en.2010-1041; RAO MC, 1978, CELL, V14, P71, DOI 10.1016/0092-8674(78)90302-1; Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Robker RL, 1998, MOL ENDOCRINOL, V12, P924, DOI 10.1210/me.12.7.924; Schumer ST, 2003, J CLIN ONCOL, V21, P1180, DOI 10.1200/JCO.2003.10.019; Shah SP, 2009, NEW ENGL J MED, V360, P2719, DOI 10.1056/NEJMoa0902542; Shimomura Y, 2010, NATURE, V464, P1043, DOI 10.1038/nature08875; Steinmetz R, 2004, MOL ENDOCRINOL, V18, P2570, DOI 10.1210/me.2004-0082; Takahashi M, 2002, CANCER RES, V62, P5651; Tania M, 2010, BIOCHEM BIOPH RES CO, V401, P493, DOI 10.1016/j.bbrc.2010.09.114; Tanwar PS, 2010, P NATL ACAD SCI USA, V107, P16142, DOI 10.1073/pnas.1011606107; TILLY JL, 1995, ENDOCRINOLOGY, V136, P232, DOI 10.1210/en.136.1.232; Trazzi S, 2010, J BIOL CHEM, V285, P10098, DOI 10.1074/jbc.M109.043711; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Tyagi G, 2009, BIOL REPROD, V81, P258, DOI 10.1095/biolreprod.108.075200; Uda M, 2004, HUM MOL GENET, V13, P1171, DOI 10.1093/hmg/ddh124; Vainio S, 1999, NATURE, V397, P405, DOI 10.1038/17068; Wagner RT, 2010, STEM CELLS, V28, P1794, DOI 10.1002/stem.502; Wang HX, 2010, BIOL REPROD, V82, P865, DOI 10.1095/biolreprod.109.080903; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Xu M, 2009, ENDOCRINOLOGY, V150, P2064, DOI 10.1210/en.2008-1265	74	36	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1504	1520		10.1038/onc.2011.341	http://dx.doi.org/10.1038/onc.2011.341			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860425	Green Accepted			2022-12-17	WOS:000302132000004
J	Indovina, P; Giorgi, F; Rizzo, V; Khadang, B; Schenone, S; Di Marzo, D; Forte, IM; Tomei, V; Mattioli, E; D'Urso, V; Grilli, B; Botta, M; Giordano, A; Pentimalli, F				Indovina, P.; Giorgi, F.; Rizzo, V.; Khadang, B.; Schenone, S.; Di Marzo, D.; Forte, I. M.; Tomei, V.; Mattioli, E.; D'Urso, V.; Grilli, B.; Botta, M.; Giordano, A.; Pentimalli, F.			New pyrazolo[3,4-d] pyrimidine SRC inhibitors induce apoptosis in mesothelioma cell lines through p27 nuclear stabilization	ONCOGENE			English	Article						SRC inhibitors; meso thelioma; apoptosis; p27; AKT; cyclin D1	CANCER CELLS; CYCLE INHIBITORS; MICE LACKING; KINASE; EXPRESSION; P27(KIP1); OVEREXPRESSION; HYPERPLASIA; ACTIVATION; MIGRATION	Malignant mesothelioma (MM) is a highly aggressive tumor of the serous membranes for which there is currently no effective curative modality. Recent data suggest that hyperactivation of the tyrosine kinase SRC has a key role in MM development and therefore this kinase represents an important molecular target for MM therapy. We tested new pyrazolo[3,4-d] pyrimidine SRC inhibitors on a panel of MM cell lines expressing the active form of SRC. These SRC inhibitors exerted a significant proapoptotic effect on MM cells without affecting the normal mesothelial cell line MET-5A, supporting a possible use of these SRC inhibitors for a safe treatment of MM. We also showed that SRC inhibitor-induced apoptosis occurred concomitantly with an increase in the nuclear stability of the cyclin-dependent kinase inhibitor p27. This finding is remarkable considering that loss of nuclear p27 expression is a well-established adverse prognostic factor in MM, and p27 nuclear localization is crucial for its tumor-suppressive function. Consistently, SRC inhibition seems to promote the increase in p27 nuclear level also by inactivating the AKT kinase and downregulating cyclin D1, which would otherwise delay p27 nuclear import and provoke its cytoplasmic accumulation. To determine whether p27 stabilization has a direct role in apoptosis induced by SRC inhibition, we stably silenced the CDKN1B gene, encoding p27, in MSTO-211H and REN mesothelioma cells by transduction with lentiviral vectors expressing short hairpin RNAs against the CDKN1B transcript. Strikingly, p27 silencing was able to suppress the apoptosis induced by these SRC inhibitors in both MM cell lines, suggesting that p27 has a crucial proapoptotic role in MM cells treated with SRC inhibitors. Our findings reveal a new mechanism, dependent on p27 nuclear stabilization, by which SRC inhibition can induce apoptosis in MM cells and provide a new rationale for the use of SRC inhibitors in MM therapy. Oncogene (2012) 31, 929-938; doi: 10.1038/onc.2011.286; published online 25 July 2011	[Di Marzo, D.; Forte, I. M.; D'Urso, V.; Giordano, A.; Pentimalli, F.] Pascale Fdn, INT CROM, Natl Canc Inst, Canc Res Ctr, Mercogliano, Italy; [Indovina, P.; Giorgi, F.; Rizzo, V.; Khadang, B.; Forte, I. M.; Tomei, V.; Mattioli, E.; Giordano, A.] Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; [Indovina, P.; Tomei, V.; Grilli, B.; Giordano, A.] Temple Univ, Coll Sci & Technol, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; [Schenone, S.] Univ Genoa, Dept Pharmaceut Sci, Genoa, Italy; [D'Urso, V.] Univ Sassari, Dept Biomed Sci, Natl Inst Biostruct & Biosyst, Div Biochem & Biophys, I-07100 Sassari, Italy; [Botta, M.] Univ Siena, Dept Pharmaceut & Appl Chem, I-53100 Siena, Italy	IRCCS Fondazione Pascale; University of Siena; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Genoa; University of Sassari; University of Siena	Pentimalli, F (corresponding author), Pascale Fdn, INT CROM, Natl Canc Inst, Canc Res Ctr, Via Ammiraglio Bianco, I-83013 Avellino, Italy.	francesca.pentimalli@gmail.com	Mattioli, Eliseo/AAC-5018-2022; Forte, Iris Maria/K-7588-2016; Pentimalli, Francesca/K-4936-2014; Giordano, Antonio/F-1927-2010	Mattioli, Eliseo/0000-0002-2456-7867; Forte, Iris Maria/0000-0001-9490-5844; Pentimalli, Francesca/0000-0003-4740-6801; Giordano, Antonio/0000-0002-5959-016X; Indovina, Paola/0000-0001-8416-435X; Grilli, Bruna/0000-0003-3698-9503	Human Health Foundation; Sbarro Health Research Organization	Human Health Foundation; Sbarro Health Research Organization	We thank Giuseppe Viglietto for providing lentiviral vectors and Giovanni Gaudino for providing REN cells. PI, FG and VR are the recipients of Human Health Foundation fellowships. FP is also Adjunct Assistant Professor at Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA. This work was funded by Sbarro Health Research Organization (http://www.shro.org) and Human Health Foundation (http://www.hhfonlus.org).	Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Baldi A, 2004, THORAX, V59, P428, DOI 10.1136/thx.2003.008912; Beer TW, 2001, HISTOPATHOLOGY, V38, P535, DOI 10.1046/j.1365-2559.2001.01136.x; Bertino P, 2008, CLIN CANCER RES, V14, P541, DOI 10.1158/1078-0432.CCR-07-1388; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Bloom J, 2003, SEMIN CANCER BIOL, V13, P41, DOI 10.1016/S1044-579X(02)00098-6; Bongiovanni M, 2001, CANCER-AM CANCER SOC, V92, P1245, DOI 10.1002/1097-0142(20010901)92:5<1245::AID-CNCR1444>3.0.CO;2-G; Bravo SB, 2003, ONCOGENE, V22, P7819, DOI 10.1038/sj.onc.1207029; Carraro F, 2006, J MED CHEM, V49, P1549, DOI 10.1021/jm050603r; Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chiappetta G, 2007, ENDOCR-RELAT CANCER, V14, P405, DOI 10.1677/ERC-06-0030; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Cursi S, 2006, EMBO J, V25, P1895, DOI 10.1038/sj.emboj.7601085; Faraonio R, 2006, ANTIOXID REDOX SIGN, V8, P365, DOI 10.1089/ars.2006.8.365; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Katayose Y, 1997, CANCER RES, V57, P5441; Kettunen E, 2001, INT J CANCER, V91, P492, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1094>3.0.CO;2-M; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kudo Y, 2000, CLIN CANCER RES, V6, P916; Lee AY, 2007, CANCER-AM CANCER SOC, V109, P1454, DOI 10.1002/cncr.22552; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masuda A, 2001, AM J PATHOL, V158, P87, DOI 10.1016/S0002-9440(10)63947-8; Menges Craig W, 2010, Genes Cancer, V1, P493; Mezquita B, 2010, J CELL BIOCHEM, V110, P732, DOI 10.1002/jcb.22584; Mikami I, 2010, ONCOL REP, V24, P1677, DOI 10.3892/or_00001033; Motti ML, 2005, AM J PATHOL, V166, P737, DOI 10.1016/S0002-9440(10)62295-X; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; Schenone S, 2004, BIOORG MED CHEM LETT, V14, P2511, DOI 10.1016/j.bmcl.2004.03.013; Schenone S, 2010, EXPERT OPIN INV DRUG, V19, P931, DOI 10.1517/13543784.2010.499898; Schenone S, 2008, EUR J MED CHEM, V43, P2665, DOI 10.1016/j.ejmech.2008.01.034; Schweppe RE, 2009, J CLIN ENDOCR METAB, V94, P2199, DOI 10.1210/jc.2008-2511; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Spreafico A, 2008, FASEB J, V22, P1560, DOI 10.1096/fj.07-9873com; Tsao AS, 2007, MOL CANCER THER, V6, P1962, DOI 10.1158/1535-7163.MCT-07-0052; Tsao AS, 2009, J CLIN ONCOL, V27, P2081, DOI 10.1200/JCO.2008.19.8523; Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450; Wang Z, 2005, CELL DEATH DIFFER, V12, P98, DOI 10.1038/sj.cdd.4401515; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Yamaguchi H, 2008, J BIOL CHEM, V283, P19112, DOI 10.1074/jbc.M709882200; Yang H, 2006, ONCOGENE, V25, P4585, DOI 10.1038/sj.onc.1209481; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85	50	36	36	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	7					929	938		10.1038/onc.2011.286	http://dx.doi.org/10.1038/onc.2011.286			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	897BL	21785466				2022-12-17	WOS:000300615800011
J	Rao, S; Lyons, LS; Fahrenholtz, CD; Wu, F; Farooq, A; Balkan, W; Burnstein, KL				Rao, S.; Lyons, L. S.; Fahrenholtz, C. D.; Wu, F.; Farooq, A.; Balkan, W.; Burnstein, K. L.			A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer	ONCOGENE			English	Article						Vav3; pleckstrin homology; coactivator; androgen receptor; castration-resistant prostate cancer; guanine nucleotide exchange factor	PLECKSTRIN-HOMOLOGY DOMAINS; MOLECULAR DETERMINANTS; STRUCTURAL BASIS; ACTIVATION; BINDING; RECOGNITION; PROGRESSION; ONCOGENE; FAMILY; PH	Increased androgen receptor (AR) transcriptional activity mediated by coactivator proteins may drive castration-resistant prostate cancer (CRPC) growth. Vav3, a Rho GTPase guanine nucleotide exchange factor (GEF), is overexpressed in human prostate cancers, particularly in models of CRPC progression. Vav3 coactivates AR in a Vav3 pleckstrin homology (PH) domain-dependent but GEF-independent manner. Ectopic expression of Vav3 in androgen-dependent human prostate cancer cells conferred robust castration-resistant xenograft tumor growth. Vav3 but not a Vav3 PH mutant greatly stimulated interaction between the AR amino and carboxyl termini (N-C interaction), which is required for maximal receptor transcriptional activity. Vav3 was distributed between the cytoplasm and nucleus with nuclear localization-dependent on the Vav3 PH domain. Membrane targeting of Vav3 abolished Vav3 potentiation of AR activity, whereas nuclear targeting of a Vav3 PH mutant rescued AR coactivation, suggesting that nuclear localization is an important function of the Vav3 PH domain. A nuclear role for Vav3 was further demonstrated by sequential chromatin immunoprecipitation assays, which revealed that Vav3 and AR were recruited to the same transcriptional complexes of an AR target gene enhancer. These data demonstrate the importance of Vav3 in CRPC and define a novel nuclear function of Vav3 in regulating AR activity. Oncogene (2012) 31, 716-727; doi:10.1038/onc.2011.273; published online 18 July 2011	[Rao, S.; Fahrenholtz, C. D.; Wu, F.; Burnstein, K. L.] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; [Lyons, L. S.] Nova SE Univ, Ft Lauderdale, FL 33314 USA; [Farooq, A.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [Balkan, W.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA	University of Miami; Nova Southeastern University; University of Miami; University of Miami	Burnstein, KL (corresponding author), Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave,R-189, Miami, FL 33136 USA.	kburnstein@med.miami.edu	Rao, Shuyun/AAE-9724-2019; Fahrenholtz, Cale/GWZ-4512-2022; Farooq, Amjad/B-5084-2012		National Institutes of Health [RO1CA132200]; US Department of Defense [PC060504];  [T32-HL007188];  [R01GM083897]; NATIONAL CANCER INSTITUTE [R01CA132200] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083897] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Dr Zafar Nawaz and his laboratory for advice on ChIP assays. We thank Drs Adena Rosenblatt, Omar Flores and Carlos Perez-Stable for helpful suggestions. Zhe Ma provided assistance with the mammalian two-hybrid assays. A National Institutes of Health Grant RO1CA132200 (to KLB) supported this work. LSL and FW were supported by US Department of Defense post-doctoral fellowship (PC060504); SR was an American Heart Association Pre-doctoral Fellow; CDF was supported by T32-HL007188 and AF acknowledges funding from R01GM083897.	Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Banach-Petrosky W, 2007, CANCER RES, V67, P9089, DOI 10.1158/0008-5472.CAN-07-2887; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Brantley-Sieders DM, 2009, MOL CANCER RES, V7, P615, DOI 10.1158/1541-7786.MCR-08-0401; Bustelo XR, 2001, ONCOGENE, V20, P6372, DOI 10.1038/sj.onc.1204780; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Dong ZY, 2006, MOL ENDOCRINOL, V20, P2315, DOI 10.1210/me.2006-0048; Fernandez-Zapico ME, 2005, CANCER CELL, V7, P39, DOI 10.1016/j.ccr.2004.11.024; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Fujikawa K, 2003, J EXP MED, V198, P1595, DOI 10.1084/jem.20030874; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Hornstein I, 2003, J PATHOL, V199, P526, DOI 10.1002/path.1314; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; John B, 2003, NUCLEIC ACIDS RES, V31, P3982, DOI 10.1093/nar/gkg460; Korenchuk S, 2001, IN VIVO, V15, P163; Lemmon MA, 2003, TRAFFIC, V4, P201, DOI 10.1034/j.1600-0854.2004.00071.x; Lemmon MA, 2004, BIOCHEM SOC T, V32, P707, DOI 10.1042/BST0320707; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Lemmon MA, 1999, BIOCHEM SOC T, V27, P617, DOI 10.1042/bst0270617; Lemmon MA, 2008, NAT REV MOL CELL BIO, V9, P99, DOI 10.1038/nrm2328; Lemmon MA, 2007, BIOCHEM SOC SYMP, V74, P81, DOI 10.1042/BSS2007c08; Liu Y, 2008, CANCER RES, V68, P6396, DOI 10.1158/0008-5472.CAN-08-0645; Liu Y, 2010, INT J ONCOL, V36, P623, DOI 10.3892/ijo_00000538; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lyons LS, 2008, MOL ENDOCRINOL, V22, P597, DOI 10.1210/me.2007-0158; Lyons LS, 2006, MOL ENDOCRINOL, V20, P1061, DOI 10.1210/me.2005-0346; Maffucci T, 2003, MOL ENDOCRINOL, V17, P1568, DOI 10.1210/me.2001-0211; Mahadevan D, 2008, MOL CANCER THER, V7, P2621, DOI 10.1158/1535-7163.MCT-07-2276; Marques RB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013500; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Miller SL, 2005, MOL ENDOCRINOL, V19, P939, DOI 10.1210/me.2004-0443; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Movilla N, 1999, MOL CELL BIOL, V19, P7870; O'Malley BW, 2009, CANCER RES, V69, P8217, DOI 10.1158/0008-5472.CAN-09-2223; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Palmby TR, 2002, J BIOL CHEM, V277, P39350, DOI 10.1074/jbc.M202641200; Patel V, 2007, CARCINOGENESIS, V28, P1145, DOI 10.1093/carcin/bgm008; Rapley J, 2008, EMBO REP, V9, P655, DOI 10.1038/embor.2008.80; Sartor O, 2002, UROLOGY, V60, P138; Savkur RS, 2004, J PEPT RES, V63, P207, DOI 10.1111/j.1399-3011.2004.00126.x; Schmidt LJ, 2009, PROSTATE, V69, P1730, DOI 10.1002/pros.21022; Shen HC, 2005, BIOL CHEM, V386, P69, DOI 10.1515/BC.2005.009; Tindall DJ, 2001, UROLOGY, V57, P28, DOI 10.1016/S0090-4295(00)00932-8; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Varnai P, 2005, J CELL SCI, V118, P4879, DOI 10.1242/jcs.02606; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Xi SL, 2010, FEBS LETT, V584, P1223, DOI 10.1016/j.febslet.2010.02.036; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000	57	36	39	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					716	727		10.1038/onc.2011.273	http://dx.doi.org/10.1038/onc.2011.273			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21765461	Green Accepted			2022-12-17	WOS:000300222100005
J	Singh, P; Wedeken, L; Waters, LC; Carr, MD; Klempnauer, KH				Singh, P.; Wedeken, L.; Waters, L. C.; Carr, M. D.; Klempnauer, K-H			Pdcd4 directly binds the coding region of c-myb mRNA and suppresses its translation	ONCOGENE			English	Article						Pdcd4; c-myb; translation; RNA binding	PROTEIN PDCD4; EUKARYOTIC TRANSLATION; STRUCTURAL BASIS; GENE-EXPRESSION; C/EBP-BETA; V-MYB; TRANSFORMATION; INITIATION; CELLS; MA-3	Pdcd4 is a novel tumor suppressor protein that functions in the nucleus and the cytoplasm, and appears to be involved in the regulation of transcription and translation. In the cytoplasm, Pdcd4 has been implicated in the suppression of translation of mRNAs containing structured 5'-untranslated regions; however, the mechanisms that recruit Pdcd4 to specific target mRNAs and the identities of these mRNAs are mostly unknown. In this study, we have identified c-myb mRNA as the first natural translational target mRNA of Pdcd4. We have found that translational suppression of c-myb mRNA by Pdcd4 is dependent on sequences located within the c-myb-coding region. Furthermore, we have found that the N-terminal domain of Pdcd4 has an important role in targeting Pdcd4 to c-myb RNA by mediating preferential RNA binding to the Pdcd4-responsive region of c-myb mRNA. Overall, our work demonstrates for the first time that Pdcd4 is directly involved in translational suppression of a natural mRNA and provides the first evidence for a key role of the RNA-binding domain in targeting Pdcd4 to a specific mRNA. Oncogene (2011) 30, 4864-4873; doi:10.1038/onc.2011.202; published online 6 June 2011	[Singh, P.; Wedeken, L.; Klempnauer, K-H] Univ Munster, Inst Biochem, D-48149 Munster, Germany; [Waters, L. C.; Carr, M. D.] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Munster; University of Leicester	Klempnauer, KH (corresponding author), Univ Munster, Inst Biochem, Wilhelm Klemm Str 2, D-48149 Munster, Germany.	klempna@uni-muenster.de	Singh, Priyanka/N-1372-2018; Singh, Priyanka/GRF-6098-2022	Singh, Priyanka/0000-0003-0841-1544; Singh, Priyanka/0000-0002-5928-6280; Wedeken, Lena/0000-0003-1061-9459; Carr, Mark/0000-0002-3939-0996	Deutsche Krebshilfe [10-1716]; Wilhelm-Sander-Stiftung [2004.088.1]; Wellcome Trust; Graduate School of Chemistry (GSC-MS) at the University of Munster	Deutsche Krebshilfe(Deutsche Krebshilfe); Wilhelm-Sander-Stiftung; Wellcome Trust(Wellcome TrustEuropean Commission); Graduate School of Chemistry (GSC-MS) at the University of Munster	We thank M Hentze and D Ostareck for providing plasmids. This work was supported by the Deutsche Krebshilfe (10-1716), the Wilhelm-Sander-Stiftung (2004.088.1) and the Wellcome Trust. PS and LW were supported by the Graduate School of Chemistry (GSC-MS) at the University of Munster.	Afonja O, 2004, ONCOGENE, V23, P8135, DOI 10.1038/sj.onc.1207983; Appl H, 2002, ONCOGENE, V21, P3076, DOI 10.1038/sj.onc.1205427; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bitomsky N, 2008, ONCOGENE, V27, P4820, DOI 10.1038/onc.2008.115; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; Bohm M, 2003, ONCOGENE, V22, P4905, DOI 10.1038/sj.onc.1206710; Chang JH, 2009, P NATL ACAD SCI USA, V106, P3148, DOI 10.1073/pnas.0808275106; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; ErcikanAbali EA, 1997, BIOCHEMISTRY-US, V36, P12317, DOI 10.1021/bi971026e; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hogan DJ, 2008, PLOS BIOL, V6, P2297, DOI 10.1371/journal.pbio.0060255; Lancaster AM, 2006, RNA, V12, P894, DOI 10.1261/rna.2342306; Lankat-Buttgereit B, 2009, BIOL CELL, V101, P309, DOI 10.1042/BC20080191; LaRonde-LeBlanc N, 2007, MOL CELL BIOL, V27, P147, DOI 10.1128/MCB.00867-06; Leupold JH, 2007, ONCOGENE, V26, P4550, DOI 10.1038/sj.onc.1210234; Lin XK, 2000, NUCLEIC ACIDS RES, V28, P1381, DOI 10.1093/nar/28.6.1381; Loh PG, 2009, EMBO J, V28, P274, DOI 10.1038/emboj.2008.278; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mink S, 1996, MOL CELL BIOL, V16, P1316; Mudduluru G, 2007, CANCER-AM CANCER SOC, V110, P1697, DOI 10.1002/cncr.22983; Nottrott S, 2006, NAT STRUCT MOL BIOL, V13, P1108, DOI 10.1038/nsmb1173; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Plachetka A, 2008, MOL CELL BIOL, V28, P2102, DOI 10.1128/MCB.01943-07; Prechtel AT, 2006, J BIOL CHEM, V281, P10912, DOI 10.1074/jbc.M510306200; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Schlichter U, 2001, ONCOGENE, V20, P231, DOI 10.1038/sj.onc.1204071; Schlichter U, 2001, BBA-GENE STRUCT EXPR, V1520, P99, DOI 10.1016/S0167-4781(01)00252-4; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Singh P, 2009, ONCOGENE, V28, P3758, DOI 10.1038/onc.2009.239; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Suzuki C, 2008, P NATL ACAD SCI USA, V105, P3274, DOI 10.1073/pnas.0712235105; Waters LC, 2007, ONCOGENE, V26, P4941, DOI 10.1038/sj.onc.1210305; Waters LC, 2011, J BIOL CHEM, V286, P17270, DOI 10.1074/jbc.M110.166157; Wedeken Lena, 2010, Genes Cancer, V1, P293, DOI 10.1177/1947601910364227; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2003, ONCOGENE, V22, P3712, DOI 10.1038/sj.onc.1206433; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhang YY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010618	43	36	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	49					4864	4873		10.1038/onc.2011.202	http://dx.doi.org/10.1038/onc.2011.202			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	865YI	21643008				2022-12-17	WOS:000298346400003
J	Reimer, D; Hubalek, M; Kiefel, H; Riedle, S; Skvortsov, S; Erdel, M; Hofstetter, G; Concin, N; Fiegl, H; Muller-Holzner, E; Marth, C; Altevogt, P; Zeimet, AG				Reimer, D.; Hubalek, M.; Kiefel, H.; Riedle, S.; Skvortsov, S.; Erdel, M.; Hofstetter, G.; Concin, N.; Fiegl, H.; Mueller-Holzner, E.; Marth, C.; Altevogt, P.; Zeimet, A. G.			Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer	ONCOGENE			English	Article						E2F3a; EGFR; miR-34a; 6p22 amplification; ovarian cancer; prognosis	COMPARATIVE GENOMIC HYBRIDIZATION; BLADDER; AMPLIFICATION; APOPTOSIS; GROWTH; OVEREXPRESSION; PROLIFERATION; CARCINOMA; MIR-34A	Recently we showed an integral epidermal growth factor receptor (EGFR)-E2F3a signaling path, in which E2F3a was found to be essential in EGFR-mediated proliferation in ovarian cancer cells. The present work evaluates the clinical relevance of this novel axis and of E2F3a itself in a large set of 130 ovarian cancer specimens. For this purpose E2F3a and its counterpart, E2F3b, were measured by RT-PCR and activated EGFR was assessed by immunohistochemistry. When compared with healthy control tissue, both E2F3 isoforms were overexpressed in the cancers, but only E2F3a expression correlated with tumor stage (rho = 0.349, P = 0.0001) and residual disease (rho = 0.254, P = 0.004). Univariate survival analyses showed E2F3a and activated EGFR to be associated with poor PFS and OS. Furthermore, a strong, positive correlation between activated EGFR and E2F3a expression was shown (P 0.0001). We further identified two EGFR-independent mechanisms that regulate E2F3a expression, namely one, acting by promoter methylation of miR-34a, which by its physical interaction with E2F3a transcripts causes their degradation, and the second based on 6p22 gene locus amplification. MiRIDIAN-based knockdown and induction of miR-34a evidenced a direct regulatory link between miR-34a and E2F3a, and the tumor-suppressive character of miR-34a was documented by its association with improved survival. Although, 6p22 gene locus amplification was detected in a significant number of ovarian cancer specimens, 6p22 ploidy was not relevant in predicting survival. In Cox regression analysis, E2F3a, but not activated EGFR or miR-34a expression, retained independent prognostic significance (PFS: hazards ratio 3.785 (1.326-9.840), P = 0.013; OS: hazards ratio 4.651 (1.189-15.572), P 0.013). These clinical findings highlight the relevance of E2F3a in the biology of ovarian cancer. Moreover, identification of EGFR-independent mechanisms in E2F3a control can be helpful in explaining the non-responsiveness of therapeutic EGFR targeting in ovarian cancer. Oncogene (2011) 30, 4038-4049; doi:10.1038/onc.2011.119; published online 25 April 2011	[Reimer, D.; Hubalek, M.; Hofstetter, G.; Concin, N.; Fiegl, H.; Mueller-Holzner, E.; Marth, C.; Zeimet, A. G.] Innsbruck Med Univ, Dept Obstet & Gynecol, A-6020 Innsbruck, Austria; [Kiefel, H.; Riedle, S.; Altevogt, P.] German Canc Res Ctr, D-6900 Heidelberg, Germany; [Skvortsov, S.] Innsbruck Med Univ, Dept Radiotherapy, A-6020 Innsbruck, Austria; [Erdel, M.] Krankenhaus Barmherzigen Schwestern Linz, Lab Mol Biol & Cytogenet, Linz, Austria	Medical University of Innsbruck; Helmholtz Association; German Cancer Research Center (DKFZ); Medical University of Innsbruck; Konventhospital Der Barmherzigen Bruder	Zeimet, AG (corresponding author), Innsbruck Med Univ, Dept Obstet & Gynecol, Anichstr 35, A-6020 Innsbruck, Austria.	alain.zeimet@i-med.ac.at	Hubalek, Michael/ABD-8041-2021; Fiegl, Heidi/K-4445-2017	Concin, Nicole/0000-0002-9795-2643; Hofstetter, Gerda/0000-0001-8912-3725; Fiegl, Heidi/0000-0002-1236-6806	Verein fur Krebsforschung in der Frauenheilkunde; Department of Obstetrics and Gynecology; Innsbruck Medical University	Verein fur Krebsforschung in der Frauenheilkunde; Department of Obstetrics and Gynecology; Innsbruck Medical University	This work was supported by the 'Verein fur Krebsforschung in der Frauenheilkunde', Department of Obstetrics and Gynecology, Innsbruck Medical University. We thank Annemarie Wiedemair, Martina Champson, Julia Rossler and Martina Fleischer for technical assistance. We also thank Dr Wolfgang A Schulz (Department of Urology, University Hospital Dusseldorf, Germany) for his generous gift of the bladder cancer cell lines.	Bruch J, 2000, CANCER RES, V60, P4526; Bubendorf L, 2001, J PATHOL, V195, P72, DOI 10.1002/path.893; Chen CX, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000912; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Gordon AN, 2005, INT J GYNECOL CANCER, V15, P785, DOI 10.1111/j.1525-1438.2005.00137.x; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Krugmann J, 2004, J CLIN PATHOL, V57, P360, DOI 10.1136/jcp.2003.012369; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Markman M, 2008, DRUGS, V68, P771, DOI 10.2165/00003495-200868060-00004; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Reimer D, 2007, CLIN CANCER RES, V13, P144, DOI 10.1158/1078-0432.CCR-06-0780; Reimer D, 2010, CANCER RES, V70, P4613, DOI 10.1158/0008-5472.CAN-09-3551; Schilder RJ, 2009, GYNECOL ONCOL, V113, P21, DOI 10.1016/j.ygyno.2008.12.003; Simon R, 2000, INT J ONCOL, V17, P1025; Stadlmann S, 2006, MODERN PATHOL, V19, P607, DOI 10.1038/modpathol.3800575; Takai Daiya, 2003, In Silico Biology, V3, P235; Tarasov V, 2007, CELL CYCLE, V6, P1586, DOI 10.4161/cc.6.13.4436; Van Cutsem E, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.2; Veltman JA, 2003, CANCER RES, V63, P2872; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Zeimet AG, 2009, INT J CANCER, V124, P2353, DOI 10.1002/ijc.24214	24	36	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2011	30	38					4038	4049		10.1038/onc.2011.119	http://dx.doi.org/10.1038/onc.2011.119			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21516127				2022-12-17	WOS:000295121600005
J	Duque-Afonso, J; Yalcin, A; Berg, T; Abdelkarim, M; Heidenreich, O; Lubbert, M				Duque-Afonso, J.; Yalcin, A.; Berg, T.; Abdelkarim, M.; Heidenreich, O.; Luebbert, M.			The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO	ONCOGENE			English	Article						chromosomal translocations; acute myeloid leukemia; adaptor molecule; HDAC inhibitor; epigenetic regulation	ACUTE MYELOID-LEUKEMIA; HISTONE DEACETYLASE INHIBITORS; T-CELL-ACTIVATION; T(8/21) FUSION PROTEIN; NEGATIVE REGULATION; VALPROIC ACID; DNA METHYLATION; C/EBP-ALPHA; DIFFERENTIATION; EXPRESSION	The chromosomal translocation (8; 21) fuses the hematopoietic transcription factor AML1 (RUNX1) with ETO (RUNX1T1, MTG8), resulting in the leukemia-specific chimeric protein AML1/ETO. This fusion protein has been implicated in epigenetic silencing, recruiting histone deacetylases (HDACs) and DNA methyltransferases to target promoters. Previously, we have identified a novel in vivo AML1/ETO target gene, LAT2 (NTAL/LAB/WBSCR5), which is involved in FceR I, c-Kit, B-cell and T-cell receptor signalling. We have now addressed the molecular mechanisms of AML1/ETO-mediated LAT2 repression. In Kasumi-1 cells, where AML1/ETO bound to the LAT2 gene, small interfering RNA (siRNA)mediated AML1/ETO depletion caused upregulation of LAT2, suggesting a possible direct mechanism of repression. Expression of AML1/ETO was associated with a decrease in acetylation of histones H3, H3K9 and H4, and an increase in H3K9 and H3K27 trimethylation. The class I-specific HDAC inhibitors entinostat (MS-275) and mocetinostat (MGCD0103) induced LAT2 expression specifically in AML1/ETO-expressing cells, resulting in induction of several activating histone marks on the LAT2 gene, including trimethylation of histone H3K4. The combination of entinostat and decitabine increased acetylation of histones H3 and H4, as well as LAT2 mRNA expression, in an at least additive fashion. In conclusion, several repressive histone modifications mark the LAT2 gene in the presence of AML1/ETO, and LAT2 gene derepression is achieved by pharmacological inhibition of HDACs. Oncogene (2011) 30, 3062-3072; doi: 10.1038/onc.2011.32; published online 16 May 2011	[Duque-Afonso, J.; Yalcin, A.; Berg, T.; Abdelkarim, M.; Luebbert, M.] Univ Freiburg, Univ Med Ctr Freiburg, Dept Med, Div Hematol Oncol, D-79106 Freiburg, Germany; [Heidenreich, O.] Newcastle Univ, No Inst Canc Res, Dept Mol Paediat Oncol, Newcastle Upon Tyne, Tyne & Wear, England; [Berg, T.] British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	University of Freiburg; Newcastle University - UK; British Columbia Cancer Agency	Lubbert, M (corresponding author), Univ Freiburg, Med Ctr, Dept Med, Div Hematol Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	michael.luebbert@uniklinik-freiburg.de	Heidenreich, Olaf/AAP-5045-2021; Berg, Tobias/AAT-5094-2021	Heidenreich, Olaf/0000-0001-5404-6483; Berg, Tobias/0000-0003-2668-0449	LaCaixa-DAAD [314, A/05/29785]; Department of Hematology/Oncology of the University of Freiburg; German Jose-Carreras Foundation [R 06/40f]; DFG [SPP 1463, Lu 429/7-1]	LaCaixa-DAAD(Deutscher Akademischer Austausch Dienst (DAAD)); Department of Hematology/Oncology of the University of Freiburg; German Jose-Carreras Foundation; DFG(German Research Foundation (DFG))	We would like to thank Constanze Bonifer (Leeds, UK) and Manfred Jung (Freiburg, Germany) for critically reviewing the manuscript, Eric Metzger and Roland Schule (Freiburg) for many helpful comments during establishment of the chromatin immunoprecipitation assay, and Harald Binder (Freiburg) for statistical support. Bernhard Kleine performed the bisulfite sequencing analysis of the LAT2 promoter. We are grateful to Joost Martens and Henk Stunnenberg (Nijmegen, The Netherlands) for sharing unpublished data. J Duque-Afonso was funded by a grant from LaCaixa-DAAD (ref. 314, A/05/29785) and the fellowship program of the Department of Hematology/Oncology of the University of Freiburg. This work was supported by the German Jose-Carreras Foundation (R 06/40f). ML is supported by the DFG (SPP 1463, Lu 429/7-1).	Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; Barbetti V, 2008, ONCOGENE, V27, P1767, DOI 10.1038/sj.onc.1210820; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Berg T, 2007, LEUKEMIA RES, V31, P497, DOI 10.1016/j.leukres.2006.08.008; Berg T, 2008, HAEMATOL-HEMATOL J, V93, P1728, DOI 10.3324/haematol.13044; Blum W, 2007, J CLIN ONCOL, V25, P3884, DOI 10.1200/JCO.2006.09.4169; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Claus R, 2006, J LEUKOCYTE BIOL, V80, P1462, DOI 10.1189/jlb.0106005; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Dunne J, 2006, ONCOGENE, V25, P6067, DOI 10.1038/sj.onc.1209638; DUQUEAFONSO J, 2011, BR J HAEMATOL; ERICKSON P, 1992, BLOOD, V80, P1825; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fazi F, 2007, BLOOD, V109, P4432, DOI 10.1182/blood-2006-09-045781; Fliegauf M, 2004, ONCOGENE, V23, P9070, DOI 10.1038/sj.onc.1208042; Garcia-Manero G, 2006, BLOOD, V108, P3271, DOI 10.1182/blood-2006-03-009142; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gore SD, 2006, CANCER RES, V66, P6361, DOI 10.1158/0008-5472.CAN-06-0080; Hauswald S, 2009, CLIN CANCER RES, V15, P3705, DOI 10.1158/1078-0432.CCR-08-2048; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Hoogenkamp M, 2009, BLOOD, V114, P299, DOI 10.1182/blood-2008-11-191890; Janssen E, 2003, NAT IMMUNOL, V4, P117, DOI 10.1038/ni882; Jiemjit A, 2008, ONCOGENE, V27, P3615, DOI 10.1038/sj.onc.1211018; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Klisovic MI, 2003, LEUKEMIA, V17, P350, DOI 10.1038/sj.leu.2402776; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Lamprecht B, 2010, NAT MED, V16, P571, DOI 10.1038/nm.2129; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Liu SJ, 2007, J PHARMACOL EXP THER, V321, P953, DOI 10.1124/jpet.106.118406; Liu SJ, 2005, CANCER RES, V65, P1277, DOI 10.1158/0008-5472.CAN-04-4532; Lubbert M, 2003, LEUKEMIA, V17, P1762, DOI 10.1038/sj.leu.2403045; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Maslak P, 2006, LEUKEMIA, V20, P212, DOI 10.1038/sj.leu.2404050; Nightingale KP, 2007, J BIOL CHEM, V282, P4408, DOI 10.1074/jbc.M606773200; Pabst T, 2001, NAT MED, V7, P444, DOI 10.1038/86515; Paul TA, 2010, BLOOD, V115, P3098, DOI 10.1182/blood-2009-07-233858; Peterson LF, 2007, BLOOD, V109, P4392, DOI 10.1182/blood-2006-03-012575; Pober BR, 2010, NEW ENGL J MED, V362, P239, DOI 10.1056/NEJMra0903074; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Stork B, 2004, IMMUNITY, V21, P681, DOI 10.1016/j.immuni.2004.09.007; Tan JH, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-5; Tkaczyk C, 2004, BLOOD, V104, P207, DOI 10.1182/blood-2003-08-2769; Viale A, 2009, NATURE, V457, P51, DOI 10.1038/nature07618; Volna P, 2004, J EXP MED, V200, P1001, DOI 10.1084/jem.20041213; Wang Y, 2005, MOL CELL BIOL, V25, P4455, DOI 10.1128/MCB.25.11.4455-4465.2005; Yang G, 2007, ONCOGENE, V26, P91, DOI 10.1038/sj.onc.1209760; Zhu MH, 2004, J EXP MED, V200, P991, DOI 10.1084/jem.20041223; Zhu MH, 2006, IMMUNITY, V25, P757, DOI 10.1016/j.immuni.2006.08.025	51	36	37	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2011	30	27					3062	3072		10.1038/onc.2011.32	http://dx.doi.org/10.1038/onc.2011.32			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	789IW	21577204				2022-12-17	WOS:000292510100006
J	Pontier, SM; Huck, L; White, DE; Rayment, J; Sanguin-Gendreau, V; Hennessy, B; Zuo, D; St-Arnaud, R; Mills, GB; Dedhar, S; Marshall, CJ; Muller, WJ				Pontier, S. M.; Huck, L.; White, D. E.; Rayment, J.; Sanguin-Gendreau, V.; Hennessy, B.; Zuo, D.; St-Arnaud, R.; Mills, G. B.; Dedhar, S.; Marshall, C. J.; Muller, W. J.			Integrin-linked kinase has a critical role in ErbB2 mammary tumor progression: implications for human breast cancer	ONCOGENE			English	Article						integrin-linked kinase; ErbB2; mammary tumorigenesis	EPITHELIAL-SPECIFIC DISRUPTION; GLYCOGEN-SYNTHASE KINASE; TRANSGENIC MOUSE MODEL; PROTEIN-KINASE; CELL-SURVIVAL; GROWTH-FACTOR; THERAPEUTIC TARGET; MET AMPLIFICATION; B/AKT ACTIVATION; LUNG-CANCER	Elevated expression of the integrin-linked kinase (ILK) has been observed in a variety of cancers and has been further correlated with poor clinical outcome. Here, we show that mammary epithelial disruption of ILK results in a profound block in mammary tumor induction. Consistent with these observations, inhibition of ILK function in ErbB2-expressing cells with small molecule inhibitor or RNA interference resulted in profound block in their in vitro invasive properties due to the induction of apoptotic cell death. The rare ILK-deficient tumors that eventually arose overcame this block in tumor induction by an upregulation of ErB3 phosphorylation. These observations provide direct evidence that ILK has a critical role in the initiation phase of ErbB2 tumor induction. Oncogene (2010) 29, 3374-3385; doi:10.1038/onc.2010.86; published online 22 March 2010	[Pontier, S. M.; Huck, L.; Rayment, J.; Sanguin-Gendreau, V.; Zuo, D.; Muller, W. J.] McGill Univ, Goodman Canc Ctr, Dept Med, Montreal, PQ H3A 1A3, Canada; [White, D. E.; Marshall, C. J.] Canc Res UK Ctr Cell & Mol Biol, Inst Canc Res, London, England; [Hennessy, B.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [St-Arnaud, R.] Shriners Hosp Crippled Children, Genet Unit, Montreal, PQ, Canada; [Dedhar, S.] Univ British Columbia, BC Canc Agcy, Dept Biochem, Vancouver, BC, Canada	McGill University; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Texas System; UTMD Anderson Cancer Center; McGill University; British Columbia Cancer Agency; University of British Columbia	Muller, WJ (corresponding author), McGill Univ, Goodman Canc Ctr, Dept Med, 1160 Ave Pins Ouest,Room 509, Montreal, PQ H3A 1A3, Canada.	william.muller@mcgill.ca	Pontier, Stéphanie/A-3836-2015	Pontier, Stéphanie/0000-0002-9124-9228; Dedhar, Shoukat/0000-0003-4355-1657; Rayment, Jonathan/0000-0003-4955-8876; Hennessy, Bryan/0000-0002-7871-6477	The Terry Fox Foundation through an award from the National Cancer Institute of Canada (NCIC); US Department of Defense (BCRP/CDMRP Era of Hope Postdoctoral award); Cancer Research UK; Canadian Institutes of Health Research (CIHR)/Canadian Breast Cancer Research Alliance (CBCRA) [64280]; National Institutes of Health [5PO1GA-099031-05]	The Terry Fox Foundation through an award from the National Cancer Institute of Canada (NCIC); US Department of Defense (BCRP/CDMRP Era of Hope Postdoctoral award)(United States Department of Defense); Cancer Research UK(Cancer Research UK); Canadian Institutes of Health Research (CIHR)/Canadian Breast Cancer Research Alliance (CBCRA)(Canadian Institutes of Health Research (CIHR)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We are grateful to Cynthia Lavoie, Vassilios Papavassiliou, Celine Champigny and Kay Savage for excellent technical help during the project. We also thank all members of the Muller laboratory for their critical commentaries as well as Richard Lamb and Maria Cerone for critical discussions and reading. SMP was funded by a fellowship of The Terry Fox Foundation through an award from the National Cancer Institute of Canada (NCIC). DW was funded by the US Department of Defense (BCRP/CDMRP Era of Hope Postdoctoral award) as well as JR. CJM is a Cancer Research UK Gibb Fellow. WJM was supported by CRC Chair in Molecular Oncology. This work was supported by grants from Cancer Research UK, the Canadian Institutes of Health Research (CIHR)/Canadian Breast Cancer Research Alliance (CBCRA) (#64280), the US Department of Defense and the National Institutes of Health 5PO1GA-099031-05.	Ahmed F, 2002, CANCER RES, V62, P7166; Akhtar N, 2009, DEVELOPMENT, V136, P1019, DOI 10.1242/dev.028423; Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Attwell S, 2003, MOL BIOL CELL, V14, P4813, DOI 10.1091/mbc.E03-05-0308; Attwell S, 2000, ONCOGENE, V19, P3811, DOI 10.1038/sj.onc.1203711; Cowin P, 2007, J MAMMARY GLAND BIOL, V12, P99, DOI 10.1007/s10911-007-9041-9; D'Amico M, 2000, J BIOL CHEM, V275, P32649, DOI 10.1074/jbc.M000643200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fielding AB, 2008, J CELL BIOL, V180, P681, DOI 10.1083/jcb.200710074; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Fukuda T, 2003, J CELL BIOL, V160, P1001, DOI 10.1083/jcb.200212113; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hennessy BT, 2007, CLIN CANCER RES, V13, P7421, DOI 10.1158/1078-0432.CCR-07-0760; Kawamoto S, 2000, FEBS LETT, V470, P263, DOI 10.1016/S0014-5793(00)01338-7; Koul D, 2005, MOL CANCER THER, V4, P1681, DOI 10.1158/1535-7163.MCT-05-0258; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Li N, 2005, EMBO J, V24, P1942, DOI 10.1038/sj.emboj.7600674; McDonald PC, 2008, J CELL SCI, V121, P3121, DOI 10.1242/jcs.017996; McDonald PC, 2008, CANCER RES, V68, P1618, DOI 10.1158/0008-5472.CAN-07-5869; Mongroo PS, 2004, ONCOGENE, V23, P8959, DOI 10.1038/sj.onc.1208112; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; PRIGENT SA, 1994, EMBO J, V13, P2831, DOI 10.1002/j.1460-2075.1994.tb06577.x; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Provenzano PP, 2006, BMC MED, V4, DOI 10.1186/1741-7015-4-38; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Ranger JJ, 2009, CANCER RES, V69, P6823, DOI 10.1158/0008-5472.CAN-09-1684; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Somasiri A, 2001, J CELL SCI, V114, P1125; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Tibes R, 2006, MOL CANCER THER, V5, P2512, DOI 10.1158/1535-7163.MCT-06-0334; Troussard AA, 2003, J BIOL CHEM, V278, P22374, DOI 10.1074/jbc.M303083200; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Tu YZ, 1999, MOL CELL BIOL, V19, P2425; Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; White DE, 2001, ONCOGENE, V20, P7064, DOI 10.1038/sj.onc.1204910; White DE, 2006, GENE DEV, V20, P2355, DOI 10.1101/gad.1458906; Younes MN, 2005, MOL CANCER THER, V4, P1146, DOI 10.1158/1535-7163.MCT-05-0078	47	36	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3374	3385		10.1038/onc.2010.86	http://dx.doi.org/10.1038/onc.2010.86			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20305688				2022-12-17	WOS:000278622700006
J	Peuhu, E; Rivero-Muller, A; Stykki, H; Torvaldson, E; Holmbom, T; Eklund, P; Unkila, M; Sjoholm, R; Eriksson, JE				Peuhu, E.; Rivero-Muller, A.; Stykki, H.; Torvaldson, E.; Holmbom, T.; Eklund, P.; Unkila, M.; Sjoholm, R.; Eriksson, J. E.			Inhibition of Akt signaling by the lignan matairesinol sensitizes prostate cancer cells to TRAIL-induced apoptosis	ONCOGENE			English	Article						matairesinol; lignans; apoptosis; TRAIL	MAMMALIAN LIGNANS; SECOISOLARICIRESINOL DIGLYCOSIDE; BCL-2 FAMILY; DEATH; RECEPTOR; PROTEIN; LIGAND; GROWTH; LNCAP; RESISTANCE	Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to be selectively pro-apoptotic in cancer cells, with minimal toxicity to normal tissues. Although this feature makes TRAIL a promising anticancer agent, not all cancer cell types are sensitive to TRAIL-induced apoptosis despite abundant expression of TRAIL receptors. Thus, combinatorial treatments to sensitize tumor cells to TRAIL-induced apoptosis have been in the focus of extensive research. Dietary lignans have shown cancer preventive and antitumorigenic activity, but the mechanisms behind these effects are poorly known. Here we observed that of the three tested lignan molecules, matairesinol (MAT) was the most effective as a death receptor-sensitizing agent. MAT sensitized the androgen-dependent LNCaP cells to TRAIL-induced apoptosis both in the presence and absence of androgens. Treatment with MAT markedly decreased Akt activity, which has been implicated as a key signaling mechanism in the TRAIL resistance of LNCaP prostate cancer cells. The involvement of the pathway in the MAT-mediated sensitization was shown in rescue experiments using ectopic expression of constitutively active Akt. Owing to the high activity of phosphatidylinositol 3-kinase/Akt signaling in cancer, targeting this survival pathway with MAT could markedly benefit TRAIL-based tumor therapies, including those aimed at prostate cancer. Oncogene (2010) 29, 898-908; doi:10.1038/onc.2009.386; published online 23 November 2009	[Peuhu, E.; Stykki, H.; Torvaldson, E.; Eriksson, J. E.] Abo Akad Univ, Dept Biol, Turku 20520, Finland; [Peuhu, E.; Rivero-Muller, A.; Stykki, H.; Torvaldson, E.; Eriksson, J. E.] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Rivero-Muller, A.] Univ Turku, Inst Biomed, Turku, Finland; [Holmbom, T.] Abo Akad Univ, Lab Fiber & Cellulose Technol, Turku 20520, Finland; [Eklund, P.; Sjoholm, R.] Abo Akad Univ, Organ Chem Lab, Turku 20520, Finland; [Unkila, M.] Hormos Med Ltd, Turku, Finland	Abo Akademi University; University of Turku; University of Turku; Abo Akademi University; Abo Akademi University	Eriksson, JE (corresponding author), Abo Akad Univ, Dept Biol, Tykistokatu 6B, Turku 20520, Finland.	john.eriksson@abo.fi	Rivero-Muller, Adolfo/A-5120-2008	Rivero-Muller, Adolfo/0000-0002-9794-802X; Peuhu, Emilia/0000-0003-4945-3046; Torvaldson, Elin/0000-0002-7175-6396	Academy of Finland; Sigrid Juselius Foundation; Research Institute of the Abo Akademi University; Foundation of the Abo Akademi University; K Albin Johansson Foundation; Liv och Halsa Foundation; Magnus Ehrnrooth Foundation	Academy of Finland(Academy of Finland); Sigrid Juselius Foundation(Sigrid Juselius Foundation); Research Institute of the Abo Akademi University; Foundation of the Abo Akademi University; K Albin Johansson Foundation; Liv och Halsa Foundation; Magnus Ehrnrooth Foundation	We thank Henning Walczak for providing the recombinant izTRAIL, Julian Downward for the ca-Akt construct and Perttu Terho for technical assistance in flow cytometry. We also thank Cecilia Sahlgren and all the members of our laboratory for critical comments on the paper and technical help during the course of this study. This work was supported by the Academy of Finland, the Sigrid Juselius Foundation, the Research Institute of the Abo Akademi University, the Foundation of the Abo Akademi University, K Albin Johansson Foundation, Liv och Halsa Foundation and Magnus Ehrnrooth Foundation.	ADLERCREUTZ H, 1993, J STEROID BIOCHEM, V44, P147, DOI 10.1016/0960-0760(93)90022-O; Adlercreutz H, 2007, CRIT REV CL LAB SCI, V44, P483, DOI 10.1080/10408360701612942; Aslan JE, 2009, MOL CELL, V34, P497, DOI 10.1016/j.molcel.2009.04.011; AXELSON M, 1982, NATURE, V298, P659, DOI 10.1038/298659a0; Bucur O, 2006, FRONT BIOSCI-LANDMRK, V11, P1549, DOI 10.2741/1903; Bylund A, 2005, EXP BIOL MED, V230, P217; Chen LH, 2007, MOL CANCER THER, V6, P2581, DOI 10.1158/1535-7163.MCT-07-0220; Chen LH, 2009, J NUTR, V139, P653, DOI 10.3945/jn.108.101832; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Fulda S, 2004, CURR OPIN PHARMACOL, V4, P327, DOI 10.1016/j.coph.2004.02.005; Hausott B, 2003, J CANCER RES CLIN, V129, P569, DOI 10.1007/s00432-003-0461-7; Huang HJ, 2004, ONCOGENE, V23, P2161, DOI 10.1038/sj.onc.1207326; Jemal A, 2008, JNCI-J NATL CANCER I, V100, P1672, DOI 10.1093/jnci/djn389; Jin ZY, 2004, J BIOL CHEM, V279, P35829, DOI 10.1074/jbc.M405538200; Kim KM, 2005, J BIOL CHEM, V280, P41047, DOI 10.1074/jbc.M503713200; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kitts DD, 1999, MOL CELL BIOCHEM, V202, P91, DOI 10.1023/A:1007022329660; Koschny R, 2007, J MOL MED, V85, P923, DOI 10.1007/s00109-007-0194-1; Li DH, 1999, CANCER LETT, V142, P91, DOI 10.1016/S0304-3835(99)00158-5; Lin X, 2001, ANTICANCER RES, V21, P3995; Mahalingam D, 2009, CANCER TREAT REV, V35, P280, DOI 10.1016/j.ctrv.2008.11.006; McCann MJ, 2008, MOL NUTR FOOD RES, V52, P567, DOI 10.1002/mnfr.200700052; McCann MJ, 2005, NUTR CANCER, V52, P1, DOI 10.1207/s15327914nc5201_1; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Raja SM, 2008, MOL CANCER THER, V7, P2212, DOI 10.1158/1535-7163.MCT-07-2409; Ray S, 2005, APOPTOSIS, V10, P1411, DOI 10.1007/s10495-005-2490-y; Rokhlin OW, 2002, CANCER BIOL THER, V1, P631, DOI 10.4161/cbt.311; Rokhlin OW, 2005, ONCOGENE, V24, P6773, DOI 10.1038/sj.onc.1208833; Saarinen NM, 2008, INT J CANCER, V123, P1196, DOI 10.1002/ijc.23614; Schaefer U, 2007, FRONT BIOSCI, V12, P3813, DOI 10.2741/2354; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Sprick MR, 2004, BBA-MOL CELL RES, V1644, P125, DOI 10.1016/j.bbamcr.2003.11.002; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Thompson LU, 1996, NUTR CANCER, V26, P159, DOI 10.1080/01635589609514472; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Yokoyama T, 2003, BIOL PHARM BULL, V26, P371, DOI 10.1248/bpb.26.371	41	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2010	29	6					898	908		10.1038/onc.2009.386	http://dx.doi.org/10.1038/onc.2009.386			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553WP	19935713				2022-12-17	WOS:000274397800012
J	Farrall, AL; Whitelaw, ML				Farrall, A. L.; Whitelaw, M. L.			The HIF1 alpha-inducible pro-cell death gene BNIP3 is a novel target of SIM2s repression through cross-talk on the hypoxia response element	ONCOGENE			English	Article						SIM2; BNIP3; HIF1 alpha; hypoxia; cell death; cancer	DRUG-THERAPY TARGET; SINGLE-MINDED GENE; PANCREATIC-CANCER; PROSTATE-CANCER; COLORECTAL-CANCER; UP-REGULATION; EXPRESSION; AUTOPHAGY; PROTEIN; APOPTOSIS	The short isoform of single-minded 2 (SIM2s), a basic helix-loop-helix/PAS (bHLH/PAS) transcription factor, is upregulated in pancreatic and prostate tumours; however, a mechanistic role for SIM2s in these cancers is unknown. Microarray studies in prostate DU145 cells identified the pro-cell death gene, BNIP3 (Bcl-2/adenovirus E1B 19 kDa interacting protein 3), as a novel putative target of SIM2s repression. Further validation showed BNIP3 repression in several prostate and pancreatic carcinoma-derived cell lines with ectopic expression of human SIM2s. BNIP3 levels are enhanced in prostate carcinoma cells upon short interfering (si) RNA-mediated knockdown of endogenous SIM2s. Chromatin immunoprecipitation and promoter studies show that SIM2s represses BNIP3 through its activities at the proximal promoter hypoxia response element (HRE), the site through which the bHLH/PAS family member, hypoxia-inducible factor 1 alpha (HIF1 alpha), induces BNIP3. SIM2s attenuates BNIP3 hypoxic induction via the HRE, and increased hypoxic induction of BNIP3 occurs with siRNA knockdown of endogenous SIM2s in prostate PC3AR+ cells. BNIP3 is implicated in hypoxia-induced cell death processes. Prolonged treatment of PC3AR+ cells with hypoxia mimetics, DP and DMOG, confers hypoxia-induced autophagy, measured by enhanced LC3-II levels and SQSTM1/p62 turnover. We show that PC3AR+ cells expressing ectopic SIM2s have enhanced survival in these conditions. Induction of LC3-II and turnover of SQSTM1/p62 are attenuated in PC3AR+/SIM2s DMOG and hypoxia-treated cells, suggesting that SIM2s may attenuate autophagic cell death processes, perhaps through BNIP3 repression. These data show, for the first time, SIM2s cross-talk on an endogenous HRE. SIM2s' functional interference with HIF1 alpha activities on BNIP3 may indicate a novel role for SIM2s in promoting tumourigenesis. Oncogene (2009) 28, 3671-3680; doi: 10.1038/onc.2009.228; published online 10 August 2009	[Farrall, A. L.; Whitelaw, M. L.] Univ Adelaide, Discipline Biochem, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia; [Farrall, A. L.; Whitelaw, M. L.] Ctr Mol Genet Dev, Adelaide, SA, Australia	University of Adelaide	Farrall, AL (corresponding author), Univ Adelaide, Discipline Biochem, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia.	alexandra.farrall@adelaide.edu.au	Farrall, Alexandra/ABD-2079-2020	Farrall, Alexandra/0000-0002-0909-8978	Australian Cancer Research Foundation; Australian Research Council; Cancer Council South Australia	Australian Cancer Research Foundation; Australian Research Council(Australian Research Council); Cancer Council South Australia(Cancer Council South Australia)	We thank M van Bekkum and C Bindloss for their kind technical assistance, and Dr S Woods for reagents and critical reading of the manuscript. PC3AR+ cells were a kind gift from Prof W Tilley, Hanson Research Institute, Adelaide, Australia. Tet-inducible lentiviral vectors were a kind gift from Dr S Barry, Children's Health Research Institute, SA, Australia (Drabsch et al., 2007). Anti-HIF1 alpha-CAD antibody was obtained from the laboratory of Prof J Pouyssegur, CNRS UMR6543, University of Nice, France (Richard et al., 1999). We acknowledge the contribution of the Australian Cancer Research Foundation for their support of the Adelaide Microarray Facility, Adelaide, Australia, which supplied, processed and analysed the microarrays. This work was supported by grants from the Australian Research Council and the Cancer Council South Australia.	Abe T, 2005, J GASTROENTEROL, V40, P504, DOI 10.1007/s00535-005-1576-1; Akada M, 2005, CLIN CANCER RES, V11, P3094, DOI 10.1158/1078-0432.CCR-04-1785; Aleman MJ, 2005, P NATL ACAD SCI USA, V102, P12765, DOI 10.1073/pnas.0505484102; Azad MB, 2008, AUTOPHAGY, V4, P195, DOI 10.4161/auto.5278; Bacon AL, 2007, ONCOGENE, V26, P132, DOI 10.1038/sj.onc.1209761; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Burton TR, 2009, CELL DEATH DIFFER, V16, P515, DOI 10.1038/cdd.2008.185; Chandran UR, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-45; Chrast R, 1997, GENOME RES, V7, P615, DOI 10.1101/gr.7.6.615; Daido S, 2004, CANCER RES, V64, P4286, DOI 10.1158/0008-5472.CAN-03-3084; De Angelis PM, 2004, INT J ONCOL, V24, P1279; DeYoung MP, 2003, CANCER LETT, V200, P25, DOI 10.1016/S0304-3835(03)00409-9; DeYoung MP, 2003, P NATL ACAD SCI USA, V100, P4760, DOI 10.1073/pnas.0831000100; Deyoung MP, 2002, ANTICANCER RES, V22, P3149; Drabsch Y, 2007, P NATL ACAD SCI USA, V104, P13762, DOI 10.1073/pnas.0700104104; Ema M, 1996, MOL CELL BIOL, V16, P5865; Erkan M, 2005, ONCOGENE, V24, P4421, DOI 10.1038/sj.onc.1208642; Goshu E, 2002, MOL CELL BIOL, V22, P4147, DOI 10.1128/MCB.22.12.4147-4157.2002; Halvorsen OJ, 2007, CLIN CANCER RES, V13, P892, DOI 10.1158/1078-0432.CCR-06-1207; Ishiguro M, 2007, ANN SURG ONCOL, V14, P1752, DOI 10.1245/s10434-006-9285-4; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Kewley RJ, 2004, INT J BIOCHEM CELL B, V36, P189, DOI 10.1016/S1357-2725(03)00211-5; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07; Lee H, 2006, MOL CELLS, V21, P1; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Mahon PC, 2007, CANCER RES, V67, P6786, DOI 10.1158/0008-5472.CAN-07-0440; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Mellor HR, 2007, CANCER METAST REV, V26, P553, DOI 10.1007/s10555-007-9080-0; Metz RP, 2006, J BIOL CHEM, V281, P10839, DOI 10.1074/jbc.M508858200; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Moffett P, 1997, MOL CELL BIOL, V17, P4933, DOI 10.1128/MCB.17.9.4933; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Murai M, 2005, CLIN CANCER RES, V11, P1021; Okami J, 2004, CANCER RES, V64, P5338, DOI 10.1158/0008-5472.CAN-04-0089; Probst MR, 1997, J BIOL CHEM, V272, P4451, DOI 10.1074/jbc.272.7.4451; Pursiheimo JP, 2009, ONCOGENE, V28, P334, DOI 10.1038/onc.2008.392; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Semenza GL, 2000, GENE DEV, V14, P1983; Shamblott MJ, 2002, DEV DYNAM, V224, P373, DOI 10.1002/dvdy.10116; Sowter HM, 2001, CANCER RES, V61, P6669; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200; Woods S, 2008, NUCLEIC ACIDS RES, V36, P3716, DOI 10.1093/nar/gkn247; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhou J, 2006, CANCER LETT, V237, P10, DOI 10.1016/j.canlet.2005.05.028	51	36	38	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3671	3680		10.1038/onc.2009.228	http://dx.doi.org/10.1038/onc.2009.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19668230				2022-12-17	WOS:000270851800008
J	Sher, YP; Tzeng, TF; Kan, SF; Hsu, J; Xie, X; Han, Z; Lin, WC; Li, LY; Hung, MC				Sher, Y-P; Tzeng, T-F; Kan, S-F; Hsu, J.; Xie, X.; Han, Z.; Lin, W-C; Li, L-Y; Hung, M-C			Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival	ONCOGENE			English	Article						targeted gene therapy; lung cancer; BiKDD; VISA; survivin	CELL-DIVISION; EXPRESSION; APOPTOSIS; PROMOTER; CARCINOMA; PULMONARY; MODELS; TUMORS	Lung cancer is a leading cause of cancer death due to the high incidence of metastasis; therefore, novel and effective treatments are urgently needed. A current strategy is cancer-specific targeted gene therapy. Although many identified that cancer-specific promoters are highly specific, they tend to have low activity compared with the ubiquitous cytomegalovirus (CMV) promoter, limiting their application. We developed a targeted gene therapy expression system for lung cancer that is highly specific with strong activity. Our expression vector uses the survivin promoter, highly expressed in many cancers but not normal adult tissues. We enhanced the survivin promoter activity comparable to the CMV promoter in lung cancer cell lines using an established platform technology, whereas the survivin promoter remained weak in normal cells. In mouse models, the transgene was specifically expressed in the lung tumor tissue, compared with the CMV promoter that was expressed in both normal and tumor tissues. In addition, the therapeutic gene BikDD, a mutant form of pro-apoptotic Bcl2 interacting killer, induced cell killing in vitro, and inhibited cell growth and prolonged mouse survival in vivo. Importantly, there was virtually no toxicity when BikDD was expressed with our expression system. Thus, the current report provides a therapeutic efficacy and safe strategy worthy of development in clinical trials treating lung cancer. Oncogene (2009) 28, 3286-3295; doi:10.1038/onc.2009.187; published online 13 July 2009	[Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 079, Houston, TX 77030 USA; [Sher, Y-P; Tzeng, T-F; Kan, S-F; Li, L-Y; Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Sher, Y-P; Tzeng, T-F; Kan, S-F; Li, L-Y; Hung, M-C] China Med Univ & Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Lin, W-C] China Med Univ, Dept Pharmacol, Sch Med, Taichung, Taiwan; [Li, L-Y; Hung, M-C] Asia Univ, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 079, 1515 Holcombe Blvd, Houston, TX 77030 USA.	lyl@mail.cmu.edu.tw; mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Li, Long-Yuan/0000-0001-7472-8318	NRPGM [DOH97-TD-G-111-041]; MDACC SPORE [P20 CA101936, 1P50 CA116199, DOH97-TD-111-TM003]; National Health Research Institutes, Taiwan [PD9602]; NATIONAL CANCER INSTITUTE [P20CA101936, P01CA099031, P50CA116199, R01CA109311] Funding Source: NIH RePORTER	NRPGM; MDACC SPORE; National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants from NRPGM in DOH97-TD-G-111-041 and MDACC SPORE grants in pancreatic (P20 CA101936) and breast (1P50 CA116199) cancer ( to M-C Hung) and DOH97-TD-111-TM003 ( to L-Y Li). YP Sher was also supported by a postdoctoral fellowship award from the National Health Research Institutes, Taiwan (PD9602). In memory of Mr Nan-Tu Huang, the late Chairman of Wei-Chuan Group in Taiwan for his courageous battle in lung cancer.	Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Altieri DC, 2003, ONCOGENE, V22, P8581, DOI 10.1038/sj.onc.1207113; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Chen JS, 2004, CANCER GENE THER, V11, P740, DOI 10.1038/sj.cgt.7700752; Day CP, 2006, CANCER GENE THER, V13, P706, DOI 10.1038/sj.cgt.7700945; Fitzsimons HL, 2002, METHODS, V28, P227, DOI 10.1016/S1046-2023(02)00227-X; Fukazawa T, 2007, MOL CANCER THER, V6, P244, DOI 10.1158/1535-7163.MCT-06-0408; Gunther Michael, 2005, Curr Med Chem Anticancer Agents, V5, P157, DOI 10.2174/1568011053174855; Hay RJ, 1996, J CELL BIOCHEM, P107; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Huang L., 2005, NONVIRAL VECTORS G 1; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Li FZ, 2006, J CELL PHYSIOL, V208, P476, DOI 10.1002/jcp.20634; Li YM, 2003, CANCER RES, V63, P7630; MCLEMORE TL, 1988, CANCER RES, V48, P2880; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6; Oshikiri T, 2006, CANCER GENE THER, V13, P856, DOI 10.1038/sj.cgt.7700953; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; Retzer-Lidl M, 2007, INT J CANCER, V121, P66, DOI 10.1002/ijc.22619; Russ V, 2007, PHARM RES-DORDR, V24, P1047, DOI 10.1007/s11095-006-9233-9; Templeton NS, 1997, NAT BIOTECHNOL, V15, P647, DOI 10.1038/nbt0797-647; Tsai MF, 2006, JNCI-J NATL CANCER I, V98, P825, DOI 10.1093/jnci/djj229; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Zaffaroni N, 2005, J CELL MOL MED, V9, P360, DOI 10.1111/j.1582-4934.2005.tb00361.x	25	36	37	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2009	28	37					3286	3295		10.1038/onc.2009.187	http://dx.doi.org/10.1038/onc.2009.187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495LS	19597463	Green Accepted			2022-12-17	WOS:000269893700003
J	Jiang, Y; Luo, W; Howe, PH				Jiang, Y.; Luo, W.; Howe, P. H.			Dab2 stabilizes Axin and attenuates Wnt/beta-catenin signaling by preventing protein phosphatase 1 (PP1)-Axin interactions	ONCOGENE			English	Article						Disabled-2 (Dab2); Axin-protein phosphatase 1 (PP1); Wnt-beta-catenin signaling	BETA-CATENIN; DISABLED-2 DAB2; PHOSPHORYLATION; PATHWAY; ENDOCYTOSIS; ACTIVATION; ADAPTER; AP-2; LRP6	Wnt/beta-catenin signaling plays a pivotal role in modulating cellular proliferation, differentiation, tissue organization and embryonic development. Earlier, we found that the endocytic adaptor disabled-2 (Dab2) could attenuate Wnt/beta-catenin signaling by stabilizing Axin and preventing its translocation to the membrane. Recently, protein phosphatase 1 (PP1) has been shown to interact with, and dephosphorylate Axin, leading to its destabilization. Here, we show that Dab2 functions upstream of PP1 to block the interaction between Axin and PP1, inhibiting Axin dephosphorylation and thereby stabilizing its expression, ultimately leading to inhibition of Wnt/beta-catenin. We show that Dab2 acts as a competitive inhibitor of PP1 by binding to the same C-terminal domain of Axin. Both PP1 and Axin bind to the N-terminus of Dab2 and a Dab2 truncation mutant consisting of the N-terminal phosphotyrosine binding domain blocks PP1-Axin interactions and inhibits Wnt signaling. We confirm the inhibitory effect of Dab2 on Wnt/beta-catenin signaling in zebrafish embryos, showing that its ectopic expression phenocopies Axin overexpression resulting in altered dorsoventral patterning. We conclude that Dab2 stabilizes Axin and attenuates Wnt/beta-catenin signaling by preventing PP1 from binding Axin. Oncogene (2009) 28, 2999-3007; doi:10.1038/onc.2009.157; published online 6 July 2009	[Luo, W.] Univ Utah, Huntsman Canc Inst, Dept Oncol Sci, Ctr Children, Salt Lake City, UT USA; [Jiang, Y.; Howe, P. H.] Cleveland Clin, Dept Canc Biol NB4, Lerner Res Inst, Cleveland, OH 44195 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Cleveland Clinic Foundation	Howe, PH (corresponding author), Cleveland Clin, Dept Canc Biol, Lerner Res Inst, NB4, Cleveland, OH 44195 USA.	howep@ccf.org			National Cancer Institute [CA55536, CA80095]; NATIONAL CANCER INSTITUTE [R01CA055536, R01CA080095, R29CA055536] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr S Takada for the generous provision of control Wnt-3A-producing mouse L cells and Drs Furuhashi, Wu, Zeng and He for generous provision of the Myc-Axin, Flag-tagged LRP5 plasmids and LRP5/6 antibody, respectively. We also thank Dr David Virshup and Dr Sheng-Cai Lin for generous provision of PP1 and Axin reagents. We are also grateful to Drs Sanjay Pimplikar and Ping Song for all their help with the zebrafish studies. This work was supported by Grant CA55536 and CA80095 from the National Cancer Institute to PHH.	Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bilic J, 2007, SCIENCE, V316, P1619, DOI 10.1126/science.1137065; Cliffe A, 2003, CURR BIOL, V13, P960, DOI 10.1016/S0960-9822(03)00370-1; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Hocevar BA, 2003, EMBO J, V22, P3084, DOI 10.1093/emboj/cdg286; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Jiang Y, 2008, ONCOGENE, V27, P1865, DOI 10.1038/sj.onc.1210829; Jones WM, 2003, CURR BIOL, V13, pR479, DOI 10.1016/S0960-9822(03)00407-X; Luo W, 2007, EMBO J, V26, P1511, DOI 10.1038/sj.emboj.7601607; Morris SM, 2002, TRAFFIC, V3, P331, DOI 10.1034/j.1600-0854.2002.30503.x; Morris SM, 2001, TRAFFIC, V2, P111, DOI 10.1034/j.1600-0854.2001.020206.x; Prunier C, 2005, J BIOL CHEM, V280, P17540, DOI 10.1074/jbc.M500974200; Prunier C, 2004, GROWTH FACTORS, V22, P141, DOI 10.1080/08977190410001720860; Rui YN, 2007, DEV CELL, V13, P268, DOI 10.1016/j.devcel.2007.07.006; Smith ER, 2001, J BIOL CHEM, V276, P47303, DOI 10.1074/jbc.M106158200; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Yamamoto H, 2008, DEV CELL, V15, P37, DOI 10.1016/j.devcel.2008.04.015; Yu A, 2007, DEV CELL, V12, P129, DOI 10.1016/j.devcel.2006.10.015; Yun M, 2003, J BIOL CHEM, V278, P36572, DOI 10.1074/jbc.M304384200; Zeng X, 2005, NATURE, V438, P873, DOI 10.1038/nature04185	20	36	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2009	28	33					2999	3007		10.1038/onc.2009.157	http://dx.doi.org/10.1038/onc.2009.157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485SA	19581931	Green Accepted			2022-12-17	WOS:000269142800008
J	Izumi, H; Matsumoto, Y; Ikeuchi, T; Saya, H; Kajii, T; Matsuura, S				Izumi, H.; Matsumoto, Y.; Ikeuchi, T.; Saya, H.; Kajii, T.; Matsuura, S.			BubR1 localizes to centrosomes and suppresses centrosome amplification via regulating Plk1 activity in interphase cells	ONCOGENE			English	Article						centrosome; BubR1; Plk1; chromosome instability syndrome	MOSAIC VARIEGATED ANEUPLOIDY; PREMATURE CHROMATID SEPARATION; POLO-LIKE KINASE-1; MITOTIC-SPINDLE CHECKPOINT; CENTROMERE DIVISION PCD; AURORA-A; CANCER; MUTATIONS; OVEREXPRESSION; PROGRESSION	BubR1 is a critical component of the mitotic checkpoint that delays the onset of anaphase until all chromosomes have established bipolar attachment to the microtubules. We previously reported that mutations of the BUB1B gene ( encoding BubR1) caused premature chromatid separation (PCS) syndrome, a condition characterized by constitutional aneuploidy and a high risk of childhood cancer. We here report that the cells from PCS syndrome patients have loss of regulation of the centrosome duplication machinery, resulting in centrosome amplification and multipolar mitosis. PCS syndrome cells show increased activity of Polo-like kinase 1 (Plk1), whose knockdown suppresses centrosome amplification. BubR1 localizes to centrosomes, physically interacts with Plk1 and inhibits Plk1 phosphorylation and its kinase activity during interphase. These results unravel a crucial role of BubR1 in preventing centrosome reduplication through negative regulation of Plk1 in interphase cells. Oncogene (2009) 28, 2806-2820; doi:10.1038/onc.2009.141; published online 8 June 2009	[Matsuura, S.] Hiroshima Univ, RIRBM, Dept Radiat Biol, Minami Ku, Hiroshima 7348553, Japan; [Ikeuchi, T.] Tokyo Med & Dent Univ, Med Res Inst, Div Mol Cytogenet, Tokyo, Japan; [Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Tokyo, Japan; [Kajii, T.] Hachioji, Tokyo, Japan	Hiroshima University; Tokyo Medical & Dental University (TMDU); Keio University	Matsuura, S (corresponding author), Hiroshima Univ, RIRBM, Dept Radiat Biol, Minami Ku, Kasumi 1-2-3, Hiroshima 7348553, Japan.	shinya@hiroshima-u.ac.jp	Saya, Hideyuki/J-4325-2013; Matsuura, Shinya/U-4182-2017	Matsuura, Shinya/0000-0001-5294-081X; Saya, Hideyuki/0000-0001-6610-1902	Analysis Center of Life Science, Hiroshima University; Japanese Ministry of Education, Science, Sports and Culture; MEXT priority research projects; Haraguchi Memorial Cancer Grant Foundation	Analysis Center of Life Science, Hiroshima University; Japanese Ministry of Education, Science, Sports and Culture(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); MEXT priority research projects; Haraguchi Memorial Cancer Grant Foundation	We are grateful to Dr S Tanaka for providing anti- pericentrin antibody and Dr M Ohsugi for providing Flag- Plk1 plasmids. We are also grateful to Dr Y Yamamoto and Dr N Watanabe for technical advice. We thank H Ikeda and H Hatakeyama for technical assistance, and T Jo and A Kamesako for secretarial assistance. We also thank our laboratory members for their continuous encouragement. This work was partly carried out at the Analysis Center of Life Science, Hiroshima University. This work was supported by Grants- in- Aid for Scientific Research from the Japanese Ministry of Education, Science, Sports and Culture ( to HI and to SM), MEXT priority research projects ( to HI and to SM) and the Haraguchi Memorial Cancer Grant Foundation ( to HI).	Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Barr FA, 2004, NAT REV MOL CELL BIO, V5, P429, DOI 10.1038/nrm1401; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Bornens M, 1999, METHOD CELL BIOL, V61, P13; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carney SA, 2002, LAB INVEST, V82, P719, DOI 10.1097/01.LAB.0000017499.51216.3E; Chiba S, 2000, EXP CELL RES, V258, P310, DOI 10.1006/excr.2000.4916; Cleveland DW, 2003, CELL, V112, P407, DOI 10.1016/S0092-8674(03)00115-6; Elowe S, 2007, GENE DEV, V21, P2205, DOI 10.1101/gad.436007; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Jacquemont S, 2002, AM J MED GENET, V109, P17, DOI 10.1002/ajmg.10281; Kajii T, 1998, AM J MED GENET, V78, P245, DOI 10.1002/(SICI)1096-8628(19980707)78:3<245::AID-AJMG7>3.0.CO;2-O; Kajii T, 2001, AM J MED GENET, V104, P57, DOI 10.1002/ajmg.1580; Kawame H, 1999, J HUM GENET, V44, P219, DOI 10.1007/s100380050147; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1997, MOL CELL BIOL, V17, P3408, DOI 10.1128/MCB.17.6.3408; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Loncarek J, 2008, NAT CELL BIOL, V10, P322, DOI 10.1038/ncb1694; Macurek L, 2008, NATURE, V455, P119, DOI 10.1038/nature07185; Matsumura S, 2007, J BIOL CHEM, V282, P15217, DOI 10.1074/jbc.M611053200; Matsuura S, 2000, AM J HUM GENET, V67, P483, DOI 10.1086/303022; Matsuura S, 2006, AM J MED GENET A, V140A, P358, DOI 10.1002/ajmg.a.31069; Matsuura S, 1997, AM J HUM GENET, V60, P1487, DOI 10.1086/515461; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; Plaja A, 2001, AM J MED GENET, V98, P216, DOI 10.1002/1096-8628(20010122)98:3<216::AID-AJMG1091>3.0.CO;2-0; Rieder CL, 2003, SCIENCE, V300, P91, DOI 10.1126/science.1082177; Seki A, 2008, SCIENCE, V320, P1655, DOI 10.1126/science.1157425; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; Yu HT, 2002, CURR OPIN CELL BIOL, V14, P706, DOI 10.1016/S0955-0674(02)00382-4	37	36	38	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2009	28	31					2806	2820		10.1038/onc.2009.141	http://dx.doi.org/10.1038/onc.2009.141			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479TS	19503101				2022-12-17	WOS:000268684400004
J	Larive, RM; Urbach, S; Poncet, J; Jouin, P; Mascre, G; Sahuquet, A; Mangeat, PH; Coopman, PJ; Bettache, N				Larive, R. M.; Urbach, S.; Poncet, J.; Jouin, P.; Mascre, G.; Sahuquet, A.; Mangeat, P. H.; Coopman, P. J.; Bettache, N.			Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion	ONCOGENE			English	Article						Syk signaling; proteomics; tyrosine kinase; tumor suppressor; cell-cell adhesion	HUMAN BREAST-CANCER; SPLEEN TYROSINE KINASE; ENDOTHELIAL-CELLS; ANTIGEN RECEPTOR; CROSS-LINKING; PROTEIN; PHOSPHORYLATION; EXPRESSION; PROLIFERATION; PROGRESSION	The spleen tyrosine kinase Syk has predominantly been studied in hematopoietic cells in which it is involved in immunoreceptor-mediated signaling. Recently, Syk expression was evidenced in numerous nonhematopoietic cells and shown to be involved in tumor formation and progression. The Syk downstream signaling effectors in nonhematopoietic cells remain, however, to be uncovered, and were investigated using MS-based quantitative phosphoproteomics. Two strategies, based on the inhibition of the Syk catalytic activity and on the loss of Syk expression were employed to identify phosphotyrosine-dependent complexes. Quantitative measurements were obtained on 350 proteins purified with phosphotyrosine affinity columns using the SILAC method. Forty-one proteins are dependent on both Syk expression and catalytic activity and were selected as signaling effectors. They are involved in a variety of biological processes such as signal transduction, cell-cell adhesion and cell polarization. We investigated the functional involvement of Syk in cell-cell adhesion and demonstrated the phosphorylation of E-cadherin and alpha-catenin. In addition, Syk is localized at cell-cell contacts, and Syk-mediated phosphorylation of E-cadherin seems to be important for the proper localization of p120-catenin at adherens junctions. Identification of the biochemical pathways regulated by Syk in human cancer cells will help to uncover its role in tumor formation and progression. Oncogene (2009) 28, 2337-2347; doi:10.1038/onc.2009.99; published online 4 May 2009	[Bettache, N.] Univ Montpellier 2, UMR 5237, CRBM, CNRS, F-34095 Montpellier 5, France; [Larive, R. M.; Mascre, G.; Sahuquet, A.; Mangeat, P. H.; Coopman, P. J.; Bettache, N.] Univ Montpellier 1, UMR 5237, IFR 122, CNRS,CRBM,Equipe Labellisee Ligue Natl Canc 2007, F-34095 Montpellier 5, France; [Urbach, S.; Poncet, J.; Jouin, P.] Univ Montpellier 1, Inst Genom Fonct, UMR 5203, CNRS,INSERM,U661, F-34095 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Bettache, N (corresponding author), Univ Montpellier 2, UMR 5237, CRBM, CNRS, Cc 107,Pl Eugene Bataillon, F-34095 Montpellier 5, France.	bettache@univ-montp2.fr	; Coopman, Peter/G-7416-2019	Larive, Romain/0000-0001-8479-209X; Coopman, Peter/0000-0003-3720-523X; Bettache, Nadir/0000-0001-5426-7024	Centre National de la Recherche Scientifique; Institut National du Cancer [PL06-111]; Ligue Nationale contre le Cancer; LNCC; Association pour la Recherche sur le Cancer (ARC)	Centre National de la Recherche Scientifique(Centre National de la Recherche Scientifique (CNRS)); Institut National du Cancer(Institut National du Cancer (INCA) France); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); LNCC; Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer)	We thank A Morel and M Saen for skilled technical assistance; F Raynaud and C Roy for valuable technical advice; G Freiss for IRS-1 and S Baghdiguian for p65-NF-kappa B antibodies; M Dunach and A Garcia de Herreros for GST constructs; Montpellier RIO Imaging platform for image analysis. MS experiments were performed at the Functional Proteomics Platform located at the IGF. This study was supported by the Centre National de la Recherche Scientifique, the Institut National du Cancer (no. PL06-111 to PJ Coopman) and the Ligue Nationale contre le Cancer (LNCC; Equipe Labellisee Ligue 2007 to PJ Coopman). RM Larive is a recipient of a PhD fellowship funded by the LNCC and the Association pour la Recherche sur le Cancer (ARC).	Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bijli KM, 2008, J BIOL CHEM, V283, P14674, DOI 10.1074/jbc.M802094200; Coopman PJ, 2006, CANCER LETT, V241, P159, DOI 10.1016/j.canlet.2005.11.004; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gonzalez-Mariscal L, 2007, PROG HISTOCHEM CYTO, V42, P1, DOI 10.1016/j.proghi.2007.01.001; Hoeller C, 2005, J INVEST DERMATOL, V124, P1293, DOI 10.1111/j.0022-202X.2005.23685.x; Lang ML, 2002, BIOCHEM J, V364, P517, DOI 10.1042/BJ20011696; Ma H, 2001, J IMMUNOL, V166, P1507, DOI 10.4049/jimmunol.166.3.1507; Maeda A, 1999, ONCOGENE, V18, P2291, DOI 10.1038/sj.onc.1202552; Maruyama S, 1996, J BIOL CHEM, V271, P6631, DOI 10.1074/jbc.271.12.6631; Moroni M, 2004, CANCER RES, V64, P7346, DOI 10.1158/0008-5472.CAN-03-3520; NAGAI K, 1995, J BIOL CHEM, V270, P6824, DOI 10.1074/jbc.270.12.6824; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Peters JD, 1996, J BIOL CHEM, V271, P4755; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Sada K, 2001, J BIOCHEM-TOKYO, V130, P177, DOI 10.1093/oxfordjournals.jbchem.a002970; Schymeinsky J, 2006, BLOOD, V108, P3919, DOI 10.1182/blood-2005-12-030387; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Toyama T, 2003, CANCER LETT, V189, P97, DOI 10.1016/S0304-3835(02)00463-9; von Willebrand M, 1998, CELL SIGNAL, V10, P407, DOI 10.1016/S0898-6568(97)00139-3; Wang L, 2005, CANCER RES, V65, P10289, DOI 10.1158/0008-5472.CAN-05-2231; Xu JW, 2007, MOL ENDOCRINOL, V21, P564, DOI 10.1210/me.2006-0354; Yanagi S, 2001, BIOCHEM BIOPH RES CO, V288, P495, DOI 10.1006/bbrc.2001.5788; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022; Yuan YF, 2001, CANCER RES, V61, P5558; Zolodz MD, 2004, J PROTEOME RES, V3, P743, DOI 10.1021/pr049967i; Zyss D, 2005, CANCER RES, V65, P10872, DOI 10.1158/0008-5472.CAN-05-1270	33	36	40	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2337	2347		10.1038/onc.2009.99	http://dx.doi.org/10.1038/onc.2009.99			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421152				2022-12-17	WOS:000267089100004
J	Martin, V; Xu, J; Pabbisetty, SK; Alonso, MM; Liu, D; Lee, OH; Gumin, J; Bhat, KP; Colman, H; Lang, FF; Fueyo, J; Gomez-Manzano, C				Martin, V.; Xu, J.; Pabbisetty, S. K.; Alonso, M. M.; Liu, D.; Lee, O-H; Gumin, J.; Bhat, K. P.; Colman, H.; Lang, F. F.; Fueyo, J.; Gomez-Manzano, C.			Tie2-mediated multidrug resistance in malignant gliomas is associated with upregulation of ABC transporters	ONCOGENE			English	Article						Tie2; gliomas; chemoresistance; ABC transporters; brain tumor stem cells	TUMOR STEM-CELLS; DRUG-RESISTANCE; EXPRESSION; CANCER; CHEMORESISTANCE; GLIOBLASTOMA; RECEPTOR; GENES; TIE2	Resistance and relapse are still primary causes that result in poor effectiveness of chemotherapy in malignant gliomas. Therefore, development of new therapeutic strategies requires the identification of key molecular pathways regulating chemoresistance. We previously found that abnormal high expression of the Tie2 receptor in gliomas was associated with tumor malignancy. Here, we studied the role of Tie2 activation in drug resistance by testing the cytotoxicity of several chemotherapeutic drugs in a panel of human glioma cell lines and brain tumor stem cells and found that Tie2 activation was significantly related to chemoresistance. The essential role of Tie2 in this phenotype was illustrated by silencing Tie2 using specific siRNA, and the subsequent abrogation of the angiopoietin 1 (Ang1)-mediated chemoresistance. Using quantitative real-time PCR and functional drug efflux studies, we observed that Tie2 activation resulted in increased expression of ATP-binding cassette (ABC) transporters. Consistent with these results, downmodulation of ABCG2 or ABCC2 resulted in the inability of Tie2 activation to induce a chemoresistant phenotype. Our results indicate that Tie2 activation may be important in modifying the evolution of gliomas during conventional chemotherapy regimens, and open new avenues for the search of more effective therapies to avoid the inevitable brain tumor recurrence. Oncogene (2009) 28, 2358-2363; doi:10.1038/onc.2009.103; published online 4 May 2009	[Gomez-Manzano, C.] Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurooncol, Unit 1002, Houston, TX 77030 USA; [Gumin, J.; Lang, F. F.] Univ Texas MD Anderson Canc Ctr, Dept Neurosurg, Houston, TX 77030 USA; [Bhat, K. P.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Gomez-Manzano, C.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Gomez-Manzano, C (corresponding author), Univ Texas MD Anderson Canc Ctr, Brain Tumor Ctr, Dept Neurooncol, Unit 1002, 1515 Holcombe Blvd, Houston, TX 77030 USA.	cmanzano@mdanderson.org	Alonso, Marta M/AAI-9457-2020; Pabbisetty, Sudheer Kumar/H-3338-2019; MARTIN, VANESA/A-7312-2012; Colman, Howard/L-5433-2019	Alonso, Marta M/0000-0002-7520-7351; Pabbisetty, Sudheer Kumar/0000-0001-7490-1352; MARTIN, VANESA/0000-0001-6923-2529; Fueyo, Juan/0000-0001-6941-2335; Gomez-Manzano, Candelaria/0000-0002-1259-2133	Department of Education and Science, Spain; American Brain Tumor Association; Elsa U Pardee Foundation; NIH/Developmental Research Program [P50CA127001]; NATIONAL CANCER INSTITUTE [P50CA127001] Funding Source: NIH RePORTER	Department of Education and Science, Spain; American Brain Tumor Association; Elsa U Pardee Foundation; NIH/Developmental Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Alyson Todd (Department of Scientific Publications, The University of Texas MD Anderson Cancer Center) for editorial assistance. This work was supported by a postdoctoral fellowship from the Department of Education and Science, Spain (to VM), an American Brain Tumor Association postdoctoral fellowship (to DL), Elsa U Pardee Foundation Award (to CGM), and an NIH/Developmental Research Program P50CA127001 (to CGM).	Alonso MM, 2007, CANCER RES, V67, P11499, DOI 10.1158/0008-5472.CAN-07-5312; Arai F, 2004, CELL, V118, P149, DOI 10.1016/j.cell.2004.07.004; Bredel M, 2001, BRAIN RES REV, V35, P161, DOI 10.1016/S0165-0173(01)00045-5; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Decleves X, 2006, CURR CANCER DRUG TAR, V6, P433, DOI 10.2174/156800906777723930; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Jiang H, 2007, J NATL CANCER I, V99, P1410, DOI 10.1093/jnci/djm102; Jin F, 2008, NEUROSCIENCE, V154, P541, DOI 10.1016/j.neuroscience.2008.03.054; Lee OH, 2008, ONCOGENE, V27, P1310, DOI 10.1038/sj.onc.1210731; Lee OH, 2006, MOL CANCER RES, V4, P915, DOI 10.1158/1541-7786.MCR-06-0184; Lu C, 2008, MOL CELL BIOCHEM, V312, P71, DOI 10.1007/s11010-008-9722-8; Martin V, 2008, HISTOL HISTOPATHOL, V23, P773, DOI 10.14670/HH-23.773; Shervington A, 2008, CANCER INVEST, V26, P535, DOI 10.1080/07357900801904140; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Zadeh G, 2004, AM J PATHOL, V164, P467, DOI 10.1016/S0002-9440(10)63137-9; Zhang WD, 2003, FASEB J, V17, P2085, DOI 10.1096/fj.02-1131fje	17	36	40	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2009	28	24					2358	2363		10.1038/onc.2009.103	http://dx.doi.org/10.1038/onc.2009.103			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459GJ	19421150	Green Accepted			2022-12-17	WOS:000267089100006
J	Lau, LMS; Wolter, JK; Lau, JTML; Cheng, LS; Smith, KM; Hansford, LM; Zhang, L; Baruchel, S; Robinson, F; Irwin, MS				Lau, L. M. S.; Wolter, J. K.; Lau, J. T. M. L.; Cheng, L. S.; Smith, K. M.; Hansford, L. M.; Zhang, L.; Baruchel, S.; Robinson, F.; Irwin, M. S.			Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma	ONCOGENE			English	Article						neuroblastoma; COX inhibitor; celecoxib; p73; E2F-1	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; IN-VIVO; UP-REGULATION; HUMAN TUMORS; P53 FAMILY; APOPTOSIS; CELECOXIB; CANCER; EXPRESSION; CELL	p73 encodes multiple functionally distinct isoforms. Proapoptotic TAp73 isoforms contain a transactivation (TA) domain, and like p53, have tumor suppressor properties and are activated by chemotherapies to induce cell death. In contrast, antiapoptotic Delta Np73 isoforms lack the TA domain and are dominant-negative inhibitors of p53 and TAp73. Delta Np73 proteins are overexpressed in a variety of tumors including neuroblastoma. Thus, identification of drugs that upregulate TAp73 and/or downregulate Delta Np73 represents a potential therapeutic strategy. Here, we report that cyclooxygenase (COX) inhibitors induce apoptosis independent of p53, and differentially modulate endogenous p73 isoforms in neuroblastoma and other tumors. COX inhibitor-mediated apoptosis is associated with the induction of TAp73 beta and its target genes. COX inhibitors also downregulate the alternative-spliced Delta Np73(AS) isoforms, Delta exon2 and Delta exon2/3. Furthermore, forced expression of Delta Np73(AS) results in diminished apoptosis in response to the selective COX-2 inhibitor celecoxib. Celecoxib-mediated downregulation of DNp73AS is associated with decreased E2F1 levels and diminished E2F1 activation of the p73 promoter. These results provide the first evidence that COX inhibitors differentially modulate p73 isoforms leading to enhanced apoptosis, and support the potential use of COX inhibitors as novel regulators of p73 to enhance chemosensitivity in tumors with deregulated E2F1 and in those with wild-type (wt) or mutant p53. Oncogene (2009) 28, 2024-2033; doi:10.1038/onc.2009.59; published online 13 April 2009	[Irwin, M. S.] Univ Toronto, MARS Ctr, Div Haematol Oncol, Hosp Sick Children, Toronto, ON M5G 1L7, Canada; [Lau, L. M. S.; Wolter, J. K.; Lau, J. T. M. L.; Cheng, L. S.; Smith, K. M.; Hansford, L. M.; Robinson, F.; Irwin, M. S.] Hosp Sick Children, Res Inst, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Zhang, L.; Baruchel, S.] Hosp Sick Children, Res Inst, Physiol & Expt Med Program, Toronto, ON M5G 1X8, Canada; [Irwin, M. S.] Univ Toronto, Dept Pediat, Inst Med Sci & Lab Med & Pathobiol, Toronto, ON M5G 1L7, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Irwin, MS (corresponding author), Univ Toronto, MARS Ctr, Div Haematol Oncol, Hosp Sick Children, Toronto Med Discovery Tower,101 Coll St, Toronto, ON M5G 1L7, Canada.	meredith.irwin@sickkids.ca	Lau, Loretta MS/B-1565-2008	Lau, Loretta MS/0000-0002-3172-0970; Zhang, Libo/0000-0001-7072-4408; Smith, Kristen/0000-0003-0960-0937	Canadian Cancer Society; National Cancer Institute of Canada (CCS) [019274]; James Fund for Neuroblastoma Research at SickKids Foundation; Lloyd Carr-Harris Foundation; Terry Fox Foundation	Canadian Cancer Society(Canadian Cancer Society (CCS)); National Cancer Institute of Canada (CCS); James Fund for Neuroblastoma Research at SickKids Foundation; Lloyd Carr-Harris Foundation; Terry Fox Foundation	This study was supported by the Canadian Cancer Society and the National Cancer Institute of Canada (CCS Grant no. 019274, MS Irwin), the James Fund for Neuroblastoma Research at SickKids Foundation and Lloyd Carr-Harris Foundation. MS Irwin is a Canada Research Chair in Cancer Biology. L Lau was supported by the Terry Fox Foundation Clinical Research Fellowship (National Cancer Institute of Canada).	Amin ARMR, 2007, CANCER RES, V67, P5617, DOI 10.1158/0008-5472.CAN-07-0655; Balint E, 2002, P NATL ACAD SCI USA, V99, P3529, DOI 10.1073/pnas.062491899; Bock JM, 2007, CANCER RES, V67, P3801, DOI 10.1158/0008-5472.CAN-06-3780; Buhlmann S, 2008, BBA-REV CANCER, V1785, P207, DOI 10.1016/j.bbcan.2008.01.002; Casciano I, 2002, CELL DEATH DIFFER, V9, P246, DOI 10.1038/sj.cdd.4400993; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Dominguez G, 2006, J CLIN ONCOL, V24, P805, DOI 10.1200/JCO.2005.02.2350; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Gonzalez S, 2005, CANCER RES, V65, P2186, DOI 10.1158/0008-5472.CAN-04-3047; Grosch S, 2006, JNCI-J NATL CANCER I, V98, P736, DOI 10.1093/jnci/djj206; Hansford LM, 2007, CANCER RES, V67, P11234, DOI 10.1158/0008-5472.CAN-07-0718; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Irwin MS, 2004, CELL CYCLE, V3, P319; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Johnsen JI, 2004, CANCER RES, V64, P7210, DOI 10.1158/0008-5472.CAN-04-1795; Johnson AJ, 2005, BLOOD, V105, P2504, DOI 10.1182/blood-2004-05-1957; Kashfi K, 2005, BIOCHEM PHARMACOL, V70, P969, DOI 10.1016/j.bcp.2005.05.004; Lau L, 2007, ONCOGENE, V26, P1920, DOI 10.1038/sj.onc.1209981; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Ponthan F, 2007, CLIN CANCER RES, V13, P1036, DOI 10.1158/1078-0432.CCR-06-1908; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Putzer BM, 2007, J CELL MOL MED, V11, P239, DOI 10.1111/j.1582-4934.2007.00030.x; Putzer B, 2003, CELL DEATH DIFFER, V10, P612, DOI 10.1038/sj.cdd.4401205; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Stempak D, 2002, CLIN PHARMACOL THER, V72, P490, DOI 10.1067/mcp.2002.129322; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Xue C, 2007, CANCER RES, V67, P10351, DOI 10.1158/0008-5472.CAN-06-4345; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zhu JX, 2004, CANCER RES, V64, P4309, DOI 10.1158/0008-5472.CAN-03-4063	34	36	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2009	28	19					2024	2033		10.1038/onc.2009.59	http://dx.doi.org/10.1038/onc.2009.59			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445BF	19363520				2022-12-17	WOS:000266023900003
J	Thomas, WD; Chen, J; Gao, YR; Cheung, B; Koach, J; Sekyere, E; Norris, MD; Haber, M; Ellis, T; Wainwright, B; Marshall, GM				Thomas, W. D.; Chen, J.; Gao, Y. R.; Cheung, B.; Koach, J.; Sekyere, E.; Norris, M. D.; Haber, M.; Ellis, T.; Wainwright, B.; Marshall, G. M.			Patched1 deletion increases N-Myc protein stability as a mechanism of medulloblastoma initiation and progression	ONCOGENE			English	Article						N-Myc; PP2A-B56; Sonic Hedgehog; medulloblastoma; initiation; Myc	HEDGEHOG-INDUCED MEDULLOBLASTOMA; EXTERNAL GRANULAR LAYER; C-MYC; SONIC HEDGEHOG; GENE-EXPRESSION; NEURONAL PRECURSORS; MICE; PROLIFERATION; CEREBELLUM; PATHWAY	Medulloblastoma tumorigenesis caused by inactivating mutations in the PATCHED1 (PTCH1) gene is initiated by persistently activated Sonic Hedgehog (Shh) signaling in granule neuron precursors (GNPs) during the late stages of cerebellar development. Both normal cerebellar development and Shh-driven medulloblastoma tumorigenesis require N-Myc expression. However, the mechanisms by which N-Myc affects the stages of medulloblastoma initiation and progression are unknown. Here we used a mouse model of Ptch1 heterozygosity and medulloblastoma to show that increased N-Myc expression characterized the earliest selection of focal GNP hyperplasia destined for later tumor progression. Step-wise loss of Ptch1 expression, from tumor initiation to progression, led to incremental increases in N-Myc protein, rather than mRNA, expression. Increased N-Myc resulted in enhanced proliferation and death resistance of perinatal GNPs at tumor initiation. Sequential N-Myc protein phosphorylation at serine-62 and serine-62/threonine-58 characterized the early and late stages of medulloblastoma tumorigenesis, respectively. Shh pathway activation led to increased Myc protein stability and reduced expression of key regulatory factors. Taken together our data identify N-Myc protein stability as the result of loss of Ptch1, which distinguishes normal cerebellar development from medulloblastoma tumorigenesis.	[Marshall, G. M.] Childrens Canc Inst Australia Med Res, Mol Carcinogenesis Program, Randwick, NSW 2031, Australia; [Ellis, T.; Wainwright, B.] Univ Queensland, Inst Mol Biosci, Brisbane, Qld, Australia; [Marshall, G. M.] Prince Wales Childrens Hosp, Ctr Childrens Canc & Blood Disorders, Randwick, NSW 2031, Australia	Children's Cancer Institute; University of Queensland	Marshall, GM (corresponding author), Childrens Canc Inst Australia Med Res, Mol Carcinogenesis Program, POB 81, Randwick, NSW 2031, Australia.	Glenn.Marshall@SESIAHS.HEALTH.NSW.GOV.AU	Chen, Jinbiao/N-9905-2019; Chen, Jinbiao/J-5868-2013	Chen, Jinbiao/0000-0003-0339-5880; Chen, Jinbiao/0000-0003-0339-5880; Norris, Murray/0000-0002-0632-4589; Wainwright, Brandon/0000-0003-0406-2092; Haber, Michelle/0000-0003-2036-8817; Cheung, Belamy/0000-0001-8784-860X	Cure For Life Foundation; Cure Cancer Australia Foundation; National Health and Medical Research Council; Cancer Institute New South Wales; John Trivett Foundation; The Children's Cancer Institute Australia; University of New South Wales; Sydney Children's Hospital	Cure For Life Foundation; Cure Cancer Australia Foundation; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute New South Wales; John Trivett Foundation; The Children's Cancer Institute Australia; University of New South Wales; Sydney Children's Hospital	This work was supported by funds from the Cure For Life Foundation (WT), the Cure Cancer Australia Foundation (WT), the National Health and Medical Research Council (Australia; GMM, MDN, BW and MH), the Cancer Institute New South Wales (Australia; GMM, MDN and MH) and John Trivett Foundation (TE). The Children's Cancer Institute Australia for Medical Research is affiliated with the University of New South Wales and Sydney Children's Hospital.	Arnold HK, 2006, MOL CELL BIOL, V26, P2832, DOI 10.1128/MCB.26.7.2832-2844.2006; Arnold HK, 2008, CANCER METAST REV, V27, P147, DOI 10.1007/s10555-008-9128-9; Bahram F, 2000, BLOOD, V95, P2104, DOI 10.1182/blood.V95.6.2104; Barnes EA, 2005, ONCOGENE, V24, P902, DOI 10.1038/sj.onc.1208240; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Browd SR, 2006, CANCER RES, V66, P2666, DOI 10.1158/0008-5472.CAN-05-2198; Corcoran RB, 2001, J NEURO-ONCOL, V53, P307, DOI 10.1023/A:1012260318979; Corrales JD, 2006, DEVELOPMENT, V133, P1811, DOI 10.1242/dev.02351; Dahmane N, 1999, DEVELOPMENT, V126, P3089; Dang CV, 1999, MOL CELL BIOL, V19, P1; Eberhart CG, 2004, J NEUROPATH EXP NEUR, V63, P441, DOI 10.1093/jnen/63.5.441; Ellis T, 2003, GENESIS, V36, P158, DOI 10.1002/gene.10208; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 2008, CANCER RES, V68, P3081, DOI 10.1158/0008-5472.CAN-07-5832; FERRER I, 1992, PROG NEUROBIOL, V39, P1, DOI 10.1016/0301-0082(92)90029-E; Fogarty MP, 2005, J NEUROBIOL, V64, P458, DOI 10.1002/neu.20166; GARSON JA, 1989, BRIT J CANCER, V59, P889, DOI 10.1038/bjc.1989.188; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Haber M, 1999, ONCOGENE, V18, P2777, DOI 10.1038/sj.onc.1202859; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; Hansford LM, 2004, P NATL ACAD SCI USA, V101, P12664, DOI 10.1073/pnas.0401083101; Hatton BA, 2008, CANCER RES, V68, P1768, DOI 10.1158/0008-5472.CAN-07-5092; Hatton BA, 2006, CANCER RES, V66, P8655, DOI 10.1158/0008-5472.CAN-06-1621; Junttila MR, 2007, CELL, V130, P51, DOI 10.1016/j.cell.2007.04.044; KADIN ME, 1970, J NEUROPATH EXP NEUR, V29, P583, DOI 10.1097/00005072-197010000-00005; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kim JYH, 2003, DEV BIOL, V263, P50, DOI 10.1016/S0012-1606(03)00434-2; Knoepfler PS, 2006, CELL CYCLE, V5, P47, DOI 10.4161/cc.5.1.2292; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOPPEL H, 1983, NEUROPATH APPL NEURO, V9, P207, DOI 10.1111/j.1365-2990.1983.tb00108.x; Lelievre V, 2008, DEV BIOL, V313, P359, DOI 10.1016/j.ydbio.2007.10.031; Lossi L, 2003, PROG NEUROBIOL, V69, P287, DOI 10.1016/S0301-0082(03)00051-0; Lum L, 2004, SCIENCE, V304, P1755, DOI 10.1126/science.1098020; Moriuchi S, 1996, ANTICANCER RES, V16, P2687; Murone M, 1999, CURR BIOL, V9, P76, DOI 10.1016/S0960-9822(99)80018-9; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oliver TG, 2005, DEVELOPMENT, V132, P2425, DOI 10.1242/dev.01793; Oliver TG, 2003, P NATL ACAD SCI USA, V100, P7331, DOI 10.1073/pnas.0832317100; Pizzo P.A., 2002, PRINCIPLES PRACTICE, V4th; Pomeroy SL, 2002, NATURE, V415, P436, DOI 10.1038/415436a; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Pritchard JI, 2008, CANCER GENET CYTOGEN, V180, P47, DOI 10.1016/j.cancergencyto.2007.09.008; Romer JT, 2004, CANCER CELL, V6, P229, DOI 10.1016/j.ccr.2004.08.019; RUIZ IAA, 2004, CANC LETT, V204, P145; Sasai K, 2006, CANCER RES, V66, P4215, DOI 10.1158/0008-5472.CAN-05-4505; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Smith DP, 2006, BLOOD, V108, P653, DOI 10.1182/blood-2006-01-0172; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; Wechsler-Reya RJ, 2003, RECENT PROG HORM RES, V58, P227, DOI 10.1210/rp.58.1.227; Wetmore C, 2000, CANCER RES, V60, P2239; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; ZAKHARY R, 2001, BRAIN TUMORS ENCY AP, P605	57	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2009	28	13					1605	1615		10.1038/onc.2009.3	http://dx.doi.org/10.1038/onc.2009.3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427LJ	19234491				2022-12-17	WOS:000264780500005
J	Vecchione, A; Fassan, M; Anesti, V; Morrione, A; Goldoni, S; Baldassarre, G; Byrne, D; D'Arca, D; Palazzo, JP; Lloyd, J; Scorrano, L; Gomella, LG; Iozzo Renato, V; Baffa, R				Vecchione, A.; Fassan, M.; Anesti, V.; Morrione, A.; Goldoni, S.; Baldassarre, G.; Byrne, D.; D'Arca, D.; Palazzo, J. P.; Lloyd, J.; Scorrano, L.; Gomella, L. G.; Iozzo Renato, V.; Baffa, R.			MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancer	ONCOGENE			English	Article						bladder cancer; breast cancer; mitochondria; chromosome 12q; tumor suppressor	COMPARATIVE GENOMIC HYBRIDIZATION; HEAT-SHOCK-PROTEIN; GROWTH-FACTOR RECEPTOR; SMALL STRESS-PROTEINS; PROSTATE-CANCER; CELL CARCINOMA; ANDROGEN ABLATION; BINDING PROTEIN; IN-VIVO; HSP27	Allelic deletions on human chromosome 12q24 are frequently reported in a variety of malignant neoplasms, indicating the presence of a tumor suppressor gene(s) in this chromosomal region. However, no reasonable candidate has been identified so far. In this study, we report the cloning and functional characterization of a novel mitochondrial protein with tumor suppressor activity, henceforth designated MITOSTATIN. Human MITOSTATIN was found within a 3.2-kb transcript, which encoded a similar to 62 kDa, ubiquitously expressed protein with little homology to any known protein. We found homozygous deletions and mutations of MITOSTATIN gene in similar to 5 and similar to 11% of various cancer-derived cells and solid tumors, respectively. When transiently overexpressed, MITOSTATIN inhibited colony formation, tumor cell growth and was proapoptotic, all features shared by established tumor suppressor genes. We discovered a specific link between MITOSTATIN overexpression and downregulation of Hsp27. Conversely, MITOSTATIN knockdown cells showed an increase in cell growth and cell survival rates. Finally, MITOSTATIN expression was significantly reduced in primary bladder and breast tumors, and its reduction was associated with advanced tumor stages. Our findings support the hypothesis that MITOSTATIN has many hallmarks of a classical tumor suppressor in solid tumors and may play an important role in cancer development and progression.	[Vecchione, A.; Fassan, M.; Morrione, A.; Byrne, D.; D'Arca, D.; Gomella, L. G.; Baffa, R.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Urol, Philadelphia, PA 19107 USA; [Anesti, V.; Scorrano, L.] Venetian Inst Mol Med, Dulbecco Telethon Inst, Padua, Italy; [Goldoni, S.; Palazzo, J. P.; Lloyd, J.; Iozzo Renato, V.] Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA; [Baldassarre, G.] CRO IRCCS, Div Expt Oncol 2, Aviano, Italy	Jefferson University; Fondazione Telethon; Dulbecco Telethon Institute (DTI); Veneto Institute Molecular Medicine; Jefferson University; IRCCS Aviano (CRO)	Baffa, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Urol, 233 S 10th St,BLSB 526, Philadelphia, PA 19107 USA.	R_Baffa@mail.jci.tju.edu	Scorrano, Luca/K-3967-2019; Fassan, Matteo/F-5152-2012; Scorrano, Luca/A-6652-2008; Baldassarre, Gustavo/K-1350-2016; D'Arca, Domenico/B-9212-2016	Scorrano, Luca/0000-0002-8515-8928; Fassan, Matteo/0000-0001-6515-5482; Scorrano, Luca/0000-0002-8515-8928; Baldassarre, Gustavo/0000-0002-9750-8825; D'Arca, Domenico/0000-0002-7240-6005; Vecchione, Andrea/0000-0002-5497-6856; Iozzo, Renato/0000-0002-5908-5112	Sidney Kimmel Foundation for Cancer Research; Benjamin Perkins Bladder Cancer Fund; Martin Greitzer Fund; Telethon Italy; AIRC Italy; National Institutes of Health [RO1 CA39481, RO1 CA47282, RO1 CA120975, RO1 DK068419]; NATIONAL CANCER INSTITUTE [R01CA120975, R01CA039481, R01CA047282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK068419] Funding Source: NIH RePORTER	Sidney Kimmel Foundation for Cancer Research; Benjamin Perkins Bladder Cancer Fund; Martin Greitzer Fund; Telethon Italy(Fondazione Telethon); AIRC Italy(Fondazione AIRC per la ricerca sul cancro); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Florencia Bullrich for the FISH analysis, Jonathan Brody for providing CAPAN1 cells and Jason Zoeller for help with the phylogenetic tree. Dr Scorrano is a Senior Scientist of the Dulbecco-Telethon Institute. GenBank = GenBank accession number AY007230. NCBI Protein Database = NCB accession number AAG12971. This study was in part supported by the Sidney Kimmel Foundation for Cancer Research, the Benjamin Perkins Bladder Cancer Fund and the Martin Greitzer Fund (to RB), by Telethon Italy and AIRC Italy (to LS), the National Institutes of Health Grants RO1 CA39481, RO1 CA47282 and RO1 CA120975 (to RVI), RO1 DK068419 ( to AM).	Anesti V, 2006, BBA-BIOENERGETICS, V1757, P692, DOI 10.1016/j.bbabio.2006.04.013; Aubele M, 1999, CANCER GENET CYTOGEN, V110, P94, DOI 10.1016/S0165-4608(98)00205-2; Aubele MM, 2000, DIAGN MOL PATHOL, V9, P14, DOI 10.1097/00019606-200003000-00003; BOURGERON T, 1992, BIOCHEM BIOPH RES CO, V186, P16, DOI 10.1016/S0006-291X(05)80769-7; Bruey JM, 2000, ONCOGENE, V19, P4855, DOI 10.1038/sj.onc.1203850; Cereghetti GM, 2006, ONCOGENE, V25, P4717, DOI 10.1038/sj.onc.1209605; Cornford PA, 2000, CANCER RES, V60, P7099; Csordas G, 2000, J BIOL CHEM, V275, P32879, DOI 10.1074/jbc.M005609200; De Vos K, 1998, J BIOL CHEM, V273, P9673, DOI 10.1074/jbc.273.16.9673; Dimmer KS, 2008, HUM MOL GENET, V17, P201, DOI 10.1093/hmg/ddm297; EHRENFRIED JA, 1995, SURG ONCOL, V4, P197, DOI 10.1016/S0960-7404(10)80036-2; FIELD JK, 1995, BRIT J CANCER, V72, P1180, DOI 10.1038/bjc.1995.483; Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200; Goldoni S, 2007, ONCOGENE, V26, P368, DOI 10.1038/sj.onc.1209803; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Jiang F, 1998, AM J PATHOL, V153, P1467, DOI 10.1016/S0002-9440(10)65734-3; Kamada M, 2007, MOL CANCER THER, V6, P299, DOI 10.1158/1535-7163.MCT-06-0417; Kimura M, 1998, CANCER RES, V58, P2456; Knudson AG, 2000, ANNU REV GENET, V34, P1, DOI 10.1146/annurev.genet.34.1.1; Koo SH, 1999, CANCER GENET CYTOGEN, V110, P87, DOI 10.1016/S0165-4608(98)00193-9; Langdon SP, 1995, CLIN CANCER RES, V1, P1603; Lebret T, 2003, CANCER, V98, P970, DOI 10.1002/cncr.11594; LOVE S, 1994, BRIT J CANCER, V69, P743, DOI 10.1038/bjc.1994.140; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Monami G, 2006, CANCER RES, V66, P7103, DOI 10.1158/0008-5472.CAN-06-0633; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; Nishizawa M, 2005, J CELL SCI, V118, P1081, DOI 10.1242/jcs.01667; Parcellier A, 2003, MOL CELL BIOL, V23, P5790, DOI 10.1128/MCB.23.16.5790-5802.2003; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Rijken AM, 1999, GENE CHROMOSOME CANC, V26, P185, DOI 10.1002/(SICI)1098-2264(199911)26:3<185::AID-GCC1>3.0.CO;2-9; Rocchi P, 2005, CANCER RES, V65, P11083, DOI 10.1158/0008-5472.CAN-05-1840; Rocchi P, 2004, CANCER RES, V64, P6595, DOI 10.1158/0008-5472.CAN-03-3998; Santra M, 1997, J CLIN INVEST, V100, P149, DOI 10.1172/JCI119507; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; Sattler HP, 1999, PROSTATE, V39, P79; Schmutte C, 1997, CANCER RES, V57, P3010; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Takashi M, 1998, UROL RES, V26, P395, DOI 10.1007/s002400050075; Tirkkonen M, 1997, CANCER RES, V57, P1222; Vecchione A, 2002, AM J PATHOL, V160, P1345, DOI 10.1016/S0002-9440(10)62561-8; Xu GX, 2002, BIOL REPROD, V67, P681, DOI 10.1095/biolreprod67.2.681	43	36	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2009	28	2					257	269		10.1038/onc.2008.381	http://dx.doi.org/10.1038/onc.2008.381			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	395CY	18931701	Green Submitted, Green Accepted, Green Published			2022-12-17	WOS:000262501100009
J	Zalzali, H; Naudin, C; Bastide, P; Quittau-Prevostel, C; Yaghi, C; Poulat, F; Jay, P; Blache, P				Zalzali, H.; Naudin, C.; Bastide, P.; Quittau-Prevostel, C.; Yaghi, C.; Poulat, F.; Jay, P.; Blache, P.			CEACAM1, a SOX9 direct transcriptional target identified in the colon epithelium	ONCOGENE			English	Article						CEACAM1; colon epithelium; SOX9	CARCINOEMBRYONIC ANTIGEN; GENE; EXPRESSION; ENHANCER; PROTEIN; CELLS; MODEL	A deletion of the transcription factor SOX9 gene in the mice intestine affects the morphology of the colon epithelium and leads to hyperplasia. Nevertheless, direct transcriptional targets of SOX9 in this tissue are still unknown. A microarray analysis identified the tumor suppressor carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) as a possible SOX9 target gene and we demonstrate here that SOX9 upregulates CEACAM1 in human colonic cells. Moreover, CEACAM1 expression is reduced in colon of SOX9-deficient mouse, suggesting an important function for SOX9 in the transcriptional activation of the CEACAM1 gene. We further identified SOX9-binding sequences in the human and rat CEACAM1 promoters, and an electrophoretic mobility shift together with a chromatin immunoprecipitation provided an additional evidence of the SOX9 binding to the human promoter. In addition, we established that histone acyl-transferase p300 behaves as an SOX9 coactivator of the rat and human CEACAM1 promoters. These results highlight CEACAM1 as the first direct target of SOX9 identified in the colon epithelium.	[Blache, P.] Univ Montpellier, CNRS, UMR 5203, Inst Genome Fonct, F-34094 Montpellier 5, France; [Zalzali, H.; Naudin, C.; Bastide, P.; Quittau-Prevostel, C.; Jay, P.; Blache, P.] INSERM, U661, Montpellier, France; [Zalzali, H.; Naudin, C.; Bastide, P.; Quittau-Prevostel, C.; Jay, P.; Blache, P.] Univ Montpellier 1, Montpellier, France; [Yaghi, C.] Univ St Joseph Achrafieh, Serv Gastroenterol, CHU Hotel Dieu France, Beirut, Lebanon; [Poulat, F.] Inst Genet Humaine, CNRS, UPR 1142, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Blache, P (corresponding author), Univ Montpellier, CNRS, UMR 5203, Inst Genome Fonct, 141 Rue Cardonille, F-34094 Montpellier 5, France.	philippe.blache@igf.cnrs.fr	Jay, Philippe/ABD-9223-2020; POULAT, FRANCIS/AAV-2170-2020; Prevostel, Corinne/AAO-1433-2020; Jay, Philippe/I-7116-2016	Jay, Philippe/0000-0003-0156-5700; POULAT, FRANCIS/0000-0003-2070-1296; Jay, Philippe/0000-0003-0156-5700; Yaghi, Cesar/0000-0003-4130-2606; PREVOSTEL, Corinne/0000-0002-7553-087X	Agence Nationale pour la Recherche; Association pour la Recherche contre le Cancer [3570, 3636]; Ligue Nationale contre le Cancer (Equipe Labellisee); Fondation pour la Recherche Medicale; Groupement des Entreprises Francaises dans la Lutte contre le Cancer; National Council for Scientific Research Lebanon	Agence Nationale pour la Recherche(French National Research Agency (ANR)); Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue Nationale contre le Cancer (Equipe Labellisee)(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Groupement des Entreprises Francaises dans la Lutte contre le Cancer; National Council for Scientific Research Lebanon	This work was supported by Agence Nationale pour la Recherche, Association pour la Recherche contre le Cancer (nos. 3570 and 3636), Ligue Nationale contre le Cancer (Equipe Labellisee), Fondation pour la Recherche Medicale, Groupement des Entreprises Francaises dans la Lutte contre le Cancer and the National Council for Scientific Research Lebanon. We thank Dr Horst and Dr Beauchemin for the anti-CEACAM1 antibodies, Dr Najjar and Dr Beauchemin for the luciferase reporter.	Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152; Blache P, 2004, J CELL BIOL, V166, P37, DOI 10.1083/jcb.200311021; Chen CJ, 1996, J BIOL CHEM, V271, P28181, DOI 10.1074/jbc.271.45.28181; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; HAUCK W, 1994, EUR J BIOCHEM, V223, P529, DOI 10.1111/j.1432-1033.1994.tb19022.x; Hemmila E, 2004, J VIROL, V78, P10156, DOI 10.1128/JVI.78.18.10156-10165.2004; Jay P, 2005, CANCER RES, V65, P2193, DOI 10.1158/0008-5472.CAN-04-1484; Jenkins E, 2005, MATRIX BIOL, V24, P177, DOI 10.1016/j.matbio.2005.02.004; Kuespert K, 2006, CURR OPIN CELL BIOL, V18, P565, DOI 10.1016/j.ceb.2006.08.008; Leung N, 2006, ONCOGENE, V25, P5527, DOI 10.1038/sj.onc.1209541; Lu BJ, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-40; Mertin S, 1999, NUCLEIC ACIDS RES, V27, P1359, DOI 10.1093/nar/27.5.1359; Najjar SM, 1996, J BIOL CHEM, V271, P8809, DOI 10.1074/jbc.271.15.8809; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Notarnicola C, 2006, GENE EXPR PATTERNS, V6, P695, DOI 10.1016/j.modgep.2006.01.001; Tsuda M, 2003, J BIOL CHEM, V278, P27224, DOI 10.1074/jbc.M303471200; WAGENER C, 1983, J IMMUNOL, V130, P2308; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989	18	36	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2008	27	56					7131	7138		10.1038/onc.2008.331	http://dx.doi.org/10.1038/onc.2008.331			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376PQ	18794798				2022-12-17	WOS:000261195900007
J	Hishiya, A; Takayama, S				Hishiya, A.; Takayama, S.			Molecular chaperones as regulators of cell death	ONCOGENE			English	Review						heat-shock proteins; Hsp27; Hsp70; Hsp90; molecular chaperone; co-chaperone	HEAT-SHOCK-PROTEIN; ALPHA-B-CRYSTALLIN; ENDOPLASMIC-RETICULUM STRESS; ISCHEMIA-REPERFUSION INJURY; TRANSGENIC MOUSE MODEL; DOMINANT CONGENITAL CATARACT; TRUNCATED ANDROGEN RECEPTOR; MARINESCO-SJOGREN-SYNDROME; POSTERIOR POLAR CATARACT; FOCAL CEREBRAL-ISCHEMIA	Molecular chaperones have been reported as multifunctional antistress molecules that can regulate diverse biological processes to maintain cellular homeostasis. Molecular chaperones have critical roles for maintaining proper protein folding, protein translocation, degradation of unfolded protein, regulating signal-transduction proteins and so on. Under pathological conditions, inducible or constitutively expressed molecular chaperones protect cells from stress. Non-dividing terminally differentiated cells accumulate abnormal proteins due to chronic environmental or physiological stress; thus, proper chaperone function is critical for maintaining homeostasis of those cells, such as neuronal and muscular cells. Cancer cells also have overexpression of molecular chaperone proteins for promoting survival from stress related to growth, cell cycle, hypoxia, metastasis and genetic mutations. Here, we will focus on the function of molecular chaperone proteins for the regulation of cell death in degenerative diseases, ischemic diseases and in cancer.	[Hishiya, A.; Takayama, S.] Boston Biomed Res Inst, Cardiovasc Program, Watertown, MA 02472 USA	Boston Biomedical Research Institute	Takayama, S (corresponding author), Boston Biomed Res Inst, Cardiovasc Program, 64 Grove St, Watertown, MA 02472 USA.	takayama@bbri.org						Adachi H, 2003, J NEUROSCI, V23, P2203; Adachi H, 2007, J NEUROSCI, V27, P5115, DOI 10.1523/JNEUROSCI.1242-07.2007; Aghdassi A, 2007, CANCER RES, V67, P616, DOI 10.1158/0008-5472.CAN-06-1567; Al-Ramahi I, 2006, J BIOL CHEM, V281, P26714, DOI 10.1074/jbc.M601603200; An JJ, 2008, FEBS J, V275, P1296, DOI 10.1111/j.1742-4658.2008.06291.x; Anttonen AK, 2005, NAT GENET, V37, P1309, DOI 10.1038/ng1677; Arndt V, 2005, MOL BIOL CELL, V16, P5891, DOI 10.1091/mbc.E05-07-0660; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bailey CK, 2002, HUM MOL GENET, V11, P515, DOI 10.1093/hmg/11.5.515; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Berry V, 2001, AM J HUM GENET, V69, P1141, DOI 10.1086/324158; Blagosklonny MV, 1996, P NATL ACAD SCI USA, V93, P8379, DOI 10.1073/pnas.93.16.8379; Boeri D, 2003, EUR J CLIN INVEST, V33, P500, DOI 10.1046/j.1365-2362.2003.01157.x; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Boyle Daniel L, 2003, BMC Ophthalmol, V3, P3, DOI 10.1186/1471-2415-3-3; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Bu L, 2002, NAT GENET, V31, P276, DOI 10.1038/ng921; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; CAIGNARD A, 1985, INT J CANCER, V36, P273, DOI 10.1002/ijc.2910360221; Carra S, 2008, J BIOL CHEM, V283, P1437, DOI 10.1074/jbc.M706304200; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Chai YH, 1999, J NEUROSCI, V19, P10338; Chauhan D, 2003, BLOOD, V102, P3379, DOI 10.1182/blood-2003-05-1417; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Christians E, 2000, NATURE, V407, P693, DOI 10.1038/35037669; Chun W, 2002, FEBS LETT, V515, P61, DOI 10.1016/S0014-5793(02)02436-5; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Cummings CJ, 2001, HUM MOL GENET, V10, P1511, DOI 10.1093/hmg/10.14.1511; Dai Q, 2005, J BIOL CHEM, V280, P38673, DOI 10.1074/jbc.M507986200; Dai Q, 2003, EMBO J, V22, P5446, DOI 10.1093/emboj/cdg529; Dedmon MM, 2005, J BIOL CHEM, V280, P14733, DOI 10.1074/jbc.m413024200; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; Denzel A, 2002, MOL CELL BIOL, V22, P7398, DOI 10.1128/MCB.22.21.7398-7404.2002; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; Dickey CA, 2006, FASEB J, V20, P753, DOI 10.1096/fj.05-5343fje; DILLMANN WH, 1986, CIRC RES, V59, P110, DOI 10.1161/01.RES.59.1.110; Dix DJ, 1996, P NATL ACAD SCI USA, V93, P3264, DOI 10.1073/pnas.93.8.3264; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; Efthymiou CA, 2004, BASIC RES CARDIOL, V99, P392, DOI 10.1007/s00395-004-0483-6; Eizirik DL, 2008, ENDOCR REV, V29, P42, DOI 10.1210/er.2007-0015; Ekegren T, 1999, ACTA NEUROL SCAND, V100, P317; Elliott E, 2007, J BIOL CHEM, V282, P37276, DOI 10.1074/jbc.M706379200; Evans CG, 2006, J BIOL CHEM, V281, P33182, DOI 10.1074/jbc.M606192200; Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354; Fares MA, 2002, NATURE, V417, P398, DOI 10.1038/417398a; Fernandez-Chacon R, 2004, NEURON, V42, P237, DOI 10.1016/S0896-6273(04)00190-4; Florin L, 2004, J VIROL, V78, P5546, DOI 10.1128/JVI.78.11.5546-5553.2004; Fujimoto M, 2004, EMBO J, V23, P4297, DOI 10.1038/sj.emboj.7600435; Fujimoto M, 2005, J BIOL CHEM, V280, P34908, DOI 10.1074/jbc.M506288200; Garrido C, 1999, FASEB J, V13, P2061, DOI 10.1096/fasebj.13.14.2061; Garrido C, 1998, CANCER RES, V58, P5495; Gaspary H, 1995, MOL BRAIN RES, V34, P327, DOI 10.1016/0169-328X(95)00195-X; Giffard RG, 2004, J EXP BIOL, V207, P3213, DOI 10.1242/jeb.01034; Gotz R, 2005, NAT NEUROSCI, V8, P1169, DOI 10.1038/nn1524; Grad I, 2006, MOL CELL BIOL, V26, P8976, DOI 10.1128/MCB.00734-06; Gu F, 2008, HUM MUTAT, V29, P769, DOI 10.1002/humu.20724; Gupta S, 2002, CIRCULATION, V106, P2727, DOI 10.1161/01.CIR.0000038112.64503.6E; Hansen JJ, 2002, AM J HUM GENET, V70, P1328, DOI 10.1086/339935; Hansson O, 2003, BRAIN RES, V970, P47, DOI 10.1016/S0006-8993(02)04275-0; Hartmann A, 2001, J NEUROSCI, V21, P2247, DOI 10.1523/JNEUROSCI.21-07-02247.2001; Hata R, 1999, METAB BRAIN DIS, V14, P117, DOI 10.1023/A:1020709814456; Hatakeyama S, 2004, J NEUROCHEM, V91, P299, DOI 10.1111/j.1471-4159.2004.02713.x; Havasi A, 2008, J BIOL CHEM, V283, P12305, DOI 10.1074/jbc.M801291200; Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144; Hayashi M, 2006, NAT MED, V12, P128, DOI 10.1038/nm1327; Held T, 2006, MOL CELL BIOL, V26, P8099, DOI 10.1128/MCB.01332-06; Helmlinger D, 2004, J BIOL CHEM, V279, P55969, DOI 10.1074/jbc.M409062200; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; Homma S, 2007, J NEUROSCI, V27, P7974, DOI 10.1523/JNEUROSCI.0006-07.2007; Homma S, 2006, AM J PATHOL, V169, P761, DOI 10.2353/ajpath.2006.060250; Hosaka S, 2006, CANCER SCI, V97, P623, DOI 10.1111/j.1349-7006.2006.00217.x; Howarth JL, 2007, MOL THER, V15, P1100, DOI 10.1038/sj.mt.6300163; Hu BR, 2000, J NEUROSCI, V20, P3191, DOI 10.1523/JNEUROSCI.20-09-03191.2000; Huang L, 2001, MOL CELL BIOL, V21, P8575, DOI 10.1128/MCB.21.24.8575-8591.2001; Huang L, 2007, GENESIS, V45, P487, DOI 10.1002/dvg.20319; Hunter PJ, 1999, DEVELOPMENT, V126, P1247; Hwang IK, 2007, EXP NEUROL, V208, P247, DOI 10.1016/j.expneurol.2007.08.017; Hwang JR, 2005, CELL STRESS CHAPERON, V10, P147, DOI 10.1379/CSC-90R.1; Ikawa M, 1997, NATURE, V387, P607, DOI 10.1038/42484; Irobi J, 2004, NAT GENET, V36, P597, DOI 10.1038/ng1328; Ishihara K, 2003, J BIOL CHEM, V278, P25143, DOI 10.1074/jbc.M302975200; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jana NR, 2005, J BIOL CHEM, V280, P11635, DOI 10.1074/jbc.M412042200; Jana NR, 2005, NEUROSCI LETT, V378, P171, DOI 10.1016/j.neulet.2004.12.031; Jones EL, 2004, INT J HYPERTHER, V20, P835, DOI 10.1080/02656730410001721807; Kalinowska M, 2005, APOPTOSIS, V10, P821, DOI 10.1007/s10495-005-0410-9; Kallio M, 2002, EMBO J, V21, P2591, DOI 10.1093/emboj/21.11.2591; Kaur J, 2000, INT J CANCER, V85, P1; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kelly S, 2002, ANN NEUROL, V52, P160, DOI 10.1002/ana.10264; Kieran D, 2004, NAT MED, V10, P402, DOI 10.1038/nm1021; Kim HE, 2008, MOL CELL, V30, P239, DOI 10.1016/j.molcel.2008.03.014; KINOUCHI H, 1993, BRAIN RES, V619, P334, DOI 10.1016/0006-8993(93)91630-B; Kitagawa K, 1998, STROKE, V29, P2616, DOI 10.1161/01.STR.29.12.2616; Kitamura A, 2006, NAT CELL BIOL, V8, P1163, DOI 10.1038/ncb1478; Klucken J, 2004, J BIOL CHEM, V279, P25497, DOI 10.1074/jbc.M400255200; KNOWLTON AA, 1991, J CLIN INVEST, V87, P139, DOI 10.1172/JCI114963; Kobayashi Y, 2000, J BIOL CHEM, V275, P8772, DOI 10.1074/jbc.275.12.8772; Kuboki S, 2007, AM J PHYSIOL-GASTR L, V292, pG1141, DOI 10.1152/ajpgi.00491.2006; Kumar LVS, 1999, J BIOL CHEM, V274, P24137, DOI 10.1074/jbc.274.34.24137; Ladiges WC, 2005, DIABETES, V54, P1074, DOI 10.2337/diabetes.54.4.1074; Lau S, 1997, CIRCULATION, V96, P2287; Lee S, 2005, PROTEIN SCI, V14, P593, DOI 10.1110/ps.041020705; Lee SH, 2004, STROKE, V35, P2195, DOI 10.1161/01.STR.0000136150.73891.14; Lee SH, 2001, STROKE, V32, P2905, DOI 10.1161/hs1201.099604; Li H, 2008, BBA-MOL BASIS DIS, V1782, P303, DOI 10.1016/j.bbadis.2008.01.011; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Li MW, 2000, SCIENCE, V288, P335, DOI 10.1126/science.288.5464.335; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Litt M, 1998, HUM MOL GENET, V7, P471, DOI 10.1093/hmg/7.3.471; Liu J, 2005, J NEUROCHEM, V93, P875, DOI 10.1111/j.1471-4159.2005.03054.x; Liu MG, 2006, INVEST OPHTH VIS SCI, V47, P3461, DOI 10.1167/iovs.05-1438; Liu YZ, 2006, INVEST OPHTH VIS SCI, V47, P1069, DOI 10.1167/iovs.05-1004; Lo JF, 2004, MOL CELL BIOL, V24, P2226, DOI 10.1128/MCB.24.6.2226-2236.2004; Lu AG, 2002, J NEUROCHEM, V81, P355, DOI 10.1046/j.1471-4159.2002.00835.x; Luo SZ, 2006, MOL CELL BIOL, V26, P5688, DOI 10.1128/MCB.00779-06; Mackay DS, 2003, EUR J HUM GENET, V11, P784, DOI 10.1038/sj.ejhg.5201046; Magrane J, 2004, J NEUROSCI, V24, P1700, DOI 10.1523/JNEUROSCI.4330-03.2004; Maisnier-Patin S, 2005, NAT GENET, V37, P1376, DOI 10.1038/ng1676; Maloyan A, 2005, CIRCULATION, V112, P3451, DOI 10.1161/CIRCULATIONAHA.105.572552; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; MARBER MS, 1994, J CLIN INVEST, V93, P1087, DOI 10.1172/JCI117059; MARTIN F, 1983, INT J CANCER, V32, P623, DOI 10.1002/ijc.2910320517; Martin LJ, 1999, J NEUROPATH EXP NEUR, V58, P459, DOI 10.1097/00005072-199905000-00005; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; Matsui H, 2007, MOL CELL, V25, P99, DOI 10.1016/j.molcel.2006.12.007; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; McMillan DR, 2002, MOL CELL BIOL, V22, P8005, DOI 10.1128/MCB.22.22.8005-8014.2002; MEHTA HB, 1988, CIRC RES, V63, P512, DOI 10.1161/01.RES.63.3.512; Meldrum KK, 2003, CIRC RES, V92, P293, DOI 10.1161/01.RES.0000057754.35180.99; Meldrum KK, 2001, AM J PHYSIOL-REG I, V281, pR359, DOI 10.1152/ajpregu.2001.281.1.R359; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; Min JN, 2008, MOL CELL BIOL, V28, P4018, DOI 10.1128/MCB.00296-08; Min JN, 2004, GENESIS, V40, P205, DOI 10.1002/gene.20087; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Morozov V, 2006, DEVELOPMENT, V133, P813, DOI 10.1242/dev.02262; Morrison LE, 2004, AM J PHYSIOL-HEART C, V286, pH847, DOI 10.1152/ajpheart.00715.2003; Muchowski PJ, 2000, P NATL ACAD SCI USA, V97, P7841, DOI 10.1073/pnas.140202897; Muchowski PJ, 2005, NAT REV NEUROSCI, V6, P11, DOI 10.1038/nrn1587; Nagai N, 2000, J CELL BIOL, V150, P1499, DOI 10.1083/jcb.150.6.1499; Nagel F, 2008, J NEUROCHEM, V105, P853, DOI 10.1111/j.1471-4159.2007.05204.x; Nakai A, 2000, EMBO J, V19, P1545, DOI 10.1093/emboj/19.7.1545; NISHI S, 1993, BRAIN RES, V615, P281, DOI 10.1016/0006-8993(93)90039-P; Nishimoto S, 2003, NATURE, V424, P1071, DOI 10.1038/nature01895; Novoselova TV, 2005, J NEUROCHEM, V94, P597, DOI 10.1111/j.1471-4159.2005.03119.x; Nylandsted J, 2002, CANCER RES, V62, P7139; Nylandsted J, 2000, P NATL ACAD SCI USA, V97, P7871, DOI 10.1073/pnas.97.14.7871; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Ouyang YB, 2001, NEUROSCI LETT, V298, P159, DOI 10.1016/S0304-3940(00)01721-3; Papadopoulos MC, 1996, NEUROREPORT, V7, P429, DOI 10.1097/00001756-199601310-00013; Petrucelli L, 2004, HUM MOL GENET, V13, P703, DOI 10.1093/hmg/ddh083; Phillips PA, 2007, CANCER RES, V67, P9407, DOI 10.1158/0008-5472.CAN-07-1077; Pinz I, 2008, FASEB J, V22, P84, DOI 10.1096/fj.07-8130com; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Plumier JCL, 1997, CELL STRESS CHAPERON, V2, P162, DOI 10.1379/1466-1268(1997)002<0162:TMETHI>2.3.CO;2; Pras E, 2000, INVEST OPHTH VIS SCI, V41, P3511; Radford NB, 1996, P NATL ACAD SCI USA, V93, P2339, DOI 10.1073/pnas.93.6.2339; Rajdev S, 2000, ANN NEUROL, V47, P782, DOI 10.1002/1531-8249(200006)47:6<782::AID-ANA11>3.3.CO;2-V; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Ray PS, 2001, FASEB J, V15, P393, DOI 10.1096/fj.00-0199com; Rohn TT, 2002, NEUROBIOL DIS, V11, P341, DOI 10.1006/nbdi.2002.0549; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Sanbe A, 2005, P NATL ACAD SCI USA, V102, P13592, DOI 10.1073/pnas.0503324102; Sanbe A, 2004, P NATL ACAD SCI USA, V101, P10132, DOI 10.1073/pnas.0401900101; Santhiya S, 2006, MOL VIS, V12, P768; Santos SD, 2004, NEUROSCIENCE, V126, P657, DOI 10.1016/j.neuroscience.2004.03.023; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Schaffar G, 2004, MOL CELL, V15, P95, DOI 10.1016/j.molcel.2004.06.029; Schmitt E, 2006, CANCER RES, V66, P4191, DOI 10.1158/0008-5472.CAN-05-3778; Selcen D, 2003, ANN NEUROL, V54, P804, DOI 10.1002/ana.10767; Senderek J, 2005, NAT GENET, V37, P1312, DOI 10.1038/ng1678; Seo JS, 1996, BIOCHEM BIOPH RES CO, V218, P582, DOI 10.1006/bbrc.1996.0103; SHARP FR, 1993, STROKE S1, V24, P72; Sharp PS, 2008, NEUROBIOL DIS, V30, P42, DOI 10.1016/j.nbd.2007.12.002; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Shimura H, 2004, J BIOL CHEM, V279, P17957, DOI 10.1074/jbc.M400351200; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Simon S, 2007, BIOCHEMISTRY-US, V46, P9605, DOI 10.1021/bi7003125; Singh D, 2006, MOL VIS, V12, P1372; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Sugawara T, 2002, J NEUROSCI, V22, P209, DOI 10.1523/JNEUROSCI.22-01-00209.2002; Suzuki K, 2002, CIRCULATION, V106, pI270, DOI 10.1161/01.cir.0000032880.55215.92; Suzuki K, 1999, ANN THORAC SURG, V68, P1266, DOI 10.1016/S0003-4975(99)00726-2; Suzuki T, 2007, ARCH BIOCHEM BIOPHYS, V468, P1, DOI 10.1016/j.abb.2007.09.004; Takada H, 2003, MOL CELL BIOL, V23, P4026, DOI 10.1128/MCB.23.11.4026-4033.2003; Takaki E, 2006, J BIOL CHEM, V281, P4931, DOI 10.1074/jbc.M506911200; Tam S, 2006, NAT CELL BIOL, V8, P1155, DOI 10.1038/ncb1477; Tang BS, 2005, HUM GENET, V116, P222, DOI 10.1007/s00439-004-1218-3; Tatton NA, 2000, EXP NEUROL, V166, P29, DOI 10.1006/exnr.2000.7489; Terada K, 2005, EMBO J, V24, P611, DOI 10.1038/sj.emboj.7600549; Toulmond S, 2004, BRIT J PHARMACOL, V141, P689, DOI 10.1038/sj.bjp.0705662; Trapp T, 2003, MOL CELL NEUROSCI, V23, P302, DOI 10.1016/S1044-7431(03)00013-7; Treweek TM, 2005, FEBS J, V272, P711, DOI 10.1111/j.1742-4658.2004.04507.x; Trost SU, 1998, J CLIN INVEST, V101, P855, DOI 10.1172/JCI265; Tsuchiya D, 2003, NEUROSURGERY, V53, P1179, DOI 10.1227/01.NEU.0000090341.38659.CF; Tsuchiya D, 2003, J CEREBR BLOOD F MET, V23, P718, DOI 10.1097/01.WCB.0000054756.97390.F7; Uchiyama Y, 2006, J BIOCHEM, V140, P805, DOI 10.1093/jb/mvj212; Vacher C, 2005, HUM MOL GENET, V14, P3425, DOI 10.1093/hmg/ddi372; Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765; Volloch VZ, 1999, ONCOGENE, V18, P3648, DOI 10.1038/sj.onc.1202525; Voloboueva LA, 2008, J CEREBR BLOOD F MET, V28, P1009, DOI 10.1038/sj.jcbfm.9600600; Voss AK, 2000, DEVELOPMENT, V127, P1; Wacker JL, 2004, NAT STRUCT MOL BIOL, V11, P1215, DOI 10.1038/nsmb860; Wanderling S, 2007, MOL BIOL CELL, V18, P3764, DOI 10.1091/mbc.E07-03-0275; Wang GH, 2004, GENESIS, V38, P66, DOI 10.1002/gene.20005; Wang GH, 2003, GENESIS, V36, P48, DOI 10.1002/gene.10200; Wang XJ, 2003, CIRC RES, V93, P998, DOI 10.1161/01.RES.0000102401.77712.ED; Wang XJ, 2001, CIRC RES, V89, P84, DOI 10.1161/hh1301.092688; Wang YH, 1999, KIDNEY INT, V55, P2224, DOI 10.1046/j.1523-1755.1999.00476.x; Watase K, 2002, NEURON, V34, P905, DOI 10.1016/S0896-6273(02)00733-X; WEI YQ, 1995, CANCER IMMUNOL IMMUN, V40, P73, DOI 10.1007/s002620050146; Williamson CL, 2008, AM J PHYSIOL-HEART C, V294, pH249, DOI 10.1152/ajpheart.00775.2007; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Xi JH, 2008, J BIOL CHEM, V283, P5801, DOI 10.1074/jbc.M708704200; Xiao XZ, 1999, EMBO J, V18, P5943, DOI 10.1093/emboj/18.21.5943; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JCI26373; Xu DG, 1999, J NEUROSCI, V19, P5026; Xu DG, 1997, NAT MED, V3, P997, DOI 10.1038/nm0997-997; Xu LJ, 2003, NEUROL RES, V25, P697, DOI 10.1179/016164103101202183; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Zhang LG, 2007, J BIOL CHEM, V282, P11795, DOI 10.1074/jbc.M610430200; Zhang PL, 2008, ANN CLIN LAB SCI, V38, P57; Zhao M, 2003, NEUROCHEM RES, V28, P307, DOI 10.1023/A:1022337519035; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200; Zourlidou A, 2007, HUM MOL GENET, V16, P1078, DOI 10.1093/hmg/ddm057	236	36	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2008	27	50					6489	6506		10.1038/onc.2008.314	http://dx.doi.org/10.1038/onc.2008.314			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	366RR	18955975				2022-12-17	WOS:000260501600008
J	Brondello, JM; Pillaire, MJ; Rodriguez, C; Gourraud, PA; Selves, J; Cazaux, C; Piette, J				Brondello, J-M; Pillaire, M. J.; Rodriguez, C.; Gourraud, P-A; Selves, J.; Cazaux, C.; Piette, J.			Novel evidences for a tumor suppressor role of Rev3, the catalytic subunit of Pol zeta	ONCOGENE			English	Article						Rev3; DNA damage; Chk2; colon carcinoma	DNA-DAMAGE CHECKPOINTS; STRAND-BREAK REPAIR; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; POSTREPLICATION REPAIR; ANTICANCER BARRIER; POLYMERASE-KAPPA; MAMMALIAN-CELLS; CANCER; TUMORIGENESIS	Cell cycle checkpoints and DNA repair act in concert to ensure DNA integrity during perturbation of normal replication or in response to genotoxic agents. Deficiencies in these protective mechanisms can lead to cellular transformation and ultimately tumorigenesis. Here we focused on Rev3, the catalytic subunit of the low-fidelity DNA repair polymerase zeta. Rev3 is believed to play a role in double-strand break (DSB)-induced DNA repair by homologous recombination. In line with this hypothesis, we show the accumulation of chromatin-bound Rev3 protein in late S-G2 of untreated cells and in response to clastogenic DNA damage as well as an gamma-H2AX accumulation in Rev3-depleted cells. Moreover, serine 995 of Rev3 is in vitro phosphorylated by the DSB-inducible checkpoint kinase, Chk2. Our data also disclose a significant reduction of rev3 gene expression in 74 colon carcinomas when compared to the normal adjacent tissues. This reduced expression is independent of the carcinoma stages, suggesting that the downregulation of rev3 might have occurred early during tumorigenesis.	[Brondello, J-M] Hop St Eloi, INSERM, U844, F-34091 Montpellier 05, France; [Brondello, J-M; Rodriguez, C.; Piette, J.] Univ Montpellier 1, INSERM, U868, Ctr Reg Cancerol Montpellier,CRCM Val Aurelle Lam, Montpellier 5, France; [Pillaire, M. J.; Cazaux, C.] CNRS, IPBS, UMR 5089, Toulouse, France; [Gourraud, P-A] Univ Toulouse 3, CHU Toulouse, Serv Hosp Epidemiol,Unite Rech Clin, INSERM U558,Fac Med,Dept Epidemiol & Sante Publ, F-31062 Toulouse, France; [Selves, J.] Univ Toulouse 3, INSERM, Ctr Physiopathol Toulouse Purpan, U563, F-31062 Toulouse, France; [Selves, J.] Univ Toulouse 3, Dept Anatomopathol, F-31062 Toulouse, France; [Piette, J.] CNRS, UMR5535, Inst Genet Mol Montpellier, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier	Brondello, JM (corresponding author), Hop St Eloi, INSERM, U844, Batiment INM BP74103,80 Rue A Fiche, F-34091 Montpellier 05, France.	jean-marc.brondello@inserm.fr	Gourraud, Pierre-Antoine FD/O-3024-2015; Brondello, Jean-Marc/U-8232-2017; Piette, Jacques/F-7109-2011; Pillaire, Marie-Jeanne/P-1579-2014	Brondello, Jean-Marc/0000-0001-5991-3945; Pillaire, Marie-Jeanne/0000-0001-6866-7416; Gourraud, Pierre-Antoine/0000-0003-1131-9554	Canceropole Grand Sud Ouest; Association pour la Recherche sur le Cancer	Canceropole Grand Sud Ouest; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We gratefully thank Professor CW Lawrence for providing Rev3 cDNA and Dr C Jorgensen for gift of human mesenchymal stem cells. We also greatly thank R Guimbaud and K Gordien (Inserm/CHU Purpan, Toulouse) for collection and annotation of the tumors, as well as JM Maoret from the plateforme de Genomique et Biologie Moleculaire', IFR31 Toulouse for his technical help on the 7900HT fast real-time PCR systems. This work was supported by the Canceropole Grand Sud Ouest grant 2003-2006 and the Association pour la Recherche sur le Cancer.	Barbour L, 2006, GENETICS, V174, P1789, DOI 10.1534/genetics.106.056283; Bartek J, 2007, CELL CYCLE, V6, P2344, DOI 10.4161/cc.6.19.4754; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bavoux C, 2005, CANCER RES, V65, P325; Bindra RS, 2007, CANCER METAST REV, V26, P249, DOI 10.1007/s10555-007-9061-3; Blais V, 2004, MOL BIOL CELL, V15, P552, DOI 10.1091/mbc.E03-08-0580; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Brondello JM, 2007, BIOCHEM BIOPH RES CO, V354, P1028, DOI 10.1016/j.bbrc.2007.01.091; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Canitrot Y, 2004, NUCLEIC ACIDS RES, V32, P5104, DOI 10.1093/nar/gkh848; Chomczynski P, 2006, NAT PROTOC, V1, P581, DOI 10.1038/nprot.2006.83; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Guo CX, 2003, EMBO J, V22, P6621, DOI 10.1093/emboj/cdg626; Hochegger H, 2004, BIOESSAYS, V26, P151, DOI 10.1002/bies.10403; Ishikawa K, 2006, DNA CELL BIOL, V25, P406, DOI 10.1089/dna.2006.25.406; Johnson RE, 1998, GENE DEV, V12, P3137, DOI 10.1101/gad.12.19.3137; Kai M, 2003, GENE DEV, V17, P64, DOI 10.1101/gad.1043203; Laiho M, 2003, ANN MED, V35, P391, DOI 10.1080/07853890310014605; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lawrence CW, 1996, CANCER SURV, V28, P21; Lemee F, 2007, ONCOGENE, V26, P3387, DOI 10.1038/sj.onc.1210116; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Lisby M, 2004, CURR OPIN CELL BIOL, V16, P328, DOI 10.1016/j.ceb.2004.03.011; Lisby M, 2003, CELL CYCLE, V2, P479, DOI 10.4161/cc.2.5.483; Liu VF, 1999, MOL CELL BIOL, V19, P1126; McIlwraith MJ, 2005, MOL CELL, V20, P783, DOI 10.1016/j.molcel.2005.10.001; Melo J, 2002, CURR OPIN CELL BIOL, V14, P237, DOI 10.1016/S0955-0674(02)00312-5; Nelson JR, 1996, SCIENCE, V272, P1646, DOI 10.1126/science.272.5268.1646; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Rattray AJ, 2003, ANNU REV GENET, V37, P31, DOI 10.1146/annurev.genet.37.042203.132748; Rattray AJ, 2005, MOL CELL, V20, P658, DOI 10.1016/j.molcel.2005.11.018; Sabbioneda S, 2005, J BIOL CHEM, V280, P38657, DOI 10.1074/jbc.M507638200; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Sonoda E, 2003, EMBO J, V22, P3188, DOI 10.1093/emboj/cdg308; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; STRATHERN JN, 1995, GENETICS, V140, P965; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Van Sloun PPH, 2002, MOL CELL BIOL, V22, P2159, DOI 10.1128/MCB.22.7.2159-2169.2002; Yamamoto Ken-ichi, 2006, Subcell Biochem, V40, P327; Zhang JR, 2004, MOL CELL BIOL, V24, P708, DOI 10.1128/MCB.24.2.708-718.2004; Zhu F, 2003, WORLD J GASTROENTERO, V9, P1165, DOI 10.3748/wjg.v9.i6.1165	45	36	38	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2008	27	47					6093	6101		10.1038/onc.2008.212	http://dx.doi.org/10.1038/onc.2008.212			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	360UJ	18622427				2022-12-17	WOS:000260083100002
J	Impens, F; Van Damme, P; Demol, H; Van Damme, J; Vandekerckhove, J; Gevaert, K				Impens, F.; Van Damme, P.; Demol, H.; Van Damme, J.; Vandekerckhove, J.; Gevaert, K.			Mechanistic insight into taxol-induced cell death	ONCOGENE			English	Article						protease substrates; caspase-like activity; taxol; cytotoxic granule	LUNG-CANCER CELLS; INDUCED APOPTOSIS; PACLITAXEL TREATMENT; PROTEOMICS; IDENTIFICATION; PROTEASE; ACTIVATION; INHIBITION; PEPTIDES; PROTEINS	We analysed the involvement of proteases during taxol-mediated cell death of human A549 non-small-cell lung carcinoma cells using a proteomics approach that specifically targets protein N termini and further detects newly formed N termini that are the result of protein processing. Our analysis revealed 27 protease-mediated cleavages, which we divided in sites C-terminal to aspartic acid (Asp) and sites C-terminal to non-Asp residues, as the result of caspase and non-caspase protease activities, respectively. Remarkably, some of the former were insensitive to potent pancaspase inhibitors, and we therefore suggest that previous inhibitor-based studies that report on the caspase-independent nature of taxol-induced cell death should be judged with care. Furthermore, many of the sites C-terminal to non-Asp residues were also uniquely observed in a model of cytotoxic granule-mediated cell death and/or found by in vitro cataloging human mu-calpain substrates using a similar proteomics technique. This thus raises the hypothesis that killing tumor cells by chemotherapy or by immune cells holds similar non-Asp-specific proteolytic components with strong indications to calpain activity.	[Gevaert, K.] Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, B-9000 Ghent, Belgium; [Impens, F.; Van Damme, P.; Demol, H.; Van Damme, J.; Vandekerckhove, J.; Gevaert, K.] Univ Ghent VIB, Dept Med Prot Res, Ghent, Belgium	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Gevaert, K (corresponding author), Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, Baertsoenkaai 3, B-9000 Ghent, Belgium.	kris.gevaert@ugent.be	Gevaert, Kris/D-6489-2017; Van Damme, Petra/C-7269-2008; Impens, Francis/C-3335-2009; Gevaert, Kris/AAE-4212-2019; Gevaert, Kris/H-3637-2013	Gevaert, Kris/0000-0002-4237-0283; Van Damme, Petra/0000-0001-9090-027X; Gevaert, Kris/0000-0002-4237-0283; Gevaert, Kris/0000-0002-4237-0283; Demol, Hans/0000-0001-7595-0148; Impens, Francis/0000-0003-2886-9616				Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; Broker LE, 2002, CANCER RES, V62, P4081; Day TW, 2006, BIOCHEM PHARMACOL, V71, P1551, DOI 10.1016/j.bcp.2006.02.015; de Bruin EC, 2003, CELL DEATH DIFFER, V10, P1204, DOI 10.1038/sj.cdd.4401296; DIGWEED M, 1995, MOL CELL BIOL, V15, P305, DOI 10.1128/MCB.15.1.305; Ehrlichova M, 2005, ANTICANCER RES, V25, P4215; Enoksson M, 2007, J PROTEOME RES, V6, P2850, DOI 10.1021/pr0701052; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gevaert K, 2006, J PROTEOME RES, V5, P1415, DOI 10.1021/pr060026a; Gevaert K, 2003, NAT BIOTECHNOL, V21, P566, DOI 10.1038/nbt810; Ghesquiere B, 2006, J PROTEOME RES, V5, P2438, DOI 10.1021/pr060186m; Huisman C, 2002, CLIN CANCER RES, V8, P596; Janssen K, 2007, BLOOD, V110, P3662, DOI 10.1182/blood-2007-02-073213; Karmakar S, 2007, APOPTOSIS, V12, P671, DOI 10.1007/s10495-006-0024-x; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Krishan A, 1990, Methods Cell Biol, V33, P121; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lu KH, 2005, CLIN CHIM ACTA, V357, P65, DOI 10.1016/j.cccn.2005.02.003; Martens L, 2005, BIOINFORMATICS, V21, P3584, DOI 10.1093/bioinformatics/bti588; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038/sj.cdd.4401012; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Pineiro D, 2007, EXP CELL RES, V313, P369, DOI 10.1016/j.yexcr.2006.10.020; PYTELA R, 1980, P NATL ACAD SCI-BIOL, V77, P4808, DOI 10.1073/pnas.77.8.4808; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Smyth MJ, 2001, J LEUKOCYTE BIOL, V70, P18; Staes A, 2004, J PROTEOME RES, V3, P786, DOI 10.1021/pr049956p; Torres K, 1998, CANCER RES, V58, P3620; Van Damme P, 2005, NAT METHODS, V2, P771, DOI 10.1038/NMETH792; Vande Walle L, 2007, J PROTEOME RES, V6, P1006, DOI 10.1021/pr060510d; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Yan R, 2006, CELL MOL LIFE SCI, V63, P877, DOI 10.1007/s00018-005-5338-2; Zhao JS, 2005, INT J ONCOL, V27, P247; Zhao M, 2000, FEBS LETT, V485, P104, DOI 10.1016/S0014-5793(00)02195-5	42	36	37	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4580	4591		10.1038/onc.2008.96	http://dx.doi.org/10.1038/onc.2008.96			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408750				2022-12-17	WOS:000258077300007
J	Toschi, A; Edelstein, J; Rockwell, P; Ohh, M; Foster, DA				Toschi, A.; Edelstein, J.; Rockwell, P.; Ohh, M.; Foster, D. A.			HIF alpha expression in VHL-deficient renal cancer cells is dependent on phospholipase	ONCOGENE			English	Article						phospholipase D; HIF alpha; VHL; survival; signals; apoptosis; hypoxia	TUMOR-SUPPRESSOR PROTEIN; HYPOXIA-INDUCIBLE FACTORS; HIPPEL-LINDAU PROTEIN; PHOSPHATIDIC-ACID; SURVIVAL SIGNALS; FIBRONECTIN MATRIX; MTOR; PATHWAY; D2; INHIBITION	Loss of the von Hippel-Lindau (VHL) tumor suppressor gene contributes to proliferative disorders including renal cell carcinoma. The consequence of VHL loss is increased levels of hypoxia-inducible factor-alpha (HIF alpha), which is targeted for proteolytic degradation by the VHL gene product pVHL. HIF is a transcription factor that increases the expression of factors critical for tumorigenesis in renal cell carcinoma. We report here another regulatory component of HIFa expression in renal cancer cells. Phospholipase D (PLD), which is commonly elevated in renal and other cancers, is required for elevated levels of both HIF1 alpha and HIF2 alpha in VHL-deficient renal cancer cells. The induction of both HIF1 alpha and HIF2 alpha by hypoxic mimetic conditions was also dependent on PLD in renal cancer cells with restored pVHL expression. The effect of PLD activity upon HIFa expression was at the level of translation. PLD activity also provides a survival signal that suppresses apoptosis induced by serum deprivation in the renal cancer cells. Suppression of HIF2 alpha has been shown to reverse tumorigenesis with renal cancer cells. The finding here that HIF2a expression is dependent on PLD in renal cancer cells suggests that targeting PLD signals may represent an alternative therapeutic strategy for targeting HIF2 alpha in renal cancers where HIF2 alpha is critical for tumorigenesis and elevated PLD activity is common.	[Toschi, A.; Edelstein, J.; Rockwell, P.; Foster, D. A.] CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA; [Ohh, M.] Univ Toronto, Fac Med, Dept Lab Med & Pathobiol, Toronto, ON, Canada	City University of New York (CUNY) System; Hunter College (CUNY); University of Toronto	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Pk Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu			NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [S06GM060654] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RR-03037] Funding Source: Medline; NIGMS NIH HHS [GM60654] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernardi R, 2006, NATURE, V442, P779, DOI 10.1038/nature05029; Chen YH, 2005, ONCOGENE, V24, P672, DOI 10.1038/sj.onc.1208099; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Foster DA, 2003, MOL CANCER RES, V1, P789; Foster DA, 2006, CURR SIGNAL TRANSD T, V1, P295, DOI 10.2174/157436206778226941; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Foster David A, 2004, Expert Rev Anticancer Ther, V4, P691, DOI 10.1586/14737140.4.4.691; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gordan JD, 2007, CURR OPIN GENET DEV, V17, P71, DOI 10.1016/j.gde.2006.12.006; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hickey MM, 2006, CURR TOP DEV BIOL, V76, P217, DOI 10.1016/S0070-2153(06)76007-0; Hui L, 2005, J BIOL CHEM, V280, P35829, DOI 10.1074/jbc.M504192200; Hui L, 2004, MOL CELL BIOL, V24, P5677, DOI 10.1128/MCB.24.13.5677-5686.2004; Kaelin WG, 2005, BIOCHEM BIOPH RES CO, V338, P627, DOI 10.1016/j.bbrc.2005.08.165; Kaelin WG, 2007, CLIN CANCER RES, V13, p680S, DOI 10.1158/1078-0432.CCR-06-1865; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maxwell PH, 2005, SEMIN CELL DEV BIOL, V16, P523, DOI 10.1016/j.semcdb.2005.03.001; Maynard MA, 2004, AM J NEPHROL, V24, P1, DOI 10.1159/000075346; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Ohh M, 2006, NEOPLASIA, V8, P623, DOI 10.1593/neo.06442; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rodrik V, 2005, MOL CELL BIOL, V25, P7917, DOI 10.1128/MCB.25.17.7917-7925.2005; Rodrik V, 2006, FEBS LETT, V580, P5647, DOI 10.1016/j.febslet.2006.09.013; Sawyers CL, 2003, CANCER CELL, V4, P343, DOI 10.1016/S1535-6108(03)00275-7; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719; Zheng Y, 2006, J BIOL CHEM, V281, P15862, DOI 10.1074/jbc.M600660200; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8	37	36	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 24	2008	27	19					2746	2753		10.1038/sj.onc.1210927	http://dx.doi.org/10.1038/sj.onc.1210927			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292IK	17998935				2022-12-17	WOS:000255259500009
J	Cooper, WN; Dickinson, RE; Dallol, A; Grigorieva, EV; Pavlova, T; Hesson, LB; Bieche, I; Broggini, M; Maher, ER; Zabarovsky, ER; Clark, GJ; Latif, F				Cooper, W. N.; Dickinson, R. E.; Dallol, A.; Grigorieva, E. V.; Pavlova, T. V.; Hesson, L. B.; Bieche, I.; Broggini, M.; Maher, E. R.; Zabarovsky, E. R.; Clark, G. J.; Latif, F.			Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer	ONCOGENE			English	Article						RASSF2; breast cancer; lung cancer; epigenetic inactivation; nuclear localization signal	ISLAND PROMOTER HYPERMETHYLATION; TUMOR-SUPPRESSOR; CPG ISLAND; K-RAS; GENE; INACTIVATION; 3P21.3; REGION; IDENTIFICATION; OVARIAN	RASSF2 is a recently identified member of a class of novel tumour suppressor genes, all containing a ras-association domain. RASSF2 resides at 20p13, a region frequently lost in human cancers. In this report we investigated methylation status of the RASSF2 promoter CpG island in a series of breast, ovarian and non-small cell lung cancers (NSCLC). RASSF2 was frequently methylated in breast tumour cell lines (65%, 13/20) and in primary breast tumours (38%, 15/40). RASSF2 expression could be switched back on in methylated breast tumour cell lines after treatment with 5'-aza-2'deoxycytidine. RASSF2 was also frequently methylated in NSCLC tumours (44%, (22/50). The small number of corresponding normal breast and lung tissue DNA samples analysed were unmethylated. We also did not detect RASSF2 methylation in ovarian tumours (0/17). Furthermore no mutations were found in the coding region of RASSF2 in these ovarian tumours. We identified a highly conserved putative bipartite nuclear localization signal (NLS) and demonstrated that endogenous RASSF2 localized to the nucleus. Mutation of the putative NLS abolished the nuclear localization. RASSF2 suppressed breast tumour cell growth in vitro and in vivo, while the ability of NLS-mutant RASSF2 to suppress growth was much diminished. Hence we demonstrate that RASSF2 has a functional NLS that is important for its tumour suppressor gene function. Our data from this and a previous report indicate that RASSF2 is frequently methylated in colorectal, breast and NSCLC tumours. We have identified RASSF2 as a novel methylation marker for multiple malignancies and it has the potential to be developed into a valuable marker for screening several cancers in parallel using promoter hypermethylation profiles.	[Cooper, W. N.; Dickinson, R. E.; Dallol, A.; Hesson, L. B.; Maher, E. R.; Latif, F.] Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England; [Grigorieva, E. V.; Pavlova, T. V.; Zabarovsky, E. R.] Karolinska Inst, MTC, Stockholm, Sweden; [Grigorieva, E. V.] Inst Mol Biol & Biophys SD RAMS, Novosibirsk, Russia; [Pavlova, T. V.] Russian Acad Sci, Engelhardt Inst Mol Biol, Moscow, Russia; [Bieche, I.] Ctr Rene Huguenin, INSERM, Lab Oncogenet E0017, St Cloud, France; [Broggini, M.] Ist Ric Farmacol Mario Negri, Mol Pharmacol Lab, Milan, Italy; [Clark, G. J.] Univ Louisville, Dept Med, JG Brown Canc Ctr, Mol Targets Grp, Louisville, KY 40292 USA	University of Birmingham; Karolinska Institutet; Russian Academy of Medical Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Institut National de la Sante et de la Recherche Medicale (Inserm); Rene Huguenin Hospital; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Louisville	Latif, F (corresponding author), Univ Birmingham, Inst Biomed Res, Div Reprod & Child Hlth, Dept Med & Mol Genet, Birmingham B15 2TT, W Midlands, England.	f.latif@bham.ac.uk	Bièche, Ivan/O-7399-2017; Dallol, Ashraf/H-8661-2012; broggini, massimo/AAA-6460-2020; MAHER, EAMONN R/A-9507-2008; Grigorieva, Elvira/A-4937-2010; Zabarovsky, Eugene R/A-6645-2010; Hesson, Luke/HDM-0311-2022	Bièche, Ivan/0000-0002-2430-5429; Dallol, Ashraf/0000-0002-8803-228X; MAHER, EAMONN R/0000-0002-6226-6918; Grigorieva, Elvira/0000-0003-2457-9179; BROGGINI, MASSIMO/0000-0002-8138-9358; Pavlova, Tatiana/0000-0002-2857-5696	Cancer Research UK [A7205] Funding Source: Medline; Breast Cancer Now [2005NOV13] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Breast Cancer Now		Agathanggelou A, 2005, CANCER RES, V65, P3497, DOI 10.1158/0008-5472.CAN-04-4088; Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Akino K, 2005, GASTROENTEROLOGY, V129, P156, DOI 10.1053/j.gastro.2005.03.051; ALLEN NP, 2007, ONCOGENE; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Dallol A, 2005, CANCER RES, V65, P7653, DOI 10.1158/0008-5472.CAN-05-0247; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson L, 2003, ONCOGENE, V22, P947, DOI 10.1038/sj.onc.1206191; Hesson LB, 2005, ONCOGENE, V24, P3987, DOI 10.1038/sj.onc.1208566; HESSON LB, 2007, ONCOGENE; Irimia M, 2004, ONCOGENE, V23, P8695, DOI 10.1038/sj.onc.1207914; Kashuba VI, 2004, P NATL ACAD SCI USA, V101, P4906, DOI 10.1073/pnas.0401238101; Lambros MBK, 2005, J PATHOL, V205, P29, DOI 10.1002/path.1681; Lerman MI, 2000, CANCER RES, V60, P6116; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Park HW, 2007, INT J CANCER, V120, P7, DOI 10.1002/ijc.22276; Protopopov AI, 2002, J GENE MED, V4, P397, DOI 10.1002/jgm.283; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; Schubbert S, 2007, CURR OPIN GENET DEV, V17, P15, DOI 10.1016/j.gde.2006.12.004; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Tommasi S, 2005, CANCER RES, V65, P92; Tommasi S, 2002, ONCOGENE, V21, P2713, DOI 10.1038/sj.onc.1205365; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; Vos MD, 2003, J BIOL CHEM, V278, P28045, DOI 10.1074/jbc.M300554200; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466; Zhang Z, 2007, INT J CANCER, V120, P32, DOI 10.1002/ijc.22185	31	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 13	2008	27	12					1805	1811		10.1038/sj.onc.1210805	http://dx.doi.org/10.1038/sj.onc.1210805			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	273WF	17891178	Green Accepted			2022-12-17	WOS:000253962100017
J	Zhu, S; Korzh, V; Gong, Z; Low, BC				Zhu, S.; Korzh, V.; Gong, Z.; Low, B. C.			RhoA prevents apoptosis during zebrafish embryogenesis through activation of Mek/Erk pathway	ONCOGENE			English	Article						RhoA; Mek/Erk; Bcl-2; apoptosis; embryogenesis; zebrafish	MAMMARY EPITHELIAL-CELLS; ACTIN DEPOLYMERIZATION; SIGNALING PATHWAY; BCL-2 EXPRESSION; PROTEIN-KINASE; SURVIVAL; DIFFERENTIATION; PROLIFERATION; METASTASIS; INHIBITION	RhoA small GTPase, as a key regulator for actin cytoskeletal rearrangement, plays pivotal roles during morphogenesis, cytokinesis, phagocytosis and cell migration, but little is known about its signaling mechanism that controls cell survival in vivo. Using zebrafish as a model, we show that non-overlapping antisense morpholinos that block either translation or splicing of rhoA lead to extensive apoptosis during embryogenesis, resulting in overall reduction of body size and body length. These defects are associated with reduced activation of growth-promoting Erk and decreased expression of anti-apoptotic bcl-2. Moreover, ectopic expression of rhoA, Mek or BCL-2 mRNA rescues such phenotypes. Consistently, combined suppression of RhoA and Mek/Erk or Bcl-2 pathways by sub-optimal dose of rhoA morpholino and pharmacological inhibitors for either Mek (U0126) or Bcl-2 (HA 14-1) can induce developmental abnormalities and enhanced apoptosis, similar to those caused by effective RhoA knockdown. Furthermore, U0126 abrogates the rescue by RhoA and MEK but not BCL-2. In contrast, HA 14-1 effectively abolishes all functional rescues by RhoA, MEK or BCL-2, supporting that RhoA prevents apoptosis by activation of Mek/ Erk pathway and requiring Bcl-2. These findings reveal an important genetic and functional relationship between RhoA with Mek/ Erk and Bcl-2 for cell survival control during embryogenesis.	[Zhu, S.; Korzh, V.; Low, B. C.] Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, Singapore 117543, Singapore; [Zhu, S.; Gong, Z.] Natl Univ Singapore, Dept Biol Sci, Mol Biol Lab, Singapore 117543, Singapore; [Korzh, V.] Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117548, Singapore	National University of Singapore; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore	Low, BC (corresponding author), Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, 14 Sci Dr 4, Singapore 117543, Singapore.	dbslowbc@nus.edu.sg	Korzh, Vladimir P/H-1596-2011; Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012; Gong, Zhiyuan/H-8794-2012	Korzh, Vladimir P/0000-0002-6580-7986; Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X; Gong, Zhiyuan/0000-0002-9660-5260				Aznar S, 2001, CANCER LETT, V165, P1, DOI 10.1016/S0304-3835(01)00412-8; Beis D, 2006, TRENDS CELL BIOL, V16, P105, DOI 10.1016/j.tcb.2005.12.001; Bijian K, 2005, AM J PHYSIOL-RENAL, V289, pF1313, DOI 10.1152/ajprenal.00106.2005; Blanco-Colio LM, 2002, ATHEROSCLEROSIS, V161, P17, DOI 10.1016/S0021-9150(01)00613-X; Cole LK, 2001, DEV BIOL, V240, P123, DOI 10.1006/dbio.2001.0432; Coleman ML, 2001, NAT CELL BIOL, V3, P339, DOI 10.1038/35070009; Corson LB, 2003, DEVELOPMENT, V130, P4527, DOI 10.1242/dev.00669; Del Re DP, 2007, J BIOL CHEM, V282, P8069, DOI 10.1074/jbc.M604298200; Deng X, 2001, J Natl Cancer Inst Monogr, P30; Doshi JM, 2006, J MED CHEM, V49, P7731, DOI 10.1021/jm060968r; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fromigue O, 2006, CELL DEATH DIFFER, V13, P1845, DOI 10.1038/sj.cdd.4401873; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Gomez J, 1997, EUR J IMMUNOL, V27, P2793, DOI 10.1002/eji.1830271108; Harms C, 2004, MOL CELL NEUROSCI, V25, P69, DOI 10.1016/j.mcn.2003.09.012; Henning SW, 1997, EMBO J, V16, P2397, DOI 10.1093/emboj/16.9.2397; Hong CC, 2006, CURR BIOL, V16, P1366, DOI 10.1016/j.cub.2006.05.046; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Kobayashi K, 2004, J NEUROSCI, V24, P3480, DOI 10.1523/JNEUROSCI.0295-04.2004; Korichneva I, 1999, J CELL SCI, V112, P2521; Krens SFG, 2006, GENE EXPR PATTERNS, V6, P1019, DOI 10.1016/j.modgep.2006.04.008; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Martin S, 2001, MOL CELL BIOL, V21, P6529, DOI 10.1128/MCB.21.19.6529-6536.2001; McClintock JM, 2002, DEVELOPMENT, V129, P2339; McWhorter ML, 2003, J CELL BIOL, V162, P919, DOI 10.1083/jcb.200303168; Miyake H, 1999, BRIT J CANCER, V79, P1651, DOI 10.1038/sj.bjc.6690264; Navarro P, 1999, J BIOL CHEM, V274, P18857, DOI 10.1074/jbc.274.27.18857; Pinkas J, 2004, MOL CANCER RES, V2, P551; Posey SC, 1999, J BIOL CHEM, V274, P4259, DOI 10.1074/jbc.274.7.4259; Rikitake Y, 2000, ARTERIOSCL THROM VAS, V20, P1006, DOI 10.1161/01.ATV.20.4.1006; Rios-Munoz W, 2005, J NEUROCHEM, V93, P1422, DOI 10.1111/j.1471-4159.2005.03129.x; Tahinci E, 2003, DEV BIOL, V259, P318, DOI 10.1016/S0012-1606(03)00206-9; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE; Wick W, 1998, FEBS LETT, V440, P419, DOI 10.1016/S0014-5793(98)01494-X; Wullimann MF, 2000, ANAT EMBRYOL, V202, P385, DOI 10.1007/s004290000115; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100; Zhao M, 2006, MOL PHARMACOL, V69, P66, DOI 10.1124/mol.105.016923; Zhu SZ, 2006, CELL SIGNAL, V18, P359, DOI 10.1016/j.cellsig.2005.05.019	42	36	38	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2008	27	11					1580	1589		10.1038/sj.onc.1210790	http://dx.doi.org/10.1038/sj.onc.1210790			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873909				2022-12-17	WOS:000253815800010
J	Peng, ZG; Zhou, MY; Huang, Y; Qiu, JH; Wang, LS; Liao, SH; Dong, S; Chen, GQ				Peng, Z. G.; Zhou, M. Y.; Huang, Y.; Qiu, J. H.; Wang, L. S.; Liao, S. H.; Dong, S.; Chen, G. Q.			Physical and functional interaction of Runt-related protein 1 with hypoxia-inducible factor-1 alpha	ONCOGENE			English	Article						hypoxia-inducible factor-1 alpha (HIF-1 alpha); runt-related protein 1 (Runx1); protein-protein interaction; angiogenesis	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; LEUKEMIC-CELL DIFFERENTIATION; STIMULATING FACTOR-RECEPTOR; FUSION PROTEIN; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; OXYGEN-TENSION; ANGIOGENESIS; ALPHA; HEMATOPOIESIS	Angiogenesis and hematopoiesis are closely linked and interactive with each other, but few studies were given to identify possible links between angiogenesis-promoting proteins and hematopoiesis-related transcription factors. Here we investigated the potential relationship of oxygen-sensitive alpha-subunit of angiogenesis-related hypoxia-inducible factor-1 alpha (HIF-1 alpha) with Runt-related protein 1 (Runx1, also known as acute myeloid leukemia-1, AML-1), an important hematopoietic transcription factor. The results demonstrated that Runx1 and HIF-1 alpha proteins directly interacted with each other to a degree, in which Runt homology domain of Runx1 was mainly involved. Leukemia-related abnormal Runx1 fusion protein AML1-ETO, which fuses the N-terminal 177 amino acid residues of the Runx1 protein in frame to ETO (eight-twenty-one) protein, also interacted with HIF-1 alpha protein with greater ability than Runx1 itself. More intriguingly, Runx1 overexpression inhibited DNA-binding and transcriptional activity of HIF-1 protein with reduced expression of HIF-1-targeted genes such as vascular endothelial growth factor, while silence of Runx1 expression by specific small interfering RNA significantly increased transcriptional activity of HIF-1 protein, suggesting that Runx1 inhibited transcription-dependent function of HIF-1. Vice versa, HIF-1 alpha increased DNA-binding ability and transcriptional activity of Runx1 protein. All these data would shed new insight to understanding Runx1 and HIF-1 alpha-related hematopoietic cell differentiation and angiogenesis.	[Peng, Z. G.; Zhou, M. Y.; Liao, S. H.; Chen, G. Q.] Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Dept Pathophysiol, Shanghai Inst Biol Sci,Inst Hlth Sci, Shanghai 200025, Peoples R China; [Huang, Y.; Wang, L. S.; Chen, G. Q.] SJTU SM, Chinese Minist Educ, Key Lab Cell Differentiat & Apoptosis, Dept Pathophysiol, Shanghai, Peoples R China; [Huang, Y.; Qiu, J. H.; Dong, S.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Baylor College of Medicine	Chen, GQ (corresponding author), Shanghai Jiao Tong Univ, Chinese Acad Sci, Sch Med,Dept Pathophysiol, Shanghai Inst Biol Sci,Inst Hlth Sci, 280 Chong Qing S Rd, Shanghai 200025, Peoples R China.	chengq@shsmu.edu.cn						Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Alberghini A, 2005, J BIOL CHEM, V280, P30120, DOI 10.1074/jbc.M500971200; Bernardin-Fried F, 2004, J BIOL CHEM, V279, P15678, DOI 10.1074/jbc.M310023200; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; Desplat V, 2002, STEM CELLS, V20, P347, DOI 10.1634/stemcells.20-4-347; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Fatyol K, 2001, J BIOL CHEM, V276, P28421, DOI 10.1074/jbc.M102847200; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Friedman AD, 2002, J CELL BIOCHEM, V86, P624, DOI 10.1002/jcb.10271; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hirota K, 2006, CRIT REV ONCOL HEMAT, V59, P15, DOI 10.1016/j.critrevonc.2005.12.003; Huang Y, 2003, LEUKEMIA, V17, P2065, DOI 10.1038/sj.leu.2403141; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Kilic M, 2007, ONCOGENE, V26, P2027, DOI 10.1038/sj.onc.1210008; Klampfer L, 1996, P NATL ACAD SCI USA, V93, P14059, DOI 10.1073/pnas.93.24.14059; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Kurokawa M, 2003, CANCER SCI, V94, P841, DOI 10.1111/j.1349-7006.2003.tb01364.x; Li G, 1998, J CELL BIOL, V140, P975, DOI 10.1083/jcb.140.5.975; Liu W, 2006, BLOOD, V107, P698, DOI 10.1182/blood-2005-03-1278; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Namba K, 2000, ONCOGENE, V19, P106, DOI 10.1038/sj.onc.1203257; Nguyen-Khac F, 2006, ONCOGENE, V25, P4840, DOI 10.1038/sj.onc.1209503; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; Odaka R, 2000, ONCOGENE, V19, P3584, DOI 10.1038/sj.onc.1203689; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rhoades KL, 1996, P NATL ACAD SCI USA, V93, P11895, DOI 10.1073/pnas.93.21.11895; SONG LP, 2007, IN PRESS ONCOGENE; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Suda T, 2000, INT J HEMATOL, V71, P99; Werner MH, 1999, NAT MED, V5, P1356, DOI 10.1038/70920; Zhang DE, 1996, MOL CELL BIOL, V16, P1231; Zhao KW, 2004, BLOOD, V104, P3731, DOI 10.1182/blood-2004-04-1630	37	36	42	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2008	27	6					839	847		10.1038/sj.onc.1210676	http://dx.doi.org/10.1038/sj.onc.1210676			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17684492				2022-12-17	WOS:000252884500013
J	Nakajima, A; Kojima, Y; Nakayama, M; Yagita, H; Okumura, K; Nakano, H				Nakajima, A.; Kojima, Y.; Nakayama, M.; Yagita, H.; Okumura, K.; Nakano, H.			Downregulation of c-FLIP promotes caspase-dependent JNK activation and reactive oxygen species accumulation in tumor cells	ONCOGENE			English	Article						c-FLIP; tumor necrosis factor; reactive oxygen species; c-Jun N-terminal kinase; apoptosis; necrosis	NF-KAPPA-B; ALPHA-INDUCED APOPTOSIS; INHIBITORY PROTEIN; CYTOCHROME-C; DEATH; KINASE; AUTOPHAGY; NECROSIS; PATHWAY; REQUIREMENT	Nuclear factor-kappa B (NF-kappa B) inhibits cell death through suppression of the caspase cascade, the c-Jun N-terminal kinase (JNK) pathway, and reactive oxygen species (ROS) accumulation. To suppress this antiapoptotic function of NF-kappa B might be a promising strategy to increase susceptibility of tumor cells to stress-induced cell death. We have recently shown that tumor necrosis factor (TNF)alpha induces caspase-dependent and -independent JNK activation and ROS accumulation in cellular FLICE-inhibitory protein (c-Flip)(-/-) murine embryonic fibroblasts (MEFs). To apply this observation to tumor therapy, we knocked down c-FLIP by RNA interference in various tumor cells. Consistent with the results using c-Flip(-/-) MEFs, we found that TNF alpha stimulation induced caspase-dependent prolonged JNK activation and ROS accumulation, followed by apoptotic and necrotic cell death in various tumor cells. Furthermore, TNF alpha and Fas induced the cleavage of mitogen-activated protein kinase/ ERK kinase kinase (MEKK)1, resulting in generation of a constitutive active form of MEKK1 leading to JNK activation in c-FLIP knockdown cells. Given that ROS accumulation and necrotic cell death enhance inflammation followed by compensatory proliferation of tumor cells, selective suppression of caspase-dependent ROS accumulation will be an alternative strategy to protect cells from ROS-dependent DNA damage and compensatory tumor progression.	[Nakajima, A.; Kojima, Y.; Nakayama, M.; Yagita, H.; Okumura, K.; Nakano, H.] Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Nakajima, A (corresponding author), Juntendo Univ, Sch Med, Dept Immunol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	hnakano@med.juntendo.ac.jp		Nakano, Hiroyasu/0000-0003-4843-1427				Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Budd RC, 2006, NAT REV IMMUNOL, V6, P196, DOI 10.1038/nri1787; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Deng YB, 2003, CELL, V115, P61, DOI 10.1016/S0092-8674(03)00757-8; Djerbi M, 1999, J EXP MED, V190, P1025, DOI 10.1084/jem.190.7.1025; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Lee KK, 1998, ONCOGENE, V16, P3029, DOI 10.1038/sj.onc.1201840; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Medema JP, 1999, J EXP MED, V190, P1033, DOI 10.1084/jem.190.7.1033; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Nakajima A, 2006, EMBO J, V25, P5549, DOI 10.1038/sj.emboj.7601423; Nakano H, 2006, CELL DEATH DIFFER, V13, P730, DOI 10.1038/sj.cdd.4401830; Nakayama M, 2002, J IMMUNOL, V168, P734, DOI 10.4049/jimmunol.168.2.734; Ohsumi Y, 2001, NAT REV MOL CELL BIO, V2, P211, DOI 10.1038/35056522; Pham CG, 2004, CELL, V119, P529, DOI 10.1016/j.cell.2004.10.017; Ricci JE, 2004, CELL, V117, P773, DOI 10.1016/j.cell.2004.05.008; Rudel T, 1998, J IMMUNOL, V160, P7; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakon S, 2003, EMBO J, V22, P3898, DOI 10.1093/emboj/cdg379; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Ventura JJ, 2004, GENE DEV, V18, P2905, DOI 10.1101/gad.1223004; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Yeh WC, 2000, IMMUNITY, V12, P633, DOI 10.1016/S1074-7613(00)80214-9	31	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 3	2008	27	1					76	84		10.1038/sj.onc.1210624	http://dx.doi.org/10.1038/sj.onc.1210624			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17599041				2022-12-17	WOS:000252118700008
J	Quereda, V; Martinalbo, J; Dubus, P; Carnero, A; Malumbres, M				Quereda, V.; Martinalbo, J.; Dubus, P.; Carnero, A.; Malumbres, M.			Genetic cooperation between p21(Cip1) and INK4 inhibitors in cellular senescence and tumor suppression	ONCOGENE			English	Article						cell-cycle inhibition; cyclin-dependent kinase; senescence; tumor development; p21(Cip1) and INK4 inhibitors	CYCLIN-DEPENDENT KINASES; HUMAN FIBROBLASTS; REPLICATIVE SENESCENCE; ONCOGENIC RAS; SKIN CARCINOGENESIS; MURINE FIBROBLASTS; MAMMALIAN-CELLS; CDK INHIBITORS; G(1) CONTROL; MICE	Cell-cycle inhibitors of the Cip/Kip and INK4 families are involved in cellular senescence and tumor suppression. Some of these proteins, p21(Cip1), p16(INK4a) and p15(INK4b), are coexpressed in response to antiproliferative signals such as cellular senescence resulting in cell-cycle arrest. To understand the roles of these inhibitors and their synergistic effect, we have characterized the growth properties and senescent behavior of primary cells deficient in p21Cip1 and expressing an endogenous Cdk4(R24C) (cyclin-dependent kinase) mutant (Cdk4R24C knock-in cells) insensitive to INK4 proteins. Inactivation of both p21Cip1 and INK4 pathways strongly cooperate in suppressing cellular senescence in vitro. These double mutant cells behavior as immortal cultures and display high sensitivity to cellular transformation by oncogenes. Moreover, mice double mutant in the INK4 and p21Cip1 pathways (Cdk4R24C; p21(Cip1)-null mice) display an increased incidence of specific sarcomas, suggesting a significant cooperation between these two families of cell-cycle inhibitors in senescence responses and tumor suppression in vivo.	[Quereda, V.; Martinalbo, J.; Malumbres, M.] Ctr Nacl Invest Oncol, Cell Div, E-28029 Madrid, Spain; [Quereda, V.; Martinalbo, J.; Malumbres, M.] Ctr Nacl Invest Oncol, Canc Grp, E-28029 Madrid, Spain; [Dubus, P.] Univ Bordeaux 2, EA2406, F-33076 Bordeaux, France; [Carnero, A.] CNIO, Assays Dev Grp, Madrid, Spain	UDICE-French Research Universities; Universite de Bordeaux; Centro Nacional de Investigaciones Oncologicas (CNIO)	Malumbres, M (corresponding author), Ctr Nacl Invest Oncol, Cell Div, Melchor Fernandez Almagro 3, E-28029 Madrid, Spain.	acarnero@cnio.es; malumbres@cnio.es	IBIS, CANCER/P-3323-2015; Quereda, Victor/J-8120-2019; Malumbres, Marcos/E-8834-2011	Quereda, Victor/0000-0002-9966-9104; Malumbres, Marcos/0000-0002-0829-6315; Dubus, Pierre/0000-0003-1803-4711; Carnero, Amancio/0000-0003-4357-3979				Adnane J, 2000, ONCOGENE, V19, P5338, DOI 10.1038/sj.onc.1203956; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Bagui TK, 2003, MOL CELL BIOL, V23, P7285, DOI 10.1128/MCB.23.20.7285-7290.2003; Bearss DJ, 2002, CANCER RES, V62, P2077; Braig M, 2006, CANCER RES, V66, P2881, DOI 10.1158/0008-5472.CAN-05-4006; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Carnero A, 2000, NUCLEIC ACIDS RES, V28, P2234, DOI 10.1093/nar/28.11.2234; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; De la Cueva E, 2006, ONCOGENE, V25, P4128, DOI 10.1038/sj.onc.1209432; Duan ZJ, 2005, MOL CELL BIOL, V25, P10338, DOI 10.1128/MCB.25.23.10338-10351.2005; Franciotta D, 1998, CEPHALALGIA, V18, P4, DOI 10.1046/j.1468-2982.1998.1801001-5.x; Franklin DS, 2000, MOL CELL BIOL, V20, P6147, DOI 10.1128/MCB.20.16.6147-6158.2000; Gregory V, 2002, VIROLOGY, V300, P1, DOI 10.1006/viro.2002.1513; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Janzen V, 2006, NATURE, V443, P421, DOI 10.1038/nature05159; Korenjak M, 2005, CURR OPIN GENET DEV, V15, P520, DOI 10.1016/j.gde.2005.07.001; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Krishnamurthy J, 2006, NATURE, V443, P453, DOI 10.1038/nature05092; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 2001, NAT REV CANCER, V1, P222, DOI 10.1038/35106065; Malumbres Marcos, 2003, Prog Cell Cycle Res, V5, P5; Martin A, 2005, CANCER CELL, V7, P591, DOI 10.1016/j.ccr.2005.05.006; Martin J A, 2001, Iowa Orthop J, V21, P1; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Medcalf ASC, 1996, CANCER RES, V56, P4582; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Palmero I, 1997, ONCOGENE, V15, P495, DOI 10.1038/sj.onc.1201212; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Philipp J, 1999, ONCOGENE, V18, P4689, DOI 10.1038/sj.onc.1202840; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Rane SG, 1999, NAT GENET, V22, P44, DOI 10.1038/8751; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Sotillo R, 2001, P NATL ACAD SCI USA, V98, P13312, DOI 10.1073/pnas.241338598; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Vogt M, 1998, CELL GROWTH DIFFER, V9, P139; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Weinberg WC, 1999, CANCER RES, V59, P2050; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Yang WC, 2001, CANCER RES, V61, P565; Zindy F, 2000, MOL CELL BIOL, V20, P372, DOI 10.1128/MCB.20.1.372-378.2000	60	36	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 6	2007	26	55					7665	7674		10.1038/sj.onc.1210578	http://dx.doi.org/10.1038/sj.onc.1210578			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17599058				2022-12-17	WOS:000251537800008
J	Goldfarb, AN				Goldfarb, A. N.			Transcriptional control of megakaryocyte development	ONCOGENE			English	Review						megakaryocyte; platelet; development; transcription factor	FAMILIAL PLATELET DISORDER; X-LINKED THROMBOCYTOPENIA; ACUTE MYELOGENOUS LEUKEMIA; ACUTE MYELOID-LEUKEMIA; C-MYB; ADULT HEMATOPOIESIS; INHERITED MUTATION; DROSOPHILA HEMATOPOIESIS; LINEAGE COMMITMENT; GENE-EXPRESSION	Megakaryocytes are highly specialized cells that arise from a bipotent megakaryocytic- erythroid progenitor ( MEP). This developmental leap requires coordinated activation of megakaryocyte- specific genes, radical changes in cell cycle properties, and active prevention of erythroid differentiation. These programs result from upregulation of megakaryocyte- selective transcription factors, down-regulation of erythroid- selective transcription factors and ongoing mediation of common erythro- megakaryocytic transcription factors. Unlike most developmental programs, no single lineage- unique family of master regulators exerts executive control over the megakaryocytic plan. Rather, an assemblage of non- unique factors and signals converge to determine lineage and differentiation. In human megakaryopoiesis, hereditary disorders of platelet production have confirmed contributions from three distinct transcription factor families. Murine models have extended this repertoire to include multiple additional factors. At a mechanistic level, the means by which these non- unique factors collaborate in the establishment of a perfectly unique cell type remains a central question.	Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia	Goldfarb, AN (corresponding author), Univ Virginia, Hlth Sci Ctr, Sch Med, Dept Pathol, Box 800904, Charlottesville, VA 22908 USA.	ang3x@virginia.edu			NATIONAL CANCER INSTITUTE [R01CA100057, R56CA100057, R01CA093735] Funding Source: NIH RePORTER; NCI NIH HHS [CA93735, CA100057] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adolfsson J, 2005, CELL, V121, P295, DOI 10.1016/j.cell.2005.02.013; Akashi K, 2000, NATURE, V404, P193, DOI 10.1038/35004599; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; BRETONGORIUS J, 1995, BLOOD, V85, P1805, DOI 10.1182/blood.V85.7.1805.bloodjournal8571805; Buijs A, 2001, BLOOD, V98, P2856, DOI 10.1182/blood.V98.9.2856; Cantor AB, 2002, ONCOGENE, V21, P3368, DOI 10.1038/sj.onc.1205326; Carpinelli MR, 2004, P NATL ACAD SCI USA, V101, P6553, DOI 10.1073/pnas.0401496101; Debili N, 1996, BLOOD, V88, P1284, DOI 10.1182/blood.V88.4.1284.bloodjournal8841284; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; DOWTON SB, 1985, BLOOD, V65, P557; Elagib KE, 2003, BLOOD, V101, P4333, DOI 10.1182/blood-2002-09-2708; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; Fossett N, 2003, P NATL ACAD SCI USA, V100, P11451, DOI 10.1073/pnas.1635050100; Freson K, 2002, HUM MOL GENET, V11, P147, DOI 10.1093/hmg/11.2.147; Freson K, 2001, BLOOD, V98, P85, DOI 10.1182/blood.V98.1.85; Growney JD, 2005, BLOOD, V106, P494, DOI 10.1182/blood-2004-08-3280; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Heller PG, 2005, BLOOD, V105, P4664, DOI 10.1182/blood-2005-01-0050; Ho CJ, 1996, J SYMB COMPUT, V21, P1, DOI 10.1006/jsco.1996.0001; Hock H, 2004, GENE DEV, V18, P2336, DOI 10.1101/gad.1239604; Hollanda LM, 2006, NAT GENET, V38, P807, DOI 10.1038/ng1825; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Kuhl C, 2005, MOL CELL BIOL, V25, P8592, DOI 10.1128/MCB.25.19.8592-8606.2005; Kundu M, 2002, BLOOD, V100, P2449, DOI 10.1182/blood-2002-04-1064; Kuo YH, 2006, CANCER CELL, V9, P57, DOI 10.1016/j.ccr.2005.12.014; Levanon D, 2001, MECH DEVELOP, V109, P413, DOI 10.1016/S0925-4773(01)00537-8; Liew CK, 2005, P NATL ACAD SCI USA, V102, P583, DOI 10.1073/pnas.0407511102; Liu YZ, 2006, CANCER CELL, V9, P249, DOI 10.1016/j.ccr.2006.03.012; Lorsbach RB, 2004, BLOOD, V103, P2522, DOI 10.1182/blood-2003-07-2439; Ludlow LB, 1996, J BIOL CHEM, V271, P22076, DOI 10.1074/jbc.271.36.22076; Lulli V, 2006, CELL DEATH DIFFER, V13, P1064, DOI 10.1038/sj.cdd.4401811; Manz MG, 2002, P NATL ACAD SCI USA, V99, P11872, DOI 10.1073/pnas.172384399; Matheny CJ, 2007, EMBO J, V26, P1163, DOI 10.1038/sj.emboj.7601568; Mehaffey MG, 2001, BLOOD, V98, P2681, DOI 10.1182/blood.V98.9.2681; MICHIELS JJ, 2002, SEM VASC MED, V1, P1; Mukai HY, 2006, MOL CELL BIOL, V26, P7953, DOI 10.1128/MCB.00718-06; Muntean AG, 2005, BLOOD, V106, P1223, DOI 10.1182/blood-2005-02-0551; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Pang LY, 2006, BLOOD, V108, P2198, DOI 10.1182/blood-2006-04-019760; Phillips JD, 2007, BLOOD, V109, P2618, DOI 10.1182/blood-2006-06-022848; Putz G, 2006, ONCOGENE, V25, P929, DOI 10.1038/sj.onc.1209136; Raskind WH, 2000, BLOOD, V95, P2262, DOI 10.1182/blood.V95.7.2262.007k32_2262_2268; Raslova H, 2004, J CLIN INVEST, V114, P77, DOI 10.1172/JCI200421197; Sandberg ML, 2005, DEV CELL, V8, P153, DOI 10.1016/j.devcel.2004.12.015; Song WJ, 1999, NAT GENET, V23, P166, DOI 10.1038/13793; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Stachura DL, 2006, BLOOD, V107, P87, DOI 10.1182/blood-2005-07-2740; Starck J, 2003, MOL CELL BIOL, V23, P1390, DOI 10.1128/MCB.23.4.1390-1402.2003; Stumpf M, 2006, P NATL ACAD SCI USA, V103, P18504, DOI 10.1073/pnas.0604494103; Sun LS, 2004, BLOOD, V103, P948, DOI 10.1182/blood-2003-07-2299; Sun W, 2004, BLOOD, V104, P3565, DOI 10.1182/blood-2003-12-4349; Talebian L, 2007, BLOOD, V109, P11, DOI 10.1182/blood-2006-05-021188; Tracey WD, 2000, SEMIN CELL DEV BIOL, V11, P337, DOI 10.1006/scdb.2000.0186; Vyas P, 1999, BLOOD, V93, P2867; Walker LC, 2002, BRIT J HAEMATOL, V117, P878, DOI 10.1046/j.1365-2141.2002.03512.x; Waltzer L, 2003, EMBO J, V22, P6516, DOI 10.1093/emboj/cdg622; Wang X, 2002, EMBO J, V21, P5225, DOI 10.1093/emboj/cdf527; Xu G, 2006, LEUKEMIA, V20, P1002, DOI 10.1038/sj.leu.2404223; Yu CN, 2002, BLOOD, V100, P2040, DOI 10.1182/blood-2002-02-0387	60	36	36	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2007	26	47					6795	6802		10.1038/sj.onc.1210762	http://dx.doi.org/10.1038/sj.onc.1210762			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220HE	17934486				2022-12-17	WOS:000250147000010
J	Kamimura, K; Mishima, Y; Obata, M; Endo, T; Aoyagi, Y; Kominami, R				Kamimura, K.; Mishima, Y.; Obata, M.; Endo, T.; Aoyagi, Y.; Kominami, R.			Lack of Bcl11b tumor suppressor results in vulnerability to DNA replication stress and damages	ONCOGENE			English	Article						DNA replication stress; Chk1; p27; apoptosis; Bcl11b tumor suppressor	CELL-DEATH; TRANSCRIPTIONAL REPRESSION; CHECKPOINT KINASE-1; THYMIC LYMPHOMAS; T-LYMPHOCYTES; GENE; MICE; CHK1; PATHWAY; MOUSE	Bcl11b/Rit1 is involved in T-cell development and undergoes chromosomal rearrangements in human T-cell leukemias. Thymocytes of Bcl11b(-/-) newborn mice exhibit apoptosis at a certain developmental stage when thymocytes re-enter into the cell-cycle. Here, we show that Bcl11b-knockdown T-cell lines, when exposed to growth stimuli, exhibited a poptosis at the S phase with concomitant decreases in a cell-cycle inhibitor, p27 and an antiapoptotic protein, Bcl-xL, owing to transcriptional repression. This repression was a likely consequence of the impairment of Sirt1, a nicotinamide adenine dinucleotide-dependent deacetylase associating with Bcl11b. Activation of the apoptotic process cleaved the mediator protein, Claspin, and inhibited phosphorylation of cell-cycle checkpoint kinase 1 ( Chk1) that plays a central role in sensing and responding to incomplete replication. Bcl11b(-/-) thymocytes also failed to phosphorylate Chk1 when UV irradiated. These results implicate Bcl11b in the remedy for DNA replication stress and maintenance of genomic integrity.	Niigata Univ, Dept Mol Genet, Grad Sch Med & Dent Sci, Niigata 9518510, Japan; Niigata Univ, Ctr Trandisciplinary Res, Niigata 9518510, Japan	Niigata University; Niigata University	Kominami, R (corresponding author), Niigata Univ, Dept Mol Genet, Grad Sch Med & Dent Sci, Asahimachi 1-757, Niigata 9518510, Japan.	rykomina@med.niigata-u.ac.jp	Kamimura, Kenya/U-6797-2019					Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Alam A, 1999, J EXP MED, V190, P1879, DOI 10.1084/jem.190.12.1879; Andegeko Y, 2001, J BIOL CHEM, V276, P38224; Avram D, 2000, J BIOL CHEM, V275, P10315, DOI 10.1074/jbc.275.14.10315; Bagheri-Yarmand R, 2004, DEVELOPMENT, V131, P3469, DOI 10.1242/dev.01213; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Chen YH, 2004, DNA REPAIR, V3, P1025, DOI 10.1016/j.dnarep.2004.03.003; Cismasiu VB, 2005, ONCOGENE, V24, P6753, DOI 10.1038/sj.onc.1208904; Clarke CAL, 2005, J BIOL CHEM, V280, P35337, DOI 10.1074/jbc.M506460200; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Eguchi-Ishimae M, 2001, BLOOD, V97, P737, DOI 10.1182/blood.V97.3.737; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Flatten K, 2005, J BIOL CHEM, V280, P14349, DOI 10.1074/jbc.M411890200; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Gounari F, 2001, NAT IMMUNOL, V2, P863, DOI 10.1038/ni0901-863; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; Inoue J, 2006, J IMMUNOL, V176, P5871, DOI 10.4049/jimmunol.176.10.5871; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Lin SY, 2004, P NATL ACAD SCI USA, V101, P6484, DOI 10.1073/pnas.0401847101; Liu QH, 2000, GENE DEV, V14, P1448; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nagel S, 2003, CANCER RES, V63, P5329; Nakano T, 1996, SYST COMPUT JPN, V27, P1, DOI 10.1002/scj.4690270601; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Przybylski GK, 2005, LEUKEMIA, V19, P201, DOI 10.1038/sj.leu.2403619; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Sakata J, 2004, CARCINOGENESIS, V25, P1069, DOI 10.1093/carcin/bgh094; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Satterwhite E, 2001, BLOOD, V98, P3413, DOI 10.1182/blood.V98.12.3413; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Shinbo T, 1999, ONCOGENE, V18, P4131, DOI 10.1038/sj.onc.1202767; Takai H, 2000, GENE DEV, V14, P1439; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; Wakabayashi Y, 2003, NAT IMMUNOL, V4, P533, DOI 10.1038/ni927; Wakabayashi Y, 2003, BIOCHEM BIOPH RES CO, V301, P598, DOI 10.1016/S0006-291X(02)03069-3; WALWORTH N, 1993, NATURE, V363, P368, DOI 10.1038/363368a0; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299; Zhou BBS, 2004, NAT REV CANCER, V4, P216, DOI 10.1038/nrc1296; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	45	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 30	2007	26	40					5840	5850		10.1038/sj.onc.1210388	http://dx.doi.org/10.1038/sj.onc.1210388			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205OH	17369851				2022-12-17	WOS:000249123100002
J	Aufsatz, W; Stoiber, T; Rakic, B; Naumann, K				Aufsatz, W.; Stoiber, T.; Rakic, B.; Naumann, K.			Arabidopsis histone deacetylase 6: a green link to RNA silencing	ONCOGENE			English	Review						RNA silencing; cytosine methylation; histone deacetylation; epigenetics; Arabidopsis; transcriptional gene silencing	DIRECTED DNA METHYLATION; SMALL INTERFERING RNA; DOUBLE-STRANDED-RNA; GROUP PROTEIN EZH2; DE-NOVO; FUNCTIONAL DIVERSIFICATION; CHROMATIN-STRUCTURE; GENE-EXPRESSION; BINDING DOMAIN; ABSCISIC-ACID	Epigenetic reprogramming is at the base of cancer initiation and progression. Generally, genome-wide reduction in cytosine methylation contrasts with the hypermethylation of control regions of functionally well-established tumor suppressor genes and many other genes whose role in cancer biology is not yet clear. While insight into mechanisms that induce aberrant cytosine methylation in cancer cells is just beginning to emerge, the initiating signals for analogous promoter methylation in plants are well documented. In Arabidopsis, the silencing of promoters requires components of the RNA interference machinery and promoter double-stranded RNA ( dsRNA) to induce a repressive chromatin state that is characterized by cytosine methylation and histone deacetylation catalysed by the RPD3-type histone deacetylase AtHDA6. Similar mechanisms have been shown to occur in fission yeast and mammals. This review focuses on the connections between cytosine methylation, dsRNA and AtHDA6- controlled histone deacetylation during promoter silencing in Arabidopsis and discusses potential mechanistic similarities of these silencing events in cancer and plant cells.	Austrian Acad Sci, Gregor Mendel Inst Mol Plant Biol, A-1030 Vienna, Austria	Austrian Academy of Sciences; Vienna Biocenter (VBC); Gregor Mendel Institute of Molecular Plant Biology (GMI)	Aufsatz, W (corresponding author), Austrian Acad Sci, Gregor Mendel Inst Mol Plant Biol, Dr Bohr Gasse 3, A-1030 Vienna, Austria.	werner.aufsatz@gmi.oeaw.ac.at						Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; Aravind L., 1998, SCIENCE, V280, P1167, DOI DOI 10.1126/SCIENCE.280.5367.1167A; Aufsatz W, 2004, PLANT MOL BIOL, V54, P793, DOI 10.1007/s11103-004-0179-1; Aufsatz W, 2002, EMBO J, V21, P6832, DOI 10.1093/emboj/cdf663; Aufsatz W, 2002, P NATL ACAD SCI USA, V99, P16499, DOI 10.1073/pnas.162371499; Battaglioli E, 2002, J BIOL CHEM, V277, P41038, DOI 10.1074/jbc.M205691200; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Benhamed M, 2006, PLANT CELL, V18, P2893, DOI 10.1105/tpc.106.043489; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Cao XF, 2002, CURR BIOL, V12, P1138, DOI 10.1016/S0960-9822(02)00925-9; Cao XF, 2003, CURR BIOL, V13, P2212, DOI 10.1016/j.cub.2003.11.052; Castanotto D, 2005, MOL THER, V12, P179, DOI 10.1016/j.ymthe.2005.03.003; Chan SWL, 2005, NAT REV GENET, V6, P351, DOI 10.1038/nrg1601; Chan SWL, 2004, SCIENCE, V303, P1336, DOI 10.1126/science.1095989; Chang S, 2005, J BIOL CHEM, V280, P796, DOI 10.1074/jbc.M409053200; Chen ZJ, 1997, GENE DEV, V11, P2124, DOI 10.1101/gad.11.16.2124; Cigan AM, 2005, PLANT J, V43, P929, DOI 10.1111/j.1365-313X.2005.02492.x; COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; Datta J, 2003, J CELL BIOCHEM, V88, P855, DOI 10.1002/jcb.10457; De Marzo AM, 1999, CANCER RES, V59, P3855; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; Earley K, 2006, GENE DEV, V20, P1283, DOI 10.1101/gad.1417706; Fahrner JA, 2002, CANCER RES, V62, P7213; Finnin MS, 1999, NATURE, V401, P188, DOI 10.1038/43710; Fuks F, 2001, EMBO J, V20, P2536, DOI 10.1093/emboj/20.10.2536; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Fuks F, 2003, NUCLEIC ACIDS RES, V31, P2305, DOI 10.1093/nar/gkg332; Furner IJ, 1998, GENETICS, V149, P651; Gartenberg MR, 2000, CURR OPIN MICROBIOL, V3, P132, DOI 10.1016/S1369-5274(00)00064-3; Goll MG, 2005, ANNU REV BIOCHEM, V74, P481, DOI 10.1146/annurev.biochem.74.010904.153721; Grimaud C, 2006, CELL, V124, P957, DOI 10.1016/j.cell.2006.01.036; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; Guarente L, 2000, GENE DEV, V14, P1021; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Herr AJ, 2005, SCIENCE, V308, P118, DOI 10.1126/science.1106910; Holst CR, 2003, CANCER RES, V63, P1596; Huettel B, 2006, EMBO J, V25, P2828, DOI 10.1038/sj.emboj.7601150; Jacobsen SE, 2000, CURR BIOL, V10, P179, DOI 10.1016/S0960-9822(00)00324-9; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kanno T, 2005, NAT GENET, V37, P761, DOI 10.1038/ng1580; Kanno T, 2004, CURR BIOL, V14, P801, DOI 10.1016/j.cub.2004.04.037; Kawai T, 2006, NAT IMMUNOL, V7, P131, DOI 10.1038/ni1303; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Kim DH, 2006, NAT STRUCT MOL BIOL, V13, P793, DOI 10.1038/nsmb1142; Klimov Dmitry, 2006, Journal of Bioinformatics and Computational Biology, V4, P515, DOI 10.1142/S0219720006001795; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kondo Y, 2003, MOL CELL BIOL, V23, P206, DOI 10.1128/MCB.23.1.206-215.2003; Lawrence RJ, 2004, MOL CELL, V13, P599, DOI 10.1016/S1097-2765(04)00064-4; Li CF, 2006, CELL, V126, P93, DOI 10.1016/j.cell.2006.05.032; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Lippman Z, 2004, NATURE, V431, P364, DOI 10.1038/nature02875; Lippman Z, 2003, PLOS BIOL, V1, P420, DOI 10.1371/journal.pbio.0000067; Long JA, 2006, SCIENCE, V312, P1520, DOI 10.1126/science.1123841; Lu C, 2005, SCIENCE, V309, P1567, DOI 10.1126/science.1114112; Lusser A, 1997, SCIENCE, V277, P88, DOI 10.1126/science.277.5322.88; Martienssen RA, 2005, TRENDS GENET, V21, P450, DOI 10.1016/j.tig.2005.06.005; Mathieu O, 2004, J CELL SCI, V117, P4881, DOI 10.1242/jcs.01479; Matzke MA, 2005, NAT REV GENET, V6, P24, DOI 10.1038/nrg1500; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Melquist S, 2003, GENE DEV, V17, P2036, DOI 10.1101/gad.1081603; Momparler RL, 2003, ONCOGENE, V22, P6479, DOI 10.1038/sj.onc.1206774; Morris KV, 2004, SCIENCE, V305, P1289, DOI 10.1126/science.1101372; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Murfett J, 2001, PLANT CELL, V13, P1047, DOI 10.1105/tpc.13.5.1047; Nguyen CT, 2001, NUCLEIC ACIDS RES, V29, P4598, DOI 10.1093/nar/29.22.4598; Nicolai M, 2006, PLANT PHYSIOL, V141, P663, DOI 10.1104/pp.106.079418; Onodera Y, 2005, CELL, V120, P613, DOI 10.1016/j.cell.2005.02.007; Pandey R, 2002, NUCLEIC ACIDS RES, V30, P5036, DOI 10.1093/nar/gkf660; Pontes O, 2006, CELL, V126, P79, DOI 10.1016/j.cell.2006.05.031; Pontier D, 2005, GENE DEV, V19, P2030, DOI 10.1101/gad.348405; Probst AV, 2004, PLANT CELL, V16, P1021, DOI 10.1105/tpc.018754; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; Robertson KD, 1999, NUCLEIC ACIDS RES, V27, P2291, DOI 10.1093/nar/27.11.2291; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Selker EU, 1998, P NATL ACAD SCI USA, V95, P9430, DOI 10.1073/pnas.95.16.9430; Song CP, 2006, PLANT MOL BIOL, V60, P241, DOI 10.1007/s11103-005-3880-9; Song CP, 2005, PLANT CELL, V17, P2384, DOI 10.1105/tpc.105.033043; Sridha S, 2006, PLANT J, V46, P124, DOI 10.1111/j.1365-313X.2006.02678.x; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Tian L, 2003, GENETICS, V165, P399; Tian L, 2001, P NATL ACAD SCI USA, V98, P200, DOI 10.1073/pnas.011347998; Ting AH, 2005, NAT GENET, V37, P906, DOI 10.1038/ng1611; Tran RK, 2005, CURR BIOL, V15, P154, DOI 10.1016/j.cub.2005.01.008; Ueno Y, 2007, PLANT CELL, V19, P445, DOI 10.1105/tpc.106.042325; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Verdel A, 2005, FEBS LETT, V579, P5872, DOI 10.1016/j.febslet.2005.08.083; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wassenegger M, 2000, PLANT MOL BIOL, V43, P203, DOI 10.1023/A:1006479327881; Weinberg MS, 2006, RNA, V12, P256, DOI 10.1261/rna.2235106; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wu KQ, 2000, PLANT J, V22, P19, DOI 10.1046/j.1365-313x.2000.00711.x; Xie ZX, 2004, PLOS BIOL, V2, P642, DOI 10.1371/journal.pbio.0020104; Xu CR, 2005, P NATL ACAD SCI USA, V102, P14469, DOI 10.1073/pnas.0503143102; Zemach A, 2007, TRENDS PLANT SCI, V12, P80, DOI 10.1016/j.tplants.2006.12.004; Zhang XY, 2006, CELL, V126, P1189, DOI 10.1016/j.cell.2006.08.003; Zhao YD, 2003, SCIENCE, V301, P1107, DOI 10.1126/science.1084161; Zhou CH, 2005, PLANT CELL, V17, P1196, DOI 10.1105/tpc.104.028514; Zhou CH, 2004, PLANT J, V38, P715, DOI 10.1111/j.1365-313X.2004.02083.x; Zilberman D, 2003, SCIENCE, V299, P716, DOI 10.1126/science.1079695; Zilberman D, 2007, NAT GENET, V39, P61, DOI 10.1038/ng1929	112	36	38	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 13	2007	26	37					5477	5488		10.1038/sj.onc.1210615	http://dx.doi.org/10.1038/sj.onc.1210615			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CR	17694088				2022-12-17	WOS:000248674300015
J	Chlenski, A; Guerrero, LJ; Yang, Q; Tian, Y; Peddinti, R; Salwen, HR; Cohn, SL				Chlenski, A.; Guerrero, L. J.; Yang, Q.; Tian, Y.; Peddinti, R.; Salwen, H. R.; Cohn, S. L.			SPARC enhances tumor stroma formation and prevents fibroblast activation	ONCOGENE			English	Article						tumor stroma; activated fibroblast; SPARC; tumor microenvironment	GRANULATION-TISSUE; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; GROWTH; EXPRESSION; CARCINOMA; ANGIOGENESIS; GLYCOPROTEIN; MYOFIBROBLASTS; TUMORIGENESIS	Tumor growth is influenced by interactions between malignant cells and the tumor stroma. Although the normal host microenvironment is nonpermissive for neoplastic progression, tumor-reactive stroma, characterized by the presence of activated fibroblasts, promotes neoplastic growth and metastasis. Secreted protein, acidic and rich in cysteine (SPARC) is a matricellular glycoprotein that is capable of inhibiting the growth of several different types of cancer. Recently, we reported that SPARC also impairs the growth of xenografts comprised of 293 cells. In this study, we show that in addition to enhancing stroma formation, SPARC prevents fibroblast activation in 293 xenografts, suggesting that the anticancer effects of SPARC may be due, at least in part, to the formation of tumor stroma that is not supportive of tumor growth. In vitro, 3T3 fibroblasts cocultured with SPARC-transfected 293 cells remain negative for alpha-smooth muscle actin, whereas wild-type 293 cells induce fibroblast activation. Moreover, activation of 3T3 cells and primary fibroblasts by transforming growth factor beta is blocked by SPARC treatment. We also demonstrate that SPARC significantly increases basic fibroblast growth factor-induced fibroblast migration in vitro, indicating that it may recruit host fibroblasts to the tumor stroma. Taken together, our results suggest that in addition to blocking angiogenesis, SPARC may inhibit tumor growth by promoting the assembly of stroma that is nonpermissive for tumor progression.	Univ Chicago, Inst Mol Pediat Sci, Div Clin Sci, Chicago, IL 60637 USA; Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA; Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL USA	University of Chicago; Ann & Robert H. Lurie Children's Hospital of Chicago; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine	Cohn, SL (corresponding author), Univ Chicago, Inst Mol Pediat Sci, Div Clin Sci, 5841 Maryland Ave,MC 4060,Rm N114, Chicago, IL 60637 USA.	scohn@peds.bsd.uchicago.edu	Cohn, Susan/AAB-6010-2021	Cohn, Susan/0000-0001-5749-7650; , Qiwei Yang/0000-0001-7131-8946	NCI NIH HHS [5P30CA60553] Funding Source: Medline; NINDS NIH HHS [NS 049814] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA060553] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS049814] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; Barker TH, 2005, J BIOL CHEM, V280, P36483, DOI 10.1074/jbc.M504663200; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken RA, 2003, J CLIN INVEST, V111, P487, DOI 10.1172/JCI200316804; Chlenski A, 2006, INT J CANCER, V118, P310, DOI 10.1002/ijc.21357; Chlenski A, 2002, CANCER RES, V62, P7357; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Framson PE, 2004, J CELL BIOCHEM, V92, P679, DOI 10.1002/jcb.20091; Francki A, 2004, J CELL BIOCHEM, V91, P915, DOI 10.1002/jcb.20008; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; GABBIANI G, 1971, EXPERIENTIA, V27, P549, DOI 10.1007/BF02147594; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamid T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-3; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Liu SQ, 2005, AM J PATHOL, V166, P891, DOI 10.1016/S0002-9440(10)62309-7; Maeshima AM, 2002, CANCER, V95, P2546, DOI 10.1002/cncr.11006; Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Paget S., 1889, 1889 CANC METASTASIS, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Perdue N, 2006, EXP EYE RES, V83, P1154, DOI 10.1016/j.exer.2006.06.007; Pichler RH, 1996, AM J PATHOL, V148, P1153; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; ROSEN ST, 1987, LAB INVEST, V56, P302; SAGE H, 1984, J BIOL CHEM, V259, P3993; Schiemann BJ, 2003, MOL BIOL CELL, V14, P3977, DOI 10.1091/mbc.E03-01-0001; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008-5472.CAN-05-1522; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; Yazhou C, 2004, TUMOR BIOL, V25, P290, DOI 10.1159/000081394	35	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4513	4522		10.1038/sj.onc.1210247	http://dx.doi.org/10.1038/sj.onc.1210247			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17260013				2022-12-17	WOS:000247836100005
J	Tomida, S; Yanagisawa, K; Koshikawa, K; Yatabe, Y; Mitsudomi, T; Osada, H; Takahashi, T				Tomida, S.; Yanagisawa, K.; Koshikawa, K.; Yatabe, Y.; Mitsudomi, T.; Osada, H.; Takahashi, T.			Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach	ONCOGENE			English	Article						lung cancer; metastasis; expression profile; DLX4; gene ontology	LUNG-CANCER; MICROARRAY ANALYSIS; EXPRESSION; GENE; TUMORS; PROGRESSION; SURVIVAL; MODELS; GROWTH	Although widespread metastasis is the major cause of human lung cancer-related deaths, its underlying mechanism remains largely unclear. Our genome-wide comparison of the expression profiles of a highly metastatic lung cancer cell line, NCI-H460-LNM35 (LNM35), and its parental clone, NCI-H460-N15 (N15), resulted in the identification of a cancer metastasis signature composed of 45 genes. Through gene ontology analysis, our study also provided insights into how this 45-gene metastasis signature may contribute to the acquisition of metastatic potential. By applying the signature to datasets of human cancer cases, we could demonstrate significant associations with a subset of cases with poor prognosis not only for the two datasets of cancers of the lung but also for cancers of the breast. Furthermore, we were able to show that enforced expression of the DLX4 homeobox gene, which was identified as a gene with significant downregulation in LNM35 as well as with significant association with favorable prognosis for lung cancer patients, markedly inhibited in vitro motility and invasion as well as in vivo metastasis via both hematogenous and lymphogenous routes. Taken together, these findings indicate that our combined transcriptome analysis is an efficient approach in the search for genes possessing both clinical usefulness in terms of prognostic prediction in human cancer cases and clear functional relevance for studying cancer biology in relation to metastasis.	Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Nagoya, Aichi, Japan; Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 464, Japan; Aichi Canc Ctr Hosp, Dept Thorac Surg, Nagoya, Aichi 464, Japan; Aichi Canc Ctr, Res Inst, Div Mol Oncol, Nagoya, Aichi 464, Japan	Nagoya University; Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis,Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi, Japan.	tak@med.nagoya-u.ac.jp	Osada, Hiroyuki/AAY-6254-2020; Yanagisawa, Kiyoshi/I-7263-2014; YATABE, Yasushi/J-6461-2014; Takahashi, Takashi/I-7262-2014	YATABE, Yasushi/0000-0003-1788-559X; Takahashi, Takashi/0000-0003-0615-7001; Mitsudomi, Tetsuya/0000-0001-9860-8505				Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Ayala GE, 2004, CANCER RES, V64, P6082, DOI 10.1158/0008-5472.CAN-04-0838; Bernal JA, 2002, NAT GENET, V32, P306, DOI 10.1038/ng997; Bobrovnikova-Marjon EV, 2004, CANCER RES, V64, P4858, DOI 10.1158/0008-5472.CAN-04-0682; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Dasgupta B, 2005, CANCER RES, V65, P9843, DOI 10.1158/0008-5472.CAN-05-1842; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Gallagher PG, 2005, CANCER RES, V65, P4134, DOI 10.1158/0008-5472.CAN-04-0415; GENTLEMAN RC, 1994, STAT MED, V13, P805, DOI 10.1002/sim.4780130803; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Goswami S, 2004, CANCER RES, V64, P7664, DOI 10.1158/0008-5472.CAN-04-2027; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kim YH, 2006, ONCOGENE, V25, P130, DOI 10.1038/sj.onc.1208997; Kozaki K, 2000, CANCER RES, V60, P2535; Liu FT, 2005, NAT REV CANCER, V5, P29, DOI 10.1038/nrc1527; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Miyamoto K, 2005, INT J CANCER, V116, P407, DOI 10.1002/ijc.21054; Morowitz MJ, 2005, CLIN CANCER RES, V11, P2680, DOI 10.1158/1078-0432.CCR-04-1917; Nicholson BE, 2004, CANCER RES, V64, P7813, DOI 10.1158/0008-5472.CAN-04-0826; Osada H, 2002, ONCOGENE, V21, P7421, DOI 10.1038/sj.onc.1205802; Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370; Quinn LM, 1998, PLACENTA, V19, P87, DOI 10.1016/S0143-4004(98)90103-5; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Takeuchi T, 2006, J CLIN ONCOL, V24, P1679, DOI 10.1200/JCO.2005.03.8224; Tomida S, 2004, ONCOGENE, V23, P5360, DOI 10.1038/sj.onc.1207697	29	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2007	26	31					4600	4608		10.1038/sj.onc.1210242	http://dx.doi.org/10.1038/sj.onc.1210242			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	187GR	17260014				2022-12-17	WOS:000247836100015
J	Schild-Poulter, C; Shih, A; Tantin, D; Yarymowich, NC; Soubeyrand, S; Sharp, PA; Hache, RJG				Schild-Poulter, C.; Shih, A.; Tantin, D.; Yarymowich, N. C.; Soubeyrand, S.; Sharp, P. A.; Hache, R. J. G.			DNA-PK phosphorylation sites on Oct-1 promote cell survival following DNA damage	ONCOGENE			English	Article						Ku; DNA-dependent protein kinase; Oct-1; DNA damage; phosphorylation	DEPENDENT PROTEIN-KINASE; TRANSCRIPTION FACTOR OCT-1; DOUBLE-STRAND BREAKS; CATALYTIC SUBUNIT; HISTONE H2B; MULTISITE PHOSPHORYLATION; IONIZING-RADIATION; DOWN-REGULATION; POU DOMAIN; IN-VITRO	Octamer transcription factor-1 ( Oct-1) has recently been shown to function as a stress sensor that promotes cell survival subsequent to DNA damage. Here, we show that the survival signal imparted by Oct-1 following exposure to ionizing radiation ( IR) is dependent upon DNA-dependent protein kinase ( DNA-PK)-dependent phosphorylation of a cluster of 13 specific ser/thr residues within the N-terminal transcriptional regulatory domain of Oct-1. Although IR treatment did not affect the recruitment of Oct-1 to the histone H2B promoter, the recruitment of RNA polymerase II, TATA-binding protein and histone H4 acetylation were strongly reduced, consistent with a decrease in Oct-1 transcriptional regulatory potential following IR exposure. Ser/Thr-Ala substitution of 13 sites present in Oct-1 transcriptional regulatory domain eliminated Oct-1 phosphorylation subsequent to IR exposure. Further, these substitutions prevented Oct-1 from rescuing the survival of IR-treated Oct-1(-/-) murine embryonic fibroblasts, providing a direct link between DNA-PK- dependent phosphorylation and the contribution of Oct-1 to cell survival. These results implicate Oct-1 as a primary effector in a DNA-PK-dependent cell survival pathway that is activated by double-stranded DNA breaks.	Univ Ottawa, Dept Med, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; MIT, Ctr Canc Res, Cambridge, MA 02139 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Schild-Poulter, C (corresponding author), Univ Ottawa, Dept Med, Ottawa Hlth Res Inst, 725 Parkdale Rd, Ottawa, ON K1Y 4E9, Canada.	cschild-poulter@robarts.ca; rhache@ohri.ca	Schild-Poulter, Caroline/K-4476-2013	soubeyrand, sebastien/0000-0002-9317-301X				Bailey SM, 2004, CYTOGENET GENOME RES, V104, P109, DOI 10.1159/000077474; Bharti A, 1998, MOL CELL BIOL, V18, P6719, DOI 10.1128/MCB.18.11.6719; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1999, BIOCHEMISTRY-US, V38, P1819, DOI 10.1021/bi982584b; Collis SJ, 2005, ONCOGENE, V24, P949, DOI 10.1038/sj.onc.1208332; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; EBLE MJ, 1994, INT J RADIAT BIOL, V65, P193, DOI 10.1080/09553009414550231; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; Giffin W, 1997, J BIOL CHEM, V272, P5647, DOI 10.1074/jbc.272.9.5647; Gunawardena J, 2005, P NATL ACAD SCI USA, V102, P14617, DOI 10.1073/pnas.0507322102; HECKMAN CA, 2005, ONCOGENE, V26, P26; HERR W, 1995, GENE DEV, V9, P1679, DOI 10.1101/gad.9.14.1679; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Jin SQ, 2001, ONCOGENE, V20, P2683, DOI 10.1038/sj.onc.1204390; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Lees-Miller SP, 2003, BIOCHIMIE, V85, P1161, DOI 10.1016/j.biochi.2003.10.011; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li L, 2004, BIOCHEM CELL BIOL, V82, P460, DOI 10.1139/O04-045; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Loong SLE, 2004, ONCOGENE, V23, P5562, DOI 10.1038/sj.onc.1207771; Luo XQ, 2003, ONCOGENE, V22, P7247, DOI 10.1038/sj.onc.1207010; Maiti NR, 2005, J INTERF CYTOK RES, V25, P553, DOI 10.1089/jir.2005.25.553; Meek K, 2004, IMMUNOL REV, V200, P132, DOI 10.1111/j.0105-2896.2004.00162.x; Meighan-Mantha RL, 1999, MOL CELL BIOCHEM, V199, P209, DOI 10.1023/A:1006958217143; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Pufall MA, 2005, SCIENCE, V309, P142, DOI 10.1126/science.1111915; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Schild-Poulter C, 2003, CANCER RES, V63, P7197; Schild-Poulter C, 2001, J BIOL CHEM, V276, P16848, DOI 10.1074/jbc.M100768200; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Servillo G, 2002, EXP CELL RES, V275, P143, DOI 10.1006/excr.2002.5491; SIVE HL, 1986, P NATL ACAD SCI USA, V83, P6382, DOI 10.1073/pnas.83.17.6382; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Soubeyrand S, 2004, EUR J BIOCHEM, V271, P3776, DOI 10.1111/j.1432-1033.2004.04319.x; Soubeyrand S, 2003, CANCER RES, V63, P1198; STRONG CB, 1996, ADV ENVIRONM MANAG, V1, P1; Su C, 2004, EMBO J, V23, P1133, DOI 10.1038/sj.emboj.7600120; Takahashi S, 2001, CANCER RES, V61, P1187; Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008-5472.CAN-05-2399; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Wang VEH, 2004, MOL CELL BIOL, V24, P1022, DOI 10.1128/MCB.24.3.1022-1032.2004; Whitmarsh AJ, 2000, CELL MOL LIFE SCI, V57, P1172, DOI 10.1007/PL00000757; Wilkins RC, 1999, J MOL BIOL, V285, P515, DOI 10.1006/jmbi.1998.2356; Wiper-Bergeron N, 2003, EMBO J, V22, P2135, DOI 10.1093/emboj/cdg218; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Zhao HC, 2000, CANCER RES, V60, P6276; Zhao JY, 2000, GENE DEV, V14, P2283, DOI 10.1101/gad.827700	54	36	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2007	26	27					3980	3988		10.1038/sj.onc.1210165	http://dx.doi.org/10.1038/sj.onc.1210165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177HP	17213819				2022-12-17	WOS:000247144500008
J	Montano, MM; Chaplin, LJ; Deng, H; Mesia-Vela, S; Gaikwad, N; Zahid, M; Rogan, E				Montano, M. M.; Chaplin, L. J.; Deng, H.; Mesia-Vela, S.; Gaikwad, N.; Zahid, M.; Rogan, E.			Protective roles of quinone reductase and tamoxifen against estrogen-induced mammary tumorigenesis	ONCOGENE			English	Article						quinone reductase; oxidative damage; estrogen receptor beta; estrogen; antiestrogens; mammary gland	TRANSCRIPTIONAL REGULATION; FUNCTIONAL IMPLICATIONS; F344 RAT; CARCINOGEN; INDUCTION; RECEPTOR; CANCER; DAMAGE; BETA; SUSCEPTIBILITY	We previously reported that antiestrogen-liganded estrogen receptor beta (ER beta) transcriptionally activates the major detoxifying enzyme quinone reductase (QR) (NAD(P)H:quinone oxidoreductase). Further studies on the functional role of ERb-mediated upregulation of antioxidative enzymes indicated protective effects against estrogen induced oxidative DNA damage (ODD). We now report on in vivo and in vitro studies that show that ER beta-mediated upregulation of QR are involved in the protection against estrogen-induced mammary tumorigenesis. Using the August Copenhagen Irish (ACI) model of estrogen-induced carcinogenesis, we observed that increased ODD and decreased QR expression occur early in the process of estrogen-induced mammary tumorigenesis. Prevention of ACI mammary gland tumorigenesis by tamoxifen was accompanied by decreased ODD and increased QR levels. These correlative findings were supported by our findings that down regulation of QR levels led to increased levels of estrogen quinone metabolites and enhanced transformation potential of 17 beta-estradiol treated MCF10A non-tumorigenic breast epithelial cells. Concurrent expression of ER beta and treatment with 4-hydroxytamoxifen decreased tumorigenic potential of these MCF10A cells. We conclude that upregulation of QR, through induction by tamoxifen, can inhibit estrogen-induced ODD and mammary cell tumorigenesis, representing a possible novel mechanism of tamoxifen prevention against breast cancer.	Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA; Columbia Univ, Med Ctr, Emphysema & Canc Act Program, New York, NY USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68182 USA	Case Western Reserve University; Columbia University; University of Nebraska System; University of Nebraska Medical Center	Montano, MM (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, HG Wood Bldg Room W367,2109 Adelbert Rd, Cleveland, OH 44106 USA.	mxm126@po.cwru.edu		zahid, Muhammad/0000-0002-9975-9476	NCI NIH HHS [CA92440, CA80959, P01 CA49210] Funding Source: Medline; NIEHS NIH HHS [ES05022] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092440, P01CA049210] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ansell PJ, 2004, ENDOCRINOLOGY, V145, P311, DOI 10.1210/en.2003-0817; Bianco NR, 2003, MOL ENDOCRINOL, V17, P1344, DOI 10.1210/me.2002-0382; Dawson PJ, 1996, AM J PATHOL, V148, P313; Guo M, 2001, BIOCHEM PHARMACOL, V62, P1449, DOI 10.1016/S0006-2952(01)00801-2; Harvell DME, 2000, P NATL ACAD SCI USA, V97, P2779, DOI 10.1073/pnas.050569097; Helbock HJ, 1999, METHOD ENZYMOL, V300, P156; Jefcoate C R, 2000, J Natl Cancer Inst Monogr, P95; Jones SB, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-62; Kassie F, 2003, CARCINOGENESIS, V24, P255, DOI 10.1093/carcin/24.2.255; Li JJ, 2002, MOL CARCINOGEN, V33, P56, DOI 10.1002/mc.10022; Li SA, 2002, J ENDOCRINOL, V175, P297, DOI 10.1677/joe.0.1750297; Liehr JG, 2000, ENDOCR REV, V21, P40, DOI 10.1210/er.21.1.40; Matusheski NV, 2001, J AGR FOOD CHEM, V49, P5743, DOI 10.1021/jf010809a; Montano MM, 2004, ONCOGENE, V23, P2442, DOI 10.1038/sj.onc.1207358; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Rogan EG, 2003, CARCINOGENESIS, V24, P697, DOI 10.1093/carcin/bgg004; Saji S, 2000, P NATL ACAD SCI USA, V97, P337, DOI 10.1073/pnas.97.1.337; Thomas RD, 2006, CHEM-BIOL INTERACT, V160, P204, DOI 10.1016/j.cbi.2006.01.007	19	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2007	26	24					3587	3590		10.1038/sj.onc.1210144	http://dx.doi.org/10.1038/sj.onc.1210144			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	172JC	17160017				2022-12-17	WOS:000246799200015
J	Avivi, A; Ashur-Fabian, O; Joel, A; Trakhtenbrot, L; Adamsky, K; Goldstein, I; Amariglio, N; Rechavi, G; Nevo, E				Avivi, A.; Ashur-Fabian, O.; Joel, A.; Trakhtenbrot, L.; Adamsky, K.; Goldstein, I.; Amariglio, N.; Rechavi, G.; Nevo, E.			P53 in blind subterranean mole rats - loss-of-function versus gain-offunction activities on newly cloned Spalax target genes	ONCOGENE			English	Article						subterranean mole rat; hypoxia; p53; apaf1; mdm2	ENDOTHELIAL GROWTH-FACTOR; EXPRESSION; APOPTOSIS; TOLERANCE; MUTANTS; CELLS; ERYTHROPOIETIN; ACTIVATION; CANCER; APAF-1	A tumor suppressor gene, p53, controls cellular responses to a variety of stress conditions, including DNA damage and hypoxia, leading to growth arrest and/or apoptosis. Recently, we demonstrated that in blind subterranean mole rats, Spalax, a model organism for hypoxia tolerance, the p53 DNA-binding domain contains a specific Arg174Lys amino acid substitution. This substitution reduces the p53 effect on the transcription of apoptosis genes ( apaf1, puma, pten and noxa) and enhances it on human cell cycle arrest and p53 stabilization/homeostasis genes (mdm2, pten, p21 and cycG). In the current study, we cloned Spalax apaf1 promoter and mdm2 intronic regions containing consensus p53-responsive elements. We compared the Spalax-responsive elements to those of human, mouse and rat and investigated the transcriptional activity of Spalax and human Arg174Lys-mutated p53 on target genes of both species. Spalax and human-mutated p53 lost induction of apaf1 transcription, and increased induction of mdm2 transcription. We conclude that Spalax evolved hypoxia-adaptive mechanisms, analogous to the alterations acquired by cancer cells during tumor development, with a bias against apoptosis while favoring cell arrest and DNA repair.	Univ Haifa, Inst Evolut, Lab Anim Mol Evolut, IL-31905 Haifa, Israel; Safra Childrens Hosp, Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	University of Haifa; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Avivi, A (corresponding author), Univ Haifa, Inst Evolut, Lab Anim Mol Evolut, Aba Hushi Blv, IL-31905 Haifa, Israel.	aaron@research.haifa.ac.il	Ashur, Osnat/AAC-1417-2020	Ashur-Fabian, Osnat/0000-0001-8624-3182				Ashur-Fabian C, 2004, P NATL ACAD SCI USA, V101, P12236, DOI 10.1073/pnas.0404998101; Avivi A, 2005, FASEB J, V19, P1314, DOI 10.1096/fj.04-3414fje; Avivi A, 2005, CELL CYCLE, V4, P368, DOI 10.4161/cc.4.3.1534; Avivi A, 1999, FEBS LETT, V452, P133, DOI 10.1016/S0014-5793(99)00584-0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Gagnebin J, 1998, ONCOGENE, V16, P685, DOI 10.1038/sj.onc.1201568; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Jubb AM, 2004, J CLIN PATHOL, V57, P504, DOI 10.1136/jcp.2003.012963; Kannan K, 2001, ONCOGENE, V20, P3449, DOI 10.1038/sj.onc.1204446; Kinzler KW, 1996, NATURE, V379, P19, DOI 10.1038/379019a0; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Klein G, 2004, CELL DEATH DIFFER, V11, P13, DOI 10.1038/sj.cdd.4401342; Kuramochi H, 2006, CLIN CANCER RES, V12, P29, DOI 10.1158/1078-0432.CCR-05-1275; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nevo, 1999, MOSAIC EVOLUTION SUB; NEVO E., 2001, ADAPTIVE RAD BLIND S; OLIVER FJ, 1993, BIOCHEM BIOPH RES CO, V194, P126, DOI 10.1006/bbrc.1993.1794; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Rozenfeld-Granot G, 2002, ONCOGENE, V21, P1469, DOI 10.1038/sj.onc.1205218; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Shams I, 2005, FASEB J, V19, P1749, DOI 10.1096/fj.05-3975fje; Shams I, 2004, FASEB J, V18, P307, DOI 10.1096/fj.04-2758fje; Shams I, 2004, P NATL ACAD SCI USA, V101, P9698, DOI 10.1073/pnas.0403540101; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Widmer HR, 1997, P NATL ACAD SCI USA, V94, P2062, DOI 10.1073/pnas.94.5.2062	33	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2007	26	17					2507	2512		10.1038/sj.onc.1210045	http://dx.doi.org/10.1038/sj.onc.1210045			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	158YG	17043642				2022-12-17	WOS:000245831000011
J	Bagella, L; Sun, A; Tonini, T; Abbadessa, G; Cottone, G; Paggi, MG; De Luca, A; Claudio, PP; Giordano, A				Bagella, L.; Sun, A.; Tonini, T.; Abbadessa, G.; Cottone, G.; Paggi, M. G.; De Luca, A.; Claudio, P. P.; Giordano, A.			A small molecule based on the pRb2/p130 spacer domain leads to inhibition of cdk2 activity, cell cycle arrest and tumor growth reduction in vivo	ONCOGENE			English	Article						pRb2/p130; small molecules; peptides; cdk2 inhibitor; kinase activity	DEPENDENT KINASES; CANCER-CELLS; LUNG-CANCER; RETINOBLASTOMA PROTEIN; FLAVOPIRIDOL; EXPRESSION; INDUCTION; GENE; P107; SUPPRESSION	One strategy in the development of anticancer therapeutics has been to arrest malignant proliferation through inhibition of the enzymatic activity of cyclin-dependent kinases (cdks), which are key regulatory molecules of the cell cycle. Over the past few years, numerous compounds with remarkable cdk inhibitory activity have been studied in cancer therapy, although it is very difficult to point out the best cdk to target. An excellent candidate appears to be cdk2, whose alteration is a pathogenic hallmark of tumorigenesis. The small molecule described in our study showed an inhibitory effect on the kinase activity of cdk2, a significant growth arrest observed in a colony formation assay and a reduction in the size of the tumor in nude mice, thus suggesting its potential role as a promising new type of mechanism-based antitumor drug, also for the treatment of hyperproliferative disorders.	Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA; Univ Sassari, Dept Biomed Sci, Div Biochem, I-07100 Sassari, Italy; Univ Siena, Dept Human Pathol & Oncol, I-53100 Siena, Italy; Regina Elena Inst Canc Res, Ctr Expt Res, Dept Dev Therapeut Programs, Lab C, Rome, Italy; Univ Naples 2, Dept Med & Publ Hlth, Sect Clin Anat, Naples, Italy	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Sassari; University of Siena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita della Campania Vanvitelli	Giordano, A (corresponding author), Temple Univ, Ctr Biotechnol, Sbarro Inst Canc Res & Mol Med, Bio Life Sci Bldg,Suite 333,1900 N 12th St, Philadelphia, PA 19122 USA.	giordano@temple.edu	Sun, Ang/G-1537-2015; Giordano, Antonio/F-1927-2010; Claudio, Pier Paolo/AAW-7282-2021; Paggi, Marco G./K-3494-2018; De Luca, Antonio/AAD-9562-2020	Sun, Ang/0000-0002-8644-0407; Giordano, Antonio/0000-0002-5959-016X; Claudio, Pier Paolo/0000-0001-7790-1622; De Luca, Antonio/0000-0002-3905-6154; BAGELLA, Luigi/0000-0003-2815-037X				Al-Aynati MM, 2004, CLIN CANCER RES, V10, P6598, DOI 10.1158/1078-0432.CCR-04-0524; Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; Andrews MJI, 2004, ORG BIOMOL CHEM, V2, P2735, DOI 10.1039/b409157d; BAGELLA L, 2006, J CELL BIOCH; BATES S, 1994, ONCOGENE, V9, P71; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Caputi M, 2005, J CELL PHYSIOL, V205, P319, DOI 10.1002/jcp.20424; Carlson BA, 1996, CANCER RES, V56, P2973; Caterina C, 2005, ONCOGENE, V24, P5821, DOI 10.1038/sj.onc.1208880; Chae HD, 2004, ONCOGENE, V23, P4084, DOI 10.1038/sj.onc.1207482; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; Dai Yun, 2004, Curr Oncol Rep, V6, P123, DOI 10.1007/s11912-004-0024-3; DeLuca A, 1997, J BIOL CHEM, V272, P20971, DOI 10.1074/jbc.272.34.20971; Du W, 2006, ONCOGENE, V25, P5190, DOI 10.1038/sj.onc.1209651; Fischer PM, 2003, EXPERT OPIN INV DRUG, V12, P955, DOI 10.1517/eoid.12.6.955.21792; Gallo G, 2005, J CELL PHYSIOL, V205, P176, DOI 10.1002/jcp.20451; Geng Y, 2003, CELL, V114, P431, DOI 10.1016/S0092-8674(03)00645-7; Genovese C, 2006, ONCOGENE, V25, P5201, DOI 10.1038/sj.onc.1209652; GIBBS JB, 1994, CELL, V79, P193, DOI 10.1016/0092-8674(94)90189-9; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIORDANO A, 1991, SCIENCE, V253, P1271, DOI 10.1126/science.1653969; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Harwell RM, 2004, J BIOL CHEM, V279, P12695, DOI 10.1074/jbc.M313407200; Howard CM, 2000, CANCER RES, V60, P2737; Hsu YL, 2004, LIFE SCI, V75, P2303, DOI 10.1016/j.lfs.2004.04.027; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Lee HR, 1999, INT J ONCOL, V15, P161; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; Li YW, 2000, INT J ONCOL, V17, P755; Liao C, 2004, INT J CANCER, V108, P654, DOI 10.1002/ijc.11573; LOSIEWICZ MD, 1994, BIOCHEM BIOPH RES CO, V201, P589, DOI 10.1006/bbrc.1994.1742; Macaluso M, 2006, ONCOGENE, V25, P5263, DOI 10.1038/sj.onc.1209680; MACLACHLAN TK, 1995, CRIT REV EUKAR GENE, V5, P127, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.20; Malumbres M, 2005, TRENDS BIOCHEM SCI, V30, P630, DOI 10.1016/j.tibs.2005.09.005; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; MAYOL X, 1993, ONCOGENE, V8, P2561; Merola E, 2006, J CELL PHYSIOL, V207, P512, DOI 10.1002/jcp.20590; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; Olofsson A, 2004, INT J ONCOL, V25, P1349; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Pepper C, 2001, BRIT J HAEMATOL, V114, P70, DOI 10.1046/j.1365-2141.2001.02895.x; Purev E, 2006, J CELL PHYSIOL, V206, P495, DOI 10.1002/jcp.20490; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; Senderowicz AM, 2003, ONCOGENE, V22, P6609, DOI 10.1038/sj.onc.1206954; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Song YC, 2004, BIOCHEM BIOPH RES CO, V317, P128, DOI 10.1016/j.bbrc.2004.03.019; Sunters A, 2004, J BIOL CHEM, V279, P9882, DOI 10.1074/jbc.M310184200; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Tosi GM, 2005, ONCOGENE, V24, P5827, DOI 10.1038/sj.onc.1208630; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Woo MSA, 1997, MOL CELL BIOL, V17, P3566, DOI 10.1128/MCB.17.7.3566; Xiong Y, 1996, Biochim Biophys Acta, V1288, P01; Yu CH, 2004, BIOCHEM PHARMACOL, V67, P1907, DOI 10.1016/j.bcp.2004.02.004; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740; ZHU L, 1995, EMBO J, V14, P1904, DOI 10.1002/j.1460-2075.1995.tb07182.x	64	36	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1829	1839		10.1038/sj.onc.1209987	http://dx.doi.org/10.1038/sj.onc.1209987			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043661				2022-12-17	WOS:000245117700001
J	Crosby, ME; Jacobberger, J; Gupta, D; Macklis, RM; Almasan, A				Crosby, M. E.; Jacobberger, J.; Gupta, D.; Macklis, R. M.; Almasan, A.			E2F4 regulates a stable G(2) arrest response to genotoxic stress in prostate carcinoma	ONCOGENE			English	Article						E2F4 knockdown; G(2) cell cycle arrest; apoptosis; ionizing radiation	CELL-CYCLE EXIT; DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; GENETIC INSTABILITY; DOWN-REGULATION; IN-VIVO; EXPRESSION; P53; REPLICATION; CHECKPOINT	The retinoblastoma (pRB) family proteins regulate the E2F transcription factors; their complexes regulate critical transitions through the cell cycle. The function of these pRBfamily/E2F complexes, which includes p130/E2F4, in response to genotoxic agents, is not well understood. We investigated the role of E2F4 in the genotoxic stress response. Following radiation treatment, E2F4 colocalized with p130 in the nucleus during a radiation-induced stable G2-phase arrest. Arrested cells had significantly decreased expression of Cyclins A2 and B1 and decreased phosphorylation of mitotic protein monoclonal-2 (MPM-2) mitotic proteins. Small interference RNA (siRNA)-mediated knockdown of E2F4 sensitized cells to subsequent irradiation, resulting in enhanced cellular DNA damage and cell death, as determined by caspase activation and decreased clonogenic cell survival. Downstream E2F4 targets potentially involved in the progression from G2 into M phase were identified by oligonucleotide microarray expression pro. ling. Chromatin immunoprecipitation localized E2F4 at promoter regions of the Bub3 and Pttg1 mitotic genes following irradiation, which were among the downregulated genes identified by the microarray. These data suggest that in response to radiation, E2F4 becomes active in the nucleus, enforces a stable G2 arrest by target gene repression, and thus provides increased cell survival ability by minimizing propagation of cells that have irreparable DNA damage.	Cleveland Clin, Dept Canc Biol & Radiat Oncol, Cleveland, OH 44195 USA; Lerner Res Inst, Dept Canc Biol, Cleveland, OH USA; Case Western Reserve Univ, Dept Environm Hlth Sci, Cleveland, OH 44106 USA; Case Western Reserve Univ, Case Comprehens Canc Ctr, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Almasan, A (corresponding author), Cleveland Clin, Dept Canc Biol & Radiat Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	almasaa@ccf.org	Almasan, Alex/C-2715-2008; Jacobberger, James/P-9183-2014	Almasan, Alex/0000-0002-8916-6650; Jacobberger, James/0000-0002-3092-5157; Crosby, Meredith/0000-0002-3626-9445	NATIONAL CANCER INSTITUTE [R01CA081504, R01CA082858] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA081504-08, R01 CA081504-09, R01 CA081504-07, CA82858, R01 CA082858, CA81504, R01 CA081504] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, CANCER METAST REV, V14, P59, DOI 10.1007/BF00690212; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Baus F, 2003, EMBO J, V22, P3992, DOI 10.1093/emboj/cdg387; Bindra RS, 2005, CANCER RES, V65, P11597, DOI 10.1158/0008-5472.CAN-05-2119; Bindra RS, 2005, MUTAT RES-FUND MOL M, V569, P75, DOI 10.1016/j.mrfmmm.2004.03.013; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 2000, GENE DEV, V14, P1584; Chang BD, 2000, ONCOGENE, V19, P2165, DOI 10.1038/sj.onc.1203573; Cobrinik D, 2005, ONCOGENE, V24, P2796, DOI 10.1038/sj.onc.1208619; Crosby ME, 2004, CANCER BIOL THER, V3, P1208, DOI 10.4161/cbt.3.12.1494; Crosby ME, 2004, J ENVIRON PATHOL TOX, V23, P67, DOI 10.1615/JEnvPathToxOncol.v23.i1.70; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; DuPree EL, 2004, CANCER RES, V64, P4390, DOI 10.1158/0008-5472.CAN-03-3695; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Gaubatz S, 2001, MOL CELL BIOL, V21, P1384, DOI 10.1128/MCB.21.4.1384-1392.2001; Giangrande PH, 2004, GENE DEV, V18, P2941, DOI 10.1101/gad.1239304; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jackson MW, 2005, J CELL SCI, V118, P1821, DOI 10.1242/jcs.02307; Kastan MB, 2004, NATURE, V432, P316, DOI 10.1038/nature03097; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Polager S, 2003, J BIOL CHEM, V278, P1443, DOI 10.1074/jbc.M210327200; Ray S, 2003, CANCER RES, V63, P4713; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Takahashi Y, 2000, GENE DEV, V14, P804; TAYLOR SL, 2001, FOOD ALLERGY INTOLER, V2, P53; Taylor WR, 2001, J BIOL CHEM, V276, P1998, DOI 10.1074/jbc.M005101200; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Waghray A, 2001, CANCER RES, V61, P4283; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Yan T, 2004, MOL CANCER THER, V3, P1147; Zhu WC, 2004, EMBO J, V23, P4615, DOI 10.1038/sj.emboj.7600459	46	36	39	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 22	2007	26	13					1897	1909		10.1038/sj.onc.1209998	http://dx.doi.org/10.1038/sj.onc.1209998			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	17043659	Green Accepted			2022-12-17	WOS:000245117700007
J	Matta, H; Surabhi, RM; Zhao, J; Punj, V; Sun, Q; Schamus, S; Mazzacurati, L; Chaudhary, PM				Matta, H.; Surabhi, R. M.; Zhao, J.; Punj, V.; Sun, Q.; Schamus, S.; Mazzacurati, L.; Chaudhary, P. M.			Induction of spindle cell morphology in human vascular endothelial cells by human herpesvirus 8-encoded viral FLICE inhibitory protein K13	ONCOGENE			English	Article						KSHV; HHV8; vFLIP; Kaposi's sarcoma; NF-kappa B; spindle cells	NF-KAPPA-B; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; INDUCED APOPTOSIS; ACTIVATION; TRANSFORMATION; EXPRESSION; HUMAN-HERPESVIRUS-8; VFLIP; GENE	Human herpesvirus 8(HHV8), also known as Kaposi's sarcoma-associated herpesvirus, is linked to the development of Kaposi's sarcoma, a disease characterized by the presence of distinctive proliferating spindle-like cells. Although HHV8 can induce spindle cell transformation of vascular endothelial cells in vitro, the viral gene(s) responsible for this phenotype remain to be identified. We demonstrate that expression of HHV8-encoded viral Fas-associated death domain protein-like IL-1 beta-converting enzyme inhibitory protein K13 is sufficient to induce spindle cell phenotype in human umbilical vein endothelial cells (HUVEC), which is associated with the activation of the nuclear factor-kappa B (NF-kappa B) pathway and can be blocked by Bay-11-7082, a specific inhibitor of this pathway. K13 induces the expression of several genes known to be upregulated in HHV8-transformed vascular endothelial cells, such as interleukin (IL)-6, IL-8, CXC ligand 3 (CXCL3), orphan G protein coupled receptor (RDC1), cyclooxygenase-2 (COX-2) and dual-specificity phosphatase 5 (DUSP5). Furthermore, similar to K13, HHV8-induced spindle cell transformation of HUVEC is associated with NF-kappa B activation and can be blocked by Bay-11-7082. Thus, ectopic expression of a single latent gene of HHV8 is sufficient for the acquisition of spindle cell phenotype by vascular endothelial cells and NF-kappa B activation plays an essential role in this process.	Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Pittsburgh, Med Ctr, Dept Med, Div Hematol Oncol, 5117 Ctr Ave,Suite 1-19A, Pittsburgh, PA 15213 USA.	chaudharypm@upmc.edu	Chaudhary, Preet/E-1970-2018	mazzacurati, lucia/0000-0002-8336-8032	NATIONAL CANCER INSTITUTE [R01CA085177] Funding Source: NIH RePORTER; NCI NIH HHS [CA85177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An JB, 2003, ONCOGENE, V22, P3371, DOI 10.1038/sj.onc.1206407; BECKSTEAD JH, 1985, AM J PATHOL, V119, P294; Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; Chaudhary PM, 1999, ONCOGENE, V18, P5738, DOI 10.1038/sj.onc.1202976; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Ciufo DM, 2001, J VIROL, V75, P5614, DOI 10.1128/JVI.75.12.5614-5626.2001; CORBEIL J, 1991, J IMMUNOL, V146, P2972; ENSOLI B, 1995, P ASSOC AM PHYSICIAN, V107, P8; Flore O, 1998, NATURE, V394, P588, DOI 10.1038/29093; Hu SM, 1997, J BIOL CHEM, V272, P9621; Kennedy MM, 1998, J CLIN PATHOL-MOL PA, V51, P14, DOI 10.1136/mp.51.1.14; Liu J, 2002, J VIB CONTROL, V8, P277, DOI 10.1177/107754602023821; Masood Rizwan, 1993, Current Opinion in Oncology, V5, P831, DOI 10.1097/00001622-199309000-00010; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Matta H, 2003, J BIOL CHEM, V278, P52406, DOI 10.1074/jbc.M307308200; Moore PS, 2001, PHILOS T R SOC B, V356, P499, DOI 10.1098/rstb.2000.0777; Moses AV, 1999, J VIROL, V73, P6892, DOI 10.1128/JVI.73.8.6892-6902.1999; Naranatt PP, 2004, CANCER RES, V64, P72, DOI 10.1158/0008-5472.CAN-03-2767; Picard D, 2000, METHOD ENZYMOL, V327, P385, DOI 10.1016/S0076-6879(00)27291-1; Raggo C, 2005, CANCER RES, V65, P5084, DOI 10.1158/0008-5472.CAN-04-2822; Sturzl M, 1999, J NATL CANCER I, V91, P1725, DOI 10.1093/jnci/91.20.1725; Sun Q, 2006, ONCOGENE, V25, P2717, DOI 10.1038/sj.onc.1209298; Sun Q, 2003, BLOOD, V101, P1956, DOI 10.1182/blood-2002-07-2072; Sun QM, 2003, J BIOL CHEM, V278, P52437, DOI 10.1074/jbc.M304199200; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0	25	36	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 8	2007	26	11					1656	1660		10.1038/sj.onc.1209931	http://dx.doi.org/10.1038/sj.onc.1209931			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16936773				2022-12-17	WOS:000244782500016
J	Deshpande, AM; Akunowicz, JD; Reveles, XT; Patel, BB; Saria, EA; Gorlick, RG; Naylor, SL; Leach, RJ; Hansen, MF				Deshpande, A. M.; Akunowicz, J. D.; Reveles, X. T.; Patel, B. B.; Saria, E. A.; Gorlick, R. G.; Naylor, S. L.; Leach, R. J.; Hansen, M. F.			PHC3, a component of the hPRC-H complex, associates with E2F6 during G(0) and is lost in osteosarcoma tumors	ONCOGENE			English	Article						tumor suppressor gene; osteosarcoma; polycomb gene; polyhomeotic-like; cell cycle regulation	POLYCOMB-GROUP PROTEINS; DROSOPHILA-MELANOGASTER; GENES; CHROMATIN; IDENTIFICATION; REPRESSION; HOMOLOGS; BMI1; EED; CONSTITUENTS	Polyhomeotic-like 3 (PHC3) is a ubiquitously expressed member of the polycomb gene family and part of the human polycomb complex hPRC-H. We found that in normal cells PHC3 associated with both hPRC-H complex components and with the transcription factor E2F6. In differentiating and confluent cells, PHC3 and E2F6 showed nuclear colocalization in a punctate pattern that resembled the binding of polycomb bodies to heterochromatin. This punctate pattern was not seen in proliferating cells suggesting that PHC3 may be part of an E2F6-polycomb complex that has been shown to occupy and silence target promoters in G(0). Previous loss of heterozygosity (LoH) analyses had shown that the region containing PHC3 underwent frequent LoH in primary human osteosarcoma tumors. When we examined normal bone and human osteosarcoma tumors, we found loss of PHC3 expression in 36 of 56 osteosarcoma tumors. Sequence analysis revealed that PHC3 was mutated in nine of 15 primary osteosarcoma tumors. These findings suggest that loss of PHC3 may favor tumorigenesis by potentially disrupting the ability of cells to remain in G(0).	Univ Connecticut, Ctr Hlth, Ctr Mol Med, Farmington, CT 06030 USA; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; Childrens Hosp Montefiore, Dept Pediat, Bronx, NY USA	University of Connecticut; University of Texas System; University of Texas Health San Antonio; Yeshiva University; Albert Einstein College of Medicine; Childrens Hospital at Montefiore	Hansen, MF (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Mol Med, 263 Farmington Ave, Farmington, CT 06030 USA.	mhansen@nso2.uchc.edu		GORLICK, RICHARD/0000-0001-8995-2929; Leach, Robin/0000-0002-3201-5579	NCI NIH HHS [R01 CA074802-03, CA074802, R01 CA074802-04] Funding Source: Medline; NIAMS NIH HHS [R01 AR049940-03, R01 AR049940-05, R01 AR049940-04, R01 AR049940-01A1, R01 AR049940, R01 AR049940-02, AR049940] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA074802] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049940] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ali JY, 2004, MOL CELL BIOL, V24, P7737, DOI 10.1128/MCB.24.17.7737-7747.2004; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; Bracken AP, 2006, GENE DEV, V20, P1123, DOI 10.1101/gad.381706; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; DEATRICK J, 1991, GENE, V105, P185, DOI 10.1016/0378-1119(91)90150-A; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Francis NJ, 2001, MOL CELL, V8, P545, DOI 10.1016/S1097-2765(01)00316-1; FRANKE A, 1992, EMBO J, V11, P2941, DOI 10.1002/j.1460-2075.1992.tb05364.x; Gil J, 2005, DNA CELL BIOL, V24, P117, DOI 10.1089/dna.2005.24.117; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; Harlow E LD, 1988, ANTIBODIES LAB MANUA; Isono K, 2005, MOL CELL BIOL, V25, P6694, DOI 10.1128/MCB.25.15.6694-6706.2005; Kim CA, 2002, NAT STRUCT BIOL, V9, P453, DOI 10.1038/nsb802; King IFG, 2002, MOL CELL BIOL, V22, P7919, DOI 10.1128/MCB.22.22.7919-7928.2002; Kruzelock RP, 1997, CANCER RES, V57, P106; Lavigne M, 2004, MOL CELL, V13, P415, DOI 10.1016/S1097-2765(04)00006-1; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Levine SS, 2002, MOL CELL BIOL, V22, P6070, DOI 10.1128/MCB.22.17.6070-6078.2002; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Nowak K, 2006, NUCLEIC ACIDS RES, V34, P1745, DOI 10.1093/nar/gkl119; Ogawa H, 2002, SCIENCE, V296, P1132, DOI 10.1126/science.1069861; Pasini D, 2004, CELL CYCLE, V3, P396; PONTING CP, 1995, PROTEIN SCI, V4, P1928, DOI 10.1002/pro.5560040927; Raaphorst FM, 2005, HUM MOL GENET, V14, pR93, DOI 10.1093/hmg/ddi111; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Saurin AJ, 1998, J CELL BIOL, V142, P887, DOI 10.1083/jcb.142.4.887; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Takihara Y, 1997, DEVELOPMENT, V124, P3673; Tonkin E, 2002, HUM GENET, V111, P435, DOI 10.1007/s00439-002-0814-3; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; Wang LL, 2005, CANCER J, V11, P294, DOI 10.1097/00130404-200507000-00005	38	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	12					1714	1722		10.1038/sj.onc.1209988	http://dx.doi.org/10.1038/sj.onc.1209988			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	146SS	17001316	Green Accepted			2022-12-17	WOS:000244955600005
J	Jong, K; Marchiori, E; van der Vaart, A; Chin, SF; Carvalho, B; Tijssen, M; Eijk, PP; van den IJssel, P; Grabsch, H; Quirke, P; Oudejans, JJ; Meijer, GA; Caldas, C; Ylstra, B				Jong, K.; Marchiori, E.; van der Vaart, A.; Chin, S-F; Carvalho, B.; Tijssen, M.; Eijk, P. P.; van den IJssel, P.; Grabsch, H.; Quirke, P.; Oudejans, J. J.; Meijer, G. A.; Caldas, C.; Ylstra, B.			Cross-platform array comparative genomic hybridization meta-analysis separates hematopoietic and mesenchymal from epithelial tumors	ONCOGENE			English	Article						array CGH; meta-analysis; chromosomal aberrations; cancer	COPY-NUMBER CHANGES; MICROARRAY DATA; EXPRESSION PATTERNS; COLORECTAL-CANCER; GENE-EXPRESSION; BREAST-TUMORS; PROFILES; CGH; CARCINOMA; REVEALS	A series of studies have been published that evaluate the chromosomal copy number changes of different tumor classes using array comparative genomic hybridization ( array CGH); however, the chromosomal aberrations that distinguish the different tumor classes have not been fully characterized. Therefore, we performed a meta-analysis of different array CGH data sets in an attempt to classify samples tested across different platforms. As opposed to RNA expression, a common reference is used in dual channel CGH arrays: normal human DNA, theoretically facilitating cross-platform analysis. To this aim, cell line and primary cancer data sets from three different dual channel array CGH platforms obtained by four different institutes were integrated. The cell line data were used to develop preprocessing methods, which performed noise reduction and transformed samples into a common format. The transformed array CGH profiles allowed perfect clustering by cell line, but importantly not by platform or institute. The same preprocessing procedures used for the cell line data were applied to data from 373 primary tumors pro. led by array CGH, including controls. Results indicated that there is no apparent feature related to the institute or platform and that array CGH allows for unambiguous cross-platform meta-analysis. Major clusters with common tissue origin were identified. Interestingly, tumors of hematopoietic and mesenchymal origins cluster separately from tumors of epithelial origin. Therefore, it can be concluded that chromosomal aberrations of tumors from hematopoietic and mesenchymal origin versus tumors of epithelial origin are distinct, and these differences can be picked up by meta-analysis of array CGH data. This suggests the possibility of prospectively using combined analysis of diverse copy number data sets for cancer subtype classification.	Vrije Univ Amsterdam, Med Ctr, Micro Array Core Facil, Dept Pathol, NL-1007 MB Amsterdam, Netherlands; St James Univ Hosp, Dept Pathol & Tumour Biol, Leeds, W Yorkshire, England; Vrije Univ Amsterdam, Fac Sci, NL-1007 MB Amsterdam, Netherlands; Univ Cambridge, Canc Genom Program, Dept Oncol, MRC,Hutchison Res Ctr, Cambridge, England	Vrije Universiteit Amsterdam; Saint James's University Hospital; Vrije Universiteit Amsterdam; University of Cambridge	Ylstra, B (corresponding author), Vrije Univ Amsterdam, Med Ctr, Micro Array Core Facil, Dept Pathol, Room CCA-122,POB 7057, NL-1007 MB Amsterdam, Netherlands.	b.ylstra@vumc.nl	Caldas, Carlos/A-7543-2008; Quirke, Philip/AAI-1362-2019; Carvalho, Beatriz/GXA-0720-2022; Caldas, Carlos/U-7250-2019; Ylstra, Bauke/D-2906-2012	Caldas, Carlos/0000-0003-3547-1489; Ylstra, Bauke/0000-0001-9479-3010; Meijer, Gerrit/0000-0003-0330-3130; Quirke, Philip/0000-0002-3597-5444; chin, suet-feung/0000-0001-5697-1082				Albertson DG, 2000, NAT GENET, V25, P144, DOI 10.1038/75985; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Jong K, 2004, BIOINFORMATICS, V20, P3636, DOI 10.1093/bioinformatics/bth355; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Linn SC, 2003, AM J PATHOL, V163, P2383, DOI 10.1016/S0002-9440(10)63593-6; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Mitelman F, 2004, NAT GENET, V36, P331, DOI 10.1038/ng1335; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Oostlander AE, 2004, CLIN GENET, V66, P488, DOI 10.1111/j.1399-0004.2004.00322.x; Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Schreurs MWJ, 2005, BLOOD, V106, P2663, DOI 10.1182/blood-2004-09-3742; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Snijders AM, 2003, ONCOGENE, V22, P4281, DOI 10.1038/sj.onc.1206621; van Dekken H, 2004, GENE CHROMOSOME CANC, V39, P249, DOI 10.1002/gcc.20001; van den IJssel P, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni191; Weiss MM, 2003, ONCOGENE, V22, P1872, DOI 10.1038/sj.onc.1206350; Ylstra B, 2006, NUCLEIC ACIDS RES, V34, P445, DOI 10.1093/nar/gkj456; Zardo G, 2002, NAT GENET, V32, P453, DOI 10.1038/ng1007	28	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 1	2007	26	10					1499	1506		10.1038/sj.onc.1209919	http://dx.doi.org/10.1038/sj.onc.1209919			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141DV	16936777				2022-12-17	WOS:000244558800015
J	Lacreusette, A; Nguyen, JM; Pandolfino, MC; Khammari, A; Dreno, B; Jacques, Y; Godard, A; Blanchard, F				Lacreusette, A.; Nguyen, J-M; Pandolfino, M-C; Khammari, A.; Dreno, B.; Jacques, Y.; Godard, A.; Blanchard, F.			Loss of oncostatin M receptor beta in metastatic melanoma cells	ONCOGENE			English	Article						oncostatin M; interleukin-6; STAT3; histone acetylation; melanoma	HISTONE DEACETYLASE INHIBITORS; TUMOR-INFILTRATING LYMPHOCYTES; INDUCED GROWTH-INHIBITION; INTERLEUKIN-6; EXPRESSION; STAT3; RESPONSIVENESS; ACETYLATION; PROGRESSION; ACTIVATION	Oncostatin M (OSM) is an interleukin-6 (IL-6) type cytokine originally described by its capacity to inhibit melanoma proliferation in vitro. Here, the mechanisms involved in resistance to growth inhibition by OSM were analysed for the first time on a large panel of metastatic melanoma cell lines. OSM resistance did not strictly correlate with IL-6, interferon-gamma or tumor necrosis factor-alpha resistance. Rather, it correlated with a specific loss of the OSM receptor-beta (OSMR beta) subunit, in conjunction with a lower level of histone acetylation in the OSMR beta promoter region. Treatment of various OSM-resistant melanoma cells with the histone deacetylase inhibitor Trichostatin A increased activity and histone acetylation of the OSMR beta promoter as well as expression of OSMR beta mRNA and protein, allowing OSM to activate the signal transducer and activator of transcription 3 (STAT3) and to inhibit proliferation. Other defects associated with OSM resistance were identified at the level of OSMR beta transcription or protein expression, as well as downstream of or parallel to STAT3 activation. Altogether, our results suggest a role for OSM in the prevention of melanoma progression and that metastatic melanoma cells could escape this growth control by the epigenetic silencing of OSMR beta.	INSERM, U601, Grp Rech Cytokines & Receteurs, Inst Biol, F-44035 Nantes 1, France; Univ Nantes, Inst Biol, IFR26, UFR, F-44035 Nantes, France; PIMESP, Nantes, France; CHU Nantes, Unit Skin Canc, F-44035 Nantes 01, France; CHU Nantes, Biochim Lab, F-44035 Nantes 01, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes	Godard, A (corresponding author), INSERM, U601, Grp Rech Cytokines & Receteurs, Inst Biol, 0 Quai Moncousu, F-44035 Nantes 1, France.	agodard@nantes.inserm.fr; frederic.blanchard@univ-nantes.fr	Blanchard, Frederic/AAS-1930-2021; NGUYEN, JEAN-MICHEL/K-7665-2015; Blanchard, Frederic/K-8018-2015	Blanchard, Frederic/0000-0003-1055-2573; NGUYEN, JEAN-MICHEL/0000-0001-8815-7640; Blanchard, Frederic/0000-0003-1055-2573				Bani MR, 1996, CANCER RES, V56, P3075; Blanchard F, 2005, DRUG DISCOV TODAY, V10, P197, DOI 10.1016/S1359-6446(04)03309-4; Blanchard F, 2003, HEPATOLOGY, V38, P1516, DOI 10.1016/j.hep.2003.09.029; Blanchard F, 2002, ONCOGENE, V21, P6264, DOI 10.1038/sj.onc.1205777; Blanchard F, 1997, INT IMMUNOL, V9, P1775, DOI 10.1093/intimm/9.12.1775; Bohm M, 2001, J INVEST DERMATOL, V117, P132, DOI 10.1046/j.0022-202x.2001.01372.x; Boing I, 2006, CELL SIGNAL, V18, P50, DOI 10.1016/j.cellsig.2005.03.015; Boyle GM, 2005, PIGM CELL RES, V18, P160, DOI 10.1111/j.1600-0749.2005.00228.x; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chambers AE, 2003, EUR J CANCER, V39, P1165, DOI 10.1016/S0959-8049(03)00072-8; Chipoy C, 2004, J BONE MINER RES, V19, P1850, DOI 10.1359/JBMR.040817; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; Dagoneau N, 2004, AM J HUM GENET, V74, P298, DOI 10.1086/381715; Dreno B, 2002, CANCER IMMUNOL IMMUN, V51, P539, DOI 10.1007/s00262-002-0315-1; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; GERVOIS N, 1990, EUR J IMMUNOL, V20, P825, DOI 10.1002/eji.1830200417; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HEYMANN D, 1995, IMMUNOL LETT, V46, P245, DOI 10.1016/0165-2478(95)00049-B; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jarry A, 2004, MOL CELL PROBE, V18, P349, DOI 10.1016/j.mcp.2004.05.004; Kim H, 1999, MOL CELL BIOL, V19, P5326; Klausen P, 2000, ONCOGENE, V19, P3675, DOI 10.1038/sj.onc.1203707; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Labarriere N, 2002, CANCER IMMUNOL IMMUN, V51, P532, DOI 10.1007/s00262-002-0313-3; LU C, 1993, CANCER RES, V53, P2708; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Mosley B, 1996, J BIOL CHEM, V271, P32635, DOI 10.1074/jbc.271.51.32635; MULE JJ, 1990, J EXP MED, V171, P629, DOI 10.1084/jem.171.3.629; Nawrocki S, 2000, IMMUNOL LETT, V74, P81, DOI 10.1016/S0165-2478(00)00253-4; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Ozbek S, 2001, ONCOGENE, V20, P972, DOI 10.1038/sj.onc.1204180; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Sandor V, 2002, CLIN CANCER RES, V8, P718; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Wong LH, 1997, J BIOL CHEM, V272, P28779, DOI 10.1074/jbc.272.45.28779; Yannelli JR, 2004, VACCINE, V23, P97, DOI 10.1016/j.vaccine.2003.12.036; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739	44	36	37	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2007	26	6					881	892		10.1038/sj.onc.1209844	http://dx.doi.org/10.1038/sj.onc.1209844			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	134DT	16909117				2022-12-17	WOS:000244063800009
J	Oeggerli, M; Schraml, P; Ruiz, C; Bloch, M; Novotny, H; Mirlacher, M; Sauter, G; Simon, R				Oeggerli, M.; Schraml, P.; Ruiz, C.; Bloch, M.; Novotny, H.; Mirlacher, M.; Sauter, G.; Simon, R.			E2F3 is the main target gene of the 6p22 amplicon with high specificity for human bladder cancer	ONCOGENE			English	Article						E2F3; 6p22; bladder cancer; amplification target gene	TUMOR-CELL PROLIFERATION; MAMMALIAN-CELLS; AMPLIFICATION; OVEREXPRESSION; EXPRESSION; GROWTH	Amplification of 6p22 occurs in about 10-20% of bladder cancers and is associated with enhanced tumour cell proliferation. Candidate target genes for the 6p22 amplicon include E2F3 and the adjacent gene NM_017774. To clarify which gene is representing the main target, we compared the prevalence of the amplification and the functional role of both genes. Ampli.cation of E2F3 and NM_017774 was analysed by fluorescence in situ hybridization on a bladder cancer tissue microarray composed of 2317 cancer samples. Both genes showed amplification in 104 of 893 (11.6%) interpretable tumours and were exclusively found co-amplified. Additional gene expression analysis by real-time polymerase chain reaction in 12 tumour-derived cell lines revealed that amplification of 6p22 was always associated with co-overexpression of E2F3 and NM_017774. Furthermore, RNA interference was used to study the influence of reduced gene expression on cell growth. In tumour cells with and without the 6p22 amplicon, knockdown of E2F3 always lead to unequivocal reduction of proliferation, whereas knockdown of NM_017774 was only capable to slow down cell proliferation in non-amplified cells. Our findings point out that E2F3 but not NM_017774 is driving enhanced proliferation of 6p22 amplified tumour cells. We conclude that E2F3 must be responsible for the growth advantage of 6p22 amplified bladder cancer cells.	Univ Basel Hosp, Inst Pathol, Dept Mol Pathol, CH-4031 Basel, Switzerland; Univ Zurich, Dept Pathol, Zurich, Switzerland; Univ Hamburg, Med Ctr, Dept Pathol, Hamburg, Germany	University of Basel; University of Zurich; University of Hamburg	Oeggerli, M (corresponding author), Univ Basel Hosp, Inst Pathol, Dept Mol Pathol, Schonbeinstr 40, CH-4031 Basel, Switzerland.	martin.oeggerli@unibas.ch						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bruch J, 2000, CANCER RES, V60, P4526; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Lee JM, 2003, GENOME RES, V13, P875, DOI 10.1101/gr.737703; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lindl T., 1989, ZELL GEWEBEKULTUR; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; QIAN YY, 1992, MOL CELL BIOL, V12, P5363, DOI 10.1128/MCB.12.12.5363; Tomovska S, 2001, INT J ONCOL, V18, P1239; Wagner S, 1997, GASTROENTEROLOGY, V113, P1836, DOI 10.1016/S0016-5085(97)70003-9; WANG WW, 1995, GENOMICS, V26, P563, DOI 10.1016/0888-7543(95)80176-M	17	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2006	25	49					6538	6543		10.1038/sj.onc.1209946	http://dx.doi.org/10.1038/sj.onc.1209946			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	096RS	16953223	Bronze			2022-12-17	WOS:000241395100010
J	Gupta, SK; Gupta, M; Hoffman, B; Liebermann, DA				Gupta, S. K.; Gupta, M.; Hoffman, B.; Liebermann, D. A.			Hematopoietic cells from gadd45a-deficient and gadd45b-deficient mice exhibit impaired stress responses to acute stimulation with cytokines, myeloablation and inflammation	ONCOGENE			English	Article						hematopoiesis; differentiation; stress; apoptosis	KINASE INHIBITORS; UV-IRRADIATION; GENE MYD118; MAP KINASE; STEM-CELLS; GADD45; EXPRESSION; DIFFERENTIATION; GROWTH; APOPTOSIS	The gadd45 family of gene(s) is rapidly induced by genotoxic stress or by differentiation-inducing cytokines. Using bone marrow ( BM) from gadd45a-/-, gadd45b-/- and wild-type (wt) mice, we investigated their role in stress responses of myeloid cells to acute stimulation with differentiating cytokines, myelotoxic agents and inflammatory substances. Bone marrow cells from gadd45a -/- and gadd45b -/- mice displayed compromised myeloid differentiation and higher apoptosis in vitro, following acute stimulation with a variety of differentiating cytokines. Intriguingly, gadd45a -/- and gadd45b -/- colony forming units granulocyte/macrophage progenitors displayed prolonged proliferation capacity compared to wt controls upon re-plating in methylcellulose supplemented with interleukin-3. The recovery of the BM myeloid compartment following 5-Fluorouracil-induced myeloablation was much slower in gadd45a -/- and gadd45b -/- mice compared to wt controls. Furthermore, the response of myeloid cells to inflammatory stress, inflicted via intraperitoneal administration of sodium caseinate was impaired in gadd45a -/- and gadd45b -/- mice compared to age-matched wt mice, as indicated by lower percentage of Gr-1-positive cells in the BM and lower number of myeloid cells in peritoneal exudates. Overall, these data indicate that both gadd45a and gadd45b play a role in modulating physiological stress responses of myeloid cells to acute stimulation with differentiating cytokines, myelo-ablation and inflammation. These findings should aid in understanding the response of normal and malignant hematopoietic cells to physiological and chemical stressors including anticancer agents.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Dept Biochem, 3307 N Broad St,Room 331, Philadelphia, PA 19140 USA.	lieberma@temple.edu			NHLBI NIH HHS [R01 HL70530-03] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070530] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDOLLAHI A, 1991, ONCOGENE, V6, P165; Amanullah A, 2003, NATURE, V424, P741, DOI 10.1038/424741b; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Azam N, 2001, J BIOL CHEM, V276, P2766, DOI 10.1074/jbc.M005626200; BEADLING C, 1993, P NATL ACAD SCI USA, V90, P2719, DOI 10.1073/pnas.90.7.2719; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; DAEMS WT, 1978, CELL TISSUE RES, V190, P47; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Gupta M, 2005, ONCOGENE, V24, P7170, DOI 10.1038/sj.onc.1208847; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HESTDAL K, 1991, J IMMUNOL, V147, P22; Hildesheim J, 2002, CANCER RES, V62, P7305; Hoffmeyer A, 2001, MOL CELL BIOL, V21, P3137, DOI 10.1128/MCB.21.9.3137-3143.2001; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Lang R, 2002, J IMMUNOL, V169, P2253, DOI 10.4049/jimmunol.169.5.2253; Liebermann D A, 1994, Curr Opin Hematol, V1, P24; Liebermann DA, 2003, BLOOD CELL MOL DIS, V31, P213, DOI 10.1016/S1079-9796(03)00160-8; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Lu BF, 2001, IMMUNITY, V14, P583, DOI 10.1016/S1074-7613(01)00141-8; Marone M, 2002, LEUKEMIA LYMPHOMA, V43, P51, DOI 10.1080/10428190210195; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; NAKAHATA T, 1982, P NATL ACAD SCI-BIOL, V79, P3843, DOI 10.1073/pnas.79.12.3843; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; Papa S, 2004, NAT CELL BIOL, V6, P146, DOI 10.1038/ncb1093; Platanias LC, 2003, BLOOD, V101, P4667, DOI 10.1182/blood-2002-12-3647; Randall TD, 1997, BLOOD, V89, P3596, DOI 10.1182/blood.V89.10.3596.3596_3596_3606; RICHMAN CM, 1976, BLOOD, V47, P1031; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Smith ML, 1996, ONCOGENE, V13, P2255; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Takekawa M, 2002, EMBO J, V21, P6473, DOI 10.1093/emboj/cdf643; Taylor PR, 2003, EUR J IMMUNOL, V33, P2090, DOI 10.1002/eji.200324003; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Vairapandi M, 2002, J CELL PHYSIOL, V192, P327, DOI 10.1002/jcp.10140; Vairapandi M, 1996, ONCOGENE, V12, P2579; Vairapandi M, 2000, J BIOL CHEM, V275, P16810, DOI 10.1074/jbc.275.22.16810; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Yoo JY, 2003, J BIOL CHEM, V278, P43001, DOI 10.1074/jbc.M307869200; Zazzeroni F, 2003, BLOOD, V102, P3270, DOI 10.1182/blood-2003-03-0689; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zhang W, 1999, ONCOGENE, V18, P4899, DOI 10.1038/sj.onc.1202885	47	36	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5537	5546		10.1038/sj.onc.1209555	http://dx.doi.org/10.1038/sj.onc.1209555			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16732331				2022-12-17	WOS:000240370400007
J	Hsu, LC; Huang, X; Seasholtz, S; Potter, DM; Gollin, SM				Hsu, L-C; Huang, X.; Seasholtz, S.; Potter, D. M.; Gollin, S. M.			Gene amplification and overexpression of protein phosphatase 1 alpha in oral squamous cell carcinoma cell lines	ONCOGENE			English	Article						PP1 alpha; cyclin D1; gene amplification; OSCC tumorigenesis	ANTISENSE CYCLIN D1; CATALYTIC SUBUNIT; HUMAN CANCER; RETINOBLASTOMA PROTEIN; HEPATOMA-CELLS; BAND 11Q13; HEAD; NECK; ONCOGENES; TYPE-1	Gene amplification of chromosomal band 11q13 is observed frequently in oral squamous cell carcinomas (OSCC). Several genes have been identified in the 11q13 amplicon, including FGF3, FGF4, CCND1, EMS1 and TAOS1. Some of these genes show good correlation between gene copy number and gene expression, and are thought to play a role in driving 11q13 amplification. The PPP1CA gene, which encodes the catalytic subunit of serine/threonine protein phosphatase protein phosphatase 1 alpha (PP1 alpha), is also located in 11q13. Protein phosphatase 1a, one of the isoforms of PP1, regulates critical cellular events, such as cell cycle progression, and apoptosis. We sought to explore the possibility that PPP1CA was amplified and overexpressed in OSCC cells. Indeed, some OSCC cell lines had PPP1CA gene amplification, as analysed by fluorescence in situ hybridization. We have also demonstrated that PPP1CA gene copy number is increased in 21% of the OSCC cell lines determined by quantitative microsatellite analysis. PP1a RNA expression determined by quantitative reverse transcription-polymerase chain reaction was significantly higher in OSCC cell lines with 11q13 amplification compared to those without 11q13 amplification (P= 0.011). The difference was even more significant between cell lines with at least three copies of the PPP1CA gene and those with less than three copies of the gene (P= 0.00045). Relative PP1a protein levels were also significantly associated with PPP1CA gene copy number (P= 0.014). Furthermore, knockdown of PP1 alpha and/or cyclin D1 by small interfering RNA suppressed OSCC cell growth, at least in part by modulating pRB phosphorylation, resulting in G0 growth arrest. These data suggest that like the cyclin D1 gene, CCND1, amplification and overexpression of the PP1a gene, PPP1CA, may be involved in OSCC tumorigenesis and/or progression.	Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Sch Med, Magee Womens Res Inst, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hsu, LC (corresponding author), Univ Pittsburgh, Dept Obstet Gynecol & Reprod Sci, Sch Med, Magee Womens Res Inst, 204 Craft Ave, Pittsburgh, PA 15213 USA.	rsilh@mwri.magee.edu		Gollin, Susanne/0000-0001-5438-6808; HSU, LIH-CHING/0000-0002-7816-3825	NCI NIH HHS [P30 CA47904, R01 CA111436] Funding Source: Medline; NIDCR NIH HHS [R01 DE14729] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA047904, R01CA111436] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014729] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; ALBERTS AS, 1993, P NATL ACAD SCI USA, V90, P388, DOI 10.1073/pnas.90.2.388; Ayllon V, 2001, J IMMUNOL, V166, P7345, DOI 10.4049/jimmunol.166.12.7345; BARKER HM, 1990, GENOMICS, V7, P159, DOI 10.1016/0888-7543(90)90536-4; Ceulemans H, 2004, PHYSIOL REV, V84, P1, DOI 10.1152/physrev.00013.2003; Chu EC, 2004, MED SCI MONITOR, V10, pRA235; Cohen PTW, 2002, J CELL SCI, V115, P241; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; GAUDRAY P, 1992, MUTAT RES, V276, P317, DOI 10.1016/0165-1110(92)90018-5; Ginzinger DG, 2000, CANCER RES, V60, P5405; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Hsu LC, 1998, P NATL ACAD SCI USA, V95, P12983, DOI 10.1073/pnas.95.22.12983; Huang X, 2002, P NATL ACAD SCI USA, V99, P11369, DOI 10.1073/pnas.172285799; Imai Y, 1999, INT J ONCOL, V14, P121; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Jin YS, 1998, GENE CHROMOSOME CANC, V22, P312, DOI 10.1002/(SICI)1098-2264(199808)22:4<312::AID-GCC7>3.0.CO;2-Y; Kohno T, 1999, CANCER RES, V59, P4170; LESE CM, 1995, GENE CHROMOSOME CANC, V12, P288, DOI 10.1002/gcc.2870120409; Liu Y, 2002, CANCER RES, V62, P6357; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; PARK NH, 1991, CARCINOGENESIS, V12, P1627, DOI 10.1093/carcin/12.9.1627; Reshmi SC, 2004, GENE CHROMOSOME CANC, V41, P38, DOI 10.1002/gcc.20064; SAADAT M, 1995, CANCER LETT, V94, P165, DOI 10.1016/0304-3835(95)03846-O; Savelyeva L, 2001, CANCER LETT, V167, P115, DOI 10.1016/S0304-3835(01)00472-4; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shuster MI, 2000, GENE CHROMOSOME CANC, V28, P153, DOI 10.1002/(SICI)1098-2264(200006)28:2<153::AID-GCC4>3.0.CO;2-9; Sogawa K, 1997, CANCER LETT, V112, P263, DOI 10.1016/S0304-3835(96)04589-2; Wang MB, 1998, OTOLARYNG HEAD NECK, V119, P593, DOI 10.1016/S0194-5998(98)70017-8; Wang SJ, 2001, OTOLARYNG HEAD NECK, V124, P656, DOI 10.1067/mhn.2001.116039	35	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5517	5526		10.1038/sj.onc.1209563	http://dx.doi.org/10.1038/sj.onc.1209563			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16619035				2022-12-17	WOS:000240370400005
J	Paul, C; Lacroix, M; Iankova, I; Julien, E; Schafer, BW; Labalette, C; Wei, Y; Le Cam, A; Le Cam, L; Sardet, C				Paul, C.; Lacroix, M.; Iankova, I.; Julien, E.; Schaefer, B. W.; Labalette, C.; Wei, Y.; Le Cam, A.; Le Cam, L.; Sardet, C.			The LIM-only protein FHL2 is a negative regulator of E4F1	ONCOGENE			English	Article						FHL2; DRAL; E4F1; p53; proliferation; repression	TRANSCRIPTION FACTOR P120(E4F); DOMAIN PROTEIN; BETA-CATENIN; CELL-CYCLE; COACTIVATOR FHL2; INTERACTS; IDENTIFICATION; ACTIVATION; GENE; BINDING	The E1A-targeted transcription factor E4F1 is a key player in the control of mammalian embryonic and somatic cell proliferation and survival. Mouse embryos lacking E4F die at an early developmental stage, whereas enforced expression of E4F1 in various cell lines inhibits cell cycle progression. E4F1-antiproliferative effects have been shown to depend on its capacity to repress transcription and to interact with pRb and p53. Here we show that full-length E4F1 protein (p120(E4F1)) but not its E1A-activated and truncated form (p50(E4F1)), interacts directly in vitro and in vivo with the LIM-only protein FHL2, the product of the p53-responsive gene FHL2/DRAL (downregulated in rhabdomyosarcoma Lim protein). This E4F1-FHL2 association occurs in the nuclear compartment and inhibits the capacity of E4F1 to block cell proliferation. Consistent with this effect, ectopic expression of FHL2 inhibits E4F1 repressive effects on transcription and correlates with a reduction of nuclear E4F-p53 complexes. Overall, these results suggest that FHL2/DRAL is an inhibitor of E4F1 activity. Finally, we show that endogenous E4F1-FHL2 complexes form in U2OS cells upon UV-light-induced nuclear accumulation of FHL2.	CNRS, Inst Mol Genet, UMR 5535, IFR122, F-34293 Montpellier 5, France; Univ Zurich, Dept Pediat, Div Clin Chem & Biochem, CH-8006 Zurich, Switzerland; Inst Pasteur, Unite Oncogenese & Virol Mol, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; University of Zurich; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Sardet, C (corresponding author), CNRS, Inst Mol Genet, UMR 5535, IFR122, 1919 Route Mende, F-34293 Montpellier 5, France.	claude.sardet@igmm.cnrs.fr	Lacroix, Matthieu/O-1928-2018; Le Cam, Laurent/O-1408-2016; JULIEN, ERIC/Y-5873-2019; Wei, Yu/A-7289-2016	Lacroix, Matthieu/0000-0002-1268-9058; JULIEN, ERIC/0000-0003-2976-666X; LE CAM, Laurent/0000-0003-0325-878X; Schafer, Beat/0000-0001-5988-2915				Ahmed-Choudhury J, 2005, CANCER RES, V65, P2690, DOI 10.1158/0008-5472.CAN-04-3593; Amaar YG, 2002, J BIOL CHEM, V277, P12053, DOI 10.1074/jbc.M110872200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chan KK, 1998, GENE, V210, P345, DOI 10.1016/S0378-1119(97)00644-6; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; CHU PH, 2000, J MECH DEV, V95, P265; Colombo R, 2003, ONCOGENE, V22, P2541, DOI 10.1038/sj.onc.1206379; Dantonel JC, 2000, MOL CELL, V6, P715, DOI 10.1016/S1097-2765(00)00069-1; DU X, 2002, BIOCHIM BIOPHYS ACTA, V577, P93; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fajas L, 2000, P NATL ACAD SCI USA, V97, P7738, DOI 10.1073/pnas.130198397; Fenton SL, 2004, CANCER RES, V64, P102, DOI 10.1158/0008-5472.CAN-03-2622; Fernandes ER, 1999, MOL CELL BIOL, V19, P4739; Fernandes ER, 1997, MOL CELL BIOL, V17, P1890, DOI 10.1128/MCB.17.4.1890; Fernandes ER, 1998, MOL CELL BIOL, V18, P459, DOI 10.1128/MCB.18.1.459; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; FOGNANI C, 1993, EMBO J, V12, P4985, DOI 10.1002/j.1460-2075.1993.tb06192.x; Gabriel B, 2004, ANTICANCER RES, V24, P921; Genini M, 1997, DNA CELL BIOL, V16, P433, DOI 10.1089/dna.1997.16.433; Hill AA, 2004, MOL CELL BIOL, V24, P9835, DOI 10.1128/MCB.24.22.9835-9847.2004; Kang CM, 2003, RADIAT RES, V159, P312, DOI 10.1667/0033-7587(2003)159[0312:PBFIRE]2.0.CO;2; Kong YF, 2001, CIRCULATION, V103, P2731; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Le Cam L, 2004, MOL CELL BIOL, V24, P6467, DOI 10.1128/MCB.24.14.6467-6475.2004; Li HY, 2001, CELL MOTIL CYTOSKEL, V48, P11, DOI 10.1002/1097-0169(200101)48:1<11::AID-CM2>3.0.CO;2-I; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Purcell NH, 2004, MOL CELL BIOL, V24, P1081, DOI 10.1128/MCB.24.3.1081-1095.2004; RAYCHAUDHURI P, 1987, EMBO J, V6, P4073, DOI 10.1002/j.1460-2075.1987.tb02753.x; Retaux S, 2002, MOL NEUROBIOL, V26, P269, DOI 10.1385/MN:26:2-3:269; Rizos H, 2003, J BIOL CHEM, V278, P4981, DOI 10.1074/jbc.M210978200; Sandy P, 2000, ONCOGENE, V19, P188, DOI 10.1038/sj.onc.1203250; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Stilo R, 2002, FEBS LETT, V521, P165, DOI 10.1016/S0014-5793(02)02869-7; Tanahashi H, 2000, HUM MOL GENET, V9, P2281, DOI 10.1093/oxfordjournals.hmg.a018919; Tessari MA, 2003, MOL CELL BIOL, V23, P9104, DOI 10.1128/MCB.23.24.9104-9116.2003; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570	44	36	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2006	25	40					5475	5484		10.1038/sj.onc.1209567	http://dx.doi.org/10.1038/sj.onc.1209567			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	082EV	16652157				2022-12-17	WOS:000240370400001
J	Cohen, Z; Bacharach, E; Lavi, S				Cohen, Z.; Bacharach, E.; Lavi, S.			Mouse major satellite DNA is prone to eccDNA formation via DNA Ligase IV-dependent pathway	ONCOGENE			English	Article						eccDNA; spcDNA; genomic instability; major satellite DNA; DNA Ligase IV	EXTRACHROMOSOMAL CIRCULAR DNAS; MAMMALIAN-CELLS; GENOMIC INSTABILITY; RECOMBINATION; CIRCLES; MOLECULES; SPCDNA; DROSOPHILA; TELOMERES; SEQUENCES	Elevated levels of extrachromosomal circular DNA (eccDNA or spcDNA) are closely associated with genomic instability and aging. Despite extensive studies, the mechanism of its generation in mammalian cells is unknown. We report here that mouse major satellite DNA (MSD) is prone to eccDNA formation and that the resulting molecules are multimeres of the basic repeat. Extrachromosomal circular major satellite (ECMS) DNA constitutes the majority of eccDNA in B16 mouse melanoma cells and is highly abundant in other mouse cells. Production of these molecules is enhanced in proliferating cells, suggesting that processes associated with DNA replication are involved in their appearance. Using siRNA technique we show that DNA Ligase IV is engaged in ECMS synthesis. Based on our findings we propose a novel two-step model for eccDNA formation in mammalian cells.	Tel Aviv Univ, Fac Life Sci, Dept Cell Res & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Lavi, S (corresponding author), Tel Aviv Univ, Fac Life Sci, Dept Cell Res & Immunol, POB 39040, IL-69978 Tel Aviv, Israel.	lavisara@post.tau.ac.il		Cohen, Zoya/0000-0002-1284-3035; Bacharach, Eran/0000-0001-8341-2833				ASSUM G, 1993, HUM GENET, V91, P489; Autiero M, 2002, INT J CANCER, V99, P370, DOI 10.1002/ijc.10368; BERTELSEN AH, 1982, BIOCHEMISTRY-US, V21, P2076, DOI 10.1021/bi00538a015; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cesare AJ, 2004, MOL CELL BIOL, V24, P9948, DOI 10.1128/MCB.24.22.9948-9957.2004; CHATTERJEE B, 1989, J MOL BIOL, V210, P303, DOI 10.1016/0022-2836(89)90332-X; Cohen S, 1997, ONCOGENE, V14, P977, DOI 10.1038/sj.onc.1200917; Cohen S, 2003, GENOME RES, V13, P1133, DOI 10.1101/gr.907603; Cohen S, 1996, MOL CELL BIOL, V16, P2002; Cohen S, 1999, MOL CELL BIOL, V19, P6682; Cohen S, 2001, NUCLEIC ACIDS RES, V29, P2542, DOI 10.1093/nar/29.12.2542; DEGROOTE F, 1989, CHROMOSOMA, V89, P201; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; GAUBATZ JW, 1990, MUTAT RES, V237, P29, DOI 10.1016/0921-8734(90)90029-Q; GAUBATZ JW, 1990, MUTAT RES, V237, P271, DOI 10.1016/0921-8734(90)90009-G; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; KIYAMA R, 1987, J MOL BIOL, V193, P591, DOI 10.1016/0022-2836(87)90342-1; KUNISADA T, 1985, MECH AGEING DEV, V29, P89, DOI 10.1016/0047-6374(85)90050-8; LEWIS JD, 1992, CELL, V69, P905, DOI 10.1016/0092-8674(92)90610-O; MOTEJLEK K, 1993, MUTAT RES, V293, P205, DOI 10.1016/0921-8777(93)90071-N; NEHLS M, 1995, TRENDS GENET, V11, P39, DOI 10.1016/S0168-9525(00)88990-8; Ohki R, 1995, NUCLEIC ACIDS RES, V23, P4971, DOI 10.1093/nar/23.24.4971; Park PU, 1999, MOL CELL BIOL, V19, P3848; PONT G, 1988, NUCLEIC ACIDS RES, V16, P8817, DOI 10.1093/nar/16.18.8817; Regev A, 1998, ONCOGENE, V17, P3455, DOI 10.1038/sj.onc.1202250; Sambrook J, 1989, MOL CLONING LAB MANU; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; Silver L.M., 1995, MOUSE GENETICS CONCE; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Takeuchi Y, 2003, GENE DEV, V17, P1497, DOI 10.1101/gad.1085403; VANLOON N, 1994, NUCLEIC ACIDS RES, V13, P2447; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Zhong Q, 2002, CANCER RES, V62, P3966	34	36	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 3	2006	25	33					4515	4524		10.1038/sj.onc.1209485	http://dx.doi.org/10.1038/sj.onc.1209485			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	069OG	16547499				2022-12-17	WOS:000239457500002
J	Oh, J; Diaz, T; Wei, B; Chang, H; Noda, M; Stetler-Stevenson, WG				Oh, J.; Diaz, T.; Wei, B.; Chang, H.; Noda, M.; Stetler-Stevenson, W. G.			TIMP-2 upregulates RECK expression via dephosphorylation of paxillin tyrosine residues 31 and 118	ONCOGENE			English	Article						TIMP-2; RECK; Rac1; paxillin; Src	CYSTEINE-RICH PROTEIN; FOCAL ADHESION KINASE; CELL LUNG-CANCER; NBT-II CELLS; TYROSINE PHOSPHORYLATION; CLINICAL-SIGNIFICANCE; TISSUE INHIBITORS; SIGNALING COMPLEX; KAZAL MOTIFS; SRC	We previously demonstrated that TIMP-2 increases the association of Crk with C3G and via subsequent activation of Rap1 enhances the expression of RECK, a membrane-anchored MMP inhibitor. In the present study, we investigate the mechanism of how the TIMP-2 signal is transduced from the alpha 3 beta 1 integrin receptor to the Crk-C3G-Rap1 molecular complex. TIMP-2 treatment of human microvascular endothelial cells (hMVECs) increased the phosphorylation levels of Src at Tyr-527, the negative regulatory site, through enhanced association of Src with Csk. This results in the reduction of Src kinase activity and dephosphorylation of paxillin at Tyr-31/118, the target sites for Src kinase phosphorylation and also the binding sites for the downstream effector Crk. Such TIMP-2 effects accompany the disassembly of paxillin-Crk-DOCK180 molecular complex and, in turn, Rac1 inactivation. On the contrary, levels of paxillin-Crk-C3G complex formation are not reduced, rather slightly increased, which is consistent with our previous finding. Therefore, TIMP-2-mediated inhibition of Src kinase activity leads to the signaling switch from Rac1 to Rap1, thereby leading to enhanced RECK expression.	Korea Univ, Cellular Oncol Lab, Grad Sch Med, Ansan 425707, Gyeonggi Do, South Korea; NCI, Ctr Canc Res, Cell & Canc Biol Branch, Bethesda, MD 20892 USA; Kyoto Univ, Dept Mol Oncol, Grad Sch Med, Kyoto, Japan	Korea University; Korea University Medicine (KU Medicine); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Kyoto University	Oh, J (corresponding author), Korea Univ, Cellular Oncol Lab, Grad Sch Med, Gojan 1 Dong, Ansan 425707, Gyeonggi Do, South Korea.	ohjs@korea.ac.kr	Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William/0000-0002-5500-5808; Oh, Junseo/0000-0002-0754-4946	Intramural NIH HHS [Z01 SC009179] Funding Source: Medline; NCI NIH HHS [Z01 SC009179-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01SC009179] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahn SM, 2004, CANCER LETT, V207, P49, DOI 10.1016/j.canlet.2003.11.025; Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Baumeister U, 2005, EMBO J, V24, P1686, DOI 10.1038/sj.emboj.7600647; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Chen HY, 2004, MOL CELL BIOL, V24, P10558, DOI 10.1128/MCB.24.24.10558-10572.2004; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Furumoto K, 2001, HEPATOLOGY, V33, P189, DOI 10.1053/jhep.2001.21048; Harrison SC, 2003, CELL, V112, P737, DOI 10.1016/S0092-8674(03)00196-X; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Masui T, 2003, CLIN CANCER RES, V9, P1779; Nakamura K, 2000, J BIOL CHEM, V275, P27155; Oh J, 2001, CELL, V107, P789, DOI 10.1016/S0092-8674(01)00597-9; Oh J, 2004, CANCER RES, V64, P9062, DOI 10.1158/0008-5472.CAN-04-1981; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; Perez-Martinez L, 2005, J NEUROSCI, V25, P4917, DOI 10.1523/JNEUROSCI.5066-04.2005; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V331, P1, DOI 10.1016/j.bbrc.2005.03.012; Sasahara RM, 2002, CANCER DETECT PREV, V26, P435, DOI 10.1016/S0361-090X(02)00123-X; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Span PN, 2003, CANCER, V97, P2710, DOI 10.1002/cncr.11395; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takenaka K, 2005, ANN SURG ONCOL, V12, P817, DOI 10.1245/ASO.2005.09.018; Takenaka K, 2004, EUR J CANCER, V40, P1617, DOI 10.1016/j.ejca.2004.02.028; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Valles AM, 2004, J BIOL CHEM, V279, P44490, DOI 10.1074/jbc.M405144200; VANDERJAGT MF, 2005, IN PRESS CANC LETT; Wingfield PT, 1999, J BIOL CHEM, V274, P21362, DOI 10.1074/jbc.274.30.21362; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4	35	36	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4230	4234		10.1038/sj.onc.1209444	http://dx.doi.org/10.1038/sj.onc.1209444			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16491114	Green Accepted, Green Submitted			2022-12-17	WOS:000239004800010
J	Kawakami, T; Zhang, C; Okada, Y; Okamoto, K				Kawakami, T.; Zhang, C.; Okada, Y.; Okamoto, K.			Erasure of methylation imprint at the promoter and CTCF-binding site upstream of H19 in human testicular germ cell tumors of adolescents indicate their fetal germ cell origin	ONCOGENE			English	Article						testicular cancer; methylation; imprinting; DNA reprogramming; H19	GROWTH-FACTOR-II; CARCINOMA-IN-SITU; X-LINKED GENES; WILMS-TUMOR; DNA METHYLATION; MAMMALIAN DEVELOPMENT; BIALLELIC EXPRESSION; COLORECTAL-CANCER; MOUSE EMBRYO; IGF2 GENE	Genome-wide epigenetic modi. cation plays a crucial role in regulating genome functions at critical stages of development. In particular, DNA methylation is known to be reprogrammed on a genome-wide level in germ cells and in preimplantation embryos, although it is relatively stable in somatic cells. In this reprogramming process, the genome becomes demethylated, and methylated de novo during later stages of development. Reprogramming of DNA methylation in male germ cells has not been fully investigated. Testicular germ cell tumors (TGCTs) possess a pluripotential nature and display protean histology from germ cells to embryonal and somatic cell differentiation. These properties make TGCT a unique model for studying germ cell development and gametogenesis in respect of DNA reprogramming. In order to obtain an insight into the epigenetic dynamics of TGCTs, we conducted a comprehensive analysis of differential methylated regions (DMRs) on H19 and IGF2 in TGCTs compared with testicular malignant lymphomas. In the present study, we show that methylation imprint at the promoter and CTCF-binding site upstream of H19 was completely erased in both seiminomatous and non-seminomatous TGCTs, whereas differential methylation was observed in testicular lymphomas. The erasure of methylation imprint was also observed in TGCTs with malignant transformation. We found biallelic unmethylation at the promoter and the CTCF-binding site upstream of H19 is required, but not sufficient for the biallelic expression of H19 in TGCTs. These data suggest that factors other than methylation contribute to transcriptional regulation of imprinted genes in TGCTs. The present data have shown that TGCTs carry distinctive epigenetic profiles at the core-imprinting domain of H19/IGF2 from other neoplasms of somatic cell origin. The data also suggest that both seminomatous and nonseminomatous TGCTs carry methylation profiles similar to fetal germ cells, but not adult germ cells, indicating the origin of TGCTs as fetal germ cells.	Shiga Univ Med Sci, Dept Urol, Otsu, Shiga 5202192, Japan	Shiga University of Medical Science	Kawakami, T (corresponding author), Shiga Univ Med Sci, Dept Urol, Otsu, Shiga 5202192, Japan.	keisei@belle.shiga-med.ac.jp						ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui HM, 2001, CANCER RES, V61, P4947; Davis TL, 2000, HUM MOL GENET, V9, P2885, DOI 10.1093/hmg/9.19.2885; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; Frevel MAE, 1999, J BIOL CHEM, V274, P29331, DOI 10.1074/jbc.274.41.29331; GRANT M, 1992, NAT GENET, V2, P161, DOI 10.1038/ng1092-161; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Holstein A. F., 1993, European Urology, V23, P9; Huber R, 1999, P NATL ACAD SCI USA, V96, P616, DOI 10.1073/pnas.96.2.616; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jinno Y, 1996, HUM MOL GENET, V5, P1155, DOI 10.1093/hmg/5.8.1155; JORGENSEN N, 1995, LAB INVEST, V72, P223; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; Kato Y, 1999, DEVELOPMENT, V126, P1823; Kawakami T, 2004, LANCET, V363, P40, DOI 10.1016/S0140-6736(03)15170-7; Kawakami T, 2004, ONCOGENE, V23, P6163, DOI 10.1038/sj.onc.1207808; Kawakami T, 2003, J UROLOGY, V169, P1546, DOI 10.1097/01.ju.0000044927.23323.5a; Kerjean A, 2000, HUM MOL GENET, V9, P2183, DOI 10.1093/hmg/9.14.2183; KIRCHGESSNER CU, 1995, J MED GENET, V32, P925, DOI 10.1136/jmg.32.12.925; Klenova EA, 2002, SEMIN CANCER BIOL, V12, P399, DOI 10.1016/S1044-579X(02)00060-3; Lee J, 2002, DEVELOPMENT, V129, P1807; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Looijenga LHJ, 2003, CANCER RES, V63, P2244; Loukinov DI, 2002, P NATL ACAD SCI USA, V99, P6806, DOI 10.1073/pnas.092123699; MOLLER H, 1989, J NATL CANCER I, V81, P1668, DOI 10.1093/jnci/81.21.1668-a; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Nakagawa H, 2001, P NATL ACAD SCI USA, V98, P591, DOI 10.1073/pnas.011528698; Nonomura N, 1997, J UROLOGY, V157, P1977, DOI 10.1016/S0022-5347(01)64913-9; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Oosterhuis JW, 2005, NAT REV CANCER, V5, P210, DOI 10.1038/nrc1568; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; Rajpert-De Meyts E, 2004, HUM REPROD, V19, P1338, DOI 10.1093/humrep/deh265; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Ross JA, 1999, CANCER, V85, P1389, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1389::AID-CNCR24>3.3.CO;2-M; Shiota K, 2002, DIFFERENTIATION, V69, P162, DOI 10.1046/j.1432-0436.2002.690406.x; SKAKKEBAEK NE, 1972, LANCET, V2, P516; SKAKKEBAEK NE, 1987, INT J ANDROL, V10, P19, DOI 10.1111/j.1365-2605.1987.tb00161.x; Smiraglia DJ, 2002, ONCOGENE, V21, P3909, DOI 10.1038/sj.onc.1205488; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096; SZABO PE, 1995, GENE DEV, V9, P1857, DOI 10.1101/gad.9.15.1857; Szabo PE, 1995, GENE DEV, V9, P3097, DOI 10.1101/gad.9.24.3097; Tada T, 1998, DEV GENES EVOL, V207, P551, DOI 10.1007/s004270050146; Takai D, 2001, HUM MOL GENET, V10, P2619, DOI 10.1093/hmg/10.23.2619; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Ulaner GA, 2003, ENDOCRINOLOGY, V144, P4420, DOI 10.1210/en.2003-0681; ULBRIGHT TM, 1993, AM J SURG PATHOL, V17, P1075, DOI 10.1097/00000478-199311000-00001; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; Verkerk AJMH, 1997, ONCOGENE, V14, P95, DOI 10.1038/sj.onc.1200802; VILLAR AJ, 1995, DEV BIOL, V172, P264, DOI 10.1006/dbio.1995.0021; Vu TH, 2000, GENOMICS, V64, P132, DOI 10.1006/geno.1999.6094; Yun K, 1999, J PATHOL, V187, P518, DOI 10.1002/(SICI)1096-9896(199904)187:5<518::AID-PATH276>3.0.CO;2-3; Zhang C, 2005, GENE CHROMOSOME CANC, V43, P104, DOI 10.1002/gcc.20160; ZHANG YH, 1993, AM J HUM GENET, V53, P113	63	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2006	25	23					3225	3236		10.1038/sj.onc.1209362	http://dx.doi.org/10.1038/sj.onc.1209362			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MM	16434968				2022-12-17	WOS:000237951200001
J	Di Fulvio, M; Lehman, N; Lin, X; Lopez, I; Gomez-Cambronero, J				Di Fulvio, M.; Lehman, N.; Lin, X.; Lopez, I.; Gomez-Cambronero, J.			The elucidation of novel SH2 binding sites on PLD2	ONCOGENE			English	Article						PLD; Grb2; SOS; SH2 domains; cell signalling; cell proliferation; Ras/Erk pathway; site-directed mutagenesis	KINASE SIGNAL-TRANSDUCTION; RECEPTOR TYROSINE KINASES; COLONY-STIMULATING FACTOR; ADP-RIBOSYLATION FACTOR; GROWTH-FACTOR RECEPTOR; PHOSPHOLIPASE-D; REGULATORY MECHANISM; CELL-PROLIFERATION; HUMAN NEUTROPHILS; PROTEIN GRB2	Our laboratory has recently reported that the enzyme phospholipase D2 (PLD2) exists as a ternary complex with PTP1b and the growth factor receptor bound protein 2 (Grb2). Here, we establish the mechanistic underpinnings of the PLD2/Grb2 association. We have identified residues Y-169 and Y-179 in the PLD2 protein as being essential for the Grb2 interaction. We present evidence indicating that Y-169 and Y179 are located within two consensus sites in PLD2 that mediate an SH2 interaction with Grb2. This was demonstrated with an SH2-deficient GSTGrb2 R86K mutant that failed to pull-down PLD2 in vitro. In order to elucidate the functions of the two neighboring tyrosines, we created a new class of deletion and point mutants in PLD2. Phenylalanine replacement of Y-169 (PLD2 Y169F)or Y-179 (PLD2 Y179F) reduced Grb2 binding while simultaneous mutation completely abolished it. The role of the two binding sites on PLD2 was found to be functionally nonequivalent: Y-169 serves to modulate the activity of the enzyme, whereas Y-179 regulates total tyrosine phosphorylation of the protein. Interestingly, binding of Grb2 to PLD2 occurs irrespectively of lipase activity, since Grb2 binds to catalytically inactive PLD2 mutants. Finally, PLD2 residues Y-169 and Y-179 are necessary for the recruitment of Sos, but only overexpression of the PLD2 Y179F mutant resulted in increased Ras activity, p44/42(Erk) phosphorylation and enhanced DNA synthesis. Since Y-169 remains able to modulate enzyme activity and is capable of binding to Grb2 in the PLD2 Y179F mutant, we propose that Y-169 is kept under negative regulation by Y-179. When this is released, Y-169 mediates cellular proliferation through the Ras/MAPK pathway.	Wright State Univ, Dept Physiol & Biophys, Sch Med, Dayton, OH 45435 USA; Univ Illinois, Dept Pharmacol, Chicago, IL USA	Wright State University Dayton; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gomez-Cambronero, J (corresponding author), Wright State Univ, Dept Physiol & Biophys, Sch Med, Dayton, OH 45435 USA.	julian.cambronero@wright.edu		Gomez-Cambronero, Julian/0000-0002-7581-9227	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL056653, R01HL056653] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL056653-09, R29 HL056653, HL056653, R01 HL056653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn BH, 2003, MOL CELL BIOL, V23, P3103, DOI 10.1128/MCB.23.9.3103-3115.2003; Banno Y, 2005, J BIOL CHEM, V280, P16319, DOI 10.1074/jbc.M410903200; BOURGOIN S, 1992, J BIOL CHEM, V267, P11908; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; Choi WS, 2004, MOL CELL BIOL, V24, P6980, DOI 10.1128/MCB.24.16.6980-6992.2004; Cockcroft S, 2001, CELL MOL LIFE SCI, V58, P1674, DOI 10.1007/PL00000805; Di Fulvio M, 2000, J ENDOCRINOL, V166, P173, DOI 10.1677/joe.0.1660173; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Exton JH, 1998, BBA-MOL CELL BIOL L, V1436, P105, DOI 10.1016/S0005-2760(98)00124-6; Foster DA, 2003, MOL CANCER RES, V1, P789; Gomez-Cambronero J, 2003, J IMMUNOL, V171, P6846, DOI 10.4049/jimmunol.171.12.6846; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Horn J, 2005, BIOCHEM BIOPH RES CO, V332, P58, DOI 10.1016/j.bbrc.2005.04.093; Horn JM, 2001, BBA-MOL CELL BIOL L, V1530, P97, DOI 10.1016/S1388-1981(00)00172-4; Houle MG, 1999, BBA-MOL CELL BIOL L, V1439, P135, DOI 10.1016/S1388-1981(99)00090-6; Jang IH, 2003, J BIOL CHEM, V278, P18184, DOI 10.1074/jbc.M208438200; Kim JH, 2002, BIOCHEMISTRY-US, V41, P3414, DOI 10.1021/bi015700a; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lehman JA, 2003, J BIOL CHEM, V278, P28130, DOI 10.1074/jbc.M300376200; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Li SG, 2001, EMBO J, V20, P6793, DOI 10.1093/emboj/20.23.6793; Liu MY, 2002, CANCER RES, V62, P6475; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Park JB, 2000, J BIOL CHEM, V275, P21295, DOI 10.1074/jbc.M002463200; Park SK, 1997, J BIOL CHEM, V272, P29263, DOI 10.1074/jbc.272.46.29263; Powner DJ, 2002, FEBS LETT, V531, P62, DOI 10.1016/S0014-5793(02)03410-5; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Xu Y, 2001, BIOCHEM J, V360, P513, DOI 10.1042/0264-6021:3600513; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	35	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 18	2006	25	21					3032	3040		10.1038/sj.onc.1209340	http://dx.doi.org/10.1038/sj.onc.1209340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	048MI	16407827	Green Accepted			2022-12-17	WOS:000237950800007
J	Campbell, MR; Wang, Y; Andrew, SE; Liu, Y				Campbell, MR; Wang, Y; Andrew, SE; Liu, Y			Msh2 deficiency leads to chromosomal abnormalities, centrosome amplification, and telomere capping defect	ONCOGENE			English	Article						mismatch repair; centrosome amplification; telomere capping; chromosomal abnormalities	DNA MISMATCH REPAIR; CANCER-CELLS; GENE; SUSCEPTIBILITY; PROLIFERATION; RECOMBINATION; ABERRATIONS; MUTATION; MOUSE; MICE	Msh2 is a key mammalian DNA mismatch repair (MMR) gene and mutations or deficiencies in mammalian Msh2 gene result in microsatellite instability (MSI+) and the development of cancer. Here, we report that primary mouse embryonic fibroblasts (MEFs) deficient in the murine MMR gene Msh2 (Msh2(-/-)) showed a significant increase in chromosome aneuploidy, centrosome amplification, and defective mitotic spindle organization and unequal chromosome segregation. Although Msh2(-/-) mouse tissues or primary MEFs had no apparent change in telomerase activity, telomere length, or recombination at telomeres, Msh2(-/-) MEFs showed an increase in chromosome end-to-end fusions or chromosome ends without detectable telomeric DNA. These data suggest that MSH2 helps to maintain genomic stability through the regulation of the centrosome and normal telomere capping in vivo and that defects in MMR can contribute to oncogenesis through multiple pathways.	Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Univ Alberta, Dept Med Genet, Edmonton, AB, Canada	United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Alberta	Liu, Y (corresponding author), Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA.	liuy3@ornl.gov						Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bailey SM, 2004, NUCLEIC ACIDS RES, V32, P3743, DOI 10.1093/nar/gkh691; Bechter OE, 2004, CANCER RES, V64, P3444, DOI 10.1158/0008-5472.CAN-04-0323; Bellacosa A, 2001, CELL DEATH DIFFER, V8, P1076, DOI 10.1038/sj.cdd.4400948; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; ELANGE T, 2002, ONCOGENE, V21, P532; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Pickett HA, 2004, ONCOGENE, V23, P3434, DOI 10.1038/sj.onc.1207477; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Rizki A, 2001, NATURE, V411, P713, DOI 10.1038/35079641; Rufer N, 1998, NAT BIOTECHNOL, V16, P743, DOI 10.1038/nbt0898-743; Saunders W, 2005, SEMIN CANCER BIOL, V15, P25, DOI 10.1016/j.semcancer.2004.09.003; Zijlmans JMJM, 1997, P NATL ACAD SCI USA, V94, P7423, DOI 10.1073/pnas.94.14.7423	20	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	17					2531	2536		10.1038/sj.onc.1209277	http://dx.doi.org/10.1038/sj.onc.1209277			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	034RJ	16331258				2022-12-17	WOS:000236948000011
J	Li, Y; Clevenger, CV; Minkovsky, N; Kumar, KGS; Raghunath, PN; Tomaszewski, JE; Spiegelman, VS; Fuchs, SY				Li, Y; Clevenger, CV; Minkovsky, N; Kumar, KGS; Raghunath, PN; Tomaszewski, JE; Spiegelman, VS; Fuchs, SY			Stabilization of prolactin receptor in breast cancer cells	ONCOGENE			English	Article						prolactin; receptor; beta-TrCP; ubiquitin; E3 ligase; breast cancer	E3 UBIQUITIN LIGASE; MAMMARY-CARCINOMA; TRANSGENIC MICE; GROWTH-HORMONE; ACTIVATION; EXPRESSION; INDUCTION; TUMORS; RISK; GENE	The role of the hormone prolactin (PRL) in the pathogenesis of breast cancer is mediated by its cognate receptor (PRLr). Ubiquitin-dependent degradation of the PRLr that negatively regulates PRL signaling is triggered by PRL-mediated phosphorylation of PRLr on Ser349 followed by the recruitment of the beta-transducin repeats-containing protein ( beta-TrCP) ubiquitin-protein isopeptide ligase. We report here for the first time that interaction between PRLr and beta-TrCP is less efficient in human breast cancer cells than in non-tumorigenic human mammary epithelial cells. Furthermore, we demonstrate that both PRLr degradation and PRLr phosphorylation on Ser349 are impaired in breast tumor cells and tissues, an observation that directly correlates with enhanced expression of the PRLr in malignant breast epithelium. These findings represent a novel mechanism through which altered PRLr stability may directly influence the pathogenesis of breast cancer.	Univ Penn, Dept Anim Biol, Philadelphia, PA 19104 USA; Northwestern Univ, Dept Pathol, Chicago, IL 60611 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Wisconsin, Dept Dermatol, Madison, WI USA	University of Pennsylvania; Northwestern University; University of Pennsylvania; University of Wisconsin System; University of Wisconsin Madison	Fuchs, SY (corresponding author), Univ Penn, Dept Anim Biol, 3800 Spruce St,Room 161E VET, Philadelphia, PA 19104 USA.	syfuchs@vet.upenn.edu		Spiegelman, Vladimir S/0000-0003-4847-155X; Minkovsky, Natalie/0000-0002-2707-0506	NCI NIH HHS [CA069294, R01 CA115281] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA115281, R01CA069294] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Canbay E, 2004, CURR MED RES OPIN, V20, P533, DOI 10.1185/030079904125003232; CARTUN RW, 1989, J HISTOTECHNOL, V12, P273; Clevenger CV, 2004, AM J PATHOL, V165, P1449, DOI 10.1016/S0002-9440(10)63403-7; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Clevenger CV, 2003, ENDOCR REV, V24, P1, DOI 10.1210/er.2001-0036; Das R, 1997, J MAMMARY GLAND BIOL, V2, P29, DOI 10.1023/A:1026369412612; Diehl JA, 2002, CANCER BIOL THER, V1, P226, DOI 10.4161/cbt.72; Glasow A, 2001, J CLIN ENDOCR METAB, V86, P3826, DOI 10.1210/jc.86.8.3826; Goffin V, 2005, ENDOCR REV, V26, P400, DOI 10.1210/er.2004-0016; Harvey PW, 2005, J APPL TOXICOL, V25, P179, DOI 10.1002/jat.1063; Kim H, 2002, BIOCHEM J, V365, P765, DOI 10.1042/BJ20011848; Kline JB, 2002, MOL ENDOCRINOL, V16, P2310, DOI 10.1210/me.2001-0033; Li Y, 2004, MOL CELL BIOL, V24, P4038, DOI 10.1128/MCB.24.9.4038-4048.2004; Meng JP, 2004, CANCER RES, V64, P5677, DOI 10.1158/0008-5472.CAN-04-1019; Perks CC, 2004, BRIT J CANCER, V91, P305, DOI 10.1038/sj.bjc.6601947; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Reynolds C, 1997, ENDOCRINOLOGY, V138, P5555, DOI 10.1210/en.138.12.5555; Rose-Hellekant TA, 2003, ONCOGENE, V22, P4664, DOI 10.1038/sj.onc.1206619; Spiegelman VS, 2002, J BIOL CHEM, V277, P36624, DOI 10.1074/jbc.M204524200; Tang WG, 2005, CANCER RES, V65, P1904, DOI 10.1158/0008-5472.CAN-04-2597; Tworoger SS, 2004, CANCER RES, V64, P6814, DOI 10.1158/0008-5472.CAN-04-1870; Wennbo H, 2000, ONCOGENE, V19, P1072, DOI 10.1038/sj.onc.1203349; Wennbo H, 1997, J CLIN INVEST, V100, P2744, DOI 10.1172/JCI119820	24	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1896	1902		10.1038/sj.onc.1209214	http://dx.doi.org/10.1038/sj.onc.1209214			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16278670				2022-12-17	WOS:000236224800006
J	Howlin, J; McBryan, J; Napoletano, S; Lambe, T; McArdle, E; Shioda, T; Martin, F				Howlin, J; McBryan, J; Napoletano, S; Lambe, T; McArdle, E; Shioda, T; Martin, F			CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis	ONCOGENE			English	Article						mammary gland; development; ductal morphogenesis; puberty; CITED1; amphiregulin	GROWTH-FACTOR-BETA; ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER CELLS; EPITHELIAL-CELLS; TRANSFORMING GROWTH-FACTOR-BETA-1; NUCLEAR-PROTEIN; TGF-BETA; EXPRESSION; GLAND; GENES	Expression microarray analysis identified CITED1 among a group of genes specifically upregulated in the pubertal mouse mammary gland. At puberty, CITED1 localizes to the luminal epithelial cell population of the mammary ducts and the body cells of the terminal end buds. Generation of CITED1 gene knockout mice showed that homozygous null mutants exhibit retarded mammary ductal growth at puberty and, in addition, dilated ductal structures with a lack of spatial restriction of the subtending branches. Analysis of CITED1 homozygous null and heterozygous null mammary gland gene expression using microarrays suggested that the mammary specific phenotype seen in the homozygous null females is due to a disturbance in the transcription of a number of key mediators of pubertal ductal morphogenesis. These include estrogen and TGF beta responsive genes, such as the EGFR/ErbB2 ligand, amphiregulin, whose transcription we suggest is directly or indirectly regulated by CITED1.	Univ Coll Dublin, Conway Inst, Dublin 4, Ireland; Univ Coll Dublin, Sch Biomol & Biomed Sci, Dublin 4, Ireland; Massachusetts Gen Hosp, Ctr Canc, Lab Tumour Biol, Charlestown, MA USA	University College Dublin; University College Dublin; Harvard University; Massachusetts General Hospital	Martin, F (corresponding author), Univ Coll Dublin, Conway Inst, Dublin 4, Ireland.	finian.martin@ucd.ie	Lambe, Teresa/E-5733-2016; Howlin, Jill/G-9665-2011	Lambe, Teresa/0000-0001-7711-897X; Howlin, Jill/0000-0002-2766-3002; McBryan, Jean/0000-0002-7568-2208	NCI NIH HHS [CA082230] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082230] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aldred MA, 2004, J CLIN ONCOL, V22, P3531, DOI 10.1200/JCO.2004.08.127; Berking C, 2001, CANCER RES, V61, P8306; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Chen CR, 2001, P NATL ACAD SCI USA, V98, P992, DOI 10.1073/pnas.98.3.992; D'Cruz CM, 2002, MOL ENDOCRINOL, V16, P2034, DOI 10.1210/me.2002-0073; Daniel CW, 1996, J MAMMARY GLAND BIOL, V1, P331, DOI 10.1007/BF02017389; DEGROOT RP, 1992, ONCOGENE, V7, P2281; Dunwoodie SL, 1998, MECH DEVELOP, V72, P27, DOI 10.1016/S0925-4773(98)00011-2; Ewan KB, 2002, AM J PATHOL, V160, P2081, DOI 10.1016/S0002-9440(10)61158-3; Ewan KBR, 2005, AM J PATHOL, V167, P409, DOI 10.1016/S0002-9440(10)62985-9; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; Gallagher J, 2003, FEBS LETT, V551, P8, DOI 10.1016/S0014-5793(03)00823-8; Humphreys RC, 1999, J MAMMARY GLAND BIOL, V4, P213, DOI 10.1023/A:1018733426625; KENNEY NJ, 1995, MOL REPROD DEV, V41, P277, DOI 10.1002/mrd.1080410302; Kenney NJ, 1996, CELL GROWTH DIFFER, V7, P1769; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; Li HC, 1998, EXP CELL RES, V242, P478, DOI 10.1006/excr.1998.4123; Luetteke NC, 1999, DEVELOPMENT, V126, P2739; MARTINEZLACACI I, 1995, ENDOCRINOLOGY, V136, P3983, DOI 10.1210/en.136.9.3983; Morse DL, 2005, ANAL BIOCHEM, V342, P69, DOI 10.1016/j.ab.2005.03.034; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; Murtagh J, 2004, J CELL BIOL, V166, P133, DOI 10.1083/jcb.200403020; Nair SS, 2001, PIGM CELL RES, V14, P206, DOI 10.1034/j.1600-0749.2001.140311.x; NEGOESCU A, 1995, EXP CELL RES, V217, P404, DOI 10.1006/excr.1995.1103; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Connell FC, 2000, CELL DEATH DIFFER, V7, P360, DOI 10.1038/sj.cdd.4400647; Prasad ML, 2005, MODERN PATHOL, V18, P48, DOI 10.1038/modpathol.3800235; Prasad ML, 2004, THYROID, V14, P169, DOI 10.1089/105072504773297830; ROBINSON SD, 1991, DEVELOPMENT, V113, P867; Russo J, 1999, BREAST CANCER RES TR, V53, P217, DOI 10.1023/A:1006186719322; Shioda T, 1998, P NATL ACAD SCI USA, V95, P9785, DOI 10.1073/pnas.95.17.9785; Shioda T, 1996, P NATL ACAD SCI USA, V93, P12298, DOI 10.1073/pnas.93.22.12298; Sid B, 2004, CRIT REV ONCOL HEMAT, V49, P245, DOI 10.1016/j.critrevonc.2003.09.009; SILBERSTEIN GB, 1987, SCIENCE, V237, P291, DOI 10.1126/science.3474783; Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259; Stern DF, 2003, EXP CELL RES, V284, P89, DOI 10.1016/S0014-4827(02)00103-9; Stewart HJS, 1995, GLIA, V15, P419, DOI 10.1002/glia.440150406; Tang SH, 2004, NUCLEIC ACIDS RES, V32, pD533, DOI 10.1093/nar/gkh083; Verrecchia F, 2001, J BIOL CHEM, V276, P17058, DOI 10.1074/jbc.M100754200; Wiesen JF, 1999, DEVELOPMENT, V126, P335; WILLIAMS JM, 1983, DEV BIOL, V97, P274, DOI 10.1016/0012-1606(83)90086-6; Wu LY, 2003, J BIOL CHEM, V278, P15192, DOI 10.1074/jbc.M212332200; Xie L, 2003, BREAST CANCER RES, V5, pR187, DOI 10.1186/bcr640; Xie W, 1997, MOL ENDOCRINOL, V11, P1766, DOI 10.1210/me.11.12.1766; Yahata T, 2000, J BIOL CHEM, V275, P8825, DOI 10.1074/jbc.275.12.8825; Yahata T, 2001, GENE DEV, V15, P2598, DOI 10.1101/gad.906301; Zeps N, 1998, DIFFERENTIATION, V62, P221, DOI 10.1046/j.1432-0436.1998.6250221.x; Zhou A, 2003, ONCOGENE, V22, P2054, DOI 10.1038/sj.onc.1206262	48	36	38	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	10					1532	1542		10.1038/sj.onc.1209183	http://dx.doi.org/10.1038/sj.onc.1209183			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	020EE	16278680				2022-12-17	WOS:000235890400010
J	Bouleau, S; Grimal, H; Rincheval, V; Godefroy, N; Mignotte, B; Vayssiere, JL; Renaud, F				Bouleau, S; Grimal, H; Rincheval, V; Godefroy, N; Mignotte, B; Vayssiere, JL; Renaud, F			FGF1 inhibits p53-dependent apoptosis and cell cycle arrest via an intracrine pathway	ONCOGENE			English	Article						FGF1; p53; apoptosis	FIBROBLAST-GROWTH-FACTOR; P53-MEDIATED TRANSCRIPTIONAL REPRESSION; WILD-TYPE P53; MESSENGER-RNA; EXPRESSION; SURVIVAL; GENE; BCL-2; FIBROBLAST-GROWTH-FACTOR-1; PROTEIN	We analysed the relationships between p53-induced apoptosis and the acidic fibroblast growth factor 1 (FGF1) survival pathway. We found that p53 activation in rat embryonic fibroblasts induced the downregulation of FGF1 expression. These data suggest that the fgf1 gene is a repressed target of p53. Unlike extracellular FGF1, which has no effect on p53-dependent pathways, intracellular FGF1 inhibits both p53-dependent apoptosis and cell growth arrest via an intracrine pathway. FGF1 increases MDM2 expression at both mRNA and protein levels. This increase is associated with an acceleration of p53 degradation, which may partly account for the ability of endogenous FGF1 to counteract p53 pathways. In the presence of FGF1, p53 was unable to transactivate bax, but no modi. cation of p21 gene transactivation was observed. As Bax is an essential component of the p53-dependent apoptosis pathway, this suggests that intracellular FGF1 inhibits p53 pathways not only by decreasing the stability of p53, but also by modifying some of its transactivation properties. In conclusion, we showed that p53 and FGF1 pathways may interact in the cell to determine cell fate. Deregulation of one of these pathways modifies the balance between cell proliferation and cell death and may lead to tumor progression.	Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, F-78035 Versailles, France; Ecole Prat Hautes Etud, Lab Genet Mol & Physiol, F-78035 Versailles, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Renaud, F (corresponding author), Univ Versailles, Lab Genet & Biol Cellulaire, CNRS, FRE 2445, 45 Ave Etats Unis, F-78035 Versailles, France.	frenaud@genetique.uvsq.fr	Godefroy, Nelly/AAG-2052-2020; Mignotte, Bernard/A-3499-2009	Mignotte, Bernard/0000-0002-8512-8518				Ashe PC, 2003, PROG NEURO-PSYCHOPH, V27, P199, DOI 10.1016/S0278-5846(03)00016-2; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chiu IM, 2001, PROG NUCLEIC ACID RE, V70, P155, DOI 10.1016/S0079-6603(01)70016-5; CRUMLEY GR, 1989, GENE, V85, P489, DOI 10.1016/0378-1119(89)90443-5; D'Souza S, 2001, J BIOL CHEM, V276, P298, DOI 10.1074/jbc.M007155200; Desire L, 1998, EXP CELL RES, V241, P210, DOI 10.1006/excr.1998.4048; Galy B, 2001, ONCOGENE, V20, P4613, DOI 10.1038/sj.onc.1204630; Galy B, 2001, ONCOGENE, V20, P1669, DOI 10.1038/sj.onc.1204271; Godefroy N, 2004, NUCLEIC ACIDS RES, V32, P4480, DOI 10.1093/nar/gkh773; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Hashimoto M, 2002, J BIOL CHEM, V277, P32985, DOI 10.1074/jbc.M202803200; Haupt Ygal, 1997, Leukemia (Basingstoke), V11, P337; Heron-Milhavet L, 2002, J BIOL CHEM, V277, P15600, DOI 10.1074/jbc.M111142200; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Lin YZ, 1996, J BIOL CHEM, V271, P5305, DOI 10.1074/jbc.271.10.5305; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Murray SA, 2003, ONCOGENE, V22, P1703, DOI 10.1038/sj.onc.1206327; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Ornitz DM, 2001, GENOME BIOL, V2; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; PHILIPPE JM, 1992, BIOCHEM BIOPH RES CO, V188, P843, DOI 10.1016/0006-291X(92)91133-B; Philippe JM, 1996, DNA CELL BIOL, V15, P703, DOI 10.1089/dna.1996.15.703; Powers CJ, 2000, ENDOCR-RELAT CANCER, V7, P165, DOI 10.1677/erc.0.0070165; Prudovsky I, 2002, J CELL BIOL, V158, P201, DOI 10.1083/jcb.200203084; Raguenez G, 1999, BIOCHEM BIOPH RES CO, V258, P745, DOI 10.1006/bbrc.1999.0613; RENAUD F, 1992, BIOCHEM BIOPH RES CO, V184, P945, DOI 10.1016/0006-291X(92)90682-B; Renaud F, 1996, BIOCHEM BIOPH RES CO, V219, P679, DOI 10.1006/bbrc.1996.0294; Renaud F, 1996, J BIOL CHEM, V271, P2801, DOI 10.1074/jbc.271.5.2801; RENAUD F, 1994, J CELL PHYSIOL, V158, P435, DOI 10.1002/jcp.1041580307; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rincheval V, 2002, BIOCHEM BIOPH RES CO, V298, P282, DOI 10.1016/S0006-291X(02)02454-3; Rincheval V, 1999, FEBS LETT, V460, P203, DOI 10.1016/S0014-5793(99)01345-9; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Singh B, 2002, GENE DEV, V16, P984, DOI 10.1101/gad.973602; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067	48	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 24	2005	24	53					7839	7849		10.1038/sj.onc.1208932	http://dx.doi.org/10.1038/sj.onc.1208932			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	986PU	16091747				2022-12-17	WOS:000233463000003
J	Lomonosova, E; Subramanian, T; Chinnadurai, G				Lomonosova, E; Subramanian, T; Chinnadurai, G			Mitochondrial localization of p53 during adenovirus infection and regulation of its activity by E1B-19K	ONCOGENE			English	Article						adenovirus; apoptosis; mitochondria; p53; E1B-19K	WILD-TYPE P53; COLORECTAL-CANCER CELLS; TUMOR-SUPPRESSOR P53; BCL-2 PROTEINS; E1B 19K; TRANSCRIPTIONAL ACTIVATION; E4ORF6 PROTEIN; P53-DEPENDENT APOPTOSIS; SV40-TRANSFORMED CELLS; HOST PROTEIN	Recent results have revealed that the p53 tumor suppressor protein possesses a direct transcription-independent apoptotic activity. During apoptosis induced by genotoxic stress, a small fraction of p53 is targeted to mitochondria where it initiates apoptosis by causing mitochondrial dysfunction. In adenovirus-infected cells, the expression of E1A protein enhances the accumulation of p53 during early phases of infection and during late times after infection, it is targeted for degradation by the combined action of E1B-55K and E4-orf6 proteins. The functional significance of E1A-mediated accumulation of p53 during early phases of viral replication is not known. Our studies with isogenic epithelial cell lines that differ only on the status of p53 indicate that Ad infection induces apoptosis by p53-dependent and -independent pathways and both pathways are suppressed by E1B-19K. We show that during early phase of Ad infection, a fraction of p53 is targeted to the mitochondria. In virus infected cells, a large fraction of the viral antiapoptosis protein E1B-19K is also localized in mitochondria during early and late phases of infection. Coimmunoprecipitation analysis has revealed that p53 and E1B-19K form a complex in mitochondria. The interaction of 19K involves two noncontiguous regions located around amino-acid residues 14-15 and 123-124. On p53, the mutations within the DNA-binding domain reduce interaction with E1B-19K. Our studies also suggest that 19K may additionally complex with the multidomain mitochondrial proapoptotic protein BAK, thereby reducing the level of p53 interaction with BAK. We suggest that p53-induced apoptosis may be important for efficient cell lysis and viral spread and that E1B-19K may neutralize the apoptotic activity of p53 at multiple levels.	St Louis Univ, Sch Med, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Sch Med, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu			NATIONAL CANCER INSTITUTE [R01CA033616] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33616, R01 CA033616] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1984, J VIROL, V50, P202, DOI 10.1128/JVI.50.1.202-212.1984; BACCHETTI S, 1993, INT J ONCOL, V3, P781; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; BECK GR, 1998, HUMAN TUMOR VIRUSES, P51; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; BETT AJ, 1995, VIRUS RES, V39, P75; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BOYD JM, 1995, ONCOGENE, V11, P1921; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chen G, 1996, J BIOL CHEM, V271, P24221, DOI 10.1074/jbc.271.39.24221; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chinnadurai G, 1998, SEMIN VIROL, V8, P399, DOI 10.1006/smvy.1997.0139; Chiou SK, 1997, J VIROL, V71, P3515, DOI 10.1128/JVI.71.5.3515-3525.1997; CHIOU SK, 1994, J VIROL, V68, P6553, DOI 10.1128/JVI.68.10.6553-6566.1994; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Collett D., 2003, MODELLING SURVIVAL D; Collot-Teixeira S, 2004, REV MED VIROL, V14, P301, DOI 10.1002/rmv.431; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; Cuconati A, 2002, GENE DEV, V16, P2465, DOI 10.1101/gad.1012702; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Degenhardt K, 2000, Symp Soc Exp Biol, V52, P241; Dix BR, 2000, CANCER RES, V60, P2666; Dobner T, 1996, SCIENCE, V272, P1470, DOI 10.1126/science.272.5267.1470; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erster S, 2004, CELL CYCLE, V3, P1492, DOI 10.4161/cc.3.12.1318; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; FARROW SN, 1995, NATURE, V374, P731, DOI 10.1038/374731a0; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; GRAND RJA, 1994, VIROLOGY, V203, P229, DOI 10.1006/viro.1994.1480; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Hale TK, 1999, J BIOL CHEM, V274, P23777, DOI 10.1074/jbc.274.34.23777; Hall AR, 1998, NAT MED, V4, P1068, DOI 10.1038/2057; Han J, 1996, MOL CELL BIOL, V16, P5857; HAN J, 1996, WANG, V10, P461; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Henry H, 2002, ONCOGENE, V21, P748, DOI 10.1038/sj.onc.1205125; Hobom U, 2004, J VIROL, V78, P7685, DOI 10.1128/JVI.78.14.7685-7697.2004; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Koch P, 2001, CANCER RES, V61, P5941; Kokontis JM, 2001, ONCOGENE, V20, P659, DOI 10.1038/sj.onc.1204139; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Liang SH, 2001, EUR J BIOCHEM, V268, P2779, DOI 10.1046/j.1432-1327.2001.02227.x; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Lomonosova E, 2002, J VIROL, V76, P11283, DOI 10.1128/JVI.76.22.11283-11290.2002; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Mahyar-Roemer M, 2004, ONCOGENE, V23, P6226, DOI 10.1038/sj.onc.1207637; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Mathai JP, 2002, ONCOGENE, V21, P2534, DOI 10.1038/sj.onc.1205340; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; Moll UM, 2003, MOL CANCER RES, V1, P1001; Moore M, 1996, P NATL ACAD SCI USA, V93, P11295, DOI 10.1073/pnas.93.21.11295; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Petros AM, 2004, FEBS LETT, V559, P171, DOI 10.1016/s0014-5793(04)00059-6; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Querido E, 1997, J VIROL, V71, P3788, DOI 10.1128/JVI.71.5.3788-3798.1997; Querido E, 2001, J VIROL, V75, P699, DOI 10.1128/JVI.75.2.699-709.2001; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; Shen YQ, 2001, J VIROL, V75, P4297, DOI 10.1128/JVI.75.9.4297-4307.2001; Steegenga WT, 1998, ONCOGENE, V16, P349, DOI 10.1038/sj.onc.1201540; Subramanian T, 1995, ONCOGENE, V11, P2403; Subramanian T, 2003, J CELL BIOCHEM, V89, P1102, DOI 10.1002/jcb.10573; SUBRAMANIAN T, 1993, GENE, V124, P173, DOI 10.1016/0378-1119(93)90391-F; SUBRAMANIAN T, 1984, J VIROL, V52, P336, DOI 10.1128/JVI.52.2.336-343.1984; SUBRAMANIAN T, 1995, CELL GROWTH DIFFER, V6, P131; TARODI B, 1993, INT J ONCOL, V3, P467; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Theodorakis P, 2002, CANCER RES, V62, P3373; Theodorakis P, 1996, ONCOGENE, V12, P1707; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; Turnell AS, 2000, EMBO J, V19, P4759, DOI 10.1093/emboj/19.17.4759; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang GD, 2004, ONCOL REP, V12, P955; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE E, 1984, MOL CELL BIOL, V4, P2865, DOI 10.1128/MCB.4.12.2865; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Xu Y, 2003, CELL DEATH DIFFER, V10, P1213, DOI 10.1038/sj.cdd.4401292; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100	99	36	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 13	2005	24	45					6796	6808		10.1038/sj.onc.1208836	http://dx.doi.org/10.1038/sj.onc.1208836			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	973MV	16007153				2022-12-17	WOS:000232527800007
J	Zochbauer-Muller, S; Fong, KM; Geradts, J; Xu, X; Seidl, S; End-Pfutzenreuter, A; Lang, G; Heller, G; Zielinski, CC; Gazdar, AF; Minna, JD				Zochbauer-Muller, S; Fong, KM; Geradts, J; Xu, X; Seidl, S; End-Pfutzenreuter, A; Lang, G; Heller, G; Zielinski, CC; Gazdar, AF; Minna, JD			Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation	ONCOGENE			English	Article						tumor suppressor gene; lung cancer; hSRBC; epigenetic; methylation-specific PCR	ABERRANT PROMOTER METHYLATION; EPIGENETIC INACTIVATION; MULTIPLE GENES; BREAST; HETEROZYGOSITY; SMOKERS; CARCINOMAS; CHROMOSOME-11; PROGRESSION; EPITHELIUM	Recently, the human SRBC (hSRBC) gene, a candidate tumor suppressor gene (TSG), has been mapped to the chromosomal region 11p15.5-p15.4 where frequent allele loss has been described in lung cancer. Aberrant methylation ( referred to as methylation) of the promoter region of TSGs has been identified as an important mechanism for gene silencing. Loss of hSRBC protein expression occurs frequently in lung cancer cell lines and sodium bisulfite sequencing of the promoter region of hSRBC in several lung cancer cell lines suggested that methylation plays an important role in inactivating hSRBC. To determine the methylation status of hSRBC in a large collection of primary lung cancer samples, corresponding nonmalignant lung tissues and lung cancer cell lines (N=52), we designed primers for a methylation-specific PCR assay. Methylation was detected in 41% of primary non-small-cell lung cancers (NSCLC)(N=107) and in 80% of primary small-cell lung cancers (SCLC)(N=5), but was seen only in 4% of corresponding nonmalignant lung tissues (N=103). In all, 79% of lung cancer cell lines were methylated and the frequency of hSRBC methylation was significantly higher in SCLC (100%) than in NSCLC (58%) cell lines. Normal hSRBC protein expression was detected in only 18% of primary NSCLCs (N=93) by immunostaining and a significant association between loss of protein expression and methylation was found. hSRBC re-expression was observed after treatment of lung cancer cells with the demethylating agent 5-aza-2'-deoxycytidine. In addition, 45% of the 76 hSRBC immunostaining-negative NSCLCs did not have hSRBC promoter methylation, indicating that other mechanisms of hSRBC expression silencing also exist. Both hSRBC immunostaining and methylation results did not correlate with clinicopathological characteristics of these patients. Our ndings suggest that hSRBC is a candidate TSG involved in lung cancer pathogenesis, where expression is frequently inactivated by methylation and other mechanisms.	Univ Hosp Vienna, Clin Div Oncol, Dept Med 1, A-1090 Vienna, Austria; Univ Hosp Vienna, Ctr Excellence Clin & Expt Oncol, Vienna, Austria; Prince Charles Hosp, Brisbane, Qld 4032, Australia; Roswell Pk Canc Inst, Buffalo, NY 14263 USA; Sagres Discovery, Davis, CA USA; Univ Hosp Vienna, Dept Cardiothorac Surg, Vienna, Austria; Koranyi Natl Inst Pulmonol, Dept Thorac Surg, Budapest, Hungary; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75230 USA	University Hospital Vienna; University Hospital Vienna; Prince Charles Hospital; Roswell Park Cancer Institute; University Hospital Vienna; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Zochbauer-Muller, S (corresponding author), Univ Hosp Vienna, Clin Div Oncol, Dept Med 1, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	sabine.zoechbauer-mueller@meduniwien.ac.at	heller, gerwin/E-6521-2011; Zöchbauer-Müller, Sabine/B-8399-2012; Fong, Kwun M/G-6369-2010	heller, gerwin/0000-0001-8742-5631; Zöchbauer-Müller, Sabine/0000-0002-6777-1729; Fong, Kwun/0000-0002-6507-1403	NCI NIH HHS [CA709907] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Baffa R, 1996, CANCER RES, V56, P268; Belinsky SA, 2002, CANCER RES, V62, P2370; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dammann R, 2001, ONCOGENE, V20, P3563, DOI 10.1038/sj.onc.1204469; FONG KM, 1995, CANCER RES, V55, P220; FONG KM, 1995, CANCER RES, V55, P28; Fong KM, 1996, BRIT J CANCER, V74, P1975, DOI 10.1038/bjc.1996.662; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kersting M, 2000, J CLIN ONCOL, V18, P3221, DOI 10.1200/JCO.2000.18.18.3221; Phelps RM, 1996, J CELL BIOCHEM, P32; Soria JC, 2002, CANCER RES, V62, P351; Toyooka S, 2001, MOL CANCER THER, V1, P61; Tran YK, 1996, CANCER RES, V56, P2916; VANDAMME B, 1992, CANCER RES, V52, P6646; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; WINQVIST R, 1995, CANCER RES, V55, P2660; Wistuba II, 1999, CLIN CANCER RES, V5, P991; Xu XL, 2001, CANCER RES, V61, P7943; Zochbauer-Muller S, 2001, CANCER RES, V61, P249; Zochbauer-Muller S, 2003, INT J CANCER, V107, P612, DOI 10.1002/ijc.11458; Zochbauer-Muller S, 2001, CANCER RES, V61, P3581	24	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2005	24	41					6249	6255		10.1038/sj.onc.1208775	http://dx.doi.org/10.1038/sj.onc.1208775			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	964JM	15940253				2022-12-17	WOS:000231877100006
J	Himes, SR; Cronau, S; Mulford, C; Hume, DA				Himes, SR; Cronau, S; Mulford, C; Hume, DA			The Runx1 transcription factor controls CSF-1-dependent and -independent growth and survival of macrophages	ONCOGENE			English	Article						Runx1; macrophage; CSF-1; survival	CORE-BINDING-FACTOR; ACUTE MYELOMONOCYTIC LEUKEMIA; AML1/ETO FUSION TRANSCRIPT; ACUTE MYELOGENOUS LEUKEMIA; FETAL LIVER HEMATOPOIESIS; ACUTE MYELOID-LEUKEMIA; MYOSIN HEAVY-CHAIN; C-FMS; FACTOR BETA; DEFINITIVE HEMATOPOIESIS	Gene translocations that repress the function of the Runx1 transcription factor play a critical role in the development of myeloid leukemia. In this report, we demonstrate that Runx1 precisely regulates c-fms (CSF-1 receptor) gene expression. Runx1 controlled expression by binding to multiple sites within the mouse c-fms gene, allowing interaction between promoter and downstream enhancer elements. The runx1 and c-fms genes showed an identical pattern of expression in mature macrophages. Runx1 expression was repressed in CSF-1 stimulated, proliferating bone marrow-derived macrophages (BMM) and significantly increased in quiescent, CSF-1 starved cells. The RAW264.7 and Mono-Mac-6, macrophage-like cell lines expressed low levels of Runx1 and both showed growth arrest and cell death with ectopic expression of Runx1. The EM-3 cell line, which represents an early myeloid progenitor cell line, showed growth arrest with Runx1 expression in the absence of any detectable changes in cell differentiation. These findings suggest that Runx1 regulates growth and survival of myeloid cells and provide a novel insight into the role of Runx family gene translocations in leukemogenesis.	Univ Queensland, Inst Mol Biosci, CRC Chron Inflammatory Dis, Queensland Biosci Precint, Brisbane, Qld 4072, Australia	University of Queensland	Hume, DA (corresponding author), Univ Queensland, Inst Mol Biosci, CRC Chron Inflammatory Dis, Queensland Biosci Precint, Bldg 80,Serv Rd, Brisbane, Qld 4072, Australia.	d.hume@imb.uq.edu.au	Hume, David A/C-7695-2013	Hume, David/0000-0002-2615-1478				Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Cecchini MG, 1997, MOL REPROD DEV, V46, P75; Cochet O, 1998, MOL IMMUNOL, V35, P1097, DOI 10.1016/S0161-5890(98)00105-9; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; DOWNING JR, 1993, BLOOD, V81, P2860; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121; Hiebert SW, 2001, CANCER CHEMOTH PHARM, V48, pS31, DOI 10.1007/s002800100302; Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812; Hume DA, 1997, MOL REPROD DEV, V46, P46; Ichikawa M, 2004, NAT MED, V10, P299, DOI 10.1038/nm997; Levanon D, 2003, BLOOD CELL MOL DIS, V30, P161, DOI 10.1016/S1079-9796(03)00023-8; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Linggi B, 2002, NAT MED, V8, P743, DOI 10.1038/nm726; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; MARUYAMA F, 1993, CANCER RES, V53, P4449; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Petrovick HS, 1998, MOL CELL BIOL, V18, P3915, DOI 10.1128/MCB.18.7.3915; Sasaki K, 1996, P NATL ACAD SCI USA, V93, P12359, DOI 10.1073/pnas.93.22.12359; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; SATAKE M, 1992, JPN J CANCER RES, V83, P714, DOI 10.1111/j.1349-7006.1992.tb01971.x; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sudo T, 1995, ONCOGENE, V11, P2469; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002; THOMPSON PW, 1991, CANCER GENET CYTOGEN, V55, P269, DOI 10.1016/0165-4608(91)90089-D; Tracey WD, 2000, SEMIN CELL DEV BIOL, V11, P337, DOI 10.1006/scdb.2000.0186; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; Yang YD, 2002, CANCER RES, V62, P2232; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; Zhang DE, 1996, MOL CELL BIOL, V16, P1231	36	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2005	24	34					5278	5286		10.1038/sj.onc.1208657	http://dx.doi.org/10.1038/sj.onc.1208657			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	954MF	16007221	Bronze			2022-12-17	WOS:000231158500002
J	Kyng, KJ; May, A; Stevnsner, T; Becker, KG; Kolvra, S; Bohr, VA				Kyng, KJ; May, A; Stevnsner, T; Becker, KG; Kolvra, S; Bohr, VA			Gene expression responses to DNA damage are altered in human aging and in Werner Syndrome	ONCOGENE			English	Article						microarray; Werner syndrome; DNA damage; aging	REPLICATIVE SENESCENCE; CALORIC RESTRICTION; 4-NITROQUINOLINE 1-OXIDE; SACCHAROMYCES-CEREVISIAE; SYNDROME FIBROBLASTS; ADAPTIVE RESPONSE; OXIDATIVE STRESS; CELL-LINES; LIFE-SPAN; REPAIR	The accumulation of DNA damage and mutations is considered a major cause of cancer and aging. While it is known that DNA damage can affect changes in gene expression, transcriptional regulation after DNA damage is poorly understood. We characterized the expression of 6912 genes in human primary. broblasts after exposure to three different kinds of cellular stress that introduces DNA damage: 4- nitroquinoline-1-oxide (4NQO), gamma-irradiation, or UV-irradiation. Each type of stress elicited damage specific gene expression changes of up to 10-fold. A total of 85 genes had similar changes in expression of 3-40- fold after all three kinds of stress. We examined transcription in cells from young and old individuals and from patients with Werner syndrome (WS), a segmental progeroid condition with a high incidence of cancer, and found various age-associated transcriptional changes depending upon the type of cellular stress. Compared to young individuals, both WS and old individuals had similarly aberrant transcriptional responses to gamma- and UV-irradiation, suggesting a role for Werner protein in stress- induced gene expression. Our results suggest that aberrant DNA damage-induced gene regulation may contribute to the aging process and the premature aging in WS.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Aarhus Univ, Dept Mol Biol, Danish Ctr Mol Gerontol, DK-8000 Aarhus, Denmark; NIA, Gene Express & Genom Unit, Baltimore, MD 21224 USA; Univ Aarhus, Inst Human Genet, DK-8000 Aarhus, Denmark	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Aarhus University	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Kyng, Kasper/AAA-5339-2019	Kyng, Kasper/0000-0001-7940-1656; Stevnsner, Tinna/0000-0003-1007-0427; Becker, Kevin/0000-0002-6794-6656	NATIONAL INSTITUTE ON AGING [ZIAAG000726, Z01AG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4; Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365; Busuttil RA, 2003, AGING CELL, V2, P287, DOI 10.1046/j.1474-9728.2003.00066.x; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Choi DH, 2001, FASEB J, V15, P1014, DOI 10.1096/fj.00-0104com; COLLIER IE, 1982, MECH AGEING DEV, V19, P141, DOI 10.1016/0047-6374(82)90005-7; Davis T, 2003, J CELL SCI, V116, P1349, DOI 10.1242/jcs.00331; Fan JS, 2002, P NATL ACAD SCI USA, V99, P10611, DOI 10.1073/pnas.162212399; Friedberg E.C., 2016, DNA REPAIR MUTAGENES, V33, P35; Gasch Audrey P, 2002, Funct Integr Genomics, V2, P181, DOI 10.1007/s10142-002-0058-2; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; Hasty P, 2003, SCIENCE, V299, P1355, DOI 10.1126/science.1079161; Hilsenbeck SG, 1999, J NATL CANCER I, V91, P453, DOI 10.1093/jnci/91.5.453; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Jelinsky SA, 2000, MOL CELL BIOL, V20, P8157, DOI 10.1128/MCB.20.21.8157-8167.2000; JONES CJ, 1989, CARCINOGENESIS, V10, P1197, DOI 10.1093/carcin/10.7.1197; Kayo T, 2001, P NATL ACAD SCI USA, V98, P5093, DOI 10.1073/pnas.081061898; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Kyng KJ, 2003, P NATL ACAD SCI USA, V100, P12259, DOI 10.1073/pnas.2130723100; Kyng KJ, 2003, ONCOGENE, V22, P1135, DOI 10.1038/sj.onc.1206187; LAMBERT B, 1979, CANCER RES, V39, P2792; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee CK, 2000, NAT GENET, V25, P294, DOI 10.1038/77046; Lee J, 1995, MICROBIOL-SGM, V141, P3127, DOI 10.1099/13500872-141-12-3127; Ljungman M, 2004, NAT REV CANCER, V4, P727, DOI 10.1038/nrc1435; Lu T, 2004, NATURE, V429, P883, DOI 10.1038/nature02661; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Matsumoto T, 1997, NAT GENET, V16, P335, DOI 10.1038/ng0897-335; Miller RA, 2001, J GERONTOL A-BIOL, V56, pB52, DOI 10.1093/gerona/56.2.B52; Moggs JG, 2003, TOXICOL LETT, V140, P149, DOI 10.1016/S0378-4274(02)00501-5; Moradas-Ferreira P, 2000, REDOX REP, V5, P277, DOI 10.1179/135100000101535816; MURANO S, 1991, MOL CELL BIOL, V11, P3905, DOI 10.1128/MCB.11.8.3905; Nakura J, 2000, CELL MOL LIFE SCI, V57, P716, DOI 10.1007/s000180050036; Nantel A, 2002, MOL BIOL CELL, V13, P3452, DOI 10.1091/mbc.E02-05-0272; NIEDERMULLER H, 1985, MECH AGEING DEV, V29, P221, DOI 10.1016/0047-6374(85)90064-8; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Ostermeier GC, 2002, LANCET, V360, P772, DOI 10.1016/S0140-6736(02)09899-9; Park WY, 2001, BIOCHEM BIOPH RES CO, V282, P934, DOI 10.1006/bbrc.2001.4632; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Prince PR, 1999, HUM GENET, V105, P132, DOI 10.1007/s004390051075; Seluanov A, 2004, P NATL ACAD SCI USA, V101, P7624, DOI 10.1073/pnas.0400726101; Smith L, 2003, HUM MOL GENET, V12, pR1, DOI 10.1093/hmg/ddg053; SNYDERWINE EG, 1992, CANCER RES, V52, P4183; Volkert MR, 2001, CURR OPIN MICROBIOL, V4, P178, DOI 10.1016/S1369-5274(00)00186-7; von Kobbe C, 2004, FASEB J, V18, P1970, DOI 10.1096/fj.04-1895fje; Webb DK, 1996, EXP CELL RES, V224, P272, DOI 10.1006/excr.1996.0137; Weindruch R, 2001, J NUTR, V131, p918S, DOI 10.1093/jn/131.3.918S; WEIRICHSCHWAIGER H, 1994, MUTAT RES, V316, P37, DOI 10.1016/0921-8734(94)90006-X; Welle S, 2002, EXP GERONTOL, V37, P583, DOI 10.1016/S0531-5565(01)00231-5; Welle S, 2001, PHYSIOL GENOMICS, V5, P67, DOI 10.1152/physiolgenomics.2001.5.2.67; Xu GG, 2000, MUTAT RES-DNA REPAIR, V459, P195, DOI 10.1016/S0921-8777(99)00069-5; Yang LJ, 2004, J BIOL CHEM, V279, P11639, DOI 10.1074/jbc.M312895200; Zahn RK, 2000, MECH AGEING DEV, V119, P101, DOI 10.1016/S0047-6374(00)00170-6; Zou S, 2000, P NATL ACAD SCI USA, V97, P13726, DOI 10.1073/pnas.260496697	58	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 28	2005	24	32					5026	5042		10.1038/sj.onc.1208692	http://dx.doi.org/10.1038/sj.onc.1208692			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	949VT	15897889				2022-12-17	WOS:000230816900003
J	Baris, O; Mirebeau-Prunier, D; Savagner, F; Rodien, P; Ballester, B; Loriod, B; Granjeaud, S; Guyetant, S; Franc, B; Houlgatte, R; Reynier, P; Malthiery, Y				Baris, O; Mirebeau-Prunier, D; Savagner, F; Rodien, P; Ballester, B; Loriod, B; Granjeaud, S; Guyetant, S; Franc, B; Houlgatte, R; Reynier, P; Malthiery, Y			Gene profiling reveals specific oncogenic mechanisms and signaling pathways in oncocytic and papillary thyroid carcinoma	ONCOGENE			English	Article						carcinoma; thyroid; mitochondria	CYTOCHROME-C-OXIDASE; NITRIC-OXIDE; EXPRESSION; CANCER; CELL; PATHOGENESIS; TUMOR	The oncogenic pathways in mitochondrial-rich thyroid carcinomas are not clearly understood. To investigate the possible implication of mitochondrial abundance in the genesis of thyroid tumors, we have explored the gene expression profile of six oncocytic carcinomas and six mitochondrial-rich papillary carcinomas using cDNA-microarray technology. A supervised approach allowed us to identify 83 genes differentially expressed in the two types of carcinoma. These genes were classified according to their ontologic profiles. Three genes, NOS3, alphaactinin-2 and alpha-catenin, suspected of playing a role in tumor genesis, were explored by quantitative RT - PCR analysis and immunohistochemistry. Of the 59 genes overexpressed in papillary carcinomas, 51% were involved in cell communication. Of the 24 genes overexpressed in oncocytic carcinomas, 84% were involved in mitochondrial and cellular metabolism. Our results suggest that mitochondrial respiratory chain complexes III and IV play a significant role in the regulation of reactive oxygen species production by oncocytic tumors.	CHU Angers, Lab Biochim & Biol Mol, INSERM EMI U 0018, F-49033 Angers, France; CHU Angers, Serv Endocrinol Nutr & Med Interne, F-49033 Angers, France; INSERM ERM 206, Lab TAGC, F-13009 Marseille, France; CHRU, Anat Pathol Lab, F-37044 Tours, France; Hop Ambroise Pare, Anat Pathol Lab, F-92104 Boulogne, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	Baris, O (corresponding author), CHU Angers, Lab Biochim & Biol Mol, INSERM EMI U 0018, 4 Rue Larrey, F-49033 Angers, France.	olivier.baris@med.univ-angers.fr	Reynier, Pascal/K-3677-2015; Rodien, Patrice/AAT-7909-2021; Ballester, Benoit/N-6127-2016; Granjeaud, Samuel/AAE-6488-2022; Baris, Olivier R/L-3463-2016; Prunier, Delphine/K-3301-2015; loriod, beatrice bl/L-2948-2016; Houlgatte, Remi/P-3020-2017	Ballester, Benoit/0000-0002-0834-7135; Granjeaud, Samuel/0000-0001-9245-1535; Baris, Olivier R/0000-0003-0974-6856; loriod, beatrice bl/0000-0001-5801-2264; Reynier, Pascal/0000-0003-0802-4608				Al-Shahrour F, 2004, BIOINFORMATICS, V20, P578, DOI 10.1093/bioinformatics/btg455; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Augenlicht LH, 1999, ANN NY ACAD SCI, V889, P20, DOI 10.1111/j.1749-6632.1999.tb08720.x; Baris O, 2004, J CLIN ENDOCR METAB, V89, P994, DOI 10.1210/jc.2003-031238; CAMIEL MR, 1968, NEW ENGL J MED, V279, P326; Cheung CC, 2000, AM J SURG PATHOL, V24, P1622, DOI 10.1097/00000478-200012000-00005; Chua EL, 2000, GENOMICS, V69, P342, DOI 10.1006/geno.2000.6348; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; EBNER D, 1991, VIRCHOWS ARCH B, V60, P139, DOI 10.1007/BF02899539; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FUSCO A, 1987, NATURE, V328, P170, DOI 10.1038/328170a0; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Haugen DRF, 2003, THYROID, V13, P613; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Ishigaki K, 2002, J CLIN ENDOCR METAB, V87, P3433, DOI 10.1210/jc.87.7.3433; Kim JY, 2002, ACTA CYTOL, V46, P679, DOI 10.1159/000326975; Kimura ET, 2003, CANCER RES, V63, P1454; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Maeta H, 2001, VIRCHOWS ARCH, V438, P121, DOI 10.1007/s004280000286; Magrangeas F, 2003, BLOOD, V101, P4998, DOI 10.1182/blood-2002-11-3385; Moretti F, 2000, BEST PRACT RES CL EN, V14, P517, DOI 10.1053/beem.2000.0101; Nisoli E, 2003, SCIENCE, V299, P896, DOI 10.1126/science.1079368; Papa S, 1997, BIOSCIENCE REP, V17, P23, DOI 10.1023/A:1027331116866; Savagner F, 2001, J CLIN ENDOCR METAB, V86, P4920, DOI 10.1210/jc.86.10.4920; Savagner F, 2001, THYROID, V11, P327, DOI 10.1089/10507250152039055; Savagner F, 2003, BIOCHEM BIOPH RES CO, V310, P779, DOI 10.1016/j.bbrc.2003.09.076; Thieblemont C, 2004, BLOOD, V103, P2727, DOI 10.1182/blood-2003-06-2160	29	36	39	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 9	2005	24	25					4155	4161		10.1038/sj.onc.1208578	http://dx.doi.org/10.1038/sj.onc.1208578			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15806164				2022-12-17	WOS:000229680300014
J	Zhu, Z; Mukhina, S; Zhu, T; Mertani, HC; Lee, KO; Lobie, PE				Zhu, Z; Mukhina, S; Zhu, T; Mertani, HC; Lee, KO; Lobie, PE			p44/42 MAP kinase-dependent regulation of catalase by autocrine human growth hormone protects human mammary carcinoma cells from oxidative stress-induced apoptosis	ONCOGENE			English	Article						growth hormone; autocrine; mammary carcinoma; oxidative stress; catalase	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; MN-SUPEROXIDE DISMUTASE; GENE-EXPRESSION; ANTIOXIDANT ENZYMES; GLUTATHIONE-PEROXIDASE; HYDROGEN-PEROXIDE; EPITHELIAL-CELLS; ACTIVATION; CANCER; OVEREXPRESSION	Previous microarray expression analyses have indicated autocrine human growth hormone (hGH) regulation of genes involved in the oxidative stress response. Expression analysis of antioxidant enzymes revealed that autocrine hGH increased both the mRNA and protein levels of catalase, superoxide dismutase 1 (SOD1), glutathione peroxidase and glutamylcysteine synthetase but not that of SOD2. As a consequence, autocrine hGH increased the antioxidant capacity of mammary carcinoma cells and protected against oxidative stress-induced apoptosis. Catalase activity was increased by autocrine production of hGH in mammary carcinoma cells and a catalase inhibitor abrogated protection from oxidative stress afforded by autocrine hGH. Autocrine hGH transcriptionally regulated catalase gene expression in a p44/42 MAP kinase-dependent manner and inhibition of MEK concordantly abrogated the protective effect of autocrine hGH against oxidative stress-induced apoptosis. Given that increased cellular oxidative stress is a key effector mechanism of specific chemotherapeutic agents, we propose that antagonism of autocrine hGH will improve the efficacy of chemotherapeutic regimes utilized for human mammary carcinoma.	Univ Auckland, Liggins Inst, Auckland 1, New Zealand; Natl Univ Singapore, Dept Med, Singapore 117609, Singapore; Natl Univ Singapore, Inst Mol & Cell Biol, Singapore 117609, Singapore; Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA; Univ Lyon 1, CNRS, UMR 5578, F-69365 Lyon, France; Univ Auckland, Natl Res Ctr Growth & Dev, Auckland 1, New Zealand	University of Auckland; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Johns Hopkins University; Johns Hopkins Medicine; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, 2-6 Pk Ave, Auckland 1, New Zealand.	p.lobie@auckland.ac.nz	MERTANI, Hichem-Claude/AAR-6415-2020; Lee, Kok-Onn/E-9874-2011	Lee, Kok-Onn/0000-0002-3040-1185				AKMAN SA, 1990, CANCER RES, V50, P1397; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Brown-Borg HM, 2000, EXP GERONTOL, V35, P199, DOI 10.1016/S0531-5565(00)00079-6; Brown-Borg HM, 2003, MECH AGEING DEV, V124, P1013, DOI 10.1016/j.mad.2003.07.001; Brown-Borg HM, 1999, ENDOCRINE, V11, P41, DOI 10.1385/ENDO:11:1:41; BRYANT RW, 1982, J BIOL CHEM, V257, P4937; CAMPBELL GS, 1992, J BIOL CHEM, V267, P6074; CAPDEVILA JH, 1995, BIOCHEMISTRY-US, V34, P3325, DOI 10.1021/bi00010a023; Chelikani P, 2004, CELL MOL LIFE SCI, V61, P192, DOI 10.1007/s00018-003-3206-5; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; Clarkson RWE, 1999, MOL ENDOCRINOL, V13, P619, DOI 10.1210/me.13.4.619; DIILIO C, 1985, CANCER LETT, V29, P37, DOI 10.1016/0304-3835(85)90120-X; DOROSHOW JH, 1986, J BIOL CHEM, V261, P3068; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; El Mouatassim S, 2000, EUR J OBSTET GYN R B, V89, P1, DOI 10.1016/S0301-2115(99)00169-4; FRIDOVICH I, 1978, PHOTOCHEM PHOTOBIOL, V28, P733, DOI 10.1111/j.1751-1097.1978.tb07009.x; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; Graichen R, 2002, J BIOL CHEM, V277, P26662, DOI 10.1074/jbc.M109931200; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hauck SJ, 2002, HORM METAB RES, V34, P481, DOI 10.1055/s-2002-34787; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; ISAKSSON OGP, 1985, ANNU REV PHYSIOL, V47, P483, DOI 10.1146/annurev.ph.47.030185.002411; Iscan M, 2002, BREAST CANCER RES TR, V72, P173, DOI 10.1023/A:1014828705281; Kaulsay KK, 1999, EXP CELL RES, V250, P35, DOI 10.1006/excr.1999.4492; Kaulsay KK, 2001, ENDOCRINOLOGY, V142, P767, DOI 10.1210/en.142.2.767; Kaulsay KK, 2000, ENDOCRINOLOGY, V141, P1571, DOI 10.1210/en.141.4.1571; Kennedy MA, 2003, EXP GERONTOL, V38, P997, DOI 10.1016/S0531-5565(03)00164-5; Kumaraguruparan R, 2002, CLIN CHIM ACTA, V325, P165, DOI 10.1016/S0009-8981(02)00292-9; Le Roith D, 2001, ENDOCR REV, V22, P53, DOI 10.1210/er.22.1.53; Li JJ, 1998, CARCINOGENESIS, V19, P833, DOI 10.1093/carcin/19.5.833; Mates JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009-9120(99)00075-2; Mertani HC, 1998, INT J CANCER, V79, P202; Mertani HC, 2001, J BIOL CHEM, V276, P21464, DOI 10.1074/jbc.M100437200; Mize AL, 2003, ENDOCRINOLOGY, V144, P306, DOI 10.1210/en.2002-220698; Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; Nenoi M, 2001, CANCER RES, V61, P5885; Raccurt M, 2002, J ENDOCRINOL, V175, P307, DOI 10.1677/joe.0.1750307; Ripple MO, 1997, JNCI-J NATL CANCER I, V89, P40, DOI 10.1093/jnci/89.1.40; SANDSTROM PA, 1993, P NATL ACAD SCI USA, V90, P4708, DOI 10.1073/pnas.90.10.4708; Santanam N, 1999, ARTERIOSCL THROM VAS, V19, P1912, DOI 10.1161/01.ATV.19.8.1912; SHINGU M, 1985, INFLAMMATION, V9, P309, DOI 10.1007/BF00916279; Siitonen T, 1999, ANN ONCOL, V10, P1361, DOI 10.1023/A:1008382912096; STCLAIR DK, 1991, FEBS LETT, V293, P199, DOI 10.1016/0014-5793(91)81186-C; Takahashi Miho, 2002, Frontiers of Medical and Biological Engineering, V11, P279; TEICHER BA, 1990, CANCER RES, V50, P3339; TERAO K, 1986, Journal of Free Radicals in Biology and Medicine, V2, P193; Thomas Patricia A, 1997, Pathol Oncol Res, V3, P278; Tipnis SR, 1999, BIOCHEM J, V337, P559, DOI 10.1042/0264-6021:3370559; Tome ME, 2003, BBA-MOL CELL RES, V1642, P149, DOI 10.1016/j.bbamcr.2003.08.002; VanRemmen H, 1998, J CELL PHYSIOL, V174, P18, DOI 10.1002/(SICI)1097-4652(199801)174:1<18::AID-JCP3>3.0.CO;2-J; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wen J, 2002, J BIOL CHEM, V277, P38954, DOI 10.1074/jbc.M203842200; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WOOD TJJ, 1995, J BIOL CHEM, V270, P9448, DOI 10.1074/jbc.270.16.9448; XU XQ, 2005, IN PRESS J BIOL CHEM; Yang CR, 1997, CANCER LETT, V119, P157, DOI 10.1016/S0304-3835(97)00274-7; YAO KS, 1995, CANCER RES, V55, P4367; YOKOMIZO A, 1995, CANCER RES, V55, P4293; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; ZACHARA AM, 1993, ELENIUM GLUTATHIONE; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103; Zhu T, 2005, CANCER RES, V65, P317; Zhu T, 2002, J BIOL CHEM, V277, P45592, DOI 10.1074/jbc.M201385200; Zhu T, 2001, CELL SIGNAL, V13, P599, DOI 10.1016/S0898-6568(01)00186-3; ZYAD A, 1994, CANCER RES, V54, P825	68	36	36	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 26	2005	24	23					3774	3785		10.1038/sj.onc.1208541	http://dx.doi.org/10.1038/sj.onc.1208541			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	929KZ	15782123				2022-12-17	WOS:000229346300008
J	Ameyar-Zazoua, M; Wisniewska, MB; Bakiri, L; Wagner, EF; Yaniv, M; Weitzman, JB				Ameyar-Zazoua, M; Wisniewska, MB; Bakiri, L; Wagner, EF; Yaniv, M; Weitzman, JB			AP-1 dimers regulate transcription of the p14/p19(ARF) tumor suppressor gene	ONCOGENE			English	Article						AP1; p14(ARF); p19(ARF); RAS	C-JUN; CELL-PROLIFERATION; INK4A LOCUS; ARF; RAS; TRANSFORMATION; P53; ACTIVATION; P14(ARF); P19(ARF)	Evidence is accumulating about the role of individual AP-1 components in cell proliferation and transformation. Notably, Ras-mediated transformation is characterized by the upregulation of particular AP-1 members, such as c-Jun and Fra-1. The p14/p19(ARF) tumor suppressor gene is a key link between oncogenic Ras signaling and the p53 pathway. We explored the involvement of AP4 dimers in the transcriptional regulation of the P14/p19(ARF) gene. We demonstrate that both the human and mouse ARF promoters are transcriptional targets of selective AP-1 dimers. The ARF promoter is regulated specifically by AP-1 heterodimers containing Fra-1. Overexpression of e-Jun similar to Fra-1 dimers in primary murine fibroblast cells led to the upregulation of the endogenous ARF protein and growth arrest. Conversely, inhibition of c-Jun or Fra-1 protein levels resulted in decreased ARF expression. In addition, we show that AP-1 dimers cooperate with oncogenic Ras in the transcriptional activation of the p14/p19(ARF) promoter. Thus, AP-1 heterodimers may contribute to the regulation of ARF expression upon oncogenic signaling.	Inst Pasteur, Dept Dev Biol, Unit Gene Express & Dis, F-75724 Paris, France; Res Inst Mol Pathol, A-1030 Vienna, Austria	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Weitzman, JB (corresponding author), Inst Pasteur, Dept Dev Biol, Unit Gene Express & Dis, 25 Rue Dr Roux, F-75724 Paris, France.	jonathan.weitzman@pasteur.fr	Bakiri, Latifa/N-5780-2014; Bakiri, Latifa/AAP-1674-2020; Wisniewska, Marta B./A-6691-2009	Wisniewska, Marta B./0000-0002-1593-0361; Wagner, Erwin F/0000-0001-7872-0196; Weitzman, Jonathan/0000-0001-8445-0102; bakiri, latifa/0000-0002-6300-2420				Ameyar M, 2003, BIOCHIMIE, V85, P747, DOI 10.1016/j.biochi.2003.09.006; Ameyar M, 1998, J BIOL CHEM, V273, P29002, DOI 10.1074/jbc.273.44.29002; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Behrens A, 2000, ONCOGENE, V19, P2657, DOI 10.1038/sj.onc.1203603; Berkovich E, 2003, CELL CYCLE, V2, P127, DOI 10.4161/cc.2.2.293; BOS JL, 1989, CANCER RES, V49, P4682; Brookes S, 2002, EMBO J, V21, P2936, DOI 10.1093/emboj/cdf289; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drayton S, 2003, CANCER CELL, V4, P301, DOI 10.1016/S1535-6108(03)00242-3; Eferl R, 2003, CELL, V112, P181, DOI 10.1016/S0092-8674(03)00042-4; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Johnson R, 1996, MOL CELL BIOL, V16, P4504; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kuo ML, 2003, CANCER RES, V63, P1046; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Maestro R, 1999, GENE DEV, V13, P2207, DOI 10.1101/gad.13.17.2207; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Modestou M, 2001, CANCER RES, V61, P3145; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Parisi T, 2002, BIOCHEM BIOPH RES CO, V291, P1138, DOI 10.1006/bbrc.2002.6591; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Rowland BD, 2002, CANCER CELL, V2, P55, DOI 10.1016/S1535-6108(02)00085-5; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; THIERRY F, 1987, J VIROL, V61, P134, DOI 10.1128/JVI.61.1.134-142.1987; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; Weitzman JB, 2000, MOL CELL, V6, P1109, DOI 10.1016/S1097-2765(00)00109-X; Young MR, 2002, MOL CELL BIOL, V22, P587, DOI 10.1128/MCB.22.2.587-598.2002	61	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2298	2306		10.1038/sj.onc.1208424	http://dx.doi.org/10.1038/sj.onc.1208424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15688012				2022-12-17	WOS:000227877400003
J	Soulie, P; Carrozzino, F; Pepper, MS; Strongin, AY; Poupon, MF; Montesano, R				Soulie, P; Carrozzino, F; Pepper, MS; Strongin, AY; Poupon, MF; Montesano, R			Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells	ONCOGENE			English	Article						carcinogenesis; invasion; proteolysis; MDCK; MMP	ENDOTHELIAL GROWTH-FACTOR; EXTRACELLULAR-MATRIX; CANINE KIDNEY; TUMOR-CELLS; MT1-MMP EXPRESSION; CARCINOMA-CELLS; TRANSGENIC MICE; UP-REGULATION; MIGRATION; ACTIVATION	Overexpression of membrane-type-1 matrix metalloproteinase (MT1-MMP) in tumor cells has previously been shown to enhance tumor growth and metastasis. To establish if MT1-MMP is also able to confer tumorigenicity on nonmalignant epithelial cells, we transfected human MT1-MMP cDNA into Madin-Darby canine kidney (MDCK) cells expressing a tetracycline-repressible transactivator. Induction of MT1-MMP in the absence of doxycycline (Dox) was associated with activation of exogenous MMP-2 as well as with formation of large cysts and increased invasiveness in collagen matrices. Transfected cells were inoculated subcutaneously into two groups of nude mice, one of which received Dox to inhibit expression of MT1-MMP. Formation of tumor xenografts was observed in 11 of 17 mice maintained without Dox, but only in two of nine mice that received Dox ( P<0.05). The xenografts were composed of tubular structures interspersed within a highly cellular stroma. The epithelial cells delimiting the lumen were polarized, as indicated by the basolateral distribution of Na, K-ATPase. Despite their differentiated appearance, the tumors lacked a well-defined boundary, and epithelial tubules invaded adjacent muscular layers. These results demonstrate that conditional expression of MT1-MMP in nonmalignant MDCK epithelial cells is by itself sufficient to drive formation of invasive tumors.	Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, CH-1211 Geneva 4, Switzerland; Burnham Inst, Canc Res Ctr, La Jolla, CA 92037 USA; Inst Curie, Sect Rech, F-75248 Paris, France	University of Geneva; Sanford Burnham Prebys Medical Discovery Institute; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Montesano, R (corresponding author), Univ Geneva, Med Ctr, Dept Cell Physiol & Metab, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland.	Roberto.Montesano@medecine.unige.ch	Pepper, Michael S./M-6143-2014; Strongin, Alex/R-6609-2019; Montesano, Roberto/AAV-3192-2020	Pepper, Michael S./0000-0001-6406-2380; Strongin, Alex/0000-0003-3765-3016; 	NCI NIH HHS [CA77470, CA83017] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; BOERNER P, 1985, J CELL PHYSL, V122, P299; Deryugina EI, 1997, J CELL SCI, V110, P2473; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Deryugina EI, 2000, INT J CANCER, V86, P15, DOI 10.1002/(SICI)1097-0215(20000401)86:1<15::AID-IJC3>3.0.CO;2-B; Dunbar LA, 2001, J BIOL CHEM, V276, P29617, DOI 10.1074/jbc.R100023200; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Feraille E, 2001, PHYSIOL REV, V81, P345, DOI 10.1152/physrev.2001.81.1.345; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gingras D, 2001, FEBS LETT, V507, P231, DOI 10.1016/S0014-5793(01)02985-4; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Ha HY, 2001, CANCER RES, V61, P984; Habelhah H, 1999, ONCOGENE, V18, P1771, DOI 10.1038/sj.onc.1202465; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Kadono Y, 1998, CANCER RES, V58, P2240; Kadono Y, 1998, BIOCHEM BIOPH RES CO, V251, P681, DOI 10.1006/bbrc.1998.9531; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; Maffini MV, 2004, J CELL SCI, V117, P1495, DOI 10.1242/jcs.01000; Mareel M, 2003, PHYSIOL REV, V83, P337, DOI 10.1152/physrev.00024.2002; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; MONTESANO R, 1993, J CELL SCI, V105, P1013; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; RABITO CA, 1978, J MEMBRANE BIOL, V43, P351, DOI 10.1007/BF01871696; Reno F, 2004, BIOMATERIALS, V25, P3439, DOI 10.1016/j.biomaterials.2003.10.047; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schenk S, 2003, TRENDS CELL BIOL, V13, P366, DOI 10.1016/S0962-8924(03)00129-6; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Stamenkovic I, 2003, J PATHOL, V200, P448, DOI 10.1002/path.1400; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; STILES CD, 1976, CANCER RES, V36, P1353; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Takino T, 2004, CANCER RES, V64, P1044, DOI 10.1158/0008-5472.CAN-03-1843; Thomasset N, 1998, AM J PATHOL, V153, P457, DOI 10.1016/S0002-9440(10)65589-7; Tsunezuka Y, 1996, CANCER RES, V56, P5678; Udayakumar TS, 2003, CANCER RES, V63, P2292; Vihinen P, 2002, INT J CANCER, V99, P157, DOI 10.1002/ijc.10329; Yana I, 2002, CLIN EXP METASTAS, V19, P209, DOI 10.1023/A:1015527220537; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	51	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2005	24	10					1689	1697		10.1038/sj.onc.1208360	http://dx.doi.org/10.1038/sj.onc.1208360			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	902HI	15608664				2022-12-17	WOS:000227345100005
J	Kim, EH; Kim, SU; Choi, KS				Kim, EH; Kim, SU; Choi, KS			Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP	ONCOGENE			English	Article						TRAIL; rottlerin; apoptosis; glioma	PROTEIN-KINASE-C; LIGAND-INDUCED APOPTOSIS; X-LINKED INHIBITOR; PROSTATE-CANCER CELLS; MEDIATED APOPTOSIS; GLIAL-CELLS; EXPRESSION; DELTA; FAMILY; DEATH	In the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-resistant glioma cells, treatment with TRAIL in combination with subtoxic doses of rottlerin induced rapid apoptosis. While the proteolytic processing of procaspase-3 by TRAIL was partially blocked in these cells, treatment with rottlerin efficiently recovered TRAIL-induced activation of caspases. Treatment with rottlerin significantly decreased Cdc2 activity through the downregulation of cyclin A, cyclin B, and Cdc2 proteins, whereas the sensitizing effect of rottlerin on TRAIL-induced apoptosis was independent of PKCdelta activity. Furthermore, treatment with rottlerin downregulated the protein levels of survivin and X-chromosome-linked IAP (XIAP), two major caspase inhibitors. Forced expression of Cdc2 together with cyclin B attenuated rottlerin-potentiated TRAIL-induced apoptosis by over-riding the rottlerin-mediated downregulation of survivin and XIAP protein levels. Taken together, inhibition of Cdc2 activity and the subsequent downregulation of survivin and XIAP by subtoxic doses of rottlerin contribute to amplification of caspase cascades, thereby overcoming resistance of glioma cells to TRAIL-mediated apoptosis. Since rottlerin can sensitize Bcl-2- or Bcl-xL-overexpressing glioma cells but not human astrocytes to TRAIL-induced apoptosis, this combined treatment may offer an attractive strategy for safely treating resistant gliomas.	Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea; Ajou Univ, Sch Med, Brain Dis Res Ctr, Suwon 442749, South Korea	Ajou University; Ajou University	Choi, KS (corresponding author), Ajou Univ, Sch Med, Inst Med Sci, Suwon 442749, South Korea.	kschoi@ajou.ac.kr	Kim, Eunhee/AAK-3650-2020; Kim, Eunhee/Q-9162-2016	Kim, Eunhee/0000-0001-7143-7769; Choi, Kyeong Sook/0000-0003-2331-0856				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Chakravarti A, 2002, J CLIN ONCOL, V20, P1063, DOI 10.1200/JCO.20.4.1063; Chawla-Sarkar M, 2004, CELL DEATH DIFFER, V11, P915, DOI 10.1038/sj.cdd.4401416; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; DeAngelis LM, 2001, NEW ENGL J MED, V344, P114, DOI 10.1056/NEJM200101113440207; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Griffith TS, 2002, CANCER RES, V62, P3093; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Hao CH, 2001, CANCER RES, V61, P1162; Harper N, 2003, J BIOL CHEM, V278, P44338, DOI 10.1074/jbc.M307376200; Huang DCS, 1997, ONCOGENE, V14, P405, DOI 10.1038/sj.onc.1200848; Joy AM, 2003, J CELL SCI, V116, P4409, DOI 10.1242/jcs.00712; Kim EH, 2004, ONCOGENE, V23, P446, DOI 10.1038/sj.onc.1207025; KIM SU, 1986, J NEUROSCI RES, V15, P303, DOI 10.1002/jnr.490150303; KIM SU, 1985, J NEUROIMMUNOL, V8, P255, DOI 10.1016/S0165-5728(85)80066-7; Knight MJ, 2001, ONCOGENE, V20, P5789, DOI 10.1038/sj.onc.1204810; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Lavia P, 1999, BIOESSAYS, V21, P221; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Mandil R, 2001, CANCER RES, V61, P4612; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Meng XW, 2002, J BIOL CHEM, V277, P3776, DOI 10.1074/jbc.M107218200; Ng CP, 2002, PROSTATE, V53, P286, DOI 10.1002/pros.10155; Nomura T, 2003, UROL RES, V31, P37, DOI 10.1007/s00240-003-0300-y; O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3; Ohtsuka T, 2002, J BIOL CHEM, V277, P29294, DOI 10.1074/jbc.M203342200; Rieger J, 1998, FEBS LETT, V427, P124, DOI 10.1016/S0014-5793(98)00409-8; Rohn TA, 2001, ONCOGENE, V20, P4128, DOI 10.1038/sj.onc.1204534; Rokudai S, 2000, J CELL PHYSIOL, V182, P290, DOI 10.1002/(SICI)1097-4652(200002)182:2<290::AID-JCP18>3.0.CO;2-8; Roth W, 1999, BIOCHEM BIOPH RES CO, V265, P479, DOI 10.1006/bbrc.1999.1693; Rozman-Pungercar J, 2003, CELL DEATH DIFFER, V10, P881, DOI 10.1038/sj.cdd.4401247; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shingu T, 2003, J NEUROSURG, V98, P154, DOI 10.3171/jns.2003.98.1.0154; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Susarla BTS, 2003, J NEUROCHEM, V86, P635, DOI 10.1046/j.1471-4159.2003.01886.x; TEWARI M, 1995, J BIOL CHEM, V270, P18738, DOI 10.1074/jbc.270.32.18738; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Tillman DM, 2003, CANCER RES, V63, P5118; Toth R, 1999, EUR J IMMUNOL, V29, P383, DOI 10.1002/(SICI)1521-4141(199902)29:02<383::AID-IMMU383>3.0.CO;2-A; Trauzold A, 2003, ONCOGENE, V22, P8939, DOI 10.1038/sj.onc.1207001; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Welters HJ, 2004, J MOL ENDOCRINOL, V32, P227, DOI 10.1677/jme.0.0320227; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zaffaroni N, 2002, DRUG RESIST UPDATE, V5, P65, DOI 10.1016/S1368-7646(02)00049-3; Zhang XD, 2001, CANCER RES, V61, P7339; Zhao HY, 2002, AM J PHYSIOL-RENAL, V282, pF710, DOI 10.1152/ajprenal.00303.2001; Zhao J, 2000, J CELL SCI, V113, P4363; Zhou Q, 1997, J BIOL CHEM, V272, P7797, DOI 10.1074/jbc.272.12.7797; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	64	36	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					838	849		10.1038/sj.onc.1208241	http://dx.doi.org/10.1038/sj.onc.1208241			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15531913				2022-12-17	WOS:000226577100010
J	Kim, KM; Lee, YJ				Kim, KM; Lee, YJ			Amiloride augments TRAIL-induced apoptotic death by inhibiting phosphorylation of kinases and phosphatases associated with the PI3K-Akt pathway	ONCOGENE			English	Article						amiloride; TRAIL; apoptosis; caspase; Akt; PDK-1; PTEN; PP1	NF-KAPPA-B; TUMOR-SUPPRESSOR; PHOSPHOINOSITIDE 3-KINASE; IONIZING-RADIATION; INTRACELLULAR PH; TYROSINE-KINASE; CANCER-CELLS; AKT; RECEPTOR; ACTIVATION	We have previously shown that low extracellular pH (pHe) promotes cell killing by the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). In this study, we examined whether amiloride, an inhibitor of the Na+/H+ antiporter capable of lowering the intracellular pH (pHi), can potentiate TRAIL-induced apoptotic death. Human prostate adenocarcinoma DU-145 cells were treated with various concentrations of TRAIL (10-200 ng/ml) and/or amiloride (0.1-1 mM) for 4 h. Amiloride, which caused little or no cytotoxicity by itself, enhanced TRAIL-induced apoptosis. The TRAIL-mediated activation of caspase, and PARP (poly (ADP-ribose) polymerase) cleavage were both promoted by amiloride. Western blot analysis showed that combined treatment with TRAIL and amiloride did not change the levels of TRAIL receptors (death receptor (DR)4, DR5, and DcR2 (decoy recepter 2) or antiapoptotic proteins (FLICE-inhibitory protein ( FLIP), inhibitor of apoptosis (IAP), and Bcl-2). However, unlike pHe, amiloride promoted the dephosphorylation of Akt. Interestingly, amiloride also induced the dephosphorylation of PI3K (phosphatidylinositol 3-kinase) and PDK-1 (phosphoinositide-dependent kinase-1) kinases along with PTEN (phosphatase and tensin homolog deleted on chromosome 10) and PP1alpha phosphatases. In vitro kinase assays revealed that amiloride inhibited phosphorylation of kinases and phosphatases by competing with ATP. Taken together, the present studies suggest that amiloride enhances TRAIL-induced cytotoxicity by inhibiting phosphorylation of the PI3K-Akt pathway-associated kinases and phosphatases.	Univ Pittsburgh, Sch Med, Dept Surg & Pharmacol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lee, YJ (corresponding author), Univ Pittsburgh, Dept Surg, Hillman Canc Ctr, 5117 Ctr Ave,G-5A, Pittsburgh, PA 15213 USA.	leeyj@msx.upmc.edu			NCI NIH HHS [CA48000, CA96989, CA95191] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095191, R01CA048000, R01CA096989] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burow ME, 1998, CANCER RES, V58, P4940; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen XF, 2001, ONCOGENE, V20, P6073, DOI 10.1038/sj.onc.1204736; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Das S, 2003, P NATL ACAD SCI USA, V100, P7491, DOI 10.1073/pnas.0932835100; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAVIS RJ, 1985, J BIOL CHEM, V260, P2543; Degli-Esposti MA, 1997, IMMUNITY, V7, P813, DOI 10.1016/S1074-7613(00)80399-4; DegliEsposti MA, 1997, J EXP MED, V186, P1165, DOI 10.1084/jem.186.7.1165; DEL PL, 1997, SCIENCE, V278, P687; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; ENDRICH B, 1982, J NATL CANCER I, V68, P475; FRELIN C, 1988, EUR J BIOCHEM, V174, P3, DOI 10.1111/j.1432-1033.1988.tb14055.x; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Griffith TS, 1998, J IMMUNOL, V161, P2833; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Hetman M, 2000, J NEUROSCI, V20, P2567; Hitoshi Y, 1998, IMMUNITY, V8, P461, DOI 10.1016/S1074-7613(00)80551-8; HOLLAND R, 1983, FEBS LETT, V154, P269, DOI 10.1016/0014-5793(83)80163-X; Kandasamy K, 2002, CANCER RES, V62, P4929; Kashii Y, 2000, BLOOD, V96, P941, DOI 10.1182/blood.V96.3.941.015k14_941_949; Keane MM, 1999, CANCER RES, V59, P734; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kothny-Wilkes G, 1999, J BIOL CHEM, V274, P28916, DOI 10.1074/jbc.274.41.28916; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee YJ, 2004, EXP CELL RES, V293, P129, DOI 10.1016/j.yexcr.2003.09.015; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Marsters SA, 1997, CURR BIOL, V7, P1003, DOI 10.1016/S0960-9822(06)00422-2; Martelli AM, 2003, LEUKEMIA, V17, P1794, DOI 10.1038/sj.leu.2403044; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Nagane M, 2000, CANCER RES, V60, P847; Nam SY, 2002, ONCOGENE, V21, P337, DOI 10.1038/sj.onc.1205068; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ozes ON, 1999, NATURE, V401, P82; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RALPH RK, 1982, BIOCHEM BIOPH RES CO, V104, P1054, DOI 10.1016/0006-291X(82)91356-0; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Resjo S, 2002, CELL SIGNAL, V14, P231, DOI 10.1016/S0898-6568(01)00238-8; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Sheikh MS, 1998, CANCER RES, V58, P1593; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; SMITH RL, 1982, J BIOL CHEM, V257, P773; SOLTOFF SP, 1983, SCIENCE, V220, P957, DOI 10.1126/science.6302840; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Tamm I, 1998, CANCER RES, V58, P5315; Thakkar H, 2001, J BIOL CHEM, V276, P38361, DOI 10.1074/jbc.M103321200; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Walczak H, 1997, EMBO J, V16, P5386, DOI 10.1093/emboj/16.17.5386; Wen JH, 2000, BLOOD, V96, P3900, DOI 10.1182/blood.V96.12.3900.h8003900_3900_3906; WIKEHOOLEY JL, 1984, RADIOTHER ONCOL, V2, P343, DOI 10.1016/S0167-8140(84)80077-8; Wu KL, 2004, J BIOL CHEM, V279, P26280, DOI 10.1074/jbc.M400814200; Xu WP, 2003, CANCER RES, V63, P7777	67	36	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					355	366		10.1038/sj.onc.1208213	http://dx.doi.org/10.1038/sj.onc.1208213			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15558024				2022-12-17	WOS:000226279700007
J	Bartkova, J; Guldberg, P; Gronbaek, K; Koed, K; Primdahl, H; Moller, K; Lukas, J; Orntoft, TF; Bartek, J				Bartkova, J; Guldberg, P; Gronbaek, K; Koed, K; Primdahl, H; Moller, K; Lukas, J; Orntoft, TF; Bartek, J			Aberrations of the Chk2 tumour suppressor in advanced urinary bladder cancer	ONCOGENE			English	Article						Chk2 kinase; truncating mutation; DNA damage; tumour suppressor; p53; urinary bladder carcinomas	DNA-DAMAGE CHECKPOINT; LI-FRAUMENI-SYNDROME; BREAST-CANCER; IN-VIVO; PROSTATE-CANCER; CHEK2 VARIANTS; KINASE CHK2; LUNG-CANCER; P53; MUTATIONS	Checkpoint kinase 2 (Chk2) is a tumour suppressor and signal transducer in genome integrity checkpoints that coordinate cell-cycle progression with DNA repair or cell death in response to DNA damage. Defects of Chk2 occur in subsets of diverse sporadic malignancies and predispose to several types of hereditary carcinomas. However, the status of Chk2 in tumours of the urinary bladder remains unknown. Here, we report that among 58 advanced ( grade T2 - T4) human bladder carcinomas, immunohistochemical analysis revealed tumour-specific reduction or lack of Chk2 protein in 6 ( 10.3%) cases. Genetic analysis of the latter subset showed that a Chk2-negative carcinoma # 668 harboured a truncating mutation 1100delC, in one Chk2 allele and loss of the corresponding second allele. The 1100delC mutation was also found in the germ line of this patient. Sequencing of TP53 in tumour # 668 identified two missense mutations. Furthermore, the vast majority of the tumours showed 'unscheduled' activatory phosphorylation on Thr68 of Chk2 in the absence of any DNA-damaging treatment. Our results indicate that the otherwise dormant DNA damage signal transducer Chk2 is aberrantly and constitutively activated in invasive urinary bladder carcinomas, and that such likely proapoptotic checkpoint signalling can be disabled by inactivation of Chk2 and/or p53 tumour suppressors in subsets of these tumours.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark; Aarhus Univ Hosp, Dept Clin Biochem, DK-8200 Aarhus, Denmark	Danish Cancer Society; Aarhus University	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strand Blvd 49, DK-2100 Copenhagen, Denmark.	bartek@biobase.dk	Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X; Gronbaek, Kirsten/0000-0002-1535-9601				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Ahn JY, 2000, CANCER RES, V60, P5934; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chehab NH, 2000, GENE DEV, V14, P278; Craig A, 2003, EMBO REP, V4, P787, DOI 10.1038/sj.embor.embor901; di Fagagna FD, 2003, NATURE, V426, P194, DOI 10.1038/nature02118; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Falck J, 2001, ONCOGENE, V20, P5503, DOI 10.1038/sj.onc.1204811; Gronbaek K, 2002, BLOOD, V100, P1430, DOI 10.1182/blood-2002-02-0382; Guldberg P, 1997, HUM MUTAT, V9, P348, DOI 10.1002/(SICI)1098-1004(1997)9:4<348::AID-HUMU8>3.3.CO;2-7; Hangaishi A, 2002, BLOOD, V99, P3075, DOI 10.1182/blood.V99.8.3075; Haruki N, 2000, CANCER RES, V60, P4689; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Hofmann WK, 2001, LEUKEMIA RES, V25, P333, DOI 10.1016/S0145-2126(00)00130-2; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Lee SB, 2001, CANCER RES, V61, P8062; Lukas C, 2001, CANCER RES, V61, P4990; LUKAS C, 2003, NAT CELL BIOL, V421, P952; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 2001, CANCER RES, V61, P5362; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Miller CW, 2002, GENE CHROMOSOME CANC, V33, P17, DOI 10.1002/gcc.1207; Reddy A, 2002, BRIT J CANCER, V86, P756, DOI 10.1038/sj.bjc.6600131; Schutte M, 2003, AM J HUM GENET, V72, P1023, DOI 10.1086/373965; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sodha N, 2002, HUM MUTAT, V19, P173, DOI 10.1002/humu.10031; Sodha N, 2002, BRIT J CANCER, V87, P1445, DOI 10.1038/sj.bjc.6600637; Sullivan A, 2002, ONCOGENE, V21, P1316, DOI 10.1038/sj.onc.1205207; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Tavor S, 2001, LEUKEMIA LYMPHOMA, V42, P517, DOI 10.3109/10428190109064610; Tort F, 2002, BLOOD, V100, P4602, DOI 10.1182/blood-2002-04-1078; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Vahteristo P, 2001, CANCER RES, V61, P5718; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zindy F, 2003, P NATL ACAD SCI USA, V100, P15930, DOI 10.1073/pnas.2536808100	48	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 4	2004	23	52					8545	8551		10.1038/sj.onc.1207878	http://dx.doi.org/10.1038/sj.onc.1207878			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	867VN	15361851				2022-12-17	WOS:000224870700015
J	Roche, KC; Wiechens, N; Hughes, TO; Perkins, ND				Roche, KC; Wiechens, N; Hughes, TO; Perkins, ND			The FHA domain protein SNIP1 is a regulator of the cell cycle and cyclin D1 expression	ONCOGENE			English	Article						forkhead-associated domain; p300; AP-1; Swi/Snf; BRG1	NF-KAPPA-B; DNA-DAMAGE CHECKPOINT; REPLICATION FACTOR-C; SWI/SNF COMPLEX; LARGE SUBUNIT; P53; BINDING; TRANSACTIVATION; TRANSCRIPTION; SPECIFICITY	Smad nuclear interacting protein 1 (SNIP1) is an evolutionarily conserved protein containing a forkhead-associated (FHA) domain that regulates gene expression through interactions with multiple transcriptional regulators. Here, we have used short interfering RNAs (siRNAs) to knockdown SNIP1 expression in human cell lines. Surprisingly, we found that reduction in SNIP1 levels resulted in significantly reduced cell proliferation and accumulation of cells in the G1 phase of the cell cycle. Consistent with this result, we observed that cyclin D1 protein and mRNA levels were reduced. Moreover, SNIP1 depletion results in inhibition of cyclin D1 promoter activity in a manner dependent upon a previously characterized binding site for the AP-1 transcription factor family. SNIP1 itself is induced upon serum stimulation immediately prior to cyclin D1 expression. These effects were independent of the tumour suppressors p53 and retinoblastoma (Rb), but were consistent with an interaction with BRG1, a component of the ATP-dependent chromatin remodelling complex, Swi/Snf. These results define both a new function for SNIP1 and identify a previously unrecognized regulator of the cell cycle and cyclin D1 expression.	Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, Dundee DD1 5EH, Scotland	University of Dundee	Perkins, ND (corresponding author), Univ Dundee, Sch Life Sci, Div Gene Regulat & Express, MSI WTB Complex,Dow St, Dundee DD1 5EH, Scotland.	n.d.perkins@dundee.ac.uk		Owen-Hughes, Tom/0000-0002-0618-8185				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Anderson LA, 2003, MOL CELL BIOL, V23, P721, DOI 10.1128/MCB.23.2.721-732.2003; Anderson LA, 2002, J BIOL CHEM, V277, P29550, DOI 10.1074/jbc.M200513200; Beadling C, 2001, ONCOGENE, V20, P1771, DOI 10.1038/sj.onc.1204212; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chehab NH, 2000, GENE DEV, V14, P278; Durocher D, 2000, MOL CELL, V6, P1169, DOI 10.1016/S1097-2765(00)00114-3; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; Goodman RH, 2000, GENE DEV, V14, P1553; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Ito T, 2001, J BIOL CHEM, V276, P2852, DOI 10.1074/jbc.M009633200; Kim RH, 2001, J BIOL CHEM, V276, P46297, DOI 10.1074/jbc.M103819200; Kim RH, 2000, GENE DEV, V14, P1605; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; RADNEY C, 2003, J BIOL CHEM, V278, P2370; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Rocha S, 2000, CELL GROWTH DIFFER, V11, P491; Rocha S, 2003, MOL CELL, V12, P15, DOI 10.1016/S1097-2765(03)00223-5; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watanabe G, 1996, J BIOL CHEM, V271, P22570, DOI 10.1074/jbc.271.37.22570; Webster GA, 1999, MOL CELL BIOL, V19, P3485; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Wilson JA, 2003, P NATL ACAD SCI USA, V100, P2783, DOI 10.1073/pnas.252758799; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhou MM, 2000, NAT STRUCT BIOL, V7, P1085, DOI 10.1038/81919	30	36	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 28	2004	23	50					8185	8195		10.1038/sj.onc.1208025	http://dx.doi.org/10.1038/sj.onc.1208025			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	866CC	15378006				2022-12-17	WOS:000224749500001
J	Jones, LC; Tefferi, A; Idos, GE; Kumagai, T; Hofmann, WK; Koeffler, HP				Jones, LC; Tefferi, A; Idos, GE; Kumagai, T; Hofmann, WK; Koeffler, HP			RAR beta 2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia	ONCOGENE			English	Article						myelofibrosis; CD34+; RAR beta	ACID RECEPTOR-BETA; RETINOIC ACID; LUNG-CANCER; BREAST-CANCER; EPIGENETIC INACTIVATION; BRONCHIAL EPITHELIUM; COLORECTAL-CARCINOMA; PROMOTER METHYLATION; TRANSCRIPTION FACTOR; HOMOZYGOUS DELETION	Myelofibrosis with myeloid metaplasia (MMM) is a clonal stem-cell disorder that leads to ineffective hematopoiesis, bone marrow fibrosis, and extramedullary hematopoiesis. The molecular mechanisms underlying the development of this myeloproliferative syndrome are currently unknown. In order to identify tumor suppressor genes that may be involved in the disease process, we performed an analysis for loss of heterozygosity (LOH) in CD34 + cells from 29 patients with MMM. We observed a frequency of allelic loss on chromosomal arm 3p in 24% of cases. Detailed mapping of 3p revealed a distinct region of deletion at 3p24. Among the genes known to map within this region is the retinoic acid receptor-beta (RARbeta2) gene. To determine whether RARbeta2 gene activity is diminished in this disease, we analysed its expression in CD34 + cells from 17 patients with MMM using quantitative PCR. Our results indicate that expression of RARbeta2 is significantly decreased in 100% of patient samples compared to that in CD34+ cells from 10 normal individuals. Since allelic loss at 3p24 occurs in <25% of patients, we investigated the contribution of epigenetic modifications to RAR&beta;2 inactivity. Using methylation-specific PCR, we found hypermethylation of RAR&beta;2 in 16 of 18 patients (89%), while the methylated form of the gene was absent in CD34 + cells from nine normal individuals. Our results suggest that RAR&beta;2 acts as a tumor suppressor gene in MMM and that epigenetic changes are the most significant determinants of RAR&beta;2 gene activity in these patients.	Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, Los Angeles, CA 90048 USA; Mayo Clin & Mayo Fdn, Div Hematol & Internal Med, Rochester, MN 55905 USA; Univ Hosp, Dept Hematol, D-60596 Frankfurt, Germany	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Mayo Clinic; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Jones, LC (corresponding author), Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, 8700 Beverly Blvd,Suite BM-1,Room 109, Los Angeles, CA 90048 USA.	letetiajones@yahoo.com			NATIONAL CANCER INSTITUTE [T32CA075956] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA-75956] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Batova A, 1997, CANCER RES, V57, P832; Bench AJ, 2001, BEST PRACT RES CL HA, V14, P531, DOI 10.1053/beha.2001.0153; Breems-de Ridder MC, 2000, MOL CELL ENDOCRINOL, V165, P1, DOI 10.1016/S0303-7207(00)00255-0; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; DALY MC, 1993, ONCOGENE, V8, P1721; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Grignani F, 2000, BLOOD, V96, P1531, DOI 10.1182/blood.V96.4.1531.h8001531_1531_1537; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hiltunen MO, 1997, INT J CANCER, V70, P644, DOI 10.1002/(SICI)1097-0215(19970317)70:6<644::AID-IJC3>3.3.CO;2-2; Hofmann WK, 2002, BLOOD, V100, P3553, DOI 10.1182/blood.V100.10.3553; Hofmann WK, 2001, BLOOD, V98, P787, DOI 10.1182/blood.V98.3.787; HOULE B, 1993, P NATL ACAD SCI USA, V90, P985, DOI 10.1073/pnas.90.3.985; Huebner K, 2001, P NATL ACAD SCI USA, V98, P14763, DOI 10.1073/pnas.261586598; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kastner P, 2001, ONCOGENE, V20, P7178, DOI 10.1038/sj.onc.1204757; Kurie JM, 2003, J NATL CANCER I, V95, P206, DOI 10.1093/jnci/95.3.206; Kuroki T, 2003, CANCER RES, V63, P3724; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; Lin F, 2000, CANCER RES, V60, P3271; LISITSYN NA, 1995, P NATL ACAD SCI USA, V92, P151, DOI 10.1073/pnas.92.1.151; Liu Y, 1996, MOL CELL BIOL, V16, P1138; MARTYRE MC, 1994, BRIT J HAEMATOL, V88, P9, DOI 10.1111/j.1365-2141.1994.tb04970.x; Mesa RA, 2000, BLOOD, V96, P3374; Morosetti R, 1997, BLOOD, V90, P2591, DOI 10.1182/blood.V90.7.2591.2591_2591_2600; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; OhtaniFujita N, 1997, CANCER GENET CYTOGEN, V98, P43, DOI 10.1016/S0165-4608(96)00395-0; Piazza F, 2001, ONCOGENE, V20, P7216, DOI 10.1038/sj.onc.1204855; Prowse AH, 1997, AM J HUM GENET, V60, P765; Qiu HM, 1999, AM J PATHOL, V155, P1519, DOI 10.1016/S0002-9440(10)65467-3; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Shimizu T, 2000, CANCER RES, V60, P4544; Si SP, 1996, EXP CELL RES, V223, P102, DOI 10.1006/excr.1996.0062; Tefferi A, 2000, NEW ENGL J MED, V342, P1255, DOI 10.1056/NEJM200004273421706; Tefferi A, 2001, BRIT J HAEMATOL, V113, P763, DOI 10.1046/j.1365-2141.2001.02796.x; Thiagalingam S, 2002, CURR OPIN ONCOL, V14, P65, DOI 10.1097/00001622-200201000-00012; Toulouse A, 2000, LUNG CANCER-J IASLC, V28, P127, DOI 10.1016/S0169-5002(99)00122-1; Toulouse A, 2000, FASEB J, V14, P1224, DOI 10.1096/fasebj.14.9.1224; Tyers M, 1999, P NATL ACAD SCI USA, V96, P12230, DOI 10.1073/pnas.96.22.12230; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; Virmani AK, 2000, J NATL CANCER I, V92, P1303, DOI 10.1093/jnci/92.16.1303; Widschwendter M, 1997, CANCER RES, V57, P4158; Wistuba II, 2000, CANCER RES, V60, P1949; Xian J, 2001, P NATL ACAD SCI USA, V98, P15062, DOI 10.1073/pnas.251407098; Xie D, 2000, LEUKEMIA, V14, P805, DOI 10.1038/sj.leu.2401717; Xu XC, 1997, JNCI-J NATL CANCER I, V89, P624, DOI 10.1093/jnci/89.9.624; Xu XC, 1997, CANCER RES, V57, P4992; Zhu J, 2001, BLOOD, V98, P2563, DOI 10.1182/blood.V98.8.2563; Zochbauer-Muller S, 2001, CANCER RES, V61, P249	54	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	2004	23	47					7846	7853		10.1038/sj.onc.1207510	http://dx.doi.org/10.1038/sj.onc.1207510			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361842				2022-12-17	WOS:000224331600010
J	Wang, KY; Shen, CKJ				Wang, KY; Shen, CKJ			DNA methyltransferase Dnmt1 and mismatch repair	ONCOGENE			English	Article						Dnmt1; microsatellite instability; mismatch repair	EMBRYONIC STEM-CELLS; MICROSATELLITE INSTABILITY; CANCER SUSCEPTIBILITY; MAMMALIAN DEVELOPMENT; REPLICATION FOCI; METHYLATION; MUTATION; GENES; PCNA; HYPOMETHYLATION	We have examined the relationship between DNA mismatch repair and deficiency of DNA methylation in a mouse embryonic cell line, Dnmt1(-/-) ES, with homologous deletion of the gene coding for the maintenance DNA methyltransferase Dnmt1. With the use of a sensitive PCR for the assay of two mononucleotide- and three dinucleotide microsatellite markers that exhibited instabilities in mismatch repair-deficient cells, significantly higher frequencies of instability were detected at three of the five markers in Dnmt1(-/-) ES than the wildtype ES. The data suggest that Dnmt1 enzyme plays an integrating role in DNA replication and/or repair. The implication that Dnmt1 enzyme and/or cytosine methylation may participate in the strand discrimination of mismatch repair during eukaryotic DNA replication is discussed.	Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; Natl Yang Ming Univ, Inst Genet, Taipei 112, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Shen, CKJ (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	ckshen@ccvax.sinica.edu.tw	shen, Che-Kun James/L-1343-2015					BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guo G, 2004, NATURE, V429, P891, DOI 10.1038/nature02653; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; Hofseth LJ, 2003, J CLIN INVEST, V112, P1887, DOI 10.1172/JCI200319757; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Jackson-Grusby L, 2001, NAT GENET, V27, P31, DOI 10.1038/83730; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Kabbarah O, 2003, MOL CARCINOGEN, V38, P155, DOI 10.1002/mc.10157; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; Lei H, 1996, DEVELOPMENT, V122, P3195; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; Liu YL, 1998, NUCLEIC ACIDS RES, V26, P1038, DOI 10.1093/nar/26.4.1038; Luria SE, 1943, GENETICS, V28, P491; Milutinovic S, 2003, J BIOL CHEM, V278, P14985, DOI 10.1074/jbc.M213219200; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; Slupphaug G, 2003, MUTAT RES-FUND MOL M, V531, P231, DOI 10.1016/j.mrfmmm.2003.06.002; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Vertino PM, 2002, CELL CYCLE, V1, P416, DOI 10.4161/cc.1.6.270; Wong E, 2002, P NATL ACAD SCI USA, V99, P14937, DOI 10.1073/pnas.232579299	34	36	38	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7898	7902		10.1038/sj.onc.1208111	http://dx.doi.org/10.1038/sj.onc.1208111			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15378011				2022-12-17	WOS:000224331600016
J	Wu, M; Xu, LG; Su, T; Tian, Y; Zhai, ZH; Shu, HB				Wu, M; Xu, LG; Su, T; Tian, Y; Zhai, ZH; Shu, HB			AMID is a p53-inducible gene downregulated in tumors	ONCOGENE			English	Article						AMID; p53; promoter; tumor; apoptosis	APOPTOSIS-INDUCING FACTOR; SUPPRESSOR PROTEIN P53; PROGRAMMED CELL-DEATH; CASPASE 9; IN-VIVO; PATHWAYS; TRANSCRIPTION; MITOCHONDRIA; ACTIVATION; LETHALITY	AMID, also called PRG3, is an AIF-homologous and mitochondria-associated protein that has been implicated in caspase-independent apoptosis. In this report, we demonstrated that human AMID gene promoter was activated by p53 in reporter gene assays. Chromatin immunoprecipitation experiments indicated that p53 could bind to human AMID promoter. Deletion mutagenesis indicated that human AMID promoter contains two p53-responsive elements. Furthermore, expression array analysis indicated that human AMID mRNA expression was downregulated in a majority of human tumors. Our findings point to the possibility that AMID is a p53-downstream gene involved in tumorigenesis.	Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Integrated Dept Immunol, Denver, CO 80206 USA	Peking University; National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Shu, HB (corresponding author), Peking Univ, Coll Life Sci, Dept Cell Biol & Genet, Beijing 100871, Peoples R China.	shuh@njc.org		Wu, Min/0000-0003-1372-4764; Xu, Liangguo/0000-0003-1991-2889				Amarante-Mendes GP, 1998, CELL DEATH DIFFER, V5, P298, DOI 10.1038/sj.cdd.4400354; Bidere N, 2001, APOPTOSIS, V6, P371, DOI 10.1023/A:1011390103783; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Haraguchi M, 2000, J EXP MED, V191, P1709, DOI 10.1084/jem.191.10.1709; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hunot S, 2001, SCIENCE, V292, P865, DOI 10.1126/science.1060885; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Miramar MD, 2001, J BIOL CHEM, V276, P16391, DOI 10.1074/jbc.M010498200; Ohiro Y, 2002, FEBS LETT, V524, P163, DOI 10.1016/S0014-5793(02)03049-1; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Resnick-Silverman L, 1998, GENE DEV, V12, P2102, DOI 10.1101/gad.12.14.2102; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XD, 2001, GENE DEV, V15, P2922; Wu M, 2002, J BIOL CHEM, V277, P25617, DOI 10.1074/jbc.M202285200; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X	33	36	41	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 2	2004	23	40					6815	6819		10.1038/sj.onc.1207909	http://dx.doi.org/10.1038/sj.onc.1207909			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	850ZT	15273740				2022-12-17	WOS:000223653600013
J	Poser, I; Tatzel, J; Kuphal, S; Bosserhoff, AK				Poser, I; Tatzel, J; Kuphal, S; Bosserhoff, AK			Functional role of MIA in melanocytes and early development of melanoma	ONCOGENE			English	Article						melanocytes; melanoma; migration; MIA; array	MATRIX-METALLOPROTEINASE MT1-MMP; INHIBITORY-ACTIVITY; MALIGNANT-MELANOMA; CELL-LINES; INTEGRIN ALPHA-V-BETA-3; PLASMINOGEN ACTIVATORS; IN-VITRO; EXPRESSION; PROGRESSION; PROTEIN	The protein MIA(melanoma inhibitory activity) is highly expressed in malignant melanomas but not in melanocytes. Furthermore, expression of MIA correlates with tumor progression in vivo. Here, MIA-dependent changes of gene expression after long-term inhibition of MIA expression in the human melanoma cell line HMB2 were investigated. Primarily, we observed characteristic changes in cell morphology, and also found re-established cell-cell contacts in MIA-deficient cell clones grown in monolayer culture. Real-time reverse transcription-polymerase chain reaction (RT-PCR) showed a downregulation of N-cadherin expression and a reinduction of E-cadherin expression in the MIA-deficient cell clones. Further, both cancer cDNA array and protein arrays verified a marked downregulation of several other melanoma-associated genes (e.g. membrane-type 1 matrix metalloproteinase tissue-type plasminogen activator integrin beta3, secreted protein acidic and rich in cysteins and fibronectin) in the MIA-deficient melanoma cells, confirmed by real-time RT-PCR and Western blotting. As all these molecules are associated with migration, the effect of MIA on migration of human primary melanocytes was analysed. In the presence of MIA, we observed enhanced migratory ability of melanocytic cells, induction of melanoma-associated genes as well as inhibition of apoptosis due to anoikis. These results suggest that expression of MIA promotes melanoma progression by inducing further melanoma-associated genes.	Univ Regensburg, Inst Pathol, D-93053 Regensburg, Germany	University of Regensburg	Bosserhoff, AK (corresponding author), Univ Regensburg, Inst Pathol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	anja.bosserhoff@klinik.uni-regensburg.de	Bosserhoff, Anja/GNH-4801-2022; Kuphal, Silke/AAW-2702-2020	Bosserhoff, Anja/0000-0001-8147-394X				ALIZADEH H, 1995, CURR EYE RES, V14, P449, DOI 10.3109/02713689509003755; BLESCH A, 1994, CANCER RES, V54, P5695; Bosserhoff AK, 1996, J BIOL CHEM, V271, P490, DOI 10.1074/jbc.271.1.490; Bosserhoff AK, 1999, J PATHOL, V187, P446, DOI 10.1002/(SICI)1096-9896(199903)187:4<446::AID-PATH267>3.0.CO;2-Y; Bosserhoff AK, 2003, LAB INVEST, V83, P1583, DOI 10.1097/01.LAB.0000097191.12477.5D; Bosserhoff AK, 1997, CANCER RES, V57, P3149; Bosserhoff AK, 2002, HISTOL HISTOPATHOL, V17, P289, DOI 10.14670/HH-17.289; Bosserhoff AK, 2001, MELANOMA RES, V11, P417, DOI 10.1097/00008390-200108000-00013; Bowen AR, 2003, J INVEST DERMATOL, V120, P48, DOI 10.1046/j.1523-1747.2003.12010.x; deVries TJ, 1996, MELANOMA RES, V6, P79, DOI 10.1097/00008390-199604000-00001; Felding-Habermann B, 2002, CLIN EXP METASTAS, V19, P427, DOI 10.1023/A:1016377114119; Furukawa Y, 2002, J BIOL CHEM, V277, P39760, DOI 10.1074/jbc.M200805200; Guba M, 2000, BRIT J CANCER, V83, P1216, DOI 10.1054/bjoc.2000.1424; Hofmann UB, 2000, J PATHOL, V191, P245; Hofmann UB, 2000, INT J CANCER, V87, P12, DOI 10.1002/1097-0215(20000701)87:1<12::AID-IJC3>3.0.CO;2-A; Hsu MY, 2002, DIFFERENTIATION, V70, P522, DOI 10.1046/j.1432-0436.2002.700906.x; Iida J, 2004, J INVEST DERMATOL, V122, P167, DOI 10.1046/j.0022-202X.2003.22114.x; Jacob K, 1998, MELANOMA RES, V8, P211, DOI 10.1097/00008390-199806000-00003; Krengel S, 2004, J CUTAN PATHOL, V31, P1, DOI 10.1046/j.0303-6987.2004.0106.x; Krengel S, 2002, J CUTAN PATHOL, V29, P390, DOI 10.1034/j.1600-0560.2002.290702.x; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Li G, 2001, CANCER RES, V61, P3819; Lougheed JC, 2001, P NATL ACAD SCI USA, V98, P5515, DOI 10.1073/pnas.091601698; Massi D, 1999, HUM PATHOL, V30, P339, DOI 10.1016/S0046-8177(99)90014-X; MEISSAUER A, 1991, EXP CELL RES, V192, P453, DOI 10.1016/0014-4827(91)90064-2; NATALI PG, 1995, BRIT J CANCER, V71, P1243, DOI 10.1038/bjc.1995.240; NIP J, 1992, J CLIN INVEST, V90, P1406, DOI 10.1172/JCI116007; PAGGI MG, 2003, PIGMENT CELL RES, V16, P589; SAKSELA O, 1984, INT J CANCER, V33, P609, DOI 10.1002/ijc.2910330510; Seftor REB, 2001, CANCER RES, V61, P6322; Selzer E, 1998, MELANOMA RES, V8, P197, DOI 10.1097/00008390-199806000-00001; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Sounni NE, 2002, INT J CANCER, V98, P23, DOI 10.1002/ijc.10134; Stahlecker J, 2000, ANTICANCER RES, V20, P5041; Stoll R, 2003, PROTEIN SCI, V12, P510, DOI 10.1110/ps.0222603; Stoll R, 2001, EMBO J, V20, P340, DOI 10.1093/emboj/20.3.340; Stoll R, 2000, J BIOMOL NMR, V17, P87, DOI 10.1023/A:1008306918293; Sturm RA, 2002, CANCER RES, V62, P226; Van Belle PA, 1999, HUM PATHOL, V30, P562, DOI 10.1016/S0046-8177(99)90202-2; VANGRONINGEN JJM, 1995, CANCER RES, V55, P6237; WOLLINA U, 1991, ANTICANCER RES, V11, P1405	42	36	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6115	6124		10.1038/sj.onc.1207797	http://dx.doi.org/10.1038/sj.onc.1207797			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208686				2022-12-17	WOS:000223261000011
J	McGarry, LC; Winnie, JN; Ozanne, BW				McGarry, LC; Winnie, JN; Ozanne, BW			Invasion of v-Fos(FBR)-transformed cells is dependent upon histone deacetylase activity and suppression of histone deacetylase regulated genes	ONCOGENE			English	Article						Fos; invasion; deacetylase; STAT6; protocadherin; RYBP	TRANSCRIPTION FACTOR; TRANSFORMED FIBROBLASTS; MULTIGENIC INVASION; POLYCOMB COMPLEX; FLAT PHENOTYPE; UP-REGULATION; RAS-ONCOGENE; AP-1; DIFFERENTIATION; ACETYLATION	Transformation of fibroblasts with the v-fos oncogene produces a highly invasive phenotype that is mediated by changes in gene expression. Inhibition of histone deacetylase (HDAC) activity with trichostatin A (TSA) or valproic acid (VPA) at concentrations that do not affect morphology, motility, chemotaxis or proliferation, strongly inhibits invasion and results in the re-expression of a significant proportion of those genes that are downregulated in the v-Fos-transformed cells. Independent expression of three of these re-expressed genes, (Ring1 and YY1 binding protein (RYBP); protocadherin gamma subfamily C, 3 (PCDHGC3); and signal transducer and activator of transcription 6 (STAT6)) in Fos-transformed cells, has no effect on morphology, motility, chemotaxis or proliferation, but strongly inhibits invasion. Therefore, we conclude that the ability of v-Fos-transformed cells to invade is dependent upon repression of gene expression through either direct or indirect HDAC activity.	Beatson Inst Canc Res, Canc Res UK, Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; Cancer Research UK	Ozanne, BW (corresponding author), Beatson Inst Canc Res, Canc Res UK, Beatson Labs, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	b.ozanne@beatson.gla.ac.uk						Bakin AV, 1999, SCIENCE, V283, P387, DOI 10.1126/science.283.5400.387; Buttner C, 2004, J CELL PHYSIOL, V198, P248, DOI 10.1002/jcp.10395; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Garcia E, 1999, EMBO J, V18, P3404, DOI 10.1093/emboj/18.12.3404; Gottlicher M, 2001, EMBO J, V20, P6969, DOI 10.1093/emboj/20.24.6969; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; Imai T, 2003, ONCOGENE, V22, P9231, DOI 10.1038/sj.onc.1207184; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kelly WK, 2002, EXPERT OPIN INV DRUG, V11, P1695, DOI 10.1517/13543784.11.12.1695; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Lamb RF, 1997, CURR BIOL, V7, P682, DOI 10.1016/S0960-9822(06)00295-8; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; Lehrmann H, 2002, ADV CANCER RES, V86, P41, DOI 10.1016/S0065-230X(02)86002-X; Liu LT, 2003, CANCER RES, V63, P3069; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Masui T, 2003, CLIN CANCER RES, V9, P1779; MATSUMOTO M, 1992, J ANTIBIOT, V45, P879, DOI 10.7164/antibiotics.45.879; McGaha TL, 2003, ARTHRITIS RHEUM-US, V48, P2275, DOI 10.1002/art.11089; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; Rosato RR, 2003, CANCER RES, V63, P3637; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANO K, 1993, EMBO J, V12, P2249, DOI 10.1002/j.1460-2075.1993.tb05878.x; Schlisio S, 2002, EMBO J, V21, P5775, DOI 10.1093/emboj/cdf577; Scott LA, 2004, MOL CELL BIOL, V24, P1540, DOI 10.1128/MCB.24.4.1540-1559.2004; Spence HJ, 2000, ONCOGENE, V19, P1266, DOI 10.1038/sj.onc.1203433; Stapleton G, 2002, J CELL SCI, V115, P2713; SUGITA K, 1992, BIOCHEM BIOPH RES CO, V182, P379, DOI 10.1016/S0006-291X(05)80156-1; Suzuki ST, 2000, EXP CELL RES, V261, P13, DOI 10.1006/excr.2000.5039; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	38	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 8	2004	23	31					5284	5292		10.1038/sj.onc.1207687	http://dx.doi.org/10.1038/sj.onc.1207687			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	835NX	15107823				2022-12-17	WOS:000222491600004
J	Sall, A; Caserta, S; Jolicoeur, P; Franqueville, L; de Turenne-Tessier, M; Ooka, T				Sall, A; Caserta, S; Jolicoeur, P; Franqueville, L; de Turenne-Tessier, M; Ooka, T			Mitogenic activity of Epstein-Barr virus-encoded BARF1 protein	ONCOGENE			English	Article						Epstein-Barr virus; BARF1 gene; growth factor	EPITHELIAL-CELLS; TRANSCRIPTIONAL EXPRESSION; NASOPHARYNGEAL CARCINOMA; MALIGNANT-TRANSFORMATION; GENE; EBV; ESTABLISHMENT; LYMPHOMA; GROWTH; LINE	We previously reported that BARF1 gene has either an immortalizing effect, when expressed in primary primate epithelial cells, or a malignant transforming activity, when expressed in established and nontumoral rodent fibroblast or human B-cell lines. As predicted from sequence analysis, we found that BARF1 coded protein can be secreted from different cell lines, among them BARF1-transfected Balb/c3T3 rodent fibroblasts. Thus, as an initial step to clarify BARF1 oncogenic functions, we investigated whether the secreted form of BARF1 protein can activate the cell cycle as a growth factor. Since efficient BARF1 expression could be obtained from 293-tTA cells infected with a tetracycline-regulatable recombinant adenovirus, secreted BARF1 product could be purified from the culture medium of such cells by ammonium sulfate precipitation, ion exchange chromotography and sucrose gradient sedimentation. We describe in this paper that addition of a purified product of secreted BARF1 protein to serum-free culture medium of Balb/c3T3 rodent fibroblasts, human Louckes B-cell line and primary monkey kidney epithelial cells resulted in a cell cycle activation that was inhibited by affinity-purified anti-BARF1 antibody. Our demonstration of a specific stimulation of cell cycle in vitro by BARF1 secreted product suggests that this EBV-encoded BARF1 protein could act as a growth factor in vivo.	Univ Lyon 1, Fac Med RTH Laennec, CNRS,UMR 5537, Mol Virol Lab, F-69372 Lyon 08, France; Natl Res Council Canada, Biotechnol Res Inst, Montreal, PQ H4P 2R2, Canada	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; National Research Council Canada	Ooka, T (corresponding author), Univ Lyon 1, Fac Med RTH Laennec, CNRS,UMR 5537, Mol Virol Lab, F-69372 Lyon 08, France.	ooka@laennec.univ-lyon1.fr	Caserta, Sergio/E-4602-2012	Caserta, Sergio/0000-0002-4400-0059				Cohen JI, 1999, J VIROL, V73, P7627, DOI 10.1128/JVI.73.9.7627-7632.1999; Danve C, 2001, VIROLOGY, V288, P223, DOI 10.1006/viro.2001.1072; Decaussin G, 2000, CANCER RES, V60, P5584; DETURENNETESSIE.M, UNPUB; Gao YN, 2002, ONCOGENE, V21, P825, DOI 10.1038/sj.onc.1205130; Hayes DP, 1999, J CLIN PATHOL-MOL PA, V52, P97, DOI 10.1136/mp.52.2.97; KARRAN L, 1990, INT J CANCER, V45, P763, DOI 10.1002/ijc.2910450432; Kieff E., 1996, FIELDS VIROLOGY, P2343; Massie B, 1998, CYTOTECHNOLOGY, V28, P53, DOI 10.1023/A:1008013211222; Nishikawa J, 1999, J VIROL, V73, P1286, DOI 10.1128/JVI.73.2.1286-1292.1999; OOKA T, 2001, EBV REP, V8, P177; RICKINSON AB, 2002, FIELDS VIROLOGY, P257; SbihLammali F, 1996, J MED VIROL, V49, P7, DOI 10.1002/(SICI)1096-9071(199605)49:1&lt;7::AID-JMV2&gt;3.0.CO;2-A; Sheng W, 2003, J VIROL, V77, P3859, DOI 10.1128/JVI.77.6.3859-3865.2003; Sheng W, 2001, ONCOGENE, V20, P1176, DOI 10.1038/sj.onc.1204217; Strockbine LD, 1998, J VIROL, V72, P4015, DOI 10.1128/JVI.72.5.4015-4021.1998; Tanner JE, 1997, J INFECT DIS, V175, P38, DOI 10.1093/infdis/175.1.38; WEI MX, 1989, EMBO J, V8, P2897, DOI 10.1002/j.1460-2075.1989.tb08438.x; Wei MX, 1997, ONCOGENE, V14, P3073, DOI 10.1038/sj.onc.1201128; WEI MX, 1994, CANCER RES, V54, P1843; Xue SA, 2002, INT J CANCER, V99, P635, DOI 10.1002/ijc.10372; ZHANG CX, 1992, VIRUS RES, V26, P153, DOI 10.1016/0168-1702(92)90154-2; zur Hausen A, 2000, CANCER RES, V60, P2745	23	36	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4938	4944		10.1038/sj.onc.1207607	http://dx.doi.org/10.1038/sj.onc.1207607			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15064715				2022-12-17	WOS:000222104200015
J	Makino, K; Day, CP; Wang, SC; Li, YM; Hung, MC				Makino, K; Day, CP; Wang, SC; Li, YM; Hung, MC			Upregulation of IKK alpha/IKK beta by integrin-linked kinase is required for HER2/neu-induced NF-kappa B antiapoptotic pathway	ONCOGENE			English	Article						HER2/neu; ILK; PI-3K; Akt; TNF-alpha; antiapoptotic pathway; IKK	ACTIVATED PROTEIN-KINASE; CELL-PROLIFERATION; INDUCED APOPTOSIS; MAP KINASE; AKT; PHOSPHORYLATION; HER-2/NEU; CANCER; OVEREXPRESSION; TRANSFORMATION	Constitutively active HER2/neu activates nuclear factor kappa-B (NF-kappaB) in cells and induces their resistance to apoptotic stimuli such as tumor necrosis factor-alpha (TNF-alpha). Here, we show that integrin-linked kinase (ILK), the crucial signal transducer in the integrin pathway, is involved in HER2/neu-mediated activation of NF-kappaB. Expression of HER2/neu increases ILK activity. Blocking ILK activity with a kinase-deficient mutant ILK (ILK-KD) inhibits NF-kappaB activation and sensitizes HER2/neu-transformed cells to TNF-alpha-induced apoptosis. Stable expression of ILK-KD in HER2/neu-transformed cells suppressed Akt phosphorylation and the expression of IkappaB kinase alpha and beta (IKKalpha and beta) at both the protein and mRNA levels, preventing IkappaB-alpha degradation and NF-kappaB activation. Furthermore, HER2/neu stimulated the transcriptional activity of the putative IKKbeta promoter through ILK and Akt. Our results demonstrate that upregulation of IKKalpha and IKKbeta by the ILK/Akt pathway is required for the HER2/neu-mediated NF-kappaB antiapoptotic pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; Kumamoto Univ, Sch Med, Dept Neurosurg, Kumamoto 860, Japan; Univ Texas, Hlth Sci Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Kumamoto University; University of Texas System; University of Texas Health Science Center Houston	Hung, MC (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mail.mdanderson.org	Wang, Shao-Chun/P-9904-2019; Hung, Mien-Chie/ABD-5911-2021	Wang, Shao-Chun/0000-0002-5477-1682; Hung, Mien-Chie/0000-0003-4317-4740	NCI NIH HHS [P01 CA 99031] Funding Source: Medline; PHS HHS [R01 58880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA099031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Cruet-Hennequart S, 2003, ONCOGENE, V22, P1688, DOI 10.1038/sj.onc.1206347; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Gary DS, 2003, J NEUROCHEM, V84, P878, DOI 10.1046/j.1471-4159.2003.01579.x; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hung MC, 1999, SEMIN ONCOL, V26, P51; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; MORINO N, 1995, J BIOL CHEM, V270, P269, DOI 10.1074/jbc.270.1.269; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Ozes ON, 1999, NATURE, V401, P82; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Radeva G, 1997, J BIOL CHEM, V272, P13937, DOI 10.1074/jbc.272.21.13937; Renshaw MW, 1997, EMBO J, V16, P5592, DOI 10.1093/emboj/16.18.5592; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Tan M, 2002, MOL CELL, V9, P993, DOI 10.1016/S1097-2765(02)00510-5; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	29	36	43	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 6	2004	23	21					3883	3887		10.1038/sj.onc.1207485	http://dx.doi.org/10.1038/sj.onc.1207485			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	818JX	15021910				2022-12-17	WOS:000221242500015
J	Palecek, E; Brazda, V; Jagelska, E; Pecinka, P; Karlovska, L; Brazdova, M				Palecek, E; Brazda, V; Jagelska, E; Pecinka, P; Karlovska, L; Brazdova, M			Enhancement of p53 sequence-specific binding by DNA supercoiling	ONCOGENE			English	Article						competition assay; p53; DNA sequence-specific binding; supercoiled DNA; cruciform extrusion	TUMOR-SUPPRESSOR P53; C-TERMINAL DOMAIN; CORE DOMAIN; MONOCLONAL-ANTIBODIES; CONSENSUS SEQUENCE; RESPONSE ELEMENT; ELISA TECHNIQUE; PROTEIN; CONFORMATION; MICROSCOPY	Using a new competition assay, we investigated the effect of DNA negative supercoiling on the DNA sequence-specific binding ( SSDB) of human wild- type ( wt) p53 protein. We found that supercoiled ( sc) pBluescript DNAs with different inserted p53 target sequences were stronger competitors than a mixture of scDNA pBluescript with the given 20- mer target oligodeoxynucleotide. ScDNAs were always better competitors than their linearized or relaxed forms. Two DNAs with extruded cruciforms within the target sequence were the best competitors; removal of the cruciforms resulted in a decrease of competitor strength. In contrast to the full- length wt p53, the deletion mutant p53CDelta30 and the p53 core domain ( 93 - 312 aa) showed no enhancement of p53 SSDB to scDNA, suggesting that, in addition to the p53 core domain, the C- terminal was involved in this binding. We conclude that cruciforms and DNA bends contribute to the enhancement of p53 SSDB to scDNA and that the DNA supercoiling is an important determinant in the p53 sequence-specific binding. Supercoiling may thus play a significant role in the complex p53- regulatory network.	Acad Sci Czech Republ, Inst Biophys, CS-61265 Brno, Czech Republic	Czech Academy of Sciences; Institute of Biophysics of the Czech Academy of Sciences	Palecek, E (corresponding author), Acad Sci Czech Republ, Inst Biophys, Kralovopolska 135, CS-61265 Brno, Czech Republic.	palecek@ibp.cz	Brazdova, Marie/H-1924-2014; Palecek, Emil/C-1075-2013; Václav, Brázda/F-9582-2011; Pečinka, Petr/H-8493-2014; Jagelská, Eva Brázdová -/H-1915-2014; Brazda, Vaclav/ABH-9460-2020	Palecek, Emil/0000-0003-2561-8336; Václav, Brázda/0000-0003-2837-4226; Brazda, Vaclav/0000-0003-2837-4226; Pecinka, Petr/0000-0003-1270-3646				Arrowsmith CH, 1996, ONCOGENE, V12, P1379; Ayed A, 2001, NAT STRUCT BIOL, V8, P756, DOI 10.1038/nsb0901-756; BATES AD, 1993, DNA TOPOLOGY; Brazda V, 2000, BIOCHEM BIOPH RES CO, V267, P934, DOI 10.1006/bbrc.1999.2056; Brazdova M, 2002, NUCLEIC ACIDS RES, V30, P4966, DOI 10.1093/nar/gkf616; Cherny DI, 1999, J MOL BIOL, V294, P1015, DOI 10.1006/jmbi.1999.3299; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Fojta M, 1999, J BIOL CHEM, V274, P25749, DOI 10.1074/jbc.274.36.25749; GOHLER T, 2002, J BIOL CHEM, V8, P8; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Hupp TR, 1999, CELL MOL LIFE SCI, V55, P88, DOI 10.1007/s000180050272; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jagelska E, 2002, J IMMUNOL METHODS, V267, P227, DOI 10.1016/S0022-1759(02)00182-5; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; Jett SD, 2000, J MOL BIOL, V299, P585, DOI 10.1006/jmbi.2000.3759; Kim E, 1999, ONCOGENE, V18, P7310, DOI 10.1038/sj.onc.1203139; Kim E, 1997, ONCOGENE, V15, P857, DOI 10.1038/sj.onc.1201412; Krasilnikov AS, 1999, J MOL BIOL, V292, P1149, DOI 10.1006/jmbi.1999.3117; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Mazur SJ, 1999, J MOL BIOL, V292, P241, DOI 10.1006/jmbi.1999.3064; McKinney K, 2002, MOL CELL BIOL, V22, P6797, DOI 10.1128/MCB.22.19.6797-6808.2002; MURCHIE AIH, 1992, METHOD ENZYMOL, V211, P158; Nagaich AK, 1999, P NATL ACAD SCI USA, V96, P1875, DOI 10.1073/pnas.96.5.1875; Nagaich AK, 1997, J BIOL CHEM, V272, P14830, DOI 10.1074/jbc.272.23.14830; PALECEK E, 1991, CRIT REV BIOCHEM MOL, V26, P151, DOI 10.3109/10409239109081126; Palecek E, 1997, ONCOGENE, V15, P2201, DOI 10.1038/sj.onc.1201398; Palecek E, 1999, ONCOGENE, V18, P3617, DOI 10.1038/sj.onc.1202710; Palecek E, 2001, EUR J BIOCHEM, V268, P573, DOI 10.1046/j.1432-1327.2001.01898.x; Pearson CE, 1996, J CELL BIOCHEM, V63, P1; Peter BJ, 1998, CELL, V94, P819, DOI 10.1016/S0092-8674(00)81740-7; Pospisilova S, 2000, J IMMUNOL METHODS, V237, P51, DOI 10.1016/S0022-1759(99)00246-X; Stros M, 2000, J BIOL CHEM, V275, P35699, DOI 10.1074/jbc.M007167200; VANHOLDE K, 1994, BIOESSAYS, V16, P59, DOI 10.1002/bies.950160110; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; Yakovleva T, 2001, J BIOL CHEM, V276, P15650, DOI 10.1074/jbc.M100482200; Zhou HJ, 2001, J MOL BIOL, V306, P227, DOI 10.1006/jmbi.2000.4370	41	36	36	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 18	2004	23	12					2119	2127		10.1038/sj.onc.1207324	http://dx.doi.org/10.1038/sj.onc.1207324			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14755248				2022-12-17	WOS:000220280900001
J	Qiu, HQ; Miller, WT				Qiu, HQ; Miller, WT			Role of the Brk SH3 domain in substrate recognition	ONCOGENE			English	Article						Brk; tyrosine kinase; SH3 domain; SH2 domain; substrate	NONRECEPTOR TYROSINE KINASE; MAMMARY EPITHELIAL-CELLS; C-SRC; PROCESSIVE PHOSPHORYLATION; GASTROINTESTINAL-TRACT; FAMILY; PROTEIN; HCK; EXPRESSION; RNA	Breast tumor kinase ( Brk) is a nonreceptor tyrosine kinase that is overexpressed in a high percentage of breast carcinomas. Brk contains SH3, SH2, and tyrosine kinase catalytic domains in a similar arrangement as Src family kinases. In this study, we explored the roles of the SH3 and SH2 domains in Brk regulation and substrate binding. We introduced a series of mutations into Brk that were predicted to disrupt the intramolecular interactions involving the SH3 and SH2 domains. These mutant forms of Brk displayed higher activity than wild- type Brk when expressed in human embryonic kidney HEK293 cells. These studies also allowed us to pinpoint the intramolecular binding site for the SH3 domain. To examine substrate binding, we compared binding and phosphorylation of Sam68, a physiological substrate of Brk. These experiments showed that the SH3 domain plays a particularly important role in substrate recognition. We confirmed this conclusion using a series of synthetic peptides in which a substrate sequence was coupled to an SH3 or SH2 ligand. The SH3- binding substrate had a significantly lower K-m than a control, while no difference was observed between an SH2- binding substrate and a control. Taken together, our data suggest that SH3 interactions will govern phosphorylation of many substrates by Brk.	SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu			NCI NIH HHS [CA28146] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Barker KT, 1997, ONCOGENE, V15, P799, DOI 10.1038/sj.onc.1201241; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Coyle JH, 2003, MOL CELL BIOL, V23, P92, DOI 10.1128/MCB.23.1.92-103.2003; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; Derry JJ, 2003, ONCOGENE, V22, P4212, DOI 10.1038/sj.onc.1206465; Easty DJ, 1997, INT J CANCER, V71, P1061, DOI 10.1002/(SICI)1097-0215(19970611)71:6<1061::AID-IJC24>3.0.CO;2-F; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Harvey AJ, 2003, ONCOGENE, V22, P5006, DOI 10.1038/sj.onc.1206577; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kamalati T, 2000, ONCOGENE, V19, P5471, DOI 10.1038/sj.onc.1203931; Kamalati T, 1996, J BIOL CHEM, V271, P30956, DOI 10.1074/jbc.271.48.30956; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; LIU XQ, 1993, ONCOGENE, V8, P1119; Llor X, 1999, CLIN CANCER RES, V5, P1767; MAYER BJ, 1994, MOL CELL BIOL, V14, P2883, DOI 10.1128/MCB.14.5.2883; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; McPherson RA, 2000, ONCOGENE, V19, P3616, DOI 10.1038/sj.onc.1203678; Miller WT, 2003, ACCOUNTS CHEM RES, V36, P393, DOI 10.1021/ar020116v; Mitchell PJ, 2000, ONCOGENE, V19, P4273, DOI 10.1038/sj.onc.1203775; MITCHELL PJ, 1994, ONCOGENE, V9, P2383; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nagar B, 2003, CELL, V112, P859, DOI 10.1016/S0092-8674(03)00194-6; Nguyen JT, 1997, NAT STRUCT BIOL, V4, P256, DOI 10.1038/nsb0497-256; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Serfas MS, 2003, ONCOL RES, V13, P409; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Tian MX, 1997, MOL BIOL CELL, V8, P1183, DOI 10.1091/mbc.8.7.1183; VASIOUKHIN V, 1995, ONCOGENE, V10, P349; Wang DX, 2001, BIOCHEMISTRY-US, V40, P2004, DOI 10.1021/bi002342n; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	42	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2004	23	12					2216	2223		10.1038/sj.onc.1207339	http://dx.doi.org/10.1038/sj.onc.1207339			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	804EB	14676834				2022-12-17	WOS:000220280900011
J	Rengifo-Cam, W; Konishi, A; Morishita, N; Matsuoka, H; Yamori, T; Nada, S; Okada, M				Rengifo-Cam, W; Konishi, A; Morishita, N; Matsuoka, H; Yamori, T; Nada, S; Okada, M			Csk defines the ability of integrin-mediated cell adhesion and migration in human colon cancer cells: implication for a potential role in cancer metastasis	ONCOGENE			English	Article						Src; Csk; colon cancer; integrin	PROTEIN-TYROSINE KINASE; TERMINAL SRC KINASE; ADVANCED COLORECTAL CANCERS; C-SRC; FAMILY KINASES; CODON 531; E-CADHERIN; ACTIVATION; PP60C-SRC; GENE	Progression of human colon cancer is often associated with elevated expression and activity of the Src family tyrosine kinase (SFK). SFK is ordinarily in equilibrium between inactive and primed states by a balance of negative regulatory kinase Csk and its counteracting tyrosine phosphatase(s), both of which act on the regulatory C-terminal tyrosine of SFK. To evaluate the contribution of the regulatory system of SFK in cancer progression, we here modulated the equilibrium status of SFK by introducing wild-type or dominant-negative Csk in human epithelial colon cancer cells, HCT15 and HT29. Overexpression of wild-type Csk induced decreased SFK activation, increased cell-cell contacts mediated by E-cadherin, decreased the number of focal contacts and decreased cell adhesion/migration and in vitro invasiveness. Conversely, expression of a dominant-negative Csk resulted in elevated SFK activation, enhanced phosphorylation of FAK and paxilllin, enhanced cell scattering, an increased number of focal contacts, dramatic rearrangement of actin cytoskeleton and increased cell adhesion/migration and in vitro invasiveness. In these scattered cells, however, localization, expression and phosphorylation of either E-cadherin or beta-catenin were not significantly affected, suggesting that the E-cadherin-mediated cell-cell contact is indirectly regulated by SFK. Furthermore, all these events occurred absolutely dependent on integrin-mediated cell adhesion. These findings demonstrate that Csk defines the ability of integrin-SFK-mediated cell adhesion signaling that influences the metastatic potential of cancer cells.	Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, Osaka 5650871, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Div Mol Pharmacol, Toshima Ku, Tokyo 1708455, Japan	Osaka University; Japanese Foundation for Cancer Research	Okada, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Oncogene Res, 3-1 Yamadaoka, Osaka 5650871, Japan.	okadam@biken.osaka-u.ac.jp						Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Avizienyte E, 2002, NAT CELL BIOL, V4, P632, DOI 10.1038/ncb829; BOARDMAN LA, 1995, GASTROENTEROLOGY, V108, P291, DOI 10.1016/0016-5085(95)90037-3; BOLEN JB, 1987, P NATL ACAD SCI USA, V84, P2251, DOI 10.1073/pnas.84.8.2251; CARTWRIGHT CA, 1994, J CLIN INVEST, V93, P509, DOI 10.1172/JCI117000; CARTWRIGHT CA, 1989, J CLIN INVEST, V83, P2025, DOI 10.1172/JCI114113; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Daigo Y, 1999, CANCER RES, V59, P4222; Dan S, 2002, CANCER RES, V62, P1139; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; HYAFIL F, 1980, CELL, V21, P927, DOI 10.1016/0092-8674(80)90456-0; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Irby RB, 2002, CANCER RES, V62, P2669; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Laghi L, 2001, BRIT J CANCER, V84, P196, DOI 10.1054/bjoc.2000.1560; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nakagawa T, 2000, INT J CANCER, V88, P384, DOI 10.1002/1097-0215(20001101)88:3<384::AID-IJC10>3.3.CO;2-2; Nam JS, 2002, CLIN CANCER RES, V8, P2430; Nilbert M, 2000, CANCER GENET CYTOGEN, V121, P94, DOI 10.1016/S0165-4608(00)00226-0; Ogawa A, 2002, J BIOL CHEM, V277, P14351, DOI 10.1074/jbc.C200086200; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; RENGIFOCAM W, 2001, CANCER, V92, P61; ROSEN N, 1986, J BIOL CHEM, V261, P3754; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; Suen PW, 1999, J CELL SCI, V112, P4067; Takayama Y, 1999, J BIOL CHEM, V274, P2291, DOI 10.1074/jbc.274.4.2291; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; Wang NM, 2000, CANCER LETT, V150, P201, DOI 10.1016/S0304-3835(99)00398-5	36	36	40	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 8	2004	23	1					289	297		10.1038/sj.onc.1207041	http://dx.doi.org/10.1038/sj.onc.1207041			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	761HK	14712234				2022-12-17	WOS:000187895300030
J	Loffler, H; Syljuasen, RG; Bartkova, J; Worm, J; Lukas, J; Bartek, J				Loffler, H; Syljuasen, RG; Bartkova, J; Worm, J; Lukas, J; Bartek, J			Distinct modes of deregulation of the proto-oncogenic Cdc25A phosphatase in human breast cancer cell lines	ONCOGENE			English	Article						DNA damage; cell cycle checkpoints; Cdc25A; proteolysis; breast cancer	DNA-DAMAGE; S-PHASE; CYCLIN D1; C-MYC; CHECKPOINT; EXPRESSION; PROTEIN; GENE; ATM; OVEREXPRESSION	The rapid cell cycle arrest in response to DNA damage is mediated by degradation of the Cdc25A phosphatase, a proto-oncogene whose mRNA is frequently overexpressed in human tumours. Here, we study the occurrence and mechanisms of Cdc25A deregulation in human breast cancer cell lines. We demonstrate aberrantly elevated Cdc25A protein abundance and phosphatase activity in eight out of 15 cell lines, in some cases resulting in abrogation of the Cdc25A-mediated checkpoint response to ionizing radiation (IR), and this defect correlated with hypersensitivity to IR. Furthermore, we present evidence that deregulation of Cdc25A occurs predominantly on the post-transcriptional level, as overabundant Cdc25A protein was usually not accompanied by adequate mRNA overexpression. Instead, we demonstrate that aberrantly enhanced protein stability is an important mechanism underlying Cdc25A overabundance in a subset of breast cancer cell lines. Given the frequency of this mechanism, we propose that the DNA integrity checkpoint controlling Cdc25A protein stability might be a common target for deregulation in breast cancer.	Danish Canc Soc, Inst Canc Biol, DK-2100 Copenhagen, Denmark	Danish Cancer Society	Bartek, J (corresponding author), Danish Canc Soc, Inst Canc Biol, Strandblvd 49, DK-2100 Copenhagen, Denmark.		Bartek, Jiri/G-5870-2014	Lukas, Jiri/0000-0001-9087-506X				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; Donzelli M, 2002, EMBO J, V21, P4875, DOI 10.1093/emboj/cdf491; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jiang XR, 1999, NAT GENET, V21, P111, DOI 10.1038/5056; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Mondesert O, 2002, BIOCHEM BIOPH RES CO, V295, P673, DOI 10.1016/S0006-291X(02)00739-8; Moynahan ME, 2002, ONCOGENE, V21, P8994, DOI 10.1038/sj.onc.1206177; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; Nishioka K, 2001, BRIT J CANCER, V85, P412, DOI 10.1054/bjoc.2001.1934; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Sorensen CS, 2000, MOL CELL BIOL, V20, P7613, DOI 10.1128/MCB.20.20.7613-7623.2000; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; Tauchi H, 2002, ONCOGENE, V21, P8967, DOI 10.1038/sj.onc.1206136; Vahteristo P, 2002, AM J HUM GENET, V71, P432, DOI 10.1086/341943; Varley JM, 1997, BRIT J CANCER, V76, P1, DOI 10.1038/bjc.1997.328; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Wu WG, 1998, CANCER RES, V58, P4082; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 6	2003	22	50					8063	8071		10.1038/sj.onc.1206976	http://dx.doi.org/10.1038/sj.onc.1206976			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	740LG	14603247				2022-12-17	WOS:000186403400001
J	Nawata, R; Yujiri, T; Nakamura, Y; Ariyoshi, K; Takahashi, T; Sato, Y; Oka, Y; Tanizawa, Y				Nawata, R; Yujiri, T; Nakamura, Y; Ariyoshi, K; Takahashi, T; Sato, Y; Oka, Y; Tanizawa, Y			MEK kinase 1 mediates the antiapoptotic effect of the Bcr-Abl oncogene through NF-kappa B activation	ONCOGENE			English	Article						MEK kinase 1; Bcr-Abl; NF-kappa B	CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASE; DNA-DAMAGE; GENE DISRUPTION; APOPTOSIS; TRANSFORMATION; EXPRESSION; CELLS; JUN; PROTEIN	Bcr-Abl tyrosine kinase, a chimeric oncoprotein responsible for chronic myelogenous leukemia, constitutively activates several signal transduction pathways that stimulate cell proliferation and prevent apoptosis in hematopoietic cells. The antiapoptotic function of Bcr-Abl is necessary for hematopoietic transformation, and also contributes to leukemogenesis. Herein, we show for the first time that cell transformation induced by Bcr-Abl leads to increased expression and kinase activity of MEK kinase 1 (MEKK1), which acts upstream of the c-Jun N-terminal kinase (JNK), extracellular signal regulated kinase (ERK) and NF-kappaB signaling pathways. Inhibition of MEKK1 activity using a dominant-negative MEKK1 mutant (MEKK1km) diminished the ability of Bcr-Abl to protect cells from genotoxin-induced apoptosis, but had no effect on the proliferation of Bcr-Abl-transformed cells. Expression of MEKK1km also reduced NF-kappaB activation, and inhibited antiapoptotic c-IAP1 and c-IAP2 mRNA expression in response to the genotoxin. By contrast, neither JNK nor ERK activation was affected. These results indicate that MEKK1 is a downstream target of Bcr-Abl, and that the antiapoptotic effect of Bcr-Abl in chronic myelogenous leukemia cells is mediated via the MEKK1-NF-kappaB pathway.	Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, Yamaguchi 7558505, Japan; Tohoku Univ, Grad Sch Med, Dept Internal Med, Div Mol Metab & Diabet, Sendai, Miyagi 9808575, Japan	Yamaguchi University; Tohoku University	Yujiri, T (corresponding author), Yamaguchi Univ, Grad Sch Med, Dept Biosignal Anal, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.		Yujiri, Toshiaki/AAY-8150-2020	Yujiri, Toshiaki/0000-0001-6838-3456				Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Christerson LB, 1999, CELL MOTIL CYTOSKEL, V43, P186, DOI 10.1002/(SICI)1097-0169(1999)43:3<186::AID-CM2>3.0.CO;2-1; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Druker BJ, 2002, ONCOGENE, V21, P8541, DOI 10.1038/sj.onc.1206081; Dubrez L, 1998, BLOOD, V91, P2415, DOI 10.1182/blood.V91.7.2415.2415_2415_2422; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Hirano T, 2002, ONCOGENE, V21, P5923, DOI 10.1038/sj.onc.1205643; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; KABAROWSKI JHS, 1994, EMBO J, V13, P5887, DOI 10.1002/j.1460-2075.1994.tb06934.x; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lu ZM, 2002, MOL CELL, V9, P945, DOI 10.1016/S1097-2765(02)00519-1; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; ODA T, 1994, J BIOL CHEM, V269, P22925; Onishi M, 1996, EXP HEMATOL, V24, P324; RAITANO AB, 1995, P NATL ACAD SCI USA, V92, P11746, DOI 10.1073/pnas.92.25.11746; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Salgia R, 1997, J CLIN INVEST, V100, P46, DOI 10.1172/JCI119520; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shuai K, 1996, ONCOGENE, V13, P247; Skorski T, 2002, ONCOGENE, V21, P8591, DOI 10.1038/sj.onc.1206087; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Widmann C, 1998, J BIOL CHEM, V273, P7141, DOI 10.1074/jbc.273.12.7141; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 2003, J BIOL CHEM, V278, P3846, DOI 10.1074/jbc.M206087200; Yujiri T, 1999, J BIOL CHEM, V274, P12605, DOI 10.1074/jbc.274.18.12605; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	38	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 30	2003	22	49					7774	7780		10.1038/sj.onc.1206901	http://dx.doi.org/10.1038/sj.onc.1206901			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	737PD	14586403				2022-12-17	WOS:000186240200007
J	Chen, Y; Kramer, DL; Li, FZ; Porter, CW				Chen, Y; Kramer, DL; Li, FZ; Porter, CW			Loss of inhibitor of apoptosis proteins as a determinant of polyamine analog-induced apoptosis in human melanoma cells	ONCOGENE			English	Article						survivin; apoptosis; DENSPM; IAP; ML-IAP; polyamines; siRNA	CYTOCHROME-C; BACULOVIRAL-INHIBITOR; CANCER-CELLS; IAP PROTEINS; LUNG-CANCER; PHASE-I; SURVIVIN; FAMILY; IDENTIFICATION; EXPRESSION	We have previously shown that the clinically relevant polyamine analog N-1,N-11-diethylnorspermine (DENSPM) causes rapid apoptosis in human melanoma SK-MEL-28 cells via a series of events that include mitochondrial release of cytochrome c and activation of the caspase cascade. Upstream to these events, DENSPM downregulates polyamine biosynthesis and potently upregulates polyamine catabolism at the level of spermidine/spermine All-acetyltransferase (SSAT). In searching for downstream effectors that either contribute to or abrogate the apoptotic response, we observed that DENSPM treatment of SK-MEL-28 cells for 30 h led to cytosolic release of Smac/Diablo, a mitochondrial protein known to bind and inhibit the function of inhibitor of apoptosis proteins (IAPs). Subsequently, we found that DENSPM markedly lowered survivin and ML-IAP protein (but not XIAP) levels by 18 h via an apparently Smac/Diablo-independent pathway. Proteasome inhibitors fully prevented survivin and ML-IAP protein loss as well as apoptosis, suggesting that the proteasome-mediated degradation of survivin and ML-IAP is causally linked to the cellular outcome. We also observed that structural analogs of DENSPM which differentially induced SSAT and apoptosis lowered survivin and ML-IAP levels in a manner that correlated with enzyme activity. The linkage between IAPs and SSAT was more directly established by the finding that selective prevention of SSAT induction by small interfering RNA prevented survivin and ML-IAP loss as well as apoptosis during DENSPM treatment. Among the melanoma cell lines (SK-MEL-28, MALME-3M, A375 and LOX), survivin degradation correlated temporally with the onset of DENSPM induced apoptosis or growth inhibition. By contrast, ML-IAP degradation occurred only during rapid apoptosis seen in SK-MEL-28 cells. These data suggest a sequence of events whereby DENSPM induction of SSAT leads to loss of IAP proteins and a more fulminate apoptotic response. The findings implicate survivin and ML-IAP as important determinants of polyamine analog drug action in melanoma cells.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Buffalo, NY 14263 USA	Roswell Park Cancer Institute	Porter, CW (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Elm & Carlton St, Buffalo, NY 14263 USA.	carl.porter@roswellpark.org			NATIONAL CANCER INSTITUTE [P30CA016056, R01CA022153] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA-22153, CA-16056] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Chen Y, 2001, CANCER RES, V61, P6437; CHEN Y, 2003, IN PRESS CANC RES; CHEN Y, 2003, UNPUB MOL PHARM; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; Creaven PJ, 1997, INVEST NEW DRUG, V15, P227, DOI 10.1023/A:1005827231849; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; FogelPetrovic M, 1996, FEBS LETT, V391, P89, DOI 10.1016/0014-5793(96)00710-7; Hahm HA, 2002, CLIN CANCER RES, V8, P684; Hinds MG, 1999, NAT STRUCT BIOL, V6, P648; Holcik M, 2001, NAT REV MOL CELL BIO, V2, P550, DOI 10.1038/35080103; Kasof GM, 2001, J BIOL CHEM, V276, P3238, DOI 10.1074/jbc.M003670200; Kramer DL, 2001, CANCER RES, V61, P7754; Kramer DL, 1999, CANCER RES, V59, P1278; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Olie RA, 2000, CANCER RES, V60, P2805; PORTER CW, 1991, CANCER RES, V51, P3715; PORTER CW, 1988, ADV ENZYME REGUL, V27, P57; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; SHAPPELL NW, 1992, ANTICANCER RES, V12, P1083; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Streiff RR, 2001, INVEST NEW DRUG, V19, P29, DOI 10.1023/A:1006448516938; Suzuki A, 2000, ONCOGENE, V19, P3225, DOI 10.1038/sj.onc.1203665; Tamm I, 1998, CANCER RES, V58, P5315; Tanaka K, 2000, CLIN CANCER RES, V6, P127; van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vucic D, 2000, CURR BIOL, V10, P1359, DOI 10.1016/S0960-9822(00)00781-8; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Vujcic S, 2003, BIOCHEM J, V370, P19, DOI 10.1042/BJ20021779; Vujcic S, 2002, BIOCHEM J, V367, P665, DOI 10.1042/BJ20020720; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Zhao J, 2000, J CELL SCI, V113, P4363	39	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					4964	4972		10.1038/sj.onc.1206725	http://dx.doi.org/10.1038/sj.onc.1206725			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902979				2022-12-17	WOS:000184578900004
J	Marionnet, C; Lalou, C; Mollier, K; Chazal, M; Delestaing, G; Compan, D; Verola, O; Vilmer, C; Cuminet, J; Dubertret, L; Basset-Seguin, N				Marionnet, C; Lalou, C; Mollier, K; Chazal, M; Delestaing, G; Compan, D; Verola, O; Vilmer, C; Cuminet, J; Dubertret, L; Basset-Seguin, N			Differential molecular profiling between skin carcinomas reveals four newly reported genes potentially implicated in squamous cell carcinoma development	ONCOGENE			English	Article						DNA macroarray; basal cell carcinoma; squamous cell carcinoma	EXPRESSION; CANCER; PATHWAY; CARCINOGENESIS; MUTATIONS; EMMPRIN; RHOC	Basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) are skin tumors with different invasive potential. In this work, we analysed mRNA differential expression between seven BCC and five SCC and their normal skin counterparts using 1176 cDNA macroarrays and verification by RT-PCR to identify genes modulated in each tumor type. We identified 37 genes commonly modulated in both tumors and four genes specifically modulated in SCC. Among these latter RhoC and EMMPRIN genes seem to be of particular interest and could participate in SCC aggressivity.	Hop St Louis, INSERM, U532, Inst Rech Peau, F-75010 Paris, France; Hop St Louis, IRP, Serv Stat, F-75010 Paris, France; Hop St Louis, Serv Anat Pathol, F-75010 Paris, France; Hop St Louis, Serv Chirurg Plast, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Basset-Seguin, N (corresponding author), Hop St Louis, INSERM, U532, Inst Rech Peau, Pavillon Bazin,1 Ave Claude Vellefaux, F-75010 Paris, France.	nbs@chu-stlouis.fr		LALOU, Claude/0000-0002-5271-7439				Asch PH, 1999, AM J DERMATOPATH, V21, P146, DOI 10.1097/00000372-199904000-00006; Bale AE, 2001, HUM MOL GENET, V10, P757, DOI 10.1093/hmg/10.7.757; BISWAS C, 1995, CANCER RES, V55, P434; Bordador LC, 2000, INT J CANCER, V85, P347, DOI 10.1002/(SICI)1097-0215(20000201)85:3<347::AID-IJC9>3.3.CO;2-R; Bos R, 2001, JNCI-J NATL CANCER I, V93, P309, DOI 10.1093/jnci/93.4.309; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Harris CC, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P115; Kallassy M, 1997, CANCER RES, V57, P4731; Klein MG, 1998, EXP CELL RES, V244, P26, DOI 10.1006/excr.1998.4153; Matsuyoshi N, 1997, J INVEST DERMATOL, V108, P908, DOI 10.1111/1523-1747.ep12292703; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Paul R, 1997, BRIT J UROL, V79, P37, DOI 10.1111/j.1464-410X.1997.tb00799.x; PERKINS W, 1992, J CUTAN PATHOL, V19, P476, DOI 10.1111/j.1600-0560.1992.tb01600.x; Ping XL, 2001, J INVEST DERMATOL, V116, P614, DOI 10.1046/j.1523-1747.2001.01301.x; QUINN AG, 1994, CANCER RES, V54, P4756; Ren ZP, 1996, ONCOGENE, V12, P765; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; van Golen KL, 2000, CANCER RES, V60, P5832; Zoumpourlis V, 2000, ONCOGENE, V19, P4011, DOI 10.1038/sj.onc.1203732	21	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3500	3505		10.1038/sj.onc.1206571	http://dx.doi.org/10.1038/sj.onc.1206571			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776202				2022-12-17	WOS:000183128500017
J	Hiwatari, M; Taki, T; Taketani, T; Taniwaki, M; Sugita, K; Okuya, M; Eguchi, M; Ida, K; Hayashi, Y				Hiwatari, M; Taki, T; Taketani, T; Taniwaki, M; Sugita, K; Okuya, M; Eguchi, M; Ida, K; Hayashi, Y			Fusion of an AF4-related gene, LAF4, to MLL in childhood acute lymphoblastic leukemia with t(2;11)(q11;q23)	ONCOGENE			English	Article						LAF4; AF4; AF5Q31; MLL; t(2;11)	ACUTE MYELOID-LEUKEMIA; DROSOPHILA-TRITHORAX; ABNORMALITIES; REARRANGEMENTS; T(4-11); 11Q23; IDENTIFICATION; TRANSLOCATIONS; INVOLVEMENT; FREQUENCY	We showed that the LAF4 gene on 2q11.2-12 was fused to the MLL gene on 11q23 in a pediatric patient with CD10 positive acute lymphoblastic leukemia (ALL) having t(2;11)(q11;q23). The LAF4 gene, which encodes a lymphoid nuclear protein of 1227 amino acids with transactivation potential, is thought to have a role in early lymphoid development. The LAF4 protein was homologous to AF4 and AF5q31 proteins that are fused to MLL in infant early pre-B ALL and the breakpoint of LAF4 was located within the region homologous to the transactivation domain of AF4 and AF5q31. Expression of the 8.5-kb LAF4 transcript was detected in the adult heart, brain, and placenta and in the fetal brain. LAF4 expression was found to be higher in ALL cell lines than in AML and Epstein-Barr virus-transformed B-lymphocyte cell lines. These findings suggest that LAF4, AF4 and AF5q31 might define a new family particularly involved in the pathogenesis of 11q23-associated ALL.	Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Tokyo 1138655, Japan; Kyoto Prefectural Univ Med, Dept Internal Med 3, Kamigyo Ku, Kyoto 6028655, Japan; Dokkyo Univ, Sch Med, Dept Pediat, Mibu, Tochigi 3210293, Japan	University of Tokyo; Kyoto Prefectural University of Medicine; Dokkyo Medical University	Hayashi, Y (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pediat, Bunkyo Ku, Hongo 7-3-1, Tokyo 1138655, Japan.		HIWATARI, Mitsuteru/HDM-0869-2022	Hiwatari, Mitsuteru/0000-0003-3683-4472				Ferrando AA, 2000, SEMIN HEMATOL, V37, P381, DOI 10.1053/shem.2000.16447; Gecz J, 1996, NAT GENET, V13, P105, DOI 10.1038/ng0596-105; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; Gu YH, 1996, NAT GENET, V13, P109, DOI 10.1038/ng0596-109; Hayashi Y, 2000, SEMIN HEMATOL, V37, P368, DOI 10.1016/S0037-1963(00)90017-9; Hayashi Y, 2000, CANCER RES, V60, P1139; Heerema NA, 1999, LEUKEMIA, V13, P679, DOI 10.1038/sj.leu.2401413; HUNGER SP, 1993, BLOOD, V81, P3197; Isnard P, 2000, BLOOD, V96, P705; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Niitsu N, 2001, BRIT J HAEMATOL, V112, P315, DOI 10.1046/j.1365-2141.2001.02523.x; Ono R, 2002, CANCER RES, V62, P333; Pui CH, 2002, LANCET, V359, P1909, DOI 10.1016/S0140-6736(02)08782-2; PUI CH, 1995, NEW ENGL J MED, V332, P1618, DOI 10.1056/NEJM199506153322407; Reichel M, 2001, ONCOGENE, V20, P2900, DOI 10.1038/sj.onc.1204401; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; RUBNITZ JE, 1994, BLOOD, V84, P570; Shibuya N, 2001, GENE CHROMOSOME CANC, V32, P1, DOI 10.1002/gcc.1160; SUPER HJG, 1993, BLOOD, V82, P3705; Taketani T, 2002, CANCER RES, V62, P33; Taki T, 1999, P NATL ACAD SCI USA, V96, P14535, DOI 10.1073/pnas.96.25.14535; Taki T, 1996, LEUKEMIA, V10, P1303; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9	23	36	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 8	2003	22	18					2851	2855		10.1038/sj.onc.1206389	http://dx.doi.org/10.1038/sj.onc.1206389			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FJ	12743608				2022-12-17	WOS:000182569300016
J	Stockl, L; Berting, A; Malkowski, B; Foerste, R; Hofschneider, PH; Hildt, E				Stockl, L; Berting, A; Malkowski, B; Foerste, R; Hofschneider, PH; Hildt, E			Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression	ONCOGENE			English	Article						hepatitis B virus; transactivation; replication; antivirals	NF-KAPPA-B; PROTEIN-KINASE-C; HBX PROTEIN; X-PROTEIN; TRANSCRIPTIONAL ACTIVATOR; REPLICATION; RAS; IDENTIFICATION; PATHWAYS	The genome of hepatitis B virus (HBV) encodes two transcriptional activators: the HBx protein and the PreS2-activator large surface protein (LHBs). Both proteins trigger activation of c-Raf-1/MEK kinase cascade. In case of HBx this can be mediated by a PKC-independent and Ras-dependent mechanism, in case of LHBs activation is PKC-dependent and does not require Ras. Selective destruction of either LHBs- or of HBx-specific activation does not result in significant decrease of viral production from transfected HepG2 cells. Simultaneous inhibition of LHBs- and HBx-dependent activation by blocking signaling steps common to both activators, using trans dominant negative c-Raf-1- or MEK-specific inhibitors, abolished HBV gene expression. In accordance with this no HBV propagation was observed after transfection of a mutated HBV genome defective for HBx- and PreS2-activator function. A detailed analysis revealed that the observed inhibition of HBV- propagation is because of a significant reduction of HBV-specific RNA resulting in an inhibition of the de novo synthesis of viral compounds (viral proteins and nucleic acid) and not by blocking secretion or assembly of the virus. Based on these results we conclude that transcriptional-activator function, mediated by the c-Raf-1/MEK signaling cascade, is essential for HBV gene expression.	Robert Koch Inst, D-13353 Berlin, Germany; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Robert Koch Institute; Max Planck Society	Hildt, E (corresponding author), Robert Koch Inst, Nordufer 20, D-13353 Berlin, Germany.		Małkowski, Bogdan/H-7131-2014; Hildt, Eberhard/A-1040-2015	Małkowski, Bogdan/0000-0001-6092-2283; 				Andrisani OM, 1999, INT J ONCOL, V15, P373; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BRUSS V, 1994, EMBO J, V13, P2273, DOI 10.1002/j.1460-2075.1994.tb06509.x; HEERMANN KH, 1984, J VIROL, V52, P396, DOI 10.1128/JVI.52.2.396-402.1984; Hildt E, 1996, VIROLOGY, V225, P235, DOI 10.1006/viro.1996.0594; HILDT E, 1995, ONCOGENE, V11, P2055; Hildt E, 1998, RECENT RES CANCER, V154, P315; Hildt E, 2002, EMBO J, V21, P525, DOI 10.1093/emboj/21.4.525; Hildt E, 1999, J EXP MED, V189, P1707, DOI 10.1084/jem.189.11.1707; KEKULE AS, 1990, NATURE, V343, P457, DOI 10.1038/343457a0; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MURAKAMI S, 1994, VIROLOGY, V199, P243, DOI 10.1006/viro.1994.1119; Oess S, 2000, GENE THER, V7, P750, DOI 10.1038/sj.gt.3301154; Pleschka S, 2001, NAT CELL BIOL, V3, P301, DOI 10.1038/35060098; Sambrook J, 1989, MOL CLONING LAB MANU; SCHRECK R, 1992, J VIROL, V66, P6288, DOI 10.1128/JVI.66.11.6288-6293.1992; Su F, 2001, J VIROL, V75, P215, DOI 10.1128/JVI.75.1.215-225.2001; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; Weiss L, 1996, VIROLOGY, V216, P214, DOI 10.1006/viro.1996.0049; WOLLERSHEIM M, 1988, ONCOGENE, V3, P545; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	26	36	41	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 1	2003	22	17					2604	2610		10.1038/sj.onc.1206320	http://dx.doi.org/10.1038/sj.onc.1206320			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	673FF	12730674				2022-12-17	WOS:000182569000008
J	Abdulkarim, B; Sabri, S; Zelenika, D; Deutsch, E; Frascogna, V; Klijanienko, J; Vainchenker, W; Joab, I; Bourhis, J				Abdulkarim, B; Sabri, S; Zelenika, D; Deutsch, E; Frascogna, V; Klijanienko, J; Vainchenker, W; Joab, I; Bourhis, J			Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies	ONCOGENE			English	Article						cidofovir; ionizing radiation; EBV-associated cancer; oncoproteins; apoptosis	LATENT MEMBRANE-PROTEIN; LYMPHOMA CELL-LINE; HUMAN-IMMUNODEFICIENCY-VIRUS; IMMEDIATE-EARLY GENES; IMMORTALIZED B-CELLS; NASOPHARYNGEAL CARCINOMA; HUMAN-PAPILLOMAVIRUS; BCL-2 EXPRESSION; BURKITT-LYMPHOMA; KAPPA-B	The Epstein-Barr virus (EBV) is involved in the carcinogenesis of several human cancers such as nasopharyngeal carcinoma (NPC) and Burkitt lymphoma (BL). Given the consistent role of EBV in transformation and maintenance of malignant phenotype, antiviral strategies provide an attractive approach to target EBV-expressing cells. In that aim, we have tested the Cidofovir, which is an acyclic nucleoside phosphonate analog known to exert an antiproliferative activity in some human virus-related tumors. Here, we show that Cidofovir induces a downregulation of the EBV oncoprotein LMP1 associated with a decrease of the antiapoptotic Bcl-2 and an increase of the proapoptotic Bax protein in Raji (BL) and C15 (NPC) cells. Using BL cell line BL2 B95-8 (BL2 infected with the B95.8 strain of EBV), we addressed the relation between EBV genome expression and modulation of viral oncoproteins by Cidofovir and/or ionizing radiation (IR). Cidofovir was able to significantly reduce LMP1 and EBNA2 mRNA and protein expression. This effect was associated with inhibition of proliferation, stimulation of apoptosis, and decrease of Bcl-2 expression in BL2 B95.8 cells. In addition, Cidofovir enhanced the radiation-induced apoptosis and the radiosensitivity through the proteolytic cleavage of death effectors caspase-9 and -3, which was specifically induced by combined treatment in EBV-positive cells compared to their negative counterparts. Furthermore, the combined treatment in nude mice led to a complete tumor remission without increasing toxicity in two human EBV-related cancer xenografts (Raji and C15). These results provide the basis for a novel anticancer strategy to enhance the therapeutic ratio of IR in EBV-related cancers.	Inst Gustave Roussy, Lab Radiosensibil Tumeurs & Tissus Sains, UPRESEA 27 10, F-94805 Villejuif, France; Inst Curie, Paris, France; Hop St Louis, Inst Mol Genet, Paris, France	UNICANCER; Gustave Roussy; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite	Bourhis, J (corresponding author), Inst Gustave Roussy, Lab Radiosensibil Tumeurs & Tissus Sains, UPRESEA 27 10, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	bourhis@igr.fr	Sabri, Siham/K-1101-2015	Sabri, Siham/0000-0001-5792-689X; Vainchenker, William/0000-0003-4705-202X; Bourhis, Jean/0000-0001-5162-1171; deutsch, eric/0000-0002-8223-3697				ABBOT SD, 1990, J VIROL, V64, P2126, DOI 10.1128/JVI.64.5.2126-2134.1990; Abdulkarim B, 2002, ONCOGENE, V21, P2334, DOI 10.1038/sj.onc.1205006; Abdulkarim B, 2001, LANCET ONCOL, V2, P622, DOI 10.1016/S1470-2045(01)00520-4; BALZARINI J, 1991, BIOCHEM BIOPH RES CO, V178, P329, DOI 10.1016/0006-291X(91)91818-W; BUSSON P, 1988, INT J CANCER, V42, P599, DOI 10.1002/ijc.2910420422; Chung YL, 2000, CLIN CANCER RES, V6, P1452; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DECLERCQ E, 1986, NATURE, V323, P464, DOI 10.1038/323464a0; Eliopoulos AG, 1999, J VIROL, V73, P1023, DOI 10.1128/JVI.73.2.1023-1035.1999; Eliopoulos AG, 2001, SEMIN CANCER BIOL, V11, P435, DOI 10.1006/scbi.2001.0410; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; Fagard R, 2002, ONCOGENE, V21, P4473, DOI 10.1038/sj.onc.1205554; FAHRAEUS R, 1988, INT J CANCER, V42, P329, DOI 10.1002/ijc.2910420305; FAHRAEUS R, 1990, P NATL ACAD SCI USA, V87, P7390, DOI 10.1073/pnas.87.19.7390; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; GREGORY CD, 1991, NATURE, V349, P612, DOI 10.1038/349612a0; Griffin B E, 2000, Mutat Res, V462, P395, DOI 10.1016/S1383-5742(00)00028-4; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Johnson JA, 1999, ANTIMICROB AGENTS CH, V43, P1198, DOI 10.1128/AAC.43.5.1198; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; Kieff E., 1996, FIELDS VIROLOGY, P2343; KLEIN G, 1975, INTERVIROLOGY, V5, P319, DOI 10.1159/000149930; Komano J, 1998, J VIROL, V72, P9150, DOI 10.1128/JVI.72.11.9150-9156.1998; LAHERTY CD, 1992, J BIOL CHEM, V267, P24157; Morgan MB, 1999, TUMOR TARGET, V4, P278; MURRAY RJ, 1988, J VIROL, V62, P3747, DOI 10.1128/JVI.62.10.3747-3755.1988; Neyts J, 1998, CANCER RES, V58, P384; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; PRASAD AV, 1995, RADIAT RES, V143, P263, DOI 10.2307/3579212; ROTH G, 1994, BLOOD, V84, P582, DOI 10.1182/blood.V84.2.582.bloodjournal842582; ROWE M, 1987, EMBO J, V6, P2743, DOI 10.1002/j.1460-2075.1987.tb02568.x; SHIBATA D, 1992, AM J PATHOL, V140, P769; SINCLAIR AJ, 1994, EMBO J, V13, P3321, DOI 10.1002/j.1460-2075.1994.tb06634.x; SUNG NS, 1991, J VIROL, V65, P2164, DOI 10.1128/JVI.65.5.2164-2169.1991; WANG F, 1990, J VIROL, V64, P3407, DOI 10.1128/JVI.64.7.3407-3416.1990; WEICHSELBAUM RR, 1994, INT J RADIAT ONCOL, V30, P229, DOI 10.1016/0360-3016(94)90539-8; WEISS LM, 1989, NEW ENGL J MED, V320, P502, DOI 10.1056/NEJM198902233200806; Westphal EM, 2000, CANCER RES, V60, P5781; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G	43	36	43	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2260	2271		10.1038/sj.onc.1206402	http://dx.doi.org/10.1038/sj.onc.1206402			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700662				2022-12-17	WOS:000182231500005
J	Sugano, Y; Matsuzaki, K; Tahashi, Y; Furukawa, F; Mori, S; Yamagata, H; Yoshida, K; Matsushita, M; Nishizawa, M; Fujisawa, J; Inoue, K				Sugano, Y; Matsuzaki, K; Tahashi, Y; Furukawa, F; Mori, S; Yamagata, H; Yoshida, K; Matsushita, M; Nishizawa, M; Fujisawa, J; Inoue, K			Distortion of autocrine transforming growth factor beta signal accelerates malignant potential by enhancing cell growth as well as PAI-1 and VEGF production in human hepatocellular carcinoma cells	ONCOGENE			English	Article						TGF-beta; Smad; HCC; PAI-1; VEGF	PLASMINOGEN-ACTIVATOR INHIBITOR-1; TGF-BETA; HEPATOMA-CELLS; GENE-MUTATIONS; CANCER; UROKINASE; EXPRESSION; RECEPTOR; LIVER; SMAD2	Resistance to growth inhibitory effects of transforming growth factor (TGF)-beta is a frequent consequence of malignant transformation. On the other hand, serum concentrations of TGF-beta, plasminogen activator inhibitor type 1 (PAI-1), and vascular endothelial growth factor (VEGF) are elevated as tumor progresses. The molecular mechanism of autocrine TGF-beta signaling and its effects on PAI-1 and VEGF production in human hepatocellular carcinoma (HCC) is unknown. TGF-beta signaling involves TGF-beta type I receptor-mediated phosphorylation of serine residues within the conserved SSXS motif at the C-terminus of Smad2 and Smad3. To investigate the involvement of autocrine TGF-beta signal in cell growth, PAI-1 and VEGF production of HCC, we made stable transfectants of human HCC line (HuH-7 cells) to express a mutant Smad2(3S-A), in which serine residues of SSXS motif were changed to alanine. The transfectants demonstrated an impaired Smad2 signaling. Along with the resistance to growth inhibition by TGF-beta, forced expression of Smad2(3S-A) induced endogenous TGF-beta secretion. Moreover, this increased TGF-beta enhanced ligand-dependent signaling through the activated Smad3 and Smad4 complex, and transcriptional activities of PAI-1 and VEGF genes. In conclusion, distortion of autocrine TGF-beta signals in human HCC accelerates their malignant potential by enhancing cell growth as well as PAI-1 and VEGF production.	Dept Internal Med 3, Moriguchi, Osaka 5708507, Japan; Dept Med Chem, Moriguchi, Osaka 5708507, Japan; Kansai Med Univ, Dept Microbiol, Moriguchi, Osaka 5708507, Japan	Kansai Medical University	Matsuzaki, K (corresponding author), Dept Internal Med 3, 10-15 Fumizonocho, Moriguchi, Osaka 5708507, Japan.	matsuzak@takii.kmu.ac.jp						Abelev G I, 1971, Adv Cancer Res, V14, P295, DOI 10.1016/S0065-230X(08)60523-0; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Date M, 1998, J HEPATOL, V28, P572, DOI 10.1016/S0168-8278(98)80280-8; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; Engel ME, 1998, J CELL BIOCHEM, P111; Fan GS, 1996, ONCOGENE, V12, P1909; Feng XH, 2000, EMBO J, V19, P5178, DOI 10.1093/emboj/19.19.5178; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Gutierrez LS, 2000, CANCER RES, V60, P5839; HEALY AM, 1994, J BIOL CHEM, V269, P19095; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Matsuzaki K, 2000, CANCER RES, V60, P1394; Matsuzaki K, 2000, HEPATOLOGY, V32, P218, DOI 10.1053/jhep.2000.9145; MATSUZAKI K, 1990, JPN J CANCER RES, V81, P345, DOI 10.1111/j.1349-7006.1990.tb02574.x; Mise M, 1996, HEPATOLOGY, V23, P455; Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642; Miyazono K, 2001, J CELL PHYSIOL, V187, P265, DOI 10.1002/jcp.1080; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; PEDERSEN H, 1994, CANCER RES, V54, P120; PEDERSEN H, 1994, CANCER RES, V54, P4671; Piek E, 2001, ADV CANCER RES, V83, P1, DOI 10.1016/S0065-230X(01)83001-3; Prunier C, 2001, MOL CELL BIOL, V21, P3302, DOI 10.1128/MCB.21.10.3302-3313.2001; Riggins GJ, 1997, CANCER RES, V57, P2578; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; SHIRAI Y, 1994, CANCER, V73, P2275, DOI 10.1002/1097-0142(19940501)73:9<2275::AID-CNCR2820730907>3.0.CO;2-T; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yakicier MC, 1999, ONCOGENE, V18, P4879, DOI 10.1038/sj.onc.1202866; YAMANAKA N, 1990, CANCER, V65, P1104, DOI 10.1002/1097-0142(19900301)65:5<1104::AID-CNCR2820650511>3.0.CO;2-G; Zhang Y, 1999, TRENDS CELL BIOL, V9, P274, DOI 10.1016/S0962-8924(99)01579-2; Zhou L, 2000, PATHOL INT, V50, P392, DOI 10.1046/j.1440-1827.2000.01059.x	36	36	41	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2003	22	15					2309	2321		10.1038/sj.onc.1206305	http://dx.doi.org/10.1038/sj.onc.1206305			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	667KV	12700666				2022-12-17	WOS:000182231500009
J	Katata, T; Irie, K; Fukuhara, A; Kawakatsu, T; Yamada, A; Shimizu, K; Takai, Y				Katata, T; Irie, K; Fukuhara, A; Kawakatsu, T; Yamada, A; Shimizu, K; Takai, Y			Involvement of nectin in the localization of IQGAP1 at the cell-cell adhesion sites through the actin cytoskeleton in Madin-Darby canine kidney cells	ONCOGENE			English	Article						nectin; IQGAP1; cadherin; adherens junctions; actin	SIMPLEX VIRUS TYPE-1; POLIOVIRUS RECEPTOR GENE; RASGAP-RELATED PROTEIN; ALPHA-CATENIN; CYTOPLASMIC DOMAIN; JUNCTIONAL COMPLEX; EPITHELIAL-CELLS; SMALL GTPASES; MOLECULE UVOMORULIN; ADHERENS JUNCTION	IQGAP1, a putative downstream target of the Rho family small G proteins, Cdc42 and Rac, localizes at adherens junctions (AJs) in epithelial cells. It has been suggested that IQGAP1 localizes at AJs through its binding to beta-catenin, and negatively regulates the E-cadherin-mediated cell-cell adhesion. Nectin is a Ca2+-independent, immunoglobulin-like cell-cell adhesion molecule that localizes at AJs. Nectin is associated with E-cadherin through their respective cytoplasmic tail-binding proteins, afadin and catenins, and involved in the formation of AJs cooperatively with E-cadherin. Here we investigated a role of nectin in the localization of IQGAP1 at AJs. Ca2+ chelation from the medium causes disruption of the E-cadherin-mediated cell-cell adhesion, but not the nectin-based cell-cell adhesion, in Madin-Darby canine kidney (MDCK) cells. IQGAP1 remained at the residual nectin-based cell-cell adhesion sites where the E-cadherin immunofluorescence signal disappeared. Restoration of Ca2+ in the medium causes re-accumulation of E-cadherin to the residual pectin-based cell-cell adhesion sites to reform AJs. Nectin inhibitors inhibit this re-accumulation of E-cadherin to re-form AJs by impairing the pectin-based cell-cell adhesion. The nectin inhibitors also reduced the localization of IQGAP1 at the cell-cell adhesion sites. When MDCK cells were incubated with microbeads coated with the extracellular fragment of nectin that interacts with cellular nectin, IQGAP1 also accumulated at the bead-MDCK cell contact sites. The accumulation of IQGAP1 at the cell-cell adhesion sites was inhibited by actin filament-disrupting agents, latrunculin A and cytochalasin D. These results indicate that nectin is involved in the localization of IQGAP1 at AJs through the actin cytoskeleton.	Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Fukuhara, Atsunori/A-9601-2018	Fukuhara, Atsunori/0000-0002-6289-3778				AOKI J, 1994, J BIOL CHEM, V269, P8431; Asakura T, 1999, GENES CELLS, V4, P573, DOI 10.1046/j.1365-2443.1999.00283.x; Bashour AM, 1997, J CELL BIOL, V137, P1555, DOI 10.1083/jcb.137.7.1555; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Campadelli-Fiume G, 2000, REV MED VIROL, V10, P305, DOI 10.1002/1099-1654(200009/10)10:5<305::AID-RMV286>3.0.CO;2-T; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Erickson JW, 1997, J BIOL CHEM, V272, P24443, DOI 10.1074/jbc.272.39.24443; Fukata M, 1999, J CELL SCI, V112, P4491; Fukata M, 2001, MOL CELL BIOL, V21, P2165, DOI 10.1128/MCB.21.6.2165-2183.2001; Fukuhara A, 2002, ONCOGENE, V21, P7642, DOI 10.1038/sj.onc.1205875; Fukuhara A, 2002, GENES CELLS, V7, P1059, DOI 10.1046/j.1365-2443.2002.00578.x; GEIGER B, 1991, CELL MOTIL CYTOSKEL, V20, P1, DOI 10.1002/cm.970200102; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hart MJ, 1996, EMBO J, V15, P2997, DOI 10.1002/j.1460-2075.1996.tb00663.x; HONDA T, 2003, IN PRESS GENES CELLS; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kawakatsu T, 2002, J BIOL CHEM, V277, P50749, DOI 10.1074/jbc.M209846200; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kuroda S, 1996, J BIOL CHEM, V271, P23363, DOI 10.1074/jbc.271.38.23363; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li ZG, 1999, J BIOL CHEM, V274, P37885, DOI 10.1074/jbc.274.53.37885; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; Lopez M, 2000, J VIROL, V74, P1267, DOI 10.1128/JVI.74.3.1267-1274.2000; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Machesky LM, 1998, CURR BIOL, V8, pR202, DOI 10.1016/S0960-9822(98)70125-3; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; McCallum SJ, 1996, J BIOL CHEM, V271, P21732, DOI 10.1074/jbc.271.36.21732; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; Mizoguchi A, 2002, J CELL BIOL, V156, P555, DOI 10.1083/jcb.200103113; Momose Y, 2002, BIOCHEM BIOPH RES CO, V293, P45, DOI 10.1016/S0006-291X(02)00183-3; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nakagawa M, 2001, J CELL SCI, V114, P1829; Nishioka H, 2000, J COMP NEUROL, V424, P297, DOI 10.1002/1096-9861(20000821)424:2<297::AID-CNE8>3.0.CO;2-J; Ozaki-Kuroda K, 2002, CURR BIOL, V12, P1145, DOI 10.1016/S0960-9822(02)00922-3; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PRASAD R, 1993, CANCER RES, V53, P5624; Reymond N, 2001, J BIOL CHEM, V276, P43205, DOI 10.1074/jbc.M103810200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Sakisaka T, 2001, J VIROL, V75, P4734, DOI 10.1128/JVI.75.10.4734-4743.2001; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; Spear PG, 2000, VIROLOGY, V275, P1, DOI 10.1006/viro.2000.0529; Swart-Mataraza JM, 2002, J BIOL CHEM, V277, P24753, DOI 10.1074/jbc.M111165200; Tachibana K, 2000, J CELL BIOL, V150, P1161, DOI 10.1083/jcb.150.5.1161; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; Takai Y, 2003, J CELL SCI, V116, P17, DOI 10.1242/jcs.00167; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; WEISSBACH L, 1994, J BIOL CHEM, V269, P20517; Yagi T, 2000, GENE DEV, V14, P1169; Yokoyama S, 2001, MOL BIOL CELL, V12, P1595, DOI 10.1091/mbc.12.6.1595	64	36	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 10	2003	22	14					2097	2109		10.1038/sj.onc.1206255	http://dx.doi.org/10.1038/sj.onc.1206255			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	664NJ	12687012				2022-12-17	WOS:000182066900004
J	Zhang, B; Potyagaylo, V; Fenton, RG				Zhang, B; Potyagaylo, V; Fenton, RG			IL-6-independent expression of Mcl-1 in human multiple myeloma	ONCOGENE			English	Article						Mcl-1; apoptosis; multiple myeloma; gene expression; IL-6	CHRONIC LYMPHOCYTIC-LEUKEMIA; ACTIVATED PROTEIN-KINASES; IN-VIVO; PLASMA-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; DRUG-RESISTANCE; BCL2 FAMILY; APOPTOSIS; SURVIVAL; GENE	Mcl-1 is a critical antiapoptotic survival factor for human multiple myeloma (MM). We examined the importance of IL-6 for Mcl-1 expression in five MM cell lines and in primary MM cells from 14 patients. While culture of MM.1S cells in IL-6 did induce Mcl-1 expression, four other MM cell lines exhibited high levels of Mcl-1 expression that were unaffected by IL-6. Similarly, Mcl-1 expression in 10 of 14 primary MM isolates was found to be IL-6-independent. An analysis of the mechanisms responsible for IL-6-independent Mcl-1 expression was undertaken. ERK1/2 activity did not influence Mcl-1 expression, distinct from Mcl-1 regulation that occurs during myeloid differentiation from hematopoietic progenitor cells. Inhibition of the PI3K pathway led to growth inhibition of 8226 and ANBL-6 cells without reduction of Mcl-1 levels, and high level Mcl-1 expression was maintained in the absence of activated STAT3. Analysis of the transcriptional activity of 5-regulatory sequences from the human Mcl-1 gene in MM cells demonstrated high levels of IL-6-independent indicator gene activation as predicted. These data demonstrate that the mechanisms regulating Mcl-1 levels in MM cells are heterogeneous, and are often independent from IL-6 signaling pathways.	Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Fenton, RG (corresponding author), Univ Maryland, Greenebaum Canc Ctr, Bressler Res Bldg,Rm 7-023,655 W Baltimore St, Baltimore, MD 21201 USA.	rfent001@umaryland.edu						Akgul C, 2000, FEBS LETT, V478, P72, DOI 10.1016/S0014-5793(00)01809-3; Akgul C, 2000, CELL MOL LIFE SCI, V57, P684, DOI 10.1007/PL00000728; Alcalay M, 2001, ONCOGENE, V20, P5680, DOI 10.1038/sj.onc.1204642; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bergsagel PL, 2001, ONCOGENE, V20, P5611, DOI 10.1038/sj.onc.1204641; Bergsagel PL, 1996, P NATL ACAD SCI USA, V93, P13931, DOI 10.1073/pnas.93.24.13931; Bright JJ, 1999, J IMMUNOL, V162, P6255; Calame KL, 2001, NAT IMMUNOL, V2, P1103, DOI 10.1038/ni1201-1103; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chao JR, 1998, MOL CELL BIOL, V18, P4883, DOI 10.1128/MCB.18.8.4883; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Craig RW, 2002, LEUKEMIA, V16, P444, DOI 10.1038/sj.leu.2402416; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Epling-Burnette PK, 2001, J IMMUNOL, V166, P7486, DOI 10.4049/jimmunol.166.12.7486; Fonseca R, 1999, HEMATOL ONCOL CLIN N, V13, P1169, DOI 10.1016/S0889-8588(05)70119-2; Gauthier ER, 1996, CANCER RES, V56, P1451; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Gojo I, 2002, CLIN CANCER RES, V8, P3527; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hallek M, 1998, BLOOD, V91, P3, DOI 10.1182/blood.V91.1.3.3_3_21; Halloran PJ, 1998, CANCER RES, V58, P3855; HANADA M, 1993, BLOOD, V82, P1820; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Huang HM, 2000, BLOOD, V96, P1764, DOI 10.1182/blood.V96.5.1764.h8001764_1764_1771; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Jelinek DF, 1997, J IMMUNOL, V159, P487; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jourdan M, 2000, CELL DEATH DIFFER, V7, P1244, DOI 10.1038/sj.cdd.4400758; Kaufmann SH, 1998, BLOOD, V91, P991, DOI 10.1182/blood.V91.3.991.991_991_1000; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kitada S, 2000, BLOOD, V96, P393; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; Liu HT, 2001, J EXP MED, V194, P113, DOI 10.1084/jem.194.2.113; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; McConkey DJ, 1996, J IMMUNOL, V156, P2624; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Metcalf D, 1998, STEM CELLS, V16, P314, DOI 10.1002/stem.160314; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Miguel-Garcia A, 1998, HAEMATOLOGICA, V83, P298; Moulding DA, 2000, BLOOD, V96, P1756, DOI 10.1182/blood.V96.5.1756.h8001756_1756_1763; ONG F, 1995, LEUKEMIA, V9, P1282; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; Pepper C, 1996, BRIT J HAEMATOL, V95, P513, DOI 10.1046/j.1365-2141.1996.d01-1927.x; Puthier D, 1999, LEUKEMIA, V13, P289, DOI 10.1038/sj.leu.2401302; Puthier D, 1999, BRIT J HAEMATOL, V107, P392, DOI 10.1046/j.1365-2141.1999.01705.x; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAGHOEBIER S, 1991, BLOOD, V77, P1560; Rajkumar SV, 1999, HEMATOL ONCOL CLIN N, V13, P1295, DOI 10.1016/S0889-8588(05)70128-3; REED JC, 1995, HEMATOL ONCOL CLIN N, V9, P451, DOI 10.1016/S0889-8588(18)30104-7; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; ROWLEY JD, 1988, J CLIN ONCOL, V6, P919, DOI 10.1200/JCO.1988.6.5.919; Schimmer AD, 2001, BLOOD, V98, P3541, DOI 10.1182/blood.V98.13.3541; Schubert KM, 2001, BIOCHEM J, V356, P473, DOI 10.1042/0264-6021:3560473; Slifka MK, 1998, IMMUNITY, V8, P363, DOI 10.1016/S1074-7613(00)80541-5; Sordet O, 1999, CELL DEATH DIFFER, V6, P351, DOI 10.1038/sj.cdd.4400499; Thomas A, 1996, ONCOGENE, V12, P1055; Townsend KJ, 1999, J BIOL CHEM, V274, P1801, DOI 10.1074/jbc.274.3.1801; Tricot G, 1997, J CLIN ONCOL, V15, P2659, DOI 10.1200/JCO.1997.15.7.2659; Tu YP, 1998, CANCER RES, V58, P256; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745; Zhang B, 2002, J CELL PHYSIOL, V193, P42, DOI 10.1002/jcp.10148; Zhang B, 2002, BLOOD, V99, P1885, DOI 10.1182/blood.V99.6.1885; Zhou P, 2001, BLOOD, V97, P3902, DOI 10.1182/blood.V97.12.3902	68	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2003	22	12					1848	1859		10.1038/sj.onc.1206358	http://dx.doi.org/10.1038/sj.onc.1206358			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	657QQ	12660820				2022-12-17	WOS:000181678200011
J	Kobayashi, M; Iwamatsu, A; Shinohara-Kanda, A; Ihara, S; Fukui, Y				Kobayashi, M; Iwamatsu, A; Shinohara-Kanda, A; Ihara, S; Fukui, Y			Activation of ErB3-PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas	ONCOGENE			English	Article						ErbB3; phosphatidylinositol 3-kinase; signet-ring cell carcinoma; gastric cancer; mucin	EPIDERMAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; GASTRIC-CARCINOMA; CELL-ADHESION; EGF RECEPTOR; KINASE; EXPRESSION; CANCER; ERBB3; PROTEINS	Signet-ring cell carcinomas are malignant dedifferentiated carcinomas, which are frequently found in the stomach. We previously demonstrated that a 200 kDa protein is often constitutively phosphorylated on tyrosine and bound to phosphatidylinositol 3-kinase (PI3-kinase) in signet-ring cell carcinoma cells. In this study, we purified the 200 kDa protein from an extract of NUGC-4 cells, a cell line of signet-ring cell carcinoma, and identified it as ErbB3. ErbB3 was found to be phosphorylated selectively in dedifferentiated adenocarcinoma cell lines among various gastric cancer cell lines. Expression of a constitutively active chimeric receptor consisting of ErbB2 and ErbB3 in HCC2998 cells, a highly differentiated adenocarcinoma cell line, revealed that the signaling triggered by phosphorylation of ErbB3 was important for dedifferentiated phenotypes such as loss of cell-cell interaction and high expression of MUC1/DF3 antigen, a marker of the malignant tumors. Taken together, activation of ErbB3 pathway may contribute to the development of dedifferentiated carcinomas.	Univ Tokyo, Fac Agr & Life Sci, Dept Appl Biol Chem, Biol Chem Lab,Bunkyo Ku, Tokyo 1138657, Japan; Kirin Brewery Co Ltd, Cent Labs Key Technol, Yokohama, Kanagawa 2360004, Japan	University of Tokyo; Kirin Brewery Company Limited	Fukui, Y (corresponding author), Univ Tokyo, Fac Agr & Life Sci, Dept Appl Biol Chem, Biol Chem Lab,Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.		Fukui, Yasuhisa/E-8806-2010					Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chen XM, 2000, BIOCHEM BIOPH RES CO, V277, P757, DOI 10.1006/bbrc.2000.3731; Guddo F, 1998, ANTICANCER RES, V18, P1915; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Isogaki J, 1999, CANCER DETECT PREV, V23, P204, DOI 10.1046/j.1525-1500.1999.99020.x; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KIM HH, 1994, J BIOL CHEM, V269, P24747; Klippel A, 1997, MOL CELL BIOL, V17, P338, DOI 10.1128/MCB.17.1.338; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Kondo K, 1998, CANCER RES, V58, P2014; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; LAVAN BE, 1992, J BIOL CHEM, V267, P11631; Levkowitz G, 1996, ONCOGENE, V12, P1117; Ma YY, 2000, ONCOGENE, V19, P2739, DOI 10.1038/sj.onc.1203597; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; PETER MS, 1999, EMBO J, V18, P2149; Sakaguchi T, 1998, CANCER-AM CANCER SOC, V82, P1238, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1238::AID-CNCR5>3.0.CO;2-B; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; TAHARA E, 1993, J CANCER RES CLIN, V119, P265, DOI 10.1007/BF01212724; Tanaka K, 1999, BIOSCI BIOTECH BIOCH, V63, P368, DOI 10.1271/bbb.63.368; TANAKA S, 1993, JPN J CANCER RES, V84, P279, DOI 10.1111/j.1349-7006.1993.tb02868.x; TOKUNAGA A, 1995, CANCER, V75, P1418, DOI 10.1002/1097-0142(19950315)75:6+<1418::AID-CNCR2820751505>3.0.CO;2-Y; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; Waterman H, 1999, EMBO J, V18, P3348, DOI 10.1093/emboj/18.12.3348; WONGSASANT B, 1991, BIOCHEM BIOPH RES CO, V181, P981, DOI 10.1016/0006-291X(91)92033-G; YANAGIHARA K, 1992, CANCER RES, V52, P4042; Zhang K, 1996, J BIOL CHEM, V271, P3884	36	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 6	2003	22	9					1294	1301		10.1038/sj.onc.1206256	http://dx.doi.org/10.1038/sj.onc.1206256			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	652CA	12618754				2022-12-17	WOS:000181360900003
J	Zeng, PY; Rane, N; Du, W; Chintapalli, J; Prendergast, GC				Zeng, PY; Rane, N; Du, W; Chintapalli, J; Prendergast, GC			Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors	ONCOGENE			English	Article						Ras; Rac; Rho; actin	INFLAMMATORY BREAST-CANCER; PROTEIN-KINASE; RAS TRANSFORMATION; SMALL GTPASE; N-RAS; ACTIVATION; MECHANISM; PRENYLATION; APOPTOSIS; REVERSION	Recent genetic investigations have established that RhoB gain-of-function is sufficient to mediate the antitransforming effects of farnesyltransferase inhibitors (FTIs) in H-Ras-transformed fibroblast systems. In this study, we addressed the breadth and mechanism of RhoB action in epithelial cells transformed by oncoproteins which are themselves insensitive to FTI inactivation. Rat intestinal epithelial (RIE) cells transformed by activated K-Ras or Rac1 were highly sensitive to FTI-induced actin reorganization and growth inhibition, despite the inability of FTI to block prenylation of either K-Ras or Rac1. Ectopic expression of the geranylgeranylated RhoB isoform elicited in cells by FTI treatment phenocopied these effects. Analysis of RhoB effector domain mutants pointed to a role for PRK, a Rho effector kinase implicated in the physiological function of RhoB in intracellular receptor trafficking, and these findings were supported further by experiments in a fibroblast system. We propose that FTIs recruit the antioncogenic RhoB protein in the guise of RhoB-GG to interfere with signaling by pro-oncogenic Rho proteins, possibly by sequestering common exchange factors or effectors such as PRK that are important for cell transformation.	Lankenau Inst Med Res, Wynnewood, PA 19096 USA; DuPont Pharmaceut Co, Glenolden Lab, Canc Res Grp, Glenolden, PA USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Thomas Jefferson Univ, Jefferson Med Sch, Dept Pathol Anat & Cell Biol, Philadelphia, PA 19107 USA	Lankenau Medical Center; Lankenau Institute for Medical Research; DuPont; The Wistar Institute; Jefferson University	Prendergast, GC (corresponding author), Lankenau Inst Med Res, 100 Lancaster Ave, Wynnewood, PA 19096 USA.	prendergastg@mlhs.org			NATIONAL CANCER INSTITUTE [R01CA082222] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA082222, CA82222] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Balendran A, 1999, CURR BIOL, V9, P393, DOI 10.1016/S0960-9822(99)80186-9; Cox AD, 2001, DRUGS, V61, P723, DOI 10.2165/00003495-200161060-00002; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Du W, 1999, CANCER RES, V59, P2059; Du W, 1999, MOL CELL BIOL, V19, P1831; Du W, 1999, CANCER RES, V59, P4208; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Gampel A, 1999, CURR BIOL, V9, P955, DOI 10.1016/S0960-9822(99)80422-9; HAWLEY RG, 1994, GENE THER, V1, P136; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Koh H, 2000, J BIOL CHEM, V275, P34451, DOI 10.1074/jbc.M001753200; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHL NE, 1995, NAT MED, V1, P792, DOI 10.1038/nm0895-792; LEBOWITZ PF, 1995, MOL CELL BIOL, V15, P6613; Lebowitz PF, 1997, CANCER RES, V57, P708; Lebowitz PF, 1997, J BIOL CHEM, V272, P15591, DOI 10.1074/jbc.272.25.15591; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Liao JF, 1997, J BIOL CHEM, V272, P25951, DOI 10.1074/jbc.272.41.25951; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Liu AX, 2000, FEBS LETT, V481, P205, DOI 10.1016/S0014-5793(00)02003-2; Liu AX, 2000, MOL CELL BIOL, V20, P6105, DOI 10.1128/MCB.20.16.6105-6113.2000; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Prendergast G C, 2000, Lancet Oncol, V1, P73, DOI 10.1016/S1470-2045(00)00073-5; Prendergast GC, 2001, NAT REV CANCER, V1, P162, DOI 10.1038/35101096; Prendergast GC, 2000, CURR OPIN CELL BIOL, V12, P166, DOI 10.1016/S0955-0674(99)00072-1; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Prendergast GC, 2001, EXPERT OPIN INV DRUG, V10, P2105, DOI 10.1517/13543784.10.12.2105; Prendergast GC, 2000, SEMIN CANCER BIOL, V10, P443, DOI 10.1006/scbi.2000.0335; Prendergast GC, 1999, CANCER RES, V59, P5924; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Rowinsky EK, 1999, J CLIN ONCOL, V17, P3631, DOI 10.1200/JCO.1999.17.11.3631; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sebti SM, 2000, ONCOGENE, V19, P6584, DOI 10.1038/sj.onc.1204146; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Takahashi M, 1998, P NATL ACAD SCI USA, V95, P11566, DOI 10.1073/pnas.95.20.11566; van Golen KL, 1999, CLIN CANCER RES, V5, P2511; van Golen KL, 2000, CANCER RES, V60, P5832; van Golen KL, 2002, MOL CANCER THER, V1, P575; van Golen KL, 2000, NEOPLASIA, V2, P418, DOI 10.1038/sj.neo.7900115; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Zohar M, 1998, ONCOGENE, V17, P991, DOI 10.1038/sj.onc.1202022	47	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2003	22	8					1124	1134		10.1038/sj.onc.1206181	http://dx.doi.org/10.1038/sj.onc.1206181			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650EK	12606940				2022-12-17	WOS:000181249700002
J	Gila, L; Elena, N; Yechezkel, S; Mary, B				Gila, L; Elena, N; Yechezkel, S; Mary, B			p53-associated 3 '-> 5 ' exonuclease activity in nuclear and cytoplasmic compartments of cells	ONCOGENE			English	Article						p53; 3 ' -> 5 ' exonuclease; cytoplasmic p53; nuclear p53; DNA replication fidelity	IMMUNODEFICIENCY-VIRUS TYPE-1; P53 PROTEIN; DNA-SYNTHESIS; SUBSTRATE-SPECIFICITY; REVERSE-TRANSCRIPTASE; 3 TERMINI; FIDELITY; ACCUMULATION; EXCISION; IDENTIFICATION	The tumor suppressor protein p53 plays an important role in maintenance of the genomic integrity of cells. p53 possesses an intrinsic 3' --> 5' exonuclease activity. p53 was found in the nucleus and in the cytoplasm of the cell. In order to evaluate the subcellular location and extent of p53-associated 3'--> 5' exonuclease activity, we established an in vitro experimental system of cell lines with different nuclear/cytoplasmic distribution of p53. Nuclear and cytoplasmic extracts obtained from LCC2 cells (expressing a high level of cytoplasmic wild-type p53), MCF-7 cells (expressing a high level of wild-type nuclear p53), MDA cells (expressing mutant p53) and H1299 cells (p53-null) were subjected to the analysis of exonuclease activity. Interestingly, 3' --> 5' exonuclease was predominantly cytoplasmic; the nuclear extracts derived from all cell lines tested, exerted a low level of exonuclease activity. Cytoplasmic extracts of LCC2 cells, with a high level of wild-type p53, showed an enhanced exonuclease activity in comparison to those expressing either a low level of wild-type p53 (in MCF-7 cells) or the mutant p53 (in NIDA cells). Evidence that exonuclease function detected in cytoplasmic extracts is attributed to the p53 is supported by several facts: First, this activity closely parallels with levels and status of endogenous cytoplasmic p53. Second, immunoprecipitation of p53 from cytoplasmic extracts of LCC2 cells markedly reduced the exonuclease activity. Third, the observed 3' --> 5' exonuclease in cytoplasmic fraction of LCC2 cells displays identical biochemical properties characteristic of recombinant wild-type p53. The biochemical functions include: (a) substrate specificity; exonuclease hydrolyzes single-stranded DNA in preference to double-stranded DNA and RNA/DNA template-primers, (b) efficient excision of 3'-terminal mispairs from DNA/DNA and RNA/DNA substrates, (c) the preferential excision of purine-purine mispairs over purine-pyrimidine mispairs and (d) functional interaction with exonuclease-deficient DNA polymerase, for example, murine leukemia virus reverse transcriptase (representing a relatively low fidelity enzyme), thus enhancing the fidelity of DNA synthesis by excision of mismatched nucleotides from the nascent DNA strand. Taken together, the data demonstrate that wildtype p53 in cytoplasm, in its noninduced state, is functional; it displays intrinsic 3' --> 5' exonuclease activity. The possible role of p53-associated 3' --> 5' exonuclease activity in DNA repair in nucleus and cytoplasm is discussed.	Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Med C, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Lab Expt Chemotherapy, IL-52621 Tel Hashomer, Israel	Chaim Sheba Medical Center; Chaim Sheba Medical Center; Chaim Sheba Medical Center	Mary, B (corresponding author), Chaim Sheba Med Ctr, Infect Dis Unit, IL-52621 Tel Hashomer, Israel.	bakhanus@yahoo.com						Albrechtsen N, 1999, ONCOGENE, V18, P7706, DOI 10.1038/sj.onc.1202952; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKHANASHVILI M, 1992, FEBS LETT, V306, P151, DOI 10.1016/0014-5793(92)80988-S; BAKHANASHVILI M, 1992, BIOCHEMISTRY-US, V31, P9393, DOI 10.1021/bi00154a010; Bakhanashvili M, 2001, EUR J BIOCHEM, V268, P2047, DOI 10.1046/j.1432-1327.2001.02075.x; BAKHANASHVILI M, 1993, BIOCHEMISTRY-US, V32, P7559, DOI 10.1021/bi00080a030; Bakhanashvili M, 2001, ONCOGENE, V20, P7635, DOI 10.1038/sj.onc.1204956; Ballal K, 2002, J MOL MED-JMM, V80, P25, DOI 10.1007/s00109-001-0290-6; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; BOSARI S, 1995, AM J PATHOL, V147, P790; BUTCHER S, 1994, BIOCHEM J, V298, P513, DOI 10.1042/bj2980513; COX LS, 1995, EMBO J, V14, P2099, DOI 10.1002/j.1460-2075.1995.tb07201.x; Dudenhoffer C, 1998, MOL CELL BIOL, V18, P5332, DOI 10.1128/MCB.18.9.5332; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FONTOURA BMA, 1992, MOL CELL BIOL, V12, P5145, DOI 10.1128/MCB.12.11.5145; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; Gaitonde SV, 2000, ONCOGENE, V19, P4042, DOI 10.1038/sj.onc.1203756; Genini D, 2001, FASEB J, V15, P5; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; GRAY H, 1992, J BIOL CHEM, V267, P5835; HARRINGTON JA, 1993, ANTIMICROB AGENTS CH, V37, P918, DOI 10.1128/AAC.37.4.918; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Huang P, 1998, ONCOGENE, V17, P261, DOI 10.1038/sj.onc.1201946; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Janus F, 1999, MOL CELL BIOL, V19, P2155; Janz C, 2002, ONCOGENE, V21, P2130, DOI 10.1038/sj.onc.1205292; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Lilling G, 2002, CANCER INVEST, V20, P509, DOI 10.1081/CNV-120002151; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Meek DW, 1998, INT J RADIAT BIOL, V74, P729, DOI 10.1080/095530098141005; Melle C, 2002, NUCLEIC ACIDS RES, V30, P1493, DOI 10.1093/nar/30.7.1493; MILNER J, 1990, ONCOGENE, V5, P1683; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; Mummenbrauer T, 1996, CELL, V85, P1089, DOI 10.1016/S0092-8674(00)81309-4; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; Offer H, 1999, FEBS LETT, V450, P197, DOI 10.1016/S0014-5793(99)00505-0; Okorokov AL, 2002, ONCOGENE, V21, P356, DOI 10.1038/sj.onc.1205112; OLSON MW, 1992, J BIOL CHEM, V267, P23136; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; PERRINO FW, 1994, J BIOL CHEM, V269, P16357; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; Prives C, 1999, J PATHOL, V187, P112; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; Skalski V, 2000, ONCOGENE, V19, P3321, DOI 10.1038/sj.onc.1203649; SKALSKI V, 1995, BIOCHEM PHARMACOL, V50, P815, DOI 10.1016/0006-2952(95)00205-E; SOUSSI T, 1995, MOL GENETICS CANC, P135; STEINMEYER K, 1988, ONCOGENE, V3, P501; STENMARKASKMALM M, 1994, EUR J CANCER, V30A, P175, DOI 10.1016/0959-8049(94)90082-5; SUN XF, 1992, LANCET, V340, P1369, DOI 10.1016/0140-6736(92)92558-W; VAZQUEZPADUA MA, 1990, CANCER COMMUN, V2, P55, DOI 10.3727/095535490820874740; Wang ZJ, 2002, J BIOL CHEM, V277, P4446, DOI 10.1074/jbc.M110006200; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	59	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2003	22	2					233	245		10.1038/sj.onc.1206111	http://dx.doi.org/10.1038/sj.onc.1206111			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	634CL	12527892				2022-12-17	WOS:000180322400008
J	Ren, RB				Ren, RB			The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model	ONCOGENE			English	Review						CML; BCR-ABL; mouse model; signalling; oncogene cooperation	CHRONIC MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; SEQUENCE BINDING-PROTEIN; ABL TYROSINE KINASE; ACUTE LYMPHOBLASTIC-LEUKEMIA; COILED-COIL DOMAIN; P210 BCR-ABL; MYELOPROLIFERATIVE DISEASE; INTERFERON-ALPHA; SH2 DOMAIN	Chronic myelogenous leukemia (CML) is a malignant disease resulting from the neoplastic transformation of a hematopoietic stem cell. Generation of the BCR-ABL fusion gene plays an essential role in causing the vast majority of CML. Clinical and laboratory studies have indicated that development of CML involves both the effects of BCR-ABL within its correct target cells and interactions of BCR-ABL target cells with the rest of the in vivo environment, and that the progression of the disease to blast crisis involves multiple genetic alterations. An efficient mouse bone marrow transduction and transplantation model for CML has recently been developed. This review summarizes the analysis of the roles of functional domains and downstream signaling pathways of BCR-ABL, of altered cytokine production, of interferon signaling pathways and of oncogene cooperation in the pathogenesis of CML using this murine model. The in vivo studies of leukemogenesis will help to advance mechanism-based therapies for CML, as well as to understand fundamental rules of leukemogenesis and hematopoiesis.	Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, Waltham, MA 02454 USA	Brandeis University	Ren, RB (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, MS029,415 South St, Waltham, MA 02454 USA.	ren@brandeis.edu			NATIONAL CANCER INSTITUTE [R01CA068008] Funding Source: NIH RePORTER; NCI NIH HHS [CA 68008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; AHUJA HG, 1990, BLOOD, V75, P1684; Ahuja HG, 2001, GENE CHROMOSOME CANC, V30, P410, DOI 10.1002/1098-2264(2001)9999:9999<::AID-GCC1108>3.0.CO;2-9; Bhatia R, 1998, LEUKEMIA LYMPHOMA, V28, P241, DOI 10.3109/10428199809092680; Bonifazi F, 2001, BLOOD, V98, P3074, DOI 10.1182/blood.V98.10.3074; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buchdunger E, 1996, CANCER RES, V56, P100; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Castellanos A, 1997, BLOOD, V90, P2168, DOI 10.1182/blood.V90.6.2168.2168_2168_2174; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Colovic M, 1998, MED ONCOL, V15, P199, DOI 10.1007/BF02821939; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DALEY GQ, 1991, P NATL ACAD SCI USA, V88, P11335, DOI 10.1073/pnas.88.24.11335; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Deng M, 2001, BLOOD, V97, P3491, DOI 10.1182/blood.V97.11.3491; Druker B J, 2001, Hematology Am Soc Hematol Educ Program, P87; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; ElAhmady O, 1997, ANTICANCER RES, V17, P3179; ELEFANTY AG, 1992, MOL CELL BIOL, V12, P1755, DOI 10.1128/MCB.12.4.1755; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; Era T, 2000, P NATL ACAD SCI USA, V97, P1737, DOI 10.1073/pnas.97.4.1737; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Frank DA, 1996, LEUKEMIA, V10, P1724; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; Ghaffari S, 1999, LEUKEMIA, V13, P1200, DOI 10.1038/sj.leu.2401467; GISHIZKY ML, 1993, P NATL ACAD SCI USA, V90, P3755, DOI 10.1073/pnas.90.8.3755; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; Goldman JM, 2001, BLOOD, V98, P2039, DOI 10.1182/blood.V98.7.2039; Golub TR, 1996, MOL CELL BIOL, V16, P4107; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gross AW, 1999, MOL CELL BIOL, V19, P6918; Gross AW, 2000, ONCOGENE, V19, P6286, DOI 10.1038/sj.onc.1204023; Hao SX, 2000, MOL CELL BIOL, V20, P1149, DOI 10.1128/MCB.20.4.1149-1161.2000; Harada H, 1998, BIOCHIMIE, V80, P641, DOI 10.1016/S0300-9084(99)80017-0; HAWLEY RG, 1994, ANN NY ACAD SCI, V716, P327, DOI 10.1111/j.1749-6632.1994.tb21724.x; He YP, 2002, BLOOD, V99, P2957, DOI 10.1182/blood.V99.8.2957; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Heisterkamp Nora, 1991, Transgenic Research, V1, P45, DOI 10.1007/BF02512996; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; HONDA H, 1995, BLOOD, V85, P2853, DOI 10.1182/blood.V85.10.2853.bloodjournal85102853; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JANSSEN JWG, 1995, BRIT J HAEMATOL, V90, P222, DOI 10.1111/j.1365-2141.1995.tb03407.x; Jiang XY, 1999, P NATL ACAD SCI USA, V96, P12804, DOI 10.1073/pnas.96.22.12804; Jonuleit T, 1998, BRIT J HAEMATOL, V100, P295, DOI 10.1046/j.1365-2141.1998.00564.x; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; Kieslinger M, 2000, GENE DEV, V14, P232; Landolfo S, 2000, Hematol J, V1, P7, DOI 10.1038/sj.thj.6200004; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; Melo JV, 1997, BAILLIERE CLIN HAEM, V10, P203, DOI 10.1016/S0950-3536(97)80003-0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Million RP, 2000, BLOOD, V96, P664; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; NEUBAUER A, 1994, BLOOD, V83, P1603; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Niki M, 1997, P NATL ACAD SCI USA, V94, P5697, DOI 10.1073/pnas.94.11.5697; O'Dwyer ME, 2001, J INTERN MED, V250, P3, DOI 10.1046/j.1365-2796.2001.00823.x; ODA T, 1995, LEUKEMIA, V9, P295; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Pane F, 1999, BLOOD, V94, P2200, DOI 10.1182/blood.V94.7.2200.419a33_2200_2207; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Pfeffer LM, 1998, CANCER RES, V58, P2489; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; Ren RB, 2002, LEUKEMIA LYMPHOMA, V43, P1549, DOI 10.1080/1042819021000002875; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; Roumiantsev S, 2001, BLOOD, V97, P4, DOI 10.1182/blood.V97.1.4; Sawyers CL, 2001, SEMIN HEMATOL, V38, P15, DOI 10.1053/shem.2001.27078; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; Scheijen B, 2001, BLOOD, V98, p144A; Schmidt M, 1998, BLOOD, V91, P22, DOI 10.1182/blood.V91.1.22.22_22_29; Schmidt M, 2001, BLOOD, V97, P3648, DOI 10.1182/blood.V97.11.3648; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; Shuai K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Sood R, 1999, LEUKEMIA, V13, P348, DOI 10.1038/sj.leu.2401360; Talpaz M, 2001, SEMIN HEMATOL, V38, P22, DOI 10.1053/shem.2001.27080; Tamura T, 2000, IMMUNITY, V13, P155, DOI 10.1016/S1074-7613(00)00016-9; TANAKA T, 1995, MOL CELL BIOL, V15, P2383; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Van Etten RA, 2001, BLOOD CELL MOL DIS, V27, P201, DOI 10.1006/bcmd.2000.0370; Verfaillie CM, 1997, ACTA HAEMATOL-BASEL, V97, P40; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603; VONCKEN JW, 1992, CANCER RES, V52, P4534; Wang Q, 1996, P NATL ACAD SCI USA, V93, P3444, DOI 10.1073/pnas.93.8.3444; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wolff NC, 2001, BLOOD, V98, P2808, DOI 10.1182/blood.V98.9.2808; Wong S, 2001, ONCOGENE, V20, P5644, DOI 10.1038/sj.onc.1204638; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829; Zhang XW, 2001, BLOOD, V97, P277, DOI 10.1182/blood.V97.1.277; Zhang XW, 2001, MOL CELL BIOL, V21, P840, DOI 10.1128/MCB.21.3.840-853.2001; Zhao X, 2002, NAT STRUCT BIOL, V9, P117; Zou XM, 1999, J BIOL CHEM, V274, P18141, DOI 10.1074/jbc.274.26.18141	116	36	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2002	21	56					8629	8642		10.1038/sj.onc.1206090	http://dx.doi.org/10.1038/sj.onc.1206090			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	623ZF	12476309				2022-12-17	WOS:000179734300012
J	Tworkowski, KA; Salghetti, SE; Tansey, WP				Tworkowski, KA; Salghetti, SE; Tansey, WP			Stable and unstable pools of Myc protein exist in human cells	ONCOGENE			English	Article						Myc; Max; ubiquitin-mediated proteolysis	UBIQUITIN-MEDIATED PROTEOLYSIS; C-MYC; IN-VIVO; BURKITTS-LYMPHOMA; CDK INHIBITOR; DNA-BINDING; DEGRADATION; PATHWAY; DOMAIN; TRANSCRIPTION	The oncoprotein transcription factor Myc plays a crucial role in the control of cell growth and proliferation. Consistent with its potent growth-promoting properties, cells have evolved a number of mechanisms to limit the activity and accumulation of the Myc protein. One of the most striking of these mechanisms is ubiquitin (Ub)-mediated proteolysis, which typically destroys Myc within minutes of its synthesis. Here we show that, despite the extreme instability of the Myc protein, cells contain a pool of Myc that is metabolically stable. Entry of Myc into the stable pool is signaled by an element within the carboxy-terminus of the protein, and is a cell-specific process that is regulated during mitosis and by interaction with Max. These data demonstrate that even for a rapidly turned-over protein such as Myc metabolically stable and unstable forms of a protein can co-exist in cells, and suggest that the rate of destruction of Myc molecules is linked to their specific functions.	SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA; Cold Spring Harbor Lab, New York, NY 11724 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Cold Spring Harbor Laboratory	Tansey, WP (corresponding author), SUNY Stony Brook, Mol & Cellular Biol Program, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [P30CA045508, P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008468] Funding Source: NIH RePORTER; NCI NIH HHS [CA-13106, CA45508] Funding Source: Medline; NIGMS NIH HHS [1T32-GM08468] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu Hatoum O, 1998, MOL CELL BIOL, V18, P5670, DOI 10.1128/MCB.18.10.5670; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; Furstenthal L, 2001, NAT CELL BIOL, V3, P715, DOI 10.1038/35087026; Gregory MA, 2000, MOL CELL BIOL, V20, P2423, DOI 10.1128/MCB.20.7.2423-2435.2000; Hancock R, 2000, CHROMOSOMA, V109, P219, DOI 10.1007/s004120000077; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Niklinski J, 2000, MOL CELL BIOL, V20, P5276, DOI 10.1128/MCB.20.14.5276-5284.2000; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; Rudolph C, 1999, ANAL BIOCHEM, V269, P66, DOI 10.1006/abio.1999.3095; Sacco-Bubulya P, 2002, J CELL BIOL, V156, P425, DOI 10.1083/jcb.200107017; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5	25	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 5	2002	21	55					8515	8520		10.1038/sj.onc.1205976	http://dx.doi.org/10.1038/sj.onc.1205976			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	619MQ	12466972				2022-12-17	WOS:000179480100015
J	Joosten, M; Vankan-Berkhoudt, Y; Tas, M; Lunghi, M; Jenniskens, Y; Parganas, E; Valk, PJ; Lowenberg, B; van den Akker, E; Delwel, R				Joosten, M; Vankan-Berkhoudt, Y; Tas, M; Lunghi, M; Jenniskens, Y; Parganas, E; Valk, PJ; Lowenberg, B; van den Akker, E; Delwel, R			Large-scale identification of novel potential disease loci in mouse leukemia applying an improved strategy for cloning common virus integration sites	ONCOGENE			English	Article						leukemia; disease gene; common virus integration site; insertional mutagenesis	PERIPHERAL CANNABINOID RECEPTOR; HUMAN MYELOID-LEUKEMIA; CELL-LINES; N-MYC; GENE; TRANSLOCATION; ACTIVATION; MUTATIONS; NEOPLASMS; NEUROFIBROMATOSIS	The identification of common virus integration sites (cVIS) in retrovirally induced tumors in mice provides a powerful strategy to isolate novel transforming genes. Applying virus LTR-specific inverse-PCR and RT-PCR combined with automated sequencing on CasBr-M Murine Leukemia Virus (MuLV) induced myeloid leukemias, 126 virus integration sites were cloned. Using locus- and LTR-specific primers, a nested-PCR/Southern-blotting procedure was developed on genomic DNA from a large panel of MuLV-induced leukemias, to analyse whether a particular virus insertion represented a cVIS. In fact 39 out of 41 integrations analysed this way appeared to represent a common virus integration. We recognized six previously cloned cVISs, i.e. Evil, Hoxa7, c-Myb, Cb/Evi11, Evi12, and His1 and 33 novel common insertions, designated Cas-Br Virus Integration Site (Casvis). Among this group we found integrations in or near genes encoding nuclear proteins, e.g. Dnmt-2, Nm23-M2, Ctbp1 or Erg, within receptor genes, e.g. Cb2 or mrc1, novel putative signaling or transporter genes, the ringfinger-protein gene Mid1 and a panel of genes encoding novel proteins with unknown function. The finding that 39 out of 41 integrations analysed represented a cVIS, suggests that the majority of the other virus insertions that were not yet analysed by the PCR/Southern-blotting method are located in a cVIS as well and may therefore also harbor novel disease genes.	Erasmus Univ, Inst Hematol, NL-3015 GE Rotterdam, Netherlands; St Jude Childrens Res Hosp, Memphis, TN 38105 USA	Erasmus University Rotterdam; St Jude Children's Research Hospital	Delwel, R (corresponding author), Erasmus Univ, Inst Hematol, Dr Molewaterplein 50, NL-3015 GE Rotterdam, Netherlands.	delwel@hema.fgg.eur.nl	Valk, Peter/AAX-2823-2020	Bastiaansen-Jenniskens, Yvonne/0000-0002-2921-1237				BERGERON D, 1991, J VIROL, V65, P7, DOI 10.1128/JVI.65.1.7-15.1991; Berns A, 1999, CANCER RES, V59, p1773S; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; Cox MC, 2001, LEUKEMIA RES, V25, P349, DOI 10.1016/S0145-2126(00)00136-3; deBoer CJ, 1997, ANN ONCOL, V8, P109, DOI 10.1023/A:1008207005567; Hansen GM, 2000, GENOME RES, V10, P237, DOI 10.1101/gr.10.2.237; HIRVONEN H, 1993, LEUKEMIA LYMPHOMA, V11, P197, DOI 10.3109/10428199309086996; HOLMES KL, 1986, J IMMUNOL, V137, P679; HOLMES KL, 1985, P NATL ACAD SCI USA, V82, P6687, DOI 10.1073/pnas.82.19.6687; IHLE JN, 1984, ADV VIRAL ONCOL, V4, P95; Joosten M, 2000, VIROLOGY, V268, P308, DOI 10.1006/viro.2000.0183; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; MORISHITA K, 1990, ONCOGENE RES, V5, P221; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; OFIR R, 1992, LEUKEMIA RES, V16, P797, DOI 10.1016/0145-2126(92)90159-5; Quaderi NA, 1997, NAT GENET, V17, P285, DOI 10.1038/ng1197-285; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; SETOGUCHI M, 1989, MOL CELL BIOL, V9, P4515, DOI 10.1128/MCB.9.10.4515; SHANNON KM, 1994, NEW ENGL J MED, V330, P597, DOI 10.1056/NEJM199403033300903; SHIMIZU K, 1993, P NATL ACAD SCI USA, V90, P10280, DOI 10.1073/pnas.90.21.10280; Side LE, 1998, BLOOD, V92, P267, DOI 10.1182/blood.V92.1.267.413a31_267_272; SILVER J, 1986, J VIROL, V60, P1156, DOI 10.1128/JVI.60.3.1156-1158.1986; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; Specchia G, 2001, LEUKEMIA RES, V25, P501, DOI 10.1016/S0145-2126(00)00160-0; Tanaka K, 2001, CANCER GENET CYTOGEN, V124, P27, DOI 10.1016/S0165-4608(00)00316-2; Valk P, 1997, BLOOD, V90, P1448, DOI 10.1182/blood.V90.4.1448.1448_1448_1457; Valk PJM, 1997, NUCLEIC ACIDS RES, V25, P4419, DOI 10.1093/nar/25.21.4419; Valk PJM, 1999, J VIROL, V73, P3595, DOI 10.1128/JVI.73.5.3595-3602.1999; Valk PJM, 1997, J VIROL, V71, P6796, DOI 10.1128/JVI.71.9.6796-6804.1997	33	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7247	7255		10.1038/sj.onc.1205813	http://dx.doi.org/10.1038/sj.onc.1205813			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370816	Bronze			2022-12-17	WOS:000178504600014
J	van Hogerlinden, M; Auer, G; Toftgard, R				van Hogerlinden, M; Auer, G; Toftgard, R			Inhibition of Rel/Nuclear Factor-kappa B signaling in skin results in defective DNA damage-induced cell cycle arrest and Ha-ras- and p53-independent tumor development	ONCOGENE			English	Article						NF-kappa B; skin cancer; gamma-radiation; G1 arrest; I kappa B-alpha transgene	X-LINKED DISORDER; INCONTINENTIA PIGMENTI; MOUSE SKIN; P53 MUTATIONS; ECTODERMAL DYSPLASIA; ABERRANT EXPRESSION; METHYLENE-CHLORIDE; GROWTH ARREST; LUNG-TUMORS; B6C3F1 MICE	In recent years a growth inhibitory role in skin for the Rel/NF-kappaB transcription factors has been established, and the block of Rel/NF-kappaB signaling results in rapid development of spontaneous skin cancer. The molecular mechanism underlying tumor development is however unknown. In the present study, we show that inhibition of NF-kappaB signaling in mouse skin by targeted expression of degradation resistant IkappaB-alpha generates transgenic keratinocytes unable to arrest the cell cycle in response to DNA damage induced by gamma-radiation. The results indicate that transgenic keratinocytes have a defect at the G1-S checkpoint whereas the G2-M checkpoint response was found to be intact. However, transgenic keratinocytes still respond by induction of the cyclin dependent kinase inhibitor P21(Cip1/Waf) after exposure to T-radiation. In the spontaneous skin tumors that develop in transgenic mice no mutations were found in the Ha-ras or p53 gene, suggesting that inhibition of NF-kappaB signaling in skin can induce cancer development independently of initiating mutations in the Ha-ras gene or additional mutations in the p53 gene. These findings demonstrate an involvement of NF-kappaB signaling in the DNA damage response and cell cycle checkpoint control in the skin.	Karolinska Inst, Novum, Dept Biosci, SE-14157 Huddinge, Sweden; Canc Ctr Karolinska, Dept Oncol Pathol, Div Cellular & Mol Tumor Pathol, SE-17176 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet	Toftgard, R (corresponding author), Karolinska Inst, Novum, Dept Biosci, SE-14157 Huddinge, Sweden.	rune.toftgard@cnt.ki.se		Auer, Gert/0000-0003-3911-0285				Ahmed NU, 1997, J CUTAN PATHOL, V24, P223, DOI 10.1111/j.1600-0560.1997.tb01585.x; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; AUER GU, 1994, VIRCHOWS ARCH, V424, P343; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bash J, 1997, MOL CELL BIOL, V17, P6526, DOI 10.1128/MCB.17.11.6526; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CAMPBELL C, 1993, BRIT J DERMATOL, V128, P111, DOI 10.1111/j.1365-2133.1993.tb15137.x; Chen EY, 1998, BIOCHEM BIOPH RES CO, V249, P728, DOI 10.1006/bbrc.1998.9224; COLEMAN WB, 1995, CLIN CHEM, V41, P644; DEVEREUX TR, 1993, CARCINOGENESIS, V14, P795, DOI 10.1093/carcin/14.5.795; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEGI ME, 1993, CARCINOGENESIS, V14, P803, DOI 10.1093/carcin/14.5.803; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Inohara S, 1996, DERMATOLOGY, V192, P94, DOI 10.1159/000246329; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KORSTANJE MJ, 1991, DERMATOLOGICA, V183, P234, DOI 10.1159/000247678; LANDY SJ, 1993, J MED GENET, V30, P53, DOI 10.1136/jmg.30.1.53; LARNER JM, 1994, MOL CELL BIOL, V14, P1901, DOI 10.1128/MCB.14.3.1901; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Matsuta M, 1997, J DERMATOL SCI, V14, P233, DOI 10.1016/S0923-1811(96)00579-8; MCGREGOR JM, 1992, BRIT J DERMATOL, V127, P463, DOI 10.1111/j.1365-2133.1992.tb14841.x; MITSUNAGA SI, 1995, CARCINOGENESIS, V16, P1629, DOI 10.1093/carcin/16.7.1629; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; PIERCEALL WE, 1991, MOL CARCINOGEN, V4, P196, DOI 10.1002/mc.2940040306; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Ren ZP, 1996, ONCOGENE, V12, P765; Ren ZP, 1996, INT J CANCER, V69, P174, DOI 10.1002/(SICI)1097-0215(19960621)69:3<174::AID-IJC4>3.0.CO;2-X; RO YS, 1993, BRIT J DERMATOL, V128, P237, DOI 10.1111/j.1365-2133.1993.tb00164.x; ROBELS AI, 1995, CARCINOGENESIS, V16, P781, DOI 10.1093/carcin/16.4.781; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; RUMSBY G, 1990, BRIT J CANCER, V61, P365, DOI 10.1038/bjc.1990.80; Sakai H, 2000, DERMATOLOGY, V200, P258, DOI 10.1159/000018371; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Seitz CS, 2000, CANCER RES, V60, P4085; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Smahi A, 2000, NATURE, V405, P466; Song SY, 1999, AM J PATHOL, V155, P1121, DOI 10.1016/S0002-9440(10)65215-7; SUTTER C, 1993, MOL CARCINOGEN, V8, P13, DOI 10.1002/mc.2940080106; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tong Y, 1997, J TOXICOL ENV HEALTH, V51, P219, DOI 10.1080/00984109708984023; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Tron VA, 1996, AM J PATHOL, V149, P1139; van Hogerlinden M, 1999, CANCER RES, V59, P3299; VANDERSCHROEFF JG, 1990, J INVEST DERMATOL, V94, P423, DOI 10.1111/1523-1747.ep12874504; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Weinberg WC, 1999, CANCER RES, V59, P2050; Xie GF, 1998, ONCOGENE, V16, P721, DOI 10.1038/sj.onc.1201793; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	59	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2002	21	32					4969	4977		10.1038/sj.onc.1205620	http://dx.doi.org/10.1038/sj.onc.1205620			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574EE	12118375				2022-12-17	WOS:000176874800011
J	Andersen, H; Mahmood, S; Tkach, V; Cohn, M; Kustikova, O; Grigorian, M; Berezin, V; Bock, E; Lukanidin, E; Tulchinsky, E				Andersen, H; Mahmood, S; Tkach, V; Cohn, M; Kustikova, O; Grigorian, M; Berezin, V; Bock, E; Lukanidin, E; Tulchinsky, E			The ability of Fos family members to produce phenotypic changes in epithelioid cells is not directly linked to their transactivation potentials	ONCOGENE			English	Article						c-Fos; Fra-1; Fra-2; cell shape; transcription	IN-VITRO; C-FOS; FRA-1 GENE; AP-1; TRANSFORMATION; EXPRESSION; REQUIRES; PHOSPHORYLATION; ACTIVATION; TRANSITION	Numerous studies have revealed distinct functions of Fos proteins in different mouse tissues and cell lines. Here, we perform a direct comparison of the features of exogenous c-Fos, Fra-1 and Fra-2 proteins expressed in murine tumor cells of epithelial origin, CSMLO. Although transactivation potential of c-Fos is much stronger than that of Fra-1 and Fra-2, all three proteins are capable of modulating transcription of target genes. Moreover, there is a certain degree of specificity in the induction of the transcription of AP-1-responsive genes by different Fos proteins. For instance, c-Fos and Fra-1 but not Fra-2 activated genes of the urokinase system. Additionally, not only a strong transcriptional activator c-Fos, but also Fra-1 induced morphological alterations in CSMLO cells. N-terminal domain of Fra-1 was required for this function. On the other hand, Fra-2 failed to change morphology of CSMLO cells. We therefore conclude that c-Fos, Fra-1 and Fra-2 differently activate transcription of target genes and induce morphological changes in epithelioid carcinoma cells in a manner not directly linked to their transactivation potentials.	Danish Canc Soc, Dept Mol Canc Biol, DK-2100 Copenhagen 0, Denmark; Univ Copenhagen, Inst Mol Pathol, Prot Lab, DK-2200 Copenhagen N, Denmark	Danish Cancer Society; University of Copenhagen	Tulchinsky, E (corresponding author), Leicester Gen Hosp, Div Urol, Clin Sci Unit, Gwendolen Rd, Leicester LE5 4PW, Leics, England.	et32@le.ac.uk	Tulchinsky, Eugene/ABD-7070-2021	Cohn, Martin/0000-0002-2988-3009				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Battista S, 1998, ONCOGENE, V17, P377, DOI 10.1038/sj.onc.1201953; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Brown JR, 1996, CELL, V86, P297, DOI 10.1016/S0092-8674(00)80101-4; Chiappetta G, 2000, CLIN CANCER RES, V6, P4300; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Debinski W, 2001, MOL MED, V7, P598, DOI 10.1007/BF03401866; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JEHN J, 1991, P NATL ACAD SCI USA, V88, P5077; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lepekhin EA, 2001, METH MOL B, V161, P85; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Qian XH, 1997, EXP CELL RES, V235, P403, DOI 10.1006/excr.1997.3681; Risse-Hackl G, 1998, ONCOGENE, V16, P3057, DOI 10.1038/sj.onc.1201845; SAKSELA K, 1993, MOL CELL BIOL, V13, P3698, DOI 10.1128/MCB.13.6.3698; Schreiber M, 2000, DEVELOPMENT, V127, P4937; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; Tulchinsky E, 2000, HISTOL HISTOPATHOL, V15, P921, DOI 10.14670/HH-15.921; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; WISDOM R, 1993, MOL CELL BIOL, V13, P7429, DOI 10.1128/MCB.13.12.7429; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Zajchowski DA, 2001, CANCER RES, V61, P5168	31	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2002	21	31					4843	4848		10.1038/sj.onc.1205590	http://dx.doi.org/10.1038/sj.onc.1205590			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	571KJ	12101423				2022-12-17	WOS:000176716300014
J	Regnauld, K; Nguyen, QD; Vakaet, L; Bruyneel, E; Launay, JM; Endo, T; Mareel, M; Gespach, C; Emami, S				Regnauld, K; Nguyen, QD; Vakaet, L; Bruyneel, E; Launay, JM; Endo, T; Mareel, M; Gespach, C; Emami, S			G-protein alpha olf subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells	ONCOGENE			English	Article						cAMP; PKA; rho GTPases; src; PI3 '-kinase; PTHrP; trefoil factors	HORMONE-RELATED PROTEIN; ENDOTHELIAL GROWTH-FACTOR; PROSTATE-CANCER CELLS; SMALL GTPASE; TRANSFORMING ACTIVITY; KINASE ACTIVATION; COUPLED RECEPTORS; ADENYLYL CYCLASES; TREFOIL PEPTIDES; GENE-EXPRESSION	The heterotrimeric G-protein subunits Galpha and Gbetagamma are involved in cellular transformation and tumor development. Here, we report the expression of Galphaolf in human digestive and urogenital epithelial cells using RT-PCR and Western blot. When the constitutively activated form of GalphaolfQ214L (AGalphaolf) was stably transfected in canine kidney MDCKts.src and human colonic HCT-8/S11 epithelial cells, it induced cellular invasion in collagen gels. AGalphaolf-mediated invasion was abrogated by agonists of platelet activating factor receptors (PAF-R) and protease-activated receptors -1 (PAR-1), pharmacological inhibitors of P13'-Kinase (wortmannin), protein kinase C (Go6976 and GF109203X), Rho GTPase (C3T exoenzyme), but was independent of protein kinase A. Accordingly, the invasive phenotype induced by AGalphaolf in HCT-8/S11 cells was reversed by the RhoA antagonist RhoD (G26V). Although AGaolf protected MDCKts.src cells against serum starvation-mediated apoptosis via a Rho-independent pathway, both AGalphaolf and Rho inhibition by C3T induced neuroendocrine-like differentiation linked to extensive neurite outgrowth and parathyroid hormone-related protein expression in human prostatic LNCaP-AGalphaolf cells. Since prostate tumors with a larger neuroendocrine cell population display increased invasiveness, persistent activation of the G-protein alphaolf may exert convergent adverse effects on cellular invasion and survival in solid tumors during the neoplastic progression towards metastasis.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Ghent Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Hop Lariboisiere, CRC Bernard, F-75475 Paris 10, France; Chiba Univ, Fac Sci, Dept Biol, Inage Ku, Chiba 2638522, Japan	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Chiba University	Emami, S (corresponding author), Hop St Antoine, INSERM, U482, F-75571 Paris 12, France.	emami@st-antoine.inserm.fr	Vakaet, Luc/A-6467-2010					Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Astesano A, 1999, J HISTOCHEM CYTOCHEM, V47, P289, DOI 10.1177/002215549904700303; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bolt MJG, 1998, GASTROENTEROLOGY, V115, P1494, DOI 10.1016/S0016-5085(98)70028-9; Bouvet M, 2001, J CLIN ENDOCR METAB, V86, P310, DOI 10.1210/jc.86.1.310; Carron JA, 1997, BRIT J CANCER, V76, P1095, DOI 10.1038/bjc.1997.513; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; Chien J, 1999, ONCOGENE, V18, P3376, DOI 10.1038/sj.onc.1202690; Cox ME, 1999, CANCER RES, V59, P3821; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; de Curtis I, 2001, EMBO REP, V2, P277, DOI 10.1093/embo-reports/kve072; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; Debruyne PR, 2001, MUTAT RES-FUND MOL M, V480, P359, DOI 10.1016/S0027-5107(01)00195-6; Deftos Leonard J., 2000, Cancer, V88, P3002; DEL PL, 1997, SCIENCE, V278, P687; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; Du Villard J, 2000, ONCOGENE, V19, P4896, DOI 10.1038/sj.onc.1203852; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Escande B, 2001, SEMIN PERINATOL, V25, P76, DOI 10.1053/sper.2001.23194; Faivre S, 2001, MOL PHARMACOL, V60, P363, DOI 10.1124/mol.60.2.363; Farfel Z, 1999, NEW ENGL J MED, V340, P1012, DOI 10.1056/NEJM199904013401306; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Ferrand N, 1999, J MOL CELL CARDIOL, V31, P1137, DOI 10.1006/jmcc.1999.0945; Fredriksson JM, 2000, J BIOL CHEM, V275, P13802, DOI 10.1074/jbc.275.18.13802; GORCZYCA W, 1993, CANCER RES, V53, P3186; Gratacap MP, 2001, J BIOL CHEM, V276, P47906, DOI 10.1074/jbc.M104442200; Gujral A, 2001, CANCER RES, V61, P2282; HOOSEIN NM, 1993, J UROLOGY, V149, P1209, DOI 10.1016/S0022-5347(17)36349-8; Iiri T, 1999, P NATL ACAD SCI USA, V96, P499, DOI 10.1073/pnas.96.2.499; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JIANG HP, 1993, FEBS LETT, V330, P319, DOI 10.1016/0014-5793(93)80896-3; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; Jung YD, 1999, CANCER RES, V59, P4804; Katagiri K, 2000, MOL CELL BIOL, V20, P1956, DOI 10.1128/MCB.20.6.1956-1969.2000; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kozasa T, 1998, SCIENCE, V280, P2109, DOI 10.1126/science.280.5372.2109; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; LOGOTHETIS CJ, 1994, SEMIN ONCOL, V21, P620; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; Ma YC, 1998, P NATL ACAD SCI USA, V95, P12197, DOI 10.1073/pnas.95.21.12197; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Moretti F, 2000, BEST PRACT RES CL EN, V14, P517, DOI 10.1053/beem.2000.0101; Nguyen QD, 2002, FASEB J, V16, P565, DOI 10.1096/fj.01-0525com; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Pap M, 1998, J BIOL CHEM, V273, P19929, DOI 10.1074/jbc.273.32.19929; Peri A, 2001, J CLIN ENDOCR METAB, V86, P2111, DOI 10.1210/jc.86.5.2111; Prasad MVVSV, 1999, ONCOGENE, V18, P1639, DOI 10.1038/sj.onc.1202461; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRIE D, 1995, KIDNEY INT, V47, P1310, DOI 10.1038/ki.1995.186; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Radhika V, 2001, ONCOGENE, V20, P1607, DOI 10.1038/sj.onc.1204274; Reedquist KA, 2000, J CELL BIOL, V148, P1151, DOI 10.1083/jcb.148.6.1151; Regnauld KL, 2002, AM J PHYSIOL-REG I, V282, pR870, DOI 10.1152/ajpregu.00374.2001; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIUS RA, 1994, BRAIN RES, V643, P50, DOI 10.1016/0006-8993(94)90007-8; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; RUDOLPH U, 1995, NAT GENET, V10, P143, DOI 10.1038/ng0695-143; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; Shankar PP, 2000, BRAIN RES, V868, P230, DOI 10.1016/S0006-8993(00)02335-0; Shaw LM, 2001, MOL CELL BIOL, V21, P5082, DOI 10.1128/MCB.21.15.5082-5093.2001; Spada A, 1998, MOL CELL ENDOCRINOL, V142, P1, DOI 10.1016/S0303-7207(98)00116-6; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Tsai RYL, 1997, J NEUROSCI, V17, P4159; Tsubakimoto K, 1999, ONCOGENE, V18, P2431, DOI 10.1038/sj.onc.1202604; Ueda H, 2001, J BIOL CHEM, V276, P6846, DOI 10.1074/jbc.M007541200; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vider BZ, 2000, BIOCHEM BIOPH RES CO, V272, P513, DOI 10.1006/bbrc.2000.2804; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WANG MM, 1993, MOL CELL BIOL, V13, P5805, DOI 10.1128/MCB.13.9.5805; XU NZ, 1994, BIOCHEM BIOPH RES CO, V201, P603, DOI 10.1006/bbrc.1994.1744; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; YOUNG MRI, 1995, INT J CANCER, V61, P104, DOI 10.1002/ijc.2910610118; ZIGMAN JM, 1993, ENDOCRINOLOGY, V133, P2508, DOI 10.1210/en.133.6.2508	85	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2002	21	25					4020	4031		10.1038/sj.onc.1205498	http://dx.doi.org/10.1038/sj.onc.1205498			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	556VP	12037684				2022-12-17	WOS:000175869900008
J	Yang, C; Yu, B; Zhou, DJ; Chen, SA				Yang, C; Yu, B; Zhou, DJ; Chen, SA			Regulation of aromatase promoter activity in human breast tissue by nuclear receptors	ONCOGENE			English	Article						aromatase; gene regulation; nuclear receptors; breast cancer	ESTROGEN-RELATED RECEPTOR; CYTOCHROME-P450 GENE-EXPRESSION; ORPHAN RECEPTORS; TRANSCRIPTION FACTOR; RESPONSE ELEMENTS; MESSENGER-RNA; UPSTREAM; BINDING; ALPHA; ARP-1	Using the yeast one-hybrid approach to screen a human breast tissue hybrid cDNA expression library, we have found that four orphan/nuclear receptors, ERRalpha-1, EAR-2, COUP-TFI (EAR-3), and RARgamma, bind to the silencer (SI) region of the human aromatase gene. S1 down regulates promoters 1.3 and 11 of the human aromatase gene. In this study, the interaction of EAR-2, COUP-TFI, and RARgamma with SI was confirmed by DNA mobility shift analysis. In contrast to the findings that ERRalpha-1 behaves as a positive regulatory factor, these three nuclear receptors were found, by, mammalian cell transfection experiments, to act as negative regulatory factors by binding to SI. Furthermore, the negative action of these three nuclear receptors could override the positive effect of ERRalpha-1. RT-PCR analysis of 11 cell lines and 55 human breast tumor specimens has shown that these nuclear receptors are expressed in human breast tissue. Since EAR-2, COUP-TFI, and RARgamma are expressed at high levels, it is likely that SI is a negative regulatory element that suppresses aromatase promoters 1.3 and 11 in normal breast tissue. In cancer tissue, SI may function as a positive element since ERRYalpha-1 is expressed, but EAR-2 and RARgamma are only present in a small number of tumor specimens. This hypothesis is sustained by the finding that there is a weak inverse correlation between the expression of COUP-TFI and that of aromatase in breast tumor tissue. Our studies have revealed that estrogen receptor alpha (ERalpha) can also bind to SI, in a ligand-dependent manner. By binding to S1, ERalpha down-regulates the aromatase promoter activity. These results demonstrate that nuclear receptors play important roles in modulating aromatase expression in human breast tissue.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Chen, SA (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.	schen@coh.org			NCI NIH HHS [CA44735, CA65767] Funding Source: Medline; NIEHS NIH HHS [ES08258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044735] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES008258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bonnelye E, 1997, MOL ENDOCRINOL, V11, P905, DOI 10.1210/me.11.7.905; Bulun SE, 1997, J STEROID BIOCHEM, V61, P133; CHOMCZYMSKI P, 1998, CURRENT PROTOCOLS MO, V1; Chu K, 1998, MOL CELL ENDOCRINOL, V137, P145, DOI 10.1016/S0303-7207(97)00241-4; Dotzlaw H, 1999, CLIN CANCER RES, V5, P2103; Harada N, 1997, J STEROID BIOCHEM, V61, P175; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; Johnston SD, 1997, MOL ENDOCRINOL, V11, P342, DOI 10.1210/me.11.3.342; Kao YC, 1996, CANCER RES, V56, P3451; Klinge CM, 1997, J BIOL CHEM, V272, P31465, DOI 10.1074/jbc.272.50.31465; Lazennec G, 1997, MOL CELL BIOL, V17, P5053, DOI 10.1128/MCB.17.9.5053; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; Nakamura J, 1999, J CLIN ENDOCR METAB, V84, P1432, DOI 10.1210/jc.84.4.1432; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SEGEL IH, 1976, BIOCH CALCULATIONS, P218; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; THOMPSON EA, 1974, J BIOL CHEM, V249, P5364; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; Vanacker JM, 1999, EMBO J, V18, P4270, DOI 10.1093/emboj/18.15.4270; Vorgia P, 1998, J BIOL CHEM, V273, P4188, DOI 10.1074/jbc.273.7.4188; Widschwendter M, 1997, CANCER RES, V57, P4158; Yang C, 1999, CANCER RES, V59, P4519; Yang C, 1998, CANCER RES, V58, P5695; Zeitoun K, 1999, MOL ENDOCRINOL, V13, P239, DOI 10.1210/me.13.2.239; Zhou CB, 1996, J STEROID BIOCHEM, V59, P163, DOI 10.1016/S0960-0760(96)00100-8; Zhou DJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P179, DOI 10.1006/abbi.1999.1454; Zhou DJ, 1998, ARCH BIOCHEM BIOPHYS, V353, P213, DOI 10.1006/abbi.1998.0641; Zhou DJ, 2000, MOL ENDOCRINOL, V14, P986, DOI 10.1210/me.14.7.986; ZHOU F, 1995, P NATL ACAD SCI USA, V92, P8586; 周茂堂, 1993, Chinese Journal of Polymer Science, V11, P46	36	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2854	2863		10.1038/sj.onc.1205386	http://dx.doi.org/10.1038/sj.onc.1205386			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973645				2022-12-17	WOS:000175063700010
J	Platt, G; Carbone, A; Mittnacht, S				Platt, G; Carbone, A; Mittnacht, S			P16INK4a loss and sensitivity in KSHV associated primary effusion lymphoma	ONCOGENE			English	Article						p16INK4a; retinoblastoma (Rb); Kaposi's sarcoma associated herpes virus (KSHV); human herpesvirus 8 (HHV8); primary effusion lymphoma (PEL)	KAPOSIS-SARCOMA; T-CELL; HOMOZYGOUS DELETIONS; DNA-SEQUENCES; RETINOBLASTOMA-PROTEIN; NUCLEAR ANTIGEN; B-CELL; CYCLIN; EXPRESSION; GENES	The Kaposi's Sarcoma associated Herpes virus (KSHV) encodes two genes with the potential to affect the activity of the retinoblastoma protein (Rb). Open reading frame (orf) 72 encodes a D type cyclin (kcyc) that can elicit p16INK4a resistant cdk activity and orf73 encodes the latency associated nuclear antigen (LNA) that can bind Rb and neutralize E2F regulation. This indicates that, like papilloma and adenovirus associated malignancies, those associated with KSHV are defective with respect to their Rb pathway. To address this we investigated whether KSHV associated primary effusion lymphoma (PEL) derived cell lines are resistant to growth inhibition by p16INK4a. We provide evidence that ectopic expression of p16INK4a in these cells causes an Rb dependent G1 cell cycle block. Importantly, endogenous p16INK4a expression is not detected in six PEL derived cell lines and four primary PEL samples and examination of the p16INK4a locus shows deletion in two out of six and hypermethylation in four out of six PEL lines. Treatment of the latter with the demethylating agent 5'-aza-2' deoxycytidine leads to re-expression of p16INK4a protein. Taken together these results suggest that p16INK4a loss may be a cellular change frequently associated with PEL. They furthermore argue that despite the presence of KSHV DNA and expression of a latent gene program Rb function is intact in PEL.	Inst Canc Res, Chester Beatty Labs, Ctr Mol & Cell Biol, London SW3 6JB, England; Natl Canc Inst, IRCCS, Ctr Riferimento Oncol, Div Pathol, Aviano, Italy	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; IRCCS Aviano (CRO)	Mittnacht, S (corresponding author), Inst Canc Res, Chester Beatty Labs, Ctr Mol & Cell Biol, 237 Fulham Rd, London SW3 6JB, England.	sibylle@icr.ac.uk	Carbone, Antonino/AAA-2217-2019	Carbone, Antonino/0000-0003-2211-639X				Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Baur AS, 1999, BLOOD, V94, P1773, DOI 10.1182/blood.V94.5.1773.417a12_1773_1781; Boshoff C, 1998, BLOOD, V91, P1671, DOI 10.1182/blood.V91.5.1671.1671_1671_1679; Carbone A, 2000, AM J PATHOL, V156, P1209, DOI 10.1016/S0002-9440(10)64991-7; Carbone A, 2000, LEUKEMIA, V14, P1301, DOI 10.1038/sj.leu.2401802; Carbone A, 2000, BRIT J HAEMATOL, V111, P247, DOI 10.1046/j.1365-2141.2000.02329.x; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Child ES, 2001, ONCOGENE, V20, P3311, DOI 10.1038/sj.onc.1204447; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Drexler HG, 1998, LEUKEMIA, V12, P1507, DOI 10.1038/sj.leu.2401160; Dupin N, 1999, P NATL ACAD SCI USA, V96, P4546, DOI 10.1073/pnas.96.8.4546; Friborg J, 1999, NATURE, V402, P889, DOI 10.1038/47266; Gaidano G, 1999, GENE CHROMOSOME CANC, V24, P16, DOI 10.1002/(SICI)1098-2264(199901)24:1<16::AID-GCC3>3.0.CO;2-F; Gessain A, 1997, LEUKEMIA, V11, P266, DOI 10.1038/sj.leu.2400549; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; Hangaishi A, 1996, BLOOD, V87, P4949, DOI 10.1182/blood.V87.12.4949.bloodjournal87124949; HATTA Y, 1995, BLOOD, V85, P2699, DOI 10.1182/blood.V85.10.2699.bloodjournal85102699; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; Kedes DH, 1997, J CLIN INVEST, V100, P2606, DOI 10.1172/JCI119804; Kellam P, 1997, J Hum Virol, V1, P19; KELLEY MJ, 1995, INT J CANCER, V63, P226, DOI 10.1002/ijc.2910630214; Klaes R, 2001, INT J CANCER, V92, P276, DOI 10.1002/ijc.1174; Klangby U, 1998, BLOOD, V91, P1680, DOI 10.1182/blood.V91.5.1680.1680_1680_1687; LIU Y, 1995, BLOOD, V86, P1911, DOI 10.1182/blood.V86.5.1911.bloodjournal8651911; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; Oksenhendler E, 1998, NEW ENGL J MED, V338, P1585, DOI 10.1056/NEJM199805283382204; OTTERSON GA, 1995, ONCOGENE, V11, P1211; Pinyol M, 1998, BLOOD, V91, P2977, DOI 10.1182/blood.V91.8.2977.2977_2977_2984; Platt GM, 2000, VIROLOGY, V272, P257, DOI 10.1006/viro.2000.0343; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rainbow L, 1997, J VIROL, V71, P5915, DOI 10.1128/JVI.71.8.5915-5921.1997; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SILL H, 1995, BLOOD, V85, P2013, DOI 10.1182/blood.V85.8.2013.bloodjournal8582013; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; Villuendas R, 1998, AM J PATHOL, V153, P887, DOI 10.1016/S0002-9440(10)65630-1; WREDE D, 1991, MOL CARCINOGEN, V4, P171, DOI 10.1002/mc.2940040302; Yamada Y, 1997, J CLIN ONCOL, V15, P1778, DOI 10.1200/JCO.1997.15.5.1778	46	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2002	21	12					1823	1831		10.1038/sj.onc.1205360	http://dx.doi.org/10.1038/sj.onc.1205360			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	529DJ	11896614				2022-12-17	WOS:000174284500004
J	Barone, MV; Sepe, L; Melillo, RM; Mineo, A; Santelli, G; Monaco, C; Castellone, MD; Tramontano, D; Fusco, A; Santoro, M				Barone, MV; Sepe, L; Melillo, RM; Mineo, A; Santelli, G; Monaco, C; Castellone, MD; Tramontano, D; Fusco, A; Santoro, M			RET/PTC1 oncogene signaling in PCCl 3 thyroid cells requires the small GTP-binding protein Rho	ONCOGENE			English	Article						RET; tyrosine-kinase; Rho; Ras; Rac; actin; thyroid; apoptosis	RET TYROSINE KINASE; NEOPLASTIC TRANSFORMATION; NEUROTROPHIC FACTOR; EPITHELIAL-CELLS; DOCKING SITE; FAMILY; RAS; ACTIVATION; GTPASES; SHC	Thyroid papillary carcinomas are characterized by RET/PTC rearrangements that cause the tyrosine kinase domain of the RET receptor to fuse with N-terminal sequences encoded by heterologous genes. This results in the aberrant expression of a ligand-independent and constitutively active RET kinase. We analysed actin reorganization induced by the RET/PTC1 oncogene in PC Cl 3 rat thyroid epithelial cells. Differently from oncogenes Src, Ras and Raf, RET/PTC1 caused actin filaments to form prominent stress fibers. Moreover, stress fibers were identified in human thyroid papillary carcinoma cell lines harboring RET/PTC1 rearrangements but not in thyroid carcinoma cells negative for RET/PTC rearrangements. RET/MEN 2A, a constitutively active but unrearranged membrane-bound RET oncoprotein, did not induce stress fibers in PC CI 3 cells. Induction of stress fibers by RET/PTC1 was restricted to thyroid cells; it did not occur in NIH3T3 fibroblasts or MCF7 mammary cells. RET/PTC1-mediated stress fiber formation depended on Rho but not Rac small GTPase activity. In addition, inhibition of Rho, but not of Rac, caused apoptosis of RET/PTC1-expressing thyroid cells. We conclude that Rho is implicated in the actin reorganization and cell survival mediated by the chimeric RET/PTC1 oncogene in thyroid epithelial cells, both phenotypes being cell type- and oncogene type-specific.	Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Fdn Senatore Pascale, I-80131 Naples, Italy; Univ Sannio, I-82100 Benevento, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; IRCCS Fondazione Pascale; University of Sannio	Santoro, M (corresponding author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, CNR, Ctr Endocrinol & Oncol Sperimentale, Via S Pansini 5, I-80131 Naples, Italy.	masantor@unina.it	Tramontano, Donatella/AAS-1740-2020; melillo, rosa marina/O-5255-2015	Fusco, Alfredo/0000-0003-3332-5197; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; MELILLO, Rosa Marina/0000-0002-9233-5275; Tramontano, Donatella/0000-0002-9308-034X; BARONE, Maria Vittoria/0000-0001-6190-4917				Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Airaksinen MS, 1999, MOL CELL NEUROSCI, V13, P313, DOI 10.1006/mcne.1999.0754; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Costello PS, 2000, J EXP MED, V192, P77, DOI 10.1084/jem.192.1.77; De Vita G, 2000, CANCER RES, V60, P3727; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; FAGIN JA, 1993, J CLIN INVEST, V91, P179, DOI 10.1172/JCI116168; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; ISHIZAKA Y, 1990, BIOCHEM BIOPH RES CO, V168, P402, DOI 10.1016/0006-291X(90)92335-W; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Melillo RM, 1999, CANCER RES, V59, P1120; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Moorman JP, 1999, ONCOGENE, V18, P47, DOI 10.1038/sj.onc.1202262; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; Ponder BAJ, 1999, CANCER RES, V59, p1736S; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; ROGER PP, 1988, FEBS LETT, V232, P409, DOI 10.1016/0014-5793(88)80781-6; Salvatore D, 2000, J CLIN ENDOCR METAB, V85, P3898, DOI 10.1210/jc.85.10.3898; SANTORO M, 1995, EUR J ENDOCRINOL, V133, P513, DOI 10.1530/eje.0.1330513; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Schlumberger MJ, 1998, NEW ENGL J MED, V338, P297, DOI 10.1056/NEJM199801293380506; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Scita G, 1999, NATURE, V401, P290, DOI 10.1038/45822; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; VAN AL, 1997, GENE DEV, V11, P2295; VIGLIETTO G, 1995, ONCOGENE, V11, P1207; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	46	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 25	2001	20	48					6973	6982		10.1038/sj.onc.1204886	http://dx.doi.org/10.1038/sj.onc.1204886			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704822				2022-12-17	WOS:000171739300001
J	Fan, SJ; Yuan, RQ; Ma, YX; Xiong, JB; Meng, QH; Erdos, M; Zhao, JN; Goldberg, ID; Pestell, RG; Rosen, EM				Fan, SJ; Yuan, RQ; Ma, YX; Xiong, JB; Meng, QH; Erdos, M; Zhao, JN; Goldberg, ID; Pestell, RG; Rosen, EM			Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding	ONCOGENE			English	Article						BRCA1; retinoblastoma; RB; p107; p130; p300	TUMOR-SUPPRESSOR; RETINOBLASTOMA PROTEIN; CELL-CYCLE; HISTONE DEACETYLASE; ALPHA-SUBUNIT; APOPTOSIS; P53; TRANSCRIPTION; EXPRESSION; INTERACT	The tumor suppressor activity of the BRCA1 gene product is due, in part, to functional interactions with other tumor suppressors, including p53 and the retinoblastoma (RB) protein. RB binding sites on BRCA1 were identified in the C-terminal BRCT domain (Yarden and Brody, 1999) and in the N-terminus (aa 304-394) (Aprelikova et al., 1999). The N-terminal site contains a consensus RB binding motif, LXCXE (aa 358-362), but the role of this motif in RB binding and BRCA1 functional activity is unclear. In both in vitro and in vivo assays, we found that the BRCA1:RB interaction does not require the BRCA1 LXCXE motif, nor does it require an intact A/B binding pocket of RB. In addition, nuclear co-localization of the endogenous BRCA1 and RB proteins was observed. Over-expression of wild-type BRCA1 (wtBRCA1) did not cause cell cycle arrest but did cause down-regulation of expression of RB, p107, p130, and other proteins (e.g., p300), associated with increased sensitivity to DNA-damaging agents. In contrast, expression of a full-length BRCA1 with an LXCXE inactivating mutation (LXCXE-->RXRXH) failed to down-regulate RB, blocked the down-regulation of RB by wtBRCA1, induced chemoresistance, and abrogated the ability of BRCA1 to mediate tumor growth suppression of DU-145 prostate cancer cells. wtBRCA1-induced chemosensitivity was partially reversed by expression of either Rb or p300 and fully reversed by co-expression of Rb plus p300. Our findings suggest that: (I) disruption of the LXCXE motif within the N-terminal RB binding region alters the biologic function of BRCA1; and (2) over-expression of BRCA1 inhibits the expression of RB and RB family (p107 and p130) proteins.	Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, New Hyde Pk, NY 11040 USA; NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Div Hormone Dependent Tumor Biol, Bronx, NY 10461 USA	Northwell Health; Yeshiva University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Fan, SJ (corresponding author), Albert Einstein Coll Med, Long Isl Jewish Med Ctr, Dept Radiat Oncol, Long Isl Campus,270-05 76th Ave, New Hyde Pk, NY 11040 USA.	fan@lij.edu; erosen@lij.edu	Meng, Q./GSI-6185-2022		NCI NIH HHS [R01-CA82599, R01-CA80000] Funding Source: Medline; NIEHS NIH HHS [R01-ES09169] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080000, R01CA082599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009169] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALLEY MC, 1988, CANCER RES, V48, P589; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Doostzadeh-Cizeron J, 1999, MOL BIOL CELL, V10, P3251, DOI 10.1091/mbc.10.10.3251; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; FAN SJ, 1994, CANCER RES, V54, P5824; Fan SJ, 1998, ONCOGENE, V16, P3069, DOI 10.1038/sj.onc.1202116; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FORD D, 1994, LANCET, V343, P692, DOI 10.1016/S0140-6736(94)91578-4; Freundlieb S, 1997, METHOD ENZYMOL, V283, P159; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HERRMANN M, 1994, NUCLEIC ACIDS RES, V22, P5506, DOI 10.1093/nar/22.24.5506; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lin SCJ, 1996, SEMIN CANCER BIOL, V7, P279, DOI 10.1006/scbi.1996.0036; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Pestell RG, 1996, CELL GROWTH DIFFER, V7, P1337; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SARKAR FH, 1992, PROSTATE, V21, P145, DOI 10.1002/pros.2990210207; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Shao NS, 1996, ONCOGENE, V13, P1; Somasundaram K, 1999, ONCOGENE, V18, P6605, DOI 10.1038/sj.onc.1203284; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Tirkkonen M, 1997, CANCER RES, V57, P1222; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; WANG CY, 1993, SCIENCE, V260, P1330, DOI 10.1126/science.8493578; Wang HC, 1997, ONCOGENE, V15, P143, DOI 10.1038/sj.onc.1201252; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	51	36	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4827	4841		10.1038/sj.onc.1204666	http://dx.doi.org/10.1038/sj.onc.1204666			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521194				2022-12-17	WOS:000170271800007
J	Ivanov, VN; Fodstad, O; Ronai, Z				Ivanov, VN; Fodstad, O; Ronai, Z			Expression of ring finger-deleted TRAF2 sensitizes metastatic melanoma cells to apoptosis via up-regulation of p38, TNF alpha and suppression of NF-kappa B activities	ONCOGENE			English	Article						p38; TRAF2; melanoma; apoptosis; radiation; anisomycin; actinomycin D	RECEPTOR 1; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; DOWN-REGULATION; KINASE JNK; ACTIVATION; FAS; DEATH; COMPLEX; PROTEIN	Mechanisms underlying radiation and chemotherapy resistance, the hallmark of human melanoma, are not well understood. Here we demonstrate that expression levels of signal adaptor protein TRAF2 coincide with melanoma resistance to UV-irradiation. Altered TRAF2 signaling by a form of TRAF2, which lacks the ring finger domain (TRAF2 DeltaN), increases activities of p38 MAPK, ATF2, and the level of TNF alpha expression. Forced expression of TRAF2 DeltaN in HHMSX highly metastatic melanoma cells that lack Fas expression and thus utilize the TNF alpha -TNFR1 as the major apoptotic pathway sensitized cells to UV-induced apoptosis, An over twofold increase in degree of apoptosis was observed in TRAF2 DeltaN expressing cells that were treated with actinomycin D, anisomycin or with the radiomimetic drug neocarzinostatin, Sensitization by TRAF2 DeltaN is selective since it was not observed in response to either Taxol or cis-platinum treatment. TRAF2 DeltaN effects are primarily mediated via p38 since inhibition of p38 reduces, whereas activation of p38 promotes the level of UV-induced apoptosis, Conversely, activation of IKK attenuates the sensitization of melanoma by TRAF2 DeltaN, indicating that p38-mediated suppression of NF-kappaB activity is among TRAF2 DeltaN effects. Our finding identifies p38, TNF alpha and NF-kappaB among key players that efficiently sensitizes melanoma cells to UV-, ribotoxic (anisomycin) and radiomimetic chemicals-induced programmed cell death in response to aberrant TRAF2 signaling.	CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, New York, NY 10029 USA; Norwegian Radium Hosp, Dept Tumor Biol, Oslo, Norway	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Oslo	Ronai, Z (corresponding author), CUNY Mt Sinai Sch Med, Ruttenberg Canc Ctr, 1 Gustave L Levy Pl,Box 1130, New York, NY 10029 USA.		Ivanov, Vladimir N/A-3081-2008	Ivanov, Vladimir N/0000-0003-3091-9774; RONAI, ZEEV/0000-0002-3859-0400	NATIONAL CANCER INSTITUTE [R01CA051995, R29CA051995] Funding Source: NIH RePORTER; NCI NIH HHS [CA 51995] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arch RH, 1998, GENE DEV, V12, P2821, DOI 10.1101/gad.12.18.2821; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bakker TR, 1999, INT J CANCER, V80, P320; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Fuchs SY, 1998, P NATL ACAD SCI USA, V95, P10541, DOI 10.1073/pnas.95.18.10541; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ivanov VN, 1999, J BIOL CHEM, V274, P14079, DOI 10.1074/jbc.274.20.14079; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Ivanov VN, 2000, ONCOGENE, V19, P933, DOI 10.1038/sj.onc.1203415; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Kelliher MA, 1998, IMMUNITY, V8, P297, DOI 10.1016/S1074-7613(00)80535-X; Lin X, 1998, MOL CELL BIOL, V18, P5899, DOI 10.1128/MCB.18.10.5899; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; MEIER F, 1998, BIOSCIENCE, V3, pD1005; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Moretti S, 1999, INT J CANCER, V84, P160, DOI 10.1002/(SICI)1097-0215(19990420)84:2<160::AID-IJC12>3.3.CO;2-I; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Peixoto JGP, 2000, PHYS MED BIOL, V45, P563, DOI 10.1088/0031-9155/45/3/301; Peli J, 1999, EMBO J, V18, P1824, DOI 10.1093/emboj/18.7.1824; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Ronai Z, 1998, ONCOGENE, V16, P523, DOI 10.1038/sj.onc.1201566; Ruller S, 1999, CLIN CANCER RES, V5, P2714; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tobin D, 1998, P NATL ACAD SCI USA, V95, P565, DOI 10.1073/pnas.95.2.565; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; TYERS M, 2000, IN PRESS CURR OPIN G; van Dam H, 1998, GENE DEV, V12, P1227, DOI 10.1101/gad.12.8.1227; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yang YM, 1996, ONCOGENE, V12, P2223; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	45	36	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2243	2253		10.1038/sj.onc.1204314	http://dx.doi.org/10.1038/sj.onc.1204314			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402319	Green Published			2022-12-17	WOS:000168404500006
J	Lin, J; Jinno, S; Okayama, H				Lin, J; Jinno, S; Okayama, H			Cdk6-cyclin D3 complex evades inhibition by inhibitor proteins and uniquely controls cell's proliferation competence	ONCOGENE			English	Article						Cdk6; cyclin D3; CKI; proliferation competence	CYCLIN-DEPENDENT KINASE-6; CDK INHIBITORS; TYROSINE PHOSPHORYLATION; VIRAL CYCLIN; PROGRESSION; EXPRESSION; P27(KIP1); ANCHORAGE; FAMILY; GROWTH	Mammalian cells require a cyclin D-dependent kinase for the cell cycle start, yet many mesenchymal cells express three seemingly redundant D cyclins and similarly, seemingly redundant Cdk4 and Cdk6 as their kinase partners, We have found that the Cdk6-cyclin D3 complex is unique among the D cyclin and kinase combinations in the ability to promote the cell cycle start. In an anchorage-minus G(1)-arrested rat fibroblast, only Cdk6-D3 retains kinase activity due mainly to its ability to evade inhibition by p27(KIPI) and p21(CIPI) with a resemblance to viral cyclin-bound Cdk6, Rodent fibroblasts engineered to overexpress both Cdk6 and cyclin D3 highly resist serum starvation- or cell-cell contact-imposed G(1)-arrest, In BALB/c 3T3 cells, D3 is constitutively expressed, but Cdk6 is markedly induced with concomitant activation upon stimulation with a growth-promoting factor. These results suggest a role for the Cdk6-D3 complex in regulating cell's proliferation ability in response to external stimuli.	Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan	University of Tokyo	Okayama, H (corresponding author), Univ Tokyo, Grad Sch Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan.							Belyavskyi M, 1998, P NATL ACAD SCI USA, V95, P11205, DOI 10.1073/pnas.95.19.11205; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chilosi M, 1998, AM J PATHOL, V152, P209; Dong F, 1998, MOL BIOL CELL, V9, P2081, DOI 10.1091/mbc.9.8.2081; Dong F, 1998, J BIOL CHEM, V273, P6190, DOI 10.1074/jbc.273.11.6190; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Henzinger T, 1998, J BIOL CHEM, V273, P14958, DOI 10.1074/jbc.273.24.14958; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jinno S, 1999, ONCOGENE, V18, P565, DOI 10.1038/sj.onc.1202347; Jinno S, 1999, P NATL ACAD SCI USA, V96, P13197, DOI 10.1073/pnas.96.23.13197; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; KUME K, 1992, NEW BIOL, V4, P504; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; Okayama H, 1996, ADV CANCER RES, V69, P17, DOI 10.1016/S0065-230X(08)60859-3; Orend G, 1998, ONCOGENE, V16, P2575, DOI 10.1038/sj.onc.1201791; Schulze-Gahmen U, 1999, STRUCTURE, V7, P245, DOI 10.1016/S0969-2126(99)80035-5; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; Swanton C, 1997, NATURE, V390, P184, DOI 10.1038/36606; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Van Dyk LF, 1999, J VIROL, V73, P5110, DOI 10.1128/JVI.73.6.5110-5122.1999; Wagner EF, 1998, J IMMUNOL, V161, P1123	27	36	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 12	2001	20	16					2000	2009		10.1038/sj.onc.1204375	http://dx.doi.org/10.1038/sj.onc.1204375			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	421CD	11360184				2022-12-17	WOS:000168043800008
J	Yan, W; Kero, J; Suominen, J; Toppari, J				Yan, W; Kero, J; Suominen, J; Toppari, J			Differential expression and regulation of the retinoblastoma family of proteins during testicular development and spermatogenesis: roles in the control of germ cell proliferation, differentiation and apoptosis	ONCOGENE			English	Article						retinoblastoma protein family; spermatogenesis; cell cycle; apoptosis; differentiation	MESSENGER-RIBONUCLEIC-ACID; STAGE-SPECIFIC EXPRESSION; KIT RECEPTOR; ANDROGEN RECEPTOR; MOLECULAR-CLONING; SURVIVAL FACTOR; LEYDIG-CELLS; MICE LACKING; GENE FAMILY; C-KIT	Normal spermatogenesis is highly dependent on well-balanced germ cell proliferation, differentiation, and apoptosis, However, the molecular mechanisms that govern these processes are largely unknown. Retinoblastoma family proteins (pRb, p107 and p130) are potentially important regulators of cell growth, differentiation and apoptosis, pRb has been shown to be expressed in the rat testis and involved in the regulation of spermatogenesis, In the present study, the expression and localization of the other two pRb family members, p107 and p130, were analysed at both mRNA and protein levels during testicular development and spermatogenesis using Northern, Western blotting, immunohistochemistry, and in situ hybridization, Furthermore, changes of levels and phosphorylation status of pRb family proteins in response to growth suppression and/or apoptosis induction were investigated using a seminiferous tubule culture system and three animal models, Our data suggest that: (1) pRb family proteins are differentially expressed in the rat testis and they function in a cell-type-specific manner during testicular development and spermatogenesis; (2) they participate in the control of germ cell cycle and act in a cell cycle-phase-specific fashion during germ cell proliferation, and (3) they are also involved in the regulation of apoptosis of germ cells and Leydig cells.	Univ Turku, Dept Physiol, FIN-20520 Turku, Finland; Univ Turku, Dept Pediat, FIN-20520 Turku, Finland	University of Turku; University of Turku	Toppari, J (corresponding author), Univ Turku, Dept Physiol, Kiinamyllynkatu 10, FIN-20520 Turku, Finland.		Yan, Wei/G-1618-2011; kero, jukka/G-3448-2014	kero, jukka/0000-0001-8767-7222				Beumer TL, 1999, ENDOCRINOLOGY, V140, P1834, DOI 10.1210/en.140.4.1834; Blume-Jensen P, 2000, NAT GENET, V24, P157, DOI 10.1038/72814; de Rooij DG, 1998, CURR OPIN CELL BIOL, V10, P694, DOI 10.1016/S0955-0674(98)80109-9; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; Gao M, 1999, J CELL PHYSIOL, V179, P336, DOI 10.1002/(SICI)1097-4652(199906)179:3<336::AID-JCP11>3.0.CO;2-Q; Garriga J, 1998, BIOCHEM J, V333, P645, DOI 10.1042/bj3330645; Grana X, 1998, ONCOGENE, V17, P3365, DOI 10.1038/sj.onc.1202575; Hakovirta H, 1999, ENDOCRINOLOGY, V140, P1492, DOI 10.1210/en.140.3.1492; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; HARDY MP, 1989, ENDOCRINOLOGY, V124, P762, DOI 10.1210/endo-124-2-762; HENRIKSEN K, 1995, ENDOCRINOLOGY, V136, P3285, DOI 10.1210/en.136.8.3285; Huppi K, 1996, MAMM GENOME, V7, P353, DOI 10.1007/s003359900102; JACKSON CM, 1984, J REPROD FERTIL, V71, P393; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Kasten MM, 1998, CELL DEATH DIFFER, V5, P132, DOI 10.1038/sj.cdd.4400323; Kissel H, 2000, EMBO J, V19, P1312, DOI 10.1093/emboj/19.6.1312; Krishnamurthy H, 1998, J ANDROL, V19, P710; LeCouter JE, 1996, ONCOGENE, V12, P1433; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; LeCouter JE, 1998, MOL CELL BIOL, V18, P7455, DOI 10.1128/MCB.18.12.7455; Lu JM, 1998, J BIOL CHEM, V273, P31528, DOI 10.1074/jbc.273.47.31528; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; MAYOL X, 1993, ONCOGENE, V8, P2561; MAYOL X, 1995, ONCOGENE, V11, P801; McKinnell C, 1997, INT J ANDROL, V20, P171; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; PARVINEN M, 1986, INT REV CYTOL, V104, P115, DOI 10.1016/S0074-7696(08)61925-7; PERTILE P, 1995, CELL GROWTH DIFFER, V6, P1659; Shih HH, 1998, MOL CELL BIOL, V18, P4732, DOI 10.1128/MCB.18.8.4732; Stiegler P, 1998, J CELL BIOCHEM, P30; Suter L, 1998, ARCH TOXICOL, V72, P791, DOI 10.1007/s002040050575; TAJIMA Y, 1994, J REPROD FERTIL, V102, P117, DOI 10.1530/jrf.0.1020117; Teerds K. J., 1996, LEYDIG CELL, P203; TENASEMPERE M, 1994, ENDOCRINOLOGY, V135, P1018, DOI 10.1210/en.135.3.1018; Tevosian SG, 1997, GENE DEV, V11, P383, DOI 10.1101/gad.11.3.383; Vincent S, 1998, DEVELOPMENT, V125, P4585; Yan W, 2000, DEV BIOL, V227, P169, DOI 10.1006/dbio.2000.9885; Yan W, 1997, MOL CELL ENDOCRINOL, V132, P137, DOI 10.1016/S0303-7207(97)00129-9; Yan W, 2000, MOL ENDOCRINOL, V14, P682, DOI 10.1210/me.14.5.682; Yan W, 2000, J CELL SCI, V113, P161; Yan W, 1999, ENDOCRINOLOGY, V140, P1499, DOI 10.1210/en.140.3.1499; Yan W, 2000, MOL CELL ENDOCRINOL, V165, P115, DOI 10.1016/S0303-7207(00)00257-4; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; Yeh SY, 1998, BIOCHEM BIOPH RES CO, V248, P361, DOI 10.1006/bbrc.1998.8974; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	48	36	37	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 15	2001	20	11					1343	1356		10.1038/sj.onc.1204254	http://dx.doi.org/10.1038/sj.onc.1204254			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	411JM	11313878				2022-12-17	WOS:000167495000008
J	Arevalo, JC; Conde, B; Hempstead, BI; Chao, MV; Martin-Zanca, D; Perez, P				Arevalo, JC; Conde, B; Hempstead, BI; Chao, MV; Martin-Zanca, D; Perez, P			A novel mutation within the extracellular domain of TrkA causes constitutive receptor activation	ONCOGENE			English	Article						receptor; tyrosine kinases; dimerization; cell transformation	NERVE GROWTH-FACTOR; IMMUNOGLOBULIN-LIKE DOMAINS; FACTOR BINDING-SITE; LEUCINE-RICH MOTIF; LIGAND-BINDING; SIGNAL-TRANSDUCTION; DIMERIZATION; DELETIONS; SPECIFICITY; ONCOGENES	The TrkA NGF receptor extracellular region contains three leucine repeats flanked by cysteine clusters and two immunoglobulin-like domains that are required for specific ligand binding. Deletion of the immunoglobulinlike domains abolishes NGF binding and causes ligand independent activation of the receptor. Here we report a specific mutation that increases the binding affinity of the TrkA receptor for NGF, A change of proline 203 to alanine (P203A) in the linker region between the leucine repeats and the first Ig-like domain increased NGF binding by decreasing the ligand rate of dissociation, This mutated receptor was appropriately expressed on the cell surface and promoted ligand-independent neurite outgrowth in PC12nnr5 cells. The mutant receptor was capable of spontaneous dimerization and was constitutively phosphorylated in the absence of ligand, Moreover, expression of TrkA-P203A receptor in fibroblasts induced DNA synthesis and transformation and generated tumours in nude mice. These data suggest that domains outside of the immunoglobulin-like structure contribute to ligand binding and constitutive activation of Trk receptors.	Univ Salamanca, CSIC, Dept Genet & Microbiol, Inst Microbiol Bioquim, Salamanca 37007, Spain; Univ Zaragoza, Dept Ciencias Morfol, E-50009 Zaragoza, Spain; Cornell Univ, Coll Med, Div Hematol Oncol, New York, NY 10021 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program,Dept Cell Biol, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program,Dept Physiol, New York, NY 10016 USA; NYU, Med Ctr, Skirball Inst, Mol Neurobiol Program,Dept Neurosci, New York, NY 10016 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Funcional y Genomica (IBFG); University of Salamanca; University of Zaragoza; Cornell University; New York University; New York University; New York University	Perez, P (corresponding author), Univ Salamanca, CSIC, Dept Genet & Microbiol, Inst Microbiol Bioquim, Salamanca 37007, Spain.		Arévalo, Juan Carlos/J-8154-2014; Perez, Pilar/B-4948-2010	Arévalo, Juan Carlos/0000-0003-1994-3095; Perez, Pilar/0000-0003-3557-2247; Chao, Moses/0000-0002-6969-3744				Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; BARBACID M, 1995, CURR OPIN CELL BIOL, V7, P148, DOI 10.1016/0955-0674(95)80022-0; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; Chao MV, 2000, J NEUROSCI RES, V59, P353, DOI 10.1002/(SICI)1097-4547(20000201)59:3<353::AID-JNR8>3.3.CO;2-J; COULIER F, 1990, MOL CELL BIOL, V10, P4202, DOI 10.1128/MCB.10.8.4202; Cunningham ME, 1998, EMBO J, V17, P7282, DOI 10.1093/emboj/17.24.7282; Eng C, 1997, HUM MUTAT, V9, P97, DOI 10.1002/(SICI)1098-1004(1997)9:2<97::AID-HUMU1>3.3.CO;2-Q; EZOE K, 1995, AM J HUM GENET, V56, P58; Greco A, 1998, ONCOGENE, V16, P809, DOI 10.1038/sj.onc.1201596; Greco A, 1997, GENE CHROMOSOME CANC, V19, P112, DOI 10.1002/(SICI)1098-2264(199706)19:2<112::AID-GCC7>3.0.CO;2-1; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; Holden PH, 1997, NAT BIOTECHNOL, V15, P668, DOI 10.1038/nbt0797-668; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; MacDonald JIS, 1996, MOL CELL NEUROSCI, V7, P371, DOI 10.1006/mcne.1996.0027; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; Neilson KM, 1996, J BIOL CHEM, V271, P25049, DOI 10.1074/jbc.271.40.25049; Ninkina N, 1997, J BIOL CHEM, V272, P13019, DOI 10.1074/jbc.272.20.13019; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; PEREZ P, 1995, MOL CELL NEUROSCI, V6, P97, DOI 10.1006/mcne.1995.1010; Plotnikov AN, 1999, CELL, V98, P641, DOI 10.1016/S0092-8674(00)80051-3; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Porter AC, 1998, ONCOGENE, V17, P1343, DOI 10.1038/sj.onc.1202171; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; Siegel PM, 1996, P NATL ACAD SCI USA, V93, P8878, DOI 10.1073/pnas.93.17.8878; Smith DK, 1997, J MOL BIOL, V274, P530, DOI 10.1006/jmbi.1997.1432; Stauber DJ, 2000, P NATL ACAD SCI USA, V97, P49, DOI 10.1073/pnas.97.1.49; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; WETTERS TV, 1992, EMBO J, V11, P551, DOI 10.1002/j.1460-2075.1992.tb05086.x; Wiesmann C, 1999, NATURE, V401, P184, DOI 10.1038/43705; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WINDISCH JM, 1995, BIOCHEMISTRY-US, V34, P11256, DOI 10.1021/bi00035a035; WINDISCH JM, 1995, J BIOL CHEM, V270, P28133	35	36	37	0	6	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2001	20	10					1229	1234		10.1038/sj.onc.1204215	http://dx.doi.org/10.1038/sj.onc.1204215			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	412TH	11313867				2022-12-17	WOS:000167570100010
J	Gual, P; Giordano, S; Anguissola, S; Parker, PJ; Comoglio, PM				Gual, P; Giordano, S; Anguissola, S; Parker, PJ; Comoglio, PM			Gab1 phosphorylation: a novel mechanism for negative regulation of HGF receptor signaling	ONCOGENE			English	Article						HGF; Gab1; Ser/Thr phosphorylation; negative regulation; invasive growth; PKC	HEPATOCYTE GROWTH-FACTOR; PROTEIN-KINASE-C; FACTOR SCATTER FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; INSULIN-RECEPTOR; DOCKING PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE PHOSPHORYLATION; EPITHELIAL MORPHOGENESIS; MET RECEPTOR	Signal transduction by HGF receptor, the tyrosine kinase encoded by the MET oncogene, switches on a genetic program called 'invasive growth' inducing epithelial cell dissociation, migration, growth? and ultimately leading to differentiation into branched tubular structures. Sustained tyrosine phosphorylation of the downstream adaptor protein Gab1 is required for the HGF response, Here we show that serine/threonine phosphorylation of Gab1 provides a control mechanism for negative regulation. Treatment,vith okadaic acid, a potent inhibitor of the serine/threonine protein phosphatases PP1 and PP2A, was followed by activation of a number of serine/threonine kinases, hyper-phosphorylation in serine and threonine of Gab1 and se, ere inhibition of the HGF-induced biological responses, Under these conditions, Gab1 nas found to be concomitantly hypophosphorylated in tyrosine, and thus endowed with reduced ability to recruit SH2 containing signal transducers such as PI3 kinase. Among the serine-threonine kinases activated bg PP1 and PP2A inhibition, we found that PKC-alpha and PKC-beta1 are required for negative regulation of Gab1, These data pro,ide a novel negative mechanism for the HGF receptor signaling pathways and highlight a potentially useful target for inhibitors of invasive growth.	Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Candiolo, Italy; Imperial Canc Res Fund, Prot Phosphorylat Lab, London WC2A 3PX, England	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Cancer Research UK	Gual, P (corresponding author), Univ Turin, Sch Med, Inst Canc Res & Treatment, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.		Gual, Philippe/P-9833-2019; Giordano, Silvia/J-9858-2018; Parker, Peter j/D-5192-2013; Comoglio, Paolo/G-6323-2011	Gual, Philippe/0000-0001-7393-8356; Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; parker, peter/0000-0002-6218-2933				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; Bardelli A, 1997, CIBA F SYMP, V212, P133; Bardelli A, 1997, ONCOGENE, V15, P3103, DOI 10.1038/sj.onc.1201561; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; BARON V, 1992, J BIOL CHEM, V267, P23290; BELLUSCI S, 1994, ONCOGENE, V9, P1091; Bies J, 2000, ONCOGENE, V19, P2846, DOI 10.1038/sj.onc.1203613; BLUMER KJ, 1994, TRENDS BIOCHEM SCI, V19, P236, DOI 10.1016/0968-0004(94)90147-3; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Carpino N, 1997, CELL, V88, P197, DOI 10.1016/S0092-8674(00)81840-1; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; CHIN JE, 1993, J BIOL CHEM, V268, P6338; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; Garcia-Guzman M, 1999, ONCOGENE, V18, P7775, DOI 10.1038/sj.onc.1203198; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; GUAL P, 1995, ENDOCRINOLOGY, V136, P5298, DOI 10.1210/en.136.12.5298; Herbst R, 1996, CELL, V85, P899, DOI 10.1016/S0092-8674(00)81273-8; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jones N, 1998, ONCOGENE, V17, P1097, DOI 10.1038/sj.onc.1202115; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Machide M, 1998, J NEUROCHEM, V71, P592; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; OKANO Y, 1993, BIOCHEM BIOPH RES CO, V190, P842, DOI 10.1006/bbrc.1993.1125; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PELICCI G, 1995, ONCOGENE, V10, P1631; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Raabe T, 1996, CELL, V85, P911, DOI 10.1016/S0092-8674(00)81274-X; Rakhit S, 2000, MOL PHARMACOL, V58, P413, DOI 10.1124/mol.58.2.413; Ricciarelli R, 1998, ARCH BIOCHEM BIOPHYS, V355, P197, DOI 10.1006/abbi.1998.0732; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Schoenthal Axel H., 1998, Frontiers in Bioscience, V3, pD1262; Schonwasser DC, 1998, MOL CELL BIOL, V18, P790, DOI 10.1128/MCB.18.2.790; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TAKAYAMA S, 1984, P NATL ACAD SCI-BIOL, V81, P7797, DOI 10.1073/pnas.81.24.7797; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Taylor BK, 2000, AM J PHYSIOL-LUNG C, V278, pL1062, DOI 10.1152/ajplung.2000.278.5.L1062; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; Yamanashi Y, 1997, CELL, V88, P205, DOI 10.1016/S0092-8674(00)81841-3; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608	72	36	36	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 11	2001	20	2					156	166		10.1038/sj.onc.1204047	http://dx.doi.org/10.1038/sj.onc.1204047			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313945				2022-12-17	WOS:000166410900003
J	Chapman, RS; Duff, EK; Lourenco, PC; Tonner, E; Flint, DJ; Clarke, AR; Watson, CJ				Chapman, RS; Duff, EK; Lourenco, PC; Tonner, E; Flint, DJ; Clarke, AR; Watson, CJ			A novel role for IRF-1 as a suppressor of apoptosis	ONCOGENE			English	Article						IRF-1; apoptosis; mammary gland; involution	MAMMARY-GLAND INVOLUTION; TRANSCRIPTION FACTOR IRF-1; CELL-DEATH; MICE; ACTIVATION; PATHWAYS; PROTEINS; BINDING; TISSUE	The tumour suppressor IRF-1 is a transcription factor involved in the induction of apoptosis in several in vitro systems, Post-lactational involution of the mammary gland is characterized by extensive apoptosis of the epithelial cells, We have previously shown that signal transducer and activator of transcription (Stat) 3 drives apoptosis and involution in the mouse mammary gland, Since one of the downstream targets of the Stat signalling pathway is IRF-1, we have used IRF-1 knockout mice to address the potential role of this transcription factor in involution, Surprisingly, in the absence of IRF-1 significantly higher numbers of apoptotic cells were found in involuting glands at 48 h compared to control glands, In addition, the alveolar structure in IRF-1 null mammary glands had collapsed whereas in control glands the alveoli remained intact and distended. However, by 72 h control and null glands were morphologically similar suggesting that IRF-1 suppresses apoptosis only during the early, reversible, stage of involution, This suggests a survival role for IRF-1 in mammary epithelia and demonstrates a novel role for IRF-1 in vivo - suppression of premature epithelial apoptosis during mammary gland involution.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; Univ Edinburgh, Sch Med, Dept Pathol, Canc Res Campaign Labs, Edinburgh EH8 9AG, Midlothian, Scotland; Hannah Res Inst, Ayr KA6 5HL, Scotland; Univ Wales Coll Cardiff, Sch Biosci, Cardiff CF10 3US, S Glam, Wales	University of Cambridge; University of Edinburgh; Cardiff University	Watson, CJ (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.		clarke, alan r/P-2820-2014; watson, Christine J/B-1431-2012; Clarke, Alan R/A-6256-2008	Chapman, Rachel/0000-0001-5786-1918; Clarke, Alan/0000-0002-4281-426X				Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Heermeier K, 1996, MECH DEVELOP, V56, P197, DOI 10.1016/0925-4773(96)88032-4; Horiuchi M, 1997, J BIOL CHEM, V272, P11952, DOI 10.1074/jbc.272.18.11952; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; Kumar A, 1997, SCIENCE, V278, P1630, DOI 10.1126/science.278.5343.1630; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Liu XW, 1996, MOL ENDOCRINOL, V10, P1496, DOI 10.1210/me.10.12.1496; Lund LR, 1996, DEVELOPMENT, V122, P181; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Meraro D, 1999, J IMMUNOL, V163, P6468; Nguyen H, 1997, ONCOGENE, V15, P1425, DOI 10.1038/sj.onc.1201318; Nozawa H, 1999, GENE DEV, V13, P1240, DOI 10.1101/gad.13.10.1240; Ogasawara K, 1998, NATURE, V391, P700, DOI 10.1038/35636; Philp JAC, 1996, FEBS LETT, V396, P77, DOI 10.1016/0014-5793(96)01069-1; STRANGE R, 1992, DEVELOPMENT, V115, P49; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; Tonner E, 1997, ENDOCRINOLOGY, V138, P5101, DOI 10.1210/en.138.12.5101; WALKER NI, 1989, AM J ANAT, V185, P19, DOI 10.1002/aja.1001850104; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657	25	36	39	0	4	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 14	2000	19	54					6386	6391		10.1038/sj.onc.1204016	http://dx.doi.org/10.1038/sj.onc.1204016			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	388YK	11175354				2022-12-17	WOS:000166210500023
J	Bruckheimer, EM; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ				Bruckheimer, EM; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ			Bcl-2 accelerates multistep prostate carcinogenesis in vivo	ONCOGENE			English	Article						bcl-2; prostate cancer; apoptosis; TRAMP; transgenic; androgen	TRANSGENIC MICE; TUMOR-ANTIGEN; T-ANTIGEN; CANCER PROGRESSION; TRAMP MODEL; CELL-DEATH; IN-VIVO; EXPRESSION; GENE; CARCINOMA	The impact of bcl-2 proto-oncogene expression on the pathogenesis and progression of prostate cancer was examined in a transgenic mouse model. Probasin-bcl-2 transgenic mice were crossed with TRAMP (TRansgenic Adenocarcinoma Mouse Prostate) mice that express the SV40 early genes (T/t antigens) under probasin control, Prostate size, cell proliferation, apoptosis, and the incidence and latency of tumor formation were evaluated. The double transgenic, probasin-bcl-2 X TRAMP F-1 (BxT) mice exhibited an increase in the wet weight of the prostate, This was associated with an increase in proliferation, attributable to Tit antigens, and a decrease in apoptosis attributable to bcl-2, The latency to tumor formation was also decreased in the BxT mice compared to the TRAMP mice. The incidence of metastases was identical in both the TRAMP and BxT mice, Lastly, the incidence of hormone-independent prostate cancer was reduced in the BxT mice compared to the TRAMP mice. Together, these results demonstrate that bcl-2 can facilitate multistep prostate carcinogenesis in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.			Gingrich, Jeffrey/0000-0002-4516-2893	NCI NIH HHS [T32CA67759-01, CA58204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067759, P50CA058204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bauer JJ, 1995, CLIN CANCER RES, V1, P1295; Beham AW, 1998, INT J MOL MED, V1, P953; BERNER A, 1993, BRIT J CANCER, V68, P380, DOI 10.1038/bjc.1993.344; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; Bruckheimer EM, 2000, ONCOGENE, V19, P2404, DOI 10.1038/sj.onc.1203571; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Eng MH, 1999, UROLOGY, V54, P1112, DOI 10.1016/S0090-4295(99)00297-6; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Heidenberg HB, 1996, UROLOGY, V48, P971, DOI 10.1016/S0090-4295(96)00365-2; Hsu CX, 1998, J UROLOGY, V160, P1500, DOI 10.1016/S0022-5347(01)62603-X; Johnson MI, 1998, ONCOL REP, V5, P553; Keshgegian AA, 1998, AM J CLIN PATHOL, V110, P443; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; Mateer SC, 1998, J BIOL CHEM, V273, P35339, DOI 10.1074/jbc.273.52.35339; MAY E, 1991, VIROLOGY, V180, P285, DOI 10.1016/0042-6822(91)90033-8; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; Pettaway C A, 1998, Tech Urol, V4, P35; RAFFO AJ, 1995, CANCER RES, V55, P4438; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Sullivan GF, 1998, CLIN CANCER RES, V4, P1393; THOMAS DJ, 1993, BRIT J UROL, V72, P778, DOI 10.1111/j.1464-410X.1993.tb16267.x; Westin P, 1997, INT J ONCOL, V10, P113	32	36	36	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5251	5258		10.1038/sj.onc.1203881	http://dx.doi.org/10.1038/sj.onc.1203881			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077442				2022-12-17	WOS:000165059700006
J	Modi, S; Kubo, A; Oie, H; Coxon, AB; Rehmatulla, A; Kaye, FJ				Modi, S; Kubo, A; Oie, H; Coxon, AB; Rehmatulla, A; Kaye, FJ			Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer	ONCOGENE			English	Article						RB; RBL1/p107; RBL2/p130; SV40; mesothelioma	CARCINOMA CELL-LINES; RETINOBLASTOMA PROTEIN; DIFFERENTIAL EXPRESSION; MALIGNANT MESOTHELIOMA; GROWTH SUPPRESSION; SIMIAN VIRUS-40; DNA-SEQUENCES; P107; SIMIAN-VIRUS-40; E2F	Mutational inactivation of the RE-related gene RBL2/ p130 has been reported as a common and important prognostic factor in human lung cancer. To examine the role of the RE-related gene family in lung cancer we analysed the protein expression of the RE gene in cell Lines obtained from 83 patients with small cell lung cancer (SCLC) and 114 patients with non-SCLC that included 21 novel lung tumor samples. While we detected five new SCLC with mutant RE expression (RB inactivation in 75/83; 90.4%), we did not detect any RE mutations in the new non-SCLC cell lines (RB inactivation in 13/114 non-SCLC and mesothelioma; 11.4%), In addition, we detected expression of a full-length RBL1/p107 and RBL2/p130 species in every sample tested (RBL1 or RBL2 inactivation in 0/69) and confirmed that both RE-related gene products retain functional binding activity to the E1A viral oncoprotein. Since expression of SV40 Large T antigen (Tag) has been reported in a subset of human lung tumors where it may inactivate RBL1 and RBL2, we also examined mesothelioma and non-mesothelioma lung tumors for Tag expression. Although we detected a faint 85 kDa protein species using specific anti-Tag antibodies, this signal migrated slightly faster than Tag extracted from Cos7 cells and did not exhibit binding activity to the RE or RBL1 proteins, Finally, we subjected 11 lung cancer cell lines to nucleotide sequencing and did not detect mutations within the C-terminal RBL2 exons 19-22 as recently reported. While the RB/p16 tumor suppressor pathway is targeted for mutations in 100% of lung cancers, mutational inactivation of the related RBL1 and RBL2 genes is a rare event.	Natl Naval Med Ctr, Med Branch, Bethesda, MD 20889 USA; NCI, Med Branch, Div Clin Sci, Bethesda, MD 20889 USA	Walter Reed National Military Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Kaye, FJ (corresponding author), Natl Naval Med Ctr, Med Branch, Bldg 8,Room 5101, Bethesda, MD 20889 USA.		kaye, frederic/E-2437-2011					Baldi A, 1996, CLIN CANCER RES, V2, P1239; Baldi A, 1997, CLIN CANCER RES, V3, P1691; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Brehm A, 1999, TRENDS BIOCHEM SCI, V24, P142, DOI 10.1016/S0968-0004(99)01368-7; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; CARNEY DN, 1985, CANCER RES, V45, P2913; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHENG JQ, 1994, CANCER RES, V54, P5547; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; CLAUDIO PP, 1994, CANCER RES, V54, P5556; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; CORBEIL HB, 1995, ONCOGENE, V11, P909; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Eberhard D, 1999, CANCER RES, V59, p1716S; Eberhard D, 1999, CANCER RES, V59, p1724s; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; Helin K, 1997, P NATL ACAD SCI USA, V94, P6933, DOI 10.1073/pnas.94.13.6933; HOWARD CM, 1998, J NATL CANCER I, V90, P123; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KELLEY MJ, 1995, INT J CANCER, V63, P226, DOI 10.1002/ijc.2910630214; Kohno T, 1999, CARCINOGENESIS, V20, P1403, DOI 10.1093/carcin/20.8.1403; KRATZKE RA, 1994, ONCOGENE, V9, P1321; KRATZKE RA, 1995, J NATL CANCER I, V87, P1870, DOI 10.1093/jnci/87.24.1870; LeCouter JE, 1998, DEVELOPMENT, V125, P4669; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lee MH, 1996, GENE DEV, V10, P1621, DOI 10.1101/gad.10.13.1621; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lohmann DR, 1999, HUM MUTAT, V14, P283, DOI 10.1002/(SICI)1098-1004(199910)14:4<283::AID-HUMU2>3.0.CO;2-J; Mulligan G, 1998, TRENDS GENET, V14, P223, DOI 10.1016/S0168-9525(98)01470-X; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; OTTERSON GA, 1994, ONCOGENE, V9, P3375; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHIMIZU E, 1994, ONCOGENE, V9, P2441; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Starostik P, 1996, MOL CELL BIOL, V16, P3606; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WANG JYJ, 1994, ADV CANCER RES, V64, P25, DOI 10.1016/S0065-230X(08)60834-9; Wang S, 1998, MOL CELL BIOL, V18, P7487, DOI 10.1128/MCB.18.12.7487; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yee Amy S., 1998, Frontiers in Bioscience, V3, pD532; YOKOTA J, 1988, ONCOGENE, V3, P471; ZALVIDE J, 1995, MOL CELL BIOL, V15, P5800; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	36	39	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	2000	19	40					4632	4639		10.1038/sj.onc.1203815	http://dx.doi.org/10.1038/sj.onc.1203815			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	356HQ	11030152				2022-12-17	WOS:000089438200009
J	Herr, I; Posovszky, C; Di Marzio, L; Cifone, MG; Boehler, T; Debatin, KM				Herr, I; Posovszky, C; Di Marzio, L; Cifone, MG; Boehler, T; Debatin, KM			Autoamplification of apoptosis following ligation of CD95-L, TRAIL and TNF-alpha	ONCOGENE			English	Article						FADD; JNK/SAPKs; ATF-2; cJun; APO-1/Fas	TUMOR-NECROSIS-FACTOR; APO-1/FAS LIGAND EXPRESSION; THERAPY-INDUCED APOPTOSIS; HUMAN T-CELLS; FAS LIGAND; SIGNAL-TRANSDUCTION; JNK/SAPK ACTIVITY; ACTIVATION; PROTEIN; STRESS	CD95-L, TNP-alpha and TRAIL are death-inducing ligands (DILs) which may signal apoptosis via crosslinking of their cognate receptors, The present study shows that treatment of cells with agonistic mAB alpha APO-1 (CD95), recombinant TRAIL or TNF-alpha leads to enhanced mRNA and protein expression of each DIL with concomitant death in target cells, Immunoprecipitation of CD95-L protein from supernatant as well as neutralizing antibodies suggest DIL proteins to be cooperatively acting mediators of these cytotoxic activity, Antoamplification of the death signal was blocked in cells with a defect in apoptosis signaling either due to a dysfunctional FADD molecule or to the failure to activate JNK/SAPKs, Phosphorylation and enhanced binding of cJun and ATF-2 to DIL promoters suggest JNK/SAPKs as activators of these transcription factors following death receptor triggering, In consequence, autocrine production of DILs allows the spread of death signals to sensitive target cells.	German Canc Res Ctr, Div Pediat Oncol, D-6900 Heidelberg, Germany; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; Univ Ulm, Childrens Hosp, Ulm, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); University of L'Aquila; Ulm University	Debatin, KM (corresponding author), Univ Kinderklin, Prittwitzstr 43, D-89075 Ulm, Germany.		Cifone, Maria Grazia/I-3750-2019; Cifone, Maria Grazia/ABH-1984-2021; Posovszky, Carsten/J-5966-2018; Böhler, Thomas/AAS-3986-2021; Debatin, Klaus-Michael/J-9704-2014; Di Marzio, Luisa/H-9969-2012; Di Marzio, Luisa/AAF-8052-2021	Cifone, Maria Grazia/0000-0002-9923-5445; Posovszky, Carsten/0000-0002-9487-8812; Debatin, Klaus-Michael/0000-0002-8397-1886; Di Marzio, Luisa/0000-0002-2518-7188				Afford SC, 1999, J EXP MED, V189, P441, DOI 10.1084/jem.189.2.441; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Basu S, 1998, ONCOGENE, V17, P3277, DOI 10.1038/sj.onc.1202570; Cahill MA, 1996, ONCOGENE, V13, P2087; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; Grell M, 1999, EMBO J, V18, P3034, DOI 10.1093/emboj/18.11.3034; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Herr I, 1996, CELL DEATH DIFFER, V3, P299; Herr I, 1999, CELL DEATH DIFFER, V6, P130, DOI 10.1038/sj.cdd.4400467; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; Herr I, 1999, INT J CANCER, V80, P417, DOI 10.1002/(SICI)1097-0215(19990129)80:3<417::AID-IJC14>3.0.CO;2-B; Herr I, 1997, EMBO J, V16, P6200, DOI 10.1093/emboj/16.20.6200; Jeremias I, 1998, EUR J IMMUNOL, V28, P143, DOI 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KIERNER PA, 1997, J IMMUNOL, V159, P1594; Krammer P H, 1999, Adv Immunol, V71, P163; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MILLERGRAZIANO CL, 1994, SHOCK, V1, P317, DOI 10.1097/00024382-199405000-00001; PIGUET PF, 1991, J EXP MED, V173, P673, DOI 10.1084/jem.173.3.673; Sheikh MS, 1998, CANCER RES, V58, P1593; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Vogt M, 1998, FEBS LETT, V429, P67, DOI 10.1016/S0014-5793(98)00562-6; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9	36	36	39	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 31	2000	19	37					4255	4262		10.1038/sj.onc.1203776	http://dx.doi.org/10.1038/sj.onc.1203776			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	349FL	10980599				2022-12-17	WOS:000089032900008
J	Ekman, N; Arighi, E; Rajantie, I; Saharinen, P; Ristimaki, A; Silvennoinen, O; Alitalo, K				Ekman, N; Arighi, E; Rajantie, I; Saharinen, P; Ristimaki, A; Silvennoinen, O; Alitalo, K			The Bmx tyrosine kinase is activated by IL-3 and G-CSF in a PI-3K dependent manner	ONCOGENE			English	Article						Bmx; IL-3; G-CSF; PI-3K; differentiation; apoptosis	PLECKSTRIN HOMOLOGY DOMAIN; BRUTON TYROSINE; PHOSPHOINOSITIDE 3-KINASE; B-LYMPHOCYTES; PH-DOMAIN; RECEPTOR; TEC; BTK; CELLS; FAMILY	Cytoplasmic protein tyrosine kinases play crucial roles in signaling, ia a variety of cell surface receptors, The Bmx tyrosine kinase, a member of the Tec family, is expressed in hematopoietic cells of the granulocytic and monocytic lineages. Here we show that Bmx is catalytically activated by interleukin-3 (IL-3) and granulocyte-colony stimulating factor (G-CSF) receptors, Activation of Ems required phosphatidylinositol 3-kinase (PI-3K) as demonstrated by the ability of PI-3K inhibitors to block the activation signal. A green fluorescent protein (GFP) tagged Bmx nas translocated to cellular membranes upon co-expression of a constitutively active form of PI-3K, further indicating a role for PI-3K in signaling upstream of Ems. The expression of wild type Bmx in 32D myeloid progenitor cells resulted in apoptosis in the presence of G-CSF, while cells expressing a kinase dead mutant of Bmx differentiated into mature granulocytes. However, Bmx did not modulate IL-3-dependent proliferation of the cells. These results demonstrate distinct effects of Ems in cytokine induced proliferation and differentiation of myeloid cells, and suggest that the stage specific expression of Ems is critical for the differentiation of myeloid cells.	Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, FIN-00014 Helsinki, Finland; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy; Univ Helsinki, Haartman Inst, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Obstet & Gynecol, Helsinki 00029, Finland; Tampere Univ, Tampere 33014, Finland	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University	Alitalo, K (corresponding author), Univ Helsinki, Mol Canc Biol Lab, POB 21,Haartmaninkatu 3, FIN-00014 Helsinki, Finland.		Saharinen, Pipsa I/C-9601-2016; Alitalo, Kari K/J-5013-2014	Saharinen, Pipsa I/0000-0003-2652-0584; Alitalo, Kari K/0000-0002-7331-0902				Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; AOKI Y, 1994, P NATL ACAD SCI USA, V91, P10606, DOI 10.1073/pnas.91.22.10606; Bence K, 1997, NATURE, V389, P296, DOI 10.1038/38520; BOGGS DANE R., 1967, SEMINAR HEMATOL, V4, P359; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Deng JB, 1998, J BIOL CHEM, V273, P16787, DOI 10.1074/jbc.273.27.16787; Dentelli P, 1999, J IMMUNOL, V163, P2151; DEWEERS M, 1993, EUR J IMMUNOL, V23, P3109, DOI 10.1002/eji.1830231210; Ekman N, 1997, CIRCULATION, V96, P1729, DOI 10.1161/01.CIR.96.6.1729; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; GIBSON S, 1993, BLOOD, V82, P1561; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; Hunter MG, 1998, J IMMUNOL, V160, P4979; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kaukonen J, 1996, BRIT J HAEMATOL, V94, P455; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; Kawakami Y, 1997, P NATL ACAD SCI USA, V94, P3938, DOI 10.1073/pnas.94.8.3938; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; LI TJ, 1995, IMMUNITY, V2, P451, DOI 10.1016/1074-7613(95)90026-8; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; Mano H, 1999, CYTOKINE GROWTH F R, V10, P267, DOI 10.1016/S1359-6101(99)00019-2; Mao JH, 1998, EMBO J, V17, P5638, DOI 10.1093/emboj/17.19.5638; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Migone TS, 1998, MOL CELL BIOL, V18, P6416, DOI 10.1128/MCB.18.11.6416; Miyajima A, 1999, INT J HEMATOL, V69, P137; Mohamed AJ, 1999, SCAND J IMMUNOL, V49, P113; MORISHITA K, 1987, J BIOL CHEM, V262, P3844; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nore BF, 2000, EUR J IMMUNOL, V30, P145, DOI 10.1002/1521-4141(200001)30:1<145::AID-IMMU145>3.0.CO;2-0; Okoh MP, 1999, BIOCHEM BIOPH RES CO, V265, P151, DOI 10.1006/bbrc.1999.1407; QUI Y, 1998, P NATL ACAD SCI USA, V95, P3644; Saharinen P, 1997, BLOOD, V90, P4341; SATO S, 1994, J EXP MED, V180, P2101, DOI 10.1084/jem.180.6.2101; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; SOMMERS CL, 1995, ONCOGENE, V11, P245; Suzuki H, 1999, SCIENCE, V283, P390, DOI 10.1126/science.283.5400.390; TAMAGNONE L, 1994, ONCOGENE, V9, P3683; Tomlinson MG, 1999, J BIOL CHEM, V274, P13577, DOI 10.1074/jbc.274.19.13577; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Uckun FM, 1996, SCIENCE, V273, P1096, DOI 10.1126/science.273.5278.1096; VALTIERI M, 1987, J IMMUNOL, V138, P3829; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Vassilev A, 1999, J BIOL CHEM, V274, P1646, DOI 10.1074/jbc.274.3.1646; Venkataraman C, 1998, J IMMUNOL, V160, P3322; Weil D, 1997, BLOOD, V90, P4332, DOI 10.1182/blood.V90.11.4332.4332_4332_4340; Wen X, 1999, J BIOL CHEM, V274, P38204, DOI 10.1074/jbc.274.53.38204; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687	51	36	36	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2000	19	36					4151	4158		10.1038/sj.onc.1203763	http://dx.doi.org/10.1038/sj.onc.1203763			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	347XU	10962576				2022-12-17	WOS:000088955100009
J	Pandey, P; Nakazawa, A; Ito, Y; Datta, R; Kharbanda, S; Kufe, D				Pandey, P; Nakazawa, A; Ito, Y; Datta, R; Kharbanda, S; Kufe, D			Requirement for caspase activation in monocytic differentiation of myeloid leukemia cells	ONCOGENE			English	Article						TPA; differentiation; caspases	PROTEIN-KINASE-C; ESTER-INDUCED DIFFERENTIATION; SIGNAL-TRANSDUCTION PATHWAY; CYTOCHROME-C; MACROPHAGE DIFFERENTIATION; GENE-EXPRESSION; TRANSCRIPTIONAL REGULATION; INDUCED APOPTOSIS; HL-60 CELLS; RELEASE	Human myeloid leukemia cells respond to 12-tetradecanoylphorbol-13-acetate (TPA) and other activators of protein kinase C (PKC) with the induction of terminal monocytic differentiation, The present studies demonstrate that TPA treatment of U-937 leukemia cells is associated with release of mitochondrial cytochrome c, activation of caspase-3 and induction of internucleosomal DNA fragmentation. By contrast, the TUR cell variant, which is deficient in PKC beta, failed to respond to TPA with release of cytochrome c and induction of the caspase-3 cascade. Moreover, stable overexpression of PKC beta in TUR cells reconstituted sensitivity to TPA-induced cytochrome c release and activation of caspase-3, The results also demonstrate that treatment of cells with the caspase inhibitor z-VAD-fmk blocks both TPA-induced apoptosis and monocytic differentiation, Similar results were obtained in U-937 cells stably expressing the CrmA caspase inhibitor. These findings demonstrate that TPA induces cytochrome c release by a PKC beta-dependent mechanism and that activation of caspase-mediated signaling is required for induction of the differentiated monocytic phenotype.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Pandey, P (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA29431, CA42802] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042802, R01CA029431] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; COLLINS SJ, 1987, BLOOD, V70, P1233; Datta R, 1997, J BIOL CHEM, V272, P1965, DOI 10.1074/jbc.272.3.1965; DEVENTE J, 1995, CELL GROWTH DIFFER, V6, P371; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; FUJIKI H, 1984, BIOCHEM BIOPH RES CO, V120, P339, DOI 10.1016/0006-291X(84)91259-2; GUNJI H, 1992, J CLIN INVEST, V89, P954, DOI 10.1172/JCI115677; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HASS R, 1992, CANCER RES, V52, P1445; HASS R, 1993, CELL GROWTH DIFFER, V4, P657; Jaken S, 1996, CURR OPIN CELL BIOL, V8, P168, DOI 10.1016/S0955-0674(96)80062-7; Kaneki M, 1999, MOL CELL BIOL, V19, P461; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; KHARBANDA SM, 1990, J CLIN INVEST, V86, P1517, DOI 10.1172/JCI114870; Kiley SC, 1997, CELL GROWTH DIFFER, V8, P221; Kim CN, 1997, CANCER RES, V57, P3115; KIRKEN RA, 1995, PROTEIN EXPRES PURIF, V6, P707, DOI 10.1006/prep.1995.1093; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MCFARLANE DE, 1994, J BIOL CHEM, V269, P4327; NISHIKAWA M, 1990, CANCER RES, V50, P621; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; STONE RM, 1988, BLOOD, V72, P739; STONE RM, 1988, BLOOD, V72, P208; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; TONETTI DA, 1994, J BIOL CHEM, V269, P23230; TONETTI DA, 1992, CELL GROWTH DIFFER, V3, P739; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; YAM LT, 1971, AM J CLIN PATHOL, V55, P283; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YANG KD, 1994, BLOOD, V83, P490	39	36	37	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3941	3947		10.1038/sj.onc.1203751	http://dx.doi.org/10.1038/sj.onc.1203751			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951587	Bronze			2022-12-17	WOS:000088614300013
J	Strack, P; Caligiuri, M; Pelletier, M; Boisclair, M; Theodoras, A; Beer-Romero, P; Glass, S; Parsons, T; Copeland, RA; Auger, KR; Benfield, P; Brizuela, L; Rolfe, M				Strack, P; Caligiuri, M; Pelletier, M; Boisclair, M; Theodoras, A; Beer-Romero, P; Glass, S; Parsons, T; Copeland, RA; Auger, KR; Benfield, P; Brizuela, L; Rolfe, M			SCF beta-TRCP and phosphorylation dependent ubiquitination of I kappa B alpha catalyzed by Ubc3 and Ubc4	ONCOGENE			English	Article						I kappa B alpha; NF kappa B; SCF beta-TRCP; cullin; ubiquitin	F-BOX PROTEIN; LIGASE COMPLEX; ENZYME CDC34; HUMAN CUL-1; CELL-CYCLE; DEGRADATION; CATENIN; FAMILY; PATHWAY; SKP1	NF kappa B is an important transcriptional regulator of multiple pro-inflammatory genes. In non-stimulated cells NF kappa B is anchored in the cytoplasm via the inhibitory protein I kappa B alpha. Following exposure to diverse proinflammatory signals (e.g. TNF alpha, IL1, LPS) various signal transduction cascades are initiated converging on the I kappa B kinase (IKK). IKK phosphorylates I kappa B alpha on serines 32 and 36 signaling the inhibitory protein for ubiquitin-mediated degradation. The SCFbeta-TRCP complex is the ubiquitin ligase responsible for mediating phosphorylation dependent ubiquitination of I kappa-B alpha. Here we reconstitute phosphorylation dependent ubiquitination of I kappa B alpha using recombinant components. Our results suggest that the cullin specificity of the SCF complex may reflect its ability to associate with Rbx1, We demonstrate specific ubiquitination of I kappa B alpha by Ubc3 and Ubc4 in a phosphorylation and SCFbeta-TRCP dependent manner and that both are capable of associating with the SCFbeta-TRCP complex isolated from human cells. Finally, we show that Ubc4 is in excess to Ubc3 in THP.1 cells and 19 times more efficient in catalyzing the reaction, suggesting that Ubc4 is the preferentially used Ubc in this reaction in vivo. Our results also suggest that ubiquitin is transferred directly from the Ubc to phospho-I kappa B alpha in a SCFbeta-TRCP dependent reaction.	Mitotix Inc, Cambridge, MA 02139 USA; DuPont Pharmaceut Co, Wilmington, DE 19880 USA	DuPont	Caligiuri, M (corresponding author), Mitotix Inc, 1 Kendall Sq,Bldg 600,Suite 622, Cambridge, MA 02139 USA.			Strack, Peter/0000-0003-4042-0416				BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; COPELAND RA, 1996, ENZYMES PRACTICAL IN, P93; Elledge SJ, 1998, BBA-REV CANCER, V1377, pM61, DOI 10.1016/S0304-419X(98)00005-5; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Fuchs SY, 1999, ONCOGENE, V18, P2039, DOI 10.1038/sj.onc.1202760; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408; Jiang J, 1998, NATURE, V391, P493, DOI 10.1038/35154; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Kroll M, 1999, J BIOL CHEM, V274, P7941, DOI 10.1074/jbc.274.12.7941; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Latres E, 1999, ONCOGENE, V18, P849, DOI 10.1038/sj.onc.1202653; Lisztwan J, 1998, EMBO J, V17, P368, DOI 10.1093/emboj/17.2.368; Maniatis T, 1999, GENE DEV, V13, P505, DOI 10.1101/gad.13.5.505; Margottin F, 1998, MOL CELL, V1, P565, DOI 10.1016/S1097-2765(00)80056-8; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; ROLFE M, 1995, P NATL ACAD SCI USA, V92, P3264, DOI 10.1073/pnas.92.8.3264; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Suzuki H, 1999, BIOCHEM BIOPH RES CO, V256, P127, DOI 10.1006/bbrc.1999.0289; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Vuillard L, 1999, FEBS LETT, V455, P311, DOI 10.1016/S0014-5793(99)00895-9; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159	37	36	39	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 20	2000	19	31					3529	3536		10.1038/sj.onc.1203647	http://dx.doi.org/10.1038/sj.onc.1203647			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337FJ	10918611				2022-12-17	WOS:000088346500009
J	Rameil, P; Lecine, P; Ghysdael, J; Gouilieux, F; Kahn-Perles, B; Imbert, J				Rameil, P; Lecine, P; Ghysdael, J; Gouilieux, F; Kahn-Perles, B; Imbert, J			IL-2 and long-term T cell activation induce physical and functional interaction between STAT5 and ETS transcription factors in human T cells	ONCOGENE			English	Article						T lymphocytes; IL-2/IL-2R; STAT5; ETS; transcription	RECEPTOR-ALPHA GENE; NF-KAPPA-B; DNA-BINDING ACTIVITY; COOPERATIVE INTERACTION; SYNERGISTIC ACTIVATION; PROTEIN INTERACTIONS; SIGNAL-TRANSDUCTION; CYCLE PROGRESSION; TYROSINE KINASES; INTERFERON-ALPHA	Activation of Stat5 by many cytokines implies that it cannot alone insure the specificity of the regulation of its target genes. Ne have evidenced a physical and functional interaction between members of two unrelated transcription factor families, Ets-l, Ets-2 and Stat5, which could contribute to the proliferative response to interleukin 2, Competition with GAS - and EBS-specific oligonucleotides and immunoassays with a set of anti-Stat and anti-Ets families revealed that the IL-2-induced Stat5-Ets complex recognizes several GAS motifs identified as target sites for activated Stat5 dimers, Coimmunoprecipitation experiments evidenced that a Stat5/Ets-1/2 complex is formed in vivo in absence of DNA. GST-pun down experiments demonstrated that the C-terminal domain of Ets-1 is sufficient for this interaction in vitro. Cotransfection experiments in Kit225 T cells resulted in cooperative transcriptional activity. between both transcription factors in response to a combination of IL-2, PMA and ionomycin. A Stat5-Ets protein complex mas the major inducible DNA-binding complex bound to the human IL-2rE GASd/EBSd motif in long-term proliferating normal human T cells activated by CD2 and CD28, These results suggest that the inducible Stat5-Ets protein interaction plays a role in the regulation of gene expression in response to IL-2 in human T T lmphocytes.	INSERM, U119, F-13009 Marseille, France; Inst Curie, CNRS, UMR146, F-91405 Orsay, France; Hop Cochin, ICGM, INSERM, U363, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier	Imbert, J (corresponding author), INSERM, U119, 27 Blvd Lei Roure, F-13009 Marseille, France.		Kahn-Perlès, Brigitte/M-3513-2016; Imbert, Jean/AAG-1165-2020; GHYSDAEL, Jacques/F-3377-2013; Imbert, Jean/G-3248-2013; Lecine, Patrick/H-9338-2016	Kahn-Perlès, Brigitte/0000-0001-5673-5901; Imbert, Jean/0000-0002-0478-9593; Imbert, Jean/0000-0002-0478-9593; Lecine, Patrick/0000-0002-8091-7286; Gouilleux, Fabrice/0000-0001-6047-1718				Anderson MK, 1999, DEVELOPMENT, V126, P3131; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Bassuk AG, 1997, ADV IMMUNOL, V64, P65, DOI 10.1016/S0065-2776(08)60887-1; Beadling C, 1996, EMBO J, V15, P1902, DOI 10.1002/j.1460-2075.1996.tb00541.x; BEADLING C, 1994, EMBO J, V13, P5605, DOI 10.1002/j.1460-2075.1994.tb06898.x; BHAT NK, 1989, J IMMUNOL, V142, P672; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BRADFORD AP, 1995, MOL CELL BIOL, V15, P2849; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Bucher P, 1997, IMMUNOBIOLOGY, V198, P136, DOI 10.1016/S0171-2985(97)80034-4; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Cella N, 1998, MOL CELL BIOL, V18, P1783, DOI 10.1128/MCB.18.4.1783; Cirillo G, 1999, MOL CELL BIOL, V19, P6240; COFFER P, 1994, ONCOGENE, V9, P911; COSTELLO R, 1993, CELL GROWTH DIFFER, V4, P329; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; Genuario RR, 1996, J BIOL CHEM, V271, P4388; Ghysdael J, 1997, ON COGENES TRANSCRIP, P29; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; HORI T, 1987, BLOOD, V70, P1069; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Imada K, 1998, J EXP MED, V188, P2067, DOI 10.1084/jem.188.11.2067; Jayaraman G, 1999, J BIOL CHEM, V274, P17342, DOI 10.1074/jbc.274.24.17342; John S, 1999, MOL CELL BIOL, V19, P1910; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; KahnPerles B, 1997, J BIOL CHEM, V272, P21774, DOI 10.1074/jbc.272.35.21774; Lecine P, 1996, MOL CELL BIOL, V16, P6829; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Lin Jian-Xin, 1997, Cytokine and Growth Factor Reviews, V8, P313; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Look DC, 1995, J BIOL CHEM, V270, P30264, DOI 10.1074/jbc.270.51.30264; Meyer WKH, 1997, J BIOL CHEM, V272, P31821, DOI 10.1074/jbc.272.50.31821; Miyazaki T, 1996, CANCER SURV, V27, P25; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Muhlethaler-Mottet A, 1998, IMMUNITY, V8, P157, DOI 10.1016/S1074-7613(00)80468-9; MUTHUSAMY N, 1995, NATURE, V377, P639, DOI 10.1038/377639a0; Nakajima H, 1997, IMMUNITY, V7, P691, DOI 10.1016/S1074-7613(00)80389-1; OLIVE D, 1994, FUND CLIN IMMUNOL, V2, P185; PEREZ C, 1994, MOL CELL BIOL, V14, P5023, DOI 10.1128/MCB.14.8.5023; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; RABAULT B, 1994, J BIOL CHEM, V269, P28143; Rabault B, 1996, ONCOGENE, V13, P877; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; Serdobova I, 1997, J EXP MED, V185, P1211, DOI 10.1084/jem.185.7.1211; Shen CH, 1998, MOL CELL BIOL, V18, P3395, DOI 10.1128/MCB.18.6.3395; Sieweke MH, 1996, CELL, V85, P49, DOI 10.1016/S0092-8674(00)81081-8; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SOLDAINI E, 1995, J BIOL CHEM, V270, P10733, DOI 10.1074/jbc.270.18.10733; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Thomas RS, 1997, ONCOGENE, V14, P2845, DOI 10.1038/sj.onc.1201125; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; Udy GB, 1997, P NATL ACAD SCI USA, V94, P7239, DOI 10.1073/pnas.94.14.7239; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; Yamamoto H, 1998, GENE DEV, V12, P1315, DOI 10.1101/gad.12.9.1315; Yang BS, 1996, MOL CELL BIOL, V16, P538; Zamorano J, 1998, J IMMUNOL, V160, P3502; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	68	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2000	19	17					2086	2097		10.1038/sj.onc.1203542	http://dx.doi.org/10.1038/sj.onc.1203542			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	308TB	10815800	Green Published			2022-12-17	WOS:000086728000002
J	Le, Q; Dawson, MI; Soprano, DR; Soprano, KJ				Le, Q; Dawson, MI; Soprano, DR; Soprano, KJ			Modulation of retinoic acid receptor function alters the growth inhibitory response of oral SCC cells to retinoids	ONCOGENE			English	Article						SCC cells; retinoic acid receptors; RAR agonists; RAR antagonists; conformationally restricted retinoids	OVARIAN ADENOCARCINOMA CELLS; BREAST-CANCER CELLS; SQUAMOUS CARCINOMA-CELLS; TERMINAL DIFFERENTIATION; SYNTHETIC RETINOIDS; SELECTIVE RETINOIDS; HUMAN KERATINOCYTES; DIMETHYL-SULFOXIDE; RETROVIRAL VECTORS; CYCLE PROGRESSION	Retinoids have been shown to inhibit the growth of many human tumor cells including breast, ovarian and squamous cell carcinoma (SCC), While the exact mechanism of retinoid mediated growth suppression is not known, a role for the retinoic acid receptors (RARs) and retinoid X receptors (RXRs) has been established in both the breast and ovarian tumor cell models. We set out to determine if modulation of RAR/RXR function would alter the retinoid sensitivity of oral SCC cells. We found that the growth of SCC cells was significantly inhibited by treatment with either all-trans-retinoic acid (trans-RA) or the synthetic, conformationally restricted RAR gamma selective retinoids MM11254 and MM11389. In order to demonstrate a role for RAR/RXR function in this process, stable oral SCC cell clones constitutively overexpressing the dominant negative mutant RAR beta 2 (R269Q) were prepared and shown to exhibit reduced RAR/RXR transcriptional transactivation activity. We found that oral SCC cells exhibiting reduced RAR/RXR function became resistant to growth inhibition by all-trans-RA, MM11254 and MM11389. Likewise, treatment of oral SCC cells with the RAR gamma antagonist MM11253 was found to block the ability of MM11254 and MM11389 to inhibit SCC cell growth. Thus, modulation of RAR function through the use of RAR-gamma selective agonists, an RAR-gamma selective antagonist or a pan-RAR dominant negative mutant significantly alters the growth inhibitory response of oral SCC cells to retinoids.	Temple Univ, Sch Med, Dept Microbiol & Immunol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Mol Med Res Inst, Dept Med Chem, Mt View, CA 94043 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Soprano, KJ (corresponding author), Temple Univ, Sch Med, Dept Microbiol & Immunol, 3400 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL CANCER INSTITUTE [R01CA064945, P01CA051993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049045] Funding Source: NIH RePORTER; NCI NIH HHS [CA51993, CA64945] Funding Source: Medline; NIDDK NIH HHS [DK49045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYLSWORTH CF, 1986, J NATL CANCER I, V76, P339; BENNER SE, 1994, J NATL CANCER I, V86, P140, DOI 10.1093/jnci/86.2.140; BERNARD BA, 1992, BIOCHEM BIOPH RES CO, V186, P977, DOI 10.1016/0006-291X(92)90842-9; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; CARMICHAEL J, 1987, CANCER RES, V47, P936; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chao WR, 1997, CANCER LETT, V115, P1, DOI 10.1016/S0304-3835(97)04598-9; CLINE PR, 1983, CANCER RES, V43, P3203; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; Crowe DL, 1998, CANCER RES, V58, P142; DARWICHE N, 1995, CANCER RES, V55, P2774; Dawson MI, 1998, CANCER LETT, V133, P1, DOI 10.1016/S0304-3835(98)00147-5; DAWSON MI, 1995, J MED CHEM, V38, P3368, DOI 10.1021/jm00017a021; DE LUCA LM, 1991, FASEB J, V5, P2924; GRUNT TW, 1991, J CELL SCI, V100, P657; GRUNT TW, 1992, J CELL SCI, V103, P501; Gudas Lorraine J., 1994, P443; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; HARNISH DC, 1992, DEV DYNAM, V194, P239, DOI 10.1002/aja.1001940309; HAWLEY RG, 1994, GENE THER, V1, P136; HERMANN T, 1992, MOL ENDOCRINOL, V6, P1153, DOI 10.1210/me.6.7.1153; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hong Waun Ki, 1994, P597; HU L, 1991, CANCER RES, V51, P3972; KIM KH, 1984, P NATL ACAD SCI-BIOL, V81, P4280, DOI 10.1073/pnas.81.14.4280; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; Liu Y, 1996, MOL CELL BIOL, V16, P1138; LOTAN R, 1994, CANCER RES, V54, pS1987; LOTAN R, 1990, METHOD ENZYMOL, V190, P100; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LOTAN R, 1987, INT J CANCER, V40, P224, DOI 10.1002/ijc.2910400217; LOTAN R, 1992, J CELL PHYSIOL, V151, P94, DOI 10.1002/jcp.1041510114; Mangelsdorf David J., 1994, P319; Monzon RI, 1997, MOL PHARMACOL, V51, P377; Moon Richard C., 1994, P573; MUNKER M, 1987, CANCER RES, V47, P4081; Oridate N, 1996, ONCOGENE, V12, P2019; OWEN TA, 1987, J BIOL CHEM, V262, P15111; OWEN TA, 1989, J CELL PHYSIOL, V139, P424, DOI 10.1002/jcp.1041390227; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; PELLEGRINI R, 1995, CELL GROWTH DIFFER, V6, P863; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; REISS M, 1985, J NATL CANCER I, V74, P1015; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RUBIN AL, 1986, CANCER RES, V46, P2356; SAKAR R, 1988, CANC LET, V41, P225; SAUNDERS DE, 1993, ANTI-CANCER DRUG, V4, P201, DOI 10.1097/00001813-199304000-00012; SHAO ZM, 1995, ONCOGENE, V11, P493; SOMAY C, 1992, BRIT J CANCER, V66, P93, DOI 10.1038/bjc.1992.223; SOMAY C, 1991, J CELL SCI, V100, P657; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; Soprano DR, 1996, ONCOGENE, V12, P577; Sun SY, 1997, CANCER RES, V57, P4931; TAIRIS N, 1995, J BIOL CHEM, V270, P18380, DOI 10.1074/jbc.270.31.18380; THATCHER SM, 1985, DIFFERENTIATION, V29, P82; TOSCANI A, 1988, ONCOGENE RES, V3, P223; TOSCANI A, 1987, ANAL BIOCHEM, V165, P309, DOI 10.1016/0003-2697(87)90274-0; VOLKES EE, 1993, NEW ENGL J MED, V328, P184; Wilcken NRC, 1996, CELL GROWTH DIFFER, V7, P65; Wong DTW, 1996, CRIT REV ORAL BIOL M, V7, P319, DOI 10.1177/10454411960070040201; Wu SJ, 1998, ONCOGENE, V17, P2839, DOI 10.1038/sj.onc.1202208; Wu SJ, 1997, EXP CELL RES, V237, P118, DOI 10.1006/excr.1997.3769; Wu SJ, 1998, J CELL BIOCHEM, V68, P378, DOI 10.1002/(SICI)1097-4644(19980301)68:3<378::AID-JCB8>3.0.CO;2-R; Wu SJ, 1997, EXP CELL RES, V232, P277, DOI 10.1006/excr.1997.3495; XU XC, 1994, CANCER RES, V54, P3580	66	36	39	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 9	2000	19	11					1457	1465		10.1038/sj.onc.1203436	http://dx.doi.org/10.1038/sj.onc.1203436			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295AD	10723137				2022-12-17	WOS:000085942700011
J	Li, ML; Lewis, B; Capuco, AV; Laucirica, R; Furth, PA				Li, ML; Lewis, B; Capuco, AV; Laucirica, R; Furth, PA			WAP-TAg transgenic mice and the study of dysregulated cell survival, proliferation, and mutation during breast carcinogenesis	ONCOGENE			English	Article						breast carcinogenesis; mouse model; SV40TAg; apoptosis; proliferation	SV40 T-ANTIGEN; MAMMARY-GLAND INVOLUTION; CANCER FORMATION; APOPTOSIS; PATHWAYS; ANIMALS; DEATH	Understanding the process of carcinogenesis is key to developing therapies which might interrupt or reverse tumor onset and progression. Cell growth and death signals are dependent not only upon molecular mechanisms within a cell but also upon external stimuli such as hormones, cell-cell signaling, and extracellular matrix, Mouse models can be used to dissect these complex processes, to identify key signaling pathways operating at different stages of tumorigenesis, and to test the strength of specific interventions. In the WAP-TAg mouse model, carcinogenesis is initiated by expression of the Simian Virus 40 T antigen (TAg), TAg expression is triggered by hormonal stimulation, either during estrus or pregnancy. Breast adenocarcinomas (ranging from well to poorly differentiated) develop in 100% of the female mice by approximately 8-9 months of age, Three distinct stages of tumorigenesis are easily identified: an initial proliferation, hyperplasia; and adenocarcinoma. The mean time to first palpable tumor in mice which undergo at least one pregnancy is 6 months. The tumorigenic process is marked by a competition between proliferation and apoptosis and is characterized by cellular acquisition of genetic mutations and increased stromal fibrosis. Protein levels of cell cycle control genes cyclin D1, cdk2, and E2F-1 are increased in these adenocarcinomas. c-Fos protein levels are slightly increased in these cancers, while c-Jun levels do not change. Hormonal exposure alters progression, Estrogen plays a role during the early stages of oncogenesis although the growth of the resulting adenocarcinomas is estrogen-independent. Transient hormonal stimulation by glucocorticoids that temporarily increases the rate of cell proliferation results in tetraploidy, premature appearance of irreversible hyperplasia, and early tumor development. Tumor appearance also can be accelerated through over expression of the cell survival protein, Bcl-2, Bcl-2 over expression not only reduces apoptosis during the initial proliferative process but also decreases the total rate of cell proliferation. This block in cell proliferation is lost selectively as the cells transition to adenocarcinoma, The WAP-TAg model can be utilized to investigate how the basic processes of cell proliferation, apoptosis, DNA mutation, and DNA repair are modified by external and internal signals during mammary oncogenesis.	Univ Maryland, Sch Med,Inst Human Virol, Dept Med, Div Infect Dis, Baltimore, MD 21201 USA; Baltimore Vet Affairs Med Ctr, Baltimore, MD 21201 USA; ARS, Inst Livestock & Poultry Sci, USDA, Beltsville, MD 20705 USA; Baylor Coll Med, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baltimore VA Medical Center; United States Department of Agriculture (USDA); Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; University System of Maryland; University of Maryland Baltimore	Furth, PA (corresponding author), Univ Maryland, Sch Med,Inst Human Virol, Dept Med, Div Infect Dis, 725 W Lombard St,Room N545, Baltimore, MD 21201 USA.				NCI NIH HHS [CA70545] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA070545] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		DEMERIL D, 1996, CANCER, V77, P1494; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FENG ZW, 1995, J CELL BIOL, V131, P1095, DOI 10.1083/jcb.131.4.1095; Furth PA, 1999, ONCOGENE, V18, P6589, DOI 10.1038/sj.onc.1203073; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HEDLEY DW, 1983, J HISTOCHEM CYTOCHEM, V31, P1333, DOI 10.1177/31.11.6619538; Hennighausen L, 1997, J BIOL CHEM, V272, P7567, DOI 10.1074/jbc.272.12.7567; HORAK E, 1991, ONCOGENE, V6, P2277; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; Li ML, 1997, P NATL ACAD SCI USA, V94, P3425, DOI 10.1073/pnas.94.7.3425; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; Lund LR, 1996, DEVELOPMENT, V122, P181; MEITZ JA, 1992, EMBO J, V11, P5013; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Newcomb PA, 1997, J MAMMARY GLAND BIOL, V2, P311, DOI 10.1023/A:1026344707161; Santarelli R, 1996, ONCOGENE, V12, P495; Schorr K, 1999, CANCER RES, V59, P2541; Schorr K, 1999, J MAMMARY GLAND BIOL, V4, P153, DOI 10.1023/A:1018773123899; Shibata MA, 1999, EMBO J, V18, P2692, DOI 10.1093/emboj/18.10.2692; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; Tzeng YJ, 1996, FEBS LETT, V380, P215, DOI 10.1016/0014-5793(96)00021-X; TZENG YJ, 1993, ONCOGENE, V8, P1965; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503	25	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1010	1019		10.1038/sj.onc.1203271	http://dx.doi.org/10.1038/sj.onc.1203271			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713684				2022-12-17	WOS:000085796400006
J	Pettiford, SM; Herbst, R				Pettiford, SM; Herbst, R			The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP	ONCOGENE			English	Article						signal transduction; phosphatase; HePTP; MAP-kinase	MEGAKARYOCYTIC DIFFERENTIATION; K562 CELLS; LC-PTP; SUSTAINED ACTIVATION; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; EXPRESSION; CLONING; BRAIN; GENE	HePTP is a tyrosine specific protein phosphatase that is strongly expressed in activated T-cells, It was recently demonstrated that in transfected T-cells HePTP impairs TCR-mediated activation of the MAP-kinase family members ERK2 and p38 and it was suggested that both ERK and p38 MAP-kinases are substrates of HePTP, The HePTP gene has been mapped to human chromosome 1q32.1, Abnormalities in this region are frequently found in various hematopoietic malignancies. HePTP is highly expressed in acute myeloid leukemia and its expression in fibroblasts resulted in transformation. To address a possible involvement of HePTP in hematopoietic malignancies we sought to identify HePTP substrate(s) in leukemic cells. Using substrate trapping mutants we have identified the MAP-kinase ERK2 as a specific target of HePTP in the myelogenous leukemia cell line K562, Tyrosine phosphorylated ERK2, but not ERK1, p38, or JNK1, efficiently bound to catalytically inactive HePTP mutants in which the active site cysteine (HePTP-C/S) or the conserved aspartic acid residue (HePTP-D/A) had been exchanged for serine and alanine, respectively. Moreover, the interaction of ERK2 with HePTP trapping mutants,vas dependent on ERK2 tyrosine phosphorylation, indicating that HePTP is specifically targeted to activated ERK2, Using a deletion mutant of HePTP (HePTP-dLD), in which 14 amino acid residues within the N-terminus are missing, rye show that regions outside the catalytic domain are also required for the interaction. Furthermore, overexpression of HePTP in K562 cells and fibroblasts interfered with PMA or growth factor induced MAP-kinase activation and HePTP efficiently dephosphorylated active ERK2 on the tyrosine residue in the activation loop in vitro. Together, these data identify ERK2 as a specific and direct target of HePTP and are consistent with a model in which HePTP negatively regulates ERK2 activity as part of a feedback mechanism.	DNAX Res Inst Mol & Cellular Biol Inc, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Herbst, R (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, 901 Calif Ave, Palo Alto, CA 94304 USA.							AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; ADACHI M, 1995, FEBS LETT, V372, P113, DOI 10.1016/0014-5793(95)00952-6; ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ADACHI M, 1994, FEBS LETT, V338, P47, DOI 10.1016/0014-5793(94)80114-2; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; Bult A, 1997, EUR J CELL BIOL, V72, P337; Byon JCH, 1997, P SOC EXP BIOL MED, V216, P1; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; FAUMAN EB, 1996, TIBS, P413; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GAITS F, 1994, CELL MOL BIOL, V40, P677; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Gopalbhai K, 1998, J CELL PHYSIOL, V174, P35, DOI 10.1002/(SICI)1097-4652(199801)174:1<35::AID-JCP5>3.0.CO;2-H; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HENDRIKS W, 1995, BIOCHEM J, V305, P499, DOI 10.1042/bj3050499; Herrera R, 1998, EXP CELL RES, V238, P407, DOI 10.1006/excr.1997.3847; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; KELLY K, 1995, CURR OPIN IMMUNOL, V7, P327, DOI 10.1016/0952-7915(95)80106-5; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; Lewis M, 1998, MT SINAI J MED, V65, P139; LOMBROSO PJ, 1991, P NATL ACAD SCI USA, V88, P7242, DOI 10.1073/pnas.88.16.7242; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; MITELMAN F, 1990, CYTOGENET CELL GENET, V55, P358, DOI 10.1159/000133022; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Patarca R, 1996, CRIT REV ONCOGENESIS, V7, P343, DOI 10.1615/CritRevOncog.v7.i5-6.20; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Racke FK, 1997, J BIOL CHEM, V272, P23366, DOI 10.1074/jbc.272.37.23366; Radha V, 1997, FEBS LETT, V409, P33, DOI 10.1016/S0014-5793(97)00471-7; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Rosson D, 1998, ARCH BIOCHEM BIOPHYS, V352, P298, DOI 10.1006/abbi.1998.0597; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1998, J BIOL CHEM, V273, P15340, DOI 10.1074/jbc.273.25.15340; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHARMA E, 1995, MOL BRAIN RES, V32, P87, DOI 10.1016/0169-328X(95)00066-2; SHIOZUKA K, 1995, GENE, V162, P279, DOI 10.1016/0378-1119(95)00306-Q; TAKEKAWA M, 1994, FEBS LETT, V339, P222, DOI 10.1016/0014-5793(94)80420-6; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Urushibara N, 1998, INT J ONCOL, V12, P603; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; van Huijsduijnen RH, 1998, GENE, V225, P1; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; ZANKE B, 1994, LEUKEMIA, V8, P236; ZANKE B, 1992, EUR J IMMUNOL, V22, P235, DOI 10.1002/eji.1830220134; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161	48	36	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 17	2000	19	7					858	869		10.1038/sj.onc.1203408	http://dx.doi.org/10.1038/sj.onc.1203408			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	288MW	10702794				2022-12-17	WOS:000085567700003
J	Calvo, KR; Knoepfler, P; McGrath, S; Kamps, MP				Calvo, KR; Knoepfler, P; McGrath, S; Kamps, MP			An inhibitory switch derepressed by Pbx, Hox, and Meis/Prep1 partners regulates DNA-binding by Pbx1 and E2a-Pbx1 and is dispensable for myeloid immortalization by E2a-Pbx1	ONCOGENE			English	Article						Pbx; E2a-Pbx1; t(1;19) pre-B ALL; Hox; Meis; Prep1; leukemia	GLUCOCORTICOID RESPONSE ELEMENT; ACUTE LYMPHOBLASTIC-LEUKEMIA; HUMAN PROTOONCOGENE PBX1; ONCOPROTEIN E2A-PBX1; PRE-B; TRANSCRIPTION FACTOR; TRANSLOCATION PROTEIN; CHIMERIC ONCOPROTEIN; HOMEODOMAIN PROTEIN; MAPKAP KINASE-2	The Pbx/Exd family of homeodomain (HD) proteins contribute to the transcriptional and developmental roles of other Hox and Meis/Prep1/Hth HD proteins through heterodimer formation, E2a-Pbx1 is an oncogenic derrivative of Pbx1 produced by the t(1;19) translocation in pediatric pre-B cell acute lymphoblastic leukemia. E2a-Pbx1 heterodimerizes with Hox but not with Meis/ Prep1 proteins, produces acute myeloid leukemia in mice, and blocks differentiation of cultured murine myeloid progenitors, Here, we characterize negative and positive regulatory sequences that flank the Pbx1 HD and determine their importance for myeloid immortalization by E2a-Pbx1. A 25 residue predicted alpha helix preceding the Pbx1 HD bound the HD and prevented both its binding to DNA and its ability to heterodimerize with Hox proteins, Addition of 39 residues N-terminal to this inhibitory helix exposed a Pbs dimerization interface that orchestrated cooperative DNA-binding of E2a-Pbx1 and all Pbx proteins as homodimers and heterdimers, Sequences inhibiting DNA-binding and mediating Pbs dimerization coincided with those reported to have nuclear export function. An additional 103 residues N-terminal to the Pbx dimerization interface restored heterodimerization with Hox and Meis1/Prep1 proteins. This negative switch domain comprised of the inhibitory helix and N-terminal regions required for its partner-mediated derepression - was dispensable for myeloid immortalization by E2a-Pbx1, While stabilizing the heterodimer, the 3(10) helix C-terminal to the Pbx1 HD was also dispensable for the ability of E2a-Pbx1 to heterodimerize with Hox proteins and immortalize myeloblasts. Retention of myeloid immortalization by E2a-Pbx1 proteins lacking all Pbx1 sequences N- or C-terminal to the HD indicates that Has proteins, or a get undefined factor that binds the Pbx1 HD and derepresses DNA-binding by the HD, cooperate with E2a-Pbx1 in myeloid immortalization.	Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Calvo, KR (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Calvo, Katherine/A-8109-2009	Knoepfler, Paul/0000-0001-5444-334X; Calvo, Katherine/0000-0002-0771-4191	NATIONAL CANCER INSTITUTE [R01CA056876] Funding Source: NIH RePORTER; NCI NIH HHS [CA56876] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; Ben-Levy R, 1998, CURR BIOL, V8, P1049, DOI 10.1016/S0960-9822(98)70442-7; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bischof LJ, 1998, J BIOL CHEM, V273, P7941, DOI 10.1074/jbc.273.14.7941; CARROLL AJ, 1984, BLOOD, V63, P721; CHAN SK, 1994, CELL, V78, P603, DOI 10.1016/0092-8674(94)90525-8; Chang CP, 1997, MOL CELL BIOL, V17, P81, DOI 10.1128/MCB.17.1.81; Chang CP, 1997, MOL CELL BIOL, V17, P5679, DOI 10.1128/MCB.17.10.5679; Chang CP, 1996, MOL CELL BIOL, V16, P1734; DeCesare D, 1997, J BIOL CHEM, V272, P23921, DOI 10.1074/jbc.272.38.23921; DEDERA DA, 1993, CELL, V74, P833, DOI 10.1016/0092-8674(93)90463-Z; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Engel K, 1998, EMBO J, V17, P3363, DOI 10.1093/emboj/17.12.3363; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Green NC, 1998, J BIOL CHEM, V273, P13273, DOI 10.1074/jbc.273.21.13273; Grieder NC, 1997, EMBO J, V16, P7402, DOI 10.1093/emboj/16.24.7402; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jonsen MD, 1996, MOL CELL BIOL, V16, P2065; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KAMPS MP, 1991, GENE DEV, V5, P358, DOI 10.1101/gad.5.3.358; Kamps MP, 1996, ONCOGENE, V12, P19; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; KAMPS MP, 1994, ONCOGENE, V9, P3159; Kanno T, 1998, MOL CELL BIOL, V18, P2444, DOI 10.1128/MCB.18.5.2444; Kasper LH, 1999, MOL CELL BIOL, V19, P764; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, ONCOGENE, V14, P2521, DOI 10.1038/sj.onc.1201097; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; Lu Q, 1996, MOL CELL BIOL, V16, P1632; Lu QA, 1997, ONCOGENE, V14, P75, DOI 10.1038/sj.onc.1200799; LU QA, 1995, MOL CELL BIOL, V15, P3786; McWhirter JR, 1997, DEVELOPMENT, V124, P3221; MONICA K, 1994, MOL CELL BIOL, V14, P8304, DOI 10.1128/MCB.14.12.8304; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; Neuteboom STC, 1997, MOL CELL BIOL, V17, P4696, DOI 10.1128/MCB.17.8.4696; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; NUMATA SI, 1993, LEUKEMIA, V7, P1441; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; Passner JM, 1999, NATURE, V397, P714, DOI 10.1038/17833; PEERS B, 1995, MOL CELL BIOL, V15, P7091; Peltenburg LTC, 1997, DEVELOPMENT, V124, P1089; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; Piper DE, 1999, CELL, V96, P587, DOI 10.1016/S0092-8674(00)80662-5; POPPERL H, 1995, CELL, V81, P1031, DOI 10.1016/S0092-8674(05)80008-X; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RAUSKOLB C, 1994, EMBO J, V13, P3561, DOI 10.1002/j.1460-2075.1994.tb06663.x; RAUSKOLB C, 1993, CELL, V74, P1101, DOI 10.1016/0092-8674(93)90731-5; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; ROBERTS VJ, 1995, MECH DEVELOP, V51, P193, DOI 10.1016/0925-4773(95)00364-9; ROBERTS VJ, 1993, P NATL ACAD SCI USA, V90, P7583, DOI 10.1073/pnas.90.16.7583; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; Subramaniam N, 1997, DNA CELL BIOL, V16, P153, DOI 10.1089/dna.1997.16.153; Subramaniam N, 1998, J BIOL CHEM, V273, P23567, DOI 10.1074/jbc.273.36.23567; VANDIJK MA, 1994, CELL, V78, P617, DOI 10.1016/0092-8674(94)90526-6; WASYLYK C, 1992, GENE DEV, V6, P965, DOI 10.1101/gad.6.6.965; WILLIAMS DL, 1984, CELL, V36, P101, DOI 10.1016/0092-8674(84)90078-3	65	36	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 23	1999	18	56					8033	8043		10.1038/sj.onc.1203377	http://dx.doi.org/10.1038/sj.onc.1203377			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637514				2022-12-17	WOS:000084634600012
J	Fu, LN; Ma, WL; Benchimol, S				Fu, LN; Ma, WL; Benchimol, S			A translation repressor element resides in the 3 ' untranslated region of human p53 mRNA	ONCOGENE			English	Article						p53; translational control; 3 ' UTR	CELLULAR TUMOR-ANTIGEN; DNA-DAMAGING AGENTS; MESSENGER-RNA; ADULT TISSUES; PROTEIN; EXPRESSION; APOPTOSIS; RADIATION; BINDING; CELLS	The 3' untranslated region of human p53 mRNA represses translation both irt vitro and in vivo. Here, we identify a cis-acting 66-nucleotide U-rich sequence in the human p53 mRNA 3' untranslated region that mediates translational repression. Using UV crosslinking, we detect a 40 kDa protein that interacts specifically with the p53 3'UTR containing the repressor element. Enhanced translation of p53 mRNA contributes to the accumulation of p53 protein in cells exposed to gamma-radiation and could be a consequence of relieving the inhibition mediated by the repressor element.	Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Benchimol, S (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.			Benchimol, Samuel/0000-0003-3433-890X				Bashaw GJ, 1997, CELL, V89, P789, DOI 10.1016/S0092-8674(00)80262-7; BAUM EZ, 1988, DEV BIOL, V126, P141, DOI 10.1016/0012-1606(88)90247-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRITSCHE M, 1993, ONCOGENE, V8, P307; Fu LN, 1997, EMBO J, V16, P4117, DOI 10.1093/emboj/16.13.4117; Fu LN, 1996, EMBO J, V15, P4392, DOI 10.1002/j.1460-2075.1996.tb00812.x; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HAKE LE, 1994, CELL, V79, P617, DOI 10.1016/0092-8674(94)90547-9; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HERZOG H, 1990, NUCLEIC ACIDS RES, V18, P4600, DOI 10.1093/nar/18.15.4600; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI G, 1984, EMBO J, V3, P3257, DOI 10.1002/j.1460-2075.1984.tb02287.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOSNER J, 1995, EMBO J, V14, P442; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Ostareck DH, 1997, CELL, V89, P597, DOI 10.1016/S0092-8674(00)80241-X; PENNICA D, 1984, VIROLOGY, V134, P477, DOI 10.1016/0042-6822(84)90316-7; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; STANDART N, 1994, BIOCHIMIE, V76, P867, DOI 10.1016/0300-9084(94)90189-9; TISHLER RB, 1993, CANCER RES, V53, P2212; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3	33	36	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6419	6424		10.1038/sj.onc.1203064	http://dx.doi.org/10.1038/sj.onc.1203064			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597243				2022-12-17	WOS:000083709200003
J	Philips, A; Chambeyron, S; Lamb, N; Vie, A; Blanchard, JM				Philips, A; Chambeyron, S; Lamb, N; Vie, A; Blanchard, JM			CHF: a novel factor binding to cyclin A CHR corepressor element	ONCOGENE			English	Article						cyclin A; transcription; cell cycle	CELL-CYCLE; RETINOBLASTOMA PROTEIN; REGULATED TRANSCRIPTION; GENE-EXPRESSION; DNA-SYNTHESIS; A EXPRESSION; E2F SITE; REPRESSION; FIBROBLASTS; PROMOTER	Cell cycle modulation of cyclin A expression is due to the periodic relief of a transcriptional repression mediated by a bipartite negative DNA regulatory region. The 5' element (Cell Cycle Responsive Element: CCRE; cell CYcle Dependent Element: CDE) is clearly occupied in a cyclic manner in vivo, whereas the 3' element, whose sequence is shared by B-myb, cdc25C and cdc2 genes (cell Cycle gene Homology Region: CHR), is involved in more subtle interactions. Mutation of either element results in complete deregulation of cyclin A promoter activity. Whereas some reports claim that E2F/DP can bind to the CCRE/CDE, the nature of the protein(s) interacting with the CHR is unknown. In the present work me have characterized an activity present in quiescent cells and absent in cells blocked in S phase, which binds specifically to cyclin A CHR, but not to B-myb, or to cdc25C, or to cdc2 CHRs. A 90 kD protein, named CHF (cyclin A CHR binding factor), has been identified through preparative electrophoresis and UV crosslinking experiments. In order to address in more functional terms the binding of CHF to cyclin A CHR, we developed in vitro and in vivo oligonucleotide competition assays. Both in vitro transcription and in vivo microinjection experiments demonstrate that a functional difference exists between the composite CCRE/CDE-CHR repressor regions of cell cycle regulated genes such as cyclin A and cdc25C.	Inst Genet Mol, CNRS, UMR 5535, F-34293 Montpellier 5, France; Inst Genet Humaine, CNRS, F-34396 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Blanchard, JM (corresponding author), Inst Genet Mol, CNRS, UMR 5535, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020	Chambeyron, severine/0000-0003-2775-6556				BARLAT I, 1995, ONCOGENE, V11, P1309; BARLAT I, 1993, CELL GROWTH DIFFER, V4, P105; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Huet X, 1996, MOL CELL BIOL, V16, P3789; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Korner K, 1997, NUCLEIC ACIDS RES, V25, P4933, DOI 10.1093/nar/25.24.4933; Liu NS, 1996, NUCLEIC ACIDS RES, V24, P2905, DOI 10.1093/nar/24.15.2905; Liu NS, 1997, NUCLEIC ACIDS RES, V25, P4915, DOI 10.1093/nar/25.24.4915; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Lucibello FC, 1997, NUCLEIC ACIDS RES, V25, P4921, DOI 10.1093/nar/25.24.4921; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Philips A, 1998, ONCOGENE, V16, P1373, DOI 10.1038/sj.onc.1201655; PHILIPS A, 1999, IN PRESS ONCOGENE; Plet A, 1997, ONCOGENE, V14, P2575, DOI 10.1038/sj.onc.1201103; SARDET C, 1997, ONCOGENES TRANSCRIPT, V2; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x; ZWICKER J, 1998, TIG, V13, P3	24	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 4	1999	18	46					6222	6232		10.1038/sj.onc.1203017	http://dx.doi.org/10.1038/sj.onc.1203017			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	260DK	10597220				2022-12-17	WOS:000083934100005
J	Movilla, N; Crespo, P; Bustelo, XR				Movilla, N; Crespo, P; Bustelo, XR			Signal transduction elements of TC21, an oncogenic member of the R-Ras subfamily of GTP-binding proteins	ONCOGENE			English	Article						TC21; RasGRF; Raf; JNK; MAPK	NUCLEOTIDE-RELEASING FACTOR; VAV PROTOONCOGENE; GDP/GTP EXCHANGE; CELL-LINE; ACTIVATION; TRANSFORMATION; TC21/R-RAS2; PATHWAY; FIBROBLASTS; CLONING	TC21 is a Ras-like GTPase with high oncogenic potential that is found mutated in some human tumors and overexpressed in breast cancer cell lines. We have conducted cellular and biochemical studies in order to understand the role of this protein in signal transduction and to unveil the signaling elements that participate in the TC21 pathway. Using gene transfer experiments, we demonstrate here that the TC21 oncogene can induce both cellular transformation in mouse fibroblasts and neuronal-like differentiation in rat PC12 cells. Interestingly, the proto-oncogenic version of TC21 shows also a lower, but significant, activity in both biological processes. We also demonstrate that the similarity of the cellular responses induced by TC21 and Ras derive from the utilization of overlapping pathways. Thus, the exchange of guanosine nucleotides in wild type TC21 is catalyzed by Ras exchange factors. Moreover, TC21 binds physically to c-Raf-1 in a GTP-dependent manner. Finally, overexpression of TC21(G23V) in NIH3T3 cells results in the activation of c-Raf-1 and the MAPK and the JNK branches of serine/threonine cascades. From these results, we conclude that TC21 promotes Ras-like responses in diverse cell types due to the use of overlapping, if not identical, signaling elements of the Ras oncogenic pathway.	SUNY Stony Brook, Univ Hosp, Dept Pathol, Stony Brook, NY 11794 USA; Univ Cantabria, Dept Biol Mol, E-39005 Santander, Spain	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Stony Brook University Hospital; Universidad de Cantabria	Bustelo, XR (corresponding author), SUNY Stony Brook, Univ Hosp, Dept Pathol, Level 2,Room 718-B, Stony Brook, NY 11794 USA.		Bustelo, Xose R./AAD-2081-2022; Bustelo, Xose R./A-9526-2010; Crespo, Piero/M-3273-2014	Bustelo, Xose R./0000-0001-9398-6072; Bustelo, Xose R./0000-0001-9398-6072; Crespo, Piero/0000-0003-2825-7783	NCI NIH HHS [CA7373501] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; BUSTELO XR, 1994, ONCOGENE, V9, P2405; CARBONI JM, 1995, ONCOGENE, V10, P1905; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; Clark GJ, 1996, ONCOGENE, V12, P169; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, ONCOGENE, V9, P3281; Crespo P, 1996, ONCOGENE, V13, P455; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; Graham SM, 1996, MOL CELL BIOL, V16, P6132; GRAHAM SM, 1994, MOL CELL BIOL, V14, P4108, DOI 10.1128/MCB.14.6.4108; HUANG Y, 1995, ONCOGENE, V11, P1255; Kozian DH, 1997, FEBS LETT, V414, P239, DOI 10.1016/S0014-5793(97)01038-7; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; LopezBarahona M, 1996, ONCOGENE, V12, P463; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MORRISON DK, 1995, METHOD ENZYMOL, V255, P301; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SUEN KL, 1995, ONCOGENE, V11, P825; van der Eb A J, 1980, Methods Enzymol, V65, P826	35	36	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 21	1999	18	43					5860	5869		10.1038/sj.onc.1202968	http://dx.doi.org/10.1038/sj.onc.1202968			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	248JE	10557073				2022-12-17	WOS:000083270700003
J	Osborn, MT; Berry, A; Ruberu, MS; Ning, BT; Bell, LM; Chambers, TC				Osborn, MT; Berry, A; Ruberu, MS; Ning, BT; Bell, LM; Chambers, TC			Phorbol ester induced MDR1 expression in K562 cells occurs independently of mitogen-activated protein kinase signaling pathways	ONCOGENE			English	Article						MDR1 expression; P-glycoprotein; phorbol ester; PKC; MAPK; K562 cells	MULTIDRUG-RESISTANCE GENE; P-GLYCOPROTEIN; TRANSCRIPTIONAL REGULATION; CALPHOSTIN-C; INHIBITOR; RAF-1; PROMOTER; STRESS; TRANSDUCTION; POTENT	The MDR1 gene encoding the multidrug pump P-glycoprotein is transcriptionally activated in response to diverse extracellular stimuli, including the tumor promoting phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA). Hone, er, the signal transduction pathway responsible is unknown. Downstream of protein kinase C (PKC), the effects of TPA are often mediated by the Raf-1/MEK/ERK mitogen-activated protein kinase (MAPK) cascade, and Raf-1 has been implicated in MDR1 induction by serum and mitogens, Therefore, we examined the potential role of MAK activation in TPA-mediated MDR1 induction in human leukemia K562 cells. MDR1 mRNA expression was significantly increased by TPA in the concentration range of 4-100 nM, with a maximal response 5-10 h after TPA addition. TPA-mediated MDR1 induction was inhibited by several PKC inhibitors including staurosporine, H7 and calphostin C, TPA stimulated the subcellular translocation of PKC alpha from the cytosol to the membrane and nucleus but did not affect other PKC isozymes, TPA also activated the Raf1/MEK/ERK cascade and activated another MAPK member, p38, but not JNK, In order to determine the potential role of MAPKs in MDR1 induction by TPA, specific inhibitors were utilized. The MEK inhibitor PD 098059, as well as the PKC inhibitors, completely blocked TPA-mediated ERK activation. However, under identical conditions, MDR1 induction by TPA was completely unaffected by PD 098059, Furthermore, SB 202190, which effectively inhibited TPA-mediated p38 activation, failed to inhibit TPA-induced MDR1 mRNA expression. These data demonstrate that MDR1 induction by TPA occurs via a PKC-dependent mechanism that operates independently of ERK, p38 or JNK pathways, and thus have important implications for understanding the mechanisms of MDR1 induction by extracellular stimuli.	Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences	Chambers, TC (corresponding author), Univ Arkansas Med Sci, Dept Biochem & Mol Biol, Mail Slot 516,4301 W Markham St, Little Rock, AR 72205 USA.			Ning, Baitang/0000-0003-0798-0331	NCI NIH HHS [CA75577] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075577] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM I, 1996, MULTIDRUG RESISTANCE, P273; BRADLEY G, 1994, CANCER METAST REV, V13, P223, DOI 10.1007/BF00689638; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; BUCHNER K, 1995, EUR J BIOCHEM, V228, P211; BURT RK, 1988, CARCINOGENESIS, V9, P2329, DOI 10.1093/carcin/9.12.2329; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHIN KV, 1993, ADV CANCER RES, V60, P157; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CORNWELL MM, 1993, J BIOL CHEM, V268, P15347; CORNWELL MM, 1996, MULTIDRUG RESISTANCE, P39; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Frantz B, 1998, BIOCHEMISTRY-US, V37, P13846, DOI 10.1021/bi980832y; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; Germann UA, 1998, CYTOTECHNOLOGY, V27, P31, DOI 10.1023/A:1008023629269; Germann UA, 1996, EUR J CANCER, V32A, P927, DOI 10.1016/0959-8049(96)00057-3; GLAZER RI, 1994, BREAST CANCER RES TR, V31, P263, DOI 10.1007/BF00666159; GOTTESMAN MM, 1991, MOL CELLULAR BIOL MU, P279; IGNATOVA TN, 1996, MULTIDRUG RESISTANCE, P177; INCE TA, 1997, ENCY CANC, V3, P1751; Izquierdo MA, 1996, EUR J CANCER, V32A, P979, DOI 10.1016/0959-8049(96)00053-6; Janosch P, 1996, J BIOL CHEM, V271, P13868, DOI 10.1074/jbc.271.23.13868; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lee DW, 1996, EUR J CANCER, V32A, P945, DOI 10.1016/0959-8049(96)00046-9; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; Liu JP, 1996, MOL CELL ENDOCRINOL, V116, P1, DOI 10.1016/0303-7207(95)03706-3; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; NOONAN KE, 1991, MOL CELLULAR BIOL MU, P319; OHKAWA T, 1996, MULTIDRUG RESISTANCE, P413; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; RISCHIN D, 1993, LEUKEMIA ADV RES TRE, P269; Simon C, 1998, CANCER RES, V58, P1135; Thorgeirsson S S, 1994, Cancer Treat Res, V73, P57; UEDA K, 1987, J BIOL CHEM, V262, P505; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; ZHENG B, 1994, J BIOL CHEM, V269, P12332; Zhou G, 1997, J BIOL CHEM, V272, P15174, DOI 10.1074/jbc.272.24.15174	44	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	1999	18	42					5756	5764		10.1038/sj.onc.1202943	http://dx.doi.org/10.1038/sj.onc.1202943			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523856				2022-12-17	WOS:000083095100004
J	Imyanitov, EN; Birrell, GW; Filippovich, I; Sorokina, N; Arnold, J; Mould, MA; Wright, K; Walsh, M; Mok, SC; Lavin, MF; Chenevix-Trench, G; Khanna, KK				Imyanitov, EN; Birrell, GW; Filippovich, I; Sorokina, N; Arnold, J; Mould, MA; Wright, K; Walsh, M; Mok, SC; Lavin, MF; Chenevix-Trench, G; Khanna, KK			Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target	ONCOGENE			English	Article						p73; ovarian adenocarcinoma; loss of heterozygosity; tumour suppressor	REGION; P53; NEUROBLASTOMA; MUTATIONS; NEOPLASMS; CANCERS	Loss of heterozygosity (LOH) involving the distal part of the short arm of chromosome 1 occurs frequently in ovarian adenocarcinomas but the tumour suppressor gene(s) targeted by this event is unknown, We have used five microsatellite markers in a panel of 56 ovarian adenocarcinomas to determine which part of 1p34-36 is the focus of this LOH, LOH was considerably more common at 1p36 (43%) than at 1p34-35 (18%), and 11 tumours showed LOH at 1p36 but not at 1p34-35, These data strongly suggest the presence of a tumour suppressor gene inactivated in ovarian adenocarcinoma at 1p36, The p53 homologue, p73, has recently been isolated and mapped to 1p36 and therefore is a candidate for this tumour suppressor gene, However, RT-PCR and Western analyses revealed strong expression of p73 in ovarian adenocarcinoma cell lines but very low or undetectable levels in normal ovarian surface epithelial cells. Immunohistochemical analysis of primary ovarian tumours showed that only 3/22 (14%) contained p73 expressing cells. There was no association between 1p36 LOH and p73 expression in ovarian tumours, nor between p73 and p53 expression, These findings strongly suggest that p73 is not the target of 1p36 LOH in ovarian adenocarcinomas but indicate the presence of an, as yet unidentified, tumour suppressor gene in this region that plays an important role in ovarian tumorigenesis.	PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia; NN Petrov Inst Oncol, Grp Mol Diagnost, St Petersburg 189646, Russia; Russian Federat Minist Hlth, Inst Biophys, Lab Mol Radiol, Moscow 123182, Russia; Univ Queensland, PO Royal Brisbane Hosp, Dept Pathol, Brisbane, Qld 4029, Australia; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA; Univ Queensland, PO Royal Brisbane Hosp, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; N.N. Petrov Research Institute of Oncology; Ministry of Health of the Russian Federation; Royal Brisbane & Women's Hospital; University of Queensland; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Royal Brisbane & Women's Hospital; University of Queensland	Khanna, KK (corresponding author), PO Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia.		Lavin, Martin F/F-5961-2014; Imyanitov, Evgeny/ABG-8619-2021; Chenevix-Trench, Georgia/AAV-2014-2020; Khanna, Kum Kum/I-1747-2013	Lavin, Martin F/0000-0002-5940-4769; Chenevix-Trench, Georgia/0000-0002-1878-2587; Birrell, Geoff/0000-0002-6593-1514; Khanna, Kum Kum/0000-0001-8650-5381				CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; ChenevixTrench G, 1997, GENE CHROMOSOME CANC, V18, P75, DOI 10.1002/(SICI)1098-2264(199702)18:2<75::AID-GCC1>3.0.CO;2-Y; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; LUNDGREN R, 1992, GENE CHROMOSOME CANC, V4, P16, DOI 10.1002/gcc.2870040103; Marin MC, 1998, MOL CELL BIOL, V18, P6316, DOI 10.1128/MCB.18.11.6316; NAGAI H, 1995, CANCER RES, V55, P1752; PARKIN DM, 1993, INT J CANCER, V54, P594, DOI 10.1002/ijc.2910540413; SHELLING AN, 1995, BRIT J CANCER, V72, P521, DOI 10.1038/bjc.1995.367; TENERIELLO MG, 1993, CANCER RES, V53, P3103; Thompson FH, 1997, CANCER GENET CYTOGEN, V96, P106, DOI 10.1016/S0165-4608(96)00307-X; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; WEBB PM, IN PRESS J NATL CANC; WHITE PS, 1995, P NATL ACAD SCI USA, V92, P5520, DOI 10.1073/pnas.92.12.5520	15	36	38	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	1999	18	32					4640	4642		10.1038/sj.onc.1202863	http://dx.doi.org/10.1038/sj.onc.1202863			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226KF	10467409				2022-12-17	WOS:000082018600014
J	Chien, J; Wong, E; Nikes, E; Noble, MJ; Pantazis, CG; Shah, GV				Chien, J; Wong, E; Nikes, E; Noble, MJ; Pantazis, CG; Shah, GV			Constitutive activation of stimulatory guanine nucleotide binding protein (G(s)alpha QL)-mediated signaling increases invasiveness and tumorigenicity of PC-3M prostate cancer cells	ONCOGENE			English	Article						G(s)alpha; invasiveness; tumorigenicity; prostate cancer	INTESTINAL-PEPTIDE RECEPTORS; RAT VENTRAL PROSTATE; NEUROENDOCRINE DIFFERENTIATION; COUPLED RECEPTORS; ADENYLYL-CYCLASE; GROWTH; KINASE; CARCINOMA; EXPRESSION; TUMORS	An abnormal stimulation of cAMP signaling cascade has been implicated in various human carcinomas, Since the agents activating G(s)alpha-mediated signaling pathways have been shown to increase in vitro proliferation of prostate cancer cells, present studies examined the G(s)alpha-mediated signaling in tumorigenicity and invasiveness of PC-3M prostate cancer cells. PC-3M cells were stably transfected with plasmids containing either wild type (G(s)alpha-WT) or constitutively active (gsp mutant of G(s)alpha or G(s)alpha-QL) CDNAs. The stable transfectants were then tested for: (1) colony formation in soft agar; (2) cell migration and penetration of basement matrix in an in vitro invasion assay; and (3) the ability to form tumors and metastases in nude mice. PC-3M cells expressing G(s)alpha-QL protein displayed 15-fold increase in their ability to migrate and penetrate the basement membrane as compared to parental PC-3M cells or those expressing G(s)alpha-WT. G(s)alpha-QL transfectants also displayed a dramatically greater rate of growth in soft agar, and greater tumorigenicity and metastasis forming ability when orthotopically implanted in nude mice. All mice receiving PC-3M cells produced primary tumors within 5 weeks after implantation. However, the cells expressing G(s)alpha-QL displayed a significantly faster tumor growth as assessed by prostate weight (greater than 20-fold as compared to PC-3M cells), and produced metastases in kidneys, 12 mph nodes, blood vessels, bon el mesentery and intestine. Interestingly, expression of G(s)alpha-WT reduced the ability of PC-3M cells to form tumors in nude mice. These results suggest that persistent activation of G(s)alpha-mediated signaling cascade can dramatically accelerate tumorigenesis and metastasizing ability of prostate cancer cells.	Univ Kansas, Med Ctr, Dept Urol Surg, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Shah, GV (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Pharmaceut Sci, 1300 Coulter Dr, Amarillo, TX 79106 USA.		Chien, Jeremy/AID-8939-2022	Chien, Jeremy/0000-0003-4744-8374	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045044] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45044, R01 DK045044] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDUL M, 1994, ANTICANCER RES, V14, P1215; APRIKIAN AG, 1994, J UROLOGY, V151, P914, DOI 10.1016/S0022-5347(17)35121-2; Aprikian AG, 1996, J MOL ENDOCRINOL, V16, P297, DOI 10.1677/jme.0.0160297; BANERJEE A, 1992, CANCER RES, V52, P6297; CARMENA MJ, 1995, PROSTATE, V27, P204, DOI 10.1002/pros.2990270405; Chen CL, 1996, J STEROID BIOCHEM, V58, P489, DOI 10.1016/0960-0760(96)00069-6; CLAPHAM DE, 1993, CELL, V75, P1237, DOI 10.1016/0092-8674(93)90609-T; COHEN MK, 1994, CANCER, V74, P1899, DOI 10.1002/1097-0142(19941001)74:7<1899::AID-CNCR2820740712>3.0.CO;2-U; DISANTAGNESE PA, 1992, CANCER-AM CANCER SOC, V70, P254, DOI 10.1002/1097-0142(19920701)70:1+<254::AID-CNCR2820701312>3.0.CO;2-E; DREWS RT, 1992, MOL CELL ENDOCRINOL, V87, P125, DOI 10.1016/0303-7207(92)90240-7; FAURE M, 1995, MOL BIOL CELL, V6, P1025, DOI 10.1091/mbc.6.8.1025; GAIDDON C, 1994, J BIOL CHEM, V269, P22663; GUP DI, 1990, J UROLOGY, V143, P179, DOI 10.1016/S0022-5347(17)39906-8; HOOSEIN NM, 1993, J UROLOGY, V149, P1209, DOI 10.1016/S0022-5347(17)36349-8; HUANG ZY, 1994, CHUNG HUA I HSUEH TS, V74, P23; JUARRANZ MG, 1994, GEN PHARMACOL-VASC S, V25, P509, DOI 10.1016/0306-3623(94)90207-0; KADMON D, 1991, J UROLOGY, V146, P358, DOI 10.1016/S0022-5347(17)37793-5; KILLAM AL, 1995, EUR J PHARMACOL, V273, P7, DOI 10.1016/0014-2999(94)00613-C; LANGER DJ, 1993, CIRC RES, V72, P330, DOI 10.1161/01.RES.72.2.330; LEFKOWITZ RJ, 1993, NATURE, V365, P603, DOI 10.1038/365603a0; LEPOR H, 1984, J UROLOGY, V132, P397, DOI 10.1016/S0022-5347(17)49636-4; LOGOTHETIS C, 1992, J CELL BIOCHEM, V16, pH128; LOGOTHETIS CJ, 1994, SEMIN ONCOL, V21, P620; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; MIRAYLOPEZ R, 1992, J BIOL CHEM, V267, P23063; MUCA C, 1994, ONCOGENE, V9, P3647; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Newling DWW, 1996, EUR UROL, V29, P69; NEWLING DWW, 1992, PROSTATE, P139; Rayford W, 1997, PROSTATE, V30, P160, DOI 10.1002/(SICI)1097-0045(19970215)30:3<160::AID-PROS3>3.0.CO;2-Q; REUBI JC, 1995, J NUCL MED, V36, P1846; SEGAL NH, 1994, ARCH PATHOL LAB MED, V118, P616; SHAH GV, 1994, ENDOCRINOLOGY, V134, P596, DOI 10.1210/en.134.2.596; SHINTANI Y, 1995, ENDOCR J, V42, P331, DOI 10.1507/endocrj.42.331; Solano RM, 1996, ENDOCRINOLOGY, V137, P2815, DOI 10.1210/en.137.7.2815; SOLANO RM, 1994, NEUROPEPTIDES, V27, P31, DOI 10.1016/0143-4179(94)90014-0; STEPHENSON RA, 1992, J NATL CANCER I, V84, P951, DOI 10.1093/jnci/84.12.951; TANAKA K, 1995, CANCER RES, V55, P2927; VANWEERDEN WM, 1993, CELL PROLIFERAT, V26, P67, DOI 10.1111/j.1365-2184.1993.tb00007.x; Wu GA, 1996, UROLOGY, V47, P376, DOI 10.1016/S0090-4295(99)80456-7; YOUNG MRI, 1995, INT J CANCER, V61, P104, DOI 10.1002/ijc.2910610118; ZEIGER MA, 1993, SURGERY, V114, P458	42	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3376	3382		10.1038/sj.onc.1202690	http://dx.doi.org/10.1038/sj.onc.1202690			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362358				2022-12-17	WOS:000080589300008
J	Dijkers, PF; van Dijk, TB; de Groot, RP; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ				Dijkers, PF; van Dijk, TB; de Groot, RP; Raaijmakers, JAM; Lammers, JWJ; Koenderman, L; Coffer, PJ			Regulation and function of protein kinase B and MAP kinase activation by the IL-5/GM-CSF/IL-3 receptor	ONCOGENE			English	Article						cytokine; proliferation; apoptosis; PKB; ERK; STAT	COLONY-STIMULATING FACTOR; COMMON BETA-SUBUNIT; INDUCE TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION PATHWAYS; HUMAN HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; GM-CSF; INTERLEUKIN-5 RECEPTOR; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN	Interleukin (IL)-3, IL-5 and granulocyte-macrophage colony-stimulating factor (GM-CSF) regulate proliferation, differentiation and apoptosis of target cells. Receptors for these cytokines consist of a cytokine-specific alpha subunit and a common shared beta c subunit, Tyrosine phosphorylation of the beta c is thought to play a critical role in mediating signal transduction events. We have examined the effect of mutation of beta c tyrosines on the activation of multiple signal transduction pathways. Activation of protein kinase B (PKB) required JAK2 and was inhibited by dominant-negative phosphatidylinositol 3-kinase (PI3K). Overexpression of JAK2 was sufficient to activate both protein kinase B (PKB) and extracellular regulated kinase-1 (ERK1). Tyrosine 577 and 612 were found to be critical for the activation of PKB and ERK1, but not activation of STAT transcription factors, Activation of both PKB and ERK have been implicated in the regulation of proliferation and apoptosis. We generated GM-CSFR stable cell lines expressing receptor mutants to evaluate their effect on these processes. Activation of both PKB and ERK was perturbed, while STAT activation remained unaffected. Tyrosines 577 and 612 were necessary for optimal proliferation, however, mutation of these tyrosine residues did not affect GM-CSF mediated rescue from apoptosis. These data demonstrate that while phosphorylation of beta c tyrosine residues 577 and 612 are important for optimal cell proliferation, rescue from apoptosis can be mediated bg alternative signalling routes apparently independent of PKB or ERK activation.	Univ Utrecht Hosp, Dept Pulm Dis, NL-3584 CX Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Coffer, PJ (corresponding author), Univ Utrecht Hosp, Dept Pulm Dis, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.		Koenderman, Leo/AAE-7870-2020; Coffer, Paul/AAF-7970-2020; Coffer, Paul J/A-5769-2009	Koenderman, Leo/0000-0002-5636-6453; 				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; AlShami A, 1997, BLOOD, V89, P1035, DOI 10.1182/blood.V89.3.1035; Anderson SM, 1997, J BIOL CHEM, V272, P739, DOI 10.1074/jbc.272.2.739; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CALDENHOVEN E, 1995, J BIOL CHEM, V270, P25778, DOI 10.1074/jbc.270.43.25778; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; Chin H, 1997, BIOCHEM BIOPH RES CO, V239, P412, DOI 10.1006/bbrc.1997.7480; Coffer PJ, 1998, BLOOD, V91, P2547, DOI 10.1182/blood.V91.7.2547.2547_2547_2557; Coffer PJ, 1998, BIOCHEM J, V329, P121; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; deGroot RP, 1997, J BIOL CHEM, V272, P2319; DEGROOT RP, 1998, IN PRESS CELL SIGNAL; delPeso L, 1997, SCIENCE, V278, P687; Durstin M, 1996, J IMMUNOL, V157, P534; FRANK SJ, 1995, J BIOL CHEM, V270, P14776, DOI 10.1074/jbc.270.24.14776; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Gale RE, 1998, BLOOD, V91, P54, DOI 10.1182/blood.V91.1.54.54_54_63; GOLD MR, 1994, J BIOL CHEM, V269, P5403; Haas-Kogan D, 1998, CURR BIOL, V8, P1195, DOI 10.1016/S0960-9822(07)00493-9; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HE TC, 1995, J BIOL CHEM, V270, P11055, DOI 10.1074/jbc.270.19.11055; Itoh T, 1996, J BIOL CHEM, V271, P7587, DOI 10.1074/jbc.271.13.7587; Itoh T, 1998, MOL CELL BIOL, V18, P742, DOI 10.1128/MCB.18.2.742; Iversen PO, 1997, BLOOD, V90, P4910, DOI 10.1182/blood.V90.12.4910.4910_4910_4917; JUCKER M, 1995, J BIOL CHEM, V270, P27817; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; LANFRANCONE L, 1995, ONCOGENE, V10, P907; LOPEZ AF, 1992, IMMUNOL TODAY, V13, P495, DOI 10.1016/0167-5699(92)90025-3; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; MULI AL, 1996, EMBO J, V15, P2425; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Okuda K, 1997, BLOOD, V90, P4759, DOI 10.1182/blood.V90.12.4759.4759_4759_4766; OKUDA K, 1994, J BIOL CHEM, V269, P24602; Pazdrak K, 1997, J EXP MED, V186, P561, DOI 10.1084/jem.186.4.561; Perkins GR, 1996, BLOOD, V87, P3669, DOI 10.1182/blood.V87.9.3669.bloodjournal8793669; POLOTSKAYA A, 1993, CELL GROWTH DIFFER, V4, P523; POLOTSKAYA A, 1994, J BIOL CHEM, V269, P14607; Pratt JC, 1996, J BIOL CHEM, V271, P12137, DOI 10.1074/jbc.271.21.12137; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Rivas CI, 1998, BLOOD, V91, P1037, DOI 10.1182/blood.V91.3.1037.1037_1037_1043; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; SATO N, 1993, EMBO J, V12, P4181, DOI 10.1002/j.1460-2075.1993.tb06102.x; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TAKAKI S, 1994, MOL CELL BIOL, V14, P7404, DOI 10.1128/MCB.14.11.7404; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; TERADA K, 1995, J BIOL CHEM, V270, P27880, DOI 10.1074/jbc.270.46.27880; van Weeren PC, 1998, J BIOL CHEM, V273, P13150, DOI 10.1074/jbc.273.21.13150; vanDijk TB, 1997, FEBS LETT, V412, P161, DOI 10.1016/S0014-5793(97)00768-0; Wei S, 1996, J IMMUNOL, V157, P5155; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; ZHAO YM, 1995, J BIOL CHEM, V270, P13814, DOI 10.1074/jbc.270.23.13814; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	68	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	1999	18	22					3334	3342		10.1038/sj.onc.1202678	http://dx.doi.org/10.1038/sj.onc.1202678			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	201HL	10362354	Bronze			2022-12-17	WOS:000080589300004
J	Lee, CM; Reddy, EP				Lee, CM; Reddy, EP			The v-myc oncogene	ONCOGENE			English	Article						v-myc; gag-Myc; transformation; proliferation; apoptosis; differentiation	CHICKEN-C-MYC; NUCLEOTIDE-SEQUENCE ANALYSIS; MYELOCYTOMATOSIS VIRUS MC29; AVIAN RETROVIRUS MC29; FELINE LEUKEMIA-VIRUS; CELL LYMPHOMA LINE; N-TERMINAL DOMAIN; WILD-TYPE P53; MYELOMONOCYTIC CELLS; FIBROBLAST TRANSFORMATION	v-myc is the viral homolog of c-myc transduced by several acute transforming retroviruses, many of which encode this gene as a Gag-Myc fusion protein, The v-myc oncogene can transform several lineages of mammalian and avian cells either alone or in cooperation with other oncogenes, While the Gag portion of the Gag-Myc fusion protein and the nuclear localization signal each appear to be dispensable for transformation, the N- and C-termini of the Myc sequence have been found to be essential for transformation. All v-myc genes contain point mutations which seem to confer a greater potency to v-myc in the process of transformation, proliferation, and apoptosis, In v-myc-transformed myelomonocytic cells, secondary events occur, such as the expression of colony stimulating factor-1 (CSF-1) which play a critical role in immortalization and subsequent tumor progression, Inhibition of the autocrine loop of CSF-I was found to induce apoptosis in the immortalized cells, While overexpression of v-Myc blocks terminal differentiation of hematopoietic cells, this is not sufficient to block the differentiation of certain neural and skeletal muscle cells. Recent developments on the effects of v-myc on cell growth, transformation, differentiation and apoptosis are discussed in this review.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reddy, EP (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.		Reddy, E. Premkumar/F-6233-2011; Lee, Clement M./E-7104-2012	Lee, Clement M./0000-0003-3486-8492				ALBERT T, 1994, ONCOGENE, V9, P759; ALEXANDER RW, 1979, J NATL CANCER I, V62, P359; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P100, DOI 10.1073/pnas.80.1.100; BAUMBACH WR, 1986, J VIROL, V59, P276, DOI 10.1128/JVI.59.2.276-283.1986; BEARD JW, 1976, CANCER RES, V36, P339; BEARD JW, 1975, CANCER RES, V35, P1603; BECHADE C, 1988, J VIROL, V62, P1211; BECHADE C, 1985, NATURE, V316, P559, DOI 10.1038/316559a0; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BONHAM L, 1991, ONCOGENE, V6, P1073; CHEN C, 1989, J VIROL, V63, P5092, DOI 10.1128/JVI.63.12.5092-5100.1989; CHISHOLM O, 1992, ONCOGENE, V7, P1827; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DOGGETT DL, 1989, J VIROL, V63, P2108, DOI 10.1128/JVI.63.5.2108-2117.1989; Dolnikov A, 1996, ONCOGENE, V12, P1189; Dolnikov A, 1998, LEUKEMIA, V12, P542, DOI 10.1038/sj.leu.2400968; ENRIETTO PJ, 1983, VIROLOGY, V124, P164, DOI 10.1016/0042-6822(83)90300-8; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; FRYKBERG L, 1987, ONCOGENE, V1, P415; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; HALTMEIER H, 1990, J CELL BIOL, V110, P2087, DOI 10.1083/jcb.110.6.2087; HAYFLICK J, 1985, P NATL ACAD SCI USA, V82, P2718, DOI 10.1073/pnas.82.9.2718; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFFMANLIEBERMANN B, 1991, ONCOGENE, V6, P903; HORTLING L, 1978, ACTA PATH MICRO IM B, V86, P185; Hoshimaru M, 1996, P NATL ACAD SCI USA, V93, P1518, DOI 10.1073/pnas.93.4.1518; IVANOV K, 1964, IZV I SRAVN PATOL ZH, V10, P5; KAN NC, 1984, P NATL ACAD SCI-BIOL, V81, P3000, DOI 10.1073/pnas.81.10.3000; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LEVY LS, 1984, NATURE, V308, P853, DOI 10.1038/308853a0; LO LC, 1991, DEV BIOL, V145, P139, DOI 10.1016/0012-1606(91)90220-W; Loliger H C, 1964, Dtsch Tierarztl Wochenschr, V71, P207; LOLIGER HC, 1966, PATHOL VET, V3, P492; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; Marthyn P, 1998, EXP CELL RES, V243, P94, DOI 10.1006/excr.1998.4149; MIN SY, 1992, ONCOGENE, V7, P1531; MIN SY, 1993, ONCOGENE, V8, P2691; MLADENOV Z, 1967, JNCI-J NATL CANCER I, V38, P251; MULLINS JI, 1984, NATURE, V308, P856, DOI 10.1038/308856a0; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; OBERG F, 1991, P NATL ACAD SCI USA, V88, P5567, DOI 10.1073/pnas.88.13.5567; Oberst C, 1997, ONCOGENE, V14, P1109, DOI 10.1038/sj.onc.1200930; OKERBLOM N, 1978, J GEN VIROL, V40, P623, DOI 10.1099/0022-1317-40-3-623; PALMIERI S, 1987, J VIROL, V61, P1717, DOI 10.1128/JVI.61.5.1717-1721.1987; Petropoulos CJ, 1996, ONCOGENE, V12, P2611; PIRAMI L, 1991, P NATL ACAD SCI USA, V88, P7543, DOI 10.1073/pnas.88.17.7543; PRINCIPATO M, 1990, MOL CELL BIOL, V10, P3562, DOI 10.1128/MCB.10.7.3562; PULVERER BJ, 1994, ONCOGENE, V9, P59; RAMSAY GM, 1990, P NATL ACAD SCI USA, V87, P2102, DOI 10.1073/pnas.87.6.2102; RAPP UR, 1985, NATURE, V317, P434, DOI 10.1038/317434a0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; Sakamuro D, 1995, ONCOGENE, V11, P2411; SCHWARTZ RC, 1986, MOL CELL BIOL, V6, P3221, DOI 10.1128/MCB.6.9.3221; SHAW J, 1985, J VIROL, V56, P943, DOI 10.1128/JVI.56.3.943-950.1985; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STAPLETON P, 1991, ONCOGENE, V6, P807; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; SUTRAVE P, 1984, NATURE, V309, P85, DOI 10.1038/309085a0; SYMONDS G, 1989, ONCOGENE, V4, P285; Tikhonenko AT, 1996, J BIOL CHEM, V271, P30741, DOI 10.1074/jbc.271.48.30741; TIKHONENKO AT, 1992, J VIROL, V66, P946, DOI 10.1128/JVI.66.2.946-955.1992; TIKHONENKO AT, 1995, ONCOGENE, V11, P1499; TIKHONENKO AT, 1993, MOL CELL BIOL, V13, P3623, DOI 10.1128/MCB.13.6.3623; VONWEIZSACKER F, 1986, EMBO J, V5, P1521, DOI 10.1002/j.1460-2075.1986.tb04392.x; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALTHER N, 1985, J VIROL, V54, P576, DOI 10.1128/JVI.54.2.576-585.1985; WANG YS, 1993, ONCOGENE, V8, P3427; WANG YS, 1993, CELL GROWTH DIFFER, V4, P467; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; ZIMMERMAN K, 1990, Critical Reviews in Oncogenesis, V2, P75	77	36	42	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	1999	18	19					2997	3003		10.1038/sj.onc.1202786	http://dx.doi.org/10.1038/sj.onc.1202786			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378695				2022-12-17	WOS:000080387800009
J	Shaughnessy, JD; Largaespada, DA; Tian, EM; Fletcher, CF; Cho, BC; Vyas, P; Jenkins, NA; Copeland, NG				Shaughnessy, JD; Largaespada, DA; Tian, EM; Fletcher, CF; Cho, BC; Vyas, P; Jenkins, NA; Copeland, NG			Mrvil, a common MRV integration site in BXH2 myeloid leukemias, encodes a protein with homology to a lymphoid-restricted membrane protein Jaw1	ONCOGENE			English	Article						myeloid leukemia model; retroviral insertional mutagenesis; common sites of integration	C-MPL LIGAND; VIRUS; GENE; EXPRESSION; MICE; MEGAKARYOCYTOPOIESIS; CHROMOSOME-11; SEQUENCES; T(7-11)(P15-P15); TRANSLOCATION	Ecotropic MuLVs induce myeloid leukemia in BXH2 mice by insertional mutagenesis of cellular protooncogenes or tumor suppressor genes, Disease genes can thus be identified by viral tagging as common sites of viral integration in BXH2 leukemias. Previous studies showed that a frequent common integration site in BXH2 leukemias is the NJ1 tumor suppressor gene. Unexpectedly, about half of the viral integrations at Nf1 represented a previously undiscovered defective nonecotropic virus, termed MRV, Because other common integration sites in BXH2 leukemias encoding protooncogenes contain ecotropic rather than MRV viruses, it has been speculated that MRV viruses may selectively target tumor suppressor genes. To determine if this were the case, 21 MRV-positive BXH2 leukemias were screened for new MRV common integration sites. One new site, Mrvi1 was identified that was disrupted by MRV in two of the leukemias. Ecotropic virus did not disrupt Mrvi1 in 205 ecotropic virus-positive leukemias, suggesting that Mrvi1 is specifically targeted by MRV, Mrvi1 encodes a novel protein with homology to Jaw1, a lymphoid restricted type II membrane protein that localizes to the endoplasmic reticulum, MRV integration occurs at the 5' end of the gene between two differentially used promoters. Within hematopoietic cells, Mrvi1 expression is restricted to megakaryocytes and some myeloid leukemias, Like Jaw1, which is downregulated during lymphoid differentiation, Mrv1 is do downregulated during monocytic differentiation of BXH2 leukemias, Taken together, these data suggest that MRV integration at Mrvi1 induces myeloid leukemia by altering the expression of a gene important for myeloid cell growth and/or differentiation. Experiments are in progress to test whether Mrvi1 is a tumor suppressor gene.	Univ Arkansas Med Sci, Dept Med, Div Hematol & Oncol, Little Rock, AR 72205 USA; Univ Minnesota, Ctr Canc, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; NCI, Mammalian Genet Lab, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA; Thomas Jefferson Univ, Inst Canc, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Childrens Hosp, Dept Hematol & Oncol, Boston, MA 02115 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Jefferson University; Harvard University; Boston Children's Hospital	Shaughnessy, JD (corresponding author), Univ Arkansas Med Sci, Dept Med, Div Hematol & Oncol, Little Rock, AR 72205 USA.		Vyas, Paresh/B-5708-2009; Largaespada, David/C-9832-2014	Vyas, Paresh/0000-0003-3931-0914; 				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; AZIZ DC, 1989, NATURE, V338, P505, DOI 10.1038/338505a0; Baffa R, 1996, CANCER RES, V56, P268; BEDIGIAN HG, 1984, J VIROL, V51, P586, DOI 10.1128/JVI.51.3.586-594.1984; BEDIGIAN HG, 1981, J VIROL, V39, P632, DOI 10.1128/JVI.39.2.632-640.1981; BEDIGIAN HG, 1993, J VIROL, V67, P6105, DOI 10.1128/JVI.67.10.6105-6109.1993; BEHRENS TW, 1994, J IMMUNOL, V153, P682; BEPLER G, 1994, P NATL ACAD SCI USA, V91, P5513, DOI 10.1073/pnas.91.12.5513; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; BUCHBERG AM, 1990, MOL CELL BIOL, V10, P4658, DOI 10.1128/MCB.10.9.4658; CHATTOPDAHYAY SK, 1989, P NATL ACAD SCI USA, V486, P3862; CHO BC, 1995, J VIROL, V69, P7138, DOI 10.1128/JVI.69.11.7138-7146.1995; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; COPELAND NG, 1991, TRENDS GENET, V7, P44; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FENG DF, 1987, J MOL EVOL, V25, P351, DOI 10.1007/BF02603120; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JENKINS NA, 1982, J VIROL, V42, P379, DOI 10.1128/JVI.42.2.379-388.1982; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LARGAESPADA DA, 1995, J VIROL, V69, P5095, DOI 10.1128/JVI.69.8.5095-5102.1995; LOH WE, 1992, P NATL ACAD SCI USA, V89, P1755, DOI 10.1073/pnas.89.5.1755; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCAFFERY CA, 1986, EMBO J, V5, P3167, DOI 10.1002/j.1460-2075.1986.tb04625.x; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; METHIA N, 1993, BLOOD, V82, P1395; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Mostert MC, 1998, ONCOGENE, V16, P2617, DOI 10.1038/sj.onc.1201787; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Nakamura T, 1996, NAT GENET, V12, P149, DOI 10.1038/ng0296-149; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Sambrook J, 1989, MOL CLONING LAB MANU; SHANNON KM, 1994, NEW ENGL J MED, V330, P579; Shaughnessy JD, 1997, GENOMICS, V39, P192, DOI 10.1006/geno.1996.4502; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; SUEDHOF TC, 1989, SCIENCE, V245, P1474; TESSAROLLO L, 1995, METHOD ENZYMOL, V254, P419; TETTEROO PAT, 1984, LEUKEMIA RES, V8, P197, DOI 10.1016/0145-2126(84)90143-7; TSAO SGS, 1983, ANAL BIOCHEM, V131, P365, DOI 10.1016/0003-2697(83)90185-9; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X	47	36	38	1	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2069	2084						16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321731				2022-12-17	WOS:000079346200004
J	Furukawa, Y; Iwase, S; Kikuchi, J; Nakamura, M; Yamada, H; Matsuda, M				Furukawa, Y; Iwase, S; Kikuchi, J; Nakamura, M; Yamada, H; Matsuda, M			Transcriptional repression of the E2F-1 gene by interferon-alpha is mediated through induction of E2F-4/pRB and E2F-4/p130 complexes	ONCOGENE			English	Article						interferon; transcription; E2F-1; E2F-4; pRB; p130	CELL-CYCLE REGULATION; SENSITIVE HEMATOPOIETIC-CELLS; DNA-BINDING ACTIVITY; GROWTH-FACTOR-BETA; RETINOBLASTOMA PROTEIN; IN-VIVO; INTERLEUKIN-6 SUPPRESS; CDC2 GENE; EXPRESSION; ACTIVATION	E2F is a heterodimeric transcription factor composed of one of five E2F subunits (E2F-1 to E2F-5) and a DP subunit, E2F regulates the expression of several growth-promoting genes, and thus, can be a target of antiproliferative action of interferons (IFNs), In this study, me investigated the mechanisms whereby IFN-alpha suppresses transcription of the E2F-1 gene. Transfection studies revealed that E2F-1 promoter was functionally divided into two parts: upstream activation sequences (UAS) and a downstream negative-regulatory element (E2F-binding sites). When cells were proliferating, transcription of the E2F-1 gene was primarily driven by the UAS, while E2F sites were not involved in activation. IFN-alpha markedly reduced E2F-1 promoter activity, but introduction of non-binding mutation at the E2F sites completely abrogated the inhibition. Free E2F-1 was found to be the predominant species bound to the E2F sites in proliferating cells. IFN-alpha induced upregulation of E2F-4 along with dephosphorylation of PRE and p130, which resulted in the formation of E2F-4/pRB and E2F-4/p130 complexes on the E2F-1 promoter, These complexes function as transcriptional repressors to inhibit E2F-1 mRNA expression. Our findings indicate that E2F-4 is a critical regulator of E2F-1, which offer an excellent paradigm for understanding functional diversity within the E2F family.	Jichi Med Sch, Ctr Mol Med, Div Mol Hemopoiesis, Minamimaki, Tochigi 3290498, Japan; Jichi Med Sch, Dept Hematol, Minami Kawachi, Tochigi 3290498, Japan; Hitachi Ltd, Katsuta Res Lab, Katsuta, Ibaraki 312, Japan; Jikei Univ, Sch Med, DNA Res Inst, Dept Internal Med,Aoto, Tokyo 105, Japan; Jikei Univ, Sch Med, DNA Res Inst, Dept Genet, Tokyo 105, Japan	Jichi Medical University; Jichi Medical University; Hitachi Limited; Jikei University; Jikei University	Furukawa, Y (corresponding author), Jichi Med Sch, Ctr Mol Med, Div Mol Hemopoiesis, 3311-1 Yakushiji, Minamimaki, Tochigi 3290498, Japan.		Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; Beijersbergen RL, 1996, BBA-REV CANCER, V1287, P103, DOI 10.1016/0304-419X(96)00002-9; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Cress WD, 1996, MOL CELL BIOL, V16, P2119; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; Einhorn S, 1996, J INTERF CYTOK RES, V16, P275, DOI 10.1089/jir.1996.16.275; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; Furukawa Y, 1996, J BIOL CHEM, V271, P28469, DOI 10.1074/jbc.271.45.28469; FURUKAWA Y, 1994, J BIOL CHEM, V269, P26249; Geng Y, 1996, ONCOGENE, V12, P1173; GUTTERMAN JU, 1994, P NATL ACAD SCI USA, V91, P1198, DOI 10.1073/pnas.91.4.1198; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; HUBER HE, 1994, J BIOL CHEM, V269, P6999; Iwase S, 1997, J BIOL CHEM, V272, P12406, DOI 10.1074/jbc.272.19.12406; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KITAGAWA M, 1995, ONCOGENE, V10, P229; Kramer A, 1996, J BIOL CHEM, V271, P6579; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LENGYEL P, 1993, P NATL ACAD SCI USA, V90, P5893, DOI 10.1073/pnas.90.13.5893; Li JM, 1997, P NATL ACAD SCI USA, V94, P4948, DOI 10.1073/pnas.94.10.4948; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MELAMED D, 1993, MOL CELL BIOL, V13, P5255, DOI 10.1128/MCB.13.9.5255; Moberg K, 1996, MOL CELL BIOL, V16, P1436; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; Ohtani K, 1996, MOL CELL BIOL, V16, P6977; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; Sangfelt O, 1997, ONCOGENE, V14, P415, DOI 10.1038/sj.onc.1200832; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Selleri C, 1996, BLOOD, V87, P4149, DOI 10.1182/blood.V87.10.4149.bloodjournal87104149; SEN GC, 1992, J BIOL CHEM, V267, P5017; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Smith EJ, 1996, MOL CELL BIOL, V16, P6965; Tao YX, 1997, MOL CELL BIOL, V17, P6994, DOI 10.1128/MCB.17.12.6994; THOMAS NSB, 1988, J BIOL CHEM, V264, P13697; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VAIRO G, 1995, GENE DEV, V9, P869, DOI 10.1101/gad.9.7.869; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Williams CD, 1997, BRIT J HAEMATOL, V96, P688, DOI 10.1046/j.1365-2141.1997.d01-2086.x; Williams CD, 1997, BLOOD, V90, P194; XU JH, 1994, MOL CELL BIOL, V14, P8018, DOI 10.1128/MCB.14.12.8018; YAMADA H, 1994, MOL CELL BIOCHEM, V136, P117, DOI 10.1007/BF00926071; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	54	36	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	1999	18	11					2003	2014		10.1038/sj.onc.1202500	http://dx.doi.org/10.1038/sj.onc.1202500			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	177DC	10208422				2022-12-17	WOS:000079191300010
J	Kubota, S; Copeland, TD; Pomerantz, RJ				Kubota, S; Copeland, TD; Pomerantz, RJ			Nuclear and nucleolar targeting of human ribosomal protein S25: Common features shared with HIV-1 regulatory proteins	ONCOGENE			English	Article						ribosome; protein; nuclear targeting; rev; HIV-1	IMMUNODEFICIENCY-VIRUS TYPE-1; REV TRANS-ACTIVATOR; GENE-EXPRESSION; MESSENGER-RNA; POSTTRANSCRIPTIONAL REGULATION; FUNCTIONAL-ANALYSIS; VISNA VIRUS; I REX; LOCALIZATION; SEQUENCE	The nuclear and nucleolar targeting properties of human ribosomal protein S25 (RPS25) were analysed by the expression of epitope-tagged RPS25 cDNAs in Cos-l cells. The tagged RPS25 was localized to the cell nucleus, with a strong predominance in the nucleolus. At the amino terminus of RPS25, two stretches of highly basic residues juxtapose. This configuration shares common features with the nucleolar targeting signals (NOS) of lentiviral RNA-binding transactivators, including human immunodeficiency viruses' (HIV) Rev proteins. Deletion and site-directed mutational analyses demonstrated that the first NOS-like stretch is dispensable for both nuclear and nucleolar localization of RPS25, and that the nuclear targeting signal is located within the second NOS-like stretch. It has also been suggested that a set of continuous basic residues and the total number of basic residues should be required for nucleolar targeting. Signal-mediated nuclear/nucleolar targeting was further characterized by the construction and expression of a variety of chimeric constructs, utilizing three different backbones with RPS25 cDNA fragments. Immunofluorescence analyses demonstrated a 17 residue peptide of RPS25 as a potential nuclear/nucleolar targeting signal. The identified peptide signal may belong to a putative subclass of NOS, characterized by compact structure, together with lentiviral RNA binding transactivators.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Div Infect Dis,Ctr Human Virol, Philadelphia, PA 19107 USA; NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Ft Detrick, MD 21702 USA	Jefferson University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Pomerantz, RJ (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med,Dorrance H Hamilton Labs, Div Infect Dis,Ctr Human Virol, Philadelphia, PA 19107 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036552] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36552] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI Y, 1992, J BIOL CHEM, V267, P21977; AGRAWAL MG, 1987, J BIOL CHEM, V262, P4868; AKEY CW, 1989, J CELL BIOL, V109, P971, DOI 10.1083/jcb.109.3.971; ALONI R, 1992, MOL CELL BIOL, V12, P2203, DOI 10.1128/MCB.12.5.2203; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANG CV, 1989, J BIOL CHEM, V264, P18019; ENG FJ, 1991, CELL, V65, P797, DOI 10.1016/0092-8674(91)90387-E; FISCHER U, 1994, EMBO J, V13, P4105, DOI 10.1002/j.1460-2075.1994.tb06728.x; GOLDFARB DS, 1997, CURR BIOL, V7, P1213; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GRITZ L, 1985, MOL CELL BIOL, V5, P3436, DOI 10.1128/MCB.5.12.3436; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; IMAI T, 1994, GENOMICS, V20, P142, DOI 10.1006/geno.1994.1145; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALLAND KH, 1994, MOL CELL BIOL, V14, P7436, DOI 10.1128/MCB.14.11.7436; KUBOTA S, 1991, J VIROL, V65, P2452, DOI 10.1128/JVI.65.5.2452-2456.1991; KUBOTA S, 1989, BIOCHEM BIOPH RES CO, V162, P963, DOI 10.1016/0006-291X(89)90767-5; Kubota S, 1996, J VIROL, V70, P1282, DOI 10.1128/JVI.70.2.1282-1287.1996; LI H, 1995, J MOL BIOL, V250, P447, DOI 10.1006/jmbi.1995.0389; LI ML, 1991, GENE, V107, P329, DOI 10.1016/0378-1119(91)90335-9; MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6; MALIM MH, 1991, CELL, V65, P241, DOI 10.1016/0092-8674(91)90158-U; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MALIM MH, 1989, CELL, V58, P205, DOI 10.1016/0092-8674(89)90416-9; MartinNieto J, 1997, J CELL SCI, V110, P955; MELCHIOR F, 1995, CURR OPIN CELL BIOL, V7, P310, DOI 10.1016/0955-0674(95)80084-0; MEYER BE, 1994, GENE DEV, V8, P1538, DOI 10.1101/gad.8.13.1538; Michael WM, 1996, J BIOL CHEM, V271, P11571, DOI 10.1074/jbc.271.19.11571; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; NOSAKA T, 1993, EXP CELL RES, V209, P89, DOI 10.1006/excr.1993.1289; PECULIS BA, 1992, J CELL BIOL, V116, P1, DOI 10.1083/jcb.116.1.1; RICHARD N, 1994, VIROLOGY, V204, P123, DOI 10.1006/viro.1994.1516; Rout MP, 1997, CELL, V89, P715, DOI 10.1016/S0092-8674(00)80254-8; Russo G, 1997, J BIOL CHEM, V272, P5229, DOI 10.1074/jbc.272.8.5229; SCHMIDT C, 1995, MOL BIOL CELL, V6, P1875, DOI 10.1091/mbc.6.12.1875; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; SCHOBORG RV, 1994, VIROLOGY, V202, P485, DOI 10.1006/viro.1994.1367; SEIKI M, 1988, P NATL ACAD SCI USA, V85, P7124, DOI 10.1073/pnas.85.19.7124; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; SIOMI H, 1990, J VIROL, V64, P1803, DOI 10.1128/JVI.64.4.1803-1807.1990; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SODROSKI J, 1985, SCIENCE, V227, P171, DOI 10.1126/science.2981427; SOLLNERWEBB B, 1991, TRENDS BIOCHEM SCI, V16, P58, DOI 10.1016/0968-0004(91)90025-Q; SOMMERVILLE J, 1986, TRENDS BIOCHEM SCI, V11, P438, DOI 10.1016/0968-0004(86)90242-2; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TANG CK, 1990, BIOCHEMISTRY-US, V29, P4434, DOI 10.1021/bi00470a025; TASHEVA ES, 1995, GENE DEV, V9, P304, DOI 10.1101/gad.9.3.304; TILEY LS, 1991, J VIROL, V65, P3877, DOI 10.1128/JVI.65.7.3877-3881.1991; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; YAN C, 1993, J CELL BIOL, V123, P1081, DOI 10.1083/jcb.123.5.1081; ZAPP ML, 1989, NATURE, V342, P714, DOI 10.1038/342714a0	51	36	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 18	1999	18	7					1503	1514		10.1038/sj.onc.1202429	http://dx.doi.org/10.1038/sj.onc.1202429			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	167UK	10050887				2022-12-17	WOS:000078651600012
J	Ponzio, G; Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Dulic, V; Rossi, B				Ponzio, G; Loubat, A; Rochet, N; Turchi, L; Rezzonico, R; Far, DF; Dulic, V; Rossi, B			Early G(1) growth arrest of hybridoma B cells by DMSO involves cyclin D2 inhibition and p21([CIP1]) induction	ONCOGENE			English	Article						cyclin D2; cell cycle; DMSO; CDKs; p21([CIP1]); p27([KIP1])	RETINOBLASTOMA GENE-PRODUCT; DEPENDENT KINASE-ACTIVITY; REVERSIBLE G1 ARREST; NEUROBLASTOMA-CELLS; DIMETHYL-SULFOXIDE; SUSCEPTIBILITY GENE; PHASE PROGRESSION; NUCLEAR-PROTEIN; MAMMALIAN-CELLS; DOWN-REGULATION	Dimethylsulfoxide (DMSO) was shown to inhibit the proliferation of several B cell lines including Raji, Daudi, and SKW6-CL4 but the mechanisms involved in this growth arrest are still unclear. We show that in 7TD1 mouse hybridoma cells a DMSO-induced reversible G(1) arrest involves inactivation of Rb kinases, cyclin D2/CDK4 and cyclin E/CDK2. This occurs by at least three distinct mechanisms. Inhibition of cyclin D2 neosynthesis leads to a dramatic decrease of cyclinD2/CDK4 complexes. This in turn enables the redistribution of p27([KIP1]) from cyclin D2/CDK4 to cyclin E/CDK2 complexes. In addition, the simultaneous accumulation of p21([CIP1]) entails increasing association with cyclin D3/CDK4 and cyclin E/CDK2. Thus, p21([CIP1]) and p27([KIP1]), act in concert to inhibit cyclin E/CDK2 activity which, together with CDK4 inactivation, confers a G(1)-phase arrest.	Fac Med, INSERM U364, F-06107 Nice 02, France; Hop Cantonal Geneva, Lab Immunol Clin, CH-1211 Geneva 14, Switzerland; CNRS, CRBM, ERS 155, F-34033 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Ponzio, G (corresponding author), Fac Med, INSERM U364, Ave Valombrose, F-06107 Nice 02, France.		ROCHET, Nathalie/N-1819-2018; ROCHET, Nathalie/S-3027-2019; Ponzio, Gilles/Q-1256-2016; REZZONICO, Roger/N-9626-2016	ROCHET, Nathalie/0000-0002-9995-6699; ROCHET, Nathalie/0000-0002-9995-6699; Ponzio, Gilles/0000-0003-2741-0248; REZZONICO, Roger/0000-0002-8460-1641; Dulic, Vjekoslav/0000-0003-1201-3901; Turchi, Laurent/0000-0003-2020-5831				BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BURGER C, 1994, J CELL SCI, V107, P2047; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Florenes VA, 1996, ONCOGENE, V13, P2447; GIRARD F, 1992, J CELL BIOL, V118, P785, DOI 10.1083/jcb.118.4.785; Gorospe M, 1996, MOL CELL BIOL, V16, P762; HALL M, 1995, ONCOGENE, V11, P1581; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HENGST L, 1994, P NATL ACAD SCI USA, V91, P5291, DOI 10.1073/pnas.91.12.5291; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HORIGUCHIYAMADA J, 1993, MOL CELL BIOCHEM, V119, P29, DOI 10.1007/BF00926850; JIANG HP, 1994, ONCOGENE, V9, P3397; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; KLINKEN SP, 1988, EXP CELL RES, V178, P185, DOI 10.1016/0014-4827(88)90390-4; KLUGE N, 1976, P NATL ACAD SCI USA, V73, P1237, DOI 10.1073/pnas.73.4.1237; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koyama H, 1996, CELL, V87, P1069, DOI 10.1016/S0092-8674(00)81801-2; KRANENBURG O, 1995, J CELL BIOL, V131, P227, DOI 10.1083/jcb.131.1.227; LAllemain G, 1997, ONCOGENE, V14, P1981, DOI 10.1038/sj.onc.1201038; LUKAS J, 1995, MOL CELL BIOL, V15, P2600; LUKAS J, 1994, ONCOGENE, V9, P707; MAEDA S, 1978, J CELL PHYSIOL, V94, P181, DOI 10.1002/jcp.1040940207; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Musgrove EA, 1997, MOL ENDOCRINOL, V11, P54, DOI 10.1210/me.11.1.54; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PETERS G, 1994, NATURE, V371, P204, DOI 10.1038/371204a0; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; PROUDFOOT AEI, 1993, J PROTEIN CHEM, V12, P489, DOI 10.1007/BF01025050; REAGAN LP, 1990, MOL PHARMACOL, V38, P878; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; REYNERI LM, 1995, NEURAL PROCESS LETT, V2, P2, DOI 10.1007/BF02311571; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; SAWAI M, 1990, EXP CELL RES, V187, P4, DOI 10.1016/0014-4827(90)90108-M; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAKASE K, 1992, CELL GROWTH DIFFER, V3, P515; TAKASE K, 1994, CELL GROWTH DIFFER, V5, P1051; Teraoka H, 1996, EXP CELL RES, V222, P218, DOI 10.1006/excr.1996.0027; Tiefenbrun N, 1996, MOL CELL BIOL, V16, P3934; Vadiveloo PK, 1996, ONCOGENE, V13, P599; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503	60	36	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	1998	17	9					1159	1166		10.1038/sj.onc.1202040	http://dx.doi.org/10.1038/sj.onc.1202040			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764826				2022-12-17	WOS:000075598400011
J	Janssen, JWG; Schleithoff, L; Bartram, CR; Schulz, AS				Janssen, JWG; Schleithoff, L; Bartram, CR; Schulz, AS			An oncogenic fusion product of the phosphatidylinositol 3-kinase p85 beta subunit and HUMORF8, a putative deubiquitinating enzyme	ONCOGENE			English	Article						p85 beta; phosphatidylinositol 3-kinase; HUMORF8; deubiquitinating enzyme	EXPRESSION CDNA CLONING; NUCLEOTIDE EXCHANGE FACTORS; HUMAN MYELOID-LEUKEMIA; GTP-BINDING PROTEINS; T-CELL ACTIVATION; TRANSFORMING GENE; MOLECULAR-CLONING; P85 SUBUNIT; TYROSINE KINASE; PHOSPHOINOSITIDE 3-KINASE	Peripheral blood cell DNA from a patient with a chronic myeloproliferative disorder was tested in the tumorigenicity assay. Upon tumor induction in nude mice we isolated a human oncogene by means of genomic cloning, exon trap analysis and cDNA cloning. Sequence analysis revealed a fusion product of the p85 beta subunit of phosphatidylinositol (PI) 3-kinase and HUMORF8, a putative deubiquitinating enzyme, which has been generated during the DNA transfection process. Application of the tumorigenicity assay to various p85 beta and HUMORF8 cDNA constructs indicated that the recombination of both genes rather than the truncation of one of the fusion partners renders the chimeric protein tumorigenic. Moreover, sequence analysis of human wildtype p85 beta revealed an alanine for serine substitution at a site important for the regulation of the Lipid kinase activity of PI 3-kinase in human p85 alpha. This variation may relate to differences in the mode of signal transduction from both p85 isoforms.	Univ Heidelberg, Inst Humangenet, D-69120 Heidelberg, Germany; Univ Ulm, Kinderklin, D-89075 Ulm, Germany	Ruprecht Karls University Heidelberg; Ulm University	Janssen, JWG (corresponding author), Univ Heidelberg, Inst Humangenet, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.							AUCH D, 1990, NUCLEIC ACIDS RES, V18, P6743, DOI 10.1093/nar/18.22.6743; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Carpenter CL, 1996, BBA-REV CANCER, V1288, pM11, DOI 10.1016/0304-419X(96)00018-2; CHAN AML, 1993, ONCOGENE, V8, P1329; Chan AML, 1996, ONCOGENE, V12, P1259; CHAN AML, 1994, P NATL ACAD SCI USA, V91, P7558, DOI 10.1073/pnas.91.16.7558; CHAN AML, 1994, ONCOGENE, V9, P1057; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; GUPTA K, 1994, ONCOGENE, V9, P1729; HARRISONFINDIK D, 1995, ONCOGENE, V10, P1385; HEMMINGS A, 1997, SCIENCE, V275, P1899; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HORII Y, 1994, EMBO J, V13, P4776, DOI 10.1002/j.1460-2075.1994.tb06803.x; IKAWA S, 1988, MOL CELL BIOL, V8, P2651, DOI 10.1128/MCB.8.6.2651; JANSSEN JWG, 1991, ONCOGENE, V6, P2113; JANSSEN JWG, 1985, CANCER RES, V45, P3262; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Klippel A, 1996, MOL CELL BIOL, V16, P4117; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LORENZI MV, 1995, ONCOGENE, V10, P2051; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; McIlroy J, 1997, MOL CELL BIOL, V17, P248, DOI 10.1128/MCB.17.1.248; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; OCHIYA T, 1986, P NATL ACAD SCI USA, V83, P4993, DOI 10.1073/pnas.83.14.4993; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; PONS S, 1995, MOL CELL BIOL, V15, P4453; REIF K, 1993, J BIOL CHEM, V268, P10780; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SHIBASAKI F, 1994, BIOCHEM J, V302, P551, DOI 10.1042/bj3020551; SHIH C, 1981, NATURE, V290, P261, DOI 10.1038/290261a0; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; Susa M, 1996, BIOCHEM BIOPH RES CO, V220, P729, DOI 10.1006/bbrc.1996.0472; TAKAHASHI M, 1985, CELL, V42, P581, DOI 10.1016/0092-8674(85)90115-1; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKSOZ D, 1994, ONCOGENE, V9, P621; VOGELSTEIN B, 1987, ANAL BIOCHEM, V160, P115, DOI 10.1016/0003-2697(87)90620-8; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WANG SM, 1993, ONCOGENE, V8, P1009; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANG SS, 1990, CANCER RES, V50, pS5658; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	64	36	45	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 2	1998	16	13					1767	1772		10.1038/sj.onc.1201695	http://dx.doi.org/10.1038/sj.onc.1201695			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZE573	9582025				2022-12-17	WOS:000072807600015
J	Habib, AA; Gulcher, JR; Hognason, T; Zheng, LY; Stefansson, K				Habib, AA; Gulcher, JR; Hognason, T; Zheng, LY; Stefansson, K			The OMgp gene, a second growth suppressor within the NF1 gene	ONCOGENE			English	Article						Oligodendrocyte-Myelin glycoprotein; OMgp; neurofibromin; growth suppressor; NIH3T3 fibroblasts; PDGF signaling	NEUROFIBROMATOSIS TYPE-1 GENE; OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; PROTEIN-TYROSINE KINASES; NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; SRC-FAMILY; SCHWANN-CELLS; T-CELLS; RAS; PHOSPHORYLATION	The Oligodendrocyte-Myelin glycoprotein gene (OMgp) is placed within an intron of the NF1 gene, Neurofibromin, the product of NF1, acts as a RasGAP and suppresses growth; inactivating mutations in NF1 lead to neurofibromatosis type 1. We report that OMgp also has growth suppressive effects and downregulates mitogenic signaling pathways closely related to those influenced by neurofibromin. Overexpression of OMgp alters mitogenic signaling in NIH3T3 fibroblasts. Cells overexpressing OMgp grow more slowly in serum compared to controls and show a partial G(1) block upon cell cycle analysis, PDGF is the primary mitogen for fibroblasts in serum, Overexpression of OMgp alters PDGF signaling in fibroblasts which results in a block of mitogenic signaling, PDGF induced activation of c-Src is blocked, as is the induction of c-Myc and c-Fos, while tyrosine phosphorylation of the PDGF beta receptor, PLC gamma 1 and induction of c-Jun are intact, Although a number of genes embedded within other genes have been described, the biological significance of this arrangement remains unknown, We demonstrate here that structurally unrelated products of two such genes may exercise closely related functions, Our data also raise the possibility of a role for OMgp in disorders of cell proliferation such as NF1.	Harvard Univ, Sch Med, Inst Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02115 USA; DeCode Genet, IS-110 Reykjavik, Iceland	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Habib, AA (corresponding author), Harvard Univ, Sch Med, Inst Med, Room 807,77 Ave Louis Pasteur, Boston, MA 02115 USA.		Stefansson, Kari/AAE-7187-2019		NINDS NIH HHS [R0INS32977] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032977] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Agarwal P, 1993, Methods Mol Biol, V15, P45, DOI 10.1385/0-89603-244-2:45; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1992, NATURE, V356, P663, DOI 10.1038/356663a0; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; CAI H, 1990, MOL CELL BIOL, V10, P5314, DOI 10.1128/MCB.10.10.5314; CHENG HC, 1992, J BIOL CHEM, V267, P9248; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Cooper Jonathan A., 1993, V5, P44; DASTON MM, 1992, NEURON, V8, P415, DOI 10.1016/0896-6273(92)90270-N; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; FRACKELTON AR, 1984, J BIOL CHEM, V259, P7909; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GUTMANN DH, 1993, NEURON, V10, P335, DOI 10.1016/0896-6273(93)90324-K; HALL CL, 1994, J CELL BIOL, V126, P575, DOI 10.1083/jcb.126.2.575; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HSI ED, 1989, J BIOL CHEM, V264, P10836; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KHOCHBIN S, 1989, EMBO J, V8, P4107, DOI 10.1002/j.1460-2075.1989.tb08595.x; KIM HA, 1995, ONCOGENE, V11, P325; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MCCORMICK F, 1995, CURR OPIN GENET DEV, V5, P51, DOI 10.1016/S0959-437X(95)90053-5; MIKOL DD, 1993, GENOMICS, V17, P604, DOI 10.1006/geno.1993.1379; MIKOL DD, 1988, J CELL BIOL, V106, P1273, DOI 10.1083/jcb.106.4.1273; MIKOL DD, 1990, J CELL BIOL, V110, P471, DOI 10.1083/jcb.110.2.471; MUIR D, 1990, ANAL BIOCHEM, V185, P377, DOI 10.1016/0003-2697(90)90310-6; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NORI M, 1992, MOL CELL BIOL, V12, P936, DOI 10.1128/MCB.12.3.936; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Riccardi V. M., 1992, NEUROFIBROMATOSIS PH; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; SCHER CD, 1979, BIOCHIM BIOPHYS ACTA, V560, P217, DOI 10.1016/0304-419X(79)90020-9; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHENOYSCARIA AM, 1992, J IMMUNOL, V149, P3535; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; VISKOCHIL D, 1991, MOL CELL BIOL, V11, P906, DOI 10.1128/MCB.11.2.906; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; Weksberg R, 1996, NAT GENET, V12, P225, DOI 10.1038/ng0396-225; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	53	36	43	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 26	1998	16	12					1525	1531		10.1038/sj.onc.1201683	http://dx.doi.org/10.1038/sj.onc.1201683			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZD962	9569019				2022-12-17	WOS:000072743200002
J	Meili, R; Cron, P; Hemmings, BA; Ballmer-Hofer, K				Meili, R; Cron, P; Hemmings, BA; Ballmer-Hofer, K			Protein kinase B/Akt is activated by polyomavirus middle-T antigen via a phosphatidylinositol 3-kinase-dependent mechanism	ONCOGENE			English	Article						middle-T; PI 3-kinase; protein kinase B/Akt; polyomavirus	TUMOR-ANTIGEN; PHOSPHOINOSITIDE 3-KINASE; PHOSPHORYLATION; TRANSFORMATION; ASSOCIATION; PP60C-SRC; BINDING; AKT; PHOSPHATASE-2A; INTERACTS	The middle tumor antigen (middle-T) of mouse polyomavirus is responsible for the transforming potential of this virus, Middle-T has been shown to interact with a variety of cellular proteins known to mediate mitogenic signaling, like phosphatase-2A, Src family kinases, phosphatidylinositol 3-kinase (PI3-kinase), the adapter protein SHC, phospholipase C gamma-1 and 14-3-3 family proteins, Association with SHC and PI 3-kinase, respectively, stimulates two independent signaling pathways that are indispensible for viral oncogenicity. SHC activates the Ras/MAPK pathway via Grb2/SOS resulting in changes in early gene expression, The downstream targets of PI 3-kinase are less well studied but seem to impinge on serum response factor (SRF) which is also involved in regulating early gene expression, Recently, the protein kinase B/Akt (PKB/Akt) has been identified as a target of PI 3-kinase in receptor tyrosine kinase signaling, Here we show that PKB/Akt is a target of wild type middle-T, but not of mutants unable to activate PI 3-kinase, These data were confirmed using inhibitors of PI 3-kinase as well as dominant-negative alleles of the catalytic subunit of this lipid kinase, In addition, mutants of PKB/Akt lacking a pleckstrin homology domain and therefore unable to bind to D3 phospatidylinositides were not activated by middle-T, Taken together these data suggest that middle-T activates PKB/Akt in a PI 3-kinase-dependent manner, Furthermore, direct association with D3 phosphatidylinositides seems to be essential for activation of PKB/Akt.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Ballmer-Hofer, K (corresponding author), Inst Med Radiobiol, CH-5232 Villigen, Switzerland.			Ballmer-Hofer, Kurt/0000-0002-3800-9129				Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BOS JL, 1995, TRENDS BIOCHEM SCI, V20, P441, DOI 10.1016/S0968-0004(00)89097-0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; COURTNEIDGE SA, 1989, ONCOGENE RES, V4, P75; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dahl J, 1996, MOL CELL BIOL, V16, P2728; Didichenko SA, 1996, CURR BIOL, V6, P1271, DOI 10.1016/S0960-9822(02)70713-6; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KIEFER F, 1994, ADV CANCER RES, V64, P125, DOI 10.1016/S0065-230X(08)60837-4; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LING LE, 1992, J VIROL, V66, P1702, DOI 10.1128/JVI.66.3.1702-1708.1992; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RASSOULZADEGAN M, 1982, NATURE, V300, P713, DOI 10.1038/300713a0; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SU W, 1995, J BIOL CHEM, V270, P12331, DOI 10.1074/jbc.270.21.12331; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TALMAGE DA, 1988, MOL CELL BIOL, V8, P2309, DOI 10.1128/MCB.8.6.2309; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; Urich M, 1997, ONCOGENE, V14, P1235, DOI 10.1038/sj.onc.1200982; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0	37	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					903	907		10.1038/sj.onc.1201605	http://dx.doi.org/10.1038/sj.onc.1201605			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484781				2022-12-17	WOS:000072053200009
J	Zhuang, SM; Schippert, A; Haugen-Strano, A; Wiseman, RW; Soderkvist, P				Zhuang, SM; Schippert, A; Haugen-Strano, A; Wiseman, RW; Soderkvist, P			Inactivations of p16(INK4a)-alpha, p16(INK4a)-beta and p15(INK4b) genes in 2 ',3 '-dideoxycytidine- and 1,3-butadiene-induced murine lymphomas	ONCOGENE			English	Article						p16(INK4a)-alpha; p16(INK4a)-beta; p15(INK4b); murine lymphomas; 1,3-butadiene; 2 ',3 '-dideoxycytidine	TUMOR-SUPPRESSOR GENE; DEPENDENT KINASE INHIBITORS; ACUTE LYMPHOCYTIC-LEUKEMIA; CELL-CYCLE INHIBITION; METHYL-N-NITROSOUREA; RETINOBLASTOMA-PROTEIN; PANCREATIC-CANCER; THYMIC LYMPHOMAS; CPG ISLAND; MICE	The p16(INK4a) (alpha and beta form) and p15(INK4b) genes were analysed for homozygous deletion, hypermethylation and point mutation in B6C3F1 mouse lymphomas induced by 2',3'-dideoxycytidine or 1,3-butadiene, Although the p16(INK4a)-alpha gene appeared normal in DNA from 2',3'-dideoxycytidine-induced lymphomas, Southern analyses revealed homozygous deletions or rearrangements of the p16(INK4a)-beta and/or p15(INK4b) genes in four of 16 tumours, Surprisingly, two of these lymphomas showed exclusive deletions of the p16(INK4a) EI beta exon, The p15(INK4b) promoter region was hypermethylated in two additional 2',3'-dideoxycytidine-induced lymphomas, In contrast, homozygous deletions spanning the p16(INK4a), and p15(INK4b) loci were observed in only two of 31 1,3-butadiene-induced tumours, Thus, these cyclin dependent kinase inhibitor genes may play a significant role in chemically induced mouse lymphomas and support the contention of tumour suppressor activity for the p19(ARF) protein encoded by the p16(INK4a)-beta gene, Different genetic pathways may be involved in the development of these chemically induced tumours since we have previously shown that mutations in p53 and rns genes are common in 1,3-butadiene- but not 2',3'-dideoxycytidine-induced lymphomas,.	Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, S-58185 Linkoping, Sweden; NIEHS, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA	Linkoping University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Zhuang, SM (corresponding author), Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, S-58185 Linkoping, Sweden.			Zhuang, Shi-Mei/0000-0002-2512-3942				ANGEL JM, 1989, J NATL CANCER I, V81, P1652, DOI 10.1093/jnci/81.21.1652; Arap W, 1997, ONCOGENE, V14, P603, DOI 10.1038/sj.onc.1200870; Batova A, 1997, CANCER RES, V57, P832; CAIRNS P, 1995, NAT GENET, V11, P210, DOI 10.1038/ng1095-210; DIVINE BJ, 1990, ENVIRON HEALTH PERSP, V86, P119, DOI 10.2307/3430943; DRINKWATER NR, 1991, PROG EXP TUMOR RES, V33, P1; Flores JF, 1996, CANCER RES, V56, P5023; Fueyo J, 1996, ONCOGENE, V13, P1615; GOLDSTEIN AM, 1995, NEW ENGL J MED, V333, P970, DOI 10.1056/NEJM199510123331504; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARRIS G, 1994, CARCINOGENESIS, V15, P1211, DOI 10.1093/carcin/15.6.1211; Herman JG, 1996, CANCER RES, V56, P722; Herman JG, 1997, CANCER RES, V57, P837; Herzog CR, 1996, ONCOGENE, V13, P1885; HERZOG CR, 1994, CANCER RES, V54, P4007; Heyman M, 1996, BLOOD, V87, P1657, DOI 10.1182/blood.V87.4.1657.bloodjournal8741657; HIRAMA T, 1995, BLOOD, V86, P841; HOOPER WC, 1991, LEUKEMIA RES, V15, P179, DOI 10.1016/0145-2126(91)90118-D; HUSSUSSIAN CJ, 1994, NAT GENET, V8, P15, DOI 10.1038/ng0994-15; *IARC, 1992, IARC MON EV CARC RIS, V54, P237; ISHIZAKA ST, 1989, CANCER RES, V49, P1214; JEN J, 1994, CANCER RES, V54, P6353; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Liggett WH, 1996, CANCER RES, V56, P4119; Lilischkis R, 1996, INT J CANCER, V66, P249, DOI 10.1002/(SICI)1097-0215(19960410)66:2<249::AID-IJC19>3.0.CO;2-7; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; LOIS AF, 1995, CANCER RES, V55, P4010; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MAO L, 1995, CANCER RES, V55, P2995; MATANOSKI GM, 1990, ENVIRON HEALTH PERSP, V86, P107, DOI 10.2307/3430942; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; MELNICK RL, 1990, CANCER RES, V50, P6592; MERLO A, 1995, NAT MED, V1, P686, DOI 10.1038/nm0795-686; NEWCOMB EW, 1988, CANCER RES, V48, P5514; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Rao GN, 1996, CANCER RES, V56, P4666; RASOOL O, 1995, BLOOD, V85, P3431, DOI 10.1182/blood.V85.12.3431.bloodjournal85123431; SADO T, 1985, J IMMUNOL, V134, P704; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SIEBERT R, 1995, BRIT J HAEMATOL, V91, P350, DOI 10.1111/j.1365-2141.1995.tb05302.x; STARNES MC, 1987, J BIOL CHEM, V262, P988; STONE S, 1995, CANCER RES, V55, P2988; WHELAN AJ, 1995, NEW ENGL J MED, V333, P975, DOI 10.1056/NEJM199510123331505; YANG R, 1995, CANCER RES, V55, P2503; Zhuang SM, 1996, CANCER RES, V56, P3338; Zhuang SM, 1997, CANCER RES, V57, P2710	52	36	37	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 12	1998	16	6					803	808		10.1038/sj.onc.1201600	http://dx.doi.org/10.1038/sj.onc.1201600			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488045				2022-12-17	WOS:000071931800013
J	Guerrero, C; Fernandez-Medarde, A; Rojas, JM; de Mora, JF; Esteban, LM; Santos, E				Guerrero, C; Fernandez-Medarde, A; Rojas, JM; de Mora, JF; Esteban, LM; Santos, E			Transformation suppressor activity of C3G is independent of its CDC25-homology domain	ONCOGENE			English	Article						malignant transformation; focus formation; C3G; Ras; Raf; Sis	GUANINE-NUCLEOTIDE EXCHANGE; DEPENDENT ACTIVATION; RAS P21; H-RAS; R-RAS; CEREVISIAE CDC25; POINT MUTATIONS; SEVENLESS GENE; SH3 DOMAIN; PH DOMAIN	The guanine nucleotide releasing protein C3G was initially identified as a Crk SH3-binding protein and recently shown to exhibit exchange activity on Rap1 proteins. Overexpression in NIH3T3 cells of a full-length C3G cDNA isolated from human placenta markedly reduced the focus forming activity of cotransfected, malignantly activated, ras oncogenes (5-7-fold). C3G also had a reverting effect on sis-mediated transformation, decreasing the number of c-sis-induced foci by a factor of 5-10-fold. The observed inhibitory effect of C3G on focus-forming activity of Ras and Sis was always higher than that observed with Rap1A, a known target of C3G. The inhibition of focus formation observed in the presence of C3G was not due to toxic effects on cell viability, since transfected C3G cells exhibited the same survival and growth rates as untransfected NIH3T3 cells or cells transfected with plasmid vector alone. Surprisingly, as opposed to Rap1A, which has no effect on Raf-1 oncogene-mediated transformation, C3G also reduced dramatically (6-8-fold) the number of v-raf-induced foci in transfected NIH3T3 cells. The inhibitory effect on Raf-induced transformation suggests that C3G has other functional targets in addition to Rap1. A C3G mutant (C3G Delta Cat) lacking the catalytic domain (CDC25-H) but retaining the rest of the N-terminal sequences, including the Crk-binding domain, exhibited similar ability than full length C3G to inhibit focus formation. In contrast, a C3G mutant (C3G Cat), containing the catalytic domain only but lacking the rest of the N-terminal sequences, did not have any inhibitory effect on transformation mediated by the oncogenes tested. The C3G-derived gene products overexpressed in our transfected cell lines localized to the cytoplasm and did not change the basal MAPK or JNK activity of those cell lines nor their ability to activate the kinases in response to agonists. Our results suggest that the N-terminal region of C3G, and not its catalytic domain, may be responsible for the inhibitory effects observed.	NCI, Cellular & Mol Biol Lab, DBS, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Santos, E (corresponding author), NCI, Cellular & Mol Biol Lab, DBS, NIH, Bldg 37, Bethesda, MD 20892 USA.		Rojas, José M/D-3718-2018; Rojas, José M./AAA-3354-2021; Guerrero, Carmen/F-1776-2010; Fernández-Medarde, Alberto/B-3839-2017; de Mora, Jaime Font/H-6304-2015; de Mora, Jaime Font/AAK-7591-2021	Rojas, José M/0000-0002-5383-3482; Rojas, José M./0000-0002-7547-2825; Guerrero, Carmen/0000-0002-8747-6831; Fernández-Medarde, Alberto/0000-0002-1230-5501; de Mora, Jaime Font/0000-0002-6816-2095; de Mora, Jaime Font/0000-0002-6816-2095				BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN LP, 1993, DEV GENET, V14, P339, DOI 10.1002/dvg.1020140503; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COX AD, 1994, ONCOGENE, V9, P685; CUADRADO A, 1993, ONCOGENE, V8, P2443; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; Fam NP, 1997, GENOMICS, V39, P118, DOI 10.1006/geno.1996.4484; Fam NP, 1997, MOL CELL BIOL, V17, P1396, DOI 10.1128/MCB.17.3.1396; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FELLER SM, 1995, ONCOGENE, V10, P1465; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; Gotoh T, 1997, J BIOL CHEM, V272, P18602, DOI 10.1074/jbc.272.30.18602; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; Greulich H, 1996, CELL GROWTH DIFFER, V7, P1443; Guerrero C, 1996, ONCOGENE, V12, P1097; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; JACKMAN M, 1995, EMBO J, V14, P1646, DOI 10.1002/j.1460-2075.1995.tb07153.x; JACQUET E, 1992, J BIOL CHEM, V267, P24181; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWRY DR, 1993, ANNU REV BIOCHEM, V62, P851; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; Mattingly RR, 1996, NATURE, V382, P268, DOI 10.1038/382268a0; MIKI T, 1989, GENE, V83, P137, DOI 10.1016/0378-1119(89)90411-3; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAEZ R, 1994, ONCOGENE, V9, P2977; SAKODA T, 1992, ONCOGENE, V7, P1705; SCHELESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; WANG HG, 1995, J CELL BIOL, V129, P1103, DOI 10.1083/jcb.129.4.1103; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	53	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 5	1998	16	5					613	624		10.1038/sj.onc.1201569	http://dx.doi.org/10.1038/sj.onc.1201569			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YV376	9482107				2022-12-17	WOS:000071816600006
J	Madamanchi, NR; Bukoski, RD; Runge, MS; Rao, GN				Madamanchi, NR; Bukoski, RD; Runge, MS; Rao, GN			Arachidonic acid activates Jun N-terminal kinase in vascular smooth muscle cells	ONCOGENE			English	Article						arachidonic acid; cytokines; growth factors; JNK1; signaling	CYTOSOLIC PHOSPHOLIPASE A(2); JNK/SAPK SIGNALING PATHWAY; BINDING PROTEINS RAC1; RAT MESANGIAL CELLS; C-JUN; MASTOCYTOMA-CELLS; GROWTH; LIPOXYGENASE; METABOLITES; EXPRESSION	We have previously demonstrated that arachidonic acid activates extracellular signal-regulated protein kinases (ERKs) group of mitogen-activated protein kinases (MAPKs) in vascular smooth muscle cells (VSMC). To understand the role of arachidonic acid in cellular signaling events, we have now studied its effect on jun N-terminal kinases (JNKs) group of MAPKs in VSMC. Arachidonic acid activated JNK1 in a time-and concentration-dependent manner with maximum effects at 10 min and 50 mu M. Induced activation of JNK1 by arachidonic acid is specific as other fatty acids such as linoleic and stearic acids had no such effect. Indomethacin and nordihydroguaiaretic acid (NDGA), potent inhibitors of the cyclooxygenase (COX) and the lipoxygenase (LOX)/monooxygenase (MOX) pathways, respectively, had no effect on arachidonic acid activation of JNK1 suggesting that the observed phenomenon is independent of its metabolism through either pathway. 12-hydroperoxyeicosatetraenoic acid (12-HpETE), the LOX metabolite of arachidonic acid significantly induced JNK1 activity. Protein kinase C (PKC) depletion by prolonged treatment of VSMC with phorbol 12-myristate 13-acetate (PMA) resulted in partial decrease in the responsiveness of JNK1 to arachidonic acid suggesting a role for both PKC-dependent and -independent mechanisms in the activation of JNK1 by this important fatty acid. On the other hand, the responsiveness of JNK1 to 12-HpETE was completely abolished in PKC-depleted cells, suggesting a major role for PKC in l2-HpETE-induced JNK1 activation. IL-1 beta and TNF-alpha activated JNK1 in a time-dependent manner with maximum effect at 10 min. Desensitization of JNK1 by arachidonic acid significantly reduced its responsiveness to both the cytokines. In addition, 4-bromophenacyl bromide (4-BPB), a potent and selective inhibitor of phospholipase A(2) (PLA(2)), significantly attenuated the cytokine-induced activation of JNK1. Together, these results show that (1) arachidonic acid and its LOX metabolite, 12-HpETE, activate JNK1 in VSMC, (2) PKC-dependent and -independent mechanisms play a role in the activation of JNK1 by arachidonic acid and 12-HpETE, and (3) arachidonic acid mediates, at least partially, the cytokine-induced activation of JNK1.	Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sect Hypertens & Vasc Res, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Rao, GN (corresponding author), Univ Texas, Med Branch, Div Cardiol, Galveston, TX 77555 USA.			Madamanchi, Nageswara/0000-0003-0590-0908				ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P716, DOI 10.1073/pnas.90.2.716; ASAOKA Y, 1993, P NATL ACAD SCI USA, V90, P4917, DOI 10.1073/pnas.90.11.4917; BUTCHER RD, 1993, CANCER RES, V53, P3405; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Crespo P, 1996, ONCOGENE, V13, P455; Cui XL, 1997, P NATL ACAD SCI USA, V94, P3771, DOI 10.1073/pnas.94.8.3771; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DETHLEFSEN SM, 1994, EXP CELL RES, V212, P262, DOI 10.1006/excr.1994.1142; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; FAFEUR V, 1991, J CELL PHYSIOL, V149, P277, DOI 10.1002/jcp.1041490214; GLASGOW WC, 1992, J BIOL CHEM, V267, P10771; HALIDAY EM, 1991, EMBO J, V10, P109, DOI 10.1002/j.1460-2075.1991.tb07926.x; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; HANSSON A, 1986, BIOCHEM BIOPH RES CO, V134, P1215, DOI 10.1016/0006-291X(86)90380-3; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; JAATTELA M, 1995, ONCOGENE, V10, P2297; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIKKAWA U, 1988, PHILOS T ROY SOC B, V320, P313, DOI 10.1098/rstb.1988.0079; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; Knoepp SM, 1996, J BIOL CHEM, V271, P1678, DOI 10.1074/jbc.271.3.1678; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LIN L, 1994, CIRC RES, V74, P197, DOI 10.1161/01.RES.74.2.197; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIU B, 1995, P NATL ACAD SCI USA, V92, P9323, DOI 10.1073/pnas.92.20.9323; Lu G, 1996, CIRC RES, V79, P611, DOI 10.1161/01.RES.79.3.611; MA YH, 1993, CIRC RES, V72, P126, DOI 10.1161/01.RES.72.1.126; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Mitsui H, 1997, J BIOL CHEM, V272, P4904, DOI 10.1074/jbc.272.8.4904; NAKAO J, 1982, ATHEROSCLEROSIS, V44, P339, DOI 10.1016/0021-9150(82)90008-9; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; Piomelli D, 1993, CURR OPIN CELL BIOL, V5, P274, DOI 10.1016/0955-0674(93)90116-8; RALPH RK, 1990, CANCER LETT, V49, P181, DOI 10.1016/0304-3835(90)90156-R; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RAO GN, 1994, BIOCHEM J, V299, P197, DOI 10.1042/bj2990197; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RAO GN, 1994, J BIOL CHEM, V269, P32586; RAO GN, 1995, BBA-MOL CELL RES, V1265, P67, DOI 10.1016/0167-4889(95)91997-Z; Rao GN, 1996, J BIOL CHEM, V271, P20805, DOI 10.1074/jbc.271.34.20805; Rizzo MT, 1996, BLOOD, V88, P3792, DOI 10.1182/blood.V88.10.3792.bloodjournal88103792; SAKATA A, 1987, J IMMUNOL, V138, P4353; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHALKWIJK C, 1992, J BIOL CHEM, V267, P8846; SCHWARTZMAN ML, 1994, J BIOL CHEM, V269, P24321; SELLMAYER A, 1991, J BIOL CHEM, V266, P3800; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; YAN MH, 1994, NATURE, V372, P798; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	62	36	40	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 22	1998	16	3					417	422		10.1038/sj.onc.1201551	http://dx.doi.org/10.1038/sj.onc.1201551			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT262	9467967				2022-12-17	WOS:000071582100014
J	Harris, TM; Rogler, LE; Rogler, CE				Harris, TM; Rogler, LE; Rogler, CE			Reactivation of the maternally imprinted IGF2 allele in TGF alpha induced hepatocellular carcinomas in mice	ONCOGENE			English	Article						IGF2; imprinting; DEN; hepatocellular carcinoma; transgenic mice	GROWTH-FACTOR-II; INSULIN-RECEPTOR SUBSTRATE-1; HEPATITIS-VIRUS CARRIERS; TRANSGENIC MICE; DIFFERENTIAL EXPRESSION; MESSENGER-RNA; GENE-EXPRESSION; LIVER-TUMORS; OVEREXPRESSION; APOPTOSIS	The Insulin like growth factor 2 (IGF2) gene is expressed in several types of tumors in humans and mice and has been implicated as an important growth factor in tumor progression. IGF2 expression in the TGF alpha transgenic mice was analysed in liver and tumors from animals which also contained one or two functional IGF2 alleles. In a two by two mating experiment using transgenic mice containing either a TGF alpha transgene or a IGF2 gene knockout, we have investigated whether IGF2 imprinting is reversed during hepatocarcinogenesis and the consequences of IGF2 expression for tumor growth. We observed that: (1) 100% of the hepatocellular carcinomas expressed IGF2 (2) the normally imprinted maternal allele is active in the tumors in which the paternal allele is knocked out and (3) all three of the murine IGF2 promoters upstream of the reactivated maternal alleles are transcriptionally active in tumors. We also observed that the total tumor burden of animals with two wild type IGF-2 alleles (paternal and maternal) was the same as the tumor burden in animals which contained only a single reactivated maternal allele. The 100% incidence of reactivation of the imprinted maternal allele suggests that IGF2 expression is selected during murine hepatocarcinogenesis and can substitute for the paternal allele when it is inactivated.	Yeshiva Univ Albert Einstein Coll Med, Dept Med, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Rogler, LE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Med, Marion Bessin Liver Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.				NCI NIH HHS [CA56076] Funding Source: Medline; NIDDK NIH HHS [T32 DK 07218] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056076] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007218] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; CARIANI E, 1988, CANCER RES, V48, P6844; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTOFORI G, 1995, NAT GENET, V10, P196, DOI 10.1038/ng0695-196; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; COLLIER JD, 1993, LIVER, V13, P151; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DEMOOR CH, 1994, EUR J BIOCHEM, V226, P1039; DEMOOR CH, 1995, BIOCHEM J, V307, P225, DOI 10.1042/bj3070225; DEPAGTERHOLTHUIZEN P, 1988, BIOCHIM BIOPHYS ACTA, V950, P282, DOI 10.1016/0167-4781(88)90124-8; FLORINI JR, 1993, ADV EXP MED BIOL, V343, P319; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; FURUSAKA A, 1994, CANCER LETT, V84, P85, DOI 10.1016/0304-3835(94)90361-1; GREENBLATT MS, 1994, CANCER RES, V54, P4855; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; JIRTLE R, 1995, LIVER REGENERATION C, P199; KAUFMANN WK, 1992, CARCINOGENESIS, V13, P1481, DOI 10.1093/carcin/13.8.1481; KIESS W, 1994, HORM RES, V41, P66, DOI 10.1159/000183963; LAUTERIO TJ, 1992, ADV EXP MED BIOL, V321, P31; LEE GH, 1992, CANCER RES, V52, P5162; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; OHLSSON R, 1989, DEVELOPMENT, V106, P555; Pimentel E., 1994, HDB GROWTH FACTORS, VII, P55; PINTAR JE, 1991, ADV EXP MED BIOL, V293, P325; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Rossetti L, 1996, J BIOL CHEM, V271, P203, DOI 10.1074/jbc.271.1.203; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; SHINAR DM, 1993, ENDOCRINOLOGY, V132, P1158, DOI 10.1210/en.132.3.1158; SINGER C, 1995, CANCER RES, V55, P2448; Steinmetz KL, 1996, TOXICOL APPL PHARM, V140, P131, DOI 10.1006/taap.1996.0206; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TAKAGI H, 1992, CANCER RES, V52, P5171; Tanaka S, 1996, J CLIN INVEST, V98, P2100, DOI 10.1172/JCI119016; Tanaka S, 1996, CANCER RES, V56, P3391; Ueda K, 1996, J VIROL, V70, P1375, DOI 10.1128/JVI.70.3.1375-1383.1996; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WAKIYAMA M, 1992, NUCL ACIDS S SERIES, V27, P159; YANG D, 1993, CANCER RES, V53, P2020; Yang DY, 1996, J VIROL, V70, P6260, DOI 10.1128/JVI.70.9.6260-6268.1996; YANG DY, 1991, CARCINOGENESIS, V12, P1893, DOI 10.1093/carcin/12.10.1893; Yun K, 1996, AM J PATHOL, V148, P1081; Zhang N, 1997, HEPATOLOGY, V25, P900, DOI 10.1002/hep.510250419	45	36	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 15	1998	16	2					203	209		10.1038/sj.onc.1201519	http://dx.doi.org/10.1038/sj.onc.1201519			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YQ827	9464538				2022-12-17	WOS:000071427100007
J	Geley, S; Hartmann, BL; Hattmannstorfer, R; Loffler, M; Ausserlechner, MJ; Bernhard, D; Sgonc, R; StrasserWozak, EMC; Ebner, M; Auer, B; Kofler, R				Geley, S; Hartmann, BL; Hattmannstorfer, R; Loffler, M; Ausserlechner, MJ; Bernhard, D; Sgonc, R; StrasserWozak, EMC; Ebner, M; Auer, B; Kofler, R			p53-induced apoptosis in the human T-ALL cell line CCRF-CEM	ONCOGENE			English	Article						p53; apoptosis; CCRF-CEM; human leukemia; caspase; chemotherapy	GLUCOCORTICOID-INDUCED APOPTOSIS; WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; PROTEASE INHIBITORS; ICE/CED-3 PROTEASE; BREAST-CANCER; DNA-BINDING; DEATH; GENE; RESISTANCE	The tumor suppressor p53 has been implicated in apoptosis induction and is mutated in human T-ALL CCRF-CEM cells. To investigate possible consequences of wild-type p53 loss, we reconstituted CEM-C7H2, a subclone of CCRF-CEM, with a temperature-sensitive p53 allele (p53ts). Stably transfected lines expressed high levels of p53ts and shift to the permissive temperature (32 degrees C) caused rapid induction of p53-regulated genes, such as p21(CIP1/WAF1), mdm-2 and bax. This was followed by extensive apoptosis within 24 h to 36 h, supporting the notion that mutational p53 inactivation contributed to the malignant phenotype. p53-dependent apoptosis was preceded by digestion of poly(ADP-ribose) polymerase, a typical target of interleukin-1 beta-converting enzyme (ICE)-like proteases/caspases, and was markedly resistant to the ICE/caspase-1 and FLICE/caspase-8 inhibitor acetyl-Tyr-Val-Afa-Asp.chloromethylketone (YVAD), but sensitive to the CPP32/caspase-3 inhibitor benzyloxycarbonyl-Asp-Glu-Val-Asp.fluoromethylketone (DEVD) and benzyloxycarbonyl-Val-Ala-Asp.fluoromethylketone (zVAD), a caspase inhibitor with broader specificity. This indicated an essential involvement of caspases, but argued against a significant role of ICE/caspase-1 or FLICE/caspase-8. Actinomycin D or cycloheximide prevented cell death, suggesting that, in this system, p53-induced apoptosis depends upon macromolecule biosynthesis. Introduction of functional p53 into CEM cells enhanced their sensitivity to the DNA-damaging agent doxorubicin, but not to the tubulin-active compound vincristine. Thus, mutational p53 inactivation in ALL might entail relative resistance to DNA-damaging, but not to tubulin-destabilizing, chemotherapy.	UNIV INNSBRUCK, INST GEN & EXPT PATHOL, DIV MOL PATHOPHYSIOL, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK, INST BIOCHEM, A-6020 INNSBRUCK, AUSTRIA	University of Innsbruck; University of Innsbruck				Bernhard, David/0000-0002-2383-6607; Ausserlechner, Michael/0000-0002-1015-2302				Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anthoney DA, 1996, CANCER RES, V56, P1374; Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CANMAN CE, 1994, COLD SPRING HARB SYM, V59, P277, DOI 10.1101/SQB.1994.059.01.032; Chandler JM, 1997, BIOCHEM J, V322, P19, DOI 10.1042/bj3220019; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Geley S, 1997, FEBS LETT, V402, P36, DOI 10.1016/S0014-5793(96)01496-2; Geley S, 1996, CANCER RES, V56, P5033; Geley S, 1997, FEBS LETT, V400, P15, DOI 10.1016/S0014-5793(96)01284-7; Gorospe M, 1996, CANCER RES, V56, P475; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HALDAR S, 1994, CANCER RES, V54, P2095; Haupt Y, 1996, Behring Inst Mitt, P32; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KUIDA K, 1995, SCIENCE, V267, P200; KUMAR S, 1995, TRENDS BIOCHEM SCI, V20, P198, DOI 10.1016/S0968-0004(00)89007-6; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Lotem J, 1996, P NATL ACAD SCI USA, V93, P12507, DOI 10.1073/pnas.93.22.12507; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NORMAN MR, 1977, CANCER RES, V37, P3785; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; PARK DJ, 1994, ONCOGENE, V9, P1899; Perego P, 1996, CANCER RES, V56, P556; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; PROKOCIMER M, 1994, BLOOD, V84, P2391; ROLLEY N, 1995, ONCOGENE, V11, P763; SGONC R, 1994, TRENDS GENET, V10, P41, DOI 10.1016/0168-9525(94)90140-6; SGONC R, 1994, INT ARCH ALLERGY IMM, V105, P327, DOI 10.1159/000236777; Slee EA, 1996, BIOCHEM J, V315, P21, DOI 10.1042/bj3150021; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Srinivasula SM, 1996, P NATL ACAD SCI USA, V93, P14486, DOI 10.1073/pnas.93.25.14486; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Thomas A, 1996, ONCOGENE, V12, P1055; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; Weinstein JN, 1997, SCIENCE, V275, P343, DOI 10.1126/science.275.5298.343; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHITE E, 1994, COLD SPRING HARB SYM, V59, P395, DOI 10.1101/SQB.1994.059.01.044; WHITE E, 1995, CURR TOP MICROBIOL, V199, P33; Yin CY, 1997, NATURE, V385, P637, DOI 10.1038/385637a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	72	36	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 13	1997	15	20					2429	2437		10.1038/sj.onc.1201399	http://dx.doi.org/10.1038/sj.onc.1201399			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YE963	9395239				2022-12-17	WOS:A1997YE96300005
J	Suhasini, M; Reddy, CD; Reddy, EP; DiDonato, JA; Pilz, RB				Suhasini, M; Reddy, CD; Reddy, EP; DiDonato, JA; Pilz, RB			cAMP-induced NF-kappa B (p50/relB) binding to a c-myb intronic enhancer correlates with c-myb up-regulation and inhibition of erythroleukemia cell differentiation	ONCOGENE			English	Article						c-myb; NF-kappa B; cAMP; erythroid differentiation; murine erythroleukemia cells	DEPENDENT PROTEIN-KINASE; INDUCED ERYTHROID-DIFFERENTIATION; JUN FAMILY MEMBERS; GENE-EXPRESSION; DOWN-REGULATION; TRANSCRIPTION FACTORS; MESSENGER-RNA; B/REL FAMILY; ACTIVATION; LINE	During hexamethylene bisactamide (HMBA)-induced differentiation of murine erythroleukemia (MEL) cells erythroid genes are transcriptionally activated while c-myb and several other nuclear proto-oncogenes are down-regulated. Differentiation is inhibited by cAMP analogues and the adenyl cyclase-stimulating agent forskolin. We found that these drugs prevented the late down-regulation of c-myb which is known to be critical for MEL cell differentiation. Since the increase in c-myb mRNA levels was due to increased mRNA transcription, we examined the transcription factors NF-kappa B and AP-1 which have been implicated in the regulation of c-myb expression. Binding of MEL cell nuclear proteins to a NF-kappa B recognition sequence in c-myb intron 1 was strongly induced by 8-Br-cAMP or forskolin; induction was delayed and correlated with the up-regulation of c-myb. The cAMP-induced NF-kappa B complex contained p50 and RelB; in co-transfection assays, p50 and RelB transactivated a reporter construct containing the c-myb intronic NF-kappa B site upstream of a minimal promoter. 8-Br-cAMP and forskolin also increased the DNA binding activity of AP-1 complexes containing JunB, JunD and c-Fos in MEL cells Which could cooperate with NF-kappa B. We conclude that inhibition of MEL cell differentiation by pharmacological doses of cAMP can be explained by the up-regulation of c-myb which is mediated, at least in part, by NF-kappa B p50/RelB heterodimers.	UNIV CALIF SAN DIEGO,DEPT MED,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,CTR CANC,SAN DIEGO,CA 92093; UNIV CALIF SAN DIEGO,DEPT PHARMACOL,SAN DIEGO,CA 92093; TEMPLE UNIV,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011; Hazen, Stanley L/ABD-5845-2021					ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BEEBE SJ, 1986, ENZYMES, V17, P43; CHANG TJ, 1993, MOL ENDOCRINOL, V7, P528, DOI 10.1210/me.7.4.528; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COPPOLA JA, 1989, MOL CELL BIOL, V9, P1714, DOI 10.1128/MCB.9.4.1714; DANISH R, 1992, ONCOGENE, V7, P901; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; ELDRIDGE MG, 1992, BIOTECHNIQUES, V12, P848; FRANCASTEL C, 1994, ONCOGENE, V9, P1957; FRASER PJ, 1987, GENE DEV, V1, P855, DOI 10.1101/gad.1.8.855; GARINGO AD, 1995, J BIOL CHEM, V270, P9169, DOI 10.1074/jbc.270.16.9169; GERONDAKIS S, 1993, CELL GROWTH DIFFER, V4, P617; GHERSA P, 1994, GENE, V151, P331, DOI 10.1016/0378-1119(94)90681-5; GRUMONT RJ, 1994, P NATL ACAD SCI USA, V91, P4367, DOI 10.1073/pnas.91.10.4367; Gudi T, 1996, J BIOL CHEM, V271, P4597; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LI CCH, 1994, J BIOL CHEM, V269, P30089; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LIOU HC, 1994, MOL CELL BIOL, V14, P5349, DOI 10.1128/MCB.14.8.5349; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MacKichan ML, 1996, J BIOL CHEM, V271, P6084, DOI 10.1074/jbc.271.11.6084; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MELLONI E, 1990, P NATL ACAD SCI USA, V87, P4417, DOI 10.1073/pnas.87.12.4417; MELLONI E, 1989, J BIOL CHEM, V264, P18414; Melotti P, 1996, BLOOD, V87, P2221, DOI 10.1182/blood.V87.6.2221.bloodjournal8762221; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1990, J BIOL CHEM, V265, P22090; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOUDRY R, 1990, EXP CELL RES, V191, P278, DOI 10.1016/0014-4827(90)90015-3; MUROI M, 1993, CELL SIGNAL, V5, P289, DOI 10.1016/0898-6568(93)90019-I; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Olashaw NE, 1996, J BIOL CHEM, V271, P30307; PILZ RB, 1993, J BIOL CHEM, V268, P20252; PILZ RB, 1992, J BIOL CHEM, V267, P16161; PILZ RB, 1995, FASEB J, V9, P552, DOI 10.1096/fasebj.9.7.7737465; PROCHOWNIK EV, 1990, BLOOD, V76, P1830; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; ROHLFF C, 1993, J BIOL CHEM, V268, P5774; ROSSON D, 1995, MOL CELL BIOL, V15, P772; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; SCHEELE JS, 1994, J BIOL CHEM, V269, P18599; SCHWARTZ DA, 1985, J BIOL CHEM, V260, P6296; SERKKOLA E, 1993, FEBS LETT, V334, P327, DOI 10.1016/0014-5793(93)80704-X; SHERMAN ML, 1988, J CELL PHYSIOL, V134, P429, DOI 10.1002/jcp.1041340314; SHERMAN ML, 1986, BIOCHEM BIOPH RES CO, V134, P845, DOI 10.1016/S0006-291X(86)80497-1; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOLOMON WB, 1993, J BIOL CHEM, V268, P5089; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; YAMASAKI H, 1977, P NATL ACAD SCI USA, V74, P3451, DOI 10.1073/pnas.74.8.3451; ZONG H, 1997, CELL, V89, P413	67	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 9	1997	15	15					1859	1870		10.1038/sj.onc.1201530	http://dx.doi.org/10.1038/sj.onc.1201530			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XZ725	9362453				2022-12-17	WOS:A1997XZ72500013
J	Gutmann, DH; SaporitoIrwin, S; DeClue, JE; Wienecke, R; Guha, A				Gutmann, DH; SaporitoIrwin, S; DeClue, JE; Wienecke, R; Guha, A			Alterations in the rap1 signaling pathway are common in human gliomas	ONCOGENE			English	Article						astrocytomas; tumor suppressor gene; tuberous sclerosis complex 2; tuberin	CELL-LINES; GENE; AMPLIFICATION; TUMORS; PRODUCT; TUBERIN; CDK4; OVEREXPRESSION; NEUROBLASTOMA; EXPRESSION	Several inherited predisposition to cancer syndromes are associated with the development of nervous system tumors. Tuberous sclerosis complex (TSC) is an autosomal dominant disorder in which affected individuals are at risk for developing astrocytomas. One of the genes responsible for this disorder is TSC2, located on chromosome 16p, and encoding a 180 kDa protein (tuberin) that functions in part as a negative regulator of rap1. Previous studies from our laboratory demonstrated that 30% of sporadic astrocytomas have reduced or absent tuberin expression, In addition to loss of tuberin in sporadic astrocytomas, aberrant rap1 mediated signaling may also result from overexpression of rap1. In this study, we test the hypothesis that alterations in the rap1 signaling pathway are frequently observed in certain subsets of gliomas compared to other tumors of the nervous system. Analysis of sporadic astrocytomas and ependymomas demonstrated either increased rap1 or reduced/absent tuberin protein expression in 50-60% of different cohorts of these gliomas, compared to 30-33% of sporadic schwannomas and meningiomas and none of eight oligodendrocyte tumors. These results suggest that alterations in the rap1 signaling pathway are important in the development of certain sporadic human gliomas.	NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; UNIV TORONTO,MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV NEUROSURG,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,TORONTO HOSP,TORONTO,ON M5T 2S8,CANADA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Gutmann, DH (corresponding author), WASHINGTON UNIV,SCH MED,DEPT NEUROL,BOX 8111,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.			Gutmann, David/0000-0002-3127-5045				CHENG YT, 1995, MOL CARCINOGEN, V13, P173, DOI 10.1002/mc.2940130307; Geist RT, 1996, NEUROBIOL DIS, V3, P111, DOI 10.1006/nbdi.1996.0011; Gutmann DH, 1996, ONCOGENE, V12, P2121; HE J, 1995, CANCER RES, V55, P4833; HE J, 1994, CANCER RES, V54, P5804; HEWETT SJ, 1995, NEUROREPORT, V6, P1505; Jin F, 1996, P NATL ACAD SCI USA, V93, P9154, DOI 10.1073/pnas.93.17.9154; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; KHATIB ZA, 1993, CANCER RES, V53, P5535; KRAUS J, 1996, J NEUROPATH EXPER NE, V54, P91; LOUIS DN, 1995, TRENDS GENET, V11, P111; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; OLSON JJ, 1995, NEUROSURGERY, V36, P740, DOI 10.1227/00006123-199504000-00015; Reifenberger G, 1996, CANCER RES, V56, P5141; REIFENBERGER J, 1994, AM J PATHOL, V145, P1175; ROY NV, 1995, CANC GENET CYTOGENET, V82, P151; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; Wienecke R, 1996, ONCOGENE, V13, P913; Wienecke R, 1997, AM J PATHOL, V150, P43; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; WIENECKE R, 1997, IN PRESS ANN NEUROLO; YOSHIDA Y, 1992, MOL CELL BIOL, V12, P3407, DOI 10.1128/MCB.12.8.3407	22	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1611	1616		10.1038/sj.onc.1201314	http://dx.doi.org/10.1038/sj.onc.1201314			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380414				2022-12-17	WOS:A1997XX36900013
J	Schreiber, M; Poirier, C; Franchi, A; Kurzbauer, R; Guenet, JL; Carle, GF; Wagner, EF				Schreiber, M; Poirier, C; Franchi, A; Kurzbauer, R; Guenet, JL; Carle, GF; Wagner, EF			Structure and chromosomal assignment of the mouse fra-1 gene, and its exclusion as a candidate gene for oc (osteosclerosis)	ONCOGENE			English	Article						AP-1 target gene; Fos gene family; Fos11 genomic locus; fra-1; MMU 19; osteosclerosis (oc)	TRANSCRIPTION FACTOR AP-1; FOS-TRANSGENIC MICE; LACKING C-FOS; REGULATORY FUNCTION; CELL-PROLIFERATION; MAP; TRANSFORMATION; EXPRESSION; REGION; BONE	We have determined the genomic structure of the mouse fra-1 gene, which consists of four exons and three introns at positions also found in the other members of the fos gene family, Fra-1 is expressed rather highly in the brain and testes of adult mice, and at low levels in most other tissues, Absence of c-Fos leads to significantly reduced serum stimulation of fra-1 expression in gene targeted mouse fibroblasts, demonstrating that mitogen induction of fra-1 is partially mediated by c-Fos/AP-1. A polymorphic (CA)(n) microsatellite marker was found in intron 2 of fra-1 and used to map the gene to the centromeric region of mouse chromosome 19, Since fra-1 maps to the same genomic region as oc (osteosclerosis), an autosomal recessive disorder leading to the bone remodelling disease osteopetrosis, we tested it as a candidate gene for oc, The segregation of fra-1 in two different crosses of mice carrying oc and an allelism test between oc and a targeted disruption of fra-1 demonstrate that fra-1 and oc are two distinct genes rather than oc being a mutant allele of fra-1.	RES INST MOL PATHOL, A-1030 VIENNA, AUSTRIA; INST PASTEUR, UNITE GENET MAMMIFERES, F-75724 PARIS 15, FRANCE; UNIV NICE, FAC MED, LAB ETUD GENOME MURIN, CNRS, UMR 6549, F-06107 NICE 2, FRANCE	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur			Martin, Schreiber/F-2175-2013; Carle, Georges/GWC-5240-2022	Martin, Schreiber/0000-0003-1102-7789; Wagner, Erwin F/0000-0001-7872-0196; Carle, Georges/0000-0002-3901-1052				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BROOKES S, 1992, GENE CHROMOSOME CANC, V4, P290, DOI 10.1002/gcc.2870040404; BRUSSELBACH S, 1995, ONCOGENE, V10, P79; Chandrasekharappa SC, 1997, SCIENCE, V276, P404, DOI 10.1126/science.276.5311.404; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN DR, 1993, ONCOGENE, V8, P443; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COHEN DR, 1994, P NATL ACAD SCI USA, V91, P4372, DOI 10.1073/pnas.91.10.4372; DEUSTACHIO P, 1984, J EXP MED, V160, P827, DOI 10.1084/jem.160.3.827; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; FOLETTA VC, 1994, ONCOGENE, V9, P3305; GACK S, 1994, J BIOL CHEM, V269, P10363; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GROSKOPF JC, 1994, MOL CELL BIOL, V14, P6013, DOI 10.1128/MCB.14.9.6013; HSU JC, 1993, CANCER RES, V53, P3789; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; LAZO PS, 1992, NUCLEIC ACIDS RES, V20, P343, DOI 10.1093/nar/20.2.343; Lemmens I, 1997, HUM MOL GENET, V6, P1177, DOI 10.1093/hmg/6.7.1177; MANLY KF, 1993, MAMM GENOME, V4, P303, DOI 10.1007/BF00357089; MARKS SC, 1985, J HERED, V76, P171, DOI 10.1093/oxfordjournals.jhered.a110059; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; SCHREIBER M, 1996, THESIS VIENNA; Silver L. M., 1995, MOUSE GENETICS; SINKE RJ, 1993, GENOMICS, V18, P165, DOI 10.1006/geno.1993.1447; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; TANIGAMI A, 1992, GENOMICS, V13, P16, DOI 10.1016/0888-7543(92)90195-X; UDAGAWA N, 1992, BIOCHEM BIOPH RES CO, V184, P67, DOI 10.1016/0006-291X(92)91158-M; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; WISDOM R, 1993, MOL CELL BIOL, V13, P2635, DOI 10.1128/MCB.13.5.2635; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972	40	36	39	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	1997	15	10					1171	1178		10.1038/sj.onc.1201460	http://dx.doi.org/10.1038/sj.onc.1201460			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XU991	9294610				2022-12-17	WOS:A1997XU99100006
J	Badiani, PA; Kioussis, D; Swirsky, DM; Lampert, IA; Weston, K				Badiani, PA; Kioussis, D; Swirsky, DM; Lampert, IA; Weston, K			T-cell lymphomas in v-Myb transgenic mice	ONCOGENE			English	Article						Myb; T cell; lymphoma; transgenic mice	MURINE HEMATOPOIETIC-CELLS; RECEPTOR-DELTA-ENHANCER; C-MYB; LEUKEMIA-VIRUS; PROTO-ONCOGENE; ANTISENSE OLIGODEOXYNUCLEOTIDES; INSERTIONAL MUTAGENESIS; PROMONOCYTIC LEUKEMIAS; GENE-EXPRESSION; RAPID INDUCTION	v-Myb, the transforming protein of avian myeloblastosis virus, causes acute myeloid leukemia in chickens. Similarly, truncation and rearrangement of the c-myb proto-oncogene to yield a v-Myb-like protein leads to myeloid and B cell lymphomas in chickens and mice, and may be a factor in a number of human cancers. To study the effects of deregulation of v-Myb on T cell development, we have generated lines of transgenic mice in which the v-Myb oncoprotein is expressed in a T-cell-specific fashion. Analysis of T cell development in the v-Myb transgenic mice shows that ectopic expression of v-Myb affects the ratio of helper to cytotoxic T cells, by increasing the number of CD4(+) helper cells, and inhibits thymic involution, such that mature animals have elevated numbers of thymocytes and circulating mature T cells. In a significant proportion of older animals, high grade T cell lymphomas develop, demonstrating that v-Myb is oncogenic in T cells.	INST CANC RES, CRC, CTR CELLULAR & MOL BIOL, LONDON SW3 6JB, ENGLAND; NATL INST MED RES, LAB MOL IMMUNOL, LONDON NW7 1AA, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT HAEMATOL, LONDON W12 0NN, ENGLAND; ROYAL POSTGRAD MED SCH, DEPT HISTOPATHOL, LONDON W12 0NN, ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; MRC National Institute for Medical Research; Imperial College London; Imperial College London								ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; BARLETTA C, 1987, SCIENCE, V235, P1064, DOI 10.1126/science.3469751; BERNS A, 1989, INT J CANCER, P22; BEUG H, 1987, GENE DEV, V1, P277, DOI 10.1101/gad.1.3.277; Bies J, 1996, ONCOGENE, V12, P355; BLICK M, 1984, BLOOD, V64, P1234; BLOOMFIELD CD, 1983, CANCER RES, V43, P2975; BORN W, 1985, P NATL ACAD SCI USA, V82, P2925, DOI 10.1073/pnas.82.9.2925; BURGESS TL, 1995, P NATL ACAD SCI USA, V92, P4051, DOI 10.1073/pnas.92.9.4051; CALABRETTA B, 1991, CANCER RES, V51, P4505; CALABRETTA B, 1991, P NATL ACAD SCI USA, V88, P2351, DOI 10.1073/pnas.88.6.2351; CALNAN BJ, 1995, IMMUNITY, V3, P273; CHURILLA AM, 1989, J EXP MED, V170, P105, DOI 10.1084/jem.170.1.105; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; Coligan JKA, 1991, CURRENT PROTOCOLS IM; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERRAO P, 1995, ONCOGENE, V11, P1631; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; HERNANDEZMUNAIN C, 1995, MOL CELL BIOL, V15, P3090; HERNANDEZMUNAIN C, 1994, MOL CELL BIOL, V14, P473, DOI 10.1128/MCB.14.1.473; Hogan B., 1986, MANIPULATING MOUSE E; HOWE KM, 1991, NUCLEIC ACIDS RES, V19, P3913, DOI 10.1093/nar/19.14.3913; HSIANG YHH, 1995, J IMMUNOL, V154, P5195; JACOBS SM, 1994, CANCER GENET CYTOGEN, V75, P31, DOI 10.1016/0165-4608(94)90212-7; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KRYCEVEMARTINERIE C, 1987, FEBS LETT, V214, P81, DOI 10.1016/0014-5793(87)80017-0; LANG G, 1988, EMBO J, V7, P1675, DOI 10.1002/j.1460-2075.1988.tb02995.x; LAOUAR Y, 1994, J IMMUNOL, V153, P3948; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; MCCRACKEN S, 1994, ONCOGENE, V9, P3609; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Moscovici C., 1982, ADV VIRAL ONCOL, V1, P83; MOUNTZ JD, 1984, SCIENCE, V226, P1087, DOI 10.1126/science.6494925; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; MUKHOPADHYAYA R, 1992, J VIROL, V66, P6035, DOI 10.1128/JVI.66.10.6035-6044.1992; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; NAZAROV V, 1995, J VIROL, V69, P3885, DOI 10.1128/JVI.69.6.3885-3888.1995; OHYASHIKI K, 1988, CANCER GENET CYTOGEN, V33, P83, DOI 10.1016/0165-4608(88)90053-2; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PIZER ES, 1992, J VIROL, V66, P512, DOI 10.1128/JVI.66.1.512-523.1992; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1995, ONCOGENE, V11, P525; PRUDHOMME GJ, 1991, J IMMUNOL, V147, P3314; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO PH, 1993, GENOMICS, V16, P426, DOI 10.1006/geno.1993.1206; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SHEINESS D, 1984, MOL CELL BIOL, V4, P1206, DOI 10.1128/MCB.4.7.1206; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SLAMON DJ, 1986, SCIENCE, V233, P347, DOI 10.1126/science.3014652; SMARDA J, 1994, ONCOGENE, V9, P237; SOUZA LM, 1980, P NATL ACAD SCI-BIOL, V77, P5177, DOI 10.1073/pnas.77.9.5177; STERN JB, 1986, SCIENCE, V233, P203, DOI 10.1126/science.3523754; STRASSER A, 1993, ONCOGENE, V8, P1; TAO W, 1994, J EXP MED, V179, P145, DOI 10.1084/jem.179.1.145; TESCH H, 1992, LEUKEMIA RES, V16, P265, DOI 10.1016/0145-2126(92)90064-E; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043	70	36	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2205	2212						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950988				2022-12-17	WOS:A1996VV14500018
J	White, DW; Gilmore, TD				White, DW; Gilmore, TD			Bcl-2 and CrmA have different effects on transformation, apoptosis and the stability of I kappa B-alpha in chicken spleen cells transformed by temperature-sensitive v-Rel oncoproteins	ONCOGENE			English	Article						v-Rel; Bcl-2; CrmA; I kappa B-alpha; malignant transformation; apoptosis	INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; UBIQUITIN-PROTEASOME PATHWAY; IL-1-BETA-CONVERTING ENZYME; TRANSCRIPTIONAL ACTIVATION; ONCOGENIC TRANSFORMATION; RECOGNITION SEQUENCE; PRECURSOR PROTEIN; MAMMALIAN HOMOLOG; C-MYC	The retroviral oncoprotein v-Rel is a member of the Rel/ NF-kappa B family of transcription factors, We have previously characterized two v-Rel mutants (v-G37E and v-R273H) that are temperature-sensitive (ts) for transformation and immortalization of chicken spleen cells in vitro. We have now constructed vectors for the co-expression of wild-type or ts mutant v-Rel proteins and the anti-apoptosis proteins Bcl-2 or CrmA. The formation of v-Rel-transformed colonies is enhanced in the presence of overexpressed Bcl-2, Moreover, coexpression of Bcl-2 suppresses apoptosis that is induced when ts v-Rel-transformed cells are shifted to the nonpermissive temperature. However, co-expression of Bcl-2 in these cells does not affect ts functions of v-Rel, such as DNA binding and stabilization of I kappa B-alpha. In contrast, coexpression of CrmA does not suppress apoptosis, but does block an amino-terminal proteolysis of I kappa B-alpha that occurs in ts v-G37E-transformed cells shifted to the nonpermissive temperature, indicating that an ICE-like protease activity is not involved in apoptosis in these cells but is involved in proteolysis of I kappa B-alpha. In addition, CrmA can block cycloheximide-induced amino-terminal processing of I kappa B-alpha in spleen cells transformed by wild-type v-Rel. In summary, these results suggest that v-Rel immortalizes chicken spleen cells through a pathway that involves the Bcl-2 family of proteins, and suggest that one pathway of proteolysis of I kappa B-alpha involves an ICE-like protease.	BOSTON UNIV,DEPT BIOL,BOSTON,MA 02215	Boston University					NCI NIH HHS [CA 47763] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047763, R01CA047763] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1990, ONCOGENE, V5, P257; CAZELSHATEM DL, 1992, BIOCHIM BIOPHYS ACTA, V1132, P109; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cellbio.7.1.663; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GELINAS C, 1988, ONCOGENE, V3, P349; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GIOMORE TD, 1995, DNA PROVIRUS H TEMIN, P109; HALDAR S, 1989, NATURE, V342, P195, DOI 10.1038/342195a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HRDLICKOVA R, 1995, J VIROL, V69, P403; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; KORSMEYER SJ, 1992, CANCER SURV, V15, P105; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI CCH, 1995, BIOCHEM BIOPH RES CO, V215, P292, DOI 10.1006/bbrc.1995.2465; LU D, 1991, ONCOGENE, V6, P1235; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MORRISON LE, 1991, ONCOGENE, V6, P1657; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; MOSIALOS G, 1993, ONCOGENE, V8, P721; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Sambrook J, 1989, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHWARTZMAN RA, 1993, ENDOCR REV, V14, P133, DOI 10.1210/er.14.2.133; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1985, SCIENCE, V228, P1440, DOI 10.1126/science.3874430; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WHITE DW, 1993, J VIROL, V67, P6876, DOI 10.1128/JVI.67.11.6876-6881.1993; White DW, 1996, MOL CELL BIOL, V16, P1169; WHITE DW, 1995, ONCOGENE, V10, P857; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUNIS JJ, 1989, NEW ENGL J MED, V320, P1047, DOI 10.1056/NEJM198904203201605	73	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 5	1996	13	5					891	899						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806678				2022-12-17	WOS:A1996VG76600002
J	Gotley, DC; Reeder, JA; Fawcett, J; Walsh, MD; Bates, P; Simmons, DL; Antalis, TM				Gotley, DC; Reeder, JA; Fawcett, J; Walsh, MD; Bates, P; Simmons, DL; Antalis, TM			The deleted in colon cancer (DCC) gene is consistently expressed in colorectal cancers and metastases	ONCOGENE			English	Article						DCC; monoclonal antibodies; colon cancer; Dukes Stage; Western blotting	HUMAN TISSUES; FREQUENT LOSS; CARCINOMAS; CELLS; RNA; DIFFERENTIATION; PROGRESSION; INHIBITION	The DCC (deleted in colorectal cancer) gene was originally identified as a candidate tumour suppressor gene in colon carcinogenesis on the basis of allelic losses in chromosome 18q.21 in 70% of colon cancers, Reverse transcriptase polymerase chain reaction (RT-PCR) of DCC mRNA suggests that DCC expression may also be reduced in colon cancers, We have used monoclonal antibodies generated against the DCC immunoglobulinlike domain to investigate DCC isoforms and DCC protein expression during colon cancer progression, Normal mucosa and colonic tumour specimens representative of the range of colonic tumour progression from benign adenomatous polyps to metastases were compared by Western blot analyses, We show that while M(r) 194 000 DCC is present in normal colonic mucosa and adenomatous polyps, it is also similarly expressed in colorectal carcinomas and colonic metastases in the liver, The presence of DCC protein is consistent with the presence of DCC mRNA transcripts in the same tissue specimens. Notably DCC was not completely lost in any colonic tumour specimens examined, even those that had progressed to metastatic cancers, Quantitation of DCC protein expression in tissue specimens by densitometry demonstrated that both normal and malignant specimens exhibit a wide range of DCC protein levels and there was no significant correlation between diminished DCC protein expression and colon cancer progression, These results demonstrate the pattern of expression of the DCC gene product in colonic tumour progression and show that absence of DCC expression is not associated with colonic tumour progression.	ROYAL BRISBANE HOSP,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,PRINCESS ALEXANDRA HOSP,DEPT SURG,BRISBANE,QLD 4029,AUSTRALIA; QUEENSLAND CANC FUND EXPT ONCOL UNIT,BRISBANE,QLD 4029,AUSTRALIA; GRIFFITH UNIV,QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA; GRIFFITH UNIV,FAC SCI & TECHNOL,BRISBANE,QLD 4029,AUSTRALIA; JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,CELL ADHES LAB,OXFORD OX3 9DU,ENGLAND; JOHN RADCLIFFE HOSP,INST MOL MED,IMPERIAL CANC RES FUND,MOL ONCOL UNIT,OXFORD OX3 9DU,ENGLAND	QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; Griffith University; QIMR Berghofer Medical Research Institute; Griffith University; University of Oxford; University of Oxford			Gotley, David/F-5481-2013	Gotley, David/0000-0002-8604-253X				ANTALIS TM, 1992, EUR J BIOCHEM, V205, P203, DOI 10.1111/j.1432-1033.1992.tb16769.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; Ekstrand BC, 1995, ONCOGENE, V11, P2393; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOX SB, 1994, CANCER RES, V54, P4539; GIMA T, 1994, INT J CANCER, V57, P480, DOI 10.1002/ijc.2910570407; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; HEDRICK L, 1992, COLD SPRING HARB SYM, V57, P345, DOI 10.1101/SQB.1992.057.01.039; HEDRICK L, 1994, GENE DEV, V8, P1174, DOI 10.1101/gad.8.10.1174; HOHNE MW, 1992, CANCER RES, V52, P2616; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; ITOH F, 1993, INT J CANCER, V53, P260, DOI 10.1002/ijc.2910530215; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; JOHNSON JP, 1991, CANCER METAST REV, V10, P11, DOI 10.1007/BF00046840; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KLINGELHUTZ AJ, 1995, ONCOGENE, V10, P1581; KUAN SF, 1989, J BIOL CHEM, V264, P19271; MIYAKE S, 1994, CANCER RES, V54, P3007; NARAYANAN R, 1992, ONCOGENE, V7, P553; OOKAWA K, 1993, INT J CANCER, V53, P382, DOI 10.1002/ijc.2910530307; REALE MA, 1994, CANCER RES, V54, P4493; SCHECK AC, 1993, CANCER RES, V53, P5605; TKACZ JS, 1975, BIOCHEM BIOPH RES CO, V65, P248, DOI 10.1016/S0006-291X(75)80086-6; TURLEY H, 1995, CANCER RES, V55, P5628; UCHINO S, 1992, CANCER RES, V52, P3099; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901	28	36	36	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 15	1996	13	4					787	795						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VD433	8761300				2022-12-17	WOS:A1996VD43300014
J	Huang, TS; Kuo, ML; Shew, JY; Chou, YW; Yang, WK				Huang, TS; Kuo, ML; Shew, JY; Chou, YW; Yang, WK			Distinct p53-mediated G(1)/S checkpoint responses in two NIH3T3 subclone cells following treatment with DNA-damaging agents	ONCOGENE			English	Article						apoptosis; cell growth arrest; G(1)/S checkpoint; MMS; gamma-radiation; TPA	CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR P53; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; CELLULAR-RESPONSE; GENE-EXPRESSION; BAX GENE; IN-VIVO; PROTEIN; APOPTOSIS	N-3T3 and P-3T3 cells, originally isolated from a NIH3T3 cell clone on the basis of their negative and positive transformation by v-Abl, v-Src and Bcr-Abl, were previously found to show distinct cyclin activity changes following 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment, which is anti-mitogenic for N-3T3 cells and mitogenic for P-3T3 cells. We have found in this study that, while the G(1)/S arrest and cell death induced by serum starvation and TPA treatment in N-3T3 cells did not involve p53-mediated checkpoint or apoptosis, N-3T3 and P-3T3 cells evidently responded differently in these aspects of cell cycle regulation to DNA-damaging agents, methylmethane sulfonate (MMS) and gamma-radiation. In N-3T3 cells, DNA damages elicit cell growth arrest at G(1)/S transition with concomitant accumulation of p53 and p53-inducible Waf1/Cip1 proteins and also signs of apoptosis such as DNA ladder patterns and apoptotic (subgenomic) peak in flow cytograph. Conversely, P-3T3 cells treated with the DNA-damaging agents showed no cell cycle interruption nor accumulation of p53 or Waf1/Cip1. However, both P-3T3 and N-3T3 cells showed the same p53 protein half-life of 40 min or less, the same wild-type p53 DNA sequence and the same co-immunoprecipitable cellular proteins in complexes with p53, suggesting that an alteration in a signal transduction pathway upstream of p53 might account for the evasion of p53-mediated G(1) checkpoint in P-3T3 cells.	ACAD SINICA,NATL HLTH RES INST,CLIN RES INST,TAIPEI,TAIWAN; ACAD SINICA,INST BIOMED SCI,VGH TAIPEI,COOPERAT CLIN RES LAB,TAIPEI,TAIWAN; NATL TAIWAN UNIV,COLL MED,INST TOXICOL,TAIPEI 10764,TAIWAN; NATL TAIWAN UNIV,COLL MED,INST BIOCHEM,TAIPEI 10764,TAIWAN	Academia Sinica - Taiwan; National Health Research Institutes - Taiwan; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University			Kuo, Min-Liang/C-4872-2009; Huang, Tze-Sing/E-3667-2010; Huang, Tze-Sing/C-9361-2013	Huang, Tze-Sing/0000-0001-8736-4330; KUO, MIN-LIANG/0000-0002-7139-0144				CANMAN CE, 1994, CANCER RES, V54, P5054; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HARPER JW, 1993, CELL, V75, P805; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HUANG TS, 1995, P NATL ACAD SCI USA, V92, P4793, DOI 10.1073/pnas.92.11.4793; KADOHAMA T, 1994, ONCOGENE, V9, P2845; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; KHANNA KK, 1993, ONCOGENE, V8, P3307; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; OLSON DC, 1993, ONCOGENE, V8, P2353; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; RENSHAW MW, 1995, MOL CELL BIOL, V15, P1286; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; ZHAN QM, 1993, MOL CELL BIOL, V13, P4242, DOI 10.1128/MCB.13.7.4242	34	36	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG 1	1996	13	3					625	632						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VB328	8760304				2022-12-17	WOS:A1996VB32800020
J	Matoskova, B; Wong, WT; Nomura, N; Robbins, KC; DiFiore, PP				Matoskova, B; Wong, WT; Nomura, N; Robbins, KC; DiFiore, PP			RN-tre specifically binds to the SH3 domain of eps8 with high affinity and confers growth advantage to NIH3T3 upon carboxy-terminal truncation	ONCOGENE			English	Article						eps8; SH3; tre; signal transduction	GUANINE-NUCLEOTIDE EXCHANGE; ADAPTER PROTEIN; TYROSINE KINASE; EGF RECEPTOR; GRB2; RAS; ONCOGENE; CELLS; SOS; ACTIVATOR	We isolated a cDNA encoding a protein, RN-tre, which shows homology to the N-terminus of the tre oncogene product and has SH3-binding ability as well as an evolutionarily conserved domain, termed TrH, with protein-binding ability in vitro. In the present study, we identify the product of the RN-tre gene as a 97 - 100 kDa protein. We demonstrate stable association in vivo and in vitro between RN-tre and eps8, mediated by the SH3 domain of the latter. In vitro, RN-tre displayed remarkable preference for binding to the eps8-SH3, as compared to eight other SH3s. The Kd for the in vitro interaction between RN-tre and eps8-SH3 was between 10(-8) and 10(-7) M. A role for RN-tre in cell proliferation was suggested by the finding that a C-terminal truncated mutant was able to confer proliferative advantage and reduced serum-requirement to NIH3T3 fibroblasts. Finally, comparison of the structure and biological activities of RN-tre and of the tre oncogene product, provided insight into the mechanism of oncogenic activation of tre.	IST EUROPEO ONCOL, DEPT EXPTL ONCOL, I-20141 MILAN, ITALY; NIDR, CELLULAR DEV & ONCOL LAB, NIH, BETHESDA, MD 20892 USA; NCI, LAB CELLULAR & MOL BIOL, NIH, BETHESDA, MD 20892 USA; KAZASA DNA RES INST, CHIBA 292, JAPAN; FAC MED & CHIRURG, IST MICROBIOL, BARI, ITALY	IRCCS European Institute of Oncology (IEO); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Di Fiore, Pier Paolo/K-2130-2012	Di Fiore, Pier Paolo/0000-0002-2252-0950				BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FINAN P, 1994, J BIOL CHEM, V269, P13752; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HUEBNER K, 1988, ONCOGENE, V3, P449; KARLSSON T, 1995, IN PRESS ONCOGENE; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; Matoskova B, 1996, ONCOGENE, V12, P2563; MATOSKOVA B, 1995, MOL CELL BIOL, V15, P3805; NAKAMURA T, 1992, ONCOGENE, V7, P733; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; RICHARDSON PM, 1995, ONCOGENE, V11, P1139; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SEEDORF K, 1994, J BIOL CHEM, V269, P16009; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; WENG ZG, 1994, MOL CELL BIOL, V14, P4509, DOI 10.1128/MCB.14.7.4509; WONG WT, 1994, ONCOGENE, V9, P3057	31	36	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2679	2688						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700527				2022-12-17	WOS:A1996UW48700022
J	Soprano, DR; Chen, LX; Wu, S; Donigan, AM; Borghaei, RC; Soprano, KJ				Soprano, DR; Chen, LX; Wu, S; Donigan, AM; Borghaei, RC; Soprano, KJ			Overexpression of both RAR and RXR restores AP-1 repression in ovarian adenocarcinoma cells resistant to retinoic acid-dependent growth inhibition	ONCOGENE			English	Article						retinoic acid receptor; retinoic acid resistance; ovarian carcinoma cells; AP-1 antagonism	RECEPTOR-ALPHA; X RECEPTOR; EXPRESSION; LINES; CARCINOMA; COMPLEX; GAMMA; BETA; MICE; GENE	Retinoids including retinoic acid (RA) have been demonstrated to be effective growth inhibitors of a number of human cancer cell lines including ovarian adenocarcinoma cells, To begin to determine the mechanism of action by which RA inhibits the growth of ovarian carcinoma cells, we have examined AP-1 activity in two representative cell lines: CaOV-3 a RA-sensitive cell line and SK-OV-3 a RA-resistant cell line, AP-1 activity was found to be inhibited by 50% upon RA treatment of the RA-sensitive cells while there was no change in AP-1 activity following RA treatment of the RA-resistant cells, Maximal inhibition of AP-1 activity could be achieved in the RA-resistant SK-OV-3 cells by overexpression of any one of the three retinoic acid receptor (RAR) subtypes in conjunction with retinoid X receptor (RXR) alpha. This inhibition of AP-1 activity was nearly comparable to that of the RA-sensitive cells, A similar change in AP-1 complex formation in vitro has also been observed, These results suggest that one mechanism by which RA inhibits growth of RA-sensitive ovarian carcinoma cells is by repressing AP-1 activity, Moreover, in the RA-resistant cells the RAR/RXR signalling pathway leading to inhibition of AP-1 activity is impaired however overexpression of one of the RAR subtypes along with RXR alpha is sufficient to restore this pathway.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Borghaei, Ruth/0000-0003-4206-0231	NATIONAL CANCER INSTITUTE [R01CA064945] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044517, R01DK049045] Funding Source: NIH RePORTER; NCI NIH HHS [CA 64945] Funding Source: Medline; NIDDK NIH HHS [DK44517, DK 49045] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Baserga R, 1969, AUTORADIOGRAPHY TECH; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; CARTER R, 1991, ONCOGENE, V6, P229; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; GRUNT TW, 1991, J CELL SCI, V100, P657; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hong Waun Ki, 1994, P597; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; LANGDON SP, 1988, CANCER RES, V48, P6161; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; Mangelsdorf David J., 1994, P319; MARTH C, 1989, ANTICANCER RES, V9, P461; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2723; NAGPAL S, 1995, J BIOL CHEM, V270, P923, DOI 10.1074/jbc.270.2.923; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; OWEN TA, 1987, J BIOL CHEM, V262, P15111; PAN LY, 1992, NUCLEIC ACIDS RES, V20, P3105, DOI 10.1093/nar/20.12.3105; PAN LY, 1995, J CELL BIOCHEM, V57, P575, DOI 10.1002/jcb.240570402; PENA A, 1993, J BIOL CHEM, V268, P27277; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; SALBERT G, 1993, MOL ENDOCRINOL, V7, P1347, DOI 10.1210/me.7.10.1347; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839	32	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					577	584						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637715				2022-12-17	WOS:A1996TV59700015
J	Waber, PG; Lee, NK; Nisen, PD				Waber, PG; Lee, NK; Nisen, PD			Frequent allelic loss at chromosome arm 3p is distinct from genetic alterations of the Von-Hippel Lindau tumor suppressor gene in head and neck cancer	ONCOGENE			English	Article						Von-Hippel Lindau Syndrome; chromosome 3; loss of heterozygosity; head and neck cancer	SQUAMOUS-CELL CARCINOMAS; UPPER AERODIGESTIVE TRACT; P53 MUTATIONS; DISEASE GENE; IDENTIFICATION; POLYMORPHISMS; LINES	Previous molecular genetic studies revealed that allelic loss of chromosome arm 3p is a frequent event in upper aerodigestive tract squamous cell carcinoma (UADT SCC), Recently, the Von-Hippel Lindau (VHL) tumor suppressor gene was identified at chromosome band 3p25-26. To determine if the VHL locus is altered in these tumors, a paired series of 26 tumors and blood from patients with UADT SCC that were previously shown to exhibit allelic loss of 3p were tested for LOH surrounding the VHL locus using four different polymorphic markers, All of the samples (100%) exhibited LOH for at least 1 marker, However, no LOH was detected using a polymorphism within exon 1 of the VHL gene which was informative for 18 of the 26 cases, Furthermore, mutations of the VHL gene could not be identified by single-strand conformation polymorphism, dideoxyfingerprint or direct DNA sequence analysis, In addition, the VHL gene was not inactivated by hypermethylation in any of the 26 tumor samples studied, These findings demonstrate that allelic loss of chromosome arm 3p in UADT SCC involves regions surrounding the VHL locus but does not include the VHL gene, The VHL gene, therefore, does not appear to be involved in the pathogenesis of UADT SCC.	UNIV TEXAS, SW MED CTR, DEPT PEDIAT, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT OTOLARYNGOL HEAD & NECK SURG, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BARDENHEUER W, 1994, GENOMICS, V19, P291, DOI 10.1006/geno.1994.1060; BRENNAN JA, 1995, NEW ENGL J MED, V332, P429, DOI 10.1056/NEJM199502163320704; BURNS JE, 1993, BRIT J CANCER, V67, P1274, DOI 10.1038/bjc.1993.238; CHUNG KY, 1993, CANCER RES, V53, P1676; CROSSEY PA, 1994, HUM GENET, V93, P53; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOSOE S, 1990, GENOMICS, V8, P634, DOI 10.1016/0888-7543(90)90249-T; Jones Michael H., 1992, Human Molecular Genetics, V1, P131, DOI 10.1093/hmg/1.2.131; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; LEE NK, 1994, INT J ONCOL, V5, P205; LEE NK, 1994, ONCOL REP, V1, P637; LEE NK, 1993, ARCH OTOLARYNGOL, V119, P1125; LI H, 1993, HUM MOL GENET, V2, P1326, DOI 10.1093/hmg/2.8.1326; LI XH, 1994, J NATL CANCER I, V86, P1524, DOI 10.1093/jnci/86.20.1524; MAESTRO R, 1993, CANCER RES, V53, P5775; NAWROZ H, 1994, CANCER RES, V54, P1152; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; PONDER B, 1988, NATURE, V335, P400, DOI 10.1038/335400a0; RICHARDS FM, 1993, HUM MOL GENET, V2, P879, DOI 10.1093/hmg/2.7.879; Sambrook J., 1989, MOL CLONING LAB MANU; SARKAR G, 1992, GENOMICS, V13, P441, DOI 10.1016/0888-7543(92)90266-U; SEKIDO Y, 1994, ONCOGENE, V9, P1599; SHUIN T, 1994, CANCER RES, V54, P2852; SOMERS KD, 1992, CANCER RES, V52, P5997; VANDERRIET P, 1994, CANCER RES, V54, P1156; WABER PG, 1993, CANCER RES, V53, P6028; WEBER JL, 1989, AM J HUM GENET, V44, P388; WU CL, 1994, CANCER RES, V54, P6484; YIN XY, 1993, INT J CANCER, V54, P322, DOI 10.1002/ijc.2910540226	32	36	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	1996	12	2					365	369						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TR538	8570213				2022-12-17	WOS:A1996TR53800015
J	XIAO, GH; JIN, F; YEUNG, RS				XIAO, GH; JIN, F; YEUNG, RS			GERM-LINE TSC2 MUTATION IN A DOMINANTLY INHERITED CANCER MODEL DEFINES A NOVEL FAMILY OF RAT INTRACISTERNAL-A PARTICLE ELEMENTS	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENE; ANIMAL MODEL; IAP ELEMENT; TUBEROUS SCLEROSIS; EKER RAT	LONG TERMINAL REPEATS; RENAL-CELL CARCINOMA; EKER RAT; SUSCEPTIBILITY GENE; DNA REARRANGEMENT; SEQUENCE; PROMOTER; INSERTION; CHROMOSOME-10; GENOME	A spontaneous hereditary cancer syndrome in the Eker rat serves as a useful model for studying tissue-specific tumorigenesis. The genetic basis of this germline mutation was found to involve the tuberous sclerosis 2 (Tsc2) gene. In this study, we have identified and characterized a full-length rat intracisternal A-particle (IAP) element that has undergone an intronic transposition as the mechanism of inactivating the Tsc2 gene. The insertion of this 6253 basepair element disrupted the transcription of the gene to give rise to multiple abnormal mRNA. Genomic organization of this novel IAP element is similar to a typical retroviral structure including the gag, pol and env domains with flanking LTRs. This Eker rat associated CERA) IAP sequence was found to contain multiple termination codons rendering it non-functional with respect to its endogenous genes. The element is conserved among different rat strains and the distribution of the estimated similar to 580 copies throughout the rat genome would support their random integration. The net effect of the mutation causes the expression of abnormal predicted proteins devoid of the rap1GAP-like catalytic domain that lies 3' to the insertion. These results provide evidence that cancer predisposition can be the direct consequence of germ-like insertional mutation by retrotransposition targeting a tumor suppressor gene.	FOX CHASE CANC CTR,DIV MED SCI,PHILADELPHIA,PA 19111	Fox Chase Cancer Center								BLANKENSTEIN T, 1990, J EXP MED, V171, P965, DOI 10.1084/jem.171.3.965; CHRISTY RJ, 1988, MOL CELL BIOL, V8, P1093, DOI 10.1128/MCB.8.3.1093; DONEHOWER LA, 1981, J VIROL, V37, P226, DOI 10.1128/JVI.37.1.226-238.1981; DUHL DMJ, 1994, NAT GENET, V8, P59, DOI 10.1038/ng0994-59; EKER R, 1954, ACTA PATHOL MIC SC, V34, P554; EKER R, 1981, DIAGN HISTOPATHOL, V4, P99; FURTER CS, 1989, J BIOL CHEM, V264, P18276; FURTER CS, 1992, BIOCHIM BIOPHYS ACTA, V1130, P213, DOI 10.1016/0167-4781(92)90531-4; GOFF SP, 1990, CANCER CELL-MON REV, V2, P172; HINO O, 1993, P NATL ACAD SCI USA, V90, P327, DOI 10.1073/pnas.90.1.327; HINO O, 1993, JPN J CANCER RES, V84, P1106, DOI 10.1111/j.1349-7006.1993.tb02808.x; KAZAZIAN HH, 1988, NATURE, V322, P164; KINGSMORE SF, 1994, NAT GENET, V7, P136, DOI 10.1038/ng0694-136; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; KUFF EL, 1988, ADV CANCER RES, V51, P183, DOI 10.1016/S0065-230X(08)60223-7; KUFF EL, 1990, CANCER CELL-MON REV, V2, P398; LUEDERS KK, 1983, NUCLEIC ACIDS RES, V11, P4391, DOI 10.1093/nar/11.13.4391; LUEDERS KK, 1984, MOL CELL BIOL, V4, P2128, DOI 10.1128/MCB.4.10.2128; MIETZ JA, 1987, J VIROL, V61, P3020, DOI 10.1128/JVI.61.10.3020-3029.1987; MIKI Y, 1992, CANCER RES, V52, P643; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; NARITA N, 1993, J CLIN INVEST, V91, P1862, DOI 10.1172/JCI116402; RECHAVI G, 1982, NATURE, V300, P607, DOI 10.1038/300607a0; SHIZUYA H, 1992, P NATL ACAD SCI USA, V89, P8794, DOI 10.1073/pnas.89.18.8794; SONG CS, 1990, BIOCHEMISTRY-US, V29, P542, DOI 10.1021/bi00454a031; WALKER C, 1992, SCIENCE, V255, P1693, DOI 10.1126/science.1553556; YEUNG RS, 1993, P NATL ACAD SCI USA, V90, P8038, DOI 10.1073/pnas.90.17.8038; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; YEUNG RS, 1993, CYTOGENET CELL GENET, V62, P149, DOI 10.1159/000133459; YEUNG RS, 1995, IN PRESS MOL CARCINO; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	31	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					81	87						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624135				2022-12-17	WOS:A1995RJ29500010
J	MATTIONI, T; JACKSON, PK; VANHUIJSDUIJNEN, OBH; PICARD, D				MATTIONI, T; JACKSON, PK; VANHUIJSDUIJNEN, OBH; PICARD, D			CELL-CYCLE ARREST BY TYROSINE KINASE ABL INVOLVES ALTERED EARLY MITOGENIC RESPONSE	ONCOGENE			English	Article						ABL TRYOSINE KINASE; CELL CYCLE; ESTROGEN RECEPTOR; MITOGENIC RESPONSE; GROWTH INHIBITION	C-ABL; V-ABL; SIGNAL-TRANSDUCTION; FUSION PROTEINS; FOS PROTEINS; GENE-PRODUCT; TRANSFORMATION; LEUKEMIA; BINDING; LOCALIZATION	Activated forms of the nuclear and cytoplasmic tyrosine kinase c-Abl are completely cytoplasmic and oncogenic, The overexpression of c-AbI, and in certain fibroblast cell lines even of v-Abl, leads to a cell cycle arrest revealing an alternative Abl function, To facilitate the analysis of this growth inhibitory function we have taken advantage of regulable Abl-estrogen receptor (ABL:ER) fusion proteins, Oncogenic in the presence of estrogen, they are reversibly switched to inhibit cell proliferation upon removal of hormone, Using this system, we demonstrate that inhibition is effected by Abl derivatives which we have previously shown to be hypo-phosphorylated and to have low kinase activity. Since an almost exclusively cytoplasmic ABL:ER protein is fully growth inhibitory, relevant interactions may occur in the cytoplasm. We identify the cell cycle arrest as an early G1 or G0-like block. Interestingly, growth inhibition correlates with an altered expression pattern of early serum response genes; c-Jun mRNA and c-Fos protein levels are elevated in Abl-blocked cells. In view of the two functional modes of overexpressed Abl proteins, one can speculate that normal c-Abl may be involved in relaying growth regulatory signals from the membrane to the nucleus.	UNIV GENEVA, DEPT BIOL CELLULAIRE, CH-1211 GENEVA 4, SWITZERLAND	University of Geneva				Jackson, Peter/0000-0002-1742-2539				AUWERX J, 1991, CELL, V64, P983, DOI 10.1016/0092-8674(91)90322-P; BASKARAN R, 1993, P NATL ACAD SCI USA, V90, P11167, DOI 10.1073/pnas.90.23.11167; BENNETT RL, 1992, DEVELOPMENT, V116, P953; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEVELAND JL, 1989, MOL CELL BIOL, V9, P5685, DOI 10.1128/MCB.9.12.5685; DALEY GQ, 1991, ADV CANCER RES, V57, P151; DHUT S, 1991, ONCOGENE, V6, P1459; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; GOFF SP, 1982, J VIROL, V41, P271, DOI 10.1128/JVI.41.1.271-285.1982; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HOFFMANN FM, 1991, TRENDS GENET, V7, P351, DOI 10.1016/0168-9525(91)90254-F; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JACKSON P, 1993, EMBO J, V12, P2809, DOI 10.1002/j.1460-2075.1993.tb05942.x; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MATTIONI T, 1994, METHOD CELL BIOL, V43, P335; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; Picard Didier, 1993, Trends in Cell Biology, V3, P278, DOI 10.1016/0962-8924(93)90057-8; Picard Didier, 1994, Current Opinion in Biotechnology, V5, P511, DOI 10.1016/0958-1669(94)90066-3; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; RIABOWOL KT, 1988, MOL CELL BIOL, V8, P1670, DOI 10.1128/MCB.8.4.1670; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCHIFFMAKER L, 1986, J VIROL, V57, P1182, DOI 10.1128/JVI.57.3.1182-1186.1986; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SCHWARTZBERG PL, 1989, SCIENCE, V246, P799, DOI 10.1126/science.2554496; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VANETTEN RA, 1994, J CELL BIOL, V124, P325, DOI 10.1083/jcb.124.3.325; WANG JYJ, 1993, CURR OPIN GENET DEV, V3, P35, DOI 10.1016/S0959-437X(05)80338-7; WATANABE SM, 1983, J VIROL, V45, P1028, DOI 10.1128/JVI.45.3.1028-1036.1983; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WICK M, 1994, J CELL SCI, V107, P227; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	40	36	36	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	1995	10	7					1325	1333						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR651	7731683				2022-12-17	WOS:A1995QR65100009
J	AMLER, LC; CORVI, R; PRAML, C; SAVELYEVA, L; LEPASLIER, D; SCHWAB, M				AMLER, LC; CORVI, R; PRAML, C; SAVELYEVA, L; LEPASLIER, D; SCHWAB, M			A RECIPROCAL TRANSLOCATION (1-15) (36.2-Q24) IN A NEUROBLASTOMA CELL-LINE IS ACCOMPANIED BY DNA DUPLICATION AND MAY SIGNAL THE SITE OF A PUTATIVE TUMOR SUPPRESSOR-GENE	ONCOGENE			English	Article						D1S1160/D1S244; PEDIATRIC YEAST ARTIFICIAL CHROMOSOME (YAC); FLUORESCENCE IN SITU HYBRIDIZATION (FISH)	HUMAN NEURO-BLASTOMA; YEAST ARTIFICIAL CHROMOSOMES; N-MYC AMPLIFICATION; HUMAN GENOME; SHORT ARM; INSITU HYBRIDIZATION; LINKAGE MAP; HETEROZYGOSITY; ABNORMALITIES; DEFINITION	Cytogenetic analyses and molecular deletion studies of human neuroblastomas have indicated the chromosomal bands 1p36.1-1p36.2 as a location of genetic information which may be involved in tumorigenesis. To define this putative neuroblastoma locus in more detail we have analysed cell lines with alterations of distal Ip, Here we show, by fluorescence in situ hybridization (FISH), that cell line NGP has a reciprocal 1;15 translocation. Loci D1S214/D1S96 could be shown to map telomeric/distal, D1S228 centromeric/proximal to the break, We have identified yeast artificial chromosomes (YACs) that cover the break and map to D1S160 and D1S244. This chromosomal position is within the smallest region of overlap (SRO) found in neuroblastoma tumors (Weith et al., 1989; Caron et al., 1993; Schleiermacher ct al., 1994) and within the region of a constitutional interstitial deletion of a neuroblastoma patient (Biegel et al., 1993). Mapping studies with FISH revealed that the translocation is associated with duplication of DNA. It appears, as if the subchromosomal region we describe here is a good candidate for harboring the postulated neuroblastoma suppressor-gene.	CTR ETUD POLYMORPHISME HUMAIN,F-75010 PARIS,FRANCE		AMLER, LC (corresponding author), GERMAN CANC RES CTR,DEPT CYTOGENET,NEUENHEIMER FELD 280,D-69120 HEIDELBERG,GERMANY.			Le Paslier, Denis/0000-0003-4335-9956				ALBERTSEN HM, 1990, P NATL ACAD SCI USA, V87, P4256, DOI 10.1073/pnas.87.11.4256; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; BARILLOT E, 1992, NUCLEIC ACIDS RES, V19, P6241; BARKER PE, 1993, ONCOGENE, V8, P3353; BELLANNECHANTEL.C, 1992, CELL, V70, P1059; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1977, CANCER-AM CANCER SOC, V40, P2256, DOI 10.1002/1097-0142(197711)40:5<2256::AID-CNCR2820400536>3.0.CO;2-1; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; BUROKER N, 1987, HUM GENET, V77, P175, DOI 10.1007/BF00272388; CARON H, 1994, AM J HUM GENET, V55, P341; CARON H, 1993, NAT GENET, V4, P187, DOI 10.1038/ng0693-187; CHRISTIANSEN H, 1988, BRIT J CANCER, V57, P121, DOI 10.1038/bjc.1988.24; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; DONTI E, 1988, CANCER GENET CYTOGEN, V30, P225, DOI 10.1016/0165-4608(88)90188-4; DRIESEN MS, 1991, GENOMICS, V11, P1079, DOI 10.1016/0888-7543(91)90035-D; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; GILBERT F, 1984, CANCER RES, V44, P5444; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HUNT JD, 1990, GENE CHROMOSOME CANC, V2, P137, DOI 10.1002/gcc.2870020210; LAHTI MJ, 1994, NAT GENET, V7, P370; LANGER PR, 1981, P NATL ACAD SCI-BIOL, V78, P6633, DOI 10.1073/pnas.78.11.6633; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LAUREYS G, IN PRESS ONCOGENE; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; PIETSCH T, 1988, ANTICANCER RES, V8, P1329; ROMANI M, 1990, GENE, V95, P231, DOI 10.1016/0378-1119(90)90366-Y; Sambrook J, 1989, J SAMBROOK MOL CLONI; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; SCHAFER BW, 1993, GENOMICS, V17, P249, DOI 10.1006/geno.1993.1315; SCHLEIERMACHER G, 1994, GENE CHROMOSOME CANC, V10, P275, DOI 10.1002/gcc.2870100409; SCHWAB M, 1990, GENE CHROMOSOME CANC, V1, P181, DOI 10.1002/gcc.2870010302; SEEGER RC, 1982, J IMMUNOL, V128, P983; SEEGER RC, 1977, CANCER RES, V37, P1364; SHAPIRO DN, 1993, AM J PATHOL, V142, P1339; TAKEDA O, 1994, GENE CHROMOSOME CANC, V10, P30, DOI 10.1002/gcc.2870100106; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; WADA RK, 1988, ADV NEUROBLASTOMA RE, V2, P57; WEISS MJ, 1986, P NATL ACAD SCI USA, V83, P7182, DOI 10.1073/pnas.83.19.7182; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WELCH HM, 1989, GENOMICS, V5, P423, DOI 10.1016/0888-7543(89)90005-0	45	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1095	1101						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700634				2022-12-17	WOS:A1995QN35300009
J	ALEXANDER, WS; DUNN, AR				ALEXANDER, WS; DUNN, AR			STRUCTURE AND TRANSCRIPTION OF THE GENOMIC LOCUS ENCODING MURINE C-MPL, A RECEPTOR FOR THROMBOPOIETIN	ONCOGENE			English	Note						C-MPL; THROMBOPOIETIN; HEMATOPOIETIN RECEPTOR; ALTERNATIVE SPLICING; GENE STRUCTURE	GROWTH-HORMONE RECEPTOR; MOLECULAR-CLONING; SUPERFAMILY; EXPRESSION; MEMBER; BINDING; FAMILY; PROTOONCOGENE; INITIATOR; ONCOGENE	We have cloned and characterised the murine gene encoding c-Mpl, a receptor for thrombopoietin and member of the hematopoietin receptor superfamily. The gene encompasses 15 kb of the mouse genome and the organisation of its 12 exons conforms closely to the pattern observed for the genes of other hematopoietin receptor family members. A site for initiation of c-mpl transcription was identified 13 nucleotides upstream of the proposed translation initiation codon. The murine mpl promoter sequence lacks conventional TATA and CAAT motifs although the transcription initiation site shares homology with the initiator sequence that specifies transcription initiation in the terminal deoxynucleotidyl transferase gene. The promoter contains consensus binding sequences for several transcriptional regulators including Ets and GATA factors, which have been implicated in control of transcription in megakaryocytes, a cell type that expresses mpl. The generation of multiple transcripts is a feature of the mpl locus. Two distinct mpl transcripts differing by an in-frame insertion of 24 nucleotides were detected in mouse spleen cells. Genomic sequence analysis identified differential splicing of alternative exon 4 sequences as the likely basis for these transcripts, which are predicted to encode receptors which differ within the first Mpl hematopoietin receptor domain.			ALEXANDER, WS (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA.							AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; GORDON MS, 1992, BLOOD, V80, P302; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KAUSHANSKY K, 1994, NATURE, V369, P568, DOI 10.1038/369568a0; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; METHIA N, 1993, BLOOD, V82, P1395; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; ONEAL KD, 1993, LYMPHOKINE CYTOK RES, V12, P309; ORKIN SH, 1992, BLOOD, V80, P575; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; VIGON I, 1993, ONCOGENE, V8, P2607; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640; WANG HM, 1992, J BIOL CHEM, V267, P979; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WENDLING F, 1994, NATURE, V369, P571, DOI 10.1038/369571a0; WENDLING F, 1989, LEUKEMIA, V3, P475; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014	32	36	36	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	1995	10	4					795	803						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QH612	7862460				2022-12-17	WOS:A1995QH61200023
J	THEILE, M; HARTMANN, S; SCHERTHAN, H; ARNOLD, W; DEPPERT, W; FREGE, R; GLAAB, F; HAENSCH, W; SCHERNECK, S				THEILE, M; HARTMANN, S; SCHERTHAN, H; ARNOLD, W; DEPPERT, W; FREGE, R; GLAAB, F; HAENSCH, W; SCHERNECK, S			SUPPRESSION OF TUMORIGENICITY OF BREAST-CANCER CELLS BY TRANSFER OF HUMAN-CHROMOSOME-17 DOES NOT REQUIRE TRANSFERRED BRCA1 AND P53 GENES	ONCOGENE			English	Article						BREAST CANCER CELLS; HUMAN CHROMOSOME 17; CHROMOSOME TRANSFER; TUMOR SUPPRESSOR GENES	DENATURANT GEL-ELECTROPHORESIS; LINKAGE ANALYSIS; OVARIAN-CANCER; ALLELE LOSS; LINE; CARCINOMAS; DISTINCT; REGIONS; HYBRIDIZATION; POLYMORPHISMS	A number of candidate tumor suppressor genes located on the human chromosome 17 are thought to have a role to play in the development of breast cancer. In addition to the p53 gene on 17p13.1 and the BRCA1 gene mapped to 17q12-21, other chromosomal regions for tumor suppressor genes have been suggested to exist on 17p13.3 and both the central and the distal parts of 17q, although definitive functional proof of their involvement in breast cancer tumorigenesis is still lacking. In this report we show that microcell transfer of a human chromosome 17 into wild-type p53 breast cancer cells CAL51 results in loss of tumorigenicity and anchorage-independent growth, changes in cell morphology and a reduction of cell growth rates of the neo-selected microcell hybrids. In the hybrid cells, which express the p53 wild-type protein, only the p- and the distal parts of the q arm of donor chromosome 17 are transferred. Thus, our results provide functional evidence for the presence of one or more tumor suppressor gene(s) on chromosome 17, which are distinct from the p53 and the BRCA1 genes.	MAX DELBRUCK CTR MOLEK MED,FORSCH GRP MED ONKOL & TUMORIMMUNOL,D-13122 BERLIN,GERMANY; FREE UNIV BERLIN,KLINIKUM RUDOLF VIRCHOW,ROBERT ROSSLE KLIN,BEREICH PATHOL,D-13122 BERLIN,GERMANY; UNIV KAISERSLAUTERN,HUMANBIOL & HUMANGENET ABT,D-67663 KAISERSLAUTERN,GERMANY; HEINRICH PETTE INST EXPTL VIROL & IMMUNOL,TUMORVIROL ABT,D-20251 HAMBURG,GERMANY	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kaiserslautern; Heinrich Pette Institute	THEILE, M (corresponding author), MAX DELBRUCK CTR MOLEK MED,ARBEITSGRP TUMORGENET,ROBERT ROSSLE STR 10,D-13122 BERLIN,GERMANY.							ALBERTSEN H, 1994, AM J HUM GENET, V54, P516; ANDERSEN TI, 1992, GENE CHROMOSOME CANC, V4, P113, DOI 10.1002/gcc.2870040203; ANDERSON MJ, 1993, FASEB J, V7, P826, DOI 10.1096/fasebj.7.10.8344482; BAKER JM, 1993, ONCOGENE, V8, P497; BENCHEICKH M, 1992, INT J CANCER, V51, P542, DOI 10.1002/ijc.2910510407; BORG A, 1994, J NATL CANCER I, V86, P792, DOI 10.1093/jnci/86.10.792; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BOWCOCK AM, 1993, AM J HUM GENET, V52, P718; CASEY G, 1993, HUM MOL GENET, V2, P1921, DOI 10.1093/hmg/2.11.1921; CHANG F, 1993, BRIT J CANCER, V68, P653, DOI 10.1038/bjc.1993.404; CHEN LC, 1991, P NATL ACAD SCI USA, V88, P3847, DOI 10.1073/pnas.88.9.3847; COLES C, 1990, LANCET, V336, P761, DOI 10.1016/0140-6736(90)93236-I; COLLINS C, 1991, GENOMICS, V11, P997, DOI 10.1016/0888-7543(91)90025-A; CORNELIS RS, 1993, ONCOGENE, V8, P781; CORNELIS RS, 1994, CANCER RES, V54, P4200; CROPP CS, 1993, CANCER RES, V53, P5617; CROPP CS, 1994, CANCER RES, V54, P2548; EASTON DF, 1993, AM J HUM GENET, V52, P678; EMI M, 1993, NAT GENET, V5, P151, DOI 10.1038/ng1093-151; FUJIMORI M, 1991, CANCER RES, V51, P89; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GIOANNI J, 1990, BRIT J CANCER, V62, P8, DOI 10.1038/bjc.1990.219; GOLDGAR DE, 1993, AM J HUM GENET, V52, P743; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HALL JM, 1992, AM J HUM GENET, V50, P1235; ISOMURA M, 1994, GENE CHROMOSOME CANC, V9, P173, DOI 10.1002/gcc.2870090305; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KIRCHWEGER R, 1994, INT J CANCER, V56, P193, DOI 10.1002/ijc.2910560208; KLEIN G, 1993, FASEB J, V7, P821, DOI 10.1096/fasebj.7.10.8344481; KLEVER M, 1991, HUM GENET, V86, P484; KOI M, 1989, JPN J CANCER RES, V80, P413, DOI 10.1111/j.1349-7006.1989.tb02329.x; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KUGOH HM, 1990, ONCOGENE, V5, P1637; LALLE P, 1994, ONCOGENE, V9, P437; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MALKIN D, 1991, SCIENCE, V250, P1233; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; MERLO GR, 1992, AM J PATHOL, V140, P215; NAGAI MA, 1994, BRIT J CANCER, V69, P754, DOI 10.1038/bjc.1994.142; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1994, CANCER RES, V54, P1818; NEGRINI M, 1992, ONCOGENE, V7, P2013; NORMAND T, 1993, HUM MOL GENET, V2, P479, DOI 10.1093/hmg/2.4.479; OCONNELL P, 1994, AM J HUM GENET, V54, P526; POLYMEROPOULOS MH, 1991, NUCLEIC ACIDS RES, V19, P689, DOI 10.1093/nar/19.3.689; SATO T, 1992, CANCER RES, V52, P1643; SATO T, 1990, CANCER RES, V50, P7184; SAXENA A, 1992, CANCER RES, V52, P6716; SHIMIZU M, 1990, ONCOGENE, V5, P185; SMITH SA, 1994, GENE CHROMOSOME CANC, V10, P71, DOI 10.1002/gcc.2870100112; SMITHSORENSEN B, 1993, HUM MUTAT, V2, P274, DOI 10.1002/humu.1380020407; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Stanbridge E.J., 1987, ADV VIRAL ONCOL, V6, P83; TAKITA K, 1992, CANCER RES, V52, P3914; THEILE M, 1994, INT J ONCOL, V4, P1067; THOMPSON AM, 1990, BRIT J CANCER, V61, P74, DOI 10.1038/bjc.1990.17; TRIPATHY D, 1993, ONCOGENES THMOR SUPP; VALERA A, 1994, HUM GENE THER, V5, P449, DOI 10.1089/hum.1994.5.4-449; VONDERWETH A, 1993, J VIROL, V67, P886, DOI 10.1128/JVI.67.2.886-893.1993; WATATANI M, 1993, BREAST CANCER RES TR, V28, P231, DOI 10.1007/BF00666584; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; ZIMMERMANN W, 1993, AM J HUM GENET, V52, P789	63	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					439	447						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845668				2022-12-17	WOS:A1995QF64800004
J	FUKASAWA, K; SHEN, RL; RESAU, J; DASILVA, PP; VANDEWOUDE, GF				FUKASAWA, K; SHEN, RL; RESAU, J; DASILVA, PP; VANDEWOUDE, GF			OVEREXPRESSION OF MOS ONCOGENE PRODUCT IN SWISS 3T3 CELLS INDUCES APOPTOSIS PREFERENTIALLY DURING S-PHASE	ONCOGENE			English	Article						APOPTOSIS; MOS ONCOGENE; CELL CYCLE; S-PHASE	MURINE SARCOMA-VIRUS; MEIOTIC MATURATION; XENOPUS-OOCYTES; MAP KINASE; PROTO-ONCOGENE; EARLY EVENT; DEATH; ENDONUCLEASE; INVITRO; FIBROBLASTS	When Swiss 3T3 cells are acutely infected with Moloney murine sarcoma virus containing the v-mos oncogene, 90% of the cells round up and detach from the monolayer (floating cells) and express high levels of v-Mos. The majority of the floating cells are generated between 30 and 70 h post infection when the cellular level of Mos reaches similar to 0.1% of the total protein. Seventy percent of the floating cells exclude trypan blue but are growth arrested with 2C or 4C DNA content, whereas the remaining floating cells with <2C DNA content, are dead or dying, and show characteristic apoptotic phenotypes. The apoptotic cells are most likely generated from cells in S-phase since these cells are absent from the viable floating cell population and the percentage of cells with <2C DNA approximated the expected S-phase fraction of logarithmically growing cells. In addition, 5'-bromo-2'-deoxyuridine-labeling studies showed that similar to 50% of the floating cells with typical apoptotic phenotypes were metabolically-labeled with the drug. These analyses show that cell populations in different stages of the cell cycle are differently affected by high levels of v-Mos expression and cells in S-phase appear to be uniquely sensitive and undergo apoptosis.	NCI, FREDERICK CANC RES & DEV CTR, ABL, BASIC RES PROGRAM, FREDERICK, MD 21702 USA; NCI, DIV CANC BIOL DIAG & CTR,INTRAMURAL RES PROGRAM, MATH BIOL LAB,MEMBRANE BIOL SECT, FREDERICK, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Shen, Rulong/E-4079-2011		OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS SI, 1989, J IMMUNOL, V142, P1789; ARENDS MJ, 1990, AM J PATHOL, V136, P593; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; DUKE RC, 1983, P NATL ACAD SCI-BIOL, V80, P6361, DOI 10.1073/pnas.80.20.6361; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FISCHINGER PJ, 1971, J GEN VIROL, V13, P203, DOI 10.1099/0022-1317-13-2-203; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; FUKASAWA K, 1994, CELL GROWTH DIFFER, V5, P1093; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KERR JFR, 1971, J PATHOL, V105, P13, DOI 10.1002/path.1711050103; KUNG AL, 1990, CANCER RES, V50, P7307; KYPRIANOU N, 1988, PROSTATE, V13, P103, DOI 10.1002/pros.2990130203; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LENNON SV, 1990, BIOCHEM SOC T, V18, P343, DOI 10.1042/bst0180343; LOCK RB, 1990, CANCER RES, V50, P3761; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1992, EUR J BIOCHEM, V205, P287, DOI 10.1111/j.1432-1033.1992.tb16779.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; UCKER DS, 1991, NEW BIOL, V3, P103; VERLHAC MH, 1993, DEV BIOL, V158, P330, DOI 10.1006/dbio.1993.1192; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YEW N, 1992, NATURE, V355, P649, DOI 10.1038/355649a0; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	40	36	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	1995	10	1					1	8						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA980	7824263				2022-12-17	WOS:A1995QA98000001
J	WADMAN, IA; HSU, HL; COBB, MH; BAER, R				WADMAN, IA; HSU, HL; COBB, MH; BAER, R			THE MAP KINASE PHOSPHORYLATION SITE OF TAL1 OCCURS WITHIN A TRANSCRIPTIONAL ACTIVATION DOMAIN	ONCOGENE			English	Note							LOOP-HELIX PROTEINS; T-CELL LEUKEMIA; DNA-BINDING; ENHANCER-BINDING; MAMMALIAN-CELLS; GENE; TRANSLOCATION; MOTIF; EXPRESSION; YEAST	Alteration of the TAL1 gene is the most common genetic lesion found in patients with T cell acute lymphoblastic leukemia. TAL1 encodes a basic helix-loop-helix transcription factor that is phosphorylated on serine residue 122 by the mitogen-activated protein (MAP) kinase ERK1. Here we show that the amino-terminal sequences of TAL1 (residues 1-166) function in vivo as a transcriptional activation domain. Mutation of serine residue 122 reduces the potency of the transactivation domain by more than half. The data suggest that the amino-terminal transactivation domain of TAL1 is positively regulated by S122 phosphorylation and that the functional properties of TAL1 can be influenced by signal transduction pathways that involve the MAP kinases.	UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Cobb, Melanie/0000-0003-0833-5473	NATIONAL CANCER INSTITUTE [R01CA063191] Funding Source: NIH RePORTER; NCI NIH HHS [CA63191] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; ARONHEIM A, 1993, P NATL ACAD SCI USA, V90, P8063, DOI 10.1073/pnas.90.17.8063; BAER R, 1993, SEMIN CANCER BIOL, V4, P341; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BERNARD O, 1991, ONCOGENE, V6, P1477; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHENG JT, 1993, MOL CELL BIOL, V13, P801, DOI 10.1128/MCB.13.2.801; CHENG JT, 1993, ONCOGENE, V8, P677; COBB MH, 1991, CELL REGUL, V2, P965, DOI 10.1091/mbc.2.12.965; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GOODWIN G, 1991, NUCLEIC ACIDS RES, V20, P368; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HSU HL, 1994, P NATL ACAD SCI USA, V91, P5947, DOI 10.1073/pnas.91.13.5947; HSU HL, 1991, MOL CELL BIOL, V11, P3037, DOI 10.1128/MCB.11.6.3037; HSU HL, 1994, MOL CELL BIOL, V14, P1256, DOI 10.1128/MCB.14.2.1256; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MOUTHON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QUONG MW, 1993, MOL CELL BIOL, V13, P792, DOI 10.1128/MCB.13.2.792; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SADOWSKI I, 1988, NATURE, V335, P559; SETH A, 1991, J BIOL CHEM, V266, P23521; TRAUTWEIN C, 1993, NATURE, V364, P544, DOI 10.1038/364544a0; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416	36	36	37	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3713	3716						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970731				2022-12-17	WOS:A1994PT39200037
J	MA, QF; WADLEIGH, D; CHI, TH; HERSCHMAN, H				MA, QF; WADLEIGH, D; CHI, TH; HERSCHMAN, H			THE DROSOPHILA TIS11-HOMOLOG ENCODES A DEVELOPMENTALLY CONTROLLED GENE	ONCOGENE			English	Article							TETRADECANOYL PHORBOL ACETATE; PRIMARY RESPONSE GENE; SWISS 3T3 CELLS; NUCLEOTIDE EXCHANGE; TYROSINE KINASE; SEQUENCE; PROTEIN; RECEPTOR; GRB2; RAS	We previously identified a murine primary response gene family containing three members; TIS11, TIS11B and TIS11D. Using degenerate oligonucleotides derived from conserved regions of the mouse TIS11 family cDNAs as primers and Drosophila genomic DNA as template for polymerase chain reaction amplification, we have identified a fly TIS11 homologue called DTIS11. The DTIS11 protein shares 90% sequence identity with the murine TIS11B and TIS11D proteins, over a 74 amino acid region that contains two CX(8)CX(5)CX(3)H repeated motifs separated by 18 amino acids. DTIS11 maps to region 11B(14-16) on the X-chromosome. Northern blot and in situ hybridization show that a maternal 3 kb message is present in embryos of early developmental stages. A 6 kb DTIS11 mRNA subsequently appears. In KC embryonal cells, both a strong 3 kb message and a less intense 6 kb message are present. The larger (6 kb) message is modestly induced in KC cells by both forskolin and tetradecanoyl phorbol acetate, and is stabilized by cycloheximide.	UNIV CALIF LOS ANGELES,CTR HLTH SCI,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DOE,DEPT BIOL CHEM,STRUCT BIOL & MOLEC MED LAB,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; United States Department of Energy (DOE); University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24797] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BARNARD RC, 1993, NUCLEIC ACIDS RES, V21, P3580, DOI 10.1093/nar/21.15.3580; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; Gall JG, 1971, METHOD ENZYMOL, V21, P470; GOMPERTS M, 1990, ONCOGENE, V5, P1081; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KANEDA N, 1992, GENE, V118, P289, DOI 10.1016/0378-1119(92)90202-Z; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAI WS, 1990, J BIOL CHEM, V265, P16556; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM RW, 1987, ONCOGENE, V1, P263; MA QF, 1991, ONCOGENE, V6, P1277; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STADEN R, 1980, NUCLEIC ACIDS RES, V8, P3673, DOI 10.1093/nar/8.16.3673; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580	31	36	40	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3329	3334						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936658				2022-12-17	WOS:A1994PM65800027
J	KHARBANDA, S; YUAN, ZM; TANEJA, N; WEICHSELBAUM, R; KUFE, D				KHARBANDA, S; YUAN, ZM; TANEJA, N; WEICHSELBAUM, R; KUFE, D			P56/P53(LYN) TYROSINE KINASE ACTIVATION IN MAMMALIAN-CELLS TREATED WITH MITOMYCIN-C	ONCOGENE			English	Article							DNA-BINDING PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASE; NITROGEN-MUSTARD; LYMPHOCYTES-B; CROSS-LINKING; MEMBRANE IMMUNOGLOBULIN; PHOSPHORYLATION; MECHANISM; P34CDC2; DAMAGE	The present studies have examined the effects of mitomycin C (MMC), a genotoxic alkylating agent, on the activation of Src-like protein tyrosine kinases in HL-60 myeloid leukemia cells. The results demonstrate no detectable induction of p59/(fyn) or pp60(c-src) activity. The response of HL-60 cells to MMC however was associated with rapid activation of p56/p53(lyn). Similar findings were obtained with other alkylating agents such as nitrogen mustard and cis-platinum. Activation of p56/p53(lyn) was associated with increased autophosphorylation on tyrosine and sensitivity to the tyrosine kinase inhibitors herbimycin A and genistein. Studies with a glutathione S-transferase-Lyn fusion protein were performed to explore the potential significance of p56/p53(lyn) activation. Analysis of the adsorbates demonstrates interaction of Lyn with the cell cycle regulatory protein, p34(cdc2). Coimmunoprecipitation studies further confirmed the association of p56/p53(lyn) and p34(cdc2) in MMC-treated cells. We also demonstrate that p34(cdc2) undergoes increased phosphorylation on tyrosine following MMC exposure and that p56/p53(lyn) phosphorylates the Tyr-15 site of p34(cdc2)in vitro. These findings indicate that the cellular response to MMC includes activation of p56/p53(lyn) and that this event may contribute to signals transduced by the DNA damage-dependent mitotic checkpoint.	HARVARD UNIV, SCH MED, DANA FARBER CANC INST, DIV CANC PHARMACOL, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL CANCER INSTITUTE [P01CA019589] Funding Source: NIH RePORTER; NCI NIH HHS [CA19589] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P592; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; BARBET NC, 1993, NATURE, V364, P824, DOI 10.1038/364824a0; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BHUYAN BK, 1992, CANCER RES, V52, P5687; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRANO AV, 1979, MUTAT RES, V63, P175, DOI 10.1016/0027-5107(79)90114-3; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CASILLAS A, 1991, J BIOL CHEM, V266, P19088; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUSRE L, 1989, CHEM-BIOL INTERACT, V71, P63, DOI 10.1016/0009-2797(89)90090-2; EWIG RAG, 1977, CANCER RES, V37, P2114; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GOLD MR, 1992, J IMMUNOL, V148, P2012; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GOULD KL, 1990, SCIENCE, V250, P1573, DOI 10.1126/science.1703321; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTLEY JA, 1992, NUCLEIC ACIDS RES, V20, P3175, DOI 10.1093/nar/20.12.3175; HEMPEL WM, 1992, J IMMUNOL, V148, P3021; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HURLEY LH, 1984, SCIENCE, V226, P843, DOI 10.1126/science.6494915; KATAGIRI K, 1991, J IMMUNOL, V146, P701; KHARBANDA S, 1994, CANCER RES, V54, P1412; KONOPA J, 1988, BIOCHEM PHARMACOL, V37, P2303, DOI 10.1016/0006-2952(88)90355-3; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; LOCK RB, 1990, CANCER RES, V50, P3761; NAKAMURA S, 1988, EUR J BIOCHEM, V174, P471, DOI 10.1111/j.1432-1033.1988.tb14122.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OCONNOR PM, 1992, CELL GROWTH DIFFER, V3, P43; PARKER LL, 1991, EMBO J, V10, P1255, DOI 10.1002/j.1460-2075.1991.tb08067.x; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PINES J, 1990, New Biologist, V2, P389; PLEIMAN CM, 1993, MOL CELL BIOL, V13, P5877, DOI 10.1128/MCB.13.9.5877; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; TOBEY RA, 1975, NATURE, V254, P245, DOI 10.1038/254245a0; TOMASZ M, 1988, BIOCHEMISTRY-US, V27, P3182, DOI 10.1021/bi00409a009; UEHARA Y, 1989, CANCER RES, V49, P780; WONG TW, 1984, J BIOL CHEM, V259, P8505; YAMANASHI Y, 1987, MOL CELL BIOL, V7, P237, DOI 10.1128/MCB.7.1.237; YAMANASHI Y, 1989, P NATL ACAD SCI USA, V86, P6538, DOI 10.1073/pnas.86.17.6538; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	50	36	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1994	9	10					3005	3011						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	8084605				2022-12-17	WOS:A1994PG82200028
J	LIU, XH; GE, RW; WESTMORELAND, S; COONEY, AJ; TSAI, SY; TSAI, MJ; RICCIARDI, RP				LIU, XH; GE, RW; WESTMORELAND, S; COONEY, AJ; TSAI, SY; TSAI, MJ; RICCIARDI, RP			NEGATIVE REGULATION BY THE R2 ELEMENT OF THE MHC CLASS-I ENHANCER IN ADENOVIRUS-12 TRANSFORMED-CELLS CORRELATES WITH HIGH-LEVELS OF COUP-TF BINDING	ONCOGENE			English	Article							PROMOTER-TRANSCRIPTION FACTOR; RETINOID-X-RECEPTOR; HORMONE RECEPTOR; ORPHAN RECEPTORS; THYROID-HORMONE; RAT-CELLS; RESPONSE ELEMENT; GENE-EXPRESSION; ACID RECEPTORS; DNA-BINDING	The transcriptional down-regulation of the major histocompatibility complex (MHC) class I antigens in adenovirus type 12 (Ad12) transformed cells gives them the potential to escape immunosurveillance and to form tumors. The enhancer of the class I promoter is the target of transcriptional repression which is mediated by the E1A gene of Ad12. The R2 region within the class I enhancer acts as a negative element in Ad12-transformed cells and exhibits a stronger binding activity than is observed in nontumorigenic Ad5-transformed cells, which are not reduced in class I expression. The R2 element contains a nuclear hormone receptor half-site consensus sequence, AGGTCA, which is required for both the binding activity and the ability of R2 to act as a negative element in Ad12-transformed cells. In this study, we show that an orphan hormone receptor protein, COUP-TF, contributes to the differential R2 binding activity observed between Ad12- and Ad5-transformed cells. Additionally, COUP-TF was shown to bind as a dimer to the R2 element and to use the consensus AGGTCA as one half-site and its 3' flanking sequence as a probable second degenerate half-site. Since COUP-TF can act as a transcriptional repressor, we suggest that the higher COUP-TF binding activity to the R2 element in Ad12-transformed cells contributes to down-regulation of class I transcription and, consequently, tumorigenesis.	UNIV PENN, SCH DENT MED, DEPT MICROBIOL, PHILADELPHIA, PA 19104 USA; BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	University of Pennsylvania; Baylor College of Medicine			Ge, Ruowen/D-8352-2012	Ge, Ruowen/0000-0002-0750-7336	NATIONAL CANCER INSTITUTE [R01CA029797] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045641, R01DK045641] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29797] Funding Source: Medline; NIDDK NIH HHS [DK-45641] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COONEY AJ, 1992, MOL CELL BIOL, V12, P4153, DOI 10.1128/MCB.12.9.4153; COONEY AJ, 1993, J BIOL CHEM, V268, P4152; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EAGER KB, 1985, P NATL ACAD SCI USA, V82, P5525, DOI 10.1073/pnas.82.16.5525; FRIEDMAN DJ, 1988, VIROLOGY, V165, P303, DOI 10.1016/0042-6822(88)90689-7; GE RW, 1992, J VIROL, V66, P6969, DOI 10.1128/JVI.66.12.6969-6978.1992; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; HWUNG YP, 1988, J BIOL CHEM, V263, P13470; KIMURA A, 1993, J BIOL CHEM, V268, P11125; KIMURA A, 1986, CELL, V44, P261, DOI 10.1016/0092-8674(86)90760-9; KLIEWER SA, 1992, P NATL ACAD SCI USA, V89, P1448, DOI 10.1073/pnas.89.4.1448; KRALLI A, 1992, J VIROL, V66, P6979, DOI 10.1128/JVI.66.12.6979-6988.1992; KRALLI A, 1991, THESIS U PENNSYLVANI; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LUTZ B, 1994, DEVELOPMENT, V120, P25, DOI 10.1242/dev.120.1.25; QIU Y, 1994, IN PRESS P NATL ACAD; Sambrook J., 1989, MOL CLONING LAB MANU; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SEGARS JH, 1993, MOL CELL BIOL, V13, P6157, DOI 10.1128/MCB.13.10.6157; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TRAN P, 1992, MOL CELL BIOL, V12, P4666, DOI 10.1128/MCB.12.10.4666; TSUKIYAMA T, 1992, MOL CELL BIOL, V12, P1286, DOI 10.1128/MCB.12.3.1286; UEDA H, 1992, MOL CELL BIOL, V12, P5667, DOI 10.1128/MCB.12.12.5667; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; Wang Lee-Ho, 1991, Gene Expression, V1, P207; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; YEWDELL JW, 1988, VIROLOGY, V162, P236, DOI 10.1016/0042-6822(88)90413-8	37	36	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2183	2190						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8036004				2022-12-17	WOS:A1994NX62900009
J	PORCU, P; GRANA, X; LI, S; SWANTEK, J; DELUCA, A; GIORDANO, A; BASERGA, R				PORCU, P; GRANA, X; LI, S; SWANTEK, J; DELUCA, A; GIORDANO, A; BASERGA, R			AN E2F BINDING SEQUENCE NEGATIVELY REGULATES THE RESPONSE OF THE INSULIN-LIKE GROWTH-FACTOR-1 (IGF-I) PROMOTER TO SIMIAN-VIRUS-40T ANTIGEN AND TO SERUM	ONCOGENE			English	Article							TRANSCRIPTION FACTOR E2F; LARGE T-ANTIGEN; RETINOBLASTOMA GENE-PRODUCT; CYCLIN-A; HUMAN-FIBROBLASTS; CELL-CYCLE; VIRAL ONCOPROTEINS; RAT GLIOBLASTOMA; NUCLEAR FACTOR; TUMOR-ANTIGEN	The promoter of the Insulin-like growth factor I (IGF-I) gene is activated by the Simian Virus 40 large T antigen (SVLT), and one of the elements responding to SVLT activation has been localized to a short 124 bp immediately upstream of the first initiation of transcription site. This short promoter contains an E2F binding site, that, in gel shifts, binds a protein complex, but only when the promoter activity is reduced or absent. A mutation in the E2F binding site deregulates the activity of the promoter, which becomes active even in those conditions in which the wild type promoter is inactive. By using antibodies in gel retardation analyses, we can show that the different protein complexes include, at least, the following proteins: E2F, cyclin A and p107. We conclude that the short IGF-I promoter is negatively regulated by an E2F binding site that complexes with several proteins. Our data suggest that disaggregation of these complexes by the action of SVLT (or other activators) increases expression from the promoter, thus establishing a link between the regulation of cell proliferation by growth factors and the E2F-associated proteins.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,PHILADELPHIA,PA 19107; TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Jefferson University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Giordano, Antonio/F-1927-2010	Giordano, Antonio/0000-0002-5959-016X; Grana, Xavier/0000-0001-7134-0473	NATIONAL CANCER INSTITUTE [P01CA056309, T32CA009678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033694] Funding Source: NIH RePORTER; NCI NIH HHS [CA 56309, 5-T32-CA 09678-02] Funding Source: Medline; NIGMS NIH HHS [GM33694] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMO ML, 1993, ENDOCRINOLOGY, V132, P935, DOI 10.1210/en.132.2.935; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; Baserga Renato, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P47; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P7873, DOI 10.1093/nar/14.20.7873; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CLEMMONS DR, 1983, J CELL PHYSIOL, V115, P137, DOI 10.1002/jcp.1041150206; CLEMMONS DR, 1981, TISSUE GROWTH FACTOR, P161; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DEPPERT W, 1991, ONCOGENE, V6, P1931; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERBER A, 1993, J BIOL CHEM, V268, P17883; FLOROS J, 1981, EXP CELL RES, V132, P215, DOI 10.1016/0014-4827(81)90097-5; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GRITZ L, 1983, GENE, V25, P179, DOI 10.1016/0378-1119(83)90223-8; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOLIFF K, 1993, NUCLEIC ACIDS RES, V19, P2267; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KIM SJ, 1992, MOL CELL BIOL, V12, P2455, DOI 10.1128/MCB.12.6.2455; KOZMA LM, 1990, MOL CELL BIOL, V10, P3626, DOI 10.1128/MCB.10.7.3626; LAM EWF, 1993, EMBO J, V12, P2706; LAMMERS R, 1989, EMBO J, V8, P1369, DOI 10.1002/j.1460-2075.1989.tb03517.x; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEROITH D, 1991, TRENDS ENDOCRIN MET, V2, P134, DOI 10.1016/1043-2760(91)90003-6; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; MAYOL X, 1993, ONCOGENE, V8, P2561; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; NEVINS JR, 1992, SCIENCE, V258, P424; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PONTEN J, 1971, SPONTANEOUS VIRUS IN; PORCU P, 1992, MOL CELL BIOL, V12, P5069, DOI 10.1128/MCB.12.11.5069; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RAPPOLEE DA, 1989, J CELL BIOCHEM, V39, P1, DOI 10.1002/jcb.240390102; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TOPP CW, 1980, DNA TUMOR VIRUSES; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; WERNER H, 1991, INSULIN LIKE GROWTH, P17	63	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1994	9	8					2125	2134						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NX629	8035997				2022-12-17	WOS:A1994NX62900002
J	BANERJEE, AC; RECUPERO, AJ; MAL, A; PIOTRKOWSKI, AM; WANG, DM; HARTER, ML				BANERJEE, AC; RECUPERO, AJ; MAL, A; PIOTRKOWSKI, AM; WANG, DM; HARTER, ML			THE ADENOVIRUS E1A 289R AND 243R PROTEINS INHIBIT THE PHOSPHORYLATION OF P300	ONCOGENE			English	Note							REGION 1A PROTEINS; RETINOBLASTOMA PROTEIN; ESCHERICHIA-COLI; ASSOCIATION; KINASE; TRANSCRIPTION; POLYPEPTIDES; COMPLEXES; PRODUCTS; CYCLINS	A protein of 300 kDa (p300) associates with the adenovirus E1A proteins and has been implicated in the control of cell cycle progression. In mammalian cells, p300 is actively phosphorylated in both quiescent and proliferating cells and its level of phosphorylation increases as it travels from late G1 into M phase. E1A requires p300 for the induction of cellular DNA synthesis and the repression of enhancer mediated transcription, suggesting that p300 may be involved in pathways that are important to cell proliferation and gene expression. Since the activities of most cell cycle regulatory proteins depend on their phosphorylation state, the possibility exists that certain activities of p300 might also be controlled by phosphorylation and that E1A might in fact be affecting these events. We show here by in vitro analysis that E1A inhibits the phosphorylation of p300 by decreasing the rate of incorporation of phosphate into p300. We also show that p300 can be used as a substrate for the cyclin-dependent p33(cdk2) and p34(cdc2) kinases, and propose that E1A might be antagonistic to these enzymes in phosphorylating p300. Thus, these results indicate a possible novel function by which E1A can interfere with cellular pathways.	CLEVELAND CLIN FDN,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Cleveland Clinic Foundation								ABRAHAM SE, 1993, ONCOGENE, V8, P1639; BRUNER M, 1988, J BIOL CHEM, V263, P3984; DATTA S, 1991, J VIROL, V65, P5297, DOI 10.1128/JVI.65.10.5297-5304.1991; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1992, CANCER SURV, V12, P161; ENGSTROM L, 1984, METHOD ENZYMOL, V107, P130; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FAHA B, 1993, J VIROL, V67, P2456, DOI 10.1128/JVI.67.5.2456-2465.1993; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HU Q, 1991, MOL CELL BIOL, V11, P5729; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; RIKITAKE Y, 1992, MOL CELL BIOL, V12, P2826, DOI 10.1128/MCB.12.6.2826; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; YEE SP, 1985, VIROLOGY, V147, P142, DOI 10.1016/0042-6822(85)90234-X; YU IJ, 1991, J CELL BIOL, V114, P1217, DOI 10.1083/jcb.114.6.1217	22	36	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1733	1737						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183570				2022-12-17	WOS:A1994NL81500027
J	JORDAN, KL; HAAS, AR; LOGAN, TJ; HALL, DJ				JORDAN, KL; HAAS, AR; LOGAN, TJ; HALL, DJ			DETAILED ANALYSIS OF THE BASIC DOMAIN OF THE E2F1 TRANSCRIPTION FACTOR INDICATES THAT IT IS UNIQUE AMONG BHLH PROTEINS	ONCOGENE			English	Article							DNA-BINDING ACTIVITY; LEUCINE ZIPPER; MINOR GROOVE; CYCLIN-A; C-MYC; HELIX; DIMERIZATION; COMPLEX; BOX; SPECIFICITY	The E2F1 transcription factor binds to sites within the promoters of a number of cell cycle regulated genes through a basic-helix-loop-helix motif (bHLH). It is shown here that the basic region of E2F1 is distinct from that of all other bHLH proteins. The center of the basic region contains a helix breaking proline-glycine pair, (P122, G123), implying a turn within this region. This is in contrast to the known bHLH containing proteins where the basic region is alpha-helical. Substitution of P122 and G123 with alanines results in a significant reduction in DNA binding levels, with the predicted formation of an alpha-helix. Also in contrast to other bHLH proteins, mutations generated in conserved basic residues of E2F1 do not effect DNA binding. In addition, a single leucine (191) between helix no. 2 and the leucine zipper is required for DNA binding while the leucine zipper itself is not necessary. Finally, E2F1 interacts with ail of the G-residues in the sequence GGCGG-GAAA while the A-residues are not required for DNA binding. The uniqueness of the E2F1 DNA binding domain is likely to play a role in its binding a DNA site that is distinct from that of all other bHLH proteins (CACGTG).	THOMAS JEFFERSON UNIV,DEPT BIOCHEM & MOLEC BIOL,233 S 10TH ST,PHILADELPHIA,PA 19107	Jefferson University			Jordan-Sciutto, Kelly L/A-1046-2007		NCI NIH HHS [CA51170] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051170] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DEVOTO SH, 1992, CELL, V68, P167, DOI 10.1016/0092-8674(92)90215-X; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FISHER F, 1992, EMBO J, V11, P4103, DOI 10.1002/j.1460-2075.1992.tb05503.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; HALL DJ, 1990, ONCOGENE, V5, P47; Hall FL, 1991, CURR OPIN CELL BIOL, V3, P176, DOI 10.1016/0955-0674(91)90136-M; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; JONES N, 1992, CELL, V70, P351; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NEVINS JR, 1992, SCIENCE, V258, P424; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722	34	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1994	9	4					1177	1185						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NC048	8134120				2022-12-17	WOS:A1994NC04800021
J	FRANKE, TF; TARTOF, KD; TSICHLIS, PN				FRANKE, TF; TARTOF, KD; TSICHLIS, PN			THE SH2-LIKE AKT HOMOLOGY (AH) DOMAIN OF C-AKT IS PRESENT IN MULTIPLE COPIES IN THE GENOME OF VERTEBRATE AND INVERTEBRATE EUKARYOTES - CLONING AND CHARACTERIZATION OF THE DROSOPHILA-MELANOGASTER C-AKT HOMOLOG DAKT1	ONCOGENE			English	Article							PROTEIN-KINASE-C; SEQUENCE-ANALYSIS; GENE; DNA; CHROMOSOME; ONCOGENE	The Akf proto-oncogene encodes a serine-threonine protein kinase whose carboxyterminal catalytic domain is closely related to the catalytic domains of all the known members of the protein kinase C (PKC) family. Akt, however, differs from PKC in its N-terminal region which contains a domain related distantly to the SH2 domain of cytoplasmic tyrosine kinases and other signalling proteins, which we have named Akt homology (AH) domain. Low stringency hybridization of a c-akt AH probe to a panel of genomic DNAs from vertebrate and invertebrate eucaryotes detected multiple DNA bands (perhaps multiple genes) in all tested species. Drosophila DNA contains at least three hybridizing DNA bands. One of them was cloned, and found by sequence analysis, to define an Akt related gene (Dakt1). Comparison between the coding regions of c-akt and Dakt1 revealed 64.6% identity at the nucleotide level and 76.5% similarity at the amino acid level. The highest degree of homology was detected in the AH domain (68.3% similarity at the amino acid level) and the catalytic domain (83.3% similarity). Additional sequence comparisons revealed that the amino acid similarity between the catalytic domains of Dakt1 and the three known members of the Drosophila protein kinase C (PKC) family, Dpkc1, Dpkc2 and Dpkc3, is 68%, 63.6% and 67.1%, respectively. Dakt1 was mapped to Drosophila chromosome 3R 89BC. Its expression is subject to developmental regulation with the highest levels detected within the fourth hour of embryonic development. These results confirm that the AH domain of Akt defines new protein families in both vertebrate and invertebrate eucaryotes. The high degree of homology between the catalytic domains of Dakt1 and the three known members of the Drosophila PKC family suggests an evolutionarily conserved functional relationship between the members of the two families.	FOX CHASE CANC CTR,PHILADELPHIA,PA 19111	Fox Chase Cancer Center					NCI NIH HHS [CA-06927, CA-38047] Funding Source: Medline; NCRR NIH HHS [RR-05539] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA038047] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED NN, 1993, ONCOGENE, V8, P1957; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BEDIAN V, 1991, DEV GENET, V12, P188, DOI 10.1002/dvg.1020120303; BELLACOSA A, 1993, ONCOGENE, V8, P745; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CASSILL JA, 1991, P NATL ACAD SCI USA, V88, P11067, DOI 10.1073/pnas.88.24.11067; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ENGELS WR, 1986, FOCUS, V8, P6; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HICKS JL, 1992, J CELL SCI, V101, P247; Jowett T., 1986, DROSOPHILA, P275; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KALDERON D, 1989, J BIOL CHEM, V264, P10738; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LAWRENCE PA, 1992, MAKING FLY, P13; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NELSON CR, 1992, MOL GEN GENET, V235, P11, DOI 10.1007/BF00286176; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; ROSENTHAL A, 1987, EMBO J, V6, P433, DOI 10.1002/j.1460-2075.1987.tb04773.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SIEGFRIED E, 1990, TRENDS GENET, V6, P357, DOI 10.1016/0168-9525(90)90277-D; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; VASLET CA, 1980, NATURE, V285, P674, DOI 10.1038/285674a0; Wieschaus E., 1986, P199	32	36	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					141	148						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302573				2022-12-17	WOS:A1994MW24700017
J	ELWOOD, NJ; COOK, WD; METCALF, D; BEGLEY, CG				ELWOOD, NJ; COOK, WD; METCALF, D; BEGLEY, CG			SCL, THE GENE IMPLICATED IN HUMAN T-CELL LEUKEMIA, IS ONCOGENIC IN A MURINE T-LYMPHOCYTE CELL-LINE	ONCOGENE			English	Article							ABELSON LEUKEMIA-VIRUS; DNA-BINDING MOTIF; LOOP-HELIX GENES; C-MYC; ERYTHROID-DIFFERENTIATION; CHROMOSOMAL TRANSLOCATION; TRANSGENIC MICE; BALB/C MICE; TAL-1 GENE; EXPRESSION	SCL (TAL-1) is implicated in the generation of human T-cell acute lymphoblastic leukaemia. To directly examine the role of this putative oncogene, an SCL retrovirus was constructed and used to infect a v-ABL transformed T-lymphocyte cell line. Thirteen independent SCL-infected and four control cell lines were established and injected subcutaneously into syngeneic mice. Mice injected with SCL-infected clonal cell lines died significantly more rapidly than control animals. By day 200 46% (40/87) of animals injected with SCL-infected cell lines had died due to disseminated transplantable lymphoid tumours. In contrast only 22% of control mice were dead by day 200 (P < 0.0015). Of possible relevance to the enhanced tumourigenesis, some SCL-infected cell lines displayed increased clonogenicity in agar. Increased cell growth was even more striking when ex-vivo tumour-derived cell lines were studied. Thus, SCL can co-operate with v-ABL to hasten T-cell tumourigenesis. This is the first direct evidence demonstrating that SCL can behave as an oncogene.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT SURG,PARKVILLE,VIC 3050,AUSTRALIA; ROYAL MELBOURNE HOSP,DEPT DIAGNOST HAEMATOL,PARKVILLE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Royal Melbourne Hospital; Royal Melbourne Hospital				Elwood, Ngaire/0000-0002-4740-2416				ABELSON HT, 1970, CANCER RES, V30, P2208; ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; APLAN PD, 1992, EMBO J, V11, P4073, DOI 10.1002/j.1460-2075.1992.tb05500.x; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; BEGLEY CG, 1991, P NATL ACAD SCI USA, V88, P869, DOI 10.1073/pnas.88.3.869; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BOWTELL DDL, 1987, ANAL BIOCHEM, V162, P463, DOI 10.1016/0003-2697(87)90421-0; BOWTELL DDL, 1987, MOL BIOL MED, V4, P229; BOYD AW, 1989, BLOOD, V73, P1896; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHUNG SW, 1991, P NATL ACAD SCI USA, V88, P1858; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; ELWOOD NJ, 1991, TODAYS LIFE SCI, V3, P16; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GONDA TJ, 1989, EMBO J, V8, P1767, DOI 10.1002/j.1460-2075.1989.tb03570.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GREEN AR, 1991, ONCOGENE, V6, P475; GREEN AR, 1992, ONCOGENE, V7, P653; GREEN AR, 1991, EMBO J, V10, P4153, DOI 10.1002/j.1460-2075.1991.tb04993.x; Hariharan I K, 1988, Oncogene Res, V3, P387; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HAUPT Y, 1992, ONCOGENE, V7, P981; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MENDOZA GR, 1976, J IMMUNOL, V117, P1573; MOUTHON MA, 1993, BLOOD, V81, P647; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NAUMOVSKI L, 1992, BLOOD S1, V80, pA301; POTTER M, 1973, SCIENCE, V182, P592, DOI 10.1126/science.182.4112.592; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; ROSENBAUM H, 1990, EMBO J, V9, P897, DOI 10.1002/j.1460-2075.1990.tb08187.x; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; TANIGAWA T, 1993, IN PRESS P NATL ACAD; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VISVADER J, 1991, ONCOGENE, V6, P187; VISVADER J, 1991, TRENDS BIOCHEM SCI, V16, P330, DOI 10.1016/0968-0004(91)90137-K; WANECK GL, 1981, CELL, V26, P79, DOI 10.1016/0092-8674(81)90035-0; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862	56	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					3093	3101						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	8414511				2022-12-17	WOS:A1993MC09300026
J	DAVIS, LJ; HALAZONETIS, TD				DAVIS, LJ; HALAZONETIS, TD			BOTH THE HELIX-LOOP-HELIX AND THE LEUCINE ZIPPER MOTIFS OF C-MYC CONTRIBUTE TO ITS DIMERIZATION SPECIFICITY WITH MAX	ONCOGENE			English	Article							DNA-BINDING; PROTEIN; SEQUENCE; GENE; TRANSCRIPTION; ONCOGENE; DIMER; TRANSFORMATION; FIBROBLASTS; COMPLEXES	The oncoprotein c-Myc contains two dimerization motifs - the helix-loop-helix (HLH) and the leucine zipper (LZ) - through which c-Myc specifically dimerizes with Max. We substituted regions of the c-Myc HLH and LZ motifs with the corresponding regions of structurally related proteins that do not interact with Max. Specific association of c-Myc with Max was dictated by helices 1 and 2 of the HLH motif and by the LZ. Within helix 2, residues 6 and 7 were important determinants of dimerization specificity. c-Myc and Max proteins with three amino acids inserted between their HLH and LZ motifs interacted efficiently, suggesting that the spacing between the motifs can be varied. Furthermore, alignment of the motifs at the primary sequence level was not obligatory, since Max with the three amino acid insertion could interact with wild-type c-Myc. These findings are consistent with our recently proposed model for the architecture of HLH/LZ domains.	MERCK SHARP & DOHME LTD,DEPT CANC RES,WP 16-3,W POINT,PA 19486	Merck & Company			Halazonetis, Thanos/D-7923-2011					ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1992, P NATL ACAD SCI USA, V89, P599, DOI 10.1073/pnas.89.2.599; DANG CV, 1991, MOL CELL BIOL, V11, P954, DOI 10.1128/MCB.11.2.954; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; ENRIETTO PJ, 1989, VIROLOGY, V168, P256, DOI 10.1016/0042-6822(89)90265-1; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HALAZONETIS TD, 1992, SCIENCE, V255, P464, DOI 10.1126/science.1734524; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PRENDERGAST GC, 1991, SCIENCE, V251, P186, DOI 10.1126/science.1987636; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x	38	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					125	132						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423990				2022-12-17	WOS:A1993KN00500015
J	SLEEMAN, JP; LASKEY, RA				SLEEMAN, JP; LASKEY, RA			XENOPUS C-SKI CONTAINS A NOVEL COILED-COIL PROTEIN DOMAIN, AND IS MATERNALLY EXPRESSED DURING DEVELOPMENT	ONCOGENE			English	Article							MESSENGER-RNA; ONCOGENE PRODUCT; SKELETAL-MUSCLE; TGF-BETA; SEQUENCE; CLONING; CELLS; GENE; DIFFERENTIATION; IDENTIFICATION	v-ski is a virally transduced nuclear oncogene. The biology of its cellular progenitors is only poorly understood. The early development of Xenopus laevis provides an excellent model system for studying the role of genes in proliferation, differentiation and development. We have therefore characterized Xenopus c-ski. We report that Xenopus c-ski transcripts are maternally regulated during early development, and are widely expressed in adult tissues. Structural predictions indicate the presence of a previously unreported extensive C-terminal helical domain in Xenopus c-ski and ski-related proteins from other species. This domain shows homologies with proteins which contain heptad repeats characteristic of elongated coiled-coil formation, like myosin and the intermediate filament proteins, and itself has a heptad repeat structure. The ski C-terminal domain also contains two other previously unreported elements, a novel strictly alternating hydrophobic-basic motif that repeats along the helical domain, and an underlying 25-mer repeated sequence. The significance of these findings is discussed with reference to c-ski function and to the oncogenic activation of v-ski, which is a truncated version of c-ski and thus does not have the C-terminal helical domain.	WELLCOME CRC INST,CAMBRIDGE CB2 1QR,ENGLAND				Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARKAS AE, 1986, VIROLOGY, V151, P131, DOI 10.1016/0042-6822(86)90111-X; Berger S.L., 1987, METHODS ENZYMOLOGY, V152; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLAYCOMB WC, 1987, BIOCHEM J, V247, P701, DOI 10.1042/bj2470701; COLMENARES C, 1989, CELL, V59, P293, DOI 10.1016/0092-8674(89)90291-2; COLMENARES C, 1991, MOL CELL BIOL, V11, P1167, DOI 10.1128/MCB.11.2.1167; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; Davidson E. H., 1986, GENE ACTIVITY EARLY; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; ENOCH T, 1991, J CELL BIOL, V112, P797, DOI 10.1083/jcb.112.5.797; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUNAHASHI S, 1988, J GEN VIROL, V69, P35, DOI 10.1099/0022-1317-69-1-35; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GREEN KJ, 1990, J BIOL CHEM, V265, P2603; Gurdon J.B., 1977, Methods Cell Biol, V16, P125; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOYLE GW, 1988, J BIOL CHEM, V263, P7487; KAVINSKY CJ, 1984, J BIOL CHEM, V259, P2775; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; KIRSCHNER M, 1985, TRENDS GENET, V1, P41, DOI 10.1016/0168-9525(85)90021-6; KLYMKOWSKY MW, 1989, DEV BIOL, V134, P479, DOI 10.1016/0012-1606(89)90121-8; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; LIPMAN DJ, 1985, SCIENCE, V227, P1435, DOI 10.1126/science.2983426; MANJULA BN, 1984, J BIOL CHEM, V259, P3686; McKeon F, 1991, CURR OPIN CELL BIOL, V3, P82, DOI 10.1016/0955-0674(91)90169-Y; NAGASE T, 1990, NUCLEIC ACIDS RES, V18, P337, DOI 10.1093/nar/18.2.337; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; PARRY DAD, 1981, J MOL BIOL, V153, P459, DOI 10.1016/0022-2836(81)90290-4; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; Robson RM, 1989, CURR OPIN CELL BIOL, V1, P36, DOI 10.1016/S0955-0674(89)80034-1; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STADEN R, 1982, NUCLEIC ACIDS RES, V10, P431; STAVNEZER E, 1989, MOL CELL BIOL, V9, P4038, DOI 10.1128/MCB.9.9.4038; STAVNEZER E, 1981, J VIROL, V39, P920, DOI 10.1128/JVI.39.3.920-934.1981; Stavnezer E., 1988, ONCOGENE HDB, P393; SUTRAVE P, 1990, MOL CELL BIOL, V10, P3137, DOI 10.1128/MCB.10.6.3137; SUTRAVE P, 1989, MOL CELL BIOL, V9, P4046, DOI 10.1128/MCB.9.9.4046; SUTRAVE P, 1991, ONCOGENE, V6, P353; SUTRAVE P, 1990, GENE DEV, V4, P1462, DOI 10.1101/gad.4.9.1462; WEBER BL, 1990, SCIENCE, V249, P1291, DOI 10.1126/science.2205003; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; [No title captured]	50	36	41	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					67	77						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423997				2022-12-17	WOS:A1993KN00500008
J	DEVOUGE, MW; MUKHERJEE, BB				DEVOUGE, MW; MUKHERJEE, BB			TRANSFORMATION OF NORMAL RAT-KIDNEY CELLS BY V-K-RAS ENHANCES EXPRESSION OF TRANSIN-2 AND AN S-100-RELATED CALCIUM-BINDING PROTEIN	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; EPIDERMAL GROWTH-FACTOR; COMPARATIVE BIOCHEMICAL-PROPERTIES; GUANINE NUCLEOTIDE-BINDING; MESSENGER-RNA; SIGNAL TRANSDUCTION; POLYACRYLAMIDE GELS; MOLECULAR-CLONING; GENE-PRODUCT; 3T3 CELLS	v-K-ras transformants of normal rat kidney cells (KNRK) exhibit cell surface-related, transformation-specific properties, including cell-surface fibronectin depletion, induction of anchorage- and density-independent growth, and increased synthesis of transforming growth factors-alpha and beta. To search for potential distal effectors of v-K-ras-mediated transformation, we prepared a rabbit antiserum directed against intact KNRK cells to immunoprecipitate and compare proteins from detergent lysates and conditioned media of labeled NRK, KNRK, B77-NRK (a v-src transformant) and ts-371-NRK cells (a Ki-MSV encoding a temperature-sensitive p21v-K-ras). Proteins with enhanced expression in both wild-type v-K-ras and v-src transformants included a cell-surface phosphoglycoprotein with apparent M(r) of 79 000 (79K) modified from an 85K protein observed in NRK cell lysates, a cytoplasmic 47K and a 10K protein, and a 57K secreted glycoprotein. A KNRK-specific 21K membrane-associated protein and secreted 59K and 36K secreted glycoproteins were also detected. The expression of the 36K and 59K proteins best correlated with temperature-dependent activation of the ts-371-NRK p21v-K-ras. Immunoselection of recombinant clones from a KNRK-specific lambda-gt11 cDNA library allowed identification of the 59K and 10K proteins as transin 2 and an S-100-related calcium-binding protein identified as p9Ka/42A but not previously associated with oncogenic transformation of rat cells. Transin 2 detection by a cell-derived antiserum may also suggest the presence of specific cell-surface binding sites for this enzyme.	MCGILL UNIV,CTR HUMAN GENET,MONTREAL H3A 1B1,QUEBEC,CANADA	McGill University	DEVOUGE, MW (corresponding author), MCGILL UNIV,DEPT BIOL,1205 AV DOCTEUR PENFIELD,MONTREAL H3A 1B1,QUEBEC,CANADA.							ALONSO T, 1988, P NATL ACAD SCI USA, V85, P4271, DOI 10.1073/pnas.85.12.4271; ANZANO MA, 1982, CANCER RES, V42, P4776; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; AXELROD JH, 1989, MOL CELL BIOL, V9, P2133, DOI 10.1128/MCB.9.5.2133; BALLIN M, 1988, BIOCHEM BIOPH RES CO, V154, P832, DOI 10.1016/0006-291X(88)90215-X; BARRACLOUGH R, 1984, NUCLEIC ACIDS RES, V12, P8097, DOI 10.1093/nar/12.21.8097; BARRACLOUGH R, 1987, J MOL BIOL, V198, P13, DOI 10.1016/0022-2836(87)90453-0; BARRACLOUGH R, 1990, BIOCHEM BIOPH RES CO, V169, P660, DOI 10.1016/0006-291X(90)90381-V; BENJAMIN CW, 1988, P NATL ACAD SCI USA, V85, P4345, DOI 10.1073/pnas.85.12.4345; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BLACK FM, 1990, BIOCHEM J, V267, P809, DOI 10.1042/bj2670809; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BREATHNACH R, 1987, NUCLEIC ACIDS RES, V15, P1139, DOI 10.1093/nar/15.3.1139; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHARDIN P, 1988, BIOCHIMIE, V70, P865, DOI 10.1016/0300-9084(88)90226-X; CHIN JR, 1985, J BIOL CHEM, V260, P2367; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DENHARDT DT, 1987, ONCOGENE, V2, P55; DER CJ, 1981, CELL, V26, P429, DOI 10.1016/0092-8674(81)90212-9; DEVOUGE MW, 1982, VIROLOGY, V121, P327, DOI 10.1016/0042-6822(82)90172-6; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; DURKIN JP, 1983, CANCER RES, V43, P5390; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; GAL S, 1986, J BIOL CHEM, V261, P1760; GILLEN MF, 1987, J BIOL CHEM, V262, P5308; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDBERG AR, 1979, COLD SPRING HARB SYM, V44, P991; GOTO K, 1988, J BIOCHEM-TOKYO, V103, P48, DOI 10.1093/oxfordjournals.jbchem.a122237; GOTTESMAN MM, 1980, CELL, V19, P449, DOI 10.1016/0092-8674(80)90519-X; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; ISOBE T, 1981, EUR J BIOCHEM, V116, P79, DOI 10.1111/j.1432-1033.1981.tb05303.x; JACKSONGRUSBY LL, 1987, NUCLEIC ACIDS RES, V15, P6677, DOI 10.1093/nar/15.16.6677; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; Marston F. A. O., 1987, DNA CLONING, P59; MASIAKOWSKI P, 1988, P NATL ACAD SCI USA, V85, P1277, DOI 10.1073/pnas.85.4.1277; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MONCRIEF ND, 1990, J MOL EVOL, V30, P522, DOI 10.1007/BF02101108; MORRIS JDH, 1989, ONCOGENE, V4, P27; NEMIR M, 1989, J BIOL CHEM, V264, P18202; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAPAGEORGE A, 1982, J VIROL, V44, P509, DOI 10.1128/JVI.44.2.509-519.1982; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PREISS J, 1986, J BIOL CHEM, V261, P8597; PRICE BD, 1989, J BIOL CHEM, V264, P16638; REYNOLDS FH, 1981, NATURE, V292, P259, DOI 10.1038/292259a0; Sambrook J., 1989, MOL CLONING LAB MANU; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARIS CJM, 1987, J BIOL CHEM, V262, P10663; SCOLNICK EM, 1979, P NATL ACAD SCI USA, V76, P5355, DOI 10.1073/pnas.76.10.5355; SHIH TY, 1979, J VIROL, V31, P546, DOI 10.1128/JVI.31.2.546-546.1979; SHIH TY, 1980, NATURE, V287, P686, DOI 10.1038/287686a0; SISTONEN L, 1987, EXP CELL RES, V168, P518, DOI 10.1016/0014-4827(87)90024-3; SMITH MR, 1990, SCIENCE, V247, P1074, DOI 10.1126/science.2408147; STEIN RB, 1986, J VIROL, V60, P782, DOI 10.1128/JVI.60.2.782-786.1986; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TODARO GJ, 1980, CONTROL MECHANISMS A, V1, P223; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; USHIRO H, 1980, J BIOL CHEM, V255, P8363; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WHITMAN M, 1988, Biochimica et Biophysica Acta, V948, P327; WILLINGHAM MC, 1980, CELL, V19, P1005, DOI 10.1016/0092-8674(80)90091-4; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; ZAGURSKY RJ, 1985, GENE ANAL TECH, V2, P89, DOI 10.1016/0735-0651(85)90011-1; ZIMMER DB, 1986, J BIOL CHEM, V261, P1424	76	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1992	7	1					109	119						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741158				2022-12-17	WOS:A1992HC22700015
J	FURUKAWA, Y; DECAPRIO, JA; BELVIN, M; GRIFFIN, JD				FURUKAWA, Y; DECAPRIO, JA; BELVIN, M; GRIFFIN, JD			HETEROGENEOUS EXPRESSION OF THE PRODUCT OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE IN PRIMARY HUMAN LEUKEMIA-CELLS	ONCOGENE			English	Article							SV40 LARGE-T; OSTEO-SARCOMA; RB GENE; CYCLE; PHOSPHORYLATION; PROTEIN; BINDING; ABNORMALITIES; INACTIVATION; ANTIONCOGENE	To investigate the possible role of the product of the retinoblastoma susceptibility gene, pRB, in leukemogenesis, we examined fresh leukemia cells from 56 cases of primary leukemia (AML, 32; ALL, 12; CML-BC, 9; CLL, 3) for expression of pRB by using an immunoblotting assay with anti-pRB monoclonal antibodies PMG 3-245 or 3-340. Expression of the 70 kDa heat shock protein (Hsp70) was examined simultaneously as an internal control. pRB was found to be absent or expressed at an abnormally low level in 13 of 56 cases. Abnormal expression of pRB was most common in AML (8/32) and CML-BC (4/9), and less common in ALL (1/12). Expression of pRB was not induced in two cases of pRB- AML cultured for 24 h with GM-CSF, indicating that pRB expression could not be induced by increasing the rate of proliferation. The eight cases of AML lacking pRB protein were examined for RB1 mRNA by Northern blot. Two lacked RBI mRNA and six had a normal-sized mRNA (approximately 4.7 kb), although the amount of RB mRNA was very low in some cases. RB1 gene structure was normal by Southern blot in all eight cases lacking pRB protein which were studied. These results show that lack of pRB expression is relatively common in human myeloid leukemias, and suggests that loss of pRB expression could contribute to the altered growth control of these cells.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dryja T P, 1986, Symp Fundam Cancer Res, V39, P115; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FITCHETT M, 1987, CANCER GENET CYTOGEN, V24, P143, DOI 10.1016/0165-4608(87)90091-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1989, CANCER, V63, P1888, DOI 10.1002/1097-0142(19890515)63:10<1888::AID-CNCR2820631004>3.0.CO;2-L; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; NADLER LM, 1981, PROG HEMATOL, V12, P187; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	32	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1343	1346						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886710				2022-12-17	WOS:A1991GX27200008
J	KRUGER, A; ANDERSON, SM				KRUGER, A; ANDERSON, SM			THE V-SRC ONCOGENE BLOCKS THE DIFFERENTIATION OF A MURINE MYELOID PROGENITOR-CELL LINE AND INDUCES A TUMORIGENIC PHENOTYPE	ONCOGENE			English	Article							POLYMERASE CHAIN-REACTION; HEMATOPOIETIC-CELLS; LEUKEMIA-VIRUS; GRANULOCYTIC DIFFERENTIATION; INTERLEUKIN-3 DEPENDENCE; MYELOGENOUS LEUKEMIA; FACTOR INDEPENDENCE; MOLECULAR CONTROL; TRANSGENIC MICE; IL-3 DEPENDENCE	We have investigated the ability of the v-src oncogene to block the differentiation of the murine myeloid progenitor cell line 32D cl3. In response to granulocyte-colony stimulating factor (G-CSF), 32D cl3 cells are induced to differentiate into mature granulocytes (Valtieri et al., 1987). In contrast, no differentiation was observed following G-CSF treatment of 32D cl3 cells infected with a murine retrovirus carrying the wild-type v-src oncogene. Furthermore, cells infected with a v-src temperature-sensitive (ts) mutant did not differentiate at the permissive temperature, however, at the nonpermissive temperature G-CSF induced granulocytic differentiation. Differentiation of 32D cl3 cells infected with ts WP31A (ts LA31A src gene inserted into amphotropic murine leukemia virus 4070A; Anderson et al., 1987) occurred with the same kinetics as uninfected 32D cl3 cells. Temperature-shift experiments indicate that after 72 hours of treatment with G-CSF at the nonpermissive temperature, approximately half of the 32D cl3 cells infected with ts WP31A virus become committed to differentiation. Prior to that time, activation of v-src by shifting the cells to the permissive temperature resulted in the presence of only undifferentiated blast cells after six days in culture. In contrast to normal 32D cl3 cells, cells infected with the wild-type v-src were tumorigenic when injected into nu/nu Swiss mice. Lesions appeared in the spleen, liver, kidney, lungs and lymph nodes following subcutaneous injection. Growth factor-independent cells were recovered from the tumor, spleen, bone marrow and a lymph node of tumor-bearing nude mouse. Analysis of the proviral integration sites by inverse polymerase chain reaction (PCR) demonstrated that the tumor cells were of donor cell origin.	SUNY STONY BROOK,DEPT PATHOL,BHS-9,ROOM 153,STONY BROOK,NY 11794; SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R29CA045241, R01CA045241] Funding Source: NIH RePORTER; NCI NIH HHS [CA45241] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ALEXANDER WS, 1989, MOL CELL BIOL, V9, P67, DOI 10.1128/MCB.9.1.67; ALEXANDER WS, 1989, ONCOGENE, V4, P575; ANDERSON SM, 1987, VIROLOGY, V160, P263, DOI 10.1016/0042-6822(87)90070-5; ANDERSON SM, 1990, ONCOGENE, V5, P317; ANDERSON SM, 1984, J VIROL, V46, P594; ANDREJAUSKAS E, 1989, EMBO J, V8, P2575, DOI 10.1002/j.1460-2075.1989.tb08396.x; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BOS JL, 1987, BLOOD, V69, P1237; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; CHATTOPADHYAY SK, 1981, VIROLOGY, V113, P465, DOI 10.1016/0042-6822(81)90175-6; CHIRGWIN JJ, 1979, BIOCHEMISTRY-US, V13, P5294; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; COUSSENS PM, 1985, MOL CELL BIOL, V5, P2753, DOI 10.1128/MCB.5.10.2753; CRAMER E, 1985, BLOOD, V65, P423; FARR CJ, 1988, P NATL ACAD SCI USA, V85, P1629, DOI 10.1073/pnas.85.5.1629; GAMBKE C, 1985, P NATL ACAD SCI USA, V82, P879, DOI 10.1073/pnas.82.3.879; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; IBA H, 1985, MOL CELL BIOL, V5, P1058, DOI 10.1128/MCB.5.5.1058; JOHNSON GR, 1989, EMBO J, V8, P441, DOI 10.1002/j.1460-2075.1989.tb03396.x; KIPREOS ET, 1988, ONCOGENE RES, V2, P277; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MAVILIO F, 1989, ONCOGENE, V4, P301; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METCALF D, 1985, BLOOD, V65, P357; NEEDLEMAN SW, 1986, BLOOD, V67, P753; OLIFF A, 1985, P NATL ACAD SCI USA, V82, P3306, DOI 10.1073/pnas.82.10.3306; OTT D, 1990, J VIROL, V64, P757, DOI 10.1128/JVI.64.2.757-766.1990; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; ROVERA G, 1987, ONCOGENE, V1, P29; SACHS L, 1987, SCIENCE, V238, P1374, DOI 10.1126/science.3317831; SACHS L, 1985, ANNU REV MED, V36, P177; SILVER J, 1989, J VIROL, V63, P1924, DOI 10.1128/JVI.63.5.1924-1928.1989; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; STOCKING C, 1989, CURR TOP MICROBIOL, V149, P117; TAKEYA T, 1982, J VIROL, V44, P1; VALTIERI M, 1987, J IMMUNOL, V138, P3829; VOGT M, 1986, MOL CELL BIOL, V6, P3545, DOI 10.1128/MCB.6.10.3545; WATSON JD, 1987, J IMMUNOL, V139, P123	50	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					245	256						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1705687				2022-12-17	WOS:A1991FZ13400010
J	DMITROVSKY, E; MURTY, VVVS; MOY, D; MILLER, WH; NANUS, D; ALBINO, AP; SAMANIEGO, F; BOSL, G; CHAGANTI, RSK				DMITROVSKY, E; MURTY, VVVS; MOY, D; MILLER, WH; NANUS, D; ALBINO, AP; SAMANIEGO, F; BOSL, G; CHAGANTI, RSK			ISOCHROMOSOME 12P IN NONSEMINOMA CELL-LINES - KARYOLOGIC AMPLIFICATION OF C-KI-RAS2 WITHOUT POINT-MUTATIONAL ACTIVATION	ONCOGENE			English	Article									MEM HOSP CANC & ALLIED DIS,DEPT MED,SOLID TUMOR SERV,GENITOURINARY SECT,NEW YORK,NY 10021; SLOAN KETTERING MEM CANC CTR,IMMUNOL PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	DMITROVSKY, E (corresponding author), CORNELL UNIV,MED CTR,COLL MED,MEM SLOAN KETTERING CANC CTR,DEPT,CANC GENET & CYTOGENET LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [P01CA005826] Funding Source: NIH RePORTER; NCI NIH HHS [CA-05826] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; ANDREWS PW, 1984, LAB INVEST, V50, P147; ATKIN NB, 1982, LANCET, V2, P1349; ATKIN NB, 1983, CANCER GENET CYTOGEN, V10, P199, DOI 10.1016/0165-4608(83)90125-5; BALAZS I, 1984, HUM GENET, V68, P57, DOI 10.1007/BF00293873; BOS JL, 1984, NUCLEIC ACIDS RES, V12, P9155, DOI 10.1093/nar/12.23.9155; BOSL GJ, 1989, J NATL CANCER I, V81, P1874; CASTEDO SMMJ, 1988, CANCER GENET CYTOGEN, V32, P51, DOI 10.1016/0165-4608(88)90311-1; CASTEDO SMMJ, 1989, CANCER RES, V49, P672; CASTEDO SMMJ, 1989, CANCER RES, V49, P439; CHAGANTI RSK, 1986, MALIGNANT LYMPHOMA, P184; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DELOZIERBLANCHET CD, 1985, CANCER GENET CYTOGEN, V15, P375, DOI 10.1016/0165-4608(85)90182-7; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; FENDERSON BA, 1987, DEV BIOL, V122, P21, DOI 10.1016/0012-1606(87)90328-9; Fogh J, 1978, Natl Cancer Inst Monogr, P5; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; Harnden DG, 1985, INT SYSTEM HUMAN CYT; HEIM S, 1987, CANCER CYTOGENETICS, P227; KAZAZIAN HH, 1987, CYTOGENET CELL GENET, V46, P189; MCBRIDE LJ, 1988, BIOTECHNIQUES, V6, P362; MCCOY MS, 1984, MOL CELL BIOL, V4, P1577, DOI 10.1128/MCB.4.8.1577; MILLER WE, IN PRESS ONCOGENE; POPESCU NC, 1985, SOMAT CELL MOLEC GEN, V11, P149, DOI 10.1007/BF01534703; RODENHUIS S, 1987, NEW ENGL J MED, V317, P929, DOI 10.1056/NEJM198710083171504; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TURCCAREL C, 1987, ONCOGENE RES, V1, P397; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WANG LC, 1987, CANCER RES, V47, P4192; WANG N, 1980, CANCER RES, V40, P796; ZEUTHEN J, 1980, INT J CANCER, V25, P19, DOI 10.1002/ijc.2910250104	32	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					543	548						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2183156				2022-12-17	WOS:A1990DB85300013
J	MURAKAMI, Y; ASANO, M; SATAKE, M; ITO, Y				MURAKAMI, Y; ASANO, M; SATAKE, M; ITO, Y			A TUMOR PROMOTING PHORBOL ESTER, TPA, ENHANCES POLYOMAVIRUS DNA-REPLICATION BY ACTIVATING THE FUNCTION OF THE VIRAL ENHANCER	ONCOGENE			English	Article									KYOTO UNIV,DEPT VIRUS RES,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Murakami, Yota/F-8850-2012					ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAKER TA, 1988, CELL, V55, P113, DOI 10.1016/0092-8674(88)90014-1; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEPAMPHILIS ML, 1986, PAPOVARIRIDAE, P1; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; Furth M., 1983, LAMBDA 2, P145; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAI T, 1988, GENE DEV, V2, P1216, DOI 10.1101/gad.2.10.1216; HAI T, 1988, CELL, V54, P1034; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HEARING P, 1983, CELL, V33, P695, DOI 10.1016/0092-8674(83)90012-0; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; ITO Y, 1979, VIROLOGY, V98, P261, DOI 10.1016/0042-6822(79)90545-2; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRYSZKE MH, 1987, NATURE, V328, P254, DOI 10.1038/328254a0; LACAL JC, 1987, MOL CELL BIOL, V7, P4146, DOI 10.1128/MCB.7.11.4146; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; MARINUS MG, 1973, J BACTERIOL, V114, P1143, DOI 10.1128/JB.114.3.1143-1150.1973; MARTIN ME, 1988, P NATL ACAD SCI USA, V85, P5839, DOI 10.1073/pnas.85.16.5839; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; MCMACKEN R, 1988, CANCER CELL, V6, P25; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MULLER WJ, 1988, MOL CELL BIOL, V8, P5000, DOI 10.1128/MCB.8.11.5000; MULLER WJ, 1983, J VIROL, V47, P586, DOI 10.1128/JVI.47.3.586-599.1983; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; ONDEK B, 1988, NATURE, V333, P40, DOI 10.1038/333040a0; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; ONEILL EA, 1988, SCIENCE, V241, P1210, DOI 10.1126/science.3413485; ONEILL EA, 1988, J BIOL CHEM, V263, P931; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SATAKE M, 1988, ONCOGENE, V3, P69; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TWIGG AJ, 1980, NATURE, V283, P216, DOI 10.1038/283216a0; TYNDALL C, 1981, NUCLEIC ACIDS RES, V9, P6231, DOI 10.1093/nar/9.23.6231; VELDMAN GM, 1985, MOL CELL BIOL, V5, P649, DOI 10.1128/MCB.5.4.649; WASYLYK B, 1988, P NATL ACAD SCI USA, V85, P7952, DOI 10.1073/pnas.85.21.7952; WASYLYK C, 1987, CELL, V48, P525, DOI 10.1016/0092-8674(87)90203-0; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YAMAGUCHI Y, 1989, J VIROL, V63, P1040, DOI 10.1128/JVI.63.3.1040-1048.1989; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	66	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					5	13						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2157181				2022-12-17	WOS:A1990CM62000002
J	RUGGIERO, M; SRIVASTAVA, SK; FLEMING, TP; RON, D; EVA, A				RUGGIERO, M; SRIVASTAVA, SK; FLEMING, TP; RON, D; EVA, A			NIH3T3 FIBROBLASTS TRANSFORMED BY THE DBL ONCOGENE SHOW ALTERED EXPRESSION OF BRADYKININ RECEPTORS - EFFECT ON INOSITOL LIPID TURNOVER	ONCOGENE			English	Article									NCI,CELLULAR & MOLEC BIOL LAB,BLDG 37,RM 1E24,BETHESDA,MD 20892; UNIFORMED SERV UNIV HLTH SCI,DEPT PATHOL & SURG,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA			Eva, Alessandra/J-8268-2016	Eva, Alessandra/0000-0003-2949-078X	NCI NIH HHS [CA-46455] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA046455] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERRIDGE MJ, 1987, BIOCHIM BIOPHYS ACTA, V907, P33, DOI 10.1016/0304-419X(87)90017-5; BERRIDGE MJ, 1987, PHILOS T ROY SOC B, V317, P525, DOI 10.1098/rstb.1987.0079; BERRIIDGE MJ, 1983, BIOCHEM J, V212, P843; CHIARUGI V, 1987, ONCOGENE, V2, P37; CHIARUGI V, 1987, CANCER INVEST, V5, P215, DOI 10.3109/07357908709011738; CHIARUGI VP, 1986, BIOCHEM BIOPH RES CO, V141, P591, DOI 10.1016/S0006-291X(86)80214-5; DOWNWARD J, 1988, P NATL ACAD SCI USA, V86, P2648; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FINZI E, 1987, P NATL ACAD SCI USA, V84, P3733, DOI 10.1073/pnas.84.11.3733; FLEISCHMAN LF, 1986, SCIENCE, V231, P407, DOI 10.1126/science.3001936; FOWLER CJ, 1987, PHARMACOL TOXICOL, V60, P274, DOI 10.1111/j.1600-0773.1987.tb01751.x; FRY MJ, 1985, EMBO J, V4, P3173, DOI 10.1002/j.1460-2075.1985.tb04061.x; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; KATO M, 1987, J BIOL CHEM, V262, P5696; LACAL JC, 1987, NATURE, V330, P269, DOI 10.1038/330269a0; LAPETINA EG, 1985, J BIOL CHEM, V260, P7078; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MANNING DC, 1982, NATURE, V299, P256, DOI 10.1038/299256a0; MILLER RJ, 1987, TRENDS NEUROSCI, V10, P226, DOI 10.1016/0166-2236(87)90161-5; PALMER S, 1986, BIOCHEM J, V238, P491, DOI 10.1042/bj2380491; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PREISS J, 1986, J BIOL CHEM, V261, P8597; REGOLI D, 1980, PHARMACOL REV, V32, P1; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; ROSCHER AA, 1983, J CLIN INVEST, V72, P626, DOI 10.1172/JCI111012; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SNYDER SH, 1980, SCIENCE, V209, P976, DOI 10.1126/science.6157191; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; WAEKELAM MJO, 1988, FEBS LETT, V228, P182; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WHITFIELD JF, 1970, P SOC EXP BIOL MED, V133, P1270; WOLFMAN A, 1987, NATURE, V325, P359, DOI 10.1038/325359a0; YANO K, 1984, J BIOL CHEM, V259, P201	35	36	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1989	4	6					767	771						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA660	2543945				2022-12-17	WOS:A1989AA66000013
J	LIPP, M; SCHILLING, R; BERNHARDT, G				LIPP, M; SCHILLING, R; BERNHARDT, G			TRANS-ACTIVATION OF HUMAN MYC - THE 2ND-PROMOTER IS TARGET FOR THE STIMULATION BY ADENOVIRUS E1A PROTEINS	ONCOGENE			English	Article											LIPP, M (corresponding author), UNIV MUNICH,INST BIOCHEM,KARLSTR 23,D-8000 MUNICH 2,FED REP GER.		Lipp, Martin/G-2235-2010; Bernhardt, Günter/F-6946-2012	Bernhardt, Günter/0000-0002-0510-2853				ALLAN M, 1984, CELL, V38, P399, DOI 10.1016/0092-8674(84)90495-1; ANTOINE G, 1982, EMBO J, V4, P453; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BACCHETTI S, 1977, P NATL ACAD SCI USA, V74, P1590, DOI 10.1073/pnas.74.4.1590; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; COLE MD, 1987, ANNU REV GENET, V13, P361; DUSSAIX E, 1982, VIROLOGY, V116, P641, DOI 10.1016/0042-6822(82)90156-8; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; GAYNOR RB, 1984, P NATL ACAD SCI-BIOL, V81, P1193, DOI 10.1073/pnas.81.4.1193; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN MR, 1983, CELL, V35, P137, DOI 10.1016/0092-8674(83)90216-7; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; JONES N, 1979, P NATL ACAD SCI USA, V76, P3665, DOI 10.1073/pnas.76.8.3665; KEATH EJ, 1984, CELL, V37, P521, DOI 10.1016/0092-8674(84)90382-9; KELEKAR A, 1987, MOL CELL BIOL, V7, P3899, DOI 10.1128/MCB.7.11.3899; KELEKAR A, 1986, MOL CELL BIOL, V6, P7, DOI 10.1128/MCB.6.1.7; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LALLY C, 1984, EMBO J, V3, P333, DOI 10.1002/j.1460-2075.1984.tb01807.x; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANGNER KD, 1986, P NATL ACAD SCI USA, V83, P1598, DOI 10.1073/pnas.83.6.1598; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; MCCORMACK JE, 1984, P NATL ACAD SCI-BIOL, V81, P5546, DOI 10.1073/pnas.81.17.5546; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RULEY HE, 1984, CANCER CELL, V2, P481; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; THALMEIER K, 1989, IN PRESS GENES DEV, V3; TREISMAN R, 1983, P NATL ACAD SCI-BIOL, V80, P7428, DOI 10.1073/pnas.80.24.7428; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	42	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1989	4	5					535	541						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U7688	2471129				2022-12-17	WOS:A1989U768800002
J	ETIEMBLE, J; MOROY, T; JACQUEMIN, E; TIOLLAIS, P; BUENDIA, MA				ETIEMBLE, J; MOROY, T; JACQUEMIN, E; TIOLLAIS, P; BUENDIA, MA			FUSED TRANSCRIPTS OF C-MYC AND A NEW CELLULAR LOCUS, HCR IN A PRIMARY LIVER-TUMOR	ONCOGENE			English	Article									HOP BICETRE,INSERM,U56,F-94275 KREMLIN BICETRE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	ETIEMBLE, J (corresponding author), INST PASTEUR,UNITE RECOMBINAISON & EXPRESS GENET,CNRS,UA 271,INSERM,U163,F-75724 PARIS 15,FRANCE.		Moroy, Tarik/D-9923-2011; jacquemin, emmanuel/J-8673-2013					ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DANI C, 1984, P NATL ACAD SCI USA, V83, P295; DEAN M, 1983, NATURE, V305, P443, DOI 10.1038/305443a0; FERRE F, 1986, CR ACAD SCI III-VIE, V303, P633; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; KAKKIS E, 1988, NUCLEIC ACIDS RES, V16, P77, DOI 10.1093/nar/16.1.77; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LECH K, 1988, CELL, V52, P179, DOI 10.1016/0092-8674(88)90506-5; Maniatis T., 1982, MOL CLONING; MOROY T, 1985, EMBO J, V4, P1507, DOI 10.1002/j.1460-2075.1985.tb03810.x; MOROY T, 1986, NATURE, V324, P276, DOI 10.1038/324276a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NISHIKURA K, 1984, SCIENCE, V224, P399, DOI 10.1126/science.6424234; NISHIKURA K, 1983, P NATL ACAD SCI-BIOL, V80, P4822, DOI 10.1073/pnas.80.15.4822; PACHL C, 1983, CELL, V33, P335, DOI 10.1016/0092-8674(83)90415-4; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; PREHN J, 1984, NUCLEIC ACIDS RES, V23, P8987; RAMSAY G, 1980, NATURE, V288, P170, DOI 10.1038/288170a0; RAY D, 1987, MOL CELL BIOL, V7, P940, DOI 10.1128/MCB.7.2.940; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SNYDER RL, 1980, COLD SPRING HARBOR C, V7, P447; STANTON LW, 1983, NATURE, V303, P401, DOI 10.1038/303401a0; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; SULLIVAN NF, 1986, COLD SPRING HARB SYM, V51, P943, DOI 10.1101/SQB.1986.051.01.107; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175	49	36	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1989	4	1					51	57						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5674	2644611				2022-12-17	WOS:A1989U567400008
J	HUEBNER, K; CANNIZZARO, LA; NAKAMURA, T; HILLOVA, J; MARIAGESAMSON, R; HECHT, F; HILL, M; CROCE, CM				HUEBNER, K; CANNIZZARO, LA; NAKAMURA, T; HILLOVA, J; MARIAGESAMSON, R; HECHT, F; HILL, M; CROCE, CM			A REARRANGED TRANSFORMING GENE, TRE, IS MADE UP OF HUMAN SEQUENCES DERIVED FROM CHROMOSOME REGION-5Q, REGION-17Q AND REGION-18Q	ONCOGENE			English	Article									INST CANCEROL & IMMUNOGENET,CNRS,ER 148,F-94804 VILLEJUIF,FRANCE; SW BIOMED RES INST,CTR GENET,TEMPE,AZ 85281	Centre National de la Recherche Scientifique (CNRS)	HUEBNER, K (corresponding author), WISTAR INST ANAT & BIOL,36TH ST & SPRUCE,PHILADELPHIA,PA 19114, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647	NATIONAL CANCER INSTITUTE [R35CA039860, P01CA021124, P01CA025875] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39860, CA-25875, CA-21124] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BODMER WF, 1987, NATURE, V328, P614, DOI 10.1038/328614a0; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CANAANI E, 1984, LANCET, V1, P593; CANNIZZARO LA, 1984, CYTOGENET CELL GENET, V38, P308, DOI 10.1159/000132079; CANNIZZARO LA, 1987, AM J HUM GENET, V41, P1; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CROCE CM, 1987, P NATL ACAD SCI USA, V84, P7174, DOI 10.1073/pnas.84.20.7174; DAYTON AI, 1984, P NATL ACAD SCI-BIOL, V81, P4495, DOI 10.1073/pnas.81.14.4495; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P7581, DOI 10.1073/pnas.80.24.7581; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; FAVERA RD, 1982, P NATL ACAD SCI USA, V79, P7824; FAVERA RD, 1982, SCIENCE, V218, P686; GROFFEN J, 1983, NUCLEIC ACIDS RES, V11, P6331, DOI 10.1093/nar/11.18.6331; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HUEBNER K, 1985, SCIENCE, V230, P1282, DOI 10.1126/science.2999978; HUEBNER K, 1986, P NATL ACAD SCI USA, V83, P1403, DOI 10.1073/pnas.83.5.1403; ISOBE M, 1986, NATURE, V320, P84, DOI 10.1038/320084a0; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; KAWASAKI ES, 1985, SCIENCE, V230, P291, DOI 10.1126/science.2996129; KRAUS MH, 1987, EMBO J, V6, P605, DOI 10.1002/j.1460-2075.1987.tb04797.x; LEBEAU MM, 1986, SCIENCE, V231, P984, DOI 10.1126/science.3484837; LEPPERT M, 1987, SCIENCE, V238, P1411, DOI 10.1126/science.3479843; LESSIN S, 1988, IN PRESS J INVEST DE; MERGIA A, 1986, BIOCHEM BIOPH RES CO, V138, P644, DOI 10.1016/S0006-291X(86)80545-9; NAKAMURA T, 1988, ONCOGENE RES, V2, P357; NIENHUIS AW, 1985, CELL, V42, P421, DOI 10.1016/0092-8674(85)90099-6; OHYASHIKI JH, 1987, CANCER GENET CYTOGEN, V25, P341, DOI 10.1016/0165-4608(87)90195-6; PETTENATI MJ, 1987, P NATL ACAD SCI USA, V84, P2970, DOI 10.1073/pnas.84.9.2970; ROWLEY JD, 1977, INT J CANCER, V20, P869, DOI 10.1002/ijc.2910200608; SCHECHTER AL, 1985, SCIENCE, V229, P976, DOI 10.1126/science.2992090; SOLOMON E, 1987, NATURE, V328, P616, DOI 10.1038/328616a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; TURCCAREL C, 1987, P NATL ACAD SCI USA, V84, P1981, DOI 10.1073/pnas.84.7.1981; VANDENBERGHE H, 1985, CANCER GENET CYTOGEN, V17, P189, DOI 10.1016/0165-4608(85)90016-0; WEINBERGER C, 1985, CYTOGENET CELL GENET, V40, P776	41	36	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1988	3	4					449	455						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3274085				2022-12-17	WOS:A1988Q773900014
J	BERGMAN, P; USTAV, M; SEDMAN, J; MORENOLOPEZ, J; VENNSTROM, B; PETTERSSON, U				BERGMAN, P; USTAV, M; SEDMAN, J; MORENOLOPEZ, J; VENNSTROM, B; PETTERSSON, U			THE E5 GENE OF BOVINE PAPILLOMAVIRUS TYPE-1 IS SUFFICIENT FOR COMPLETE ONCOGENIC TRANSFORMATION OF MOUSE FIBROBLASTS	ONCOGENE			English	Article									UNIV UPPSALA,CTR BIOMED,DEPT MED GENET,BOX 589,S-75123 UPPSALA,SWEDEN	Uppsala University			Sedman, Juhan/H-1820-2011; Ustav, Mart/G-6484-2017	Sedman, Juhan/0000-0003-2081-1452				AHOLA H, 1983, NUCLEIC ACIDS RES, V11, P2639, DOI 10.1093/nar/11.9.2639; ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BAKER CC, 1987, EMBO J, V6, P1027, DOI 10.1002/j.1460-2075.1987.tb04855.x; Broker T.R., 1986, CANCER CELL, V4, P17; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; CHEN CY, 1982, NATURE, V299, P530; CHUVPILO SA, 1983, BIOORG KHIM+, V9, P1634; CONE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6349, DOI 10.1073/pnas.81.20.6349; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DIMAIO D, 1987, CANCER CELLS, V5, P187; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; Favaloro J, 1980, Methods Enzymol, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GROFF DE, 1986, VIROLOGY, V150, P221, DOI 10.1016/0042-6822(86)90281-3; HAUGEN TH, 1987, EMBO J, V6, P145, DOI 10.1002/j.1460-2075.1987.tb04732.x; HERMAN B, 1985, J CELL BIOL, V100, P1031, DOI 10.1083/jcb.100.4.1031; HOWLEY PM, 1985, MOL CELL BIOL, V5, P3310, DOI 10.1128/MCB.5.11.3310; KAISER K, 1985, DNA CLONING PRACTICA, V1, P1; LAMBERT PF, 1987, CELL, V50, P69, DOI 10.1016/0092-8674(87)90663-5; LANCASTER WD, 1982, MICROBIOL REV, V46, P191, DOI 10.1128/MMBR.46.2.191-207.1982; LAW MF, 1981, P NATL ACAD SCI-BIOL, V78, P2727, DOI 10.1073/pnas.78.5.2727; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; LUSKY M, 1985, J VIROL, V53, P955, DOI 10.1128/JVI.53.3.955-965.1985; MANIATIS T, 1982, MOL CLONING LABORATO; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MANN R, 1985, J VIROL, V54, P401, DOI 10.1128/JVI.54.2.401-407.1985; NAKABAYASHI Y, 1983, P NATL ACAD SCI-BIOL, V80, P5832, DOI 10.1073/pnas.80.19.5832; RABSON MS, 1986, J VIROL, V60, P626, DOI 10.1128/JVI.60.2.626-634.1986; SARVER N, 1984, J VIROL, V52, P377, DOI 10.1128/JVI.52.2.377-388.1984; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPALHOLZ RA, 1987, J VIROL, V61, P2128; STEFFEN D, 1978, CELL, V15, P1003, DOI 10.1016/0092-8674(78)90284-2; STENLUND A, 1985, J MOL BIOL, V182, P541, DOI 10.1016/0022-2836(85)90240-2; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WAGNER EF, 1985, EMBO J, V4, P663, DOI 10.1002/j.1460-2075.1985.tb03680.x; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YANG YC, 1985, P NATL ACAD SCI USA, V82, P1030, DOI 10.1073/pnas.82.4.1030; YANG YC, 1985, NATURE, V318, P575, DOI 10.1038/318575a0	43	36	37	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1988	2	5					453	459						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N4348	2836779				2022-12-17	WOS:A1988N434800006
J	BADING, H; HANSEN, J; MOELLING, K				BADING, H; HANSEN, J; MOELLING, K			SELECTIVE DNA-BINDING OF THE HUMAN CELLULAR MYB-PROTEIN ISOLATED BY IMMUNOAFFINITY CHROMATOGRAPHY USING A MONOCLONAL-ANTIBODY	ONCOGENE			English	Article									MAX PLANCK INST MOLEC GENET,SCHUSTER ABT,IHNESTR 73,D-1000 BERLIN 33,FED REP GER	Max Planck Society								ALITALO K, 1984, P NATL ACAD SCI-BIOL, V81, P4534, DOI 10.1073/pnas.81.14.4534; BADING H, 1987, IN PRESS MODERN TREN, V7; BEIMLING P, 1985, BIOCHEMISTRY-US, V24, P6349, DOI 10.1021/bi00344a005; BISTER K, 1982, P NATL ACAD SCI-BIOL, V79, P3677, DOI 10.1073/pnas.79.12.3677; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BOYLE WJ, 1983, P NATL ACAD SCI-BIOL, V80, P2834, DOI 10.1073/pnas.80.10.2834; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; CHEN JH, 1981, VIROLOGY, V110, P128, DOI 10.1016/0042-6822(81)90014-3; DESPLAN C, 1985, NATURE, V318, P630, DOI 10.1038/318630a0; DONNER P, 1983, P NATL ACAD SCI-BIOL, V80, P2861, DOI 10.1073/pnas.80.10.2861; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GONDA TJ, 1981, CELL, V23, P279, DOI 10.1016/0092-8674(81)90292-0; GONDA TJ, 1985, EMBO J, V4, P2003, DOI 10.1002/j.1460-2075.1985.tb03884.x; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREISERWILKE I, 1981, J VIROL, V39, P325, DOI 10.1128/JVI.39.1.325-329.1981; KLEMPNAUER KH, 1986, EMBO J, V5, P1903, DOI 10.1002/j.1460-2075.1986.tb04443.x; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; MCKAY RDG, 1981, J MOL BIOL, V145, P471, DOI 10.1016/0022-2836(81)90540-4; MOELLING K, 1986, J CANCER RES CLIN, V112, P97, DOI 10.1007/BF00404389; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; Moscovici C, 1975, Curr Top Microbiol Immunol, V71, P79; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; REMAUT E, 1981, GENE, V15, P81, DOI 10.1016/0378-1119(81)90106-2; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260	35	36	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene		1987	1	4					395	401						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	K7483	2455264				2022-12-17	WOS:A1987K748300008
J	Poorebrahim, M; Melief, J; de Coana, YP; Wickstrom, SL; Cid-Arregui, A; Kiessling, R				Poorebrahim, Mansour; Melief, Jeroen; Pico de Coana, Yago; Wickstrom, Stina L.; Cid-Arregui, Angel; Kiessling, Rolf			Counteracting CAR T cell dysfunction	ONCOGENE			English	Review							ARYL-HYDROCARBON RECEPTOR; INHIBITORY RECEPTORS; 4-1BB COSTIMULATION; ANTITUMOR EFFICACY; EFFECTOR FUNCTIONS; TUMOR STROMA; LIFE-SPAN; EXHAUSTION; SENESCENCE; PD-1	In spite of high rates of complete remission following chimeric antigen receptor (CAR) T cell therapy, the efficacy of this approach is limited by generation of dysfunctional CAR T cells in vivo, conceivably induced by immunosuppressive tumor microenvironment (TME) and excessive antigen exposure. Exhaustion and senescence are two critical dysfunctional states that impose a pivotal hurdle for successful CAR T cell therapies. Recently, modified CAR T cells with an "exhaustion-resistant" phenotype have shown superior antitumor functions and prolonged lifespan. In addition, several studies have indicated the feasibility of senescence delay in CAR T cells. Here, we review the latest reports regarding blockade of CAR T cell exhaustion and senescence with a particular focus on the exhaustion-inducing pathways. Subsequently, we describe what potential these latest insights offer for boosting the potency of adoptive cell transfer (ACT) therapies involving CAR T cells. Furthermore, we discuss how induction of costimulation, cytokine exposure, and TME modulation can impact on CAR T cell efficacy and persistence, while potential safety issues associated with reinvigorated CAR T cells will also be addressed.	[Poorebrahim, Mansour; Melief, Jeroen; Pico de Coana, Yago; Wickstrom, Stina L.; Kiessling, Rolf] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden; [Poorebrahim, Mansour; Cid-Arregui, Angel] German Canc Res Ctr, Targeted Tumor Vaccines Grp, Clin Cooperat Unit Appl Tumor Immun, Heidelberg, Germany	Karolinska Institutet; Helmholtz Association; German Cancer Research Center (DKFZ)	Poorebrahim, M; Kiessling, R (corresponding author), Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.; Poorebrahim, M (corresponding author), German Canc Res Ctr, Targeted Tumor Vaccines Grp, Clin Cooperat Unit Appl Tumor Immun, Heidelberg, Germany.	mansour.poorebrahim@dkfz-heidelberg.de; rolf.kiessling@ki.se	Poorebrahim, Mansour/AAP-4133-2021; Cid-Arregui, Angel/ABC-5812-2021; Wickström, Stina L/AAJ-2194-2020; Pico de Coana, Yago/E-2102-2018	Cid-Arregui, Angel/0000-0003-1433-2922; Kiessling, Rolf/0000-0003-0663-5763; Pico de Coana, Yago/0000-0002-5362-8761; Wickstrom, Stina/0000-0003-0349-4918	Swedish Cancer Society [CAN2016/315]	Swedish Cancer Society(Swedish Cancer Society)	MP was supported by a postdoctoral fellowship from Rolf Kiessling's project grant from the Swedish Cancer Society (CAN2016/315). He is now an Alexander von Humboldt fellow. ACA gratefully acknowledges Prof. Harald zur Hausen for his continuous scientific support and encouragement.	Abu Eid R, 2017, CANCER RES, V77, P4135, DOI 10.1158/0008-5472.CAN-16-1925; Akbar AN, 2011, NAT REV IMMUNOL, V11, P289, DOI 10.1038/nri2959; Alizadeh D, 2019, CANCER IMMUNOL RES, V7, P759, DOI 10.1158/2326-6066.CIR-18-0466; Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528; Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001; Appay V, 2002, NAT MED, V8, P379, DOI 10.1038/nm0402-379; Bae J, 2014, J IMMUNOL, V193, P3101, DOI 10.4049/jimmunol.1401025; Bai Y, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.40; Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024; Batra SA, 2020, CANCER IMMUNOL RES, V8, P309, DOI 10.1158/2326-6066.CIR-19-0293; Beavis PA, 2017, J CLIN INVEST, V127, P929, DOI 10.1172/JCI89455; Beltra JC, 2020, IMMUNITY, V52, P825, DOI 10.1016/j.immuni.2020.04.014; Bengsch B, 2016, IMMUNITY, V45, P358, DOI 10.1016/j.immuni.2016.07.008; Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679; Blagosklonny MV, 2012, AGING-US, V4, P159, DOI 10.18632/aging.100443; Bonifant CL, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.11; Bowers JS, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01221; Boyerinas B, 2017, BLOOD, V130; Brenchley JM, 2003, BLOOD, V101, P2711, DOI 10.1182/blood-2002-07-2103; Cassetta L, 2018, IMMUNOLOGY, V155, P285, DOI 10.1111/imm.12976; Cham CM, 2008, EUR J IMMUNOL, V38, P2438, DOI 10.1002/eji.200838289; Chen J, 2019, NATURE, V567, P530, DOI 10.1038/s41586-019-0985-x; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Cherkassky L, 2016, J CLIN INVEST, V126, P3130, DOI 10.1172/JCI83092; Chmielewski M, 2017, CELL REP, V21, P3205, DOI 10.1016/j.celrep.2017.11.063; Chong EA, 2017, BLOOD, V129, P1039, DOI 10.1182/blood-2016-09-738245; Cui J, 2020, CANCERS, V12, DOI 10.3390/cancers12010139; Davis T, 2007, BIOORG MED CHEM LETT, V17, P6832, DOI 10.1016/j.bmcl.2007.10.036; Garrod KR, 2012, CELL REP, V2, P1438, DOI 10.1016/j.celrep.2012.10.015; Gomes-Silva D, 2017, CELL REP, V21, P17, DOI 10.1016/j.celrep.2017.09.015; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; Guedan S, 2020, J CLIN INVESTIG; Guedan S, 2018, JCI INSIGHT, V11; Guedan S, 2014, BLOOD, V124, P1070, DOI 10.1182/blood-2013-10-535245; Hartley J, 2019, CLIN TRANSL IMMUNOL, V8, DOI 10.1002/cti2.1064; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Hoogi S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0721-y; Hu BL, 2017, CELL REP, V20, P3025, DOI 10.1016/j.celrep.2017.09.002; Huang BZ, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1684127; Hui EF, 2017, SCIENCE, V355, P1428, DOI 10.1126/science.aaf1292; Jia B, 2019, CANCER RES, V79, P1635, DOI 10.1158/0008-5472.CAN-18-3107; John LB, 2013, CLIN CANCER RES, V19, P5636, DOI 10.1158/1078-0432.CCR-13-0458; Katz SC, 2016, CANCER GENE THER, V23, P142, DOI 10.1038/cgt.2016.14; Kerkar SP, 2013, MOL THER, V21, P1369, DOI 10.1038/mt.2013.58; Kerkar SP, 2011, J CLIN INVEST, V121, P4746, DOI 10.1172/JCI58814; Khan O, 2019, NATURE, V571, P211, DOI 10.1038/s41586-019-1325-x; Kim EH, 2012, J IMMUNOL, V188, P4305, DOI 10.4049/jimmunol.1103568; Klebanoff CA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95103; Kloss CC, 2018, MOL THER, V26, P1855, DOI 10.1016/j.ymthe.2018.05.003; Kong KF, 2011, NAT IMMUNOL, V12, P1105, DOI 10.1038/ni.2120; LaFleur MW, 2019, NAT IMMUNOL, V20, P1335, DOI 10.1038/s41590-019-0480-4; Leclerc M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11280-z; Leone RD, 2020, NAT REV CANCER, V20, P516, DOI 10.1038/s41568-020-0273-y; Leontieva OV, 2010, AGING-US, V2, P924, DOI 10.18632/aging.100265; Li GB, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121322; Li JJ, 2018, FRONT NEUROL, V9, P1, DOI 10.3389/fneur.2018.00623; Ligtenberg MA, 2018, MOL THER, V26, P1482, DOI 10.1016/j.ymthe.2018.04.015; Ligtenberg MA, 2016, J IMMUNOL, V196, P759, DOI 10.4049/jimmunol.1401710; Lim AR, 2020, ELIFE, V9, DOI 10.7554/eLife.55185; Liu X, 2020, J CLIN INVEST, V130, P1073, DOI 10.1172/JCI133679; Liu XD, 2019, NATURE, V567, P525, DOI 10.1038/s41586-019-0979-8; Loffek S, 2018, J ONCOL, V2018, DOI 10.1155/2018/9732939; Long AH, 2016, CANCER IMMUNOL RES, V4, P869, DOI 10.1158/2326-6066.CIR-15-0230; Long AH, 2015, NAT MED, V21, P581, DOI 10.1038/nm.3838; Luiten RM, 2003, BLOOD, V101, P4512, DOI 10.1182/blood-2002-07-2018; Lynn RC, 2019, NATURE, V576, P293, DOI 10.1038/s41586-019-1805-z; Man K, 2017, IMMUNITY, V47, P1129, DOI 10.1016/j.immuni.2017.11.021; Marro BS, 2019, CELL REP, V29, P3293, DOI 10.1016/j.celrep.2019.10.119; Martinez M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00128; Masoumi E, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01546-6; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; McKinney EF, 2018, NAT IMMUNOL, V19, P213, DOI 10.1038/s41590-018-0045-y; Mezrich JD, 2010, J IMMUNOL, V185, P3190, DOI 10.4049/jimmunol.0903670; Moon E, 2017, AACR, V77, P13; Newick K, 2016, CANCER IMMUNOL RES, V4, P541, DOI 10.1158/2326-6066.CIR-15-0263; Ninomiya S, 2015, BLOOD, V125, P3905, DOI 10.1182/blood-2015-01-621474; Odorizzi PM, 2015, J EXP MED, V212, P1125, DOI 10.1084/jem.20142237; Parihar R, 2019, CANCER IMMUNOL RES, V7, P363, DOI 10.1158/2326-6066.CIR-18-0572; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Parry RV, 2005, MOL CELL BIOL, V25, P9543, DOI 10.1128/MCB.25.21.9543-9553.2005; Pegram HJ, 2012, BLOOD, V119, P4133, DOI 10.1182/blood-2011-12-400044; Petersen C, 2019, NEURO-ONCOLOGY, V21, P95, DOI 10.1093/neuonc/noz036.134; Philipson BI, 2020, SCI SIGNAL, V13, DOI 10.1126/scisignal.aay8248; Poorebrahim M, 2020, PHARMACOL THERAPEUT, V214, DOI 10.1016/j.pharmthera.2020.107603; Poorebrahim M, 2019, CRIT REV CL LAB SCI, V56, P393, DOI 10.1080/10408363.2019.1633512; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Rafiq S, 2018, NAT BIOTECHNOL, V36, P847, DOI 10.1038/nbt.4195; Rao RR, 2012, IMMUNITY, V36, P374, DOI 10.1016/j.immuni.2012.01.015; Ravishankar B, 2015, P NATL ACAD SCI USA, V112, P10774, DOI 10.1073/pnas.1504276112; Ren JT, 2017, ONCOTARGET, V8, P17002, DOI 10.18632/oncotarget.15218; Rota G, 2018, CELL REP, V23, P39, DOI 10.1016/j.celrep.2018.03.026; Roth A, 2003, BLOOD, V102, P849, DOI 10.1182/blood-2002-07-2015; Rupp LJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00462-8; Sacchetti B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20081903; Scharping NE, 2016, IMMUNITY, V45, P374, DOI [10.1016/j.immuni.2016.07.009, 10.1016/j.immuni.2016.08.009]; Schorer M, 2020, NAT COMMUN, V11, P1; Seo H, 2019, P NATL ACAD SCI USA, V116, P12410, DOI 10.1073/pnas.1905675116; Shah NN, 2019, NAT REV CLIN ONCOL, V16, P372, DOI 10.1038/s41571-019-0184-6; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3; Singh H, 2011, CANCER RES, V71, P3516, DOI 10.1158/0008-5472.CAN-10-3843; Song YZ, 2018, AGING CELL, V17, DOI 10.1111/acel.12716; Staron MM, 2014, IMMUNITY, V41, P802, DOI 10.1016/j.immuni.2014.10.013; Suarez ER, 2016, ONCOTARGET, V7, P34341, DOI 10.18632/oncotarget.9114; Sun C, 2020, CANCER CELL, V37, P216, DOI 10.1016/j.ccell.2019.12.014; Tang N, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.133977; Tanoue K, 2017, CANCER RES, V77, P2040, DOI 10.1158/0008-5472.CAN-16-1577; van der Stegen SJC, 2015, NAT REV DRUG DISCOV, V14, P499, DOI 10.1038/nrd4597; Wang J, 2019, CELL, V176, P334, DOI 10.1016/j.cell.2018.11.010; Wang LCS, 2014, CANCER IMMUNOL RES, V2, P154, DOI 10.1158/2326-6066.CIR-13-0027; Wang XC, 2019, J HEPATOL, V71, P731, DOI 10.1016/j.jhep.2019.05.015; Warrington KJ, 2003, BLOOD, V101, P3543, DOI 10.1182/blood-2002-08-2574; Wei P, 2014, LAB INVEST, V94, P528, DOI 10.1038/labinvest.2014.8; Wentink MWJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00446; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862; Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035; Wiede F, 2020, EMBO J, V39, DOI 10.15252/embj.2019103637; Wilkinson B, 2002, NAT IMMUNOL, V3, P272, DOI 10.1038/ni767; Xie YJ, 2019, P NATL ACAD SCI USA, V116, P7624, DOI 10.1073/pnas.1817147116; Xu Y, 2014, BLOOD, V123, P3750, DOI 10.1182/blood-2014-01-552174; Yazdanifar M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091070; Ye BX, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0814-0; Yin YB, 2018, MOL THER-ONCOLYTICS, V11, P20, DOI 10.1016/j.omto.2018.08.002; Yokosuka T, 2012, J EXP MED, V209, P1201, DOI 10.1084/jem.20112741; Yoo HJ, 2019, INT J MOL SCI, V18, P2469; Young A, 2016, CANCER CELL, V30, P391, DOI 10.1016/j.ccell.2016.06.025; Yu SN, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1057-4; Zeng Sulin, 2018, Cancer Transl Med, V4, P70, DOI 10.4103/ctm.ctm_22_18; Zhang P, 2018, IMMUNOTHERAPY-UK, V10, P935, DOI 10.2217/imt-2018-0012; Zhao YJ, 2020, CELL MOL IMMUNOL, V17, P27, DOI 10.1038/s41423-019-0344-8; Zheng WT, 2018, LEUKEMIA, V32, P1157, DOI 10.1038/s41375-017-0008-6; Zhou JX, 2019, PROTEIN CELL, V10, P764, DOI 10.1007/s13238-019-0643-y; Zou F, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11893-4	135	35	35	3	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					421	435		10.1038/s41388-020-01501-x	http://dx.doi.org/10.1038/s41388-020-01501-x		NOV 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33168929	hybrid, Green Published			2022-12-17	WOS:000587997700002
J	Wagner, V; Gil, J				Wagner, Verena; Gil, Jesus			Senescence as a therapeutically relevant response to CDK4/6 inhibitors	ONCOGENE			English	Review							DEPENDENT KINASE 4/6; CELLULAR SENESCENCE; BREAST-CANCER; TUMOR-CELLS; STROMAL SENESCENCE; LUNG-CANCER; GROWTH; CDK6; P53; PROLIFERATION	Cyclin-dependent kinases 4 and 6 (CDK4/6) phosphorylate and inhibit retinoblastoma (RB) family proteins. Hyperphosphorylated RB releases E2F transcription factors, activating a transcriptional program that initiates S phase. Due to the critical role that this pathway has in regulating cell cycle progression, inhibiting CDK4/6 is an attractive therapeutic strategy. Indeed, CDK4/6 inhibitors in combination with antiestrogens produce a significant benefit in patients with ER+/HER2(-)breast cancer. Clinical trials are currently investigating if the use of CDK4/6 inhibitors alone or in combination can be extended to other cancer types. Inhibition of CDK4/6 can result in different cell fates such as quiescence, senescence, or apoptosis. Senescence is a stress response that can be induced by stimuli that include oncogenic activation, chemotherapy, irradiation, and targeted therapies such as CDK4/6 inhibitors. Senescent cells undergo a stable cell cycle arrest and produce a bioactive secretome that remodels their microenvironment and engages the immune system. In this review, we analyze the therapeutic relevance of senescence induction by CDK4/6 inhibitors. We also discuss how different therapies, including checkpoint inhibitors and drugs targeting MEK or PI3K, can be used in combination with CDK4/6 inhibitors to reinforce or exploit senescence. Recently, a lot of effort has been put into identifying compounds that selectively kill senescent cells (termed senolytics). Thus, sequential treatment with senolytics might be an additional strategy to potentiate the antitumor effects of CDK4/6 inhibitors.	[Wagner, Verena; Gil, Jesus] MRC, London Inst Med Sci LMS, Du Cane Rd, London W12 0NN, England; [Wagner, Verena; Gil, Jesus] Imperial Coll London, Inst Clin Sci ICS, Fac Med, Du Cane Rd, London W12 0NN, England	Imperial College London	Gil, J (corresponding author), MRC, London Inst Med Sci LMS, Du Cane Rd, London W12 0NN, England.; Gil, J (corresponding author), Imperial Coll London, Inst Clin Sci ICS, Fac Med, Du Cane Rd, London W12 0NN, England.	jesus.gil@imperial.ac.uk		Gil, Jesus/0000-0002-4303-6260; Wagner, Verena/0000-0003-2604-0759	CRUK [C15075/A28647]; MRC [MC_U120085810]; German Cancer Aid Mildred-Scheel Postdoc Program	CRUK(Cancer Research UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); German Cancer Aid Mildred-Scheel Postdoc Program	Grants from CRUK (C15075/A28647) and core support from MRC (MC_U120085810) funded this research in J. Gil's Laboratory. VW was funded by the German Cancer Aid Mildred-Scheel Postdoc Program.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Alvarez-Fernandez M, 2020, CANCER CELL, V37, P514, DOI 10.1016/j.ccell.2020.03.010; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Andre F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904; Asghar U, 2015, NAT REV DRUG DISCOV, V14, P130, DOI 10.1038/nrd4504; Asghar US, 2017, CLIN CANCER RES, V23, P5561, DOI 10.1158/1078-0432.CCR-17-0369; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Basisty N, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000599; Bellutti F, 2018, CANCER DISCOV, V8, P884, DOI 10.1158/2159-8290.CD-17-0912; Bollard J, 2017, GUT, V66, P1286, DOI 10.1136/gutjnl-2016-312268; Chang BD, 1999, CANCER RES, V59, P3761; Chang JH, 2016, NAT MED, V22, P78, DOI 10.1038/nm.4010; Chen L, 2017, BRIT J PHARMACOL, V174, P2427, DOI 10.1111/bph.13836; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Condorelli R, 2018, ANN ONCOL, V29, P640, DOI 10.1093/annonc/mdx784; Coppe JP, 2006, J BIOL CHEM, V281, P29568, DOI 10.1074/jbc.M603307200; Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071; Dall'Acqua A, 2017, EMBO MOL MED, V9, P1415, DOI 10.15252/emmm.201607012; Damsky W, 2015, CANCER CELL, V27, P41, DOI 10.1016/j.ccell.2014.11.014; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241; Deng JH, 2018, CANCER DISCOV, V8, P216, DOI 10.1158/2159-8290.CD-17-0915; Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437; Eggert T, 2016, CANCER CELL, V30, P533, DOI 10.1016/j.ccell.2016.09.003; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Franco J, 2016, CELL REP, V14, P979, DOI 10.1016/j.celrep.2015.12.094; Fry DW, 2004, MOL CANCER THER, V3, P1427; Gelbert LM, 2014, INVEST NEW DRUG, V32, P825, DOI 10.1007/s10637-014-0120-7; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465; Gong XQ, 2017, CANCER CELL, V32, P761, DOI 10.1016/j.ccell.2017.11.006; Gorgoulis V, 2019, CELL, V179, P813, DOI 10.1016/j.cell.2019.10.005; Guan XN, 2017, MOL CANCER RES, V15, P237, DOI 10.1158/1541-7786.MCR-16-0319; Guerrero A, 2019, NAT METAB, V1, P1074, DOI 10.1038/s42255-019-0122-z; Hafner M, 2019, CELL CHEM BIOL, V26, P1067, DOI 10.1016/j.chembiol.2019.05.005; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Haugstetter AM, 2010, BRIT J CANCER, V103, P505, DOI 10.1038/sj.bjc.6605784; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; He SH, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3986; Herrera-Abreu MT, 2016, CANCER RES, V76, P2301, DOI 10.1158/0008-5472.CAN-15-0728; Iannello A, 2013, J EXP MED, V210, P2057, DOI 10.1084/jem.20130783; Jerby-Arnon L, 2018, CELL, V175, P984, DOI 10.1016/j.cell.2018.09.006; Jiang SH, 2017, NATURE, V544, P460, DOI 10.1038/nature22032; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kim S., 2013, MOL CANCER THER, V12, pPR02, DOI DOI 10.1158/1535-7163.TARG-13-PR02; Kim YH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15208; Klein ME, 2018, CANCER CELL, V34, P9, DOI 10.1016/j.ccell.2018.03.023; Kollmann K, 2016, CANCER CELL, V30, P359, DOI 10.1016/j.ccell.2016.07.003; Kovatcheva M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00540-5; Kovatcheva M, 2015, ONCOTARGET, V6, P8226, DOI 10.18632/oncotarget.3364; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kumarasamy V, 2020, ONCOGENE, V39, P1831, DOI 10.1038/s41388-019-1102-1; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Li J, 2010, CANCER INVEST, V28, P350, DOI 10.3109/07357900903286966; Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836; McHugh D, 2018, J CELL BIOL, V217, P65, DOI 10.1083/jcb.201708092; Miettinen TP, 2018, EMBO J, V37, DOI 10.15252/embj.201798359; Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167; Munoz-Espin D, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809355; Patnaik A, 2016, CANCER DISCOV, V6, P740, DOI 10.1158/2159-8290.CD-16-0095; Petrova NV, 2016, AGING CELL, V15, P999, DOI 10.1111/acel.12518; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Rader J, 2013, CLIN CANCER RES, V19, P6173, DOI 10.1158/1078-0432.CCR-13-1675; Reddy HKDL, 2005, CANCER RES, V65, P10174, DOI 10.1158/0008-5472.CAN-05-2639; Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270; Roberts PJ, 2012, JNCI-J NATL CANCER I, V104, P476, DOI 10.1093/jnci/djs002; Ruhland MK, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11762; Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008; Ruscetti M, 2018, SCIENCE, V362, P1416, DOI 10.1126/science.aas9090; Salvador-Barbero B, 2020, CANCER CELL, V37, P340, DOI 10.1016/j.ccell.2020.01.007; Sawai CM, 2012, CANCER CELL, V22, P452, DOI 10.1016/j.ccr.2012.09.016; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schuler MH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9519; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sherr CJ, 2016, CANCER DISCOV, V6, P353, DOI 10.1158/2159-8290.CD-15-0894; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009; Tao YF, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0405-y; te Poele RH, 2002, CANCER RES, V62, P1876; Teo ZL, 2017, CANCER RES, V77, P6340, DOI 10.1158/0008-5472.CAN-17-2210; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Torres-Guzman R, 2017, ONCOTARGET, V8, P69493, DOI 10.18632/oncotarget.17778; Turner NC, 2019, J CLIN ONCOL, V37, P1169, DOI 10.1200/JCO.18.00925; Valenzuela CA, 2017, EXP CELL RES, V360, P390, DOI 10.1016/j.yexcr.2017.09.031; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Vora SR, 2014, CANCER CELL, V26, P136, DOI 10.1016/j.ccr.2014.05.020; Walter DM, 2019, NATURE, V569, P423, DOI 10.1038/s41586-019-1172-9; Wander SA, 2020, CANCER DISCOV; Wang C, 2019, NATURE, V574, P268, DOI 10.1038/s41586-019-1607-3; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yoshida A, 2016, CANCER RES, V76, P2990, DOI 10.1158/0008-5472.CAN-15-2931; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	100	35	36	4	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 16	2020	39	29					5165	5176		10.1038/s41388-020-1354-9	http://dx.doi.org/10.1038/s41388-020-1354-9		JUN 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ML6WO	32541838	Green Accepted			2022-12-17	WOS:000540391900002
J	Azad, T; Nouri, K; van Rensburg, HJJ; Maritan, SM; Wu, LQ; Hao, YW; Montminy, T; Yu, JH; Khanal, P; Mulligan, LM; Yang, XL				Azad, Taha; Nouri, Kazem; van Rensburg, Helena J. Janse; Maritan, Sarah M.; Wu, Liqing; Hao, Yawei; Montminy, Tess; Yu, Jihang; Khanal, Prem; Mulligan, Lois M.; Yang, Xiaolong			A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis	ONCOGENE			English	Article							TUMOR-SUPPRESSOR; NUCLEAR TRANSLOCATION; CELL-PROLIFERATION; CONTACT INHIBITION; RET PROTOONCOGENE; PANCREATIC-CANCER; YAP; GROWTH; DROSOPHILA; APOPTOSIS	The Hippo pathway has emerged as a key signaling pathway that regulates various biological functions. Dysregulation of the Hippo pathway has been implicated in a broad range of human cancer types. While a number of stimuli affecting the Hippo pathway have been reported, its upstream kinase and extracellular regulators remain largely unknown. Here we performed the first comprehensive gain-of-functional screen for receptor tyrosine kinases (RTKs) regulating the Hippo pathway using an RTK overexpression library and a Hippo signaling activity biosensor. Surprisingly, we found that the majority of RTKs could regulate the Hippo signaling activity. We further characterized several of these novel relationships [TAM family members (TYRO3, AXL, METRK), RET, and FGFR family members (FGFR1 and FGFR2)] and found that the Hippo effectors YAP/TAZ are central mediators of the tumorigenic phenotypes (e.g., increased cell proliferation, transformation, increased cell motility, and angiogenesis) induced by these RTKs and their extracellular ligands (Gas6, GDNF, and FGF) through either PI3K or MAPK signaling pathway. Significantly, we identify FGFR, RET, and MERTK as the first RTKs that can directly interact with and phosphorylate YAP/TAZ at multiple tyrosine residues independent of upstream Hippo signaling, thereby activating their functions in tumorigenesis. In conclusion, we have identified several novel kinases and extracellular stimuli regulating the Hippo pathway. Our findings also highlight the pivotal role of the Hippo pathway in mediating Gas6/GDNF/FGF-TAM/RET/FGFR-MAPK/PI3K signaling during tumorigenesis and provide a compelling rationale for targeting YAP/TAZ in RTK-driven cancers.	[Azad, Taha; Nouri, Kazem; van Rensburg, Helena J. Janse; Maritan, Sarah M.; Wu, Liqing; Hao, Yawei; Montminy, Tess; Yu, Jihang; Khanal, Prem; Mulligan, Lois M.; Yang, Xiaolong] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada	Yang, XL (corresponding author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada.	yangx@queensu.ca	Mulligan, Lois/D-1893-2010	Mulligan, Lois/0000-0002-9308-8245; Janse van Rensburg, Helena/0000-0002-4066-7489; Nouri, Kazem/0000-0001-7787-1304; Azad, Taha/0000-0002-9498-0657; Maritan, Sarah/0000-0002-9703-7429	Canadian Institute of Health Research (CIHR) [119325, 148629]; Canadian Breast Cancer Foundation; CIHR [142303]; Vanier Canada Graduate Scholarship; Ontario International Graduate Scholarship; Queen Elizabeth II Graduate Scholarship in Science and Technology; Master's CIHR award; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research	Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); CIHR(Canadian Institutes of Health Research (CIHR)); Vanier Canada Graduate Scholarship; Ontario International Graduate Scholarship; Queen Elizabeth II Graduate Scholarship in Science and Technology; Master's CIHR award; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research	This work was supported by grants from Canadian Institute of Health Research (CIHR#119325, 148629), Canadian Breast Cancer Foundation to XY and CIHR (CIHR#142303) to LMM. TA is supported by the Vanier Canada Graduate Scholarship and Ontario International Graduate Scholarship. HJJvR was supported by a Queen Elizabeth II Graduate Scholarship in Science and Technology. SMM was supported by a Master's CIHR award. SMM, TM, PK, and TA are supported by studentships from the Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research. We thank Dr David Lillicrap and Dr Paula James for providing the HUVEC, Telo-HEC, and BOEC cells; Dr Camargo for STBS-luc reporter plasmid; Mina Ghahremani for help in making figures; Dr Abdi Ghafari for Aortic ring angiogenesis assay; Elham Ghourbanpour and Dr Lillicrap for helping in Nucleofection transfection; Dr Guan for providing us with HEK293A-LATS knockout cells, and Carrie Wei for help in analyzing motility assay; and Dr Peter Greer for reading the manuscript.	Alvarez H, 2010, CANCER BIOL THER, V10, P1009, DOI 10.4161/cbt.10.10.13248; Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025; Attisano Liliana, 2013, F1000Prime Rep, V5, P17, DOI 10.12703/P5-17; Axelrod H, 2014, ONCOTARGET, V5, P1, DOI 10.18632/oncotarget.2422; Azad T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03278-w; Azad T, 2018, JOVE-J VIS EXP, V139, P11; Azad T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050407; Calses PC, 2019, TRENDS CANCER, V5, P297, DOI 10.1016/j.trecan.2019.04.001; Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chen LM, 2010, GENE DEV, V24, P290, DOI 10.1101/gad.1865310; Chioni AM, 2012, J CELL BIOL, V197, P801, DOI 10.1083/jcb.201108077; Choura M, 2011, J RECEPT SIG TRANSD, V31, P387, DOI 10.3109/10799893.2011.625425; Coleman SJ, 2014, EMBO MOL MED, V6, P467, DOI 10.1002/emmm.201302698; Edwards DN, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aan4667; Fan R, 2013, P NATL ACAD SCI USA, V110, P2569, DOI 10.1073/pnas.1216462110; Gainor JF, 2013, ONCOLOGIST, V2, P13; Gorelik R, 2014, NAT PROTOC, V9, P1931, DOI 10.1038/nprot.2014.131; Gumbiner BM, 2014, J CELL SCI, V127, P709, DOI 10.1242/jcs.140103; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Haskins JW, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005770; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; Huang SM, 2014, ENDOCR-RELAT CANCER, V21, P73, DOI 10.1530/ERC-13-0351; Ishida M, 2007, CANCER SCI, V98, P815, DOI 10.1111/j.1349-7006.2007.00457.x; Jang EJ, 2012, MOL CELL BIOL, V32, P4925, DOI 10.1128/MCB.00392-12; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; JUSTICE RW, 1995, GENE DEV, V9, P534, DOI 10.1101/gad.9.5.534; Keshet R, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.995006; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee YW, 2012, J CELL BIOCHEM, V113, P2920, DOI 10.1002/jcb.24170; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Li P, 2016, GENE DEV, V30, P798, DOI 10.1101/gad.274951.115; Lian EY, 2017, ENDOCR-RELAT CANCER, V24, P53, DOI 10.1530/ERC-16-0393; Liu AM, 2012, BBA-REV CANCER, V1826, P357, DOI 10.1016/j.bbcan.2012.05.006; Meng ZP, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9357; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Moroishi T, 2015, GENE DEV, V29, P1271, DOI 10.1101/gad.262816.115; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Reddy BVVG, 2013, DEV CELL, V24, P459, DOI 10.1016/j.devcel.2013.01.020; Rizvi S, 2016, J BIOL CHEM, V115, P72; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; Romano D, 2014, NAT CELL BIOL, V16, P673, DOI 10.1038/ncb2986; Romei C, 2016, NAT REV ENDOCRINOL, V12, P192, DOI 10.1038/nrendo.2016.11; Saucedo LJ, 2007, NAT REV MOL CELL BIO, V8, P613, DOI 10.1038/nrm2221; Schlessinger J, 2014, COLD SPRING HARB PER, V6, P89; Sugihara T, 2018, MOL CANCER RES, V2, P158; Taha Z, 2018, CANCERS, V10, DOI 10.3390/cancers10040094; Tamm C, 2011, J CELL SCI, V124, P1136, DOI 10.1242/jcs.075796; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; van Rensburg HJJ, 2018, CELL SIGNAL, V52, P12, DOI 10.1016/j.cellsig.2018.08.012; Vasudevan HN, 2016, CURR TOP DEV BIOL, V117, P393, DOI 10.1016/bs.ctdb.2015.10.016; Wang WQ, 2014, MOL CELL PROTEOMICS, V13, P119, DOI 10.1074/mcp.M113.030049; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Xu MZ, 2011, ONCOGENE, V30, P1229, DOI 10.1038/onc.2010.504; Yang XP, 2011, NAT METHODS, V8, P659, DOI [10.1038/NMETH.1638, 10.1038/nmeth.1638]; Yu FX, 2013, GENE DEV, V27, P355, DOI 10.1101/gad.210773.112; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zhang XM, 2009, CANCER RES, V69, P6033, DOI 10.1158/0008-5472.CAN-08-4592; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhao YL, 2018, MOL CANCER RES, V16, P1046, DOI 10.1158/1541-7786.MCR-17-0593	64	35	36	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					334	355		10.1038/s41388-019-0988-y	http://dx.doi.org/10.1038/s41388-019-0988-y			22	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477837				2022-12-17	WOS:000507766400007
J	Kweon, J; Jang, AH; Shin, HR; See, JE; Lee, W; Lee, JW; Chang, S; Kim, K; Kim, Y				Kweon, Jiyeon; Jang, An-Hee; Shin, Ha Rim; See, Ji-Eun; Lee, Woochang; Lee, Jong Won; Chang, Suhwan; Kim, Kyunggon; Kim, Yongsub			A CRISPR-based base-editing screen for the functional assessment of BRCA1 variants	ONCOGENE			English	Article							GENOMIC DNA; SITES	Genetic mutations in BRCA1, which is crucial for the process of DNA repair and maintenance of genomic integrity, are known to increase markedly the risk of breast and ovarian cancers. Clinical genetic testing has been used to identify new BRCA1 variants; however, functional assessment and determination of their pathogenicity still poses challenges for clinical management. Here, we describe that CRISPR-mediated cytosine base editor, known as BE3, can be used for the functional analysis of BRCA1 variants. We performed CRISPR-mediated base-editing screening using 745 gRNAs targeting all exons in BRCA1 to identify loss-of-function variants and identified variants whose function has heretofore remained unknown, such as c.-97C>T, c.154C>T, c.3847C>T, c.5056C>T, and c.4986+5G>A. Our results show that CRISPR-mediated base editor is a powerful tool for the reclassification of variants of uncertain significance (VUSs) in BRCA1.	[Kweon, Jiyeon; Jang, An-Hee; Shin, Ha Rim; See, Ji-Eun; Chang, Suhwan; Kim, Yongsub] Univ Ulsan, Coll Med, Asan Med Inst Convergence Sci & Technol, Dept Biomed Sci,Asan Med Ctr, Seoul, South Korea; [Kweon, Jiyeon; Jang, An-Hee; Shin, Ha Rim; See, Ji-Eun; Kim, Yongsub] Univ Ulsan, Coll Med, Stem Cell Immunomodulat Res Ctr, Seoul, South Korea; [Lee, Woochang] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Lab Med, Seoul, South Korea; [Lee, Jong Won] Univ Ulsan, Coll Med, Asan Med Ctr, Div Breast Surg,Dept Surg, Seoul, South Korea; [Kim, Kyunggon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Convergence Med, Seoul, South Korea; [Kim, Kyunggon] Asan Inst Life Sci, Clin Prote Core Lab, Seoul, South Korea	University of Ulsan; University of Ulsan; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center	Kim, Y (corresponding author), Univ Ulsan, Coll Med, Asan Med Inst Convergence Sci & Technol, Dept Biomed Sci,Asan Med Ctr, Seoul, South Korea.; Kim, Y (corresponding author), Univ Ulsan, Coll Med, Stem Cell Immunomodulat Res Ctr, Seoul, South Korea.	yongsub1.kim@gmail.com		Chang, Suhwan/0000-0002-0282-0120; Kim, Yongsub/0000-0002-9334-4333	National Research Foundation of Korea [2017M3A9B4062419, 2019R1F1A1057637, 2018R1A5A2020732]; Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea [HI17C0337]; Asan institute for Life Sciences, Republic of Korea [2018-784, 2018-725]	National Research Foundation of Korea(National Research Foundation of Korea); Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea; Asan institute for Life Sciences, Republic of Korea	This work was supported by the National Research Foundation of Korea (grants 2017M3A9B4062419, 2019R1F1A1057637, and 2018R1A5A2020732 to Y.K.), the Korean Health Technology R&D Project, Ministry of Health and Welfare, Republic of Korea (grant HI17C0337 to Y.K.), and Asan institute for Life Sciences, Republic of Korea (grants 2018-784, and 2018-725 to Y.K.).	Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048; Blomen VA, 2015, SCIENCE, V350, P1092, DOI 10.1126/science.aac7557; BRUNAK S, 1991, J MOL BIOL, V220, P49, DOI 10.1016/0022-2836(91)90380-O; Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Findlay GM, 2018, NATURE, V562, P217, DOI 10.1038/s41586-018-0461-z; Findlay GM, 2014, NATURE, V513, P120, DOI 10.1038/nature13695; Gaudelli NM, 2017, NATURE, V551, P464, DOI 10.1038/nature24644; Gibson TJ, 2013, NAT METHODS, V10, P715, DOI 10.1038/nmeth.2534; Hess GT, 2016, NAT METHODS, V13, P1036, DOI [10.1038/NMETH.4038, 10.1038/nmeth.4038]; Hu JH, 2018, NATURE, V556, P57, DOI 10.1038/nature26155; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Kim K, 2017, NAT BIOTECHNOL, V35, P435, DOI 10.1038/nbt.3816; Kim Y, 2013, NAT BIOTECHNOL, V31, P251, DOI 10.1038/nbt.2517; Knott GJ, 2018, SCIENCE, V361, P866, DOI 10.1126/science.aat5011; Komor AC, 2016, NATURE, V533, P420, DOI 10.1038/nature17946; Kuchenbaecker KB, 2017, JAMA-J AM MED ASSOC, V317, P2402, DOI 10.1001/jama.2017.7112; Kweon J, 2018, ARCH PHARM RES, V41, P875, DOI 10.1007/s12272-018-1029-z; Kweon J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199473; Landrum MJ, 2016, NUCLEIC ACIDS RES, V44, pD862, DOI 10.1093/nar/gkv1222; Millot GA, 2012, HUM MUTAT, V33, P1526, DOI 10.1002/humu.22150; Nishimasu H, 2018, SCIENCE, V361, P1259, DOI 10.1126/science.aas9129; Park DS, 2017, MOL CELLS, V40, P823, DOI 10.14348/molcells.2017.0262; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Sayers EW, 2019, NUCLEIC ACIDS RES, V47, pD94, DOI 10.1093/nar/gky989; Wang T, 2015, SCIENCE, V350, P1096, DOI 10.1126/science.aac7041	26	35	35	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					30	35		10.1038/s41388-019-0968-2	http://dx.doi.org/10.1038/s41388-019-0968-2			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31467430	Green Published, hybrid			2022-12-17	WOS:000509849200003
J	Hu, X; Xiang, DX; Xie, Y; Tao, LW; Zhang, Y; Jin, Y; Pinello, L; Wan, YZ; Yuan, GC; Li, Z				Hu, Xin; Xiang, Dongxi; Xie, Ying; Tao, Luwei; Zhang, Yu; Jin, Yue; Pinello, Luca; Wan, Youzhong; Yuan, Guo-Cheng; Li, Zhe			LSD1 suppresses invasion, migration and metastasis of luminal breast cancer cells via activation of GATA3 and repression of TRIM37 expression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MOLECULAR PORTRAITS; MAMMARY-GLAND; DIFFERENTIATION; DEMETHYLATION; INHIBITION; PROGRAMS; TARGETS; GENOME; EMT	LSD1 (KDM1A) is a histone demethylase that plays both oncogenic and tumor suppressor roles in breast cancer. However, the exact contexts under which it plays these opposite functions remain largely elusive. By characterizing its role in luminal breast epithelial cells, here we show that inhibition of LSD1 by both genetic and pharmacological approaches increases their invasion and migration, whereas its inhibition by genetic approach, but not by pharmacological approach, impairs their proliferation/survival. Induced loss of LSD1 in luminal cells in a mouse model of luminal breast cancer, MMTV-PyMT, leads to a profound increase in lung metastasis. Mechanistically, LSD1 interacts with GATA3, a key luminal-specific transcription factor (TF), and their common target genes are highly related to breast cancer. LSD1 positively regulates GATA3 expression. It also represses expression of TRIM37, a breast epithelial oncogene encoding a histone H2A ubiquitin ligase, and ELF5, a key TF gene for luminal progenitors and alveolar luminal cells. LSD1-loss also leads to reduced expression of several cell-cell adhesion genes (e.g., CDH1, VCL, CTNNA1), possibly via TRIM37-upregulation and subsequently TRIM37-mediated repression. Collectively, our data suggest LSD1 largely plays a tumor suppressor role in luminal breast cancer and the oncogenic program associated with LSD1-inhibition may be suppressed via TRIM37-inhibition.	[Hu, Xin; Zhang, Yu; Jin, Yue; Wan, Youzhong] Jilin Univ, Sch Life Sci, Changchun, Jilin, Peoples R China; [Hu, Xin; Xiang, Dongxi; Xie, Ying; Tao, Luwei; Li, Zhe] Harvard Med Sch, Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA; [Hu, Xin; Xiang, Dongxi; Xie, Ying; Tao, Luwei; Li, Zhe] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Pinello, Luca; Yuan, Guo-Cheng] Harvard Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostatist & Computat Biol, Boston, MA 02115 USA	Jilin University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard T.H. Chan School of Public Health	Li, Z (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.; Li, Z (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.	zli4@rics.bwh.harvard.edu		Li, Zhe/0000-0002-3434-0885; HU, XIN/0000-0002-5105-8929	U.S. Department of Defense [W81XWH-15-1-0100]; NCI/NIH [SG-0062-10, CA126980, CA222560]; Harvard Stem Cell Institute [DP-0137-13-00]; Brigham and Women's Hospital; National Natural Science Foundation of China [NSFC31471356]; Jilin Province Science and Technology Development Project [20180101240JC, 20190701005GH]; NATIONAL CANCER INSTITUTE [R01CA222560] Funding Source: NIH RePORTER	U.S. Department of Defense(United States Department of Defense); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Harvard Stem Cell Institute; Brigham and Women's Hospital; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jilin Province Science and Technology Development Project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr. Stuart Orkin for the Lsd1<SUP>L/L</SUP> conditional knockout mouse line, and Drs. Alan Cantor, Hui Huang, and Andrew Woo (Boston Children's Hospital) for help with gel filtration chromatography. This research was supported by Breakthrough Award from U.S. Department of Defense (W81XWH-15-1-0100), Pathway-to-Independence K99/R00 grant (CA126980) and R01 grant (CA222560) from NCI/NIH, Seed Grant (SG-0062-10) and Cancer Program Pilot Grant (DP-0137-13-00) from Harvard Stem Cell Institute, and Start-up Fund from Brigham and Women's Hospital to ZL. This work was also supported by National Natural Science Foundation of China (NSFC31471356) and Jilin Province Science and Technology Development Project (20180101240JC, 20190701005GH) to XH.	Ahuja N, 2014, J CLIN INVEST, V124, P56, DOI 10.1172/JCI69736; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Asselin-Labat ML, 2011, MOL CELL BIOL, V31, P4609, DOI 10.1128/MCB.05766-11; Benner C, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003906; Bhatnagar S, 2014, NATURE, V516, P116, DOI 10.1038/nature13955; Choi HJ, 2015, EMBO REP, V16, P1288, DOI 10.15252/embr.201540244; Choi YS, 2009, DEV BIOL, V329, P227, DOI 10.1016/j.ydbio.2009.02.032; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; Feng JX, 2016, BREAST CANCER RES TR, V159, P443, DOI 10.1007/s10549-016-3959-9; Gallego-Ortega D, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002330; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Hu X, 2009, P NATL ACAD SCI USA, V106, P10141, DOI 10.1073/pnas.0900437106; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Huang Y, 2012, BREAST CANCER RES TR, V131, P777, DOI 10.1007/s10549-011-1480-8; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kouros-Mehr H, 2008, CANCER CELL, V13, P141, DOI 10.1016/j.ccr.2008.01.011; Kouros-Mehr H, 2006, CELL, V127, P1041, DOI 10.1016/j.cell.2006.09.048; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lee JY, 2014, ONCOGENE, V33, P1325, DOI 10.1038/onc.2013.53; Lee MG, 2005, NATURE, V437, P432, DOI 10.1038/nature04021; Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Lynch JT, 2012, EXPERT OPIN THER TAR, V16, P1239, DOI 10.1517/14728222.2012.722206; Maes T, 2018, CANCER CELL, V33, P495, DOI 10.1016/j.ccell.2018.02.002; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Mould DP, 2015, MED RES REV, V35, P586, DOI 10.1002/med.21334; Oakes SR, 2008, GENE DEV, V22, P581, DOI 10.1101/gad.1614608; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Serce N, 2012, BMC CLIN PATHOL, V12, DOI 10.1186/1472-6890-12-13; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shen H, 2013, CELL, V153, P38, DOI 10.1016/j.cell.2013.03.008; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Si WZ, 2015, CANCER CELL, V27, P822, DOI 10.1016/j.ccell.2015.04.011; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tao LW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14431; Tao LW, 2015, STEM CELL REP, V5, P60, DOI 10.1016/j.stemcr.2015.05.014; Tao LW, 2014, STEM CELL REP, V2, P770, DOI 10.1016/j.stemcr.2014.04.004; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Woo AJ, 2008, MOL CELL BIOL, V28, P2675, DOI 10.1128/MCB.01945-07; Wu YD, 2013, CELL REP, V5, P224, DOI 10.1016/j.celrep.2013.08.030; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Zhang XM, 2013, CELL REP, V5, P445, DOI 10.1016/j.celrep.2013.09.018; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	53	35	35	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2019	38	44					7017	7034		10.1038/s41388-019-0923-2	http://dx.doi.org/10.1038/s41388-019-0923-2			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ1AO	31409898	Green Accepted			2022-12-17	WOS:000493892900005
J	D'Errico, G; Alonso-Nocelo, M; Vallespinos, M; Hermann, PC; Alcala, S; Garcia, CP; Martin-Hijano, L; Valle, S; Earl, J; Cassiano, C; Lombardia, L; Feliu, J; Monti, MC; Seufferlein, T; Garcia-Bermejo, L; Martinelli, P; Carrato, A; Sainz, B				D'Errico, Gabriele; Alonso-Nocelo, Marta; Vallespinos, Mireia; Hermann, Patrick C.; Alcala, Sonia; Pedrero Garcia, Coral; Martin-Hijano, Laura; Valle, Sandra; Earl, Julie; Cassiano, Chiara; Lombardia, Luis; Feliu, Jaime; Monti, Maria Chiara; Seufferlein, Thomas; Garcia-Bermejo, Laura; Martinelli, Paola; Carrato, Alfredo; Sainz, Bruno, Jr.			Tumor-associated macrophage-secreted 14-3-3 zeta signals via AXL to promote pancreatic cancer chemoresistance	ONCOGENE			English	Article							DUCTAL ADENOCARCINOMA; CELL-DEATH; GROWTH; CHEMOTHERAPY; METASTASIS; INHIBITION; LIVER; IDENTIFICATION; INFLAMMATION; EXPRESSION	Pancreatic ductal adenocarcinoma (PDAC) is an inherently chemoresistant tumor. Chemotherapy leads to apoptosis of cancer cells, and in previous studies we have shown that tumor-associated macrophage (TAM) infiltration increases following chemotherapy in PDAC. Since one of the main functions of macrophages is to eliminate apoptotic cells, we hypothesized that TAMs phagocytose chemotherapy-induced apoptotic cells and secrete factors, which favor PDAC chemoresistance. To test this hypothesis, primary human PDAC cultures were treated with conditioned media (CM) from monocyte-derived macrophage cultures incubated with apoptotic PDAC cells (Mempty set(Apop)CM). Mempty set(Apop)CM pretreatment rendered naive PDAC cells resistant to Gemcitabine- or Abraxane-induced apoptosis. Proteomic analysis of Mempty set(Apop)CM identified YWHAZ/14-3-3 protein zeta/delta (14-3-3 zeta), a major regulator of apoptotic cellular pathways, as a potential mediator of chemoresistance, which was subsequently validated in patient transcriptional datasets, serum samples from PDAC patients and using recombinant 14-3-3 zeta and inhibitors thereof Moreover, in mice bearing orthotopic PDAC tumors, the antitumor potential of Gemcitabine was significantly enhanced by elimination of TAMs using clodronate liposomes or by pharmacological inhibition of the Axl receptor tyrosine kinase, a 14-3-3 zeta interacting partner. These data highlight a unique regulatory mechanism by which chemotherapy-induced apoptosis acts as a switch to initiate a protumor/antiapoptotic mechanism in PDAC via 14-3-3 zeta/Axl signaling, leading to phosphorylation of Akt and activation of cellular prosurvival mechanisms The data presented therefore challenge the idea that apoptosis of tumor cells is therapeutically beneficial, at least when immune sensor cells, such as macrophages, are present.	[D'Errico, Gabriele; Alonso-Nocelo, Marta; Vallespinos, Mireia; Alcala, Sonia; Pedrero Garcia, Coral; Martin-Hijano, Laura; Valle, Sandra; Sainz, Bruno, Jr.] UAM, Dept Biochem, Madrid, Spain; [D'Errico, Gabriele; Feliu, Jaime] La Paz Univ Hosp, Dept Med Oncol, Madrid, Spain; [Alonso-Nocelo, Marta; Vallespinos, Mireia; Alcala, Sonia; Pedrero Garcia, Coral; Martin-Hijano, Laura; Valle, Sandra; Sainz, Bruno, Jr.] CSIC UAM, Inst Invest Biomed Alberto Sols IIBM, Dept Canc Biol, Madrid, Spain; [Alonso-Nocelo, Marta; Vallespinos, Mireia; Alcala, Sonia; Pedrero Garcia, Coral; Martin-Hijano, Laura; Valle, Sandra; Earl, Julie; Carrato, Alfredo; Sainz, Bruno, Jr.] IRYCIS, Chron Dis & Canc Area 3, Madrid, Spain; [Hermann, Patrick C.; Seufferlein, Thomas] Ulm Univ, Dept Internal Med 1, Ulm, Germany; [Earl, Julie; Feliu, Jaime; Carrato, Alfredo] Biomed Res Network Canc CIBERONC, CB16 12 00446, Madrid, Spain; [Earl, Julie; Feliu, Jaime; Carrato, Alfredo] Biomed Res Network Canc CIBERONC, CB16 12 00398, Madrid, Spain; [Earl, Julie; Carrato, Alfredo] Alcala Univ, Ramon y Cajal Univ Hosp, Med Oncol Dept, Madrid, Spain; [Cassiano, Chiara; Monti, Maria Chiara] Univ Salerno, Dept Pharm, Salerno, Italy; [Lombardia, Luis] Spanish Natl Canc Res Ctr CNIO, Mol Diagnost Unit, Clin Res Programme, Madrid, Spain; [Garcia-Bermejo, Laura] Biomarkers & Therapeut Targets Grp IRYCIS, Madrid, Spain; [Martinelli, Paola] Med Univ Wien, Inst Canc Res, Comprehens Canc Ctr, Vienna, Austria	Autonomous University of Madrid; Hospital Universitario La Paz; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Ulm University; Hospital Universitario Ramon y Cajal; Universidad de Alcala; University of Salerno; Centro Nacional de Investigaciones Oncologicas (CNIO); Medical University of Vienna	Sainz, B (corresponding author), UAM, Dept Biochem, Madrid, Spain.; Sainz, B (corresponding author), CSIC UAM, Inst Invest Biomed Alberto Sols IIBM, Dept Canc Biol, Madrid, Spain.; Sainz, B (corresponding author), IRYCIS, Chron Dis & Canc Area 3, Madrid, Spain.	bruno.sainz@uam.es	Vallespinós, Mireia/AAL-1708-2021; Vallespinós, Mireia/AAC-9628-2022; Anding, Bruno Sainz/ABH-5365-2020; Hermann, Patrick/Y-6254-2019; Seufferlein, Thomas TW/P-7147-2018	Anding, Bruno Sainz/0000-0003-4829-7651; Hermann, Patrick/0000-0003-0418-0478; Alcala, Sonia/0000-0002-7644-4973; CARRATO, ALFREDO/0000-0001-7749-8140; Alonso-Nocelo, Marta/0000-0001-8838-363X; Earl, Julie/0000-0001-9360-4716	Ministerio de Economia y Competitividad, Spain [RYC-2012-12104]; Clinic and Laboratory Integration Program (CLIP) grant from the Cancer Research Institute (CRI), NY; Fundacion Asociacion Espanola Contra el Cancer (AECC) [GC16173694BARB]; Fondo de Investigaciones Sanitarias (FIS) from the Instituto de Salud Carlos III (ISCIII), Spain [PI15/01507, PI15/01715, PI15/02101]; Fondo Europeo de Desarrollo Regional (FEDER); Biomedical Research Network in Cancer [CIBER-ONC:CB16/12/00446]; Austrian Science Fund [FWF-B27361]; Ingrid Shaker-Nessmann Foundation; Max Eder Fellowship of the German Cancer Aid [111746]; German Research Foundation (DFG) [CRC 1279]	Ministerio de Economia y Competitividad, Spain; Clinic and Laboratory Integration Program (CLIP) grant from the Cancer Research Institute (CRI), NY; Fundacion Asociacion Espanola Contra el Cancer (AECC); Fondo de Investigaciones Sanitarias (FIS) from the Instituto de Salud Carlos III (ISCIII), Spain; Fondo Europeo de Desarrollo Regional (FEDER)(European Commission); Biomedical Research Network in Cancer; Austrian Science Fund(Austrian Science Fund (FWF)); Ingrid Shaker-Nessmann Foundation; Max Eder Fellowship of the German Cancer Aid; German Research Foundation (DFG)(German Research Foundation (DFG))	We are indebted to Jose German Casas for CD14-enriched monocyte preparations, Carmen Sanchez Palomo and Esperanza Macarena Rodriguez Serrano for IHC and histological assistance, and Maria Gonzalez Dionis for in vitro technical assistance. The research was supported by a Ramon y Cajal Merit Award (RYC-2012-12104) from the Ministerio de Economia y Competitividad, Spain (BS, Jr.), a Clinic and Laboratory Integration Program (CLIP) grant from the Cancer Research Institute (CRI), NY (BS, Jr.), a Coordinated grant (GC16173694BARB) from the Fundacion Asociacion Espanola Contra el Cancer (AECC) (AC and BS, Jr.), Fondo de Investigaciones Sanitarias (FIS) grants PI15/01507 (BS, Jr.), PI15/01715 (LGB) and PI15/02101 (AC) (co-financed through Fondo Europeo de Desarrollo Regional (FEDER) "Una manera de hacer Europa") from the Instituto de Salud Carlos III (ISCIII), Spain, funding from the Biomedical Research Network in Cancer (CIBER-ONC:CB16/12/00446) for clinical sample and data collection (AC), funding from the Austrian Science Fund (FWF-B27361) and Ingrid Shaker-Nessmann Foundation for Cancer Research (PM), a Max Eder Fellowship of the German Cancer Aid (111746) (PCH), and by the German Research Foundation (DFG, CRC 1279 "Exploiting the human peptidome for Novel Antimicrobial and Anticancer Agents") (PCH).	Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; D'Costa Z, 2017, CANCER RES, V77, P5952, DOI 10.1158/0008-5472.CAN-16-2833; Dengler M, 2017, ONCOTARGET, V8, P46234, DOI 10.18632/oncotarget.17598; DUVALL E, 1985, IMMUNOLOGY, V56, P351; Eng EW, 2007, MOL BIOL CELL, V18, P2389, DOI 10.1091/mbc.e06-12-1128; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Hidalgo M, 2015, PANCREATOLOGY, V15, P8, DOI 10.1016/j.pan.2014.10.001; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hu H, 2016, TUMOR BIOL, V37, P8657, DOI 10.1007/s13277-015-4741-z; Ireland L, 2016, CANCER RES, V76, P6851, DOI 10.1158/0008-5472.CAN-16-1201; Jandaghi P, 2016, GASTROENTEROLOGY, V151, P1218, DOI 10.1053/j.gastro.2016.08.040; Janky R, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2540-6; Kariolis MS, 2017, J CLIN INVEST, V127, P183, DOI 10.1172/JCI85610; Khorrami A, 2017, HORM MOL BIOL CLIN I, V32, DOI 10.1515/hmbci-2017-0032; Kirane A, 2015, CANCER RES, V75, P3699, DOI 10.1158/0008-5472.CAN-14-2887-T; Kitamura T, 2015, NAT REV IMMUNOL, V15, P73, DOI 10.1038/nri3789; Klemm C, 2014, PATHOL RES PRACT, V210, P335, DOI 10.1016/j.prp.2014.01.001; Ko AH, 2015, J CLIN ONCOL, V33, P1779, DOI 10.1200/JCO.2014.59.7625; Kobayashi R, 2009, CANCER IMMUNOL IMMUN, V58, P247, DOI 10.1007/s00262-008-0549-7; Korshunov VA, 2012, CLIN SCI, V122, P361, DOI 10.1042/CS20110411; Ludwig KF, 2018, CANCER RES, V78, P246, DOI 10.1158/0008-5472.CAN-17-1973; Martinelli P, 2017, GUT, V66, P1665, DOI 10.1136/gutjnl-2015-311256; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Matta A, 2016, PROTEOMICS, V16, P1079, DOI 10.1002/pmic.201500489; Matta A, 2012, EXPERT OPIN THER TAR, V16, P515, DOI 10.1517/14728222.2012.668185; Mueller MT, 2009, GASTROENTEROLOGY, V137, P1102, DOI 10.1053/j.gastro.2009.05.053; Nielsen SR, 2016, NAT CELL BIOL, V18, P549, DOI 10.1038/ncb3340; Nywening TM, 2016, LANCET ONCOL, V17, P651, DOI 10.1016/S1470-2045(16)00078-4; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Olson OC, 2017, CELL REP, V19, P101, DOI 10.1016/j.celrep.2017.03.038; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155; Reichl P, 2015, HEPATOLOGY, V61, P930, DOI 10.1002/hep.27492; Sainz B, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9012369; Sainz B, 2015, GUT, V64, P1921, DOI 10.1136/gutjnl-2014-308935; Sainz B, 2014, CANCER RES, V74, P7309, DOI 10.1158/0008-5472.CAN-14-1354; Seifert L, 2016, GASTROENTEROLOGY, V150, P1659, DOI 10.1053/j.gastro.2016.02.070; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Wang WQ, 2016, BRIT J SURG, V103, P1189, DOI 10.1002/bjs.10187; Wang XC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0180-7; Weizman N, 2014, ONCOGENE, V33, P3812, DOI 10.1038/onc.2013.357; Werba G, 2016, CELL CYCLE, V15, P2095, DOI 10.1080/15384101.2016.1191251; Wu GL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.113; Zhang X, 2016, CANCER LETT, V381, P305, DOI 10.1016/j.canlet.2016.08.004; Zhou N, 2015, INT J MOL SCI, V16, P11966, DOI 10.3390/ijms160611966	48	35	35	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5469	5485		10.1038/s41388-019-0803-9	http://dx.doi.org/10.1038/s41388-019-0803-9			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30936462				2022-12-17	WOS:000473842500010
J	Echizen, K; Horiuchi, K; Aoki, Y; Yamada, Y; Minamoto, T; Oshima, H; Oshima, M				Echizen, Kanae; Horiuchi, Keigo; Aoki, Yayoi; Yamada, Yoichi; Minamoto, Toshinari; Oshima, Hiroko; Oshima, Masanobu			NF-kappa B-induced NOX1 activation promotes gastric tumorigenesis through the expansion of SOX2-positive epithelial cells	ONCOGENE			English	Article							OXIDATIVE STRESS; ROS GENERATION; STEM; INFLAMMATION; EXPRESSION; PHOSPHORYLATION; DIFFERENTIATION; SURVIVAL; OXIDASES; STOMACH	We previously showed that NADPH oxidase organizer 1 (Noxol), a component of NADPH oxidase 1 (NOX1), is a TNF-alpha-induced tumor-promoting factor in gastric tumorigenesis. However, the mechanism of NOX1-induced reactive oxygen species (ROS) signaling for the gastric tumorigenesis has not been understood. Here, we showed that expression of NOX1 complex components, including Noxol, but not other NOX family members was significantly upregulated in both mouse models for gastritis and gastric tumors, which was associated with increased ROS levels. We also found that NF-kB directly regulated NOXO1 expression in TNF-a-stimulated gastric cancer cells, suggesting that inflammation induces NOX1 complex activation through TNF-alpha/NF-kappa B pathway. Notably, in situ hybridization indicated that Noxol mRNA was detected in proliferating cells of gastritis and gastric tumors, and pharmacological inhibition of NOX activity significantly suppressed the proliferation of MKN45 gastric cancer cells and gastric hyperplasia of K19-C2mE mice. These results suggest that NOX1/ROS signaling has an important role in increased proliferation of stomach epithelial cells in the inflamed mucosa. Moreover, we found that expression of SOX2, a marker of gastric epithelial stem cells, was increased by NOX1/ROS signaling. Furthermore, disruption of Noxol in K19-C2mE mice significantly suppressed gastritis-associated metaplastic hyperplasia, a potent preneoplastic lesion, which was associated with decreased number of SOX2-positive cells. These results indicate that inflammation-induced Noxol expression is responsible for development of metaplastic hyperplasia in the stomach through an increase in SOX2-expressing undifferentiated epithelial cells. Therefore, inhibition of the NOX1/ROS signaling pathway is a possible strategy for prevention and therapy for gastric cancer development.	[Echizen, Kanae; Horiuchi, Keigo; Aoki, Yayoi; Oshima, Hiroko; Oshima, Masanobu] Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan; [Echizen, Kanae; Oshima, Masanobu] Japan Agcy Med Res & Dev, AMED, AMED CREST, Tokyo 1000004, Japan; [Yamada, Yoichi] Kanazawa Univ, Fac Elect & Comp Engn, Inst Sci & Engn, Kanazawa, Ishikawa 9201192, Japan; [Minamoto, Toshinari] Kanazawa Univ, Canc Res Inst, Div Translat & Clin Oncol, Kanazawa, Ishikawa 9208640, Japan; [Oshima, Hiroko; Oshima, Masanobu] Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa 9201192, Japan	Kanazawa University; Kanazawa University; Kanazawa University; Kanazawa University	Oshima, M (corresponding author), Kanazawa Univ, Canc Res Inst, Div Genet, Kanazawa, Ishikawa 9201192, Japan.; Oshima, M (corresponding author), Japan Agcy Med Res & Dev, AMED, AMED CREST, Tokyo 1000004, Japan.; Oshima, M (corresponding author), Kanazawa Univ, WPI Nano Life Sci Inst, Kanazawa, Ishikawa 9201192, Japan.	oshimam@staff.kanazawa-u.ac.jp	Oshima, Masanobu/F-9958-2014; Minamoto, Toshinari/D-8442-2015	Oshima, Masanobu/0000-0002-3304-0004; Minamoto, Toshinari/0000-0003-4168-996X; Oshima, Hiroko/0000-0001-6855-4008	AMEDCREST [JP17gm0410014]; AMED [JP18ck0106259]; Japan Agency for Medical Research and Development, Japan [JP15H02362, JP15K18405]; Ministry of Education, Culture, Sports, Science and Technology of Japan; Takeda Foundation; Mitsubishi Foundation	AMEDCREST; AMED(Japan Agency for Medical Research and Development (AMED)); Japan Agency for Medical Research and Development, Japan(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Foundation(Takeda Science Foundation (TSF)); Mitsubishi Foundation	We thank Ayako Tsuda and Manami Watanabe for their technical assistance. This work was supported by AMEDCREST (JP17gm0410014) and AMED (JP18ck0106259), Japan Agency for Medical Research and Development, Japan; Grants-in-Aid for Scientific Research (A) (JP15H02362), and Grants-in-Aid for Young Scientists (B) (JP15K18405) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and Takeda Foundation and The Mitsubishi Foundation.	Adachi Y, 2008, ONCOGENE, V27, P4921, DOI 10.1038/onc.2008.133; Arnold K, 2011, CELL STEM CELL, V9, P317, DOI 10.1016/j.stem.2011.09.001; Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Block K, 2012, NAT REV CANCER, V12, P627, DOI 10.1038/nrc3339; Butcher LD, 2017, CELL MOL GASTROENTER, V3, P316, DOI 10.1016/j.jcmgh.2017.02.002; Debbabi M, 2013, FASEB J, V27, P1733, DOI 10.1096/fj.12-216432; Echizen K, 2016, CANCER SCI, V107, P391, DOI 10.1111/cas.12901; El-Omar EM, 2003, GASTROENTEROLOGY, V124, P1193, DOI 10.1016/S0016-5085(03)00157-4; Goldenring JR, 2006, AM J PHYSIOL-GASTR L, V291, pG999, DOI 10.1152/ajpgi.00187.2006; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Joo JH, 2016, CANCER RES, V76, P855, DOI 10.1158/0008-5472.CAN-15-1512; Kamata T, 2009, CANCER SCI, V100, P1382, DOI 10.1111/j.1349-7006.2009.01207.x; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Kennedy CL, 2014, ONCOGENE, V33, P2540, DOI 10.1038/onc.2013.205; Machado JC, 2003, GASTROENTEROLOGY, V125, P364, DOI 10.1016/S0016-5085(03)00899-0; Maeda Y, 2016, CANCER PREV RES, V9, P253, DOI 10.1158/1940-6207.CAPR-15-0315; Morgan MJ, 2011, CELL RES, V21, P103, DOI 10.1038/cr.2010.178; Morgan MJ, 2010, MOL CELLS, V30, P1, DOI 10.1007/s10059-010-0105-0; Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006; Oshima H, 2014, ONCOGENE, V33, P3820, DOI 10.1038/onc.2013.356; Oshima H, 2004, EMBO J, V23, P1669, DOI 10.1038/sj.emboj.7600170; Oshima H, 2006, GASTROENTEROLOGY, V131, P1086, DOI 10.1053/j.gastro.2006.07.014; Oshima H, 2011, CANCER SCI, V102, P713, DOI 10.1111/j.1349-7006.2011.01847.x; Oshima M, 2005, CANCER RES, V65, P9147, DOI 10.1158/0008-5472.CAN-05-1936; Park MT, 2014, CELL DEATH DIFFER, V21, P1185, DOI 10.1038/cdd.2014.34; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Ristimaki A, 1997, CANCER RES, V57, P1276; Roy K, 2015, CLIN SCI, V128, P863, DOI 10.1042/CS20140542; Sarkar A, 2016, CELL REP, V16, P1929, DOI 10.1016/j.celrep.2016.07.034; Scheeren FA, 2014, NAT CELL BIOL, V16, P1238, DOI 10.1038/ncb3058; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Tan P, 2015, GASTROENTEROLOGY, V149, P1153, DOI 10.1053/j.gastro.2015.05.059; Terashima M, 2012, CLIN CANCER RES, V18, P5992, DOI 10.1158/1078-0432.CCR-12-1318; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421	38	35	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 30	2019	38	22					4250	4263		10.1038/s41388-019-0702-0	http://dx.doi.org/10.1038/s41388-019-0702-0			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IA1RB	30700829	Green Published, hybrid			2022-12-17	WOS:000469339100004
J	Han, QR; Xu, LJ; Lin, WH; Yao, XQ; Jiang, MH; Zhou, R; Sun, XG; Zhao, L				Han, Qinrui; Xu, Lijun; Lin, Weihao; Yao, Xueqing; Jiang, Muhong; Zhou, Rui; Sun, Xuegang; Zhao, Liang			Long noncoding RNA CRCMSL suppresses tumor invasive and metastasis in colorectal carcinoma through nucleocytoplasmic shuttling of HMGB2	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; CANCER; PROGRESSION; CHROMATIN; COLON; PROTEINS; PROMOTES; BINDING; CELLS; LIM	Long noncoding RNAs (lncRNAs) are pervasive transcripts that play pivotal roles in regulating chromatin dynamics, gene and protein expression. Aberrant expression and mutations of lncRNAs represent a driving force behind tumor invasion and metastasis, making them attractive cancer targets. However, most of the lncRNAs are still being discovered and conclusive experimental evidence for their functional relevance is still lacking for most malignancies. In this study, a differentially expressed 1ncRNA, designated as lnc-CRCMSL, is identified by microarray-based screenings on non-metastatic and metastatic CRC specimens. Lnc-CRCMSL is verified as an anti-metastatic gene and negatively correlated with the poor prognosis of CRC patients. Lnc-CRCMSL overexpression restricts tumor growth and metastasis in vivo and in vitro. Instead, lnc-CRCMSL silencing accelerates CRC cell proliferation and migration. RNA-pulldown assay identifies high mobility group box 2 (HMGB2) as a downstream protein of lnc-CRCMSL. Mechanically, lnc-CRCMSL physically binds to HMGB2 and stabilizes the localization of HMGB2 in the cytoplasm. Notably, lnc-CRCMSL knockdown lead to the shift of HMGB2 into nuclear, in which it triggers epithelial to mesenchymal transition (EMT) programming. Importantly, lnc-CRCMSL controls the cytoplasmic retention of HMGB2 and attenuates the interaction between HMGB2 and OCT4 to suppress EMT. Treatment of leptomycin B (LMB), a potent and specific nuclear export inhibitor, counteracts lnc-CRCMSL-mediated suppression of aggressive phenotypes and EMT process by accumulating the nuclear HMGB2. Conclusion Our data highlight the anti-metastatic role of lnc-CRCMSL in stabilizing HMGB2 through lncRNA-protein interactions in the cytoplasm, and suggest that targeting lnc-CRCMSL may represent a therapeutic opportunity for managing metastatic CRC.	[Han, Qinrui; Sun, Xuegang] Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China; [Xu, Lijun; Zhao, Liang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Xu, Lijun; Lin, Weihao; Jiang, Muhong; Zhou, Rui; Zhao, Liang] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China; [Lin, Weihao] Southern Med Univ, Sch Clin Med 2, Guangzhou 510515, Guangdong, Peoples R China; [Yao, Xueqing] Guangdong Gen Hosp, Dept Gastrointestinal Surg, Guangzhou 510120, Guangdong, Peoples R China; [Jiang, Muhong; Zhou, Rui; Zhao, Liang] Southern Med Univ, Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China	Sun, XG (corresponding author), Southern Med Univ, Sch Tradit Chinese Med, Guangzhou 510515, Guangdong, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou 510515, Guangdong, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou 510515, Guangdong, Peoples R China.	sxg_smu@126.com; liangsmu@foxmail.com	Zhao, Liang/T-9147-2019		National Natural Science Foundation of China [81572813, 81773082, 81573848, 81774172]; Guangdong Natural Science Foundation [2015A030313274]; Science and Technology Program of Guangzhou [1563000235]; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation [pdjhb0105]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Science and Technology Program of Guangzhou; Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation	This work was supported by the National Natural Science Foundation of China (Nos. 81572813, 81773082, 81573848, 81774172), Guangdong Natural Science Foundation (2015A030313274), Science and Technology Program of Guangzhou (1563000235) and Special Funds for the Cultivation of Guangdong College Students' Scientific and Technological Innovation (pdjhb0105).	Aird KM, 2016, J CELL BIOL, V215, P325, DOI 10.1083/jcb.201608026; Barsyte-Lovejoy D, 2006, CANCER RES, V66, P5330, DOI 10.1158/0008-5472.CAN-06-0037; Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634; Campbell PA, 2013, STEM CELLS, V31, P1107, DOI 10.1002/stem.1365; Cao CH, 2015, GASTROENTEROLOGY, V148, P415, DOI 10.1053/j.gastro.2014.10.012; Castillo-Quan JI, 2016, CELL, V167, P1670, DOI 10.1016/j.cell.2016.11.058; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Fu DY, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0219-0; Huang QH, 2018, CANCER METAST REV, V37, P75, DOI 10.1007/s10555-017-9713-x; Islam SS, 2016, MOL CARCINOGEN, V55, P537, DOI 10.1002/mc.22300; Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011; Kwon JH, 2010, CLIN CANCER RES, V16, P5511, DOI 10.1158/1078-0432.CCR-10-0825; Lagarde J, 2017, NAT GENET, V49, P1731, DOI 10.1038/ng.3988; Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112; Mandal G, 2018, BBA-MOL BASIS DIS, V1864, P2053, DOI 10.1016/j.bbadis.2018.03.010; Pennisi E, 2013, SCIENCE, V340, P910; Reeves R, 2015, DNA REPAIR, V36, P122, DOI 10.1016/j.dnarep.2015.09.015; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236; Takeuchi T, 2013, UROL J, V10, P960; Ueda T, 2010, BBA-GENE REGUL MECH, V1799, P114, DOI 10.1016/j.bbagrm.2009.11.005; Ugrinova I, 2009, BIOCHEMISTRY-US, V48, P6502, DOI 10.1021/bi9004304; Ulitsky I, 2016, NAT REV GENET, V17, P601, DOI 10.1038/nrg.2016.85; Wang H, 2014, CLIN CANCER RES, V20, P5835, DOI 10.1158/1078-0432.CCR-14-0485; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wang KC, 2011, NATURE, V472, P120, DOI 10.1038/nature09819; Wang P, 2016, ONCOL LETT, V12, P4605, DOI 10.3892/ol.2016.5288; Weidle UH, 2017, CANCER GENOM PROTEOM, V14, P143, DOI 10.21873/cgp.20027; Yue B, 2016, J GASTROEN HEPATOL, V31, P595, DOI 10.1111/jgh.13206; Zhang FF, 2016, CANCER LETT, V373, P203, DOI 10.1016/j.canlet.2016.01.037; Zhang Yan-Fei, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P126; Zhang YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep37821; Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739; Zhao YL, 2017, HEPATOL COMMUN, V1, P816, DOI 10.1002/hep4.1086; Zhi XL, 2015, HEPATOLOGY, V61, P598, DOI 10.1002/hep.27558	35	35	38	3	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 18	2019	38	16					3019	3032		10.1038/s41388-018-0614-4	http://dx.doi.org/10.1038/s41388-018-0614-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU3IV	30575817				2022-12-17	WOS:000465167600011
J	Umakoshi, M; Takahashi, S; Itoh, G; Kuriyama, S; Sasaki, Y; Yanagihara, K; Yashiro, M; Maeda, D; Goto, A; Tanaka, M				Umakoshi, Michinobu; Takahashi, So; Itoh, Go; Kuriyama, Sei; Sasaki, Yuto; Yanagihara, Kazuyoshi; Yashiro, Masakazu; Maeda, Daichi; Goto, Akiteru; Tanaka, Masamitsu			Macrophage-mediated transfer of cancer-derived components to stromal cells contributes to establishment of a pro-tumor microenvironment	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CARCINOMA-ASSOCIATED-FIBROBLASTS; MESOTHELIAL CELLS; INVASION; EXOSOMES; PROMOTE; METASTASIS; ROLES; BETA	Tumor-derived extracellular vesicles (TEVs) secreted into the blood create a pre-metastatic niche in distant organs; however, it is unclear how TEVs are delivered and how they affect stromal cells in the tumor microenvironment. Tumor-associated macrophages (TAMs) have pivotal roles in cancer progression by interacting with cancer cells and other stromal cells. Here, we report a novel function of TAMs: delivery and transmission of TEV contents. TEV-incorporating macrophages (TEV-M Phi s) showed increased invasiveness and were disseminated widely. Upon contact with host stromal cells (peritoneal mesothelial cells (PMCs), fibroblasts, and endothelial cells), TEV-MFs released membrane blebs containing TEVs, a process dependent upon localized activation of caspase-3 in M Phi s. Scattered blebs were incorporated into stromal cells, leading to transfer of cancer-derived RNA and proteins such as TGF-beta, activated Src, Wnt3, and HIF1 alpha. TEV-M Phi-secreted blebs containing cancer-derived components contributed to myofibroblastic changes in recipient stromal cells. TEVs delivered by M Phi s penetrated deep into the parenchyma of the stomach in TEV-injected mice, and transmitted TEVs to PMCs lining the stomach surface; this process induced PMCs to undergo mesothelial-mesenchymal transition. PMCs infiltrated the gastric wall and created a niche, thereby promoting tumor invasion. Depletion of M Phi s prevented these events. Moreover, TEV-M Phi s created a pro-metastatic niche. Taken together, these results suggest a novel function for TAMs: transfer of cancer-derived components to surrounding stromal cells and induction of a pro-tumor microenvironment via an increase in the number of CAF-like cells.	[Umakoshi, Michinobu; Takahashi, So; Itoh, Go; Kuriyama, Sei; Sasaki, Yuto; Tanaka, Masamitsu] Akita Univ, Dept Mol Med & Biochem, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan; [Umakoshi, Michinobu; Maeda, Daichi; Goto, Akiteru] Akita Univ, Grad Sch Med, Dept Cellular & Organ Pathol, 1-1-1 Hondo, Akita 0108543, Japan; [Takahashi, So] Akita Univ, Grad Sch Med, Dept Gastroenterol & Neurol, 1-1-1 Hondo, Akita 0108543, Japan; [Sasaki, Yuto] Akita Univ, Fac & Grad Sch Engn & Resource Sci, Dept Life Sci, 1-1 Tegata Gakuenmachi, Akita 0108502, Japan; [Yanagihara, Kazuyoshi] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Pathol, 6-5-1 Kashiwashi, Chiba 2770882, Japan; [Yashiro, Masakazu] Osaka City Univ, Dept Surg Oncol, Grad Sch Med, Abeno Ku, 1-4-3 Asahimachi, Osaka 5458545, Japan; [Maeda, Daichi] Osaka Univ, Grad Sch Med, Dept Clin Genom, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan	Akita University; Akita University; Akita University; Akita University; National Cancer Center - Japan; Osaka Metropolitan University; Osaka University	Tanaka, M (corresponding author), Akita Univ, Dept Mol Med & Biochem, Grad Sch Med, 1-1-1 Hondo, Akita 0108543, Japan.; Goto, A (corresponding author), Akita Univ, Grad Sch Med, Dept Cellular & Organ Pathol, 1-1-1 Hondo, Akita 0108543, Japan.	akigoto@med.akita-u.ac.jp; mastanak@med.akita-u.ac.jp	Goto, Akiteru/P-5775-2014; Kuriyama, Sei/AAV-2368-2020	Kuriyama, Sei/0000-0002-5502-7177; Goto, Akiteru/0000-0001-8776-9004; Takahashi, So/0000-0002-0321-2784	JSPS KAKENHI Grants [17K19579, 16H04691]; Princess Takamatsu Cancer Research Fund [14-24620]; Takeda Science Foundation; Project Mirai Cancer Research	JSPS KAKENHI Grants; Princess Takamatsu Cancer Research Fund; Takeda Science Foundation(Takeda Science Foundation (TSF)); Project Mirai Cancer Research	This work was supported by JSPS KAKENHI Grants (Nos. 17K19579 and 16H04691 to M. Tanaka), a Research Grant from the Princess Takamatsu Cancer Research Fund (14-24620 to M. Tanaka), the Takeda Science Foundation, and Project Mirai Cancer Research grants to M. Tanaka.	Antwi-Baffour SS, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-015-0174-7; Bao XL, 2012, MOL VIS, V18, P1983; Barile L, 2017, PHARMACOL THERAPEUT, V174, P63, DOI 10.1016/j.pharmthera.2017.02.020; Che DH, 2017, MOL IMMUNOL, V90, P197, DOI 10.1016/j.molimm.2017.06.018; Chen R, 2012, BIO PROTOC, V2, pISS3; Ciardiello C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17020175; Crescitelli R, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20677; Fackler OT, 2008, J CELL BIOL, V181, P879, DOI 10.1083/jcb.200802081; Feng D, 2010, TRAFFIC, V11, P675, DOI 10.1111/j.1600-0854.2010.01041.x; Fuyuhiro Y, 2011, BRIT J CANCER, V105, P996, DOI 10.1038/bjc.2011.330; Genard G, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00828; Hashimoto O, 2016, J PATHOL, V240, P211, DOI 10.1002/path.4769; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Itoh G, 2017, ONCOGENE, V36, P4434, DOI 10.1038/onc.2017.49; Lin SS, 2017, ONCOTARGET, V8, P110426, DOI 10.18632/oncotarget.22786; Liu CY, 2013, LAB INVEST, V93, P844, DOI 10.1038/labinvest.2013.69; Lv ZD, 2013, MOL CELL BIOCHEM, V377, P177, DOI 10.1007/s11010-013-1583-0; Maia J, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00018; Mulcahy LA, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24641; Naito Y, 2017, CELL MOL LIFE SCI, V74, P697, DOI 10.1007/s00018-016-2346-3; Nakase I, 2015, SCI REP-UK, V5, DOI 10.1038/srep10300; Patel A, 2016, LIFE SCI, V157, P52, DOI 10.1016/j.lfs.2016.05.036; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Qian ZR, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/649161; Roh-Johnson M, 2017, DEV CELL, V43, P549, DOI 10.1016/j.devcel.2017.11.003; Rothschild PR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07329-y; Rynne-Vidal A, 2015, CANCERS, V7, P1994, DOI 10.3390/cancers7040872; Sandoval P, 2013, J PATHOL, V231, P517, DOI 10.1002/path.4281; Satoyoshi R, 2015, ONCOGENE, V34, P3176, DOI 10.1038/onc.2014.246; Shan B, 2008, J BIOL CHEM, V283, P21065, DOI 10.1074/jbc.M802786200; Shimoda M, 2017, BBA-MOL CELL RES, V1864, P1989, DOI 10.1016/j.bbamcr.2017.05.027; Song WZ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01106; Steinbichler TB, 2017, SEMIN CANCER BIOL, V44, P170, DOI 10.1016/j.semcancer.2017.02.006; Syn N, 2016, TRENDS PHARMACOL SCI, V37, P606, DOI 10.1016/j.tips.2016.04.006; Takahashi H, 2017, ONCOTARGET, V8, P8633, DOI 10.18632/oncotarget.14374; Tanaka M, 2017, CANCER RES, V77, P684, DOI 10.1158/0008-5472.CAN-16-0964; Wang S, 2016, ONCOTARGET, V7, P8809, DOI 10.18632/oncotarget.6604; Yanagihara K, 2004, CANCER SCI, V95, P575, DOI 10.1111/j.1349-7006.2004.tb02489.x; Yuyama K, 2012, J BIOL CHEM, V287, P10977, DOI 10.1074/jbc.M111.324616; Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027; Zhou B, 2008, NATURE, V454, P109, DOI 10.1038/nature07060	42	35	36	0	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2019	38	12					2162	2176		10.1038/s41388-018-0564-x	http://dx.doi.org/10.1038/s41388-018-0564-x			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HP6UR	30459356				2022-12-17	WOS:000461822600012
J	Li, QG; Wei, P; Wu, JT; Zhang, M; Li, GC; Li, YQ; Xu, Y; Li, XX; Xie, DC; Cai, SJ; Xie, KP; Li, DW				Li, Qingguo; Wei, Ping; Wu, Jitao; Zhang, Meng; Li, Guichao; Li, Yaqi; Xu, Ye; Li, Xinxiang; Xie, Dacheng; Cai, Sanjun; Xie, Keping; Li, Dawei			The FOXC1/FBP1 signaling axis promotes colorectal cancer proliferation by enhancing the Warburg effect	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; INDICATES POOR-PROGNOSIS; HEPATOCELLULAR-CARCINOMA; COLON-CANCER; GLUCOSE-METABOLISM; TUMOR-METASTASIS; FOXM1 PROMOTES; EXPRESSION; GROWTH; PROGRESSION	Aberrant expression of Forkhead box (FOX) transcription factors plays vital roles in carcinogenesis. However, the function of the FOX family member FOXC1 in maintenance of colorectal cancer (CRC) malignancy is unknown. Herein, FOXC1 expression in CRC specimens in The Cancer Genome Atlas (TCGA) cohort was analyzed and validated using immunohistochemistry with a tissue microarray. The effect of FOXC1 expression on proliferation of and glycolysis in CRC cells was assessed by altering its expression in vitro and in vivo. Mechanistic investigation was carried out using cell and molecular biological approaches. Our results showed that FOXC1 expression was higher in CRC specimens than in adjacent benign tissue specimens. Univariate survival analyses of the patients from whom the study specimens were obtained, and validated cohorts indicated that ectopic FOXC1 expression was significantly correlated with shortened survival. Silencing FOXC1 expression in CRC cells inhibited their proliferation and colony formation and decreased their glucose consumption and lactate production. In contrast, FOXC1 overexpression had the opposite effect. Furthermore, increased expression of FOXC1 downregulated that of a key glycolytic enzyme, fructose-1,6-bisphosphatase 1 (FBP1). Mechanistically, FOXC1 bound directly to the promoter regions of the FBP1 gene and negatively regulated its transcriptional activity. Collectively, aberrant FBP1 expression contributed to CRC tumorigenicity, and decreased FBP1 expression coupled with increased FOXC1 expression provided better prognostic information than did FOXC1 expression alone. Therefore, the FOXC1/FBP1 axis induces CRC cell proliferation, reprograms metabolism in CRCs, and constitutes potential prognostic predictors and therapeutic targets for CRC.	[Li, Qingguo; Li, Yaqi; Xu, Ye; Li, Xinxiang; Cai, Sanjun; Li, Dawei] Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, Shanghai, Peoples R China; [Li, Qingguo; Wei, Ping; Zhang, Meng; Li, Guichao; Li, Yaqi; Xu, Ye; Li, Xinxiang; Cai, Sanjun; Li, Dawei] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China; [Wei, Ping; Zhang, Meng] Fudan Univ, Shanghai Canc Ctr, Dept Pathol, Shanghai, Peoples R China; [Wei, Ping] Fudan Univ, Shanghai Canc Ctr, Inst Canc, Shanghai, Peoples R China; [Wu, Jitao] Yantai Yuhuangding Hosp, Dept Urol, Yantai, Peoples R China; [Li, Guichao] Fudan Univ, Dept Radiat Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China; [Xie, Dacheng; Xie, Keping] Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA	Fudan University; Fudan University; Fudan University; Fudan University; Fudan University; University of Texas System; UTMD Anderson Cancer Center	Li, DW (corresponding author), Fudan Univ, Dept Colorectal Surg, Shanghai Canc Ctr, Shanghai, Peoples R China.; Li, DW (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai, Peoples R China.; Xie, KP (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.	kepingxie@gmail.com; li_dawei@fudan.edu.cn	xu, ye/GQO-8972-2022		National Science Foundation of China [81472222, 81702353, 81772583, 81572254, 81372646, 81302097, 81672374]; Shanghai Rising-Star Program [17QA1400900]; Shanghai Municipal Natural Science Foundation [17ZR1406400]; Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai [2017YQ046]; National Key Basic Research Program of China [2014CBA02002]; National Cancer Institute, National Institutes of Health [R01-CA129956, R01-CA148954, R01CA152309, R01CA172233, R01CA195651]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Rising-Star Program; Shanghai Municipal Natural Science Foundation; Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai; National Key Basic Research Program of China(National Basic Research Program of China); National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by grants from the National Science Foundation of China (81472222, 81702353, 81772583, 81572254, 81372646, 81302097, and 81672374) and Shanghai Rising-Star Program(17QA1400900), Shanghai Municipal Natural Science Foundation (17ZR1406400), Municipal Human Resources Development Program for Outstanding Young Talents in Medical and Health Sciences in Shanghai (2017YQ046), National Key Basic Research Program of China (2014CBA02002) and grants R01-CA129956, R01-CA148954, R01CA152309, R01CA172233, and R01CA195651 from the National Cancer Institute, National Institutes of Health.	Aravalli RN, 2015, GASTROENTEROLOGY, V149, P861, DOI 10.1053/j.gastro.2015.08.032; Cekaite L, 2016, ONCOTARGET, V7, P6476, DOI 10.18632/oncotarget.6390; Courtnay R, 2015, MOL BIOL REP, V42, P841, DOI 10.1007/s11033-015-3858-x; Cui JJ, 2014, CLIN CANCER RES, V20, P2595, DOI 10.1158/1078-0432.CCR-13-2407; Dang CV, 2008, ERNST SCHERING FOUND, V4, P35, DOI 10.1007/2789_2008_088; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dong CF, 2013, CANCER CELL, V23, P316, DOI 10.1016/j.ccr.2013.01.022; Golson ML, 2016, DEVELOPMENT, V143, P4558, DOI 10.1242/dev.112672; Guo K, 2017, CLIN CANCER RES, V23, P687, DOI 10.1158/1078-0432.CCR-16-1064; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hannenhalli S, 2009, NAT REV GENET, V10, P233, DOI 10.1038/nrg2523; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hirata H, 2016, CANCER RES, V76, P3265, DOI 10.1158/0008-5472.CAN-15-2601; Huang WJ, 2015, GASTROENTEROLOGY, V149, P1053, DOI 10.1053/j.gastro.2015.05.058; Jensen TW, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv148; Kaneda H, 2010, CANCER RES, V70, P2053, DOI 10.1158/0008-5472.CAN-09-2161; Khan AO, 2013, J AAPOS, V17, P105, DOI 10.1016/j.jaapos.2012.09.011; Kondaveeti Y, 2015, CANCER LETT, V364, P44, DOI 10.1016/j.canlet.2015.04.025; Li B, 2014, NATURE, V513, P251, DOI 10.1038/nature13557; Li DW, 2013, CLIN CANCER RES, V19, P62, DOI 10.1158/1078-0432.CCR-12-1588; Li DW, 2011, CLIN CANCER RES, V17, P3558, DOI 10.1158/1078-0432.CCR-10-2729; Li QG, 2016, INT J CANCER, V139, P2502, DOI 10.1002/ijc.30388; Li QG, 2016, MOL CANCER RES, V14, P830, DOI 10.1158/1541-7786.MCR-16-0032; Li QG, 2015, AM J CANCER RES, V5, P2022; Liu X, 2010, ONCOGENE, V29, P442, DOI 10.1038/onc.2009.332; Marin-Hernandez A, 2006, FEBS J, V273, P1975, DOI 10.1111/j.1742-4658.2006.05214.x; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nagel S, 2014, GENE CHROMOSOME CANC, V53, P917, DOI 10.1002/gcc.22204; Paylakhi SH, 2013, EXP EYE RES, V111, P112, DOI 10.1016/j.exer.2013.03.009; PIERROU S, 1994, EMBO J, V13, P5002, DOI 10.1002/j.1460-2075.1994.tb06827.x; Quan M, 2015, CANCER RES, V75, P4778, DOI 10.1158/0008-5472.CAN-14-1952; Ray PS, 2010, CANCER RES, V70, P3870, DOI 10.1158/0008-5472.CAN-09-4120; Shi M, 2014, CLIN CANCER RES, V20, P4370, DOI 10.1158/1078-0432.CCR-14-0186; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Somerville TDD, 2015, CANCER CELL, V28, P329, DOI 10.1016/j.ccell.2015.07.017; Sun J, 2016, ONCOTARGET, V7, P43534, DOI 10.18632/oncotarget.9780; Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994; Velpula KK, 2013, CANCER RES, V73, P7277, DOI 10.1158/0008-5472.CAN-13-1868; Walenta S, 2000, CANCER RES, V60, P916; Wang J, 2012, ONCOGENE, V31, P4798, DOI 10.1038/onc.2011.635; Wang L, 2013, TUMOR BIOL, V34, P853, DOI 10.1007/s13277-012-0617-7; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weber GF, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00257; Wechatekar K, 2005, CLIN RADIOL, V60, P1143, DOI 10.1016/j.crad.2005.05.018; Wei LX, 2013, TUMOR BIOL, V34, P941, DOI 10.1007/s13277-012-0629-3; Weng WH, 2016, CLIN CANCER RES, V22, P4947, DOI 10.1158/1078-0432.CCR-16-0360; Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243; Xia LM, 2013, HEPATOLOGY, V57, P610, DOI 10.1002/hep.26029; Xu ZY, 2012, INT J BIOL SCI, V8, P1130, DOI 10.7150/ijbs.4769; Yang WW, 2012, NAT CELL BIOL, V14, P1295, DOI 10.1038/ncb2629; Zhang J, 2016, MOL CELL BIOCHEM, V411, P331, DOI 10.1007/s11010-015-2595-8; Zhang N, 2011, CANCER CELL, V20, P427, DOI 10.1016/j.ccr.2011.08.016; Zhang Y, 2013, CANCER BIOL THER, V14, P81, DOI 10.4161/cbt.22958; Zhou AD, 2016, NAT CELL BIOL, V18, P954, DOI 10.1038/ncb3396; Zhu Y, 2015, ONCOTARGET, V6, P21443, DOI 10.18632/oncotarget.4167	56	35	37	1	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2019	38	4					483	496		10.1038/s41388-018-0469-8	http://dx.doi.org/10.1038/s41388-018-0469-8			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HI6UB	30171256				2022-12-17	WOS:000456589800003
J	Hodgkinson, K; Forrest, LA; Vuong, N; Garson, K; Djordjevic, B; Vanderhyden, BC				Hodgkinson, Kendra; Forrest, Laura A.; Nhung Vuong; Garson, Kenneth; Djordjevic, Bojana; Vanderhyden, Barbara C.			GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer	ONCOGENE			English	Article							MESENCHYMAL TRANSITION; PI3K/AKT PATHWAY; E-CADHERIN; GROWTH; ALPHA; 17-BETA-ESTRADIOL; INVASION; ACTIVATION; TARGETS; CELLS	Estrogenic hormone replacement therapy increases the risk of developing ovarian cancer, and estrogen promotes tumour initiation and growth in mouse models of this disease. GREB1 (Growth regulation by estrogen in breast cancer 1) is an ESR1 (estrogen receptor 1)-upregulated protein which may mediate estrogen action. GREB1 knockdown prevents hormone-driven proliferation of several breast and prostate cancer cell lines and prolongs survival of mice engrafted with ovarian cancer cells, but its mechanism of action remains unclear. In this study, we explored GREB1 function in ovarian cancer. GREB1 overexpression in ovarian cancer cell lines increased cell proliferation and migration and promoted a mesenchymal morphology associated with increased Col1a2, which encodes a collagen I subunit. GREB1 knockdown inhibited proliferation and promoted an epithelial morphology associated with decreased Col1a2. In human tissues, GREB1 was expressed in all ESR1-expressing tissues throughout the normal female reproductive tract, in addition to several tissues that did not show ESR1 expression. In a TMA of ovarian cancer cases, GREB1 was expressed in 75-85% of serous, endometrioid, mucinous, and clear cell carcinomas. Serous, endometrioid, and mucinous ovarian cancers were almost always positive for either ESR1 or GREB1, suggesting a possible reliance on signalling through ESR1 and/or GREB1. Targeting GREB1 may inhibit tumour-promoting pathways both downstream and independent of ESR1 and is therefore a possible treatment strategy worthy of further investigation.	[Hodgkinson, Kendra; Forrest, Laura A.; Nhung Vuong; Garson, Kenneth; Vanderhyden, Barbara C.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Hodgkinson, Kendra; Forrest, Laura A.; Nhung Vuong; Garson, Kenneth; Vanderhyden, Barbara C.] Ottawa Hosp, Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada; [Djordjevic, Bojana] Univ Ottawa, Ottawa Hosp, Dept Pathol & Lab Med, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute	Vanderhyden, BC (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada.; Vanderhyden, BC (corresponding author), Ottawa Hosp, Res Inst, Ctr Canc Therapeut, Ottawa, ON, Canada.	bvanderhyden@ohri.ca			Canadian Institutes of Health Research	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We thank Dr. Kenneth S. Korach for kindly providing us with his conditional ESR1-deletion mice (30). We also thank the tissue donors and their families, who made this research possible. This work was supported by a grant from the Canadian Institutes of Health Research (BCV), a donation from The Carol Annibale Ovarian Cancer Foundation, Ontario Graduate Scholarships (to K.H., N.V.), and a Queen Elizabeth II Graduate Scholarship in Science and Technology (to K.H.).	Allred DC, 2010, MODERN PATHOL, V23, pS52, DOI 10.1038/modpathol.2010.55; Armaiz-Pena GN, 2009, CLIN CANCER RES, V15, P2971, DOI 10.1158/1078-0432.CCR-08-2525; Brodeur AC, 2017, INT J NEPHROL RENOV, V10, P251, DOI 10.2147/IJNRD.S141393; Cardenas H, 2014, EPIGENETICS-US, V9, P1461, DOI 10.4161/15592294.2014.971608; Cheng JC, 2011, CANCER LETT, V304, P107, DOI 10.1016/j.canlet.2011.02.008; Deschenes J, 2007, J BIOL CHEM, V282, P17335, DOI 10.1074/jbc.C700030200; Ding JX, 2006, GYNECOL ONCOL, V103, P623, DOI 10.1016/j.ygyno.2006.04.023; Ebell MH, 2016, AM J PREV MED, V50, P384, DOI 10.1016/j.amepre.2015.09.023; Gamwell LF, 2012, BIOL REPROD, V87, DOI 10.1095/biolreprod.112.100347; Gapstur SM, 2015, LANCET, V385, P1835, DOI 10.1016/S0140-6736(14)61687-1; Gershenson DM, 2017, J CLIN ONCOL, V35, P1103, DOI 10.1200/JCO.2016.71.0632; Ghosh MG, 2000, CANCER RES, V60, P6367; Gupta PB, 2007, CANCER RES, V67, P2062, DOI 10.1158/0008-5472.CAN-06-3895; Haakensen VD, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-332; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1043/1543-2165-134.6.907, 10.1200/JCO.2009.25.6529, 10.1200/JOP.777003]; Hewitt SC, 2010, FASEB J, V24, P4660, DOI 10.1096/fj.10-163428; Hnatyszyn HJ, 2010, BREAST CANCER RES TR, V122, P371, DOI 10.1007/s10549-009-0584-x; Hua KQ, 2008, INT J ONCOL, V33, P959, DOI 10.3892/ijo_00000083; Laviolette LA, 2014, INT J CANCER, V135, P1072, DOI 10.1002/ijc.28741; Laviolette LA, 2010, ENDOCRINOLOGY, V151, P929, DOI 10.1210/en.2009-0602; Lee Kyu-Sup, 1992, Kurume Medical Journal, V39, P285; Lim D, 2013, PATHOLOGY, V45, P229, DOI 10.1097/PAT.0b013e32835f2264; Lippman Marc E, 2008, Trans Am Clin Climatol Assoc, V119, P77; Lu ZY, 2014, MOL MED REP, V10, P2433, DOI 10.3892/mmr.2014.2561; Mabuchi S, 2015, GYNECOL ONCOL, V137, P173, DOI 10.1016/j.ygyno.2015.02.003; McCloskey CW, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00053; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Mori Y, 2008, EXP CELL RES, V314, P1094, DOI 10.1016/j.yexcr.2007.12.010; Mullany LK, 2014, MOL ENDOCRINOL, V28, P127, DOI 10.1210/me.2013-1308; Okano K, 2012, MOL CELL BIOCHEM, V369, P247, DOI 10.1007/s11010-012-1388-6; Pellegrini C, 2012, FERTIL STERIL, V98, P1200, DOI 10.1016/j.fertnstert.2012.06.056; Rae JM, 2006, PROSTATE, V66, P886, DOI 10.1002/pros.20403; Rae JM, 2005, BREAST CANCER RES TR, V92, P141, DOI 10.1007/s10549-005-1483-4; Ribeiro JR, 2014, J STEROID BIOCHEM, V143, P160, DOI 10.1016/j.jsbmb.2014.02.010; SAWADA M, 1990, INT J CANCER, V45, P359, DOI 10.1002/ijc.2910450225; Shu DY, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20611; Spillman MA, 2010, CANCER RES, V70, P8927, DOI 10.1158/0008-5472.CAN-10-1238; Sun J, 2007, MOL ENDOCRINOL, V21, P2651, DOI 10.1210/me.2007-0082; Sundar S, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4443; Tan S, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3644; Welboren WJ, 2009, ENDOCR-RELAT CANCER, V16, P1073, DOI 10.1677/ERC-09-0086; Yan Y, 2013, MOL CELL BIOCHEM, V378, P1, DOI 10.1007/s11010-013-1579-9	42	35	37	3	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 1	2018	37	44					5873	5886		10.1038/s41388-018-0377-y	http://dx.doi.org/10.1038/s41388-018-0377-y			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GY9EX	29973689	Green Published, hybrid			2022-12-17	WOS:000448943100005
J	Rehrauer, H; Wu, LC; Blum, W; Pecze, L; Henzi, T; Serre-Beinier, V; Aquino, C; Vrugt, B; de Perrot, M; Schwaller, B; Felley-Bosco, E				Rehrauer, Hubert; Wu, Licun; Blum, Walter; Pecze, Lazslo; Henzi, Thomas; Serre-Beinier, Veronique; Aquino, Catherine; Vrugt, Bart; de Perrot, Marc; Schwaller, Beat; Felley-Bosco, Emanuela			How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations	ONCOGENE			English	Article							T-CELLS; MOUSE MODEL; GENE; CANCER; MURINE; IDENTIFICATION; EXPRESSION; NF2; REPOPULATION; CHEMOTHERAPY	Chronic exposure to intraperitoneal asbestos triggered a marked response in the mesothelium well before tumor development. Macrophages, mesothelial precursor cells, cytokines, and growth factors accumulated in the peritoneal lavage. Transcriptome profiling revealed YAP/TAZ activation in inflamed mesothelium with further activation in tumors, paralleled by increased levels of cells with nuclear YAP/TAZ. Arg1 was one of the highest upregulated genes in inflamed tissue and tumor. Inflamed tissue showed increased levels of single-nucleotide variations, with an RNA-editing signature, which were even higher in the tumor samples. Subcutaneous injection of asbestos-treated, but tumor-free mice with syngeneic mesothelioma tumor cells resulted in a significantly higher incidence of tumor growth when compared to naive mice supporting the role of the environment in tumor progression.	[Rehrauer, Hubert; Aquino, Catherine] Swiss Fed Inst Technol, Funct Genom Ctr Zurich, CH-8057 Zurich, Switzerland; [Rehrauer, Hubert; Aquino, Catherine] Univ Zurich, CH-8057 Zurich, Switzerland; [Wu, Licun; de Perrot, Marc] Univ Toronto, Toronto Gen Hosp, Univ Hlth Network, Latner Thorac Surg Res Labs,Div Thorac Surg, Toronto, ON, Canada; [Blum, Walter; Pecze, Lazslo; Henzi, Thomas; Schwaller, Beat] Univ Fribourg, Dept Med, Unit Anat, Route Albert Gockel 1, CH-1700 Fribourg, Switzerland; [Serre-Beinier, Veronique] Univ Hosp Geneva, Dept Thorac Surg, Geneva, Switzerland; [Vrugt, Bart] Univ Hosp Zurich, Inst Surg Pathol, Zurich, Switzerland; [Felley-Bosco, Emanuela] Univ Hosp Zurich, Lab Mol Oncol, Lungen & Thoraxonkol Zentrum, Sternwartstr 14, CH-8091 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Fribourg; University of Geneva; University of Zurich; University Zurich Hospital; University of Zurich; University Zurich Hospital	Felley-Bosco, E (corresponding author), Univ Hosp Zurich, Lab Mol Oncol, Lungen & Thoraxonkol Zentrum, Sternwartstr 14, CH-8091 Zurich, Switzerland.	emanuela.felley-bosco@usz.ch	Felley-Bosco, Emanuela/E-7484-2017; Wu, Licun/AAL-9596-2021; Serre-Beinier, Véronique/T-8064-2019	Felley-Bosco, Emanuela/0000-0002-3408-0294; Wu, Licun/0000-0003-4803-9361; Serre-Beinier, Véronique/0000-0002-6016-1645; de Perrot, Marc/0000-0003-2000-9427; Schwaller, Beat/0000-0002-8277-7555	Swiss National Science Foundation Sinergia Grant CRSII3 [147697]	Swiss National Science Foundation Sinergia Grant CRSII3(Swiss National Science Foundation (SNSF))	The project is financed by the Swiss National Science Foundation Sinergia Grant CRSII3 #147697.	Altomare DA, 2005, CANCER RES, V65, P8090, DOI 10.1158/0008-5472.CAN-05-2312; Banchereau J, 2005, NAT REV IMMUNOL, V5, P296, DOI 10.1038/nri1592; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bera TK, 2000, MOL CELL BIOL, V20, P2902, DOI 10.1128/MCB.20.8.2902-2906.2000; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Blum W, 2015, IN VITRO CELL DEV-AN, V51, P714, DOI 10.1007/s11626-015-9885-z; Bott M, 2011, NAT GENET, V43, P668, DOI 10.1038/ng.855; Broad Institute TCGA Genome Data Analysis Center, 2014, PARADIGM PATHW AN MR; Bueno R, 2016, NAT GENET, V48, P407, DOI 10.1038/ng.3520; Burt BM, 2011, CANCER-AM CANCER SOC, V117, P5234, DOI 10.1002/cncr.26143; Carmona R, 2011, J CELL MOL MED, V15, P1200, DOI 10.1111/j.1582-4934.2010.01087.x; Chen LL, 2013, NAT MED, V19, P209, DOI 10.1038/nm.3043; CHERIE AL, 2016, J THORAC ONCOL, V11, P1765, DOI DOI 10.1016/J.JTHO.2016.06.022; Cherkassky L, 2016, J CLIN INVEST, V126, P3130, DOI 10.1172/JCI83092; Chow MT, 2012, IMMUNOL CELL BIOL, V90, P983, DOI 10.1038/icb.2012.46; Cornelissen R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106742; Crews LA, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-014-0370-3; Dixit R, 2013, DEVELOPMENT, V140, P4398, DOI 10.1242/dev.098079; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Dostert C, 2008, SCIENCE, V320, P674, DOI 10.1126/science.1156995; Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137; Echeverry N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.124; Fleury-Feith J, 2003, ONCOGENE, V22, P3799, DOI 10.1038/sj.onc.1206593; Foley-Comer AJ, 2002, J CELL SCI, V115, P1383; Frei C, 2011, CARCINOGENESIS, V32, P1324, DOI 10.1093/carcin/bgr127; Fujii M, 2012, J EXP MED, V209, P479, DOI 10.1084/jem.20111653; Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506; George CX, 1999, GENE, V229, P203, DOI 10.1016/S0378-1119(99)00017-7; GORMLEY IP, 1980, CARCINOGENESIS, V1, P219, DOI 10.1093/carcin/1.3.219; Hara T, 1999, IMMUNITY, V11, P567, DOI 10.1016/S1074-7613(00)80132-6; Huaux F, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0158-0; Jean D, 2011, AM J PATHOL, V178, P881, DOI 10.1016/j.ajpath.2010.10.039; Jiang QF, 2017, NAT REV CANCER, V17, P381, DOI 10.1038/nrc.2017.23; Jinushi M, 2011, P NATL ACAD SCI USA, V108, P12425, DOI 10.1073/pnas.1106645108; Jongsma J, 2008, CANCER CELL, V13, P261, DOI 10.1016/j.ccr.2008.01.030; Kadariya Y, 2016, CANCER PREV RES, V9, P406, DOI 10.1158/1940-6207.CAPR-15-0347; Khanna S, 2016, J THORAC ONCOL, V11, P1993, DOI 10.1016/j.jtho.2016.07.033; Kitayama J, 2014, CELL IMMUNOL, V288, P8, DOI 10.1016/j.cellimm.2014.01.008; Liao Y, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt214; Lievense LA, 2016, J THORAC ONCOL, V11, P1755, DOI 10.1016/j.jtho.2016.06.021; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mapara MY, 2004, J CLIN ONCOL, V22, P1136, DOI 10.1200/JCO.2004.10.041; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; MOALLI PA, 1987, AM J PATHOL, V128, P426; Moore DA, 2013, J MOL DIAGN, V15, P687, DOI 10.1016/j.jmoldx.2013.04.008; Mori M, 2014, CELL, V156, P893, DOI 10.1016/j.cell.2013.12.043; Musah S, 2014, P NATL ACAD SCI USA, V111, P13805, DOI 10.1073/pnas.1415330111; Napolitano A, 2016, ONCOGENE, V35, P1996, DOI 10.1038/onc.2015.243; Nishikura K, 2016, NAT REV MOL CELL BIO, V17, P83, DOI 10.1038/nrm.2015.4; Parrotta R, 2017, J THORAC ONCOL, V12, P1309, DOI 10.1016/j.jtho.2017.03.023; PASS HI, 1995, ANN THORAC SURG, V59, P835, DOI 10.1016/0003-4975(95)00045-M; Piccolo S, 2014, PHYSIOL REV, V94, P1287, DOI 10.1152/physrev.00005.2014; Ren YZR, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.193458; Rinkevich Y, 2012, NAT CELL BIOL, V14, P1251, DOI 10.1038/ncb2610; Robinson C, 2011, EUR J CANCER, V47, P151, DOI 10.1016/j.ejca.2010.08.015; Roca H, 2009, J BIOL CHEM, V284, P34342, DOI 10.1074/jbc.M109.042671; SEKIDO Y, 1995, CANCER RES, V55, P1227; Shi YD, 2012, CLIN CANCER RES, V18, P4646, DOI 10.1158/1078-0432.CCR-12-0599; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Soucie EL, 2016, SCIENCE, V351, DOI 10.1126/science.aad5510; Strowig T, 2012, NATURE, V481, P278, DOI 10.1038/nature10759; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800; Suraokar MB, 2014, ANN ONCOL, V25, P1184, DOI 10.1093/annonc/mdu127; Swift J, 2013, SCIENCE, V341, DOI 10.1126/science.1240104; Tamminen JA, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.29; Tartour E, 2011, CANCER METAST REV, V30, P83, DOI 10.1007/s10555-011-9281-4; Veltman JD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-464; WAGNER JC, 1962, NATURE, V196, P180, DOI 10.1038/196180a0; Wang J, 2016, CELL, V165, P668, DOI 10.1016/j.cell.2016.03.009; Wu LC, 2017, CLIN CANCER RES, V23, P1060, DOI 10.1158/1078-0432.CCR-16-0844; Wu LC, 2012, MOL CANCER THER, V11, P1809, DOI 10.1158/1535-7163.MCT-11-1014; Wu LC, 2011, J THORAC ONCOL, V6, P1578, DOI 10.1097/JTO.0b013e3182208ee0; Zervos E, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0314-2; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408	76	35	35	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	20					2645	2659		10.1038/s41388-018-0153-z	http://dx.doi.org/10.1038/s41388-018-0153-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG2TH	29507420	Green Submitted, Green Published, Green Accepted, hybrid			2022-12-17	WOS:000432545100003
J	Tusa, I; Gagliardi, S; Tubita, A; Pandolfi, S; Urso, C; Borgognoni, L; Wang, JH; Deng, XM; Gray, NS; Stecca, B; Rovida, E				Tusa, Ignazia; Gagliardi, Sinforosa; Tubita, Alessandro; Pandolfi, Silvia; Urso, Carmelo; Borgognoni, Lorenzo; Wang, Jinhua; Deng, Xianming; Gray, Nathanael S.; Stecca, Barbara; Rovida, Elisabetta			ERK5 is activated by oncogenic BRAF and promotes melanoma growth	ONCOGENE			English	Article							SIGNAL-REGULATED KINASE-5; CELL-PROLIFERATION; MEK5/ERK5 PATHWAY; IMPROVED SURVIVAL; BREAST-CANCER; TUMOR-GROWTH; PROTEIN; INHIBITORS; MUTATIONS; RESISTANCE	Malignant melanoma is among the most aggressive cancers and its incidence is increasing worldwide. Targeted therapies and immunotherapy have improved the survival of patients with metastatic melanoma in the last few years; however, available treatments are still unsatisfactory. While the role of the BRAF-MEK1/2-ERK1/2 pathway in melanoma is well established, the involvement of mitogen-activated protein kinases MEK5-ERK5 remains poorly explored. Here we investigated the function of ERK5 signaling in melanoma. We show that ERK5 is consistently expressed in human melanoma tissues and is active in melanoma cells. Genetic silencing and pharmacological inhibition of ERK5 pathway drastically reduce the growth of melanoma cells and xenografts harboring wild-type (wt) or mutated BRAF (V600E). We also found that oncogenic BRAF positively regulates expression, phosphorylation, and nuclear localization of ERK5. Importantly, ERK5 kinase and transcriptional transactivator activities are enhanced by BRAF. Nevertheless, combined pharmacological inhibition of BRAFV600E and MEK5 is required to decrease nuclear ERK5, that is critical for the regulation of cell proliferation. Accordingly, combination of MEK5 or ERK5 inhibitors with BRAFV600E inhibitor vemurafenib is more effective than single treatments in reducing colony formation and growth of BRAFV600E melanoma cells and xenografts. Overall, these data support a key role of the ERK5 pathway for melanoma growth in vitro and in vivo and suggest that targeting ERK5, alone or in combination with BRAF-MEK1/2 inhibitors, might represent a novel approach for melanoma treatment.	[Tusa, Ignazia; Tubita, Alessandro; Rovida, Elisabetta] Univ Florence, Dept Clin & Expt Biomed Sci, Florence, Italy; [Gagliardi, Sinforosa; Pandolfi, Silvia; Stecca, Barbara] Ist Toscano Tumori, Core Res Lab, Florence, Italy; [Pandolfi, Silvia] VIB KU Leuven Ctr Canc Biol, Leuven, Belgium; [Urso, Carmelo] SM Annunziata Hosp, Dermatopathol Sect, Anat Pathol Unit, Florence, Italy; [Borgognoni, Lorenzo] SM Annunziata Hosp, Plast Surg Unit, Reg Melanoma Referral Ctr, Florence, Italy; [Wang, Jinhua; Deng, Xianming; Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Wang, Jinhua; Deng, Xianming; Gray, Nathanael S.] Harvard Med Sch, Dept Biol Chem & Mol Pharmacol, Boston, MA USA; [Deng, Xianming] Xiamen Univ, Sch Life Sci, Innovat Ctr Cell Signaling Network, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China	University of Florence; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; Flanders Institute for Biotechnology (VIB); Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Xiamen University	Rovida, E (corresponding author), Univ Florence, Dept Clin & Expt Biomed Sci, Florence, Italy.; Stecca, B (corresponding author), Ist Toscano Tumori, Core Res Lab, Florence, Italy.	barbara.stecca@ittumori.it; erovida@unifi.it	Rovida, Elisabetta/F-3565-2015; Borgognoni, Lorenzo/X-1981-2019	Rovida, Elisabetta/0000-0002-5949-3239; Borgognoni, Lorenzo/0000-0002-3571-0366; Stecca, Barbara/0000-0003-1197-1622; URSO, CARMELO/0000-0002-3746-2917; Deng, Xianming/0000-0002-9354-5864	Associazione Italiana per la Ricerca sul Cancro, AIRC [IG-15282, IG-14184]	Associazione Italiana per la Ricerca sul Cancro, AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by a grant from Associazione Italiana per la Ricerca sul Cancro, AIRC, (IG-15282 to ER and IG-14184 to BS). We are grateful to Dr P. Dello Sbarba (University of Florence, Florence, Italy) and to Dr Chiariello (Istituto Toscano Tumori, Siena, Italy) for critical revision of the manuscript. We also thank Dr A. Pandiella for providing antibodies and Dr L. Poliseno (Istituto Toscano Tumori, Pisa, Italy) for providing melanoma cells and plasmids.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Al-Ejeh F, 2014, ONCOTARGET, V5, P3145, DOI 10.18632/oncotarget.1865; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Buschbeck M, 2005, J BIOL CHEM, V280, P2659, DOI 10.1074/jbc.M412599200; Carvajal-Vergara X, 2005, BLOOD, V105, P4492, DOI 10.1182/blood-2004-08-2985; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Jong PR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11551; Diaz-Rodriguez E, 2010, J CELL SCI, V123, P3146, DOI 10.1242/jcs.070516; Drew BA, 2012, BBA-REV CANCER, V1825, P37, DOI 10.1016/j.bbcan.2011.10.002; Erazo T, 2013, MOL CELL BIOL, V33, P1671, DOI 10.1128/MCB.01246-12; Esparis-Ogando A, 2002, MOL CELL BIOL, V22, P270, DOI 10.1128/MCB.22.1.270-285.2002; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gomez N, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00105; Honda T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117914; Inesta-Vaquera FA, 2010, CELL SIGNAL, V22, P1829, DOI 10.1016/j.cellsig.2010.07.010; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lin ECK, 2016, P NATL ACAD SCI USA, V113, P11865, DOI 10.1073/pnas.1609019113; Lo JA, 2014, SCIENCE, V346, P945, DOI 10.1126/science.1253735; Lochhead PA, 2016, CELL CYCLE, V15, P506, DOI 10.1080/15384101.2015.1120915; Loveridge CJ, 2017, CANCER RES, V77, P3158, DOI 10.1158/0008-5472.CAN-16-2565; McCracken SRC, 2008, ONCOGENE, V27, P2978, DOI 10.1038/sj.onc.1210963; Morimoto H, 2007, J BIOL CHEM, V282, P35449, DOI 10.1074/jbc.M704079200; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Nithianandarajah-Jones GN, 2012, CELL SIGNAL, V24, P2187, DOI 10.1016/j.cellsig.2012.07.007; Paoluzzi L, 2016, CANCER MED-US, V5, P1183, DOI 10.1002/cam4.667; Perez-Madrigal D, 2012, CELL SIGNAL, V24, P2360, DOI 10.1016/j.cellsig.2012.08.001; Raviv Z, 2004, J CELL SCI, V117, P1773, DOI 10.1242/jcs.01040; Rovida E, 2008, J IMMUNOL, V180, P4166, DOI 10.4049/jimmunol.180.6.4166; Rovida E, 2015, GUT, V64, P1454, DOI 10.1136/gutjnl-2014-306761; Rovira-Clave X, 2016, J LEUKOCYTE BIOL, V99, P143, DOI 10.1189/jlb.2A0115-034R; Sala E, 2008, MOL CANCER RES, V6, P751, DOI 10.1158/1541-7786.MCR-07-2001; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Simoes AES, 2016, DRUG DISCOV TODAY, V21, P1654, DOI 10.1016/j.drudis.2016.06.010; Song CL, 2017, SCI REP-UK, V7, DOI 10.1038/srep46244; Tatake RJ, 2008, BIOCHEM BIOPH RES CO, V377, P120, DOI 10.1016/j.bbrc.2008.09.087; Teixido C, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.05.07; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Williams CAC, 2016, CELL REP, V16, P1820, DOI 10.1016/j.celrep.2016.07.033; Xia SY, 2017, CELL METAB, V25, P358, DOI 10.1016/j.cmet.2016.12.010; Yang H, 2010, CANCER RES, V70, P5518, DOI 10.1158/0008-5472.CAN-10-0646; Yang QK, 2011, CLIN CANCER RES, V17, P3527, DOI 10.1158/1078-0432.CCR-10-2504; Yang QK, 2010, CANCER CELL, V18, P258, DOI 10.1016/j.ccr.2010.08.008	50	35	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19								10.1038/s41388-018-0164-9	http://dx.doi.org/10.1038/s41388-018-0164-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29483645	Green Published, hybrid			2022-12-17	WOS:000431873400001
J	Akhter, MZ; Sharawat, SK; Kumar, V; Kochat, V; Equbal, Z; Ramakrishnan, M; Kumar, U; Mathur, S; Kumar, L; Mukhopadhyay, A				Akhter, Md Zahid; Sharawat, Surender K.; Kumar, Vikash; Kochat, Veena; Equbal, Zaffar; Ramakrishnan, Mallika; Kumar, Umesh; Mathur, Sandeep; Kumar, Lalit; Mukhopadhyay, Asok			Aggressive serous epithelial ovarian cancer is potentially propagated by EpCAM(+)CD45(+) phenotype	ONCOGENE			English	Article							MARROW-DERIVED CELLS; STEM-CELLS; MESENCHYMAL TRANSITION; SIGNALING PATHWAY; TUMOR PROGRESSION; BREAST-CANCER; THERAPY; CONTRIBUTE; EXOSOMES; CHEMORESISTANCE	Epithelial ovarian carcinoma (EOC) patients often acquire resistance against common chemotherapeutic drugs like paclitaxel and cisplatin. The mechanism responsible for the same is ambiguous. We have identified a putative drug-resistant tumour cell phenotype (EpCAM(+) CD45(+)) in the ascitic fluid of EOC patients, which appears to originate from the primary tumour. These cells represent the major tumour burden and are more drug resistant compared to EpCAM(+) tumour cells due to the over-expression of SIRT1, ABCA1 and BCL2 genes. We have found that the entire EpCAM(+) CD45+ population is highly invasive with signature mesenchymal gene expression and also consists of subpopulations of ovarian cancer stem cells (CD133(+) and CD117(+) CD44(+)). Additionally, we demonstrate that the EpCAM(+) CD45(+) tumour cells over-express major histocompatibility complex class I antigen, which enable them to evade the natural killer cell-mediated immune surveillance. Preliminary evidence obtained in OVCAR-5 cells suggests that exosomes, secreted by non-tumour cells of the ascitic fluid, play an important role in rendering drug resistance and invasive properties to the cancer cells. Identification of such aggressive tumour cells and deciphering their origin is important for designing better drug targets for EOC.	[Akhter, Md Zahid; Sharawat, Surender K.; Kumar, Vikash; Kochat, Veena; Equbal, Zaffar; Ramakrishnan, Mallika; Kumar, Umesh; Mathur, Sandeep; Kumar, Lalit; Mukhopadhyay, Asok] Natl Inst Immunol, Stem Cell Biol Lab, New Delhi, India; [Mathur, Sandeep] All India Inst Med Sci, Dept Pathol, New Delhi, India; [Kumar, Lalit] All India Inst Med Sci, Dept Med Oncol, New Delhi, India; [Akhter, Md Zahid] Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL USA; [Sharawat, Surender K.] All India Inst Med Sci, Dept Med Oncol, New Delhi, India; [Kochat, Veena] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Ramakrishnan, Mallika] Inst Tumor Biol & Expt Therapy, Georg Speyer Haus, Frankfurt, Germany; [Kumar, Umesh] Univ Delhi, Dept Biochem, Genom Facil, South Campus, New Delhi, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII); All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; All India Institute of Medical Sciences (AIIMS) New Delhi; University of Texas System; UTMD Anderson Cancer Center; University of Delhi	Mukhopadhyay, A (corresponding author), Natl Inst Immunol, Stem Cell Biol Lab, New Delhi, India.	ashok@nii.ac.in	Kochat, Veena/AAX-1915-2021; Kumar, Umesh/AAX-9989-2021; Kumar, Umesh/AAQ-9159-2021; Akhter, Zahid/AAA-8410-2022	Kumar, Umesh/0000-0002-4715-7967; Akhter, Zahid/0000-0002-1602-3704; Equbal, Zaffar/0000-0001-7791-1804; SHARAWAT, SURENDER K/0000-0001-6322-0586	Department of Biotechnology, Government of India	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India)	AM is grateful for the generous support provided by the Department of Biotechnology, Government of India to the Centre of Molecular Medicine, NII. We would like to thank Mr. Nila Ram and Mr. Ajay Sharma for acquiring confocal images. AM would like to thank Dr. Ayub Qadri, Scientist (NII, New Delhi), Prof. NK Mehra (AIIMS, New Delhi) and Dr. Awadhesh Pandit (NCBS, Bangalore) for valuable discussion in some parts of the study. Also, we are thankful to Dr. TR Santhosh Kumar (RGCB, Thiruvananthapuram, Kerala) for providing the OVCAR-5 cell line.	Ahmed N, 2010, CURR CANCER DRUG TAR, V10, P268, DOI 10.2174/156800910791190175; Ahmed N, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00256; Ahmed N, 2013, J CELL BIOCHEM, V114, P21, DOI 10.1002/jcb.24317; Al-Ejeh F, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.14; Avital I, 2007, STEM CELLS, V25, P2903, DOI 10.1634/stemcells.2007-0409; Baba T, 2009, ONCOGENE, V28, P209, DOI 10.1038/onc.2008.374; Baligar P, 2017, HEPATOLOGY, V65, P1319, DOI 10.1002/hep.29027; Baligar P, 2016, STEM CELLS, V34, P135, DOI 10.1002/stem.2210; Bamias A, 2007, GYNECOL ONCOL, V106, P75, DOI 10.1016/j.ygyno.2007.02.029; Bapat SA, 2005, CANCER RES, V65, P3025, DOI 10.1158/0008-5472.CAN-04-3931; Barker N, 2001, TRENDS MOL MED, V7, P535, DOI 10.1016/S1471-4914(01)02215-8; Chang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.407; Craveiro V, 2013, CANCER MED-US, V2, P751, DOI 10.1002/cam4.115; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Gubbels JAA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-11; Houghton J, 2004, SCIENCE, V306, P1568, DOI 10.1126/science.1099513; Kim Yonghyun, 2009, Int J Stem Cells, V2, P109; LARIZZA L, 1984, J EXP MED, V160, P1579, DOI 10.1084/jem.160.5.1579; Latifi A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046858; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317; Li HX, 2014, ARCH GYNECOL OBSTET, V290, P1067, DOI 10.1007/s00404-014-3377-3; Liu CF, 2006, NEOPLASIA, V8, P716, DOI 10.1593/neo.06253; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Matte I, 2012, AM J CANCER RES, V2, P566; Olumi AF, 1999, CANCER RES, V59, P5002; Ono M, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005231; Ozols RF, 2006, SEMIN ONCOL, V33, pS3, DOI 10.1053/j.seminoncol.2006.03.011; Paley PJ, 2001, CURR OPIN ONCOL, V13, P399, DOI 10.1097/00001622-200109000-00015; Powell AE, 2011, CANCER RES, V71, P1497, DOI 10.1158/0008-5472.CAN-10-3223; Qian JL, 2016, ONCOL LETT, V11, P1738, DOI 10.3892/ol.2016.4150; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ramakrishnan M, 2013, CANCER RES, V73, P5360, DOI 10.1158/0008-5472.CAN-13-0896; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Roccaro AM, 2013, J CLIN INVEST, V123, P1542, DOI 10.1172/JCI66517; Rousalova I, 2010, INT J ONCOL, V37, P1361, DOI 10.3892/ijo_00000788; Rubin SC, 1999, OBSTET GYNECOL, V93, P21, DOI 10.1016/S0029-7844(98)00334-2; Runz S, 2007, GYNECOL ONCOL, V107, P563, DOI 10.1016/j.ygyno.2007.08.064; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Shain KH, 2015, ONCOGENE, V34, P4673, DOI 10.1038/onc.2014.403; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Smyth MJ, 2002, NAT REV CANCER, V2, P850, DOI 10.1038/nrc928; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Sunayama J, 2010, STEM CELLS, V28, P1930, DOI 10.1002/stem.521; Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033; Thery Clotilde, 2006, Curr Protoc Cell Biol, VChapter 3, DOI 10.1002/0471143030.cb0322s30; Wang RF, 2001, TRENDS IMMUNOL, V22, P269, DOI 10.1016/S1471-4906(01)01896-8; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364	54	35	38	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2089	2103		10.1038/s41388-017-0106-y	http://dx.doi.org/10.1038/s41388-017-0106-y			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29379166				2022-12-17	WOS:000430589000002
J	Chen, ZR; Lin, SB; Li, JL; Ni, W; Guo, RF; Lu, JR; Kaye, FJ; Wu, LZ				Chen, Zirong; Lin, Shuibin; Li, Jian-Liang; Ni, Wei; Guo, Ruifeng; Lu, Jianrong; Kaye, Frederic J.; Wu, Lizi			CRTC1-MAML2 fusion-induced lncRNA LINC00473 expression maintains the growth and survival of human mucoepidermoid carcinoma cells	ONCOGENE			English	Article							LONG NONCODING RNAS; SIGNALING PATHWAY; GENE-EXPRESSION; SALIVARY; CANCER; TRANSLOCATION; ONCOGENE; PROLIFERATION; TRANSCRIPTOME; ACTIVATION	Mucoepidermoid carcinoma (MEC) arises in many glandular tissues and contributes to the most common malignant salivary gland cancers. MEC is specifically associated with a unique t(11; 19) translocation and the resulting CRTC1-MAML2 fusion is a major oncogenic driver for MEC initiation and maintenance. However, the molecular basis underlying the CRTC1-MAML2 oncogenic functions remains elusive. Through gene expression profiling analysis, we observed that LINC00473, a long non-coding RNA (lncRNA), was the top down-regulated target in CRTC1-MAML2-depleted human MEC cells. LncRNAs belong to a new class of non-coding RNAs with emerging roles in tumorigenesis and progression, but remain poorly characterized. In this study, we investigated the role of LINC00473 in mediating CRTC1-MAML2 oncogenic activity in human MEC. We found that LINC00473 transcription was significantly induced in human CRTC1-MAML2-positive MEC cell lines and primary MEC tumors, and was tightly correlated with the CRTC1-MAML2 RNA level. LINC00473 induction was dependent on the ability of CRTC1-MAML2 to activate CREB-mediated transcription. Depletion of LINC00473 significantly reduced the proliferation and survival of human MEC cells in vitro and blocked the in vivo tumor growth in a human MEC xenograft model. RNA in situ hybridization analysis demonstrated a predominantly nuclear localization pattern for LINC00473 in human MEC cells. Furthermore, gene expression profiling revealed that LINC00473 depletion resulted in differential expression of genes important in cancer cell growth and survival. LINC00473 likely regulates gene expression in part through its ability to bind to a cAMP signaling pathway component NONO, enhancing the ability of CRTC1-MAML2 to activate CREB-mediated transcription. Our overall results demonstrate that LINC00473 is a downstream target and an important mediator of the CRTC1-MAML2 oncoprotein. Therefore, LINC00473 acts as a promising biomarker and therapeutic target for human CRTC1-MAML2-positive MECs.	[Chen, Zirong; Ni, Wei; Wu, Lizi] Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32611 USA; [Chen, Zirong; Ni, Wei; Lu, Jianrong; Kaye, Frederic J.; Wu, Lizi] Univ Florida, UF Hlth Canc Ctr, Gainesville, FL 32611 USA; [Lin, Shuibin] Sun Yat Sen Univ, Affiliated Hosp 1, Ctr Translat Med, Guangzhou, Guangdong, Peoples R China; [Li, Jian-Liang] Sanford Burnham Prebys Med Discovery Inst Lake No, Orlando, FL USA; [Ni, Wei; Wu, Lizi] Univ Florida, UF Genet Inst, Gainesville, FL 32611 USA; [Guo, Ruifeng] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL USA; [Lu, Jianrong] Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; [Kaye, Frederic J.] Univ Florida, Coll Med, Dept Med, Gainesville, FL USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; Sun Yat Sen University; Sanford Burnham Prebys Medical Discovery Institute; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	Wu, LZ (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Gainesville, FL 32611 USA.; Wu, LZ (corresponding author), Univ Florida, UF Hlth Canc Ctr, Gainesville, FL 32611 USA.; Wu, LZ (corresponding author), Univ Florida, UF Genet Inst, Gainesville, FL 32611 USA.	lzwu@ufl.edu	Li, Jian-Liang/AAE-9315-2019; Guo, Ruifeng/AAK-2072-2020; Li, J L/E-6100-2018; Lu, Jianrong/F-5240-2013	Li, Jian-Liang/0000-0002-6487-081X; Li, J L/0000-0002-6487-081X; Wu, Lizi/0000-0002-0076-2617; Lu, Jianrong/0000-0002-4969-6040	NIH National Institute of Dental and Craniofacial Research [R01DE023641]; NIH National Cancer Institute [R21CA187730]; NATIONAL CANCER INSTITUTE [R21CA187730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023641] Funding Source: NIH RePORTER	NIH National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIH National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This work is supported by the NIH National Institute of Dental and Craniofacial Research (R01DE023641) and the NIH National Cancer Institute (R21CA187730).	Achcar RDD, 2009, HUM PATHOL, V40, P854, DOI 10.1016/j.humpath.2008.11.007; Amelio AL, 2007, P NATL ACAD SCI USA, V104, P20314, DOI 10.1073/pnas.0707999105; Amelio AL, 2014, P NATL ACAD SCI USA, V111, pE3260, DOI 10.1073/pnas.1319176111; Behboudi A, 2006, GENE CHROMOSOME CANC, V45, P470, DOI 10.1002/gcc.20306; Bell D, 2012, CURR ONCOL REP, V14, P166, DOI 10.1007/s11912-012-0220-5; Birkeland AC, 2017, ORAL ONCOL, V68, P5, DOI 10.1016/j.oraloncology.2017.02.025; Cabanski CR, 2015, RNA BIOL, V12, P628, DOI 10.1080/15476286.2015.1038012; Canettieri G, 2009, P NATL ACAD SCI USA, V106, P1445, DOI 10.1073/pnas.0808749106; Chen J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1827-3; Chen Z, 2014, ONCOGENE, V33, P3869, DOI 10.1038/onc.2013.348; Chen ZR, 2016, J CLIN INVEST, V126, P2267, DOI 10.1172/JCI85250; Coxon A, 2005, CANCER RES, V65, P7137, DOI 10.1158/0008-5472.CAN-05-1125; Dickson Iain, 2016, Nat Rev Gastroenterol Hepatol, V13, P122, DOI 10.1038/nrgastro.2016.21; Dinh TA, 2017, SCI REP-UK, V7, DOI 10.1038/srep44653; Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233; Du Z, 2013, NAT STRUCT MOL BIOL, V20, P908, DOI 10.1038/nsmb.2591; Eveson JW, 2011, PERIODONTOL 2000, V57, P150, DOI 10.1111/j.1600-0757.2011.00385.x; Fehr A, 2008, GENE CHROMOSOME CANC, V47, P203, DOI 10.1002/gcc.20522; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Iyer MK, 2015, NAT GENET, V47, P199, DOI 10.1038/ng.3192; Komiya T, 2006, ONCOGENE, V25, P6128, DOI 10.1038/sj.onc.1209627; Kubo T, 2009, INT J CANCER, V124, P1778, DOI 10.1002/ijc.24150; Leucci E, 2016, NATURE, V531, P518, DOI 10.1038/nature17161; Liang XH, 2016, SCI REP-UK, V6, DOI 10.1038/srep22744; Moran VA, 2012, NUCLEIC ACIDS RES, V40, P6391, DOI 10.1093/nar/gks296; Noda H, 2013, CANCER SCI, V104, P85, DOI 10.1111/cas.12039; NORDKVIST A, 1994, CANCER GENET CYTOGEN, V74, P77, DOI 10.1016/0165-4608(94)90001-9; Reitmair A, 2012, PHYSIOL GENOMICS, V44, P152, DOI 10.1152/physiolgenomics.00089.2011; Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902; Saade RE, 2016, JAMA OTOLARYNGOL, V142, P234, DOI 10.1001/jamaoto.2015.3270; Seethala RR, 2010, AM J SURG PATHOL, V34, P1106, DOI 10.1097/PAS.0b013e3181de3021; Tirado Y, 2007, GENE CHROMOSOME CANC, V46, P708, DOI 10.1002/gcc.20458; Tonon G, 2003, NAT GENET, V33, P208, DOI 10.1038/ng1083; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang LN, 2014, J INTEGR MED-JIM, V12, P20, DOI 10.1016/S2095-4964(14)60003-0; Warner KA, 2013, ORAL ONCOL, V49, P1059, DOI 10.1016/j.oraloncology.2013.08.004; White NM, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0429-8; Wu LZ, 2005, EMBO J, V24, P2391, DOI 10.1038/sj.emboj.7600719; Wu YH, 2014, TUMOR BIOL, V35, P11887, DOI 10.1007/s13277-014-2453-4; Zhen S, 2017, ONCOTARGET, V8, P9634, DOI 10.18632/oncotarget.14176	41	35	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1885	1895		10.1038/s41388-017-0104-0	http://dx.doi.org/10.1038/s41388-017-0104-0			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29353885	Green Accepted			2022-12-17	WOS:000429303300006
J	Lee, GH; Yoo, KC; An, Y; Lee, HJ; Lee, M; Uddin, N; Kim, MJ; Kim, IG; Suh, Y; Lee, SJ				Lee, Ga-Hang; Yoo, Ki-Chun; An, Yoojeong; Lee, Hae-June; Lee, Minyoung; Uddin, Nizam; Kim, Min-Jung; Kim, In-Gyu; Suh, Yongjoon; Lee, Su-Jae			FYN promotes mesenchymal phenotypes of basal type breast cancer cells through STAT5/NOTCH2 signaling node	ONCOGENE			English	Article							MOLECULAR TARGETS; NOTCH; SRC; STAT5; THERAPY; CHEMOTHERAPY; TRANSDUCER; RECURRENCE; ACTIVATION; EXPRESSION	Basal type breast cancer is the most aggressive and has mesenchymal features with a high metastatic ability. However, the signaling node that determines the basal type features in breast cancer remains obscure. Here, we report that FYN among SRC family kinases is required for the maintenance of basal type breast cancer subtype. Importantly, FYN enhanced NOTCH2 activation in basal type breast cancer cells through STAT5-mediated upregulation of Jagged-1 and DLL4 NOTCH ligands, thereby contributed to mesenchymal phenotypes. In addition, we found that high levels of FYN persist in basal type breast cancer cells by a positive feedback loop between FYN and STAT5. FYN interacted directly with STAT5 and increased p-STAT5 that further acts as a transcription factor for FYN. Taken together, our findings demonstrate a pivotal role of FYN and its downstream effectors in maintaining the basal type features in breast cancer.	[Lee, Ga-Hang; Yoo, Ki-Chun; An, Yoojeong; Uddin, Nizam; Suh, Yongjoon; Lee, Su-Jae] Hanyang Univ, Dept Life Sci, Res Inst Nat Sci, Seoul, South Korea; [Lee, Ga-Hang] Samsung Med Ctr, Dept Radiat Oncol, Seoul, South Korea; [Lee, Hae-June; Lee, Minyoung] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul, South Korea; [Uddin, Nizam] Univ Punjab, CEMB, Lahore, Pakistan; [Kim, Min-Jung] Korea Inst Radiol & Med Sci, Lab Radiat Exposure & Therapeut, Natl Radiat Emergency Med Ctr, Seoul, South Korea; [Kim, In-Gyu] Korea Atom Energy Res Inst, Environm Radiat Res Grp, Dept Radiat Biol, Daejeon, South Korea	Hanyang University; Sungkyunkwan University (SKKU); Samsung Medical Center; Korea Institute of Radiological & Medical Sciences; University of Punjab; Korea Institute of Radiological & Medical Sciences; Korea Atomic Energy Research Institute (KAERI)	Suh, Y; Lee, SJ (corresponding author), Hanyang Univ, Dept Life Sci, Res Inst Nat Sci, Seoul, South Korea.	hiswork@hanmail.net; sj0420@hanyang.ac.kr		Ud Din, Nizam/0000-0002-9845-3109	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government [NRF-2016R1E1A1A01942075, NRF-2017M2A2A7070460]	National Research Foundation (NRF); Ministry of Science, ICT and Future Planning, Korean Government	This work was supported by the National Research Foundation (NRF) and Ministry of Science, ICT and Future Planning, Korean Government, through its National Nuclear Technology Program (NRF-2016R1E1A1A01942075 and NRF-2017M2A2A7070460).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677; Barash I, 2012, CARCINOGENESIS, V33, P2320, DOI 10.1093/carcin/bgs362; Belsches-Jablonski AP, 2001, ONCOGENE, V20, P1465, DOI 10.1038/sj.onc.1204205; Britschgi A, 2012, CANCER CELL, V22, P796, DOI 10.1016/j.ccr.2012.10.023; Buettner R, 2002, CLIN CANCER RES, V8, P945; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Finn RS, 2008, ANN ONCOL, V19, P1379, DOI 10.1093/annonc/mdn291; Goldhirsch A, 2007, ANN ONCOL, V18, P1133, DOI 10.1093/annonc/mdm271; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Irwin ME, 2011, CANCER BIOL THER, V12, P718, DOI 10.4161/cbt.12.8.16907; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Miele L, 2006, CURR MOL MED, V6, P905, DOI 10.2174/156652406779010830; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Pullen NA, 2012, J BIOL CHEM, V287, P2045, DOI 10.1074/jbc.M111.311142; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Reedijk M, 2008, BREAST CANCER RES TR, V111, P439, DOI 10.1007/s10549-007-9805-3; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tryfonopoulos D, 2011, ANN ONCOL, V22, P2234, DOI 10.1093/annonc/mdq757; Walker SR, 2014, MOL CELL ENDOCRINOL, V382, P616, DOI 10.1016/j.mce.2013.03.010; Walker SR, 2013, MOL CELL BIOL, V33, P2879, DOI 10.1128/MCB.01620-12; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275	30	35	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1857	1868		10.1038/s41388-017-0114-y	http://dx.doi.org/10.1038/s41388-017-0114-y			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29348460				2022-12-17	WOS:000429303300004
J	Grither, WR; Divine, LM; Meller, EH; Wilke, DJ; Desai, RA; Loza, AJ; Zhao, PN; Lohrey, A; Longmore, GD; Fuh, KC				Grither, Whitney R.; Divine, Laura M.; Meller, Eric H.; Wilke, Daniel J.; Desai, Riva A.; Loza, Andrew J.; Zhao, Peinan; Lohrey, Anne; Longmore, Gregory D.; Fuh, Katherine C.			TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CELL METASTASIS; UP-REGULATION; INVASION; CARCINOMA; COLLAGEN; FIBRONECTIN; MATRIX; FIBROBLASTS; ACTIVATION	The mesenchymal gene program has been shown to promote the metastatic progression of ovarian cancer; however, specific proteins induced by this program that lead to these metastatic behaviors have not been identified. Using patient derived tumor cells and established human ovarian tumor cell lines, we find that the Epithelial-to-Mesenchymal Transition inducing factor TWIST1 drives expression of discoidin domain receptor 2 (DDR2), a receptor tyrosine kinase (RTK) that recognizes fibrillar collagen as ligand. The expression and action of DDR2 was critical for mesothelial cell clearance, invasion and migration in ovarian tumor cells. It does so, in part, by upregulating expression and activity of matrix remodeling enzymes that lead to increased cleavage of fibronectin and spreading of tumor cells. Additionally, DDR2 stabilizes SNAIL1, allowing for sustained mesenchymal phenotype. In patient derived ovarian cancer specimens, DDR2 expression correlated with enhanced invasiveness. DDR2 expression was associated with advanced stage ovarian tumors and metastases. In vivo studies demonstrated that the presence of DDR2 is critical for ovarian cancer metastasis. These findings indicate that the collagen receptor DDR2 is critical for multiple steps of ovarian cancer progression to metastasis, and thus, identifies DDR2 as a potential new target for the treatment of metastatic ovarian cancer.	[Grither, Whitney R.; Loza, Andrew J.; Lohrey, Anne; Longmore, Gregory D.] Washington Univ, ICCE Inst, St Louis, MO USA; [Divine, Laura M.; Meller, Eric H.; Wilke, Daniel J.; Desai, Riva A.; Fuh, Katherine C.] Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA; [Meller, Eric H.; Wilke, Daniel J.; Desai, Riva A.; Lohrey, Anne; Fuh, Katherine C.] Washington Univ, Ctr Reprod Hlth Sci CRepHS, St Louis, MO 63130 USA; [Zhao, Peinan] Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Clin Res, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Fuh, KC (corresponding author), Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA.; Fuh, KC (corresponding author), Washington Univ, Ctr Reprod Hlth Sci CRepHS, St Louis, MO 63130 USA.	kfuh@wudosis.wustl.edu		Fuh, Katherine/0000-0002-7693-2694	Cancer Frontier Fund [8002-88];  [2K12HD000849-28];  [NIHCA196205]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000849] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA196205, P30CA091842] Funding Source: NIH RePORTER	Cancer Frontier Fund; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	2K12HD000849-28 (KCF); NIHCA196205 (GDL); Cancer Frontier Fund 8002-88 (KCF and GDL).	Bildsoe H, 2016, DEV BIOL, V418, P189, DOI 10.1016/j.ydbio.2016.08.016; Borza CM, 2014, MATRIX BIOL, V34, P185, DOI 10.1016/j.matbio.2013.12.002; Burleson KM, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-6; Chen DY, 2013, INT J GYNECOL CANCER, V23, P1357, DOI 10.1097/IGC.0b013e3182a5e760; Cho A, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00245; Chua HH, 2008, HEAD NECK-J SCI SPEC, V30, P427, DOI 10.1002/hed.20724; Coelho NM, 2017, CELL REP, V18, P1774, DOI 10.1016/j.celrep.2017.01.061; Corsa CAS, 2016, CELL REP, V15, P2510, DOI 10.1016/j.celrep.2016.05.033; Davidowitz RA, 2012, JOVE, V60; Davidowitz RA, 2014, J CLIN INVEST, V124, P2611, DOI 10.1172/JCI69815; Davidson B, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00033; Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Elias MC, 2005, NEOPLASIA, V7, P824, DOI 10.1593/neo.04352; Fan Y, 2016, AM J TRANSL RES, V8, P2845; Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Iwanicki MP, 2011, CANCER DISCOV, V1, P144, DOI 10.1158/2159-8274.CD-11-0010; Kenny HA, 2008, J CLIN INVEST, V118, P1367, DOI 10.1172/JCI33775; Kenny HA, 2009, CANCER TREAT RES, V149, P335, DOI 10.1007/978-0-387-98094-2_16; Leitinger B, 2014, INT REV CEL MOL BIO, V310, P39, DOI 10.1016/B978-0-12-800180-6.00002-5; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Majkowska I, 2017, J BIOL CHEM, V292, P6633, DOI 10.1074/jbc.M116.770057; Matsuo N, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-240; Nadiarnykh O, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-94; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Pankov R, 2002, J CELL SCI, V115, P3861, DOI 10.1242/jcs.00059; Pradeep S, 2014, CANCER CELL, V26, P77, DOI 10.1016/j.ccr.2014.05.002; Rauch J, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-23; Ren TT, 2014, J PATHOL, V234, P526, DOI 10.1002/path.4415; Rodrigues R, 2007, ONCOL REP, V18, P917; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245; Terauchi M, 2007, CLIN EXP METASTAS, V24, P329, DOI 10.1007/s10585-007-9070-1; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Valiathan RR, 2012, CANCER METAST REV, V31, P295, DOI 10.1007/s10555-012-9346-z; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Wang YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep24606; Wang YL, 2015, INT J CLIN EXP MED, V8, P7388; Xie BH, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0218-6; Xu DB H, 2012, PLOS ONE, V7; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Xu JK, 2014, CANCER BIOL THER, V15, P612, DOI 10.4161/cbt.28181; Xu L, 2005, J BIOL CHEM, V280, P548, DOI 10.1074/jbc.M411036200; Yang Z, 2007, BIOCHEM BIOPH RES CO, V358, P925, DOI 10.1016/j.bbrc.2007.05.023; Yeh JE, 2013, CURR OPIN ONCOL, V25, P652, DOI 10.1097/01.cco.0000432528.88101.1a; Yeung TL, 2015, AM J PHYSIOL-CELL PH, V309, pC444, DOI 10.1152/ajpcell.00188.2015; Zhang K, 2016, J CELL SCI, V129, P1989, DOI 10.1242/jcs.180539; Zhang K, 2013, NAT CELL BIOL, V15, P677, DOI 10.1038/ncb2743; Zhang XR, 2012, CARTILAGE, V3, P267, DOI 10.1177/1947603511435273; Zhang Y, 2014, BBA-MOL BASIS DIS, V1842, P1350, DOI 10.1016/j.bbadis.2014.04.018	52	35	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	13					1714	1729		10.1038/s41388-017-0043-9	http://dx.doi.org/10.1038/s41388-017-0043-9			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA9AE	29348456	Green Accepted			2022-12-17	WOS:000428632600003
J	Howley, BV; Link, LA; Grelet, S; El-Sabban, M; Howe, PH				Howley, Breege V.; Link, Laura A.; Grelet, Simon; El-Sabban, Maya; Howe, Philip H.			A CREB3-regulated ER-Golgi trafficking signature promotes metastatic progression in breast cancer	ONCOGENE			English	Article							RETICULUM STRESS-RESPONSE; TRANSCRIPTION FACTOR; MEMBRANE-PROTEIN; LUMINAL DOMAIN; CELL-DEATH; TGF-BETA; CHOLESTEROL; GENES; PROGNOSIS; APPARATUS	In order to better understand the process of breast cancer metastasis, we have generated a mammary epithelial progression series of increasingly aggressive cell lines that metastasize to lung. Here we demonstrate that upregulation of an endoplasmic reticulum (ER) to Golgi trafficking gene signature in metastatic cells enhances transport kinetics, which promotes malignant progression. We observe increased ER-Golgi trafficking, an altered secretome and sensitivity to the retrograde transport inhibitor brefeldin A (BFA) in cells that metastasize to lung. CREB3 was identified as a transcriptional regulator of upregulated ER-Golgi trafficking genes ARF4, COPB1, and USO1, and silencing of these genes attenuated the metastatic phenotype in vitro and lung colonization in vivo. Furthermore, high trafficking gene expression significantly correlated with increased risk of distant metastasis and reduced relapse-free and overall survival in breast cancer patients, suggesting that modulation of ER-Golgi trafficking plays an important role in metastatic progression.	[Howley, Breege V.; Link, Laura A.; Grelet, Simon; El-Sabban, Maya; Howe, Philip H.] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; [Howley, Breege V.; Link, Laura A.; Grelet, Simon; Howe, Philip H.] Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA; [Link, Laura A.] Kent State Univ, Dept Biomed Sci, Kent, OH 44242 USA	Medical University of South Carolina; Medical University of South Carolina; University System of Ohio; Kent State University; Kent State University Kent; Kent State University Salem	Howe, PH (corresponding author), Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA.; Howe, PH (corresponding author), Med Univ South Carolina, Hollings Canc Ctr, Charleston, SC 29425 USA.	howep@musc.edu		Howe, Philip/0000-0002-1358-1313	National Cancer Institute [CA055536, CA154663]; Abney Foundation; NIH/NIGMS [GM103342, GM103499]; Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC; Gene Targeting and Knockout Shared Resource at MUSC;  [P30 CA138313];  [P30 GM103331]; NATIONAL CANCER INSTITUTE [R01CA154663] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Abney Foundation; NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC; Gene Targeting and Knockout Shared Resource at MUSC; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Grants CA055536 and CA154663 from the National Cancer Institute to PHH. BVH was supported by funding from the Abney Foundation. This study used the services of the MUSC Proteogenomics Facility supported by NIH/NIGMS (GM103342 and GM103499), the Cell & Molecular Imaging Shared Resource of MUSC supported by P30 CA138313, the MUSC Center for Oral Health Research (COHR), which is partially supported by P30 GM103331, the MUSC Flow Cytometry Facility supported by NIH/NIGMS GM103342, the Biorepository & Tissue Analysis Shared Resource, Hollings Cancer Center, MUSC, and the Gene Targeting and Knockout Shared Resource at MUSC. We thank Annamarie Dalton for assisting us with xenograft experiments and also thank members of the Howe laboratory for providing helpful feedback during the preparation of this manuscript.	Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Bard F, 2016, TRENDS CELL BIOL, V26, P379, DOI 10.1016/j.tcb.2015.12.004; Ben-Tekaya H, 2010, MOL BIOL CELL, V21, P4130, DOI 10.1091/mbc.E10-01-0022; BERSHADSKY AD, 1994, P NATL ACAD SCI USA, V91, P5686, DOI 10.1073/pnas.91.12.5686; Boncompain G, 2012, NAT METHODS, V9, P493, DOI [10.1038/NMETH.1928, 10.1038/nmeth.1928]; Brandizzi F, 2013, NAT REV MOL CELL BIO, V14, P382, DOI 10.1038/nrm3588; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chan CP, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-6; Chaudhury A, 2010, NAT CELL BIOL, V12, P286, DOI 10.1038/ncb2029; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; CLERMONT Y, 1993, ANAT REC, V237, P308, DOI 10.1002/ar.1092370303; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Danilov AV, 2008, CANCER METAST REV, V27, P707, DOI 10.1007/s10555-008-9159-2; Dodonova SO, 2015, SCIENCE, V349, P195, DOI 10.1126/science.aab1121; Donizy P, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101619; Feng YX, 2014, CANCER DISCOV, V4, P702, DOI 10.1158/2159-8290.CD-13-0945; Fox RM, 2010, J CELL BIOL, V191, P479, DOI 10.1083/jcb.201004062; Guizzunti G, 2016, P NATL ACAD SCI USA, V113, pE6590, DOI 10.1073/pnas.1610844113; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Halberg N, 2016, CANCER CELL, V29, P339, DOI 10.1016/j.ccell.2016.02.013; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Howley BV, 2016, ONCOGENE, V35, P1725, DOI 10.1038/onc.2015.238; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Hussey GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052624; Hussey GS, 2011, MOL CELL, V41, P419, DOI 10.1016/j.molcel.2011.02.003; Kim HC, 2010, CELL MOL LIFE SCI, V67, P3499, DOI 10.1007/s00018-010-0388-5; Kondo S, 2007, MOL CELL BIOL, V27, P1716, DOI 10.1128/MCB.01552-06; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kuzu OF, 2016, CANCER RES, V76, P2063, DOI 10.1158/0008-5472.CAN-15-2613; Li H, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-168; Li T, 2016, MOL NEUROBIOL, V53, P1377, DOI 10.1007/s12035-014-9083-0; Liang GQ, 2006, MOL CELL BIOL, V26, P7999, DOI 10.1128/MCB.01046-06; Ling ZQ, 2014, ANN ONCOL, V25, P1363, DOI 10.1093/annonc/mdu168; Lu M, 2014, SCIENCE, V345, P98, DOI 10.1126/science.1254312; Maag RS, 2003, CURR OPIN CELL BIOL, V15, P456, DOI 10.1016/S0955-0674(03)00075-9; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Murakami T, 2009, NAT CELL BIOL, V11, P1205, DOI 10.1038/ncb1963; Nadanaka S, 2007, MOL CELL BIOL, V27, P1027, DOI 10.1128/MCB.00408-06; Oku M, 2011, CELL STRUCT FUNCT, V36, P1, DOI 10.1247/csf.10014; Oliveros J.C., 2007, INTERACTIVE TOOL COM; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Popoff V, 2011, J BIOL CHEM, V286, P35634, DOI 10.1074/jbc.M111.261800; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Rashid S, 2005, P NATL ACAD SCI USA, V102, P5374, DOI 10.1073/pnas.0501652102; Reiling JH, 2013, NAT CELL BIOL, V15, P1473, DOI 10.1038/ncb2865; Reverter M, 2014, CELL REP, V7, P883, DOI 10.1016/j.celrep.2014.03.043; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Saito A, 2009, NAT CELL BIOL, V11, P1197, DOI 10.1038/ncb1962; Serebrenik Y, 2015, FASEB J, V29; Spang A, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a013391; Taniguchi M, 2016, CELL STRUCT FUNCT, V41, P93, DOI 10.1247/csf.16005; Taniguchi M, 2015, CELL STRUCT FUNCT, V40, P13, DOI 10.1247/csf.14015; Vellanki RN, 2010, ENDOCRINOLOGY, V151, P4146, DOI 10.1210/en.2010-0137; Volpicelli-Daley LA, 2005, MOL BIOL CELL, V16, P4495, DOI 10.1091/mbc.E04-12-1042; Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028; WATERS MG, 1992, J CELL BIOL, V118, P1015, DOI 10.1083/jcb.118.5.1015; Yadav S, 2009, MOL BIOL CELL, V20, P1728, DOI 10.1091/mbc.E08-10-1077; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Zhou JX, 2012, J NEURO-ONCOL, V110, P195, DOI 10.1007/s11060-012-0970-9; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	63	35	38	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1308	1325		10.1038/s41388-017-0023-0	http://dx.doi.org/10.1038/s41388-017-0023-0			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29249802	Green Accepted			2022-12-17	WOS:000427279300004
J	Schroyer, AL; Stimes, NW; Saab, WFA; Chadee, DN				Schroyer, A. L.; Stimes, N. W.; Saab, W. F. Abi; Chadee, D. N.			MLK3 phosphorylation by ERK1/2 is required for oxidative stress-induced invasion of colorectal cancer cells	ONCOGENE			English	Article							LINEAGE KINASE 3; ACTIVATION LOOP; IN-VIVO; B-RAF; IDENTIFICATION; PROMOTES; MIGRATION; COMPLEX; BINDING; SPRK	Mixed lineage kinase 3 (MLK3) functions in migration and/or invasion of several human cancers; however, the role of MLK3 in colorectal cancer (CRC) invasion is unknown. MLK3 is a mitogen-activated protein kinase (MAPK) kinase kinase (MAP3K) which activates MAPK pathways through either kinase-dependent or -independent mechanisms. Human colorectal tumors display increased levels of reactive oxygen species (ROS) or oxidative stress. ROS, such as H2O2, are important for carcinogenesis and activate MAPK signaling pathways. In human colorectal carcinoma (HCT116) cells treated with H2O2, extracellular signal-regulated kinases 1 and 2 (ERK1/2) were activated and MLK3 exhibited reduced electrophoretic mobility (shift) in sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), which was eliminated by phosphatase treatment. Pretreatment with the ROS scavenger N-acetyl-L-cysteine, the ERK1/2 inhibitor UO126, or ERK1/2 siRNA knockdown blocked the H2O2-induced shift of MLK3, while MLK3 inhibition with Cep1347 did not. In co-immunoprecipitation experiments performed on H2O2-treated HCT116 cells, endogenous MLK3 associated with endogenous ERK1/2 and B-Raf. Active ERK1 phosphorylated kinase dead FLAG-MLK3 in vitro, whereas ERK1 phosphorylation of kinase dead FLAG-MLK3-S705A-S758A was reduced. Both MLK3 siRNA knockdown and FLAGMLK3-S705A-S758A expression decreased ERK1/2 activation in H2O2-treated cells. Prolonged H2O2 treatment activated ERK1/2 and promoted invasion of colon cancer cells, which was attenuated by MLK3 siRNA knockdown. Furthermore, S705A-S758A-FLAG-MLK3 demonstrated decreased oxidative-stress induced colon cancer cell invasion, but increased interaction with GST-B-Raf as compared with wild-type-FLAG-MLK3 in H2O2-treated cells. These results suggest oxidative stress stimulates an ERK1/2-dependent phosphorylation of MLK3 on Ser(705) and Ser(758), which promotes MLK3-dependent B-Raf and ERK1/2 activation; this positive feedback loop enhances the invasion of colon cancer cells.	[Schroyer, A. L.; Stimes, N. W.; Saab, W. F. Abi; Chadee, D. N.] Univ Toledo, Dept Biol Sci, 2801 West Bancroft St, Toledo, OH 43606 USA	University System of Ohio; University of Toledo	Chadee, DN (corresponding author), Univ Toledo, Dept Biol Sci, 2801 West Bancroft St, Toledo, OH 43606 USA.	deborah.chadee@utoledo.edu			National Institutes of Health [R15 CA199164, R15 GM102831]; NATIONAL CANCER INSTITUTE [R15CA199164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM102831] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institutes of Health grants R15 CA199164 and R15 GM102831 (to DNC).	Blessing NA, 2014, MOL CELL BIOL, V34, P3132, DOI 10.1128/MCB.00296-14; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; BOULTON TG, 1991, BIOCHEMISTRY-US, V30, P278, DOI 10.1021/bi00215a038; Chadee DN, 2006, P NATL ACAD SCI USA, V103, P4463, DOI 10.1073/pnas.0510651103; Chadee DN, 2004, NAT CELL BIOL, V6, P770, DOI 10.1038/ncb1152; Chen J, 2010, ONCOGENE, V29, P4399, DOI 10.1038/onc.2010.198; Chen J, 2012, CANCER RES, V72, P4130, DOI 10.1158/0008-5472.CAN-12-0655; Chien ST, 2011, MOL CELL BIOCHEM, V350, P135, DOI 10.1007/s11010-010-0692-2; Cronan MR, 2012, ONCOGENE, V31, P3889, DOI 10.1038/onc.2011.544; Du Y, 2005, J BIOL CHEM, V280, P42984, DOI 10.1074/jbc.M502671200; GALLO KA, 1994, J BIOL CHEM, V269, P15092; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; ING YL, 1994, ONCOGENE, V9, P1745; Lan T, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-016-0486-9; Lee HS, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005260; Leung IWL, 1998, J BIOL CHEM, V273, P32408, DOI 10.1074/jbc.273.49.32408; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Marusiak AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4901; Misek SA, 2017, MOL CANC RES; Mishra P, 2010, MOL ENDOCRINOL, V24, P598, DOI 10.1210/me.2009-0387; Partridge J, 2009, JOVE-J VIS EXP, P1475; Perse M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/725710; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rattanasinchai C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.44; Schachter KA, 2006, J BIOL CHEM, V281, P19134, DOI 10.1074/jbc.M603324200; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Son Yong, 2011, J Signal Transduct, V2011, P792639, DOI 10.1155/2011/792639; Swenson-Fields KI, 2008, MOL CELL, V32, P43, DOI 10.1016/j.molcel.2008.09.007; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Vacratsis PO, 2002, BIOCHEMISTRY-US, V41, P5613, DOI 10.1021/bi016075c; Velho S, 2010, HUM MOL GENET, V19, P697, DOI 10.1093/hmg/ddp536; Wang CY, 2010, PROTEIN CELL, V1, P871, DOI 10.1007/s13238-010-0111-1; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wlochowitz D, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00042; Xu ZH, 2005, MOL CELL BIOL, V25, P9949, DOI 10.1128/MCB.25.22.9949-9959.2005; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Zhan Y, 2012, EXP CELL RES, V318, P1641, DOI 10.1016/j.yexcr.2012.05.002; Zhang J, 2014, CLIN EXP DERMATOL, V39, P376, DOI 10.1111/ced.12286	42	35	35	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1031	1040		10.1038/onc.2017.396	http://dx.doi.org/10.1038/onc.2017.396			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29084209	Green Accepted			2022-12-17	WOS:000425905700006
J	Chattaragada, MS; Riganti, C; Sassoe, M; Principe, M; Santamorena, MM; Roux, C; Curcio, C; Evangelista, A; Allavena, P; Salvia, R; Rusev, B; Scarpa, A; Cappello, P; Novelli, F				Chattaragada, M. S.; Riganti, C.; Sassoe, M.; Principe, M.; Santamorena, M. M.; Roux, C.; Curcio, C.; Evangelista, A.; Allavena, P.; Salvia, R.; Rusev, B.; Scarpa, A.; Cappello, P.; Novelli, F.			FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis	ONCOGENE			English	Article							OXYGEN SPECIES PRODUCTION; PANCREATIC-CANCER; MICROENVIRONMENTAL REGULATION; REDOX REGULATION; GENE-EXPRESSION; ALPHA-ENOLASE; IN-VITRO; CELLS; SURVIVAL; FISSION	Mitochondrial dysregulation plays a central role in cancers and drives reactive oxygen species (ROS)-dependent tumor progression. We investigated the pro-tumoral roles of mitochondrial dynamics and altered intracellular ROS levels in pancreatic ductal adenocarcinoma (PDAC). We identified 'family with sequence similarity 49 member B' (FAM49B) as a mitochondria-localized protein that regulates mitochondrial fission and cancer progression. Silencing FAM49B in PDAC cells resulted in increased fission and mitochondrial ROS generation, which enhanced PDAC cell proliferation and invasion. Notably, FAM49B expression levels in PDAC cells were downregulated by the tumor microenvironment. Overall, the results of this study show that FAM49B acts as a suppressor of cancer cell proliferation and invasion in PDAC by regulating tumor mitochondrial redox reactions and metabolism.	[Chattaragada, M. S.; Principe, M.; Santamorena, M. M.; Roux, C.; Curcio, C.; Cappello, P.; Novelli, F.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Chattaragada, M. S.; Principe, M.; Santamorena, M. M.; Roux, C.; Curcio, C.; Cappello, P.; Novelli, F.] Azienda Univ Osped Citta Salute & Sci Torino, Ctr Expt Res & Med Studies, Turin, Italy; [Riganti, C.] Univ Turin, Dept Oncol, Turin, Italy; [Sassoe, M.] Univ Turin, Dept Neurosci Rita Levi Montalcini, Turin, Italy; [Evangelista, A.] Azienda Univ Osped Citta Salute & Sci, Dept Clin Epidemiol, Turin, Italy; [Evangelista, A.] CPO Piemonte, Turin, Italy; [Allavena, P.] Humanitas Clin & Res Ctr, Dept Gastroenterol, Lab Mol Gastroenterol, Milan, Italy; [Salvia, R.] Univ & Hosp Trust Verona, Pancreas Inst, Dept Surg, Verona, Italy; [Rusev, B.] Univ & Hosp Trust Verona, Dept Pathol & Publ Hlth, Verona, Italy; [Scarpa, A.] Univ & Hosp Trust Verona, ARC NET Res Ctr, Verona, Italy; [Cappello, P.; Novelli, F.] Univ Turin, Mol Biotechnol Ctr, Turin, Italy	University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; University of Turin; University of Turin; A.O.U. Citta della Salute e della Scienza di Torino; Centro di Riferimento per Epidemiologia e la Prevenzione Oncologica in Piemonte; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona; University of Turin	Novelli, F (corresponding author), Citta Salute & Sci Torino, Ctr Expt Res & Med Studies, Via Santena 5, I-10125 Turin, Italy.	franco.novelli@unito.it	Cappello, Paola/J-3127-2018; Salvia, Roberto/J-1773-2018; Roux, Cecilia/AAB-9661-2019; Curcio, Claudia/AAB-3638-2019; Allavena, Paola/HHM-5218-2022; Novelli, Francesco/Z-5990-2019; Scarpa, Aldo/K-6832-2016	Cappello, Paola/0000-0002-5321-7794; Roux, Cecilia/0000-0002-2883-167X; Allavena, Paola/0000-0002-6697-6028; CURCIO, Claudia/0000-0001-5306-4399; evangelista, andrea/0000-0003-1901-2805; Riganti, Chiara/0000-0001-9787-4836; NOVELLI, FRANCESCO/0000-0002-6259-5666; Scarpa, Aldo/0000-0003-1678-739X; Principe, Moitza/0000-0001-5013-7388	Associazione Italiana Ricerca sul Cancro (5 x mille) [12182, 15257, 15232]; University of Turin-Progetti Ateneo-Compagnia di San Paolo (PC-METAIMMUN-OTHER); University of Turin-Progetti Ateneo-Compagnia di San Paolo (PANTHER); Italian Ministry of Health-Progetti Ricerca Finalizzata [RF-2013-02354892]; Fondazione Ricerca Molinette Onlus; Fondazione Nadia Valsecchi; European Community FP7 Grant Cam-Pac [602783]; FIMP, Ministero Salute [CUP_J33G13000210001]; Fondazione Ursula e Giorgio Cytron, Torino	Associazione Italiana Ricerca sul Cancro (5 x mille)(Fondazione AIRC per la ricerca sul cancro); University of Turin-Progetti Ateneo-Compagnia di San Paolo (PC-METAIMMUN-OTHER); University of Turin-Progetti Ateneo-Compagnia di San Paolo (PANTHER); Italian Ministry of Health-Progetti Ricerca Finalizzata; Fondazione Ricerca Molinette Onlus; Fondazione Nadia Valsecchi; European Community FP7 Grant Cam-Pac; FIMP, Ministero Salute; Fondazione Ursula e Giorgio Cytron, Torino	We thank Roberta Curto for technical support in the in vivo experiments, Elena Frola for technical support in the electron microscopy and Dr Radhika Srinivasan for critically reading the manuscript. The nature research language editing service edited this work. This work was supported by grants from the Associazione Italiana Ricerca sul Cancro (5 x mille no. 12182 to AS and FN, IG no. 15257 to FN, IG no. 15232 to AS); University of Turin-Progetti Ateneo 2014-Compagnia di San Paolo (PC-METAIMMUN-OTHER to FN and PANTHER to PC), Italian Ministry of Health-Progetti Ricerca Finalizzata (RF-2013-02354892 to FN), Fondazione Ricerca Molinette Onlus, Fondazione Nadia Valsecchi to FN, European Community FP7 Grant Cam-Pac (agreement no: 602783) to AS; FIMP, Ministero Salute (CUP_J33G13000210001) to AS. MSC was supported by Fondazione Ursula e Giorgio Cytron, Torino.	Al Saati T, 2013, AM J PATHOL, V182, P1996, DOI 10.1016/j.ajpath.2013.02.034; Bailey P, 2016, NATURE, V531, P47, DOI 10.1038/nature16965; Birgersdotter A, 2005, SEMIN CANCER BIOL, V15, P405, DOI 10.1016/j.semcancer.2005.06.009; Bleazard W, 1999, NAT CELL BIOL, V1, P298, DOI 10.1038/13014; Brahimi-Horn MC, 2015, CANCER METAB, V3, DOI 10.1186/s40170-015-0133-5; Caino MC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13730; Campia I, 2009, BRIT J PHARMACOL, V158, P1777, DOI 10.1111/j.1476-5381.2009.00465.x; Cappello P, 2013, GASTROENTEROLOGY, V144, P1098, DOI 10.1053/j.gastro.2013.01.020; Cappello P, 2009, INT J CANCER, V125, P639, DOI 10.1002/ijc.24355; Clerkin JS, 2008, CANCER LETT, V266, P30, DOI 10.1016/j.canlet.2008.02.029; Eura Y, 2003, J BIOCHEM, V134, P333, DOI 10.1093/jb/mvg150; Ferreira-da-Silva A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122308; Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hancock JT, 2009, MOL BIOTECHNOL, V43, P162, DOI 10.1007/s12033-009-9189-1; Handy DE, 2012, ANTIOXID REDOX SIGN, V16, P1323, DOI 10.1089/ars.2011.4123; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Hurd TR, 2012, TRENDS CELL BIOL, V22, P107, DOI 10.1016/j.tcb.2011.11.002; Kaistha BP, 2014, BRIT J CANCER, V111, P1780, DOI 10.1038/bjc.2014.460; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kashatus JA, 2015, MOL CELL, V57, P537, DOI 10.1016/j.molcel.2015.01.002; Kodydkova J, 2013, PANCREAS, V42, P614, DOI 10.1097/MPA.0b013e318288360a; Konstantinidis IT, 2013, ANN SURG, V257, P731, DOI 10.1097/SLA.0b013e318263da2f; Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793; Krska Zdenek, 2015, Prague Med Rep, V116, P253, DOI 10.14712/23362936.2015.65; Lorenz H, 2006, NAT METHODS, V3, P205, DOI 10.1038/nmeth857; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X; Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285; Pinzon-Daza ML, 2012, BRIT J PHARMACOL, V167, P1431, DOI 10.1111/j.1476-5381.2012.02103.x; Principe M, 2015, ONCOTARGET, V6, P11098, DOI 10.18632/oncotarget.3572; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Rambold Angelika S, 2011, Commun Integr Biol, V4, P752; Riganti C, 2008, TOXICOL APPL PHARM, V228, P277, DOI 10.1016/j.taap.2007.12.013; Riganti C, 2012, FREE RADICAL BIO MED, V53, P421, DOI 10.1016/j.freeradbiomed.2012.05.006; Rishi A, 2015, SEMIN ONCOL, V42, P28, DOI 10.1053/j.seminoncol.2014.12.004; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Saborido A, 2005, FREE RADICAL RES, V39, P921, DOI 10.1080/10715760500188887; Sassoe-Pognetto M, 2000, J NEUROSCI, V20, P2192; Schwamb B, 2015, INT J CANCER, V137, P1318, DOI 10.1002/ijc.29498; Serasinghe MN, 2015, MOL CELL, V57, P521, DOI 10.1016/j.molcel.2015.01.003; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Storz P, 2017, NAT REV GASTRO HEPAT, V14, P296, DOI 10.1038/nrgastro.2017.12; Stowe DF, 2009, ANTIOXID REDOX SIGN, V11, P1373, DOI [10.1089/ars.2008.2331, 10.1089/ARS.2008.2331]; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Tomaino B, 2007, J PROTEOME RES, V6, P4025, DOI 10.1021/pr070281a; Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578; Tung JC, 2015, FREE RADICAL BIO MED, V79, P269, DOI 10.1016/j.freeradbiomed.2014.11.020; Uzhachenko R, 2012, J PATHOL, V227, P456, DOI 10.1002/path.4039; Viltono L, 2008, J COMP NEUROL, V508, P579, DOI 10.1002/cne.21713; Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29; Wai T, 2016, TRENDS ENDOCRIN MET, V27, P105, DOI 10.1016/j.tem.2015.12.001; Wang ZW, 2010, CURR STEM CELL RES T, V5, P74, DOI 10.2174/157488810790442813; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg F, 2009, CELL MOL LIFE SCI, V66, P3663, DOI 10.1007/s00018-009-0099-y; Willems PHGM, 2015, CELL METAB, V22, P207, DOI 10.1016/j.cmet.2015.06.006; Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058; Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855; Yu TZ, 2011, ANTIOXID REDOX SIGN, V14, P425, DOI 10.1089/ars.2010.3284; Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103; Zhang L, 2015, NATURE, V527, P100, DOI 10.1038/nature15376; Zhang Q, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.215; Zhao J, 2013, ONCOGENE, V32, P4814, DOI 10.1038/onc.2012.494; Zhou LX, 2013, MOL CANCER RES, V11, P272, DOI 10.1158/1541-7786.MCR-12-0395	66	35	35	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					697	709		10.1038/onc.2017.358	http://dx.doi.org/10.1038/onc.2017.358			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059164	Green Published, hybrid			2022-12-17	WOS:000424628100002
J	Liu, L; Wong, CC; Gong, B; Yu, J				Liu, L.; Wong, C. C.; Gong, B.; Yu, J.			Functional significance and therapeutic implication of ring-type E3 ligases in colorectal cancer	ONCOGENE			English	Review							SCF-BETA-TRCP; UBIQUITIN-CONJUGATING ENZYME; WNT SIGNALING PATHWAY; CELL-CYCLE CONTROL; F-BOX PROTEINS; TUMOR-SUPPRESSOR; COLON-CANCER; NEDD8-ACTIVATING ENZYME; E-CADHERIN; KAPPA-B	Accumulative studies revealed that E3 ubiquitin ligases have important roles in colorectal carcinogenesis. The pathogenic mechanisms of colorectal cancer (CRC) initiation and progression are complex and heterogeneous, involving somatic mutations, abnormal gene fusion, deletion or amplification and epigenetic alteration, which may cause aberrant expression or altered function of E3 ligases in CRC. Defects of E3 ligases have been reported to be involved in the molecular etiology and pathogenesis of CRC. The aberrant expressed E3 ligases can function as either oncogenes or tumor suppressors depending on ubiquiting target substrates in CRC. Recently, considerable progress has been made in our understanding of the potential roles of E3 ligase-mediated ubiquitylation in colorectal carcinogenesis. There are mainly two subtypes of E3 ubiquitin ligases in humans, as defined by the presence of either a HECT domain or a RING finger domain on the basis of structural similitude. Most cancer-associated E3 ligases participate in regulating the cell cycle, apoptosis, gene transcription, cell signaling and DNA repair, the critical parts of CRC tumorigenesis. In this review, we have provided a comprehensive summary of abnormally expressed E3 ligases and their related pivotal mechanistic effects in CRC. In particular, we have highlighted the function of RING-type E3 ubiquitin enzymes in modulating cancer signaling pathways, immunity and tumor microenvironment in CRC development and progression; their mechanism(s) of action in CRC involving both ubiquitylation-dependent and ubiquitylation-independent effects; and the potential of RING E3 ligases as molecular biomarkers for predicting patient prognosis and as therapeutic targets in CRC. A better understanding of E3 ligase-mediated substrates' ubiquitylation involved in the development of CRC will provide new insights into the pathophysiology mechanisms of CRC, and unravel novel prognostic markers and therapeutic strategies for CRC.	[Liu, L.; Wong, C. C.; Yu, J.] Chinese Univ Hong Kong, Prince Wales Hosp, CUHK Shenzhen Res Inst,Inst Digest Dis,Dept Med &, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China; [Gong, B.] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Gastroenterol,Digest Endoscopy Ctr, Shanghai, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Shanghai Jiao Tong University	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, CUHK Shenzhen Res Inst,Inst Digest Dis,Dept Med &, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, Room 707A,7-F,Li Ka Shing Med Sci Bldg, Shatin, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Wong, Chi Chun/C-4636-2016; Jun, Yu/D-8569-2015	Jun, Yu/0000-0001-5008-2153	RGC-GRF Hong Kong [766613, 14106415, 14114615, 14111216]; HMRF Hong Kong [03140856]; National Key Technology RD Program [2014BAI09B05]; 135 program project [2016YFC1303200]	RGC-GRF Hong Kong(Hong Kong Research Grants Council); HMRF Hong Kong; National Key Technology RD Program(National Key Technology R&D Program); 135 program project	This project was supported by RGC-GRF Hong Kong (766613, 14106415, 14114615, 14111216), HMRF Hong Kong (03140856), The National Key Technology R&D Program (2014BAI09B05) and 135 program project (2016YFC1303200).	Abdel-Fattah G, 2000, J GASTROINTEST SURG, V4, P109, DOI 10.1016/S1091-255X(00)80041-4; Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Al-Shamsi HO, 2016, J GASTROINTEST ONCOL, V7, P882, DOI 10.21037/jgo.2016.11.02; Baker R, 2013, NAT STRUCT MOL BIOL, V20, P46, DOI 10.1038/nsmb.2430; Bashir T, 2005, NAT CELL BIOL, V7, P779, DOI 10.1038/ncb0805-779; Berndsen CE, 2014, NAT STRUCT MOL BIOL, V21, P301, DOI 10.1038/nsmb.2780; Bochis OV, 2015, J GASTROINTEST LIVER, V24, P225, DOI 10.15403/jgld.2014.1121.242.skp2; Buetow L, 2016, NAT REV MOL CELL BIO, V17, P626, DOI 10.1038/nrm.2016.91; Cantu C, 2013, EMBO REP, V14, P295, DOI 10.1038/embor.2013.21; Cardozo T, 2004, NAT REV MOL CELL BIO, V5, P739, DOI 10.1038/nrm1471; Ceccarelli DF, 2011, CELL, V145, P1075, DOI 10.1016/j.cell.2011.05.039; Chen HJ, 2014, MOL MED REP, V10, P1129, DOI 10.3892/mmr.2014.2308; Chene P, 2003, NAT REV CANCER, V3, P102, DOI 10.1038/nrc991; Coe GL, 2016, SCI REP-UK, V6, DOI 10.1038/srep30816; Conlin A, 2005, GUT, V54, P1283, DOI 10.1136/gut.2005.066514; Daniels DL, 2005, NAT STRUCT MOL BIOL, V12, P364, DOI 10.1038/nsmb912; Davis H, 2014, GUT, V63, P792, DOI 10.1136/gutjnl-2013-304719; de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Denuc A, 2010, BIOCHEM SOC T, V38, P34, DOI 10.1042/BST0380034; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Dickson KM, 2004, DEV DYNAM, V231, P122, DOI 10.1002/dvdy.20110; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Dynek JN, 2010, EMBO J, V29, P4198, DOI 10.1038/emboj.2010.300; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Ehrenschwender M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.534; Fearon ER, 2012, CURR BIOL, V22, pR849, DOI 10.1016/j.cub.2012.08.002; Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Fujita T, 2008, AM J PATHOL, V173, P217, DOI 10.2353/ajpath.2008.070957; Galban S, 2010, CELL DEATH DIFFER, V17, P54, DOI 10.1038/cdd.2009.81; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127; Glebov OK, 2006, CANCER EPIDEM BIOMAR, V15, P2253, DOI 10.1158/1055-9965.EPI-05-0694; Gonzalez-Prieto R, 2015, CELL CYCLE, V14, P1859, DOI 10.1080/15384101.2015.1040965; Grabbe C, 2011, NAT REV MOL CELL BIO, V12, P295, DOI 10.1038/nrm3099; Grim JE, 2012, MOL CELL BIOL, V32, P2160, DOI 10.1128/MCB.00305-12; Gu LB, 2016, CANCER CELL, V30, P623, DOI 10.1016/j.ccell.2016.08.015; Guardavaccaro D, 2004, ONCOGENE, V23, P2037, DOI 10.1038/sj.onc.1207413; Hadjihannas MV, 2012, EMBO REP, V13, P347, DOI 10.1038/embor.2012.12; Hanson AJ, 2012, MOL CELL, V45, P619, DOI 10.1016/j.molcel.2011.12.032; Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hernandez JM, 2011, CLIN COLORECTAL CANC, V10, P188, DOI 10.1016/j.clcc.2011.03.014; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoeller D, 2009, NATURE, V458, P438, DOI 10.1038/nature07960; Inuzuka H, 2014, SPRING CANC RES, P1, DOI 10.1007/978-3-319-05026-3; Iwatsuki M, 2010, INT J CANCER, V126, P1828, DOI 10.1002/ijc.24879; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jeon YJ, 2015, CANCER CELL, V27, P354, DOI 10.1016/j.ccell.2015.02.006; Jeong WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002242; Jiang XM, 2015, MOL CELL, V58, P522, DOI 10.1016/j.molcel.2015.03.015; Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110; Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233; Kapanidou M, 2017, TRENDS BIOCHEM SCI, V42, P193, DOI 10.1016/j.tibs.2016.12.001; Kedrin D, 2015, CLIN TRANSL GASTROEN, V6, DOI 10.1038/ctg.2015.12; Kidokoro T, 2008, ONCOGENE, V27, P1562, DOI 10.1038/sj.onc.1210799; Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401; Klampfer L, 2011, CURR CANCER DRUG TAR, V11, P451, DOI 10.2174/156800911795538066; Koo BK, 2015, P NATL ACAD SCI USA, V112, P7548, DOI 10.1073/pnas.1508113112; Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308; Kotz J., 2011, SCIBX, V4, P1, DOI [10.1038/scibx.2011.559, DOI 10.1038/SCIBX.2011.559]; Kozuch PS, 2008, J CLIN ONCOL, V26, P2320, DOI 10.1200/JCO.2007.14.0152; Krajewska M, 2005, CLIN CANCER RES, V11, P5451, DOI 10.1158/1078-0432.CCR-05-0094; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Lee OH, 2015, BBA-MOL CELL RES, V1853, P409, DOI 10.1016/j.bbamcr.2014.11.007; Lee YY, 2009, DIS MARKERS, V26, P9, DOI [10.3233/DMA-2009-0598, 10.1155/2009/821543]; Lipkowitz S, 2011, NAT REV CANCER, V11, P629, DOI 10.1038/nrc3120; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu CM, 1999, P NATL ACAD SCI USA, V96, P6273, DOI 10.1073/pnas.96.11.6273; Lugli A, 2007, HISTOPATHOLOGY, V50, P453, DOI 10.1111/j.1365-2559.2007.02620.x; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Milhollen MA, 2011, CANCER RES, V71, P3042, DOI 10.1158/0008-5472.CAN-10-2122; Minella AC, 2007, ONCOGENE, V26, P6948, DOI 10.1038/sj.onc.1210518; Miyaki M, 2009, ONCOLOGY-BASEL, V76, P430, DOI 10.1159/000217811; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Noguchi K, 2011, CARCINOGENESIS, V32, P995, DOI 10.1093/carcin/bgr068; Ougolkov A, 2004, JNCI-J NATL CANCER I, V96, P1161, DOI 10.1093/jnci/djh219; Ozato K, 2008, NAT REV IMMUNOL, V8, P849, DOI 10.1038/nri2413; Paschall AV, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-24; Pecina-Slaus N, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-17; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118; Piao MY, 2016, SCAND J GASTROENTERO, V51, P572, DOI 10.3109/00365521.2015.1124285; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Popovic D, 2014, NAT MED, V20, P1242, DOI 10.1038/nm.3739; Reyes-Turcu FE, 2009, ANNU REV BIOCHEM, V78, P363, DOI 10.1146/annurev.biochem.78.082307.091526; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; Ring A, 2014, STEM CELL REV REP, V10, P512, DOI 10.1007/s12015-014-9515-2; Sackton KL, 2014, NATURE, V514, P646, DOI 10.1038/nature13660; Sah NK, 2006, CANCER LETT, V244, P164, DOI 10.1016/j.canlet.2006.03.007; Sancho R, 2010, GASTROENTEROLOGY, V139, P929, DOI 10.1053/j.gastro.2010.05.078; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; Schile AJ, 2008, GENE DEV, V22, P2256, DOI 10.1101/gad.1663108; Schutte M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14262; Shapira M, 2005, CANCER-AM CANCER SOC, V103, P1336, DOI 10.1002/cncr.20917; Shukla S, 2014, NEOPLASIA, V16, P115, DOI 10.1593/neo.14184; Silke J, 2014, METHOD ENZYMOL, V545, P35, DOI 10.1016/B978-0-12-801430-1.00002-0; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Song E, 2001, BRIT J CANCER, V85, P1047, DOI 10.1038/sj.bjc.6692042; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Sriramachandran AM, 2014, BBA-MOL CELL RES, V1843, P75, DOI 10.1016/j.bbamcr.2013.08.022; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Steinhart Z, 2017, NAT MED, V23, P60, DOI 10.1038/nm.4219; Strack P, 2000, ONCOGENE, V19, P3529, DOI 10.1038/sj.onc.1203647; Street I, 2012, EUR J CANCER, V48, pS250, DOI 10.1016/S0959-8049(12)71650-7; Sun H, 2013, CANCER RES, V73, P4950, DOI 10.1158/0008-5472.CAN-13-0370; Sun HY, 2012, J BIOL CHEM, V287, P42071, DOI 10.1074/jbc.M112.410985; Tan MJ, 2006, NEOPLASIA, V8, P1042, DOI 10.1593/neo.06568; Tarcic O, 2016, CELL REP, V14, P1462, DOI 10.1016/j.celrep.2016.01.020; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Thomas JJ, 2016, CELL REP, V16, P3388, DOI 10.1016/j.celrep.2016.08.024; Tong J, 2017, ONCOGENE, V36, P787, DOI 10.1038/onc.2016.247; Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262; Tsai WB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011171; Tursun B, 2005, GENE DEV, V19, P2307, DOI 10.1101/gad.1340605; Uddin S, 2008, CANCER RES, V68, P3379, DOI 10.1158/0008-5472.CAN-07-6109; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wan JF, 2016, TECHNOL CANCER RES T, V15, P527, DOI 10.1177/1533034615588197; Wang XW, 2014, GUT LIVER, V8, P487, DOI 10.5009/gnl13133; Wang ZW, 2012, FEBS LETT, V586, P1409, DOI 10.1016/j.febslet.2012.03.017; Watanabe M, 2017, J BIOCHEM, V161, P135, DOI 10.1093/jb/mvw087; Watson IR, 2013, NAT REV GENET, V14, P703, DOI 10.1038/nrg3539; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wu BB, 2013, EMBO REP, V14, P347, DOI 10.1038/embor.2013.19; Wu WJ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-142; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010; Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304; Zhang T, 2016, IRAN RED CRESCENT ME, V18, DOI 10.5812/ircmj.23931; Zhang X, 2015, ONCOGENE, V34, P4412, DOI 10.1038/onc.2014.377; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao D, 2017, NATURE, V542, P484, DOI 10.1038/nature21357; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173; Zhu J, 2016, ONCOGENE, V35, P1955, DOI 10.1038/onc.2015.260; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	153	35	35	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2018	37	2					148	159		10.1038/onc.2017.313	http://dx.doi.org/10.1038/onc.2017.313			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS8AN	28925398	hybrid, Green Published			2022-12-17	WOS:000422631700002
J	Zhong, Y; Yang, J; Xu, WW; Wang, Y; Zheng, CC; Li, B; He, QY				Zhong, Y.; Yang, J.; Xu, W. W.; Wang, Y.; Zheng, C-C; Li, B.; He, Q-Y			KCTD12 promotes tumorigenesis by facilitating CDC25B/CDK1/Aurora A-dependent G2/M transition	ONCOGENE			English	Article							GASTROINTESTINAL STROMAL TUMORS; CELL-CYCLE; ESOPHAGEAL CANCER; MITOTIC KINASES; AURORA-A; PROGRESSION; CDC25B; PHOSPHORYLATION; ACTIVATION; PROTEOMICS	Cell cycle dysregulation leads to uncontrolled cell proliferation and tumorigenesis. Understanding the molecular mechanisms underlying cell cycle progression can provide clues leading to the identification of key proteins involved in cancer development. In this study, we performed proteomics analysis to identify novel regulators of the cell cycle. We found that potassium channel tetramerization domain containing 12 (KCTD12) was significantly upregulated in M phase compared with S phase. We also found that KCTD12 overexpression not only facilitated the G2/M transition and induced cancer cell proliferation, but also promoted the growth of subcutaneous tumors and Ki-67 proliferation index in mice. Regarding the mechanism underlying these phenomena, cyclin-dependent kinase 1 (CDK1) was identified as an interacting partner of KCTD12 by immunoprecipitation and mass spectrometry analysis, which showed that KCTD12 activated CDK1 and Aurora kinase A (Aurora A) and that the effects of KCTD12 on CDK1 phosphorylation and cell proliferation were abrogated by cell division cycle 25B (CDC25B) silencing. In addition, Aurora A phosphorylated KCTD12 at serine 243, thereby initiating a positive feedback loop necessary for KCTD12 to exert its cancerpromoting effects. Furthermore, we analyzed the expression levels of various genes and the correlations between the expression of these genes and survival using tumor tissue microarray and Gene Expression Omnibus (GEO) data sets. The data showed that KCTD12 expression was significantly upregulated in cervical and lung cancers. More importantly, high KCTD12 expression was associated with larger tumor sizes, higher pathological stages and poor patient survival. Collectively, our study demonstrate that KCTD12 binds to CDC25B and activates CDK1 and Aurora A to facilitate the G2/M transition and promote tumorigenesis and that Aurora A phosphorylates KCTD12 at serine 243 to trigger a positive feedback loop, thereby potentiating the effects of KCTD12. Thus, the KCTD12-CDC25B-CDK1-Aurora A axis has important implications for cancer diagnoses and prognoses.	[Zhong, Y.; Yang, J.; Wang, Y.; Zheng, C-C; Li, B.; He, Q-Y] Jinan Univ, Inst Life & Hlth Engn, Coll Life Sci & Technol, Key Lab Funct Prot Res Guangdong Higher Educ Inst, Guangzhou, Guangdong, Peoples R China; [Zhong, Y.] Jinan Univ, Dept Pathol, Coll Med, Guangzhou, Guangdong, Peoples R China; [Xu, W. W.] Jinan Univ, Inst Biomed, Natl Engn Res Ctr Genet Med, Guangdong Prov Key Lab Bioengn Med, Guangzhou, Guangdong, Peoples R China	Jinan University; Jinan University; Jinan University	Li, B; He, QY (corresponding author), Jinan Univ, Inst Life & Hlth Engn, Coll Life Sci & Technol, Guangzhou 510632, Guangdong, Peoples R China.	libin2015@jnu.edu.cn; tqyhe@jnu.edu.cn	He, Qing-Yu/H-7078-2014; Wang, Yang/GQH-2363-2022	He, Qing-Yu/0000-0003-0503-9492; Wang, Yang/0000-0001-6440-0204; Li, Bin/0000-0002-8979-610X	National Key Research and Development Program of China [2017YFA0505100]; National Natural Science Foundation of China [31770888, 31570828, 81672953, 81773085]; Guangdong Natural Science Research Grant [S2013030013315, 2016A030313838]; Fundamental Research Funds for the Central Universities [ZX20170413]	National Key Research and Development Program of China; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Research Grant; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	We thank Mr. Xing-Feng Yin and Mr. Zheng-Hua Sun for their technical assistance on mass spectrometry. This work was supported by the National Key Research and Development Program of China (No. 2017YFA0505100), the National Natural Science Foundation of China (31770888, 31570828, 81672953, 81773085), Guangdong Natural Science Research Grant (S2013030013315, 2016A030313838), and the Fundamental Research Funds for the Central Universities (ZX20170413).	Alexander RD, 2006, PROTEOMICS, V6, P1886, DOI 10.1002/pmic.200500548; Au FKC, 2017, DEV CELL, V40, P81, DOI 10.1016/j.devcel.2016.11.019; Booker SA, 2017, CEREB CORTEX, V27, P2318, DOI 10.1093/cercor/bhw090; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chen XL, 2013, PROTEOMICS, V13, P3030, DOI 10.1002/pmic.201200448; Chen Y, 2013, METHODS MOL BIOL, V1077, P105, DOI 10.1007/978-1-62703-637-5_7; Correale S, 2013, J MOL RECOGNIT, V26, P488, DOI 10.1002/jmr.2291; Davezac N, 2002, ONCOGENE, V21, P7630, DOI 10.1038/sj.onc.1205870; de Freitas AC, 2015, CURR DRUG TARGETS, V16, P77, DOI 10.2174/1389450116666141205150942; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Ivankova K, 2013, J BIOL CHEM, V288, P24848, DOI 10.1074/jbc.M113.476770; Jeong AL, 2013, BMB REP, V46, P289, DOI 10.5483/BMBRep.2013.46.6.041; Jullien D, 2011, CANCER RES, V71, P1968, DOI 10.1158/0008-5472.CAN-10-2453; Kang HJ, 2006, PROTEOMICS, V6, P1151, DOI 10.1002/pmic.200500372; Labbe DP, 2012, PROG MOL BIOL TRANSL, V106, P253, DOI 10.1016/B978-0-12-396456-4.00009-2; Lapenna S, 2009, NAT REV DRUG DISCOV, V8, P547, DOI 10.1038/nrd2907; Li B, 2017, ONCOGENE, V36, P3986, DOI 10.1038/onc.2017.29; Li B, 2016, CLIN CANCER RES, V22, P1243, DOI 10.1158/1078-0432.CCR-15-1196; Li B, 2014, CLIN CANCER RES, V20, P2651, DOI 10.1158/1078-0432.CCR-13-2735; Li B, 2009, MOL CANCER THER, V8, P2635, DOI 10.1158/1535-7163.MCT-09-0162; Li LP, 2016, SCI REP-UK, V6, DOI 10.1038/srep20460; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Ma HT, 2017, METHODS MOL BIOL, V1524, P189, DOI 10.1007/978-1-4939-6603-5_12; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Milewski D, 2017, ONCOGENE, V36, P850, DOI 10.1038/onc.2016.254; Namiki T, 2015, CANCER RES, V75, P2708, DOI 10.1158/0008-5472.CAN-13-3209; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Oh AY, 2016, CANCER RES, V76, P4791, DOI 10.1158/0008-5472.CAN-15-1025; Olsen JV, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000475; Ong SE, 2006, NAT PROTOC, V1, P2650, DOI 10.1038/nprot.2006.427; Ouchi M, 2004, J BIOL CHEM, V279, P19643, DOI 10.1074/jbc.M311780200; Resendes BL, 2004, JARO-J ASSOC RES OTO, V5, P185, DOI 10.1007/s10162-003-4042-x; Roshak AK, 2000, CELL SIGNAL, V12, P405, DOI 10.1016/S0898-6568(00)00080-2; Sobczyk GJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4319; Sprenger Adrian, 2013, Methods Mol Biol, V961, P179, DOI 10.1007/978-1-62703-227-8_10; Suehara Y, 2008, CLIN CANCER RES, V14, P1707, DOI 10.1158/1078-0432.CCR-07-1478; Taylor William R, 2004, Methods Mol Biol, V281, P293; Turecek R, 2014, NEURON, V82, P1032, DOI 10.1016/j.neuron.2014.04.015; Van Horn RD, 2010, J BIOL CHEM, V285, P21849, DOI 10.1074/jbc.M110.141010; Wang J, 2015, ONCOTARGET, V6, P1618, DOI 10.18632/oncotarget.2730; Wang Y, 2017, BIOCHEM PHARMACOL, V129, P43, DOI 10.1016/j.bcp.2017.01.006; Wang Y, 2016, APOPTOSIS, V21, P1438, DOI 10.1007/s10495-016-1300-z; Whalley HJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8437; Xu WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14399; Yang H, 2004, CANCER RES, V64, P463, DOI 10.1158/0008-5472.CAN-03-2907; Zanivan S, 2013, MOL CELL PROTEOMICS, V12, P3599, DOI 10.1074/mcp.M113.031344; Zhang W, 2011, J BIOL CHEM, V286, P35899, DOI 10.1074/jbc.M111.267690	49	35	36	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2017	36	44					6177	6189		10.1038/onc.2017.287	http://dx.doi.org/10.1038/onc.2017.287			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FL5CU	28869606	hybrid, Green Published			2022-12-17	WOS:000414249800011
J	Arslan, AD; Sassano, A; Saleiro, D; Lisowski, P; Kosciuczuk, EM; Fischietti, M; Eckerdt, F; Fish, EN; Platanias, LC				Arslan, A. D.; Sassano, A.; Saleiro, D.; Lisowski, P.; Kosciuczuk, E. M.; Fischietti, M.; Eckerdt, F.; Fish, E. N.; Platanias, L. C.			Human SLFN5 is a transcriptional co-repressor of STAT1-mediated interferon responses and promotes the malignant phenotype in glioblastoma	ONCOGENE			English	Article							GLIOMA; CELLS; CANCER; EXPRESSION; INVASION; FAMILY; GROWTH; BETA; DIFFERENTIATION; MAINTENANCE	We provide evidence that the IFN-regulated member of the Schlafen (SLFN) family of proteins, SLFN5, promotes the malignant phenotype in glioblastoma multiforme (GBM). Our studies indicate that SLFN5 expression promotes motility and invasiveness of GBM cells, and that high levels of SLFN5 expression correlate with high-grade gliomas and shorter overall survival in patients suffering from GBM. In efforts to uncover the mechanism by which SLFN5 promotes GBM tumorigenesis, we found that this protein is a transcriptional co-repressor of STAT1. Type-I IFN treatment triggers the interaction of STAT1 with SLFN5, and the resulting complex negatively controls STAT1-mediated gene transcription via interferon stimulated response elements. Thus, SLFN5 is both an IFN-stimulated response gene and a repressor of IFN-gene transcription, suggesting the existence of a negative-feedback regulatory loop that may account for suppression of antitumor immune responses in glioblastoma.	[Arslan, A. D.; Sassano, A.; Saleiro, D.; Kosciuczuk, E. M.; Fischietti, M.; Eckerdt, F.; Platanias, L. C.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, 303 East Super, Chicago, IL 60611 USA; [Arslan, A. D.; Sassano, A.; Saleiro, D.; Kosciuczuk, E. M.; Fischietti, M.; Platanias, L. C.] Northwestern Univ, Div Hematol Oncol, Dept Med, Feinberg Sch Med, Chicago, IL USA; [Lisowski, P.] Med Univ Warsaw, Dept Med Genet, Ctr Preclin Res & Technol CePT, Warsaw, Poland; [Lisowski, P.] Helmholtz Assoc, iPS Cell Based Dis Modeling Grp, Max Delbruck Ctr Mol Med MDC, Berlin, Germany; [Kosciuczuk, E. M.; Platanias, L. C.] Jesse Brown Vet Affairs Med Ctr, Dept Med, Chicago, IL USA; [Fish, E. N.] Univ Hlth Network, Toronto Res Inst, Toronto, ON, Canada; [Fish, E. N.] Univ Toronto, Dept Immunol, Toronto, ON, Canada	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Feinberg School of Medicine; Medical University of Warsaw; Helmholtz Association; Max Delbruck Center for Molecular Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Platanias, LC (corresponding author), Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, 303 East Super, Chicago, IL 60611 USA.	l-platanias@northwestern.edu	Fischietti, Mariafausta/Y-6449-2019; Kosciuczuk, Ewa Maria/AAD-2815-2022		NIH [CA161196, CA77816, CA155566, T32CA070085, T32CA080621]; Department of Veterans Affairs [5I01CX000916]; National Science Centre, Poland [2016/22/M/NZ2/00548]; NATIONAL CANCER INSTITUTE [R01CA155566, R01CA077816, T32CA070085, R01CA161796, T32CA080621] Funding Source: NIH RePORTER; Veterans Affairs [I01CX000916] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); National Science Centre, Poland(National Science Centre, Poland); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	The work was supported in part by NIH grants CA161196, CA77816 and CA155566 and by grant 5I01CX000916 from the Department of Veterans Affairs. ADA was supported in part by NIH training grant T32CA070085, DS was supported in part by NIH training grant T32CA080621, and PL was supported in part by National Science Centre, Poland Grant 2016/22/M/NZ2/00548. We thank Dr John A. Kessler for providing the JK18 and JK46 GSC lines.	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; BRADLEY NJ, 1983, BRIT J CANCER, V48, P819, DOI 10.1038/bjc.1983.272; Bustos O, 2009, GENE, V447, P1, DOI 10.1016/j.gene.2009.07.006; Desjardins A, 2005, FRONT BIOSCI-LANDMRK, V10, P2645, DOI 10.2741/1727; Eckerdt F, 2016, BIOTECHNIQUES, V60, P43, DOI 10.2144/000114372; Feng HZ, 2014, J CLIN INVEST, V124, P3741, DOI 10.1172/JCI73093; Fish EN, 2014, MOL CANCER RES, V12, P1691, DOI 10.1158/1541-7786.MCR-14-0450; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Geserick P, 2004, INT IMMUNOL, V16, P1535, DOI 10.1093/intimm/dxh155; Gil MP, 2001, P NATL ACAD SCI USA, V98, P6680, DOI 10.1073/pnas.111163898; Ji F, 2013, INT J ONCOL, V42, P1578, DOI 10.3892/ijo.2013.1878; Katsoulidis E, 2010, J BIOL CHEM, V285, P40333, DOI 10.1074/jbc.M110.151076; Kramer A, 2014, BIOINFORMATICS, V30, P523, DOI 10.1093/bioinformatics/btt703; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; Li MQ, 2012, NATURE, V491, P125, DOI 10.1038/nature11433; Madhavan S, 2009, MOL CANCER RES, V7, P157, DOI 10.1158/1541-7786.MCR-08-0435; Mavrommatis E, 2013, J INTERF CYTOK RES, V33, P206, DOI 10.1089/jir.2012.0133; Motomura K, 2011, CANCER-AM CANCER SOC, V117, P1721, DOI 10.1002/cncr.25637; Nagato S, 2005, INT J CANCER, V117, P41, DOI 10.1002/ijc.21102; Napoles OC, 2017, J GASTROENTEROL, V52, P39, DOI 10.1007/s00535-016-1202-4; Natsume A, 2005, CANCER RES, V65, P7573, DOI 10.1158/0008-5472.CAN-05-0036; Neumann B, 2008, BIOCHEM BIOPH RES CO, V370, P62, DOI 10.1016/j.bbrc.2008.03.032; Parker BS, 2016, NAT REV CANCER, V16, P131, DOI 10.1038/nrc.2016.14; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Platanias LC, 2013, J INTERF CYTOK RES, V33, P143, DOI 10.1089/jir.2013.0019; Porritt RA, 2015, TRENDS IMMUNOL, V36, P150, DOI 10.1016/j.it.2015.02.002; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Ritchie KJ, 2004, SEMIN CELL DEV BIOL, V15, P237, DOI 10.1016/j.semcdb.2003.12.005; Rusinova I, 2013, NUCLEIC ACIDS RES, V41, pD1040, DOI 10.1093/nar/gks1215; Sassano A, 2015, MOL CELL BIOL, V35, P2684, DOI 10.1128/MCB.00019-15; Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226; Srikanth M, 2013, NEURO-ONCOLOGY, V15, P319, DOI 10.1093/neuonc/nos316; Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Trapnell C, 2013, NAT BIOTECHNOL, V31, P46, DOI 10.1038/nbt.2450; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Vinci M, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-29; Wakabayashi T, 2000, J NEURO-ONCOL, V49, P57, DOI 10.1023/A:1006405512579; Wang Z, 2015, ONCOTARGET, V6, P14191, DOI 10.18632/oncotarget.3691; Yoon CH, 2012, ONCOGENE, V31, P4655, DOI 10.1038/onc.2011.634; Zhang ZF, 2013, GENOME MED, V5, DOI 10.1186/gm437; Zhu TZ, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0727-2; Zoppoli G, 2012, P NATL ACAD SCI USA, V109, P15030, DOI 10.1073/pnas.1205943109	46	35	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2017	36	43					6006	6019		10.1038/onc.2017.205	http://dx.doi.org/10.1038/onc.2017.205			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK9OT	28671669	Green Accepted			2022-12-17	WOS:000413841400009
J	Nakayama, M; Sakai, E; Echizen, K; Yamada, Y; Oshima, H; Han, TS; Ohki, R; Fujii, S; Ochiai, A; Robine, S; Voon, DC; Tanaka, T; Taketo, MM; Oshima, M				Nakayama, M.; Sakai, E.; Echizen, K.; Yamada, Y.; Oshima, H.; Han, T-S; Ohki, R.; Fujii, S.; Ochiai, A.; Robine, S.; Voon, D. C.; Tanaka, T.; Taketo, M. M.; Oshima, M.			Intestinal cancer progression by mutant p53 through the acquisition of invasiveness associated with complex glandular formation	ONCOGENE			English	Article							LI-FRAUMENI-SYNDROME; STEM-CELLS; COLORECTAL-CANCER; COLON-CANCER; PANCREATIC-CANCER; MOUSE MODEL; GAIN; EXPRESSION; GROWTH; MICROENVIRONMENT	Tumor suppressor TP53 is frequently mutated in colorectal cancer (CRC), and most mutations are missense type. Although gain-offunctions by mutant p53 have been demonstrated experimentally, the precise mechanism for malignant progression in in vivo tumors remains unsolved. We generated Apc(Delta 716) Trp53(LSL_R270H) villin-CreER compound mice, in which mutant p53(R270H) was expressed in the intestinal epithelia upon tamoxifen treatment, and examined the intestinal tumor phenotypes and tumor-derived organoids. Mutant Trp53(R270H), but not Trp53-null mutation accelerated submucosal invasion with generation of desmoplastic microenvironment. The nuclear accumulation of p53 was evident in Apc(Delta 716) Trp53(R270H/R270H) homozygous tumors like human CRC. Although p53 was distributed to the cytoplasm in Apc(Delta 716) Trp53(+/R270H) heterozygous tumors, it accumulated in the nuclei at the invasion front, suggesting a regulation mechanism for p53 localization by the microenvironment. Importantly, mutant p53 induced drastic morphological changes in the tumor organoids to complex glandular structures, which was associated with the acquisition of invasiveness. Consistently, the branching scores of human CRC that carry TP53 mutations at codon 273 significantly increased in comparison with those of TP53 wild-type tumors. Moreover, allografted Apc(Delta 716) Trp53(R270H/R270H) organoid tumors showed a malignant histology with an increased number of myofibroblasts in the stroma. These results indicate that nuclear-accumulated mutant p53(R270H) induces malignant progression of intestinal tumors through complex tumor gland formation and acquisition of invasiveness. Furthermore, RNA sequencing analyses revealed global gene upregulation by mutant p53(R270H), which was associated with the activation of inflammatory and innate immune pathways. Accordingly, it is possible that mutant p53(R270H) induces CRC progression, not only by a cell intrinsic mechanism, but also by the generation or activation of the microenvironment, which may synergistically contribute to the acceleration of submucosal invasion. Therefore, the present study indicates that nuclearaccumulated mutant p53(R270H) is a potential therapeutic target for the treatment of advanced CRCs.	[Nakayama, M.; Sakai, E.; Echizen, K.; Oshima, H.; Han, T-S; Voon, D. C.; Oshima, M.] Kanazawa Univ, Div Genet, Canc Res Inst, Kanazawa, Ishikawa 9201192, Japan; [Echizen, K.; Han, T-S; Tanaka, T.; Oshima, M.] Japan Agcy Med Res & Dev, AMED, AMED CREST, Tokyo, Japan; [Yamada, Y.] Kanazawa Univ, Inst Sci & Engn, Kanazawa, Ishikawa, Japan; [Ohki, R.] Natl Canc Ctr, Div Rare Canc Res, Tokyo, Japan; [Fujii, S.] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Pathol, Chiba, Japan; [Ochiai, A.] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Chiba, Japan; [Robine, S.] Inst Curie, Equipe Morphogenese & Signalisat Cellulaires, Paris, France; [Voon, D. C.] Kanazawa Univ, Inst Frontier Sci Initiat, Canc Res Core, Kanazawa, Ishikawa, Japan; [Tanaka, T.] Chiba Univ, Grad Sch Med, Dept Clin Cell Biol & Med, Chiba, Japan; [Taketo, M. M.] Kyoto Univ, Grad Sch Med, Dept Pharmacol, Kyoto, Japan; [Taketo, M. M.] Kanazawa Univ, Canc Res Inst, Div Expt Therapeut, Kanazawa, Ishikawa, Japan	Kanazawa University; Kanazawa University; National Cancer Center - Japan; National Cancer Center - Japan; National Cancer Center - Japan; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Kanazawa University; Chiba University; Kyoto University; Kanazawa University	Oshima, M (corresponding author), Kanazawa Univ, Div Genet, Canc Res Inst, Kanazawa, Ishikawa 9201192, Japan.	oshimam@staff.kanazawa-u.ac.jp	Oshima, Masanobu/F-9958-2014	Oshima, Masanobu/0000-0002-3304-0004; Tanaka, Tomoaki/0000-0002-9761-1750; Oshima, Hiroko/0000-0001-6855-4008; yamada, yoichi/0000-0001-6103-0658; Voon, Dominic Chih-Cheng/0000-0002-2963-9305	AMED-CREST, AMED, Japan Agency for Medical Research and Development, Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan [15H02362, 26430110]	AMED-CREST, AMED, Japan Agency for Medical Research and Development, Japan(Japan Agency for Medical Research and Development (AMED)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Yoshie Jomen, Ayako Tsuda and Manami Watanabe for technical assistance. Computations were partially performed on the NIG supercomputer at ROIS National Institute of Genetics. This work was supported by AMED-CREST, AMED, Japan Agency for Medical Research and Development, Japan, Grants-in-Aid for Scientific Research (A) (#15H02362) tand (C) (26430110) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430; Amoyel M, 2015, EMBO J, V34, P1287, DOI 10.15252/embj.201591541; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Chytil A, 2002, GENESIS, V32, P73, DOI 10.1002/gene.10046; Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Doyle B, 2010, J PATHOL, V222, P129, DOI 10.1002/path.2748; Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Fujii S, 2015, ONCOGENE, V34, P4834, DOI 10.1038/onc.2014.402; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534; Liebig B, 2005, CANCER LETT, V223, P159, DOI 10.1016/j.canlet.2004.10.013; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Matsumoto S, 2014, EMBO J, V33, P702, DOI 10.1002/embj.201386942; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2013, ONCOGENE, V32, P1252, DOI 10.1038/onc.2012.148; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Oshima H, 2015, CANCER RES, V75, P766, DOI 10.1158/0008-5472.CAN-14-2036; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pfister NT, 2015, GENE DEV, V29, P1298, DOI 10.1101/gad.263202.115; Salahudeen AA, 2015, NAT MED, V21, P215, DOI 10.1038/nm.3818; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Scheeren FA, 2014, NAT CELL BIOL, V16, P1238, DOI 10.1038/ncb3058; Schwitalla S, 2013, CELL, V152, P25, DOI 10.1016/j.cell.2012.12.012; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Weissmueller S, 2014, CELL, V157, P382, DOI 10.1016/j.cell.2014.01.066; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	42	35	36	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 19	2017	36	42					5885	5896		10.1038/onc.2017.194	http://dx.doi.org/10.1038/onc.2017.194			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FK2DN	28628120	hybrid, Green Published			2022-12-17	WOS:000413292900010
J	Lin, MC; Lin, JJ; Hsu, CL; Juan, HF; Lou, PJ; Huang, MC				Lin, M-C; Lin, J-J; Hsu, C-L; Juan, H-F; Lou, P-J; Huang, M-C			GATA3 interacts with and stabilizes HIF-1 alpha to enhance cancer cell invasiveness	ONCOGENE			English	Article							INDUCIBLE FACTOR 1-ALPHA; BREAST-CANCER; TRANSCRIPTION FACTORS; HYPOXIA; DIFFERENTIATION; EXPRESSION; DEGRADATION; METASTASIS; PROTEASOME; REPRESSION	GATA binding protein 3 (GATA3) is indispensable in development of human organs. However, the role of GATA3 in cancers remains elusive. Hypoxia inducible factor (HIF)-1 plays an important role in pathogenesis of human cancers. Regulation of HIF-1 alpha degradation is orchestrated through collaboration of its interacting proteins. In this study, we discover that GATA3 is upregulated in head and neck squamous cell carcinoma (HNSCC) and is an independent predictor for poor disease-free survival. GATA3 promotes invasive behaviours of HNSCC and melanoma cells in vitro and in immunodeficient mice. Mechanistically, GATA3 physically associates with HIF-1 alpha under hypoxia to inhibit ubiquitination and proteasomal degradation of HIF-1 alpha, which is independent of HIF-1 alpha prolyl hydroxylation. Chromatin immunoprecipitation assays show that the GATA3/HIF-1 alpha complex binds to and regulates HIF-1 target genes, which is also supported by the microarray analysis. Notably, the GATA3-mediated invasiveness can be significantly reversed by HIF-1 alpha knockdown, suggesting a critical role of HIF-1 alpha in the underlying mechanism of GATA3-mediated effects. Our findings suggest that GATA3 stabilizes HIF-1 alpha to enhance cancer invasiveness under hypoxia and support the GATA3/ HIF-1 alpha axis as a potential therapeutic target for cancer treatment.	[Lin, M-C] Natl Taiwan Univ Hosp, Hsin Chu Branch, Dept Otolaryngol, Hsinchu, Taiwan; [Lin, M-C; Lou, P-J; Huang, M-C] Natl Taiwan Univ, Coll Med, Grad Inst Anat & Cell Biol, 1,Sec 1 Jen Ai Rd, Taipei 100, Taiwan; [Lin, J-J] Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei, Taiwan; [Hsu, C-L; Juan, H-F] Natl Taiwan Univ, Dept Life Sci, Taipei, Taiwan; [Lou, P-J] Natl Taiwan Univ, Hosp & Coll Med, Dept Otolaryngol, 7 Chung Shan South Rd, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University; National Taiwan University; National Taiwan University	Lou, PJ; Huang, MC (corresponding author), Natl Taiwan Univ, Coll Med, Grad Inst Anat & Cell Biol, 1,Sec 1 Jen Ai Rd, Taipei 100, Taiwan.; Lou, PJ (corresponding author), Natl Taiwan Univ, Hosp & Coll Med, Dept Otolaryngol, 7 Chung Shan South Rd, Taipei 100, Taiwan.	pjlou@ntu.edu.tw; mchuang@ntu.edu.tw	Hsu, Chia-Lang/O-1458-2013	Hsu, Chia-Lang/0000-0002-7447-8045; LIN, JING-JER/0000-0001-8250-7398; HUANG, MIN-CHUAN/0000-0002-0704-3447; LOU, PEI-JEN/0000-0002-3383-8593	Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine; National Taiwan University Hospital [106C101-D1]; National Taiwan University Hospital, Hsinchu Branch [HCH104-045, 105-HCH020]; Ministry of Science and Technology, ROC [104-2320-B-002 -068 -MY3, 103-2314-B-002 -082 -MY2, 105-2314-B-002 -203 -MY2]; Academia Sinica, Taiwan Head and Neck Cancer Biosignature	Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine; National Taiwan University Hospital(National Taiwan University); National Taiwan University Hospital, Hsinchu Branch; Ministry of Science and Technology, ROC; Academia Sinica, Taiwan Head and Neck Cancer Biosignature	We thank Drs Mien-Chie Hung and Muh-Hwa Yang for editorial advice, Drs Jean-San Chia, Ming-Shyue Lee, Hsiu-Ni Kung, Wan-Lun Hsu and Hung-Lee Chen for technical supports, and Dr Shu-Yun Tung for performing global gene expression analysis. This study was supported by the Excellent Translational Medicine Research Projects of National Taiwan University College of Medicine, and National Taiwan University Hospital (106C101-D1), the National Taiwan University Hospital, Hsinchu Branch, HCH104-045, 105-HCH020 (MC Lin) and Ministry of Science and Technology, ROC 104-2320-B-002 -068 -MY3 (MC Huang), 103-2314-B-002 -082 -MY2 (PJ Lou), 105-2314-B-002 -203 -MY2 (MC Lin), and the Academia Sinica, Taiwan Head and Neck Cancer Biosignature (PJ Lou).	Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Cohen H, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0464-0; Engelsen IB, 2008, AM J OBSTET GYNECOL, V199, DOI 10.1016/j.ajog.2008.04.043; Hanna SC, 2013, J CLIN INVEST, V123, P2078, DOI 10.1172/JCI66715; Haraguchi T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156524; Higgins JPT, 2007, AM J SURG PATHOL, V31, P673, DOI 10.1097/01.pas.0000213438.01278.5f; Ho IC, 2007, CELL MOL IMMUNOL, V4, P15; Hosoya T, 2010, IMMUNOL REV, V238, P110, DOI 10.1111/j.1600-065X.2010.00954.x; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Joshi S, 2014, J BIOL CHEM, V289, P22785, DOI 10.1074/jbc.M114.587493; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Koh MY, 2008, MOL CELL BIOL, V28, P7081, DOI 10.1128/MCB.00773-08; Koh MY, 2010, RECENT RESULTS CANC, V180, P15, DOI 10.1007/978-3-540-78281-0_3; Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002; Krek W, 2000, NAT CELL BIOL, V2, pE121, DOI 10.1038/35017129; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Krug N, 2015, NEW ENGL J MED, V372, P1987, DOI 10.1056/NEJMoa1411776; LABASTIE MC, 1995, KIDNEY INT, V47, P1597, DOI 10.1038/ki.1995.223; Lawoko-Kerali G, 2002, J COMP NEUROL, V442, P378, DOI 10.1002/cne.10088; Lee Ji-Won, 2004, Experimental & Molecular Medicine, V36, P1; Liao D, 2007, CANCER METAST REV, V26, P281, DOI 10.1007/s10555-007-9066-y; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Mehra R, 2005, CANCER RES, V65, P11259, DOI 10.1158/0008-5472.CAN-05-2495; Moriguchi T, 2006, DEVELOPMENT, V133, P3871, DOI 10.1242/dev.02553; Peng HW, 2015, MOL MED REP, V11, P881, DOI 10.3892/mmr.2014.2809; Popp V, 2017, GASTROENTEROLOGY, V152, P176, DOI 10.1053/j.gastro.2016.09.005; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Shan L, 2014, ONCOGENE, V33, P3205, DOI 10.1038/onc.2013.270; Si WZ, 2015, CANCER CELL, V27, P822, DOI 10.1016/j.ccell.2015.04.011; SIMON MC, 1995, NAT GENET, V11, P9, DOI 10.1038/ng0995-9; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; Winter SC, 2006, CANCER-AM CANCER SOC, V107, P757, DOI 10.1002/cncr.21983; Yan Q, 2007, MOL CELL BIOL, V27, P2092, DOI 10.1128/MCB.01514-06; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691	37	35	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4243	4252		10.1038/onc.2017.8	http://dx.doi.org/10.1038/onc.2017.8			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28263977	Green Published, hybrid			2022-12-17	WOS:000406360600002
J	Gu, P; Wang, Y; Bisht, KK; Wu, L; Kukova, L; Smith, EM; Xiao, Y; Bailey, SM; Lei, M; Nandakumar, J; Chang, S				Gu, P.; Wang, Y.; Bisht, K. K.; Wu, L.; Kukova, L.; Smith, E. M.; Xiao, Y.; Bailey, S. M.; Lei, M.; Nandakumar, J.; Chang, S.			Pot1 OB-fold mutations unleash telomere instability to initiate tumorigenesis	ONCOGENE			English	Article							DNA-DAMAGE; CHECKPOINT ACTIVATION; PROTEIN; CANCER; REPAIR; PROTECTION; TPP1; CHROMOTHRIPSIS; CHROMOSOMES; BINDING	Chromosomal aberrations are a hallmark of human cancers, with complex cytogenetic rearrangements leading to genetic changes permissive for cancer initiation and progression. Protection of Telomere 1 (POT1) is an essential component of the shelterin complex and functions to maintain chromosome stability by repressing the activation of aberrant DNA damage and repair responses at telomeres. Sporadic and familial mutations in the oligosaccharide-oligonucleotide (OB) folds of POT1 have been identified in many human cancers, but the mechanism underlying how hPOT1 mutations initiate tumorigenesis has remained unclear. Here we show that the human POT1's OB-folds are essential for the protection of newly replicated telomeres. Oncogenic mutations in hPOT1 OB-fold fail to bind to single-stranded telomeric DNA, eliciting a DNA damage response at telomeres that promote inappropriate chromosome fusions via the mutagenic alternative non-homologous end joining (A-NHEJ) pathway. hPOT1 mutations also result in telomere elongation and the formation of transplantable hematopoietic malignancies. Strikingly, conditional deletion of both mPot1a and p53 in mouse mammary epithelium resulted in development of highly invasive breast carcinomas and the formation of whole chromosomes containing massive arrays of telomeric fusions indicative of multiple breakage-fusion-bridge cycles. Our results reveal that hPOT1 OB-folds are required to protect and prevent newly replicated telomeres from engaging in A-NHEJ mediated fusions that would otherwise promote genome instability to fuel tumorigenesis.	[Gu, P.; Wang, Y.; Kukova, L.; Chang, S.] Yale Univ, Sch Med, Dept Lab Med, BML 462,333 Cedar St, New Haven, CT 06520 USA; [Bisht, K. K.; Smith, E. M.; Nandakumar, J.] Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; [Bisht, K. K.; Smith, E. M.; Nandakumar, J.] Univ Michigan, Program Chem Biol, Ann Arbor, MI 48109 USA; [Wu, L.] UT MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX USA; [Xiao, Y.] Baylor Coll Med, Dept Med & Mol & Cellular Biol, Sect Hematol Oncol, Houston, TX 77030 USA; [Bailey, S. M.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA; [Lei, M.] Chinese Acad Sci, State Key Lab Mol Biol, Inst Biochem & Cell Biol, Natl Ctr Prot Sci Shanghai,Shanghai Inst Biol Sci, Shanghai, Peoples R China; [Chang, S.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Chang, S.] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06510 USA	Yale University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; Colorado State University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Yale University; Yale University	Chang, S (corresponding author), Yale Univ, Sch Med, Dept Lab Med, BML 462,333 Cedar St, New Haven, CT 06520 USA.	s.chang@yale.edu		Nandakumar, Jayakrishnan/0000-0001-9146-2785; Smith, Eric/0000-0002-5385-4558	NCI [RO1 CA129037, R01 CA202816, R21 CA200506, R21 CA182280]; CT Department of Public Health [15-002167]; NIH [NIH R00-CA-167644-03, NIH R01-AG050509]; NATIONAL CANCER INSTITUTE [R01CA129037, R21CA200506, R21CA182280, R01CA202816, R00CA167644] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000114, R01AG050509] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CT Department of Public Health; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We thank Dr Asha Multani (MDACC, Houston, TX) for SKY analyses and Dr James You (MDACC, Houston, TX) for histological analyses and Dr Christos Hatzis (Yale university School of Medicine) for POT1 mutation analyses. We thank the Chang lab for helpful suggestions. This work was supported by the NCI (RO1 CA129037, R01 CA202816, R21 CA200506 and R21 CA182280) and the CT Department of Public Health (15-002167) to Sandy Chang. Support for Jayakrishnan Nandakumar is from the NIH (NIH R00-CA-167644-03, NIH R01-AG050509 (Jayakrishnan Nandakumar, co-investigator).	Abreu E, 2011, METHODS MOL BIOL, V735, P125, DOI 10.1007/978-1-61779-092-8_12; Artandi SE, 2000, NAT MED, V6, P852, DOI 10.1038/78595; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Badie S, 2015, EMBO J, V34, P828, DOI 10.15252/embj.201570610; Bainbridge MN, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju384; Baumann P, 2002, MOL CELL BIOL, V22, P8079, DOI 10.1128/MCB.22.22.8079-8087.2002; Baumann P, 2001, SCIENCE, V292, P1171, DOI 10.1126/science.1060036; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Boboila C, 2010, P NATL ACAD SCI USA, V107, P3034, DOI 10.1073/pnas.0915067107; Calvete O, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9383; Ceccaldi R, 2016, TRENDS CELL BIOL, V26, P52, DOI 10.1016/j.tcb.2015.07.009; Chang S, 2013, NAT GENET, V45, P473, DOI 10.1038/ng.2617; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Fan JS, 2010, BLOOD, V116, P5298, DOI 10.1182/blood-2010-03-272591; Flynn RL, 2011, NATURE, V471, P532, DOI 10.1038/nature09772; Gonzalez-Suarez E, 2000, NAT GENET, V26, P114, DOI 10.1038/79089; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Gu P, 2013, CELL RES, V23, P705, DOI 10.1038/cr.2013.31; Guirouilh-Barbat J, 2007, P NATL ACAD SCI USA, V104, P20902, DOI 10.1073/pnas.0708541104; Guo X, 2007, EMBO J, V26, P4709, DOI 10.1038/sj.emboj.7601893; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Hockemeyer D, 2007, NAT STRUCT MOL BIOL, V14, P754, DOI 10.1038/nsmb1270; Hockemeyer D, 2006, CELL, V126, P63, DOI 10.1016/j.cell.2006.04.044; Jones MJK, 2012, DEV CELL, V23, P908, DOI 10.1016/j.devcel.2012.10.010; Lam YC, 2010, EMBO J, V29, P2230, DOI 10.1038/emboj.2010.58; Latrick CM, 2010, EMBO J, V29, P924, DOI 10.1038/emboj.2009.409; Lei M, 2004, NAT STRUCT MOL BIOL, V11, P1223, DOI 10.1038/nsmb867; Lei M, 2003, NATURE, V426, P198, DOI 10.1038/nature02092; Lei M, 2005, J BIOL CHEM, V280, P20449, DOI 10.1074/jbc.M502212200; Li YL, 2014, NATURE, V508, P98, DOI 10.1038/nature13115; Liu D, 2004, NAT CELL BIOL, V6, P673, DOI 10.1038/ncb1142; Loayza D, 2004, J BIOL CHEM, V279, P13241, DOI 10.1074/jbc.M312309200; Loayza D, 2003, NATURE, V423, P1013, DOI 10.1038/nature01688; Maciejowski J, 2015, CELL, V163, P1641, DOI 10.1016/j.cell.2015.11.054; Martinez P, 2009, GENE DEV, V23, P2060, DOI 10.1101/gad.543509; McClintock B, 1941, GENETICS, V26, P234; Multani AS, 2011, METHODS MOL BIOL, V735, P139, DOI 10.1007/978-1-61779-092-8_13; Nandakumar J, 2012, NATURE, V492, P285, DOI 10.1038/nature11648; Nandakumar J, 2010, P NATL ACAD SCI USA, V107, P651, DOI 10.1073/pnas.0911099107; Nussenzweig A, 2007, CELL, V131, P223, DOI 10.1016/j.cell.2007.10.005; Palm W, 2009, MOL CELL BIOL, V29, P471, DOI 10.1128/MCB.01352-08; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Quesada V, 2012, NAT GENET, V44, P47, DOI 10.1038/ng.1032; Rai R, 2011, NAT STRUCT MOL BIOL, V18, P1400, DOI 10.1038/nsmb.2172; Rai R, 2010, EMBO J, V29, P2598, DOI 10.1038/emboj.2010.142; Ramsay AJ, 2013, NAT GENET, V45, P526, DOI 10.1038/ng.2584; Robles-Espinoza CD, 2014, NAT GENET, V46, P478, DOI 10.1038/ng.2947; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Sfeir A, 2012, SCIENCE, V336, P593, DOI 10.1126/science.1218498; Shi JX, 2014, NAT GENET, V46, P482, DOI 10.1038/ng.2941; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Symington LS, 2011, ANNU REV GENET, V45, P247, DOI 10.1146/annurev-genet-110410-132435; Thanasoula M, 2012, EMBO J, V31, P3398, DOI 10.1038/emboj.2012.191; Tobin LA, 2012, MOL CANCER RES, V10, P96, DOI 10.1158/1541-7786.MCR-11-0255; Wang F, 2007, NATURE, V445, P506, DOI 10.1038/nature05454; Wang Y, 2013, J CLIN INVEST, V123, P4489, DOI 10.1172/JCI69574; Wang Y, 2011, BLOOD, V118, P6068, DOI 10.1182/blood-2011-06-361527; Wu L, 2006, CELL, V126, P49, DOI 10.1016/j.cell.2006.05.037; Xin HW, 2007, NATURE, V445, P559, DOI 10.1038/nature05469; Ye JZS, 2004, GENE DEV, V18, P1649, DOI 10.1101/gad.1215404; Zhang CZ, 2015, NATURE, V522, P179, DOI 10.1038/nature14493; Zhong FL, 2012, CELL, V150, P481, DOI 10.1016/j.cell.2012.07.012	64	35	36	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					1939	1951		10.1038/onc.2016.405	http://dx.doi.org/10.1038/onc.2016.405			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27869160	Green Accepted			2022-12-17	WOS:000398898500005
J	Blanchart, A; Fernando, R; Haring, M; Assaife-Lopes, N; Romanov, RA; Andang, M; Harkany, T; Ernfors, P				Blanchart, A.; Fernando, R.; Haring, M.; Assaife-Lopes, N.; Romanov, R. A.; Andang, M.; Harkany, T.; Ernfors, P.			Endogenous GAB(AA) receptor activity suppresses glioma growth	ONCOGENE			English	Article							INTEGRATED GENOMIC ANALYSIS; STEM-CELL; TUMOR PROGRESSION; INITIATING CELLS; SELF-RENEWAL; BRAIN-TUMORS; FACTOR-B; PDGF-B; GLIOBLASTOMA; GABA	Although genome alterations driving glioma by fueling cell malignancy have largely been resolved, less is known of the impact of tumor environment on disease progression. Here, we demonstrate functional GABAA receptor-activated currents in human glioblastoma cells and show the existence of a continuous GABA signaling within the tumor cell mass that significantly affects tumor growth and survival expectancy in mouse models. Endogenous GABA released by tumor cells, attenuates proliferation of the glioma cells with enriched expression of stem/progenitor markers and with competence to seed growth of new tumors. Our results suggest that GABA levels rapidly increase in tumors impeding further growth. Thus, shunting chloride ions by a maintained local GABAA receptor activity within glioma cells has a significant impact on tumor development by attenuating proliferation, reducing tumor growth and prolonging survival, a mechanism that may have important impact on therapy resistance and recurrence following tumor resection.	[Blanchart, A.; Fernando, R.; Haring, M.; Assaife-Lopes, N.; Harkany, T.; Ernfors, P.] Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, Scheeles VA, S-17177 Stockholm, Sweden; [Romanov, R. A.; Harkany, T.] Med Univ Vienna, Ctr Brain Res, Dept Mol Neurosci, Vienna, Austria; [Andang, M.] Karolinska Inst, Dept Physiol & Pharmacol Biophys Stem Cell & Tiss, Stockholm, Sweden; [Fernando, R.] Hop St Eloi, Inst Neurosci Montpellier, INSERM U1051, BP 74103, Montpellier, France	Karolinska Institutet; Medical University of Vienna; Karolinska Institutet; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier	Ernfors, P (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Div Mol Neurobiol, Scheeles VA, S-17177 Stockholm, Sweden.	patrik.ernfors@ki.se	Andäng, Michael/GRE-9898-2022; Romanov, Roman/J-2349-2015	Romanov, Roman/0000-0002-3937-518X; Harkany, Tibor/0000-0002-6637-5900; Andang, Michael/0000-0002-2886-7891	Wallenberg Foundation; Swedish Research Council for Medicine and Health; Swedish Cancer Society grant; SFO grant; Swedish Brain Foundation; Wallenberg Scholar and Soderberg Foundation; ERC advanced grant [232675]; European Commission FP7 (Marie Curie Actions) [GA-2012-600394]; NovoNordisk Foundation; European Commission FP7 PAINCAGE grant; Alzheimers Research UK [ART-EG2009A-1] Funding Source: researchfish; Novo Nordisk Fonden [NNF15OC0015964, NNF14OC0010695, NNF17OC0027294] Funding Source: researchfish	Wallenberg Foundation(European Commission); Swedish Research Council for Medicine and Health; Swedish Cancer Society grant; SFO grant; Swedish Brain Foundation; Wallenberg Scholar and Soderberg Foundation; ERC advanced grant(European Research Council (ERC)); European Commission FP7 (Marie Curie Actions); NovoNordisk Foundation(Novo Nordisk Foundation); European Commission FP7 PAINCAGE grant; Alzheimers Research UK(Alzheimer&apos;s Research UK (ARUK)); Novo Nordisk Fonden(Novo Nordisk Foundation)	We thank Dr Lene Uhrbom for critically reading our manuscript and for kindly providing the Gtv-a/p19ARF WT and KO mice, Dr Jonas Frisen for kindly providing the Nestin: CrexRosa26LacZ and Helena Samuelsson for technical support, the CLICK Imaging Facility supported by the Wallenberg Foundation. This work was supported by the Swedish Research Council for Medicine and Health, the Swedish Cancer Society and SFO grants, the Swedish Brain Foundation, Wallenberg Scholar and Soderberg Foundation. ERC advanced grant (232675). RAR is an EMBO long-term research fellow (ALTF 596-2014) co-funded by the European Commission FP7 (Marie Curie Actions, EMBOCOFUND2012, GA-2012-600394), NovoNordisk Foundation, Swedish Brain Foundation and European Commission FP7 PAINCAGE grant to TH.	Andang M, 2008, NAT PROTOC, V3, P1013, DOI 10.1038/nprot.2008.65; Andang M, 2008, NATURE, V451, P460, DOI 10.1038/nature06488; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barami K, 2009, J CLIN NEUROSCI, V16, P195, DOI 10.1016/j.jocn.2008.03.006; Barrett LE, 2012, CANCER CELL, V21, P11, DOI 10.1016/j.ccr.2011.11.025; Bleau AM, 2009, CELL CYCLE, V8, P2936; Bolteus AJ, 2004, J NEUROSCI, V24, P7623, DOI 10.1523/JNEUROSCI.1999-04.2004; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Carlen M, 2006, EXP CELL RES, V312, P2851, DOI 10.1016/j.yexcr.2006.05.012; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chandra D, 2010, NEUROPSYCHOPHARMACOL, V35, P999, DOI 10.1038/npp.2009.203; CURTIS DR, 1970, NATURE, V228, P676, DOI 10.1038/228676a0; D'Urso PI, 2012, INT J ONCOL, V41, P228, DOI 10.3892/ijo.2012.1420; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Fernando RN, 2011, P NATL ACAD SCI USA, V108, P5837, DOI 10.1073/pnas.1014993108; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; Holmberg J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018454; Jacques TS, 2010, EMBO J, V29, P222, DOI 10.1038/emboj.2009.327; Jiang YW, 2011, NEOPLASIA, V13, P492, DOI 10.1593/neo.11314; KROGSGAARDLARSEN P, 1979, J NEUROCHEM, V32, P1717, DOI 10.1111/j.1471-4159.1979.tb02284.x; Labrakakis C, 1998, EUR J NEUROSCI, V10, P231, DOI 10.1046/j.1460-9568.1998.00036.x; Lee C, 2012, STEM CELLS, V30, P1064, DOI 10.1002/stem.1081; Li SC, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-41; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; LoTurco JJ, 1995, NEURON, V15, P1287, DOI 10.1016/0896-6273(95)90008-X; Mares P, 2000, EPILEPSY RES, V42, P183, DOI 10.1016/S0920-1211(00)00179-0; Noble M, 2004, TRENDS NEUROSCI, V27, P148, DOI 10.1016/j.tins.2003.12.007; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Platel JC, 2008, J PHYSIOL-LONDON, V586, P3739, DOI 10.1113/jphysiol.2008.155325; Prestegarden L, 2010, CANCER RES, V70, P4274, DOI 10.1158/0008-5472.CAN-09-3904; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Smits A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037041; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Stiles CD, 2008, NEURON, V58, P832, DOI 10.1016/j.neuron.2008.05.031; Suva ML, 2014, CELL, V157, P580, DOI 10.1016/j.cell.2014.02.030; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Synowitz M, 2001, EUR J NEUROSCI, V14, P1294, DOI 10.1046/j.0953-816x.2001.01764.x; Tchougounova E, 2007, ONCOGENE, V26, P6289, DOI 10.1038/sj.onc.1210455; Terrile M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-550; Ueno S, 1997, J NEUROSCI, V17, P625; Uhrbom L, 2005, CANCER RES, V65, P2065, DOI 10.1158/0008-5472.CAN-04-3588; Uhrbom L, 1998, CANCER RES, V58, P5275; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang DD, 2003, J PHYSIOL-LONDON, V550, P785, DOI 10.1113/jphysiol.2003.042572; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Young SZ, 2009, PHYSIOLOGY, V24, P171, DOI 10.1152/physiol.00002.2009; Zhu Y, 2005, CANCER CELL, V8, P119, DOI 10.1016/j.ccr.2005.07.004; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601	55	35	35	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					777	786		10.1038/onc.2016.245	http://dx.doi.org/10.1038/onc.2016.245			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27375015				2022-12-17	WOS:000394168200005
J	Choi, EB; Yang, AY; Kim, SC; Lee, J; Choi, JK; Choi, C; Kim, MY				Choi, E-B; Yang, A-Y; Kim, S. C.; Lee, J.; Choi, J. K.; Choi, C.; Kim, M-Y			PARP1 enhances lung adenocarcinoma metastasis by novel mechanisms independent of DNA repair	ONCOGENE			English	Article							BREAST-CANCER CELLS; HUMAN PROSTATE-CANCER; E-CADHERIN EXPRESSION; GENE-EXPRESSION; POLY(ADP-RIBOSE) POLYMERASE; CHROMATIN-STRUCTURE; ANOIKIS RESISTANCE; TRANSCRIPTION; INHIBITION; INCREASES	The role of poly (ADP-ribose) polymerase 1 (PARP1) in cancer has been extensively studied in the context of DNA repair, leading to clinical trials of PARP1 inhibitors in cancers defective in homologous recombination. However, the DNA repair-independent roles of PARP1 in carcinogenesis and metastasis, particularly in lung cancer metastasis, remain largely uncharacterized. Here, we report that PARP1 promotes lung adenocarcinoma relapse to the brain and bones by regulating several steps of the metastatic process in a DNA repair-independent manner. We find that PARP1 expression is associated with overall and distant metastasis-free survival in lung adenocarcinoma patients. Consistent with this, genetic knockdown and pharmacological inhibition of PARP1 significantly attenuated the metastatic potential of lung adenocarcinoma cells. Further investigation revealed that PARP1 potentiates lung adenocarcinoma metastasis by promoting invasion, anoikis resistance, extravasation and self-renewal of lung adenocarcinoma cells and also by modifying the brain microenvironment. Finally, we identified S100A4 and CLDN7 as novel transcriptional targets and clinically relevant effectors of PARP1. Collectively, our study not only revealed previously unknown functions of PARP1 in lung adenocarcinoma metastasis but also delineated the molecular mechanisms underlying the pro-metastatic function of PARP1. Furthermore, these findings provide a foundation for the potential use of PARP1 inhibitors as a new treatment option for lung adenocarcinoma patients with elevated PARP1 expression.	[Choi, E-B; Yang, A-Y; Kim, M-Y] Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Daejeon 305701, South Korea; [Kim, S. C.] KCDC, Natl Inst Hlth, Ctr Genome Sci, Dept Biomed Informat, Choongchung Buk Do, South Korea; [Lee, J.; Choi, J. K.; Choi, C.] Korea Adv Inst Sci & Technol, Dept Bio & Brain Engn, Daejeon, South Korea; [Choi, C.; Kim, M-Y] Korea Adv Inst Sci & Technol, Canc Metastasis Control Ctr, Inst BioCentury, Daejeon, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Korea Centers for Disease Control & Prevention (KCDC); Korea National Institute of Health (KNIH); Korea CDC Center for Genome Science; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)	Kim, MY (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 291 Daehak Ro, Daejeon 305701, South Korea.	miyoungkim@kaist.ac.kr	Kim, Sun Chang/C-2026-2011; Choi, Jung Kyoon/C-2070-2011; Kim, Sun/GSN-4867-2022; Kim, Mi Young/C-1829-2011; Choi, Chulhee/C-1642-2011	Choi, Chulhee/0000-0001-5542-9136	Converging Research Center Program [2014048778]; Intelligent Synthetic Biology Center of Global Frontier Project - Ministry of Science, ICT & Future Planning [2011-0031955]; Basic Science Research Program through the National Research Foundation of Korea [NRF-2011-0020334]	Converging Research Center Program; Intelligent Synthetic Biology Center of Global Frontier Project - Ministry of Science, ICT & Future Planning; Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea)	We thank for Drs Joan Massague, Incheol Shin, Michael Davidson and W Lee Kraus for providing NCI-H2030, PC9 and their metastatic derivatives; pBabe-S100A4; mEmerald-Claudin7-C-12 (CLDN7, Addgene plasmid #54041); and PARP1 shRNA constructs and antibody, respectively. We also thank Dr Sun Kyu Kim for help with bioinformatics analysis, Dr David M Helfman for helpful discussion. This research was supported by the Converging Research Center Program (2014048778), the Intelligent Synthetic Biology Center of Global Frontier Project (2011-0031955) funded by the Ministry of Science, ICT & Future Planning, and the Basic Science Research Program through the National Research Foundation of Korea (NRF-2011-0020334).	Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Berezovskaya O, 2005, CANCER RES, V65, P2378, DOI 10.1158/0008-5472.CAN-04-2649; Botling J, 2013, CLIN CANCER RES, V19, P194, DOI 10.1158/1078-0432.CCR-12-1139; Brenner JC, 2012, CANCER RES, V72, P1608, DOI 10.1158/0008-5472.CAN-11-3648; Brenner JC, 2011, CANCER CELL, V19, P664, DOI 10.1016/j.ccr.2011.04.010; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cataldo VD, 2011, NEW ENGL J MED, V364, P947, DOI 10.1056/NEJMct0807960; Chen N, 2014, BIOCHEM BIOPH RES CO, V447, P459, DOI 10.1016/j.bbrc.2014.04.025; Chen Z, 2014, NAT REV CANCER, V14, P535, DOI 10.1038/nrc3775; Cheng HY, 2013, CARCINOGENESIS, V34, P739, DOI 10.1093/carcin/bgs393; Cheung WKC, 2013, CANCER CELL, V23, P725, DOI 10.1016/j.ccr.2013.04.009; Chitale D, 2009, ONCOGENE, V28, P2773, DOI 10.1038/onc.2009.135; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dahiya N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022119; Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805; Davies MPA, 1996, ONCOGENE, V13, P1631; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Doege CA, 2012, NATURE, V488, P652, DOI 10.1038/nature11333; Donato R, 2003, MICROSC RES TECHNIQ, V60, P540, DOI 10.1002/jemt.10296; Elser M, 2008, MOL CANCER RES, V6, P282, DOI 10.1158/1541-7786.MCR-07-0377; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; FELD R, 1984, J CLIN ONCOL, V2, P1352, DOI 10.1200/JCO.1984.2.12.1352; Frizzell KM, 2009, J BIOL CHEM, V284, P33926, DOI 10.1074/jbc.M109.023879; Gupta GP, 2007, NATURE, V446, P765, DOI 10.1038/nature05760; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778; Hoffman PC, 2000, LANCET, V355, P479, DOI 10.1016/S0140-6736(00)82038-3; Hsieh HL, 2004, BIOCHEM BIOPH RES CO, V316, P949, DOI 10.1016/j.bbrc.2004.02.135; HULETSKY A, 1989, J BIOL CHEM, V264, P8878; Rodriguez MI, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003531; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728; Kim JH, 2014, CANCER RES, V74, P1705, DOI 10.1158/0008-5472.CAN-13-1896; Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025; Kim MY, 2005, GENE DEV, V19, P1951, DOI 10.1101/gad.1331805; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kim SK, 2014, BIOINFORMATICS, V30, P3284, DOI 10.1093/bioinformatics/btu521; Kraus WL, 2013, MOL ASPECTS MED, V34, P1109, DOI 10.1016/j.mam.2013.01.005; Krishnakumar R, 2010, MOL CELL, V39, P736, DOI 10.1016/j.molcel.2010.08.014; Lee MH, 2012, ONCOGENE, V31, P5099, DOI 10.1038/onc.2012.2; Lioni M, 2007, AM J PATHOL, V170, P709, DOI 10.2353/ajpath.2007.060343; Lonn P, 2010, MOL CELL, V40, P521, DOI 10.1016/j.molcel.2010.10.029; MARTINI N, 1995, J THORAC CARDIOV SUR, V109, P120, DOI 10.1016/S0022-5223(95)70427-2; Matsubara D, 2005, CANCER SCI, V96, P844, DOI 10.1111/j.1349-7006.2005.00121.x; McPhee TR, 2008, DEV DYNAM, V237, P2737, DOI 10.1002/dvdy.21685; Michels J, 2015, ANN ONCOL, V26, P2470, DOI 10.1093/annonc/mdv393; Michels J, 2013, CANCER RES, V73, P2271, DOI 10.1158/0008-5472.CAN-12-3000; Michels J, 2013, CELL CYCLE, V12, P877, DOI 10.4161/cc.24034; Minami D, 2013, MOL CANCER RES, V11, P140; Nguyen DX, 2009, CELL, V138, P51, DOI 10.1016/j.cell.2009.04.030; Nowsheen S, 2012, CANCER RES, V72, P4796, DOI 10.1158/0008-5472.CAN-12-1287; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; OGATA N, 1981, J BIOL CHEM, V256, P4135; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Pencheva N, 2012, CELL, V151, P1068, DOI 10.1016/j.cell.2012.10.028; Piccolo SR, 2013, P NATL ACAD SCI USA, V110, P17778, DOI 10.1073/pnas.1305823110; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Rodriguez MI, 2011, ONCOGENE, V30, P4365, DOI 10.1038/onc.2011.153; Rouleau M, 2010, NAT REV CANCER, V10, P293, DOI 10.1038/nrc2812; Ryu KW, 2015, CHEM REV, V115, P2453, DOI 10.1021/cr5004248; Saleem M, 2006, P NATL ACAD SCI USA, V103, P14825, DOI 10.1073/pnas.0606747103; Senra JM, 2011, MOL CANCER THER, V10, P1949, DOI 10.1158/1535-7163.MCT-11-0278; Shan L, 2014, ONCOGENE, V33, P3205, DOI 10.1038/onc.2013.270; Shedden K, 2008, NAT MED, V14, P822, DOI 10.1038/nm.1790; Shen W, 2011, CANCER SCI, V102, P1014, DOI 10.1111/j.1349-7006.2011.01915.x; Simpson CD, 2008, CANCER LETT, V272, P177, DOI 10.1016/j.canlet.2008.05.029; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Tentori L, 2008, EUR J CANCER, V44, P1302, DOI 10.1016/j.ejca.2008.03.019; Tomida S, 2009, J CLIN ONCOL, V27, P2793, DOI 10.1200/JCO.2008.19.7053; Tsukita S, 1999, TRENDS CELL BIOL, V9, P268, DOI 10.1016/S0962-8924(99)01578-0; Tulin A, 2003, SCIENCE, V299, P560, DOI 10.1126/science.1078764; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Yu WQ, 2004, NAT GENET, V36, P1105, DOI 10.1038/ng1426	79	35	39	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4569	4579		10.1038/onc.2016.3	http://dx.doi.org/10.1038/onc.2016.3			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26898760				2022-12-17	WOS:000382336300003
J	Li, Y; Lauriola, M; Kim, D; Francesconi, M; D'Uva, G; Shibata, D; Malafa, MP; Yeatman, TJ; Coppola, D; Solmi, R; Cheng, JQ				Li, Y.; Lauriola, M.; Kim, D.; Francesconi, M.; D'Uva, G.; Shibata, D.; Malafa, M. P.; Yeatman, T. J.; Coppola, D.; Solmi, R.; Cheng, J. Q.			Adenomatous polyposis coli (APC) regulates miR17-92 cluster through beta-catenin pathway in colorectal cancer	ONCOGENE			English	Article							MIR-17-92 CLUSTER; TCF/BETA-CATENIN; CELL-MIGRATION; BREAST-CANCER; CYCLIN D1; EXPRESSION; MICRORNAS; ANGIOGENESIS; CARCINOMA; INVASION	Adenomatous polyposis coli (APC) mutation is the most common genetic change in sporadic colorectal cancer (CRC). Although deregulations of miRNAs have been frequently reported in this malignancy, APC-regulated miRNAs have not been extensively documented. Here, by using an APC-inducible cell line and array analysis, we identified a total of 26 deregulated miRNAs. Among them, members of miR-17-92 cluster were dramatically inhibited by APC and induced by enforced expression of beta-catenin. Furthermore, we demonstrate that activated beta-catenin resulted from APC loss binds to and activates the miR-17-92 promoter. Notably, enforced expression of miR-19a overrides APC tumor suppressor activity, and knockdown of miR-19a in cancer cells with compromised APC function reduced their aggressive features in vitro. Finally, we observed that expression of miR-19a significantly correlates with beta-catenin levels in colorectal cancer specimens, and it is associated to the aggressive stage of tumor progression. Thus, our study reveals that miR-17-92 cluster is directly regulated by APC/beta-catenin pathway and could be a potential therapeutic target in colon cancers with aberrant APC/beta-catenin signaling.	[Li, Y.; Lauriola, M.; Kim, D.; Cheng, J. Q.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr,SRB-3, Tampa, FL 33612 USA; [Lauriola, M.; D'Uva, G.; Solmi, R.] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Via Massarenti 9, I-40138 Bologna, Italy; [Francesconi, M.] Ctr Genom Regulat CRG, EMBL CRG Syst Biol Unit, Barcelona, Spain; [Shibata, D.; Malafa, M. P.; Yeatman, T. J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA; [Coppola, D.] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL USA; [Yeatman, T. J.] Gibbs Canc Ctr & Res Inst, Spartanburg, SC USA	H Lee Moffitt Cancer Center & Research Institute; University of Bologna; Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Cheng, JQ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr,SRB-3, Tampa, FL 33612 USA.; Solmi, R (corresponding author), Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Via Massarenti 9, I-40138 Bologna, Italy.; Coppola, D (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	domenico.coppola@moffitt.org; rossella.solmi@unibo.it; jin.cheng@moffitt.org	Kim, Donghwa/AAJ-8148-2021; francesconi, mirko/O-8080-2015; D'Uva, Gabriele/A-6252-2015	Kim, Donghwa/0000-0002-8994-8513; francesconi, mirko/0000-0002-8702-0877; D'Uva, Gabriele/0000-0001-9622-9288; lauriola, mattia/0000-0002-7966-0065	Moffitt Cancer Center Foundation; NCI Cancer Center Support Grant [P30 CA076292]; 'Fondazione del Monte di Bologna e di Ravenna' (Bologna, Italy);  [CA137041];  [CA160455]; NATIONAL CANCER INSTITUTE [P30CA076292, R01CA160455, R01CA137041] Funding Source: NIH RePORTER	Moffitt Cancer Center Foundation; NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); 'Fondazione del Monte di Bologna e di Ravenna' (Bologna, Italy); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful for the Molecular Biology and Analytic Microscopy Core and Tissue Core facilities at H. Lee Moffitt Cancer Center. We also thank Dr Thomas Ried for providing NCI-H508 cell line. This work was supported in part by CA137041, CA160455 (JQC) and the Moffitt Cancer Center Foundation. The H. Lee Moffitt Cancer Center & Research Institute is supported in part by NCI Cancer Center Support Grant #P30 CA076292. ML was supported by 'Fondazione del Monte di Bologna e di Ravenna' (Bologna, Italy).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Barth AIM, 2008, SEMIN CELL DEV BIOL, V19, P245, DOI 10.1016/j.semcdb.2008.02.003; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; D'Uva G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080742; Diosdado B, 2009, BRIT J CANCER, V101, P707, DOI 10.1038/sj.bjc.6605037; Fish JE, 2009, SCI SIGNAL, V1, DOI 10.1126/scisignal.252pe1; Grillari J, 2010, BIOGERONTOLOGY, V11, P501, DOI 10.1007/s10522-010-9272-9; Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hong LX, 2010, CANCER RES, V70, P8547, DOI 10.1158/0008-5472.CAN-10-1938; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Jiang H, 2014, AM J PATHOL, V184, P1355, DOI 10.1016/j.ajpath.2014.01.037; Koga Y, 2010, CANCER PREV RES, V3, P1435, DOI 10.1158/1940-6207.CAPR-10-0036; Kong W, 2014, ONCOGENE, V33, P679, DOI 10.1038/onc.2012.636; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kudo Y, 2004, CLIN CANCER RES, V10, P5455, DOI 10.1158/1078-0432.CCR-04-0372; Lanza G, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-54; Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9; Lindow M, 2012, J CELL BIOL, V199, P407, DOI 10.1083/jcb.201208082; Luo XY, 2011, CANCER EPIDEM BIOMAR, V20, P1272, DOI 10.1158/1055-9965.EPI-11-0035; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Mimori-Kiyosue Y, 2007, GENES CELLS, V12, P219, DOI 10.1111/j.1365-2443.2007.01045.x; Miyazawa K, 2000, VIRCHOWS ARCH, V437, P508, DOI 10.1007/s004280000283; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Necela BM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018501; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Pendas-Franco N, 2008, ONCOGENE, V27, P4467, DOI 10.1038/onc.2008.88; Phelps RA, 2009, CELL CYCLE, V8, P2549, DOI 10.4161/cc.8.16.9278; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027, 10.2202/1544-6115.1027/MACHINEREADABLECITATION/RIS]; Solmi R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-227; Song S, 2011, CANCER RES, V71, P7628, DOI 10.1158/0008-5472.CAN-11-2745; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Takahashi-Yanaga F, 2009, J PHARMACOL SCI, V109, P179, DOI 10.1254/jphs.08R28FM; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Tysnes BB, 2010, NEOPLASIA, V12, P506, DOI 10.1593/neo.10290; Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2; van Haaften G, 2010, GENE DEV, V24, P1, DOI 10.1101/gad.1887110; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yu G, 2012, J SURG ONCOL, V106, P232, DOI 10.1002/jso.22138; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200; Zhou Jiao-Jiao, 2014, World J Biol Chem, V5, P301, DOI 10.4331/wjbc.v5.i3.301	50	35	35	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 1	2016	35	35					4558	4568		10.1038/onc.2015.522	http://dx.doi.org/10.1038/onc.2015.522			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU6PE	26804172	Green Accepted, Green Submitted			2022-12-17	WOS:000382336300002
J	Buczek, ME; Miles, AK; Green, W; Johnson, C; Boocock, DJ; Pockley, AG; Rees, RC; Hulman, G; van Schalkwyk, G; Parkinson, R; Hulman, J; Powe, DG; Regad, T				Buczek, M. E.; Miles, A. K.; Green, W.; Johnson, C.; Boocock, D. J.; Pockley, A. G.; Rees, R. C.; Hulman, G.; van Schalkwyk, G.; Parkinson, R.; Hulman, J.; Powe, D. G.; Regad, T.			Cytoplasmic PML promotes TGF-beta-associated epithelial-mesenchymal transition and invasion in prostate cancer	ONCOGENE			English	Article							PROMYELOCYTIC LEUKEMIA FUSES; MOLECULAR-MECHANISMS; SUPPRESSOR PML; NUCLEAR-BODIES; ALPHA; TRANSLOCATION; INTERFERON; EXPRESSION; T(15-17); TARGETS	Epithelial-mesenchymal transition (EMT) is a key event that is involved in the invasion and dissemination of cancer cells. Although typically considered as having tumour-suppressive properties, transforming growth factor (TGF)-beta signalling is altered during cancer and has been associated with the invasion of cancer cells and metastasis. In this study, we report a previously unknown role for the cytoplasmic promyelocytic leukaemia (cPML) tumour suppressor in TGF-beta signalling-induced regulation of prostate cancer-associated EMT and invasion. We demonstrate that cPML promotes a mesenchymal phenotype and increases the invasiveness of prostate cancer cells. This event is associated with activation of TGF-beta canonical signalling pathway through the induction of Sma and Mad related family 2 and 3 (SMAD2 and SMAD3) phosphorylation. Furthermore, the cytoplasmic localization of promyelocytic leukaemia (PML) is mediated by its nuclear export in a chromosomal maintenance 1 (CRM1)-dependent manner. This was clinically tested in prostate cancer tissue and shown that cytoplasmic PML and CRM1 co-expression correlates with reduced disease-specific survival. In summary, we provide evidence of dysfunctional TGF-beta signalling occurring at an early stage in prostate cancer. We show that this disease pathway is mediated by cPML and CRM1 and results in a more aggressive cancer cell phenotype. We propose that the targeting of this pathway could be therapeutically exploited for clinical benefit.	[Buczek, M. E.; Miles, A. K.; Johnson, C.; Boocock, D. J.; Pockley, A. G.; Rees, R. C.; Powe, D. G.; Regad, T.] Nottingham Trent Univ, John Van Geest Canc Res Ctr, Sch Sci & Technol, Clifton Lane, Nottingham NG11 8NS, England; [Green, W.; Parkinson, R.] City Hosp, Nottingham Univ Hosp NHS Trust, Dept Urol, Nottingham, England; [Hulman, G.; Hulman, J.; Powe, D. G.] Nottingham Univ Hosp Trust, Queens Med Ctr, Dept Cellular Pathol, Nottingham, England; [van Schalkwyk, G.] Royal Derby Hosp, Dept Histopathol, Derby, England	Nottingham Trent University; Nottingham University Hospital NHS Trust; University of Nottingham; Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham	Regad, T (corresponding author), Nottingham Trent Univ, John Van Geest Canc Res Ctr, Sch Sci & Technol, Clifton Lane, Nottingham NG11 8NS, England.	tarik.regad@ntu.ac.uk	Regad, Tarik/A-6095-2012; Pockley, Alan G/I-4704-2015; Boocock, David/I-4666-2015	Regad, Tarik/0000-0003-4028-6368; Pockley, Alan G/0000-0001-9593-6431; Boocock, David/0000-0002-7333-3549; Miles, Amanda/0000-0002-5388-938X	John and Lucille van Geest Foundation; Cancer and Polio Research Fund	John and Lucille van Geest Foundation; Cancer and Polio Research Fund	This work was funded by the John and Lucille van Geest Foundation and Cancer and Polio Research Fund. We thank Mrs Anne Schneider, Mr Stephen Reeder, Mr Chris Nolan and Dr Claire Hawkes for their assistance in this study.	Altman DG, 2012, BMC MED, V10, DOI [10.1186/1741-7015-10-51, 10.1371/journal.pmed.1001216]; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; CAMP RL, 2004, CLIN CANCER RES, V10, P7252, DOI [10.1158/1078-0432.CCR-04-0713, DOI 10.1158/1078-0432.CCR-04-0713]; Chan JYH, 1998, EUR J CANCER, V34, P1015, DOI 10.1016/S0959-8049(97)10138-1; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Heldin CH, 2012, FEBS LETT, V586, P1959, DOI 10.1016/j.febslet.2012.02.037; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Jin GX, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00147; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Kubiczkova L, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-183; Lallemand-Breitenbach V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000661; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Mathieu MG, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.29; Mazza M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00174; MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716; Morrison CD, 2013, CANCER LETT, V341, P30, DOI 10.1016/j.canlet.2013.02.048; Nisole S, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00125; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Regad T, 2001, ONCOGENE, V20, P7274, DOI 10.1038/sj.onc.1204854; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Son H, 2010, TOX RESEARCH, V26, P245, DOI 10.5487/TR.2010.26.4.245; TERRIS B, 1995, CANCER RES, V55, P1590; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008	33	35	35	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3465	3475		10.1038/onc.2015.409	http://dx.doi.org/10.1038/onc.2015.409			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26549027	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000379270100011
J	Sheikh, BN; Bechtel-Walz, W; Lucci, J; Karpiuk, O; Hild, I; Hartleben, B; Vornweg, J; Helmstadter, M; Sahyoun, AH; Bhardwaj, V; Stehle, T; Diehl, S; Kretz, O; Voss, AK; Thomas, T; Manke, T; Huber, TB; Akhtar, A				Sheikh, B. N.; Bechtel-Walz, W.; Lucci, J.; Karpiuk, O.; Hild, I.; Hartleben, B.; Vornweg, J.; Helmstaedter, M.; Sahyoun, A. H.; Bhardwaj, V.; Stehle, T.; Diehl, S.; Kretz, O.; Voss, A. K.; Thomas, T.; Manke, T.; Huber, T. B.; Akhtar, A.			MOF maintains transcriptional programs regulating cellular stress response	ONCOGENE			English	Article							H4 LYSINE 16; HISTONE ACETYLTRANSFERASE; EMBRYONIC-DEVELOPMENT; DOSAGE COMPENSATION; PODOCYTE; AUTOPHAGY; GENE; ACETYLATION; PROTEIN; SENESCENCE	MOF (MYST1, KAT8) is the major H4K16 lysine acetyltransferase (KAT) in Drosophila and mammals and is essential for embryonic development. However, little is known regarding the role of MOF in specific cell lineages. Here we analyze the differential role of MOF in proliferating and terminally differentiated tissues at steady state and under stress conditions. In proliferating cells, MOF directly binds and maintains the expression of genes required for cell cycle progression. In contrast, MOF is dispensable for terminally differentiated, postmitotic glomerular podocytes under physiological conditions. However, in response to injury, MOF is absolutely critical for podocyte maintenance in vivo. Consistently, we detect defective nuclear, endoplasmic reticulum and Golgi structures, as well as presence of multivesicular bodies in vivo in podocytes lacking Mof following injury. Undertaking genome-wide expression analysis of podocytes, we uncover several MOF-regulated pathways required for stress response. We find that MOF, along with the members of the non-specific lethal but not the male-specific lethal complex, directly binds to genes encoding the lysosome, endocytosis and vacuole pathways, which are known regulators of podocyte maintenance. Thus, our work identifies MOF as a key regulator of cellular stress response in glomerular podocytes.	[Sheikh, B. N.; Lucci, J.; Karpiuk, O.; Sahyoun, A. H.; Bhardwaj, V.; Stehle, T.; Diehl, S.; Manke, T.; Akhtar, A.] Max Planck Inst Immunobiol & Epigenet, Dept Chromatin Regulat, Stubeweg 51, D-79108 Freiburg, Baden Wuertenbe, Germany; [Bechtel-Walz, W.; Hild, I.; Hartleben, B.; Vornweg, J.; Helmstaedter, M.; Kretz, O.; Huber, T. B.] Univ Med Ctr, Renal Div, Freiburg, Germany; [Kretz, O.] Univ Freiburg, Neuroanat, Hugstetter Str 55, D-79106 Freiburg, Germany; [Voss, A. K.; Thomas, T.] Walter & Eliza Hall Inst Med Res, Dev & Canc Div, Melbourne, Vic 3050, Australia; [Voss, A. K.; Thomas, T.] Univ Melbourne, Dept Med Biol, Melbourne, Vic, Australia; [Huber, T. B.] Univ Freiburg, BIOSS Ctr Biol Signaling Studies, Hugstetter Str 55, D-79106 Freiburg, Germany	Max Planck Society; University of Freiburg; University of Freiburg; University of Melbourne; University of Freiburg	Akhtar, A (corresponding author), Max Planck Inst Immunobiol & Epigenet, Dept Chromatin Regulat, Stubeweg 51, D-79108 Freiburg, Baden Wuertenbe, Germany.	akhtar@ie-freiburg.mpg.de	Manke, Thomas/L-9075-2019; Voss, Anne K/F-5110-2013	Voss, Anne K/0000-0002-3853-9381; Huber, Tobias B./0000-0001-7175-5062; Sahyoun, Abdullah/0000-0002-3333-8599; Thomas, Tim/0000-0002-7623-8344; Keller, Julia/0000-0001-9808-4983; Kretz, Oliver/0000-0003-1152-5956; Sheikh, Bilal/0000-0002-1970-6236; Manke, Thomas/0000-0003-3702-0868; Bechtel-Walz, Wibke/0000-0001-6032-3627; Bhardwaj, Vivek/0000-0002-5570-9338	Humboldt postdoctoral fellowship; Marie Curie Career Integration Grant; Margarete von Wrangell Habilitations-Stipendium; Australian National Health and Medical Research Council; Australian Federal Government (IRISS); Victorian State Government (OIS); DFG (Heisenberg program) [CRC992, CRC1140]; European Research Council (ERC grant); DGF [CRC992, CRC1140, CRC746]	Humboldt postdoctoral fellowship; Marie Curie Career Integration Grant; Margarete von Wrangell Habilitations-Stipendium; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Federal Government (IRISS)(National Health and Medical Research Council (NHMRC) of Australia); Victorian State Government (OIS); DFG (Heisenberg program)(German Research Foundation (DFG)); European Research Council (ERC grant)(European Research Council (ERC)); DGF(German Research Foundation (DFG))	We thank K Lam, M Shvedunova and A Chatterjee for helpful discussions. We are grateful for the assistance provided by P Kindle (MPI-IE, Imaging facility) and B Joch (University Freiburg). BNS is supported by a Humboldt postdoctoral fellowship, WBW by a Marie Curie Career Integration Grant and a Margarete von Wrangell Habilitations-Stipendium. AKV and TT were supported by the Australian National Health and Medical Research Council, operational infrastructure grants from the Australian Federal Government (IRISS) and the Victorian State Government (OIS). TBH was supported by the DFG (Heisenberg program and CRC992 and CRC1140) and the European Research Council (ERC grant). AA is supported by the DGF CRC1140, CRC992 and CRC746. AA and TBH are part of the BIOSS II (Freiburg), the Excellence Initiative of the German Federal and State Governments.	Akhtar A, 2000, MOL CELL, V5, P367, DOI 10.1016/S1097-2765(00)80431-1; ALLFREY VG, 1964, SCIENCE, V144, P559, DOI 10.1126/science.144.3618.559; Bechtel W, 2013, J AM SOC NEPHROL, V24, P727, DOI 10.1681/ASN.2012070700; Bhadra MP, 2012, CHROMOSOMA, V121, P79, DOI 10.1007/s00412-011-0344-7; Blumenthal A, 2015, AM J PHYSIOL-RENAL, V308, pF602, DOI 10.1152/ajprenal.00190.2014; Boerries M, 2013, KIDNEY INT, V83, P1052, DOI 10.1038/ki.2012.487; Brinkkoetter PT, 2013, NAT REV NEPHROL, V9, P328, DOI 10.1038/nrneph.2013.78; Cai Y, 2010, J BIOL CHEM, V285, P4268, DOI 10.1074/jbc.C109.087981; Campeau PM, 2012, AM J HUM GENET, V90, P282, DOI 10.1016/j.ajhg.2011.11.023; Carson JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099771; Chelmicki T, 2014, ELIFE, V3, DOI 10.7554/eLife.02024; Chung JJ, 2015, J CLIN INVEST, V125, P2307, DOI 10.1172/JCI79641; Cina DP, 2012, J AM SOC NEPHROL, V23, P412, DOI 10.1681/ASN.2011070690; Debacq-Chainiaux F, 2009, NAT PROTOC, V4, P1798, DOI 10.1038/nprot.2009.191; Endlich N, 2001, J AM SOC NEPHROL, V12, P413, DOI 10.1681/ASN.V123413; Fulda Simone, 2010, Int J Cell Biol, V2010, P370835, DOI 10.1155/2010/370835; Fullgrabe J, 2013, NATURE, V500, P468, DOI 10.1038/nature12313; Gupta A, 2005, MOL CELL BIOL, V25, P5292, DOI 10.1128/MCB.25.12.5292-5305.2005; Gupta A, 2008, MOL CELL BIOL, V28, P397, DOI 10.1128/MCB.01045-07; Gupta A, 2014, CELL REP, V8, P177, DOI 10.1016/j.celrep.2014.05.044; Gupta A, 2013, MUTAGENESIS, V28, P263, DOI 10.1093/mutage/ges080; Hartleben B, 2010, J CLIN INVEST, V120, P1084, DOI 10.1172/JCI39492; Howell GM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069520; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huber TB, 2012, AUTOPHAGY, V8, P1009, DOI 10.4161/auto.19821; Jiang M, 2012, KIDNEY INT, V82, P1271, DOI 10.1038/ki.2012.261; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Kim JY, 2010, TRANSPLANTATION, V89, P215, DOI 10.1097/TP.0b013e3181c353e5; Krishnan V, 2011, P NATL ACAD SCI USA, V108, P12325, DOI 10.1073/pnas.1102789108; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; Kumar R, 2011, P NATL ACAD SCI USA, V108, P3636, DOI 10.1073/pnas.1016524108; Law CW, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r29; Lee VWS, 2011, NEPHROLOGY, V16, P30, DOI 10.1111/j.1440-1797.2010.01383.x; Lenoir O, 2015, AUTOPHAGY, V11, P1130, DOI 10.1080/15548627.2015.1049799; Li XZ, 2012, CELL STEM CELL, V11, P163, DOI 10.1016/j.stem.2012.04.023; Li XZ, 2010, MOL CELL BIOL, V30, P5335, DOI 10.1128/MCB.00350-10; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liapis H, 2013, AM J PATHOL, V183, P1364, DOI 10.1016/j.ajpath.2013.06.033; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Mendjan S, 2006, MOL CELL, V21, P811, DOI 10.1016/j.molcel.2006.02.007; Merson TD, 2006, J NEUROSCI, V26, P11359, DOI 10.1523/JNEUROSCI.2247-06.2006; Moeller MJ, 2003, GENESIS, V35, P39, DOI 10.1002/gene.10164; Mundel P, 2002, J AM SOC NEPHROL, V13, P3005, DOI 10.1097/01.ASN.0000039661.06947.FD; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; Narita M, 2011, SCIENCE, V332, P966, DOI 10.1126/science.1205407; Raja SJ, 2010, MOL CELL, V38, P827, DOI 10.1016/j.molcel.2010.05.021; Schell C, 2014, SEMIN CELL DEV BIOL, V36, P39, DOI 10.1016/j.semcdb.2014.07.016; Sharma GG, 2010, MOL CELL BIOL, V30, P3582, DOI 10.1128/MCB.01476-09; Sheikh BN, 2015, ONCOGENE, V34, P5807, DOI 10.1038/onc.2015.33; Sheikh BN, 2015, BLOOD, V125, P1910, DOI 10.1182/blood-2014-08-594655; Sheikh BN, 2014, CELL TISSUE RES, V356, P553, DOI 10.1007/s00441-014-1835-7; Simpson MA, 2012, AM J HUM GENET, V90, P290, DOI 10.1016/j.ajhg.2011.11.024; Smith ER, 2005, MOL CELL BIOL, V25, P9175, DOI 10.1128/MCB.25.21.9175-9188.2005; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Taipale M, 2005, MOL CELL BIOL, V25, P6798, DOI 10.1128/MCB.25.15.6798-6810.2005; Takabatake Y, 2014, NEPHROL DIAL TRANSPL, V29, P1639, DOI 10.1093/ndt/gft535; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; Thomas T, 2000, DEVELOPMENT, V127, P2537; Thomas T, 2008, MOL CELL BIOL, V28, P5093, DOI 10.1128/MCB.02202-07; Voss AK, 2009, BIOESSAYS, V31, P1050, DOI 10.1002/bies.200900051; Weavers H, 2009, NATURE, V457, P322, DOI 10.1038/nature07526; Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401; Xu W, 2006, BLOOD, V107, P4407, DOI 10.1182/blood-2005-08-3263; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Zhang FJ, 2013, J AM SOC NEPHROL, V24, P209, DOI 10.1681/ASN.2012080795	67	35	35	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2016	35	21					2698	2710		10.1038/onc.2015.335	http://dx.doi.org/10.1038/onc.2015.335			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DO0MJ	26387537	Green Published, hybrid			2022-12-17	WOS:000377472700004
J	Kruiswijk, F; Hasenfuss, SC; Sivapatham, R; Baar, MP; Putavet, D; Naipal, KAT; van den Broek, NJF; Kruit, W; van der Spek, PJ; van Gent, DC; Brenkman, AB; Campisi, J; Burgering, BMT; Hoeijmakers, JHJ; de Keizer, PLJ				Kruiswijk, F.; Hasenfuss, S. C.; Sivapatham, R.; Baar, M. P.; Putavet, D.; Naipal, K. A. T.; van den Broek, N. J. F.; Kruit, W.; van der Spek, P. J.; van Gent, D. C.; Brenkman, A. B.; Campisi, J.; Burgering, B. M. T.; Hoeijmakers, J. H. J.; de Keizer, P. L. J.			Targeted inhibition of metastatic melanoma through interference with Pin1-FOXM1 signaling	ONCOGENE			English	Article							MEK INHIBITION; TRANSCRIPTION FACTORS; IMPROVED SURVIVAL; MITOTIC PROGRAM; BRAF; FOXM1; EXPRESSION; GENE; RESISTANCE; PHOSPHORYLATION	Melanoma is the most lethal form of skin cancer and successful treatment of metastatic melanoma remains challenging. BRAF/MEK inhibitors only show a temporary benefit due to rapid occurrence of resistance, whereas immunotherapy is mainly effective in selected subsets of patients. Thus, there is a need to identify new targets to improve treatment of metastatic melanoma. To this extent, we searched for markers that are elevated in melanoma and are under regulation of potentially druggable enzymes. Here, we show that the pro-proliferative transcription factor FOXM1 is elevated and activated in malignant melanoma. FOXM1 activity correlated with expression of the enzyme Pin1, which we found to be indicative of a poor prognosis. In functional experiments, Pin1 proved to be a main regulator of FOXM1 activity through MEK-dependent physical regulation during the cell cycle. The Pin1-FOXM1 interaction was enhanced by BRAF(V600E), the driver oncogene in the majority of melanomas, and in extrapolation of the correlation data, interference with\Pin1 in BRAF(V600E)-driven metastatic melanoma cells impaired both FOXM1 activity and cell survival. Importantly, cell-permeable Pin1-FOXM1-blocking peptides repressed the proliferation of melanoma cells in freshly isolated human metastatic melanoma ex vivo and in three-dimensional-cultured patient-derived melanoids. When combined with the BRAF(V600) Einhibitor PLX4032 a robust repression in melanoid viability was obtained, establishing preclinical value of patient-derived melanoids for prognostic use of drug sensitivity and further underscoring the beneficial effect of Pin1-FOXM1 inhibitory peptides as anti-melanoma drugs. These proof-of-concept results provide a starting point for development of therapeutic Pin1-FOXM1 inhibitors to target metastatic melanoma.	[Kruiswijk, F.; Hasenfuss, S. C.; van den Broek, N. J. F.; Brenkman, A. B.; Burgering, B. M. T.; de Keizer, P. L. J.] Univ Med Ctr, Ctr Mol Med, Mol Canc Res, Utrecht, Netherlands; [Sivapatham, R.; Campisi, J.; de Keizer, P. L. J.] Buck Inst Res Aging, Novato, CA USA; [Baar, M. P.; Putavet, D.; Naipal, K. A. T.; van Gent, D. C.; Hoeijmakers, J. H. J.; de Keizer, P. L. J.] Erasmus MC, Dept Genet, Wytemaweg 80,POB 2040, NL-3000 CA Rotterdam, Netherlands; [Kruit, W.] Erasmus MC, Dept Med Oncol, Rotterdam, Netherlands; [van der Spek, P. J.] Erasmus MC, Dept Bioinformat, Rotterdam, Netherlands; [Brenkman, A. B.] Univ Med Ctr, Dept Metab & Endocrine Dis, Utrecht, Netherlands; [Campisi, J.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA	Utrecht University; Utrecht University Medical Center; Buck Institute for Research on Aging; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Utrecht University; Utrecht University Medical Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	de Keizer, PLJ (corresponding author), Erasmus MC, Dept Genet, Wytemaweg 80,POB 2040, NL-3000 CA Rotterdam, Netherlands.	p.dekeizer@erasmusmc.nl	Sivapatham, Renuka/AAS-3650-2020; Hoeijmakers, Jan/AAX-6972-2021; de+Keizer, Peter/AAD-5320-2020	Sivapatham, Renuka/0000-0003-0309-3671; de+Keizer, Peter/0000-0002-6948-925X; van Gent, Dik C./0000-0003-1473-8148; Naipal, Kishan/0000-0001-8267-8218	NIH [R37-AG009909]; NIH/NIA [AG-17242-02]; KNAW; ERC; FP7 framework [HEALTH-F2-2010-259893]; Dutch Cancer Society [Buit-4649]; EMCR [2014-7141]; Erasmus Medical Center Rotterdam: EMC fellowship; CGC; NATIONAL INSTITUTE ON AGING [R37AG009909, P01AG017242] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); KNAW; ERC(European Research Council (ERC)European Commission); FP7 framework; Dutch Cancer Society(KWF Kankerbestrijding); EMCR; Erasmus Medical Center Rotterdam: EMC fellowship; CGC; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We would like to gratefully acknowledge Dr Richard Marais for material from BRAF<SUP>V600E-</SUP>inducible mice, Dr Hugo Snippert and Dr Rene Overmeer for advice on organoid culture and Dr Jamila Laoukili and Dr Rene Medema for general advice on FOXM1 signaling. This work has been supported by grants from the NIH: R37-AG009909 (JC), CGC (BB), NIH/NIA: AG-17242-02 (JC/JH), KNAW (JH), ERC (JH), FP7 framework HEALTH-F2-2010-259893 (JH), the Dutch Cancer Society: Buit-4649 (PDK), EMCR 2014-7141 (PDK) and the Erasmus Medical Center Rotterdam: 2013 EMC fellowship (PDK).	Alcala AM, 2012, CLIN CANCER RES, V18, P33, DOI 10.1158/1078-0432.CCR-11-0997; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Aytes A, 2014, CANCER CELL, V25, P638, DOI 10.1016/j.ccr.2014.03.017; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; Bogunovic D, 2009, P NATL ACAD SCI USA, V106, P20429, DOI 10.1073/pnas.0905139106; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Brenkman AB, 2008, CANCER RES, V68, P7597, DOI 10.1158/0008-5472.CAN-08-1059; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Damsky WE, 2014, ONCOGENE, V33, P2413, DOI 10.1038/onc.2013.194; Damsky WE, 2010, PIGM CELL MELANOMA R, V23, P853, DOI 10.1111/j.1755-148X.2010.00777.x; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; de Keizer PLJ, 2010, CANCER RES, V70, P8526, DOI 10.1158/0008-5472.CAN-10-1563; Dhomen N, 2009, HEMATOL ONCOL CLIN N, V23, P529, DOI 10.1016/j.hoc.2009.04.001; Dhomen N, 2009, CANCER CELL, V15, P294, DOI 10.1016/j.ccr.2009.02.022; Down CF, 2012, BBA-GENE REGUL MECH, V1819, P855, DOI 10.1016/j.bbagrm.2012.03.008; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Geurts-Giele WRR, 2014, J PATHOL, V234, P548, DOI 10.1002/path.4419; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Halasi M, 2009, CELL CYCLE, V8, P1966, DOI 10.4161/cc.8.12.8708; Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Jones AT, 2012, J CONTROL RELEASE, V161, P582, DOI 10.1016/j.jconrel.2012.04.003; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Li XX, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-204; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Maser RS, 2007, NATURE, V447, P966, DOI 10.1038/nature05886; Naipal KAT, 2014, CLIN CANCER RES, V20, P4816, DOI 10.1158/1078-0432.CCR-14-0571; Nakamura A, 2013, CANCER RES, V73, P7043, DOI 10.1158/0008-5472.CAN-13-1825; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; REED JA, 1995, CANCER RES, V55, P2713; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Smith AP, 2005, CANCER BIOL THER, V4, P1018, DOI 10.4161/cbt.4.9.2165; Solit D, 2010, NATURE, V468, P902, DOI 10.1038/468902a; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Verdecia MA, 2000, NAT STRUCT BIOL, V7, P639, DOI 10.1038/77929; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Walker GJ, 2011, PIGM CELL MELANOMA R, V24, P1158, DOI 10.1111/j.1755-148X.2011.00923.x; Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344; Zhang N, 2012, CLIN CANCER RES, V18, P5961, DOI 10.1158/1078-0432.CCR-12-0039	47	35	36	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2016	35	17					2166	2177		10.1038/onc.2015.282	http://dx.doi.org/10.1038/onc.2015.282			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DK5UK	26279295	Green Accepted, hybrid, Green Published, Green Submitted			2022-12-17	WOS:000374986000003
J	He, Y; Wu, AC; Harrington, BS; Davies, CM; Wallace, SJ; Adams, MN; Palmer, JS; Roche, DK; Hollier, BG; Westbrook, TF; Hamidi, H; Konecny, G; Winterhoff, B; Chetty, NP; Crandon, AJ; Oliveira, NB; Shannon, CM; Tinker, AV; Gilks, CB; Coward, JI; Lumley, JW; Perrin, LC; Armes, JE; Hooper, JD				He, Y.; Wu, A. C.; Harrington, B. S.; Davies, C. M.; Wallace, S. J.; Adams, M. N.; Palmer, J. S.; Roche, D. K.; Hollier, B. G.; Westbrook, T. F.; Hamidi, H.; Konecny, G. E.; Winterhoff, B.; Chetty, N. P.; Crandon, A. J.; Oliveira, N. B.; Shannon, C. M.; Tinker, A. V.; Gilks, C. B.; Coward, J. I.; Lumley, J. W.; Perrin, L. C.; Armes, J. E.; Hooper, J. D.			Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance	ONCOGENE			English	Article							DOMAIN-CONTAINING PROTEIN-1; SURFACE GLYCOPROTEIN CDCP1; CUB-DOMAIN; ANOIKIS RESISTANCE; SURVIVAL; PROGNOSIS; SRC; IDENTIFICATION; METASTASIS; MECHANISMS	Hematogenous metastases are rarely present at diagnosis of ovarian clear cell carcinoma (OCC). Instead dissemination of these tumors is characteristically via direct extension of the primary tumor into nearby organs and the spread of exfoliated tumor cells throughout the peritoneum, initially via the peritoneal fluid, and later via ascites that accumulates as a result of disruption of the lymphatic system. The molecular mechanisms orchestrating these processes are uncertain. In particular, the signaling pathways used by malignant cells to survive the stresses of anchorage-free growth in peritoneal fluid and ascites, and to colonize remote sites, are poorly defined. We demonstrate that the transmembrane glycoprotein CUB-domain-containing protein 1 (CDCP1) has important and inhibitable roles in these processes. In vitro assays indicate that CDCP1 mediates formation and survival of OCC spheroids, as well as cell migration and chemoresistance. Disruption of CDCP1 via silencing and antibody-mediated inhibition markedly reduce the ability of TOV21G OCC cells to form intraperitoneal tumors and induce accumulation of ascites in mice. Mechanistically our data suggest that CDCP1 effects are mediated via a novel mechanism of protein kinase B (Akt) activation. Immunohistochemical analysis also suggested that CDCP1 is functionally important in OCC, with its expression elevated in 90% of 198 OCC tumors and increased CDCP1 expression correlating with poor patient disease-free and overall survival. This analysis also showed that CDCP1 is largely restricted to the surface of malignant cells where it is accessible to therapeutic antibodies. Importantly, antibody-mediated blockade of CDCP1 in vivo significantly increased the anti-tumor efficacy of carboplatin, the chemotherapy most commonly used to treat OCC. In summary, our data indicate that CDCP1 is important in the progression of OCC and that targeting pathways mediated by this protein may be useful for the management of OCC, potentially in combination with chemotherapies and agents targeting the Akt pathway.	[He, Y.; Wu, A. C.; Harrington, B. S.; Davies, C. M.; Adams, M. N.; Palmer, J. S.; Roche, D. K.; Coward, J. I.; Armes, J. E.; Hooper, J. D.] Univ Queensland, Translat Res Inst, Mater Res Inst, Woolloongabba, Qld, Australia; [Davies, C. M.; Wallace, S. J.; Chetty, N. P.; Crandon, A. J.; Oliveira, N. B.; Shannon, C. M.; Coward, J. I.; Perrin, L. C.; Armes, J. E.] Mater Hlth Serv, South Brisbane, Qld, Australia; [Hollier, B. G.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Woolloongabba, Qld, Australia; [Westbrook, T. F.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Hamidi, H.; Konecny, G. E.] Univ Calif Los Angeles, Los Angeles, CA USA; [Winterhoff, B.] Mayo Clin, Rochester, MN USA; [Tinker, A. V.] British Columbia Canc Agcy, Div Med Oncol, Vancouver Ctr, Vancouver, BC V5Z 4E6, Canada; [Tinker, A. V.] British Columbia Canc Agcy, Cheryl Brown Ovarian Canc Outcomes Unit, Vancouver, BC V5Z 4E6, Canada; [Gilks, C. B.] Univ British Columbia, Vancouver Gen Hosp, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; [Lumley, J. W.] Wesley Hosp, Auchenflower, Qld, Australia	Mater Research; University of Queensland; Mater Health Services; Queensland University of Technology (QUT); Baylor College of Medicine; University of California System; University of California Los Angeles; Mayo Clinic; British Columbia Cancer Agency; British Columbia Cancer Agency; University of British Columbia; Wesley Hospital	Hooper, JD (corresponding author), Univ Queensland, Translat Res Inst, Canc Biol & Management, Mater Res Inst, 37 Kent St, Woolloongabba, Qld 4102, Australia.	john.hooper@mater.uq.edu.au	Coward, Jermaine/F-2903-2016; Harrington, Brittney/P-1687-2016; Hooper, John/C-1481-2016; Adams, Mark/AAE-1209-2021; Harrington, Brittney/Z-5941-2019; Hamidi, Habib/H-8030-2016; OLIVEIRA, Niara/Y-3471-2018	Coward, Jermaine/0000-0002-2309-9379; Harrington, Brittney/0000-0001-7083-069X; Hooper, John/0000-0003-1054-8486; Adams, Mark/0000-0003-1906-5018; Harrington, Brittney/0000-0001-7083-069X; Hamidi, Habib/0000-0003-0196-9852; Chetty, Naven/0000-0002-7158-7123; OLIVEIRA, Niara/0000-0001-7103-2200; Perrin, Lewis/0000-0002-6119-8458; Wu, Andy C/0000-0002-0864-4447; HE, Yaowu/0000-0002-7828-263X; Davies, Claire/0000-0001-8651-0914	Cancer Council Queensland [614205, 1021827]; Wesley Research Institute grant [2008/06]; MNA; BSH received Australian Post-Graduate Awards; BGH holds a Queensland Government Smart Futures Fund Fellowship; JDH holds Australian Research Council Future Fellowship [FT120100917]	Cancer Council Queensland(Cancer Council Queensland); Wesley Research Institute grant; MNA; BSH received Australian Post-Graduate Awards; BGH holds a Queensland Government Smart Futures Fund Fellowship; JDH holds Australian Research Council Future Fellowship	This work was supported by Cancer Council Queensland grants 614205 and 1021827 and Wesley Research Institute grant 2008/06 to JDH. MNA and BSH received Australian Post-Graduate Awards. BGH holds a Queensland Government Smart Futures Fund Fellowship. JDH holds Australian Research Council Future Fellowship FT120100917.	Adams MN, 2015, ONCOGENE, V34, P1375, DOI 10.1038/onc.2014.88; Al-Barrak J, 2011, GYNECOL ONCOL, V122, P107, DOI 10.1016/j.ygyno.2011.03.011; Alvares SM, 2008, BBA-GEN SUBJECTS, V1780, P486, DOI 10.1016/j.bbagen.2008.01.010; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Carduner L, 2014, EXP CELL RES, V320, P329, DOI 10.1016/j.yexcr.2013.11.011; Casar B, 2014, ONCOGENE, V33, P255, DOI 10.1038/onc.2012.547; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Casey RC, 2001, AM J PATHOL, V159, P2071, DOI 10.1016/S0002-9440(10)63058-1; Chan JK, 2008, GYNECOL ONCOL, V109, P370, DOI 10.1016/j.ygyno.2008.02.006; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; Dong Y, 2012, J BIOL CHEM, V287, P9792, DOI 10.1074/jbc.M111.335448; Emerling BM, 2013, P NATL ACAD SCI USA, V110, P3483, DOI 10.1073/pnas.1222435110; Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Hoskins PJ, 2012, J CLIN ONCOL, V30, P1656, DOI 10.1200/JCO.2011.40.1646; Huang RYJ, 2012, CURR DRUG TARGETS, V13, P1649; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Itamochi H, 2002, JPN J CANCER RES, V93, P723, DOI 10.1111/j.1349-7006.2002.tb01312.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Kemp Z, 2013, INT J WOMENS HEALTH, V5, P45, DOI 10.2147/IJWH.S30231; Kollmorgen G, 2013, MOL ONCOL, V7, P1142, DOI 10.1016/j.molonc.2013.08.009; Langyel E, 2010, AM J PATHOL, V177, P1053, DOI 10.2353/ajpath.2010.100105; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; McGovern JA, 2013, BRIT J DERMATOL, V168, P496, DOI 10.1111/bjd.12119; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Saga Y, 2008, ONCOL REP, V20, P1299, DOI 10.3892/or_00000144; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Smith JA, 2005, GYNECOL ONCOL, V98, P141, DOI 10.1016/j.ygyno.2005.02.006; Spassov DS, 2013, CANCER RES, V73, P1168, DOI 10.1158/0008-5472.CAN-12-2496; Sugiyama T, 2000, CANCER, V88, P2584, DOI 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.3.CO;2-X; Tan DSP, 2013, BRIT J CANCER, V108, P1553, DOI 10.1038/bjc.2013.126; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tang T, 2010, NAT BIOTECHNOL, V28, P749, DOI 10.1038/nbt.1644; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Wortmann A, 2009, IUBMB LIFE, V61, P723, DOI 10.1002/iub.198; Yu XH, 2008, CANCER SCI, V99, P543, DOI 10.1111/j.1349-7006.2007.00722.x	39	35	36	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					468	478		10.1038/onc.2015.101	http://dx.doi.org/10.1038/onc.2015.101			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25893298	hybrid, Green Published			2022-12-17	WOS:000369056700007
J	Noy, PJ; Lodhia, P; Khan, K; Zhuang, X; Ward, DG; Verissimo, AR; Bacon, A; Bicknell, R				Noy, P. J.; Lodhia, P.; Khan, K.; Zhuang, X.; Ward, D. G.; Verissimo, A. R.; Bacon, A.; Bicknell, R.			Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth	ONCOGENE			English	Article							LECTIN-LIKE DOMAIN; ENDOTHELIAL MARKERS; IDENTIFICATION; EXPRESSION; ADHESION; CELLS	We previously identified CLEC14A as a tumour endothelial marker. Here we show that CLEC14A is a regulator of sprouting angiogenesis in vitro and in vivo. Using a human umbilical vein endothelial cell spheroid-sprouting assay, we found CLEC14A to be a regulator of sprout initiation. Analysis of endothelial sprouting in aortic ring and in vivo subcutaneous sponge assays from clec14a(+/+) and clec14a(-/-) mice revealed defects in sprouting angiogenesis in CLEC14A-deficient animals. Tumour growth was retarded and vascularity reduced in clec14a(-/)-mice. Pull-down and co-immunoprecipitation experiments confirmed that MMRN2 binds to the extracellular region of CLEC14A. The CLEC14A-MMRN2 interaction was interrogated using mouse monoclonal antibodies. Monoclonal antibodies were screened for their ability to block this interaction. Clone C4, but not C2, blocked CLEC14A-MMRN2 binding. C4 antibody perturbed tube formation and endothelial sprouting in vitro and in vivo, with a similar phenotype to loss of CLEC14A. Significantly, tumour growth was impaired in C4-treated animals and vascular density was also reduced in the C4-treated group. We conclude that CLEC14A-MMRN2 binding has a role in inducing sprouting angiogenesis during tumour growth, which has the potential to be manipulated in future antiangiogenic therapy design.	[Noy, P. J.; Lodhia, P.; Khan, K.; Zhuang, X.; Verissimo, A. R.; Bicknell, R.] Univ Birmingham, Sch Med, Coll Med & Dent Sci, Angiogenesis Lab,Inst Biomed Res,Sch Immun & Infe, Birmingham, W Midlands, England; [Noy, P. J.; Lodhia, P.; Khan, K.; Zhuang, X.; Verissimo, A. R.; Bicknell, R.] Univ Birmingham, Sch Med, Coll Med & Dent Sci, Angiogenesis Lab,Inst Biomed Res,Sch Canc Sci, Birmingham, W Midlands, England; [Ward, D. G.] Univ Birmingham, Sch Canc Sci, Inst Canc Studies, Birmingham, W Midlands, England; [Bacon, A.] Univ Birmingham, Sch Med, Inst Biomed Res, Sch Immun & Infect, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Birmingham	Bicknell, R (corresponding author), Univ Birmingham, Sch Med, Coll Med & Dent Sci, Angiogenesis Lab,Inst Biomed Res,Sch Immun & Infe, Birmingham, W Midlands, England.	r.bicknell@bham.ac.uk	Khan, Kabir/U-8350-2018	Khan, Kabir/0000-0001-8453-3485; Bicknell, Roy/0000-0002-0941-8919; Noy, Peter/0000-0001-6142-8957; Zhuang, Alan Xiaodong/0000-0002-6870-9003	Cancer Research UK (CRUK) [C4719/A6766]; Portuguese Fundacao para a Ciencia e tecnologia; Technology Strategy Board [KTP007696]; MRC; University of Birmingham; Medical Research Council [1304704] Funding Source: researchfish	Cancer Research UK (CRUK)(Cancer Research UK); Portuguese Fundacao para a Ciencia e tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Technology Strategy Board; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); University of Birmingham; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Dr Laurens van der Flier, Somantix and Dr Raj Mehta, Cancer Research Technology, for helpful discussions. PN was funded by Cancer Research UK (CRUK, grant number C4719/A6766 to RB). The Portuguese Fundacao para a Ciencia e tecnologia funded AV. XZ was funded by a knowledge transfer partnership (KTP007696) from the Technology Strategy Board. PL is funded by MRC and the University of Birmingham, and KK is funded by the University of Birmingham. The University of Birmingham Transgenic Mouse Facility is part of the MRC Centre for Immune Regulation.	Aricescu AR, 2006, ACTA CRYSTALLOGR D, V62, P1243, DOI 10.1107/S0907444906029799; Baker M, 2012, NAT PROTOC, V7, P89, DOI 10.1038/nprot.2011.435; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bignon M, 2011, BLOOD, V118, P3979, DOI 10.1182/blood-2010-10-313296; Chaudhary A, 2012, CANCER CELL, V21, P212, DOI 10.1016/j.ccr.2012.01.004; Colombatti A, 2012, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00093; Cullen M, 2009, CANCER RES, V69, P6021, DOI 10.1158/0008-5472.CAN-09-1086; De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037; Desjobert C, 2009, BIOCHEM J, V417, P121, DOI 10.1042/BJ20080872; Duwel A, 2007, TUMOR BIOL, V28, P1, DOI 10.1159/000097040; Jin H, 2010, BLOOD, V116, P5773, DOI 10.1182/blood-2010-07-296210; Ki MK, 2013, ONCOGENE, V32, P5449, DOI 10.1038/onc.2013.156; Korff T, 2004, EXP CELL RES, V297, P415, DOI 10.1016/j.yexcr.2004.03.043; Lorenzon E, 2012, ONCOGENE, V31, P3136, DOI 10.1038/onc.2011.487; Masiero M, 2013, CANCER CELL, V24, P229, DOI 10.1016/j.ccr.2013.06.004; Mura M, 2012, ONCOGENE, V31, P293, DOI 10.1038/onc.2011.233; Nanda A, 2006, P NATL ACAD SCI USA, V103, P3351, DOI 10.1073/pnas.0511306103; Nanda A, 2004, CURR OPIN ONCOL, V16, P44, DOI 10.1097/00001622-200401000-00009; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pircher A, 2013, LUNG CANCER, V81, P252, DOI 10.1016/j.lungcan.2013.04.014; Rho SS, 2011, BIOCHEM BIOPH RES CO, V404, P103, DOI 10.1016/j.bbrc.2010.11.075; SANZMONCASI MP, 1994, LAB INVEST, V71, P366; Saunders Thomas L, 2003, Methods Mol Biol, V209, P125; Stapor PC., 2011, CARDIOVASC ENG TECHN, V2, P124, DOI [10.1007/s13239-011-0041-y, DOI 10.1007/S13239-011-0041-Y, 10.1007/S13239-011-0041-Y]; Suchting S, 2004, FASEB J, V18, P121, DOI 10.1096/fj.04-1991fje; Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103; Welch-Reardon KM, 2014, J CELL SCI, V127, P2017, DOI 10.1242/jcs.143420; Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212; Wilson E, 2014, J CELL SCI, V127, P3039, DOI 10.1242/jcs.140434; Zanivan S, 2013, MOL CELL PROTEOMICS, V12, P3599, DOI 10.1074/mcp.M113.031344; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x; Zhuang XD, 2011, BIOCHEM SOC T, V39, P1571, DOI 10.1042/BST20110746; Ziyad Safiyyah, 2011, Genes Cancer, V2, P1085, DOI 10.1177/1947601911432334	33	35	38	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5821	5831		10.1038/onc.2015.34	http://dx.doi.org/10.1038/onc.2015.34			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25745997	Green Accepted, Green Submitted			2022-12-17	WOS:000365035200005
J	Sarkar, M; Khare, V; Guturi, KKN; Das, N; Ghosh, MK				Sarkar, M.; Khare, V.; Guturi, K. K. N.; Das, N.; Ghosh, M. K.			The DEAD box protein p68: a crucial regulator of AKT/FOXO3a signaling axis in oncogenesis	ONCOGENE			English	Article							TRANSCRIPTION FACTORS; CANCER CELLS; EXPRESSION; PATHWAY; AKT; OVEREXPRESSION; PROGRESSION; ACTIVATION; KINASE; PLAYS	Increased abundance of proto-oncogene AKT and reduced expression of tumor suppressor Forkhead box O3 (FOXO3a), the downstream target of AKT, is frequent in carcinogenesis. Mechanistic insights of AKT gene regulation are limited. DEAD box RNA helicase p68 is overexpressed in various cancers and acts as a transcriptional co-activator of several transcription factors, including beta-catenin. Here, we report a novel mechanism of p68-mediated transcriptional activation of AKT, and its ensuing effect on FOXO3a, in colon carcinogenesis. Interestingly, we found that the expression of p68 and AKT exhibits strong positive correlation in normal and colon carcinoma patient samples. In addition, p68 increased both AKT messenger RNA (mRNA) and protein, enhanced AKT promoter activity in multiple colon cancer cell lines. Conversely, p68 knockdown led to reduced AKT mRNA and protein, diminished AKT promoter activity. Here, we demonstrated that p68 occupies AKT promoter with beta-catenin as well as nuclear factor-kappa B (NF-kappa B) and cooperates with these in potentiating AKT transcription. Furthermore, p68 and FOXO3a expression followed inverse correlation in the same set of colon carcinoma samples. We observed that p68 significantly reduced FOXO3a protein level in an AKT-dependent manner. Studies in primary tumors and metastatic lung nodules generated in mice colorectal allograft model, using syngeneic cells stably expressing p68, corroborated our in vitro findings. Hence, a new mechanism of oncogenesis is attributed to p68 by upregulation of AKT and consequent nuclear exclusion and degradation of tumor suppressor FOXO3a.	[Sarkar, M.; Khare, V.; Guturi, K. K. N.; Das, N.; Ghosh, M. K.] Indian Inst Chem Biol, CSIR, Canc Biol & Inflammatory Disorder Div, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Sarkar, M (corresponding author), Indian Inst Chem Biol, CSIR, Canc Biol & Inflammatory Disorder Div, 4 Raja SC Mullick Rd, Kolkata 700032, W Bengal, India.	mrinal.res@gmail.com		Sarkar, Dr Moumita/0000-0002-7437-5353	CSIR, India [EMPOWER-OLP-002, MEDCHEM-BSC0108, CSIR-MAYO: MLP-0017]	CSIR, India(Council of Scientific & Industrial Research (CSIR) - India)	We thank Dr Frances V Fuller-Pace, Dr KM Yamada and Dr B Alman for gifting us the pGS5-p68 construct, pGZ21dx vector and pBI-beta-catenin construct, respectively; Dr Uttara Chatterjee (Park Clinic, Kolkata, India) for providing human normal colon and colon carcinoma samples, associated pathological reports and helping in analysis of the related data; Dr Samit Adhya for kindly providing us the facility for animal lung imaging. This work is supported by grants from CSIR, India (EMPOWER-OLP-002, MEDCHEM-BSC0108 and CSIR-MAYO: MLP-0017).	Bhattacharya S, 2014, FEBS J, V281, P3061, DOI 10.1111/febs.12843; Bhowmik A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059798; Bullock MD, 2013, BRIT J CANCER, V109, P387, DOI 10.1038/bjc.2013.355; Cai BH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041742; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Causevic M, 2001, ONCOGENE, V20, P7734, DOI 10.1038/sj.onc.1204976; Crowell JA, 2007, MOL CANCER THER, V6, P2139, DOI 10.1158/1535-7163.MCT-07-0120; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; Du Qiang, 2010, For Immunopathol Dis Therap, V1, P155; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Fu Z, 2008, ONCOGENE, V27, P2312, DOI 10.1038/onc.2008.24; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; Janknecht R, 2010, AM J TRANSL RES, V2, P223; Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Malinowsky K, 2014, BRIT J CANCER, V110, P2081, DOI 10.1038/bjc.2014.100; Mandal T, 2014, CELL SIGNAL, V26, P1725, DOI 10.1016/j.cellsig.2014.04.003; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Paul I, 2013, ONCOGENE, V32, P1284, DOI 10.1038/onc.2012.144; Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Rychahou PG, 2008, P NATL ACAD SCI USA, V105, P20315, DOI 10.1073/pnas.0810715105; Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Sha JF, 2010, J VIROL, V84, P4050, DOI 10.1128/JVI.02131-09; Shin S, 2007, CANCER RES, V67, P7572, DOI 10.1158/0008-5472.CAN-06-4652; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Temraz S, 2013, INT J MOL SCI, V14, P17279, DOI 10.3390/ijms140917279; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; Tzivion G, 2011, BBA-MOL CELL RES, V1813, P1938, DOI 10.1016/j.bbamcr.2011.06.002; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang R, 2012, NEURO-ONCOLOGY, V14, P1116, DOI 10.1093/neuonc/nos131; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wang XF, 2004, ONCOGENE, V23, P1885, DOI 10.1038/sj.onc.1207312; Zhang JX, 2011, NEURO-ONCOLOGY, V13, P600, DOI 10.1093/neuonc/nor034	39	35	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 19	2015	34	47					5843	5856		10.1038/onc.2015.42	http://dx.doi.org/10.1038/onc.2015.42			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CW5KV	25745998				2022-12-17	WOS:000365035200007
J	Gomes, LR; Vessoni, AT; Menck, CFM				Gomes, L. R.; Vessoni, A. T.; Menck, C. F. M.			Three-dimensional microenvironment confers enhanced sensitivity to doxorubicin by reducing p53-dependent induction of autophagy	ONCOGENE			English	Article							BREAST-CANCER; CULTURE MODELS; DNA-DAMAGE; CELLS; INHIBITION; P53; EPIRUBICIN; MECHANISMS; APOPTOSIS; SUBTYPES	Preclinical studies of anticancer drugs are typically performed using cancer cell lines maintained in two-dimensional (2D) cultures, ignoring the influences of the extracellular matrix (ECM) and three-dimensional (3D) microenvironment. In this study, we evaluated the microenvironmental control of human breast cancer cells responses to doxorubicin (DOXO) using the 3D laminin-rich ECM (3D lrECM) cell culture model. Under 3D culture conditions, MCF-7 cells displayed drastic morphological alterations, a decrease in proliferation and elevated sensitivity to DOXO. Interestingly, the chemotherapy-mediated activation of autophagy was compromised in the 3D matrix, suggesting an association between the increased cytotoxicity of DOXO and hindered autophagy induction. Indeed, while chloroquine or ATG5 knockdown potentiated DOXO-induced cell death under the 2D culture conditions, the autophagy inducer rapamycin improved the resistance of 3D-cultured cells to this drug. Moreover, in the monolayer-cultured cells, DOXO treatment led to increases in p53 and DRAM-1 expression, which is a p53-dependent activator of autophagy that functions in response to DNA damage. Conversely, p53 and DRAM-1 expression was impaired in 3D-cultured cells. The knockdown of p53 by shRNA blocked DRAM-1 activation, impaired autophagy induction and sensitized only those cells maintained under 2D conditions to DOXO. In addition, 2D-cultured MDA-MB-231 cells (a p53-mutated breast cancer cell line) not only showed increased sensitivity to DOXO compared with MCF-7 cells but also failed to induce DRAM-1 expression or autophagy. Similar to p53 silencing, DRAM-1 knockdown potentiated DOXO cytotoxicity only in 2D-cultured cells. These results suggest that the 3D tissue microenvironment controls tumor cell sensitivity to DOXO treatment by preventing p53-DRAM-autophagy axis activation.	[Gomes, L. R.; Vessoni, A. T.; Menck, C. F. M.] Univ Sao Paulo, Dept Microbiol, Inst Biomed Sci, Sao Paulo, Brazil	Universidade de Sao Paulo	Menck, CFM (corresponding author), Inst Ciencias Biomed 2, Ave Prof Lineu Prestes 1374, BR-05508900 Sao Paulo, Brazil.	cfmmenck@usp.br	Gomes, Luciana R/M-3056-2014; Vessoni, Alexandre T/L-5754-2013; Menck, Carlos FM/G-6321-2011	Vessoni, Alexandre T/0000-0001-9170-5185; Menck, Carlos FM/0000-0003-1941-0694	FAPESP (Sao Paulo, Brazil); CAPES; CNPq (Brasilia, Brazil)	FAPESP (Sao Paulo, Brazil)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CAPES(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)); CNPq (Brasilia, Brazil)(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	We thank Professor Maria S. Solengas (Department of Dermatology, University of Michigan Comprehensive Cancer Center) for kindly providing the pEGFP-LC3 construct. We are grateful for the excellent technical assistance provided by the Core Facility for Scientific Research-USP (CEFAP-USP) in conducting the confocal fluorescence microscopy assays. This work was supported by FAPESP (Sao Paulo, Brazil), CAPES and CNPq (Brasilia, Brazil).	Ahn JH, 2011, CANCER LETT, V310, P188, DOI 10.1016/j.canlet.2011.06.034; Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634; Batista LFZ, 2007, CANCER RES, V67, P11886, DOI 10.1158/0008-5472.CAN-07-2964; Beckta JM, 2014, CELL CYCLE, V13, P710, DOI 10.4161/cc.28108; Bertheau P, 2013, BREAST, V22, pS27, DOI 10.1016/j.breast.2013.07.005; Bhana S, 2008, MUTAGENESIS, V23, P43, DOI 10.1093/mutage/gem041; Bissell MJ, 1999, CANCER RES, V59, p1757S; Bramwell VHC, 2002, CLIN CANCER RES, V8, P383; Bristol ML, 2013, J PHARMACOL EXP THER, V344, P544, DOI 10.1124/jpet.112.199802; Chen Y, 2009, CELL DEATH DIFFER, V16, P1040, DOI 10.1038/cdd.2009.49; Cheng YJ, 2008, INT J CANCER, V123, P1278, DOI 10.1002/ijc.23592; Cortat B, 2013, PHOTOCH PHOTOBIO SCI, V12, P1483, DOI 10.1039/c3pp50023c; Crighton D, 2007, AUTOPHAGY, V3, P72, DOI 10.4161/auto.3438; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; Debnath J, 2008, AUTOPHAGY, V4, P351, DOI 10.4161/auto.5523; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; do Amaral JB, 2011, TISSUE ENG PART C-ME, V17, P1097, DOI 10.1089/ten.tec.2011.0260; Edick MJ, 2007, MOL BIOL CELL, V18, P2481, DOI 10.1091/mbc.E06-04-0261; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Ghavami S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016523; Gomes LR, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-26; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Khasraw M, 2012, BREAST, V21, P142, DOI 10.1016/j.breast.2011.12.012; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li DD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045058; Li QW, 2010, J PHARMACOL EXP THER, V332, P821, DOI 10.1124/jpet.109.160390; Liang B, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-213; Lock R, 2008, CURR OPIN CELL BIOL, V20, P583, DOI 10.1016/j.ceb.2008.05.002; Manov I, 2011, FEBS J, V278, P3494, DOI 10.1111/j.1742-4658.2011.08271.x; Mathew R, 2011, COLD SH Q B, V76, P389, DOI 10.1101/sqb.2012.76.011015; Maycotte P, 2014, CANCER RES, V74, P2579, DOI 10.1158/0008-5472.CAN-13-3470; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mohan P, 2010, MOL PHARMACEUT, V7, P1959, DOI 10.1021/mp100269f; Moraes MCS, 2012, CANCER LETT, V314, P108, DOI 10.1016/j.canlet.2011.09.019; Novaro V, 2003, J CELL SCI, V116, P2975, DOI 10.1242/jcs.00523; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Pyo JO, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3300; Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044; Quinet A, 2014, DNA REPAIR, V14, P27, DOI 10.1016/j.dnarep.2013.12.005; Scherz-Shouval R, 2010, P NATL ACAD SCI USA, V107, P18511, DOI 10.1073/pnas.1006124107; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004; Sun WL, 2011, AUTOPHAGY, V7, P1035, DOI 10.4161/auto.7.9.16521; Swenson CE, 2003, ANTI-CANCER DRUG, V14, P239, DOI 10.1097/00001813-200303000-00008; Tasdemir E, 2008, AUTOPHAGY, V4, P810, DOI 10.4161/auto.6486; Tuloup-Minguez V, 2011, AUTOPHAGY, V7, P27, DOI 10.4161/auto.7.1.13851; Valbuena A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017320; Velez JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018005; Weaver VM, 1999, J MAMMARY GLAND BIOL, V4, P193, DOI 10.1023/A:1018781325716; Woodley-Cook J, 2006, MOL CANCER THER, V5, P3303, DOI 10.1158/1535-7163.MCT-06-0154	56	35	35	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5329	5340		10.1038/onc.2014.461	http://dx.doi.org/10.1038/onc.2014.461			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	25619836				2022-12-17	WOS:000363479200003
J	Martin, L; Gardner, LB				Martin, L.; Gardner, L. B.			Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine/glutamate exchanger SLC7A11	ONCOGENE			English	Article							ENDOPLASMIC-RETICULUM STRESS; UNFOLDED PROTEIN RESPONSE; PROMOTES TUMOR-GROWTH; GENE-EXPRESSION; OXIDATIVE STRESS; CELL-SURVIVAL; CANCER-CELLS; IN-VIVO; METABOLISM; AUTOPHAGY	SLC7A11 encodes a subunit of the xCT cystine/glutamate amino-acid transport system and has a critical role in the generation of glutathione and the protection of cells from oxidative stress. Expression of SLC7A11 promotes tumorigenesis and chemotherapy resistance, but while SLC7A11 has been previously noted to be upregulated in hypoxic cells, its regulation has not been fully delineated. We have recently shown that nonsense-mediated RNA decay (NMD) is inhibited by cellular stresses generated by the tumor microenvironment, including hypoxia, and augments tumorigenesis. Here we demonstrate that the inhibition of NMD by various cellular stresses leads to the stabilization and upregulation of SLC7A11 mRNA and protein. The inhibition of NMD and upregulation of SLC7A11 augments intracellular cystine transport and increases intracellular levels of cysteine and glutathione. Accordingly, the inhibition of NMD protects cells against oxidative stress via SLC7A11 upregulation. Together our studies identify a mechanism for the dynamic regulation of SLC7A11, through the stress-inhibited regulation of NMD, and add to the growing evidence that the inhibition of NMD is an adaptive response.	[Martin, L.; Gardner, L. B.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Gardner, L. B.] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA; [Gardner, L. B.] NYU, Sch Med, NYU Perlmutter Canc Ctr, New York, NY 10016 USA	New York University; New York University; New York University	Gardner, LB (corresponding author), NYU, Sch Med, Div Hematol & Med Oncol, 550 First Ave,Smilow 1204, New York, NY 10016 USA.	Lawrence.gardner@nyumc.org		Gardner, Lawrence/0000-0003-0191-0172	NYU Cancer Institute;  [RO1DK081641]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081641] Funding Source: NIH RePORTER	NYU Cancer Institute; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by RO1DK081641 (to LBG), a generous gift from Mr Arthur Levine and Ms Diane Lederman and the NYU Cancer Institute. LBG was the Saul Farber Associate Professor of Medicine.	Ahlqvist KJ, 2012, CELL METAB, V15, P100, DOI 10.1016/j.cmet.2011.11.012; BANNAI S, 1986, J BIOL CHEM, V261, P2256; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Cantor JR, 2012, CANCER DISCOV, V2, P881, DOI 10.1158/2159-8290.CD-12-0345; Chen RS, 2009, ONCOGENE, V28, P599, DOI 10.1038/onc.2008.414; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Durand S, 2007, J CELL BIOL, V178, P1145, DOI 10.1083/jcb.200611086; Fernandez PC, 1999, BIOL CHEM, V380, P1383, DOI 10.1515/BC.1999.178; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Gardner LB, 2008, CELL CYCLE, V7, P1916, DOI 10.4161/cc.7.13.6203; Gardner LB, 2008, MOL CELL BIOL, V28, P3729, DOI 10.1128/MCB.02284-07; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hart LS, 2012, J CLIN INVEST, V122, P4621, DOI 10.1172/JCI62973; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Huang CC, 2010, BIOCHEM J, V429, P215, DOI 10.1042/BJ20100286; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Keeling KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060478; Krokowski D, 2013, J BIOL CHEM, V288, P17202, DOI 10.1074/jbc.M113.466920; Lewerenz J, 2009, J BIOL CHEM, V284, P1106, DOI 10.1074/jbc.M807325200; Liu LP, 2008, J BIOL CHEM, V283, P31153, DOI 10.1074/jbc.M805056200; Lo M, 2008, J CELL PHYSIOL, V215, P593, DOI 10.1002/jcp.21366; Martin L, 2010, J BIOL CHEM, V285, P31944, DOI 10.1074/jbc.M110.153148; Mendell JT, 2004, NAT GENET, V36, P1073, DOI 10.1038/ng1429; Ogunrinu TA, 2010, J BIOL CHEM, V285, P37716, DOI 10.1074/jbc.M110.161190; Sayin VI, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007653; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Timmerman LA, 2013, CANCER CELL, V24, P450, DOI 10.1016/j.ccr.2013.08.020; Tomi M, 2002, INVEST OPHTH VIS SCI, V43, P774; Wang D, 2011, J BIOL CHEM, V286, P40038, DOI 10.1074/jbc.M111.266361; Wang D, 2011, MOL CELL BIOL, V31, P3670, DOI 10.1128/MCB.05704-11; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Wengrod J, 2013, MOL CELL BIOL, V33, P2128, DOI 10.1128/MCB.00174-13; Ye JB, 2010, EMBO J, V29, P2082, DOI 10.1038/emboj.2010.81; Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	42	35	39	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4211	4218		10.1038/onc.2014.352	http://dx.doi.org/10.1038/onc.2014.352			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25399695	Green Accepted			2022-12-17	WOS:000359199800007
J	Selmansberger, M; Feuchtinger, A; Zurnadzhy, L; Michna, A; Kaiser, JC; Abend, M; Brenner, A; Bogdanova, T; Walch, A; Unger, K; Zitzelsberger, H; Hess, J				Selmansberger, M.; Feuchtinger, A.; Zurnadzhy, L.; Michna, A.; Kaiser, J. C.; Abend, M.; Brenner, A.; Bogdanova, T.; Walch, A.; Unger, K.; Zitzelsberger, H.; Hess, J.			CLIP2 as radiation biomarker in papillary thyroid carcinoma	ONCOGENE			English	Article							INDUCED GENOMIC INSTABILITY; IONIZING-RADIATION; CHERNOBYL ACCIDENT; CANCER; PROTEIN; REARRANGEMENTS; EXPOSURE; KINESIN; RET/PTC; DYNEIN	A substantial increase in papillary thyroid carcinoma (PTC) among children exposed to the radioiodine fallout has been one of the main consequences of the Chernobyl reactor accident. Recently, the investigation of PTCs from a cohort of young patients exposed to the post-Chernobyl radioiodine fallout at very young age and a matched nonexposed control group revealed a radiation-specific DNA copy number gain on chromosomal band 7q11.23 and the radiation-associated mRNA overexpression of CLIP2. In this study, we investigated the potential role of CLIP2 as a radiation marker to be used for the individual classification of PTCs into CLIP2-positive and - negative cases-a prerequisite for the integration of CLIP2 into epidemiological modelling of the risk of radiation-induced PTC. We were able to validate the radiation-associated CLIP2 overexpression at the protein level by immunohistochemistry (IHC) followed by relative quantification using digital image analysis software (P = 0.0149). Furthermore, we developed a standardized workflow for the determination of CLIP2-positive and - negative cases that combines visual CLIP2 IHC scoring and CLIP2 genomic copy number status. In addition to the discovery cohort (n = 33), two independent validation cohorts of PTCs (n = 115) were investigated. High sensitivity and specificity rates for all three investigated cohorts were obtained, demonstrating robustness of the developed workflow. To analyse the function of CLIP2 in radiation-associated PTC, the CLIP2 gene regulatory network was reconstructed using global mRNA expression data from PTC patient samples. The genes comprising the first neighbourhood of CLIP2 (BAG2, CHST3, KIF3C, NEURL1, PPIL3 and RGS4) suggest the involvement of CLIP2 in the fundamental carcinogenic processes including apoptosis, mitogen-activated protein kinase signalling and genomic instability. In our study, we successfully developed and independently validated a workflow for the typing of PTC clinical samples into CLIP2-positive and CLIP2-negative and provided first insights into the CLIP2 interactome in the context of radiation-associated PTC.	[Selmansberger, M.; Michna, A.; Unger, K.; Zitzelsberger, H.; Hess, J.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Radiat Cytogenet, D-85764 Neuherberg, Germany; [Feuchtinger, A.; Walch, A.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Analyt Pathol, D-85764 Neuherberg, Germany; [Zurnadzhy, L.; Bogdanova, T.] Natl Acad Med Sci Ukraine, Inst Endocrinol & Metab, Kiev, Ukraine; [Kaiser, J. C.] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Radiat Protect, Neuherberg, Germany; [Abend, M.] Bundeswehr Inst Radiobiol, Munich, Germany; [Brenner, A.] NCI, Radiat Epidemiol Branch, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA; [Unger, K.; Zitzelsberger, H.; Hess, J.] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Clin Cooperat Grp Personalized Radiotherapy Head, D-85764 Neuherberg, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Academy of Medical Sciences of Ukraine; V. P. Komissarenko Institute of Endocrinology & Metabolism of the National Academy of Medical Science of Ukraine; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Hess, J (corresponding author), German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Res Unit Radiat Cytogenet, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.	julia.hess@helmholtz-muenchen.de	Walch, Axel/B-4554-2012; Unger, Kristian/F-3730-2018	Walch, Axel/0000-0001-5578-4023; Unger, Kristian/0000-0002-0374-2320; Bogdanova, Tetiana/0000-0001-5119-0236	European Commission, EpiRadBio project, FP7 [269553]; European Commission, DoReMi project [249689]	European Commission, EpiRadBio project, FP7; European Commission, DoReMi project	We thank the International Pathology Panel of the Chernobyl Tissue Bank for confirmation of diagnosis: Professors A Abrosimov, TI Bogdanova, G Fadda, G Hant, V LiVolsi, J Rosai and ED Williams; The Chernobyl Tissue Bank for collection of thyroid tissue samples; Professor G Thomas for establishing the matched Genrisk-T cohort; Dr Peter Jacob for discussion and determination of the proportion of radiation-induced tumours among the exposed cases in the UkrAm cohort; U Buchholz, C Innerlohinger, E Konhauser, CM Pfluger and A Selmaier for technical support; and H Braselmann for mathematical/statistical support. This study was supported by the European Commission, EpiRadBio project, FP7 Grant No. 269553 and in part by the European Commission, DoReMi project, Grant No. 249689.	Abend M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039103; Arndt V, 2005, MOL BIOL CELL, V16, P5891, DOI 10.1091/mbc.E05-07-0660; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Brenner AV, 2011, ENVIRON HEALTH PERSP, V119, P933, DOI 10.1289/ehp.1002674; Cardis E, 2011, CLIN ONCOL-UK, V23, P251, DOI 10.1016/j.clon.2011.01.510; Cardis E, 2006, J RADIOL PROT, V26, P127, DOI 10.1088/0952-4746/26/2/001; De S, 2009, CANCER RES, V69, P8035, DOI 10.1158/0008-5472.CAN-09-1224; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Ferrero GB, 2010, EUR J HUM GENET, V18, P33, DOI 10.1038/ejhg.2009.108; Fumoto K, 2006, EMBO J, V25, P5670, DOI 10.1038/sj.emboj.7601459; Galjart N, 2005, NAT REV MOL CELL BIO, V6, P487, DOI 10.1038/nrm1664; Rojo MG, 2009, FOLIA HISTOCHEM CYTO, V47, P349, DOI 10.2478/v10042-008-0114-4; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Goldstein LSB, 2001, P NATL ACAD SCI USA, V98, P6999, DOI 10.1073/pnas.111145298; Gray KA, 2013, NUCLEIC ACIDS RES, V41, pD545, DOI 10.1093/nar/gks1066; Grewal Thomas, 2011, Genes Cancer, V2, P288, DOI 10.1177/1947601911407330; Hamatani K, 2008, CANCER RES, V68, P7176, DOI 10.1158/0008-5472.CAN-08-0293; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hess J, 2011, P NATL ACAD SCI USA, V108, P9595, DOI 10.1073/pnas.1017137108; Hoogenraad CC, 2003, EMBO J, V22, P6004, DOI 10.1093/emboj/cdg592; Hoogenraad CC, 2000, J CELL SCI, V113, P2285; Hoogenraad CC, 2002, NAT GENET, V32, P116, DOI 10.1038/ng954; Hoogenraad SC, 2004, BIOESSAYS, V26, P141, DOI 10.1002/bies.10402; Huang L, 2003, ONCOGENE, V22, P5848, DOI 10.1038/sj.onc.1206697; Iizuka D, 2010, RADIAT RES, V174, P206, DOI 10.1667/RR2006.1; Ishida Y, 2010, CARCINOGENESIS, V31, P1694, DOI 10.1093/carcin/bgq145; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; Klugbauer S, 1995, ONCOGENE, V11, P2459; Lansbergen G, 2004, J CELL BIOL, V166, P1003, DOI 10.1083/jcb.200402082; Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5; Leeman-Neill RJ, 2013, CANCER-AM CANCER SOC, V119, P1792, DOI 10.1002/cncr.27893; Little MP, 2008, RADIAT ENVIRON BIOPH, V47, P39, DOI 10.1007/s00411-007-0150-z; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mandelkow E, 2002, TRENDS CELL BIOL, V12, P585, DOI 10.1016/S0962-8924(02)02400-5; Marchler-Bauer A, 2009, NUCLEIC ACIDS RES, V37, pD205, DOI 10.1093/nar/gkn845; Morgan WF, 2003, RADIAT RES, V159, P567, DOI 10.1667/0033-7587(2003)159[0567:NADEOE]2.0.CO;2; Morgan WF, 2003, RADIAT RES, V159, P581, DOI 10.1667/0033-7587(2003)159[0581:NADEOE]2.0.CO;2; Mullenders L, 2009, NAT REV CANCER, V9, P596, DOI 10.1038/nrc2677; Muresan V, 1998, MOL BIOL CELL, V9, P637, DOI 10.1091/mbc.9.3.637; Nikiforov YE, 1997, CANCER RES, V57, P1690; Nikiforov YE, 2008, MODERN PATHOL, V21, pS37, DOI 10.1038/modpathol.2008.10; Opgen-Rhein R, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-37; Pernot E, 2012, MUTAT RES-REV MUTAT, V751, P258, DOI 10.1016/j.mrrev.2012.05.003; Ricarte JC, 2013, J CLIN INVEST, V123, P4935, DOI 10.1172/JCI69766; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Strizzi L, 2009, CANCER RES, V69, P7131, DOI 10.1158/0008-5472.CAN-09-1199; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Suzuki Tsuyoshi, 2004, Brain Tumor Pathol, V21, P27, DOI 10.1007/BF02482174; Tanenbaum ME, 2006, EMBO J, V25, P45, DOI 10.1038/sj.emboj.7600916; Team RDC, 2013, R LANG ENV STAT COMP; Teider N, 2010, NEURO-ONCOLOGY, V12, P1244, DOI 10.1093/neuonc/noq091; Tronko M, 2012, J RADIOL PROT, V32, pN65, DOI 10.1088/0952-4746/32/1/N65; Tronko MD, 2006, JNCI-J NATL CANCER I, V98, P897, DOI 10.1093/jnci/djj244; Tuttle RM, 2011, CLIN ONCOL-UK, V23, P268, DOI 10.1016/j.clon.2011.01.178; Tuttle RM, 2008, THYROID, V18, P839, DOI 10.1089/thy.2008.0072; Uhlen M, 2005, MOL CELL PROTEOMICS, V4, P1920, DOI 10.1074/mcp.M500279-MCP200; Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248; Varga Z, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-615; Wang HQ, 2008, BRIT J PHARMACOL, V155, P655, DOI 10.1038/bjp.2008.302; Wieland G, 2004, MOL CELL BIOL, V24, P6620, DOI 10.1128/mcb.24.15.6620-6630.2004; Williams D, 2002, NAT REV CANCER, V2, P543, DOI 10.1038/nrc845; Williams ED, 2000, INT J SURG PATHOL, V8, P181, DOI 10.1177/106689690000800304; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xing MZ, 2013, NAT REV CANCER, V13, P184, DOI 10.1038/nrc3431; Yamashita AS, 2013, TRANSL ONCOL, V6, P197, DOI 10.1593/tlo.12442; Yang XM, 2009, J BIOL CHEM, V284, P28775, DOI 10.1074/jbc.M109.017681	66	35	36	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2015	34	30					3917	3925		10.1038/onc.2014.311	http://dx.doi.org/10.1038/onc.2014.311			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CN6KR	25284583				2022-12-17	WOS:000358544200004
J	Pritchett, TL; Bader, HL; Henderson, J; Hsu, T				Pritchett, T. L.; Bader, H. L.; Henderson, J.; Hsu, T.			Conditional inactivation of the mouse von Hippel-Lindau tumor suppressor gene results in wide-spread hyperplastic, inflammatory and fibrotic lesions in the kidney	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; MODIFYING GENES; IMAGE-ANALYSIS; URETERAL BUD; CANCER; EXPRESSION; PROTEIN; HYPOXIA; DISEASE; MUTATION	Mutations of the tumor suppressor gene von Hippel-Lindau (VHL) can lead to benign and malignant tumors, including clear-cell renal cell carcinoma (ccRCC). To understand the progression of ccRCC, we generated a novel mouse Vhlh conditional knockout, using Hoxb7-driven Cre that is specific for the collecting ducts and a subset of distal tubules. These mice exhibited wide-spread epithelial disruption and interstitial inflammation as early as 2 months of age with high penetrance. Lesions are cystic, show severe fibrosis and display significant hyperplasia. An abundance of infiltrating macrophages and lymphocytes was detected. Interestingly, the Vhlh mutant lesions could be rescued when Hif-1 alpha, but not Hif-2 alpha, was also knocked out. In addition, administration of a JAK1/2 kinase inhibitor alleviated the Vhlh knockout phenotypes. Taken together, these results suggest that HIF-1 alpha-dependent inflammation and fibrosis may be an early event in the development of ccRCC.	[Pritchett, T. L.; Bader, H. L.; Henderson, J.; Hsu, T.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Henderson, J.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; [Hsu, T.] Natl Cent Univ, Inst Syst Biol & Bioinformat, Jhongli 32001, Taiwan	Boston University; Boston University; National Central University	Hsu, T (corresponding author), Boston Univ, Sch Med, Hematol Oncol Sect, 650 Albany St,EBRC 440, Boston, MA 02118 USA.	tienh@bu.edu		Hsu, Tien/0000-0003-2308-4297; Pritchett, Tracy/0000-0002-3336-9336	National Institutes of Health, USA [R01CA109860, T32HL007501]; NATIONAL CANCER INSTITUTE [R01CA109860] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007501] Funding Source: NIH RePORTER	National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Paraffin embedding and sectioning were performed at the Immunohistochemistry Core of Boston Medical Center. We thank Richard Near (the Boston University School of Medicine) for technical support and Weining Lu (the Boston University School of Medicine) for a gift of the Hoxb7-Cre-EGFP mouse strain. This work was supported by a grant to TH from the National Institutes of Health, USA (#R01CA109860) and a postdoctoral fellowship to HLB from the National Institutes of Health, USA (#T32HL007501).	An JB, 2005, MOL CELL BIOL, V25, P7546, DOI 10.1128/MCB.25.17.7546-7556.2005; Becker LC, 2005, CIRC RES, V96, P812, DOI 10.1161/01.RES.0000165652.82726.d9; Brukamp K, 2007, AM J PHYSIOL-RENAL, V293, pF1397, DOI 10.1152/ajprenal.00133.2007; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Frew IJ, 2008, MOL CELL BIOL, V28, P4536, DOI 10.1128/MCB.02132-07; Frew IJ, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.124pe30; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Haase VH, 2001, P NATL ACAD SCI USA, V98, P1583, DOI 10.1073/pnas.98.4.1583; Hakimi AA, 2013, CLIN CANCER RES, V19, P3259, DOI 10.1158/1078-0432.CCR-12-3886; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Higgins DF, 2007, J CLIN INVEST, V117, P3810, DOI 10.1172/JCI30487; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Ibragimova I, 2013, EPIGENETICS-US, V8, P486, DOI 10.4161/epi.24552; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634; Khurana KK, 1998, MODERN PATHOL, V11, P339; Kim Nayoung, 2013, Genomics & Informatics, V11, P239, DOI 10.5808/GI.2013.11.4.239; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kimura K, 2008, AM J PHYSIOL-RENAL, V295, pF1023, DOI 10.1152/ajprenal.90209.2008; Kramann R, 2013, J PATHOL, V231, P273, DOI 10.1002/path.4253; Kraus S, 2002, HUM PATHOL, V33, P60, DOI 10.1053/hupa.2002.29682; Kraus S, 2009, CURR OPIN PHARMACOL, V9, P405, DOI 10.1016/j.coph.2009.06.006; Kundu JK, 2012, FREE RADICAL BIO MED, V52, P2013, DOI 10.1016/j.freeradbiomed.2012.02.035; Larkin J, 2012, NAT REV UROL, V9, P147, DOI 10.1038/nrurol.2011.236; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Maher ER, 2011, EUR J HUM GENET, V19, P617, DOI 10.1038/ejhg.2010.175; Mandriota SJ, 2002, CANCER CELL, V1, P459, DOI 10.1016/S1535-6108(02)00071-5; Martelli F, 2005, BLOOD, V106, P4102, DOI 10.1182/blood-2005-03-1060; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Nakagawa Naoki, 2013, Curr Pathobiol Rep, V1, DOI 10.1007/s40139-013-0025-8; Ozcan A, 2009, AM J CLIN PATHOL, V131, P393, DOI 10.1309/AJCPM7DW0XFHDHNY; Perrier S, 2006, FEBS LETT, V580, P6289, DOI 10.1016/j.febslet.2006.10.061; Quintas-Cardama A, 2010, BLOOD, V115, P3109, DOI 10.1182/blood-2009-04-214957; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ries C, 2014, CELL MOL LIFE SCI, V71, P659, DOI 10.1007/s00018-013-1457-3; Schietke RE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031034; Shay JES, 2012, SEMIN CELL DEV BIOL, V23, P389, DOI 10.1016/j.semcdb.2012.04.004; Shen SS, 2005, MODERN PATHOL, V18, P933, DOI 10.1038/modpathol.3800373; Srinivas S, 1999, DEV GENET, V24, P241; Steenhard BM, 2010, AM J PATHOL, V177, P84, DOI 10.2353/ajpath.2010.090767; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wadleigh Martha, 2010, Clin Adv Hematol Oncol, V8, P557; Wu KL, 2007, AM J PHYSIOL-RENAL, V293, pF1836, DOI 10.1152/ajprenal.00096.2007; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Yoshida N, 2002, BRIT J CANCER, V86, P1396, DOI 10.1038/sj.bjc.6600257; Yu J, 2002, DEVELOPMENT, V129, P5301; Zhao HT, 2004, DEV BIOL, V276, P403, DOI 10.1016/j.ydbio.2004.09.002	53	35	35	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 14	2015	34	20					2631	2639		10.1038/onc.2014.197	http://dx.doi.org/10.1038/onc.2014.197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CI1YN	25023703				2022-12-17	WOS:000354541300009
J	Ryan, AE; Colleran, A; O'Gorman, A; O'Flynn, L; Pindjacova, J; Lohan, P; O'Malley, G; Nosov, M; Mureau, C; Egan, LJ				Ryan, A. E.; Colleran, A.; O'Gorman, A.; O'Flynn, L.; Pindjacova, J.; Lohan, P.; O'Malley, G.; Nosov, M.; Mureau, C.; Egan, L. J.			Targeting colon cancer cell NF-kappa B promotes an anti-tumour M1-like macrophage phenotype and inhibits peritoneal metastasis	ONCOGENE			English	Article							TUMOR-ASSOCIATED MACROPHAGES; COLORECTAL-CANCER; CYTOREDUCTIVE SURGERY; MOUSE MODEL; T-CELLS; INFLAMMATION; ALPHA; CARCINOMATOSIS; MONOCYTES; GROWTH	In a model of peritoneal metastasis in immune-competent mice, we show that nuclear factor (NF)-kappa B inhibition in CT26 colon cancer cells prevents metastasis. NF-kappa B inhibition, by stable overexpression of I kappa B-a super-repressor, induced differential polarization of co-cultured macrophages to an M1-like anti-tumour phenotype in vitro. NF-kappa B-deficient cancer cell-conditioned media (CT26/I kappa B-alpha SR) induced interleukin (IL)-12 and nitric oxide (NO) synthase (inducible NO synthase (iNOS)) expression in macrophages. Control cell (CT26/EV) conditioned media induced high levels of IL-10 and arginase in macrophages. In vivo, this effect translated to reduction in metastasis in mice injected with CT26/I kappa B-alpha SR cells and was positively associated with increased CD8(+)CD44(+)CD62L- and CD4(+)CD44(+)CD62L-effector T cells. Furthermore, inhibition of NF-kappa B activity induced high levels of NO in infiltrating immune cells and decreases in matrix metalloproteinase-9 expression, simultaneous with increases in tissue inhibitor of metalloproteinases 1 and 2 within tumours. CT26/I kappa B-alpha SR tumours displayed increased pro-inflammatory gene expression, low levels of angiogenesis and extensive intratumoral apoptosis, consistent with the presence of an anti-tumour macrophage phenotype. Macrophage depletion reduced tumour size in CT26/EV-injected animals and increased tumour size in CT26/I kappa B-alpha SR cells compared with untreated tumours. Our data demonstrate, for the first time, that an important implication of targeting tumour cell NF-kappa B is skewing of macrophage polarization to an anti-tumour phenotype. This knowledge offers novel therapeutic opportunities for anticancer treatment.	[Ryan, A. E.; Colleran, A.; O'Gorman, A.; O'Malley, G.; Mureau, C.; Egan, L. J.] Natl Univ Ireland, Sch Med, Discipline Pharmacol & Therapeut, Galway, Ireland; [Ryan, A. E.; O'Flynn, L.; Pindjacova, J.; Lohan, P.; O'Malley, G.; Nosov, M.] Natl Univ Ireland, Sch Med, NCBES, Regenerat Med Inst REMEDI, Galway, Ireland	Ollscoil na Gaillimhe-University of Galway; Ollscoil na Gaillimhe-University of Galway	Egan, LJ (corresponding author), Univ Hosp Galway, Inst Clin Sci, Newcastle Rd, Galway, Ireland.	laurence.egan@nuigalway.ie	Ryan, Aideen/H-3909-2019	Ryan, Aideen/0000-0002-5831-6783	Irish Cancer Society [CRF12RYA]; Science Foundation Ireland [04/IN3/B748]; Irish Cancer Society	Irish Cancer Society; Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Irish Cancer Society	This work was supported by funding from the Irish Cancer Society to AER (CRF12RYA) and from the Science Foundation Ireland (04/IN3/B748) and the Irish Cancer Society to LJE.	Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bingle L, 2002, J PATHOL, V196, P254, DOI 10.1002/path.1027; Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654; Cintron JR, 1996, SEMIN SURG ONCOL, V12, P267, DOI 10.1002/(SICI)1098-2388(199607/08)12:4<267::AID-SSU6>3.0.CO;2-3; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47; De Palma M, 2008, CANCER CELL, V14, P299, DOI 10.1016/j.ccr.2008.09.004; DeNardo DG, CANC METASTASIS REV, V29, P309; Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017; Eaden J, 2003, ALIMENT PHARM THER, V18, P15, DOI 10.1046/j.1365-2036.18.s2.3.x; Egan LJ, 1999, J BIOL CHEM, V274, P26448, DOI 10.1074/jbc.274.37.26448; Flemming A, 2011, NAT REV DRUG DISCOV, V10, DOI 10.1038/nrd3399; Foran E, MOL CANC RES, V8, P471; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Hallam S, 2009, J PATHOL, V219, P143, DOI 10.1002/path.2602; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kianmanesh R, 2007, ANN SURG, V245, P597, DOI 10.1097/01.sla.0000255561.87771.11; Klug F, 2013, CANCER CELL, V24, P589, DOI 10.1016/j.ccr.2013.09.014; Kojima M, 2004, ANTICANCER RES, V24, P675; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Koppe MJ, 2006, ANN SURG, V243, P212, DOI 10.1097/01.sla.0000197702.46394.16; Koppelman B, 1997, IMMUNITY, V7, P861, DOI 10.1016/S1074-7613(00)80404-5; Kubota Y, 2009, J EXP MED, V206, P1089, DOI 10.1084/jem.20081605; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lin Y, 2010, EXPERT OPIN THER TAR, V14, P45, DOI 10.1517/14728220903431069; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; MANCINO A, CLIN CANC RES, V16, P784; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Matsuzaki S, 2005, ALLERGY, V60, P780, DOI 10.1111/j.1398-9995.2005.00793.x; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; O'Gorman A, 2010, AM J PHYSIOL-GASTR L, V299, pG96, DOI 10.1152/ajpgi.00460.2009; Pages F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Ridnour LA, 2007, P NATL ACAD SCI USA, V104, P16898, DOI 10.1073/pnas.0702761104; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Ryan AE, 2014, MOL THER, V22, P655, DOI 10.1038/mt.2013.261; Shen P, 2004, ANN SURG ONCOL, V11, P178, DOI 10.1245/ASO.2004.05.009; Soudja SM, 2012, IMMUNITY, V37, P549, DOI 10.1016/j.immuni.2012.05.029; Toruner M, 2006, J BIOL CHEM, V281, P8686, DOI 10.1074/jbc.M512178200; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Wang YC, 2010, CANCER RES, V70, P4840, DOI 10.1158/0008-5472.CAN-10-0269; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Zins K, 2007, CANCER RES, V67, P1038, DOI 10.1158/0008-5472.CAN-06-2295	49	35	39	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 19	2015	34	12					1563	1574		10.1038/onc.2014.86	http://dx.doi.org/10.1038/onc.2014.86			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CD9KI	24704833				2022-12-17	WOS:000351416800009
J	Hu, CM; Zhu, J; Guo, XE; Chen, W; Qiu, XL; Ngo, B; Chien, R; Wang, YV; Tsai, CY; Wu, G; Kim, Y; Lopez, R; Chamberlin, AR; Lee, EH; Lee, WH				Hu, C-M; Zhu, J.; Guo, X. E.; Chen, W.; Qiu, X-L; Ngo, B.; Chien, R.; Wang, Y. V.; Tsai, C. Y.; Wu, G.; Kim, Y.; Lopez, R.; Chamberlin, A. R.; Lee, Ey-Hp; Lee, W-H			Novel small molecules disrupting Hec1/Nek2 interaction ablate tumor progression by triggering Nek2 degradation through a death-trap mechanism	ONCOGENE			English	Article							FAITHFUL CHROMOSOME SEGREGATION; CENTROSOMAL KINASE NEK2; HUMAN BREAST-CANCER; IN-VIVO; MICROTUBULE DYNAMICS; TUMORIGENIC GROWTH; PROTEIN-KINASE; P53 FUNCTION; HEC1; CHECKPOINT	Hec1 (highly expressed in cancer 1) or Nek2 (NIMA-related kinase 2) is often overexpressed in cancers with poor prognosis. Both are critical mitotic regulators, and phosphorylation of Hec1 S165 by Nek2 is required for proper chromosome segregation. Therefore, inactivation of Hec1 and Nek2 by targeting their interaction with small molecules represents an ideal strategy for tackling these types of cancers. Here we showed that new derivatives of INH (inhibitor for Nek2 and Hec1 binding) bind to Hec1 at amino acids 394-408 on W395, L399 and K400 residues, effectively blocking Hec1 phosphorylation on S165 by Nek2, and killing cancer cells at the nanomolar range. Mechanistically, the D-box (destruction-box) region of Nek2 specifically binds to Hec1 at amino acids 408-422, immediately adjacent to the INH binding motif. Subsequent binding of Nek2 to INH-bound Hec1 triggered proteasome-mediated Nek2 degradation, whereas the Hec1 binding defective Nek2 mutant, Nek2 R361L, resisted INH-induced Nek2 degradation. This finding unveils a novel drug-action mechanism where the binding of INHs to Hec1 forms a virtual death-trap to trigger Nek2 degradation and eventually cell death. Furthermore, analysis of the gene expression profiles of breast cancer patient samples revealed that co-elevated expressions of Hec1 and Nek2 correlated with the shortest survival. Treatment of mice with this kind of tumor with INHs significantly suppressed tumor growth without obvious toxicity. Taken together, the new INH derivatives are suitable for translation into clinical application.	[Hu, C-M; Zhu, J.; Guo, X. E.; Chen, W.; Qiu, X-L; Ngo, B.; Chien, R.; Wang, Y. V.; Tsai, C. Y.; Wu, G.; Kim, Y.; Lee, Ey-Hp; Lee, W-H] Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA; [Hu, C-M; Lee, W-H] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lopez, R.; Chamberlin, A. R.] Univ Calif Irvine, Dept Chem, Irvine, CA 92717 USA; [Lee, W-H] China Med Univ, Grad Inst Clin Med Sci, Taichung, Taiwan	University of California System; University of California Irvine; Academia Sinica - Taiwan; University of California System; University of California Irvine; China Medical University Taiwan	Lee, WH (corresponding author), Univ Calif Irvine, Sch Med, Dept Biol Chem, 240 Med Sci D, Irvine, CA 92697 USA.	whlee@uci.edu	Zhu, Jiewen/P-8220-2018	Zhu, Jiewen/0000-0002-6742-8138; Ngo, Bryan/0000-0002-7733-2658	NIH [CA107568]; NATIONAL CANCER INSTITUTE [R01CA107568] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the initial efforts by Guideng Li, Randy Wei and Yumay Chen on this project. This work was supported by an NIH grant (CA107568) to WHL.	Andreasson U, 2009, AM J HEMATOL, V84, P803, DOI 10.1002/ajh.21549; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Barbagallo F, 2009, J PATHOL, V217, P431, DOI 10.1002/path.2471; Bieche I, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-23; Cavasotto CN, 2003, PROTEINS, V51, P423, DOI 10.1002/prot.10362; Chan KS, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.148; Chen YM, 1997, MOL CELL BIOL, V17, P6049, DOI 10.1128/MCB.17.10.6049; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; DeLuca JG, 2006, CELL, V127, P969, DOI 10.1016/j.cell.2006.09.047; Diaz-Rodriguez E, 2008, P NATL ACAD SCI USA, V105, P16719, DOI 10.1073/pnas.0803504105; Foley EA, 2013, NAT REV MOL CELL BIO, V14, P25, DOI 10.1038/nrm3494; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gurzov EN, 2006, GENE THER, V13, P1, DOI 10.1038/sj.gt.3302595; Hames RS, 2001, EMBO J, V20, P7117, DOI 10.1093/emboj/20.24.7117; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Hu J, 2012, J AM CHEM SOC, V124, P10940; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Jackson JR, 2007, NAT REV CANCER, V7, P107, DOI 10.1038/nrc2049; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kokuryo T, 2007, CANCER RES, V67, P9637, DOI 10.1158/0008-5472.CAN-07-1489; Li L, 2007, GENE THER, V14, P814, DOI 10.1038/sj.gt.3302933; Lin YT, 2006, ONCOGENE, V25, P6901, DOI 10.1038/sj.onc.1209687; Martin-Lluesma S, 2002, SCIENCE, V297, P2267, DOI 10.1126/science.1075596; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Ngo B, 2013, J BIOL CHEM, V288, P34403, DOI 10.1074/jbc.M113.490524; Perez EA, 2009, MOL CANCER THER, V8, P2086, DOI 10.1158/1535-7163.MCT-09-0366; Qiu XL, 2009, J MED CHEM, V52, P1757, DOI 10.1021/jm8015969; Rath O, 2012, NAT REV CANCER, V12, P527, DOI 10.1038/nrc3310; Rowinsky EK, 1997, ANNU REV MED, V48, P353; Sakowicz R, 2004, CANCER RES, V64, P3276, DOI 10.1158/0008-5472.CAN-03-3839; SCHMID I, 1994, CYTOMETRY, V15, P12, DOI 10.1002/cyto.990150104; Schmit TL, 2007, MOL CANCER THER, V6, P1920, DOI 10.1158/1535-7163.MCT-06-0781; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Sundin LJR, 2011, MOL BIOL CELL, V22, P759, DOI 10.1091/mbc.E10-08-0671; Umbreit NT, 2012, P NATL ACAD SCI USA, V109, P16113, DOI 10.1073/pnas.1209615109; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Walczak CE, 2010, NAT REV MOL CELL BIO, V11, P91, DOI 10.1038/nrm2832; Wang SL, 2012, J CELL BIOCHEM, V113, P1904, DOI 10.1002/jcb.24059; Wei R, 2011, MOL BIOL CELL, V22, P3584, DOI 10.1091/mbc.E11-01-0012; Wu GK, 2008, CANCER RES, V68, P8393, DOI 10.1158/0008-5472.CAN-08-1915; Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001; Zhu JW, 2013, EMBO MOL MED, V5, P353, DOI 10.1002/emmm.201201760	48	35	40	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 5	2015	34	10					1220	1230		10.1038/onc.2014.67	http://dx.doi.org/10.1038/onc.2014.67			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CC9JX	24662830	Green Accepted, Green Submitted			2022-12-17	WOS:000350687100002
J	Ren, T; Takahashi, Y; Liu, X; Loughran, TP; Sun, SC; Wang, HG; Cheng, H				Ren, T.; Takahashi, Y.; Liu, X.; Loughran, T. P.; Sun, S-C; Wang, H-G; Cheng, H.			HTLV-1 Tax deregulates autophagy by recruiting autophagic molecules into lipid raft microdomains	ONCOGENE			English	Article						HTLV-1 Tax; IKK; autophagy; lipid rafts; Beclin1; Bif-1	NF-KAPPA-B; STARVATION-INDUCED AUTOPHAGY; CELL LEUKEMIA-CELLS; IKK-BETA; PERSISTENT ACTIVATION; TRANSFORMING PROTEIN; METABOLIC STRESS; KINASE SUBUNITS; BECLIN 1; T-CELLS	The retroviral oncoprotein Tax from human T-cell leukemia virus type 1 (HTLV-1), an etiological factor that causes adult T-cell leukemia and lymphoma, has a crucial role in initiating T-lymphocyte transformation by inducing oncogenic signaling activation. We here report that Tax is a determining factor for dysregulation of autophagy in HTLV-1-transformed T cells and Tax-immortalized CD4 memory T cells. Tax facilitated autophagic process by activating inhibitor of kappa B (I kappa B) kinase (IKK) complex, which subsequently recruited an autophagy molecular complex containing Beclin1 and Bif-1 to the lipid raft microdomains. Tax engaged a crosstalk between IKK complex and autophagic molecule complex by directly interacting with both complexes, promoting assembly of LC3 + autophagosomes. Moreover, expression of lipid raft-targeted Bif-1 or Beclin1 was sufficient to induce formation of LC3+ autophagosomes, suggesting that Tax recruitment of autophagic molecules to lipid rafts is a dominant strategy to deregulate autophagy in the context of HTLV-1 transformation of T cells. Furthermore, depletion of autophagy molecules such as Beclin1 and PI3 kinase class III resulted in impaired growth of HTLV-1-transformed T cells, indicating a critical role of Tax-deregulated autophagy in promoting survival and transformation of virally infected T cells.	[Ren, T.; Liu, X.; Loughran, T. P.] Penn State Univ, Penn State Hershey Canc Inst, Coll Med, Hershey, PA USA; [Ren, T.] Penn State Univ, Dept Microbiol & Immunol, Coll Med, Hershey, PA USA; [Takahashi, Y.; Wang, H-G] Penn State Univ, Dept Pharmacol, Coll Med, Hershey, PA USA; [Sun, S-C] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Cheng, H.] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Texas System; UTMD Anderson Cancer Center; University System of Maryland; University of Maryland Baltimore	Cheng, H (corresponding author), Univ Maryland, Sch Med, Inst Human Virol, 725 W Lombard St,S219, Baltimore, MD 21201 USA.	hcheng@ihv.umaryland.edu	Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Takahashi, Yoshinori/0000-0002-8004-4817	National Institute of Allergy And Infectious Diseases of the National Institutes of Health [R01AI090113];  [CA129682]; NATIONAL CANCER INSTITUTE [R01CA129682] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI090113] Funding Source: NIH RePORTER	National Institute of Allergy And Infectious Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Atsushi Koito and Takeo Ohsugi for MT-1 cell line, and Wen Dong, Li Chen, Dan Liu, Di Xiang and Huan Zhang for technical assistance. Research reported in this publication was supported by the National Institute of Allergy And Infectious Diseases of the National Institutes of Health under award number R01AI090113 to H Cheng and was partly supported by the award CA129682 to HG Wang.	ADYA N, 1995, J VIROL, V69, P1834, DOI 10.1128/JVI.69.3.1834-1841.1995; Ai HW, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-13; Balgi AD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007124; Baudhuin P, 1966, Brux Med, V46, P1059; Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x; Carew JS, 2007, AUTOPHAGY, V3, P464, DOI 10.4161/auto.4311; Carter RS, 2001, J BIOL CHEM, V276, P24445, DOI 10.1074/jbc.C000777200; Chen ZH, 2010, P NATL ACAD SCI USA, V107, P18880, DOI 10.1073/pnas.1005574107; Cheng H, 2005, MOL CELL BIOL, V25, P44, DOI 10.1128/MCB.25.1.44-59.2005; Chu WM, 2000, CELL, V103, P909, DOI 10.1016/S0092-8674(00)00194-X; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Chu ZL, 1998, J BIOL CHEM, V273, P15891, DOI 10.1074/jbc.273.26.15891; Criollo A, 2010, EMBO J, V29, P619, DOI 10.1038/emboj.2009.364; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Dreux M, 2009, AUTOPHAGY, V5, P1224, DOI 10.4161/auto.5.8.10219; Dreux M, 2009, P NATL ACAD SCI USA, V106, P14046, DOI 10.1073/pnas.0907344106; Furuta S, 2004, ONCOGENE, V23, P3898, DOI 10.1038/sj.onc.1207539; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Harhaj NS, 2007, J BIOL CHEM, V282, P4185, DOI 10.1074/jbc.M611031200; Hatanaka M, 1992, Uirusu, V42, P13; Horiuchi S, 2006, INT J CANCER, V119, P823, DOI 10.1002/ijc.21918; Huang JN, 2009, J BIOL CHEM, V284, P6208, DOI 10.1074/jbc.M806390200; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karantza-Wadsworth V, 2007, GENE DEV, V21, P1621, DOI 10.1101/gad.1565707; Katayama M, 2007, CELL DEATH DIFFER, V14, P548, DOI 10.1038/sj.cdd.4402030; Lee DY, 2008, ONCOGENE, V27, P2833, DOI 10.1038/sj.onc.1210946; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; Liu Y, 2001, ONCOGENE, V20, P2514, DOI 10.1038/sj.onc.1204364; Maddodi N, 2010, J INVEST DERMATOL, V130, P1657, DOI 10.1038/jid.2010.26; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mathew R, 2009, METHOD ENZYMOL, V453, P53, DOI 10.1016/S0076-6879(08)04004-4; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mizui T, 2010, J GASTROENTEROL, V45, P195, DOI 10.1007/s00535-009-0132-9; MORI N, 1995, CANCER RES, V55, P3592; Nakamura N, 1999, ONCOGENE, V18, P2667, DOI 10.1038/sj.onc.1202608; Niso-Santano M, 2012, AUTOPHAGY, V8, P268, DOI 10.4161/auto.8.2.18845; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650, DOI 10.1002/jlb.63.6.650; Omodei Zorini A, 1965, Lotta Tuberc, V35, P946; Paul S, 2012, IMMUNITY, V36, P947, DOI 10.1016/j.immuni.2012.04.008; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Ren T, 2012, J BIOL CHEM, V287, P34683, DOI 10.1074/jbc.M112.377143; ROBB RJ, 1984, J EXP MED, V160, P1126, DOI 10.1084/jem.160.4.1126; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; Shcherbo D, 2009, BIOCHEM J, V418, P567, DOI 10.1042/BJ20081949; Sir D, 2010, P NATL ACAD SCI USA, V107, P4383, DOI 10.1073/pnas.0911373107; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Song JR, 2009, AUTOPHAGY, V5, P1131, DOI 10.4161/auto.5.8.9996; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Tang H, 2009, HEPATOLOGY, V49, P60, DOI 10.1002/hep.22581; Tang SW, 2013, J VIROL, V87, P1699, DOI 10.1128/JVI.02147-12; Tomita M, 2007, BIOCHEM J, V406, P317, DOI 10.1042/BJ20070286; Trushin SA, 1999, J BIOL CHEM, V274, P22923, DOI 10.1074/jbc.274.33.22923; TSUDO M, 1983, BLOOD, V61, P1014; Valentin-Acevedo A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025467; Verkade P, 1997, HISTOCHEM CELL BIOL, V108, P211, DOI 10.1007/s004180050161; VONWILLEBRAND M, 1994, EUR J IMMUNOL, V24, P234, DOI 10.1002/eji.1830240137; Wei HJ, 2011, GENE DEV, V25, P1510, DOI 10.1101/gad.2051011; WEISS RA, 1990, CANCER CELL-MON REV, V2, P281; Wen HJ, 2010, J VIROL, V84, P7448, DOI 10.1128/JVI.00024-10; Yan PR, 2007, AUTOPHAGY, V3, P600, DOI 10.4161/auto.4761; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	66	35	37	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					373	384		10.1038/onc.2013.552	http://dx.doi.org/10.1038/onc.2013.552			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24362528	Green Accepted			2022-12-17	WOS:000348145500011
J	Valdmanis, PN; Roy-Chaudhuri, B; Kim, HK; Sayles, LC; Zheng, Y; Chuang, CH; Caswell, DR; Chu, K; Zhang, Y; Winslow, MM; Sweet-Cordero, EA; Kay, MA				Valdmanis, P. N.; Roy-Chaudhuri, B.; Kim, H. K.; Sayles, L. C.; Zheng, Y.; Chuang, C-H; Caswell, D. R.; Chu, K.; Zhang, Y.; Winslow, M. M.; Sweet-Cordero, E. A.; Kay, M. A.			Upregulation of the microRNA cluster at the Dlkl-Dio3 locus in lung adenocarcinoma	ONCOGENE			English	Article						lung adenocarcinorna; NSCLC; RNAseq; nnicroRNAs	K-RAS ONCOGENE; PROMOTER HYPERMETHYLATION; HEPATOCELLULAR-CARCINOMA; SOMATIC MUTATIONS; IMPRINTED GENES; NEVER SMOKERS; CANCER; RNA; EXPRESSION; ACTIVATION	Mice in which lung epithelial cells can be induced to express an oncogenic Kras(G12D) develop lung adenocarcinomas in a manner analogous to humans. A myriad of genetic changes accompany lung adenocarcinomas, many of which are poorly understood. To get a comprehensive understanding of both the transcriptional and post-transcriptional changes that accompany lung adenocarcinomas, we took an omics approach in profiling both the coding genes and the non-coding small RNAs in an induced mouse model of lung adenocarcinoma. RNAseq transcriptome analysis of Kras(G12D) tumors from F1 hybrid mice revealed features specific to tumor samples. This includes the repression of a network of GTPase-related genes (Prkg1, Gnao1 and Rgs9) in tumor samples and an enrichment of Apobec1-mediated cytosine to uridine RNA editing. Furthermore, analysis of known single-nucleotide polymorphisms revealed not only a change in expression of Cd22 but also that its expression became allele specific in tumors. The most salient finding, however, came from small RNA sequencing of the tumor samples, which revealed that a cluster of 53 microRNAs and mRNAs at the Dlk1-Dio3 locus on mouse chromosome 12qF1 was markedly and consistently increased in tumors. Activation of this locus occurred specifically in sorted tumor-originating cancer cells. Interestingly, the 12qF1 RNAs were repressed in cultured Kras(G12D) tumor cells but reactivated when transplanted in vivo. These microRNAs have been implicated in stem cell pleuripotency and proteins targeted by these microRNAs are involved in key pathways in cancer as well as embryogenesis. Taken together, our results strongly imply that these microRNAs represent key targets in unraveling the mechanism of lung oncogenesis.	[Valdmanis, P. N.; Roy-Chaudhuri, B.; Kim, H. K.; Chu, K.; Zhang, Y.; Sweet-Cordero, E. A.; Kay, M. A.] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA; [Valdmanis, P. N.; Roy-Chaudhuri, B.; Kim, H. K.; Chuang, C-H; Caswell, D. R.; Chu, K.; Zhang, Y.; Winslow, M. M.; Kay, M. A.] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Sayles, L. C.; Zheng, Y.; Sweet-Cordero, E. A.] Stanford Univ, Dept Pediat, Div Hematol Oncol, Stanford, CA 94305 USA; [Chuang, C-H; Caswell, D. R.; Winslow, M. M.] Stanford Univ, Canc Biol Program, Stanford, CA 94305 USA; [Chuang, C-H; Caswell, D. R.; Winslow, M. M.; Sweet-Cordero, E. A.] Stanford Univ, Stanford Canc Inst, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; Stanford University; Stanford Cancer Institute; Stanford University	Kay, MA (corresponding author), Stanford Univ, Dept Pediat & Genet, 269 Campus Dr,CCSR 2105, Stanford, CA 94305 USA.	markay@stanford.edu		Valdmanis, Paul/0000-0001-8840-6969; Kay, Mark/0000-0002-2799-2615	Baxter Foundation Scholar Award; Stanford Dean's Fellowship; Canadian Institutes of Health Research;  [R01 DK078424]; NATIONAL CANCER INSTITUTE [T32CA009302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071068] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK078424] Funding Source: NIH RePORTER	Baxter Foundation Scholar Award; Stanford Dean's Fellowship; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	PNV is a Banting Postdoctoral Fellow supported by the Canadian Institutes of Health Research. MMW is funded by a Baxter Foundation Scholar Award and C-HC is supported by a Stanford Dean's Fellowship. We thank Julien Sage for SCLC samples. This work was supported by grant R01 DK078424 (MAK).	Al-Mulla F, 1999, J PATHOL, V187, P433, DOI 10.1002/(SICI)1096-9896(199903)187:4<433::AID-PATH273>3.0.CO;2-E; Castilla MA, 2011, J PATHOL, V223, P72, DOI 10.1002/path.2802; Benetatos L, 2012, CRIT REV EUKAR GENE, V22, P1; Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995; Bhaskaran M, 2009, PHYSIOL GENOMICS, V37, P268, DOI 10.1152/physiolgenomics.90268.2008; Burns MB, 2013, NAT GENET, V45, P977, DOI 10.1038/ng.2701; Chess A, 2012, NAT REV GENET, V13, P421, DOI 10.1038/nrg3239; Danecek P, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-4-r26; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dixon-McIver A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002141; DuPage M, 2009, NAT PROTOC, V4, P1064, DOI 10.1038/nprot.2009.95; Edwards CA, 2007, CURR OPIN CELL BIOL, V19, P281, DOI 10.1016/j.ceb.2007.04.013; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Garcia-Marcos M, 2011, ONCOGENE, V30, P2691, DOI 10.1038/onc.2010.645; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Hagan JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004352; Haller F, 2010, J PATHOL, V220, P71, DOI 10.1002/path.2610; Harris KS, 2006, P NATL ACAD SCI USA, V103, P2208, DOI 10.1073/pnas.0510839103; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Kaneda A, 2004, CANCER LETT, V212, P203, DOI 10.1016/j.canlet.2004.03.020; Kim JH, 2011, BMB REP, V44, P523, DOI 10.5483/BMBRep.2011.44.8.523; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee Jennifer, 2010, Genes Cancer, V1, P690, DOI 10.1177/1947601910382899; Lee S, 2009, INT J ONCOL, V34, P161, DOI 10.3892/ijo_00000138; Leung SO, 1995, MOL IMMUNOL, V32, P1413, DOI 10.1016/0161-5890(95)00080-1; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566; Luk JM, 2011, J BIOL CHEM, V286, P30706, DOI 10.1074/jbc.M111.229831; Ma Y, 2007, P NATL ACAD SCI USA, V104, P4089, DOI 10.1073/pnas.0606537104; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mita H, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-198; Mosakhani N, 2012, GENE CHROMOSOME CANC, V51, P1, DOI 10.1002/gcc.20925; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Proudfoot NJ, 2011, GENE DEV, V25, P1770, DOI 10.1101/gad.17268411; Ricketts SL, 2003, MOL CARCINOGEN, V36, P90, DOI 10.1002/mc.10101; Riely GJ, 2008, CLIN CANCER RES, V14, P5731, DOI 10.1158/1078-0432.CCR-08-0646; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Roberts SA, 2013, NAT GENET, V45, P970, DOI 10.1038/ng.2702; ROGGE RD, 1991, CELL, V64, P39, DOI 10.1016/0092-8674(91)90207-F; Rosenberg BR, 2011, NAT STRUCT MOL BIOL, V18, P230, DOI 10.1038/nsmb.1975; SANTOS E, 1984, SCIENCE, V223, P661, DOI 10.1126/science.6695174; Sekita Y, 2006, CYTOGENET GENOME RES, V113, P223, DOI 10.1159/000090836; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; Son JW, 2011, RESPIROLOGY, V16, P1203, DOI 10.1111/j.1440-1843.2011.01994.x; Stadtfeld M, 2010, NATURE, V465, P175, DOI 10.1038/nature09017; Sun S, 2007, NAT REV CANCER, V7, P778, DOI 10.1038/nrc2190; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; Takahashi N, 2009, HUM MOL GENET, V18, P1879, DOI 10.1093/hmg/ddp108; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Tuscano JM, 2012, CANCER RES, V72, P5556, DOI 10.1158/0008-5472.CAN-12-0173; Uckun FM, 2010, P NATL ACAD SCI USA, V107, P16852, DOI 10.1073/pnas.1007896107; YAMANAKA S, 1995, P NATL ACAD SCI USA, V92, P8483, DOI 10.1073/pnas.92.18.8483	65	35	37	0	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 2	2015	34	1					94	103		10.1038/onc.2013.523	http://dx.doi.org/10.1038/onc.2013.523			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB6MC	24317514	Green Accepted, Green Submitted			2022-12-17	WOS:000349740100009
J	Sato, T; Goyama, S; Kataoka, K; Nasu, R; Tsuruta-Kishino, T; Kagoya, Y; Nukina, A; Kumagai, K; Kubota, N; Nakagawa, M; Arai, S; Yoshimi, A; Honda, H; Kadowaki, T; Kurokawa, M				Sato, T.; Goyama, S.; Kataoka, K.; Nasu, R.; Tsuruta-Kishino, T.; Kagoya, Y.; Nukina, A.; Kumagai, K.; Kubota, N.; Nakagawa, M.; Arai, S.; Yoshimi, A.; Honda, H.; Kadowaki, T.; Kurokawa, M.			Evil defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; HEMATOPOIETIC STEM-CELLS; BLAST CRISIS CML; BCR-ABL; TUMOR-SUPPRESSOR; BONE-MARROW; EXPRESSION; GENE; BETA	Relapse of chronic myeloid leukemia (CML) is triggered by stem cells with a reconstituting capacity similar to that of hematopoietic stem cells (HSCs) and CML stem cells are a source of resistance in drug therapy with tyrosine kinase inhibitors (TKIs). Ecotropic viral integration site 1 (EVI1), a key transcription factor in HSC regulation, is known to predict poor outcomes in myeloid malignancies, however, incapability of prospective isolation of EVI1-high leukemic cells precludes the functional evaluation of intraindividual EVI1-high cells. Introduction of CML into Evi1-internal ribosomal entry site (IRES)-green fluorescent protein (GFP) knock-in mice, a versatile HSC-reporter strain, enables us to separate Evi1-high CML cells from the individual. Evi1-IRES-GFP allele models of CML in chronic phase (CML-CP), by retroviral overexpression of BCR-ABL and by crossing BCR-ABL transgenic mice, revealed that Evi1 is predominantly enriched in the stem cell fraction and associated with an enhanced proliferative as well as a leukemia-initiating capacity and that Evi1-high CML-CP cells exhibit resistance to TKIs. Overexpressing BCR-ABL and NUP98-HOXA9 in Evi1-IRES-GFP knock-in mice to model CML in blast crisis (CML-BC), in which Evi1-high cells turned to be a major population as opposed to a minor population in CML-CP models, showed that Evi1-high CML-BC cells have a greater potential to recapitulate the disease and appear resistant to TKIs. Furthermore, given that Evi1 heterozygosity ameliorates CML-CP and CML-BC development and that the combination of Evi1 and BCR-ABL causes acute myeloid leukemia resembling CML-BC, Evi1 could regulate CML development as a potent driver. In addition, in human CML-CP cases, we show that EVI1 is highly expressed in stem cell-enriched CD34+ CD38-CD90+ fraction at single-cell level. This is the first report to clarify directly that Evi1-high leukemic cells themselves possess the superior potential to Evi1-low cells in oncogenic self-renewal, which highlights the role of Evi1 as a valuable and a functional marker of CML stem cells.	[Sato, T.; Goyama, S.; Kataoka, K.; Nasu, R.; Tsuruta-Kishino, T.; Kagoya, Y.; Nukina, A.; Nakagawa, M.; Arai, S.; Yoshimi, A.; Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1138655, Japan; [Sato, T.] Tokyo Univ Hosp, Dept Transfus Med, Tokyo 113, Japan; [Kumagai, K.; Kubota, N.; Kadowaki, T.] Univ Tokyo, Grad Sch Med, Dept Metab & Diabet Dis, Tokyo 1138655, Japan; [Honda, H.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Hiroshima, Japan	University of Tokyo; University of Tokyo; University of Tokyo; Hiroshima University	Kurokawa, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kurokawa-tky@umin.ac.jp	Kubota, Naoto/N-7892-2015; Kagoya, Yuki/GQH-4875-2022; Kataoka, Keisuke/AAS-2546-2020; Kagoya, Yuki/AAD-9870-2019; Yoshimi, Akihide/I-3792-2019	Kataoka, Keisuke/0000-0002-8263-9902; Yoshimi, Akihide/0000-0002-0664-7281; Nakagawa, Masahiro/0000-0002-6420-2555; Sato, Tomohiko/0000-0002-8244-075X	Japan Society for the Promotion of Science and by Health; Grants-in-Aid for Scientific Research [26860474, 24790962] Funding Source: KAKEN	Japan Society for the Promotion of Science and by Health(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Takuro Nakamura for NUP98-HOXA9; Issay Kitabayashi for MOZ-TIF2; Michael Tomasson for TEL-PDGFR/IRES/AML1-ETO; Novartis for nilotinib. We appreciate expert technical supports by Yoshi Shimamura, Yuko Sawamoto and Rumi Takizawa-Toyama. We express our heartfelt sorrow over Yuko Sawamoto's sudden passing away. This work was carried out at the Joint Usage/Research Center (RIRBM), Hiroshima University, and supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science and by Health.	Arai S, 2011, BLOOD, V117, P6304, DOI 10.1182/blood-2009-07-234310; Balgobind BV, 2010, LEUKEMIA, V24, P942, DOI 10.1038/leu.2010.47; Buonamici S, 2004, J CLIN INVEST, V114, P713, DOI 10.1172/JCI200421716; Chen YY, 2009, NAT GENET, V41, P783, DOI 10.1038/ng.389; Chitteti BR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017498; Chomel JC, 2011, BLOOD, V118, P3657, DOI 10.1182/blood-2011-02-335497; Chu S, 2011, BLOOD, V118, P5565, DOI 10.1182/blood-2010-12-327437; Corbin AS, 2011, J CLIN INVEST, V121, P396, DOI 10.1172/JCI35721; Cuenco GM, 2004, ONCOGENE, V23, P569, DOI 10.1038/sj.onc.1207143; Daghistani M, 2010, BLOOD, V116, P6014, DOI 10.1182/blood-2010-01-264234; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Eguchi-Ishimae M, 2009, INT J HEMATOL, V89, P253, DOI 10.1007/s12185-009-0267-8; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; Forsberg EC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008785; Goyama S, 2004, BLOOD, V104, P3558, DOI 10.1182/blood-2004-04-1535; Goyama S, 2010, LEUKEMIA, V24, P81, DOI 10.1038/leu.2009.202; Goyama S, 2008, CELL STEM CELL, V3, P207, DOI 10.1016/j.stem.2008.06.002; Graham SM, 2002, BLOOD, V99, P319, DOI 10.1182/blood.V99.1.319; Groschel S, 2010, J CLIN ONCOL, V28, P2101, DOI 10.1200/JCO.2009.26.0646; Hamilton A, 2012, BLOOD, V119, P1501, DOI 10.1182/blood-2010-12-326843; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hermitte F, 2006, STEM CELLS, V24, P65, DOI 10.1634/stemcells.2004-0351; Honda H, 2000, BLOOD, V95, P1144, DOI 10.1182/blood.V95.4.1144.004k04_1144_1150; Honda H, 1998, BLOOD, V91, P2067, DOI 10.1182/blood.V91.6.2067.2067_2067_2075; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; Hu YG, 2006, P NATL ACAD SCI USA, V103, P16870, DOI 10.1073/pnas.0606509103; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jiang X, 2007, LEUKEMIA, V21, P926, DOI 10.1038/sj.leu.2404609; Jones D, 2008, BLOOD, V112, P5190, DOI 10.1182/blood-2008-04-148791; Kataoka K, 2011, J EXP MED, V208, P2402, DOI 10.1084/jem.20110447; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Lugthart S, 2008, BLOOD, V111, P4329, DOI 10.1182/blood-2007-10-119230; MaguerSatta V, 1996, BLOOD, V88, P1796; Morse HC, 2002, BLOOD, V100, P246, DOI 10.1182/blood.V100.1.246; Naka K, 2010, NATURE, V463, P676, DOI 10.1038/nature08734; Neviani P, 2005, CANCER CELL, V8, P355, DOI 10.1016/j.ccr.2005.10.015; O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457; Ogawa S, 1996, LEUKEMIA, V10, P788; Paquette RL, 2011, CANCER GENET-NY, V204, P392, DOI 10.1016/j.cancergen.2011.06.002; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Radich JP., 2007, HEMATOL AM SOC HEMAT, V2007, P384, DOI [10.1182/asheducation-2007.1.384, DOI 10.1182/ASHEDUCATION-2007.1.384]; Reynaud D, 2011, CANCER CELL, V20, P661, DOI 10.1016/j.ccr.2011.10.012; Roy S, 2012, BRIT J HAEMATOL, V157, P446, DOI 10.1111/j.1365-2141.2012.09078.x; RUSSELL M, 1993, LEUKEMIA, V7, P1654; Sato T, 2008, CANCER SCI, V99, P1407, DOI 10.1111/j.1349-7006.2008.00842.x; Schemionek M, 2010, BLOOD, V115, P3185, DOI 10.1182/blood-2009-04-215376; Shimabe M, 2009, ONCOGENE, V28, P4364, DOI 10.1038/onc.2009.288; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Watanabe-Okochi N, 2013, BLOOD, V121, P4142, DOI 10.1182/blood-2011-07-368654; Yoshimi A, 2011, BLOOD, V117, P3617, DOI 10.1182/blood-2009-12-261602; Yuasa H, 2005, EMBO J, V24, P1976, DOI 10.1038/sj.emboj.7600679; Zhang B, 2012, CANCER CELL, V21, P577, DOI 10.1016/j.ccr.2012.02.018; Zhang HJ, 2012, NAT GENET, V44, P861, DOI 10.1038/ng.2350; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003; Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737	60	35	35	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2014	33	42					5028	5038		10.1038/onc.2014.108	http://dx.doi.org/10.1038/onc.2014.108			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OB	24747972	Green Published, hybrid			2022-12-17	WOS:000343768000007
J	Li, D; Beisswenger, C; Herr, C; Schmid, RM; Gallo, RL; Han, G; Zakharkina, T; Bals, R				Li, D.; Beisswenger, C.; Herr, C.; Schmid, R. M.; Gallo, R. L.; Han, G.; Zakharkina, T.; Bals, R.			Expression of the antimicrobial peptide cathelicidin in myeloid cells is required for lung tumor growth	ONCOGENE			English	Article						lung cancer; cathelicidin; antimicrobial peptide; inflammation; macrophage	HOST-DEFENSE; PROTEIN HCAP18/LL-37; HUMAN KERATINOCYTES; LL-37; CANCER; GENE; RECEPTOR; MURINE; SKIN; PROLIFERATION	Antimicrobial peptides, such as the cathelicidin LL-37/hCAP-18 and its mouse homolog cathelicidin-related antimicrobial peptide ( CRAMP), are important effectors of the innate immune system with direct anti-bacterial activity. Cathelicidin is possibly involved in the regulation of tumor cell growth. The aim of this study was to characterize the role of cathelicidin expressed in non-tumorous cells in a preclinical mouse model of tumor growth. Wild-type and CRAMP-deficient animals were exposed to cigarette smoke ( CS) and Lewis lung carcinoma cells were injected to initiate the growth of tumors in the lung. CS exposure significantly increased the proliferation of lung tumors in wild-type mice, but not in CRAMP-deficient mice. CS exposure induced the recruitment of myeloid cell into tumor tissue in a CRAMP-dependent manner. Mice lacking RelA/p65 specifically in myeloid cells showed impaired recruitment of CRAMP-positive cells into the lung. In vitro studies with human cells showed that LL-37/hCAP-18 in macrophages is induced by soluble factors derived from cancer cells. Taken together, these data indicate that cathelicidin expressed from myeloid cells promotes CS-induced lung tumor growth by further recruitment of inflammatory cells. The regulation of cathelicidin expression involves myeloid p65/RelA and soluble factor from tumor cells.	[Li, D.; Beisswenger, C.; Herr, C.; Han, G.; Zakharkina, T.; Bals, R.] Saarland Univ Hosp, Dept Internal Med 5, D-66421 Homburg, Germany; [Schmid, R. M.] Tech Univ Munich, Dept Internal Med 2, D-80290 Munich, Germany; [Gallo, R. L.] Univ Calif San Diego, Div Dermatol, San Diego, CA 92103 USA	Universitatsklinikum des Saarlandes; Technical University of Munich; University of California System; University of California San Diego	Bals, R (corresponding author), Saarland Univ Hosp, Dept Internal Med 5, D-66421 Homburg, Germany.	robert.bals@uks.eu	Herr, Christian/AAH-5291-2021; Beisswenger, Christoph/GRO-6580-2022; Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Herr, Christian/0000-0001-9422-6569	Deutsche Forschungsgemeinschaft (DFG) [1641/12]; Federal Ministry of Education and Research (FKZ ) [01GI0881-0888]; LOEWE-Schwerpunkt 'Tumor and Inflammation' of the state of Hesse	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Federal Ministry of Education and Research (FKZ )(Federal Ministry of Education & Research (BMBF)); LOEWE-Schwerpunkt 'Tumor and Inflammation' of the state of Hesse	This work was supported by grants of the Deutsche Forschungsgemeinschaft (DFG Ba 1641/12), the Federal Ministry of Education and Research (FKZ 01GI0881-0888) and the LOEWE-Schwerpunkt 'Tumor and Inflammation' of the state of Hesse (to RB). We thank Thomas Damm, Andreas Kamyschnikow and Anja Honecker for excellent technical support.	Bals R, 2003, CELL MOL LIFE SCI, V60, P711, DOI 10.1007/s00018-003-2186-9; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Beisswenger C, 2004, RESPIRATION, V71, P402, DOI 10.1159/000079647; Beisswenger C, 2006, J IMMUNOL, V177, P1833, DOI 10.4049/jimmunol.177.3.1833; Bowdish DME, 2005, ANTIMICROB AGENTS CH, V49, P1727, DOI 10.1128/AAC.49.5.1727-1732.2005; Bowdish DME, 2005, CURR PROTEIN PEPT SC, V6, P35, DOI 10.2174/1389203053027494; Buchau AS, 2010, J IMMUNOL, V184, P369, DOI 10.4049/jimmunol.0902110; Buettner M, 2005, J IMMUNOL, V174, P4203, DOI 10.4049/jimmunol.174.7.4203; Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407; Coffelt SB, 2008, INT J CANCER, V122, P1030, DOI 10.1002/ijc.23186; Coffelt SB, 2009, P NATL ACAD SCI USA, V106, P3806, DOI 10.1073/pnas.0900244106; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Erdag G, 2002, ANN SURG, V235, P113, DOI 10.1097/00000658-200201000-00015; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0; Golec M, 2009, ANN AGR ENV MED, V16, P289; Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com; Grivennikov SI, 2010, CURR OPIN GENET DEV, V20, P65, DOI 10.1016/j.gde.2009.11.004; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Hase K, 2002, INFECT IMMUN, V70, P953, DOI 10.1128/IAI.70.2.953-963.2002; Heilborn JD, 2005, INT J CANCER, V114, P713, DOI 10.1002/ijc.20795; Heilborn JD, 2003, J INVEST DERMATOL, V120, P379, DOI 10.1046/j.1523-1747.2003.12069.x; Heilborn JD, 2010, EXP DERMATOL, V19, P332, DOI 10.1111/j.1600-0625.2009.00997.x; Hensel JA, 2011, PROSTATE, V71, P659, DOI 10.1002/pros.21282; Hess C, 2010, EUR RESPIR J, V35, P343, DOI 10.1183/09031936.00196408; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Kovach MA, 2012, J IMMUNOL, V189, P304, DOI 10.4049/jimmunol.1103196; Kurosaka K, 2005, J IMMUNOL, V174, P6257, DOI 10.4049/jimmunol.174.10.6257; Li D, 2014, ONCOGENE, V33, P1239, DOI 10.1038/onc.2013.75; Li GM, 2009, INT ARCH ALLERGY IMM, V150, P122, DOI 10.1159/000218115; Liu PT, 2008, CURR OPIN IMMUNOL, V20, P371, DOI 10.1016/j.coi.2008.05.014; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Mookherjee N, 2006, J IMMUNOL, V176, P2455, DOI 10.4049/jimmunol.176.4.2455; Muehleisen B, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003759; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Niyonsaba Francois, 2003, Current Drug Targets - Inflammation and Allergy, V2, P224, DOI 10.2174/1568010033484115; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Okumura K, 2004, CANCER LETT, V212, P185, DOI 10.1016/j.canlet.2004.04.006; Papi A, 2004, THORAX, V59, P679, DOI 10.1136/thx.2003.018291; Pestonjamasp VK, 2001, PEPTIDES, V22, P1643, DOI 10.1016/S0196-9781(01)00499-5; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Shaykhiev R, 2005, AM J PHYSIOL-LUNG C, V289, pL842, DOI 10.1152/ajplung.00286.2004; Sorensen OE, 2003, J IMMUNOL, V170, P5583, DOI 10.4049/jimmunol.170.11.5583; Steinstraesser L, 2006, ANN PLAS SURG, V56, P93, DOI 10.1097/01.sap.0000190883.30005.91; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Tecle T, 2010, INNATE IMMUN-LONDON, V16, P151, DOI 10.1177/1753425910365734; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; von Haussen J, 2008, LUNG CANCER, V59, P12, DOI 10.1016/j.lungcan.2007.07.014; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Weber G, 2005, J INVEST DERMATOL, V124, P1080, DOI 10.1111/j.0022-202X.2005.23687.x; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Young RP, 2009, EUR RESPIR J, V34, P380, DOI 10.1183/09031936.00144208	54	35	43	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2709	2716		10.1038/onc.2013.248	http://dx.doi.org/10.1038/onc.2013.248			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23812430				2022-12-17	WOS:000337231700004
J	Xie, X; Piao, L; Cavey, GS; Old, M; Teknos, TN; Mapp, AK; Pan, Q				Xie, X.; Piao, L.; Cavey, G. S.; Old, M.; Teknos, T. N.; Mapp, A. K.; Pan, Q.			Phosphorylation of Nanog is essential to regulate Bmi1 and promote tumorigenesis	ONCOGENE			English	Article						Head and neck cancer; protein kinase C; p300; cancer stem cells; cancer-initiating cells	SQUAMOUS-CELL CARCINOMA; STEM-LIKE CELLS; SELF-RENEWAL; KAPPA-B; PLURIPOTENCY; EXPRESSION; HEAD; PROGRESSION; ACTIVATION; PREDICTS	Emerging evidence indicates that Nanog is intimately involved in tumorigenesis, in part, through regulation of the cancer-initiating cell (CIC) population. However, the regulation and role of Nanog in tumorigenesis are still poorly understood. In this study, human Nanog was identified to be phosphorylated by human protein kinase C epsilon at multiple residues, including T200 and T280. Our work indicated that phosphorylation at T200 and T280 modulates Nanog function through several regulatory mechanisms. Results with phosphorylation-insensitive and phosphorylation-mimetic mutant Nanog revealed that phosphorylation at T200 and T280 enhance Nanog protein stability. Moreover, phosphorylation-insensitive T200A and T280A mutant Nanog had a dominant-negative function to inhibit endogenous Nanog transcriptional activity. Inactivation of Nanog was due to impaired homodimerization, DNA binding, promoter occupancy and p300, a transcriptional co-activator, recruitment resulting in a defect in target gene-promoter activation. Ectopic expression of phosphorylation-insensitive T200A or T280A mutant Nanog reduced cell proliferation, colony formation, invasion, migration and the CIC population in head and neck squamous cell carcinoma (HNSCC) cells. The in vivo cancer-initiating ability was severely compromised in HNSCC cells expressing phosphorylation-insensitive T200A or T280A mutant Nanog; 87.5% (14/16), 12.5% (1/8), and 0% (0/8) for control, T200A, and T280A, respectively. Nanog occupied the Bmi1 promoter to directly transactivate and regulate Bmi1. Genetic ablation and rescue experiments demonstrated that Bmi1 is a critical downstream signaling node for the pleiotropic, pro-oncogenic effects of Nanog. Taken together, our study revealed, for the first time, that post-translational phosphorylation of Nanog is essential to regulate Bmi1 and promote tumorigenesis.	[Xie, X.; Piao, L.; Old, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Wexner Med Ctr, Dept Otolaryngol Head & Neck Surg, Columbus, OH 43210 USA; [Xie, X.; Piao, L.; Old, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA; [Xie, X.; Piao, L.; Old, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA; [Cavey, G. S.] Van Andel Res Inst, Grand Rapids, MI USA; [Cavey, G. S.] Southwest Michigan Innovat Ctr, Kalamazoo, MI USA; [Mapp, A. K.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Van Andel Institute; University of Michigan System; University of Michigan	Pan, Q (corresponding author), Ohio State Univ, Wexner Med Ctr, Dept Otolaryngol Head & Neck Surg, 442 Tzagournis Med Res,420 West 12th Ave, Columbus, OH 43210 USA.	Quintin.Pan@osumc.edu	, Dr Anna Mapp/GPX-8261-2022; Old, Matthew/J-2315-2017; Pan, Quintin/E-3808-2011	Old, Matthew/0000-0003-1795-5877; 	National Cancer Institute at the National Institutes of Health [R01CA135096]; American Cancer Society [RSG0821901]; Michelle Theado Memorial Grant from The Joan Bisesi Fund for Head and Neck Oncology Research; Sloman Foundation; Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center; Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA135096] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Michelle Theado Memorial Grant from The Joan Bisesi Fund for Head and Neck Oncology Research; Sloman Foundation; Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center; Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in part, by the National Cancer Institute at the National Institutes of Health (R01CA135096); American Cancer Society (RSG0821901); The Michelle Theado Memorial Grant from The Joan Bisesi Fund for Head and Neck Oncology Research; The Sloman Foundation; and Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center.	Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Bourguignon LYW, 2009, J BIOL CHEM, V284, P26533, DOI 10.1074/jbc.M109.027466; Chang DF, 2009, STEM CELLS, V27, P812, DOI 10.1634/stemcells.2008-0657; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008-5472.CAN-07-5882; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Choijamts B, 2011, STEM CELLS, V29, P1485, DOI 10.1002/stem.711; Das S, 2011, J BIOL CHEM, V286, P42690, DOI 10.1074/jbc.M111.290189; Do HJ, 2009, J CELL BIOCHEM, V106, P1079, DOI 10.1002/jcb.22089; Germann M, 2012, STEM CELLS, V30, P1076, DOI 10.1002/stem.1087; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Han JH, 2012, CANCER LETT, V321, P80, DOI 10.1016/j.canlet.2012.02.021; Hayry V, 2010, BRIT J CANCER, V102, P892, DOI 10.1038/sj.bjc.6605544; Ho BT, 2012, J BIOL CHEM, V287, P18656, DOI 10.1074/jbc.M111.322883; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Lavial F, 2012, GENE DEV, V26, P1445, DOI 10.1101/gad.188193.112; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Li J, 2010, AM J PATHOL, V176, P699, DOI 10.2353/ajpath.2010.090502; Liu AG, 2013, INT J ONCOL, V42, P1399, DOI 10.3892/ijo.2013.1826; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Moretto-Zita M, 2010, P NATL ACAD SCI USA, V107, P13312, DOI 10.1073/pnas.1005847107; Mullin NP, 2008, BIOCHEM J, V411, P227, DOI 10.1042/BJ20080134; Niggeweg R, 2006, PROTEOMICS, V6, P41, DOI 10.1002/pmic.200501332; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Pan GJ, 2005, J BIOL CHEM, V280, P1401, DOI 10.1074/jbc.M407847200; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Ramakrishna S, 2011, STEM CELLS DEV, V20, P1512, DOI 10.1089/scd.2010.0410; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; Steen H, 2001, ANAL CHEM, V73, P1440, DOI 10.1021/ac001318c; Torres J, 2008, NAT CELL BIOL, V10, P194, DOI 10.1038/ncb1680; Tsai LL, 2011, J ORAL PATHOL MED, V40, P621, DOI 10.1111/j.1600-0714.2011.01015.x; Vormittag L, 2009, INT J RADIAT ONCOL, V73, P913, DOI 10.1016/j.ijrobp.2008.10.040; Vrzalikova K, 2008, J CANCER RES CLIN, V134, P1037, DOI 10.1007/s00432-008-0361-y; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Yu CC, 2011, ORAL ONCOL, V47, P202, DOI 10.1016/j.oraloncology.2010.12.001; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang PL, 2010, J BIOL CHEM, V285, P9180, DOI 10.1074/jbc.M109.077958; Zhang Y, 2012, CANCER LETT, V322, P70, DOI 10.1016/j.canlet.2012.02.010	44	35	39	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2040	2052		10.1038/onc.2013.173	http://dx.doi.org/10.1038/onc.2013.173			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23708658	Green Accepted			2022-12-17	WOS:000334599100004
J	Cao, Y; Marks, JW; Liu, Z; Cheung, LH; Hittelman, WN; Rosenblum, MG				Cao, Y.; Marks, J. W.; Liu, Z.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G.			Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies	ONCOGENE			English	Article						immunotoxin; Her2/neu; gelonin; valency; design optimization	DISULFIDE-STABILIZED FV; SINGLE-CHAIN FV; HER2-POSITIVE BREAST-CANCER; IMPROVED ANTIGEN-BINDING; RECOMBINANT IMMUNOTOXINS; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; ONCOGENE PRODUCT; ERBB-2 RECEPTOR; CARCINOMA-CELLS	Targeted therapeutics are potential therapeutic agents because of their selectivity and efficacy against tumors resistant to conventional therapy. The goal of this study was to determine the comparative activity of monovalent, engineered anti-Her2/neu immunotoxins fused to recombinant gelonin (rGel) to the activity of bivalent IgG-containing immunoconjugates. Utilizing Herceptin and its derived humanized single-chain antibody (single-chain fragment variable, designated 4D5), we generated bivalent chemical Herceptin/rGel conjugate, and the corresponding monovalent recombinant immunotoxins in two orientations, 4D5/rGel and rGel/4D5. All the constructs showed similar affinity to Her2/neu-overexpressing cancer cells, but significantly different antitumor activities. The rGel/4D5 orientation construct and Herceptin/rGel conjugate were superior to 4D5/rGel construct in in vitro and in vivo efficacy. The enhanced activity was attributed to improved intracellular toxin uptake into target cells and efficient downregulation of Her2/neu-related signaling pathways. The Her2/neu-targeted immunotoxins effectively targeted cells with Her2/neu expression level > 1.5 x 10(5) sites per cell. Cells resistant to Herceptin or chemotherapeutic agents were not cross-resistant to rGel-based immunotoxins. Against SK-OV-3 tumor xenografts, the rGel/4D5 construct with excellent tumor penetration showed impressive tumor inhibition. Although Herceptin/rGel conjugate demonstrated comparatively longer serum half-life, the in vivo efficacy of the conjugate was similar to the rGel/4D5 fusion. These comparative studies demonstrate that the monovalent, engineered rGel/4D5 construct displayed comparable in vitro and in vivo antitumor efficacy as bivalent Herceptin/rGel conjugate. Immunotoxin orientation can significantly impact the overall functionality and performance of these agents. The recombinant rGel/4D5 construct with excellent tumor penetration and rapid blood clearance may reduce the unwanted toxicity when administrating to patients, and warrants consideration for further clinical evaluation.	[Cao, Y.; Marks, J. W.; Liu, Z.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Immunopharmacol & Targeted Therapy Lab, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center	Rosenblum, MG (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77054 USA.	mrosenbl@mdanderson.org	Liu, Zhiming/GXG-6785-2022; Cao, Yu/L-6743-2014		NCI NIH HHS [P30 CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams GP, 2006, CLIN CANCER RES, V12, P1599, DOI 10.1158/1078-0432.CCR-05-2217; Adams GP, 1998, BRIT J CANCER, V77, P1405, DOI 10.1038/bjc.1998.233; Azemar M, 2003, BREAST CANCER RES TR, V82, P155, DOI 10.1023/B:BREA.0000004371.48757.19; Beckman RA, 2007, CANCER-AM CANCER SOC, V109, P170, DOI 10.1002/cncr.22402; Benhar I, 1995, CLIN CANCER RES, V1, P1023; Bera TK, 1999, CANCER RES, V59, P4018; Bera TK, 1998, J MOL BIOL, V281, P475, DOI 10.1006/jmbi.1998.1948; Brand FX, 2006, ANTICANCER RES, V26, P715; Brinkmann U, 2000, IN VIVO, V14, P21; Cao Y, 2012, MOL CANCER THER, V11, P143, DOI 10.1158/1535-7163.MCT-11-0519; Cao Y, 2009, CANCER RES, V69, P8987, DOI 10.1158/0008-5472.CAN-09-2693; Cardinale D, 2010, J CLIN ONCOL, V28, P3910, DOI 10.1200/JCO.2009.27.3615; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Daniele L, 2009, RECENT PAT ANTI-CANC, V4, P9, DOI 10.2174/157489209787002489; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Hossann M, 2006, PROTEIN EXPRES PURIF, V46, P73, DOI 10.1016/j.pep.2005.08.029; Jain KK, 2001, EXPERT OPIN BIOL TH, V1, P291, DOI 10.1517/14712598.1.2.291; Jain M, 2007, CLIN CANCER RES, V13, P1374, DOI 10.1158/1078-0432.CCR-06-2436; JAIN RK, 1988, CANCER RES, V48, P7022; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Krauss W C, 2000, Breast Dis, V11, P113; Kreitman RJ, 2003, CURR OPIN MOL THER, V5, P44; MAIER LA, 1991, CANCER RES, V51, P5361; Maurer-Gebhard M, 1998, CANCER RES, V58, P2661; Mazor Y, 2007, CANCER LETT, V257, P124, DOI 10.1016/j.canlet.2007.07.009; McLarty K, 2009, EUR J NUCL MED MOL I, V36, P81, DOI 10.1007/s00259-008-0923-x; Murphy CG, 2010, ONCOLOGY-NY, V24, P410; Nordstrom JL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3069; Pai-Scherf LH, 1999, CLIN CANCER RES, V5, P2311; Pennell CA, 2002, IMMUNOL RES, V25, P177, DOI 10.1385/IR:25:2:177; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Reiter Y, 2001, ADV CANCER RES, V81, P93, DOI 10.1016/S0065-230X(01)81003-4; RODRIGUEZ GC, 1993, AM J OBSTET GYNECOL, V168, P228, DOI 10.1016/S0002-9378(12)90918-7; Rosenblum MG, 1999, CLIN CANCER RES, V5, P865; Rosenblum MG, 2003, CANCER RES, V63, P3995; Scholl S, 2001, ANN ONCOL, V12, P81, DOI 10.1023/A:1011192622688; WELS W, 1992, CANCER RES, V52, P6310; Yee S, 1997, MICROBIOL IMMUNOL, V41, P563, DOI 10.1111/j.1348-0421.1997.tb01892.x; YOKOTA T, 1992, CANCER RES, V52, P3402	41	35	38	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					429	439		10.1038/onc.2012.612	http://dx.doi.org/10.1038/onc.2012.612			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23376850	Green Accepted, Bronze			2022-12-17	WOS:000330214600004
J	Wu, L; Runkle, C; Jin, HJ; Yu, J; Li, J; Yang, X; Kuzel, T; Lee, C; Yu, J				Wu, L.; Runkle, C.; Jin, H-J; Yu, J.; Li, J.; Yang, X.; Kuzel, T.; Lee, C.; Yu, J.			CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor	ONCOGENE			English	Article						androgen receptor; polycomb EZH2; NOV; CCN3	DIFFERENTIAL EXPRESSION; CCN PROTEINS; NOV; TRANSCRIPTION; MECHANISM; POLYCOMB; GROWTH; INHIBITION; REPRESSION; CASTRATION	Androgen receptor (AR) has essential roles during prostate cancer progression. With genome-wide AR-binding sites mapped to high resolution, studies have recently reported AR as a transcriptional repressor. How AR inhibits gene expression and how this contributes to prostate cancer, however, are incompletely understood. Through meta-analysis of microarray data, here we nominate nephroblastoma overexpressed (NOV) as a top androgen-repressed gene. We show that NOV is directly suppressed by androgen through the AR. AR occupies the NOV enhancer and communicates with the NOV promoter through DNA looping. AR activation recruits the polycomb group protein EZH2, which subsequently catalyzes histone H3 lysine 27 tri-methylation around the NOV promoter, thus leading to repressive chromatin remodeling and epigenetic silencing. Concordantly, AR and EZH2 inhibition synergistically restored NOV expression. NOV is downregulated in human prostate cancer wherein AR and EZH2 are upregulated. Functionally, NOV inhibits prostate cancer cell growth in vitro and in vivo. NOV reconstitution reverses androgen-induced cell growth and NOV knockdown drives androgen-independent cell growth. In addition, NOV expression is restored by hormone-deprivation therapies in mice and prostate cancer patients. Therefore, using NOV as a model gene we gained further understanding of the mechanisms underlying AR-mediated transcriptional repression. Our findings establish a tumor-suppressive role of NOV in prostate cancer and suggest that one important, but previously underestimated, manner by which AR contributes to prostate cancer progression is through inhibition of key tumor-suppressor genes.	[Wu, L.; Runkle, C.; Jin, H-J; Yu, J.; Li, J.; Kuzel, T.; Yu, J.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA; [Yang, X.; Kuzel, T.; Lee, C.; Yu, J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Yu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, 303 E Super St Lurie 5-117, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu	WU, Longtao/G-6477-2014	WU, Longtao/0000-0003-3463-4127; Jin, Hongjian/0000-0003-3833-7170	NIH [P50CA090386, U54CA143869, K99/R00CA129565, R01HG005119]; US Department of Defense [W81XWH-09-1-0193]; Research Scholar Award from the American Cancer Society [RSG-12-085-01]; NATIONAL CANCER INSTITUTE [R01CA172384, P30CA062203, P50CA090386, R00CA129565, U54CA143869, K99CA129565] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG005119] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); Research Scholar Award from the American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Dr Bernard Perbal (University of Paris) for the K19M anti-NOV antibody, Dr Kurt Engeland (Universitatsfrauenklinik Leipzig) for the NOV constructs, Dr Raymond Bergan for the PC-3M cells, and Dr Stephen Plymate for AR overexpression constructs. We are also grateful to Jonathan Zhao and Jung Kim for technical assistance. This work was supported by funding from the NIH P50CA090386 (to CL, JY), U54CA143869 pilot project (to JY), K99/R00CA129565 (to JY), R01HG005119 (to JY), the US Department of Defense W81XWH-09-1-0193 (to JY) and the Research Scholar Award RSG-12-085-01 (to JY) from the American Cancer Society.	Bao BY, 2008, PROSTATE, V68, P839, DOI 10.1002/pros.20749; Benini S, 2005, ONCOGENE, V24, P4349, DOI 10.1038/sj.onc.1208620; Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Bohlig L, 2008, CELL CYCLE, V7, P1254, DOI 10.4161/cc.7.9.5812; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Fu CT, 2004, J BIOL CHEM, V279, P36943, DOI 10.1074/jbc.M403952200; Fukunaga-Kalabis M, 2008, ONCOGENE, V27, P2552, DOI 10.1038/sj.onc.1210896; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Jiang WG, 2004, ENDOCR-RELAT CANCER, V11, P781, DOI 10.1677/erc.1.00825; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kimura A, 2010, J BIOL CHEM, V285, P32704, DOI 10.1074/jbc.M110.141804; Lamont KR, 2011, MOL ENDOCRINOL, V25, P897, DOI 10.1210/me.2010-0469; Lanzino M, 2010, NUCLEIC ACIDS RES, V38, P5351, DOI 10.1093/nar/gkq278; Lin BY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006589; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; MARTINERIE C, 1992, ONCOGENE, V7, P2529; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; McCallum L, 2009, BLOOD REV, V23, P79, DOI 10.1016/j.blre.2008.07.002; McCallum L, 2006, BLOOD, V108, P1716, DOI 10.1182/blood-2006-04-016113; Ohgawara T, 2011, J CELL COMMUN SIGNAL, V5, P291, DOI 10.1007/s12079-011-0133-3; Ouellet V, 2011, AM J PATHOL, V178, P2377, DOI 10.1016/j.ajpath.2011.01.033; Perbal B, 2008, J CELL COMMUN SIGNAL, V2, P3, DOI 10.1007/s12079-008-0028-0; Sin WC, 2009, J BIOL CHEM, V284, P29935, DOI 10.1074/jbc.M109.042630; Vallacchi V, 2008, CANCER RES, V68, P715, DOI 10.1158/0008-5472.CAN-07-2103; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wang XD, 2007, DIFFERENTIATION, V75, P219, DOI 10.1111/j.1432-0436.2006.00135.x; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Yu J, 2010, ONCOGENE, V29, P5370, DOI 10.1038/onc.2010.269; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111; Zuo GW, 2010, HISTOL HISTOPATHOL, V25, P795, DOI 10.14670/HH-25.795	38	35	37	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					504	513		10.1038/onc.2012.602	http://dx.doi.org/10.1038/onc.2012.602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318417	Green Accepted			2022-12-17	WOS:000330214600011
J	Bergholz, J; Zhang, Y; Wu, J; Meng, L; Walsh, EM; Rai, A; Sherman, MY; Xiao, ZXJ				Bergholz, J.; Zhang, Y.; Wu, J.; Meng, L.; Walsh, E. M.; Rai, A.; Sherman, M. Y.; Xiao, Z-X Jim			Delta Np63 alpha regulates Erk signaling via MKP3 to inhibit cancer metastasis	ONCOGENE			English	Article						p63; MKP3; Erk; metastasis; cancer	SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; LUNG-CANCER; BREAST-CANCER; UP-REGULATION; P53 HOMOLOG; EPITHELIAL DEVELOPMENT; PANCREATIC-CANCER; DOWN-REGULATION; GROWTH-FACTOR	Reduced expression of the p53 family member p63 has been suggested to play a causative role in cancer metastasis. Here, we show that Delta Np63 alpha, the predominant p63 isoform, plays a major role in regulation of cell migration, invasion and cancer metastasis. We identified mitogen-activated protein (MAP) kinase phosphatase 3 (MKP3) as a downstream target of Delta Np63 alpha that is required for mediating these effects. We show that Delta Np63 alpha regulates extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) activity via MKP3 in both cancer and non-transformed cells. We further show that exogenous Delta Np63 alpha inhibits cell invasion and is dependent on MKP3 upregulation for repression. Conversely, endogenous pan-p63 ablation results in increased cell migration and invasion, which can be reverted by reintroducing the Delta Np63 alpha isoform alone, but not by other isoforms. Interestingly, these effects require Erk2, but not Erk1 expression, and can be rescued by enforced MKP3 expression. Moreover, MKP3 expression is reduced in invasive cancers, and reduced p63 expression increases metastatic frequency in vivo. Taken together, these results suggest an important role for Delta Np63 alpha in preventing cancer metastasis by inhibition of Erk2 signaling via MKP3.	[Bergholz, J.; Wu, J.; Meng, L.; Walsh, E. M.; Rai, A.; Sherman, M. Y.; Xiao, Z-X Jim] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Bergholz, J.; Zhang, Y.; Xiao, Z-X Jim] Sichuan Univ, Ctr Growth Metab & Aging, Coll Life Sci, Chengdu 610014, Sichuan, Peoples R China; [Bergholz, J.; Zhang, Y.; Xiao, Z-X Jim] Sichuan Univ, State Key Lab Biotherapy, Chengdu 610014, Sichuan, Peoples R China	Boston University; Sichuan University; Sichuan University	Xiao, ZXJ (corresponding author), Sichuan Univ, Ctr Growth Metab & Aging, Coll Life Sci, 29 Wangjiang Rd, Chengdu 610014, Sichuan, Peoples R China.	jimzx@scu.edu.cn			NIH [CA79804, GM70017]; National Key Basic Research Program (973 Program) of China [2012CB910700]; United States Department of Defense [W81XWH-10-1-0161]; NATIONAL CANCER INSTITUTE [R01CA079804] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070017] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Key Basic Research Program (973 Program) of China(National Basic Research Program of China); United States Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Frank McKeon (Harvard Medical School, Boston, MA, USA) for providing the myc-tagged murine pcDNA3-Delta Np63 alpha, pcDNA3-Delta Np63 gamma, pcDNA3-TAp63 alpha and pcDNA3-TAp63 gamma expression plasmids, and Dr Tyler Jacks (Massachusetts Institute of Technology, Cambridge, MA, USA) for providing a plasmid encoding shRNA against human MKP3. We also thank Dr Xixi Cao (Baylor College of Medicine) for help with Oncomine bioinformatics analysis. This work was supported by NIH grants (CA79804 and GM70017) and by the National Key Basic Research Program (973 Program) of China (2012CB910700) to Z-XJX, and United States Department of Defense Congressionally Directed Medical Research Programs grant (W81XWH-10-1-0161) to JB.	Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dumesic PA, 2009, J CELL BIOL, V185, P409, DOI 10.1083/jcb.200804038; Eicheler W, 2002, J HISTOCHEM CYTOCHEM, V50, P197, DOI 10.1177/002215540205000207; Ekerot M, 2008, BIOCHEM J, V412, P287, DOI 10.1042/BJ20071512; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fu SW, 2003, BREAST CANCER RES, V5, pR82, DOI 10.1186/bcr602; Fukushima H, 2009, CANCER RES, V69, P9263, DOI 10.1158/0008-5472.CAN-09-1188; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gonfloni S, 2009, NAT MED, V15, P1179, DOI 10.1038/nm.2033; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Higashikawa K, 2007, CANCER RES, V67, P9207, DOI 10.1158/0008-5472.CAN-07-0932; Higashikawa K, 2009, INT J CANCER, V124, P2837, DOI 10.1002/ijc.24280; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jinnin M, 2005, NUCLEIC ACIDS RES, V33, P3540, DOI 10.1093/nar/gki648; Karlsson M, 2004, J BIOL CHEM, V279, P41882, DOI 10.1074/jbc.M406720200; Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kommagani R, 2009, J CELL SCI, V122, P2828, DOI 10.1242/jcs.049619; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kuo LY, 2006, J CELL PHYSIOL, V207, P729, DOI 10.1002/jcp.20616; Li CY, 2007, DEVELOPMENT, V134, P167, DOI 10.1242/dev.02701; Lindsay J, 2011, J BIOL CHEM, V286, P3915, DOI 10.1074/jbc.M110.162511; Liu J, 2006, MOL CANCER RES, V4, P803, DOI 10.1158/1541-7786.MCR-06-0201; Liu SY, 2005, CELL PHYSIOL BIOCHEM, V16, P207, DOI 10.1159/000089846; Maillet M, 2008, J BIOL CHEM, V283, P31246, DOI 10.1074/jbc.M806085200; Massion PP, 2003, CANCER RES, V63, P7113; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Meng L, 2010, ONCOGENE, V29, P5204, DOI 10.1038/onc.2010.277; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Okudela K, 2009, AM J PATHOL, V175, P867, DOI 10.2353/ajpath.2009.080489; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shalom-Feuerstein R, 2011, CELL DEATH DIFFER, V18, P887, DOI 10.1038/cdd.2010.159; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Su H, 2003, CANCER RES, V63, P3872; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Talbot SG, 2005, CANCER RES, V65, P3063, DOI 10.1158/0008-5472.CAN-04-1985; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Vanaja DK, 2003, CANCER RES, V63, P3877; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Xu SH, 2005, J HUM GENET, V50, P159, DOI 10.1007/s10038-005-0235-y; Yamamoto T, 2006, CURR BIOL, V16, P1171, DOI 10.1016/j.cub.2006.04.044; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	69	35	36	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					212	224		10.1038/onc.2012.564	http://dx.doi.org/10.1038/onc.2012.564			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23246965	Green Accepted			2022-12-17	WOS:000329440700009
J	Hayes, KE; Walk, EL; Ammer, AG; Kelley, LC; Martin, KH; Weed, SA				Hayes, K. E.; Walk, E. L.; Ammer, A. G.; Kelley, L. C.; Martin, K. H.; Weed, S. A.			Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop	ONCOGENE			English	Article						abl; imatinib mesylate; invadopodia; invasion; head and neck cancer; cortactin	SRC FAMILY KINASES; PHASE-II TRIAL; GROWTH-FACTOR; C-ABL; BREAST-CANCER; TYROSINE PHOSPHORYLATION; LUNG-CANCER; MATRIX-METALLOPROTEINASE; SARACATINIB AZD0530; IMATINIB MESYLATE	Head and neck squamous cell carcinoma (HNSCC) has a proclivity for locoregional invasion. HNSCC mediates invasion in part through invadopodia-based proteolysis of the extracellular matrix (ECM). Activation of Src, Erk1/2, Abl and Arg downstream of epidermal growth factor receptor (EGFR) modulates invadopodia activity through phosphorylation of the actin regulatory protein cortactin. In MDA-MB-231 breast cancer cells, Abl and Arg function downstream of Src to phosphorylate cortactin, promoting invadopodia ECM degradation activity and thus assigning a pro-invasive role for Ableson kinases. We report that Abl kinases have an opposite, negative regulatory role in HNSCC where they suppress invadopodia and tumor invasion. Impairment of Abl expression or Abl kinase activity with imatinib mesylate enhanced HNSCC matrix degradation and 3D collagen invasion, functions that were impaired in MDA-MB-231. HNSCC lines with elevated EGFR and Src activation did not contain increased Abl or Arg kinase activity, suggesting that Src could bypass Abl/Arg to phosphorylate cortactin and promote invadopodia ECM degradation. Src-transformed Abl(-/-)/Arg(-/-) fibroblasts produced ECM degrading invadopodia containing pY421 cortactin, indicating that Abl/Arg are dispensable for invadopodia function in this system. Imatinib-treated HNSCC cells had increased EGFR, Erk1/2 and Src activation, enhancing cortactin pY421 and pS405/418 required for invadopodia function. Imatinib stimulated shedding of the EGFR ligand heparin-binding EGF-like growth factor (HB-EGF) from HNSCC cells, where soluble HB-EGF enhanced invadopodia ECM degradation in HNSCC but not in MDA-MB-231. HNSCC cells treated with inhibitors of the EGFR-invadopodia pathway indicated that EGFR and Src are required for invadopodia function. Collectively, our results indicate that Abl kinases negatively regulate HNSCC invasive processes through suppression of an HB-EGF autocrine loop responsible for activating a EGFR-Src-cortactin cascade, in contrast to the invasion promoting functions of Abl kinases in breast and other cancer types. Our results provide mechanistic support for recent failed HNSCC clinical trials utilizing imatinib.	[Hayes, K. E.; Walk, E. L.; Ammer, A. G.; Kelley, L. C.; Martin, K. H.; Weed, S. A.] W Virginia Univ, Mary Babb Randolph Canc Ctr, Program Canc Cell Biol, Dept Neurobiol & Anat, Morgantown, WV 26506 USA	West Virginia University	Weed, SA (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr Morgantown, Morgantown, WV 26506 USA.	scweed@hsc.wvu.edu		Martin, Karen/0000-0001-8916-4092; Weed, Scott/0000-0001-7033-9999	NIH [R01 DE014578, P20 RR16440]; West Virginia University Mary Babb Randolph Cancer Center; Mary Babb Randolph Cancer, NIH [P20 RR16440, P30 RR032138/GM103488]; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016440, P30RR032138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103488] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); West Virginia University Mary Babb Randolph Cancer Center; Mary Babb Randolph Cancer, NIH; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Bruce Mayer (University of Connecticut) for Abl constructs, Anthony Koleske (Yale University) for Abl<SUP>-/-</SUP>/Arg<SUP>-/-</SUP> fibroblasts, Silja Wessler (Paul-Ehrlich Institute) for the Abl shRNA construct, Elena Pugacheva (West Virginia University) for MDA-MB-231LN cells, Jim Bear (University of North Carolina) for pLL5.0 and advice on spheroid assay development. We thank Mark Auble and Barbara Frederick for technical assistance. Saracatinib and gefitinib were provided by AstraZeneca. This study was supported by NIH Grants R01 DE014578, P20 RR16440 (to SAW) and the West Virginia University Mary Babb Randolph Cancer Center. The West Virginia University Microscopy Imaging Facility (supported by the Mary Babb Randolph Cancer, NIH Grants P20 RR16440 and P30 RR032138/GM103488) is gratefully acknowledged.	Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412; Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296; Ammer Amanda Gatesman, 2009, J Cancer Sci Ther, V1, P52; Antoku S, 2008, J CELL SCI, V121, P3071, DOI 10.1242/jcs.031575; Araujo JC, 2012, CANCER-AM CANCER SOC, V118, P63, DOI 10.1002/cncr.26204; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Boyle SN, 2007, CURR BIOL, V17, P445, DOI 10.1016/j.cub.2007.01.057; Bradley WD, 2009, J CELL SCI, V122, P3441, DOI 10.1242/jcs.039859; Brooks HD, 2011, CANCER-AM CANCER SOC, V117, P2112, DOI 10.1002/cncr.25769; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; Cai L, 2008, CELL, V134, P828, DOI 10.1016/j.cell.2008.06.054; Montero JC, 2011, CLIN CANCER RES, V17, P5546, DOI 10.1158/1078-0432.CCR-10-2616; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0021428, 10.1371/journal.pone.0017876, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0027333, 10.1371/journal.pone.0017844, 10.1371/journal.pone.0024144]; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Colicelli J, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3139re6; Destaing O, 2011, CURR OPIN CELL BIOL, V23, P597, DOI 10.1016/j.ceb.2011.04.002; Ernst T, 2012, SEMIN ONCOL, V39, P58, DOI 10.1053/j.seminoncol.2011.11.002; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Fung C, 2010, EXPERT OPIN EMERG DR, V15, P355, DOI 10.1517/14728214.2010.497754; Furlan A, 2011, CELL DEATH DIFFER, V18, P1608, DOI 10.1038/cdd.2011.23; Fury MG, 2011, ANTICANCER RES, V31, P249; Ganguly SS, 2011, ONCOGENE, P5; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Gucalp A, 2011, CLIN BREAST CANCER, V11, P306, DOI 10.1016/j.clbc.2011.03.021; Hama T, 2012, CLIN EXP METASTAS, V29, P19, DOI 10.1007/s10585-011-9425-5; Hama T, 2009, ONCOLOGIST, V14, P900, DOI 10.1634/theoncologist.2009-0058; Hatakeyama H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012702; Haura EB, 2010, J CLIN ONCOL, V28, P1387, DOI 10.1200/JCO.2009.25.4029; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang YT, 2002, INT J CANCER, V99, P505, DOI 10.1002/ijc.10373; Johnson FM, 2005, J CELL PHYSIOL, V205, P218, DOI 10.1002/jcp.20383; Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; Kelley LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013847; Kelley LC, 2010, J CELL SCI, V123, P3923, DOI 10.1242/jcs.075200; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kirkbride KC, 2011, CELL ADHES MIGR, V5, P187, DOI 10.4161/cam.5.2.14773; Koppikar P, 2008, CLIN CANCER RES, V14, P4284, DOI 10.1158/1078-0432.CCR-07-5226; Lapetina S, 2009, J CELL BIOL, V185, P503, DOI 10.1083/jcb.200809085; Lara PN, 2009, ANTI-CANCER DRUG, V20, P179, DOI 10.1097/CAD.0b013e328325a867; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Liberatore RA, 2009, P NATL ACAD SCI USA, V106, P17823, DOI 10.1073/pnas.0905935106; Lin J, 2007, ONCOGENE, V26, P6989, DOI 10.1038/sj.onc.1210500; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Martin KH, 2012, JOVE-J VIS EXP, DOI 10.3791/4119; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Neiva KG, 2009, NEOPLASIA, V11, P583, DOI 10.1593/neo.09266; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; O-charoenrat P, 2000, CANCER RES, V60, P1121; Ohnishi Y, 2012, ONCOL REP, V27, P954, DOI 10.3892/or.2011.1616; Oser M, 2010, J CELL SCI, V123, P3662, DOI 10.1242/jcs.068163; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Plattner R, 2004, MOL CELL BIOL, V24, P2573, DOI 10.1128/mcb.24.6.2573-2583.2004; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, CELL CYCLE, V2, P273, DOI 10.4161/cc.2.4.409; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Poppe M, 2007, ONCOGENE, V26, P3462, DOI 10.1038/sj.onc.1210139; Pryor DI, 2011, ASIA-PAC J CLIN ONCO, V7, P236, DOI 10.1111/j.1743-7563.2011.01420.x; Ren G, 2009, CELL MOTIL CYTOSKEL, V66, P865, DOI 10.1002/cm.20380; Rothsschild BL, 2006, CANCER RES, V66, P8017, DOI 10.1158/0008-5472.CAN-05-4490; Sen B, 2009, CANCER RES, V69, P1958, DOI 10.1158/0008-5472.CAN-08-2944; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Sibony-Benyamini H, 2012, EUR J CELL BIOL, V91, P896, DOI 10.1016/j.ejcb.2012.04.001; Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Tsao AS, 2011, J THORAC ONCOL, V6, P2104, DOI 10.1097/JTO.0b013e31822e7256; Uribe P, 2011, PATHOL RES PRACT, V207, P337, DOI 10.1016/j.prp.2011.03.002; Wang F, 2007, ONCOGENE, V26, P2006, DOI 10.1038/sj.onc.1209999; Wang Y, 2011, INT J HEMATOL, V94, P552, DOI 10.1007/s12185-011-0953-1; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Webb BA, 2007, EUR J CELL BIOL, V86, P189, DOI 10.1016/j.ejcb.2007.01.003; Wheeler DL, 2009, CANCER BIOL THER, V8, P696, DOI 10.4161/cbt.8.8.7903; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yanagawa T, 2000, ORAL ONCOL, V36, P89, DOI 10.1016/S1368-8375(99)00067-6; Yang JL, 2005, CANCER LETT, V225, P61, DOI 10.1016/j.canlet.2004.11.041; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002	87	35	35	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4766	4777		10.1038/onc.2012.513	http://dx.doi.org/10.1038/onc.2012.513			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23146907	Green Accepted			2022-12-17	WOS:000325274700005
J	Kulak, MV; Cyr, AR; Woodfield, GW; Bogachek, M; Spanheimer, PM; Li, T; Price, DH; Domann, FE; Weigel, RJ				Kulak, M. V.; Cyr, A. R.; Woodfield, G. W.; Bogachek, M.; Spanheimer, P. M.; Li, T.; Price, D. H.; Domann, F. E.; Weigel, R. J.			Transcriptional regulation of the GPX1 gene by TFAP2C and aberrant CpG methylation in human breast cancer	ONCOGENE			English	Article						TFAP2C; GPX1; breast cancer; oxidative stress	OXIDATIVE STRESS; PRO198LEU POLYMORPHISM; ACTIVATOR PROTEIN-2; CELL-LINES; EXPRESSION; AP-2; RECEPTOR; OVEREXPRESSION; CLONING; FAMILY	The complexity of gene regulation has created obstacles to defining mechanisms that establish the patterns of gene expression characteristic of the different clinical phenotypes of breast cancer. TFAP2C is a transcription factor that has a critical role in the regulation of both estrogen receptor-alpha (ER alpha) and c-ErbB2/HER2 (Her2). Herein, we performed chromatin immunoprecipitation and direct sequencing (ChIP-seq) for TFAP2C in four breast cancer cell lines. Comparing the genomic binding sites for TFAP2C, we identified that glutathione peroxidase (GPX1) is regulated by TFAP2C through an AP-2 regulatory region in the promoter of the GPX1 gene. Knockdown of TFAP2C, but not the related factor TFAP2A, resulted in an abrogation of GPX1 expression. Selenium-dependent GPX activity correlated with endogenous GPX1 expression and overexpression of exogenous GPX1 induced GPX activity and significantly increased resistance to tert-butyl hydroperoxide. Methylation of the CpG island encompassing the AP-2 regulatory region was identified in cell lines where TFAP2C failed to bind the GPX1 promoter and GPX1 expression was unresponsive to TFAP2C. Furthermore, in cell lines where GPX1 promoter methylation was associated with gene silencing, treatment with 5'-aza-2-deoxycytidine (5'-aza-dC) (an inhibitor of DNA methylation) allowed TFAP2C to bind to the GPX1 promoter resulting in the activation of GPX1 RNA and protein expression. Methylation of the GPX1 promoter was identified in similar to 20% of primary breast cancers and a highly significant correlation between the TFAP2C and GPX1 expression was confirmed when considering only those tumors with an unmethylated promoter, whereas the related factor, TFAP2A, failed to demonstrate a correlation. The results demonstrate that TFAP2C regulates the expression of GPX1, which influences the redox state and sensitivity to oxidative stress induced by peroxides. Given the established role of GPX1 in breast cancer, the results provide an important mechanism for TFAP2C to further influence oncogenesis and progression of breast carcinoma cells.	[Kulak, M. V.; Woodfield, G. W.; Bogachek, M.; Spanheimer, P. M.; Weigel, R. J.] Univ Iowa, Dept Surg, Iowa City, IA 52242 USA; [Cyr, A. R.; Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Iowa City, IA 52242 USA; [Li, T.; Price, D. H.; Weigel, R. J.] Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Weigel, RJ (corresponding author), Univ Iowa, Dept Surg, 200 Hawkins Dr,1516 JCP, Iowa City, IA 52242 USA.	Ronald-Weigel@uiowa.edu	Li, Tiandao/F-4039-2012	Li, Tiandao/0000-0003-1650-0555; Kulak, Mikhail/0000-0002-4307-5868; Price, David/0000-0002-5597-385X; Domann, Frederick/0000-0002-0489-2179; Weigel, Ronald/0000-0002-9249-0793	National Institutes of Health [R01CA109294, R01CA115438, F30 AA019856, T32CA148062]; NATIONAL CANCER INSTITUTE [R01CA109294, T32CA078586, T32CA148062, R01CA115438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [F30AA019856] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We appreciate tumor samples provided by Dr Ryan Askeland and Christine Hochstedler (Department of Pathology, University of Iowa) and statistical support from Dr Junlin Liao (Department of Surgery, University of Iowa). This work was supported in part by the National Institutes of Health grants R01CA109294 (PI: RJ Weigel) and R01CA115438 (PI: FE Domann). Anthony Cyr received salary support from NIH F30 AA019856 and Dr Philip Spanheimer was supported by the NIH grant T32CA148062 (PI: RJ Weigel). The work was also supported by a generous gift from the Kristen Olewine Milke Breast Cancer Research Fund.	Allouche A, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1851; Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200; Bosher JM, 1996, ONCOGENE, V13, P1701; Brown NS, 2001, BREAST CANCER RES, V3, P323, DOI 10.1186/bcr315; Buzdar AU, 2009, ANN ONCOL, V20, P993, DOI 10.1093/annonc/mdn739; Cox DG, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-217; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; Do Jee C, 2009, EUR J CANCER, V45, P1282, DOI 10.1016/j.ejca.2008.12.027; Eckert D, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-13-246; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Esposito LA, 2000, FREE RADICAL BIO MED, V28, P754, DOI 10.1016/S0891-5849(00)00161-1; Feng WG, 2003, MOL CELL NEUROSCI, V24, P460, DOI 10.1016/S1044-7431(03)00209-4; Gao JP, 2008, BBA-MOL CELL RES, V1783, P2020, DOI 10.1016/j.bbamcr.2008.05.027; Gouaze V, 2001, MOL PHARMACOL, V60, P488; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Hannay JAF, 2007, MOL CANCER THER, V6, P1650, DOI 10.1158/1535-7163.MCT-06-0636; He AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-279; Hu J, 2010, BREAST CANCER RES TR, V124, P425, DOI 10.1007/s10549-010-0841-z; Hu YJ, 2005, J NUTR, V135, p3021S, DOI 10.1093/jn/135.12.3021S; Hu YJ, 2003, CANCER RES, V63, P3347; Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20073, 10.3322/caac.20105]; Jenssen TK, 2002, HUM GENET, V111, P411, DOI 10.1007/s00439-002-0804-5; Johansson K, 2010, FREE RADICAL BIO MED, V49, P1638, DOI 10.1016/j.freeradbiomed.2010.08.013; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Maiti AK, 2012, INT J CANCER, V130, P1, DOI 10.1002/ijc.26306; McPherson LA, 1999, NUCLEIC ACIDS RES, V27, P4040, DOI 10.1093/nar/27.20.4040; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; McPherson LA, 2002, J BIOL CHEM, V277, P45028, DOI 10.1074/jbc.M208924200; MOSER M, 1995, DEVELOPMENT, V121, P2779; Pellikainen J, 2004, EUR J CANCER, V40, P1485, DOI 10.1016/j.ejca.2004.02.020; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; Ravn-Haren G, 2006, CARCINOGENESIS, V27, P820, DOI 10.1093/carcin/bgi267; Schumacker PT, 2006, CANCER CELL, V10, P175, DOI 10.1016/j.ccr.2006.08.015; Scibetta AG, 2010, CELL CYCLE, V9, P4525, DOI 10.4161/cc.9.22.13746; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Tan SK, 2011, EMBO J, V30, P2569, DOI 10.1038/emboj.2011.151; Thewes V, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-192; TOWNSEND AJ, 1991, CANCER COMMUN, V3, P265, DOI 10.3727/095535491820873119; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Turner BC, 1998, CANCER RES, V58, P5466; Vibet S, 2008, FREE RADICAL BIO MED, V44, P1483, DOI 10.1016/j.freeradbiomed.2008.01.009; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Woodfield GW, 2007, CANCER RES, V67, P8439, DOI 10.1158/0008-5472.CAN-07-2293; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Woodfield GW, 2009, CLIN CANCER RES, V15, P3672, DOI 10.1158/1078-0432.CCR-08-2343; Yang JW, 2006, FEBS LETT, V580, P6501, DOI 10.1016/j.febslet.2006.10.059; Yu L, 2009, J ONCOL, V2009, DOI 10.1155/2009/780874; Zhao F, 2001, J BIOL CHEM, V276, P40755, DOI 10.1074/jbc.M106284200; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200; Zhuo P, 2009, CANCER RES, V69, P8183, DOI 10.1158/0008-5472.CAN-09-1791	53	35	41	0	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					4043	4051		10.1038/onc.2012.400	http://dx.doi.org/10.1038/onc.2012.400			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	22964634	Green Accepted			2022-12-17	WOS:000323748100013
J	Chen, M; Bresnick, AR; O'Connor, KL				Chen, M.; Bresnick, A. R.; O'Connor, K. L.			Coupling S100A4 to Rhotekin alters Rho signaling output in breast cancer cells	ONCOGENE			English	Article						Rho; Rhotekin; S100A4/metastasin; lamellipodia; invasive growth	NONMUSCLE MYOSIN-II; ALPHA-6-BETA-4 INTEGRIN; LAMELLAE FORMATION; CARCINOMA CELLS; IN-VIVO; METASTASIS; PROTEIN; ACTIVATION; MIGRATION; EFFECTOR	Rho signaling is increasingly recognized to contribute to invasion and metastasis. In this study, we discovered that metastasis-associated protein S100A4 interacts with the Rho-binding domain (RBD) of Rhotekin, thus connecting S100A4 to the Rho pathway. Glutathione S-transferase pull-down and immunoprecipitation assays demonstrated that S100A4 specifically and directly binds to Rhotekin RBD, but not the other Rho effector RBDs. S100A4 binding to Rhotekin is calcium-dependent and uses residues distinct from those bound by active Rho. Interestingly, we found that S100A4 and Rhotekin can form a complex with active RhoA. Using RNA interference, we determined that suppression of both S100A4 and Rhotekin leads to loss of Rho-dependent membrane ruffling in response to epidermal growth factor, an increase in contractile F-actin 'stress' fibers and blocks invasive growth in three-dimensional culture. Accordingly, our data suggest that interaction of S100A4 and Rhotekin permits S100A4 to complex with RhoA and switch Rho function from stress fiber formation to membrane ruffling to confer an invasive phenotype.	[Chen, M.; O'Connor, K. L.] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40506 USA; [Bresnick, A. R.] Albert Einstein Coll Med, Bronx, NY 10467 USA	University of Kentucky; Yeshiva University; Albert Einstein College of Medicine	O'Connor, KL (corresponding author), Univ Kentucky, Markey Canc Ctr, 741 South Limestone St, Lexington, KY 40506 USA.	mch235@uky.edu; kloconnor@uky.edu	O'Connor, Kathleen L/H-2569-2013	O'Connor, Kathleen L/0000-0002-1088-9734	National Institutes of Health [CA109136, CA129598]; NATIONAL CANCER INSTITUTE [R01CA109136, R01CA129598] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Ren Xu for his kind aid with 3D culture-related experiments; Dr Jianhang Jia for assistance with the confocal microscopy analysis; Drs Tianyan Gao and Jianyu Liu for reagents and technical support for generating shRNA stable cell line; Drs Kohich Nagata, Shuh Narumiya and G Steven Martin for reagents; Dr Juanjuan Yang for validating select data; and Diane Wright for assistance with graphics. This work was supported with National Institutes of Health Grants CA109136 (KLO) and CA129598 (ARB).	Andersen K, 2011, DEV BIOL, V352, P181, DOI 10.1016/j.ydbio.2010.12.033; Berdeaux RL, 2004, J CELL BIOL, V166, P317, DOI 10.1083/jcb.200312168; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Boye K, 2010, AM J PATHOL, V176, P528, DOI 10.2353/ajpath.2010.090526; Chen M, 2007, AM J PHYSIOL-CELL PH, V292, pC1927, DOI 10.1152/ajpcell.00400.2006; Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Fujisawa K, 1998, J BIOL CHEM, V273, P18943, DOI 10.1074/jbc.273.30.18943; Fukata Y, 1999, J CELL BIOL, V145, P347, DOI 10.1083/jcb.145.2.347; Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Ito H, 2005, ONCOGENE, V24, P7064, DOI 10.1038/sj.onc.1208862; Ito H, 2006, NEUROSCI RES, V56, P165, DOI 10.1016/j.neures.2006.06.014; Kelloff GJ, 1997, CANCER EPIDEM BIOMAR, V6, P267; Kim EJ, 2003, J BIOL CHEM, V278, P30063, DOI 10.1074/jbc.M304909200; Kurokawa K, 2005, MOL BIOL CELL, V16, P4294, DOI 10.1091/mbc.E04-12-1076; Li ZH, 2003, BIOCHEMISTRY-US, V42, P14258, DOI 10.1021/bi0354379; Li ZH, 2006, CANCER RES, V66, P5173, DOI 10.1158/0008-5472.CAN-05-3087; Li ZH, 2010, MOL BIOL CELL, V21, P2598, DOI 10.1091/mbc.E09-07-0609; Liu CA, 2004, ONCOGENE, V23, P8731, DOI 10.1038/sj.onc.1208106; Liu CA, 2004, J BIOMED SCI, V11, P661, DOI 10.1159/000079679; Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242; Nagata K, 2009, MED MOL MORPHOL, V42, P9, DOI 10.1007/s00795-008-0433-8; Narumiya S, 2009, CANCER METAST REV, V28, P65, DOI 10.1007/s10555-008-9170-7; Nishiyama T, 1994, MOL CELL BIOL, V14, P2247; O'Connor KL, 2012, AM J PHYSIOL-CELL PH, V302, pC605, DOI 10.1152/ajpcell.00095.2011; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; O'Connor KL, 2000, J CELL BIOL, V148, P253, DOI 10.1083/jcb.148.2.253; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Pille JY, 2005, MOL THER, V11, P267, DOI 10.1016/j.ymthe.2004.08.029; Pusapati GV, 2012, J BIOL CHEM, V287, P9473, DOI 10.1074/jbc.M112.339564; Reid T, 1996, J BIOL CHEM, V271, P13556, DOI 10.1074/jbc.271.23.13556; Rudland PS, 2000, CANCER RES, V60, P1595; Sandquist JC, 2006, J BIOL CHEM, V281, P35873, DOI 10.1074/jbc.M605343200; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Sudo K, 2006, NEUROSCI RES, V56, P347, DOI 10.1016/j.neures.2006.08.003; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; Trusolino L, 2002, NAT REV CANCER, V2, P289, DOI 10.1038/nrc779; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; Vallely KM, 2002, BIOCHEMISTRY-US, V41, P12670, DOI 10.1021/bi020365r; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vicente-Manzanares M, 2009, NAT REV MOL CELL BIO, V10, P778, DOI 10.1038/nrm2786; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Wu D, 2009, ONCOGENE, V28, P2219, DOI 10.1038/onc.2009.96; Wyckoff JB, 2000, CANCER RES, V60, P2504; Xu R, 2007, J BIOL CHEM, V282, P14992, DOI 10.1074/jbc.M610316200; Ying-Tao Z, 2005, EUR J GASTROEN HEPAT, V17, P725, DOI 10.1097/00042737-200507000-00006; Zhao XS, 2009, CANCER RES, V69, P483, DOI 10.1158/0008-5472.CAN-08-2907	49	35	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2013	32	32					3754	3764		10.1038/onc.2012.383	http://dx.doi.org/10.1038/onc.2012.383			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	22964635	Green Accepted, Green Published			2022-12-17	WOS:000322904400010
J	Chen, J; Abi-Daoud, M; Wang, A; Yang, X; Zhang, X; Feilotter, HE; Tron, VA				Chen, J.; Abi-Daoud, M.; Wang, A.; Yang, X.; Zhang, X.; Feilotter, H. E.; Tron, V. A.			Stathmin 1 is a potential novel oncogene in melanoma	ONCOGENE			English	Article						STMN1; miR-193b; melanoma; oncogene	HUMAN BREAST-CANCER; PROSTATE-CANCER; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; MALIGNANT-MELANOMA; MICRORNA TARGETS; LUNG-CANCER; EXPRESSION; OVEREXPRESSION; PROGRESSION	In previous studies, we demonstrated that miR-193b expression is reduced in melanoma relative to benign nevi, and also that miR193b represses cyclin D1 and Mcl-1 expression. We suggested that stathmin 1 (STMN1) might be a target of miR-193b. STMN1 normally regulates microtubule dynamics either by sequestering free tubulin heterodimers or by promoting microtubule catastrophe. Increased expression of STMN1 has been observed in a variety of human malignancies, but its association with melanoma is unknown. We now report that STMN1 is upregulated during the progression of melanoma relative to benign nevi, and that STMN1 is directly regulated by miR-193b. Using an experimental cell culture approach, overexpression of miR-193b using synthetic microRNAs repressed STMN1 expression, whereas inhibition of miR-193b with anti-miR oligos increased STMN1 expression in melanoma cells. The use of a luciferase reporter assay confirmed that miR-193b directly regulates STMN1 by targeting the 3'-untranslated region of STMN1 mRNA. We further demonstrated that STMN1 is overexpressed in malignant melanoma compared with nevi in two independent melanoma cohorts, and that its level is inversely correlated with miR-193b expression. However, STMN1 expression was not significantly associated with patient survival, Breslow depth, mitotic count or patient age. STMN1 knockdown by small-interfering RNA in melanoma cells drastically repressed cell proliferation and migration potential, whereas ectopic expression of STMN1 using lentivirus increased cell proliferation and migration rates. Subsequent gene expression analysis indicated that interconnected cytoskeletal networks are directly affected following STMN1 knockdown. In addition, we identified deregulated genes associated with proliferation and migration, and revealed that p21(Cip1/Waf1) and p27(Kip) could be downstream effectors of STMN1 signaling. Taken together, our study suggests that downregulation of miR-193b may contribute to increased STMN1 expression in melanoma, which consequently promotes migration and proliferation of tumor cells. Oncogene (2013) 32, 1330-1337; doi:10.1038/onc.2012.141; published online 4 June 2012	[Chen, J.; Abi-Daoud, M.; Wang, A.; Yang, X.; Zhang, X.; Feilotter, H. E.; Tron, V. A.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada	Tron, VA (corresponding author), Queens Univ, Dept Pathol & Mol Med, Richardson Lab, 88 Stuart St,Room 202, Kingston, ON K7L 3N6, Canada.	tronv@queensu.ca			Canadian Institutes of Health Research (CIHR) Grant; Queen's University Terry Fox Foundation Training Program in Transdisciplinary Cancer Research; CIHR	Canadian Institutes of Health Research (CIHR) Grant(Canadian Institutes of Health Research (CIHR)); Queen's University Terry Fox Foundation Training Program in Transdisciplinary Cancer Research; CIHR(Canadian Institutes of Health Research (CIHR))	This work is supported by the Canadian Institutes of Health Research (CIHR) Grant (VAT; HEF). JC is funded in part by the Queen's University Terry Fox Foundation Training Program in Transdisciplinary Cancer Research in partnership with CIHR.	Akslen LA, 2005, J INVEST DERMATOL, V125, P312, DOI 10.1111/j.0022-202X.2005.23788.x; Andersen SSL, 1997, NATURE, V389, P640, DOI 10.1038/39382; Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Boyle GM, 2011, PIGM CELL MELANOMA R, V24, P525, DOI 10.1111/j.1755-148X.2011.00849.x; Buhusi M, 2003, J BIOL CHEM, V278, P25024, DOI 10.1074/jbc.M303084200; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Chen G, 2003, MOL CELL PROTEOMICS, V2, P107, DOI 10.1074/mcp.M200055-MCP200; Chen JM, 2011, AM J PATHOL, V179, P2162, DOI 10.1016/j.ajpath.2011.07.010; Chen JM, 2010, AM J PATHOL, V176, P2520, DOI 10.2353/ajpath.2010.091061; Cohen C, 2002, CLIN CANCER RES, V8, P3728; Curmi PA, 1999, CELL STRUCT FUNCT, V24, P345; Edlundh-Rose E, 2006, MELANOMA RES, V16, P471, DOI 10.1097/01.cmr.0000232300.22032.86; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fan T, 2011, MOL CANCER RES, V9, P418, DOI 10.1158/1541-7786.MCR-10-0511; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Ghosh R, 2007, PROSTATE, V67, P1038, DOI 10.1002/pros.20601; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Hsieh SY, 2010, MOL CARCINOGEN, V49, P476, DOI 10.1002/mc.20627; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Kumar PS, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-42; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Leivonen SK, 2009, ONCOGENE, V28, P3926, DOI 10.1038/onc.2009.241; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li XF, 2009, ONCOGENE, V28, P3937, DOI 10.1038/onc.2009.245; Li Z, 2011, J BIOL CHEM, V286, P21164, DOI 10.1074/jbc.M110.207571; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452; Niethammer P, 2004, SCIENCE, V303, P1862, DOI 10.1126/science.1094108; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Rauhala HE, 2010, INT J CANCER, V127, P1363, DOI 10.1002/ijc.25162; Rothhammer T, 2007, PIGM CELL RES, V20, P92, DOI 10.1111/j.1600-0749.2007.00367.x; Sayed D, 2011, PHYSIOL REV, V91, P827, DOI 10.1152/physrev.00006.2010; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Singer S, 2009, CANCER RES, V69, P2234, DOI 10.1158/0008-5472.CAN-08-3338; Slipicevic A, 2005, AM J CLIN PATHOL, V124, P528, DOI 10.1309/YT58WWMTA6YR1PRV; Sun ZJ, 2008, BRIT J CANCER, V99, P1656, DOI 10.1038/sj.bjc.6604712; Tong B, 1998, MOL CELL BIOL, V18, P2462, DOI 10.1128/MCB.18.5.2462; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wellen J, 2009, NEUROPHARMACOLOGY, V56, P386, DOI 10.1016/j.neuropharm.2008.09.011; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Zheng P, 2010, J PROTEOME RES, V9, P4897, DOI 10.1021/pr100712t	51	35	36	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 7	2013	32	10					1330	1337		10.1038/onc.2012.141	http://dx.doi.org/10.1038/onc.2012.141			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OP	22665054				2022-12-17	WOS:000316454500013
J	Leskov, I; Pallasch, CP; Drake, A; Iliopoulou, BP; Souza, A; Shen, CH; Schweighofer, CD; Abruzzo, L; Frenzel, LP; Wendtner, CM; Hemann, MT; Chen, J				Leskov, I.; Pallasch, C. P.; Drake, A.; Iliopoulou, B. P.; Souza, A.; Shen, C-H; Schweighofer, C. D.; Abruzzo, L.; Frenzel, L. P.; Wendtner, C. M.; Hemann, M. T.; Chen, J.			Rapid generation of human B-cell lymphomas via combined expression of Myc and Bc12 and their use as a preclinical model for biological therapies	ONCOGENE			English	Article						humanized mouse model; MYC; BCL2; double-hit lymphoma; antibody	SCID IL2R-GAMMA(NULL) MICE; HEMATOPOIETIC STEM-CELLS; CD34(+) CELLS; C-MYC; IN-VIVO; ENFORCED EXPRESSION; BURKITTS-LYMPHOMA; TRANSGENIC MICE; SELF-RENEWAL; BCL-2	Although numerous mouse models of B-cell malignancy have been developed via the enforced expression of defined oncogenic lesions, the feasibility of generating lineage-defined human B-cell malignancies using mice reconstituted with modified human hematopoietic stem cells (HSCs) remains unclear. In fact, whether human cells can be transformed as readily as murine cells by simple oncogene combinations is a subject of considerable debate. Here, we describe the development of humanized mouse model of MYC/BCL2-driven 'double-hit' lymphoma. By engrafting human HSCs transduced with the oncogene combination into immunodeficient mice, we generate a fatal B malignancy with complete penetrance. This humanized-MYC/BCL2-model (hMB) accurately recapitulates the histopathological and clinical aspects of steroid-, chemotherapy- and rituximab-resistant human 'double-hit' lymphomas that involve the MYC and BCL2 loci. Notably, this model can serve as a platform for the evaluation of antibody-based therapeutics. As a proof of principle, we used this model to show that the anti-CD52 antibody alemtuzumab effectively eliminates lymphoma cells from the spleen, liver and peripheral blood, but not from the brain. The hMB humanized mouse model underscores the synergy of MYC and BCL2 in 'double-hit' lymphomas in human patients. Additionally, our findings highlight the utility of humanized mouse models in interrogating therapeutic approaches, particularly human-specific monoclonal antibodies. Oncogene (2013) 32, 1066-1072; doi: 10.1038/onc.2012.117; published online 9 April 2012	[Leskov, I.; Pallasch, C. P.; Drake, A.; Iliopoulou, B. P.; Souza, A.; Shen, C-H; Hemann, M. T.; Chen, J.] MIT, Koch Inst Integrat Canc Res, Dept Biol, Cambridge, MA 02139 USA; [Pallasch, C. P.; Schweighofer, C. D.; Frenzel, L. P.; Wendtner, C. M.] Univ Cologne, Dept Internal Med 1, Ctr Integrated Oncol, D-50931 Cologne, Germany; [Pallasch, C. P.; Abruzzo, L.; Frenzel, L. P.; Wendtner, C. M.] Univ Cologne, Cluster Excellence Cellular Stress Response Aging, D-50931 Cologne, Germany; [Schweighofer, C. D.] UT MD Anderson Canc Ctr Houston, Dept Hematopathol, Houston, TX USA	Massachusetts Institute of Technology (MIT); University of Cologne; University of Cologne; University of Texas System; UTMD Anderson Cancer Center	Hemann, MT (corresponding author), MIT, Koch Inst Integrat Canc Res, Dept Biol, 77 Massachusetts Ave,76-310, Cambridge, MA 02139 USA.	hemann@mit.edu; jchen@mit.edu	Pallasch, Christian Philipp/T-3088-2018	Pallasch, Christian P./0000-0001-5675-6905	Marble Family Foundation; Singapore-MIT Alliance for Research and Technology; NIH [R01-CA128803]; German Research foundation; MIT School of Science Cancer Research Fellowship; Ludwig Academic Graduate Fellowship; Medical Scientist Training Program from the National Institute Of General Medical Sciences [T32GM007753]; NATIONAL CANCER INSTITUTE [P30CA014051, R01CA128803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007753] Funding Source: NIH RePORTER	Marble Family Foundation; Singapore-MIT Alliance for Research and Technology; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research foundation(German Research Foundation (DFG)); MIT School of Science Cancer Research Fellowship; Ludwig Academic Graduate Fellowship; Medical Scientist Training Program from the National Institute Of General Medical Sciences; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank P Bak and Herman Eisen for helpful discussions and the Swanson Biotechnology Center for excellent technical support. This work was partly supported by grants from the Marble Family Foundation (to JC and MTH), Singapore-MIT Alliance for Research and Technology (to JC) and the NIH (R01-CA128803 to MTH). CPP is supported by a research fellowship of the German Research foundation. IL was supported in part by the MIT School of Science Cancer Research Fellowship, the Ludwig Academic Graduate Fellowship and the Medical Scientist Training Program (Grant Number T32GM007753 from the National Institute Of General Medical Sciences). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute Of General Medical Sciences or the National Institutes of Health.	Aukema SM, 2011, BLOOD, V117, P2319, DOI 10.1182/blood-2010-09-297879; Bacher U, 2011, GENE CHROMOSOME CANC, V50, P43, DOI 10.1002/gcc.20831; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Basecke J, 2005, LEUKEMIA LYMPHOMA, V46, P265, DOI 10.1080/10428190400010767; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Buske C, 2001, BLOOD, V97, P2286, DOI 10.1182/blood.V97.8.2286; Chung KY, 2006, CANCER RES, V66, P11781, DOI 10.1158/0008-5472.CAN-06-0706; Chung KY, 2005, BLOOD, V105, P77, DOI 10.1182/blood-2003-12-4445; Gallamini A, 2007, BLOOD, V110, P2316, DOI 10.1182/blood-2007-02-074641; Giassi LJ, 2008, EXP BIOL MED, V233, P997, DOI 10.3181/0802-RM-70; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; Harrington AM, 2011, AM J CLIN PATHOL, V135, P649, DOI 10.1309/AJCPL11MAHISIJBQ; Hasserjian Robert P, 2009, J Hematop, V2, P89, DOI 10.1007/s12308-009-0039-7; Hu YP, 2009, IMMUNOLOGY, V128, P260, DOI 10.1111/j.1365-2567.2009.03115.x; Johnson NA, 2009, BLOOD, V114, P2273, DOI 10.1182/blood-2009-03-212191; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; Li S., 2011, MODERN PATHOL, V25, P145; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; Montes R, 2011, BLOOD, V117, P4746, DOI 10.1182/blood-2010-12-322230; Moreau T, 2004, MOL THER, V10, P45, DOI 10.1016/j.ymthe.2004.04.005; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; Schuringa JJ, 2004, J EXP MED, V200, P623, DOI 10.1084/jem.20041024; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; SmithSorensen B, 1996, J BIOL CHEM, V271, P5513, DOI 10.1074/jbc.271.10.5513; Snuderl M, 2010, AM J SURG PATHOL, V34, P327, DOI 10.1097/PAS.0b013e3181cd3aeb; Stern P, 2008, P NATL ACAD SCI USA, V105, P13895, DOI 10.1073/pnas.0806907105; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Tomita N, 2011, J CLIN EXP HEMATOP, V51, P7, DOI 10.3960/jslrt.51.7; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wendtner CM, 2004, LEUKEMIA, V18, P1093, DOI 10.1038/sj.leu.2403354; Wu D, 2010, AM J CLIN PATHOL, V134, P258, DOI 10.1309/AJCP7YLDTJPLCE5F; Wunderlich M, 2006, BLOOD, V108, P1690, DOI 10.1182/blood-2005-12-012773; Zhang CC, 2008, BLOOD, V111, P3415, DOI 10.1182/blood-2007-11-122119	35	35	41	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					1066	1072		10.1038/onc.2012.117	http://dx.doi.org/10.1038/onc.2012.117			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22484426	Green Accepted, Green Submitted			2022-12-17	WOS:000316523200014
J	Murfuni, I; Nicolai, S; Baldari, S; Crescenzi, M; Bignami, M; Franchitto, A; Pichierri, P				Murfuni, I.; Nicolai, S.; Baldari, S.; Crescenzi, M.; Bignami, M.; Franchitto, A.; Pichierri, P.			The WRN and MUS81 proteins limit cell death and genome instability following oncogene activation	ONCOGENE			English	Article						RecQ helicases; replication fork arrest; genome instability; Werner syndrome	DNA-DAMAGE RESPONSE; WERNERS-SYNDROME PROTEIN; REPLICATION FORK; S-PHASE; HOMOLOGOUS RECOMBINATION; SYNTHETIC LETHALITY; CANCER DEVELOPMENT; HELICASE ACTIVITY; DEPENDENT MANNER; DOWN-REGULATION	Oncogene-induced replication stress is recognized as the primary cause of accumulation of DNA damage and genome instability in precancerous cells. Although the molecular mechanisms responding to such type of replication perturbation are not fully characterized, it has been speculated that their dysfunction may enhance genonne instability and accelerate tumor progression. Here, we show that the WRN protein, a member of the human RecQ helicases, is necessary to sustain replication fork progression in response to oncogene-induced replication stress. Loss of WRN affects cell cycle progression and results in enhanced accumulation of double-strand breaks and instability at common fragile sites in cells experiencing oncogene-induced replication stress. Moreover, we demonstrate that double-strand breaks, observed upon oncogene over-expression, depend on the MUS81 endonuclease, which represents a parallel pathway collaborating with WRN to prevent cell death. Overall, our findings give insights into the mechanisms protecting replication forks in cells experiencing oncogene-induced replication stress, and identify factor\s that, when mutated or dysfunctional, may enhance genome instability in precancerous cells. In addition, because concomitant depletion of WRN and MUS81 causes synthetic sickness in cells growing under oncogene-induced replication stress, our results support the possibility of targeting cancer cells with an impaired replication fork recovery pathway by a specific inactivation of the other parallel pathway. Oncogene (2013) 32, 610-620; doi:10.1038/onc.2012.80; published online 12 March 2012	[Murfuni, I.; Nicolai, S.; Bignami, M.; Pichierri, P.] Ist Super Sanita, Sect Expt & Computat Carcinogenesis, I-00161 Rome, Italy; [Baldari, S.; Franchitto, A.] Ist Super Sanita, Sect Mol Epidemiol, Dept Environm & Primary Prevent, I-00161 Rome, Italy; [Crescenzi, M.] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Franchitto, A (corresponding author), Ist Super Sanita, Dept Primary Prevent, Sect Expt Carcinogenesis, Viale Regina Elena 299, I-00161 Rome, Italy.	annapaola.franchitto@iss.it; pietro.pichierri@iss.it	Pichierri, Pietro/AAA-5476-2021; Crescenzi, Marco/J-3603-2018; Baldari, Silvia/AAA-5959-2021; Franchitto, Annapaola/K-7564-2016	Pichierri, Pietro/0000-0002-2702-3523; Crescenzi, Marco/0000-0003-0156-1494; Baldari, Silvia/0000-0001-7982-9468; Franchitto, Annapaola/0000-0003-4232-4727	Association for International Cancer Research [07-497]; Associazione ltaliana per la Ricerca sul Cancro (AIRC) [IG 9294, IG 4400]	Association for International Cancer Research; Associazione ltaliana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	We are grateful to Dr Pavel Janscak for providing the siRNAs and antibody against RECQ5. We also thank Drs D Toniolo and M Rocchi for providing bacterial artificial chromosomes for FISH analysis. This work was supported by a grant from the Association for International Cancer Research (Grant 07-497) to PP. and by grants from Associazione ltaliana per la Ricerca sul Cancro (AIRC) to PP. (IG 9294) and A.F. (IG 4400).	Aggarwal M, 2011, P NATL ACAD SCI USA, V108, P1525, DOI 10.1073/pnas.1006423108; Agrelo R, 2006, P NATL ACAD SCI USA, V103, P8822, DOI 10.1073/pnas.0600645103; Allen C, 2011, J MOL CELL BIOL, V3, P4, DOI 10.1093/jmcb/mjq049; Ammazzalorso F, 2010, EMBO J, V29, P3156, DOI 10.1038/emboj.2010.205; Bartek J, 2007, ONCOGENE, V26, P7773, DOI 10.1038/sj.onc.1210881; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Bohr VA, 2008, TRENDS BIOCHEM SCI, V33, P609, DOI 10.1016/j.tibs.2008.09.003; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Doe CL, 2002, J BIOL CHEM, V277, P32753, DOI 10.1074/jbc.M202120200; Duker NJ, 2002, AM J MED GENET, V115, P125, DOI 10.1002/ajmg.10688; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Franchitto A, 2002, HUM MOL GENET, V11, P2447, DOI 10.1093/hmg/11.20.2447; Franchitto A, 2003, CANCER RES, V63, P3289; Franchitto A, 2008, J CELL BIOL, V183, P241, DOI 10.1083/jcb.200803173; Friedel AM, 2009, CURR OPIN CELL BIOL, V21, P237, DOI 10.1016/j.ceb.2009.01.017; Froget B, 2008, MOL BIOL CELL, V19, P445, DOI 10.1091/mbc.E07-07-0728; Gilad O, 2010, CANCER RES, V70, P9693, DOI 10.1158/0008-5472.CAN-10-2286; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hanada K, 2007, NAT STRUCT MOL BIOL, V14, P1096, DOI 10.1038/nsmb1313; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Liontos M, 2007, CANCER RES, V67, P10899, DOI 10.1158/0008-5472.CAN-07-2837; Lopez-Contreras AJ, 2010, DNA REPAIR, V9, P1249, DOI 10.1016/j.dnarep.2010.09.012; Mao FJ, 2010, CANCER RES, V70, P6548, DOI 10.1158/0008-5472.CAN-10-0475; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; OLIVE PL, 1991, CANCER RES, V51, P4671; Petermann E, 2010, NAT REV MOL CELL BIO, V11, P683, DOI 10.1038/nrm2974; Pichierri P, 2003, ONCOGENE, V22, P1491, DOI 10.1038/sj.onc.1206169; Pichierri P, 2001, MOL BIOL CELL, V12, P2412, DOI 10.1091/mbc.12.8.2412; Pichierri P, 2011, AGING-US, V3, P311, DOI 10.18632/aging.100293; Pirzio LM, 2008, J CELL BIOL, V180, P305, DOI 10.1083/jcb.200705126; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; Robinson K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005951; Roseaulin L, 2008, EMBO J, V27, P1378, DOI 10.1038/emboj.2008.65; Rossi ML, 2010, DNA REPAIR, V9, P331, DOI 10.1016/j.dnarep.2009.12.011; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; Schwendener S, 2010, J BIOL CHEM, V285, P15739, DOI 10.1074/jbc.M110.110478; Sidorova JM, 2008, CELL CYCLE, V7, P796, DOI 10.4161/cc.7.6.5566; Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076; Trowbridge K, 2007, GENETICS, V176, P1993, DOI 10.1534/genetics.106.070060; Walther A, 2008, GUT, V57, P941, DOI 10.1136/gut.2007.135004; Wechsler T, 2011, NATURE, V471, P642, DOI 10.1038/nature09790; Wu F, 2011, CANCER SCI, V102, P472, DOI 10.1111/j.1349-7006.2010.01790.x; Wu F, 2010, ANTICANCER RES, V30, P5011; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yuan SSF, 2003, MUTAT RES-FUND MOL M, V525, P85, DOI 10.1016/S0027-5107(03)00009-5	54	35	37	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2013	32	5					610	620		10.1038/onc.2012.80	http://dx.doi.org/10.1038/onc.2012.80			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	106SJ	22410776				2022-12-17	WOS:000316164700008
J	Kim, K; Jeong, KW; Kim, H; Choi, J; Lu, W; Stallcup, MR; An, W				Kim, K.; Jeong, K. W.; Kim, H.; Choi, J.; Lu, W.; Stallcup, M. R.; An, W.			Functional interplay between p53 acetylation and H1.2 phosphorylation in p53-regulated transcription	ONCOGENE			English	Article						H1.2; p53; acetylation; phosphorylation; DNA-PK; transcription	LINKER HISTONE H1; C-TERMINAL DOMAIN; IN-VITRO; CHROMATIN-STRUCTURE; DNA-BINDING; RECRUITMENT; ACTIVATION; MOBILITY; FAMILY; VIVO	Linker histone H1.2 has been shown to suppress p53-dependent transcription through the modulation of chromatin remodeling; however, little is known about the mechanisms governing the antagonistic effects of H1.2 in DNA damage response. Here, we show that the repressive action of H1.2 on p53 function is negatively regulated via acetylation of p53 C-terminal regulatory domain and phosphorylation of H1.2 C-terminal tail. p53 acetylation by p300 impairs the interaction of p53 with H1.2 and triggers a rapid activation of p53-dependent transcription. Similarly, DNA-PK-mediated phosphorylation of H1.2 at T146 enhances p53 transcriptional activity by impeding H1.2 binding to p53 and thereby attenuating its suppressive effects on p53 transactivation. Consistent with these findings, point mutations mimicking modification states of H1.2 and p53 lead to a significant increase in p53-induced apoptosis. These data suggest that p53 acetylation-H1.2 phosphorylation cascade serves as a unique mechanism for triggering p53-dependent DNA damage response pathways. Oncogene (2012) 31, 4290-4301; doi:10.1038/onc.2011.605; published online 16 January 2012	[Kim, K.; Jeong, K. W.; Kim, H.; Choi, J.; Lu, W.; Stallcup, M. R.; An, W.] Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90089 USA; [Kim, K.; Jeong, K. W.; Kim, H.; Choi, J.; Stallcup, M. R.; An, W.] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Keck Sch Med, Los Angeles, CA 90089 USA; [Lu, W.] Univ So Calif, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Keck Sch Med, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	An, W (corresponding author), Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, Los Angeles, CA 90089 USA.	woojinan@usc.edu			ACS RSG [DMC-1005001];  [NIH-R01GM84209];  [NIH-RO1DK04393]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084209] Funding Source: NIH RePORTER	ACS RSG(American Cancer Society); ; ; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge Michael Lieber for DNA-PK and Daniela Rhodes for p601-7. This research was supported by NIH-R01GM84209 (WA), ACS RSG DMC-1005001 (WA) and NIH-RO1DK04393 (MRS).	An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Ausio Juan, 2006, Briefings in Functional Genomics & Proteomics, V5, P228, DOI 10.1093/bfgp/ell020; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Beckerman R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000935; Brown DT, 2003, BIOCHEM CELL BIOL, V81, P221, DOI 10.1139/o03-049; Bustin M, 2005, MOL CELL, V17, P617, DOI 10.1016/j.molcel.2005.02.019; Caterino TL, 2011, BIOCHEM CELL BIOL, V89, P35, DOI 10.1139/O10-024; Contreras A, 2003, MOL CELL BIOL, V23, P8626, DOI 10.1128/MCB.23.23.8626-8636.2003; Dou YL, 1999, MOL CELL, V4, P641, DOI 10.1016/S1097-2765(00)80215-4; Espinosa JM, 2003, MOL CELL, V12, P1015, DOI 10.1016/S1097-2765(03)00359-9; Georgel PT, 2001, BIOCHEM CELL BIOL, V79, P313, DOI 10.1139/bcb-79-3-313; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hale TK, 2006, MOL CELL, V22, P693, DOI 10.1016/j.molcel.2006.04.016; Happel N, 2009, GENE, V431, P1, DOI 10.1016/j.gene.2008.11.003; Horn PJ, 2002, NAT STRUCT BIOL, V9, P263, DOI 10.1038/nsb776; Izzo A, 2008, BIOL CHEM, V389, P333, DOI 10.1515/BC.2008.037; Jaskelioff M, 2000, MOL CELL BIOL, V20, P3058, DOI 10.1128/MCB.20.9.3058-3068.2000; Junttila MR, 2009, NAT REV CANCER, V9, P821, DOI 10.1038/nrc2728; Kim K, 2008, J BIOL CHEM, V283, P9113, DOI 10.1074/jbc.M708205200; Lee H, 2004, SCIENCE, V304, P1675, DOI 10.1126/science.1098096; Lennox RW, 1984, H1 SUBTYPES MAMMALS; Lever MA, 2000, NATURE, V408, P873, DOI 10.1038/35048603; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Ma YM, 2006, METHOD ENZYMOL, V408, P502, DOI 10.1016/S0076-6879(06)08031-1; McBryant SJ, 2010, CELL RES, V20, P519, DOI 10.1038/cr.2010.35; Mujtaba S, 2004, MOL CELL, V13, P251, DOI 10.1016/S1097-2765(03)00528-8; Ni JQ, 2006, GENE DEV, V20, P1959, DOI 10.1101/gad.390106; Parseghian MH, 2001, BIOCHEM CELL BIOL, V79, P289; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vila R, 2000, PROTEIN SCI, V9, P627; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Woodcock CL, 2006, CHROMOSOME RES, V14, P17, DOI 10.1007/s10577-005-1024-3; Zheng YP, 2010, J CELL BIOL, V189, P407, DOI 10.1083/jcb.201001148	35	35	35	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	39					4290	4301		10.1038/onc.2011.605	http://dx.doi.org/10.1038/onc.2011.605			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22249259	Green Accepted			2022-12-17	WOS:000309520200004
J	Lin, FC; Liu, YP; Lai, CH; Shan, YS; Cheng, HC; Hsu, PI; Lee, CH; Lee, YC; Wang, HY; Wang, CH; Cheng, JQ; Hsiao, M; Lu, PJ				Lin, F-C; Liu, Y-P; Lai, C-H; Shan, Y-S; Cheng, H-C; Hsu, P-I; Lee, C-H; Lee, Y-C; Wang, H-Y; Wang, C-H; Cheng, J. Q.; Hsiao, M.; Lu, P-J			RUNX3-mediated transcriptional inhibition of Akt suppresses tumorigenesis of human gastric cancer cells	ONCOGENE			English	Article						RUNX3; Akt; beta-catenin; cyclin D1; gastric cancer	HELICOBACTER-PYLORI INFECTION; EPITHELIAL-CELLS; GROWTH-FACTOR; TUMOR-SUPPRESSOR; RUNX3 EXPRESSION; BETA-CATENIN; MICROSATELLITE INSTABILITY; PROTEIN EXPRESSION; GENE-EXPRESSION; STOMACH-CANCER	Activation of Akt signaling pathway has been suggested involving in chemoresistance, metastasis and tumorigenesis of gastric cancer. However, the mechanism of Akt regulation in gastric cancer is not fully understood. RUNX3, which was first identified as a transcription factor, suppresses gastric tumorigenesis through regulating expression of target genes. Here, we found that restoration of RUNX3 significantly downregulates the protein and mRNA expression of Akt1 in gastric cancer cell lines, AGS and SNU-1. Knockdown of RUNX3 upregulates protein and mRNA expression of Akt1 in normal gastric epithelial cell line, GES-1. The negative correlation of RUNX3 and Akt expression and downstream beta-catenin/cyclin D1 effectors was further confirmed in AGS and GES-1 cell lines, as well as clinical specimens of gastric cancer. We identified two RUNX3-binding sites in Akt1 promoter and the binding of RUNX3 on Akt1 promoter significantly inhibits Akt1 expression. The RUNX3-mediated inhibition of Akt1 caused beta-catenin protein degradation and then cyclin D1 downregulation. Restoration of cyclin D1 reverses cell growth inhibition and G1 phase arrest induced by RUNX3 in gastric cancer cells. Our results show that loss of RUNX3 expression can enhance the Akt1-mediated signaling pathway and promote the tumorigenesis process in human gastric cancer. Oncogene (2012) 31, 4302-4316; doi:10.1038/onc.2011.596; published online 9 January 2012	[Liu, Y-P; Lee, C-H; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Lin, F-C; Liu, Y-P; Lai, C-H; Shan, Y-S; Cheng, H-C; Lee, Y-C; Wang, H-Y; Lu, P-J] Natl Cheng Kung Univ, Coll Med, Inst Clin Med, Tainan 704, Taiwan; [Lin, F-C] Natl Cheng Kung Univ Hosp, Dept Radiat Oncol, Tainan 70428, Taiwan; [Shan, Y-S] Natl Cheng Kung Univ Hosp, Dept Surg, Tainan 70428, Taiwan; [Hsu, P-I] Kaohsiung Vet Gen Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Hsu, P-I] Natl Yang Ming Univ, Dept Internal Med, Taipei 112, Taiwan; [Wang, C-H] Kaohsiung Med Univ, Dept Biotechnol, Kaohsiung, Taiwan; [Cheng, J. Q.] Univ S Florida, H Lee Moffitt Canc Ctr, Dept Mol Oncol, Tampa, FL 33682 USA	Academia Sinica - Taiwan; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University Hospital; National Cheng Kung University; National Cheng Kung University Hospital; Kaohsiung Veterans General Hospital; National Yang Ming Chiao Tung University; Kaohsiung Medical University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Hsiao, M (corresponding author), Acad Sinica, Genom Res Ctr, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	mhsiao@gate.sinica.edu.tw; pjlu2190@mail.ncku.edu.tw	Hsiao, Michael/U-6238-2019; Lai, Chern-Hsiung/C-8662-2009	Hsiao, Michael/0000-0001-8529-9213; 	National Science Council of Taiwan [NSC 97-2311-B-006-003-MY3, NSC 99-2627-B-006-021]; National Cheng Kung University Hospital of Taiwan [NCKUH-9803004, NCKUH-9903051]; Chi Mei Medical Center of Taiwan [CMNCKU9901]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan); National Cheng Kung University Hospital of Taiwan; Chi Mei Medical Center of Taiwan	The study was supported by grants from the National Science Council of Taiwan (NSC 97-2311-B-006-003-MY3 and NSC 99-2627-B-006-021), National Cheng Kung University Hospital of Taiwan (NCKUH-9803004 and NCKUH-9903051) and Chi Mei Medical Center of Taiwan (CMNCKU9901). We acknowledge Dr Xiang Hong Zhang from Hebei Medical University in China for kindly providing GES-1 cell line, and Dr Ching-Shih Chen from Ohio State University for kindly providing Akt, myr-Akt and DN-Akt constructs.	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Chang TL, 2010, GASTROENTEROLOGY, V138, P255, DOI 10.1053/j.gastro.2009.08.044; Chi XZ, 2005, MOL CELL BIOL, V25, P8097, DOI 10.1128/MCB.25.18.8097-8107.2005; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; CHYOU PH, 1990, CANCER RES, V50, P7501; Clements WM, 2002, CANCER RES, V62, P3503; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Daga A, 1996, GENE DEV, V10, P1194, DOI 10.1101/gad.10.10.1194; Dihlmann S, 2005, CARCINOGENESIS, V26, P1503, DOI 10.1093/carcin/bgi120; Durst KL, 2004, ONCOGENE, V23, P4220, DOI 10.1038/sj.onc.1207122; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; Fang DC, 2003, WORLD J GASTROENTERO, V9, P655, DOI 10.3748/wjg.v9.i4.655; Fukamachi H, 2006, DEV GROWTH DIFFER, V48, P1, DOI 10.1111/j.1440-169x.2006.00832.x; Fukamachi H, 2004, ONCOGENE, V23, P4330, DOI 10.1038/sj.onc.1207121; Gargano G, 2007, ANN ONCOL, V18, P103, DOI 10.1093/annonc/mdm236; Guo CC, 2005, INT J CANCER, V116, P155, DOI 10.1002/ijc.20919; Hartgrink HH, 2009, LANCET, V374, P477, DOI 10.1016/S0140-6736(09)60617-6; Hsu PI, 2009, ANN SURG ONCOL, V16, P1686, DOI 10.1245/s10434-009-0428-2; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito K, 2008, CANCER CELL, V14, P226, DOI 10.1016/j.ccr.2008.08.004; Ito Y, 2004, ONCOGENE, V23, P4198, DOI 10.1038/sj.onc.1207755; Ito Y, 1999, GENES CELLS, V4, P685, DOI 10.1046/j.1365-2443.1999.00298.x; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Ke Yang, 1994, Zhonghua Zhongliu Zazhi, V16, P7; Kim JH, 2009, J CELL BIOCHEM, V107, P557, DOI 10.1002/jcb.22157; KIM JH, 1991, J NATL CANCER I, V83, P938, DOI 10.1093/jnci/83.13.938; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Misra UK, 2007, J CELL BIOCHEM, V100, P1022, DOI 10.1002/jcb.21086; NOMURA A, 1990, CANCER RES, V50, P627; Ogawa S, 2008, J BIOCHEM, V143, P695, DOI 10.1093/jb/mvn022; Oki E, 2005, INT J CANCER, V117, P376, DOI 10.1002/ijc.21170; Osaki M, 2004, APOPTOSIS, V9, P667, DOI 10.1023/B:APPT.0000045801.15585.dd; Otto F, 2003, J CELL BIOCHEM, V89, P9, DOI 10.1002/jcb.10491; Park S, 2005, J BIOL CHEM, V280, P38932, DOI 10.1074/jbc.M504011200; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; Peng ZH, 2006, CLIN CANCER RES, V12, P6386, DOI 10.1158/1078-0432.CCR-05-2359; Polk DB, 2010, NAT REV CANCER, V10, P403, DOI 10.1038/nrc2857; Remy I, 2004, NAT CELL BIOL, V6, P358, DOI 10.1038/ncb1113; SANO T, 1991, CANCER RES, V51, P2926; Sato F, 2006, CANCER-AM CANCER SOC, V106, P483, DOI 10.1002/cncr.21657; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Soung YH, 2006, ONCOLOGY-BASEL, V70, P285, DOI 10.1159/000096289; Stock M, 2005, GENE, V360, P1, DOI 10.1016/j.gene.2005.06.026; Suzuki H, 2009, GASTRIC CANCER, V12, P79, DOI 10.1007/s10120-009-0507-x; Tsugane S, 2007, GASTRIC CANCER, V10, P75, DOI 10.1007/s10120-007-0420-0; Ushijima T, 2004, CANCER CELL, V5, P121, DOI 10.1016/S1535-6108(04)00033-9; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Wu MS, 1997, GASTROENTEROLOGY, V112, P1457, DOI 10.1016/S0016-5085(97)70071-4; Xing X, 2011, MOL NUTR FOOD RES, V55, P749, DOI 10.1002/mnfr.201000344; Yanada M, 2005, ONCOL REP, V14, P817; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zheng Leizhen, 2004, Gastric Cancer, V7, P61	63	35	37	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	39					4302	4316		10.1038/onc.2011.596	http://dx.doi.org/10.1038/onc.2011.596			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	016LP	22231444				2022-12-17	WOS:000309520200005
J	Shahar, OD; Ram, EVSR; Shimshoni, E; Hareli, S; Meshorer, E; Goldberg, M				Shahar, O. D.; Ram, E. V. S. Raghu; Shimshoni, E.; Hareli, S.; Meshorer, E.; Goldberg, M.			Live imaging of induced and controlled DNA double-strand break formation reveals extremely low repair by homologous recombination in human cells	ONCOGENE			English	Article						DNA double-strand breaks; DNA repair; homologous recombination; genomic stability; ISceI	MAMMALIAN-CELLS; MITOTIC CYCLINS; PATHWAY CHOICE; S-PHASE; END; DEGRADATION; STABILITY; ONSET	DNA double-strand breaks (DSBs), the most hazardous DNA lesions, may result in genomic instability, a hallmark of cancer cells. The main DSB repair pathways are non-homologous end joining (NHEJ) and homologous recombination (HR). In mammalian cells, NHEJ, which can lead to inaccurate repair, predominates. HR repair (HRR) is considered accurate and is restricted to S, G2 and M phases of the cell cycle. Despite its importance, many aspects regarding HRR remain unknown. Here, we developed a novel inducible on/off switch cell system that enables, for the first time, to induce a DSB in a rapid and reversible manner in human cells. By limiting the duration of DSB induction, we found that non-persistent endonuclease-induced DSBs are rarely repaired by HR, whereas persistent DSBs result in the published HRR frequencies (non-significant HR frequency versus frequency of similar to 10%, respectively). We demonstrate that these DSBs are repaired by an accurate repair mechanism, which is distinguished from HRR (most likely, error-free NHEJ). Notably, our data reveal that HRR frequencies of endonuclease-induced DSBs in human cells are >10-fold lower than what was previously estimated by prevailing methods, which resulted in recurrent DSB formation. Our findings suggest a role for HRR mainly in repairing challenging DSBs, in contrast to uncomplicated lesions that are frequently repaired by NHEJ. Preventing HR from repairing DSBs in the complex and repetitive human genome probably has an essential role in maintaining genomic stability. Oncogene (2012) 31, 3495-3504; doi:10.1038/onc.2011.516; published online 21 November 2011	[Shahar, O. D.; Ram, E. V. S. Raghu; Shimshoni, E.; Hareli, S.; Meshorer, E.; Goldberg, M.] Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Meshorer, E (corresponding author), Hebrew Univ Jerusalem, Inst Life Sci, Dept Genet, IL-91904 Jerusalem, Israel.	meshorer@cc.huji.ac.il; goldbergm@vms.huji.ac.il	Shahar, Or/ABG-9168-2020; Edupuganti, Venkata/AAG-6486-2019	Edupuganti, Venkata/0000-0001-9414-2672; Meshorer, Eran/0000-0003-4777-986X; Goldberg, Michal/0000-0001-9397-2383; Shahar, Or/0000-0002-5039-8307	AFHU; United States Binational Science Foundation [2009286]; Israel Cancer Association; Israel Science Foundation [943/09]; Israel Cancer Research Foundation; Israel Ministry of Health [6007]; European Union [IRG-206872, 238176]; HU; Israel Psychobiology Institute; Lady Davies Fellowship program; Edmond J Safra Foundation	AFHU; United States Binational Science Foundation; Israel Cancer Association; Israel Science Foundation(Israel Science Foundation); Israel Cancer Research Foundation; Israel Ministry of Health; European Union(European Commission); HU; Israel Psychobiology Institute; Lady Davies Fellowship program; Edmond J Safra Foundation	We thank members of our laboratories, Sagiv Shifman and Liran Carmel for discussions, Naomi Melamed-Book for assistance in confocal analyses, Maya Schuldiner and Yifat Cohen for technical help. Stephan P Jackson, Tom Misteli, Amir Eden and Agnes Klochendler-Yeivin for reagents, Ilana Livyatan for critical reading of the manuscript, Evi Soutoglou for discussions and reagents, and the Edmond J Safra Foundation for financial support. MG is supported by the AFHU, The United States Binational Science Foundation (2009286) and the Israel Cancer Association. EM is a Joseph H and Belle R Braun senior lecturer in life sciences and is supported by the Israel Science Foundation (943/09), the Israel Cancer Research Foundation, the Israel Ministry of Health (6007), the European Union (IRG-206872 and 238176), the Internal Applicable Medical Grants of the HU and the Israel Psychobiology Institute. EVSRR is supported by the Lady Davies Fellowship program.	Barlow JH, 2008, MOL CELL, V30, P73, DOI 10.1016/j.molcel.2008.01.016; Bennardo N, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000683; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Chang DC, 2003, J BIOL CHEM, V278, P37865, DOI 10.1074/jbc.M306376200; Covo S, 2009, NUCLEIC ACIDS RES, V37, P6737, DOI 10.1093/nar/gkp703; Fung TK, 2005, SEMIN CELL DEV BIOL, V16, P335, DOI 10.1016/j.semcdb.2005.02.014; Hartlerode AJ, 2009, BIOCHEM J, V423, P157, DOI 10.1042/BJ20090942; Honma M, 2007, DNA REPAIR, V6, P781, DOI 10.1016/j.dnarep.2007.01.004; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Lukusa T, 2008, BBA-GENE REGUL MECH, V1779, P3, DOI 10.1016/j.bbagrm.2007.10.005; Mao ZY, 2008, CELL CYCLE, V7, P2902, DOI 10.4161/cc.7.18.6679; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Rothkamm K, 2003, MOL CELL BIOL, V23, P5706, DOI 10.1128/MCB.23.16.5706-5715.2003; Saleh-Gohari N, 2004, NUCLEIC ACIDS RES, V32, P3683, DOI 10.1093/nar/gkh703; Salpeter SJ, 2011, ENDOCRINOLOGY, V152, P2589, DOI 10.1210/en.2010-1372; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Schaaf MJM, 2003, MOL CELL BIOL, V23, P1922, DOI 10.1128/MCB.23.6.1922-1934.2003; Schwartz M, 2005, GENE DEV, V19, P2715, DOI 10.1101/gad.340905; Shibata A, 2011, EMBO J, V30, P1079, DOI 10.1038/emboj.2011.27; Shrivastav M, 2008, CELL RES, V18, P134, DOI 10.1038/cr.2007.111; Soutoglou E, 2007, NAT CELL BIOL, V9, P675, DOI 10.1038/ncb1591; Takashima Y, 2009, ENVIRON MOL MUTAGEN, V50, P815, DOI 10.1002/em.20481; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Villalobos Michael J, 2006, Methods Mol Biol, V314, P109; Wersto RP, 2001, CYTOMETRY, V46, P296, DOI 10.1002/cyto.1171; Yanez RJ, 1998, GENE THER, V5, P149, DOI 10.1038/sj.gt.3300601; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	29	35	37	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2012	31	30					3495	3504		10.1038/onc.2011.516	http://dx.doi.org/10.1038/onc.2011.516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	979UA	22105360				2022-12-17	WOS:000306844100002
J	Harma, V; Knuuttila, M; Virtanen, J; Mirtti, T; Kohonen, P; Kovanen, P; Happonen, A; Kaewphan, S; Ahonen, I; Kallioniemi, O; Grafstrom, R; Lotjonen, J; Nees, M				Harma, V.; Knuuttila, M.; Virtanen, J.; Mirtti, T.; Kohonen, P.; Kovanen, P.; Happonen, A.; Kaewphan, S.; Ahonen, I.; Kallioniemi, O.; Grafstrom, R.; Lotjonen, J.; Nees, M.			Lysophosphatidic acid and sphingosine-1-phosphate promote morphogenesis and block invasion of prostate cancer cells in three-dimensional organotypic models	ONCOGENE			English	Article						prostate cancer; epithelial plasticity; bioactive lipids; G-protein coupled receptors; lysophosphatidic acid; sphingosine-1-phosphate	SMALL-MOLECULE INHIBITOR; HUMAN OVARIAN-CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; SPHINGOSINE 1-PHOSPHATE; PHOSPHOLIPASE A(2); GENE-EXPRESSION; KINASE PATHWAY; RECEPTOR 2; LPA; ACTIVATION	Normal prostate and some malignant prostate cancer (PrCa) cell lines undergo acinar differentiation and form spheroids in three-dimensional (3-D) organotypic culture. Acini formed by PC-3 and PC-3M, less pronounced also in other PrCa cell lines, spontaneously undergo an invasive switch, leading to the disintegration of epithelial structures and the basal lamina, and formation of invadopodia. This demonstrates the highly dynamic nature of epithelial plasticity, balancing epithelial-to-mesenchymal transition against metastable acinar differentiation. This study assessed the role of lipid metabolites on epithelial maturation. PC-3 cells completely failed to form acinar structures in delipidated serum. Adding back lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) rescued acinar morphogenesis and repressed invasion effectively. Blocking LPA receptor 1 (LPAR1) functions by siRNA (small interference RNA) or the specific LPAR1 inhibitor Ki16425 promoted invasion, while silencing of other G-protein-coupled receptors responsive to LPA or S1P mainly caused growth arrest or had no effects. The G-proteins G alpha(12/13) and G alpha(i) were identified as key mediators of LPA signalling via stimulation of RhoA and Rho kinases ROCK1 and 2, activating Rac1, while inhibition of adenylate cyclase and accumulation of cAMP may be secondary. Interfering with these pathways specifically impeded epithelial polarization in transformed cells. In contrast, blocking the same pathways in non-transformed, normal cells promoted differentiation. We conclude that LPA and LPAR1 effectively promote epithelial maturation and block invasion of PrCa cells in 3-D culture. The analysis of clinical transcriptome data confirmed reduced expression of LPAR1 in a subset of PrCa's. Our study demonstrates a metastasis-suppressor function for LPAR1 and G alpha(12/13) signalling, regulating cell motility and invasion versus epithelial maturation. Oncogene (2012) 31, 2075-2089; doi: 10.1038/onc.2011.396; published online 26 September 2011	[Harma, V.; Virtanen, J.; Grafstrom, R.; Nees, M.] VTT Tech Res Ctr Finland, Med Biotechnol Knowledge Ctr, FI-20520 Turku, Finland; [Knuuttila, M.; Virtanen, J.; Kohonen, P.; Ahonen, I.] Univ Turku, Ctr Biotechnol, Turku, Finland; [Mirtti, T.; Kallioniemi, O.] Univ Helsinki, FIMM, Helsinki, Finland; [Mirtti, T.; Kovanen, P.] Univ Helsinki, Haartman Inst, Dept Pathol, Helsinki, Finland; [Mirtti, T.; Kovanen, P.] Univ Helsinki, Cent Hosp, HUSLAB, Helsinki, Finland; [Happonen, A.] Tampere Univ Technol, Dept Signal Proc, FIN-33101 Tampere, Finland; [Kaewphan, S.] Univ Turku, Dept Informat Technol, Turku, Finland; [Grafstrom, R.] Karolinska Inst, Toxicol Lab, Stockholm, Sweden; [Lotjonen, J.] VTT Tech Res Ctr Finland, Knowledge Intens Serv, Tampere, Finland	VTT Technical Research Center Finland; University of Turku; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Tampere University; University of Turku; Karolinska Institutet; VTT Technical Research Center Finland	Nees, M (corresponding author), VTT Tech Res Ctr Finland, Med Biotechnol Knowledge Ctr, POB 106, FI-20520 Turku, Finland.	matthias.nees@vtt.fi	Kohonen, Pekka/F-9596-2011; Happonen, Antti/M-7644-2014; Nees, Matthias/W-6596-2018; Kallioniemi, Olli P/H-5111-2011; Nees, Matthias/AAT-5577-2020; Grafström, Roland C/N-7217-2016	Kohonen, Pekka/0000-0002-7845-3611; Nees, Matthias/0000-0002-9034-301X; Kallioniemi, Olli P/0000-0002-3231-0332; Knuuttila, Matias/0000-0002-9953-5755; Mirtti, Tuomas/0000-0003-0455-9891; Harma, Ville/0000-0001-5767-5226	Academy of Finland [134472]	Academy of Finland(Academy of Finland)	We would like to thank Leena Saikko for expert technical assistance. This work was funded by the Academy of Finland (grant to MN), number 134472.	Akbar H, 2006, METHOD ENZYMOL, V406, P554, DOI 10.1016/S0076-6879(06)06043-5; Aziziyeh AI, 2009, CELL SIGNAL, V21, P1207, DOI 10.1016/j.cellsig.2009.03.011; Bagga S, 2004, BLOOD, V104, P4080, DOI 10.1182/blood-2004-03-1166; Brekhman V, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-415; Brizuela L, 2010, FASEB J, V24, P3882, DOI 10.1096/fj.10-160838; Chu JH, 2009, PROSTATE, V69, P428, DOI 10.1002/pros.20897; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; Deng WL, 2002, GASTROENTEROLOGY, V123, P206, DOI 10.1053/gast.2002.34209; Devine KM, 2008, GYNECOL ONCOL, V110, P237, DOI 10.1016/j.ygyno.2008.04.013; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evelyn CR, 2007, MOL CANCER THER, V6, P2249, DOI 10.1158/1535-7163.MCT-06-0782; Evelyn CR, 2010, BIOORG MED CHEM LETT, V20, P665, DOI 10.1016/j.bmcl.2009.11.056; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fishman DA, 2001, CANCER RES, V61, P3194; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Gibbs TC, 2009, PROSTATE, V69, P1493, DOI 10.1002/pros.20994; Gobeil F, 2003, J BIOL CHEM, V278, P38875, DOI 10.1074/jbc.M212481200; Goetzl EJ, 1999, CANCER RES, V59, P4732; Goetzl EJ, 1999, J IMMUNOL, V162, P2049; Groves-Kirkby N, 2010, NAT REV UROL, V7, P420; Guo R, 2006, ENDOCRINOLOGY, V147, P4883, DOI 10.1210/en.2005-1635; Hao F, 2007, BBA-MOL CELL BIOL L, V1771, P883, DOI 10.1016/j.bbalip.2007.04.010; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Harper K, 2010, CANCER RES, V70, P4634, DOI 10.1158/0008-5472.CAN-09-3813; Hasegawa Y, 2008, MOL ONCOL, V2, P54, DOI 10.1016/j.molonc.2008.03.009; Heringdorf DMZ, 1998, EMBO J, V17, P2830, DOI 10.1093/emboj/17.10.2830; Hong GY, 1999, FEBS LETT, V460, P513, DOI 10.1016/S0014-5793(99)01400-3; Hope JM, 2009, GYNECOL ONCOL, V112, P215, DOI 10.1016/j.ygyno.2008.09.019; Hwang YS, 2006, MOL CARCINOGEN, V45, P518, DOI 10.1002/mc.20183; Inman Jamie L, 2010, J Biol, V9, P2, DOI 10.1186/jbiol213; Jeong KJ, 2008, EXP MOL MED, V40, P607, DOI 10.3858/emm.2008.40.6.607; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kawamori T, 2006, FASEB J, V20, P386, DOI 10.1096/fj.05-4331fje; Kim EK, 2008, EXP MOL MED, V40, P445, DOI 10.3858/emm.2008.40.4.445; Kim J, 2002, CANCER RES, V62, P1549; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Li H, 2009, MOL CANCER THER, V8, P1692, DOI 10.1158/1535-7163.MCT-08-1106; Li SY, 2005, INT J ONCOL, V27, P1329; Li TT, 2009, MOL CANCER RES, V7, P1064, DOI 10.1158/1541-7786.MCR-08-0578; Liu SY, 2009, CELL CYCLE, V8, P3695, DOI 10.4161/cc.8.22.9937; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Morin P, 2011, EUR J CELL BIOL, V90, P13, DOI 10.1016/j.ejcb.2010.09.009; Nava VE, 2002, EXP CELL RES, V281, P115, DOI 10.1006/excr.2002.5658; Nouh MAAM, 2009, CANCER SCI, V100, P1631, DOI 10.1111/j.1349-7006.2009.01234.x; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Onesto C, 2008, METHOD ENZYMOL, V439, P111, DOI 10.1016/S0076-6879(07)00409-0; Pchejetski D, 2008, MOL CANCER THER, V7, P1836, DOI 10.1158/1535-7163.MCT-07-2322; Pchejetski D, 2010, CANCER RES, V70, P8651, DOI 10.1158/0008-5472.CAN-10-1388; Pineiro R, 2011, ONCOGENE, V30, P142, DOI 10.1038/onc.2010.417; Reuter JA, 2009, CANCER CELL, V15, P477, DOI 10.1016/j.ccr.2009.04.002; Ridky TW, 2010, NAT MED, V16, P1450, DOI 10.1038/nm.2265; Sawada K, 2002, GYNECOL ONCOL, V87, P252, DOI 10.1006/gyno.2002.6831; Sekine Y, 2011, PROSTATE, V71, P690, DOI 10.1002/pros.21285; Seo JH, 2010, CANCER LETT, V288, P50, DOI 10.1016/j.canlet.2009.06.023; Sequeira L, 2008, CLIN EXP METASTAS, V25, P569, DOI 10.1007/s10585-008-9173-3; Shida D, 2004, LAB INVEST, V84, P1352, DOI 10.1038/labinvest.3700146; Shida D, 2003, CANCER RES, V63, P1706; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Smicun Y, 2007, GYNECOL ONCOL, V107, P298, DOI 10.1016/j.ygyno.2007.06.024; Snider AJ, 2010, BIOCHIMIE, V92, P707, DOI 10.1016/j.biochi.2010.02.008; Snider AJ, 2010, AM J PHYSIOL-CELL PH, V298, pC163, DOI 10.1152/ajpcell.00001.2009; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sved P, 2004, CANCER RES, V64, P6934, DOI 10.1158/0008-5472.CAN-03-3018; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; TIGYI G, 1992, J BIOL CHEM, V267, P21360; Valet P, 1998, J CLIN INVEST, V101, P1431, DOI 10.1172/JCI806; van Dijk MCM, 1998, CURR BIOL, V8, P386, DOI 10.1016/S0960-9822(98)70157-5; van Golen KL, 2008, J CELL BIOCHEM, V104, P1587, DOI 10.1002/jcb.21652; Vogler R, 2003, J INVEST DERMATOL, V120, P693, DOI 10.1046/j.1523-1747.2003.12096.x; Wang D, 2008, MOL CANCER THER, V7, P1993, DOI 10.1158/1535-7163.MCT-08-0088; Wang FQ, 2010, GYNECOL ONCOL, V117, P88, DOI 10.1016/j.ygyno.2009.12.012; Waters CM, 2006, BIOCHEM J, V398, P55, DOI 10.1042/BJ20060155; Westermann AM, 1998, ANN ONCOL, V9, P437, DOI 10.1023/A:1008217129273; Yamaguchi H, 2003, BIOCHEM J, V374, P715, DOI 10.1042/BJ20030381; Zeng Y, 2009, PROSTATE, V69, P283, DOI 10.1002/pros.20879; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619	83	35	40	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2075	2089		10.1038/onc.2011.396	http://dx.doi.org/10.1038/onc.2011.396			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21996742	Green Published, hybrid			2022-12-17	WOS:000303008600008
J	Lee, J; Li, L; Gretz, N; Gebert, J; Dihlmann, S				Lee, J.; Li, L.; Gretz, N.; Gebert, J.; Dihlmann, S.			Absent in Melanoma 2 (AIM2) is an important mediator of interferon-dependent and -independent HLA-DRA and HLA-DRB gene expression in colorectal cancers	ONCOGENE			English	Article						IFN-gamma; AIM2; HLA class II; tumor immunity; interferon-stimulated genes; ISG	CLASS-II TRANSACTIVATOR; GAMMA IN-SITU; MICROSATELLITE INSTABILITY; ANTIGEN-EXPRESSION; CYTOPLASMIC DNA; FRANCISELLA-TULARENSIS; POSITIVE FEEDBACK; INNATE IMMUNITY; GOOD PROGNOSIS; COMMON TARGET	Absent in Melanoma 2 (AIM2) is a member of the HIN-200 family of hematopoietic, IFN-inducible, nuclear proteins, associated with both, infection defense and tumor pathology. Recently, AIM2 was found to act as a DNA sensor in innate immunity. In addition, we and others have previously demonstrated a high frequency of AIM2-alterations in microsatellite unstable (MSI-H) tumors. To further elucidate AIM2 function in colorectal tumors, we here addressed AIM2-responsive target genes by microarray based gene expression profiling of 22 244 human genes. A total of 111 transcripts were significantly upregulated, whereas 80 transcripts turned out to be significantly downregulated in HCT116 cells, constitutively expressing AIM2, compared with AIM2-negative cells. Among the upregulated genes that were validated by quantitative PCR and western blotting we recognized several interferon-stimulated genes (ISGs: IFIT1, IFIT2, IFIT3, IFI6, IRF7, ISG15, HLA-DRA, HLA-DRB, TLR3 and CIITA), as well as genes involved in intercellular adhesion and matrix remodeling. Expression of ISGs correlated with expression of AIM2 in 10 different IFN-gamma treated colorectal cancer cell lines. Moreover, small interfering RNA-mediated knock-down of AIM2 resulted in reduced expression of HLA-DRA, HLA-DRB and CIITA in IFN-gamma-treated cells. IFN-gamma independent induction of HLA-DR genes and their encoded proteins was also demonstrated upon doxy-cyclin-regulated transient induction of AIM2. Luciferase reporter assays revealed induction of the HLA-DR promoter upon AIM2 transfection in different cell lines. STAT-signaling was not involved in IFN-gamma independent induction of ISGs, arguing against participation of cytokines released in an autostimulating manner. Our data indicate that AIM2 mediates both IFN-gamma dependent and independent induction of several ISGs, including genes encoding the major histocompatibility complex (MHC) class II antigens HLA-DR-alpha and -beta. This suggests a novel role of the IFN/AIM2/ISG cascade likewise in cancer cells. Oncogene (2012) 31, 1242-1253; doi:10.1038/onc.2011.320; published online 1 August 2011	[Lee, J.; Gebert, J.] Univ Heidelberg, Inst Pathol, Dept Appl Tumor Biol, D-6900 Heidelberg, Germany; [Li, L.; Gretz, N.] Univ Heidelberg, Fac Clin Med, Ctr Med Res ZMF, D-6800 Mannheim, Germany; [Dihlmann, S.] Univ Heidelberg, Inst Pathol, Dept Gen Pathol, D-6900 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Dihlmann, S (corresponding author), Univ Heidelberg Hosp, Dept Vasc Surg, Neuenheimer Feld 110, D-69120 Heidelberg, Germany.	susanne.dihlmann@med.uni-heidelberg.de		Dihlmann, Susanne/0000-0002-3737-7755	Deutsche Forschungsgmeinschaft, DFG [Di-933 4/1]	Deutsche Forschungsgmeinschaft, DFG(German Research Foundation (DFG))	The work was funded by a grant of the Deutsche Forschungsgmeinschaft, DFG to Dr S Dihlmann (Di-933 4/1).	Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; ANDERSEN SN, 1993, BRIT J CANCER, V68, P80, DOI 10.1038/bjc.1993.290; Brennan K, 2010, CURR OPIN MICROBIOL, V13, P503, DOI 10.1016/j.mib.2010.05.007; Buckowitz A, 2005, BRIT J CANCER, V92, P1746, DOI 10.1038/sj.bjc.6602534; Burckstummer T, 2009, NAT IMMUNOL, V10, P266, DOI 10.1038/ni.1702; Chen IF, 2006, MOL CANCER THER, V5, P1, DOI 10.1158/1535-7163.MCT-05-0310; Cheriyath V, 2007, J CLIN INVEST, V117, P3107, DOI 10.1172/JCI31122; DCunha J, 1996, P NATL ACAD SCI USA, V93, P211, DOI 10.1073/pnas.93.1.211; DCunha J, 1996, J IMMUNOL, V157, P4100; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; Diederichsen ACP, 2003, CANCER IMMUNOL IMMUN, V52, P423, DOI 10.1007/s00262-003-0388-5; Dihlmann S, 1999, CANCER RES, V59, P1857; Fensterl V, 2011, J INTERF CYTOK RES, V31, P71, DOI 10.1089/jir.2010.0101; Fernandes-Alnemri T, 2010, NAT IMMUNOL, V11, P385, DOI 10.1038/ni.1859; Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Garrity-Park MM, 2009, GUT, V58, P1226, DOI 10.1136/gut.2008.166686; Harton JA, 2000, MOL CELL BIOL, V20, P6185, DOI 10.1128/MCB.20.17.6185-6194.2000; Hornung V, 2009, NATURE, V458, P514, DOI 10.1038/nature07725; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Jones JW, 2010, P NATL ACAD SCI USA, V107, P9771, DOI 10.1073/pnas.1003738107; Krawczyk M, 2006, TISSUE ANTIGENS, V67, P183, DOI 10.1111/j.1399-0039.2006.00557.x; Lee JH, 2010, GUT, V59, P907, DOI 10.1136/gut.2009.194068; Lovig T, 2002, BRIT J CANCER, V87, P756, DOI 10.1038/sj.bjc.6600507; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Matsushita K, 2006, CANCER SCI, V97, P57, DOI 10.1111/j.1349-7006.2006.00137.x; Matsushita K, 1996, BRIT J CANCER, V73, P644, DOI 10.1038/bjc.1996.112; Michel S, 2010, INT J CANCER, V127, P889, DOI 10.1002/ijc.25106; Michel S, 2010, MOL CARCINOGEN, V49, P175, DOI 10.1002/mc.20587; MuhlethalerMOttet A, 1997, EMBO J, V16, P2851, DOI 10.1093/emboj/16.10.2851; Osborne A, 2001, MOL CELL BIOL, V21, P6495, DOI 10.1128/MCB.21.19.6495-6506.2001; Oshita F, 2006, ONCOL REP, V16, P817; Patsos G, 2010, INT J CANCER, V126, P1838, DOI 10.1002/ijc.24905; PFIZENMAIER K, 1985, CANCER RES, V45, P3503; Pitha-Rowe IF, 2007, CYTOKINE GROWTH F R, V18, P409, DOI 10.1016/j.cytogfr.2007.06.017; Rathinam VAK, 2010, NAT IMMUNOL, V11, P395, DOI 10.1038/ni.1864; Roberts TL, 2009, SCIENCE, V323, P1057, DOI 10.1126/science.1169841; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Satoh A, 2004, ONCOGENE, V23, P8876, DOI 10.1038/sj.onc.1208144; Sauer JD, 2010, CELL HOST MICROBE, V7, P412, DOI 10.1016/j.chom.2010.04.004; Schroder K, 2009, CURR BIOL, V19, pR262, DOI 10.1016/j.cub.2009.02.011; Tahara E, 2005, CANCER IMMUNOL IMMUN, V54, P729, DOI 10.1007/s00262-004-0645-2; TEMPONI M, 1993, J IMMUNOL METHODS, V161, P239, DOI 10.1016/0022-1759(93)90300-V; Tsuchiya K, 2010, J IMMUNOL, V185, P1186, DOI 10.4049/jimmunol.1001058; Walsh MD, 2009, INT J CANCER, V125, P1231, DOI 10.1002/ijc.24484; Welman A, 2005, J CELL BIOCHEM, V94, P1148, DOI 10.1002/jcb.20342; Woerner SM, 2005, ONCOGENE, V24, P2525, DOI 10.1038/sj.onc.1208456; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Woerner SM, 2001, INT J CANCER, V93, P12, DOI 10.1002/ijc.1299; Woerner SM, 2007, GENE CHROMOSOME CANC, V46, P1080, DOI 10.1002/gcc.20493; Zhang LW, 2002, J INTERF CYTOK RES, V22, P95, DOI 10.1089/107999002753452700	51	35	37	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	10					1242	1253		10.1038/onc.2011.320	http://dx.doi.org/10.1038/onc.2011.320			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	906KS	21804607	Green Published, hybrid			2022-12-17	WOS:000301344600004
J	Takai, A; Marusawa, H; Minaki, Y; Watanabe, T; Nakase, H; Kinoshita, K; Tsujimoto, G; Chiba, T				Takai, A.; Marusawa, H.; Minaki, Y.; Watanabe, T.; Nakase, H.; Kinoshita, K.; Tsujimoto, G.; Chiba, T.			Targeting activation-induced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation	ONCOGENE			English	Article						AID; colitis-associated cancer; colonic inflammation; IL-10(-/-) mouse	HELICOBACTER-PYLORI INFECTION; ULCERATIVE-COLITIS; BOWEL-DISEASE; INTERLEUKIN-10-DEFICIENT MICE; DNA DEMETHYLATION; COLORECTAL-CANCER; HUMAN HEPATOCYTES; LAMINA PROPRIA; P53 MUTATIONS; CELLS	Inflammatory bowel disease (IBD) is an important etiologic factor in the development of colorectal cancer. However, the mechanism underlying carcinogenesis through chronic inflammation is still unknown. Activation-induced cytidine deaminase (AID) is induced by the inflammation and involved in various human carcinogenesis via its mutagenic activity. In the current study, we investigated whether the inflammation/AID axis plays an integral role in the development of colitis-associated cancers. Inflammation in the cecum was more severe than that in other colonic regions, and endogenous AID expression was enhanced most prominently in the inflamed cecal mucosa of interleukin (IL)-10(-/-) mice. Blockade of tumor necrosis factor (TNF)-alpha and IL-12 significantly suppressed AID expression. Although proinflammatory cytokine expression was comparable between IL-10(-/-) AID(+/+) and IL-10(-/-) AID(-/-) mice, sequencing analyses revealed a significantly lower incidence of somatic mutations in Trp53 gene in the colonic mucosa of IL-10(-/-) AID(-/-) than IL-10(-/-) AID(+/+) mice. Colon cancers spontaneously developed in the cecum in 6 of 22 (27.2%) IL-10(-/-) AID(+/+) mice. In contrast, none of the IL-10(-/-) AID(-/-) mice developed cancers except only one case of neoplasia in the distal colon. These findings suggest that the proinflammatory cytokine-induced aberrant production of AID links colonic inflammation to an enhanced genetic susceptibility to oncogenic mutagenesis. Targeting AID could be a novel strategy to prevent colitis-associated colon carcinogenesis irrespective of ongoing colonic inflammation. Oncogene (2012) 31, 1733-1742; doi:10.1038/onc.2011.352; published online 15 August 2011	[Marusawa, H.] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; [Kinoshita, K.] Shiga Med Ctr Res Inst, Moriyama, Japan; [Tsujimoto, G.] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Genom Drug Discovery Sci, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Marusawa, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	maru@kuhp.kyoto-u.ac.jp	Nakase, Hiroshi/AAZ-4425-2020; Watanabe, Tomohiro/ABA-4712-2021	Marusawa, Hiroyuki/0000-0002-4286-2712	Ministry of Education, Culture, Sports, Science; Ministry of Health, Labor, and Welfare, Japan; Princess Takamatsu Cancer Research Fund; Grants-in-Aid for Scientific Research [23390196, 21229009] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor, and Welfare, Japan(Ministry of Health, Labour and Welfare, Japan); Princess Takamatsu Cancer Research Fund; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Keiichiro Suzuki and Dr Tasuku Honjo for critical reading of this manuscript, and Dr Masamichi Muramatsu for providing information of siRNA for AID. This work was supported by grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science; a grant-in-aid for Scientific Research from the Ministry of Health, Labor, and Welfare, Japan; and a research grant of the Princess Takamatsu Cancer Research Fund.	Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Bhutani N, 2010, NATURE, V463, P1042, DOI 10.1038/nature08752; Chiba T, 2006, J GASTROENTEROL, V41, P1, DOI 10.1007/s00535-005-1743-4; Chiba T, 2009, J MOL MED-JMM, V87, P1023, DOI 10.1007/s00109-009-0527-3; Davidson NJ, 1996, J EXP MED, V184, P241, DOI 10.1084/jem.184.1.241; Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526; Endo Y, 2007, ONCOGENE, V26, P5587, DOI 10.1038/sj.onc.1210344; Endo Y, 2008, GASTROENTEROLOGY, V135, P889, DOI 10.1053/j.gastro.2008.06.091; Fagarasan S, 2002, SCIENCE, V298, P1424, DOI 10.1126/science.1077336; Fagarasan S, 2001, NATURE, V413, P639, DOI 10.1038/35098100; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fuss IJ, 1996, J IMMUNOL, V157, P1261; Glocker EO, 2009, NEW ENGL J MED, V361, P2033, DOI 10.1056/NEJMoa0907206; Guo JU, 2011, CELL, V145, P423, DOI 10.1016/j.cell.2011.03.022; Holzmann K, 1998, INT J CANCER, V76, P1; Hussain SP, 2000, CANCER RES, V60, P3333; Ikeda K, 2007, ANN INTERN MED, V146, P649, DOI 10.7326/0003-4819-146-9-200705010-00008; Inoue S, 2009, CLIN EXP IMMUNOL, V156, P172, DOI 10.1111/j.1365-2249.2008.03872.x; KERN SE, 1994, GASTROENTEROLOGY, V107, P420, DOI 10.1016/0016-5085(94)90167-8; Komori J, 2008, HEPATOLOGY, V47, P888, DOI 10.1002/hep.22125; Kou T, 2007, INT J CANCER, V120, P469, DOI 10.1002/ijc.22292; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Lashner BA, 1999, AM J GASTROENTEROL, V94, P456, DOI 10.1016/S0002-9270(98)00758-8; Leedham SJ, 2009, GASTROENTEROLOGY, V136, P542, DOI 10.1053/j.gastro.2008.10.086; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Liu RK, 2006, AM J PATHOL, V168, P757, DOI 10.2353/ajpath.2006.050907; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; MARRA F, 1993, J CLIN INVEST, V92, P1674, DOI 10.1172/JCI116753; Matsumoto Y, 2007, NAT MED, V13, P470, DOI 10.1038/nm1566; Morisawa T, 2008, INT J CANCER, V123, P2735, DOI 10.1002/ijc.23853; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nakatani T, 2004, J BIOL CHEM, V279, P16356, DOI 10.1074/jbc.M311740200; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Podolsky DK, 2002, NEW ENGL J MED, V347, P417, DOI 10.1056/NEJMra0804647; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Rai K, 2008, CELL, V135, P1201, DOI 10.1016/j.cell.2008.11.042; REDSTON MS, 1995, GASTROENTEROLOGY, V108, P383, DOI 10.1016/0016-5085(95)90064-0; Sturlan S, 2001, CARCINOGENESIS, V22, P665, DOI 10.1093/carcin/22.4.665; Suzuki K, 2004, P NATL ACAD SCI USA, V101, P1981, DOI 10.1073/pnas.0307317101; Takai A, 2009, ONCOGENE, V28, P469, DOI 10.1038/onc.2008.415; Toda Y, 1999, PATHOL INT, V49, P479, DOI 10.1046/j.1440-1827.1999.00875.x; Watanabe T, 2006, IMMUNITY, V25, P473, DOI 10.1016/j.immuni.2006.06.018; YIN J, 1993, GASTROENTEROLOGY, V104, P1633, DOI 10.1016/0016-5085(93)90639-T	44	35	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	13					1733	1742		10.1038/onc.2011.352	http://dx.doi.org/10.1038/onc.2011.352			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	918EF	21841819	Green Published			2022-12-17	WOS:000302231400011
J	Visser-Grieve, S; Hao, Y; Yang, X				Visser-Grieve, S.; Hao, Y.; Yang, X.			Human homolog of Drosophila expanded, hEx, functions as a putative tumor suppressor in human cancer cell lines independently of the Hippo pathway	ONCOGENE			English	Article						expanded; FRMD6; Willin; Hippo; LATS1; tumor suppressor	REGULATE GROWTH; PROLIFERATION; MERLIN; PROTEIN; LATS1; TUMORIGENESIS; INHIBITION; TRANSITION; APOPTOSIS; DOMAIN	The Hippo signaling network is proving to be an essential regulator within the cell, participating in multiple cellular phenotypes including cell proliferation, apoptosis, cell migration and organ size control. Much of this pathway is conserved from flies to mammals; however, how the upstream components, namely Expanded, affect downstream processes in mammalian systems has remained elusive. Only recently has human Expanded (hEx), also known as FRMD6 or Willin, been identified. However, its functional significance with respect to its putative tumor suppressor function and activation of the Hippo pathway has not been studied. In this study, we show for the first time that hEx possesses several tumor suppressor properties. First, hEx dramatically inhibits cell proliferation in two human cancer cell lines, MDA-MB-231 and MDA-MB-436 cells, and sensitizes these cells to the chemotherapeutic drug Taxol. Furthermore, downregulation of hEx in the immortalized MCF10A breast cell line leads to enhanced proliferation and resistance to Taxol treatment. As evidence for its tumor suppressor function, overexpression of hEx inhibits colony formation, soft agar colony growth in vitro and in vivo tumor growth in nude mice. Although Drosophila expanded (ex) can activate the Hippo pathway, surprisingly no significant alterations were discovered in the phosphorylation status of any of the Hippo pathway components, including downstream tumor suppressor LATS1, upon overexpression of hEx. In addition, knockdown of both LATS1 and LATS2 in hEx-overexpressing cells was unable to rescue the hEx phenotype, suggesting that hEx functions independently of the Hippo pathway in this cell line. Alternatively, we propose a mechanism through which hEx inhibits progression through the S phase of the cell cycle by upregulating p21(Cip1) and downregulating Cyclin A. This is the first study to functionally characterize hEx and show that hEx acts in a distinct manner compared with Drosophila expanded. Oncogene (2012) 31, 1189-1195; doi:10.1038/onc.2011.318; published online 25 July 2011	[Yang, X.] Queens Univ, Dept Pathol & Mol Med, Richardson Labs 201, Kingston, ON K7L 3N6, Canada	McMaster University; Queens University - Canada	Yang, X (corresponding author), Queens Univ, Dept Pathol & Mol Med, Richardson Labs 201, 88 Stuart St, Kingston, ON K7L 3N6, Canada.	yang@cliff.path.queensu.ca		Grieve, Stacy/0000-0003-3090-5583	Canadian Institute of Health Research; Ontario Ministry of Research and Innovation, Canada; Ontario Graduate Scholarship	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Ministry of Research and Innovation, Canada(Ministry of Research and Innovation, Ontario); Ontario Graduate Scholarship(Ontario Graduate Scholarship)	This work was supported by a grant from the Canadian Institute of Health Research, a New Investigator Award from the Canadian Institute of Health Research and an Early Researcher Award from the Ontario Ministry of Research and Innovation, Canada, to Xiaolong Yang; and an Ontario Graduate Scholarship to Stacy Visser-Grieve. We would like to thank Matt Gordon at the Queen's Cancer Research Institute for performing the FACS analysis and Dr Frank Gunn-Moore for providing the hEx-GFP plasmid.	Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Blaumueller CM, 2000, MECH DEVELOP, V92, P251, DOI 10.1016/S0925-4773(00)00246-X; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Boedigheimer MJ, 1997, DEV GENET, V20, P103, DOI 10.1002/(SICI)1520-6408(1997)20:2<103::AID-DVG3>3.0.CO;2-B; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Chan SW, 2008, CANCER RES, V68, P2592, DOI 10.1158/0008-5472.CAN-07-2696; Feng YQ, 2007, P NATL ACAD SCI USA, V104, P20362, DOI 10.1073/pnas.0706722105; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Gunn-Moore FJ, 2005, FEBS LETT, V579, P5089, DOI 10.1016/j.febslet.2005.07.097; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Lai D, 2011, CANCER RES, V71, P2728, DOI 10.1158/0008-5472.CAN-10-2711; Lau YKI, 2008, CANCER RES, V68, P5733, DOI 10.1158/0008-5472.CAN-08-0190; Lei QY, 2008, MOL CELL BIOL, V28, P2426, DOI 10.1128/MCB.01874-07; Li WQ, 2011, CANCER RES, V71, P2162, DOI 10.1158/0008-5472.CAN-10-3268; Li YF, 2003, ONCOGENE, V22, P4398, DOI 10.1038/sj.onc.1206603; McCartney BM, 2000, DEVELOPMENT, V127, P1315; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Ota M, 2008, DEVELOPMENT, V135, P4059, DOI 10.1242/dev.027151; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pellock BJ, 2007, DEV BIOL, V304, P102, DOI 10.1016/j.ydbio.2006.12.021; Polesello C, 2006, CURR BIOL, V16, P2459, DOI 10.1016/j.cub.2006.10.060; Radu M, 2009, CURR BIOL, V19, pR421, DOI 10.1016/j.cub.2009.04.022; Stern C, 1926, GENETICS, V11, P503; Visser S, 2010, CELL CYCLE, V9, P3892, DOI 10.4161/cc.9.19.13386; Visser S, 2010, GENE, V449, P22, DOI 10.1016/j.gene.2009.09.008; Xia H, 2002, ONCOGENE, V21, P1233, DOI 10.1038/sj.onc.1205174; Xiao L, 2011, J BIOL CHEM, V286, P7788, DOI 10.1074/jbc.M110.173468; Yang XL, 2001, ONCOGENE, V20, P6516, DOI 10.1038/sj.onc.1204817; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210	37	35	35	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1189	1195		10.1038/onc.2011.318	http://dx.doi.org/10.1038/onc.2011.318			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21785462				2022-12-17	WOS:000300945900012
J	Mor, I; Carlessi, R; Ast, T; Feinstein, E; Kimchi, A				Mor, I.; Carlessi, R.; Ast, T.; Feinstein, E.; Kimchi, A.			Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase	ONCOGENE			English	Article						DAPk; PKM2; cancer metabolism; glycolysis	DAP-KINASE; CELL-METABOLISM; CANCER-THERAPY; TUMOR-GROWTH; M2; DOMAIN; PHOSPHORYLATION; APOPTOSIS; ISOFORM; PROMOTE	Death-associated protein kinase (DAPk), a multi-domain serine/threonine kinase, regulates numerous cell death mechanisms and harbors tumor suppressor functions. In this study, we report that DAPk directly binds and functionally activates pyruvate kinase M2 (PKM2), a key glycolytic enzyme, which contributes to the regulation of cancer cell metabolism. PKM2 was identified as a novel binding partner of DAPk by a yeast two-hybrid screen. This interaction was validated in vitro by enzyme-linked immunosorbent assay using purified proteins and in vivo by co-immunoprecipitation of the two endogenous proteins from cells. In vitro interaction with full-length DAPk resulted in a significant increase in the activity of PKM2. Conversely, a fragment of DAPk harboring only the functional kinase domain (KD) could neither bind PKM2 in cells nor activate it in vitro. Indeed, DAPk failed to phosphorylate PKM2. Notably, transfection of cells, with a truncated DAPk lacking the KD, elevated endogenous PKM2 activity, suggesting that PKM2 activation by DAPk occurs independently of its kinase activity. DAPk-transfected cells displayed changes in glycolytic activity, as reflected by elevated lactate production, whereas glucose uptake remained unaltered. A mild reduction in cell proliferation was detected as well in these transfected cells. Altogether, this work identifies a new role for DAPk as a metabolic regulator, suggesting the concept of direct interactions between a tumor suppressor and a key glycolytic enzyme to limit cell growth. Moreover, the work documents a unique function of DAPk that is independent of its catalytic activity and a novel mechanism to activate PKM2 by protein-protein interaction. Oncogene (2012) 31, 683-693; doi:10.1038/onc.2011.264; published online 4 July 2011	[Mor, I.; Carlessi, R.; Ast, T.; Feinstein, E.; Kimchi, A.] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Belfer 209, IL-76100 Rehovot, Israel.	adi.kimchi@weizmann.ac.il	Carlessi, Rodrigo/J-1757-2012; Mor, Inbal/GON-5297-2022	Mor, Inbal/0000-0003-4564-9690; Carlessi, Rodrigo/0000-0003-0038-7391	Flight Attendant Medical Research Institute; European Union; Israel Science Foundation	Flight Attendant Medical Research Institute; European Union(European Commission); Israel Science Foundation(Israel Science Foundation)	We thank Dr Shani Bialik for critical reading of the manuscript. GFP-PKM2-containing plasmid was the kind gift of A Ullrich (Max Planck Institute, Martinsried, Germany). A549 cells were the kind gift of M Oren (Weizmann Institute of Science, Rehovot, Israel). This work was supported by the Center of Excellence grant from the Flight Attendant Medical Research Institute, by a grant from the European Union FP7 to APO-SYS and by a grant from the Israel Science Foundation. AK is the incumbent of Helena Rubinstein Chair of Cancer Research.	Bialik S, 2004, CELL DEATH DIFFER, V11, P631, DOI 10.1038/sj.cdd.4401386; Bialik S, 2008, MOL CELL PROTEOMICS, V7, P1089, DOI 10.1074/mcp.M700579-MCP200; Bialik S, 2010, CURR OPIN CELL BIOL, V22, P199, DOI 10.1016/j.ceb.2009.11.004; Bialik S, 2006, ANNU REV BIOCHEM, V75, P189, DOI 10.1146/annurev.biochem.75.103004.142615; Chen CH, 2005, EMBO J, V24, P294, DOI 10.1038/sj.emboj.7600510; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; Clower CV, 2010, P NATL ACAD SCI USA, V107, P1894, DOI 10.1073/pnas.0914845107; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Cohen O, 1999, J CELL BIOL, V146, P141; David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697; DeBerardinis RJ, 2008, CURR OPIN GENET DEV, V18, P54, DOI 10.1016/j.gde.2008.02.003; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Dombrauckas JD, 2005, BIOCHEMISTRY-US, V44, P9417, DOI 10.1021/bi0474923; Eisenberg-Lerner A, 2007, CELL DEATH DIFFER, V14, P1908, DOI 10.1038/sj.cdd.4402212; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; Goldschneider D, 2010, ONCOGENE, V29, P1865, DOI 10.1038/onc.2010.13; Gozuacik D, 2006, AUTOPHAGY, V2, P74, DOI 10.4161/auto.2.2.2459; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kuriyan J, 2007, NATURE, V450, P983, DOI 10.1038/nature06524; Llambi F, 2005, EMBO J, V24, P1192, DOI 10.1038/sj.emboj.7600584; Mason EF, 2011, BBA-MOL CELL RES, V1813, P645, DOI 10.1016/j.bbamcr.2010.08.011; Mazurek S, 2001, BIOCHEM J, V356, P247, DOI 10.1042/0264-6021:3560247; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Raval A, 2007, CELL, V129, P879, DOI 10.1016/j.cell.2007.03.043; Raveh T, 2000, P NATL ACAD SCI USA, V97, P1572, DOI 10.1073/pnas.020519497; Real-Hohn A, 2010, BIOCHIMIE, V92, P538, DOI 10.1016/j.biochi.2010.01.023; Spoden GA, 2008, INT J CANCER, V123, P312, DOI 10.1002/ijc.23512; Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zalckvar E, 2009, EMBO REP, V10, P285, DOI 10.1038/embor.2008.246	34	35	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	6					683	693		10.1038/onc.2011.264	http://dx.doi.org/10.1038/onc.2011.264			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891MU	21725354				2022-12-17	WOS:000300222100002
J	Storm, P; Aits, S; Puthia, MK; Urbano, A; Northen, T; Powers, S; Bowen, B; Chao, Y; Reindl, W; Lee, DY; Sullivan, NL; Zhang, J; Trulsson, M; Yang, H; Watson, JD; Svanborg, C				Storm, P.; Aits, S.; Puthia, M. K.; Urbano, A.; Northen, T.; Powers, S.; Bowen, B.; Chao, Y.; Reindl, W.; Lee, D. Y.; Sullivan, N. L.; Zhang, J.; Trulsson, M.; Yang, H.; Watson, J. D.; Svanborg, C.			Conserved features of cancer cells define their sensitivity to HAMLET-induced death; c-Myc and glycolysis	ONCOGENE			English	Article						HAMLET; metabolism; c-Myc; glycolysis	APOPTOSIS-LIKE MECHANISM; HUMAN ALPHA-LACTALBUMIN; ENERGY-METABOLISM; GLUCOSE-METABOLISM; PYRUVATE-KINASE; TUMOR-CELLS; HYPOXIA; GROWTH; 3-BROMOPYRUVATE; INHIBITION	HAMLET is the first member of a new family of tumoricidal protein-lipid complexes that kill cancer cells broadly, while sparing healthy, differentiated cells. Many and diverse tumor cell types are sensitive to the lethal effect, suggesting that HAMLET identifies and activates conserved death pathways in cancer cells. Here, we investigated the molecular basis for the difference in sensitivity between cancer cells and healthy cells. Using a combination of small-hairpin RNA (shRNA) inhibition, proteomic and metabolomic technology, we identified the c-Myc oncogene as one essential determinant of HAMLET sensitivity. Increased c-Myc expression levels promoted sensitivity to HAMLET and shRNA knockdown of c-Myc suppressed the lethal response, suggesting that oncogenic transformation with c-Myc creates a HAMLET-sensitive phenotype. Furthermore, HAMLET sensitivity was modified by the glycolytic state of tumor cells. Glucose deprivation sensitized tumor cells to HAMLET-induced cell death and in the shRNA screen, hexokinase 1 (HK1), 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 and hypoxia-inducible factor 1 alpha modified HAMLET sensitivity. HK1 was shown to bind HAMLET in a protein array containing similar to 8000 targets, and HK activity decreased within 15min of HAMLET treatment, before morphological signs of tumor cell death. In parallel, HAMLET triggered rapid metabolic paralysis in carcinoma cells. Tumor cells were also shown to contain large amounts of oleic acid and its derivatives already after 15 min. The results identify HAMLET as a novel anti-cancer agent that kills tumor cells by exploiting unifying features of cancer cells such as oncogene addiction or the Warburg effect. Oncogene (2011) 30, 4765-4779; doi: 10.1038/onc.2011.196; published online 6 June 2011	[Storm, P.; Aits, S.; Trulsson, M.; Svanborg, C.] Lund Univ, Dept Lab Med, Div Microbiol Immunol & Glycobiol, S-22362 Lund, Sweden; [Puthia, M. K.; Urbano, A.; Chao, Y.; Yang, H.] ASTAR, Inst Biomed Sci, Singapore Immunol Network SIgN, Singapore, Singapore; [Northen, T.; Bowen, B.; Reindl, W.; Lee, D. Y.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; [Powers, S.; Sullivan, N. L.; Zhang, J.; Watson, J. D.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Lund University; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Cold Spring Harbor Laboratory	Svanborg, C (corresponding author), Lund Univ, Dept Microbiol Immunol & Glycobiol MIG, Inst Lab Med, Solvegatan 23, S-22362 Lund, Sweden.	catharina.svanborg@med.lu.se	Northen, Trent/K-3139-2012; Aits, Sonja/D-1496-2011	Aits, Sonja/0000-0002-1321-0678; Northen, Trent/0000-0001-8404-3259; Storm, Petter/0000-0002-7655-3731; Chao, Yinxia/0000-0003-1185-3511; Powers, Scott/0000-0003-2769-1932; Puthia, Manoj/0000-0001-6048-7234	Sharon D Lund foundation; American Cancer Society; Swedish Cancer Society; Swedish Medical Research Council; Medical Faculty (Lund University); Soderberg Foundation; Anna-Lisa and Sven-Erik Lundgren Foundation for Medical Research; Knut and Alice Wallenberg Foundation; Lund City Jubileumsfond; John and Augusta Persson Foundation for Medical Research; Maggie Stephens Foundation; Gunnar Nilsson Cancer Foundation; Inga-Britt and Arne Lundberg Foundation; HJ Forssman Foundation for Medical Research; Royal Physiographic Society; Swedish Society for Medical Research; Network of Excellence: EuroPathoGenomics; Crafoord Foundation; Osterlund Foundation; US Department of Energy at Berkeley Lab [DE-AC02-05CH11231]; National Institutes of Health, National Cancer Institute [U54 CA 112970]; California Breast Cancer Research Program [15IB-0063]; NATIONAL CANCER INSTITUTE [U54CA112970] Funding Source: NIH RePORTER	Sharon D Lund foundation; American Cancer Society(American Cancer Society); Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Medical Faculty (Lund University); Soderberg Foundation; Anna-Lisa and Sven-Erik Lundgren Foundation for Medical Research; Knut and Alice Wallenberg Foundation(Knut & Alice Wallenberg Foundation); Lund City Jubileumsfond; John and Augusta Persson Foundation for Medical Research; Maggie Stephens Foundation; Gunnar Nilsson Cancer Foundation; Inga-Britt and Arne Lundberg Foundation; HJ Forssman Foundation for Medical Research; Royal Physiographic Society; Swedish Society for Medical Research; Network of Excellence: EuroPathoGenomics; Crafoord Foundation; Osterlund Foundation; US Department of Energy at Berkeley Lab(United States Department of Energy (DOE)); National Institutes of Health, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); California Breast Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the Sharon D Lund foundation grant and the American Cancer Society, the Swedish Cancer Society, the Swedish Medical Research Council, the Medical Faculty (Lund University), the Soderberg Foundation, the Anna-Lisa and Sven-Erik Lundgren Foundation for Medical Research, the Knut and Alice Wallenberg Foundation, the Lund City Jubileumsfond, the John and Augusta Persson Foundation for Medical Research, the Maggie Stephens Foundation, the Gunnar Nilsson Cancer Foundation, the Inga-Britt and Arne Lundberg Foundation, the HJ Forssman Foundation for Medical Research, the Royal Physiographic Society, the Swedish Society for Medical Research, the Network of Excellence: EuroPathoGenomics, the Crafoord Foundation, the Osterlund Foundation, the US Department of Energy Low Dose SFA Program at Berkeley Lab [DE-AC02-05CH11231], the National Institutes of Health, National Cancer Institute grant U54 CA 112970 and the California Breast Cancer Research Program [15IB-0063].	Abu-Hamad S, 2008, J BIOL CHEM, V283, P13482, DOI 10.1074/jbc.M708216200; Balendiran GK, 2004, CELL BIOCHEM FUNCT, V22, P343, DOI 10.1002/cbf.1149; Baran R, 2009, CURR OPIN MICROBIOL, V12, P547, DOI 10.1016/j.mib.2009.07.004; Brest P, 2007, CANCER RES, V67, P11327, DOI 10.1158/0008-5472.CAN-07-1153; Brummelkamp TR, 2003, NAT REV CANCER, V3, P781, DOI 10.1038/nrc1191; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Coleman MC, 2008, FREE RADICAL BIO MED, V44, P322, DOI 10.1016/j.freeradbiomed.2007.08.032; Dang CV, 2008, NAT REV CANCER, V8, P51, DOI 10.1038/nrc2274; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dang CV, 1999, MOL CELL BIOL, V19, P1; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Duringer C, 2003, J BIOL CHEM, V278, P42131, DOI 10.1074/jbc.M306462200; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fiehn O, 2005, LECT NOTES COMPUT SC, V3615, P224; Fischer W, 2004, CANCER RES, V64, P2105, DOI 10.1158/0008-5472.CAN-03-2661; Gustafsson L, 2004, NEW ENGL J MED, V350, P2663, DOI 10.1056/NEJMoa032454; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hernlund E, 2008, INT J CANCER, V123, P476, DOI 10.1002/ijc.23525; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Ihrlund LS, 2008, MOL ONCOL, V2, P94, DOI 10.1016/j.molonc.2008.01.003; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; LI Y, 1984, P NATL ACAD SCI-BIOL, V81, P6808, DOI 10.1073/pnas.81.21.6808; Mathupala SP, 1997, J BIOENERG BIOMEMBR, V29, P339, DOI 10.1023/A:1022494613613; Mazurek S, 2005, SEMIN CANCER BIOL, V15, P300, DOI 10.1016/j.semcancer.2005.04.009; Mossberg AK, 2007, INT J CANCER, V121, P1352, DOI 10.1002/ijc.22810; Mossberg AK, 2010, J UROLOGY, V183, P1590, DOI 10.1016/j.juro.2009.12.008; Nilsson JA, 2003, ONCOGENE, V22, P9007, DOI 10.1038/sj.onc.1207261; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Satoh J, 2006, J NEUROSCI METH, V152, P278, DOI 10.1016/j.jneumeth.2005.09.015; Scholz M, 2007, PACIFIC SYMPOSIUM ON BIOCOMPUTING 2007, P169; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650; Silva JM, 2008, SCIENCE, V319, P617, DOI 10.1126/science.1149185; Smyth GK, 2003, METHODS, V31, P265, DOI 10.1016/S1046-2023(03)00155-5; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Svanborg C, 2003, ADV CANCER RES, V88, P1; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; THOMAS DB, 1975, CELL, V5, P37, DOI 10.1016/0092-8674(75)90089-6; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WATSON PH, 1991, CANCER RES, V51, P3996; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; Yalcin A, 2009, EXP MOL PATHOL, V86, P174, DOI 10.1016/j.yexmp.2009.01.003; Zender L, 2008, CELL, V135, P852, DOI 10.1016/j.cell.2008.09.061; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001	52	35	36	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2011	30	48					4765	4779		10.1038/onc.2011.196	http://dx.doi.org/10.1038/onc.2011.196			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	863AH	21643007	Green Accepted			2022-12-17	WOS:000298134700001
J	Bu, W; Chen, J; Morrison, GD; Huang, S; Creighton, CJ; Huang, J; Chamness, GC; Hilsenbeck, SG; Roop, DR; Leavitt, AD; Li, Y				Bu, W.; Chen, J.; Morrison, G. D.; Huang, S.; Creighton, C. J.; Huang, J.; Chamness, G. C.; Hilsenbeck, S. G.; Roop, D. R.; Leavitt, A. D.; Li, Y.			Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer	ONCOGENE			English	Article						Keratin 6; TVA; RCAS; PyMT; mammary gland; normal-like breast cancer	STEM-CELLS; GENE-EXPRESSION; STEM/PROGENITOR CELLS; GLAND DEVELOPMENT; SELF-RENEWAL; MOUSE MODELS; TUMORIGENESIS; POPULATION; RECEPTOR; SYSTEM	Progenitor cells are considered an important cell of origin of human malignancies. However, there has not been any single gene that can define mammary bipotential progenitor cells, and as such it has not been possible to use genetic methods to introduce oncogenic alterations into these cells in vivo to study tumorigenesis from them. Keratin 6a is expressed in a subset of mammary luminal epithelial cells and body cells of terminal end buds. By generating transgenic mice using the Keratin 6a (K6a) gene promoter to express tumor virus A (tva), which encodes the receptor for avian leukosis virus subgroup A (ALV/A), we provide direct evidence that K6a(+) cells are bipotential progenitor cells, and the first demonstration of a non-basal location for some biopotential progenitor cells. These K6a(+) cells were readily induced to form mammary tumors by intraductal injection of RCAS (an ALV/A-derived vector) carrying the gene encoding the polyoma middle T antigen. Tumors in this K6a-tva line were papillary and resembled the normal breast-like subtype of human breast cancer. This is the first model of this subtype of human tumors and thus may be useful for preclinical testing of targeted therapy for patients with normal-like breast cancer. These observations also provide direct in vivo evidence for the hypothesis that the cell of origin affects mammary tumor phenotypes. Oncogene (2011) 30, 4399-4409; doi:10.1038/onc.2011.147; published online 2 May 2011	[Bu, W.; Morrison, G. D.; Huang, J.; Chamness, G. C.; Hilsenbeck, S. G.; Li, Y.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Chen, J.; Roop, D. R.; Li, Y.] Univ Colorado Denver, Dermatol & Charles C Gates Regenerat Med & Stem C, Aurora, CO USA; [Huang, S.; Li, Y.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Huang, S.; Creighton, C. J.; Hilsenbeck, S. G.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Leavitt, A. D.] Univ Calif San Francisco, Dept Lab Med & Med, San Francisco, CA 94143 USA	Baylor College of Medicine; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Francisco	Li, Y (corresponding author), Baylor Coll Med, Breast Ctr, 1 Baylor Plaza,BCM 600, Houston, TX 77030 USA.	liyi@bcm.edu	Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X	USAMRMC [BC030755, BC073703]; National Institutes of Health [CA113869, CA124820]; MMHCC [U01 CA084243-07]; NCI [P50 CA058183]; NATIONAL CANCER INSTITUTE [P50CA058183, U01CA084243, R01CA113869, R01CA124820] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM069234] Funding Source: NIH RePORTER	USAMRMC(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MMHCC; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Tammy Tong, Amanda McGrath, Ekaterina Bogoslovskaia, Andrei Lazarev, Meghali Goswami and Yiqun Zhang for technical assistance, Drs Jeffrey Rosen and Michael Lewis for stimulating discussions and/or critical review of this manuscript, as well as Drs Robert D Cardiff and Barry Gusterson for advice on pathological comparisons. This work was supported in part by funds from USAMRMC BC030755 and BC073703 (to YL), National Institutes of Health CA113869 and CA124820 (to YL), Project 5 of MMHCC U01 CA084243-07 (to YL; U01 PI: Dr Jeffrey Rosen) and a developmental project of NCI P50 CA058183 (to YL; SPORE PI: Dr C Kent Osborne).	Andrechek ER, 2004, P NATL ACAD SCI USA, V101, P4984, DOI 10.1073/pnas.0306802101; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Badders NM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006594; Bai LX, 2010, GENE DEV, V24, P1882, DOI 10.1101/gad.1932810; BATES P, 1993, CELL, V74, P1043, DOI 10.1016/0092-8674(93)90726-7; Desai KV, 2002, P NATL ACAD SCI USA, V99, P6967, DOI 10.1073/pnas.102172399; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Fisher GH, 1999, ONCOGENE, V18, P5253, DOI 10.1038/sj.onc.1203087; Grimm SL, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1504; Henry MD, 2004, ONCOGENE, V23, P6980, DOI 10.1038/sj.onc.1207827; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Hughes SH, 2004, FOLIA BIOL-PRAGUE, V50, P107; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Jeselsohn R, 2010, CANCER CELL, V17, P65, DOI 10.1016/j.ccr.2009.11.024; Li Y, 2005, J MAMMARY GLAND BIOL, V10, P17, DOI 10.1007/s10911-005-2537-2; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Lindvall C, 2007, STEM CELL REV, V3, P157, DOI 10.1007/s12015-007-0025-3; Mollet M, 2008, BIOTECHNOL BIOENG, V100, P260, DOI 10.1002/bit.21762; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Rosner A, 2002, AM J PATHOL, V161, P1087, DOI 10.1016/S0002-9440(10)64269-1; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sleeman KE, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1371; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Toneff MJ, 2010, NEOPLASIA, V12, P718, DOI 10.1593/neo.10516; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Wojcik SM, 2001, J CELL BIOL, V154, P619, DOI 10.1083/jcb.200102079; Zeng YA, 2010, CELL STEM CELL, V6, P568, DOI 10.1016/j.stem.2010.03.020	35	35	35	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	2011	30	43					4399	4409		10.1038/onc.2011.147	http://dx.doi.org/10.1038/onc.2011.147			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	839HQ	21532625	Green Accepted, Green Submitted			2022-12-17	WOS:000296356500003
J	Goetz, EM; Shankar, B; Zou, Y; Morales, JC; Luo, X; Araki, S; Bachoo, R; Mayo, LD; Boothman, DA				Goetz, E. M.; Shankar, B.; Zou, Y.; Morales, J. C.; Luo, X.; Araki, S.; Bachoo, R.; Mayo, L. D.; Boothman, D. A.			ATM-dependent IGF-1 induction regulates secretory clusterin expression after DNA damage and in genetic instability	ONCOGENE			English	Article						secretory clusterin; ATM; IGF-1; p53; ionizing radiation; genetic instability	Y TRANSCRIPTION FACTOR; GROWTH-FACTOR-BETA; NF-Y; GENOMIC INSTABILITY; ATAXIA-TELANGIECTASIA; SIGNALING PATHWAY; PROSTATE-CANCER; MELANOMA-CELLS; IN-VITRO; P53	Secretory clusterin (sCLU) is a stress-induced, prosurvival glycoprotein elevated in early-stage cancers, in particular in APC/Min-defective colon cancers. sCLU is upregulated after exposure to various cytotoxic agents, including ionizing radiation (IR), leading to a survival advantage. We found that stimulation of insulin-like growth factor-1 (IGF-1) and IGF-1R protein kinase signaling was required for sCLU induction after IR exposure. Here, we show that activation of Ataxia telangiectasia-mutated kinase (ATM) by endogenous or exogenous forms of DNA damage was required to relieve basal repression of IGF-1 transcription by the p53/NF-YA complex, leading to sCLU expression. Although p53 levels were stabilized and elevated after DNA damage, dissociation of NF-YA, and thereby p53, from the IGF-1 promoter resulted in IGF-1 induction, indicating that NF-YA was rate limiting. Cells with elevated endogenous DNA damage (deficient in H2AX, MDC1, NBS1, mTR or hMLH1) or cells exposed to DNA-damaging agents had elevated IGF-1 expression, resulting in activation of IGF-1R signaling and sCLU induction. In contrast, ATM-deficient cells were unable to induce sCLU after DNA damage. Our results integrate DNA damage resulting from genetic instability, IR, or chemotherapeutic agents, to ATM activation and abrogation of p53/NF-YA-mediated IGF-1 transcriptional repression, that induces IGF-1-sCLU expression. Elucidation of this pathway should uncover new mechanisms for cancer progression and reveal new targets for drug development to overcome resistance to therapy. Oncogene (2011) 30, 3745-3754; doi:10.1038/onc.2011.92; published online 4 April 2011	[Goetz, E. M.; Shankar, B.; Zou, Y.; Morales, J. C.; Luo, X.; Araki, S.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Oncol, Lab Mol Stress Responses, Dallas, TX 75390 USA; [Goetz, E. M.; Shankar, B.; Zou, Y.; Morales, J. C.; Luo, X.; Araki, S.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Lab Mol Stress Responses, Dallas, TX 75390 USA; [Goetz, E. M.; Shankar, B.; Zou, Y.; Morales, J. C.; Luo, X.; Araki, S.; Boothman, D. A.] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Lab Mol Stress Responses, Dallas, TX 75390 USA; [Bachoo, R.] Univ Texas SW Med Ctr Dallas, Simmons Comprehens Canc Ctr, Dept Neurooncol, Program Cell Stress & Canc Nanomed, Dallas, TX 75390 USA; [Mayo, L. D.] Indiana Univ Sch Med, Indiana Univ Simon Canc Ctr, Dept Pediat, Herman B Wells Ctr Pediat Res,Dept Biochem & Mol, Indianapolis, IN USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Indiana University System; Indiana University Bloomington	Boothman, DA (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Oncol, Lab Mol Stress Responses, 6001 Forest Pk Rd,ND2-210K, Dallas, TX 75390 USA.	David.Boothman@UTSouthwestern.edu	Boothman, David/Q-7776-2019	Morales, Julio/0000-0002-0854-7866	DOE [DE-FG02-06ER64186-17]; DOD BCRP [W81XWH-06-0748]; DOD PCRP [X8IXWH-09-1-0168]; Robert B and Virginia Payne Endowment; SAIR NIH [CA126608]; Imaging Shared Resource of the Simmons Cancer Center; NATIONAL CANCER INSTITUTE [U24CA126608, P30CA142543, R01CA139217] Funding Source: NIH RePORTER	DOE(United States Department of Energy (DOE)); DOD BCRP(United States Department of Defense); DOD PCRP; Robert B and Virginia Payne Endowment; SAIR NIH; Imaging Shared Resource of the Simmons Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by DOE grant (#DE-FG02-06ER64186-17) to DAB, a DOD BCRP pre-doctoral fellowship (W81XWH-06-0748) to EMG and a DOD PCRP post-doctoral fellowship (X8IXWH-09-1-0168) to XL. We are grateful to the Robert B and Virginia Payne Endowment for support of this work. We also thank the support received from the SAIR NIH U24 grant CA126608 and the Imaging Shared Resource of the Simmons Cancer Center. This is CSCN #024 and used the Flow Cytometry and Biostatistics cores of the Simmons Comprehensive Cancer Center.	Andarawewa KL, 2007, CANCER RES, V67, P8662, DOI 10.1158/0008-5472.CAN-07-1294; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Bentle MS, 2006, J BIOL CHEM, V281, P33684, DOI 10.1074/jbc.M603678200; Bocchetta M, 2008, CANCER RES, V68, P1022, DOI 10.1158/0008-5472.CAN-07-5203; Boggs LN, 1996, J NEUROCHEM, V67, P1324; BOOTHMAN DA, 1993, P NATL ACAD SCI USA, V90, P7200, DOI 10.1073/pnas.90.15.7200; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen XD, 2003, P NATL ACAD SCI USA, V100, P9530, DOI 10.1073/pnas.1233633100; Chi KN, 2010, J CLIN ONCOL, V28, P4247, DOI 10.1200/JCO.2009.26.8771; Criswell T, 2005, J BIOL CHEM, V280, P14212, DOI 10.1074/jbc.M412569200; Criswell T, 2003, CANCER BIOL THER, V2, P372, DOI 10.4161/cbt.2.4.430; DARPA P, 1990, CANCER RES, V50, P6919; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Hao LY, 2004, CHROMOSOMA, V113, P62, DOI 10.1007/s00412-004-0291-7; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Klokov D, 2004, MUTAT RES-FUND MOL M, V568, P97, DOI 10.1016/j.mrfmmm.2004.06.049; KOJIS TL, 1991, CANCER GENET CYTOGEN, V56, P143, DOI 10.1016/0165-4608(91)90164-P; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; Lou ZK, 2006, MOL CELL, V21, P187, DOI 10.1016/j.molcel.2005.11.025; Macaulay VM, 2001, ONCOGENE, V20, P4029, DOI 10.1038/sj.onc.1204565; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Matsui T, 2004, J BIOL CHEM, V279, P25093, DOI 10.1074/jbc.M403232200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Mittanck DW, 1997, MOL CELL ENDOCRINOL, V126, P153, DOI 10.1016/S0303-7207(96)03979-2; Miyake H, 2000, CANCER RES, V60, P2547; Peng Y, 2007, ONCOGENE, V26, P7576, DOI 10.1038/sj.onc.1210565; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Ryan PD, 2008, ONCOLOGIST, V13, P16, DOI 10.1634/theoncologist.2007-0199; Shahrabani-Gargir L, 2004, ENDOCRINOLOGY, V145, P5679, DOI 10.1210/en.2004-0613; So A, 2005, MOL CANCER THER, V4, P1837, DOI 10.1158/1535-7163.MCT-05-0178; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Sulkowski S, 2009, CLIN CHEM LAB MED, V47, P1439, DOI 10.1515/CCLM.2009.305; Wagner MW, 2008, J BIOL CHEM, V283, P21382, DOI 10.1074/jbc.M709953200; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; Yan J, 2006, CANCER RES, V66, P11039, DOI 10.1158/0008-5472.CAN-06-2442; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Yun JH, 2003, J BIOL CHEM, V278, P36966, DOI 10.1074/jbc.M305178200; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	46	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	35					3745	3754		10.1038/onc.2011.92	http://dx.doi.org/10.1038/onc.2011.92			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814TZ	21460853	Green Accepted			2022-12-17	WOS:000294481400002
J	Willecke, M; Toggweiler, J; Basler, K				Willecke, M.; Toggweiler, J.; Basler, K.			Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model	ONCOGENE			English	Article						cell cycle; Drosophila; PI3K; tumor	PHOSPHOINOSITIDE 3-KINASE; IMAGINAL DISC; GENETIC SCREEN; S-PHASE; PATHWAY; GROWTH; RAS; KINASE; PROLIFERATION; CANCER	Tumorigenesis is a complex process, which requires alterations in several tumor suppressor or oncogenes. Here, we use a Drosophila tumor model to identify genes, which are specifically required for tumor growth. We found that reduction of phosphoinositide 3-kinase (PI3K) activity resulted in very small tumors while only slightly affecting growth of wild-type tissue. The observed inhibition on tumor growth occurred at the level of cell-cycle progression. We conclude that tumor cells become dependent on PI3K function and that reduction of PI3K activity synthetically interferes with tumor growth. The results presented here broaden our insights into the intricate mechanisms underling tumorigenesis and illustrate the power of Drosophila genetics in revealing weak points of tumor progression. Oncogene (2011) 30, 4067-4074; doi:10.1038/onc.2011.125; published online 25 April 2011	[Willecke, M.; Toggweiler, J.; Basler, K.] Univ Zurich, Inst Mol Life Sci, CH-8057 Zurich, Switzerland	University of Zurich	Basler, K (corresponding author), Univ Zurich, Inst Mol Life Sci, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	basler@imls.uzh.ch		Basler, Konrad/0000-0003-3534-1529	FEBS; Swiss National Science Foundation; Kanton of Zurich	FEBS; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Kanton of Zurich	We would like to thank G Hausmann and J Zartman for comments on the manuscript; A Smith for help with experiments; and H Stocker, the Bloomington Stock Center, the National Institute of Genetics (NIG) and the Vienna Drosophila RNAi Center (VDRC) for fly strains. This work was supported by an FEBS Long-term Fellowship to MW, the Swiss National Science Foundation and the Kanton of Zurich.	Bach EA, 2003, GENETICS, V165, P1149; Bach EA, 2007, GENE EXPR PATTERNS, V7, P323, DOI 10.1016/j.modgep.2006.08.003; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Cleary JM, 2010, CURR ONCOL REP, V12, P87, DOI 10.1007/s11912-010-0091-6; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; EDGAR BA, 1990, CELL, V62, P469, DOI 10.1016/0092-8674(90)90012-4; Gupta S, 2007, CELL, V129, P957, DOI 10.1016/j.cell.2007.03.051; Halfar K, 2001, DEVELOPMENT, V128, P1687; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Newsome TP, 2000, DEVELOPMENT, V127, P851; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; Read RD, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000374; RICHARDSON H, 1995, DEVELOPMENT, V121, P3371; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; STEWART M, 1972, DEV BIOL, V27, P71, DOI 10.1016/0012-1606(72)90113-3; Verdu J, 1999, NAT CELL BIOL, V1, P500, DOI 10.1038/70293; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Weinkove D, 1999, CURR BIOL, V9, P1019, DOI 10.1016/S0960-9822(99)80450-3; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702	32	35	36	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	39					4067	4074		10.1038/onc.2011.125	http://dx.doi.org/10.1038/onc.2011.125			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	826ME	21516128				2022-12-17	WOS:000295357500002
J	Dalvai, M; Mondesert, O; Bourdon, JC; Ducommun, B; Dozier, C				Dalvai, M.; Mondesert, O.; Bourdon, J-C; Ducommun, B.; Dozier, C.			Cdc25B is negatively regulated by p53 through Sp1 and NF-Y transcription factors	ONCOGENE			English	Article						Cdc25B; p53; Sp1; NF-Y	CELL-CYCLE REGULATION; WILD-TYPE P53; BREAST-CANCER; DNA-DAMAGE; EXPRESSION; ACTIVATION; PHOSPHATASE; APOPTOSIS; GENES; TRIGGERS	Cdc25B phosphatases function as key players in G2/M cell cycle progression by activating the CDK1-cyclinB1 complexes. They also have an essential role in recovery from the G2/M checkpoint activated in response to DNA damage. Overexpression of Cdc25B results in bypass of the G2/M checkpoint and illegitimate entry into mitosis, and also causes replicative stress, leading to genomic instability. Thus, fine-tuning of Cdc25B expression level is critical for correct cell cycle progression and G2 checkpoint recovery. However, the transcriptional regulation of Cdc25B remains largely unknown. Earlier studies have shown that the tumor suppressor p53 overexpression transcriptionally represses Cdc25B; however, the molecular mechanism of this repression has not yet been elucidated, although it was suggested to occur through the induction of p21. Here we show that Cdc25B is downregulated by the basal level of p53 in multiple cell types. This downregulation also occurs in p21-/- cell lines, indicating that p21 is not required for p53-mediated regulation of Cdc25B. Deletion and mutation analyses of the Cdc25B promoter revealed that downregulation by p53 is dependent on the presence of functional Sp1/Sp3 and NF-Y binding sites. Furthermore, chromatin immuno-precipitation analyses show that p53 binds to the Cdc25B promoter and mediates transcriptional attenuation through the Sp1 and NF-Y transcription factors. Our results suggest that the inability to downregulate Cdc25B after loss of p53 might contribute to tumorigenesis. Oncogene (2011) 30, 2282-2288; doi:10.1038/onc.2010.588; published online 17 January 2011	[Dalvai, M.; Mondesert, O.; Ducommun, B.; Dozier, C.] Univ Toulouse, CNRS, LBCMCP, UMR 5088, F-31062 Toulouse, France; [Bourdon, J-C] Univ Dundee, Dept Surg & Mol Oncol, European Associated Lab, INSERM,U858,Coll Med, Dundee, Scotland; [Ducommun, B.] CHU Toulouse, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Dundee; CHU de Toulouse	Dozier, C (corresponding author), Univ Toulouse, CNRS, LBCMCP, UMR 5088, Bat 4R3B1,118 Route Narbonne, F-31062 Toulouse, France.	dozier@cict.fr	DOZIER, Christine/P-1539-2014; DUCOMMUN, Bernard/B-3208-2008; JC, Bourdon/A-4439-2008	JC, Bourdon/0000-0003-4623-9386; DUCOMMUN, Bernard/0000-0002-7126-8368	CNRS (Centre National de la Recherche Scientifique); Universite Paul Sabatier; CNRS, Universite Paul Sabatier, la region Midi-Pyrenees, l'Institut National du Cancer; Canceropole; la Ligue Nationale Contre le Cancer	CNRS (Centre National de la Recherche Scientifique)(Centre National de la Recherche Scientifique (CNRS)); Universite Paul Sabatier; CNRS, Universite Paul Sabatier, la region Midi-Pyrenees, l'Institut National du Cancer(Region Occitanie); Canceropole(Region Ile-de-France); la Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	We thank Dr Bert Vogelstein (Howard Hughes Medical Institute, Baltimore USA) for providing the WT, p53-/- and p21-/- HCT116 cells. MD was a recipient of a postdoctoral fellowship from the CNRS (Centre National de la Recherche Scientifique). This work was supported by CNRS, Universite Paul Sabatier, la region Midi-Pyrenees, l'Institut National du Cancer, the Canceropole Grand Sud-Ouest and la Ligue Nationale Contre le Cancer (Equipe labellisee 2008).	Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Baldin V, 1997, ONCOGENE, V14, P2485, DOI 10.1038/sj.onc.1201063; Benatti P, 2008, NUCLEIC ACIDS RES, V36, P1415, DOI 10.1093/nar/gkm1046; Bocangel D, 2009, ANTICANCER RES, V29, P3741; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Brosh R, 2010, MOL BIOSYST, V6, P17, DOI 10.1039/b911416e; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bugler B, 2006, MOL CANCER THER, V5, P1446, DOI 10.1158/1535-7163.MCT-06-0099; Bugler B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-29; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Essafi-Benkhadir K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004478; Iacovoni JS, 2010, EMBO J, V29, P1446, DOI 10.1038/emboj.2010.38; Imbriano C, 2005, MOL CELL BIOL, V25, P3737, DOI 10.1128/MCB.25.9.3737-3751.2005; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; Jin W, 2008, J BIOL CHEM, V283, P29671, DOI 10.1074/jbc.M802785200; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Korner K, 2001, J BIOL CHEM, V276, P9662, DOI 10.1074/jbc.M008696200; Koutsodontis G, 2005, BIOCHEM J, V389, P443, DOI 10.1042/BJ20041980; Lambertini C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010369; Langerod A, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1675; Lin RK, 2010, CANCER RES, V70, P5807, DOI 10.1158/0008-5472.CAN-09-4161; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; Miyata H, 2001, CANCER RES, V61, P3188; Muller GA, 2010, FEBS J, V277, P877, DOI 10.1111/j.1742-4658.2009.07508.x; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Scian MJ, 2008, ONCOGENE, V27, P2583, DOI 10.1038/sj.onc.1210898; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Torgeman A, 2001, VIROLOGY, V281, P10, DOI 10.1006/viro.2000.0779; Troester MA, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-276; Varmeh S, 2009, J BIOL CHEM, V284, P9475, DOI 10.1074/jbc.M900037200; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang B, 2010, CELL CYCLE, V9, P870, DOI 10.4161/cc.9.5.10825; Wierstra I, 2008, BIOCHEM BIOPH RES CO, V372, P1, DOI 10.1016/j.bbrc.2008.03.074; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200	39	35	39	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2011	30	19					2282	2288		10.1038/onc.2010.588	http://dx.doi.org/10.1038/onc.2010.588			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	762XD	21242964				2022-12-17	WOS:000290514600011
J	Azmi, AS; Philip, PA; Beck, FWJ; Wang, Z; Banerjee, S; Wang, S; Yang, D; Sarkar, FH; Mohammad, RM				Azmi, A. S.; Philip, P. A.; Beck, F. W. J.; Wang, Z.; Banerjee, S.; Wang, S.; Yang, D.; Sarkar, F. H.; Mohammad, R. M.			MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy	ONCOGENE			English	Article						MDM2 and p53; small molecule inhibitors; zinc; apoptosis	NF-KAPPA-B; SMALL-MOLECULE INHIBITORS; SUPPRESSOR PROTEIN P53; STRUCTURE-BASED DESIGN; DNA-BINDING ACTIVITY; ZINC-DEFICIENCY; WILD-TYPE; CANCER; APOPTOSIS; NUCLEAR	Zinc has a crucial role in the biology of p53 in that p53 binds to DNA through a structurally complex domain stabilized by zinc atom. The p53 negative regulator MDM2 protein also carries a C-terminal RING domain that coordinates two zinc atoms, which are responsible for p53 nuclear export and proteasomal degradation. In this clinically translatable study, we explored the critical role of zinc on p53 reactivation by MDM2 inhibitor, MI-219, in colon and breast cancer cells. ZnCl2 enhanced MI-219 activity (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), apoptosis and colony formation), and chelation of zinc not only blocked the activity of MI-219, but also suppressed reactivation of the p53 and its downstream effector molecules p21(WAF1) and Bax. N,N,N'N'-tetrakis(-)[2-pyridylmethyl]- ethylenediamine (TPEN), a specific zinc chelator, but not 1,2-bis-(o-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid (Bapta-AM), a calcium chelator, blocked MI-219-induced apoptosis. Nuclear localization is a prerequisite for proper functioning of p53 and our results confirm that TPEN, and not Bapta-AM, could abrogate p53 nuclear localization and it interfered with p53 transcriptional activation. Addition of zinc suppressed the known p53 feedback MDM2 activation, which could be restored by TPEN. Co-immunoprecipitation studies verified that MI-219-mediated MDM2-p53 disruption could be suppressed by TPEN and restored by zinc. As such, single-agent therapies that target MDM2 inhibition, without supplemental zinc, may not be optimal in certain patients owing to the less recognized mild zinc deficiency among the 'at-risk population' as in the elderly who are more prone to cancers. Therefore, use of supplemental zinc with MI-219 will benefit the overall efficacy of MIs and this potent combination warrants further investigation. Oncogene (2011) 30, 117-126; doi: 10.1038/onc.2010.403; published online 6 September 2010	[Philip, P. A.; Beck, F. W. J.; Mohammad, R. M.] Wayne State Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol,Karmanos Canc Inst, Detroit, MI 48201 USA; [Azmi, A. S.; Wang, Z.; Banerjee, S.; Sarkar, F. H.] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Pathol, Detroit, MI 48201 USA; [Wang, S.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; [Wang, S.] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; [Wang, S.; Yang, D.] Ascenta Therapeut Inc, Malvern, PA USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Mohammad, RM (corresponding author), Wayne State Univ, Sch Med, Dept Internal Med, Div Hematol & Oncol,Karmanos Canc Inst, 732 HWCRC,4100 John R St, Detroit, MI 48201 USA.	mohammar@karmanos.org	Wang, Zhiwei/A-6809-2011	Wang, Shaomeng/0000-0002-8782-6950; AZMI, ASFAR/0000-0003-1178-9505	National Cancer Institute, NIH [R01CA109389]; NIH [5R01CA101870]; Guido foundation; NATIONAL CANCER INSTITUTE [R01CA101870, R01CA109389, R01CA121279] Funding Source: NIH RePORTER	National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Guido foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	National Cancer Institute, NIH Grant R01CA109389 (RM Mohammad) and NIH Grant 5R01CA101870 (FH Sarkar) are acknowledged. We sincerely acknowledge the Guido foundation for their support.	Alshatwi AA, 2006, EXP BIOL MED, V231, P611; Azmi AS, 2010, EUR J CANCER, V46, P1122, DOI 10.1016/j.ejca.2010.01.015; Azmi AS, 2008, MOL CANCER THER, V7, P2884, DOI 10.1158/1535-7163.MCT-08-0438; Bao B, 2006, TOXICOL LETT, V166, P222, DOI 10.1016/j.toxlet.2006.07.306; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Beck FWJ, 2004, PROSTATE, V58, P374, DOI 10.1002/pros.10344; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Brown K, 2004, FOOD NUTR BULL, V25, P99, DOI DOI 10.1177/15648265040251S205; Butler JS, 2007, BIOCHEMISTRY-US, V46, P2630, DOI 10.1021/bi062106y; Butler JS, 2003, BIOCHEMISTRY-US, V42, P2396, DOI 10.1021/bi026635n; Canner JA, 2009, BRIT J CANCER, V101, P774, DOI 10.1038/sj.bjc.6605199; Chen GD, 2006, BIOCHEM BIOPH RES CO, V344, P272, DOI 10.1016/j.bbrc.2006.03.136; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; Collins K, 1997, P NATL ACAD SCI USA, V94, P2776, DOI 10.1073/pnas.94.7.2776; Ding K, 2005, J AM CHEM SOC, V127, P10130, DOI 10.1021/ja051147z; Ding K, 2006, J MED CHEM, V49, P3432, DOI 10.1021/jm051122a; Feng ZH, 2008, CELL CYCLE, V7, P842, DOI 10.4161/cc.7.7.5657; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Hambidge KM, 1998, AM J CLIN NUTR, V68, p410S, DOI 10.1093/ajcn/68.2.410S; Ho E, 2004, J NUTR BIOCHEM, V15, P572, DOI 10.1016/j.jnutbio.2004.07.005; Ho E, 2002, P NATL ACAD SCI USA, V99, P16770, DOI 10.1073/pnas.222679399; Ho E, 2009, CURR OPIN CLIN NUTR, V12, P640, DOI 10.1097/MCO.0b013e32833106ee; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lane DP, 2004, NATURE, V427, P789, DOI 10.1038/427789a; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lindstrom MS, 2007, MOL CELL BIOL, V27, P1056, DOI 10.1128/MCB.01307-06; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Meplan C, 2000, ONCOGENE, V19, P5227, DOI 10.1038/sj.onc.1203907; Meplan C, 1999, P NUTR SOC, V58, P565, DOI 10.1017/S0029665199000749; Mohammad RM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-115; O'Brate A, 2003, DRUG RESIST UPDATE, V6, P313, DOI 10.1016/j.drup.2003.10.004; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Prasad AS, 2004, MET IONS BIOL SYST, V41, P103; Prasad AS, 2002, J LAB CLIN MED, V140, P272, DOI 10.1067/mlc.2002.127908; PRASAD AS, 1993, NUTRITION, V9, P218; Prasad AS, 2001, NUTRITION, V17, P685, DOI 10.1016/S0899-9007(01)00598-6; Prasad AS, 2001, J LAB CLIN MED, V138, P250, DOI 10.1067/mlc.2001.118108; Shangary S, 2008, P NATL ACAD SCI USA, V105, P3933, DOI 10.1073/pnas.0708917105; Shangary S, 2009, ANNU REV PHARMACOL, V49, P223, DOI 10.1146/annurev.pharmtox.48.113006.094723; Vassilev LT, 2007, TRENDS MOL MED, V13, P23, DOI 10.1016/j.molmed.2006.11.002; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Verma R, 2010, BIOCHEM PHARMACOL, V79, P565, DOI 10.1016/j.bcp.2009.09.020; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Wawrzynow B, 2009, J BIOL CHEM, V284, P11517, DOI 10.1074/jbc.M809294200; Yu SH, 2009, J MED CHEM, V52, P7970, DOI 10.1021/jm901400z; Zalewski P D, 1994, Chem Biol, V1, P153, DOI 10.1016/1074-5521(94)90005-1; ZALEWSKI PD, 1993, BIOCHEM J, V296, P403, DOI 10.1042/bj2960403	51	35	36	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	1					117	126		10.1038/onc.2010.403	http://dx.doi.org/10.1038/onc.2010.403			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	703EQ	20818437	Green Accepted			2022-12-17	WOS:000285959300011
J	Leclercq, TM; Moretti, PAB; Pitson, SM				Leclercq, T. M.; Moretti, P. A. B.; Pitson, S. M.			Guanine nucleotides regulate sphingosine kinase 1 activation by eukaryotic elongation factor 1A and provide a mechanism for eEF1A-associated oncogenesis	ONCOGENE			English	Article						sphingosine kinase; sphingosine 1-phosphate; eEF1A; PTI-1; TCTP	CONTROLLED TUMOR PROTEIN; PTI-1 ONCOGENE; FACTOR EEF1A; CANCER; PHOSPHORYLATION; COMPLEX; GROWTH; REVERSION; ISOFORM; CLONING	Sphingosine kinase 1 (SK1) catalyses the formation of bioactive phospholipid sphingosine 1-phosphate (S1P). Elevated cellular SK1 activity and S1P levels enhance cell proliferation and survival, and are strongly implicated in tumourigenesis. Regulation of SK1 activity can occur through various mechanisms, including phosphorylation and protein-protein interactions. We have previously shown that eukaryotic elongation factor 1A (eEF1A) interacts with and directly activates SK1, but the mechanisms regulating this were undefined. Notably, eEF1A has GTPase activity and can exist in GTP- or GDP-bound forms, which are associated with distinct structural conformations of the protein. Here, we show that the guanine nucleotide-bound state of eEF1A regulates its ability to activate SK1, with eEF1A.GDP, but not eEF1A.GTP, enhancing SK1 activity in vitro. Furthermore, we show that enhancing cellular eEF1A. GDP levels through expression of a guanine nucleotide dissociation inhibitor of eEF1A, translationally controlled tumour protein (TCTP), increased SK1 activity in cells. We also examined a truncated isoform of eEF1A1, termed prostate tumour inducer-1 (PTI-1), which can induce neoplastic cell transformation through undefined mechanisms. PTI-1 lacks the G protein domain of eEF1A1 and is therefore unable to undergo the GTP-binding-induced conformational change. Notably, we found that PTI-1 can directly activate SK1 and that this seems to be essential for neoplastic transformation induced by PTI-1, as chemical SK1 inhibitors or overexpression of a dominant- negative SK1 blocked this process. Thus, this study defines the mechanism regulating eEF1A-mediated SK1 activation, and also establishes SK1 as being integral for PTI-1-induced oncogenesis. Oncogene (2011) 30, 372-378; doi:10.1038/onc.2010.420; published online 13 September 2010	[Pitson, S. M.] SA Pathol, Ctr Canc Biol, Div Human Immunol, Mol Signalling Lab, Adelaide, SA 5000, Australia; [Leclercq, T. M.; Pitson, S. M.] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia	Centre for Cancer Biology; SA Pathology; University of Adelaide	Pitson, SM (corresponding author), SA Pathol, Ctr Canc Biol, Div Human Immunol, Mol Signalling Lab, Frome Rd, Adelaide, SA 5000, Australia.	stuart.pitson@health.sa.gov.au	Pitson, Stuart/B-9342-2009	Pitson, Stuart/0000-0002-9527-2740; Moretti, Paul/0000-0002-3523-1496	Fay Fuller Foundation; Cancer Council of South Australia [399330]; National Health and Medical Research Council of Australia	Fay Fuller Foundation; Cancer Council of South Australia(Cancer Council South Australia); National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the Fay Fuller Foundation, an Australian Postgraduate Award (to TML), Project Grant 399330 from the Cancer Council of South Australia and a Senior Research Fellowship from the National Health and Medical Research Council of Australia (to SMP).	Abbott CM, 2004, TRENDS BIOCHEM SCI, V29, P25, DOI 10.1016/j.tibs.2003.11.006; Al-Maghrebir M, 2005, ANTICANCER RES, V25, P2573; Andersen GR, 2000, MOL CELL, V6, P1261, DOI 10.1016/S1097-2765(00)00122-2; Andersen GR, 2003, TRENDS BIOCHEM SCI, V28, P434, DOI 10.1016/S0968-0004(03)00162-2; Cans C, 2003, P NATL ACAD SCI USA, V100, P13892, DOI 10.1073/pnas.2335950100; Cuvillier O, 2008, EXPERT OPIN THER TAR, V12, P1009, DOI [10.1517/14728222.12.8.1009, 10.1517/14728222.12.8.1009 ]; Ejiri S, 2002, BIOSCI BIOTECH BIOCH, V66, P1, DOI 10.1271/bbb.66.1; French KJ, 2003, CANCER RES, V63, P5962; Gopalkrishnan RV, 1999, INT J BIOCHEM CELL B, V31, P151, DOI 10.1016/S1357-2725(98)00138-1; Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007; Kahns S, 1998, NUCLEIC ACIDS RES, V26, P1884, DOI 10.1093/nar/26.8.1884; Kawamori T, 2009, FASEB J, V23, P405, DOI 10.1096/fj.08-117572; Kohno M, 2006, MOL CELL BIOL, V26, P7211, DOI 10.1128/MCB.02341-05; Leclercq TM, 2008, J BIOL CHEM, V283, P9606, DOI 10.1074/jbc.M708782200; Lee Jonathan M, 2003, Reprod Biol Endocrinol, V1, P69, DOI 10.1186/1477-7827-1-69; Liu H, 2005, MOL CELL BIOL, V25, P3117, DOI 10.1128/MCB.25.8.3117-3126.2005; Mansilla F, 2005, BBA-GENE STRUCT EXPR, V1727, P116, DOI 10.1016/j.bbaexp.2004.12.012; Mansilla F, 2002, BIOCHEM J, V365, P669, DOI 10.1042/BJ20011681; Panasyuk G, 2008, INT J BIOCHEM CELL B, V40, P63, DOI 10.1016/j.biocel.2007.08.014; Pitson SM, 2000, BIOCHEM J, V350, P429, DOI 10.1042/0264-6021:3500429; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Pitson SM, 2005, J EXP MED, V201, P49, DOI 10.1084/jem.20040559; Pitson SM, 2002, J BIOL CHEM, V277, P49545, DOI 10.1074/jbc.M206687200; Roberts JL, 2004, ANAL BIOCHEM, V331, P122, DOI 10.1016/j.ab.2004.03.030; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; Soares DC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006315; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P1764, DOI 10.1073/pnas.95.4.1764; Susini L, 2008, CELL DEATH DIFFER, V15, P1211, DOI 10.1038/cdd.2008.18; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Thornton S, 2003, J MOL MED, V81, P536, DOI 10.1007/s00109-003-0461-8; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Tuynder M, 2002, P NATL ACAD SCI USA, V99, P14976, DOI 10.1073/pnas.222470799; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Yu L, 2006, TOHOKU J EXP MED, V209, P141, DOI 10.1620/tjem.209.141	35	35	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2011	30	3					372	378		10.1038/onc.2010.420	http://dx.doi.org/10.1038/onc.2010.420			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709DY	20838377				2022-12-17	WOS:000286418800012
J	Nevo, J; Mai, A; Tuomi, S; Pellinen, T; Pentikainen, OT; Heikkila, P; Lundin, J; Joensuu, H; Bono, P; Ivaska, J				Nevo, J.; Mai, A.; Tuomi, S.; Pellinen, T.; Pentikainen, O. T.; Heikkila, P.; Lundin, J.; Joensuu, H.; Bono, P.; Ivaska, J.			Mammary-derived growth inhibitor (MDGI) interacts with integrin alpha-subunits and suppresses integrin activity and invasion	ONCOGENE			English	Article						integrin; MDGI; breast cancer; adhesion; migration; invasion	FATTY-ACID-BINDING; BREAST-CANCER; PROXIMITY LIGATION; BETA(1) INTEGRIN; CELL-MIGRATION; IN-SITU; ACTIVATION; PROTEIN; ADHESION; TALIN	The majority of mortality associated with cancer is due to formation of metastases from the primary tumor. Adhesion mediated by different integrin heterodimers has an important role during cell migration and invasion. Protein interactions with the beta 1-integrin cytoplasmic tail are known to influence integrin affinity for extracellular ligands, but regulating binding partners for the alpha-subunit cytoplasmic tails have remained elusive. In this study, we show that mammary-derived growth inhibitor (MDGI) (also known as FABP-3 or H-FABP) binds directly to the cytoplasmic tail of integrin alpha-subunits and its expression inhibits integrin activity. In breast cancer cell lines, MDGI expression correlates with suppression of the active conformation of integrins. This results in reduced integrin adhesion to type I collagen and fibronectin and inhibition of cell migration and invasion. In tissue microarray of 1331 breast cancer patients, patients with MDGI-positive tumors had more favorable 10-year distant disease-free survival compared with patients with MDGI-negative tumors. Our data indicate that MDGI is a novel interacting partner for integrin alpha-subunits, and its expression modulates integrin activity and suppresses cell invasion in breast cancer patients. Retained MDGI expression is associated with favorable prognosis. Oncogene (2010) 29, 6452-6463; doi:10.1038/onc.2010.376; published online 30 August 2010	[Ivaska, J.] Univ Turku, VTT Med Biotechnol, Turku Ctr Biotechnol, FIN-20520 Turku, Finland; [Nevo, J.; Mai, A.; Tuomi, S.; Pellinen, T.; Ivaska, J.] VTT Tech Res Ctr Finland, Turku, Finland; [Nevo, J.; Mai, A.; Tuomi, S.; Pellinen, T.; Ivaska, J.] Abo Akad Univ, Turku, Finland; [Pentikainen, O. T.] Univ Jyvaskyla, Dept Biol & Environm Sci, Jyvaskyla, Finland; [Pentikainen, O. T.] Univ Jyvaskyla, Nanosci Ctr, Jyvaskyla, Finland; [Heikkila, P.] Helsinki Univ Hosp, Dept Pathol, Helsinki, Finland; [Lundin, J.; Joensuu, H.; Bono, P.] Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland; [Ivaska, J.] Univ Turku, Dept Biochem & Food Chem, FIN-20520 Turku, Finland	University of Turku; VTT Technical Research Center Finland; VTT Technical Research Center Finland; Abo Akademi University; University of Jyvaskyla; University of Jyvaskyla; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; University of Turku	Ivaska, J (corresponding author), Univ Turku, VTT Med Biotechnol, Turku Ctr Biotechnol, Itainen Pitkakatu 4C, FIN-20520 Turku, Finland.	johanna.ivaska@vtt.fi	Lundin, Johan/I-1843-2018; Lundin, Johan/AAC-8510-2020; Pentikäinen, Olli T/E-1980-2012	Lundin, Johan/0000-0002-2681-4139; Lundin, Johan/0000-0002-2681-4139; Pentikäinen, Olli T/0000-0001-7188-4016; Joensuu, Heikki/0000-0003-0281-2507; Ivaska, Johanna/0000-0002-6295-6556	Academy of Finland; ERC; Sigrid Juselius Foundation; EMBO YIP Cancer Organization; Finnish Cancer Organization; Maud Kuistila Memorial Foundation; Turku University Foundation; Turku Graduate School of Biomedical Sciences; Drug Discovery Graduate School	Academy of Finland(Academy of Finland); ERC(European Research Council (ERC)European Commission); Sigrid Juselius Foundation(Sigrid Juselius Foundation); EMBO YIP Cancer Organization; Finnish Cancer Organization; Maud Kuistila Memorial Foundation; Turku University Foundation; Turku Graduate School of Biomedical Sciences; Drug Discovery Graduate School	We thank Professor J Ylanne and Professor M Salmi for critically reviewing the paper; J Siivonen, H Marttila, O Levalampi and P Terho for the excellent technical assistance. This study has been supported by Academy of Finland, ERC Starting Grant, Sigrid Juselius Foundation, EMBO YIP and Finnish Cancer Organizations. JN has been supported by Maud Kuistila Memorial Foundation and Turku University Foundation. JN, ST and TP were supported by Turku Graduate School of Biomedical Sciences and AM by Drug Discovery Graduate School.	Anthis NJ, 2009, EMBO J, V28, P3623, DOI 10.1038/emboj.2009.287; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; Bottcher RT, 2009, CURR OPIN CELL BIOL, V21, P670, DOI 10.1016/j.ceb.2009.05.008; Bouaouina M, 2008, J BIOL CHEM, V283, P6118, DOI 10.1074/jbc.M709527200; Bouvard D, 2003, J BIOL CHEM, V278, P6567, DOI 10.1074/jbc.M211258200; Brandt DT, 2009, NAT CELL BIOL, V11, P557, DOI 10.1038/ncb1862; Byron A, 2009, J CELL SCI, V122, P4009, DOI 10.1242/jcs.056770; Clark AJ, 2000, TRANSGENIC RES, V9, P439, DOI 10.1023/A:1026552629493; Czuchra A, 2006, J CELL BIOL, V174, P889, DOI 10.1083/jcb.200604060; Gietz RD, 2002, METHOD ENZYMOL, V350, P87; Harburger DS, 2009, J BIOL CHEM, V284, P11485, DOI 10.1074/jbc.M809233200; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; Huynh H, 1997, CLIN CANCER RES, V3, P2151; Huynh H, 1996, CANCER RES, V56, P4865; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jarvius M, 2007, MOL CELL PROTEOMICS, V6, P1500, DOI 10.1074/mcp.M700166-MCP200; Kiosses WB, 2001, NAT CELL BIOL, V3, P316, DOI 10.1038/35060120; Kloeker S, 2004, J BIOL CHEM, V279, P6824, DOI 10.1074/jbc.M307978200; Koistinen P, 1999, MATRIX BIOL, V18, P239, DOI 10.1016/S0945-053X(99)00022-0; KURTZ A, 1990, J CELL BIOL, V110, P1779, DOI 10.1083/jcb.110.5.1779; Lau TL, 2009, EMBO J, V28, P1351, DOI 10.1038/emboj.2009.63; Legate KR, 2009, GENE DEV, V23, P397, DOI 10.1101/gad.1758709; Lehtonen JV, 2004, J COMPUT AID MOL DES, V18, P401, DOI 10.1007/s10822-004-3752-4; Lucke C, 2001, BIOCHEM J, V354, P259, DOI 10.1042/0264-6021:3540259; Lundin J, 2001, J CLIN ONCOL, V19, P28, DOI 10.1200/JCO.2001.19.1.28; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Mattila E, 2005, NAT CELL BIOL, V7, P78, DOI 10.1038/ncb1209; Millon-Fremillon A, 2008, J CELL BIOL, V180, P427, DOI 10.1083/jcb.200707142; Nevo J, 2009, CLIN CANCER RES, V15, P6570, DOI 10.1158/1078-0432.CCR-09-0773; Pellinen T, 2006, J CELL BIOL, V173, P767, DOI 10.1083/jcb.200509019; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Shi XH, 2007, J BIOL CHEM, V282, P20455, DOI 10.1074/jbc.M611680200; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Tadokoro S, 2003, SCIENCE, V302, P103, DOI 10.1126/science.1086652; Takala H, 2008, BLOOD, V112, P1853, DOI 10.1182/blood-2007-12-127795; Tuomi S, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000135; Vinogradova O, 2004, P NATL ACAD SCI USA, V101, P4094, DOI 10.1073/pnas.0400742101; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Wang HL, 2000, ONCOGENE, V19, P2455, DOI 10.1038/sj.onc.1203575; Wang WG, 2004, CANCER RES, V64, P8585, DOI 10.1158/0008-5472.CAN-04-1136; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wegener KL, 2007, CELL, V128, P171, DOI 10.1016/j.cell.2006.10.048; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Zhang X, 2008, NAT CELL BIOL, V10, P1062, DOI 10.1038/ncb1765	47	35	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2010	29	49					6452	6463		10.1038/onc.2010.376	http://dx.doi.org/10.1038/onc.2010.376			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	692FP	20802519				2022-12-17	WOS:000285138900005
J	Licchesi, JDF; Van Neste, L; Tiwari, VK; Cope, L; Lin, X; Baylin, SB; Herman, JG				Licchesi, J. D. F.; Van Neste, L.; Tiwari, V. K.; Cope, L.; Lin, X.; Baylin, S. B.; Herman, J. G.			Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc	ONCOGENE			English	Article						WIF-1; Wnt signaling; c-Myc; Miz-1; DNA methylation	C-MYC; EPIGENETIC INACTIVATION; DNA METHYLATION; CANCER; PROMOTER; GENE; EXPRESSION; MIZ-1; REPRESSES; PROTEIN	The Wnt signaling pathway is capable of self-regulation through positive and negative feedback mechanisms. For example, the oncoprotein c-Myc, which is upregulated by Wnt signaling activity, participates in a positive feedback loop of canonical Wnt signaling through repression of Wnt antagonists DKK1 and SFRP1. In this study, we investigated the mechanism of Wnt inhibitory factor-1 (WIF-1) silencing. Mapping of CpG island methylation of the WIF-1 promoter reveals regional methylation (-295 to -95 bp from the transcription start site) that correlates with transcriptional silencing. We identified Miz-1 as a direct activator of WIF-1 transcriptional activity, which is found at WIF-1 promoter. In addition, we show that c-Myc contributes to WIF-1 transcriptional repression in a Miz-1-dependent manner. Although the transient repression mediated by Miz-1/c-Myc is independent of de novo methylation, the stable repression by this complex is associated with CpG island methylation of the critical -295 to -95-bp region of the WIF-1 promoter. Importantly, Miz-1 and c-Myc are found at WIF-1 promoter in WIF-1 non-expressing cell lines DLD-1 and 209myc. Transient knockdown or somatic knockout of c-Myc in DLD-1 failed to restore WIF-1 expression suggesting that c-Myc is involved in initiating rather than maintaining WIF-1 epigenetic silencing. In a genome-wide screen, DNAJA4, TGF beta-induced and TRIM59 were repressed by c-Myc overexpression and DNA promoter hypermethylation. Our data reveal novel insights into c-Myc-mediated DNA methylation-dependent transcriptional silencing, a mechanism that might contribute to the dysregulation of Wnt signaling in cancer. Oncogene (2010) 29, 5923-5934; doi:10.1038/onc.2010.322; published online 9 August 2010	[Licchesi, J. D. F.] MRC Lab Mol Biol, Cambridge CB2 0QH, England; [Licchesi, J. D. F.; Tiwari, V. K.; Cope, L.; Baylin, S. B.; Herman, J. G.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Canc Biol Program, Baltimore, MD 21231 USA; [Van Neste, L.] Univ Ghent, Dept Mol Biotechnol, Fac Biosci Engn, B-9000 Ghent, Belgium; [Lin, X.] Johns Hopkins Univ, Dept Appl Math & Stat, Whiting Sch Engn, Baltimore, MD USA	MRC Laboratory Molecular Biology; Johns Hopkins University; Johns Hopkins Medicine; Ghent University; Johns Hopkins University	Licchesi, JDF (corresponding author), MRC Lab Mol Biol, Hills Rd, Cambridge CB2 0QH, England.	jlicchesi@yahoo.com; hermanji@jhmi.edu		Licchesi, Julien/0000-0003-3786-3013	NCI [CA058184, P30 CA06973-44]; AICR [07-0040]; Medical Research Council [MC_U105192713, MC_U105184273] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [P30CA006973, P50CA058184] Funding Source: NIH RePORTER; MRC [MC_U105184273, MC_U105192713] Funding Source: UKRI	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); AICR; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We acknowledge Dr Martin Eilers (Marbourg University, Germany), Dr Arthur Riggs (Beckman Research Institute, Duarte, CA, USA) and Dr Bert Vogelstein (Johns Hopkins School of Medicine, USA) for plasmids, Dr Kurt Bachman (University of Maryland, USA) for the DLD-1 c-Myc -/- DNA and cDNA. We are grateful to Dr Wayne Yu at the Johns Hopkins Microarray Core facility, Dr Kornel Schuebel for his help with the microarray experiment and Dr Mariann Bienz for her support. Finally, we thank all the members of the Baylin/Herman laboratory for useful discussions and Kathy Bender for administrative assistance. This study was supported by NCI/SPORE grant CA058184 to James G Herman, AICR grant 07-0040 to Mariann Bienz (MRC-LMB) and NCI grant P30 CA06973-44 to Leslie Cope.	Ahmed AA, 2007, CANCER CELL, V12, P514, DOI 10.1016/j.ccr.2007.11.014; Ai LB, 2006, CARCINOGENESIS, V27, P1341, DOI 10.1093/carcin/bgi379; Barr LF, 2000, CANCER RES, V60, P143; Benanti JA, 2007, MOL CANCER RES, V5, P1181, DOI 10.1158/1541-7786.MCR-06-0372; Bowen H, 2002, J BIOL CHEM, V277, P34997, DOI 10.1074/jbc.M204232200; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Bush A, 1998, GENE DEV, V12, P3797, DOI 10.1101/gad.12.24.3797; Chan SL, 2007, LAB INVEST, V87, P644, DOI 10.1038/labinvest.3700547; Chen ZX, 2005, J CELL BIOCHEM, V95, P902, DOI 10.1002/jcb.20447; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; de la Roche M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-199; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Finlan LE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000039; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Gebhardt A, 2006, J CELL BIOL, V172, P139, DOI 10.1083/jcb.200506057; Guarda A, 2009, EXP CELL RES, V315, P1895, DOI 10.1016/j.yexcr.2009.01.019; GUJRAL TS, 2009, SCI SIGNAL, V2, pNIL6; Halaban R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004563; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hsieh JC, 1999, NATURE, V398, P431, DOI 10.1038/18899; Ikegaki N, 2007, CLIN CANCER RES, V13, P6001, DOI 10.1158/1078-0432.CCR-07-0071; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Li ZJ, 2009, CANCER RES, V69, P1109, DOI 10.1158/0008-5472.CAN-08-3381; Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017; Liu X, 2008, ONCOGENE, V27, P1478, DOI 10.1038/sj.onc.1210769; Mazieres J, 2004, CANCER RES, V64, P4717, DOI 10.1158/0008-5472.CAN-04-1389; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Osborne CS, 2007, PLOS BIOL, V5, P1763, DOI 10.1371/journal.pbio.0050192; Patel JH, 2007, J BIOL CHEM, V282, P5, DOI 10.1074/jbc.M609138200; Patel JH, 2006, J BIOL CHEM, V281, P3283, DOI 10.1074/jbc.M513038200; Perini G, 2005, P NATL ACAD SCI USA, V102, P12117, DOI 10.1073/pnas.0409097102; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Reguart N, 2004, BIOCHEM BIOPH RES CO, V323, P229, DOI 10.1016/j.bbrc.2004.08.075; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Shah JN, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-284; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Tang YX, 2009, MOL CANCER THER, V8, P458, DOI 10.1158/1535-7163.MCT-08-0885; Taniguchi H, 2005, ONCOGENE, V24, P7946, DOI 10.1038/sj.onc.1208910; Tiwari VK, 2008, PLOS BIOL, V6, P2911, DOI 10.1371/journal.pbio.0060306; Urakami S, 2006, CLIN CANCER RES, V12, P383, DOI 10.1158/1078-0432.CCR-05-1344; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Villa R, 2007, CANCER CELL, V11, P513, DOI 10.1016/j.ccr.2007.04.009; Wu SQ, 2003, ONCOGENE, V22, P351, DOI 10.1038/sj.onc.1206145; Yu L, 2005, NAT GENET, V37, P265, DOI 10.1038/ng1521; Zhang Y, 2009, CANCER RES, V69, P37, DOI 10.1158/0008-5472.CAN-08-1648; Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396	52	35	42	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5923	5934		10.1038/onc.2010.322	http://dx.doi.org/10.1038/onc.2010.322			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697356	Green Accepted			2022-12-17	WOS:000283843400006
J	Olsen, BB; Issinger, OG; Guerra, B				Olsen, B. B.; Issinger, O-G; Guerra, B.			Regulation of DNA-dependent protein kinase by protein kinase CK2 in human glioblastoma cells	ONCOGENE			English	Article						DNA-PK; CK2; autophosphorylation; DNA repair; glioblastoma cells	DOUBLE-STRAND BREAKS; CATALYTIC SUBUNIT; IN-VIVO; IONIZING-RADIATION; CYCLE ARREST; AUTOPHOSPHORYLATION; REPAIR; DAMAGE; PHOSPHORYLATION; APOPTOSIS	The DNA-dependent protein kinase (DNA-PK) is a nuclear serine/threonine protein kinase composed of a large catalytic subunit (DNA-PKcs) and a heterodimeric DNA-targeting subunit Ku. DNA-PK is a major component of the nonhomologous end-joining pathway of DNA double-strand breaks repair. Although DNA-PK has been biochemically characterized in vitro, relatively little is known about its functions in the context of DNA repair and how its kinase activity is precisely regulated in vivo. Here, we report that cellular depletion of the individual catalytic subunits of protein kinase CK2 by RNA interference leads to significant cell death in M059K human glioblastoma cells expressing DNA-PKcs, but not in their isogenic counterpart, that is M059J cells, devoid of DNA-PKcs. The lack of CK2 results in enhanced DNA-PKcs activity and strongly inhibits DNA damage-induced autophosphorylation of DNA-PKcs at S2056 as well as repair of DNA double-strand breaks. By the application of the in situ proximity ligation assay, we show that CK2 interacts with DNA-PKcs in normal growing cells and that the association increases upon DNA damage. These results indicate that CK2 has an important role in the modulation of DNA-PKcs activity and its phosphorylation status providing important insights into the mechanisms by which DNA-PKcs is regulated in vivo. Oncogene (2010) 29, 6016-6026; doi:10.1038/onc.2010.337; published online 16 August 2010	[Olsen, B. B.; Issinger, O-G; Guerra, B.] Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Fyn, Denmark	University of Southern Denmark	Guerra, B (corresponding author), Univ So Denmark, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense, Fyn, Denmark.	bag@bmb.sdu.dk	Olsen, Birgitte B/U-2382-2017	Olsen, Birgitte B/0000-0002-6130-0387; Guerra, Barbara/0000-0003-1136-2413	Danish Cancer Society [DP08152, DP06083, DP07109]; Danish Natural Science Research Council [272-07-0258]	Danish Cancer Society(Danish Cancer Society); Danish Natural Science Research Council(Danish Natural Science Research Council)	This study was supported by grants from the Danish Cancer Society (DP08152) and the Danish Natural Science Research Council (272-07-0258) to BG. BBO and OGI were supported by grants from the Danish Cancer Society (DP06083, DP07109).	Achari Y, 2000, METH MOL B, V99, P85; Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875; Bibby AC, 2005, INT J BIOL SCI, V1, P67; BIEDERBICK A, 1995, EUR J CELL BIOL, V66, P3; Block WD, 2004, NUCLEIC ACIDS RES, V32, P4351, DOI 10.1093/nar/gkh761; Canton DA, 2001, BIOCHEM J, V358, P87, DOI 10.1042/0264-6021:3580087; Chan DW, 2002, GENE DEV, V16, P2333, DOI 10.1101/gad.1015202; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chen BPC, 2007, J BIOL CHEM, V282, P6582, DOI 10.1074/jbc.M611605200; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Ding Q, 2003, MOL CELL BIOL, V23, P5836, DOI 10.1128/MCB.23.16.5836-5848.2003; Douglas P, 2002, BIOCHEM J, V368, P243, DOI 10.1042/BJ20020973; Douglas P, 2007, MOL CELL BIOL, V27, P1581, DOI 10.1128/MCB.01962-06; Guerra B, 2008, CURR MED CHEM, V15, P1870, DOI 10.2174/092986708785132933; Harrison JC, 2006, ANNU REV GENET, V40, P209, DOI 10.1146/annurev.genet.40.051206.105231; Helleday T, 2007, DNA REPAIR, V6, P923, DOI 10.1016/j.dnarep.2007.02.006; Kuo LJ, 2008, IN VIVO, V22, P305; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Loizou JI, 2004, CELL, V117, P17, DOI 10.1016/S0092-8674(04)00206-5; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; Matsumoto Y, 1997, BIOCHEM BIOPH RES CO, V234, P568, DOI 10.1006/bbrc.1997.6689; Merkle D, 2002, BIOCHEMISTRY-US, V41, P12706, DOI 10.1021/bi0263558; Niefind K, 2000, ACTA CRYSTALLOGR D, V56, P1680, DOI 10.1107/S0907444900013627; Olsen BB, 2008, MOL CELL BIOCHEM, V316, P115, DOI 10.1007/s11010-008-9817-2; Olsen BB, 2008, MOL CELL BIOCHEM, V316, P37, DOI 10.1007/s11010-008-9824-3; Olsen BB, 2006, PROTEIN EXPRES PURIF, V47, P651, DOI 10.1016/j.pep.2005.12.001; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; Sandholt IS, 2009, ANTI-CANCER DRUG, V20, P238, DOI 10.1097/CAD.0b013e328326472e; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; St-Denis NA, 2009, CELL MOL LIFE SCI, V66, P1817, DOI 10.1007/s00018-009-9150-2; Trembley JH, 2009, CELL MOL LIFE SCI, V66, P1858, DOI 10.1007/s00018-009-9154-y; Uematsu N, 2007, J CELL BIOL, V177, P219, DOI 10.1083/jcb.200608077; Wang HC, 2006, CANCER RES, V66, P1391, DOI 10.1158/0008-5472.CAN-05-3270; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; Weterings E, 2007, J CELL BIOL, V179, P183, DOI 10.1083/jcb.200705106; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Yao KC, 2003, J NEUROSURG, V98, P378, DOI 10.3171/jns.2003.98.2.0378; Yde CW, 2007, MOL CANCER THER, V6, P1869, DOI 10.1158/1535-7163.MCT-07-0072; Zhan YH, 2009, BIOCHEM BIOPH RES CO, V378, P273, DOI 10.1016/j.bbrc.2008.11.038	39	35	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	45					6016	6026		10.1038/onc.2010.337	http://dx.doi.org/10.1038/onc.2010.337			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	678VA	20711232				2022-12-17	WOS:000284108700004
J	Schmidt, S; Schneider, L; Essmann, F; Cirstea, IC; Kuck, F; Kletke, A; Janicke, RU; Wiek, C; Hanenberg, H; Ahmadian, MR; Schulze-Osthoff, K; Nurnberg, B; Piekorz, RP				Schmidt, S.; Schneider, L.; Essmann, F.; Cirstea, I. C.; Kuck, F.; Kletke, A.; Jaenicke, R. U.; Wiek, C.; Hanenberg, H.; Ahmadian, M. R.; Schulze-Osthoff, K.; Nuernberg, B.; Piekorz, R. P.			The centrosomal protein TACC3 controls paclitaxel sensitivity by modulating a premature senescence program	ONCOGENE			English	Article						centrosome; mitosis; paclitaxel; p21(WAF); premature senescence; TACC3	SPINDLE POLE ORGANIZATION; CELLULAR SENESCENCE; BREAST-CANCER; AURORA-A; APOPTOSIS; CELLS; ERK; P53; PHOSPHORYLATION; CHECKPOINT	Microtubule-interfering cancer drugs such as paclitaxel (PTX) often cause chemoresistance and severe side effects, including neurotoxicity. To explore potentially novel antineoplastic molecular targets, we investigated the cellular response of breast carcinoma cells to short hairpin(sh)RNA-mediated depletion of the centrosomal protein transforming acidic coiled coil (TACC) 3, an Aurora A kinase target expressed during mitosis. Unlike PTX, knockdown of TACC3 did not trigger a cell death response, but instead resulted in a progressive loss of the pro-apoptotic Bcl-2 protein Bim that links microtubule integrity to spindle poison-induced cell death. Interestingly, TACC3-depleted cells arrested in G(1) through a cellular senescence program characterized by the upregulation of nuclear p21(WAF), downregulation of the retinoblastoma protein and extracellular signal-regulated kinase 1/2, formation of HP1 gamma (phospho-Ser83)-positive senescence-associated heterochromatic foci and increased senescence-associated beta-galactosidase activity. Remarkably, the onset of senescence following TACC3 knockdown was strongly accelerated in the presence of non-toxic PTX concentrations. Thus, we conclude that mitotic spindle stress is a major trigger of premature senescence and propose that the combined targeting of the centrosomal Aurora A-TACC3 axis together with drugs interfering with microtubule dynamics may efficiently improve the chemosensitivity of cancer cells. Oncogene (2010) 29, 6184-6192; doi:10.1038/onc.2010.354; published online 23 August 2010	[Schmidt, S.; Schneider, L.; Cirstea, I. C.; Kuck, F.; Ahmadian, M. R.; Nuernberg, B.; Piekorz, R. P.] Univ Dusseldorf, Inst Biochem & Mol Biol 2, Univ Klinikum, D-40225 Dusseldorf, Germany; [Jaenicke, R. U.] Univ Dusseldorf, Klin Strahlentherapie & Radioonkol, Univ Klinikum, D-40225 Dusseldorf, Germany; [Wiek, C.; Hanenberg, H.] Univ Dusseldorf, Klin Kinder Onkol Hamatol & Klin Immunol, Univ Klinikum, D-40225 Dusseldorf, Germany; [Essmann, F.; Schulze-Osthoff, K.] Univ Tubingen, Abt Mol Med, IFIB, Tubingen, Germany; [Hanenberg, H.] Indiana Univ Sch Med, Riley Hosp Children, Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN USA; [Nuernberg, B.] Klinikum Eberhard Karls Univ, Inst Expt & Klin Pharmakol, Tubingen, Germany; [Nuernberg, B.] Klinikum Eberhard Karls Univ, Interfak Zentrum Pharmakogenom & Arzneimittelfors, Tubingen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Eberhard Karls University of Tubingen; Indiana University System; Indiana University Bloomington; James Whitcomb Riley Hospital Children; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Piekorz, RP (corresponding author), Univ Dusseldorf, Inst Biochem & Mol Biol 2, Univ Klinikum, D-40225 Dusseldorf, Germany.	roland.piekorz@uni-duesseldorf.de	Essmann, Frank/ABG-7409-2020; Schneider, Leonid/H-3275-2013; Schulze-Osthoff, Klaus/N-9025-2013; Cirstea, Ion Cristian/AAQ-7670-2020	Essmann, Frank/0000-0003-4369-8456; Schneider, Leonid/0000-0002-6204-9470; Schulze-Osthoff, Klaus/0000-0003-1443-2720; Cirstea, Ion Cristian/0000-0003-3204-1598; Nurnberg, Bernd/0000-0002-5995-6555; Wiek, Constanze/0000-0003-2214-8148	Collaborative Research Centers of the Deutsche Forschungsgemeinschaft [SFB728, SFB773, SPP1230]; Forschungskommission (Medizinische Fakultat) of the Heinrich-Heine-Universitat; NGFNplus program [01GS08100]; Bundesministerium fur Bildung und Forschung	Collaborative Research Centers of the Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Forschungskommission (Medizinische Fakultat) of the Heinrich-Heine-Universitat; NGFNplus program; Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF))	Grant support: Collaborative Research Centers SFB728 (RUJ, RPP), SFB773 (FE, KSO), and SPP1230 (HH) of the Deutsche Forschungsgemeinschaft; Forschungskommission (Medizinische Fakultat) of the Heinrich-Heine-Universitat (ICC, MRA, RUJ, RPP); and the NGFNplus program (grant 01GS08100 to MRA) and the network for bone marrow failure syndromes (bmfs to HH) of the Bundesministerium fur Bildung und Forschung.	Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Blagosklonny MV, 2006, J CELL PHYSIOL, V209, P592, DOI 10.1002/jcp.20750; Blagosklonny MV, 2006, CELL CYCLE, V5, P1574, DOI 10.4161/cc.5.14.3113; Blagosklonny MV, 2006, CELL CYCLE, V5, P971, DOI 10.4161/cc.5.9.2711; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Broude EV, 2007, ONCOGENE, V26, P6954, DOI 10.1038/sj.onc.1210516; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Cassimeris L, 2004, MOL BIOL CELL, V15, P1580, DOI 10.1091/mbc.E03-07-0544; Collado M, 2006, NAT REV CANCER, V6, P472, DOI 10.1038/nrc1884; Czernick M, 2009, BIOCHEM BIOPH RES CO, V379, P145, DOI 10.1016/j.bbrc.2008.12.025; Demidenko ZN, 2008, ONCOGENE, V27, P4402, DOI 10.1038/onc.2008.82; Essmann F, 2004, CANCER RES, V64, P7065, DOI 10.1158/0008-5472.CAN-04-1082; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gaumont-Leclerc MF, 2004, J BIOL CHEM, V279, P46802, DOI 10.1074/jbc.M403893200; Gergely F, 2003, GENE DEV, V17, P336, DOI 10.1101/gad.245603; Gergely F, 2002, BIOESSAYS, V24, P915, DOI 10.1002/bies.10162; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Horgan AM, 2003, EXP CELL RES, V285, P208, DOI 10.1016/S0014-4827(03)00037-5; Huck JJ, 2010, MOL CANCER RES, V8, P373, DOI 10.1158/1541-7786.MCR-09-0300; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janssen K, 2007, BLOOD, V110, P3662, DOI 10.1182/blood-2007-02-073213; Jung CK, 2006, PATHOL INT, V56, P503, DOI 10.1111/j.1440-1827.2006.01998.x; Kadura S, 2005, CELL MOTIL CYTOSKEL, V61, P145, DOI 10.1002/cm.20072; Khodjakov Alexey, 2009, Journal of Biology (London), V8, P1, DOI 10.1186/jbiol195; Kiemeney LA, 2010, NAT GENET, V42, P415, DOI 10.1038/ng.558; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lauffart Brenda, 2005, BMC Womens Health, V5, P8, DOI 10.1186/1472-6874-5-8; LeRoy PJ, 2007, CANCER RES, V67, P5362, DOI 10.1158/0008-5472.CAN-07-0122; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Li Z, 2007, CELL DEATH DIFFER, V14, P318, DOI 10.1038/sj.cdd.4401983; Liang Y, 2001, ONCOGENE, V20, P6570, DOI 10.1038/sj.onc.1204815; Maehara K, 2010, MOL CELL BIOL, V30, P2090, DOI 10.1128/MCB.01318-09; Mikule K, 2007, NAT CELL BIOL, V9, P160, DOI 10.1038/ncb1529; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Pajalunga D, 2007, J CELL BIOL, V176, P807, DOI 10.1083/jcb.200608109; Piekorz RP, 2002, EMBO J, V21, P653, DOI 10.1093/emboj/21.4.653; Prencipe M, 2009, BRIT J CANCER, V101, P1900, DOI 10.1038/sj.bjc.6605419; Roninson IB, 2001, DRUG RESIST UPDATE, V4, P303, DOI 10.1054/drup.2001.0213; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Schneider L, 2008, ONCOGENE, V27, P116, DOI 10.1038/sj.onc.1210628; Schneider L, 2007, J BIOL CHEM, V282, P29273, DOI 10.1074/jbc.M704151200; Schuendeln MM, 2004, MOL CELL BIOL, V24, P6403, DOI 10.1128/MCB.24.14.6403-6409.2004; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Simstein R, 2003, EXP BIOL MED, V228, P995, DOI 10.1177/153537020322800903; Srsen V, 2006, J CELL BIOL, V174, P625, DOI 10.1083/jcb.200606051; Tierno MB, 2009, J PHARMACOL EXP THER, V328, P715, DOI 10.1124/jpet.108.147330; Torii S, 2006, CANCER SCI, V97, P697, DOI 10.1111/j.1349-7006.2006.00244.x; Tresini M, 2007, J BIOL CHEM, V282, P4136, DOI 10.1074/jbc.M604955200; Yao R, 2007, CANCER SCI, V98, P555, DOI 10.1111/j.1349-7006.2007.00433.x; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189; Zhang RG, 2007, MOL CELL BIOL, V27, P949, DOI 10.1128/MCB.01639-06; Zyss D, 2009, TRENDS CELL BIOL, V19, P334, DOI 10.1016/j.tcb.2009.04.001	55	35	37	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	46					6184	6192		10.1038/onc.2010.354	http://dx.doi.org/10.1038/onc.2010.354			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681XD	20729911				2022-12-17	WOS:000284356500010
J	Das, PM; Thor, AD; Edgerton, SM; Barry, SK; Chen, DF; Jones, FE				Das, P. M.; Thor, A. D.; Edgerton, S. M.; Barry, S. K.; Chen, D. F.; Jones, F. E.			Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells	ONCOGENE			English	Article						breast cancer; EGFR-family; epigenetics; apoptosis; heregulin	INTRACELLULAR DOMAIN 4ICD; ESTROGEN-RECEPTOR; BH3-ONLY PROTEIN; GENE-EXPRESSION; MAMMARY-GLAND; CANCER; ERBB4; METHYLATION; HER4; DIFFERENTIATION	Experimental and clinical data support a growth inhibitory role for HER4 in breast cancer. Clinically HER4 expression is extinguished during breast tumorigenesis supporting a tumor suppressor function for HER4, however, a molecular mechanism to explain the selective loss of HER4 expression has remained elusive. Epigenetic mechanisms, for example, aberrant gene promoter hypermethylation, have been shown to ablate tumor suppressor gene expression in breast carcinomas. We identified a CpG island within the HER4 promoter and show by pyrosequencing of bisulfite-treated DNA an inverse correlation between HER4 expression and the extent of promoter methylation. Treatment of the HER4-negative BT20 cell line with the DNA demethylating agent 5-aza-2'-deoxycytidine (DAC)-enhanced HER4 expression, confirming a role for DNA methylation in suppressed HER4 expression. DAC treatment to reactive HER4 expression in combination with the HER4 ligand heregulin-beta 1 (HRG) resulted in apoptosis of BT20 cells providing a novel therapeutic strategy for triple-negative tumors. The BT20 cells were rescued from apoptosis when preincubated with HER4 small interfering RNA, thereby confirming a role for HER4 in DAC/HRG-induced apoptosis. We verified HER4 promoter methylation in primary breast carcinomas and detected a significant increase in HER4 promoter methylation in HER4-negative breast tumors (P < 0.001). Furthermore, increased levels of HER4 promoter methylation were significantly associated with worse patient prognosis (P = 0.0234). Taken together, our data support a tumor suppressor function for HER4, which is epigenetically suppressed in breast tumors through promoter hypermethylation. Oncogene (2010) 29, 5214-5219; doi:10.1038/onc.2010.271; published online 5 July 2010	[Das, P. M.; Jones, F. E.] Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA; [Thor, A. D.; Edgerton, S. M.] Univ Colorado Denver, Dept Pathol, Aurora, CO USA; [Barry, S. K.; Chen, D. F.] Tulane Univ, Sch Med, New Orleans, LA 70112 USA	Tulane University; Children's Hospital Colorado; University of Colorado System; University of Colorado Anschutz Medical Campus; Tulane University	Jones, FE (corresponding author), Tulane Univ, Dept Cell & Mol Biol, 6400 Freret St, New Orleans, LA 70118 USA.	fjones3@tulane.edu	Das, Partha/C-6898-2012		National Cancer Institute/National Institutes of Health [RO1CA95783, RO1CA96717]; NATIONAL CANCER INSTITUTE [R01CA095783, R01CA096717] Funding Source: NIH RePORTER	National Cancer Institute/National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank June Allison for excellent lab management and other members of the Jones lab for valuable input. This work is dedicated to the loving memory of June Allison who will no longer be subjected to the hardships of breast cancer. This work was supported by National Cancer Institute/National Institutes of Health Grants RO1CA95783 (FEJ) and RO1CA96717 (FEJ).	Chua YL, 2009, ONCOGENE, V28, P4041, DOI 10.1038/onc.2009.259; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fernandez SV, 2010, MUTAT RES-FUND MOL M, V688, P28, DOI 10.1016/j.mrfmmm.2010.02.007; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Jones FE, 1999, J CELL BIOL, V147, P77, DOI 10.1083/jcb.147.1.77; Jones FE, 2008, J MAMMARY GLAND BIOL, V13, P247, DOI 10.1007/s10911-008-9076-6; KREIKE B, 2009, BREAST CANC RES TREA; Long WW, 2003, DEVELOPMENT, V130, P5257, DOI 10.1242/dev.00715; Muraoka-Cook RS, 2006, MOL BIOL CELL, V17, P4118, DOI 10.1091/mbc.E06-02-0101; Muraoka-Cook RS, 2006, MOL CELL BIOL, V26, P6412, DOI 10.1128/MCB.01950-05; Muraoka-Cook RS, 2009, MOL CELL BIOL, V29, P4935, DOI 10.1128/MCB.01705-08; Naresh A, 2008, CANCER RES, V68, P6387, DOI 10.1158/0008-5472.CAN-08-0538; Naresh A, 2006, CANCER RES, V66, P6412, DOI 10.1158/0008-5472.CAN-05-2368; Nguyen C, 2001, J NATL CANCER I, V93, P1465, DOI 10.1093/jnci/93.19.1465; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Rokavec M, 2007, CLIN CANCER RES, V13, P7506, DOI 10.1158/1078-0432.CCR-07-0457; Sassen A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2339; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Soung YH, 2006, INT J CANCER, V118, P1426, DOI 10.1002/ijc.21507; Strathdee G, 2004, CARCINOGENESIS, V25, P693, DOI 10.1093/carcin/bgh066; Strohecker AM, 2008, J BIOL CHEM, V283, P18269, DOI 10.1074/jbc.M802156200; Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3; Thor AD, 2009, AM J PATHOL, V175, P1802, DOI 10.2353/ajpath.2009.090204; Tvorogov D, 2009, J BIOL CHEM, V284, P5582, DOI 10.1074/jbc.M805438200; Vidal GA, 2007, ONCOGENE, V26, P462, DOI 10.1038/sj.onc.1209794; Vidal GA, 2005, J BIOL CHEM, V280, P19777, DOI 10.1074/jbc.M412457200; Williams CC, 2004, J CELL BIOL, V167, P469, DOI 10.1083/jcb.200403155; Zhu Y, 2006, CANCER RES, V66, P7991, DOI 10.1158/0008-5472.CAN-05-4397	29	35	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2010	29	37					5214	5219		10.1038/onc.2010.271	http://dx.doi.org/10.1038/onc.2010.271			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	650QZ	20603612	Green Published, hybrid			2022-12-17	WOS:000281867200010
J	Kang, J; Qian, PX; Pandey, V; Perry, JK; Miller, LD; Liu, ET; Zhu, T; Liu, DX; Lobie, PE				Kang, J.; Qian, P. X.; Pandey, V.; Perry, J. K.; Miller, L. D.; Liu, E. T.; Zhu, T.; Liu, D. X.; Lobie, P. E.			Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma	ONCOGENE			English	Article						artemin; antiestrogen resistance; mammary carcinoma	TAMOXIFEN-INDUCED APOPTOSIS; BREAST-CANCER CELLS; ER-BETA EXPRESSION; RECEPTOR-BETA; ENDOCRINE THERAPY; STIMULATES ONCOGENICITY; DOWN-REGULATION; MESSENGER-RNA; GROWTH; BCL-2	We have previously identified an oncogenic role of artemin (ARTN), a member of glial cell derived neurotrophic factor family of ligands, in mammary carcinoma. We herein report that ARTN is an estrogen-inducible gene. Meta-analysis of gene expression data sets showed that ARTN expression is positively correlated to estrogen receptor (ER) status in human mammary carcinoma. Furthermore, in patients with ER-positive mammary carcinoma treated with tamoxifen, high ARTN expression is significantly correlated with decreased survival. Forced expression of ARTN in ER-positive human mammary carcinoma cells increased ER transcriptional activity, promoted estrogen-independent growth and produced resistance to tamoxifen and fulvestrant in vitro and to tamoxifen in xenograft models. ARTN-stimulated resistance to tamoxifen and fulvestrant is mediated by increased BCL-2 expression. Conversely, depletion of endogenous ARTN by small-interfering RNA or functional antagonism of ARTN by antibody enhanced the efficacy of antiestrogens. Tamoxifen decreased ARTN expression in tamoxifen-sensitive mammary carcinoma cells whereas ARTN expression was increased in tamoxifen-resistant cells and not affected by tamoxifen treatment. Antibody inhibition of ARTN in tamoxifen-resistant cells improved tamoxifen sensitivity. Functional antagonism of ARTN therefore warrants consideration as an adjuvant therapy to enhance antiestrogen efficacy in ER-positive mammary carcinoma. Oncogene (2010) 29, 3228-3240; doi: 10.1038/onc.2010.71; published online 22 March 2010	[Kang, J.; Pandey, V.; Perry, J. K.; Liu, D. X.; Lobie, P. E.] Univ Auckland, Liggins Inst, Auckland 1, New Zealand; [Qian, P. X.; Zhu, T.] Univ Sci & Technol China, Hefei Natl Lab Phys Sci Microscale, Hefei 230026, Anhui, Peoples R China; [Qian, P. X.; Zhu, T.] Univ Sci & Technol China, Sch Life Sci, Hefei 230026, Anhui, Peoples R China; [Miller, L. D.] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC USA; [Liu, E. T.] Genome Inst Singapore, Singapore, Singapore; [Lobie, P. E.] Univ Auckland, Fac Med & Hlth Sci, Dept Mol Med & Pathol, Auckland 1, New Zealand	University of Auckland; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Wake Forest University; Wake Forest Baptist Medical Center; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); University of Auckland	Lobie, PE (corresponding author), Univ Auckland, Liggins Inst, Private Bag 92019,2-6 Pk Ave, Auckland 1, New Zealand.	p.lobie@auckland.ac.nz	Pandey, Vijay/P-2767-2016; Liu, Edison/C-4141-2008; Qian, Pengxu/B-9376-2016	Qian, Pengxu/0000-0001-5636-6704; Miller, Lance/0000-0003-3799-2528; Perry, Jo/0000-0002-4418-947X; Kang, Jian/0000-0001-9998-4975	Breast Cancer Research Trust; Foundation for Research, Science and Technology of New Zealand; Chinese Academy of Sciences; National Natural Science Foundation of China [30571030]; National Basic Research Program of China [2007CB914503]	Breast Cancer Research Trust; Foundation for Research, Science and Technology of New Zealand(New Zealand Foundation for Research, Science and Technology); Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China)	We thank Carol Chelimo (MPH) for the meta-analysis of breast cancer microarray data. This work was funded by the Breast Cancer Research Trust (NZ); the Foundation for Research, Science and Technology of New Zealand; the Hundred-Talent Scheme of Chinese Academy of Sciences, National Natural Science Foundation of China (30571030) and National Basic Research Program of China (2007CB914503).	Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Arpino G, 2008, ENDOCR REV, V29, P217, DOI 10.1210/er.2006-0045; Baloh RH, 1998, NEURON, V21, P1291, DOI 10.1016/S0896-6273(00)80649-2; Bardin A, 2004, ENDOCR-RELAT CANCER, V11, P537, DOI 10.1677/erc.1.00800; Boulay A, 2008, CANCER RES, V68, P3743, DOI 10.1158/0008-5472.CAN-07-5100; Bursch W, 1996, CARCINOGENESIS, V17, P1595, DOI 10.1093/carcin/17.8.1595; Campbell RA, 2001, J BIOL CHEM, V276, P9817, DOI 10.1074/jbc.M010840200; Carmillo P, 2005, BIOCHEMISTRY-US, V44, P2545, DOI 10.1021/bi049247p; Chung YL, 2002, INT J CANCER, V97, P306, DOI 10.1002/ijc.1614; Clarke M, 1998, LANCET, V351, P1451; Diel P, 1999, BREAST CANCER RES TR, V58, P87, DOI 10.1023/A:1006338123126; Doisneau-Sixou SF, 2003, ENDOCR-RELAT CANCER, V10, P179, DOI 10.1677/erc.0.0100179; Dowsett M, 2005, BREAST CANCER RES TR, V93, pS11, DOI 10.1007/s10549-005-9037-3; Elledge RM, 1997, J CLIN ONCOL, V15, P1916, DOI 10.1200/JCO.1997.15.5.1916; Fagan D, 2008, J MAMMARY GLAND BIOL, V13, P423, DOI 10.1007/s10911-008-9098-0; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; Heldring N, 2007, PHYSIOL REV, V87, P905, DOI 10.1152/physrev.00026.2006; Hodges-Gallagher L, 2008, BREAST CANCER RES TR, V109, P241, DOI 10.1007/s10549-007-9640-6; Johnston SRD, 2005, BREAST CANCER RES, V7, P119, DOI 10.1186/bcr1023; Kampa M, 2008, STEROIDS, V73, P953, DOI 10.1016/j.steroids.2007.12.009; Kang J, 2009, ONCOGENE, V28, P2034, DOI 10.1038/onc.2009.66; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Ke N, 2004, BIOTECHNIQUES, V36, P826, DOI 10.2144/04365ST07; Kim R, 2005, CANCER-AM CANCER SOC, V103, P2199, DOI 10.1002/cncr.21029; Knowlden JM, 2005, ENDOCRINOLOGY, V146, P4609, DOI 10.1210/en.2005-0247; Knowlden JM, 2003, ENDOCRINOLOGY, V144, P1032, DOI 10.1210/en.2002-220620; Kumar R, 1996, CLIN CANCER RES, V2, P1215; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Levin ER, 2008, BREAST CANCER RES TR, V108, P351, DOI 10.1007/s10549-007-9618-4; Liu DX, 2007, CELL DEATH DIFFER, V14, P1893, DOI 10.1038/sj.cdd.4402209; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Massarweh S, 2006, ENDOCR-RELAT CANCER, V13, pS15, DOI 10.1677/erc.1.01273; McClelland RA, 2001, ENDOCRINOLOGY, V142, P2776, DOI 10.1210/en.142.7.2776; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Murphy LC, 2006, ENDOCR-RELAT CANCER, V13, P327, DOI 10.1677/erc.1.01141; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Nicholson RI, 2007, REV ENDOCR METAB DIS, V8, P241, DOI 10.1007/s11154-007-9033-5; Nicholson RI, 2005, ENDOCR-RELAT CANCER, V12, pS29, DOI 10.1677/erc.1.00991; O'Neill PA, 2004, BRIT J CANCER, V91, P1694, DOI 10.1038/sj.bjc.6602183; Osborne CK, 1998, NEW ENGL J MED, V339, P1609, DOI 10.1056/NEJM199811263392207; Pandey V, 2008, ENDOCRINOLOGY, V149, P3909, DOI 10.1210/en.2008-0286; Pandey V, 2010, ENDOCRINOLOGY, V151, P909, DOI 10.1210/en.2009-0979; Park BW, 2003, BREAST CANCER RES TR, V80, P79, DOI 10.1023/A:1024406223619; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Pettersson K, 2000, ONCOGENE, V19, P4970, DOI 10.1038/sj.onc.1203828; Riggins RB, 2005, MOL CANCER THER, V4, P33; Riggins RB, 2007, CANCER LETT, V256, P1, DOI 10.1016/j.canlet.2007.03.016; Rody A, 2005, ENDOCR-RELAT CANCER, V12, P903, DOI 10.1677/erc.1.01088; Rotolo S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002528; SARKARIA JN, 1993, CANCER RES, V53, P4413; Shaaban AM, 2003, AM J SURG PATHOL, V27, P1502, DOI 10.1097/00000478-200312000-00002; Shaw LE, 2006, J STEROID BIOCHEM, V99, P19, DOI 10.1016/j.jsbmb.2005.11.005; Siddiqa A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-129; Speirs V, 1999, CANCER RES, V59, P5421; Tangkeangsirisin W, 2004, CANCER RES, V64, P1737, DOI 10.1158/0008-5472.CAN-03-2364; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Williams C, 2008, ONCOGENE, V27, P1019, DOI 10.1038/sj.onc.1210712; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Zhang GJ, 1999, CLIN CANCER RES, V5, P2971; Zhang X, 2003, J BIOL CHEM, V278, P7580, DOI 10.1074/jbc.M212050200; Zhu T, 2005, CANCER RES, V65, P317	63	35	38	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2010	29	22					3228	3240		10.1038/onc.2010.71	http://dx.doi.org/10.1038/onc.2010.71			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	605BA	20305694				2022-12-17	WOS:000278321100006
J	Greenhough, A; Wallam, CA; Hicks, DJ; Moorghen, M; Williams, AC; Paraskeva, C				Greenhough, A.; Wallam, C. A.; Hicks, D. J.; Moorghen, M.; Williams, A. C.; Paraskeva, C.			The proapoptotic BH3-only protein Bim is downregulated in a subset of colorectal cancers and is repressed by antiapoptotic COX-2/PGE(2) signalling in colorectal adenoma cells	ONCOGENE			English	Article						Bim; COX-2; ERK; colorectal cancer; apoptosis; PGE2	CARCINOMA CELLS; BAX ACTIVATION; KEY ROLES; IN-VITRO; BCL-X; APOPTOSIS; PROMOTES; GROWTH; EXPRESSION; SURVIVAL	Overexpression of cyclooxygenase-2 (COX-2) and elevated levels of its enzymatic product prostaglandin E2 (PGE(2)) occur in the majority of colorectal cancers and have important roles in colorectal tumorigenesis. However, despite the established prosurvival role of PGE(2) in cancer, the underlying mechanisms are not fully understood. Here, we have shown that PGE(2) suppresses apoptosis via repression of the proapoptotic BH3-only protein Bim in human colorectal adenoma cells. Repression of Bim expression was dependent upon PGE(2)-mediated activation of the Raf-MEK-ERK1/2 pathway, which promoted Bim phosphorylation and proteasomal degradation. Reduction of Bim expression using RNA interference reduced spontaneous apoptosis in adenoma cells and abrogated PGE(2)-dependent apoptosis suppression. Treatment of COX-2-expressing colorectal carcinoma cells with COX-2-selective NSAIDs-induced Bim expression, suggesting that Bim repression via PGE(2) signalling may be opposed by COX-2 inhibition. Examination of Bim expression in two established in vitro models of the adenoma-carcinoma sequence revealed that downregulation of Bim expression was associated with tumour progression towards an anchorage-independent phenotype. Finally, immunohistochemical analyses revealed that Bim expression is markedly reduced in approximately 40% of human colorectal carcinomas in vivo. These observations highlight the COX-2/PGE(2) pathway as an important negative regulator of Bim expression in colorectal tumours and suggest that Bim repression may be an important step during colorectal cancer tumorigenesis. Oncogene (2010) 29, 3398-3410; doi:10.1038/onc.2010.94; published online 29 March 2010	[Greenhough, A.; Wallam, C. A.; Hicks, D. J.; Williams, A. C.; Paraskeva, C.] Univ Bristol, Sch Med Sci, Dept Cellular & Mol Med, Canc Res UK Colorectal Tumour Biol Grp, Bristol BS8 1TD, Avon, England; [Moorghen, M.] Bristol Royal Infirm & Gen Hosp, Dept Clin Pathol, Bristol, Avon, England	University of Bristol; Bristol Royal Infirmary	Greenhough, A (corresponding author), Univ Bristol, Sch Med Sci, Dept Cellular & Mol Med, Canc Res UK Colorectal Tumour Biol Grp, Bristol BS8 1TD, Avon, England.	a.greenhough@bristol.ac.uk	Greenhough, Alexander/Y-6728-2019; Greenhough, Alexander/J-9308-2012	Greenhough, Alexander/0000-0002-8306-811X; Greenhough, Alexander/0000-0002-8306-811X; Williams, Ann/0000-0002-6009-7137	Citrina Foundation; John James Bristol Foundation; Cancer Research UK programme	Citrina Foundation; John James Bristol Foundation; Cancer Research UK programme(Cancer Research UK)	We thank Debbie Martin and Gini Tilly for help with histology; David Huang for provision of Bim wild-type and null iMEF cells; Andy Silver and Nirosha Suraweera for sequencing analysis; Andy Herman for help with flow cytometry, and members of the CP group for useful discussion. This work was funded by the Citrina Foundation, the John James Bristol Foundation, and by a Cancer Research UK programme grant.	Balmanno K, 2009, CELL DEATH DIFFER, V16, P368, DOI 10.1038/cdd.2008.148; BEDI A, 1995, CANCER RES, V55, P1811; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bresalier RS, 2005, NEW ENGL J MED, V352, P1092, DOI 10.1056/NEJMoa050493; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cartlidge RA, 2008, PIGM CELL MELANOMA R, V21, P534, DOI 10.1111/j.1755-148X.2008.00491.x; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chan TA, 1998, P NATL ACAD SCI USA, V95, P681, DOI 10.1073/pnas.95.2.681; Chell SD, 2006, CANCER RES, V66, P3106, DOI 10.1158/0008-5472.CAN-05-3702; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Clemo NK, 2008, CARCINOGENESIS, V29, P849, DOI 10.1093/carcin/bgn004; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437; Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316; Crew TE, 2000, CARCINOGENESIS, V21, P69, DOI 10.1093/carcin/21.1.69; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dehan E, 2009, MOL CELL, V33, P109, DOI 10.1016/j.molcel.2008.12.020; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Elder DJE, 2002, J PATHOL, V198, P428, DOI 10.1002/path.1232; Elder DJE, 1998, NAT MED, V4, P392, DOI 10.1038/nm0498-392; Elder DJE, 1996, CANCER RES, V56, P2273; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; Ewings KE, 2007, EMBO J, V26, P2856, DOI 10.1038/sj.emboj.7601723; Gallenne T, 2009, J CELL BIOL, V185, P279, DOI 10.1083/jcb.200809153; Gavathiotis E, 2008, NATURE, V455, P1076, DOI 10.1038/nature07396; Goessling W, 2009, CELL, V136, P1136, DOI 10.1016/j.cell.2009.01.015; Gong YX, 2007, PLOS MED, V4, P1655, DOI 10.1371/journal.pmed.0040294; Greenhough A, 2007, INT J CANCER, V121, P2172, DOI 10.1002/ijc.22917; Greenhough A, 2009, CARCINOGENESIS, V30, P377, DOI 10.1093/carcin/bgp014; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; HAGUE A, 1994, ONCOGENE, V9, P3367; HALL PA, 1994, J CELL SCI, V107, P3569; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hawcroft G, 2007, ONCOGENE, V26, P3006, DOI 10.1038/sj.onc.1210113; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Krajewska M, 1996, CANCER RES, V56, P2422; Kuroda J, 2006, P NATL ACAD SCI USA, V103, P14907, DOI 10.1073/pnas.0606176103; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Ley R, 2005, CELL DEATH DIFFER, V12, P1008, DOI 10.1038/sj.cdd.4401688; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Ley R, 2004, J BIOL CHEM, V279, P8837, DOI 10.1074/jbc.M311578200; Lovell JF, 2008, CELL, V135, P1074, DOI 10.1016/j.cell.2008.11.010; Loveridge CJ, 2008, ONCOGENE, V27, P2648, DOI 10.1038/sj.onc.1210891; Luciano F, 2003, ONCOGENE, V22, P6785, DOI 10.1038/sj.onc.1206792; Nishihara H, 2003, P NATL ACAD SCI USA, V100, P8921, DOI 10.1073/pnas.1533221100; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; PARASKEVA C, 1989, CANCER RES, V49, P1282; Pozzi A, 2004, J BIOL CHEM, V279, P29797, DOI 10.1074/jbc.M313989200; Puthalakath H, 2007, CELL, V129, P1337, DOI 10.1016/j.cell.2007.04.027; Reginato MJ, 2003, NAT CELL BIOL, V5, P733, DOI 10.1038/ncb1026; Rice PL, 2004, CANCER RES, V64, P8148, DOI 10.1158/0008-5472.CAN-04-1517; Schmelzle T, 2007, P NATL ACAD SCI USA, V104, P3787, DOI 10.1073/pnas.0700115104; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sinicrope FA, 2008, CLIN CANCER RES, V14, P5810, DOI 10.1158/1078-0432.CCR-07-5202; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Wang DZ, 2004, CANCER CELL, V6, P285, DOI 10.1016/j.ccr.2004.08.011; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Wickenden JA, 2008, ONCOGENE, V27, P7150, DOI 10.1038/onc.2008.335; Williams AC, 2007, CELL DEATH DIFFER, V14, P137, DOI 10.1038/sj.cdd.4401919; WILLIAMS AC, 1990, CANCER RES, V50, P4724; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Yang F, 2009, J VIB CONTROL, V15, P233, DOI 10.1177/1077546308091220; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510	74	35	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3398	3410		10.1038/onc.2010.94	http://dx.doi.org/10.1038/onc.2010.94			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20348947	Green Accepted			2022-12-17	WOS:000278622700008
J	Wang, SE; Yu, Y; Criswell, TL; DeBusk, LM; Lin, PC; Zent, R; Johnson, DH; Ren, X; Arteaga, CL				Wang, S. E.; Yu, Y.; Criswell, T. L.; DeBusk, L. M.; Lin, P. C.; Zent, R.; Johnson, D. H.; Ren, X.; Arteaga, C. L.			Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators	ONCOGENE			English	Article						HER2/ErbB2; Ras; TGF-beta; VEGF; EGFR ligands; tumor microenvironment	TYROSINE KINASE INHIBITOR; FACTOR-BETA; BREAST-CANCER; TRANSFORMING GROWTH-FACTOR-BETA-1; SOMATIC MUTATIONS; CELL-MIGRATION; IN-VITRO; H-RAS; RECEPTOR; ERBB2	Activating mutations in the tyrosine kinase domain of HER2 (ErbB2) have been identified in human cancers. Compared with wild-type HER2, mutant HER2 shows constitutively activate kinase activity and increased oncogenicity. Cells transformed by mutant HER2 are resistant to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and exhibit an attenuated response to the HER2 antibody trastuzumab. We investigated herein pathways through which mutant HER2 alters the extracellular environment, potentially leading to drug resistance and the effect of simultaneously targeting HER2 and the tumor cell microenvironment with a therapeutic intent. Expression of mutant HER2 in mammary epithelial cells activated autocrine transforming growth factor (TGF) beta 1 signaling through a mechanism involving Rac1 and c-Jun N-terminal kinase-activating protein 1-dependent transcription. Cells transformed by an activating mutant of H-Ras (G12V) also expressed higher TGF-beta 1 level through Rac1 activation. In addition, mutant HER2 induced the EGFR ligands TGF-alpha and amphiregulin at the mRNA and protein levels. Vascular endothelial growth factor, a target of the TGF-beta-Smad transcriptional regulation, was also induced as a result of expression of mutant HER2. Inhibition of TGF-beta signaling with the Alk5 small molecule inhibitor LY2109761 reduced growth and invasiveness of cells expressing mutant HER2. Combined inhibition of intracellular and paracrine effects of mutant HER2 by trastuzumab and the EGFR antibody cetuximab were more efficient than single-agent therapies. These data suggest that mutations in oncogenes such as HER2 and Ras not only alter intracellular signaling but also influence on other components of the tumor microenvironment by inducing several pro-invasive growth factors. In turn, these serve as extracellular targets of novel therapeutic strategies directed at both cancer-driving oncogenes and the modified tumor microenvironment. Oncogene (2010) 29, 3335-3348; doi:10.1038/onc.2010.112; published online 12 April 2010	[Wang, S. E.] Beckman Res Inst City Hope, Div Tumor Cell Biol, Duarte, CA 91010 USA; [Yu, Y.; Ren, X.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol & Biotherapy, Tianjin, PR, Peoples R China; [Criswell, T. L.; DeBusk, L. M.; Lin, P. C.; Zent, R.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA; [DeBusk, L. M.; Lin, P. C.] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA; [Zent, R.; Johnson, D. H.; Arteaga, C. L.] Vanderbilt Univ, Sch Med, Dept Med, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA; [Arteaga, C. L.] Vanderbilt Univ, Sch Med, Breast Canc Res Program, Vanderbilt Ingram Comprehens Canc Ctr, Nashville, TN 37232 USA	City of Hope; Beckman Research Institute of City of Hope; Tianjin Medical University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Wang, SE (corresponding author), Beckman Res Inst City Hope, Div Tumor Cell Biol, 1500 E Duarte Rd,KCRB Room 2007, Duarte, CA 91010 USA.	ewang@coh.org; carlos.arteaga@vanderbilt.edu			NCI [K99/R00 CA125892, NCI R01 CA62212, R01 CA80195]; ACS [CRP-07-234]; Breast Cancer Specialized Program of Research Excellence (SPORE) [P50 CA98131]; Vanderbilt-Ingram Comprehensive Cancer Center [P30 CA68485]; NATIONAL CANCER INSTITUTE [K99CA125892, ZIABC011390, P30CA068485, R01CA080195, R00CA125892, T32CA009592, R01CA062212, P50CA098131] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ACS(American Cancer Society); Breast Cancer Specialized Program of Research Excellence (SPORE); Vanderbilt-Ingram Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI K99/R00 CA125892 (SEW), NCI R01 CA62212 (CLA), R01 CA80195 (CLA), ACS Clinical Research Professorship Grant CRP-07-234 (CLA), Breast Cancer Specialized Program of Research Excellence (SPORE) P50 CA98131, and Vanderbilt-Ingram Comprehensive Cancer Center Support Grant P30 CA68485.	Adam L, 1998, J BIOL CHEM, V273, P28238, DOI 10.1074/jbc.273.43.28238; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Bakin AV, 2002, J CELL SCI, V115, P3193; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bourguignon LYW, 2001, J BIOL CHEM, V276, P48679, DOI 10.1074/jbc.M106759200; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DeBusk LM, 2004, EXP CELL RES, V298, P167, DOI 10.1016/j.yexcr.2004.04.013; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Dumont N, 2003, CANCER CELL, V3, P531, DOI 10.1016/S1535-6108(03)00135-1; Erdogan M, 2007, J BIOL CHEM, V282, P27713, DOI 10.1074/jbc.M703037200; Fahey MS, 1996, BRIT J CANCER, V74, P1074, DOI 10.1038/bjc.1996.492; Fong TAT, 1999, CANCER RES, V59, P99; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Heasley LE, 2006, MOL CELLS, V21, P167; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Josko J, 2004, MED SCI MONITOR, V10, pRA89; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; KIM SJ, 1990, MOL CELL BIOL, V10, P1492, DOI 10.1128/MCB.10.4.1492; Lee JW, 2006, CLIN CANCER RES, V12, P57, DOI 10.1158/1078-0432.CCR-05-0976; Lo RS, 2001, EMBO J, V20, P128, DOI 10.1093/emboj/20.1.128; Maity A, 2000, CANCER RES, V60, P5879; MALIPIERO U, 1990, BIOCHEM BIOPH RES CO, V171, P1145, DOI 10.1016/0006-291X(90)90804-V; Moulder SL, 2001, CANCER RES, V61, P8887; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; Muraoka RS, 2003, MOL CELL BIOL, V23, P8691, DOI 10.1128/MCB.23.23.8691-8703.2003; Muraoka-Cook RS, 2004, CANCER RES, V64, P9002, DOI 10.1158/0008-5472.CAN-04-2111; Normanno N, 2001, FRONT BIOSCI-LANDMRK, V6, pD685, DOI 10.2741/Normano; Oft M, 2002, NAT CELL BIOL, V4, P487, DOI 10.1038/ncb807; Peng SB, 2005, BIOCHEMISTRY-US, V44, P2293, DOI 10.1021/bi048851x; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Sanchez-Elsner T, 2001, J BIOL CHEM, V276, P38527, DOI 10.1074/jbc.M104536200; Sawyer JS, 2004, BIOORG MED CHEM LETT, V14, P3581, DOI 10.1016/j.bmcl.2004.04.007; Schnelzer A, 2000, ONCOGENE, V19, P3013, DOI 10.1038/sj.onc.1203621; Seton-Rogers SE, 2004, P NATL ACAD SCI USA, V101, P1257, DOI 10.1073/pnas.0308090100; Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Shirakata Y, 2000, J BIOL CHEM, V275, P5748, DOI 10.1074/jbc.275.8.5748; Siegel PM, 2003, P NATL ACAD SCI USA, V100, P8430, DOI 10.1073/pnas.0932636100; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; Ueda Y, 2004, J BIOL CHEM, V279, P24505, DOI 10.1074/jbc.M400081200; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang LM, 1998, P NATL ACAD SCI USA, V95, P6809, DOI 10.1073/pnas.95.12.6809; Wang SE, 2005, MOL CELL BIOL, V25, P4703, DOI 10.1128/MCB.25.11.4703-4715.2005; Wang SE, 2008, MOL CELL BIOL, V28, P5605, DOI 10.1128/MCB.00787-08; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Weigert C, 2000, J AM SOC NEPHROL, V11, P2007, DOI 10.1681/ASN.V11112007; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Worthylake R, 1999, J BIOL CHEM, V274, P8865, DOI 10.1074/jbc.274.13.8865; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Ye DW, 1999, ONCOGENE, V18, P731, DOI 10.1038/sj.onc.1202319	55	35	36	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2010	29	23					3335	3348		10.1038/onc.2010.112	http://dx.doi.org/10.1038/onc.2010.112			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	608YU	20383197	Green Accepted			2022-12-17	WOS:000278622700003
J	Rocher-Ros, V; Marco, S; Mao, JH; Gines, S; Metzger, D; Chambon, P; Balmain, A; Saura, CA				Rocher-Ros, V.; Marco, S.; Mao, J-H; Gines, S.; Metzger, D.; Chambon, P.; Balmain, A.; Saura, C. A.			Presenilin modulates EGFR signaling and cell transformation by regulating the ubiquitin ligase Fbw7	ONCOGENE			English	Article						carcinogenesis; epidermis; Fbw7; Notch; gamma-secretase	GROWTH-FACTOR RECEPTOR; AMYLOID PRECURSOR PROTEIN; TUMOR-SUPPRESSOR; NEGATIVE REGULATOR; DOWN-REGULATION; NOTCH; DEGRADATION; SEL-10; ENDOCYTOSIS; ACTIVATION	The epidermal growth factor receptor (EGFR) and Notch signaling pathways have antagonistic roles during epidermal differentiation and carcinogenesis. The molecular mechanisms regulating the crosstalk between EGFR and Notch during epidermal transformation are largely unknown. We found enhanced EGFR-dependent signaling, proliferation and oncogenic transformation caused by loss of presenilins (PS), the catalytic components of gamma-secretase that generates the Notch1 intracellular domain (NICD). The underlying mechanism for abnormal EGFR signaling in PS-deficient cells involves gamma-secretase-independent transcriptional upregulation of the E3 ubiquitin ligase Fbw7. Fbw7 alpha, which targets NICD for degradation, regulates positively EGFR by affecting a proteasome-dependent ubiquitination step essential for constitutive degradation and stability of EGFR. To investigate the pathological relevance of this findings in vivo, we generated a novel epidermal conditional PS-deficient (ePS cDKO) mouse by deleting both PS in keratinocytes of the basal layer of the epidermis. The ePS cDKO mice develop epidermal hyperplasia associated with enhanced expression of both EGFR and Fbw7 and reduced NICD levels in keratinocytes. These findings establish a novel role for PS on epidermal growth and transformation by reciprocally regulating the EGFR and Notch signaling pathways through Fbw7. Oncogene (2010) 29, 2950-2961; doi:10.1038/onc.2010.57; published online 8 March 2010	[Saura, C. A.] Univ Autonoma Barcelona, Inst Neurociencies, Dept Bioquim & Biol Mol,Fac Med M2 120, Ctr Invest Biomed Red Enfermedades Neurodegenerat, E-08193 Barcelona, Spain; [Mao, J-H; Balmain, A.] Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94143 USA; [Gines, S.] Univ Barcelona, Dept Biol Cellular Inmunol & Neurociencies, Ctr Invest Biomed Red Enfermedades Neurodegenerat, Barcelona, Spain; [Metzger, D.; Chambon, P.] Univ Strasbourg, Strasbourg, France; [Metzger, D.; Chambon, P.] Coll France, Dept Funct Genom, Inst Genet & Biol Mol & Cellulaire, Inserm U964,CNRS, Illkirch Graffenstaden, France	Autonomous University of Barcelona; CIBERNED; University of California System; University of California San Francisco; CIBERNED; University of Barcelona; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Saura, CA (corresponding author), Univ Autonoma Barcelona, Inst Neurociencies, Dept Bioquim & Biol Mol,Fac Med M2 120, Ctr Invest Biomed Red Enfermedades Neurodegenerat, E-08193 Barcelona, Spain.	carlos.saura@uab.es	Mao, Jian-Hua/EIZ-8595-2022; Saura, Carlos A/D-2727-2011; Saura, Carlos A/AFM-9239-2022; Gines, Silvia/L-1943-2015	Mao, Jian-Hua/0000-0001-9320-6021; Saura, Carlos A/0000-0003-3692-5657; Gines, Silvia/0000-0002-9479-8185; Metzger, Daniel/0000-0002-5555-046X; Marco, Sergi/0000-0002-9747-0388	Fundacio Marato-TV3 [050710]; Spanish Ministerio de Ciencia e Innovacion [SAF2007-64115, CIBERNED CB06/05/0042]; European Union [IRG-014860]; Generalitat de Catalunya; NATIONAL CANCER INSTITUTE [R01CA116481] Funding Source: NIH RePORTER	Fundacio Marato-TV3; Spanish Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); European Union(European Commission); Generalitat de Catalunya(Generalitat de Catalunya); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank B De Strooper for providing the immortalized PS fibroblasts, J Shen for PS1 (f/f); PS2-/- mice, G Thinakaran for the pAG3zeo-PS1 Delta loop plasmid, R Kopan for the mNICD-myc plasmid, BE Clurman for the Fbw7 alpha/beta-Flag cDNAs and A Johnson for the pER1-luc plasmid. We thank S Aznar-Benitah for histological expertise advice and E Martin and M Castillo for technical assistance. We thank Servei de Microscopia and Servei de Genomica de la UAB for the excellent technical support. This study was supported by grants from Fundacio Marato-TV3 (050710), Spanish Ministerio de Ciencia e Innovacion (SAF2007-64115, CIBERNED CB06/05/0042 and Programa Ramon y Cajal) and 6th Framework Programme of the European Union (Marie Curie International Reintegration Grant IRG-014860). VRR received a doctoral fellowship from Generalitat de Catalunya.	Alwan HAJ, 2003, J BIOL CHEM, V278, P35781, DOI 10.1074/jbc.M301326200; Bhoumik A, 2008, P NATL ACAD SCI USA, V105, P1674, DOI 10.1073/pnas.0706057105; Blanpain C, 2006, GENE DEV, V20, P3022, DOI 10.1101/gad.1477606; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; de Souza N, 2007, DEVELOPMENT, V134, P691, DOI 10.1242/dev.02767; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 2007, EMBO REP, V8, P141, DOI 10.1038/sj.embor.7400897; Demehri S, 2008, PLOS BIOL, V6, P992, DOI 10.1371/journal.pbio.0060123; Deng Y, 2006, J NEUROSCI, V26, P3845, DOI 10.1523/JNEUROSCI.5384-05.2006; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; Grim JE, 2008, J CELL BIOL, V181, P913, DOI 10.1083/jcb.200802076; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Huang F, 2007, P NATL ACAD SCI USA, V104, P16904, DOI 10.1073/pnas.0707416104; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Jost M, 2000, EUR J DERMATOL, V10, P505; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; Kang DE, 2002, CELL, V110, P751, DOI 10.1016/S0092-8674(02)00970-4; Kolev V, 2008, NAT CELL BIOL, V10, DOI 10.1038/ncb1750; Koo EH, 2004, NAT MED, V10, pS26, DOI 10.1038/nm1065; Kopan R, 1996, P NATL ACAD SCI USA, V93, P1683, DOI 10.1073/pnas.93.4.1683; Lefort K, 2004, SEMIN CANCER BIOL, V14, P374, DOI 10.1016/j.semcancer.2004.04.017; Li JH, 2002, J NEUROCHEM, V82, P1540, DOI 10.1046/j.1471-4159.2002.01105.x; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Li T, 2007, J BIOL CHEM, V282, P32264, DOI 10.1074/jbc.M703649200; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nicolas M, 2003, NAT GENET, V33, P416, DOI 10.1038/ng1099; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Pan YH, 2004, DEV CELL, V7, P731, DOI 10.1016/j.devcel.2004.09.014; Perez-Losada J, 2005, CANCER RES, V65, P6488, DOI 10.1158/0008-5472.CAN-05-1294; Pirrone A, 2004, METH MOL B, V289, P3; Proweller A, 2006, CANCER RES, V66, P7438, DOI 10.1158/0008-5472.CAN-06-0793; Repetto E, 2007, J BIOL CHEM, V282, P31504, DOI 10.1074/jbc.M704273200; Rikiyama T, 2003, BBA-GENE STRUCT EXPR, V1629, P15, DOI 10.1016/S0167-4781(03)00156-8; Saura CA, 2000, J BIOL CHEM, V275, P17136, DOI 10.1074/jbc.M909624199; Saura CA, 2004, NEURON, V42, P23, DOI 10.1016/S0896-6273(04)00182-5; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Soriano S, 2001, J CELL BIOL, V152, P785, DOI 10.1083/jcb.152.4.785; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; To MD, 2006, ONCOGENE, V25, P3557, DOI 10.1038/sj.onc.1209397; Tournoy J, 2004, HUM MOL GENET, V13, P1321, DOI 10.1093/hmg/ddh151; Vasioukhin V, 1999, P NATL ACAD SCI USA, V96, P8551, DOI 10.1073/pnas.96.15.8551; Wang JW, 2004, ONCOGENE, V23, P4089, DOI 10.1038/sj.onc.1207567; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Welcker M, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-7; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Wu GY, 1998, P NATL ACAD SCI USA, V95, P15787, DOI 10.1073/pnas.95.26.15787; Xia XF, 2001, P NATL ACAD SCI USA, V98, P10863, DOI 10.1073/pnas.191284198; Zhang YW, 2007, P NATL ACAD SCI USA, V104, P10613, DOI 10.1073/pnas.0703903104	54	35	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	20					2950	2961		10.1038/onc.2010.57	http://dx.doi.org/10.1038/onc.2010.57			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599DM	20208556	Green Accepted			2022-12-17	WOS:000277890400006
J	Schonherr, C; Yang, HL; Vigny, M; Palmer, RH; Hallberg, B				Schoenherr, C.; Yang, H-L; Vigny, M.; Palmer, R. H.; Hallberg, B.			Anaplastic lymphoma kinase activates the small GTPase Rap1 via the Rap1-specific GEF C3G in both neuroblastoma and PC12 cells	ONCOGENE			English	Article						ALK; PC12 cells; neurite outgrowth; small GTPase; Rap1; neuroblastoma	RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; NUCLEOTIDE EXCHANGE FACTOR; NON-HODGKINS-LYMPHOMA; MAP KINASE; NEURONAL DIFFERENTIATION; DROSOPHILA-MELANOGASTER; SUSTAINED ACTIVATION; PHOSPHORYLATED RAP1B; CANCER METASTASIS	Many different types of cancer originate from aberrant signaling from the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase (RTK), arising through different translocation events and overexpression. Further, activating point mutations in the ALK domain have been recently reported in neuroblastoma. To characterize signaling in the context of the full-length receptor, we have examined whether ALK is able to activate Rap1 and contribute to differentiation/proliferation processes. We show that ALK activates Rap1 via the Rap1-specific guanine-nucleotide exchange factor C3G, which binds in a constitutive complex with CrkL to activated ALK. The activation of the C3G/Rap1 pathway results in neurite outgrowth of PC12 cells, which is inhibited by either overexpression of Rap1GAP or siRNA-mediated knockdown of Rap1 itself or the guanine nucleotide exchange factor C3G. Significantly, this pathway also appears to function in the regulation of proliferation of neuroblastoma cells such as SK-N-SH and SH-SY5Y, because abrogation of Rap1 activity by Rap1-specific siRNA or overexpression of Rap1GAP reduces cellular growth. These results suggest that ALK activation of Rap1 may contribute to cell proliferation and oncogenesis of neuroblastoma driven by gain-of-function mutant ALK receptors. Oncogene (2010) 29, 2817-2830; doi: 10.1038/onc.2010.27; published online 1 March 2010	[Schoenherr, C.; Palmer, R. H.; Hallberg, B.] Umea Univ, Dept Mol Biol, S-90187 Umea, Norrland, Sweden; [Yang, H-L] Beijing Forestry Univ, Coll Biol Sci & Biotechnol, Beijing, Peoples R China; [Vigny, M.] UPMC, INSERM, IFM, U839, Paris, France	Umea University; Beijing Forestry University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Hallberg, B (corresponding author), Umea Univ, Dept Mol Biol, Buil 6L, S-90187 Umea, Norrland, Sweden.	Bengt.Hallberg@molbiol.umu.se			Swedish Cancer Foundation [08-0597]; Lions Cancer Research Foundation, Umea; Swedish Childhood Cancer Foundation [08/084]; Swedish Research Council [621-2003-3399]; Association for International Cancer Research [AICR 08-0177]	Swedish Cancer Foundation; Lions Cancer Research Foundation, Umea; Swedish Childhood Cancer Foundation(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Association for International Cancer Research	We thank Caroline Grabbe for comments and critical reading of the paper and Lovisa Olofsson for initial experiments. BH is supported by a Grant (08-0597) from the Swedish Cancer Foundation, Lions Cancer Research Foundation, Umea, and Grant (08/084) from the Swedish Childhood Cancer Foundation. RHP is a Swedish Cancer Foundation Research Fellow and is supported by grants from the Swedish Research Council (621-2003-3399), the Swedish Childhood Cancer Foundation (08/074) and the Association for International Cancer Research (AICR 08-0177).	Altschuler DL, 1998, P NATL ACAD SCI USA, V95, P7475, DOI 10.1073/pnas.95.13.7475; Bailey CL, 2009, CANCER RES, V69, P4962, DOI 10.1158/0008-5472.CAN-08-4269; Bazigou E, 2007, CELL, V128, P961, DOI 10.1016/j.cell.2007.02.024; Bilsland JG, 2008, NEUROPSYCHOPHARMACOL, V33, P685, DOI 10.1038/sj.npp.1301446; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Caren H, 2008, BIOCHEM J, V416, P153, DOI 10.1042/BJ20081834; Chen YY, 2008, NATURE, V455, P971, DOI 10.1038/nature07399; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; Degoutin J, 2007, FEBS LETT, V581, P727, DOI 10.1016/j.febslet.2007.01.039; Englund C, 2003, NATURE, V425, P512, DOI 10.1038/nature01950; FELLER SM, 1995, ONCOGENE, V10, P1465; Franke B, 1997, EMBO J, V16, P252, DOI 10.1093/emboj/16.2.252; Galkin AV, 2007, P NATL ACAD SCI USA, V104, P270, DOI 10.1073/pnas.0609412103; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; George RE, 2008, NATURE, V455, P975, DOI 10.1038/nature07397; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; Gouzi JY, 2005, J CELL SCI, V118, P5811, DOI 10.1242/jcs.02695; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; Guerrero C, 2004, ONCOGENE, V23, P4885, DOI 10.1038/sj.onc.1207622; Gyan E, 2005, LEUKEMIA, V19, P1678, DOI 10.1038/sj.leu.2403882; Hallberg B, 1998, ONCOGENE, V17, P691, DOI 10.1038/sj.onc.1201980; Hemmeryckx B, 2001, CANCER RES, V61, P1398; Henriksson ML, 2002, BIOCHEM J, V367, P617, DOI 10.1042/BJ20020714; Hisata S, 2007, J CELL BIOL, V178, P843, DOI 10.1083/jcb.200610073; Hong K, 2008, J BIOL CHEM, V283, P23129, DOI 10.1074/jbc.M800478200; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; Ishida D, 2003, CANCER CELL, V4, P55, DOI 10.1016/S1535-6108(03)00163-6; Ishihara T, 2002, CELL, V109, P639, DOI 10.1016/S0092-8674(02)00748-1; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Janoueix-Lerosey I, 2008, NATURE, V455, P967, DOI 10.1038/nature07398; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Lamant L, 2000, AM J PATHOL, V156, P1711, DOI 10.1016/S0002-9440(10)65042-0; Lee HH, 2003, NATURE, V425, P507, DOI 10.1038/nature01916; Liao EH, 2004, NATURE, V430, P345, DOI 10.1038/nature02647; Lin YL, 2000, FEBS LETT, V467, P184, DOI 10.1016/S0014-5793(00)01150-9; Lopes SS, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000026; Loren CE, 2003, EMBO REP, V4, P781, DOI 10.1038/sj.embor.embor897; Loren CE, 2001, GENES CELLS, V6, P531, DOI 10.1046/j.1365-2443.2001.00440.x; Lou LG, 2002, J BIOL CHEM, V277, P32799, DOI 10.1074/jbc.M201491200; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuse M, 2009, ENDOCR J, V56, P161, DOI 10.1507/endocrj.K08E-244; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; Minato N, 2009, CANCER SCI, V100, P17, DOI 10.1111/j.1349-7006.2008.01011.x; Miyake I, 2002, ONCOGENE, V21, P5823, DOI 10.1038/sj.onc.1205735; Moog-Lutz C, 2005, J BIOL CHEM, V280, P26039, DOI 10.1074/jbc.M501972200; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Mosse YP, 2008, NATURE, V455, P930, DOI 10.1038/nature07261; Motegi A, 2004, J CELL SCI, V117, P3319, DOI 10.1242/jcs.01183; Muramatsu T, 2002, J BIOCHEM, V132, P359, DOI 10.1093/oxfordjournals.jbchem.a003231; Osajima-Hakomori Y, 2005, AM J PATHOL, V167, P213, DOI 10.1016/S0002-9440(10)62966-5; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Piccinini G, 2002, J BIOL CHEM, V277, P22231, DOI 10.1074/jbc.M111145200; QIU MS, 1991, NEURON, V7, P937, DOI 10.1016/0896-6273(91)90339-2; Raaijmakers JH, 2009, J BIOL CHEM, V284, P10995, DOI 10.1074/jbc.R800061200; Radha V, 2008, J NEUROCHEM, V107, P1424, DOI 10.1111/j.1471-4159.2008.05710.x; Reiner DJ, 2008, CURR BIOL, V18, P1101, DOI 10.1016/j.cub.2008.06.060; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ribeiro-Neto F, 2002, P NATL ACAD SCI USA, V99, P5418, DOI 10.1073/pnas.082122499; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Schwamborn JC, 2004, NAT NEUROSCI, V7, P923, DOI 10.1038/nn1295; SHIOTA M, 1994, ONCOGENE, V9, P1567; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; Shirinian M, 2007, DIFFERENTIATION, V75, P418, DOI 10.1111/j.1432-0436.2006.00148.x; Souttou B, 2001, J BIOL CHEM, V276, P9526, DOI 10.1074/jbc.M007333200; Stoica GE, 2002, J BIOL CHEM, V277, P35990, DOI 10.1074/jbc.M205749200; Stoica GE, 2001, J BIOL CHEM, V276, P16772, DOI 10.1074/jbc.M010660200; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; Stute C, 2004, DEVELOPMENT, V131, P743, DOI 10.1242/dev.00972; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Tsygankova OA, 2007, MOL CELL BIOL, V27, P6647, DOI 10.1128/MCB.00155-07; Varshney GK, 2006, BIOCHEM BIOPH RES CO, V351, P839, DOI 10.1016/j.bbrc.2006.10.117; Vernersson E, 2006, GENE EXPR PATTERNS, V6, P448, DOI 10.1016/j.modgep.2005.11.006; Voss AK, 2003, DEVELOPMENT, V130, P355, DOI 10.1242/dev.00217; Voss AK, 2008, DEVELOPMENT, V135, P2139, DOI 10.1242/dev.016725; Voss AK, 2006, EMBO J, V25, P3652, DOI 10.1038/sj.emboj.7601234; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; WIENECKE R, 1995, J BIOL CHEM, V270, P16409, DOI 10.1074/jbc.270.27.16409; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yajnik V, 2003, CELL, V112, P673, DOI 10.1016/S0092-8674(03)00155-7; Yang HL, 2007, J EXP ZOOL PART B, V308B, P269, DOI 10.1002/jez.b.21146; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zemojtel T, 2006, LEUKEMIA, V20, P145, DOI 10.1038/sj.leu.2404040; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	86	35	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY	2010	29	19					2817	2830		10.1038/onc.2010.27	http://dx.doi.org/10.1038/onc.2010.27			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190816				2022-12-17	WOS:000277591900007
J	Zhang, W; Zeng, X; Briggs, KJ; Beaty, R; Simons, B; Yen, RWC; Tyler, MA; Tsai, HC; Ye, Y; Gesell, GS; Herman, JG; Baylin, SB; Watkins, DN				Zhang, W.; Zeng, X.; Briggs, K. J.; Beaty, R.; Simons, B.; Yen, R-W Chiu; Tyler, M. A.; Tsai, H-C; Ye, Y.; Gesell, G. S.; Herman, J. G.; Baylin, S. B.; Watkins, D. N.			A potential tumor suppressor role for Hic1 in breast cancer through transcriptional repression of ephrin-A1	ONCOGENE			English	Article						Hic1; ephrin-A1; EphA2; EphA4	MILLER-DIEKER-SYNDROME; EPHA2 RECEPTOR; CELL-MIGRATION; COLORECTAL-CANCER; GENE; EXPRESSION; LIGAND; MICE; HYPERMETHYLATED-IN-CANCER-1; PROGRESSION	The tumor suppressor gene hypermethylated in cancer 1 (HIC1), which encodes a transcriptional repressor, is epigenetically inactivated in various human cancers. In this study, we show that HIC1 is a direct transcriptional repressor of the gene encoding ephrin-A1, a cell surface ligand implicated in the pathogenesis of epithelial cancers. We also show that mouse embryos lacking both Hic1 alleles manifest developmental defects spatially associated with the misexpression of ephrin-A1, and that overexpression of ephrin-A1 is a feature of tumors arising in Hic1 heterozygous mice in which the remaining wild-type allele is epigenetically silenced. In breast cancer, we find that ephrin-A1 expression is common in vivo, but that in cell culture, expression of the EphA receptors is predominant. Restoration of HIC1 function in breast cancer cells leads to a reduction in tumor growth in vivo, an effect that can be partially rescued by co-overexpression of ephrin-A1. Interestingly, overexpression of ephrin-A1 in vitro triggers downregulation of EphA2 and EphA4 levels, resulting in an expression pattern similar to that seen in vivo. We conclude that Hic1 spatially restricts ephrin-A1 expression in development, and that upregulated expression of ephrin-A1 resulting from epigenetic silencing of HIC1 in cancer cells may be an important mechanism in epithelial malignancy. Oncogene (2010) 29, 2467-2476; doi:10.1038/onc.2010.12; published online 15 February 2010	[Zhang, W.; Zeng, X.; Briggs, K. J.; Beaty, R.; Simons, B.; Yen, R-W Chiu; Tyler, M. A.; Tsai, H-C; Ye, Y.; Gesell, G. S.; Herman, J. G.; Baylin, S. B.; Watkins, D. N.] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; [Zhang, W.; Zeng, X.; Briggs, K. J.; Beaty, R.; Simons, B.; Yen, R-W Chiu; Tyler, M. A.; Tsai, H-C; Ye, Y.; Gesell, G. S.; Herman, J. G.; Baylin, S. B.; Watkins, D. N.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21231 USA; [Zeng, X.; Briggs, K. J.; Tsai, H-C] Johns Hopkins Univ, Sch Med, Grad Training Program Cellular & Mol Med, Baltimore, MD 21231 USA; [Watkins, D. N.] Monash Univ, Ctr Canc Res, Monash Inst Med Res, Clayton, Vic, Australia	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Monash University	Watkins, DN (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, 1650 Orleans St,CRB I 541, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu; neil.watkins@med.monash.edu.au	Tsai, Hsing-Chen/AAE-7530-2021; zhang, wei/A-7015-2011; Simons, Brian W./G-7352-2015; Watkins, David N/I-6113-2013	Tsai, Hsing-Chen/0000-0002-7057-9084; Simons, Brian W./0000-0003-0644-211X; 	National Cancer Institute [R01 CA43318]; American Cancer Society; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Cancer Institute Grant R01 CA43318 (SB Baylin) and an American Cancer Society Postdoctoral Fellowship (W Zhang). We thank Craig D Peacock, Leslie Meszler and Lillian Dasko-Vincent for technical assistance, Leander Van Neste for biostatistical support and Kathy Bender for the preparation and submission of this paper.	Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Briggs KJ, 2008, GENE DEV, V22, P770, DOI 10.1101/gad.1640908; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Chong SS, 1997, HUM MOL GENET, V6, P147, DOI 10.1093/hmg/6.2.147; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; Deltour S, 1998, BBA-GENE STRUCT EXPR, V1443, P230, DOI 10.1016/S0167-4781(98)00219-X; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fujii H, 1998, ONCOGENE, V16, P2159, DOI 10.1038/sj.onc.1201976; Guo H, 2006, CANCER RES, V66, P7050, DOI 10.1158/0008-5472.CAN-06-0004; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herath NI, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-144; Hirotsune S, 1997, GENOME RES, V7, P625, DOI 10.1101/gr.7.6.625; Holder N, 1999, DEVELOPMENT, V126, P2033; Iida H, 2005, GUT, V54, P843, DOI 10.1136/gut.2004.049486; Jenal M, 2009, MOL CANCER RES, V7, P916, DOI 10.1158/1541-7786.MCR-08-0359; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Kullander K, 2002, NAT REV MOL CELL BIO, V3, P475, DOI 10.1038/nrm856; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Nakamura R, 2005, CANCER SCI, V96, P42, DOI 10.1111/j.1349-7006.2005.00007.x; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Poliakov A, 2004, DEV CELL, V7, P465, DOI 10.1016/j.devcel.2004.09.006; Potla L, 2002, CANCER LETT, V175, P187, DOI 10.1016/S0304-3835(01)00613-9; Shi L, 2008, ONCOGENE, V27, P3265, DOI 10.1038/sj.onc.1210992; Takai N, 2001, ONCOL REP, V8, P567; Tang XX, 1999, CLIN CANCER RES, V5, P1491; Van Rechem C, 2009, J BIOL CHEM, V284, P20927, DOI 10.1074/jbc.M109.022350; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wykosky J, 2008, ONCOGENE, V27, P7260, DOI 10.1038/onc.2008.328; Wykosky J, 2008, MOL CANCER RES, V6, P1795, DOI 10.1158/1541-7786.MCR-08-0244; Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349	44	35	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR	2010	29	17					2467	2476		10.1038/onc.2010.12	http://dx.doi.org/10.1038/onc.2010.12			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	589RB	20154726	Green Accepted			2022-12-17	WOS:000277169400002
J	Kulkarni, S; Reddy, KB; Esteva, FJ; Moore, HCF; Budd, GT; Tubbs, RR				Kulkarni, S.; Reddy, K. B.; Esteva, F. J.; Moore, H. C. F.; Budd, G. T.; Tubbs, R. R.			Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer	ONCOGENE			English	Article						HER2; AKT1; survival; resistance; calpain	GROWTH-FACTOR-RECEPTOR; MONOCLONAL-ANTIBODY; FACTOR-BETA; CELLS; RESISTANCE; KINASE; INTEGRIN; ACTIVATION; ERBB2; HER2	Resistance to anti-HER2 (human epithelial growth factor receptor 2) trastuzumab therapy occurs commonly in HER2-positive breast cancer and involves overactivation of HER2 and/or AKT1. Using the model of trastuzumab-sensitive or trastuzumab-resistant HER2-positive cells with wild-type PTEN, negative regulator of AKT1, we explore the involvement of cysteine protease calpain in mechanisms of trastuzumab resistance. Overexpression of calpain1 or activation of endogenous calpain during adhesion or trastuzumab treatment of trastuzumab-sensitive cells induces cleavage of cytoplasmic domains of HER2/phospho-HER2; cleavage occurs in HER2-positive tumors. Expression of the catalytically inactive mutant of calpain1 reduces the cleavage to enhance the activity of HER2, inactivates PTEN to enhance the activation of AKT1, induces desensitization to trastuzumab and promotes survival of trastuzumab-sensitive cells. In the model of trastuzumab resistance, constitutive overactivation of HER2 and AKT1 correlates with reduced activation of calpain. Moreover, inhibitors of the catalytic site of calpain reduce the increase in constitutive activity of AKT1 and survival of trastuzumab-resistant cells selectively. Together, by regulating the activation of HER2 and PTEN/AKT1, calpain regulates trastuzumab sensitivity and survival, and the deregulation of the activation of calpain promotes trastuzumab resistance. Trastuzumab-resistant cells activate AKT1 in a mechanism dependent on the residual calpain activity, inhibition of which restores trastuzumab sensitivity and rescues resistance. These data identify calpain as a new therapeutic target in HER2-positive breast cancer. Oncogene (2010) 29, 1339-1350; doi:10.1038/onc.2009.422; published online 30 November 2009	[Kulkarni, S.; Tubbs, R. R.] Cleveland Clin, Dept Mol Pathol, Pathol & Lab Med Inst, Cleveland, OH 44195 USA; [Reddy, K. B.] Cleveland Clin, Dept Mol Cardiol, Cleveland, OH 44106 USA; [Esteva, F. J.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Moore, H. C. F.; Budd, G. T.] Cleveland Clin, Taussig Canc Ctr, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; Cleveland Clinic Foundation	Kulkarni, S (corresponding author), Cleveland Clin, Dept Mol Pathol, Pathol & Lab Med Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	kulkars@ccf.org						Anastasi S, 2005, ONCOGENE, V24, P4540, DOI 10.1038/sj.onc.1208658; Anido J, 2006, EMBO J, V25, P3234, DOI 10.1038/sj.emboj.7601191; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Chan CT, 2005, BREAST CANCER RES TR, V91, P187, DOI 10.1007/s10549-004-7715-1; Clark AS, 2002, MOL CANCER THER, V1, P707; Edelstein CL, 2000, METH MOL B, V144, P233; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; Gericke A, 2006, GENE, V374, P1, DOI 10.1016/j.gene.2006.02.024; Glading A, 2004, MOL CELL BIOL, V24, P2499, DOI 10.1128/MCB.24.6.2499-2512.2004; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; GREGORIOU M, 1994, EUR J BIOCHEM, V223, P455, DOI 10.1111/j.1432-1033.1994.tb19013.x; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Kulkarni S, 1999, J BIOL CHEM, V274, P21265, DOI 10.1074/jbc.274.30.21265; Kulkarni S, 2002, J BIOL CHEM, V277, P24435, DOI 10.1074/jbc.M203457200; Lacroix M, 2004, BREAST CANCER RES TR, V83, P249, DOI 10.1023/B:BREA.0000014042.54925.cc; Lawlor MA, 2001, J CELL SCI, V114, P2903; Libertini SJ, 2007, CANCER RES, V67, P9001, DOI 10.1158/0008-5472.CAN-07-1072; Mlynarczuk-Bialy I, 2006, CANCER RES, V66, P7598, DOI 10.1158/0008-5472.CAN-05-2614; Molina MA, 2001, CANCER RES, V61, P4744; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Nahta R, 2004, CANCER CHEMOTH PHARM, V53, P186, DOI 10.1007/s00280-003-0728-3; Perrin BJ, 2006, MOL BIOL CELL, V17, P239, DOI 10.1091/mbc.e05-06-0488; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Raynaud F, 2003, EUR J BIOCHEM, V270, P4662, DOI 10.1046/j.1432-1033.2003.03859.x; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tan Y, 2006, J BIOL CHEM, V281, P17689, DOI 10.1074/jbc.M601978200; Tao Y, 2007, NAT CLIN PRACT ONCOL, V4, P591, DOI 10.1038/ncponc0934; Troussard AA, 2006, CANCER RES, V66, P393, DOI 10.1158/0008-5472.CAN-05-2304; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.2002.20.3.719; Wang SZE, 2006, CANCER RES, V66, P9591, DOI 10.1158/0008-5472.CAN-06-2071; Wang SE, 2009, CANCER RES, V69, P475, DOI 10.1158/0008-5472.CAN-08-2649; Yakes FM, 2002, CANCER RES, V62, P4132; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhu HB, 2004, MOL THER, V9, P666, DOI 10.1016/j.ymthe.2004.02.007; Zito CI, 2008, GENE CHROMOSOME CANC, V47, P633, DOI 10.1002/gcc.20566; Zutter MM, 2007, ADV EXP MED BIOL, V608, P87	44	35	37	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 4	2010	29	9					1339	1350		10.1038/onc.2009.422	http://dx.doi.org/10.1038/onc.2009.422			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	563XJ	19946330				2022-12-17	WOS:000275170600009
J	Baert, JL; Monte, D; Verreman, K; Degerny, C; Coutte, L; Launoit, Y				Baert, J-L; Monte, D.; Verreman, K.; Degerny, C.; Coutte, L.; de Launoit, Y.			The E3 ubiquitin ligase complex component COP1 regulates PEA3 group member stability and transcriptional activity	ONCOGENE			English	Article						ETS; ERM; transcription factor; Ub-modification; COP1; DET1	PHOTOMORPHOGENESIS; IDENTIFICATION; DOMAIN; JUN	In this study, we report that the PEA3 group members interact with the mammalian really interesting new gene (RING) E3 ubiquitin ligase constitutive photomorphogenetic 1 (COP1), which mediates ubiquitylation and subsequent proteasome degradation of the p53 and c-Jun transcription factors. This interaction is mediated by the central region of COP1 including the coiled-coil domain and two COP1-interacting consensus motifs localized in the well-conserved N-terminal transactivation domain of the PEA3 group members. At the transcriptional level, COP1 reduces the transcriptional activity of ERM and the two other PEA3 group proteins on Ets-responsive reporter genes; this effect being dependent on the RING domain of COP1 and the two COP1-interacting motifs of ERM. Reduced transcriptional activity was, however, not related to COP1-induced changes in ERM stability. In fact, increased ubiquitylation and subsequent proteasome-mediated degradation of ERM is achieved only when COP1 is expressed with DET1, a key COP1 partner within the ubiquitylation complex. Conversely, we show that the depletion of COP1 or DET1 by small interference RNA (siRNA) in U2OS cells stabilizes endogenous ERM whereas only COP1 knockdown enhances expression of ICAM-1, a gene regulated by this transcription factor. These results indicate that COP1 is a complex regulator of ERM and the two other PEA3 group members. Oncogene (2010) 29, 1810-1820; doi:10.1038/onc.2009.471; published online 11 January 2010	[Baert, J-L] Univ Lille Nord France, Inst Biol, Inst Pasteur, CNRS,UMR 8161,IFR 142, F-59021 Lille, France; [Degerny, C.] Univ Paris 11, Inst Andre Lwoff, CNRS, FRE 2944, Villejuif, France; [Coutte, L.] Univ Paris 11, Fac Sci, Lab Biol Anim, Orsay, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Baert, JL (corresponding author), Univ Lille Nord France, Inst Biol, Inst Pasteur, CNRS,UMR 8161,IFR 142, BP 447,1 Rue Calmette, F-59021 Lille, France.	jean-luc.baert@ibl.fr; yvan.delaunoit@ibl.fr		de Launoit, Yvan/0000-0003-1837-9808; coutte, laurent/0000-0002-0031-4742; monte, didier/0000-0002-0613-6203	'Ligue Nationale Contre le Cancer' (Comite Nord, France); 'Association pour la Recherche contre le Cancer' (France); 'Conseil Regional Nord/Pas-de-Calais' (France); European Regional Development Fund	'Ligue Nationale Contre le Cancer' (Comite Nord, France); 'Association pour la Recherche contre le Cancer' (France)(Fondation ARC pour la Recherche sur le Cancer); 'Conseil Regional Nord/Pas-de-Calais' (France)(Region Hauts-de-France); European Regional Development Fund(European Commission)	This work was carried out thanks to grants awarded by the 'Ligue Nationale Contre le Cancer' (Comite Nord, France), the 'Association pour la Recherche contre le Cancer' (France), the 'Conseil Regional Nord/Pas-de-Calais' (France) and the European Regional Development Fund (Intergenes program). We thank E Bianchi and VM Dixit for kind gifts of plasmids.	Baert JL, 2007, ONCOGENE, V26, P415, DOI 10.1038/sj.onc.1209801; Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Bianchi E, 2003, J BIOL CHEM, V278, P19682, DOI 10.1074/jbc.M212681200; Coutte L, 1999, ONCOGENE, V18, P6278, DOI 10.1038/sj.onc.1203020; de Launoit Y, 2000, ADV EXP MED BIOL, V480, P107; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; de Launoit Y, 2006, BBA-REV CANCER, V1766, P79, DOI 10.1016/j.bbcan.2006.02.002; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; Degerny C, 2005, J BIOL CHEM, V280, P24330, DOI 10.1074/jbc.M411250200; Di Bacco A, 2006, CELL CYCLE, V5, P2310, DOI 10.4161/cc.5.20.3367; Dornan D, 2004, NATURE, V429, P86, DOI 10.1038/nature02514; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gocke CB, 2005, J BIOL CHEM, V280, P5004, DOI 10.1074/jbc.M411718200; Holm M, 2001, EMBO J, V20, P118, DOI 10.1093/emboj/20.1.118; Kato S, 2008, J BIOL CHEM, V283, P35464, DOI 10.1074/jbc.M801011200; Liu Y, 2006, MOL CELL BIOL, V26, P3114, DOI 10.1128/MCB.26.8.3114-3123.2006; Sharrocks AD, 2006, GENE DEV, V20, P754, DOI 10.1101/gad.1421006; Takahashi A, 2005, BIOCHEM BIOPH RES CO, V327, P575, DOI 10.1016/j.bbrc.2004.12.045; Wertz IE, 2004, SCIENCE, V303, P1371, DOI 10.1126/science.1093549; Yi CL, 2005, TRENDS CELL BIOL, V15, P618, DOI 10.1016/j.tcb.2005.09.007	20	35	35	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	12					1810	1820		10.1038/onc.2009.471	http://dx.doi.org/10.1038/onc.2009.471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	574VR	20062082	Green Published			2022-12-17	WOS:000276022800010
J	Rodriguez-Ubreva, FJ; Cariaga-Martinez, AE; Cortes, MA; Romero-De Pablos, M; Ropero, S; Lopez-Ruiz, P; Colas, B				Rodriguez-Ubreva, F. J.; Cariaga-Martinez, A. E.; Cortes, M. A.; Romero-De Pablos, M.; Ropero, S.; Lopez-Ruiz, P.; Colas, B.			Knockdown of protein tyrosine phosphatase SHP-1 inhibits G1/S progression in prostate cancer cells through the regulation of components of the cell-cycle machinery	ONCOGENE			English	Article						prostate cancer; cell cycle; p27; CDK2; SHP-1	GROWTH-FACTOR; DEPENDENT PHOSPHORYLATION; TRANSCRIPTION FACTORS; ANTIGEN RECEPTOR; KINASE-ACTIVITY; CDK INHIBITORS; NUCLEAR IMPORT; ACTIVATION; P27(KIP1); DOMAIN	SHP-1, a haematopoietic cell-specific tyrosine phosphatase, is also expressed in human prostate. In this study, we report that SHP-1 depletion in PC-3 cells induced by small interfering RNAs causes G1 phase cell-cycle arrest accompanied by changes in some components of the cell-cycle machinery. SHP-1 knockdown increases p27(Kip1) (p27) protein stability, its nuclear localization and p27 gene transcription. These effects could be mediated by PI3K-AKT pathway as SHP-1 interacts with PI3K regulating its activity and p110 catalytic subunit phosphorylation. The increase in p27 protein stability could also because of reduced cyclin-dependent kinase (CDK2) activity. SHP-1 knockdown decreases the CDK6 levels, inducing retinoblastoma protein hypophosphorylation, downregulation of cyclin E and thereby a decrease in the CDK2 activity. However, the codepletion of SHP-1 and p27 does not produce re-entry into the cycle, implying that p27 is not required to maintain cell-cycle arrest induced by SHP-1 depletion. The maintenance of the PC-3 cell anti-proliferative response after p27 loss could be because of mislocalization of CDK2 induced by SHP-1 knockdown. This study shows that SHP-1 depletion promotes cell-cycle arrest by modulating the activity of cell-cycle regulators and suggests that SHP-1 may be required for the proper functioning of events governing cell-cycle progression. Oncogene (2010) 29, 345-355; doi:10.1038/onc.2009.329; published online 19 October 2009	[Colas, B.] Univ Alcala de Henares, Fac Med, Dept Bioquim & Biol Mol, E-28871 Madrid, Spain; [Romero-De Pablos, M.] Univ Alcala de Henares, Dept Fisiol, E-28871 Madrid, Spain	Universidad de Alcala; Universidad de Alcala	Colas, B (corresponding author), Univ Alcala de Henares, Fac Med, Dept Bioquim & Biol Mol, Madrid Barcelona Km 33,600, E-28871 Madrid, Spain.	begona.colas@uah.es	Cariaga-Martinez, Ariel Ernesto/M-3619-2018; de Pablos, Montserrat Romero/AAK-3167-2021; Cortés, María Alicia/ABG-3899-2020	Cariaga-Martinez, Ariel Ernesto/0000-0003-1457-995X; de Pablos, Montserrat Romero/0000-0002-2801-6376; Cortés, María Alicia/0000-0001-7765-5302; RODRIGUEZ-UBREVA, JAVIER/0000-0003-4707-4536	Consejeria de Sanidad de Castilla-La Mancha [04077-00]; Fundacion de Investigacion Mutua Madrilena grant; Instituto de Salud Carlos III grant [PI060109]; FPI fellowship, Comunidad de Madrid; Fundacion Carolina; FPI fellowship Consejeria de Educacion de Castilla-La Mancha	Consejeria de Sanidad de Castilla-La Mancha; Fundacion de Investigacion Mutua Madrilena grant; Instituto de Salud Carlos III grant(Instituto de Salud Carlos III); FPI fellowship, Comunidad de Madrid(Comunidad de MadridSpanish Government); Fundacion Carolina; FPI fellowship Consejeria de Educacion de Castilla-La Mancha	We are very grateful to Dr T Sakai (Department of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan) for providing human p27 promoter containing luciferase reporter construct (p27PF) and control empty vector and also to Dr FD Bohmer (Institute of Molecular Cell Biology, Medical Faculty, Friedrich Schiller University, Jena, Germany) for providing GST-SHP-1 wild type. This work was supported by Consejeria de Sanidad de Castilla-La Mancha grant (04077-00); Fundacion de Investigacion Mutua Madrilena grant; Instituto de Salud Carlos III grant (PI060109); FPI fellowship, Comunidad de Madrid (FJ Rodriguez-Ubreva); Fundacion Carolina and FPI fellowship Consejeria de Educacion de Castilla-La Mancha (AE Cariaga-Martinez).	Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Besson A, 2004, NAT REV CANCER, V4, P948, DOI 10.1038/nrc1501; Besson A, 2008, DEV CELL, V14, P159, DOI 10.1016/j.devcel.2008.01.013; Boehm M, 2002, EMBO J, V21, P3390, DOI 10.1093/emboj/cdf343; Caron D, 2008, CANCER LETT, V262, P265, DOI 10.1016/j.canlet.2007.12.012; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Craggs G, 2001, J BIOL CHEM, V276, P23719, DOI 10.1074/jbc.M102846200; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Fujita N, 2002, J BIOL CHEM, V277, P28706, DOI 10.1074/jbc.M203668200; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Martin-Orozco RM, 2007, NEOPLASIA, V9, P614, DOI 10.1593/neo.07337; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; Nakagawa H, 2001, FEBS LETT, V508, P53, DOI 10.1016/S0014-5793(01)03021-6; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pages P, 1999, J BIOL CHEM, V274, P15186, DOI 10.1074/jbc.274.21.15186; PANI G, 1995, J EXP MED, V181, P2077, DOI 10.1084/jem.181.6.2077; Pani G, 1996, J EXP MED, V184, P839, DOI 10.1084/jem.184.3.839; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Seo DW, 2006, J BIOL CHEM, V281, P3711, DOI 10.1074/jbc.M509932200; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Simoneau M, 2008, J BIOL CHEM, V283, P25544, DOI 10.1074/jbc.M804177200; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Tenev T, 2000, EUR J CELL BIOL, V79, P261, DOI 10.1078/S0171-9335(04)70029-1; Valencia AM, 1997, FEBS LETT, V406, P42, DOI 10.1016/S0014-5793(97)00235-4; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; You M, 1997, J BIOL CHEM, V272, P23376, DOI 10.1074/jbc.272.37.23376; Yu ZB, 1998, J BIOL CHEM, V273, P3687, DOI 10.1074/jbc.273.6.3687; Zapata PD, 2002, J CLIN ENDOCR METAB, V87, P915, DOI 10.1210/jc.87.2.915; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; 2005, BMC BIOINFORMATICS, V6, P62	44	35	36	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2010	29	3					345	355		10.1038/onc.2009.329	http://dx.doi.org/10.1038/onc.2009.329			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546EO	19838216				2022-12-17	WOS:000273793200004
J	Bourke, E; Brown, JAL; Takeda, S; Hochegger, H; Morrison, CG				Bourke, E.; Brown, J. A. L.; Takeda, S.; Hochegger, H.; Morrison, C. G.			DNA damage induces Chk1-dependent threonine-160 phosphorylation and activation of Cdk2	ONCOGENE			English	Article						centrosome; DNA damage response; Chk1; Cdk2; Cdk1	INDUCED CENTROSOME OVERDUPLICATION; CYCLIN-E OVEREXPRESSION; CELL-CYCLE; CHROMOSOME INSTABILITY; TUMOR-CELLS; AMPLIFICATION; PHASE; DUPLICATION; CHECKPOINT; CDC25A	Abnormal centrosome numbers arise in tumours and can cause multipolar mitoses and genome instability. Cdk2 controls normal centrosome duplication, but Chk1-dependent centrosome amplification also occurs after DNA damage. We investigated the involvement of cyclin-dependent kinases (Cdks) in DNA damage-induced centrosome amplification using cells lacking either Cdk2, or both Cdk1 and Cdk2 activity. Cdk2(-/-) DT40 cells showed robust centrosome amplification after ionizing radiation (IR), whereas Cdk1-deficient Cdk2(-/-) cells showed no centrosome amplification, demonstrating that Cdk1 can substitute for Cdk2 in this pathway. Surprisingly, we found that Cdk2 activity was upregulated by IR in wild-type but not in Chk1(-/-) DT40 cells. Cdk2 upregulation also occurred in HeLa cells after IR treatment. Chk1-dependent Cdk2 induction was not accompanied by increased levels of Cdk1, Cdk2, cyclin A or cyclin E, but activating T160 phosphorylation of Cdk2 increased after IR. Moreover, Cdk2 overexpression restored IR-induced centrosome amplification in Cdk1-deficient Cdk2(-/-) cells, but T160A mutation blocked this rescue. Our data suggest that Chk1 signalling causes centrosome amplification after IR by upregulating Cdk2 activity through activating phosphorylation. Oncogene (2010) 29, 616-624; doi: 10.1038/onc.2009.340; published online 19 October 2009	[Bourke, E.; Brown, J. A. L.; Morrison, C. G.] Natl Univ Ireland Galway, Ctr Chromosome Biol, Sch Nat Sci, Galway, Ireland; [Takeda, S.] Kyoto Univ, Sch Med, Dept Radiat Genet, Kyoto 606, Japan; [Hochegger, H.] Univ Sussex, Genome Damage & Stabil Ctr, Brighton, E Sussex, England	Ollscoil na Gaillimhe-University of Galway; Kyoto University; University of Sussex	Morrison, CG (corresponding author), Natl Univ Ireland Galway, Ctr Chromosome Biol, Sch Nat Sci, Univ Rd, Galway, Ireland.	ciaran.morrison@nuigalway.ie	Morrison, Ciaran/B-6568-2008; Brown, James/H-3437-2019; Morrison, Ciaran/AAH-2034-2019	Morrison, Ciaran/0000-0003-2401-7029; Brown, James/0000-0002-3155-0334; Morrison, Ciaran/0000-0003-2401-7029; Bourke, Emer/0000-0002-2218-3114; Hochegger, Helfrid/0000-0001-8366-6198; Takeda, Shunichi/0000-0002-7924-7991	Science Foundation Ireland [08/IN.1/B1029]; Health Research Board [RP/2006/36]	Science Foundation Ireland(Science Foundation IrelandEuropean Commission); Health Research Board	This work was supported by Science Foundation Ireland Principal Investigator award 08/IN.1/B1029 and by Health Research Board project grant RP/2006/36. We thank Helen Dodson for helping us with the initial Cdk kinase assays and Corrado Santocanale for critical reading of the paper.	Aleem E, 2005, NAT CELL BIOL, V7, P831, DOI 10.1038/ncb1284; Balczon R, 2001, CHROMOSOMA, V110, P381, DOI 10.1007/s004120100157; Beamish H, 1996, J BIOL CHEM, V271, P20486, DOI 10.1074/jbc.271.34.20486; Berthet C, 2007, ONCOGENE, V26, P4469, DOI 10.1038/sj.onc.1210243; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bettencourt-Dias M, 2007, NAT REV MOL CELL BIO, V8, P451, DOI 10.1038/nrm2180; Bourke E, 2007, EMBO REP, V8, P603, DOI 10.1038/sj.embor.7400962; Cannell EJ, 1998, FEBS LETT, V439, P297, DOI 10.1016/S0014-5793(98)01391-X; Chen MS, 2003, MOL CELL BIOL, V23, P7488, DOI 10.1128/MCB.23.21.7488-7497.2003; Dodson H, 2004, EMBO J, V23, P3864, DOI 10.1038/sj.emboj.7600393; Dodson H, 2007, CELL CYCLE, V6, P364, DOI 10.4161/cc.6.3.3834; Doxsey S, 2005, ANNU REV CELL DEV BI, V21, P411, DOI 10.1146/annurev.cellbio.21.122303.120418; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 2007, NAT REV CANCER, V7, P911, DOI 10.1038/nrc2249; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Hanashiro K, 2008, ONCOGENE, V27, P5288, DOI 10.1038/onc.2008.161; He GG, 2005, ONCOGENE, V24, P2929, DOI 10.1038/sj.onc.1208474; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hochegger H, 2007, J CELL BIOL, V178, P257, DOI 10.1083/jcb.200702034; Kawamura K, 2004, CANCER RES, V64, P4800, DOI 10.1158/0008-5472.CAN-03-3908; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2002, EMBO J, V21, P5911, DOI 10.1093/emboj/cdf567; MATSUMOTO Y, 1999, P SPIE 3 DIM IM CAPT, V2, P2; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Muller-Tidow C, 2004, MOL CELL BIOL, V24, P8917, DOI 10.1128/MCB.24.20.8917-8928.2004; Mussman JG, 2000, ONCOGENE, V19, P1635, DOI 10.1038/sj.onc.1203460; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; Prosser SL, 2009, MOL CELL BIOL, V29, P1760, DOI 10.1128/MCB.01124-08; Saladino C, 2009, ENVIRON MOL MUTAGEN, V50, P725, DOI 10.1002/em.20477; Sampath D, 2002, MOL PHARMACOL, V62, P680, DOI 10.1124/mol.62.3.680; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Satyanarayana A, 2008, MOL BIOL CELL, V19, P65, DOI 10.1091/mbc.E07-06-0525; Shimuta K, 2002, EMBO J, V21, P3694, DOI 10.1093/emboj/cdf357; Shreeram S, 2008, MOL CELL BIOL, V28, P7442, DOI 10.1128/MCB.00138-08; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Tarapore P, 2002, ONCOGENE, V21, P6234, DOI 10.1038/sj.onc.1205707; Tsou MFB, 2006, NATURE, V442, P947, DOI 10.1038/nature04985; Uto K, 2004, EMBO J, V23, P3386, DOI 10.1038/sj.emboj.7600328; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Yamazoe M, 2004, DNA REPAIR, V3, P1175, DOI 10.1016/j.dnarep.2004.03.039; Zachos G, 2003, EMBO J, V22, P713, DOI 10.1093/emboj/cdg060; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	47	35	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2010	29	4					616	624		10.1038/onc.2009.340	http://dx.doi.org/10.1038/onc.2009.340			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	549WH	19838212				2022-12-17	WOS:000274084600014
J	Bettuzzi, S; Davalli, P; Davoli, S; Chayka, O; Rizzi, F; Belloni, L; Pellacani, D; Fregni, G; Astancolle, S; Fassan, M; Corti, A; Baffa, R; Sala, A				Bettuzzi, S.; Davalli, P.; Davoli, S.; Chayka, O.; Rizzi, F.; Belloni, L.; Pellacani, D.; Fregni, G.; Astancolle, S.; Fassan, M.; Corti, A.; Baffa, R.; Sala, A.			Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread	ONCOGENE			English	Article						immunohistochemistry; tumour suppressor gene; cell cycle; NF-kappa B	NF-KAPPA-B; TRANSGENIC MOUSE MODEL; EPITHELIAL-CELLS; CANCER CELLS; CLUSTERIN; EXPRESSION; PROGRESSION; INDUCTION; APOPTOSIS; ACTIVATION	ApoJ/Clusterin (CLU) is a heterodimeric protein localized in the nucleus, cytoplasm or secretory organelles and involved in cell survival and neoplastic transformation. Its function in human cancer is still highly controversial. In this study, we examined the prostate of mice in which CLU has been genetically inactivated. Surprisingly, we observed transformation of the prostate epithelium in the majority of CLU knockout mice. Either PIN (prostate intraepithelial neoplasia) or differentiated carcinoma was observed in 100 and 87% of mice with homozygous or heterozygous deletion of CLU, respectively. Crossing CLU knockout with TRAMP (prostate cancer prone) mice results in a strong enhancement of metastatic spread. Finally, CLU depletion causes tumourigenesis in female TRAMP mice, which are normally cancer free. Mechanistically, deletion of CLU induces activation of nuclear factor-kB, a potentially oncogenic transcription factor important for the proliferation and survival of prostate cells. Oncogene (2009) 28, 4344-4352; doi: 10.1038/onc.2009.286; published online 28 September 2009	[Bettuzzi, S.; Davoli, S.; Rizzi, F.; Belloni, L.] Univ Parma, Dept Expt Med, I-43100 Parma, Italy; [Davalli, P.; Pellacani, D.; Fregni, G.; Astancolle, S.; Corti, A.] Univ Modena & Reggio Emilia, Dept Biomed Sci, Modena, Italy; [Chayka, O.; Sala, A.] Inst Child Hlth, Mol Haematol & Canc Biol Unit, London, England; [Fassan, M.; Baffa, R.] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA; [Baffa, R.] MedImmune LLC, Res, Gaithersburg, MD USA	University of Parma; Universita di Modena e Reggio Emilia; University of London; University College London; Jefferson University; AstraZeneca; Medimmune	Bettuzzi, S (corresponding author), Univ Parma, Dept Expt Med, Via Volturno 39, I-43100 Parma, Italy.	saverio.bettuzzi@unipr.it; a.sala@ich.ucl.ac.uk	Fassan, Matteo/F-5152-2012; sala, arturo/C-4959-2008; Bettuzzi, Saverio/B-2609-2009	Fassan, Matteo/0000-0001-6515-5482; Bettuzzi, Saverio/0000-0003-2080-6979; Rizzi, Federica/0000-0002-6670-2588; Sala, Arturo/0000-0002-2841-7866; Davoli, Serena Alba/0000-0002-8731-0305	Worldwide Cancer Research [06-0711] Funding Source: Medline	Worldwide Cancer Research		BETTUZZI S, 1989, BIOCHEM J, V257, P293, DOI 10.1042/bj2570293; Caccamo AE, 2005, CELL DEATH DIFFER, V12, P101, DOI 10.1038/sj.cdd.4401491; Caccamo AE, 2003, ANN NY ACAD SCI, V1010, P514, DOI 10.1196/annals.1299.095; Caporali A, 2004, CARCINOGENESIS, V25, P2217, DOI 10.1093/carcin/bgh235; Chayka O, 2009, JNCI-J NATL CANCER I, V101, P663, DOI 10.1093/jnci/djp063; Chen CD, 2002, MOL CELL BIOL, V22, P2862, DOI 10.1128/MCB.22.8.2862-2870.2002; Chen TG, 2004, CANCER RES, V64, P7412, DOI 10.1158/0008-5472.CAN-04-2077; Chiaverotti T, 2008, AM J PATHOL, V172, P236, DOI 10.2353/ajpath.2008.070602; CUSSENOT O, 1991, J UROLOGY, V146, P881, DOI 10.1016/S0022-5347(17)37953-3; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; Gleave M, 2005, WORLD J UROL, V23, P38, DOI 10.1007/s00345-004-0474-0; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; Hellebrekers DMEI, 2007, CANCER RES, V67, P4138, DOI 10.1158/0008-5472.CAN-06-3032; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; July LV, 2002, PROSTATE, V50, P179, DOI 10.1002/pros.10047; Kaplan-Lefko PJ, 2003, PROSTATE, V55, P219, DOI 10.1002/pros.10215; Lau SH, 2006, ONCOGENE, V25, P1242, DOI 10.1038/sj.onc.1209141; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; Miyake H, 2000, CANCER RES, V60, P170; Miyake H, 2006, UROLOGY, V68, P609, DOI 10.1016/j.urology.2006.03.017; Morris EJ, 2008, NATURE, V455, P552, DOI 10.1038/nature07310; Nizard P, 2007, TRAFFIC, V8, P554, DOI 10.1111/j.1600-0854.2007.00549.x; Nomura T, 2005, ONCOL REP, V14, P993; Nuutinen T, 2005, NEUROCHEM INT, V47, P528, DOI 10.1016/j.neuint.2005.07.007; Rauhala HE, 2008, INT J CANCER, V123, P1601, DOI 10.1002/ijc.23658; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Santilli G, 2003, J BIOL CHEM, V278, P38214, DOI 10.1074/jbc.C300252200; Scaltriti M, 2004, INT J CANCER, V108, P23, DOI 10.1002/ijc.11496; Shannan B, 2006, CELL DEATH DIFFER, V13, P12, DOI 10.1038/sj.cdd.4401779; Shukla S, 2005, PROSTATE, V64, P224, DOI 10.1002/pros.20217; Shukla S, 2004, NEOPLASIA, V6, P390, DOI 10.1593/neo.04112; Suh J, 2004, J CELL BIOCHEM, V91, P100, DOI 10.1002/jcb.10729; Thomas-Tikhonenko A, 2004, CANCER RES, V64, P3126, DOI 10.1158/0008-5472.CAN-03-1953; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wu ZH, 2008, EMBO J, V27, P1963, DOI 10.1038/emboj.2008.127; Zhang HL, 2005, NAT CELL BIOL, V7, P909, DOI 10.1038/ncb1291	38	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 10	2009	28	49					4344	4352		10.1038/onc.2009.286	http://dx.doi.org/10.1038/onc.2009.286			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	534DT	19784068				2022-12-17	WOS:000272876400003
J	Oh, J; Hur, MW; Lee, CE				Oh, J.; Hur, M-W; Lee, C-E			SOCS1 protects protein tyrosine phosphatases by thioredoxin upregulation and attenuates Jaks to suppress ROS-mediated apoptosis	ONCOGENE			English	Article						SOCS1; apoptosis; ROS; PTPs; Jaks thioredoxin	TUMOR-NECROSIS-FACTOR; HYDROGEN-PEROXIDE; CELL-DEATH; REDOX REGULATION; MAPK PATHWAYS; NADPH OXIDASE; ACTIVATION; INHIBITION; INDUCTION; PHOSPHORYLATION	Suppressors of cytokine signaling (SOCS) are negative regulators of cytokine-induced signal transduction, which play multiple roles in cell growth, differentiation and apoptosis. In this study, the regulatory role of SOCS in oxidative stress-induced apoptosis was investigated. In Jurkat T cells and mouse splenocytes, we have found that SOCS1 is induced in response to tumor necrosis factor-alpha or H2O2, concomitant with the activation of Jaks which act as important mediators of reactive oxygen species (ROS)-induced apoptosis upstream of p38 mitogen-activated protein kinase. Using SOCS1 overexpressing or knockdown Jurkat T-cell systems we clearly demonstrate that, SOCS1 inhibits the ROS-mediated apoptosis. The antiapoptotic action of SOCS1 was exerted not only by suppressing Jaks, but also by sustaining protein tyrosine phosphatase (PTP) activities. Notably, SOCS1-transduced cells displayed increase in thioredoxin levels and decrease in ROS generation induced by oxidative stress. In addition, the Jak-inhibiting and PTP-sustaining effect of SOCS1 was significantly reduced on thioredoxin ablation. Moreover, coimmunoprecipitation data revealed molecular interaction of SHP1 or CD45 with thioredoxin, which was promoted in SOCS1-transfected cells. Together, our data strongly suggest that both the protection of PTPs by thioredoxin from ROS attack and the attenuation of Jaks account for the antiapoptotic function of SOCS1 in immune cells under oxidative stress. Oncogene (2009) 28, 3145-3156; doi: 10.1038/onc.2009.169; published online 29 June 2009	[Oh, J.; Lee, C-E] Sungkyunkwan Univ, Dept Biol Sci, Immunol Lab, Inst Basic Sci, Suwon 440746, South Korea; [Hur, M-W] Yonsei Univ, Sch Med, Dept Biochem & Mol Biol, Brain Korea Project Med Sci 21, Seoul 120749, South Korea	Institute for Basic Science - Korea (IBS); Sungkyunkwan University (SKKU); Yonsei University	Lee, CE (corresponding author), Sungkyunkwan Univ, Dept Biol Sci, Immunol Lab, Inst Basic Sci, 300 Cheon Cheon Dong, Suwon 440746, South Korea.	celee@skku.edu		Hur, Man-Wook/0000-0002-3416-1334	Brain Korea 21 program; KOSEF [2008-01752]; KRF [314-2008-1: E00030]; MOHW [A084298]; Seoul Graduate Student Scholarship	Brain Korea 21 program(Ministry of Education & Human Resources Development (MOEHRD), Republic of Korea); KOSEF(Korea Science and Engineering Foundation); KRF(National Research Foundation of Korea); MOHW(Ministry of Health & Welfare (MOHW), Republic of Korea); Seoul Graduate Student Scholarship	This work was supported by Brain Korea 21 program and research grants from KOSEF (2008-01752), KRF (314-2008-1: E00030) and MOHW (A084298). J Oh was supported in part by the 2005 Seoul Graduate Student Scholarship.	Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Baetz A, 2008, FASEB J, V22, P4296, DOI 10.1096/fj.08-116079; Barrett DM, 2005, J BIOL CHEM, V280, P14453, DOI 10.1074/jbc.M411523200; Cao Q, 2004, J BIOL CHEM, V279, P4292, DOI 10.1074/jbc.M308351200; Chong MMW, 2002, J BIOL CHEM, V277, P27945, DOI 10.1074/jbc.M110214200; Cuncic C, 1999, J BIOL INORG CHEM, V4, P354, DOI 10.1007/s007750050322; Dang PMC, 2006, J CLIN INVEST, V116, P2033, DOI 10.1172/JCI27544; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Devadas S, 2002, J EXP MED, V195, P59, DOI 10.1084/jem.20010659; Didier C, 2001, FREE RADICAL BIO MED, V31, P585, DOI 10.1016/S0891-5849(01)00617-7; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; Han SI, 2008, BMB REP, V41, P1; He Y, 2006, J BIOL CHEM, V281, P5559, DOI 10.1074/jbc.M512338200; Hsieh CC, 2006, FASEB J, V20, P259, DOI 10.1096/fj.05-4376com; Irie-Sasaki J, 2001, NATURE, V409, P349, DOI 10.1038/35053086; Jang JY, 2006, CELL IMMUNOL, V241, P14, DOI 10.1016/j.cellimm.2006.07.006; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; Jeong SY, 2008, BMB REP, V41, P11, DOI 10.1146/annurev-genet-102108-134850; Kim BJ, 2006, J BIOL CHEM, V281, P21256, DOI 10.1074/jbc.M510644200; Kim SH, 2008, BMC IMMUNOL, V9, DOI 10.1186/1471-2172-9-64; Kimura A, 2004, INT IMMUNOL, V16, P991, DOI 10.1093/intimm/dxh102; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kubo M, 2003, NAT IMMUNOL, V4, P1169, DOI 10.1038/ni1012; Lee K, 2002, FREE RADICAL BIO MED, V33, P1121, DOI 10.1016/S0891-5849(02)01000-6; Masuhiro Y, 2008, J BIOL CHEM, V283, P31575, DOI 10.1074/jbc.M800328200; Morita Y, 2000, P NATL ACAD SCI USA, V97, P5405, DOI 10.1073/pnas.090084797; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Odaka C, 2003, J IMMUNOL, V171, P1507, DOI 10.4049/jimmunol.171.3.1507; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Reth M, 2002, NAT IMMUNOL, V3, P1129, DOI 10.1038/ni1202-1129; Rusanescu G, 2005, EMBO J, V24, P305, DOI 10.1038/sj.emboj.7600522; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; To KF, 2004, BRIT J CANCER, V91, P1335, DOI 10.1038/sj.bjc.6602133; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yoshida T, 2004, J EXP MED, V199, P1701, DOI 10.1084/jem.20031675	38	35	40	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2009	28	35					3145	3156		10.1038/onc.2009.169	http://dx.doi.org/10.1038/onc.2009.169			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	490QC	19561639				2022-12-17	WOS:000269515100006
J	Yeh, YH; Huang, YF; Lin, TY; Shieh, SY				Yeh, Y-H; Huang, Y-F; Lin, T-Y; Shieh, S-Y			The cell cycle checkpoint kinase CHK2 mediates DNA damage-induced stabilization of TTK/hMps1	ONCOGENE			English	Article						checkpoint; CHK2; TTK/hMps1	POLE BODY DUPLICATION; SPINDLE-CHECKPOINT; PROTEIN-KINASE; KINETOCHORE LOCALIZATION; CENTROSOME DUPLICATION; MITOTIC CHECKPOINT; HUMAN MPS1; CANCER-THERAPY; GENE MPS1; PHOSPHORYLATION	Cell cycle progression is monitored constantly to ensure faithful passage of genetic codes and genome stability. We have demonstrated previously that, upon DNA damage, TTK/hMps1 activates the checkpoint kinase CHK2 by phosphorylating CHK2 at Thr68. However, it remains to be determined whether and how TTK/hMps1 responds to DNA damage. In this report, we present evidence that TTK/hMps1 can be induced by DNA damage in normal human. broblasts. Interestingly, the induction depends on CHK2 because CHK2-targeting small interfering RNA or a CHK2 inhibitor abolishes the increase. Such induction is mediated through phosphorylation of TTK/hMps1 at Thr288 by CHK2 and requires the CHK2 SQ/TQ cluster domain/forkhead-associated domain. In cells, TTK/hMps1 phosphorylation at Thr288 is induced by DNA damage and forms nuclear foci, which colocalize partially with c-H2AX. Reexpression of TTK/hMps1 T288A mutant in TTK/hMps1-knockdown cells causes a defect in G2/M arrest, suggesting that phosphorylation at this site participates in the proper checkpoint execution. Our study uncovered a regulatory loop between TTK/hMps1 and CHK2 whereby DNA damage-activated CHK2 may facilitate the stabilization of TTK/hMps1, therefore maintaining the checkpoint control.	[Yeh, Y-H; Huang, Y-F; Lin, T-Y; Shieh, S-Y] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; [Huang, Y-F] Natl Tsing Hua Univ, Inst Mol & Cellular Biol, Hsinchu, Taiwan	Academia Sinica - Taiwan; National Tsing Hua University	Shieh, SY (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sect 2,Acad Rd, Taipei 115, Taiwan.	sy88@ibms.sinica.edu.tw	Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	Academia Sinica; National Science Council of Taiwan	Academia Sinica(Academia Sinica - Taiwan); National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Academia Sinica and National Science Council of Taiwan to S-Y Shieh.	Abrieu A, 2001, CELL, V106, P83, DOI 10.1016/S0092-8674(01)00410-X; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; Antoni L, 2007, NAT REV CANCER, V7, P925, DOI 10.1038/nrc2251; Bartek J, 2007, CURR OPIN CELL BIOL, V19, P238, DOI 10.1016/j.ceb.2007.02.009; Branzei D, 2005, CURR OPIN CELL BIOL, V17, P568, DOI 10.1016/j.ceb.2005.09.003; Cui Y, 2008, ONCOGENE, V27, P3122, DOI 10.1038/sj.onc.1210972; de Carcer G, 2007, CURR MED CHEM, V14, P969, DOI 10.2174/092986707780362925; Dimitrova DS, 2000, EXP CELL RES, V254, P321, DOI 10.1006/excr.1999.4770; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; Enders GH, 2006, GENE, V371, P1, DOI 10.1016/j.gene.2005.11.017; Fischer MG, 2004, CURR BIOL, V14, P2019, DOI 10.1016/j.cub.2004.11.008; Fisk HA, 2004, CELL CYCLE, V3, P439; Fisk HA, 2003, P NATL ACAD SCI USA, V100, P14875, DOI 10.1073/pnas.2434156100; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; He XW, 1998, J CELL SCI, V111, P1635; HOGG D, 1994, ONCOGENE, V9, P89; Hurley PJ, 2007, CELL CYCLE, V6, P414, DOI 10.4161/cc.6.4.3886; Iliakis G, 2003, ONCOGENE, V22, P5834, DOI 10.1038/sj.onc.1206682; Jaspersen SL, 2004, DEV CELL, V7, P263, DOI 10.1016/j.devcel.2004.07.006; Jelluma N, 2008, CELL, V132, P233, DOI 10.1016/j.cell.2007.11.046; Kang JS, 2007, P NATL ACAD SCI USA, V104, P20232, DOI 10.1073/pnas.0710519105; Kasbek C, 2007, MOL BIOL CELL, V18, P4457, DOI 10.1091/mbc.E07-03-0283; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; LINDBERG RA, 1993, ONCOGENE, V8, P351; Mattison CP, 2007, J BIOL CHEM, V282, P30553, DOI 10.1074/jbc.M707063200; MILLS GB, 1992, J BIOL CHEM, V267, P16000; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Niida H, 2006, MUTAGENESIS, V21, P3, DOI 10.1093/mutage/gei063; Poss KD, 2004, GENE DEV, V18, P1527, DOI 10.1101/gad.1182604; Poss KD, 2002, DEVELOPMENT, V129, P5141; Shieh SY, 2000, GENE DEV, V14, P289; Straight PD, 2000, MOL BIOL CELL, V11, P3525, DOI 10.1091/mbc.11.10.3525; Stucke VM, 2004, CHROMOSOMA, V113, P1, DOI 10.1007/s00412-004-0288-2; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Vigneron S, 2004, MOL BIOL CELL, V15, P4584, DOI 10.1091/mbc.E04-01-0051; Wang HC, 2006, CANCER RES, V66, P1391, DOI 10.1158/0008-5472.CAN-05-3270; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wei JH, 2005, J BIOL CHEM, V280, P7748, DOI 10.1074/jbc.M410152200; Weiss E, 1996, J CELL BIOL, V132, P111, DOI 10.1083/jcb.132.1.111; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; Winey M, 2002, ONCOGENE, V21, P6161, DOI 10.1038/sj.onc.1205712; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Zhao Y, 2006, CURR BIOL, V16, P1764, DOI 10.1016/j.cub.2006.07.058	43	35	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	10					1366	1378		10.1038/onc.2008.477	http://dx.doi.org/10.1038/onc.2008.477			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	417ZC	19151762				2022-12-17	WOS:000264116000009
J	Fleming, YM; Ferguson, GJ; Spender, LC; Larsson, J; Karlsson, S; Ozanne, BW; Grosse, R; Inman, GJ				Fleming, Y. M.; Ferguson, G. J.; Spender, L. C.; Larsson, J.; Karlsson, S.; Ozanne, B. W.; Grosse, R.; Inman, G. J.			TGF-beta-mediated activation of RhoA signalling is required for efficient (V12)HaRas and (V600E)BRAF transformation	ONCOGENE			English	Article						TGF-beta; RhoA; Ras; Raf; transformation	GROWTH-FACTOR-BETA; TRANSCRIPTION FACTORS; TUMOR-SUPPRESSOR; GTPASES; PATHWAYS; CANCER; RAS; REORGANIZATION; PROLIFERATION; KINASE	Transforming growth factor beta-1 (TGF-beta) acts as both a tumour suppressor and a tumour promoter in a context-dependent manner. The tumour-promoting activities of TGF-beta are likely to result from a combination of Smad and non-Smad signalling pathways but remain poorly understood. Here we show that TGF-beta-mediated activation of RhoA is dependent on the kinase activity of ALK5 and that continuous ALK5 activity maintains basal RhoA-ROCK signalling, cell morphology and actin dynamics in serum-starved rodent fibroblasts independently of Smad2, Smad3 and Smad4. In immortalized human diploid. broblasts, we show that oncogenic rewiring by transduction of (V12)HaRas instigates regulation of RhoA-ROCK signalling through an autocrine TGF-beta 1-ALK5 pathway. Furthermore, we show that ALK5-mediated activation of RhoA is required for efficient (V12)HaRas, V-Raf and (V600E)BRAF transformation and (V12)HaRas-mediated anchorage-independent growth. These findings identify a new pro-oncogenic activity of TGF-beta and indicate that tumours harbouring (V12)HaRas and (V600E)BRAF mutations may be susceptible to TGF-beta signalling inhibitors.	[Fleming, Y. M.; Ferguson, G. J.; Spender, L. C.; Inman, G. J.] Beatson Inst Canc Res, Growth Factor Signalling Lab, Glasgow G61 1BD, Lanark, Scotland; [Larsson, J.; Karlsson, S.] Univ Lund Hosp, Inst Lab Med, Lund, Sweden; [Larsson, J.; Karlsson, S.] Univ Lund Hosp, Lund Strateg Res Ctr Stem Cell Biol & Cell Therap, Lund, Sweden; [Ozanne, B. W.] Beatson Inst Canc Res, Invas & Metastasis Lab, Glasgow G61 1BD, Lanark, Scotland; [Grosse, R.] Univ Heidelberg, Inst Pharmacol, D-6900 Heidelberg, Germany	Beatson Institute; Lund University; Skane University Hospital; Lund University; Skane University Hospital; Beatson Institute; Ruprecht Karls University Heidelberg	Inman, GJ (corresponding author), Beatson Inst Canc Res, Growth Factor Signalling Lab, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	g.inman@beatson.gla.ac.uk		Inman, Gareth/0000-0002-6264-4253; Grosse, Robert/0000-0002-3380-5273	Association for International Cancer Research; Cancer Research UK	Association for International Cancer Research; Cancer Research UK(Cancer Research UK)	We thank P ten-Dijke, R Treisman, C Hill, T Crook, X-F Wang, R Derynck, A Hall and M Olson for valuable reagents. We thank J Wyke and M Olson for critically reading the paper and for discussions during the course of this work. This work was supported by an Association for International Cancer Research fellowship to GJI (GJI, YMF, GJF and LCS) and Cancer Research UK (YMF, GJI, GJF, LCS, and BWO).	Bhowmick NA, 2003, P NATL ACAD SCI USA, V100, P15548, DOI 10.1073/pnas.2536483100; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Chen D, 2004, GROWTH FACTORS, V22, P233, DOI 10.1080/08977190412331279890; Chen SY, 2006, J BIOL CHEM, V281, P1765, DOI 10.1074/jbc.M507771200; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Edlund S, 2002, MOL BIOL CELL, V13, P902, DOI 10.1091/mbc.01-08-0398; Goulimari P, 2005, J BIOL CHEM, V280, P42242, DOI 10.1074/jbc.M508690200; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kang YB, 2005, P NATL ACAD SCI USA, V102, P13909, DOI 10.1073/pnas.0506517102; Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663; Massague J, 2005, GENE DEV, V19, P2783, DOI 10.1101/gad.1350705; Moustakas A, 2005, J CELL SCI, V118, P3573, DOI 10.1242/jcs.02554; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Ozanne BW, 2006, CURR OPIN GENET DEV, V16, P65, DOI 10.1016/j.gde.2005.12.012; Pardali K, 2007, BBA-REV CANCER, V1775, P21, DOI 10.1016/j.bbcan.2006.06.004; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Roberts AB, 2003, P NATL ACAD SCI USA, V100, P8621, DOI 10.1073/pnas.1633291100; Sahai E, 1998, EMBO J, V17, P1350, DOI 10.1093/emboj/17.5.1350; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Shen X, 2001, J BIOL CHEM, V276, P15362, DOI 10.1074/jbc.M009534200; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Vardouli L, 2005, J BIOL CHEM, V280, P11448, DOI 10.1074/jbc.M402651200; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	30	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	2009	28	7					983	993		10.1038/onc.2008.449	http://dx.doi.org/10.1038/onc.2008.449			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079344				2022-12-17	WOS:000263457400005
J	Toscano, F; El Fajoui, Z; Gay, F; Lalaoui, N; Parmentier, B; Chayvialle, JA; Scoazec, JY; Micheau, O; Abello, J; Saurin, JC				Toscano, F.; El Fajoui, Z.; Gay, F.; Lalaoui, N.; Parmentier, B.; Chayvialle, J-A; Scoazec, J-Y; Micheau, O.; Abello, J.; Saurin, J-C			p53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cells	ONCOGENE			English	Article						oxaliplatin; TRAIL; antagonism; p53; DcR1; colon cancer	TRAIL-INDUCED APOPTOSIS; DECOY RECEPTORS; CHEMOTHERAPEUTIC-AGENTS; COLORECTAL-CANCER; DEATH RECEPTORS; TARGETING DEATH; IN-VITRO; C-FLIP; LIGAND; P53	Oxaliplatin hasemerged as a major chemotherapeutic drug in the treatment of advanced colorectal cancer, yet like most conventional cancer therapeutics, its efficacy is often compromised due to p53 mutations. Unlike oxaliplatin, tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) triggers apoptosis in a p53-independent manner, and chemotherapy is known to overcome tumour resistance to TRAIL-induced cell death in most cancer cells. Using a panel of colon cancer cell lines, we assessed the ability of oxaliplatin to sensitize to TRAIL-induced apoptosis. We demonstrate that while both drugs additively or synergistically induced apoptosis in almost all cell lines tested, p53 wild-type colon cancer cells such as HCT116, LS513 or LS174T remained resistant. Impaired TRAIL-induced cell death resulted from a strong p53 dependent, oxaliplatin-mediated, DcR1 receptor expression increase. According to our finding, downregulation of DcR1 using siRNA, in p53 wild-type colon cancer cells, restored oxaliplatin/TRAIL synergistic apoptotic activity. On the contrary, exogenous DcR1 overexpression in SW480, a p53-mutated cell line, abolished the synergy between the two drugs. Altogether we demonstrate for the first time that p53 negatively regulates oxaliplatin-mediated TRAIL-induced apoptotic activity through DcR1 upregulation. Our findings could have important implications for future therapeutic strategies, and suggest that the association oxaliplatin/TRAIL should be restricted to patients harbouring a non-functional p53 protein.	[Toscano, F.; El Fajoui, Z.; Gay, F.; Parmentier, B.; Chayvialle, J-A; Scoazec, J-Y; Abello, J.; Saurin, J-C] Fac Med Laennec, INSERM, Unite 865, Inst Fed Rech Lyon Est, F-69372 Lyon 08, France; [Toscano, F.; El Fajoui, Z.; Gay, F.; Parmentier, B.; Chayvialle, J-A; Scoazec, J-Y; Abello, J.; Saurin, J-C] Univ Lyon 1, Fac Laennec, F-69008 Lyon, France; [Lalaoui, N.; Micheau, O.] Univ Bourgogne, INSERM, U866, F-21079 Dijon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne	Abello, J (corresponding author), Fac Med Laennec, INSERM, Unite 865, Inst Fed Rech Lyon Est, 7 Rue G Paradin, F-69372 Lyon 08, France.	abello@lyon.inserm.fr	Lalaoui, Najoua/C-1410-2014; saurin, jean christophe/AAB-4077-2020; micheau, olivier/C-3574-2011	Lalaoui, Najoua/0000-0002-0165-3324; micheau, olivier/0000-0001-8499-7984				Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Bouralexis S, 2003, BRIT J CANCER, V89, P206, DOI 10.1038/sj.bjc.6601021; Bouralexis S, 2005, APOPTOSIS, V10, P35, DOI 10.1007/s10495-005-6060-0; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clancy L, 2005, P NATL ACAD SCI USA, V102, P18099, DOI 10.1073/pnas.0507329102; Davidovich IA, 2004, CANCER LETT, V211, P189, DOI 10.1016/j.canlet.2004.03.026; de Almodovar CR, 2004, J BIOL CHEM, V279, P4093, DOI 10.1074/jbc.M311243200; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; Gayet J, 2001, ONCOGENE, V20, P5025, DOI 10.1038/sj.onc.1204611; Grady WM, 2002, ANNU REV GENOM HUM G, V3, P101, DOI 10.1146/annurev.genom.3.022502.103043; Gramont Aimery de, 2005, Semin Oncol, V32, P11, DOI 10.1053/j.seminoncol.2005.06.004; He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351; Jang SH, 2004, INT J MOL MED, V13, P181; Jin H, 2004, CANCER RES, V64, P4900, DOI 10.1158/0008-5472.CAN-04-0408; Kelley SK, 2004, CURR OPIN PHARMACOL, V4, P333, DOI 10.1016/j.coph.2004.02.006; Kim YH, 2004, CARCINOGENESIS, V25, P1813, DOI 10.1093/carcin/bgh188; LeBlanc HN, 2003, CELL DEATH DIFFER, V10, P66, DOI 10.1038/sj.cdd.4401187; Liu XG, 2005, CANCER RES, V65, P9169, DOI 10.1158/0008-5472.CAN-05-0939; Merino D, 2007, EXPERT OPIN THER TAR, V11, P1299, DOI 10.1517/14728222.11.10.1299; Merino D, 2006, MOL CELL BIOL, V26, P7046, DOI 10.1128/MCB.00520-06; Micheau O, 2001, MOL CELL BIOL, V21, P5299, DOI 10.1128/MCB.21.16.5299-5305.2001; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Mita MM, 2006, ANN ONCOL, V17, P313, DOI 10.1093/annonc/mdj067; Motoki K, 2005, CLIN CANCER RES, V11, P3126, DOI 10.1158/1078-0432.CCR-04-1867; Nagane M, 2000, CANCER RES, V60, P847; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pukac L, 2005, BRIT J CANCER, V92, P1430, DOI 10.1038/sj.bjc.6602487; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Shankar S, 2004, DRUG RESIST UPDATE, V7, P139, DOI 10.1016/j.drup.2004.03.002; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; STEEL GG, 1979, INT J RADIAT ONCOL, V5, P85; Thorburn A, 2004, CELL SIGNAL, V16, P139, DOI 10.1016/j.cellsig.2003.08.007; Toscano F, 2007, BIOCHEM PHARMACOL, V74, P392, DOI 10.1016/j.bcp.2007.05.001; van Geelen CM, 2006, J CLIN ONCOL, V24, P4998, DOI 10.1200/JCO.2006.06.8809; Vignati S, 2002, EUR J CANCER, V38, P177, DOI 10.1016/S0959-8049(01)00345-8; Wajant H, 2005, CYTOKINE GROWTH F R, V16, P55, DOI 10.1016/j.cytogfr.2004.12.001; Yagita H, 2004, CANCER SCI, V95, P777, DOI 10.1111/j.1349-7006.2004.tb02181.x; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266	39	35	38	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2008	27	30					4161	4171		10.1038/onc.2008.52	http://dx.doi.org/10.1038/onc.2008.52			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18345033				2022-12-17	WOS:000257496800003
J	McCormack, E; Bruserud, O; Gjertsen, BT				McCormack, E.; Bruserud, O.; Gjertsen, B. T.			Review: genetic models of acute myeloid leukaemia	ONCOGENE			English	Review						acute myelogenous leukaemia; mouse; transgenic; retroviral transduction; homologous recombination; genetics	PML-RAR-ALPHA; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; INTERNAL TANDEM DUPLICATION; RECEPTOR TYROSINE KINASE; BONE-MARROW-CELLS; ONCOGENIC K-RAS; TRANSGENIC MICE; FUSION GENE; RETINOIC ACID	The use of genetically engineered mice ( GEM) have been critical in understanding disease states such as cancer, and none more so than acute myelogenous leukaemia ( AML), a disease characterized by over 100 distinct chromosomal translocations. A substantial proportion of cases exhibiting recurrent reciprocal translocations at diagnosis, such as t( 8; 21) or t( 15; 17) have been exhaustively studied and are currently employed in clinical diagnosis. However, a definitive conclusion regarding the leukaemogenic potential of defined transgenes for this disease remains elusive. While it is increasingly apparent that a number of cooperating mutations are necessary to develop a leukaemic phenotype, the number of models reflecting these synergisms remains few. Furthermore, little emphasis has been paid to the effect of chromosomal translocations other than recurrent genetic abnormalities, with no models reflecting the multiple abnormalities observed in high-risk cases of AML accounting for 8-10% of adult AML. Here we review the differing technologies employed in generation of GEM of AML. We discuss the relevance of GEM AML from embryonic stem cell-mediated ( for example retinoic acid receptor-alpha fusions and AML1/ ETO) models; through to the valuable retroviral-mediated gene transfer models. The latter have been used to great effect in de. ning the transforming properties of chromosomal translocation products such as MLL ( found in 5 - 6% of all AML cases) and NUP98 ( denoting poor prognosis in therapy-related disease) and particularly when co-transduced with bad prognostic factors such as Flt3 mutations. Finally, we comment on the emergence of newer transduction technologies, which can regulate the level of expression to defined cell lineages in both primary murine and human xenografts, and discuss how combining multiple genetic modalities, more relevant models of this complex disease are being generated.	[McCormack, E.; Bruserud, O.; Gjertsen, B. T.] Univ Bergen, Haematol Sect, Inst Med, N-5021 Bergen, Norway	University of Bergen	Gjertsen, BT (corresponding author), Univ Bergen, Dept Internal Med, Haukeland Univ Hosp, Haematol Sect, N-5021 Bergen, Norway.	bjorn.gjertsen@med.uib.no	Gjertsen, Bjørn T/AAP-3281-2020; Gjertsen, Bjorn T/O-1542-2015; Cormack, Emmet Mc/D-2922-2012	Gjertsen, Bjørn T/0000-0001-9358-9704; Gjertsen, Bjorn T/0000-0001-9358-9704; Cormack, Emmet Mc/0000-0002-7621-4625				Bockamp E, 2002, PHYSIOL GENOMICS, V11, P115, DOI 10.1152/physiolgenomics.00067.2002; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; Bruserud O, 2003, HAEMATOLOGICA, V88, P416; Buchholz F, 2000, EMBO REP, V1, P133, DOI 10.1093/embo-reports/kvd027; Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046; Castilla LH, 1999, NAT GENET, V23, P144, DOI 10.1038/13776; Castilla LH, 1996, CELL, V87, P687, DOI 10.1016/S0092-8674(00)81388-4; Chan IT, 2006, BLOOD, V108, P1708, DOI 10.1182/blood-2006-04-015040; Chan IT, 2004, CELL CYCLE, V3, P536; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; Christianson SW, 1997, J IMMUNOL, V158, P3578; Collins EC, 2000, EMBO REP, V1, P127, DOI 10.1093/embo-reports/kvd021; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Cuenco GM, 2000, P NATL ACAD SCI USA, V97, P1760, DOI 10.1073/pnas.030421197; Cuenco GM, 2001, ONCOGENE, V20, P8236, DOI 10.1038/sj.onc.1205095; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; de Guzman CG, 2003, BLOOD CELL MOL DIS, V30, P201, DOI 10.1016/S1079-9796(03)00025-1; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Dobson CL, 2000, EMBO J, V19, P843, DOI 10.1093/emboj/19.5.843; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; Fenske TS, 2004, P NATL ACAD SCI USA, V101, P15184, DOI 10.1073/pnas.0400751101; Gabriele L, 1999, J EXP MED, V190, P411, DOI 10.1084/jem.190.3.411; GORDON JW, 1983, METHOD ENZYMOL, V101, P411; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; Grimwade D, 1998, BLOOD, V92, P2322, DOI 10.1182/blood.V92.7.2322; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisolano JL, 2003, P NATL ACAD SCI USA, V100, P9506, DOI 10.1073/pnas.1531730100; GRISOLANO JL, 1994, P NATL ACAD SCI USA, V91, P8989, DOI 10.1073/pnas.91.19.8989; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; Guillemin MC, 2002, J EXP MED, V196, P1373, DOI 10.1084/jem.20021129; Gurevich RM, 2004, BLOOD, V104, P1127, DOI 10.1182/blood-2003-10-3550; Harris N L, 2000, Hematol J, V1, P53, DOI 10.1038/sj.thj.6200013; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Higuchi M, 2002, CANCER CELL, V1, P63, DOI 10.1016/S1535-6108(02)00016-8; Holtschke T, 1996, CELL, V87, P307, DOI 10.1016/S0092-8674(00)81348-3; Ishikawa F, 2005, BLOOD, V106, P1565, DOI 10.1182/blood-2005-02-0516; JAENISCH R, 1981, CELL, V24, P519, DOI 10.1016/0092-8674(81)90343-3; JAENISCH R, 1980, CELL, V19, P181, DOI 10.1016/0092-8674(80)90399-2; Jaisser F, 2000, J AM SOC NEPHROL, V11, pS95; Kawagoe H, 2005, BLOOD, V106, P4278, DOI 10.1182/blood-2005-04-1674; Kelly LM, 2002, P NATL ACAD SCI USA, V99, P8283, DOI 10.1073/pnas.122233699; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Kottaridis PD, 2001, BLOOD, V98, P1752, DOI 10.1182/blood.V98.6.1752; Kroon E, 2001, EMBO J, V20, P350, DOI 10.1093/emboj/20.3.350; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kundu M, 2002, BLOOD, V100, P2449, DOI 10.1182/blood-2002-04-1064; Lavau C, 2000, P NATL ACAD SCI USA, V97, P10984, DOI 10.1073/pnas.190167297; Lavau C, 2000, EMBO J, V19, P4655, DOI 10.1093/emboj/19.17.4655; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lee BH, 2005, ONCOGENE, V24, P7882, DOI 10.1038/sj.onc.1208933; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Liao C, 2001, P NATL ACAD SCI USA, V98, P6853, DOI 10.1073/pnas.121540098; Marcucci G, 2007, J CLIN ONCOL, V25, P3337, DOI 10.1200/JCO.2007.10.8720; Mc Cormack E, 2005, LEUKEMIA, V19, P687, DOI 10.1038/sj.leu.2403670; McCormack E, 2007, MOL IMAGING, V6, P193, DOI 10.2310/7290.2007.00016; Minucci S, 2002, BLOOD, V100, P2989, DOI 10.1182/blood-2001-11-0089; Mrozek K, 2001, BEST PRACT RES CL HA, V14, P19, DOI 10.1053/beha.2000.0114; Mrozek K, 2004, BLOOD REV, V18, P115, DOI 10.1016/S0268-960X(03)00040-7; Mueller BU, 2006, BLOOD, V107, P3330, DOI 10.1182/blood-2005-07-3068; Muller U, 1999, MECH DEVELOP, V82, P3, DOI 10.1016/S0925-4773(99)00021-0; Mulloy JC, 2003, BLOOD, V102, P4369, DOI 10.1182/blood-2003-05-1762; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Okuda T, 1998, BLOOD, V91, P3134, DOI 10.1182/blood.V91.9.3134.3134_3134_3143; Ono R, 2005, J CLIN INVEST, V115, P919, DOI 10.1172/JCI200522725; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Rhoades KL, 2000, BLOOD, V96, P2108; ROBERTSON E, 1986, NATURE, V323, P445, DOI 10.1038/323445a0; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Ryding ADS, 2001, J ENDOCRINOL, V171, P1, DOI 10.1677/joe.0.1710001; Sanz MA, 2005, ONCOLOGIST, V10, P806, DOI 10.1634/theoncologist.10-10-806; Scheller M, 1999, BLOOD, V94, P3764, DOI 10.1182/blood.V94.11.3764.423k03_3764_3771; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Shankar DB, 2005, CANCER-AM CANCER SOC, V104, P1819, DOI 10.1002/cncr.21401; Shen SW, 2004, EXP HEMATOL, V32, P852, DOI 10.1016/j.exphem.2004.06.001; Sipkins DA, 2005, NATURE, V435, P969, DOI 10.1038/nature03703; SMITHIES O, 1985, NATURE, V317, P230, DOI 10.1038/317230a0; So CW, 2004, BLOOD, V103, P3192, DOI 10.1182/blood-2003-10-3722; So CW, 2002, MOL CELL BIOL, V22, P6542, DOI 10.1128/MCB.22.18.6542-6552.2002; Sohal J, 2003, BLOOD, V101, P3188, DOI 10.1182/blood-2002-06-1800; SORIANO P, 1986, CELL, V46, P19, DOI 10.1016/0092-8674(86)90856-1; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Sukhai MA, 2004, ONCOGENE, V23, P665, DOI 10.1038/sj.onc.1207073; Testa G, 2000, EMBO REP, V1, P120, DOI 10.1093/embo-reports/kvd035; Thorsteinsdottir U, 1999, MOL CELL BIOL, V19, P6355; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Van der Weyden L, 2002, PHYSIOL GENOMICS, V11, P133, DOI 10.1152/physiolgenomics.00074.2002; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; Wang J, 2005, EMBO J, V24, P368, DOI 10.1038/sj.emboj.7600521; Wang Q, 1996, CELL, V87, P697, DOI 10.1016/S0092-8674(00)81389-6; Wang ZG, 1998, SCIENCE, V279, P1547; Warner JK, 2005, LEUKEMIA, V19, P1794, DOI 10.1038/sj.leu.2403917; Westervelt P, 2003, BLOOD, V102, P1857, DOI 10.1182/blood-2002-12-3779; Wheatley K, 1999, BRIT J HAEMATOL, V107, P69, DOI 10.1046/j.1365-2141.1999.01684.x; Wunderlich M, 2006, BLOOD, V108, P1690, DOI 10.1182/blood-2005-12-012773; Yan M, 2006, NAT MED, V12, P945, DOI 10.1038/nm1443; Yang R, 1999, BLOOD, V93, P2067; Yang YD, 2002, CANCER RES, V62, P2232; Yergeau DA, 1997, NAT GENET, V15, P303, DOI 10.1038/ng0397-303; Yu YJ, 2001, NAT REV GENET, V2, P780, DOI 10.1038/35093564; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298; Zhu J, 2007, CANCER CELL, V12, P23, DOI 10.1016/j.ccr.2007.06.004	114	35	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2008	27	27					3765	3779		10.1038/onc.2008.16	http://dx.doi.org/10.1038/onc.2008.16			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	315UC	18264136				2022-12-17	WOS:000256904700001
J	Laulajainen, M; Muranen, T; Carpen, O; Gronholm, M				Laulajainen, M.; Muranen, T.; Carpen, O.; Groenholm, M.			Protein kinase A-mediated phosphorylation of the NF2 tumor suppressor protein merlin at serine 10 affects the actin cytoskeleton	ONCOGENE			Unspecified	Article						NF2; merlin; PKA; phosphorylation; actin	NEUROFIBROMATOSIS TYPE-2; P21-ACTIVATED KINASE; SCHWANN-CELLS; GROWTH; EZRIN; GENE; MEMBRANE; INHIBITION; PRODUCT; BINDING	Mutations in the neuro. bromatosis 2 tumor suppressor gene (NF2) encoding merlin (moesin-ezrin-radixin like-protein) induce tumors of the nervous system. Merlin localizes to the cell membrane where it links the actin cytoskeleton to membrane proteins. Cell proliferation is regulated by merlin in many cell types, but merlin's tumor suppressor function still remains unclear. Phosphorylation has been suggested to regulate merlin's activity. The C-terminal serine 518 is phosphorylated both by p21-activated kinases (PAKs) and protein kinase A (PKA). In this work, we identify a novel PKA phosphorylation site, serine 10, in the N terminus of merlin. We show that a non-phosphorylatable form of serine 10 (S10A) affects cellular morphology. Regulation of this site also influences actin cytoskeleton organization and dynamics in vivo, as merlin S10A reduces the amount of cellular F-actin and merlin S10D stabilizes F-actin. laments. By using a wound-healing assay and live cell imaging, we demonstrate that dephosphorylation of serine 10 leads to defects in migration, possibly through altered ability of the cells to form lamellipodia. This study suggests a role for merlin in mediating PKA-induced changes of the actin cytoskeleton.	[Laulajainen, M.; Muranen, T.; Carpen, O.; Groenholm, M.] Univ Helsinki, Dept Pathol, Helsinki 14, Finland; [Carpen, O.] Univ Turku, Dept Pathol, Turku, Finland; Univ Turku, Cent Hosp, FIN-20520 Turku, Finland	University of Helsinki; University of Turku; University of Turku	Laulajainen, M (corresponding author), Univ Helsinki, Dept Pathol, Haartmaninkatu 8,PL 63, Helsinki 14, Finland.	minja.laulajainen@helsinki.fi	Muranen, Taru/AAM-9349-2021; Gronholm, Mikaela/B-4225-2010	Muranen, Taru/0000-0003-4158-9002; Gronholm, Mikaela/0000-0002-2378-8924				Alfthan K, 2004, J BIOL CHEM, V279, P18559, DOI 10.1074/jbc.M313916200; Bai Y, 2007, ONCOGENE, V26, P836, DOI 10.1038/sj.onc.1209849; Baser ME, 2003, CURR OPIN NEUROL, V16, P27, DOI 10.1097/00019052-200302000-00004; Bohling T, 1996, AM J PATHOL, V148, P367; Brault E, 2001, J CELL SCI, V114, P1901; Bretscher A, 2002, NAT REV MOL CELL BIO, V3, P586, DOI 10.1038/nrm882; DENBAKKER MA, 1995, AM J PATHOL, V147, P1339; Giovannini M, 2000, GENE DEV, V14, P1617; Golovnina K, 2005, BMC EVOL BIOL, V5, DOI 10.1186/1471-2148-5-69; Gonzalez-Agosti C, 1999, J BIOL CHEM, V274, P34438, DOI 10.1074/jbc.274.48.34438; GonzalezAgosti C, 1996, ONCOGENE, V13, P1239; Gronholm M, 2003, J BIOL CHEM, V278, P41167, DOI 10.1074/jbc.M306149200; Gronholm M, 1999, J CELL SCI, V112, P895; Hotulainen P, 2006, J CELL BIOL, V173, P383, DOI 10.1083/jcb.200511093; Howe AK, 2004, BBA-MOL CELL RES, V1692, P159, DOI 10.1016/j.bbamcr.2004.03.005; James MF, 2001, BIOCHEM J, V356, P377, DOI 10.1042/0264-6021:3560377; Jin HC, 2006, NATURE, V442, P576, DOI 10.1038/nature04856; Kim HA, 1997, J NEUROSCI RES, V49, P236; Kissil JL, 2002, J BIOL CHEM, V277, P10394, DOI 10.1074/jbc.M200083200; Manent J, 2003, J NEUROSCI METH, V123, P167, DOI 10.1016/S0165-0270(02)00349-7; Morrison H, 2001, GENE DEV, V15, P968, DOI 10.1101/gad.189601; Muranen T, 2007, HUM MOL GENET, V16, P1742, DOI 10.1093/hmg/ddm122; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Rong R, 2004, ONCOGENE, V23, P8447, DOI 10.1038/sj.onc.1207794; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sainio M, 1997, J CELL SCI, V110, P2249; Schulze KMM, 2002, HUM MOL GENET, V11, P69, DOI 10.1093/hmg/11.1.69; Shaw RJ, 1998, J BIOL CHEM, V273, P7757, DOI 10.1074/jbc.273.13.7757; Shaw RJ, 2001, DEV CELL, V1, P63, DOI 10.1016/S1534-5807(01)00009-0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Shimizu T, 2002, J BIOL CHEM, V277, P10332, DOI 10.1074/jbc.M109979200; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Surace EI, 2004, ONCOGENE, V23, P580, DOI 10.1038/sj.onc.1207142; Tang XL, 2007, NAT CELL BIOL, V9, P1199, DOI 10.1038/ncb1641; Thaxton C, 2007, MOL CELL NEUROSCI, V34, P231, DOI 10.1016/j.mcn.2006.11.003; Trofatter J A, 1993, Cell, V75, P826; Turunen O, 1998, BBA-PROTEIN STRUCT M, V1387, P1, DOI 10.1016/S0167-4838(98)00103-4; Xiao GH, 2002, J BIOL CHEM, V277, P883, DOI 10.1074/jbc.C100553200; Xu HM, 1998, J NEUROSCI RES, V51, P403, DOI 10.1002/(SICI)1097-4547(19980201)51:3<403::AID-JNR13>3.0.CO;2-7; Zhou RH, 2003, J BIOL CHEM, V278, P35651, DOI 10.1074/jbc.M303416200	40	35	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	23					3233	3243		10.1038/sj.onc.1210988	http://dx.doi.org/10.1038/sj.onc.1210988			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	304LQ	18071304				2022-12-17	WOS:000256111400002
J	Phillips, A; Blaydes, JP				Phillips, A.; Blaydes, J. P.			MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA	ONCOGENE			English	Article						p53; MDM2; mRNA export; breast cancer; eIF4E	SINGLE NUCLEOTIDE POLYMORPHISM; INITIATION-FACTOR EIF4E; TRANSLATION INITIATION; NEGATIVE REGULATION; GENE-EXPRESSION; P53 PATHWAY; MDM2; PROTEIN; ACTIVATION; TRANSPORT	Regulation of the synthesis, function and degradation of HDM2 (Mdm2 in mouse) plays a key role in controlling the abundance and activity of the transcription factor p53, with consequent implications for the proliferation and survival of normal and cancer cells. We have previously identified the regulation of export of HDM2 mRNA from the nucleus as a novel point of control of HDM2 synthesis. This process is dependent on the activity of the growth factor-regulated MAP-kinase kinases ( MEKs). Here, we provide evidence that the eIF4E kinase MNK1 is a key downstream effector of MEKs in this regulatory pathway. We show that HDM2 mRNA export in breast cancer cells is promoted by overexpressed eIF4E in a MEK- and MNK1-dependent manner, and inhibition of MNK1 suppresses endogenous HDM2 mRNA export pathways. This MNK1- and eIF4E-dependent HDM2 regulation occurs through sequences in the 30 untranslated region of HDM2 mRNA, and consequently HDM2 mRNA transcripts from both the constitutive P1 and inducible P2 promoters are regulated by this pathway. eIF4E is a known oncogene that is overexpressed in human tumours, including the majority of breast cancers. This pathway, therefore, may play an important role in the dysregulation of HDM2 oncoprotein expression that occurs in many human tumours.	[Phillips, A.; Blaydes, J. P.] Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Southampton SO16 6YD, Hants, England	University of Southampton	Blaydes, JP (corresponding author), Univ Southampton, Southampton Gen Hosp, Canc Sci Div, Somers Res Bldg,MP824, Southampton SO16 6YD, Hants, England.	jpb1@soton.ac.uk	Blaydes, Jeremy/AAC-6939-2019	Blaydes, Jeremy/0000-0001-8525-0209				Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Bond GL, 2007, ONCOGENE, V26, P1317, DOI 10.1038/sj.onc.1210199; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Buxade M, 2005, IMMUNITY, V23, P177, DOI 10.1016/j.immuni.2005.06.009; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Culjkovic B, 2005, J CELL BIOL, V169, P245, DOI 10.1083/jcb.200501019; Culjkovic B, 2006, J CELL BIOL, V175, P415, DOI 10.1083/jcb.200607020; Culjkovic B, 2007, CELL CYCLE, V6, P65, DOI 10.4161/cc.6.1.3688; Cullen BR, 2003, J CELL SCI, V116, P587, DOI 10.1242/jcs.00268; Erkmann JA, 2004, EXP CELL RES, V296, P12, DOI 10.1016/j.yexcr.2004.03.015; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; HARVEY M, 1993, ONCOGENE, V8, P2457; Keene JD, 2003, NAT GENET, V33, P111, DOI 10.1038/ng0203-111; Knauf U, 2001, MOL CELL BIOL, V21, P5500, DOI 10.1128/MCB.21.16.5500-5511.2001; Mamane Y, 2004, ONCOGENE, V23, P3172, DOI 10.1038/sj.onc.1207549; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Onel K, 2004, MOL CANCER RES, V2, P1; Phelps M, 2005, J BIOL CHEM, V280, P16651, DOI 10.1074/jbc.M412334200; Phelps M, 2003, CANCER RES, V63, P2616; Phillips A, 2006, ONCOGENE, V25, P4183, DOI 10.1038/sj.onc.1209451; Phillips A, 2006, FEBS LETT, V580, P300, DOI 10.1016/j.febslet.2005.12.026; Ries S, 2000, CELL, V103, P321, DOI 10.1016/S0092-8674(00)00123-9; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Topisirovic I, 2003, MOL CELL BIOL, V23, P8992, DOI 10.1128/MCB.23.24.8992-9002.2003; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; von der Haar T, 2004, NAT STRUCT MOL BIOL, V11, P503, DOI 10.1038/nsmb779; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Wallace M, 2006, MOL CELL, V23, P251, DOI 10.1016/j.molcel.2006.05.029; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	36	35	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1645	1649		10.1038/sj.onc.1210785	http://dx.doi.org/10.1038/sj.onc.1210785			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17828301	Green Accepted			2022-12-17	WOS:000253815800017
J	Baldanzi, G; Cutrupi, S; Chianale, F; Gnocchi, V; Rainero, E; Porporato, P; Filigheddu, N; van Blitterswijk, WJ; Parolini, O; Bussolino, F; Sinigaglia, F; Graziani, A				Baldanzi, G.; Cutrupi, S.; Chianale, F.; Gnocchi, V.; Rainero, E.; Porporato, P.; Filigheddu, N.; van Blitterswijk, W. J.; Parolini, O.; Bussolino, F.; Sinigaglia, F.; Graziani, A.			Diacylglycerol kinase-alpha phosphorylation by Src on Y335 is required for activation, membrane recruitment and Hgf-induced cell motility	ONCOGENE			English	Article						hepatocyte growth factor; Src; diacylglycerol kinase; tyrosine kinase; signal transduction; cell migration	SUBTYPE-SPECIFIC TRANSLOCATION; TYROSINE PHOSPHORYLATION; PROCESSIVE PHOSPHORYLATION; PHOSPHATIDIC-ACID; T-LYMPHOCYTES; V-SRC; PROTEIN; DOMAINS; BINDING; SPECIFICITY	Diacylglycerol (DAG) kinases (Dgk), which phosphorylate DAG to generate phosphatidic acid, act as either positive or negative key regulators of cell signaling. We previously showed that Src mediates growth factors-induced activation of Dgk-alpha, whose activity is required for cell motility, proliferation and angiogenesis. Here, we demonstrate that both hepatocytes growth factor (HGF) stimulation and v-Src transformation induce tyrosine phosphorylation of Dgk-alpha on Y335, through a mechanism requiring its proline-rich C-terminal sequence. Moreover, we show that both proline-rich sequence and phosphorylation of Y335 of Dgk-alpha mediate: (i) its enzymatic activation, (ii) its ability to interact respectively with SH3 and SH2 domains of Src, (iii) its recruitment to the membrane. In addition, we show that phosphorylation of Dgk-alpha on Y335 is required for HGF-induced motility, while its constitutive recruitment at the membrane by myristylation is sufficient to trigger spontaneous motility in absence of HGF. Providing the first evidence that tyrosine phosphorylation of Dgk-alpha is required for growth-factors-induced activation and membrane recruitment, these findings underscore its relevance as a rheostat, whose activation is a threshold to elicit growth factors-induced migratory signaling.	[Baldanzi, G.; Chianale, F.; Gnocchi, V.; Rainero, E.; Porporato, P.; Sinigaglia, F.; Graziani, A.] Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, I-28100 Novara, Italy; [Baldanzi, G.; Parolini, O.] Ctr Di Ricerca E Menni, Fond Poliambulanza, Ist Osp, Brescia, Italy; [Cutrupi, S.] Univ Turin, Dept Human & Anim Biol, Turin, Italy; [Filigheddu, N.] Univ Amedeo Avogadro Piemonte Orientale, Dept Clin & Expt Med, Novara, Italy; [van Blitterswijk, W. J.] Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands; [Bussolino, F.] Univ Turin, Inst Canc Res & Treatment IRCC, Turin, Italy; [Bussolino, F.] Univ Turin, Dept Oncol Sci, Turin, Italy	University of Eastern Piedmont Amedeo Avogadro; Fondazione Poliambulanza di Brescia; University of Turin; University of Eastern Piedmont Amedeo Avogadro; Netherlands Cancer Institute; IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; University of Turin	Graziani, A (corresponding author), Univ Amedeo Avogadro Piemonte Orientale, Dept Med Sci, V Solaroli 17, I-28100 Novara, Italy.	graziani@med.unipmn.it	cutrupi, santina/AAC-4479-2022; Baldanzi, Gianluca/AAO-7673-2021; Filigheddu, Nicoletta/N-7219-2015; Bussolino, Federico/AES-3951-2022; PAROLINI, ORNELLA/ABI-7862-2020; Graziani, Andrea/AAB-6301-2022; PAROLINI, ORNELLA/C-7946-2013; Porporato, Paolo E./A-9932-2018; graziani, andrea/B-2554-2009; Bussolino, Federico/K-2500-2016	Baldanzi, Gianluca/0000-0002-1370-9903; Filigheddu, Nicoletta/0000-0002-3848-611X; PAROLINI, ORNELLA/0000-0002-5211-6430; Graziani, Andrea/0000-0002-6302-2317; PAROLINI, ORNELLA/0000-0002-5211-6430; Porporato, Paolo E./0000-0001-8519-1552; graziani, andrea/0000-0002-6302-2317; Bussolino, Federico/0000-0002-5348-1341; CUTRUPI, SANTINA/0000-0002-2358-5852; Rainero, Elena/0000-0003-1402-8701	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Alonso R, 2005, J BIOL CHEM, V280, P28439, DOI 10.1074/jbc.M501112200; Bacchiocchi R, 2005, BLOOD, V106, P2175, DOI 10.1182/blood-2005-01-0316; Baldanzi G, 2004, ONCOGENE, V23, P4828, DOI 10.1038/sj.onc.1207633; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Carrasco S, 2004, MOL BIOL CELL, V15, P2932, DOI 10.1091/mbc.E03-11-0844; Cipres A, 2003, J BIOL CHEM, V278, P35629, DOI 10.1074/jbc.M305635200; Cutrupi S, 2000, EMBO J, V19, P4614, DOI 10.1093/emboj/19.17.4614; Flores I, 1999, J IMMUNOL, V163, P708; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; Fukunaga-Takenaka R, 2005, GENES CELLS, V10, P311, DOI 10.1111/j.1365-2443.2005.00842.x; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Hurley JH, 1997, PROTEIN SCI, V6, P477; Jones DR, 2002, FASEB J, V16, P595, DOI 10.1096/fj.01-0762fje; Kanemitsu MY, 1997, J BIOL CHEM, V272, P22824, DOI 10.1074/jbc.272.36.22824; KAPLAN KB, 1992, J CELL BIOL, V118, P321, DOI 10.1083/jcb.118.2.321; Kooijman EE, 2003, TRAFFIC, V4, P162, DOI 10.1034/j.1600-0854.2003.00086.x; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Luo B, 2003, J BIOL CHEM, V278, P39542, DOI 10.1074/jbc.M307153200; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Nagaya H, 2002, MOL BIOL CELL, V13, P302, DOI 10.1091/mbc.01-05-0255; OHASHI M, 1995, NATURE, V377, P544, DOI 10.1038/377544a0; Olenchock BA, 2006, NAT IMMUNOL, V7, P1174, DOI 10.1038/ni1400; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Sandilands E, 2004, DEV CELL, V7, P855, DOI 10.1016/j.devcel.2004.09.019; Sanjuan MA, 2003, J IMMUNOL, V170, P2877, DOI 10.4049/jimmunol.170.6.2877; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; Santarius M, 2006, BIOCHEM J, V398, P1, DOI 10.1042/BJ20060565; Schmitz R, 1996, J MOL BIOL, V260, P664, DOI 10.1006/jmbi.1996.0429; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Shirai Y, 2000, J BIOL CHEM, V275, P24760, DOI 10.1074/jbc.M003151200; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Tran NH, 2003, J BIOL CHEM, V278, P11221, DOI 10.1074/jbc.M210318200; van Blitterswijk WJ, 2000, CELL SIGNAL, V12, P595, DOI 10.1016/S0898-6568(00)00113-3; WENG ZG, 1995, MOL CELL BIOL, V15, P5627; Yeo MG, 2006, MOL CELL BIOL, V26, P4399, DOI 10.1128/MCB.01147-05; Zha YY, 2006, NAT IMMUNOL, V7, P1166, DOI 10.1038/ni1394; Zhong XP, 2003, NAT IMMUNOL, V4, P882, DOI 10.1038/ni958; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	40	35	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 7	2008	27	7					942	956		10.1038/sj.onc.1210717	http://dx.doi.org/10.1038/sj.onc.1210717			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	259NP	17700527				2022-12-17	WOS:000252946300006
J	Mangold, U; Hayakawa, H; Coughlin, M; Munger, K; Zetter, BR				Mangold, U.; Hayakawa, H.; Coughlin, M.; Munger, K.; Zetter, B. R.			Antizyme, a mediator of ubiquitin-independent proteasomal degradation and its inhibitor localize to centrosomes and modulate centriole amplification	ONCOGENE			English	Article						antizyme; antizyme inhibitor; centrosome; proteasome; genomic instability; cancer	ORNITHINE DECARBOXYLASE-ANTIZYME; CELL-CYCLE; PROTEIN; GROWTH; OVEREXPRESSION; DUPLICATION; CANCER; IDENTIFICATION; POLYAMINES; ANEUPLOIDY	The potential tumor suppressor antizyme and its endogenous inhibitor (antizyme inhibitor, AZI) have been implicated in the ubiquitin-independent proteasomal degradation of proteins involved in cell proliferation as well as in the regulation of polyamine levels. We show here that both antizyme and AZI concentrate at centrosomes and that antizyme preferentially associates with the maternal centriole. Interestingly, alterations in the levels of these proteins have opposing effects on centrosomes. Depletion of antizyme in various cell lines and primary cells leads to centrosome overduplication, whereas overexpression of antizyme reduces numerical centrosome abnormalities. Conversely, silencing of the antizyme inhibitor, AZI, results in a decrease of numerical centrosome abnormalities, whereas overexpression of AZI leads to centrosome overduplication. We further show that the numerical centrosome abnormalities are due to daughter centriole amplification. In summary, our results demonstrate that alterations in the antizyme/AZI balance cause numerical centrosomal defects and suggest a role for ubiquitin-independent proteasomal degradation in centrosome duplication.	[Mangold, U.; Zetter, B. R.] Childrens Hosp Boston, Program Vasc Biol, Boston, MA USA; [Mangold, U.; Zetter, B. R.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Hayakawa, H.; Munger, K.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Coughlin, M.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Zetter, BR (corresponding author), Harvard Univ, Sch Med, Childrens Hosp, 1 Blackfan Circle, Boston, MA 02115 USA.	bruce.zetter@childrens.harvard.edu	Loizides-Mangold, Ursula/I-9061-2014	Loizides-Mangold, Ursula/0000-0001-9233-2974; Munger, Karl/0000-0003-3288-9935	NATIONAL CANCER INSTITUTE [R01CA037393, R01CA066980, R37CA037393] Funding Source: NIH RePORTER; NCI NIH HHS [CA066980, CA37393] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Choi KS, 2005, BIOCHEM BIOPH RES CO, V328, P206, DOI 10.1016/j.bbrc.2004.11.172; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; D'Assoro AB, 2002, ONCOGENE, V21, P6146, DOI 10.1038/sj.onc.1205772; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Fabunmi RP, 2000, J BIOL CHEM, V275, P409, DOI 10.1074/jbc.275.1.409; Fong LYY, 2003, CANCER RES, V63, P3945; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; Guarguaglini G, 2005, MOL BIOL CELL, V16, P1095, DOI 10.1091/mbc.E04-10-0939; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Iwata S, 1999, ONCOGENE, V18, P165, DOI 10.1038/sj.onc.1202275; Jung MH, 2000, GENOMICS, V69, P281, DOI 10.1006/geno.2000.6338; Keren-Paz A, 2006, ONCOGENE, V25, P5163, DOI 10.1038/sj.onc.1209521; Kim SW, 2006, J CELL SCI, V119, P2853, DOI 10.1242/jcs.02966; Koike C, 1999, CANCER RES, V59, P6109; LANGE BMH, 1995, J CELL BIOL, V130, P919, DOI 10.1083/jcb.130.4.919; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Lin Y, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-15; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; Meraldi P, 2002, FEBS LETT, V521, P9, DOI 10.1016/S0014-5793(02)02865-X; Mitchell JLA, 1998, BIOCHEM J, V329, P453; Murai N, 2003, J BIOL CHEM, V278, P44791, DOI 10.1074/jbc.M308059200; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Murakami Y, 1996, J BIOL CHEM, V271, P3340, DOI 10.1074/jbc.271.7.3340; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Newman RM, 2004, J BIOL CHEM, V279, P41504, DOI 10.1074/jbc.M407349200; Nigg EA, 2006, INT J CANCER, V119, P2717, DOI 10.1002/ijc.22245; Oredsson SM, 2003, BIOCHEM SOC T, V31, P366, DOI 10.1042/BST0310366; Sluder G, 2005, NAT REV MOL CELL BIO, V6, P743, DOI 10.1038/nrm1712; Tsou MFB, 2006, CURR OPIN CELL BIOL, V18, P74, DOI 10.1016/j.ceb.2005.12.008; Tsuji T, 2001, ONCOGENE, V20, P24, DOI 10.1038/sj.onc.1204051; Zou CZ, 2005, J CELL BIOL, V171, P437, DOI 10.1083/jcb.200506185	33	35	40	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 24	2008	27	5					604	613		10.1038/sj.onc.1210685	http://dx.doi.org/10.1038/sj.onc.1210685			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	255RK	17667942				2022-12-17	WOS:000252674900005
J	Liu, S; Vinall, RL; Tepper, C; Shi, XB; Xue, LR; Ma, AH; Wang, LY; Fitzgerald, LD; Wu, Z; Gandour-Edwards, R; White, RWD; Kung, HJ				Liu, S.; Vinall, R. L.; Tepper, C.; Shi, X-B; Xue, L. R.; Ma, A-H; Wang, L-Y; Fitzgerald, L. D.; Wu, Z.; Gandour-Edwards, R.; White, R. W. deVere; Kung, H-J			Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway	ONCOGENE			English	Article						H2-relaxin; GPCR; beta-catenin; Wnt; androgen receptor; prostate cancer	PROSTATE-CANCER CELLS; GLYCOGEN-SYNTHASE KINASE-3; INDEPENDENT GROWTH; NEUROENDOCRINE DIFFERENTIATION; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAYS; COLON-CANCER; H2 RELAXIN; WNT; EXPRESSION	We have previously demonstrated that human H2-relaxin can mediate androgen-independent growth of LNCaP through a mechanism that involves the activation of the androgen receptor (AR) signaling pathway. The goal of the current study is to elucidate the mechanism(s) by which H2-relaxin causes activation of the AR pathway. Our data indicate that there is cross-talk between AR and components of the Wnt signaling pathway. Addition of H2-relaxin to LNCaP cells resulted in increased phosphorylation of protein kinase B (Akt) and inhibitory phosphorylation of glycogen synthase kinase-3 beta (GSK-3 beta) with subsequent cytoplasmic accumulation of beta-catenin. Immunoprecipitation and immunocytochemical studies demonstrated that the stabilized b-catenin formed a complex with AR, which was then translocated into the nucleus. Chromatin immunoprecipitation analysis determined that the AR/beta-catenin complex binds to the proximal region of the prostate-specific antigen promoter. Inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, using LY294002, prevented both H2-relaxin-mediated phosphorylation of Akt and GSK-3b and translocation of beta-catenin/AR into the nucleus. Knockdown of beta-catenin levels using a beta-cateninspecific small interfering RNA inhibited H2-relaxin-induced AR activity. The combined data demonstrate that PI3K/Akt and components of the Wnt pathway can facilitate H2-relaxin-mediated activation of the AR pathway.	[Liu, S.; Vinall, R. L.; Tepper, C.; Shi, X-B; Xue, L. R.; Ma, A-H; Wang, L-Y; Fitzgerald, L. D.; Wu, Z.; Gandour-Edwards, R.; White, R. W. deVere; Kung, H-J] Univ Calif, Ctr Canc, Sacramento, CA USA; [Liu, S.; Tepper, C.; Ma, A-H; Wang, L-Y; Fitzgerald, L. D.; Wu, Z.; Kung, H-J] Univ Calif, Sch Med, Dept Biochem & Mol Med, Sacramento, CA USA; [Vinall, R. L.; Shi, X-B; Xue, L. R.; White, R. W. deVere] Univ Calif, Sch Med, Dept Urol, Sacramento, CA USA; [Gandour-Edwards, R.] Univ Calif, Sch Med, Dept Pathol, Sacramento, CA USA		White, RWD (corresponding author), Univ Calif Davis, Ctr Canc, UCDMC, Res 3,4645,2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013; Vinall, Ruth/L-7026-2019	Wang, Ling-Yu/0000-0002-1413-817X				Bartsch O, 2001, MOL HUM REPROD, V7, P799, DOI 10.1093/molehr/7.9.799; Castellone MD, 2005, SCIENCE, V310, P1504, DOI 10.1126/science.1116221; Cronauer MV, 2005, INT J ONCOL, V26, P1033; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Desai SJ, 2006, CANCER RES, V66, P10449, DOI 10.1158/0008-5472.CAN-06-2582; DESANTAGNESE P, 1996, CANCER, V78, P357; Dessauer CW, 2005, ANN NY ACAD SCI, V1041, P272, DOI 10.1196/annals.1282.040; DINJENS WNM, 1994, INT J CANCER, V56, P630, DOI 10.1002/ijc.2910560504; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Figueiredo KA, 2005, ANN NY ACAD SCI, V1041, P320, DOI 10.1196/annals.1282.051; Halls ML, 2005, ANN NY ACAD SCI, V1041, P288, DOI 10.1196/annals.1282.042; Halls ML, 2005, ANN NY ACAD SCI, V1041, P292, DOI 10.1196/annals.1282.043; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Huss WJ, 2004, PROSTATE, V60, P91, DOI 10.1002/pros.20032; Ivell R, 2002, SCIENCE, V295, P637, DOI 10.1126/science.1069234; Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344; Louie MC, 2003, P NATL ACAD SCI USA, V100, P2226, DOI 10.1073/pnas.0437824100; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Nguyen BT, 2003, MOL ENDOCRINOL, V17, P1075, DOI 10.1210/me.2002-0284; Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; Palejwala S, 1998, ENDOCRINOLOGY, V139, P1208, DOI 10.1210/en.139.3.1208; Pang S, 1997, CANCER RES, V57, P495; Polakis P, 2000, GENE DEV, V14, P1837; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Shi XB, 2004, BJU INT, V94, P996, DOI 10.1111/j.1464-410X.2004.05093.x; Silvertown JD, 2003, ENDOCRINOLOGY, V144, P3683, DOI 10.1210/en.2003-0248; Song SY, 2004, J CLIN GASTROENTEROL, V38, P252, DOI 10.1097/00004836-200403000-00011; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Truica CI, 2000, CANCER RES, V60, P4709; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Vinall RL, 2006, ONCOGENE, V25, P2082, DOI 10.1038/sj.onc.1209246; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yang X, 2006, ONCOGENE, V25, P3436, DOI 10.1038/sj.onc.1209366; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yuan TC, 2006, ENDOCR-RELAT CANCER, V13, P151, DOI 10.1677/erc.1.01043; Zhang Q, 2002, J CELL BIOCHEM, V85, P536, DOI 10.1002/jcb.10150	42	35	36	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 17	2008	27	4					499	505		10.1038/sj.onc.1210671	http://dx.doi.org/10.1038/sj.onc.1210671			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	252DU	17653089				2022-12-17	WOS:000252426100010
J	Zhao, C; Inoue, J; Imoto, I; Otsuki, T; Iida, S; Ueda, R; Inazawa, J				Zhao, C.; Inoue, J.; Imoto, I.; Otsuki, T.; Iida, S.; Ueda, R.; Inazawa, J.			POU2AF1, an amplification target at 11q23, promotes growth of multiple myeloma cells by directly regulating expression of a B-cell maturation factor, TNFRSF17	ONCOGENE			English	Article						multiple myeloma; POU2AF1; amplification TNFRSF17; array-CGH	CYCLIN D1 GENE; IDENTIFICATION; LYMPHOMA; PLASMA; OVEREXPRESSION; HYBRIDIZATION; ABNORMALITIES; BOB.1/OBF.1; ABERRATIONS; ACTIVATION	Multiple myeloma (MM), a progressive hematological neoplasm, is thought to result from multiple genetic events affecting the terminal plasma cell. However, genetic aberrations related to MM are seldom reported. Using our in-house array-based comparative genomic hybridization system to locate candidate target genes with following their expression analysis, we identified POU2AF1 at 11q23.1 as a probable amplification target in MM cell lines. POU2AF1 is a B-cell-specific transcriptional coactivator, which interacts with octamer-binding transcription factors Oct-1 and Oct-2, and augments their function. Downregulation of POU2AF1 expression by specific small-interfering RNA (siRNA) inhibited MM cell growth, whereas ectopic expression of POU2AF1 promoted growth of MM cells. Among putative transcriptional targets for POU2AF1, B-cell maturation factor, TNFRSF17, enhanced its transcription by POU2AF1, and POU2AF1 directly bound to an octamer site within the 50 region of TNFRSF17. Expression level of TNFRSF17 was closely correlated with that of POU2AF1 in cell lines and primary samples of MM, and decreasing TNFRSF17 expression by means of TNFRSF17 siRNA inhibited MM cell growth. Taken together, our results suggest that POU2AF1, when activated by amplification or other mechanisms, may contribute to progression of MM by accelerating growth of MM cells through direct transactivation of one of its target genes, TNFRSF17.	[Zhao, C.; Inoue, J.; Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, Tokyo 1138510, Japan; [Zhao, C.; Inazawa, J.] 21st Century Ctr Excellence Program Mol Destruct, Tokyo, Japan; [Inoue, J.; Imoto, I.; Inazawa, J.] Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Saitama, Japan; [Imoto, I.; Inazawa, J.] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo, Japan; [Otsuki, T.] Kawasaki Med Sch, Dept Hyg, Okayama, Japan; [Iida, S.; Ueda, R.] Nagoya City Univ, Grad Sch Med Sci, Dept Med Oncol & Immunol, Aichi, Japan	Tokyo Medical & Dental University (TMDU); Japan Science & Technology Agency (JST); Tokyo Medical & Dental University (TMDU); Kawasaki Medical School; Nagoya City University	Inazawa, J (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Cytogenet, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.	johinaz.cgen@mri.tmd.ac.jp	imoto, Issei/D-8065-2012; Zhao, Chen/D-8664-2012; Imoto, Issei/AAD-5799-2020					Brunner C, 2003, J EXP MED, V197, P1205, DOI 10.1084/jem.20022014; Carrasco DR, 2006, CANCER CELL, V9, P313, DOI 10.1016/j.ccr.2006.03.019; Cepek KL, 1996, GENE DEV, V10, P2079, DOI 10.1101/gad.10.16.2079; Cigudosa JC, 1998, BLOOD, V91, P3007, DOI 10.1182/blood.V91.8.3007.3007_3007_3010; Claudio JO, 2002, BLOOD, V100, P2175, DOI 10.1182/blood-2002-01-0008; Cremer FW, 2005, CANCER GENET CYTOGEN, V161, P116, DOI 10.1016/j.cancergencyto.2005.02.015; Cremer FW, 2005, GENE CHROMOSOME CANC, V44, P194, DOI 10.1002/gcc.20231; Fonseca R, 2002, BLOOD, V100, P1417, DOI 10.1182/blood.V100.4.1417.h81602001417_1417_1424; Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876; Gonzalez MB, 2004, HAEMATOLOGICA, V89, P1213; Greiner A, 2000, AM J PATHOL, V156, P501, DOI 10.1016/S0002-9440(10)64754-2; Gstaiger M, 1996, EMBO J, V15, P2781, DOI 10.1002/j.1460-2075.1996.tb00638.x; Gutierrez NC, 2001, LEUKEMIA, V15, P840, DOI 10.1038/sj.leu.2402116; Hatzoglou A, 2000, J IMMUNOL, V165, P1322, DOI 10.4049/jimmunol.165.3.1322; Heckman CA, 2006, ONCOGENE, V25, P888, DOI 10.1038/sj.onc.1209127; Hideshima T, 2004, BLOOD, V104, P607, DOI 10.1182/blood-2004-01-0037; Hoechtlen-Vollmar W, 2000, BRIT J HAEMATOL, V109, P30, DOI 10.1046/j.1365-2141.2000.02007.x; Husson H, 2002, BLOOD, V99, P282, DOI 10.1182/blood.V99.1.282; Inazawa J, 2004, CANCER SCI, V95, P559, DOI 10.1111/j.1349-7006.2004.tb02486.x; Inoue J, 2004, AM J PATHOL, V165, P71, DOI 10.1016/S0002-9440(10)63276-2; KABAT D, 1972, SCIENCE, V175, P134, DOI 10.1126/science.175.4018.134; Kim U, 2003, P NATL ACAD SCI USA, V100, P8868, DOI 10.1073/pnas.1033108100; Kim U, 1996, NATURE, V383, P542, DOI 10.1038/383542a0; Kuehl WM, 2002, NAT REV CANCER, V2, P175, DOI 10.1038/nrc746; LADANYI M, 1992, AM J PATHOL, V141, P949; Largo C, 2006, HAEMATOL-HEMATOL J, V91, P184; Lins K, 2003, EMBO J, V22, P2188, DOI 10.1093/emboj/cdg199; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Miura K, 2003, CANCER SCI, V94, P350, DOI 10.1111/j.1349-7006.2003.tb01445.x; Moreau LA, 2006, CLIN CANCER RES, V12, P5693, DOI 10.1158/1078-0432.CCR-06-1500; Nielsen PJ, 1996, EUR J IMMUNOL, V26, P3214, DOI 10.1002/eji.1830261255; Novak AJ, 2004, BLOOD, V103, P689, DOI 10.1182/blood-2003-06-2043; Robetorye RS, 2002, J MOL DIAGN, V4, P123, DOI 10.1016/S1525-1578(10)60693-9; Samardzic T, 2002, MOL CELL BIOL, V22, P8320, DOI 10.1128/MCB.22.23.8320-8331.2002; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; SCHUSCHEREBA ST, 2001, P SOC PHOTO-OPT INS, V2, P1; Seidl S, 2003, LANCET ONCOL, V4, P557, DOI 10.1016/S1470-2045(03)01195-1; Sonoda I, 2004, CANCER RES, V64, P3741, DOI 10.1158/0008-5472.CAN-04-0172; Sonoki T, 1998, INT J HEMATOL, V68, P459; Standal T, 2004, HAEMATOLOGICA, V89, P174; Takada H, 2005, CANCER SCI, V96, P100, DOI 10.1111/j.1349-7006.2005.00016.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Teitell MA, 2003, TRENDS IMMUNOL, V24, P546, DOI 10.1016/j.it.2003.08.002; TRICOT G, 1995, BLOOD, V86, P4250, DOI 10.1182/blood.V86.11.4250.bloodjournal86114250; Yu X, 2001, IMMUNITY, V14, P157, DOI 10.1016/S1074-7613(09)00090-9; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	48	35	35	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 3	2008	27	1					63	75		10.1038/sj.onc.1210637	http://dx.doi.org/10.1038/sj.onc.1210637			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	247YO	17621271				2022-12-17	WOS:000252118700007
J	Yokoyama, S; Chen, CJ; Nguyen, T; Shively, JE				Yokoyama, S.; Chen, C-J; Nguyen, T.; Shively, J. E.			Role of CEACAM1 isoforms in an in vivo model of mammary morphogenesis: mutational analysis of the cytoplasmic domain of CEACAM1-4S reveals key residues involved in lumen formation	ONCOGENE			English	Article						CEACAM1-4S; phosphorylation; breast cancer; lumen formation; myofibroblast	CELL-ADHESION MOLECULE; BILIARY GLYCOPROTEIN CD66A; BREAST-CANCER CELLS; CARCINOEMBRYONIC ANTIGEN; EXPRESSION; GROWTH; SUPPRESSION; APOPTOSIS; FAMILY; GENE	CEACAM1 (carcinoembryonic antigen-related cell adhesion molecule 1) is a type I transmembrane glycoprotein expressed in epithelial cells with three or four extracellular domains (ECDs) and either long or short cytoplasmic domain isoforms. We have previously shown that the four extracellular domains, short cytoplasmic domain isoform, CEACAM1-4S, plays an essential role in lumen formation in an in vitro model of mammary morphogenesis. In this study, we transfected MCF-7 cells with either the long or short cytoplasmic domain isoforms of CEACAM1, and grew the cells in humanized mammary mouse fat pads in NOD/SCID mice. In this in vivo model, only the long cytoplasmic domain isoform, CEACAM1-4L, formed glands with lumen. On the basis of other studies that revealed phosphorylation of key Thr and Ser residues in the short cytoplasmic domain, we introduced phosphorylation mimic ( for example, Thr or Ser to Asp) or null ( Thr or Ser to Ala) mutations into the cytoplasmic domain of CEACAM1-4S and tested them in the in vivo model. Mutation of either Thr or Ser to Asp or the double mutant Thr+Ser to Asp, but not the null mutants, induced gland formation with a central lumen-containing apoptotic cells. Moreover, the phosphorylation mimic mutants of CEACAM1-4S induced downregulation of beta 1-integrin, overexpression of beta 2-integrin, inhibited phosphorylation of focal adhesion kinase (pTyr-397) and resulted in myo.broblast differentiation as characterized by expression of vimentin, a-smooth muscle actin and beta 2-integrin, as well as the production of abundant extracellular matrix.	[Yokoyama, S.; Chen, C-J; Nguyen, T.; Shively, J. E.] City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Shively, JE (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, H138,Hilton Bldg,1500 E Duarte Rd, Duarte, CA 91010 USA.	jshively@coh.org						BARNETT TR, 1993, MOL CELL BIOL, V13, P1273, DOI 10.1128/MCB.13.2.1273; BRUMMER J, 1995, ONCOGENE, V11, P1649; Busch C, 2002, HUM PATHOL, V33, P290, DOI 10.1053/hupa.2002.32218; Chen CJ, 2007, J BIOL CHEM, V282, P5749, DOI 10.1074/jbc.M610903200; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Greenberg RS, 2006, FASEB J, V20, P1006, DOI 10.1096/fj.05-4838fje; Huang J, 1998, ANTICANCER RES, V18, P3203; Huang J, 1999, J CELL SCI, V112, P4193; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Kirshner J, 2003, J BIOL CHEM, V278, P50338, DOI 10.1074/jbc.M309115200; Kirshner J, 2003, P NATL ACAD SCI USA, V100, P521, DOI 10.1073/pnas.232711199; Klein H, 1995, Violence Against Women, V1, P55, DOI 10.1177/1077801295001001004; Kleinerman DI, 1996, CANCER RES, V56, P3431; Kunath T, 1995, ONCOGENE, V11, P2375; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Laurie NA, 2005, CANCER RES, V65, P11010, DOI 10.1158/0008-5472.CAN-04-2841; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Luo WP, 1999, CANCER GENE THER, V6, P313, DOI 10.1038/sj.cgt.7700055; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; Nittka S, 2004, ONCOGENE, V23, P9306, DOI 10.1038/sj.onc.1208259; Nollau P, 1997, CANCER RES, V57, P2354; Obrink B, 1997, CURR OPIN CELL BIOL, V9, P616, DOI 10.1016/S0955-0674(97)80114-7; OHWADA A, 1994, AM J RESP CELL MOL, V11, P214, DOI 10.1165/ajrcmb.11.2.8049082; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Peters KS, 2005, J PHYS ORG CHEM, V18, P1, DOI 10.1002/poc.849; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1, DOI 10.1152/ajpcell.1999.277.1.C1; Schumann D, 2001, J BIOL CHEM, V276, P47421, DOI 10.1074/jbc.M109110200; Shi SR, 2001, J HISTOCHEM CYTOCHEM, V49, P931, DOI 10.1177/002215540104900801; SVENBERG T, 1979, CLIN EXP IMMUNOL, V36, P436; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; WAGENER C, 1983, J IMMUNOL, V130, P2302	35	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7637	7646		10.1038/sj.onc.1210577	http://dx.doi.org/10.1038/sj.onc.1210577			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17546042				2022-12-17	WOS:000251537800005
J	Cheng, K; Grisendi, S; Clohessy, JG; Majid, S; Bernardi, R; Sportoletti, P; Pandolfi, PP				Cheng, K.; Grisendi, S.; Clohessy, J. G.; Majid, S.; Bernardi, R.; Sportoletti, P.; Pandolfi, P. P.			The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence	ONCOGENE			English	Article						NPMc; E1A; Arf; senescence; cell transformation	TUMOR-SUPPRESSOR; GENE-EXPRESSION; ADENOVIRUS E1A; P53; INHIBITION; ACTIVATION; MUTATIONS; FUSION; NPM1	Mutations leading to aberrant cytoplasmic localization of Nucleophosmin 1 (NPM1) have been recently identified as the most frequent genetic alteration in acute myelogenous leukemia. However, the oncogenic potential of this nucleophosmin mutant (NPMc+) has never been established, which casts doubt on its role in leukemogenesis. By performing classical transformation assays, we find that NPMc+, but not wild-type NPM, cooperates specifically with adenovirus E1A to transform primary mouse embryonic. broblasts in soft agar. We demonstrate that NPMc+ blocks the p19(Arf) (Arf) induction elicited by E1A. Surprisingly, however, we find that NPMc+ induces cellular senescence and that E1A is able to overcome this response. We propose a model whereby the NPMc+ pro-senescence activity needs to be evaded for oncogenic transformation, even though NPMc+ can concomitantly blunt the Arf/p53 pathway. These findings identify for the first time NPMc+ as an oncogene and shed new unexpected light on its mechanism of action.	Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, Canc Biol & Genet Program, New York, NY 10021 USA; Cornell Univ, Grad Program Biochem Mol & Cell Biol, Ithaca, NY 14853 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University	Pandolfi, PP (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 110, New York, NY 10021 USA.	p-pandol@ski.mskcc.org	bernardi, rosa/B-1650-2013; Sportoletti, Paolo/AAE-5907-2020; SPORTOLETTI, PAOLO/K-6013-2016	bernardi, rosa/0000-0002-3607-6336; SPORTOLETTI, PAOLO/0000-0002-5630-9862; Clohessy, John/0000-0001-5186-9775				Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; den Besten W, 2005, CELL CYCLE, V4, P1593; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DYSON N, 1992, CANCER SURV, V12, P161; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Frehlick LJ, 2007, BIOESSAYS, V29, P49, DOI 10.1002/bies.20512; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Grisendi S, 2005, NATURE, V437, P147, DOI 10.1038/nature03915; Grisendi S, 2006, NAT REV CANCER, V6, P493, DOI 10.1038/nrc1885; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lin CY, 2006, CELL SIGNAL, V18, P2041, DOI 10.1016/j.cellsig.2006.04.001; LIN HJL, 1995, MOL CELL BIOL, V15, P4536; Mendes-da-Silva P, 2000, J CLIN PATHOL-MOL PA, V53, P184, DOI 10.1136/mp.53.4.184; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Olney HJ, 2002, BAS CLIN ON, V27, P89; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; Sauerbrey A, 1998, LEUKEMIA LYMPHOMA, V28, P275, DOI 10.3109/10428199809092683; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Thiede C, 2006, BLOOD, V107, P4011, DOI 10.1182/blood-2005-08-3167; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Verhaak RGW, 2005, BLOOD, V106, P3747, DOI 10.1182/blood-2005-05-2168; YEW PR, 1992, NATURE, V357, P82, DOI 10.1038/357082a0; YonedaKato N, 1996, ONCOGENE, V12, P265; Zhang X, 2004, J BIOL CHEM, V279, P25122, DOI 10.1074/jbc.M403287200	36	35	46	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2007	26	53					7391	7400		10.1038/sj.onc.1210549	http://dx.doi.org/10.1038/sj.onc.1210549			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	236DA	17546053				2022-12-17	WOS:000251282000001
J	Zhang, X; Leung, YK; Ho, SM				Zhang, X.; Leung, Y-K; Ho, S-M			AP-2 regulates the transcription of estrogen receptor (ER)-beta by acting through a methylation hotspot of the 0N promoter in prostate cancer cells	ONCOGENE			English	Article						epigenetics; promoter analysis; non-canonical; cis-element; tumor suppressor; gene regulation	ER-BETA; ACTIVATOR PROTEIN-2-ALPHA; GENE-EXPRESSION; BREAST-CANCER; BINDING; CLONING; FAMILY; DNA; CARCINOGENESIS; CARCINOMA	We reported previously that the loss of expression of estrogen receptor (ER)-beta during the development of prostate cancer (PCa) is associated with methylation of a CpG island located in the 5'-flanking sequence of the 0N promoter. Three methylation hotspots, referred to as centers 1, 2 and 3, were identified in the CpG island. In this study, we demonstrated that a 581-bp region with these three centers within it is sufficient for the promoter activity in PCa cells. Deletion analyses indicated that center 1 ( 16 bp), with a putative activator protein-2 (AP-2) binding site, is essential for gene transactivation. Chromatin immunoprecipitation assays showed that AP-2 alpha occupies a short sequence containing center 1. Forced expression of AP-2 alpha or -2 gamma, but not -2 beta, increased activity of the ER beta 0N promoter and the accumulation of mRNA. Conversely, siRNA-mediated AP-2 alpha and -2 gamma knockdown reduced levels of ERb transcript and promoter activity. Quantitative reverse transcription - PCR showed that AP-2 alpha and -2 gamma are the predominant transcripts expressed in PCa cells, and levels of ERb transcript correlate with levels of these AP-2 transcripts among different PCa cell lines. These results provide the first evidence that ERb is an AP-2-regulated gene. They also support the hypothesis that certain cis-acting elements are methylation hotspots susceptible to epigenetic modi. cations during cancer progression.	Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Ho, SM (corresponding author), Univ Cincinnati, Coll Med, Dept Environm Hlth, 130 Kettering,3223 Eden Ave,PO Box 670056, Cincinnati, OH 45267 USA.	shuk-mei.ho@uc.edu	Zhang, Xiang/D-3632-2009; Leung, Ricky/H-5958-2019	Leung, Ricky/0000-0003-2063-277X	NIDDK NIH HHS [DK061084] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061084] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Eli M, 2001, PIGM CELL RES, V14, P78, DOI 10.1034/j.1600-0749.2001.140202.x; Baylin Stephen B, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS4, DOI 10.1038/ncponc0354; Bosher JM, 1996, ONCOGENE, V13, P1701; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Comhaire F, 2004, Aging Male, V7, P155; Garinis GA, 2002, HUM GENET, V111, P115, DOI 10.1007/s00439-002-0783-6; HERMANN R, 1991, FEBS LETT, V281, P191, DOI 10.1016/0014-5793(91)80391-F; Hilger-Eversheim K, 2000, GENE, V260, P1, DOI 10.1016/S0378-1119(00)00454-6; Hirata S, 2001, J STEROID BIOCHEM, V78, P33, DOI 10.1016/S0960-0760(01)00071-1; Ho SM, 2006, ANN NY ACAD SCI, V1089, P177, DOI 10.1196/annals.1386.005; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Horvath LG, 2001, CANCER RES, V61, P5331; Imamov O, 2005, BIOL REPROD, V73, P866, DOI 10.1095/biolreprod.105.043497; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lai JS, 2004, UROLOGY, V64, P814, DOI 10.1016/j.urology.2004.05.036; Lau KM, 2000, CANCER RES, V60, P3175; Leav I, 2001, AM J PATHOL, V159, P79, DOI 10.1016/S0002-9440(10)61676-8; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Marreiros A, 2005, ONCOGENE, V24, P637, DOI 10.1038/sj.onc.1208216; Mitchell DC, 2006, J BIOL CHEM, V281, P51, DOI 10.1074/jbc.M506245200; Mohibullah N, 1999, NUCLEIC ACIDS RES, V27, P2760, DOI 10.1093/nar/27.13.2760; Nieto M, 2007, INT J BIOCHEM CELL B, V39, P1562, DOI 10.1016/j.biocel.2007.01.005; Ockrim J, 2006, NAT CLIN PRACT ONCOL, V3, P552, DOI 10.1038/ncponc0602; Pellikainen JM, 2007, INT J CANCER, V120, P2061, DOI 10.1002/ijc.22648; Ruiz M, 2001, CLIN CANCER RES, V7, P4086; Shoda T, 2002, J STEROID BIOCHEM, V82, P201, DOI 10.1016/S0960-0760(02)00186-3; Signoretti S, 2001, AM J PATHOL, V159, P13, DOI 10.1016/S0002-9440(10)61666-5; Tummala R, 2003, GENE, V321, P93, DOI 10.1016/S0378-1119(03)00840-0; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200; ZHU X, 2004, AM J PATHOL, V546, P17	30	35	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2007	26	52					7346	7354		10.1038/sj.onc.1210537	http://dx.doi.org/10.1038/sj.onc.1210537			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NP	17525739				2022-12-17	WOS:000250955700006
J	Mak, HHL; Peschard, P; Lin, T; Naujokas, MA; Zuo, D; Park, M				Mak, H. H. L.; Peschard, P.; Lin, T.; Naujokas, M. A.; Zuo, D.; Park, M.			Oncogenic activation of the Met receptor tyrosine kinase fusion protein, Tpr-Met, involves exclusion from the endocytic degradative pathway	ONCOGENE			English	Article						transforming gene; signal transduction; endocytosis; RTK; Cbl; ubiquitin	GROWTH-FACTOR RECEPTOR; DOMAIN BINDING-SITE; DOWN-REGULATION; C-CBL; JUXTAMEMBRANE DOMAIN; UBIQUITINATION; MULTIUBIQUITINATION; UBIQUITYLATION; CANCER	Multiple mechanisms of dysregulation of receptor tyrosine kinases (RTKs) are observed in human cancers. In addition to gain-of-function, loss of negative regulation also contributes to oncogenic activation of RTKs. Negative regulation of many RTKs involves their internalization and degradation in the lysosome, a process regulated through ubiquitination. RTK oncoproteins activated following chromosomal translocation, are no longer transmembrane proteins, and are predicted to escape lysosomal degradation. To test this, we used the Tpr-Met oncogene, generated following chromosomal translocation of the hepatocyte growth factor receptor (Met). Unlike Met, Tpr-Met is localized in the cytoplasm and also lacks the binding site for Cbl ubiquitin ligases. We determined whether subcellular localization of Tpr-Met, and/or loss of its Cbl-binding site, is important for oncogenic activity. Presence of a Cbl-binding site and ubiquitination of cytosolic Tpr-Met oncoproteins does not alter their transforming activity. In contrast, plasma membrane targeting allows Tpr-Met to enter the endocytic pathway, and Tpr-Met transforming activity as well as protein stability are decreased in a Cbl-dependent manner. We show that transformation by Tpr-Met is in part dependent on its ability to escape normal downregulatory mechanisms. This provides a paradigm for many RTK oncoproteins activated following chromosomal translocation.	McGill Univ, Ctr Hlth, Mol Oncol Grp, Montreal, PQ, Canada; McGill Univ, Dept Biochem, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Park, M (corresponding author), McGill Univ, Ctr Hlth, Dept Med, Mol Oncol Grp, 687 Ave Pins Ouest, Rm H5-21, Montreal, PQ H3A 1A1, Canada.	morag.park@mcgill.ca		Peschard, Pascal/0000-0001-6395-5566				Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Carter S, 2004, J BIOL CHEM, V279, P52835, DOI 10.1074/jbc.M407769200; Grovdal LM, 2004, EXP CELL RES, V300, P388, DOI 10.1016/j.yexcr.2004.07.003; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Huang FT, 2006, MOL CELL, V21, P737, DOI 10.1016/j.molcel.2006.02.018; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Lamorte L, 2001, Surg Oncol Clin N Am, V10, P271; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Naslavsky N, 2003, MOL BIOL CELL, V14, P417, DOI 10.1091/mbc.02-04-0053; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; RODRIGUES CA, 1994, CURR OPIN GENET DEV, V4, P15, DOI 10.1016/0959-437X(94)90086-8; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; Shtiegman K, 2003, SEMIN CANCER BIOL, V13, P29, DOI 10.1016/S1044-579X(02)00097-4; Thien CBF, 2005, BIOCHEM J, V391, P153, DOI 10.1042/BJ20050892; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Urbe S, 2003, J CELL SCI, V116, P4169, DOI 10.1242/jcs.00723; Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303	28	35	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 8	2007	26	51					7213	7221		10.1038/sj.onc.1210522	http://dx.doi.org/10.1038/sj.onc.1210522			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	231NO	17533376				2022-12-17	WOS:000250955600005
J	Darwiche, N; Ryscavage, A; Perez-Lorenzo, R; Wright, L; Bae, DS; Hennings, H; Yuspa, SH; Glick, AB				Darwiche, N.; Ryscavage, A.; Perez-Lorenzo, R.; Wright, L.; Bae, D-S; Hennings, H.; Yuspa, S. H.; Glick, A. B.			Expression profile of skin papillomas with high cancer risk displays a unique genetic signature that clusters with squamous cell carcinomas and predicts risk for malignant conversion	ONCOGENE			English	Article						skin carcinogenesis; microarray; squamous cell carcinoma; tumor immunology	MOUSE SKIN; EPITHELIAL-CELLS; MESSENGER-RNA; IN-VIVO; CARCINOGENESIS; TUMORS; INFLAMMATION; SURVEILLANCE; PROGRESSION; RECEPTORS	Chemical induction of squamous tumors in the mouse skin induces multiple benign papillomas: high-frequency terminally benign low-risk papillomas and low-frequency high-risk papillomas, the putative precursor lesions to squamous cell carcinoma (SCC). We have compared the gene expression profile of twenty different early low- and high-risk papillomas with normal skin and SCC. Unsupervised clustering of 514 differentially expressed genes (P<0.001) showed that 9/10 high-risk papillomas clustered with SCC, while 1/10 clustered with low-risk papillomas, and this correlated with keratin markers of tumor progression. Prediction analysis for microarrays (PAM) identified 87 genes that distinguished the two papilloma classes, and a majority of these had a similar expression pattern in both high-risk papillomas and SCC. Additional classifier algorithms generated a gene list that correctly classified unknown benign tumors as low- or high-risk concordant with promotion protocol and keratin profiling. Reduced expression of immune function genes characterized the high-risk papillomas and SCC. Immunohistochemistry confirmed reduced T-cell number in high-risk papillomas, suggesting that reduced adaptive immunity defines papillomas that progress to SCC. These results demonstrate that murine premalignant lesions can be segregated into subgroups; by gene expression patterns that correlate with risk for malignant conversion, and suggest a paradigm for generating diagnostic biomarkers for human premalignant lesions with unknown individual risk for malignant conversion.	Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16801 USA; Amer Univ Beirut, Dept Biol, Beirut, Lebanon; NCI, Lab Canc Biol & Genet, Bethesda, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; American University of Beirut; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Glick, AB (corresponding author), Penn State Univ, Ctr Mol Toxicol & Carcinogenesis, Dept Vet & Biomed Sci, University Pk, PA 16801 USA.	abg11@psu.edu		Perez-Lorenzo, Rolando/0000-0002-9355-9617; Ryscavage, Andrew/0000-0002-4156-6903; Darwiche, Nadine/0000-0002-1862-5426	NATIONAL CANCER INSTITUTE [Z01BC005445, R01CA117957] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [CA117957] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Callen JP, 1997, J AM ACAD DERMATOL, V36, P650, DOI 10.1016/S0190-9622(97)70265-2; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Darwiche N, 1996, CANCER RES, V56, P4942; de Visser KE, 2005, CANCER CELL, V7, P411, DOI 10.1016/j.ccr.2005.04.014; DIGHE AS, 1994, IMMUNITY, V1, P447, DOI 10.1016/1074-7613(94)90087-6; Dong G, 1997, J CELL BIOCHEM, P90; Dooley TP, 2003, BIOCHEM BIOPH RES CO, V306, P1026, DOI 10.1016/S0006-291X(03)01099-4; Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009; Girardi M, 2003, J EXP MED, V198, P747, DOI 10.1084/jem.20021282; Girardi M, 2001, SCIENCE, V294, P605, DOI 10.1126/science.1063916; GLICK AB, 1993, P NATL ACAD SCI USA, V90, P6076, DOI 10.1073/pnas.90.13.6076; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; HENNINGS H, 1985, CARCINOGENESIS, V6, P1607, DOI 10.1093/carcin/6.11.1607; Hummerich L, 2006, ONCOGENE, V25, P111, DOI 10.1038/sj.onc.1209016; Juric D, 2005, P NATL ACAD SCI USA, V102, P17763, DOI 10.1073/pnas.0509082102; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; LARCHER F, 1992, MOL CARCINOGEN, V6, P112, DOI 10.1002/mc.2940060206; Lossos IS, 2004, NEW ENGL J MED, V350, P1828, DOI 10.1056/NEJMoa032520; Ma C, 1996, BLOOD, V87, P734, DOI 10.1182/blood.V87.2.734.bloodjournal872734; Morris RJ, 1997, CANCER RES, V57, P3436; Morris RJ, 2000, CANCER RES, V60, P226; Nambiar PR, 2004, CANCER RES, V64, P6394, DOI 10.1158/0008-5472.CAN-04-0933; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Nishimura H, 1998, J IMMUNOL, V160, P936; Ozaki K, 2004, NATURE, V429, P72, DOI 10.1038/nature02502; Perez-Losada J, 2003, NAT REV CANCER, V3, P434, DOI 10.1038/nrc1095; Peyssonnaux C, 2006, BLOOD, V107, P3727, DOI 10.1182/blood-2005-06-2259; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ridd K, 2006, CARCINOGENESIS, V27, P1556, DOI 10.1093/carcin/bgl007; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Serewko MM, 2002, CANCER RES, V62, P3759; Smyth MJ, 2000, J EXP MED, V192, P755, DOI 10.1084/jem.192.5.755; TENNENBAUM T, 1993, CANCER RES, V53, P4803; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Yuspa SH, 1998, J DERMATOL SCI, V17, P1, DOI 10.1016/S0923-1811(97)00071-6	38	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6885	6895		10.1038/sj.onc.1210491	http://dx.doi.org/10.1038/sj.onc.1210491			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17525749				2022-12-17	WOS:000250188400004
J	Ambrose, HE; Papadopoulou, V; Beswick, RW; Wagner, SD				Ambrose, H. E.; Papadopoulou, V.; Beswick, R. W.; Wagner, S. D.			Poly-(ADP-ribose) polymerase-1 (Parp-1) binds in a sequence-specific manner at the Bcl-6 locus and contributes to the regulation of Bcl-6 transcription	ONCOGENE			English	Article						Parp-1; Bcl-6; lymphoma	B-CELL LYMPHOMA; GERMINAL-CENTER FORMATION; POLY(ADP-RIBOSE) POLYMERASE; DNA-BINDING; NEGATIVE AUTOREGULATION; CHROMATIN-STRUCTURE; GENE-EXPRESSION; SCL LOCI; COACTIVATOR; PROMOTER	Bcl-6 is a transcription factor that is normally expressed in germinal centre B cells. It is essential for the formation of germinal centres and the production of high-affinity antibodies. Transcriptional downregulation of Bcl-6 occurs on terminal differentiation to plasma cells. Bcl-6 is highly expressed in B-cell non-Hodgkin's lymphoma and, in a subset of cases of diffuse large cell lymphoma, the mechanism of Bcl-6 overexpression involves interruption of normal transcriptional controls. Transcriptional control of Bcl-6 is, therefore, important for normal antibody responses and lymphomagenesis, but little is known of the cis-acting control elements. This report focuses on a region of mouse/human sequence homology in the first intron of Bcl-6, which is a candidate site for such a control element. We demonstrate that poly-(ADP-ribose) polymerase-1 (Parp-1) binds in vitro and in vivo to specific sequences in this region. We further show that PARP inhibitors, and Parp-1 knockdown by siRNA induce Bcl-6 mRNA expression in Bcl-6 expressing cell lines. We speculate that Parp-1 activation plays a role in switching off Bcl-6 transcription and subsequent B-cell exit from the germinal centre.	Hammersmith Hosp, Imperial Coll London, Dept Haematol, Div Invest Sci, London, England	Imperial College London	Wagner, SD (corresponding author), Hammersmith Hosp, Imperial Coll London, Dept Haematol, Du Cane rd, London W12 0NN, England.	simon.wagner@imperial.ac.uk		Wagner, Simon/0000-0002-8914-0370	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akiyama T, 2001, P NATL ACAD SCI USA, V98, P48, DOI 10.1073/pnas.240458597; Ame JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085; Amiri KI, 2006, ONCOGENE, V25, P7714, DOI 10.1038/sj.onc.1209751; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Bernardin F, 1997, ONCOGENE, V14, P849, DOI 10.1038/sj.onc.1200903; Borggrefe T, 1998, J BIOL CHEM, V273, P17025, DOI 10.1074/jbc.273.27.17025; Bross L, 2000, IMMUNITY, V13, P589, DOI 10.1016/S1074-7613(00)00059-5; Butler AJ, 1999, MOL CELL BIOL, V19, P296; CATTORETTI G, 1995, BLOOD, V86, P45, DOI 10.1182/blood.V86.1.45.bloodjournal86145; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; Chapman MA, 2004, GENOME RES, V14, P313, DOI 10.1101/gr.1759004; Chattopadhyay A, 2006, ONCOGENE, V25, P2223, DOI 10.1038/sj.onc.1209252; Chevallier N, 2004, BLOOD, V103, P1454, DOI 10.1182/blood-2003-06-2081; D'Amours D, 1999, BIOCHEM J, V342, P249, DOI 10.1042/0264-6021:3420249; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DURKACZ BW, 1980, NATURE, V283, P593, DOI 10.1038/283593a0; Fujita N, 2004, CELL, V119, P75, DOI 10.1016/j.cell.2004.09.014; Gottgens B, 2001, GENOME RES, V11, P87, DOI 10.1101/gr.153001; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Haince JF, 2006, SCIENCE, V312, P1752, DOI 10.1126/science.1129808; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Huang K, 2004, BIOCHEMISTRY-US, V43, P217, DOI 10.1021/bi0301800; Huber A, 2004, DNA REPAIR, V3, P1103, DOI 10.1016/j.dnarep.2004.06.002; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Ju BG, 2004, CELL, V119, P815, DOI 10.1016/j.cell.2004.11.017; Ju BG, 2006, SCIENCE, V312, P1798, DOI 10.1126/science.1127196; Kikuchi M, 2000, ONCOGENE, V19, P4941, DOI 10.1038/sj.onc.1203864; Kim MY, 2004, CELL, V119, P803, DOI 10.1016/j.cell.2004.11.002; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lonskaya I, 2005, J BIOL CHEM, V280, P17076, DOI 10.1074/jbc.M413483200; Ma LM, 2002, J IMMUNOL, V168, P2835, DOI 10.4049/jimmunol.168.6.2835; Margalit O, 2006, BLOOD, V107, P1599, DOI 10.1182/blood-2005-04-1629; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; Nirodi C, 2001, J BIOL CHEM, V276, P9366, DOI 10.1074/jbc.M009897200; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; Ouararhni K, 2006, GENE DEV, V20, P3324, DOI 10.1101/gad.396106; Pasqualucci L, 2003, BLOOD, V101, P2914, DOI 10.1182/blood-2002-11-3387; Pavri R, 2005, MOL CELL, V18, P83, DOI 10.1016/j.molcel.2005.02.034; Pirrotta V, 2003, SCIENCE, V299, P528, DOI 10.1126/science.1081520; POIRIER GG, 1982, P NATL ACAD SCI-BIOL, V79, P3423, DOI 10.1073/pnas.79.11.3423; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Potaman VN, 2005, J MOL BIOL, V348, P609, DOI 10.1016/j.jmb.2005.03.010; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Sale JE, 1998, IMMUNITY, V9, P859, DOI 10.1016/S1074-7613(00)80651-2; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Simbulan-Rosenthal CM, 2003, ONCOGENE, V22, P8460, DOI 10.1038/sj.onc.1206897; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Walker SR, 2007, ONCOGENE, V26, P224, DOI 10.1038/sj.onc.1209775; Wang X, 2002, P NATL ACAD SCI USA, V99, P15018, DOI 10.1073/pnas.232581199; Ye BH, 1997, NAT GENET, V16, P161, DOI 10.1038/ng0697-161; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Zhang Z, 2002, VIROLOGY, V296, P107, DOI 10.1006/viro.2002.1385	57	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 13	2007	26	42					6244	6252		10.1038/sj.onc.1210434	http://dx.doi.org/10.1038/sj.onc.1210434			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209PU	17404575				2022-12-17	WOS:000249401300016
J	Fujiki, T; Miura, T; Maura, M; Shiraishi, H; Nishimura, S; Imada, Y; Uehara, N; Tashiro, K; Shirahata, S; Katakura, Y				Fujiki, T.; Miura, T.; Maura, M.; Shiraishi, H.; Nishimura, S.; Imada, Y.; Uehara, N.; Tashiro, K.; Shirahata, S.; Katakura, Y.			TAK1 represses transcription of the human telomerase reverse transcriptase gene	ONCOGENE			English	Article						telomerase; hTERT; TAK1; Sp1; HDAC	HISTONE DEACETYLASE INHIBITOR; BETA SIGNAL-TRANSDUCTION; CATALYTIC SUBUNIT HTERT; CANCER-CELLS; PROMOTER; IDENTIFICATION; ACTIVATION; DIFFERENTIATION; BINDING; PATHWAY	In human cells, telomerase activity is tightly regulated by the expression of its catalytic subunit, namely, the human telomerase reverse transcriptase ( hTERT). However, the molecular mechanisms involved in the regulation of hTERT expression have not been completely clarified. We have previously reported that transforming growth factor beta (TGF-beta) represses the expression of the hTERT gene. In the present study, we demonstrated that TGF-beta-activated kinase 1 (TAK1), originally identified as a mitogen-activated kinase kinase kinase, represses the hTERT core promoter activity in an E-box-independent manner, and it also represses the transcription of the hTERT gene in human lung adenocarcinoma cell line, A549 cells. This TAK1-induced repression was found to be caused by the recruitment of histone deacetylase to Sp1 at the hTERT promoter and a consequent reduction in the amount of acetylated histone H4 at the hTERT promoter. Finally, we demonstrated that TAK1 induces cellular senescence programs in normal human diploid cells. Thus, we assume that TAK1 triggers the repression mechanisms of the hTERT gene as a result of evoking cellular senescence programs. Considered together, TAK1 is thought to play a causative role in the determination of a finite replicative lifespan of normal and cancer cells.	Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Fukuoka 8128581, Japan	Kyushu University	Katakura, Y (corresponding author), Kyushu Univ, Fac Agr, Dept Genet Resources Technol, Fukuoka 8128581, Japan.	katakura@grt.kyushu-u.ac.jp	Uehara, Norihisa/ABB-8106-2020; Uehara, Norihisa/F-5933-2012					Aisner DL, 2002, CURR OPIN GENET DEV, V12, P80, DOI 10.1016/S0959-437X(01)00268-4; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ducrest AL, 2002, ONCOGENE, V21, P541, DOI 10.1038/sj.onc.1205081; EMAMI KH, 1995, MOL CELL BIOL, V15, P5906; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Horikawa I, 2002, MOL BIOL CELL, V13, P2585, DOI 10.1091/mbc.E01-11-0107; Horikawa I, 1999, CANCER RES, V59, P826; Hou M, 2002, EXP CELL RES, V274, P25, DOI 10.1006/excr.2001.5462; Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; Katakura Y, 2005, BIOCHEM BIOPH RES CO, V334, P450, DOI 10.1016/j.bbrc.2005.06.109; Kyo S, 2002, ONCOGENE, V21, P688, DOI 10.1038/sj.onc.1205163; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; Takakura M, 1999, CANCER RES, V59, P551; Takakura M, 2001, NUCLEIC ACIDS RES, V29, P3006, DOI 10.1093/nar/29.14.3006; Tzukerman M, 2000, MOL BIOL CELL, V11, P4381, DOI 10.1091/mbc.11.12.4381; Won J, 2002, J BIOL CHEM, V277, P38230, DOI 10.1074/jbc.M206064200; Xu DW, 2001, P NATL ACAD SCI USA, V98, P3826, DOI 10.1073/pnas.071043198; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008	21	35	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 9	2007	26	36					5258	5266		10.1038/sj.onc.1210331	http://dx.doi.org/10.1038/sj.onc.1210331			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	199CQ	17325661				2022-12-17	WOS:000248674200009
J	Wikman, H; Ruosaari, S; Nymark, P; Sarhadi, V; Saharinen, J; Vanhala, E; Karjalainen, A; Hollmen, J; Knuutila, S; Anttila, S				Wikman, H.; Ruosaari, S.; Nymark, P.; Sarhadi, V. K.; Saharinen, J.; Vanhala, E.; Karjalainen, A.; Hollmen, J.; Knuutila, S.; Anttila, S.			Gene expression and copy number profiling suggests the importance of allelic imbalance in 19p in asbestos-associated lung cancer	ONCOGENE			English	Article						lung cancer; asbestos; microarrays; microsatellite; analysis	CELL-LINES; ADENOCARCINOMA; DNA; IDENTIFICATION; WORKERS; EXPOSURE; SMOKING; TISSUE; BLOOD	Asbestos is a pulmonary carcinogen known to give rise to DNA and chromosomal damage, but the exact carcinogenic mechanisms are still largely unknown. In this study, gene expression arrays were performed on lung tumor samples from 14 heavily asbestos-exposed and 14 non-exposed patients matched for other characteristics. Using a two-step statistical analysis, 47 genes were revealed that could differentiate the tumors of asbestos-exposed from those of non-exposed patients. To identify asbestos-associated regions with DNA copy number and expressional changes, the gene expression data were combined with comparative genomic hybridization microarray data. As a result, a combinatory pro. le of DNA copy number aberrations and expressional changes significantly associated with asbestos exposure was obtained. Asbestos-related areas were detected in 2p21-p16.3, 3p21.31, 5q35.2-q35.3, 16p13.3, 19p13.3-p13.1 and 22q12.3-q13.1. The most prominent of these, 19p13, was further characterized by microsatellite analysis in 62 patients for the differences in allelic imbalance (AI) between the two groups of lung tumors. 79% of the exposed and 45% of the non-exposed patients (P = 0.008) were found to be carriers of AI in their lung tumors. In the exposed group, AI in 19p was prevalent regardless of the histological tumor type. In adenocarcinomas, AI in 19p appeared to occur independently of the asbestos exposure.	Finnish Inst Occupat Hlth, FI-00250 Helsinki, Finland; Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Hamburg, Germany; Aalto Univ, Lab Comp & Informat Sci, FIN-02150 Espoo, Finland; Univ Helsinki, Dept Pathol, Haartman Inst, Helsinki, Finland; Univ Helsinki, Cent Hosp, HUSLAB, Helsinki, Finland; Natl Publ Hlth Inst, Dept Mol Med, Biomedicum, Helsinki, Finland	Finnish Institute of Occupational Health; University of Hamburg; University Medical Center Hamburg-Eppendorf; Aalto University; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; Finland National Institute for Health & Welfare; University of Helsinki	Anttila, S (corresponding author), Finnish Inst Occupat Hlth, Topeliuksenkatu 41aA, FI-00250 Helsinki, Finland.	sisko.anttila@ttl.fi	Nymark, Penny/AAC-9890-2019; Nymark, Penny/B-5246-2014	Nymark, Penny/0000-0002-3435-7775; Wikman, Harriet/0000-0001-6862-0888				Balsara BR, 2002, ONCOGENE, V21, P6877, DOI 10.1038/sj.onc.1205836; Blyth K, 2005, NAT REV CANCER, V5, P376, DOI 10.1038/nrc1607; Bossolasco M, 1999, MOL CARCINOGEN, V26, P189, DOI 10.1002/(SICI)1098-2744(199911)26:3<189::AID-MC8>3.0.CO;2-T; Dano L, 2000, GENE CHROMOSOME CANC, V29, P1, DOI 10.1002/1098-2264(2000)9999:9999<000::AID-GCC1000>3.3.CO;2-S; De Rienzo A, 2000, Clin Ter, V151, P433; FATMA N, 1991, BRIT J IND MED, V48, P103; Gupta N, 2005, BBA-MOL BASIS DIS, V1741, P215, DOI 10.1016/j.bbadis.2005.04.002; Hellstrom I, 2003, CANCER RES, V63, P3695; Hoang JM, 1997, CANCER RES, V57, P300; Hyman E, 2002, CANCER RES, V62, P6240; Ionov Y, 2004, ONCOGENE, V23, P639, DOI 10.1038/sj.onc.1207178; KARJALAINEN A, 1993, AM J IND MED, V23, P461, DOI 10.1002/ajim.4700230309; KARJALAINEN A, 1997, ADV ENV CONTROL TECH, P127; Kettunen E, 2004, CANCER GENET CYTOGEN, V149, P98, DOI 10.1016/s0165-4608(03)00300-5; Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289; Marczynski B, 2000, MUTAT RES-GEN TOX EN, V468, P195, DOI 10.1016/S1383-5718(00)00053-X; MARCZYNSKI B, 1994, HUM EXP TOXICOL, V13, P3, DOI 10.1177/096032719401300102; Marsit CJ, 2004, CANCER RES, V64, P8702, DOI 10.1158/0008-5472.CAN-04-2558; Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091; Michiels S, 2005, LANCET, V365, P488, DOI 10.1016/S0140-6736(05)17866-0; Nymark P, 2006, CANCER RES, V66, P5737, DOI 10.1158/0008-5472.CAN-06-0199; Radak Z, 2005, CANCER LETT, V219, P191, DOI 10.1016/j.canlet.2004.07.008; Reisman DN, 2003, CANCER RES, V63, P560; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; Sakakura C, 2005, INT J CANCER, V113, P221, DOI 10.1002/ijc.20551; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sanchez-Cespedes M, 2001, CANCER RES, V61, P1309; SELIKOFF IJ, 1968, J AMER MED ASSOC, V204, P106, DOI 10.1001/jama.204.2.106; Shukla A, 2003, INT J BIOCHEM CELL B, V35, P1198, DOI 10.1016/S1357-2725(02)00315-1; Shukla A, 2003, FREE RADICAL BIO MED, V34, P1117, DOI 10.1016/S0891-5849(03)00060-1; Takamochi K, 2004, LUNG CANCER, V46, P271, DOI 10.1016/j.lungcan.2004.05.001; Upadhyay D, 2003, EXP BIOL MED, V228, P650, DOI 10.1177/153537020322800602; Wikman H, 2002, ONCOGENE, V21, P5804, DOI 10.1038/sj.onc.1205726	33	35	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 12	2007	26	32					4730	4737		10.1038/sj.onc.1210270	http://dx.doi.org/10.1038/sj.onc.1210270			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297452				2022-12-17	WOS:000248037900014
J	Winter, SF; Acevedo, VD; Gangula, RD; Freeman, KW; Spencer, DM; Greenberg, NM				Winter, S. F.; Acevedo, V. D.; Gangula, R. D.; Freeman, K. W.; Spencer, D. M.; Greenberg, N. M.			Conditional activation of FGFR1 in the prostate epithelium induces angiogenesis with concomitant differential regulation of Ang-1 and Ang-2	ONCOGENE			English	Article						FGFR1; prostate; angiogenesis; angiopoietin; transgenic	FIBROBLAST GROWTH-FACTORS; HYPOXIA-INDUCIBLE FACTOR-1; RECEPTOR TYROSINE KINASE; INTRAEPITHELIAL NEOPLASIA; CANCER PROGRESSION; TUMOR ANGIOGENESIS; GENE-EXPRESSION; ANGIOPOIETIN-2; PROMOTER; HYPERPLASIA	The expression of. broblast growth factor receptor (FGFR)-1 correlates with angiogenesis and is associated with prostate cancer (CaP) progression. To more precisely de. ne the molecular mechanisms whereby FGFR1 causes angiogenesis in the prostate we exploited a transgenic mouse model, JOCK-1, in which activation of a conditional FGFR1 allele in the prostate epithelium caused rapid angiogenesis and progressive hyperplasia. By labeling the vasculature in vivo and applying a novel method to measure the vasculature in three dimensions, we were able to observe a signi. cant increase in vascular volume 1 week after FGFR1 activation. Although vessel volume and branching both continued to increase throughout a 6-week period of FGFR1 activation, importantly, we discovered that continued activation of FGFR1 was not required to maintain the new vasculature. Exploring the molecular mediators of the angiogenic phenotype, we observed consistent upregulation of HIF-1 alpha, vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), whereas expression of Ang-1 was lost. Further analysis revealed that loss of Ang-1 expression occurred in the basal epithelium, whereas the increase in Ang-2 expression occurred in the luminal epithelium. Reporter assays con. rmed that the Ang-2 promoter was regulated by FGFR1 signaling and a small molecule inhibitor of FGFR activity, PD173074, could abrogate this response. These. ndings establish a method to follow spontaneous angiogenesis in a conditional autochthonous system, implicate the angiopoietins as downstream effectors of FGFR1 activation in vivo, and suggest that therapies targeting FGFR1 could be used to inhibit neovascularization during initiation and progression of CaP.	Fred Hutchinson Canc Res Ctr, Clin Res Div, Seattle, WA 98109 USA; Baylor Coll Med, Dept Immunol, Houston, TX USA	Fred Hutchinson Cancer Center; Baylor College of Medicine	Greenberg, NM (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div, 1100 Fairview Ave N,D4-100, Seattle, WA 98109 USA.	ngreenberg@fhcrc.org			NCI NIH HHS [CA64851] Funding Source: Medline; NIGMS NIH HHS [R25 GM056929] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R25GM056929] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		American Cancer Society, 2006, CANC FACTS FIG 2006; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bicknell R, 2004, ANNU REV PHARMACOL, V44, P219, DOI 10.1146/annurev.pharmtox.44.101802.121650; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012; Doll JA, 2001, PROSTATE, V49, P293, DOI 10.1002/pros.10025; Dorkin TJ, 1999, J PATHOL, V189, P564, DOI 10.1002/(SICI)1096-9896(199912)189:4<564::AID-PATH480>3.0.CO;2-1; FOLEY KP, 1993, TRENDS GENET, V9, P380, DOI 10.1016/0168-9525(93)90137-7; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Foster BA, 1999, PROSTATE CANCER P D, V2, P76; Freeman KW, 2003, CANCER RES, V63, P8256; Giri D, 1999, CLIN CANCER RES, V5, P1063; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Hayward SW, 1996, ACTA ANAT, V155, P81; Hobbs S, 1998, BIOCHEM BIOPH RES CO, V252, P368, DOI 10.1006/bbrc.1998.9646; Huss WJ, 2003, PROSTATE, V54, P8, DOI 10.1002/pros.10163; Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8; Jin CL, 2004, CANCER RES, V64, P4555, DOI 10.1158/0008-5472.CAN-03-3752; Kim I, 2000, J BIOL CHEM, V275, P18550, DOI 10.1074/jbc.M910084199; Kwabi-Addo B, 2004, ENDOCR-RELAT CANCER, V11, P709, DOI 10.1677/erc.1.00535; Lind AJ, 2005, PROSTATE, V62, P394, DOI 10.1002/pros.20163; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V289, P801, DOI 10.1006/bbrc.2001.6046; Tait CR, 2004, J PATHOL, V204, P1, DOI 10.1002/path.1618; Thomson AA, 2001, REPRODUCTION, V121, P187, DOI 10.1530/rep.0.1210187; Wang F, 2004, PROSTATE, V58, P1, DOI 10.1002/pros.10311; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P409; Welm BE, 2002, J CELL BIOL, V157, P703, DOI 10.1083/jcb.200107119; Winter SF, 2003, PROSTATE CANCER P D, V6, P204, DOI 10.1038/sj.pcan.4500655; Zhang JF, 2000, ENDOCRINOLOGY, V141, P4698, DOI 10.1210/en.141.12.4698; Zhang L, 2003, CANCER RES, V63, P3403	40	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL	2007	26	34					4897	4907		10.1038/sj.onc.1210288	http://dx.doi.org/10.1038/sj.onc.1210288			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194CV	17297442				2022-12-17	WOS:000248322500002
J	Yoo, YG; Na, TY; Yang, WK; Kim, HJ; Lee, IK; Kong, G; Chung, JH; Lee, MO				Yoo, Y-G; Na, T-Y; Yang, W-K; Kim, H-J; Lee, I-K; Kong, G.; Chung, J-H; Lee, M-O			6-Mercaptopurine, an activator of Nur77, enhances transcriptional activity of HIF-1 alpha resulting in new vessel formation	ONCOGENE			English	Article						6-mercaptopurine; Nur77; hypoxia-inducible factor-1 alpha; vascular endothelial growth factor	HYPOXIA-INDUCIBLE-FACTOR; UBIQUITIN-PROTEASOME PATHWAY; VASCULAR ENDOTHELIAL-CELLS; SERUM GROWTH-FACTORS; ORPHAN RECEPTOR TR3; NUCLEAR RECEPTOR; PROTEIN-KINASE; FACTOR 1-ALPHA; NGFI-B; EXPRESSION	Hypoxia-inducible factor-1 alpha (HIF-1 alpha) plays a central role in oxygen homeostasis. Previously, we reported that the orphan nuclear receptor Nur77 functions in stabilizing HIF-1 alpha. Here, we demonstrate that 6-mercaptopurine (6-MP), an activator of the NR4A family members, enhances transcriptional activity of HIF-1. 6-MP enhanced the protein-level of HIF-1 alpha as well as vascular endothelial growth factor (VEGF) in a dose- and time-dependent manner. The induction of HIF-1 alpha was abolished by the transfection of either a dominant-negative Nur77 mutant or si-Nur77, indicating a critical role of Nur77 in the 6-MP action. The HIF-1 alpha protein level remained up to 60 min in the presence of 6-MP when de novo protein synthesis was blocked by cycloheximide, suggesting that 6-MP induces stabilization of the HIF-1 alpha protein. The fact that 6-MP decreased the association of HIF-1 alpha with von Hippel - Lindau protein and the acetylation of HIF-1 alpha, may explain how 6-MP induced stability of HIF-1 alpha. Further, 6-MP induced the transactivation function of HIF-1 alpha by recruiting co-activator cyclic-AMP-response-element- binding protein. Finally, 6-MP enhanced the expression of HIF-1 alpha and VEGF, and the formation of capillary tubes in human umbilical vascular endothelial cells. Together, our results provide a new insight for 6-MP action in the stabilization of HIF-1a and imply a potential application of 6-MP in hypoxia-associated human vascular diseases.	Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; Seoul Natl Univ, Bio MAX Inst, Seoul 151742, South Korea; Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; Kyungpook Natl Univ, Sch Med, Dept Internal Med, Taegu, South Korea	Seoul National University (SNU); Seoul National University (SNU); Hanyang University; Kyungpook National University	Lee, MO (corresponding author), Seoul Natl Univ, Coll Pharm, San 56-1 Shillim Dong, Seoul 151742, South Korea.	molee@snu.ac.kr	Lee, In-Kyu/AAR-6374-2021					Aarbakke J, 1997, TRENDS PHARMACOL SCI, V18, P3, DOI 10.1016/S0165-6147(96)01007-3; Arkenbout EK, 2003, ARTERIOSCL THROM VAS, V23, P1535, DOI 10.1161/01.ATV.0000084639.16462.7A; Arkenbout EK, 2002, CIRCULATION, V106, P1530, DOI 10.1161/01.CIR.0000028811.03056.BF; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bilton R, 2005, J BIOL CHEM, V280, P31132, DOI 10.1074/jbc.M504482200; Cheng LEC, 1997, EMBO J, V16, P1865, DOI 10.1093/emboj/16.8.1865; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Chintharlapalli S, 2005, J BIOL CHEM, V280, P24903, DOI 10.1074/jbc.M500107200; Cioffi CL, 2003, BIOCHEM BIOPH RES CO, V303, P947, DOI 10.1016/S0006-291X(03)00453-4; Cuenda A, 2000, METH MOL B, V99, P161; DAVIS IJ, 1993, MOL ENDOCRINOL, V7, P953, DOI 10.1210/me.7.8.953; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Erez N, 2003, CANCER RES, V63, P8777; Fisher TS, 2005, J BIOL CHEM, V280, P17749, DOI 10.1074/jbc.M412055200; GIMBRONE MA, 1974, J CELL BIOL, V60, P673, DOI 10.1083/jcb.60.3.673; Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; Hsu Hui-Chen, 2004, Current Drug Targets - Inflammation and Allergy, V3, P413, DOI 10.2174/1568010042634523; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kim SH, 2006, BIOCHEM BIOPH RES CO, V340, P422, DOI 10.1016/j.bbrc.2005.12.018; Kolluri SK, 2003, MOL CELL BIOL, V23, P8651, DOI 10.1128/MCB.23.23.8651-8667.2003; Kong TQ, 2004, P NATL ACAD SCI USA, V101, P10440, DOI 10.1073/pnas.0401339101; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Li MH, 2004, CLIN CANCER RES, V10, P8266, DOI 10.1158/1078-0432.CCR-04-0951; Li Y, 1998, MOL CELL BIOL, V18, P4719, DOI 10.1128/MCB.18.8.4719; Maddika S, 2005, J CELL SCI, V118, P4485, DOI 10.1242/jcs.02580; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Martinez-Gonzalez J, 2005, CARDIOVASC RES, V65, P609, DOI 10.1016/j.cardiores.2004.10.002; Martinez-Gonzalez J, 2003, CIRC RES, V92, P96, DOI 10.1161/01.ES.0000050921.53008.47; Murphy EP, 2001, ARTHRITIS RHEUM-US, V44, P782, DOI 10.1002/1529-0131(200104)44:4<782::AID-ANR134>3.3.CO;2-8; MURRAY JE, 1963, NEW ENGL J MED, V268, P1315, DOI 10.1056/NEJM196306132682401; Ordentlich P, 2003, J BIOL CHEM, V278, P24791, DOI 10.1074/jbc.M302167200; RICHTER JE, 1999, CLIN PRACTICE GASTRO, V1, P1; Rius J, 2006, ATHEROSCLEROSIS, V184, P276, DOI 10.1016/j.atherosclerosis.2005.04.008; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SCEARCE LM, 1993, J BIOL CHEM, V268, P8855; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Slagsvold HH, 2002, BIOCHEM BIOPH RES CO, V291, P1146, DOI 10.1006/bbrc.2002.6579; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tiede I, 2003, J CLIN INVEST, V111, P1133, DOI 10.1172/JCI200316432; Wang ZL, 2003, NATURE, V423, P555, DOI 10.1038/nature01645; Wansa KDSA, 2003, J BIOL CHEM, V278, P24776, DOI 10.1074/jbc.M300088200; Weigel G, 1999, THROMB RES, V94, P87, DOI 10.1016/S0049-3848(98)00199-6; WILLIAMS GT, 1993, MOL CELL BIOL, V13, P6124, DOI 10.1128/MCB.13.10.6124; Winoto A, 1997, Semin Immunol, V9, P51, DOI 10.1006/smim.1996.0053; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Yoo YG, 2003, J BIOL CHEM, V278, P39076, DOI 10.1074/jbc.M305101200; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248; Zhang QZ, 2005, MOL CANCER THER, V4, P1465, DOI 10.1158/1535-7163.MCT-05-0198; Zhou T, 1996, J EXP MED, V183, P1879, DOI 10.1084/jem.183.4.1879	57	35	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 31	2007	26	26					3823	3834		10.1038/sj.onc.1210149	http://dx.doi.org/10.1038/sj.onc.1210149			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	175PV	17146432				2022-12-17	WOS:000247026400006
J	Urbanska, K; Trojanek, J; Del Valle, L; Eldeen, MB; Hofmann, F; Garcia-Echeverria, C; Khalili, K; Reiss, K				Urbanska, K.; Trojanek, J.; Del Valle, L.; Eldeen, M. B.; Hofmann, F.; Garcia-Echeverria, C.; Khalili, K.; Reiss, K.			Inhibition of IGF-I receptor in anchorage-independence attenuates GSK-3 beta constitutive phosphorylation and compromises growth and survival of medulloblastoma cell lines	ONCOGENE			English	Article						IGF-I receptor; NVP-AEW541; GSK3 beta; medulloblastoma; anchorage-independence	GLYCOGEN-SYNTHASE KINASE-3-BETA; INTEGRIN-LINKED KINASE; VIRUS T-ANTIGEN; TUMOR-GROWTH; ANTITUMOR-ACTIVITY; INDUCED APOPTOSIS; CARCINOMA CELLS; SONIC HEDGEHOG; INSULIN; LOCALIZATION	We have previously reported that insulin-like growth factor-I (IGF-I) supports growth and survival of mouse and human medulloblastoma cell lines, and that IGF-I receptor (IGF-IR) is constitutively phosphorylated in human medulloblastoma clinical samples. Here, we demonstrate that a specific inhibitor of insulin-like growth factor-I receptor (IGF-IR), NVP-AEW541, attenuated growth and survival of mouse (BsB8) and human (D384, Daoy) medulloblastoma cell lines. Cell cycle analysis demonstrated that G1 arrest and apoptosis contributed to the action of NVP-AEW54. Interestingly, very aggressive BsB8 cells, which derive from cerebellar tumors of transgenic mice expressing viral oncoprotein (large T-antigen from human polyomavirus JC) became much more sensitive to NVP-AEW541 when exposed to anchorage-independent culture conditions. This high sensitivity to NVP-AEW54 in suspension was accompanied by the loss of GSK-3 beta constitutive phosphorylation and was independent from T-antigen-mediated cellular events (Supplementary Materials). BsB8 cells were partially rescued from NVP-AEW541 by GSK3 beta inhibitor, lithium chloride and were sensitized by GSK3b activator, sodium nitroprusside (SNP). Importantly, human medulloblastoma cells, D384, which demonstrated partial resistance to NVP-AEW541 in suspension cultures, become much more sensitive following SNP-mediated GSK3 beta dephosphorylation (activation). Our results indicate that hypersensitivity of medulloblastoma cells in anchorage-independence is linked to GSK-3 beta activity and suggest that pharmacological intervention against IGF-IR with simultaneous activation of GSK3 beta could be highly effective against medulloblastomas, which have intrinsic ability of disseminating the CNS via cerebrospinal fluid.	Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, Philadelphia, PA 19122 USA; Jagiellonian Univ, Dept Cell Biol, Fac Biotechnol, Krakow, Poland; Novartis Pharma AG, Novartis Inst Biomed Res, Basel, Switzerland	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Jagiellonian University; Novartis	Reiss, K (corresponding author), Temple Univ, Sch Med, Dept Neurosci, Ctr Neurovirol, Biol Life Sci Bldg,Room 230,1900 N 12th St, Philadelphia, PA 19122 USA.	kreiss@temple.edu	Del Valle, Luis/J-4085-2015	Del Valle, Luis/0000-0003-3894-9206; Trojanek, Joanna/0000-0002-3200-735X	NCI NIH HHS [R01CA095518-01] Funding Source: Medline; NINDS NIH HHS [P01 NS36466-06] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Andrews DW, 2001, J CLIN ONCOL, V19, P2189, DOI 10.1200/JCO.2001.19.8.2189; Araki K, 2006, INT J CANCER, V118, P2602, DOI 10.1002/ijc.21653; Arevalo JC, 2005, CURR OPIN CELL BIOL, V17, P112, DOI 10.1016/j.ceb.2005.01.004; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1997, ENDOCRINE, V7, P99, DOI 10.1007/BF02778073; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; Beurel E, 2004, EXP CELL RES, V300, P354, DOI 10.1016/j.yexcr.2004.08.001; Blackburn RV, 1998, CANCER, V82, P1137, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1137::AID-CNCR19>3.0.CO;2-7; Chao JI, 2004, J BIOL CHEM, V279, P20267, DOI 10.1074/jbc.M312381200; Cheng ZJ, 2005, J HYPERTENS, V23, P1757, DOI 10.1097/01.hjh.0000179765.48324.b4; Cordes N, 2003, BRIT J CANCER, V88, P1470, DOI 10.1038/sj.bjc.6600912; Cui H, 1998, DEV BRAIN RES, V111, P177, DOI 10.1016/S0165-3806(98)00136-9; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Del Valle L, 2002, J NEUROVIROL, V8, P138, DOI 10.1080/13550280290101111; Del Valle L, 2002, CLIN CANCER RES, V8, P1822; Desbois-Mouthon C, 2002, HEPATOLOGY, V36, P1528, DOI 10.1053/jhep.2002.37192; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Garcia-Echeverria C, 2004, CANCER CELL, V5, P231, DOI 10.1016/S1535-6108(04)00051-0; GLICK RP, 1993, ANN NY ACAD SCI, V692, P223; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; Hahn H, 2000, J BIOL CHEM, V275, P28341, DOI 10.1074/jbc.C000352200; HANGER DP, 1992, NEUROSCI LETT, V147, P58, DOI 10.1016/0304-3940(92)90774-2; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jope RS, 2003, TRENDS PHARMACOL SCI, V24, P441, DOI 10.1016/S0165-6147(03)00206-2; Kang UG, 2004, FEBS LETT, V560, P115, DOI 10.1016/S0014-5793(04)00082-1; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kim AJ, 2005, J CELL SCI, V118, P89, DOI 10.1242/jcs.01562; Knoepfler PS, 2006, CELL CYCLE, V5, P47, DOI 10.4161/cc.5.1.2292; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Kumar AS, 2004, ONCOGENE, V23, P3454, DOI 10.1038/sj.onc.1207473; Kurihara M, 1989, No To Shinkei, V41, P719; Lassak A, 2002, J BIOL CHEM, V277, P17231, DOI 10.1074/jbc.M110885200; LEROITH D, 1993, ANN NY ACAD SCI, V692, P22; Liao HT, 2005, OLIGONUCLEOTIDES, V15, P196, DOI 10.1089/oli.2005.15.196; Linseman DA, 2004, J NEUROSCI, V24, P9993, DOI 10.1523/JNEUROSCI.2057-04.2004; Patti R, 2000, INT J ONCOL, V16, P577; Rao G, 2004, ONCOGENE, V23, P6156, DOI 10.1038/sj.onc.1207818; Reiss K, 1999, J CELL PHYSIOL, V181, P124, DOI 10.1002/(SICI)1097-4652(199910)181:1<124::AID-JCP13>3.0.CO;2-0; Reiss K, 1998, CLIN CANCER RES, V4, P2647; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; Reiss Krzysztof, 2002, Expert Opin Ther Targets, V6, P539, DOI 10.1517/14728222.6.5.539; Resnicoff M, 1996, J Exp Ther Oncol, V1, P385; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; SELL C, 1995, CANCER RES, V55, P303; Sjostrom SK, 2005, DEV CELL, V9, P327, DOI 10.1016/j.devcel.2005.07.014; Szatmari E, 2005, J BIOL CHEM, V280, P37526, DOI 10.1074/jbc.M502699200; Trojanek J, 2003, MOL CELL BIOL, V23, P7510, DOI 10.1128/MCB.23.21.7510-7524.2003; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; Wang JY, 2004, J EXP CLIN CANC RES, V23, P373; Wang Y, 2005, MOL CANCER THER, V4, P1214, DOI 10.1158/1535-7163.MCT-05-0048; Yau CYF, 2005, CANCER RES, V65, P1497, DOI 10.1158/0008-5472.CAN-04-2940; Zhang YH, 2005, FEBS LETT, V579, P6230, DOI 10.1016/j.febslet.2005.09.095	57	35	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 5	2007	26	16					2308	2317		10.1038/sj.onc.1210018	http://dx.doi.org/10.1038/sj.onc.1210018			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	153WC	17016438				2022-12-17	WOS:000245466000007
J	Jeong, KW; Kim, HZ; Kim, S; Kim, YS; Choe, J				Jeong, K. W.; Kim, H-Z; Kim, S.; Kim, Y. S.; Choe, J.			Human papillomavirus type 16 E6 protein interacts with cystic fibrosis transmembrane regulator-associated ligand and promotes E6-associated protein-mediated ubiquitination and proteasomal degradation	ONCOGENE			English	Article						HPV; E6; E6AP; proteasome; ubiquitination	CERVICAL-CANCER CELLS; GOLGI PROTEIN; ADENOVIRUS E4-ORF1; EARLY GENES; HPV-18 E6; IN-VITRO; P53; IDENTIFICATION; BINDING; ONCOPROTEINS	The PDZ proteins such as hDLG, hScrib and MAGIs function as the membrane-associated protein scaffolds and have been shown to interact with the high-risk human papillomavirus (HPV) E6s. In this report, we identify a Golgi-associated PDZ protein, cystic fibrosis transmembrane regulator-associated ligand (CAL) as a cellular target of HPV16 E6 by the proteomic approach. The carboxy-terminal PDZ-binding motif of HPV16 E6 specifically interacts with the PDZ domain of CAL, and the interaction enhances proteasome-mediated degradation of CAL. HPV16 E6 interacts with CAL more strongly and degrades it better than HPV18 E6 owing to the more compatible PDZ-binding motif. CAL is ubiquitinated by the E6/E6-associated protein (E6AP) complex or by E6AP alone, albeit less efficiently, which indicates that it could be a normal target of E6AP. Although it downregulates CAL at the transcript level, small interfering RNA-induced depletion of HPV16 E6 in Caski cells stabilizes CAL at the protein level, suggesting that HPV16 E6 mediates the proteasomal degradation of CAL in HPV-positive cervical cancer cells. HPV16 E6 may tightly regulate the vesicular trafficking processes by interacting with CAL, and such a modification can contribute to the development of cervical cancer.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Yonsei Univ, Dept Biochem, Seoul 120749, South Korea	Korea Advanced Institute of Science & Technology (KAIST); Yonsei University	Choe, J (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, 373-1 Guseong Dong, Taejon 305701, South Korea.	jchoe@kaist.ac.kr	Choe, Joonho/F-3066-2011					Butz K, 2003, ONCOGENE, V22, P5938, DOI 10.1038/sj.onc.1206894; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2004, J BIOL CHEM, V279, P1892, DOI 10.1074/jbc.M308640200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; Cuadra AE, 2004, J NEUROSCI, V24, P7491, DOI 10.1523/JNEUROSCI.1255-04.2004; Gao QS, 2002, CANCER RES, V62, P3315; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Glaunsinger BA, 2000, ONCOGENE, V19, P5270, DOI 10.1038/sj.onc.1203906; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grassmann K, 1996, J VIROL, V70, P2339, DOI 10.1128/JVI.70.4.2339-2349.1996; Hassel B, 2003, J BIOL CHEM, V278, P40136, DOI 10.1074/jbc.M305577200; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; Humbert P, 2003, BIOESSAYS, V25, P542, DOI 10.1002/bies.10286; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; KANDA T, 1991, VIROLOGY, V185, P536, DOI 10.1016/0042-6822(91)90523-E; Kao WH, 2000, J VIROL, V74, P6408, DOI 10.1128/JVI.74.14.6408-6417.2000; Kelley ML, 2005, J VIROL, V79, P3737, DOI 10.1128/JVI.79.6.3737-3747.2005; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuhne C, 1998, J BIOL CHEM, V273, P34302, DOI 10.1074/jbc.273.51.34302; Kumar S, 1999, J BIOL CHEM, V274, P18785, DOI 10.1074/jbc.274.26.18785; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; Nakagawa S, 2000, MOL CELL BIOL, V20, P8244, DOI 10.1128/MCB.20.21.8244-8253.2000; NAKAGAWA S, 1995, VIROLOGY, V212, P535, DOI 10.1006/viro.1995.1511; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Pim D, 2000, ONCOGENE, V19, P719, DOI 10.1038/sj.onc.1203374; Piserchio A, 2005, BIOCHEMISTRY-US, V44, P16158, DOI 10.1021/bi0516475; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHNEIDERGADICKE A, 1988, CANCER RES, V48, P2969; SEDMAN SA, 1991, J VIROL, V65, P4860, DOI 10.1128/JVI.65.9.4860-4866.1991; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; Thomas M, 2001, ONCOGENE, V20, P5431, DOI 10.1038/sj.onc.1204719; Thomas M, 2005, ONCOGENE, V24, P6222, DOI 10.1038/sj.onc.1208757; Thomas M, 2002, ONCOGENE, V21, P5088, DOI 10.1038/sj.onc.1205668; Thomas M, 1998, ONCOGENE, V17, P2943, DOI 10.1038/sj.onc.1202223; Yao RJ, 2002, P NATL ACAD SCI USA, V99, P11211, DOI 10.1073/pnas.162027899; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999; zur Hausen H, 2000, JNCI-J NATL CANCER I, V92, P690, DOI 10.1093/jnci/92.9.690; zurHausen H, 1996, BBA-REV CANCER, V1288, pF55	48	35	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2007	26	4					487	499		10.1038/sj.onc.1209837	http://dx.doi.org/10.1038/sj.onc.1209837			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	129LS	16878151				2022-12-17	WOS:000243731600002
J	Davalos, V; Dopeso, H; Velho, S; Ferreira, AM; Cirnes, L; Diaz-Chico, N; Bilbao, C; Ramirez, R; Rodriguez, G; Falcon, O; Leon, L; Niessen, RC; Keller, G; Dallenbach-Hellweg, G; Espin, E; Armengol, M; Plaja, A; Perucho, M; Imai, K; Yamamoto, H; Gebert, JF; Diaz-Chico, JC; Hofstra, RM; Woerner, SM; Seruca, R; Schwartz, S; Arango, D				Davalos, V.; Dopeso, H.; Velho, S.; Ferreira, A. M.; Cirnes, L.; Diaz-Chico, N.; Bilbao, C.; Ramirez, R.; Rodriguez, G.; Falcon, O.; Leon, L.; Niessen, R. C.; Keller, G.; Dallenbach-Hellweg, G.; Espin, E.; Armengol, M.; Plaja, A.; Perucho, M.; Imai, K.; Yamamoto, H.; Gebert, J. F.; Diaz-Chico, J. C.; Hofstra, R. M.; Woerner, S. M.; Seruca, R.; Schwartz, S., Jr.; Arango, D.			High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability	ONCOGENE			English	Article						EPHB2; cancer; microsatellite instability; colorectal; stomach; endometrium	RECEPTOR TYROSINE KINASE; FRAMESHIFT MUTATIONS; COLORECTAL TUMORS; TARGET GENES; CANCER; EXPRESSION	The EPH/EFN family of receptor tyrosine kinases regulates cell adhesion and migration and has an important role in controlling cell positioning in the normal intestinal epithelium. Inactivation of EPHB2 has recently been shown to accelerate tumorigenesis in the colon and rectum, and we have previously demonstrated frequent frameshift mutations (41%) in an A9 coding microsatellite repeat in exon 17 of EPHB2 in colorectal tumors with microsatellite instability (MSI). In this study, we extended these analyses to extracolonic MSI cancers, and found frameshift EPHB2 mutations in 39% (25/64) of gastric tumors and 14% (8/56) of endometrial tumors. Regression analysis of these EPHB2 mutation data on the basis of our previously proposed statistical model identified EPHB2 as a selective target of frameshift mutations in MSI gastric cancers but not in MSI endometrial carcinomas. These results suggest a functional role for EPHB2 in gastric tumor progression, and emphasize the differences between the tumorigenic processes in MSI gastrointestinal and endometrial cancer.	Valle Hebron Hosp Res Inst, CIBBIM, Funct Genom Program, Mol Oncol & Aging Grp,Mol Biol & Biochem Res Ctr, Barcelona 08035, Spain; Valle Hebron Hosp Res Inst, Mol Oncol Program, Mol Oncol & Aging Grp, Barcelona 08035, Spain; Univ Porto, Inst Mol Pathol & Immunol, IPATIMUP, P-4100 Oporto, Portugal; Univ Groningen, Med Ctr, Dept Genet, Groningen, Netherlands; Canc Res Inst Canary Isl, Endometrial Canc Study Grp, ICIC, Canary Isl, Spain; Univ Las Palmas Gran Canaria, Fac Hlth Sci, Dept Biochem & Physiol, Las Palmas Gran Canaria, Canary Islands, Spain; Tech Univ Munich, Inst Pathol, D-8000 Munich, Germany; Hosp Univ Materno Infantil Canarias, Dept Obstet & Gynecol, Las Palmas Gran Canaria, Canary Islands, Spain; Dr Falcon Gynecol Inst, Las Palmas Gran Canaria, Canary Islands, Spain; Hosp Univ Materno Infantil Canarias, Dept Pathol, Las Palmas Gran Canaria, Canary Islands, Spain; Inst Pathol, Mannheim, Germany; Vall Hebron Hosp Res Inst, CIBBIM, Program Cytogenet & Epigenet, Mol Oncol & Aging Grp,Mol Biol & Biochem Res Ctr, Barcelona 08035, Spain; Burnham Inst Med Res, La Jolla, CA USA; Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan; Inst Pathol, ATB, Dept Appl Tumor Biol, Heidelberg, Germany	Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Universidade do Porto; University of Groningen; Universidad de Las Palmas de Gran Canaria; Technical University of Munich; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Sanford Burnham Prebys Medical Discovery Institute; Sapporo Medical University	Arango, D (corresponding author), Valle Hebron Hosp Res Inst, CIBBIM, Funct Genom Program, Mol Oncol & Aging Grp,Mol Biol & Biochem Res Ctr, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	darango@ir.vhebron.net	seruca, raquel/F-8187-2011; SIEYRO, CRISTINA BILBAO/R-6779-2018; Velho, Sérgia/B-8501-2013; Schwartz, Simo/H-7776-2012; Arango, Diego/AFW-0125-2022; Ramirez-Moreno, Raquel/J-4905-2018; Ramírez, Raquel/GSO-1079-2022; Arango, Diego/M-5667-2016; Woerner, Stefan/A-2187-2010; Davalos, Veronica/AAR-8547-2020; Diaz-Chico, Juan/H-1527-2015; Dopeso, Higinio/H-7575-2019; Davalos, Veronica/S-1668-2016	SIEYRO, CRISTINA BILBAO/0000-0002-4796-1445; Velho, Sérgia/0000-0002-7104-8234; Arango, Diego/0000-0003-2953-3284; Ramirez-Moreno, Raquel/0000-0002-0351-9073; Arango, Diego/0000-0003-2953-3284; Diaz-Chico, Juan/0000-0002-0944-990X; Dopeso, Higinio/0000-0003-0060-1861; Ferreira, Ana/0000-0001-6290-1320; Hofstra, Robert/0000-0001-7498-3829; Seruca, Raquel/0000-0002-8851-4166; Schwartz, Simo/0000-0001-8297-7971; Armengol, Manuel/0000-0002-3211-3195; Espin-Basany, Eloy/0000-0002-9139-4548; Davalos, Veronica/0000-0003-4077-5137; Rodriguez Gonzalez, Francisco G/0000-0002-8509-0804; Perucho, Manuel/0000-0002-2169-2662; Diaz Chico, Bonifacio Nicolas/0000-0001-5633-6185	NATIONAL CANCER INSTITUTE [R37CA063585] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA63585] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alazzouzi H, 2005, CANCER RES, V65, P10170, DOI 10.1158/0008-5472.CAN-05-2580; Batlle E, 2005, NATURE, V435, P1126, DOI 10.1038/nature03626; Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2; Bilbao C, 2006, INT J CANCER, V119, P563, DOI 10.1002/ijc.21862; Duval A, 2002, CANCER RES, V62, P1609; Elowe S, 2001, MOL CELL BIOL, V21, P7429, DOI 10.1128/MCB.21.21.7429-7441.2001; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Guo DL, 2006, CARCINOGENESIS, V27, P454, DOI 10.1093/carcin/bgi259; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Holder N, 1999, DEVELOPMENT, V126, P2033; Huet S., 2003, STAT TOOLS NONLINEAR; Lugli A, 2005, CLIN CANCER RES, V11, P6450, DOI 10.1158/1078-0432.CCR-04-2458; Schwartz S, 1999, CANCER RES, V59, P2995; Woerner SM, 2003, ONCOGENE, V22, P2226, DOI 10.1038/sj.onc.1206421; Yamamoto H, 1999, J EXP CLIN CANC RES, V18, P103	15	35	43	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	2					308	311		10.1038/sj.onc.1209780	http://dx.doi.org/10.1038/sj.onc.1209780			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	124VM	16819508				2022-12-17	WOS:000243398300015
J	Heidenblad, M; Hallor, KH; Staaf, J; Jonsson, G; Borg, A; Hoglund, M; Mertens, F; Mandahl, N				Heidenblad, M.; Hallor, K. H.; Staaf, J.; Jonsson, G.; Borg, A.; Hoglund, M.; Mertens, F.; Mandahl, N.			Genomic profiling of bone and soft tissue tumors with supernumerary ring chromosomes using tiling resolution bacterial artificial chromosome microarrays	ONCOGENE			English	Article						sarcoma; array-based CGH; genome-wide; gene amplification; ring chromosome	MALIGNANT FIBROUS HISTIOCYTOMAS; HUMAN SARCOMAS; LIPOMATOUS TUMORS; HYBRIDIZATION ANALYSIS; DEDIFFERENTIATED LIPOSARCOMAS; PAROSTEAL OSTEOSARCOMA; MARKER CHROMOSOMES; SEQUENCES; IDENTIFICATION; AMPLICON	Ring chromosomes and/or giant marker chromosomes have been observed in a variety of human tumor types, but they are particularly common in a subgroup of mesenchymal tumors of low-grade or borderline malignancy. These rings and markers have been shown to contain amplified material predominantly from 12q13-15, but also sequences from other chromosomes. Such amplified sequences were mapped in detail by genome-wide array comparative genomic hybridization in ring-containing tumor samples from soft tissue (n = 15) and bone (n = 6), using tiling resolution microarrays, encompassing 32 433 bacterial artificial chromosome clones. The DNA copy number profiles revealed multiple amplification targets, in many cases highly discontinuous, leading to delineation of large numbers of very small amplicons. A total number of 356 (median size: 0.64 Mb) amplicons were seen in the soft tissue tumors and 90 (median size: 1.19 Mb) in the bone tumors. Notably, more than 40% of all amplicons in both soft tissue and bone tumors were mapped to chromosome 12, and at least one of the previously reported recurrent amplifications in 12q13.3-14.1 and 12q15.1, including SAS and CDK4, and MDM2, respectively, were present in 85% of the soft tissue tumors and in all of the bone tumors. Although chromosome 12 was the only chromosome displaying recurrent amplification in the bone tumors, the soft tissue tumors frequently showed recurrent amplicons mapping to other chromosomes, that is, 1p32, 1q23-24, 3p11-12, 6q24-25 and 20q11-12. Of particular interest, amplicons containing genes involved in the c-jun NH2-terminal kinase/mitogen-activated protein kinase pathway, that is, JUN in 1p32 and MAP3K7IP2 (TAB2) in 6q24-25, were found to be independently amplified in eight of 11 cases with 12q amplification, providing strong support for the notion that aberrant expression of this pathway is an important step in the dedifferentiation of liposarcomas.	Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden; Univ Lund Hosp, Dept Oncol, SE-22185 Lund, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital	Heidenblad, M (corresponding author), Univ Lund Hosp, Dept Clin Genet, SE-22185 Lund, Sweden.	markus.heidenblad@med.lu.se	Jönsson, Göran/D-1212-2014	Hansen Nord, Karolin/0000-0002-2397-2254; Hoglund, Mattias/0000-0001-9283-4421; Mertens, Fredrik/0000-0002-6278-5232				Autio R, 2003, BIOINFORMATICS, V19, P1714, DOI 10.1093/bioinformatics/btg230; Berner JM, 1996, GENE CHROMOSOME CANC, V17, P254, DOI 10.1002/(SICI)1098-2264(199612)17:4<254::AID-GCC7>3.0.CO;2-2; Chibon F, 2004, GENE CHROMOSOME CANC, V40, P32, DOI 10.1002/gcc.20012; Chibon F, 2002, CANCER GENET CYTOGEN, V139, P24, DOI 10.1016/S0165-4608(02)00614-3; Coindre JM, 2004, J PATHOL, V203, P822, DOI 10.1002/path.1579; Coindre JM, 2003, MODERN PATHOL, V16, P256, DOI 10.1097/01.MP.0000056983.78547.77; Dahlen A, 2003, INT J CANCER, V103, P616, DOI 10.1002/ijc.10864; DALCIN P, 1993, CANCER GENET CYTOGEN, V68, P85, DOI 10.1016/0165-4608(93)90001-3; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P15, DOI 10.1002/gcc.2870140104; Forus A, 1998, BRIT J CANCER, V78, P495, DOI 10.1038/bjc.1998.521; FORUS A, 1995, GENE CHROMOSOME CANC, V14, P8, DOI 10.1002/gcc.2870140103; GAMBERI G, 2000, CLIN ORTHOP RELAT R, V377, P195; Gisselsson D, 2002, GENE CHROMOSOME CANC, V33, P133, DOI 10.1002/gcc.1219; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Jonsson G, 2005, JNCI-J NATL CANCER I, V97, P1377, DOI 10.1093/jnci/dji280; Kanoe H, 1999, ONCOGENE, V18, P721, DOI 10.1038/sj.onc.1202364; Kresse SH, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-39; Mairal A, 1999, CANCER GENET CYTOGEN, V111, P134, DOI 10.1016/S0165-4608(98)00227-1; Mansoor A, 2004, CANCER GENET CYTOGEN, V152, P61, DOI 10.1016/j.cancergencyto.2003.10.004; MELTZER PS, 1991, CELL GROWTH DIFFER, V2, P495; Mertens F, 2004, CYTOGENET GENOME RES, V106, P33, DOI 10.1159/000078557; Mertens F, 1998, GENE CHROMOSOME CANC, V22, P16, DOI 10.1002/(SICI)1098-2264(199805)22:1<16::AID-GCC3>3.0.CO;2-A; Meza-Zepeda LA, 2002, ONCOGENE, V21, P2261, DOI 10.1038/sj.onc.1205339; Meza-Zepeda LA, 2001, GENE CHROMOSOME CANC, V31, P264, DOI 10.1002/gcc.1143; Micci F, 2002, CYTOGENET GENOME RES, V97, P13, DOI 10.1159/000064038; Mitelman F, 2005, MITELMAN DATABASE CH; NILBERT M, 1994, GENE CHROMOSOME CANC, V9, P261, DOI 10.1002/gcc.2870090406; Nilsson M, 2004, INT J CANCER, V109, P363, DOI 10.1002/ijc.11716; ORNDAL C, 1992, CANCER GENET CYTOGEN, V60, P170, DOI 10.1016/0165-4608(92)90011-V; PEDEUTOUR F, 1994, GENE CHROMOSOME CANC, V10, P85, DOI 10.1002/gcc.2870100203; Pedeutour F, 1999, GENE CHROMOSOME CANC, V24, P30, DOI 10.1002/(SICI)1098-2264(199901)24:1<30::AID-GCC5>3.0.CO;2-P; Platzer P, 2002, CANCER RES, V62, P1134; Saal LH, 2002, GENOME BIOL, V3; Sabah M, 2005, VIRCHOWS ARCH, V447, P842, DOI 10.1007/s00428-005-0024-1; Simons A, 2000, CANCER GENET CYTOGEN, V118, P89, DOI 10.1016/S0165-4608(99)00178-8; Sirvent N, 2003, GENE CHROMOSOME CANC, V37, P1, DOI 10.1002/gcc.10202; Smith DI, 2006, CANCER LETT, V232, P48, DOI 10.1016/j.canlet.2005.06.049; Szymanska J, 1996, GENE CHROMOSOME CANC, V16, P31; Szymanska J, 1997, CANCER GENET CYTOGEN, V99, P14, DOI 10.1016/S0165-4608(96)00436-0; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15	40	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2006	25	53					7106	7116		10.1038/sj.onc.1209693	http://dx.doi.org/10.1038/sj.onc.1209693			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	103TV	16732325				2022-12-17	WOS:000241910500010
J	Borgne, A; Versteege, I; Mahe, M; Studeny, A; Leonce, S; Naime, I; Rodriguez, M; Hickman, JA; Meijer, L; Golsteyn, RM				Borgne, A.; Versteege, I.; Mahe, M.; Studeny, A.; Leonce, S.; Naime, I.; Rodriguez, M.; Hickman, J. A.; Meijer, L.; Golsteyn, R. M.			Analysis of cyclin B1 and CDK activity during apoptosis induced by camptothecin treatment	ONCOGENE			English	Article						mitotic catastrophe; cyclins; cyclin-dependent kinases; roscovitine; CYC202; seliciclib; camptothecin	DEPENDENT KINASE-ACTIVITIES; DAMAGE-INDUCED APOPTOSIS; CANCER-CELL-LINES; DNA-DAMAGE; HEMATOPOIETIC-CELLS; MITOTIC CATASTROPHE; PROTEIN-KINASES; TUMOR-CELLS; DEATH; PHOSPHORYLATION	We have studied the role of cyclins and cyclin-dependent kinase (CDK) activity in apoptosis induced by camptothecin (CPT). In this model, 22% of the cells stain for annexin-V at 24 h and then proceed to be 93% positive by 72 h. This time window permits the analysis of cyclins in cells that are committed to apoptosis but not yet dead. We provide evidence that cyclin protein levels and then associated kinase levels increase after CPT treatment. Strikingly, cyclin B1 and cyclin E1 proteins are present at the same time in CPT treated HT29 cells. Although cyclin B1 and E1 CDK complexes are activated in CPT treated cells, only the cyclin B1 complex is required for apoptosis since reduction of cyclin B1 by RNAi or roscovitine treatment reduces the number of annexin-V-stained cells. We have detected poorly organized chromosomes and phosphorylated histone H3 epitopes at the time of maximum cyclin B1/CDK kinase activity in CPT-treated cells, which suggests that these cells enter a mitotic catastrophe. Understanding which CDKs are required for apoptosis may allow us to better adapt CDK inhibitors for use as anti-cancer compounds.	Inst Rech Servier, F-78290 Croissy Sur Seine, France; CNRS, Biol Stn, Roscoff, France	Servier; Institut de Recherches Internationales Servier; Centre National de la Recherche Scientifique (CNRS)	Golsteyn, RM (corresponding author), Inst Rech Servier, 125 Chemin Ronde, F-78290 Croissy Sur Seine, France.	roy.golsteyn@fr.netgrs.com	MEIJER, Laurent/ABE-7465-2021	, laurent/0000-0003-3511-4916				Abal M, 2004, ONCOGENE, V23, P1737, DOI 10.1038/sj.onc.1207299; Adachi S, 2001, MOL CELL BIOL, V21, P4929, DOI 10.1128/MCB.21.15.4929-4937.2001; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Borgne Annie, 2003, Prog Cell Cycle Res, V5, P453; Castedo M, 2002, CELL DEATH DIFFER, V9, P1287, DOI 10.1038/sj.cdd.4401130; Castedo M, 2002, EMBO J, V21, P4070, DOI 10.1093/emboj/cdf391; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; DE LA, 1997, J CELL BIOCHEM, V64, P579; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Golsteyn RM, 2005, CANCER LETT, V217, P129, DOI 10.1016/j.canlet.2004.08.005; Guo M, 1999, CURR OPIN CELL BIOL, V11, P745, DOI 10.1016/S0955-0674(99)00046-0; Hakem A, 1999, J EXP MED, V189, P957, DOI 10.1084/jem.189.6.957; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Harvey KJ, 2000, J CELL BIOL, V148, P59, DOI 10.1083/jcb.148.1.59; Harvey KJ, 1998, MOL CELL BIOL, V18, P2912, DOI 10.1128/MCB.18.5.2912; Hiromura K, 1999, J CLIN INVEST, V103, P597, DOI 10.1172/JCI5461; Hsu SL, 1999, EXP CELL RES, V252, P332, DOI 10.1006/excr.1999.4625; Hyzy M, 2005, BIOCHEM PHARMACOL, V69, P801, DOI 10.1016/j.bcp.2004.11.028; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Konishi Y, 2002, MOL CELL, V9, P1005, DOI 10.1016/S1097-2765(02)00524-5; Leonce S, 2001, MOL PHARMACOL, V60, P1383, DOI 10.1124/mol.60.6.1383; Li KY, 2003, CANCER RES, V63, P3593; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Maity A, 1996, ONCOGENE, V13, P1647; Mazumder S, 2002, MOL CELL BIOL, V22, P2398, DOI 10.1128/MCB.22.7.2398-2409.2002; Mazumder S, 2000, ONCOGENE, V19, P2828, DOI 10.1038/sj.onc.1203623; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Padmanabhan J, 1999, J NEUROSCI, V19, P8747, DOI 10.1523/JNEUROSCI.19-20-08747.1999; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; Porter DC, 2001, MOL CELL BIOL, V21, P6254, DOI 10.1128/MCB.21.18.6254-6269.2001; Porter LA, 2003, BLOOD, V101, P1928, DOI 10.1182/blood-2002-04-1103; Porter LA, 2000, BLOOD, V95, P2645; Price PM, 2004, AM J PHYSIOL-RENAL, V286, pF378, DOI 10.1152/ajprenal.00192.2003; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; Scatena CD, 1998, J BIOL CHEM, V273, P30777, DOI 10.1074/jbc.273.46.30777; Shao RG, 1997, CANCER RES, V57, P4029; Shen Manli, 2002, Zhonghua Zhongliu Zazhi, V24, P215; Shen ML, 2004, CANCER RES, V64, P1607, DOI 10.1158/0008-5472.CAN-03-3321; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; Shi LF, 1996, J IMMUNOL, V157, P2381; SHIMIZU T, 1995, CANCER RES, V55, P228; Shirvan A, 1998, NEUROCHEM RES, V23, P767, DOI 10.1023/A:1022415611545; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; TANIZAWA A, 1994, J NATL CANCER I, V86, P836, DOI 10.1093/jnci/86.11.836; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Yuan JP, 2004, ONCOGENE, V23, P5843, DOI 10.1038/sj.onc.1207757	56	35	36	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2006	25	56					7361	7372		10.1038/sj.onc.1209718	http://dx.doi.org/10.1038/sj.onc.1209718			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16785996				2022-12-17	WOS:000242419100005
J	Cooper, K				Cooper, K.			Rb, whi it's not just for metazoans anymore	ONCOGENE			English	Review						cyclin; cyclin dependent kinases; retinoblastoma; heterodimeric transcription factors; cell cycle; G1 progression	START-SPECIFIC TRANSCRIPTION; YEAST-CELL CYCLE; SACCHAROMYCES-CEREVISIAE; MATING-PHEROMONE; S-PHASE; CLN3-CDC28 KINASE; PROTEIN-KINASE; BUDDING YEAST; G(1) CONTROL; E2F	The E2F family of heterodimeric transcription factors controls the expression of genes required in G1 for cell cycle progression. The retinoblastoma ( Rb) family of pocket proteins which, upon binding to E2F, inhibit this complex from initiating transcription. Upon mitogen stimulation, this repression is relieved by hyperphosphorylation of Rb by the cyclin D Cdk4/6 complex. Initiation of the cell cycle in yeast is similar. The heterodimeric transcription factor SBF controls most G1-specific transcription. Its activation is dependent upon the removal of Whi5; a functional homolog of Rb. Similar to Rb, disassociation of Whi5 from SBF is controlled by G1 cyclin/Cdk-dependent phosphorylation. Although Rb and Whi5 play similar roles in regulating G1 gene expression, they exhibit no sequence homology. This review will discuss the difference and similarities between how these proteins play similar roles in controlling G1 progression.	Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Mol Biol, Stratford, NJ 08084 USA	Rowan University; Rowan University School of Osteopathic Medicine; Rutgers State University New Brunswick; Rutgers State University Medical Center	Cooper, K (corresponding author), Univ Med & Dent New Jersey, Sch Osteopath Med, Dept Mol Biol, 2 Med Ctr Dr, Stratford, NJ 08084 USA.	cooperka@umdnj.edu						AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; Bean CJ, 2001, HUM MOL GENET, V10, P963, DOI 10.1093/hmg/10.9.963; Breeden L, 1996, CURR TOP MICROBIOL, V208, P95; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Cho RJ, 2001, NAT GENET, V27, P48, DOI 10.1038/83751; Cosma MP, 2001, MOL CELL, V7, P1213, DOI 10.1016/S1097-2765(01)00266-0; Costanzo M, 2004, CELL, V117, P899, DOI 10.1016/j.cell.2004.05.024; Costanzo M, 2003, MOL CELL BIOL, V23, P5064, DOI 10.1128/MCB.23.14.5064-5077.2003; CROSS FR, 1995, CURR OPIN CELL BIOL, V7, P790, DOI 10.1016/0955-0674(95)80062-X; CROSS FR, 1990, MOL CELL BIOL, V10, P6482, DOI 10.1128/MCB.10.12.6482; CROSS FR, 1988, MOL CELL BIOL, V8, P4675, DOI 10.1128/MCB.8.11.4675; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; de Bruin RAM, 2004, CELL, V117, P887, DOI 10.1016/j.cell.2004.05.025; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Flick JS, 1998, GENETICS, V148, P33; Frolov MV, 2004, J CELL SCI, V117, P2173, DOI 10.1242/jcs.01227; Geymonat M, 2004, MOL CELL BIOL, V24, P2277, DOI 10.1128/MCB.24.6.2277-2285.2004; Hall DD, 1998, EMBO J, V17, P4370, DOI 10.1093/emboj/17.15.4370; Harrington LA, 1996, NUCLEIC ACIDS RES, V24, P558, DOI 10.1093/nar/24.4.558; HARTWELL LH, 1967, J BACTERIOL, V93, P1662, DOI 10.1128/JB.93.5.1662-1670.1967; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kato M, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-8-r56; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lukas J, 1996, MOL CELL BIOL, V16, P6917; MacKay VL, 2001, MOL CELL BIOL, V21, P4140, DOI 10.1128/MCB.21.13.4140-4148.2001; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; Nasmyth K, 2005, PHILOS T R SOC B, V360, P483, DOI 10.1098/rstb.2004.1604; Nasmyth K, 1996, TRENDS GENET, V12, P405, DOI 10.1016/0168-9525(96)10041-X; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Parviz F, 1998, J BACTERIOL, V180, P4508, DOI 10.1128/JB.180.17.4508-4515.1998; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; RICHARDSON HE, 1989, CELL, V59, P1127, DOI 10.1016/0092-8674(89)90768-X; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Rupes I, 2002, TRENDS GENET, V18, P479, DOI 10.1016/S0168-9525(02)02745-2; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SIDOROVA JM, 1995, MOL BIOL CELL, V6, P1641, DOI 10.1091/mbc.6.12.1641; Siegmund RF, 1996, MOL CELL BIOL, V16, P2647; Stevaux O, 2002, CURR OPIN CELL BIOL, V14, P684, DOI 10.1016/S0955-0674(02)00388-5; STUART D, 1995, GENE DEV, V9, P2780, DOI 10.1101/gad.9.22.2780; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; Ubersax JA, 2003, NATURE, V425, P859, DOI 10.1038/nature02062; Wang XC, 1997, T NONFERR METAL SOC, V7, P45; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WITTENBERG C, 1990, CELL, V62, P225, DOI 10.1016/0092-8674(90)90361-H; Zhang J, 2002, CURR BIOL, V12, P1992, DOI 10.1016/S0960-9822(02)01305-2	55	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 28	2006	25	38					5228	5232		10.1038/sj.onc.1209630	http://dx.doi.org/10.1038/sj.onc.1209630			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077XD	16936741	Bronze			2022-12-17	WOS:000240064100007
J	Kansaku, A; Hirabayashi, S; Mori, H; Fujiwara, N; Kawata, A; Ikeda, M; Rokukawa, C; Kurihara, H; Hata, Y				Kansaku, A.; Hirabayashi, S.; Mori, H.; Fujiwara, N.; Kawata, A.; Ikeda, M.; Rokukawa, C.; Kurihara, H.; Hata, Y.			Ligand-of-Numb protein X is an endocytic scaffold for junctional adhesion molecule 4	ONCOGENE			English	Article						endocytosis; scaffold; cell adhesion	HEPATOCYTE GROWTH-FACTOR; EPITHELIAL-MESENCHYMAL TRANSITION; PHOSPHOTYROSINE-BINDING DOMAIN; ASYMMETRIC CELL-DIVISION; FATE DETERMINANT NUMB; MAMMALIAN NUMB; TIGHT JUNCTION; FAMILY PROTEINS; MDCK CELLS; TGF-BETA	Junctional adhesion molecule 4 (JAM4) is a cell adhesion molecule that interacts with a tight junction protein, membrane-associated guanylate kinase inverted 1 (MAGI-1). Our previous studies suggest that JAM4 is implicated in the regulation of paracellular permeability and the signalings of hepatocyte growth factor. In this study, we performed yeast two-hybrid screening to search for an unidentified JAM4-binding protein and obtained one isoform of Ligand-of-Numb protein X1 (LNX1), LNXp70, that is an interactor of Numb. Ligand-of-Numb protein X1 is expressed in kidney glomeruli and intestinal epithelial cells, where JAM4 is also detected. Immunoprecipitation from kidney lysates supports the in vivo interaction of proteins. Biochemical studies reveal that JAM4 directly binds the second PDZ domain of LNX1 through its carboxyl terminus. Junctional adhesion molecule 4, LNX1 and Numb form a tripartite complex in vitro and are partially colocalized in heterologous cells. Ligand-of-Numb protein X1 facilitates endocytosis of JAM4 and is involved in transforming growth factor beta-induced redistribution of JAM4 in mammary epithelial cells. Experiments using dominant-negative constructs and RNA interference insure that Numb is necessary for the LNX1-mediated endocytosis of JAM4. All these findings indicate that LNX1 provides an endocytic scaffold for JAM4 that is implicated in the reorganization of cell junctions.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Biochem Med, Bunkyo Ku, Tokyo, Japan; Juntendo Univ, Sch Med, Dept Anat, Tokyo 113, Japan	Tokyo Medical & Dental University (TMDU); Juntendo University	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Biochem Med, Bunkyo Ku, 15-45 Yushima, Tokyo, Japan.	yuhammch@med.tmd.ac.jp						Beckers J, 1999, MECH DEVELOP, V84, P165, DOI 10.1016/S0925-4773(99)00065-9; Berdnik D, 2002, DEV CELL, V3, P221, DOI 10.1016/S1534-5807(02)00215-0; Cayouette M, 2001, J NEUROSCI, V21, P5643, DOI 10.1523/JNEUROSCI.21-15-05643.2001; Cereijido M, 2000, AM J PHYSIOL-GASTR L, V279, pG477, DOI 10.1152/ajpgi.2000.279.3.G477; Coyne CB, 2005, ADV DRUG DELIVER REV, V57, P869, DOI 10.1016/j.addr.2005.01.007; Dejana E, 2000, INT J DEV BIOL, V44, P743; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Dho SE, 1998, J BIOL CHEM, V273, P9179, DOI 10.1074/jbc.273.15.9179; Dievart A, 1999, ONCOGENE, V18, P5973, DOI 10.1038/sj.onc.1202991; Feldman GJ, 2005, ADV DRUG DELIVER REV, V57, P883, DOI 10.1016/j.addr.2005.01.009; Fre S, 2005, NATURE, V435, P964, DOI 10.1038/nature03589; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Guo M, 1996, NEURON, V17, P27, DOI 10.1016/S0896-6273(00)80278-0; Heiz M, 2004, J BIOL CHEM, V279, P31149, DOI 10.1074/jbc.M403587200; Hirabayashi S, 2003, MOL CELL BIOL, V23, P4267, DOI 10.1128/MCB.23.12.4267-4282.2003; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Jensen J, 2000, NAT GENET, V24, P36, DOI 10.1038/71657; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Mandell KJ, 2005, ADV DRUG DELIVER REV, V57, P857, DOI 10.1016/j.addr.2005.01.005; McCright B, 2001, DEVELOPMENT, V128, P491; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Mirza M, 2005, EXP CELL RES, V309, P110, DOI 10.1016/j.yexcr.2005.05.023; Mori H, 2004, GENES CELLS, V9, P811, DOI 10.1111/j.1365-2443.2004.00765.x; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; Nie J, 2004, J BIOL CHEM, V279, P20807, DOI 10.1074/jbc.M311396200; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Politi K, 2004, SEMIN CANCER BIOL, V14, P341, DOI 10.1016/j.semcancer.2004.04.013; Pollack AL, 2004, AM J PHYSIOL-CELL PH, V286, pC482, DOI 10.1152/ajpcell.00377.2003; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Rice DS, 2001, MOL CELL NEUROSCI, V18, P525, DOI 10.1006/mcne.2001.1024; Roegiers F, 2004, CURR OPIN CELL BIOL, V16, P195, DOI 10.1016/j.ceb.2004.02.010; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805; Santolini E, 2000, J CELL BIOL, V151, P1345, DOI 10.1083/jcb.151.6.1345; Schneeberger EE, 2004, AM J PHYSIOL-CELL PH, V286, pC1213, DOI 10.1152/ajpcell.00558.2003; Smith CA, 2004, MOL BIOL CELL, V15, P3698, DOI 10.1091/mbc.E04-01-0026; Sollerbrant K, 2003, J BIOL CHEM, V278, P7439, DOI 10.1074/jbc.M205927200; Spana EP, 1996, NEURON, V17, P21, DOI 10.1016/S0896-6273(00)80277-9; STOKER M, 1985, J CELL SCI, V77, P209; Tajima M, 2003, GENES CELLS, V8, P759, DOI 10.1046/j.1365-2443.2003.00673.x; Tanaka Y, 2002, BIOCHEM BIOPH RES CO, V299, P472, DOI 10.1016/S0006-291X(02)02681-5; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VANITALLIE CM, 2005, ANN REV PHYSL; Verdi J, 1996, CURR BIOL, V6, P1134, DOI 10.1016/S0960-9822(02)70680-5; Wakamatsu Y, 1999, NEURON, V23, P71, DOI 10.1016/S0896-6273(00)80754-0; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang YW, 2003, J CELL BIOCHEM, V88, P408, DOI 10.1002/jcb.10358; Zhong WM, 1996, NEURON, V17, P43, DOI 10.1016/S0896-6273(00)80279-2	57	35	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 24	2006	25	37					5071	5084		10.1038/sj.onc.1209468	http://dx.doi.org/10.1038/sj.onc.1209468			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16832352	Bronze			2022-12-17	WOS:000240063700001
J	Ellerhorst, JA; Ekmekcioglu, S; Johnson, MK; Cooke, CP; Johnson, MM; Grimm, EA				Ellerhorst, J. A.; Ekmekcioglu, S.; Johnson, M. K.; Cooke, C. P.; Johnson, M. M.; Grimm, E. A.			Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma	ONCOGENE			English	Article						N-Ras; B-Raf; ERK; iNOS; melanoma	NITRIC-OXIDE SYNTHASE; KAPPA-B; RAS MUTATIONS; N-RAS; MELANOCYTIC LESIONS; TUMOR PROGRESSION; GENE-EXPRESSION; BRAF GENE; CANCER; CELLS	Activating mutations of the genes for NRAS and BRAF, components of the p44/42 mitogen-activated protein kinase (MAPK) pathway, are common findings in melanoma. Recent evidence in several nonmelanoma cell systems supports the regulation of the inducible nitric oxide synthase ( iNOS) gene by this pathway. On the basis of our data showing that melanoma iNOS expression predicts shortened patient survival, we formulated the hypothesis that activating mutations of NRAS or BRAF, which lead to constitutive activation of the p44/42 MAPK pathway, drive iNOS expression in human melanoma. In the present study, we have shown that inhibition of melanoma iNOS activity by S-methylisothiourea leads to decreased cell proliferation, confirming the importance of iNOS activity for melanoma cell growth. Regulation of melanoma iNOS expression by the p44/42 MAPK pathway was demonstrated by inhibition of the pathway by U0126, and by BRAF RNA interference. To explore this regulatory pathway in human tissue, 20 melanoma tumors were examined for NRAS and BRAF mutations, immunohistochemical evidence of ERK phosphorylation, and iNOS expression. A significant association was found among these three features. We conclude that in human melanoma, activating mutations of NRAS and BRAF drive constitutive iNOS expression and, implicitly, nitric oxide production, contributing to the poor survival of these patients.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Ellerhorst, JA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, 1515 Holcombe Blvd,Unit 362, Houston, TX 77030 USA.	jaellerh@mdanderson.org	Ekmekcioglu, Suhendan/A-9686-2009		NCI NIH HHS [P50 CA093459, CA16672, R01 CA90282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090282, P30CA016672, P50CA093459] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bhat NR, 2002, BRAIN RES, V948, P93, DOI 10.1016/S0006-8993(02)02953-0; Brose MS, 2002, CANCER RES, V62, P6997; Colasanti M, 2000, TRENDS PHARMACOL SCI, V21, P249, DOI 10.1016/S0165-6147(00)01499-1; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x; Ekmekcioglu S, 2003, MOL CANCER THER, V2, P9; Ekmekcioglu S, 2000, CLIN CANCER RES, V6, P4768; Gay RD, 1998, BBA-GENE STRUCT EXPR, V1443, P315, DOI 10.1016/S0167-4781(98)00234-6; Goodall J, 2004, MOL CELL BIOL, V24, P2923, DOI 10.1128/MCB.24.7.2923-2931.2004; Gorden A, 2003, CANCER RES, V63, P3955; Guan KL, 2000, J BIOL CHEM, V275, P27354; Jaramillo M, 2003, J IMMUNOL, V171, P4243, DOI 10.4049/jimmunol.171.8.4243; JENKINS DC, 1995, P NATL ACAD SCI USA, V92, P4392, DOI 10.1073/pnas.92.10.4392; Jiang BB, 2004, J BIOL CHEM, V279, P1323, DOI 10.1074/jbc.M307521200; Kleinert H, 2003, BIOL CHEM, V384, P1343, DOI 10.1515/BC.2003.152; Kristof AS, 2001, J BIOL CHEM, V276, P8445, DOI 10.1074/jbc.M009563200; Liu XJ, 2002, J BIOL CHEM, V277, P39312, DOI 10.1074/jbc.M205107200; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Massi D, 2001, J PATHOL, V194, P194, DOI 10.1002/1096-9896(200106)194:2<194::AID-PATH851>3.0.CO;2-S; Mercer KE, 2003, BBA-REV CANCER, V1653, P25, DOI 10.1016/S0304-419X(03)00016-7; Omholt K, 2002, CLIN CANCER RES, V8, P3468; Park SK, 1997, BIOCHEM J, V322, P609, DOI 10.1042/bj3220609; Perrotta C, 2004, CANCER RES, V64, P3767, DOI 10.1158/0008-5472.CAN-04-0668; Salvucci O, 2001, CANCER RES, V61, P318; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; SZABO C, 1994, P NATL ACAD SCI USA, V91, P12472, DOI 10.1073/pnas.91.26.12472; Tang CH, 2004, J BIOL CHEM, V279, P288, DOI 10.1074/jbc.M310821200; Wink DA, 1998, FREE RADICAL BIO MED, V25, P434, DOI 10.1016/S0891-5849(98)00092-6; Wink DA, 2003, FREE RADICAL BIO MED, V34, P951, DOI 10.1016/S0891-5849(02)01362-X; Yazdi AS, 2003, J INVEST DERMATOL, V121, P1160, DOI 10.1046/j.1523-1747.2003.12559.x; Zheng MZ, 2004, MELANOMA RES, V14, P165, DOI 10.1097/01.cmr.0000129374.76399.19	31	35	40	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3956	3962		10.1038/sj.onc.1209419	http://dx.doi.org/10.1038/sj.onc.1209419			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474847				2022-12-17	WOS:000238668800009
J	Lu, Z; Lam, KS; Wang, N; Xu, X; Cortes, M; Andersen, B				Lu, Z.; Lam, K. S.; Wang, N.; Xu, X.; Cortes, M.; Andersen, B.			LMO4 can interact with Smad proteins and modulate transforming growth factor-beta signaling in epithelial cells	ONCOGENE			English	Article						LMO4; transforming growth factor-beta; Smads; mammary gland epithelial cells; cellular proliferation	LIM-ONLY PROTEIN; HOMEODOMAIN TRANSCRIPTION FACTORS; DOMAIN-BINDING-PROTEIN; NEURAL-TUBE CLOSURE; ACTIVITY IN-VIVO; ADULT-MOUSE; PLASMINOGEN-ACTIVATOR; MAMMARY-GLAND; KNOCKOUT MICE; BREAST-CANCER	LIM- only protein 4 ( LMO4) plays critical roles in mammalian development, and has been proposed to play roles in epithelial oncogenesis, including breast cancer. As LMO4 is highly expressed in the epithelial compartments at locations of active mesenchymal - epithelial interactions, we reasoned that LMO4 might act by modulating signaling pathways involved in mesenchymal - epithelial signaling. One such candidate signal is the transforming growth factor- beta ( TGF beta) cytokine pathway, which plays important roles both in development and cancer. We show here that the transcriptional response to TGFb in epithelial cells is sensitive to LMO4 levels; both up- and downregulation of LMO4 can enhance TGF beta signaling as assessed by a TGF beta- responsive reporter gene. Furthermore, LMO4 can interact with the MH1 and linker domains of receptor- mediated Smad proteins, and associate with the endogenous TGF beta- responsive Plasminogen Activator Inhibitor- 1 gene promoter in a TGF beta- dependent manner, suggesting that such interactions may mediate the effects of LMO4 on TGFb signaling. When introduced into mammary epithelial cells, LMO4 potentiated the growth- inhibitory effects of TGF beta in those cells. These results de. ne a new function for LMO4 as a coactivator in TGFb signaling, and provide a potential novel mechanism for LMO4- mediated regulation in development and oncogenesis.	Univ Calif Irvine, Dept Med, Div Endocrinol, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92717 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Andersen, B (corresponding author), Univ Calif Irvine, Dept Med, Div Endocrinol, Sprague Hall,Room 206, Irvine, CA 92697 USA.	bogi@uci.edu	Lu, ZX/G-4586-2010		NIAMS NIH HHS [AR44882] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044882] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Agulnick AD, 1996, NATURE, V384, P270, DOI 10.1038/384270a0; Aoyama M, 2005, CANCER RES, V65, P4587, DOI 10.1158/0008-5472.CAN-04-4630; Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Bach I, 1999, NAT GENET, V22, P394, DOI 10.1038/11970; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; Bach I, 1997, GENE DEV, V11, P1370, DOI 10.1101/gad.11.11.1370; Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; Chang H, 1999, DEVELOPMENT, V126, P1631; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; de la Calle-Mustienes E, 2003, DEV BIOL, V264, P564, DOI 10.1016/j.ydbio.2003.09.002; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Dong-Le Bourhis X, 1998, BRIT J CANCER, V77, P396, DOI 10.1038/bjc.1998.63; Grutz G, 1998, ONCOGENE, V17, P2799, DOI 10.1038/sj.onc.1202502; Hahm KM, 2004, MOL CELL BIOL, V24, P2074, DOI 10.1128/MCB.24.5.2074-2082.2004; Hata A, 1997, NATURE, V388, P82, DOI 10.1038/40424; Hermanson O, 1999, CELL MOL BIOL, V45, P677; Hinks GL, 1997, J NEUROSCI, V17, P5549; Jurata LW, 1996, P NATL ACAD SCI USA, V93, P11693, DOI 10.1073/pnas.93.21.11693; Kenny DA, 1998, P NATL ACAD SCI USA, V95, P11257, DOI 10.1073/pnas.95.19.11257; Kudryavtseva EI, 2003, DEV DYNAM, V226, P604, DOI 10.1002/dvdy.10255; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; Lee K, 2004, J IMMUNOL, V172, P6539, DOI 10.4049/jimmunol.172.11.6539; Lee SK, 2003, NEURON, V38, P731, DOI 10.1016/S0896-6273(03)00296-4; Lee SK, 2005, MOL CELL NEUROSCI, V28, P205, DOI 10.1016/j.mcn.2004.04.010; Lin KK, 2004, P NATL ACAD SCI USA, V101, P15955, DOI 10.1073/pnas.0407114101; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Manetopoulos C, 2003, BIOCHEM BIOPH RES CO, V307, P891, DOI 10.1016/S0006-291X(03)01298-1; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Matsuda K, 2002, CANCER RES, V62, P5611; Matthews JM, 2003, EMBO REP, V4, P1132, DOI 10.1038/sj.embor.7400030; McMahon JA, 1998, GENE DEV, V12, P1438, DOI 10.1101/gad.12.10.1438; Milan M, 1999, MOL CELL, V4, P267, DOI 10.1016/S1097-2765(00)80374-3; Milan M, 1998, GENE DEV, V12, P2912, DOI 10.1101/gad.12.18.2912; Milan M, 2000, DEVELOPMENT, V127, P3069; Mizunuma H, 2003, BRIT J CANCER, V88, P1543, DOI 10.1038/sj.bjc.6600952; Mousses S, 2002, CANCER RES, V62, P1256; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Rabbitts TH, 1998, GENE DEV, V12, P2651, DOI 10.1101/gad.12.17.2651; Racevskis J, 1999, BBA-GENE STRUCT EXPR, V1445, P148, DOI 10.1016/S0167-4781(99)00037-8; Ramain P, 2000, MOL CELL, V6, P781, DOI 10.1016/S1097-2765(05)00079-1; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Sugihara TM, 2001, J BIOL CHEM, V276, P33036, DOI 10.1074/jbc.M103000200; Sugihara TM, 1998, P NATL ACAD SCI USA, V95, P15418, DOI 10.1073/pnas.95.26.15418; Sum EYM, 2005, P NATL ACAD SCI USA, V102, P7659, DOI 10.1073/pnas.0502990102; Sum EYM, 2005, J HISTOCHEM CYTOCHEM, V53, P475, DOI 10.1369/jhc.4A6553.2005; Sum EYM, 2005, ONCOGENE, V24, P4820, DOI 10.1038/sj.onc.1208638; Sum EYM, 2002, J BIOL CHEM, V277, P7849, DOI 10.1074/jbc.M110603200; Thaler JP, 2002, CELL, V110, P237, DOI 10.1016/S0092-8674(02)00823-1; Torigoi E, 2000, P NATL ACAD SCI USA, V97, P2686, DOI 10.1073/pnas.050586397; Tse E, 2004, MOL CELL BIOL, V24, P2063, DOI 10.1128/MCB.24.5.2063-2073.2004; van Meyel DJ, 1999, MOL CELL, V4, P259, DOI 10.1016/S1097-2765(00)80373-1; Visvader JE, 1997, P NATL ACAD SCI USA, V94, P13707, DOI 10.1073/pnas.94.25.13707; Visvader JE, 2001, P NATL ACAD SCI USA, V98, P14452, DOI 10.1073/pnas.251547698; WADMAN I, 1994, EMBO J, V13, P4831, DOI 10.1002/j.1460-2075.1994.tb06809.x; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wang N, 2004, ONCOGENE, V23, P1507, DOI 10.1038/sj.onc.1207288; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Yamada Y, 1998, P NATL ACAD SCI USA, V95, P3890, DOI 10.1073/pnas.95.7.3890; Zeng CY, 1998, P NATL ACAD SCI USA, V95, P10637, DOI 10.1073/pnas.95.18.10637	63	35	37	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2006	25	20					2920	2930		10.1038/sj.onc.1209318	http://dx.doi.org/10.1038/sj.onc.1209318			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	041IN	16331278				2022-12-17	WOS:000237448200010
J	Bastien, J; Plassat, JL; Payrastre, B; Rochette-Egly, C				Bastien, J; Plassat, JL; Payrastre, B; Rochette-Egly, C			The phosphoinositide 3-kinase/Akt pathway is essential for the retinoic acid-induced differentiation of F9 cells	ONCOGENE			English	Article						retinoic acid receptors; PI3K; Akt; p85 alpha; F9 cells	PROTEIN-KINASE; SIGNALING PATHWAY; DEPENDENT MECHANISM; LEUKEMIA-CELLS; BREAST-CANCER; RAR-GAMMA; ACTIVATION; PHOSPHORYLATION; PKB/AKT; BETA	Retinoic acid ( RA) induces cell growth arrest and differentiation through two families of nuclear receptors, the RARs and the RXRs. The phosphoinositide 3-kinase (PI3K)/Akt pathway also plays key roles in these processes, that is, cell cycle progression, cell differentiation and cell survival. We report that, in mouse embryocarcinoma cells (F9 cells), RA induces an early activation of PI3K and Akt via an increase in the expression of the p85 alpha regulatory subunit. This effect is followed by an inhibition of Akt. Both effects require the integrity of the RA pathway as they are not observed in RA-resistant RAR gamma null cells. We propose a model through which RA induces a biphasic regulation of Akt with an activation participitating to the differentiation process, followed by an inhibition, which has been correlated to the RA-induced growth arrest.	CU Strasbourg, Dept Cell Biol & Signal Transduct, IGBMC, CNRS,INSERM,ULP, F-67404 Illkirch Graffenstaden, France; CHU Purpan, CPTP, Unite INSERM 563, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Rochette-Egly, C (corresponding author), CU Strasbourg, Dept Cell Biol & Signal Transduct, IGBMC, CNRS,INSERM,ULP, BP 10142, F-67404 Illkirch Graffenstaden, France.	cegly@igbmc.u-strasbg.fr		, Bernard/0000-0002-8693-0190				Antonyak MA, 2002, J BIOL CHEM, V277, P14712, DOI 10.1074/jbc.M112259200; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bour G, 2005, J BIOL CHEM, V280, P17027, DOI 10.1074/jbc.M501344200; Bovenzi V, 1999, ANTI-CANCER DRUG, V10, P471, DOI 10.1097/00001813-199906000-00007; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Cabane C, 2004, CELL SIGNAL, V16, P1405, DOI 10.1016/j.cellsig.2004.05.003; Calautti E, 2005, J BIOL CHEM, V280, P32856, DOI 10.1074/jbc.M506119200; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carter CA, 2003, EXP MOL PATHOL, V75, P34, DOI 10.1016/S0014-4800(03)00033-9; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; del Rincon SV, 2004, ONCOGENE, V23, P9269, DOI 10.1038/sj.onc.1208104; del Rincon SV, 2003, ONCOGENE, V22, P3353, DOI 10.1038/sj.onc.1206485; Di-Poi N, 2002, MOL CELL, V10, P721, DOI 10.1016/S1097-2765(02)00646-9; Farias EF, 2005, ONCOGENE, V24, P1598, DOI 10.1038/sj.onc.1208347; Feng JH, 2004, J BIOL CHEM, V279, P41189, DOI 10.1074/jbc.M406731200; Gonzalez I, 2004, MOL CELL BIOL, V24, P3607, DOI 10.1128/MCB.24.9.3607-3622.2004; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; Hanada M, 2004, BBA-PROTEINS PROTEOM, V1697, P3, DOI 10.1016/j.bbapap.2003.11.009; Ishida S, 2004, BIOCHEM PHARMACOL, V68, P2177, DOI 10.1016/j.bcp.2004.08.017; Kang S, 2005, CELL CYCLE, V4, P578, DOI 10.4161/cc.4.4.1593; Kocki J, 2003, J APPL GENET, V44, P553; Lal L, 2005, BLOOD, V105, P1669, DOI 10.1182/blood-2004-06-2078; Laudet V, 2002, NUCL RECEPTOR FACTSB; Leslie NR, 2002, CELL SIGNAL, V14, P285, DOI 10.1016/S0898-6568(01)00234-0; Lopez-Carballo G, 2002, J BIOL CHEM, V277, P25297, DOI 10.1074/jbc.M201869200; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Neri LM, 2003, MOL CANCER RES, V1, P234; Oridate N, 1996, ONCOGENE, V12, P2019; Parent CA, 2002, CELL, V109, P541, DOI 10.1016/S0092-8674(02)00765-1; Payrastre B, 2001, CELL SIGNAL, V13, P377, DOI 10.1016/S0898-6568(01)00158-9; Puscheck EE, 1998, MOL REPROD DEV, V49, P386, DOI 10.1002/(SICI)1098-2795(199804)49:4&lt;386::AID-MRD5&gt;3.0.CO;2-J; Rieusset J, 2001, FEBS LETT, V502, P98, DOI 10.1016/S0014-5793(01)02674-6; Rochette-Egly C, 2001, HISTOL HISTOPATHOL, V16, P909, DOI 10.14670/HH-16.909; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarker KP, 2004, ONCOGENE, V23, P6064, DOI 10.1038/sj.onc.1207819; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; Tari AM, 2002, ONCOGENE, V21, P5224, DOI 10.1038/sj.onc.1205660; Ueki K, 2003, J BIOL CHEM, V278, P48453, DOI 10.1074/jbc.M305602200; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839	42	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2040	2047		10.1038/sj.onc.1209241	http://dx.doi.org/10.1038/sj.onc.1209241			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16288212				2022-12-17	WOS:000236359700007
J	Vinall, RL; Tepper, CG; Shi, XB; Xue, LA; Gandour-Edwards, R; White, RWV				Vinall, RL; Tepper, CG; Shi, XB; Xue, LA; Gandour-Edwards, R; White, RWV			The R273H p53 mutation can facilitate the androgen-independent growth of LNCaP by a mechanism that involves H2 relaxin and its cognate receptor LGR7	ONCOGENE			English	Article						mutant p53; prostate cancer; relaxin	GAIN-OF-FUNCTION; REFRACTORY PROSTATE-CANCER; PROTEIN-COUPLED RECEPTORS; SUPPRESSOR GENE P53; MUTANT P53; FUNCTION PHENOTYPE; FACTOR-I; CELLS; EXPRESSION; CARCINOMA	Mutations in p53 occur at a rate of approximately 70% in hormone-refractory prostate cancer (CaP), suggesting that p53 mutations facilitate the progression of CaP to androgen-independent ( AI) growth. We have previously reported that transfection of p53 gain of function mutant alleles into LNCaP, an androgen-sensitive cell line, allows for AI growth of LNCaP in vitro. We herein confirm the in vivo relevance of those findings by demonstrating that the R273H p53 mutation ( p53(R273H)) facilitates AI growth in castrated nude mice. In addition, we demonstrate that H2 relaxin is responsible for facilitating p53(R273H)-mediated AI CaP. H2 relaxin is overexpressed in the LNCaP-R273H subline. Downregulation of H2 relaxin expression results in significant inhibition of AI growth, whereas addition of recombinant human H2 relaxin to parental LNCaP promotes AI growth. Inhibition of AI growth was also achieved by blocking expression of LGR7, the cognate receptor of H2 relaxin. Chromatin immunoprecipitation analysis was used to demonstrate that p53(R273H) binds directly to the relaxin promoter, further confirming a role for H2 relaxin signaling in p53(R273H)-mediated AI CaP. Lastly, we used a reporter gene assay to demonstrate that H2 relaxin can induce the expression of prostate-specific antigen via an androgen receptor-mediated pathway.	Univ Calif Davis, Med Ctr, Dept Urol, Sch Med & Canc Ctr, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med & Canc Ctr, Dept Biol Chem, Sacramento, CA 95817 USA; Univ Calif Davis, Sch Med & Canc Ctr, Dept Pathol, Sacramento, CA USA	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis	White, RWV (corresponding author), Univ Calif Davis, Med Ctr, Dept Urol, Sch Med & Canc Ctr, 4860 Y St,Suite 3500, Sacramento, CA 95817 USA.	ralph.devere-white@ucdmc.ucdavis.edu	Vinall, Ruth/L-7026-2019; Tepper, Clifford G/H-6527-2011		NATIONAL CANCER INSTITUTE [R01CA077612] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA77612] Funding Source: Medline; PHS HHS [R0192069] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Amorino GP, 2004, CRIT REV EUKAR GENE, V14, P287, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i4.40; Bartsch O, 2001, MOL HUM REPROD, V7, P799, DOI 10.1093/molehr/7.9.799; Bathgate RAD, 2003, TRENDS ENDOCRIN MET, V14, P207, DOI 10.1016/S1043-2760(03)00081-X; Cadwell C, 2001, GENE, V277, P15, DOI 10.1016/S0378-1119(01)00696-5; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; Culig Z, 2005, ENDOCR-RELAT CANCER, V12, P229, DOI 10.1677/erc.1.00775a; CULIG Z, 1994, CANCER RES, V54, P5474; DEB S, 1992, J VIROL, V66, P6164, DOI 10.1128/JVI.66.10.6164-6170.1992; DEB SP, 1994, ONCOGENE, V9, P1341; DINJENS WNM, 1994, INT J CANCER, V56, P630, DOI 10.1002/ijc.2910560504; El-Hizawi S, 2002, CANCER RES, V62, P3264; Figueiredo KA, 2005, ANN NY ACAD SCI, V1041, P320, DOI 10.1196/annals.1282.051; Garibay-Tupas JL, 2000, J MOL ENDOCRINOL, V24, P241, DOI 10.1677/jme.0.0240241; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HEIDENBERG HB, 1995, J UROLOGY, V154, P414, DOI 10.1016/S0022-5347(01)67065-4; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Huggins C, 1972, CA Cancer J Clin, V22, P232, DOI 10.3322/canjclin.22.4.232; IVELL R, 1989, MOL CELL ENDOCRINOL, V66, P251, DOI 10.1016/0303-7207(89)90037-3; Ivell R, 2002, TRENDS ENDOCRIN MET, V13, P343, DOI 10.1016/S1043-2760(02)00664-1; Kasamon KM, 2004, CURR OPIN UROL, V14, P185, DOI 10.1097/00042307-200405000-00008; Koul HK, 2004, ANN NY ACAD SCI, V1030, P243, DOI 10.1196/annals.1329.030; KYPRIANOU N, 1990, CANCER RES, V50, P3748; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NAVONE NM, 1993, J NATL CANCER I, V85, P1657, DOI 10.1093/jnci/85.20.1657; Nesslinger NJ, 2003, CANCER RES, V63, P2228; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Palejwala S, 2002, BIOL REPROD, V66, P1743, DOI 10.1095/biolreprod66.6.1743; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Raj GV, 2002, J UROLOGY, V167, P1458, DOI 10.1016/S0022-5347(05)65345-1; Roemer K, 1999, BIOL CHEM, V380, P879, DOI 10.1515/BC.1999.108; Samuel CS, 2003, LAB INVEST, V83, P1055, DOI 10.1097/01.LAB.0000079784.81186.B9; Scian MJ, 2004, ONCOGENE, V23, P4430, DOI 10.1038/sj.onc.1207553; Shah RB, 2004, CANCER RES, V64, P9209, DOI 10.1158/0008-5472.CAN-04-2442; Sherwood OD, 2004, ENDOCR REV, V25, P205, DOI 10.1210/er.2003-0013; Shi XB, 2004, BJU INT, V94, P996, DOI 10.1111/j.1464-410X.2004.05093.x; Shi XB, 2004, PROSTATE, V60, P257, DOI 10.1002/pros.20039; Shi XB, 2002, PROSTATE, V51, P59, DOI 10.1002/pros.10072; Silvertown JD, 2006, INT J CANCER, V118, P62, DOI 10.1002/ijc.21288; Silvertown JD, 2003, INT J CANCER, V107, P513, DOI 10.1002/ijc.11424; Silvertown JD, 2003, ENDOCRINOLOGY, V144, P3683, DOI 10.1210/en.2003-0248; STEMMERMANN GN, 1994, J ENDOCRINOL, V140, P321, DOI 10.1677/joe.0.1400321; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; TASHIMA LS, 1994, J MOL ENDOCRINOL, V12, P351, DOI 10.1677/jme.0.0120351; Tepper CG, 2005, PROSTATE, V65, P375, DOI 10.1002/pros.20308; van Oijen MGCT, 2000, CLIN CANCER RES, V6, P2138; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Zhang Q, 2002, J CELL BIOCHEM, V85, P536, DOI 10.1002/jcb.10150; AFFYMETRIX GENECHIP	55	35	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2082	2093		10.1038/sj.onc.1209246	http://dx.doi.org/10.1038/sj.onc.1209246			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16434975				2022-12-17	WOS:000236359700011
J	McCormick, F				McCormick, F			Future prospects for oncolytic therapy	ONCOGENE			English	Review						oncolytic viruses; adenovirus; targeted therapy; oncology	AGENTS; POTENT	Viruses have been engineered to replicate selectively in cancer cells, based on a number of innovative principles. Several of these viruses have entered clinical trials and have proven relatively safe, and have shown evidence of efficacy. However, further research is required to enable these agents to function systemically. This might involve attempts to suppress immune responses to virus antigens, and re-targeting of viruses to favor tumor infection and increased potency. When these barriers are overcome, oncolytic viruses could enter the mainstream of clinical oncology.	Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA	University of California System; University of California San Francisco	McCormick, F (corresponding author), Univ Calif San Francisco, Canc Res Inst, 2340 Sutter St, San Francisco, CA 94115 USA.	mccormick@cc.ucsf.edu						Aghi M, 2005, ONCOGENE, V24, P7802, DOI 10.1038/sj.onc.1209037; Fueyo J, 2003, J NATL CANCER I, V95, P652, DOI 10.1093/jnci/95.9.652; Heise C, 2000, NAT MED, V6, P1134, DOI 10.1038/80474; Johnson L, 2002, CANCER CELL, V1, P325, DOI 10.1016/S1535-6108(02)00060-0; Ko D, 2005, ONCOGENE, V24, P7763, DOI 10.1038/sj.onc.1209048; McCormick F, 2001, NAT REV CANCER, V1, P130, DOI 10.1038/35101008; Nemunaitis J, 2002, CANCER GENE THER, V9, P987, DOI 10.1038/sj.cgt.7700547; O'Shea CC, 2004, CANCER CELL, V6, P611, DOI 10.1016/j.ccr.2004.11.012; Reid T, 2001, GENE THER, V8, P1618, DOI 10.1038/sj.gt.3301512; Reid T, 2002, CANCER GENE THER, V9, P979, DOI 10.1038/sj.cgt.7700539; YU C, 2001, CANCER RES, V61, P5453	11	35	36	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 21	2005	24	52					7817	7819		10.1038/sj.onc.1209064	http://dx.doi.org/10.1038/sj.onc.1209064			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	985JD	16299540	Bronze			2022-12-17	WOS:000233372600016
J	Loughran, G; Huigsloot, M; Kiely, PA; Smith, LM; Floyd, S; Ayllon, V; O'Connor, R				Loughran, G; Huigsloot, M; Kiely, PA; Smith, LM; Floyd, S; Ayllon, V; O'Connor, R			Gene expression profiles in cells transformed by overexpression of the IGF-I receptor	ONCOGENE			English	Article						IGF-I receptor; cancer; transformation; apoptosis; Mystique; lasp-1	INSULIN-LIKE-GROWTH; BREAST-CANCER; HEMATOPOIETIC-CELLS; MICROARRAY ANALYSIS; PROSTATE-CANCER; PROTEIN FAMILY; ANTISENSE RNA; FIBROBLASTS; BINDING; IDENTIFICATION	To identify genes associated with insulin-like growth factor-I receptor ( IGF-IR)-mediated cellular transformation, we isolated genes that are differentially expressed in R- cells ( derived from the IGF-IR knockout mouse) and R+ cells ( R- cells that overexpress the IGF-IR). From these, 45 genes of known function were expressed at higher levels in R+ cells and 22 were expressed at higher levels in R- cells. Differential expression was confirmed by Northern blot analysis of R+ and R+ cells. Genes expressed more abundantly in R+ cells are associated with ( 1) tumour growth and metastasis including, beta ig H3, mts1, igfbp5 protease, and mystique; ( 2) cell division, including cyclin A1 and cdk1; ( 3) signal transduction, including pkc delta bp and lmw-ptp; and ( 4) metabolism including ATPase H+ transporter and ferritin. In MCF-7 cells IGF-I induced expression of two genes, lasp-1 and mystique, which could contribute to metastasis. Lasp-1 expression required activity of the PI3-kinase signalling pathway. Mystique was highly expressed in metastatic but not in androgen-dependent prostate cancer cell lines and Mystique overexpression in MCF-7 cells promoted cell migration and invasion. We conclude that genes identified in this screen may mediate IGF-IR function in cancer progression.	Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Cork, Ireland	University College Cork	O'Connor, R (corresponding author), Natl Univ Ireland Univ Coll Cork, BioSci Inst, Dept Biochem, Cell Biol Lab, Cork, Ireland.	r.oconnor@ucc.ie	Loughran, Gary/AAQ-8791-2020; O'Connor, Rosemary/B-7902-2014; Ayllon, Veronica/L-7069-2014	Loughran, Gary/0000-0002-2683-5597; O'Connor, Rosemary/0000-0002-0687-3422; Ayllon, Veronica/0000-0002-7322-9282; Atkins, John/0000-0001-7933-0165				Ambartsumian NS, 1996, ONCOGENE, V13, P1621; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dunn SE, 1998, CANCER RES, V58, P3353; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FIASCHI T, 2001, J BIOL CHEM, V10, P10; FLIER JS, 1986, P NATL ACAD SCI USA, V83, P664, DOI 10.1073/pnas.83.3.664; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hellawell GO, 2002, CANCER RES, V62, P2942; Izumi Y, 1997, J BIOL CHEM, V272, P7381, DOI 10.1074/jbc.272.11.7381; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; Lee CT, 1996, CANCER RES, V56, P3038; LeRoith D, 2004, CANCER CELL, V5, P201, DOI 10.1016/S1535-6108(04)00054-6; Lin YH, 2004, J CELL BIOL, V165, P421, DOI 10.1083/jcb.200311045; Liu TJ, 2001, CIRC RES, V88, P1231, DOI 10.1161/hh1201.092036; Long L, 1998, CANCER RES, V58, P3243; LONG L, 1995, CANCER RES, V55, P1006; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; Mauro L, 2001, J BIOL CHEM, V276, P39892, DOI 10.1074/jbc.M106673200; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; Playford MP, 2000, P NATL ACAD SCI USA, V97, P12103, DOI 10.1073/pnas.210394297; RODRIGUEZTARDUCHY G, 1992, J IMMUNOL, V149, P535; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/0968-0004(96)10020-7; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Surmacz E, 1998, BREAST CANCER RES TR, V47, P255, DOI 10.1023/A:1005907101686; SURMACZ E, 1992, EXP CELL RES, V199, P275, DOI 10.1016/0014-4827(92)90435-B; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; TOMASETTO C, 1995, GENOMICS, V28, P367, DOI 10.1006/geno.1995.1163; Tsujimoto H, 1999, MOL CARCINOGEN, V26, P298, DOI 10.1002/(SICI)1098-2744(199912)26:4<298::AID-MC8>3.0.CO;2-M; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	43	35	38	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 8	2005	24	40					6185	6193		10.1038/sj.onc.1208772	http://dx.doi.org/10.1038/sj.onc.1208772			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	962GD	15940254				2022-12-17	WOS:000231718100012
J	Belville, C; Jamin, SP; Picard, JY; Josso, N; di Clemente, N				Belville, C; Jamin, SP; Picard, JY; Josso, N; di Clemente, N			Role of type I receptors for anti-Mullerian hormone in the SMAT-1 Sertoli cell line	ONCOGENE			English	Article						anti-Mullerian hormone; Mullerian inhibiting substance; transforming growth factor-beta; receptors; activin-like kinases; Smad	INHIBITING SUBSTANCE; DUCT REGRESSION; TRANSDUCTION PATHWAY; SEXUAL DEVELOPMENT; SMAD PROTEINS; MEMBRANE; DIFFERENTIATION; MECHANISMS; EXPRESSION; MUTATION	Anti-Mullerian hormone (AMH) is a member of the transforming growth factor-beta family responsible for regression of Mullerian ducts during male sexual differentiation and for regulation of gonadal steroidogenesis. AMH is also a gonadal tumor suppressor which mediates its effects through a specific type II receptor and the bone morphogenetic protein (BMP)-specific Smad proteins, suggesting that AMH and BMPs could also share type I receptors, namely activin-like kinases (ALKs)2, 3 or 6. However, attempts to identify a unique AMH type I receptor among them were unsuccessful. Here, using kinase-deficient type I receptors and small interfering RNA technology, we demonstrate that, in an AMH Sertoli target cell line, ALK3 mediates AMH effects on both Smad1 activation and P450 side-chain cleavage enzyme. In addition, transfecting a combination of normal and kinase-deficient receptors, we show that ALK2 can compensate for the absence of ALK3 and probably acts in synergy with ALK3 at high concentrations of AMH to activate Smad1, whereas ALK6 has a competitive inhibitory effect. These results are a first step in understanding how AMH transduces its effects in immature Sertoli cells.	Univ Paris 11, Inst Natl Sante & Rech Med, Unite 493 Endocrinol Dev, F-92140 Clamart, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	di Clemente, N (corresponding author), Univ Paris 11, Inst Natl Sante & Rech Med, Unite 493 Endocrinol Dev, Rue Carnets, F-92140 Clamart, France.	nathalie.diclemente@inserm.ipsc.u-psud.fr	Jamin, Soazik P./K-1507-2019; Jamin, Soazik/F-6796-2015	Jamin, Soazik P./0000-0002-1688-0167; di Clemente, Nathalie/0000-0001-9087-3486; belville, corinne/0000-0002-7841-214X				Allard S, 2000, DEVELOPMENT, V127, P3349; Aoki H, 2001, J CELL SCI, V114, P1483; Arango NA, 1999, CELL, V99, P409, DOI 10.1016/S0092-8674(00)81527-5; Clarke TR, 2001, MOL ENDOCRINOL, V15, P946, DOI 10.1210/me.15.6.946; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; Dutertre M, 1997, MOL CELL ENDOCRINOL, V136, P57, DOI 10.1016/S0303-7207(97)00214-1; Dutertre M, 2001, ENDOCRINOLOGY, V142, P4040, DOI 10.1210/en.142.9.4040; Faure E, 1996, J BIOL CHEM, V271, P30571, DOI 10.1074/jbc.271.48.30571; Gouedard L, 2000, J BIOL CHEM, V275, P27973; Hay E, 2004, J BIOL CHEM, V279, P1650, DOI 10.1074/jbc.M300969200; Hoshiya Y, 2003, MOL CELL ENDOCRINOL, V211, P43, DOI 10.1016/j.mce.2003.09.010; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; Jamin SP, 2003, MOL CELL ENDOCRINOL, V211, P15, DOI 10.1016/j.mce.2003.09.006; Jamin SP, 2002, NAT GENET, V32, P408, DOI 10.1038/ng1003; Josso N, 2003, TRENDS ENDOCRIN MET, V14, P91, DOI 10.1016/S1043-2760(03)00005-5; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lo RS, 1998, EMBO J, V17, P996, DOI 10.1093/emboj/17.4.996; Long WQ, 2000, J CLIN ENDOCR METAB, V85, P540, DOI 10.1210/jc.85.2.540; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Messika-Zeitoun L, 2001, J CLIN ENDOCR METAB, V86, P4390, DOI 10.1210/jc.86.9.4390; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; Shi YG, 2003, CELL, V113, P685, DOI 10.1016/S0092-8674(03)00432-X; Teixeira J, 2001, ENDOCR REV, V22, P657, DOI 10.1210/er.22.5.657; ten Dijke P, 2003, MOL CELL ENDOCRINOL, V211, P105, DOI 10.1016/j.mce.2003.09.016; VIGIER B, 1984, ENDOCRINOLOGY, V114, P1315, DOI 10.1210/endo-114-4-1315; Visser JA, 2001, MOL ENDOCRINOL, V15, P936, DOI 10.1210/me.15.6.936; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239	27	35	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 21	2005	24	31					4984	4992		10.1038/sj.onc.1208686	http://dx.doi.org/10.1038/sj.onc.1208686			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	947LO	15897891				2022-12-17	WOS:000230646500011
J	Yun, JH; Zhong, Q; Kwak, JY; Lee, WH				Yun, JH; Zhong, Q; Kwak, JY; Lee, WH			Hypersensitivity of Brca1-deficient MEF to the DNA interstrand crosslinking agent mitomycin C is associated with defect in homologous recombination repair and aberrant S-phase arrest	ONCOGENE			English	Article						Brca1; mitomycin C; DNA interstrand crosslink (ICL) repair; Rad51; S phase	FANCONI-ANEMIA; CHROMOSOME BREAKAGE; BRCA1; CHECKPOINT; PROTEIN; SUSCEPTIBILITY; INVOLVEMENT; RADIATION; PATHWAY; COMPLEX	Hypersensitivity of Brca1-deficient cells to interstrand crosslinking (ICL) agents such as cisplatin and mitomycin C (MMC) implicates an important role for Brca1 in cellular response to the ICL DNA damage repair. However, the detailed mechanism of how Brca1 is involved in the ICL response remains unclear. In this study, we analysed the cellular response to MMC treatment using isogenic mouse embryonic fibroblasts (MEFs) including wild type, p53(-/-) and p53(-/-) Brca1(-/-). Marked hypersensitivity of p53(-/-) Brca1(-/-) MEFs to MMC was found, and the reconstitution of Brca1 expression in these cells restored resistance to MMC. Upon MMC treatment, wild-type MEF was temporarily arrested at G2/M phase but subsequently resumed a normal cell cycle progression. In contrast, Brca1-deficient MEF exhibited a marked time-dependent accumulation of cells arrested at S phase and a prolonged increase in the G2/M population, followed by extensive cell deaths. Importantly, DNA damage-induced Rad51 foci were not formed in these cells, suggesting a defect in homologous recombination. Such defects are fully rescued by reconstitution of Brca1 expression in Brca1-deficient MEF, suggesting that Brca1 directly plays an essential role in ICL repair, which depends on homologous recombination during S phase.	Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA; Dong A Univ, Coll Med, Med Res Ctr Canc Mol Therapy, Pusan 602714, South Korea; Dong A Univ, Coll Med, Dept Biochem, Pusan 602714, South Korea	University of California System; University of California Irvine; Dong A University; Dong A University	Lee, WH (corresponding author), Univ Calif Irvine, Sch Med, Dept Biol Chem, 124 Sprague Hall,839 Med Sci Court, Irvine, CA 92697 USA.	whlee@uci.edu	Zhong, Qing/GLT-4858-2022	Zhong, Qing/0000-0001-6979-955X	NCI NIH HHS [CA94170] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094170] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; BERGER R, 1993, CANCER GENET CYTOGEN, V69, P13, DOI 10.1016/0165-4608(93)90104-T; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; Chen JJ, 1999, CANCER RES, V59, p1752S; COLLINS AR, 1993, MUTAT RES, V293, P99, DOI 10.1016/0921-8777(93)90062-L; D'Andrea AD, 2003, NAT REV CANCER, V3, P23, DOI 10.1038/nrc970; DARDALHON M, 1995, MUTAT RES-DNA REPAIR, V336, P49, DOI 10.1016/0921-8777(94)00037-7; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; Dronkert MLG, 2001, MUTAT RES-DNA REPAIR, V486, P217, DOI 10.1016/S0921-8777(01)00092-1; ElShamy WM, 2004, NAT CELL BIOL, V6, P954, DOI 10.1038/ncb1171; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; Hartmann JT, 1999, INT J CANCER, V83, P866, DOI 10.1002/(SICI)1097-0215(19991210)83:6<866::AID-IJC34>3.3.CO;2-0; Heinrich MC, 1998, BLOOD, V91, P275, DOI 10.1182/blood.V91.1.275.275_275_287; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Kruyt FAE, 1997, CANCER RES, V57, P2244; KUBBIES M, 1985, AM J HUM GENET, V37, P1022; Kupfer GM, 1996, BLOOD, V88, P1019; Larminat F, 2004, BIOL CELL, V96, P545, DOI 10.1016/j.biolcel.2004.06.001; McHugh PJ, 2000, MOL CELL BIOL, V20, P3425, DOI 10.1128/MCB.20.10.3425-3433.2000; METZLER M, 1986, J CANCER RES CLIN, V112, P210, DOI 10.1007/BF00395914; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Moynahan ME, 2001, CANCER RES, V61, P4842; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Niedernhofer LJ, 2004, MOL CELL BIOL, V24, P5776, DOI 10.1128/MCB.24.13.5776-5787.2004; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rothfuss A, 2004, MOL CELL BIOL, V24, P123, DOI 10.1128/MCB.24.1.123-134.2004; Sala-Trepat M, 2000, EXP CELL RES, V260, P208, DOI 10.1006/excr.2000.4994; SASAKI MS, 1973, CANCER RES, V33, P1829; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Ting NSY, 2004, DNA REPAIR, V3, P935, DOI 10.1016/j.dnarep.2004.03.026; van den Bosch M, 2002, BIOL CHEM, V383, P873; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yu VPCC, 2000, GENE DEV, V14, P1400; Zheng L, 2000, MOL CELL, V6, P757, DOI 10.1016/S1097-2765(00)00075-7; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968; Zhong Q, 2002, J BIOL CHEM, V277, P28641, DOI 10.1074/jbc.M200748200; Zhong Q, 2002, CANCER RES, V62, P3966; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	43	35	36	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 9	2005	24	25					4009	4016		10.1038/sj.onc.1208575	http://dx.doi.org/10.1038/sj.onc.1208575			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	934BA	15782115				2022-12-17	WOS:000229680300001
J	Hideshima, T; Chauhan, D; Ishitsuka, K; Yasui, H; Raje, N; Kumar, S; Podar, K; Mitsiades, C; Hideshima, H; Bonham, L; Munshi, NC; Richardson, PG; Singer, JW; Anderson, KC				Hideshima, T; Chauhan, D; Ishitsuka, K; Yasui, H; Raje, N; Kumar, S; Podar, K; Mitsiades, C; Hideshima, H; Bonham, L; Munshi, NC; Richardson, PG; Singer, JW; Anderson, KC			Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors	ONCOGENE			English	Article						lysophosphatidic acid acyltransferase-beta inhibitor; bortezomib; PS-341; caspase; necrosis; cell cycle	PROTEASOME INHIBITOR PS-341; MULTIPLE-MYELOMA CELLS; REFRACTORY HEMATOLOGIC MALIGNANCIES; ACID ACYLTRANSFERASE-BETA; DNA FRAGMENTATION FACTOR; HIGH-DOSE THERAPY; NF-KAPPA-B; LYSOPHOSPHATIDIC ACID; DRUG-RESISTANCE; CAM-DR	PS-341 (bortezomib, Velcade(TM)) is a promising novel agent for treatment of advanced multiple myeloma ( MM); however, 65% of patients with relapsed refractory disease in a phase II study do not respond to PS-341. We have previously shown that lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitor CT-32615 triggers caspase-dependent apoptosis, and can overcome resistance to conventional therapeutics (i.e., dexamethasone, doxorubicin, melphalan) in MM cells. In this study, we therefore determined whether CT-32615 could also overcome resistance to PS- 341. We first characterized molecular mechanisms of resistance to PS- 341 in DHL-4 cells. DHL-4 cells express low levels of caspase-3 and caspase-8; furthermore, no cleavage in caspase-8, caspase-9, caspase-3, poly ADP-ribose polymerase ( PARP), or DNA fragmentation factor 45 was triggered by PS- 341 treatment. We have previously shown that PS- 341 treatment triggers phosphorylation of c-Jun NH2-terminal kinase (JNK), which subsequently induces caspase-dependent apoptosis; conversely, JNK inhibition blocks PS- 341-induced apoptosis. We here show that phosphorylation of SEK-1, JNK, and c-Jun are not induced by PS-341 treatment, suggesting that PS- 341 does not trigger a stress response in DHL-4 cells. Importantly, CT-32615 inhibits growth of DHL-4 cells in a time-and dose-dependent fashion: a transient G2/M cell cycle arrest induced by CT-32615 is mediated via downregulation of cdc25c and cdc2. CT-32615 triggered swelling and lysis of DHL-4 cells, without caspase/PARP cleavage or TUNEL-positivity, suggesting a necrotic response. Our studies therefore demonstrate that LPAAT-beta inhibitor CT-32615 triggers necrosis, even in PS-341-resistant DHL-4 cells, providing the framework for its evaluation to overcome clinical PS- 341 resistance and improve patient outcome.	Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Cell Therapeut Inc, Seattle, WA 98119 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Jerome Lipper Multiple Myeloma Ctr, Mayer 557,44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Podar, Klaus/ABD-1112-2020; Munshi, Nikhil/ABE-2338-2021	Podar, Klaus/0000-0002-7414-3632; Yasui, Hiroshi/0000-0003-0905-6855; Singer, Jack/0000-0003-4001-4549	NATIONAL CANCER INSTITUTE [R01CA050947] Funding Source: NIH RePORTER; NCI NIH HHS [IP50 CA10070-01, R0-1 CA 50947] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Attal M, 2001, SEMIN HEMATOL, V38, P226, DOI 10.1053/shem.2001.26005; Bonham L, 2003, EXPERT OPIN THER TAR, V7, P643; Chauhan D, 2003, CANCER RES, V63, P6174; Coon M, 2003, MOL CANCER THER, V2, P1067; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Fermand JP, 1998, BLOOD, V92, P3131, DOI 10.1182/blood.V92.9.3131.421k30_3131_3136; GREGORY WM, 1992, J CLIN ONCOL, V10, P334, DOI 10.1200/JCO.1992.10.2.334; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2004, ONCOGENE, V23, P8766, DOI 10.1038/sj.onc.1208118; Hideshima T, 2003, CANCER RES, V63, P8428; Hideshima T, 2003, ONCOGENE, V22, P8386, DOI 10.1038/sj.onc.1207170; Hideshima T, 2003, IMMUNOL REV, V194, P164, DOI 10.1034/j.1600-065X.2003.00053.x; Hideshima T, 2003, BLOOD, V101, P1530, DOI 10.1182/blood-2002-08-2543; Hideshima T, 2002, NAT REV CANCER, V2, P927, DOI 10.1038/nrc952; Hideshima T, 2002, J BIOL CHEM, V277, P16639, DOI 10.1074/jbc.M200360200; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Inohara N, 1998, EMBO J, V17, P2526, DOI 10.1093/emboj/17.9.2526; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Koester SK, 1997, CYTOMETRY, V29, P306; Landowski TH, 2003, ONCOGENE, V22, P2417, DOI 10.1038/sj.onc.1206315; LeBlanc R, 2002, CANCER RES, V62, P4996; Lenhoff S, 2000, BLOOD, V95, P7; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mitsiades CS, 2004, P NATL ACAD SCI USA, V101, P540, DOI 10.1073/pnas.2536759100; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Mitsiades N, 2003, BLOOD, V101, P2377, DOI 10.1182/blood-2002-06-1768; Orlowski RZ, 2002, J CLIN ONCOL, V20, P4420, DOI 10.1200/JCO.2002.01.133; Orlowski RZ, 2003, BLOOD, V102, p449A; Pasquali S, 1998, J CLIN ONCOL, V16, P3832; Richardson PG, 2003, NEW ENGL J MED, V348, P2609, DOI 10.1056/NEJMoa030288; Yang F, 2003, CYTOGENET GENOME RES, V102, P235, DOI 10.1159/000075755	34	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 28	2005	24	19					3121	3129		10.1038/sj.onc.1208522	http://dx.doi.org/10.1038/sj.onc.1208522			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	920XF	15735676				2022-12-17	WOS:000228728100006
J	Perri, P; Bachetti, T; Longo, L; Matera, I; Seri, M; Tonini, GP; Ceccherini, I				Perri, P; Bachetti, T; Longo, L; Matera, I; Seri, M; Tonini, GP; Ceccherini, I			PHOX2B mutations and genetic predisposition to neuroblastoma	ONCOGENE			English	Article						familial neuroblastoma; PHOX2B; cancer predisposition; oligogenic model	CENTRAL HYPOVENTILATION SYNDROME; CRITERIA; LINKAGE	Neuroblastoma ( NB) is a childhood malignancy originating from neural crest cells, which seldom occurs in association with other neurocristopathies. Owing to the rarity of familial NB cases, only a few linkage data are available and no mutations in candidate genes have been demonstrated up till now. Germline mutations in a small proportion of NB patients have been recently reported in the paired-like homeobox 2B (PHOX2B) gene, suggesting its role in NB predisposition. On the basis of this indication, we screened three Italian families with recurrence of NB and one family with occurrence of ganglioneuroblastoma and isolated Hirschsprung disease for PHOX2B defects. Our analysis did not show any mutation, excluding PHOX2B as the NB susceptibility gene in the families we analysed. Our findings combined with those derived from other PHOX2B mutation screenings and from genome-wide linkage analysis support a remarkable genetic heterogeneity of NB and suggest an oligogenic model of disease transmission. Furthermore, as PHOX2B mutations were mainly observed in some NB families with multifocal and syndromic NB, features that are missing in the families we have studied, we suggest they represent second-site modi. cations responsible for a specific phenotype rather than causal mutations of a major locus.	CBA, Fdn Italiana Lotta Neuroblastoma, Lab Neuroblastoma Res, I-16132 Genoa, Italy; G Gaslini Inst Children, Mol Genet Lab, Genoa, Italy; Natl Inst Canc Res, Lab Neuroblastoma, Genoa, Italy; Univ Bologna, Dept Internal Med Cardioangiol & Hepatol, Bologna, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); University of Genoa; IRCCS Istituto Giannina Gaslini; University of Genoa; IRCCS AOU San Martino IST; University of Bologna	Perri, P (corresponding author), CBA, Fdn Italiana Lotta Neuroblastoma, Lab Neuroblastoma Res, Lgo R Benzi 10, I-16132 Genoa, Italy.	perri@cba.unige.it	Perri, Patrizia/I-8124-2018; Perri, Patrizia/AFV-5794-2022; Ceccherini, Isabella/P-8195-2014; Bachetti, Tiziana/AAB-4516-2021; Bachetti, Tiziana/K-6405-2016; Longo, Luca/K-6156-2018; Seri, Marco/A-4339-2014	Perri, Patrizia/0000-0003-2538-8278; Perri, Patrizia/0000-0003-2538-8278; Ceccherini, Isabella/0000-0001-8732-1955; Bachetti, Tiziana/0000-0002-9456-8945; Longo, Luca/0000-0002-5153-4243; Seri, Marco/0000-0003-2425-2176	Telethon [GGP04257] Funding Source: Medline	Telethon(Fondazione Telethon)		Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; BRODEUR GM, 1993, J CLIN ONCOL, V11, P1466, DOI 10.1200/JCO.1993.11.8.1466; Croaker GDH, 1998, ARCH DIS CHILD, V78, P316, DOI 10.1136/adc.78.4.316; GRISERI P, 2000, GENE FUNCT DIS, V1, P184; Katsanis N, 2004, HUM MOL GENET, V13, pR65, DOI 10.1093/hmg/ddh092; KNUDSON AG, 1972, AM J HUM GENET, V24, P514; Maris JM, 2002, CANCER RES, V62, P6651; Matera I, 2004, J MED GENET, V41, P373, DOI 10.1136/jmg.2003.015412; Ming JE, 2002, AM J HUM GENET, V71, P1017, DOI 10.1086/344412; Mosse YP, 2004, AM J HUM GENET, V75, P727, DOI 10.1086/424530; Origone P, 2003, AM J MED GENET A, V118A, P309, DOI 10.1002/ajmg.a.10167; Pattyn A, 1999, NATURE, V399, P366, DOI 10.1038/20700; Perri P, 2002, ANN NY ACAD SCI, V963, P74; Perri P, 2002, ONCOGENE, V21, P8356, DOI 10.1038/sj.onc.1206009; Shimada H, 1999, CANCER, V86, P349, DOI 10.1002/(SICI)1097-0142(19990715)86:2<349::AID-CNCR20>3.3.CO;2-P; Tonini GP, 2003, CANCER LETT, V197, P41, DOI 10.1016/S0304-3835(03)00080-6; Trochet D, 2004, AM J HUM GENET, V74, P761, DOI 10.1086/383253; van Limpt V, 2004, ONCOGENE, V23, P9280, DOI 10.1038/sj.onc.1208157; Weese-Mayer DE, 2003, AM J MED GENET A, V123A, P267, DOI 10.1002/ajmg.a.20527	19	35	36	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					3050	3053		10.1038/sj.onc.1208532	http://dx.doi.org/10.1038/sj.onc.1208532			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735672	Bronze			2022-12-17	WOS:000228649500014
J	Ghosh, S; Wu, YM; Li, R; Hu, YF				Ghosh, S; Wu, YM; Li, R; Hu, YF			Jun proteins modulate the ovary-specific promoter of aromatase gene in ovarian granulosa cells via a cAMP-responsive element	ONCOGENE			English	Article						Jun; aromatase; transcriptional repression; granulosa cells; ovary	MESSENGER-RIBONUCLEIC-ACID; C-JUN; TRANSCRIPTIONAL ACTIVATION; CONSTITUTIVE EXPRESSION; ESTROGEN BIOSYNTHESIS; BINDING PROTEIN; RECEPTOR; AP-1; TRANSFORMATION; MECHANISMS	Estrogen is critical to both normal mammary gland and breast cancer development. Circulating levels of estrogen in premenopausal women are primarily determined by the action of aromatase in ovarian granulosa cells that converts testosterone to estradiol. In the current study, we unraveled an important role of Jun proteins in modulating ovary-specific aromatase expression. Ectopic expression of the Jun proteins in a human granulosa cell line significantly inhibited an ovary-specific promoter (PII) of the aromatase gene, whereas expression of dominant-negative mutants of Jun led to increased promoter activity. The Jun-mediated repression was specific to the aromatase promoter, as Jun proteins stimulated known AP1-responsive promoters in the same cellular context. Both the activation and basic leucine zipper domains of Jun were required for the transcriptional repression. Electrophoretic gel mobility assay showed that endogenous Jun proteins bound to a functionally important cAMP-responsive element (CRE) in the PII promoter-proximal region. Alteration of the CRE-like site impaired both the cAMP-responsive transcriptional activation and Jun-mediated repression. Furthermore, chromatin immunoprecipitation indicated the presence of cJun at the proximal region of the native PII promoter. Taken together, our work suggests that Jun proteins may attenuate estrogen biosynthesis by directly downregulating transcription of the aromatase gene in ovarian granulosa cells.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Hu, YF (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.	yh4b@virginia.edu			NCI NIH HHS [CA093506] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093506] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiyar SE, 2004, GENE DEV, V18, P2134, DOI 10.1101/gad.1214104; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BROWN PH, 1993, ONCOGENE, V8, P877; Bulun SE, 2003, J STEROID BIOCHEM, V86, P219, DOI 10.1016/S0960-0760(03)00359-5; Carlone DL, 1997, MOL ENDOCRINOL, V11, P292, DOI 10.1210/me.11.3.292; Christenson LK, 2001, ENDOCRINOLOGY, V142, P28, DOI 10.1210/endo.142.1.7867; Chu S, 2004, MOL ENDOCRINOL, V18, P1919, DOI 10.1210/me.2004-0021; DELIDOW BC, 1992, BIOL REPROD, V47, P428, DOI 10.1095/biolreprod47.3.428; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; FITZPATRICK SL, 1991, ENDOCRINOLOGY, V129, P1452, DOI 10.1210/endo-129-3-1452; Gerald D, 2004, CELL, V118, P781, DOI 10.1016/j.cell.2004.08.025; Gonzalez-Robayna IJ, 1999, MOL ENDOCRINOL, V13, P1318, DOI 10.1210/me.13.8.1318; Guberman AS, 2003, J BIOL CHEM, V278, P2317, DOI 10.1074/jbc.M205057200; HERBER B, 1994, ONCOGENE, V9, P1295; HICKEY GJ, 1988, ENDOCRINOLOGY, V122, P1426, DOI 10.1210/endo-122-4-1426; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hu YF, 2002, GENE DEV, V16, P1509, DOI 10.1101/gad.995502; Johnson R, 1996, MOL CELL BIOL, V16, P4504; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; Kamat A, 2002, TRENDS ENDOCRIN MET, V13, P122, DOI 10.1016/S1043-2760(02)00567-2; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; LAMPH WW, 1990, P NATL ACAD SCI USA, V87, P4320, DOI 10.1073/pnas.87.11.4320; LOPEZ G, 1993, MOL CELL BIOL, V13, P3042, DOI 10.1128/MCB.13.5.3042; Manna PR, 2004, MOL ENDOCRINOL, V18, P558, DOI 10.1210/me.2003-0223; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; Morinaga H, 2004, ENDOCRINOLOGY, V145, P1860, DOI 10.1210/en.2003-1182; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; Mukasa C, 2003, ENDOCRINOLOGY, V144, P1603, DOI 10.1210/en.2002-220978; Nishi Y, 2001, ENDOCRINOLOGY, V142, P437, DOI 10.1210/en.142.1.437; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; PESTELL RG, 1994, J BIOL CHEM, V269, P31090; Richards JS, 1998, MOL CELL ENDOCRINOL, V145, P47, DOI 10.1016/S0303-7207(98)00168-3; RICHARDS JS, 1995, RECENT PROG HORM RES, V50, P223; RICHARDS JS, 1994, ENDOCR REV, V15, P725, DOI 10.1210/er.15.6.725; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Sasano H, 1998, ENDOCR REV, V19, P593, DOI 10.1210/er.19.5.593; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Simpson ER, 2001, ENDOCRINOLOGY, V142, P4589, DOI 10.1210/endo.142.11.8547; Simpson ER, 2002, ANNU REV PHYSIOL, V64, P93, DOI 10.1146/annurev.physiol.64.081601.142703; Thepot D, 2000, DEVELOPMENT, V127, P143; WOODRUFF TK, 1987, MOL ENDOCRINOL, V1, P561, DOI 10.1210/mend-1-8-561; WU Y, 2004, IN PRESS ENDOCRINOLO; Young M, 1997, J STEROID BIOCHEM, V61, P341	49	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2005	24	13					2236	2246		10.1038/sj.onc.1208415	http://dx.doi.org/10.1038/sj.onc.1208415			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909KD	15688015				2022-12-17	WOS:000227857900011
J	Yordy, JS; Moussa, O; Pei, HP; Chaussabel, D; Li, RZ; Watson, DK				Yordy, JS; Moussa, O; Pei, HP; Chaussabel, D; Li, RZ; Watson, DK			SP100 inhibits ETS1 activity in primary endothelial cells	ONCOGENE			English	Article						ETS1; SP100; angiogenesis; microarray; migration; transcription	TISSUE GROWTH-FACTOR; TRANSCRIPTION FACTOR ETS-1; ANGIOGENESIS IN-VIVO; NF-KAPPA-B; GENE-EXPRESSION; MICROARRAY DATA; TUMOR ANGIOGENESIS; INTERFERON-ALPHA; ANTISENSE OLIGONUCLEOTIDES; PLASMINOGEN-ACTIVATOR	SP100 was first identified as a nuclear autoimmune antigen and is a constituent of the nuclear body. SP100 interacts with the ETS1 transcription factor, and we have previously shown that SP100 reduces ETS1-DNA binding and inhibits ETS1 transcriptional activity on the MMP1 and uPA promoters. We now demonstrate that SP100 expression is upregulated by interferons, which have been shown to be antiangiogenic, in primary endothelial cells. As ETS1 is functionally important in promoting angiogenesis, we tested the hypothesis that ETS1 activity is negatively modulated by SP100 in endothelial cells. SP100 directly antagonizes ETS1-mediated morphological changes in human umbilical vein endothelial cell (HUVEC) network formation and reduces HUVEC migration and invasion. To further understand the functional relationship between ETS1 and SP100, cDNA microarray analysis was utilized to assess reprogramming of gene expression by ETS1 and SP100. A subset of the differentially regulated genes, including heat-shock proteins (HSPs) H11, HSPA1L, HSPA6, HSPA8, HSPE1 and AXIN1, BRCA1, CD14, CTGF (connective tissue growth factor), GABRE (gamma-aminobutyric acid A receptor epsilon), ICAM1, SNAI1, SRD5A1 (steroid-5-alpha-reductase 1) and THY1, were validated by real-time PCR and a majority showed reciprocal expression in response to ETS1 and SP100. Interestingly, genes that are negatively regulated by ETS1 and upregulated by SP100 have antimigratory or antiangiogenic properties. Collectively, these data indicate that SP100 negatively modulates ETS1-dependent downstream biological processes.	Med Univ S Carolina, Dept Pathol & Lab Med, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Hollings Canc Ctr, Charleston, SC 29425 USA; Baylor Inst Immunol Res, Dallas, TX USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; Baylor Scott & White Health	Watson, DK (corresponding author), Med Univ S Carolina, Dept Pathol & Lab Med, Hollings Canc Ctr, Room 332,86 Jonathan Lucas St, Charleston, SC 29425 USA.	watsondk@musc.edu	Chaussabel, Damien/AAX-1909-2020	Chaussabel, Damien/0000-0002-6131-7242	NCI NIH HHS [P01CA78582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Babic AM, 1999, MOL CELL BIOL, V19, P2958; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; Bell SE, 2001, J CELL SCI, V114, P2755; Brigstock David R., 2002, Angiogenesis, V5, P153, DOI 10.1023/A:1023823803510; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang CC, 2004, JNCI-J NATL CANCER I, V96, P364, DOI 10.1093/jnci/djh059; Chaussabel D, 2003, BLOOD, V102, P672, DOI 10.1182/blood-2002-10-3232; Chaussabel D, 2002, GENOME BIOL, V3; Chen ZQ, 1997, CANCER RES, V57, P2013; Cui Y, 2004, OMICS, V8, P106, DOI 10.1089/1536231041388320; Czuwara-Ladykowska J, 2002, J BIOL CHEM, V277, P20399, DOI 10.1074/jbc.M200206200; Dahlquist KD, 2002, NAT GENET, V31, P19, DOI 10.1038/ng0502-19; Dandre F, 2004, AM J PHYSIOL-HEART C, V286, pH2042, DOI 10.1152/ajpheart.00625.2003; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; Dirkx AEM, 2003, CANCER RES, V63, P2322; Dittmer Jurgen, 2003, Mol Cancer, V2, P29, DOI 10.1186/1476-4598-2-29; Doniger SW, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-1-r7; Edwards AD, 2003, J IMMUNOL, V171, P47, DOI 10.4049/jimmunol.171.1.47; Entschladen F, 2004, LANCET ONCOL, V5, P254, DOI 10.1016/S1470-2045(04)01431-7; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; FOLKMAN J, 2000, CANC MED, P132; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Galea E, 2002, NEUROREPORT, V13, P1469, DOI 10.1097/00001756-200208070-00024; Gerritsen ME, 2002, PHYSIOL GENOMICS, V10, P13, DOI 10.1152/physiolgenomics.00035.2002; Goetze S, 2001, ATHEROSCLEROSIS, V159, P93, DOI 10.1016/S0021-9150(01)00497-X; Griffioen AW, 1996, CANCER RES, V56, P1111; GULDNER HH, 1992, J IMMUNOL, V149, P4067; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; Hastings M M, 1997, J AAPOS, V1, P226, DOI 10.1016/S1091-8531(97)90042-2; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Igarashi T, 2001, TOHOKU J EXP MED, V194, P35, DOI 10.1620/tjem.194.35; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jang HS, 2004, MOL THER, V9, P464, DOI 10.1016/j.ymthe.2003.12.002; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kevil CG, 2004, J BIOL CHEM, V279, P19230, DOI 10.1074/jbc.M312025200; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Kita D, 2001, CANCER RES, V61, P7985; Kumar P, 2002, J THORAC CARDIOV SUR, V124, P404, DOI 10.1067/mtc.2002.122540; Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010; Lee WS, 1998, CIRC RES, V82, P845; Lelievre E, 2001, INT J BIOCHEM CELL B, V33, P391, DOI 10.1016/S1357-2725(01)00025-5; Li RH, 1999, P NATL ACAD SCI USA, V96, P3876, DOI 10.1073/pnas.96.7.3876; Li RZ, 2000, ONCOGENE, V19, P745, DOI 10.1038/sj.onc.1203385; LI WW, 1991, INVEST OPHTH VIS SCI, V32, P2906; Lincoln DW, 2003, BREAST CANCER RES TR, V78, P167, DOI 10.1023/A:1022904624054; Marler JJ, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e37; Mattot V, 2000, ONCOGENE, V19, P762, DOI 10.1038/sj.onc.1203248; Mercurio S, 2004, DEVELOPMENT, V131, P2137, DOI 10.1242/dev.01045; Nakano T, 2000, J CELL PHYSIOL, V184, P255, DOI 10.1002/1097-4652(200008)184:2<255::AID-JCP14>3.0.CO;2-J; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Okubo T, 2001, CANCER RES, V61, P1338; Ortega A, 2003, TRENDS PHARMACOL SCI, V24, P151, DOI 10.1016/S0165-6147(03)00052-X; Pelicano L, 1997, ONCOGENE, V15, P2349, DOI 10.1038/sj.onc.1201410; Pollet I, 2003, BLOOD, V102, P1740, DOI 10.1182/blood-2003-01-0288; Pourtier-Manzanedo A, 2003, ONCOGENE, V22, P1795, DOI 10.1038/sj.onc.1206215; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Raouf A, 2000, ONCOGENE, V19, P1969, DOI 10.1038/sj.onc.1203505; Roca C, 2003, CANCER RES, V63, P1500; Roy J, 2001, J BIOL CHEM, V276, P14553, DOI 10.1074/jbc.M005067200; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Sato Y, 2001, CELL STRUCT FUNCT, V26, P19, DOI 10.1247/csf.26.19; Schneikert J, 1996, J BIOL CHEM, V271, P23907, DOI 10.1074/jbc.271.39.23907; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Shimizu S, 2004, INT J BIOCHEM CELL B, V36, P114, DOI 10.1016/S1357-2725(03)00170-5; Shimo T, 1999, J BIOCHEM-TOKYO, V126, P137, DOI 10.1093/oxfordjournals.jbchem.a022414; St Croix B, 2000, SCIENCE, V289, P1197; Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tolwinski NS, 2004, TRENDS GENET, V20, P177, DOI 10.1016/j.tig.2004.02.003; Tomita N, 2003, CIRCULATION, V107, P1411, DOI 10.1161/01.CIR.0000055331.41937.AA; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Tryfonas GI, 1998, PEDIATR SURG INT, V13, P590, DOI 10.1007/s003830050411; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; von Marschall Z, 2003, J NATL CANCER I, V95, P437, DOI 10.1093/jnci/95.6.437; Wang L, 2003, J GASTROINTEST SURG, V7, P587, DOI 10.1016/S1091-255X(03)00072-6; Watanabe D, 2004, AM J PATHOL, V164, P1827, DOI 10.1016/S0002-9440(10)63741-8; Wernert N, 1999, ANGEW CHEM INT EDIT, V38, P3228, DOI 10.1002/(SICI)1521-3773(19991102)38:21<3228::AID-ANIE3228>3.0.CO;2-8; WERNERT N, 1992, AM J PATHOL, V140, P119; Wu XX, 2003, BIOL REPROD, V69, P1308, DOI 10.1095/biolreprod.103.015420; Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8; Yordy JS, 2004, ONCOGENE, V23, P6654, DOI 10.1038/sj.onc.1207891	92	35	39	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 27	2005	24	5					916	931		10.1038/sj.onc.1208245	http://dx.doi.org/10.1038/sj.onc.1208245			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891JM	15592518				2022-12-17	WOS:000226577100017
J	Li, WL; Kessler, P; Williams, BRG				Li, WL; Kessler, P; Williams, BRG			Transcript profiling of Wilms tumors reveals connections to kidney morphogenesis and expression patterns associated with anaplasia	ONCOGENE			English	Article						Wilms tumor; pro. ling; kidney morphogenesis; anaplasia	WOLF-HIRSCHHORN-SYNDROME; P53 GENE-MUTATIONS; N-MYC; MESSENGER-RNA; GROWTH-FACTOR; CELL-LINE; METANEPHRIC MESENCHYME; ONCOGENE EXPRESSION; EMBRYONIC LETHALITY; MULTIPLE-MYELOMA	Anaplasia (unfavorable histology) is associated with therapy resistance and poor prognosis of Wilms tumor, but the molecular basis for this phenotype is unclear. Here, we used a cDNA array with 9240 clones relevant to cancer biology and/or kidney development to examine the expression profiles of 54 Wilms tumors, five normal kidneys and fetal kidney. By linking genes differentially expressed between fetal kidney and Wilms tumors to kidney morphogenesis, we found that genes expressed at a higher level in Wilms tumors tend to be expressed more in uninduced metanephrogenic mesenchyme or blastema than in their differentiated structures. Conversely, genes expressed at a lower level in Wilms tumors tend to be expressed less in uninduced metanephrogenic mesenchyme or blastema. We also identified 97 clones representing 76 Unigenes or unclustered ESTs that clearly separate anaplastic Wilms tumors from tumors with favorable histology. Genes in this set provide insight into the nature of the abnormal nuclear morphology of anaplastic tumors and may facilitate identification of molecular targets to improve their responsiveness to treatment.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Genet, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University	Williams, BRG (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	williab@ccf.org	Williams, Bryan R. G./A-5021-2009; Li, Wenliang/A-1022-2010	Williams, Bryan R. G./0000-0002-4969-1151; 	NCI NIH HHS [R01-CA89279] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089279] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aglipay JA, 2003, ONCOGENE, V22, P8931, DOI 10.1038/sj.onc.1207057; Alli E, 2002, CANCER RES, V62, P6864; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; Bard JBL, 2002, BIOESSAYS, V24, P72, DOI 10.1002/bies.10024; BARDEESY N, 1995, CANCER RES, V55, P215; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; BARNES JD, 1994, DEV BIOL, V161, P168, DOI 10.1006/dbio.1994.1018; Bates CM, 2000, DEV BIOL, V222, P317, DOI 10.1006/dbio.2000.9716; BECKWITH JB, 1978, CANCER-AM CANCER SOC, V41, P1937, DOI 10.1002/1097-0142(197805)41:5<1937::AID-CNCR2820410538>3.0.CO;2-U; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; BONADIO JF, 1985, J CLIN ONCOL, V3, P513, DOI 10.1200/JCO.1985.3.4.513; Cabello OA, 2001, MOL BIOL CELL, V12, P3527, DOI 10.1091/mbc.12.11.3527; Cancilla B, 1999, KIDNEY INT, V56, P2025, DOI 10.1046/j.1523-1755.1999.00781.x; CHARRON J, 1992, GENE DEV, V6, P2248, DOI 10.1101/gad.6.12a.2248; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; Conte N, 2002, ONCOGENE, V21, P5619, DOI 10.1038/sj.onc.1205658; Cook DM, 1996, ONCOGENE, V13, P1789; DIAZRUIZ C, 1993, CELL TISSUE RES, V271, P3, DOI 10.1007/BF00297536; Eggert A, 2001, J CLIN ONCOL, V19, P689, DOI 10.1200/JCO.2001.19.3.689; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Frevel MAE, 2003, MOL CELL BIOL, V23, P425, DOI 10.1128/MCB.23.2.425-436.2003; FUJII T, 1994, DEV DYNAM, V199, P73, DOI 10.1002/aja.1001990108; Gow KW, 2002, J PEDIATR SURG, V37, P823, DOI 10.1053/jpsu.2002.32880; Grisaru S, 2000, PEDIATR NEPHROL, V14, P146, DOI 10.1007/s004670050031; HARDING MA, 1992, KIDNEY INT, V41, P317, DOI 10.1038/ki.1992.44; HASTIE ND, 1994, ANNU REV GENET, V28, P523; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Higinbotham KG, 1998, MOL CARCINOGEN, V23, P53, DOI 10.1002/(SICI)1098-2744(199810)23:2<53::AID-MC1>3.0.CO;2-T; Hippo Y, 2001, CANCER RES, V61, P889; Ho R, 2002, CANCER RES, V62, P6462; Jaboin J, 2002, CANCER RES, V62, P6756; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Kang DH, 2001, AM J KIDNEY DIS, V37, P601, DOI 10.1053/ajkd.2001.22087; Karavanov AA, 1998, INT J DEV BIOL, V42, P61; Kim IG, 1997, BBA-MOL CELL RES, V1359, P181, DOI 10.1016/S0167-4889(97)00103-1; Kimura K, 2001, J BIOL CHEM, V276, P5417, DOI 10.1074/jbc.C000873200; Kline-Smith SL, 2004, MOL BIOL CELL, V15, P1146, DOI 10.1091/mbc.E03-08-0581; Kooistra R, 1997, MOL CELL BIOL, V17, P6097, DOI 10.1128/MCB.17.10.6097; Kooistra R, 1999, MOL CELL BIOL, V19, P6269; Korkola JE, 2003, CANCER RES, V63, P7167; Korshunov A, 2003, AM J PATHOL, V163, P1721, DOI 10.1016/S0002-9440(10)63530-4; KUSSEL P, 1995, MOL GEN GENET, V248, P351, DOI 10.1007/BF02191602; Lahoti C, 1996, AM J PATHOL, V148, P1577; Lechner MS, 1997, MECH DEVELOP, V62, P105, DOI 10.1016/S0925-4773(97)00667-9; Li CM, 2002, AM J PATHOL, V160, P2181, DOI 10.1016/S0002-9440(10)61166-2; LUO G, 1995, GENE DEV, V9, P2808, DOI 10.1101/gad.9.22.2808; Malgeri U, 2000, CANCER RES, V60, P4058; MALKIN D, 1994, CANCER RES, V54, P2077; MIERAU GW, 1987, ULTRASTRUCT PATHOL, V11, P313, DOI 10.3109/01913128709048329; MUGRAUER G, 1988, J CELL BIOL, V107, P1325, DOI 10.1083/jcb.107.4.1325; Niimura F, 1997, AM J PHYSIOL-REG I, V272, pR142, DOI 10.1152/ajpregu.1997.272.1.R142; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Raff JW, 2002, TRENDS CELL BIOL, V12, P222, DOI 10.1016/S0962-8924(02)02268-7; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; ROTH J, 1988, AM J PATHOL, V133, P596; ROTH J, 1989, VERH DEUT G, V73, P372; Sato N, 2003, CANCER RES, V63, P3735; SAWAI S, 1991, NEW BIOL, V3, P861; Scholl FA, 2000, BRIT J CANCER, V82, P1239; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; SHAWLOT W, 1995, NATURE, V374, P425, DOI 10.1038/374425a0; Skacel M, 2002, APPL IMMUNOHISTO M M, V10, P1, DOI 10.1097/00022744-200203000-00001; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Sperger JM, 2003, P NATL ACAD SCI USA, V100, P13350, DOI 10.1073/pnas.2235735100; Stanhope-Baker P, 2004, J BIOL CHEM, V279, P33575, DOI 10.1074/jbc.M404787200; STANTON BR, 1992, BRAIN PATHOL, V2, P71; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; Stec I, 1998, HUM MOL GENET, V7, P1071, DOI 10.1093/hmg/7.7.1071; Stuart RO, 2003, KIDNEY INT, V64, P1997, DOI 10.1046/j.1523-1755.2003.00383.x; Stuart RO, 2001, P NATL ACAD SCI USA, V98, P5649, DOI 10.1073/pnas.091110798; Stucke VM, 2002, EMBO J, V21, P1723, DOI 10.1093/emboj/21.7.1723; Sugata N, 2000, HUM MOL GENET, V9, P2919, DOI 10.1093/hmg/9.19.2919; Tanaka K, 1999, PEDIATR SURG INT, V15, P243, DOI 10.1007/s003830050567; Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Vukicevic S, 1996, P NATL ACAD SCI USA, V93, P9021, DOI 10.1073/pnas.93.17.9021; WANG YQ, 1995, MECH DEVELOP, V52, P275, DOI 10.1016/0925-4773(95)00408-S; Wittmann T, 2004, J BIOL CHEM, V279, P6196, DOI 10.1074/jbc.M307261200; Zhang Hui-Zhong, 2004, Ai Zheng, V23, P493; Zhang XH, 1999, ANTICANCER RES, V19, P1641; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581; ZUPPAN CW, 1988, HUM PATHOL, V19, P1199, DOI 10.1016/S0046-8177(88)80152-7	86	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					457	468		10.1038/sj.onc.1208228	http://dx.doi.org/10.1038/sj.onc.1208228			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531917				2022-12-17	WOS:000226279700016
J	Kondo, T; Oue, N; Mitani, Y; Kuniyasu, H; Noguchi, T; Kuraoka, K; Nakayama, H; Yasui, W				Kondo, T; Oue, N; Mitani, Y; Kuniyasu, H; Noguchi, T; Kuraoka, K; Nakayama, H; Yasui, W			Loss of heterozygosity and histone hypoacetylation of the PINX1 gene are associated with reduced expression in gastric carcinoma	ONCOGENE			English	Article						PINX1; telomerase; LOH; histone H4; acetylation; hSir2; gastric carcinoma	PUTATIVE-TUMOR-SUPPRESSOR; TELOMERASE REVERSE-TRANSCRIPTASE; PROMOTER HYPERMETHYLATION; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; CHROMOSOME 8P; PROTEIN SIR2; LUNG-CANCER; EARLY EVENT; CELL-LINES	The expression of PINX1, a possible telomerase inhibitor and a putative tumor suppressor, has not been studied in human cancers, including gastric cancer (GC). We examined expression of PINX1 by quantitative reverse transcription (RT)-PCR in 73 cases of GC, and 45 of these cases were further studied for loss of heterozygosity (LOH) by PCR with microsatellite marker D8S277. Reduced expression (tumor vs normal ratio<0.5) of PINX1 was detected in 50 (68.5%) of 73 cases of GC. GC tissues with reduced expression of PINX1 showed significantly higher telomerase activities as measured by telomeric repeat amplification protocol than those with normal expression of PINX1 (P = 0.031). LOH of PINX1 locus was detected in 15 (33.3%) of 45 cases of GC and was correlated significantly with reduced expression of PINX1 (P = 0.031). Expression of PINX1 in a GC cell line, MKN-74, was induced by treatment with trichostatin A (TSA) or nicotinamide (NAM). Chromatin immunoprecipitation assay of MKN-74 cells revealed that acetylation of histone H4 in the 5' untranslated region (UTR) of PINX1 was enhanced by treatment with TSA or NAM, whereas acetylation of histone H3 was not changed by TSA or NAM. In addition, TSA or NAM treatment led to inhibition of telomerase activity in MKN-74 cells. These results indicate that LOH of PINX1 locus and hypoacetylation of histone H4 in the 5' UTR of PINX1 are associated with reduced expression of PINX1 in GC.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, Hiroshima 7348551, Japan; Nara Med Univ, Dept Mol Pathol, Kashihara, Nara 634, Japan; Oita Univ, Fac Med, Dept Oncol Sci Surg 2, Oita 87011, Japan	Hiroshima University; Nara Medical University; Oita University	Yasui, W (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Mol Pathol, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	wyasui@hiroshima-u.ac.jp	Mitani, Yoshitsugu/ABA-2736-2021	Mitani, Yoshitsugu/0000-0002-8661-4702				Akiyama Y, 2004, ONCOL REP, V11, P871; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Baffa R, 2000, CLIN CANCER RES, V6, P1372; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Cong YS, 2002, MICROBIOL MOL BIOL R, V66, P407, DOI 10.1128/MMBR.66.3.407-425.2002; DePinho RA, 2000, NATURE, V408, P248, DOI 10.1038/35041694; EMI M, 1992, CANCER RES, V52, P5368; Ferreira R, 2001, EMBO REP, V2, P794, DOI 10.1093/embo-reports/kve173; FUJIWARA Y, 1993, CANCER RES, V53, P1172; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hamai Y, 2003, CANCER SCI, V94, P692, DOI 10.1111/j.1349-7006.2003.tb01504.x; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kass SU, 1997, TRENDS GENET, V13, P444, DOI 10.1016/S0168-9525(97)01268-7; Kondo T, 2004, CANCER RES, V64, P523, DOI 10.1158/0008-5472.CAN-03-1196; Kuniyasu H, 1997, JPN J CANCER RES, V88, P103, DOI 10.1111/j.1349-7006.1997.tb00353.x; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Liao C, 2000, HEPATOLOGY, V32, P721, DOI 10.1053/jhep.2000.17967; Liao C, 2003, WORLD J GASTROENTERO, V9, P89, DOI 10.3748/wjg.v9.i1.89; Liao C, 2002, WORLD J GASTROENTERO, V8, P1050, DOI 10.3748/wjg.v8.i6.1050; Liloglou T, 2000, INT J ONCOL, V16, P5; Liloglou T, 2001, CANCER RES, V61, P1624; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; MACOSKA JA, 1995, CANCER RES, V55, P5390; Meeker AK, 2002, CANCER RES, V62, P6405; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; O'Sullivan JN, 2002, NAT GENET, V32, P280, DOI 10.1038/ng989; OCHIAI A, 1985, JPN J CANCER RES, V76, P1064; OHATA H, 1993, GENE CHROMOSOME CANC, V7, P85, DOI 10.1002/gcc.2870070204; Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090; Oue N, 2001, INT J CANCER, V93, P805, DOI 10.1002/ijc.1403; Oue N, 2004, CANCER RES, V64, P2397, DOI 10.1158/0008-5472.CAN-03-3514; Oue N, 2003, ONCOLOGY-BASEL, V64, P423, DOI 10.1159/000070302; Oue N, 2002, J PATHOL, V198, P55, DOI 10.1002/path.1170; Park WS, 2002, CANCER LETT, V178, P199, DOI 10.1016/S0304-3835(01)00841-2; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Sobin L. H., 1997, TNM CLASSIFICATION M; Suzuki T, 2000, INT J CANCER, V88, P992, DOI 10.1002/1097-0215(20001215)88:6<992::AID-IJC24>3.0.CO;2-9; Tahara H, 1995, CLIN CANCER RES, V1, P1245; van Heek NT, 2002, AM J PATHOL, V161, P1541, DOI 10.1016/S0002-9440(10)64432-X; YANAGIHARA K, 1991, CANCER RES, V51, P381; YAREMKO ML, 1995, GENE CHROMOSOME CANC, V13, P186, DOI 10.1002/gcc.2870130308; Yasui W, 1999, JPN J CANCER RES, V90, P589, DOI 10.1111/j.1349-7006.1999.tb00787.x; Yasui W, 1998, JPN J CANCER RES, V89, P1099, DOI 10.1111/j.1349-7006.1998.tb00502.x; Yasui Wataru, 2000, Journal of Gastroenterology, V35, P111; Yustein AS, 1999, CANCER RES, V59, P1437; Zhou XZ, 2001, CELL, V107, P347, DOI 10.1016/S0092-8674(01)00538-4	54	35	43	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					157	164		10.1038/sj.onc.1207832	http://dx.doi.org/10.1038/sj.onc.1207832			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15637589				2022-12-17	WOS:000226125800018
J	McIntyre, A; Summersgill, B; Jafer, O; Rodriguez, S; Zafarana, G; Oosterhuis, JW; Gillis, AJM; Looijenga, L; Cooper, C; Huddart, R; Clark, J; Shipley, J				McIntyre, A; Summersgill, B; Jafer, O; Rodriguez, S; Zafarana, G; Oosterhuis, JW; Gillis, AJM; Looijenga, L; Cooper, C; Huddart, R; Clark, J; Shipley, J			Defining minimum genomic regions of imbalance involved in testicular germ cell tumors of adolescents and adults through genome wide microarray analysis of cDNA clones	ONCOGENE			English	Article						TGCT; microarray CGH; regions of imbalance	DIFFERENTIAL EXPRESSION; BREAST-CANCER; HYBRIDIZATION; GENES; KIT; MUTATIONS; PROTEIN; TESTIS; DNA; IDENTIFICATION	Identifying changes in DNA copy number can pinpoint genes that may be involved in tumor development. Here we have defined the smallest overlapping regions of imbalance (SORI) in testicular germ cell tumors other than the 12p region, which has been previously investigated. Definition of the regions was achieved through comparative genomic hybridization (CGH) analysis of a 4559 cDNA clone microarray. A total of 14 SORI were identified, which involved at least five of the 11 samples analysed. Many of these refined regions were previously reported using chromosomal or allelic imbalance studies. The SORI included gain of material from the regions 4q12, 17q21.3, 22q11.23 and Xq22, and loss from 5q33, 11q12.1, 16q22.3 and 22q11. Comparison with parallel chromosomal CGH data supported involvement of most regions. The various SORI span between one and 20 genes and highlight potential oncogenes/tumor suppressor genes to be investigated further (Supplementary material is available at http://www.crukdmf.icr.ac.uk/array/array.html).	Inst Canc Res, Male Urol Canc Res Ctr, Sect Mol Carcinognesis, Sutton SM2 5NG, Surrey, England; Erasmus Univ, Med Ctr, Daniel den Hoed Canc Ctr, Josephine Nefkens Inst, NL-3000 DR Rotterdam, Netherlands; Royal Marsden Natl Hlth Serv Trust, Acad Dept Urol, Sutton, Surrey, England	University of London; Institute of Cancer Research - UK; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Royal Marsden NHS Foundation Trust	Shipley, J (corresponding author), Inst Canc Res, Male Urol Canc Res Ctr, Sect Mol Carcinognesis, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	janet.shipley@icr.ac.uk	Looijenga, Leendert/B-8145-2019; Zafarana, Gaetano/L-8352-2017	Looijenga, Leendert/0000-0002-8146-1911; McIntyre, Alan/0000-0002-4791-7292; huddart, robert/0000-0003-3604-1990; Zafarana, Gaetano/0000-0003-1391-4488; Shipley, Janet/0000-0001-6748-8678				Bartkova J, 2001, ONCOGENE, V20, P5897, DOI 10.1038/sj.onc.1204746; Bokemeyer C, 1996, J CANCER RES CLIN, V122, P301, DOI 10.1007/BF01261407; Bosl GJ, 1997, NEW ENGL J MED, V337, P242, DOI 10.1056/NEJM199707243370406; Chen JZ, 2002, BIOCHEM BIOPH RES CO, V294, P161, DOI 10.1016/S0006-291X(02)00446-1; Clark J, 2002, GENE CHROMOSOME CANC, V34, P104, DOI 10.1002/gcc.10039; Draper JS, 2004, NAT BIOTECHNOL, V22, P53, DOI 10.1038/nbt922; Huang ZD, 2004, MOL CELL BIOL, V24, P1582, DOI 10.1128/MCB.24.4.1582-1594.2004; IZQUIERDO MA, 1995, J PATHOL, V177, P253, DOI 10.1002/path.1711770307; Jakobi R, 2003, J BIOL CHEM, V278, P38675, DOI 10.1074/jbc.M306494200; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; Korn WM, 1996, GENE CHROMOSOME CANC, V17, P78, DOI 10.1002/(SICI)1098-2264(199610)17:2<78::AID-GCC2>3.0.CO;2-Y; Kraggerud SM, 2002, GENE CHROMOSOME CANC, V34, P168, DOI 10.1002/gcc.10058; Looijenga LHJ, 2003, CANCER RES, V63, P7674; Looijenga LHJ, 2000, J PATHOL, V191, P187, DOI 10.1002/(SICI)1096-9896(200006)191:2<187::AID-PATH584>3.0.CO;2-T; Lu YJ, 1999, LUNG CANCER-J IASLC, V23, P61, DOI 10.1016/S0169-5002(98)00093-2; Mitchell RA, 2000, SEMIN CANCER BIOL, V10, P359, DOI 10.1006/scbi.2000.0328; Mostert MMC, 1996, CANCER GENET CYTOGEN, V89, P146, DOI 10.1016/0165-4608(96)00043-X; MOSTOFI FK, 1973, CANCER-AM CANCER SOC, V32, P1186, DOI 10.1002/1097-0142(197311)32:5<1186::AID-CNCR2820320527>3.0.CO;2-8; Ottesen AM, 1997, GENE CHROMOSOME CANC, V20, P412; Pollack JR, 1999, NAT GENET, V23, P41, DOI 10.1038/12640; Rapley EA, 2004, BRIT J CANCER, V90, P2397, DOI 10.1038/sj.bjc.6601880; Rapley EA, 2003, APMIS, V111, P128, DOI 10.1034/j.1600-0463.2003.11101171.x; Ren Y, 2004, ONCOGENE, V23, P4146, DOI 10.1038/sj.onc.1207490; Reome JB, 2004, CLIN IMMUNOL, V111, P69, DOI 10.1016/j.clim.2003.11.013; Rodriguez S, 2003, ONCOGENE, V22, P1880, DOI 10.1038/sj.onc.1206302; SAMBROOK J, 2001, MOL CLONING LA MANUA, V3; Sandberg AA, 1996, J UROLOGY, V155, P1531, DOI 10.1016/S0022-5347(01)66124-X; SHUIN T, 1994, CANCER, V73, P1721, DOI 10.1002/1097-0142(19940315)73:6<1721::AID-CNCR2820730628>3.0.CO;2-W; Skotheim RI, 2001, CANCER GENET CYTOGEN, V127, P64, DOI 10.1016/S0165-4608(00)00433-7; Skotheim RI, 2002, CANCER RES, V62, P2359; Skotheim RI, 2001, NEOPLASIA, V3, P196, DOI 10.1038/sj.neo.7900153; Summersgill BM, 2001, CANCER GENET CYTOGEN, V128, P120, DOI 10.1016/S0165-4608(01)00414-9; VANECHTEN J, 1995, GENE CHROMOSOME CANC, V14, P133, DOI 10.1002/gcc.2870140208; WATSON JV, 1986, BRIT J CANCER, V53, P331, DOI 10.1038/bjc.1986.56; Zafarana G, 2003, ONCOGENE, V22, P7695, DOI 10.1038/sj.onc.1207011	36	35	37	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	2004	23	56					9142	9147		10.1038/sj.onc.1208115	http://dx.doi.org/10.1038/sj.onc.1208115			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	876JN	15489896				2022-12-17	WOS:000225492800016
J	Li, YX; Wu, DC; Chen, B; Ingram, A; He, LH; Liu, LQ; Zhu, DH; Kapoor, A; Tang, DM				Li, YX; Wu, DC; Chen, B; Ingram, A; He, LH; Liu, LQ; Zhu, DH; Kapoor, A; Tang, DM			ATM activity contributes to the tumor-suppressing functions of p14(ARF)	ONCOGENE			English	Article						ARF tumor suppressor; p53 and ATM	CELL-CYCLE ARREST; DNA-DAMAGE; P16(INK4A) GENES; TRANSCRIPTION FACTOR; P53 PROTEIN; MDM2; PATHWAY; CHECKPOINT; APOPTOSIS; P19(ARF)	P14/p19(ARF) (ARF) plays a major role in the activation of p53 by oncogenic signals. The biochemical basis of this has not been fully elucidated. We report here that forced expression of p14(ARF) enhances phosphorylation of p53 serine 15 (p53S15) in NIH3T3, IMR90 and MCF7 cells. Ectopic expression of the oncogenes c-myc, E2F1 and E1A, all of which activate p53 at least partially via ARF, lead to p53S15 phosphorylation in IMR90 cells. In addition, ectopic expression of p53 also results in p53S15 phosphorylation, suggesting that this is a common event in the ARF p53 tumor suppression system. Furthermore, p53-, p14(ARF)-, c-myc- and E2F1-, but not E1A-, induced p53S15 phosphorylation was substantially reduced in AT fibroblasts (GM05823). Downregulation of ATM in MCF7 cells using RNA interference (RNAi) technology significantly attenuated p14ARF- and p53- induced phosphorylation of p53S15. Ectopically expressed ARF in NIH3T3 cells induced ATM nuclear foci and activated ATM kinase. Functionally, ectopic expression of p14(ARF) and c-myc inhibited the proliferation of IMR90 but not ATM null GM05823 cells, and p14ARF- induced inhibition of MCF7 cell proliferation was significantly attenuated by downregulation of ATM by RNAi. Taken together, these data show a functional role for ATM in ARF-mediated tumor suppression.	St Josephs Hosp, Father Sean OSullivan Res Inst, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; Peking Union Med Coll, Natl Lab Med Mol Biol, Dept Biochem, Beijing, Peoples R China; McMaster Univ, Dept Surg, Hamilton, ON L8S 4L8, Canada	McGill University; McMaster University; McMaster University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; McMaster University	Tang, DM (corresponding author), St Josephs Hosp, Father Sean OSullivan Res Inst, L305,50 Carlton Ave E, Hamilton, ON L8N 4A6, Canada.	damut@mcmaster.ca	Kapoor, Anil/AAQ-7184-2021; Zhu, Dahai/ABA-5315-2021; Tang, Damu/AAQ-1786-2021	Kapoor, Anil/0000-0001-9180-8029; Tang, Damu/0000-0002-3282-9521				Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Burri N, 2001, LAB INVEST, V81, P217, DOI 10.1038/labinvest.3780230; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DEOCALUNA R, 1995, NATURE, V0378; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Ho GH, 2001, BREAST CANCER RES TR, V65, P225, DOI 10.1023/A:1010686518990; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Ichimura K, 2000, CANCER RES, V60, P417; Inoue K, 1999, P NATL ACAD SCI USA, V96, P3993, DOI 10.1073/pnas.96.7.3993; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; Jin SK, 2001, J CELL SCI, V114, P4139; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kashuba Elena, 2003, Mol Cancer, V2, P18, DOI 10.1186/1476-4598-2-18; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lyakhovich A, 2003, MOL CELL BIOL, V23, P2463, DOI 10.1128/MCB.23.7.2463-2475.2003; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Olivier A, 2003, ONCOGENE, V22, P1945, DOI 10.1038/sj.onc.1206214; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; QUELLE DE, 1995, CELL, V83, P993; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Rogoff HA, 2002, MOL CELL BIOL, V22, P5308, DOI 10.1128/MCB.22.15.5308-5318.2002; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shintani S, 2001, ORAL ONCOL, V37, P498, DOI 10.1016/S1368-8375(00)00142-1; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Tang DM, 2002, J BIOL CHEM, V277, P12710, DOI 10.1074/jbc.M111598200; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Watanabe T, 2001, ACTA NEUROPATHOL, V101, P185; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu DC, 2002, J BIOL CHEM, V277, P12001, DOI 10.1074/jbc.M109219200; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	53	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2004	23	44					7355	7365		10.1038/sj.onc.1207957	http://dx.doi.org/10.1038/sj.onc.1207957			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	856CO	15258567				2022-12-17	WOS:000224021400006
J	Spierings, DCJ; de Vries, EGE; Stel, AJ; Rietstap, NT; Vellenga, E; de Jong, S				Spierings, DCJ; de Vries, EGE; Stel, AJ; Rietstap, NT; Vellenga, E; de Jong, S			Low p21(Waf1/Cip1) protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis	ONCOGENE			English	Article						TGCT; p21; Fas; cisplatin; irradiation	BCL-X-L; CISPLATIN-INDUCED APOPTOSIS; 3/P21 COMPLEX-FORMATION; WILD-TYPE P53; GAMMA-IRRADIATION; DNA-DAMAGE; C-ABL; TRANSCRIPTION FACTOR; RNA INTERFERENCE; SUPPRESSOR GENE	In the present study, we investigated the relation between p21 expression and the sensitivity of testicular germ cell tumor (TGCT) cells to apoptotic stimuli. Despite similar cisplatin-induced wild-type p53 accumulation, the TGCT cell lines Tera and Scha expressed low p21 protein and mRNA levels in comparison to A2780 ovarian cancer cells. Inhibition of the proteasome complex with MG-132 increased p21 protein levels in TGCT cells but much more in A2780 cells, whereas cisplatin had no additional effect on p21 protein levels. Inhibition of caspase-3 activity in TGCT cells with the broad-spectrum caspase inhibitor zVAD-fmk had no effect on p21 levels and also not upon cisplatin treatment. A similar induction of p53 irradiation, in contrast to cisplatin, substantially increased both p21 mRNA and protein expression in Tera cells. Cisplatin-treated Tera cells expressing low p21 protein levels were Fas-sensitive, while irradiation-induced p21, which was mainly localized in the cytosol, rendered irradiated Tera cells resistant to Fas-induced apoptosis. Sensitivity of irradiated Tera cells to Fas-induced apoptosis was restored by short interfering RNA-specific suppression of p21 expression. These results strongly indicate that the low p21 protein levels are caused by reduced p21 gene transcription and sensitize cisplatin-treated TGCT cells to the Fas death pathway.	Univ Groningen Hosp, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands; Univ Groningen Hosp, Dept Hematol, NL-9713 GZ Groningen, Netherlands	University of Groningen; University of Groningen	de Jong, S (corresponding author), Univ Groningen Hosp, Dept Med Oncol, NL-9713 GZ Groningen, Netherlands.	s.de.jong@int.azg.nl		Spierings, Diana/0000-0001-8403-474X; de Vries, Elisabeth/0000-0002-8949-7425				Agami R, 1999, NATURE, V399, P809; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Arriola EL, 1999, ONCOGENE, V18, P1457, DOI 10.1038/sj.onc.1202420; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bartkova J, 2000, INT J CANCER, V85, P370, DOI 10.1002/(SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO;2-A; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Burger H, 1997, INT J CANCER, V73, P592, DOI 10.1002/(SICI)1097-0215(19971114)73:4<592::AID-IJC22>3.0.CO;2-A; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; Burger H, 1998, INT J RADIAT ONCOL, V41, P415, DOI 10.1016/S0360-3016(98)00065-0; Butz K, 1998, ONCOGENE, V17, P781, DOI 10.1038/sj.onc.1201995; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Charette SJ, 2000, MOL CELL BIOL, V20, P7602, DOI 10.1128/MCB.20.20.7602-7612.2000; Chresta CM, 1996, CANCER RES, V56, P1834; Cram EJ, 1998, J BIOL CHEM, V273, P2008, DOI 10.1074/jbc.273.4.2008; Datta MW, 2001, MODERN PATHOL, V14, P437, DOI 10.1038/modpathol.3880331; DEJONG S, 1993, INT J CANCER, V53, P110, DOI 10.1002/ijc.2910530121; DEJONG S, 1999, P AM ASSOC CANC RES, V40, P4588; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dijkhuizen T, 1996, INT J CANCER, V68, P47, DOI 10.1002/(SICI)1097-0215(19960927)68:1<47::AID-IJC9>3.0.CO;2-X; Einhorn LH, 2002, P NATL ACAD SCI USA, V99, P4592, DOI 10.1073/pnas.072067999; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fillippovich I, 2001, ONCOGENE, V20, P514, DOI 10.1038/sj.onc.1204118; Fulda S, 1998, CELL DEATH DIFFER, V5, P884, DOI 10.1038/sj.cdd.4400419; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Glaser T, 2001, ONCOGENE, V20, P4757, DOI 10.1038/sj.onc.1204498; Gong JG, 1999, NATURE, V399, P806; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Guillou L, 1996, AM J PATHOL, V149, P1221; Hara S, 2001, UROLOGY, V58, P471, DOI 10.1016/S0090-4295(01)01172-4; Hiyama H, 1998, ONCOGENE, V16, P1513, DOI 10.1038/sj.onc.1201667; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; HUDDART RA, 1995, EUR J CANCER, V31A, P739, DOI 10.1016/0959-8049(95)00047-M; Johnstone RW, 2002, MOL CELL, V10, P695, DOI 10.1016/S1097-2765(02)00693-7; Kersemaekers AMF, 2002, J PATHOL, V196, P423, DOI 10.1002/path.1058; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kimura K, 2000, J BIOL CHEM, V275, P8610, DOI 10.1074/jbc.275.12.8610; Ko YG, 2001, J BIOL CHEM, V276, P39103, DOI 10.1074/jbc.M105928200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Levrero M, 2000, J CELL SCI, V113, P1661; Lundberg AS, 1999, EUR J CANCER, V35, P1886, DOI 10.1016/S0959-8049(99)00292-0; Lutzker SG, 1998, APMIS, V106, P85, DOI 10.1111/j.1699-0463.1998.tb01323.x; Lutzker SG, 2001, ONCOGENE, V20, P2982, DOI 10.1038/sj.onc.1204394; Malashicheva AB, 2000, ONCOGENE, V19, P3858, DOI 10.1038/sj.onc.1203736; MASTERS JRW, 1993, INT J CANCER, V53, P340, DOI 10.1002/ijc.2910530228; MICHIELI P, 1994, CANCER RES, V54, P3391; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Ogawa Y, 1998, INT J MOL MED, V2, P435; Prives C, 1999, J PATHOL, V187, P112; RIOU G, 1995, MOL CARCINOGEN, V12, P124, DOI 10.1002/mc.2940120303; SARK MWJ, 1995, BRIT J CANCER, V71, P684, DOI 10.1038/bjc.1995.135; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Schepers H, 2003, LEUKEMIA, V17, P2113, DOI 10.1038/sj.leu.2403106; Sheard MA, 1999, BRIT J CANCER, V80, P1689, DOI 10.1038/sj.bjc.6690585; Shen Y, 2001, ADV CANCER RES, V82, P55, DOI 10.1016/S0065-230X(01)82002-9; Skilling JS, 1996, GYNECOL ONCOL, V60, P72, DOI 10.1006/gyno.1996.0014; Snowden AW, 2000, MOL CELL BIOL, V20, P2676, DOI 10.1128/MCB.20.8.2676-2686.2000; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Spierings DCJ, 2003, CELL DEATH DIFFER, V10, P808, DOI 10.1038/sj.cdd.4401248; Spierings DCJ, 2003, J PATHOL, V200, P137, DOI 10.1002/path.1373; Stiewe T, 2002, J BIOL CHEM, V277, P14177, DOI 10.1074/jbc.M200480200; Sugihara A, 1997, ANTICANCER RES, V17, P3861; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Suzuki A, 1999, MOL CELL BIOL, V19, P3842; Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429; Tsai KKC, 2003, CANCER RES, V63, P3418; Vikhanskaya F, 2000, NUCLEIC ACIDS RES, V28, P513, DOI 10.1093/nar/28.2.513; Xiang H, 2002, ONCOGENE, V21, P3611, DOI 10.1038/sj.onc.1205449; Xu SQ, 2000, BIOCHEM BIOPH RES CO, V269, P179, DOI 10.1006/bbrc.2000.2247; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78; Zhang YK, 1999, ONCOGENE, V18, P1131, DOI 10.1038/sj.onc.1202426	78	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2004	23	28					4862	4872		10.1038/sj.onc.1207617	http://dx.doi.org/10.1038/sj.onc.1207617			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	830EK	15122333				2022-12-17	WOS:000222104200007
J	Lu, M; Xia, LJ; Luo, D; Waxman, S; Jing, YK				Lu, M; Xia, LJ; Luo, D; Waxman, S; Jing, YK			Dual effects of glutathione-S-transferase pi on As2O3 action in prostate cancer cells: enhancement of growth inhibition and inhibition of apoptosis	ONCOGENE			English	Article						arsenic trioxide; prostate cancer; glutathione-S-transferase pi	ACUTE PROMYELOCYTIC LEUKEMIA; ARSENIC TRIOXIDE AS2O3; ACTIVATION; RESISTANT; EXPRESSION; PROTEIN; ERK; DIFFERENTIATION; TOXICITY; INDUCER	To determine the effects of glutathione-S-transferase pi (GSTpi) on the actions of As2O3, As2O3-induced growth inhibition and apoptosis was studied in three prostate cancer cell lines: DU-145, PC-3 and LNCaP cells. As2O3 inhibited cell proliferation of DU-145 and PC-3 cells ( both cells express GSTpi), but not of LNCaP cells ( which lack GSTpi expression) at concentrations below 1 muM. LNCaP cells stably transfected and expressed GSTpi (LNCaP/GSTpi) became sensitive to As2O3 growth inhibition. As2O3 arrested cell growth of DU-145, PC-3 and LNCaP/GSTpi cells in the G2/M phase of the cell cycle at low concentrations (<2 mu M), but did not induce apoptosis. At higher concentrations (10-20 mu M), As2O3 induced apoptosis in LNCaP cells, but not in DU-145 or PC-3 cells. The apoptosis induction due to As2O3 treatment of LNCaP cell correlated with the activation of JNK and p38 and induction of p53 protein. LNCaP/GSTp cells became insensitive to As2O3-induced apoptosis with reduced JNK activition. These data indicate that GST pi increases growth inhibition due to As2O3 treatment and prevents As2O3-induced apoptosis in prostate cancer cells. Therefore, it appears that As2O3 inhibits cell growth and induces apoptosis through different mechanisms.	CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Jing, YK (corresponding author), CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, Box 1178, New York, NY 10029 USA.	yongkui.jing@mssm.edu			NCI NIH HHS [CA93533, CA85478] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA093533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Blagosklonny MV, 2002, INT J CANCER, V98, P161, DOI 10.1002/ijc.10158; Bode A, 2000, DRUG RESIST UPDATE, V3, P21, DOI 10.1054/drup.2000.0114; Chen GQ, 2003, CANCER RES, V63, P1853; Chen GQ, 1997, BLOOD, V89, P3345; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; Cookson MS, 1997, J UROLOGY, V157, P673, DOI 10.1016/S0022-5347(01)65248-0; Dai J, 1999, BLOOD, V93, P268, DOI 10.1182/blood.V93.1.268.401a21_268_277; Gurr JR, 1999, MOL PHARMACOL, V56, P102, DOI 10.1124/mol.56.1.102; Huang CS, 1999, J BIOL CHEM, V274, P14595, DOI 10.1074/jbc.274.21.14595; Huang MJ, 2002, LEUKEMIA LYMPHOMA, V43, P2191, DOI 10.1080/1042819021000032980; Iwama K, 2001, INT J CANCER, V92, P518, DOI 10.1002/ijc.1220; Jing YK, 1997, CANCER RES, V57, P1668; Jing YK, 1999, BLOOD, V94, P2102, DOI 10.1182/blood.V94.6.2102; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Leszczyniecka M, 2002, P NATL ACAD SCI USA, V99, P16636, DOI 10.1073/pnas.252643699; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Liu J, 2001, MOL PHARMACOL, V60, P302, DOI 10.1124/mol.60.2.302; Liu YS, 1996, FREE RADICAL BIO MED, V21, P771, DOI 10.1016/0891-5849(96)00176-1; LO JF, 1992, BIOCHEM J, V288, P977, DOI 10.1042/bj2880977; Ludwig S, 1998, J BIOL CHEM, V273, P1917, DOI 10.1074/jbc.273.4.1917; Moskaluk CA, 1997, CANCER-AM CANCER SOC, V79, P1595, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1595::AID-CNCR23>3.0.CO;2-S; Park JW, 2001, BIOCHEM BIOPH RES CO, V286, P726, DOI 10.1006/bbrc.2001.5416; Polek TC, 2003, ENDOCRINOLOGY, V144, P50, DOI 10.1210/en.2001-210109; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551, DOI 10.1152/ajplung.1998.275.3.L551; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Styblo M, 2002, ENVIRON HEALTH PERSP, V110, P767, DOI 10.1289/ehp.02110s5767; Styblo M, 2000, ARCH TOXICOL, V74, P289, DOI 10.1007/s002040000134; WANG HF, 1993, BIOCHEM BIOPH RES CO, V192, P1093, DOI 10.1006/bbrc.1993.1529; Wang T, 2001, J BIOL CHEM, V276, P20999, DOI 10.1074/jbc.M101355200; Wang ZL, 1996, TOXICOL APPL PHARM, V137, P112, DOI 10.1006/taap.1996.0062; Wu GS, 1998, ONCOGENE, V16, P2177, DOI 10.1038/sj.onc.1201755; Yang CH, 1999, BRIT J CANCER, V81, P796, DOI 10.1038/sj.bjc.6690766; Yin ZM, 2000, CANCER RES, V60, P4053	36	35	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 13	2004	23	22					3945	3952		10.1038/sj.onc.1207500	http://dx.doi.org/10.1038/sj.onc.1207500			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	820IQ	15007384				2022-12-17	WOS:000221382000006
J	Chen, J; Yu, WM; Bunting, KD; Qu, CK				Chen, J; Yu, WM; Bunting, KD; Qu, CK			A negative role of SHP-2 tyrosine phosphatase in growth factor-dependent hematopoietic cell survival	ONCOGENE			English	Article						SHP-2; tyrosine phosphatase; hematopoietic cell survival; STAT5; IL-3	CYCLE PROGRESSION; BONE-MARROW; STAT5; PROTEIN; EXPRESSION; DIFFERENTIATION; PHOSPHORYLATION; APOPTOSIS; BINDING; DEATH	SHP-2 tyrosine phosphatase is highly expressed in hematopoietic cells; however, the function of SHP-2 in hematopoietic cell processes is not fully understood. Recent identification of SHP-2 mutations in childhood leukemia further emphasizes the importance of SHP-2 regulation in hematopoietic cells. We previously reported that SHP-2 played a positive role in IL-3-induced activation of Jak2 kinase in a catalytic-dependent manner. Interestingly, enforced expression of wild-type (WT) SHP-2 in Ba/F3 cells enhanced growth factor deprivation-induced apoptosis. Biochemical analyses revealed that although IL-3 activation of Jak2 kinase was increased, tyrosyl phosphorylation of its downstream substrate STAT5 was disproportionately decreased by the overexpression of SHP-2. Following IL-3 deprivation, the tyrosyl phosphorylation of STAT5 that is required for its antiapoptotic activity was rapidly diminished in SHP-2 overexpressing cells. As a result, reduction of the putative downstream targets of STAT5- Bcl-X-L and pim-1 was accelerated by overexpression of SHP-2. Further investigation showed that SHP-2 associated with STAT5, and that it was indeed able to dephosphorylate STAT5. Finally, overexpression of SHP-2 in primary bone marrow hematopoietic progenitor cells compromised their differentiative and proliferative potential, and enhanced growth factor withdrawal-induced cell death. And, the effect of SHP-2 overexpression on growth factor-dependent survival was diminished in STAT5-deficient hematopoietic cells. Taken together, these results suggest that SHP-2 tyrosine phosphatase negatively regulates hematopoietic cell survival by dephosphorylation of STAT5.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, Rockville, MD 20855 USA; George Washington Univ, Med Ctr, Dept Anat & Cell Biol, Washington, DC 20037 USA	American Red Cross; George Washington University	Qu, CK (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, Dept Hematopoiesis, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.	quc@usa.redcross.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068212] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059380] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL68212] Funding Source: Medline; NIDDK NIH HHS [R01 DK059380] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aoki N, 2000, J BIOL CHEM, V275, P39718, DOI 10.1074/jbc.M005615200; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Chan RJ, 2003, BLOOD, V102, P2074, DOI 10.1182/blood-2003-04-1171; CHEN Y, 2003, J BIOL CHEM, V278, P165; Chughtai N, 2002, J BIOL CHEM, V277, P31107, DOI 10.1074/jbc.M200156200; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Qu CK, 1998, ONCOGENE, V17, P433, DOI 10.1038/sj.onc.1201920; Qu CK, 2002, BBA-MOL CELL RES, V1592, P297, DOI 10.1016/S0167-4889(02)00322-1; Qu CK, 2001, BLOOD, V97, P911, DOI 10.1182/blood.V97.4.911; Qu CK, 1998, MOL CELL BIOL, V18, P6075, DOI 10.1128/MCB.18.10.6075; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Rane SG, 2002, ONCOGENE, V21, P3334, DOI 10.1038/sj.onc.1205398; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Shelburne CP, 2003, BLOOD, V102, P1290, DOI 10.1182/blood-2002-11-3490; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Shinjyo T, 2001, MOL CELL BIOL, V21, P854, DOI 10.1128/MCB.21.3.854-864.2001; Silva M, 1999, J BIOL CHEM, V274, P22165, DOI 10.1074/jbc.274.32.22165; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Wheadon H, 2003, BIOCHEM J, V376, P147, DOI 10.1042/BJ20031160; Wickremasinghe RG, 1999, BLOOD, V93, P3587, DOI 10.1182/blood.V93.11.3587.411k46_3587_3600; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; Yu WM, 2003, ONCOGENE, V22, P5995, DOI 10.1038/sj.onc.1206846; Yu WM, 2002, BLOOD, V99, P2351, DOI 10.1182/blood.V99.7.2351; Yuan LP, 2003, J BIOL CHEM, V278, P15208, DOI 10.1074/jbc.M211327200; Zamorano J, 1998, J IMMUNOL, V160, P3502; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	42	35	37	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 29	2004	23	20					3659	3669		10.1038/sj.onc.1207471	http://dx.doi.org/10.1038/sj.onc.1207471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	816HT	15116097				2022-12-17	WOS:000221101700018
J	Rivat, C; De Wever, O; Bruyneel, E; Mareel, M; Gespach, C; Attoub, S				Rivat, C; De Wever, O; Bruyneel, E; Mareel, M; Gespach, C; Attoub, S			Disruption of STAT3 signaling leads to tumor cell invasion through alterations of homotypic cell-cell adhesion complexes	ONCOGENE			English	Article						beta-catenin; E-cadherin tumor suppressor gene; EGF-R; PI3-kinase; Rho GTPases; Wnt pathway	EPIDERMAL-GROWTH-FACTOR; ANCHORAGE-INDEPENDENT GROWTH; HUMAN COLON-CANCER; BETA-CATENIN; TYROSINE PHOSPHORYLATION; FACTOR RECEPTOR; CONSTITUTIVE ACTIVATION; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; FOCAL ADHESIONS	STAT3 is frequently overexpressed and constitutively activated by tyrosine phosphorylation during malignant transformation. Despite the clear importance of STAT3 in cell proliferation and survival in diverse human cancers, its possible contribution to tumor cell adhesion, motility and invasion remains hypothetical. We therefore compared the transforming properties of STAT3wt, its constitutively activated dimeric form STAT3C, and the dominant negative mutant STAT3-Y705F in human colorectal HCT8/S11 cancer cells. Both STAT3wt and STAT3C exert a permissive action to the proinvasive activity of the scatter factor HGF in HCT8/S11 cells. In contrast, the monomeric and cytoplasmic mutant Y705F induces a constitutive invasive phenotype through Wnt/Rho-independent and EGFR/PI3-kinase-dependent pathways. Accordingly, Y705F decreases cell-cell homotypic adhesions, and increases cell motility and scattering, as well as lamellipodia-type cellular extensions. STAT3-Y705F-transfected HCT8/S11 cells display an increased tyrosine phosphorylation of the cell-cell adhesion regulator beta-catenin and its dissociation from the invasion suppressor E-cadherin at cell-cell contacts. Our data imply that both invasion promoter and repressor genes are controlled by the canonical STAT3 transcription pathways. Disruption of this cascade by Y705F reveals the proinvasive potential of altered forms of STAT3 as a persistent signaling adaptor in cytokine/transforming growth factor receptor scaffolds and oncogenic pathways.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital	Attoub, S (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	attoub@st-antoine.inserm.fr	Attoub, Samir/N-6852-2018; de wever, olivier/J-3094-2013	de wever, olivier/0000-0002-5453-760X				Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Boterberg T, 2000, CELL ADHES COMMUN, V7, P299, DOI 10.3109/15419060009015001; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; BRACKE ME, 2000, COLLAGEN INVASION AS, V58, P81; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; Danilkovitch-Miagkova A, 2001, MOL CELL BIOL, V21, P5857, DOI 10.1128/MCB.21.17.5857-5868.2001; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Florenes VA, 1999, ONCOGENE, V18, P1023, DOI 10.1038/sj.onc.1202382; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Goiot H, 2001, GASTROENTEROLOGY, V121, P1417, DOI 10.1053/gast.2001.29581; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hellyer NJ, 1998, BIOCHEM J, V333, P757, DOI 10.1042/bj3330757; Hiscox S, 1999, J CELL SCI, V112, P3081; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huang M, 2000, GYNECOL ONCOL, V79, P67, DOI 10.1006/gyno.2000.5931; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Ilan N, 1999, J CELL SCI, V112, P3005; Irby RB, 2002, CANCER RES, V62, P2669; Kim K, 2001, CELL BIOL INT, V25, P421, DOI 10.1006/cbir.2000.0650; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; Kortylewski M, 1999, ONCOGENE, V18, P3742, DOI 10.1038/sj.onc.1202708; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Laird AD, 2003, MOL CANCER THER, V2, P461; Matsui T, 2002, J BIOL CHEM, V277, P36167, DOI 10.1074/jbc.M203184200; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Ning ZQ, 2001, ONCOGENE, V20, P4528, DOI 10.1038/sj.onc.1204590; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; OSUGI T, 2001, J BIOL CHEM, V14, P14; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Price JT, 1996, EUR J CANCER, V32A, P1977, DOI 10.1016/0959-8049(96)00207-9; RADINSKY R, 1995, CLIN CANCER RES, V1, P19; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Rodrigues S, 2003, ONCOGENE, V22, P4488, DOI 10.1038/sj.onc.1206685; Rosenblum CI, 1996, ENDOCRINOLOGY, V137, P5178, DOI 10.1210/en.137.11.5178; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sartor CI, 1997, CANCER RES, V57, P978; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Spiotto MT, 2000, PROSTATE, V42, P186, DOI 10.1002/(SICI)1097-0045(20000215)42:3<186::AID-PROS4>3.0.CO;2-E; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Turner T, 1996, CLIN EXP METASTAS, V14, P409, DOI 10.1007/BF00123400; Uttamsingh S, 2003, J BIOL CHEM, V278, P18798, DOI 10.1074/jbc.M211522200; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Xi SC, 2003, J BIOL CHEM, V278, P31574, DOI 10.1074/jbc.M303499200; Xia L, 2002, J BIOL CHEM, V277, P30716, DOI 10.1074/jbc.M202823200; Xie H, 1998, J CELL SCI, V111, P615; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yoshioka K, 1998, J BIOL CHEM, V273, P5146, DOI 10.1074/jbc.273.9.5146; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	75	35	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2004	23	19					3317	3327		10.1038/sj.onc.1207437	http://dx.doi.org/10.1038/sj.onc.1207437			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	814LA	15077188				2022-12-17	WOS:000220975000006
J	Sukhai, MA; Wu, XM; Xuan, YL; Zhang, T; Reis, PP; Dube, K; Rego, EM; Bhaumik, M; Bailey, DJ; Wells, RA; Kamel-Reid, S; Pandolfi, PP				Sukhai, MA; Wu, XM; Xuan, YL; Zhang, T; Reis, PP; Dube, K; Rego, EM; Bhaumik, M; Bailey, DJ; Wells, RA; Kamel-Reid, S; Pandolfi, PP			Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RAR alpha	ONCOGENE			English	Article						acute promyelocytic leukemia; NuMA-RAR alpha; transgenic model; immunophenotype	ACID RECEPTOR-ALPHA; CHROMOSOMAL-ABNORMALITIES; PML/RAR-ALPHA; T(15-17) TRANSLOCATION; VARIANT TRANSLOCATION; PMLRAR-ALPHA; BONE-MARROW; PROTEIN; FUSION; APL	Acute promyelocytic leukemia (APL) is characterized by the accumulation of abnormal promyelocytes in the bone marrow (BM), and by the presence of a reciprocal chromosomal translocation involving retinoic acid receptor alpha (RARalpha). To date, five RARalpha partner genes have been identified in APL. NuMA-RARalpha was identified in a pediatric case of APL carrying a translocation t(11;17)(q13;q21). Using a construct containing the NuMA-RARalpha fusion gene driven by the human cathepsin G promoter (hCG-NuMA-RARalpha), two transgenic mouse lines were generated. Transgenic mice were observed to have a genetic myeloproliferation (increased granulopoiesis in BM) at an early age, and rapidly developed a myeloproliferative disease-like myeloid leukemia. This leukemia was morphologically and immunophenotypically indistinguishable from human APL, with a penetrance of 100%. The phenotype of transgenic mice was consistent with a blockade of neutrophil differentiation. NuMA-RARalpha is therefore sufficient for disease development in this APL model.	Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Hlth Network, Ontario Canc Inst, Dept Cellular & Mol Biol, Toronto, ON, Canada; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Mol & Dev Biol Lab, Program Mol Biol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Pathol, New York, NY 10021 USA; Univ Hlth Network, Ontario Canc Inst, Dept Pathol, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Kamel-Reid, S (corresponding author), Princess Margaret Hosp, Ontario Canc Inst, Room 9-622,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	s.kamel.reid@utoronto.ca	Rego, Eduardo M/A-1058-2012; Rego, Eduardo/AFS-7973-2022; Rego, Eduardo M./Y-5572-2019; dos Reis, Patricia Pintor/F-4701-2012	Rego, Eduardo M/0000-0003-1567-4086; Rego, Eduardo/0000-0003-1567-4086; Rego, Eduardo M./0000-0003-1567-4086; dos Reis, Patricia Pintor/0000-0003-3775-3797; Kamel-Reid, Suzanne/0000-0002-4386-0292	NCI NIH HHS [R01 CA71692, U01 CA84292, R01 CA74031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA084292, R01CA071692, R01CA074031] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Cheng GX, 1999, P NATL ACAD SCI USA, V96, P6318, DOI 10.1073/pnas.96.11.6318; COMPTON DA, 1993, J CELL BIOL, V120, P947, DOI 10.1083/jcb.120.4.947; COMPTON DA, 1992, J CELL BIOL, V116, P1395, DOI 10.1083/jcb.116.6.1395; David G, 1997, ONCOGENE, V14, P1547, DOI 10.1038/sj.onc.1200989; de Botton S, 2000, BRIT J HAEMATOL, V111, P801, DOI 10.1046/j.1365-2141.2000.02442.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Early E, 1996, P NATL ACAD SCI USA, V93, P7900, DOI 10.1073/pnas.93.15.7900; GRIGNANI F, 1994, BLOOD, V83, P10; Grisolano JL, 1997, BLOOD, V89, P376, DOI 10.1182/blood.V89.2.376; HARMON DC, 1991, LEUKEMIAS, P399; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; He LZ, 1999, ONCOGENE, V18, P5278, DOI 10.1038/sj.onc.1203088; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Kelly LM, 2002, P NATL ACAD SCI USA, V99, P8283, DOI 10.1073/pnas.122233699; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Labrecque J, 1998, BLOOD, V92, P607, DOI 10.1182/blood.V92.2.607.414k06_607_615; Lane AA, 2002, BLOOD, V100, p538A; Le Beau MM, 2002, BLOOD, V99, P2985, DOI 10.1182/blood.V99.8.2985; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; Okubo T, 2000, CELL STRUCT FUNCT, V25, P133, DOI 10.1247/csf.25.133; PAIETTA E, 1994, LEUKEMIA, V8, P1108; Pollock JL, 1999, P NATL ACAD SCI USA, V96, P15103, DOI 10.1073/pnas.96.26.15103; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Rego EM, 2001, SEMIN HEMATOL, V38, P54, DOI 10.1053/shem.2001.20865; Reis PP, 2002, ONCOGENE, V21, P6480, DOI 10.1038/sj.onc.1205864; Rizzatti EG, 2002, AM J CLIN PATHOL, V118, P31, DOI 10.1309/6U82-2WNG-4KX3-HBMA; ROWLEY JD, 1977, INT J CANCER, V20, P869, DOI 10.1002/ijc.2910200608; ROWLEY JD, 1977, LANCET, V1, P549; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Vickers M, 2000, LEUKEMIA, V14, P722, DOI 10.1038/sj.leu.2401722; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Weir EG, 2001, SEMIN HEMATOL, V38, P124, DOI 10.1053/shem.2001.21924; Wells RA, 1996, LEUKEMIA, V10, P735; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Westervelt P, 1998, BLOOD, V92, p211A; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zimonjic DB, 2000, P NATL ACAD SCI USA, V97, P13306, DOI 10.1073/pnas.97.24.13306	48	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 22	2004	23	3					665	678		10.1038/sj.onc.1207073	http://dx.doi.org/10.1038/sj.onc.1207073			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	765VK	14737102				2022-12-17	WOS:000188304900005
J	Wolff, L; Garin, MT; Koller, R; Bies, J; Liao, W; Malumbres, M; Tessarollo, L; Powell, D; Perella, C				Wolff, L; Garin, MT; Koller, R; Bies, J; Liao, W; Malumbres, M; Tessarollo, L; Powell, D; Perella, C			Hypermethylation of the Ink4b locus in murine myeloid leukemia and increased susceptibility to leukemia in p15(Ink4b)-defficient mice	ONCOGENE			English	Article						tumor suppressor; myeloid leukemia; hypermethylation; retrovirus; Ink4b	KINASE INHIBITOR P15(INK4B); TUMOR-SUPPRESSOR; C-MYB; METHYLATION; INACTIVATION; P16(INK4A); EXPRESSION; P19(ARF); CELLS; ASSAY	The Ink4b gene (Cdkn2b) encodes p15(Ink4b), a cyclin-dependent kinase inhibitor. It has been implicated in playing a role in the development of acute myeloid leukemia (AML) in man, since it is hypermethylated with high frequency. We provide evidence that the gene is a tumor suppressor for myeloid leukemia in mice. The evidence is twofold: (1) retrovirus-induced myeloid leukemias of the myelomonocytic phenotype were found to have hypermethylation of the 5' CpG island of the Ink4b gene, and this could be correlated with reduced mRNA expression, as demonstrated by TaqMan real-time PCR. p15(Ink4b) mRNA expression in a leukemia cell line, with hypermethylation at the locus, was induced following treatment with 5-aza-2'-deoxycytidine.(2) Targeted deletion of one allele in mice by removal of exon 2 increases their susceptibility to retrovirus-induced myeloid leukemia. Mice deficient in both alleles were not more susceptible to myeloid disease than those deficient in one allele, raising the possibility that there are opposing forces related to the development of myeloid leukemia in Ink4b null mice.	NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Ctr Nacl Invest Oncol, E-28029 Madrid, Spain; NCI, SAIC Frederick, Bethesda, MD 20892 USA; NCI, Data Management Serv, Frederick, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wolff, L (corresponding author), NCI, Ctr Canc Res, NIH, Bldg 37,Room 4124A,37 Convent Dr MSC 4255, Bethesda, MD 20892 USA.	lwolff@helix.nih.gov	Malumbres, Marcos/E-8834-2011	Malumbres, Marcos/0000-0002-0829-6315				Amanullah A, 2000, BLOOD, V96, P475; Bonin A, 2000, METH MOL B, V158, P121; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chin L, 1998, TRENDS BIOCHEM SCI, V23, P291, DOI 10.1016/S0968-0004(98)01236-5; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Fekete E, 1938, AM J PATHOL, V14, P557; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Haviernik P, 2003, ONCOGENE, V22, P1600, DOI 10.1038/sj.onc.1206268; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P16; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; NAZAROV V, 1994, VIROLOGY, V205, P479, DOI 10.1006/viro.1994.1668; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; Ruas M, 1998, BIOCHIM BIOPHYS ACTA, V1378, P115, DOI 10.1016/s0304-419x(98)00017-1; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schmidt M, 2001, ONCOGENE, V20, P6205, DOI 10.1038/sj.onc.1204821; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Stirewalt DEREK L., 2000, Hematology, V5, P15; Teofili L, 2000, EXP HEMATOL, V28, P519, DOI 10.1016/S0301-472X(00)00139-9; Tessarollo L, 2000, METH MOL B, V158, P47; Wolff L, 2003, J VIROL, V77, P4965, DOI 10.1128/JVI.77.8.4965-4971.2003; Wolff L, 2001, BLOOD CELL MOL DIS, V27, P483, DOI 10.1006/bcmd.2001.0409	31	35	35	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 18	2003	22	58					9265	9274		10.1038/sj.onc.1207092	http://dx.doi.org/10.1038/sj.onc.1207092			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	755JU	14681685				2022-12-17	WOS:000187400400008
J	Germani, A; Prabel, A; Mourah, S; Podgorniak, MP; Di Carlo, A; Ehrlich, R; Gisselbrecht, S; Varin-Blank, N; Calvo, F; Bruzzoni-Giovanelli, H				Germani, A; Prabel, A; Mourah, S; Podgorniak, MP; Di Carlo, A; Ehrlich, R; Gisselbrecht, S; Varin-Blank, N; Calvo, F; Bruzzoni-Giovanelli, H			SIAH-1 interacts with CtIP and promotes its degradation by the proteasome pathway	ONCOGENE			English	Article						SIAH-1; CtIP; p21(Waf-1/Cip-1); protein degradation; transcription; ubiquitin; E3 ligase	TRANSCRIPTIONAL REPRESSOR; CHROMOSOME ALIGNMENT; TUMOR SUPPRESSION; BINDING-PROTEIN; DNA-DAMAGE; BRCA1; CTBP; COREPRESSOR; MECHANISM; XKID	SIAH-1 and SIAH-2 are the human members of an evolutionary highly conserved E3 ligase family. SIAH-1 is a p53 and p21(Waf-1/Cip-1) induced gene during apoptosis and tumor suppression. In stable-transfected clones of MCF-7 cells, SIAH-1 overexpression was associated with apoptosis, mitotic alterations and p21(Waf-1/Cip-1) induction of expression. Using a two-hybrid screening, we identified here the transcriptional corepressor CtBP-interacting protein (CtIP) as a SIAH-1-interacting protein. CtIP has been proposed as a regulator of p21(Waf-1/Cip-1) gene transcription through a protein complex involving BRCA1. We demonstrate that SIAH-1 associates with CtIP both in vitro and in vivo. This interaction led to CtIP degradation by the ubiquitin-proteasome pathway. As expected, SIAH-1 induced p21(Waf-1/Cip-1) transcription in Jurkat-T cell. Surprisingly, a SIAH protein deleted of its RING finger, SIAH-1DeltaN, which is able to interact with CtIP but does not promote its degradation, also induced transcription from the p21(Waf-1) promoter in a similar extent as did SIAH-1. Our results suggest that p21(Waf-1/Cip-1) induction by SIAH-1 could not be mediated by CtIP degradation.	Hop St Louis, INSERM, EMI 0334, Inst Genet Mol,Lab Pharmacol Expt & Clin, F-75010 Paris, France; Ctr Cardiol Fdn I Monzino, IRCCS, Lab Vasc Biol & Gene Therapy, I-20138 Milan, Italy; Univ Paris 05, Hop Cochin, Inst Cochin, Dept Hematol,CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France; Fac Ciencias, Secc Bioquim, Montevideo, Uruguay	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; IRCCS Centro Cardiologico Monzino; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universidad de la Republica, Uruguay	Bruzzoni-Giovanelli, H (corresponding author), Hop St Louis, INSERM, EMI 0334, Inst Genet Mol,Lab Pharmacol Expt & Clin, 27 Rue Juliette Dodu, F-75010 Paris, France.		Di Carlo, Anna/AAY-4368-2021; Varin-Blank, Nadine/G-4396-2013	Di Carlo, Anna/0000-0002-6037-6160; calvo, fabien/0000-0002-0298-7633; VARIN-BLANK, Nadine/0000-0003-2769-018X				Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; Boehm J, 2001, EMBO J, V20, P4153, DOI 10.1093/emboj/20.15.4153; Bruzzoni-Giovanelli H, 1999, ONCOGENE, V18, P7101, DOI 10.1038/sj.onc.1203187; Chen YM, 1999, J CELL PHYSIOL, V181, P385, DOI 10.1002/(SICI)1097-4652(199912)181:3<385::AID-JCP2>3.0.CO;2-4; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Koipally J, 2002, J BIOL CHEM, V277, P23143, DOI 10.1074/jbc.M202079200; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Linares-Cruz G, 1998, P NATL ACAD SCI USA, V95, P1131, DOI 10.1073/pnas.95.3.1131; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Matsuzawa S, 2001, MOL CELL, V7, P915, DOI 10.1016/S1097-2765(01)00242-8; Matsuzawa S, 2003, J BIOL CHEM, V278, P1837, DOI 10.1074/jbc.M210263200; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Nemani M, 1996, P NATL ACAD SCI USA, V93, P9039, DOI 10.1073/pnas.93.17.9039; Polekhina G, 2002, NAT STRUCT BIOL, V9, P68, DOI 10.1038/nsb743; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; Tang AH, 1997, CELL, V90, P459, DOI 10.1016/S0092-8674(00)80506-1; Tiedt R, 2001, EMBO J, V20, P4143, DOI 10.1093/emboj/20.15.4143; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang JS, 1998, GENE DEV, V12, P1775, DOI 10.1101/gad.12.12.1775	26	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 4	2003	22	55					8845	8851		10.1038/sj.onc.1206994	http://dx.doi.org/10.1038/sj.onc.1206994			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654780				2022-12-17	WOS:000186982200005
J	Pession, A; Martino, V; Tonelli, R; Beltramini, C; Locatelli, F; Biserni, G; Franzoni, M; Freccero, F; Montemurro, L; Pattacini, L; Paolucci, G				Pession, A; Martino, V; Tonelli, R; Beltramini, C; Locatelli, F; Biserni, G; Franzoni, M; Freccero, F; Montemurro, L; Pattacini, L; Paolucci, G			MLL-AF9 oncogene expression affects cell growth but not terminal differentiation and is downregulated during monocyte-macrophage maturation in AML-M5 THP-1 cells	ONCOGENE			English	Article						MLL-AF9; cell growth; differentiation; expression; THP-1	FUSION GENE; HEMATOLOGICAL MALIGNANCIES; M-CSF; LEUKEMIA; MLL; LINE; PROTEIN; LEUKEMOGENESIS; MICE; ESTABLISHMENT	The MLL-AF9 oncogene - one of the most frequent MLL/HRX/ALL-1 rearrangements found in infantile and therapy-related leukaemias - originates from t(9;11) (p22;q23) and is mainly associated with monocytic acute myeloid leukaemia (AML-M5; FAB-classification). Here, we investigated the MLL-AF9 function by means of an antisense phosphorothioate-oligodeoxyribonucleotide (MLL-AF9-PS-ODNas) using the THP-1 AML-M5 cell line carrying t(9;11). Having confirmed that MLL-AF9-PS-ODNas induces strong inhibition of THP-1 cell growth, but only a moderate increase in apoptosis, we found that MLL-AF9-PS-ODNas did not induce morphofunctional terminal differentiation or restore M-CSF-, G-CSF- or GM-CSF-induced differentiation. Moreover, THP-1 cells showed the same phenotype with/without MLL-AF9-PS-ODNas. In THP-1 cells differentiated to mature macrophage-like cells by PMA/TPA or ATRA, MLL-AF9 expression was downregulated. Thus, in the monocytic lineage, MLL-AF9 may be expressed only in early phases and can induce deregulated amplification in both nonmalignant and malignant cells, maintaining the monocytic phenotype without blocking final maturation. Our findings suggest that: (1) as well as directly promoting cell growth, MLL-AF9 may also indirectly determine phenotype; (2) other leukaemogenic mutations associated with MLL-AF9-related leukaemias should be searched for mainly in processes of resistance to apoptosis (where MLL-AF9 may play only a limited role) and differentiation blockage (where MLL-AF9 may play no role).	Univ Bologna, Policlin S Orsola Malpighi, Dept Paediat, I-40138 Bologna, Italy; Univ Pavia, Policlin San Matteo, IRCCS, I-27100 Pavia, Italy; Univ Bologna, Policlin S Orsola Malpighi, Inst Haematol & Med Oncol LA Seragnoli, I-40138 Bologna, Italy	IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna; IRCCS Fondazione San Matteo; University of Pavia; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Bologna	Pession, A (corresponding author), Policlin S Orsola Malpighi, Dipartimento Sci Pediat Med & Chirurg, Unita Terapia Cellulare, Via Massarenti 11, I-40138 Bologna, Italy.		Pession, Andrea/O-3200-2013	Pession, Andrea/0000-0002-0379-9562				Adler HT, 1999, MOL CELL BIOL, V19, P7050; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Biondi A, 2000, BLOOD, V96, P24, DOI 10.1182/blood.V96.1.24; BRACH MA, 1990, VIRCHOWS ARCH B, V59, P54, DOI 10.1007/BF02899387; Butler LH, 1997, BLOOD, V89, P3361, DOI 10.1182/blood.V89.9.3361; Caslini C, 2000, P NATL ACAD SCI USA, V97, P2797, DOI 10.1073/pnas.040574897; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 1999, BRIT J HAEMATOL, V106, P614, DOI 10.1046/j.1365-2141.1999.01439.x; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Ennas MG, 1997, CANCER RES, V57, P2035; Friedman AD, 2002, ONCOGENE, V21, P3377, DOI 10.1038/sj.onc.1205324; Giles RV, 1998, NUCLEIC ACIDS RES, V26, P1567, DOI 10.1093/nar/26.7.1567; IIDA S, 1993, ONCOGENE, V8, P3085; Ikeda T, 1998, BIOCHEM BIOPH RES CO, V253, P265, DOI 10.1006/bbrc.1998.9702; Ikeda T, 1998, BLOOD, V91, P4543, DOI 10.1182/blood.V91.12.4543.412k27_4543_4553; Joh T, 1999, ONCOGENE, V18, P1125, DOI 10.1038/sj.onc.1202400; Joh T, 1997, ONCOGENE, V15, P1681, DOI 10.1038/sj.onc.1201332; Joh T, 1996, ONCOGENE, V13, P1945; Johnson JJ, 2003, BLOOD, V101, P3229, DOI 10.1182/blood-2002-05-1515; Kawagoe H, 1999, LEUKEMIA, V13, P687, DOI 10.1038/sj.leu.2401410; Kawagoe H, 2001, LEUKEMIA, V15, P1743, DOI 10.1038/sj.leu.2402262; Lafarge S, 2001, ONCOGENE, V20, P6597, DOI 10.1038/sj.onc.1204812; MATIKAINEN S, 1994, INT J CANCER, V57, P98, DOI 10.1002/ijc.2910570118; Niitsu N, 2001, ONCOGENE, V20, P375, DOI 10.1038/sj.onc.1204081; Odero MD, 2000, GENE CHROMOSOME CANC, V29, P333, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1040>3.3.CO;2-Q; Owens BM, 2002, STEM CELLS, V20, P364, DOI 10.1634/stemcells.20-5-364; Schulte CE, 2002, EMBO J, V21, P4297, DOI 10.1093/emboj/cdf429; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555, DOI 10.1002/jlb.59.4.555; Swansbury GJ, 1998, LEUKEMIA, V12, P792, DOI 10.1038/sj.leu.2401014; Taghon T, 2002, BLOOD, V99, P1197, DOI 10.1182/blood.V99.4.1197; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	32	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8671	8676		10.1038/sj.onc.1207125	http://dx.doi.org/10.1038/sj.onc.1207125			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647461				2022-12-17	WOS:000186844900004
J	Harmala-Brasken, AS; Mikhailov, A; Soderstrom, TS; Meinander, A; Holmstrom, TH; Damuni, Z; Eriksson, JE				Harmala-Brasken, AS; Mikhailov, A; Soderstrom, TS; Meinander, A; Holmstrom, TH; Damuni, Z; Eriksson, JE			Type-2A protein phosphatase activity is required to maintain death receptor responsiveness	ONCOGENE			English	Article						PP2A; inhibition; I-2(PP2A); calyculin A; receptor-induced apoptosis	OKADAIC ACID; CELL-TRANSFORMATION; MEDIATED APOPTOSIS; TUMOR PROMOTION; KINASE-ACTIVITY; 2A; EXPRESSION; INHIBITORS; CANCER; FAS	Type-2A protein phosphatase (PP2A) is a key regulator in many different cell signaling pathways and an important determinant in tumorigenesis. One of the signaling targets of PP2A is the mitogen-activated protein kinase (MAPK/ ERK) cascade. In this study, we wanted to determine whether PP2A could be involved in regulation of death receptor activity through its capacity to regulate MAPK/ ERK. To this end, we studied the effects of two different routes of protein phosphatase inhibition on death receptor-mediated apoptosis. We demonstrated that the apoptosis mediated by Fas, TNF-alpha, and TRAIL in U937 cells is suppressed by calyculin A, an inhibitor of type-1 and type-2A protein phosphatases. The inhibition of the protein phosphatase activity was shown to subsequently increase the MAPK activity in these cells, and the level of activation corresponded to the degree of suppression of cytokine-mediated apoptosis. A more physiological inhibitor, the intracellular PP2A inhibitor protein I-2(PP2A), protected transfected HeLa cells in a similar way from Fas-mediated apoptosis and induced activation of MAPK in I-2(PP2A) transfected cells. A corresponding inhibition could also be obtained by stable transfection with a constitutively active form of the MAPK kinase, MKK1 (also referred to as MEK1). The inhibitor-mediated protection was highly efficient in preventing early stages of apoptosis, as no caspase-8 cleavage occurred in these cells. The observed apoptosis suppression is likely to facilitate the tumor-promoting effect of a range of different type-2A protein phosphatase inhibitors, and could explain the reported tumor association of I-2(PP2A).	Univ Turku, Abo Akad Univ, Turku Ctr Biotechnol, FIN-20521 Turku, Finland; Abo Akad Univ, Dept Biochem & Pharm, FIN-20521 Turku, Finland; Abo Akad Univ, Dept Biol, FIN-20520 Turku, Finland; Univ Turku, Dept Biol, Physiol Anim Lab, FIN-20014 Turku, Finland; Glogozymes, Carlsbad, CA 92009 USA	Abo Akademi University; University of Turku; Abo Akademi University; Abo Akademi University; University of Turku	Eriksson, JE (corresponding author), Univ Turku, Abo Akad Univ, Turku Ctr Biotechnol, POB 123, FIN-20521 Turku, Finland.	john.eriksson@utu.fl	Meinander, Annika/E-9260-2017	Meinander, Annika/0000-0002-3878-2293				Al-Murrani SWK, 1999, BIOCHEM J, V341, P293, DOI 10.1042/0264-6021:3410293; AMARAL MC, 1993, IMMUNOLOGY, V79, P24; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Brautigan DL, 1997, ADV SEC MESS PHOSPH, V31, P113; BRAUTIGAN DL, 1993, MOL CELL BIOCHEM, V128, P121; Carlson SG, 1998, J AM SOC NEPHROL, V9, P1873; Chiang CW, 2001, BLOOD, V97, P1289, DOI 10.1182/blood.V97.5.1289; Chung HY, 1999, CELL SIGNAL, V11, P575, DOI 10.1016/S0898-6568(99)00033-9; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; COHEN P, 1989, J BIOL CHEM, V264, P21435; ERIKSSON JE, 1990, BIOCHIM BIOPHYS ACTA, V1025, P60, DOI 10.1016/0005-2736(90)90190-Y; Fernandez JJ, 2002, CURR MED CHEM, V9, P229, DOI 10.2174/0929867023371247; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fladmark KE, 1999, CELL DEATH DIFFER, V6, P1099, DOI 10.1038/sj.cdd.4400590; FUJIKI H, 1993, ADV CANCER RES, V61, P143, DOI 10.1016/S0065-230X(08)60958-6; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; Hahn WC, 2002, NAT REV CANCER, V2, P331, DOI 10.1038/nrc795; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Holmstrom TH, 1998, J IMMUNOL, V160, P2626; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Holmstrom TH, 2000, CRIT REV IMMUNOL, V20, P121; Holmstrom TH, 2000, EMBO J, V19, P5418, DOI 10.1093/emboj/19.20.5418; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Lengyel E, 1997, ONCOGENE, V14, P2563, DOI 10.1038/sj.onc.1201098; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; OHOKA Y, 1993, BIOCHEM BIOPH RES CO, V197, P916, DOI 10.1006/bbrc.1993.2566; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; Quintaje SB, 1996, BIOCHEM BIOPH RES CO, V221, P539, DOI 10.1006/bbrc.1996.0632; Rosenberger SF, 1996, ONCOGENE, V12, P2301; Santoro MF, 1998, J BIOL CHEM, V273, P13119, DOI 10.1074/jbc.273.21.13119; Sato S, 2000, P NATL ACAD SCI USA, V97, P10832, DOI 10.1073/pnas.170276797; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; Soderstrom TS, 2002, J IMMUNOL, V169, P2851, DOI 10.4049/jimmunol.169.6.2851; SONG QZ, 1993, BIOCHEM BIOPH RES CO, V190, P47, DOI 10.1006/bbrc.1993.1009; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WALTER G, 1993, BIOCHIM BIOPHYS ACTA, V1155, P207, DOI 10.1016/0304-419X(93)90005-W; WRIGHT SC, 1994, FASEB J, V8, P654, DOI 10.1096/fasebj.8.9.8005393	41	35	37	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2003	22	48					7677	7686		10.1038/sj.onc.1207077	http://dx.doi.org/10.1038/sj.onc.1207077			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576831				2022-12-17	WOS:000186113000016
J	Cattaneo, M; Orlandini, S; Beghelli, S; Moore, PS; Sorio, C; Bonora, A; Bassi, C; Talamini, G; Zamboni, G; Orlandi, R; Menard, S; Bernardi, LR; Biunno, I; Scarpa, A				Cattaneo, M; Orlandini, S; Beghelli, S; Moore, PS; Sorio, C; Bonora, A; Bassi, C; Talamini, G; Zamboni, G; Orlandi, R; Menard, S; Bernardi, LR; Biunno, I; Scarpa, A			SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo	ONCOGENE			English	Article						pancreas; adenocarcinoma; SEL1L; DPC4/Smad4; TGF beta-pathway	C-ELEGANS SEL-1; NEGATIVE REGULATOR; NEOPLASTIC TRANSFORMATION; HUMAN HOMOLOG; NOTCH-GENE; DPC4 GENE; CELLS; INHIBITION; CANCER; PROLIFERATION	Recent data suggest that SEL1L may play an important role in pancreatic carcinoma, similar to breast cancer, where the expression of SEL1L has been associated with a reduction in both proliferative activity in vitro and clinical tumor aggressiveness. To investigate this possibility, we examined the expression of Sel1L in a series of primary pancreatic carcinomas by immunohistochemistry and characterized the effects of Sel1L overexpression both in vitro and in vivo. In 74 pancreatic cancers analysed, 36% lacked Sel1L expression, although there was no significant correlation between the expression of Sel1L and any clinicopathologic parameter, including survival. However, immunohistochemical reactivity for Sel1L and Dpc4/Smad4 was concordant in 69% of cases (chi(2) test P < 0.004). Overexpression of SEL1L in stably transfected pancreatic cancer cells caused both a decrease in clonogenicity and anchorage-independent growth as well as a significant increase in the levels of activin A and SMAD4. When implanted in nude mice, Suit-2-SEL1L-overexpressing clones displayed a considerably reduced rate of tumor growth. Thus, it can be hypothesized that Sel1L plays an important function in the growth and aggressiveness of pancreatic carcinoma. Moreover, our data provide evidence that SEL1L has an impact on the expression of genes involved in regulation of cellular growth, possibly through the TGF-beta signaling pathway.	Univ Verona, Dept Pathol, I-37134 Verona, Italy; CNR, Inst Biomed Technol, Milan, Italy; Univ Verona, Dept Surg & Gastroenterol Sci, I-37100 Verona, Italy; Ist Nazl Tumori, Dept Expt Oncol, Mol Targeting Unit, I-20133 Milan, Italy; Univ Milan, Ctr Excellence, I-20122 Milan, Italy	University of Verona; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Verona; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Milan	Scarpa, A (corresponding author), Univ Verona, Dept Pathol, Str Grazie 8, I-37134 Verona, Italy.	ida.biunno@ltb.cnr.it; aldo.scarpa@univr.it	Giuseppe, Zamboni/L-6029-2019; Moore, Patrick/GVR-8294-2022; Sorio, Claudio/F-2764-2018; scarpa, aldo/K-6832-2016; Orlandi, Rosaria/C-1182-2017; menard, sylvie mm/C-7940-2011	Giuseppe, Zamboni/0000-0001-7428-4673; Sorio, Claudio/0000-0003-2739-4014; scarpa, aldo/0000-0003-1678-739X; Orlandi, Rosaria/0000-0002-0533-9041; SALVIA, Roberto/0000-0002-3514-8473; /0000-0002-1866-5866; , IDA_2/0000-0002-1068-4763				Apelqvist A, 1999, NATURE, V400, P877, DOI 10.1038/23716; Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Biunno I, 2000, HUM GENET, V106, P227, DOI 10.1007/s004390051032; Biunno I, 1997, GENOMICS, V46, P284, DOI 10.1006/geno.1997.5018; Biunno Ida, 2002, OMICS A Journal of Integrative Biology, V6, P187, DOI 10.1089/153623102760092788; Capobianco AJ, 1997, MOL CELL BIOL, V17, P6265, DOI 10.1128/MCB.17.11.6265; Cattaneo M, 2001, DNA CELL BIOL, V20, P1, DOI 10.1089/10445490150504648; Cattaneo M, 2000, INT J BIOL MARKER, V15, P26, DOI 10.1177/172460080001500105; Chen YG, 2002, EXP BIOL MED, V227, P75, DOI 10.1177/153537020222700201; Cocolakis E, 2001, J BIOL CHEM, V276, P18430, DOI 10.1074/jbc.M010768200; COOK PW, 1988, MOL CELL BIOL, V8, P1449, DOI 10.1128/MCB.8.4.1449; Donoviel DB, 1998, MECH DEVELOP, V78, P203, DOI 10.1016/S0925-4773(98)00146-4; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; Furue M, 2001, BIOCHEM BIOPH RES CO, V282, P745, DOI 10.1006/bbrc.2001.4633; Grant B, 1997, DEVELOPMENT, V124, P637; Grant B, 1996, GENETICS, V143, P237; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Harada Y, 1999, J HUM GENET, V44, P330, DOI 10.1007/s100380050171; Jensen J, 2000, DIABETES, V49, P163, DOI 10.2337/diabetes.49.2.163; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; Kloppel G, 2000, WHO CLASSIFICATION T, P219; Kudawara I, 2001, EUR J CANCER, V37, P1703, DOI 10.1016/S0959-8049(01)00185-X; Lei JY, 1996, ONCOGENE, V13, P2459; Liu QY, 1996, CANCER RES, V56, P1155; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Moore PS, 2001, BRIT J CANCER, V84, P253, DOI 10.1054/bjoc.2000.1567; Moore PS, 2001, VIRCHOWS ARCH, V439, P798, DOI 10.1007/s004280100474; NORMAN J, 1994, J SURG RES, V57, P33, DOI 10.1006/jsre.1994.1105; Orlandi R, 2002, CANCER RES, V62, P567; Orlandi R, 2002, INT J BIOL MARKER, V17, P104, DOI 10.1177/172460080201700205; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; Roberts AB, 1999, MICROBES INFECT, V1, P1265, DOI 10.1016/S1286-4579(99)00258-0; Rooke HM, 2001, PATHOLOGY, V33, P73; Rozenblum E, 1997, CANCER RES, V57, P1731; Scarpa A, 2002, VIRCHOWS ARCH, V440, P155, DOI 10.1007/s00428-001-0569-6; Schutte M, 1996, CANCER RES, V56, P2527; Schwarte-Waldhoff I, 1999, ONCOGENE, V18, P3152, DOI 10.1038/sj.onc.1202641; Schwarte-Waldhoff I, 2000, P NATL ACAD SCI USA, V97, P9624, DOI 10.1073/pnas.97.17.9624; Shelly LL, 1999, J CELL BIOCHEM, V73, P164, DOI 10.1002/(SICI)1097-4644(19990501)73:2<164::AID-JCB3>3.0.CO;2-0; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; THOMPSON EA, 1989, CANCER RES, V49, pS2259; Weinmaster G, 1997, MOL CELL NEUROSCI, V9, P91, DOI 10.1006/mcne.1997.0612	43	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2003	22	41					6359	6368		10.1038/sj.onc.1206665	http://dx.doi.org/10.1038/sj.onc.1206665			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	725GK	14508516				2022-12-17	WOS:000185535300006
J	Vilchez, RA; Butel, JS				Vilchez, RA; Butel, JS			SV40 in human brain cancers and non-Hodgkin's lymphoma	ONCOGENE			English	Article						SV40; human cancers; brain tumors; non-Hodgkin'slymphoma	LARGE-T-ANTIGEN; HUMAN MESOTHELIAL CELLS; SIMIAN VIRUS 40; DNA-SEQUENCES; SIMIAN-VIRUS-40 SEQUENCES; MOLECULAR-BIOLOGY; HUMAN INFECTIONS; CHOROID-PLEXUS; POLIO VACCINE; HUMAN TUMORS	Simian virus 40 (SV40) is a potent DNA tumor virus that is known to induce primary brain cancers and lymphomas in laboratory animals. SV40 oncogenesis is mediated by the viral large tumor antigen (T-ag), which inactivates the tumor-suppressor proteins p53 and pRb family members. During the last decade, independent studies using different molecular biology techniques have shown the presence of SV40 DNA, T-ag, or other viral markers in primary human brain cancers, and a systematic assessment of the data indicates that the virus is significantly associated with this group of human tumors. In addition, recent large independent studies showed that SV40 T-ag DNA is significantly associated with human non-Hodgkin's lymphoma (NHL). Although the prevalence of SV40 infections in humans is not known, numerous observations suggest that SV40 is a pathogen in the human population today. This review examines the molecular biology, pathology, and clinical data implicating SV40 in the pathogenesis of primary human brain cancers and NHL and discusses future research directions needed to define a possible etiologic role for SV40 in these malignancies.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Butel, JS (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Mail Stop BCM-385,1 Baylor Plaza, Houston, TX 77030 USA.	jbutel@bcm.tmc.edu		Butel, Janet/0000-0002-6876-3245	NATIONAL CANCER INSTITUTE [R21CA096951] Funding Source: NIH RePORTER; NCI NIH HHS [R21CA96951] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ali SH, 2001, SEMIN CANCER BIOL, V11, P15, DOI 10.1006/scbi.2000.0342; American Cancer Society, 2002, CANC FACTS FIG 2002; ARRINGTON AS, 2001, HUMAN POLYOMAVIRUSES, P461; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Bocchetta M, 2003, ONCOGENE, V22, P81, DOI 10.1038/sj.onc.1206097; Butel J S, 1972, Adv Cancer Res, V15, P1, DOI 10.1016/S0065-230X(08)60371-1; Butel JS, 1999, JNCI-J NATL CANCER I, V91, P119, DOI 10.1093/jnci/91.2.119; Butel JS, 2000, CARCINOGENESIS, V21, P405, DOI 10.1093/carcin/21.3.405; Butel JS, 1999, HUM PATHOL, V30, P1496, DOI 10.1016/S0046-8177(99)90173-9; Cacciotti P, 2002, AM J RESP CELL MOL, V26, P189, DOI 10.1165/ajrcmb.26.2.4673; Cacciotti P, 2001, P NATL ACAD SCI USA, V98, P12032, DOI 10.1073/pnas.211026798; Carbone M, 1997, ONCOGENE, V15, P1877, DOI 10.1038/sj.onc.1201375; Carbone M, 1997, NAT MED, V3, P908, DOI 10.1038/nm0897-908; Carroll-Pankhurst C, 2001, BRIT J CANCER, V85, P1295, DOI 10.1054/bjoc.2001.2065; CICALA C, 1992, VIROLOGY, V190, P475, DOI 10.1016/0042-6822(92)91237-O; COE JE, 1975, J NATL CANCER I, V54, P269, DOI 10.1093/jnci/54.1.269; David H, 2001, CANCER LETT, V162, P57, DOI 10.1016/S0304-3835(00)00628-5; DeLuca A, 1997, NAT MED, V3, P913, DOI 10.1038/nm0897-913; DIAMANDOPOULOS GT, 1972, SCIENCE, V176, P173, DOI 10.1126/science.176.4031.173; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; EDDY BE, 1962, VIROLOGY, V17, P65, DOI 10.1016/0042-6822(62)90082-X; Engels EA, 2002, INT J CANCER, V101, P348, DOI 10.1002/ijc.10621; Farwell J R, 1979, Trans Am Neurol Assoc, V104, P261; Fisher SG, 1999, ANTICANCER RES, V19, P2173; Foddis R, 2002, ONCOGENE, V21, P1434, DOI 10.1038/sj.onc.1205203; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P85; GEISSLER E, 1990, PROG MED VIROL, V37, P211; Gerard L, 2001, J ACQ IMMUN DEF SYND, V26, P182, DOI 10.1097/00126334-200102010-00013; GIRARDI AJ, 1962, P SOC EXP BIOL MED, V109, P649, DOI 10.3181/00379727-109-27298; Gomez-Brouchet A, 2001, J CLIN PATHOL, V54, P617, DOI 10.1136/jcp.54.8.617; HEINONEN OP, 1973, INT J EPIDEMIOL, V2, P229, DOI 10.1093/ije/2.3.229; Huang HT, 1999, BRAIN PATHOL, V9, P33; IBELGAUFTS H, 1982, ACTA NEUROPATHOL, V56, P118, DOI 10.1007/BF00690582; INNIS MD, 1968, NATURE, V219, P972, DOI 10.1038/219972a0; Jafar S, 1998, J MED VIROL, V54, P276, DOI 10.1002/(SICI)1096-9071(199804)54:4<276::AID-JMV7>3.0.CO;2-1; Jaffe ES, 2001, WHO CLASSIFICATION T; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; Kleihues, 2000, WHO CLASSIFICATION T; Kouhata T, 2001, J NEUROSURG, V95, P96, DOI 10.3171/jns.2001.95.1.0096; KRIEG P, 1981, P NATL ACAD SCI-BIOL, V78, P6446, DOI 10.1073/pnas.78.10.6446; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; Lednicky JA, 1999, FRONT BIOSCI, V4, P153; LEWIS AM, 1973, BIOHAZARDS BIOL RES, P96; Li RM, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000028249.06596.CF; Malkin D, 2001, ONCOGENE, V20, P4441, DOI 10.1038/sj.onc.1204583; Martini F, 1996, CANCER RES, V56, P4820; Martini F, 2002, CANCER-AM CANCER SOC, V94, P1037, DOI 10.1002/cncr.10272; Martini F, 1998, INT J CANCER, V78, P669, DOI 10.1002/(SICI)1097-0215(19981209)78:6<669::AID-IJC1>3.0.CO;2-B; MEINKE W, 1979, NEUROLOGY, V29, P1590, DOI 10.1212/WNL.29.12.1590; Mendoza SM, 1998, ONCOGENE, V17, P2457, DOI 10.1038/sj.onc.1202179; Ohgaki H, 2000, J NATL CANCER I, V92, P495, DOI 10.1093/jnci/92.6.495; Olin P, 1998, DEV BIOL STAND, V94, P227; *PAN AM HLTH ORG, 1960, SCI PUBL, V50; Ries L, 1998, SEER CANC STAT REV 1; Rizzo P, 1999, CHEST, V116, p470S, DOI 10.1378/chest.116.suppl_3.470S; Rizzo P, 1999, CANCER RES, V59, P6103; ROLLISON DE, 2001, HUMAN POLYOMAVIRUSES, P561; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Shivapurkar N, 2000, INT J CANCER, V85, P743, DOI 10.1002/(SICI)1097-0215(20000301)85:5<743::AID-IJC24>3.3.CO;2-V; STEWART AM, 1965, LANCET, V2, P789; STRATTON K, 2003, IN PRESS IMMUNIZATIO; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Sullivan CS, 2002, MICROBIOL MOL BIOL R, V66, P179, DOI 10.1128/MMBR.66.2.179-202.2002; Suzuki S O, 1997, Brain Tumor Pathol, V14, P125, DOI 10.1007/BF02478881; TABUCHI K, 1978, INT J CANCER, V21, P12, DOI 10.1002/ijc.2910210104; Toyooka S, 2002, ONCOGENE, V21, P4340, DOI 10.1038/sj.onc.1205381; Vastag B, 2002, JAMA-J AM MED ASSOC, V288, P1337, DOI 10.1001/jama.288.11.1337; Vilchez RA, 2002, LANCET, V359, P817, DOI 10.1016/S0140-6736(02)07950-3; Vilchez RA, 2003, AM J MED, V114, P675, DOI 10.1016/S0002-9343(03)00087-1; Vilchez RA, 2003, LANCET ONCOL, V4, P188, DOI 10.1016/S1470-2045(03)01024-6; Vilchez RA, 2002, J ACQ IMMUN DEF SYND, V29, P109, DOI 10.1097/00042560-200202010-00001; Weggen S, 2000, BRAIN PATHOL, V10, P85; WEISS AF, 1975, P NATL ACAD SCI USA, V72, P609, DOI 10.1073/pnas.72.2.609; Zhen HN, 1999, CANCER, V86, P2124, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2124::AID-CNCR34>3.0.CO;2-D; Zhu YA, 2002, NAT REV CANCER, V2, P616, DOI 10.1038/nrc866	77	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 11	2003	22	33					5164	5172		10.1038/sj.onc.1206547	http://dx.doi.org/10.1038/sj.onc.1206547			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	709FL	12910253				2022-12-17	WOS:000184615100007
J	David, MD; Bertoglio, J; Pierre, J				David, MD; Bertoglio, J; Pierre, J			Functional characterization of IL-13 receptor alpha 2 gene promoter: a critical role of the transcription factor STAT6 for regulated expression	ONCOGENE			English	Article						cytokine receptors; gene regulation; transcription factors; cytokines; keratinocytes	MESSENGER-RNA; HUMAN B; HUMAN MONOCYTES; GAMMA-CHAIN; INTERLEUKIN-13; PROTEIN; CLONING; CELLS; ACTIVATION; BINDING	Interleukin (IL)-4 and IL-13 are two structurally and functionally related cytokines that have overlapping but also distinct biological activities. One of the components of the IL-13 receptor, the alpha2 chain (IL-13Ralpha2), has been reported to downregulate the cell responsiveness to IL-13, without affecting IL-4 signaling. Here, we report that TNFalpha synergizes with either IL-4 or IL-13 in inducing the IL-13Ralpha2 chain at both the mRNA and protein levels in the HaCaT human keratinocyte cell line. Further studies by 5'RACE identified as yet undescribed exonic sequences of the IL-13Ralpha2 5'UTR, provided evidence for the expression of alternatively spliced IL-13Ralpha2 transcripts and defined the transcription start of the IL-13Ralpha2 gene. A 1.5 kb region upstream of the first exon of the IL-13Ralpha2 gene displayed basal promoter activity when inserted in a reporter plasmid and transiently transfected in HaCaT cells. This promoter activity was further increased in response to IL-4 and IL-13. Furthermore, by electrophoretic mobility shift assay and site-directed mutagenesis, we showed that the IL-4/IL-13-induced promoter activity depended upon a positively acting STAT6 response element. Finally, TNFalpha was shown to potentiate IL-4/IL-13-induced IL-13Ralpha2 promoter activity when the same reporter construct was studied in stably but not in transiently transfected cells. These results suggest that the synergistic effect of TNFalpha on IL-4/IL-13-induced IL-13Ralpha2 expression is dependent upon chromatin re-modeling events.	Fac Pharm Chatenay Malabry, U461, INSERM, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Pierre, J (corresponding author), Fac Pharm Chatenay Malabry, U461, INSERM, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	josiane.pierre@cep.u-psud.fr	David, Muriel/F-9592-2012	David, Muriel/0000-0003-1392-2701				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Daines MO, 2002, J BIOL CHEM, V277, P10387, DOI 10.1074/jbc.M108109200; David M, 2001, ONCOGENE, V20, P6660, DOI 10.1038/sj.onc.1204629; Debinski W, 1999, INT J ONCOL, V15, P481; Debinski W, 1999, CLIN CANCER RES, V5, P985; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775, DOI 10.1074/jbc.270.28.16775; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Feng NP, 1998, LAB INVEST, V78, P591; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Gauchat JF, 1997, EUR J IMMUNOL, V27, P971, DOI 10.1002/eji.1830270425; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Guo DQ, 1998, J IMMUNOL, V160, P2742; Guo JA, 1997, GENOMICS, V42, P141, DOI 10.1006/geno.1997.4628; Hart PH, 1999, J LEUKOCYTE BIOL, V66, P575, DOI 10.1002/jlb.66.4.575; Husain SR, 2000, BLOOD, V95, P3506, DOI 10.1182/blood.V95.11.3506.011k47_3506_3513; Ince TA, 1995, J BIOL CHEM, V270, P30249, DOI 10.1074/jbc.270.51.30249; Jeannin P, 1997, J BIOL CHEM, V272, P15613, DOI 10.1074/jbc.272.25.15613; Kambayashi T, 1996, CELL IMMUNOL, V171, P153, DOI 10.1006/cimm.1996.0186; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Maini A, 1997, J UROLOGY, V158, P948, DOI 10.1016/S0022-5347(01)64369-6; MALEFYT RD, 1993, J IMMUNOL, V151, P6370; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Murata T, 1997, BIOCHEM BIOPH RES CO, V238, P90, DOI 10.1006/bbrc.1997.7248; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Ogata H, 1998, J BIOL CHEM, V273, P9864, DOI 10.1074/jbc.273.16.9864; Pesu M, 2002, J BIOL CHEM, V277, P38254, DOI 10.1074/jbc.M201427200; ROUSSET F, 1991, J EXP MED, V173, P705, DOI 10.1084/jem.173.3.705; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; Sheppard KA, 1999, MOL CELL BIOL, V19, P6367; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Wery-Zennaro S, 2000, ONCOGENE, V19, P1596, DOI 10.1038/sj.onc.1203458; Wery-Zennaro S, 1999, FEBS LETT, V464, P91, DOI 10.1016/S0014-5793(99)01680-4; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhang JG, 1997, J BIOL CHEM, V272, P9474	43	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2003	22	22					3386	3394		10.1038/sj.onc.1206352	http://dx.doi.org/10.1038/sj.onc.1206352			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	683CB	12776189				2022-12-17	WOS:000183128500004
J	Klein, A; Guhl, E; Tzeng, YJ; Fuhrhop, J; Levrero, M; Graessmann, M; Graessmann, A				Klein, A; Guhl, E; Tzeng, YJ; Fuhrhop, J; Levrero, M; Graessmann, M; Graessmann, A			HBX causes cyclin D1 overexpression and development of breast cancer in transgenic animals that are heterozygous for p53	ONCOGENE			English	Article						HBX; transgenic animals; ME-cell immortalization; cyclin D1; differentiation; tumor formation	HEPATITIS-B VIRUS; CELLULAR DNA-REPAIR; X-PROTEIN; HEPATOCELLULAR-CARCINOMA; P53-INDUCED APOPTOSIS; GENE; MICE; ANTIGEN; LIVER; HEPATOCARCINOGENESIS	Transgenic mice, which selectively express the WAP-HBX transgene in mammary gland epithelial cells (ME-cells), were established in order to elucidate the consequences of HBX gene expression on organ differentiation, cell death program and tumor development. Transgene expression was demonstrable by RT-PCR, Northern and Western blot analysis during pregnancy, lactation and after weaning. HBX synthesis neither affect mammary gland differentiation nor apoptosis in ME-cells. Although breast cancer formation was rare in WAP-HBX animals (<1%), WAP-HBX.p53+/- hybrid animals developed breast tumors at an increased rate (12/85) after a latency period of 8-18 months. We also show here for the first time that HBX can immortalize ME-cells generated from mammary gland tissue segments in a p53-independent fashion. HBX causes cyclin D1 gene overexpression during early pregnancy, and this is maintained in ME-cells isolated either from mammary gland or from breast tumors. Intranuclear cyclin D1 accumulation also occurs in the absence of external growth factors and the BrdU incorporation rate remains high under serum starvation conditions. Finally, both cyclin D1 induction and HBX mitotic activity are dependent on p38 and c-Jun N-terminal kinase, but not on MEK-1 kinase activity.	Free Univ Berlin, Inst Mol Biol & Biochem, D-14195 Berlin, Germany; Tzu Chi Univ, Grad Inst Mol & Cell Biol, Hualien 970, Taiwan; Univ Roma La Sapienza, Fdn A Cesalpino, Gene Express Lab, I-00161 Rome, Italy	Free University of Berlin; Tzu Chi University; Sapienza University Rome	Graessmann, A (corresponding author), Free Univ Berlin, Inst Mol Biol & Biochem, Arnimallee 22, D-14195 Berlin, Germany.		Klein, Andreas/AAG-4506-2021; Levrero, Massimo/G-5680-2016	Klein, Andreas/0000-0002-3496-7215; Levrero, Massimo/0000-0002-4978-0875				Arbuthnot P, 2000, J GASTROEN HEPATOL, V15, P357, DOI 10.1046/j.1440-1746.2000.02069.x; BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; BRISON O, 1993, BIOCHIM BIOPHYS ACTA, V1155, P25, DOI 10.1016/0304-419X(93)90020-D; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DRAGANI TA, 1990, CARCINOGENESIS, V11, P953, DOI 10.1093/carcin/11.6.953; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goetz F, 2001, ONCOGENE, V20, P2325, DOI 10.1038/sj.onc.1204355; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; GRAESSMANN M, 1983, METHOD ENZYMOL, V101, P482; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; Joo M, 2001, LIVER, V21, P89, DOI 10.1034/j.1600-0676.2001.021002089.x; Kim YC, 1998, WATER SCI TECHNOL, V38, P1, DOI 10.1016/S0273-1223(98)00671-4; Kohzato N, 2001, HEPATOL RES, V21, P27, DOI 10.1016/S1386-6346(00)00150-9; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Kumar V, 1996, P NATL ACAD SCI USA, V93, P5647, DOI 10.1073/pnas.93.11.5647; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; Madden CR, 2000, J VIROL, V74, P5266, DOI 10.1128/JVI.74.11.5266-5272.2000; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; NATOLI G, 1994, ONCOGENE, V9, P2837; Pollicino T, 1998, BIOMED PHARMACOTHER, V52, P363, DOI 10.1016/S0753-3322(99)80003-1; Sambrook J, 1989, MOL CLONING LAB MANU; Santarelli R, 1996, ONCOGENE, V12, P495; Siegel PM, 2000, BIOESSAYS, V22, P554, DOI 10.1002/(SICI)1521-1878(200006)22:6<554::AID-BIES8>3.0.CO;2-A; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; Su F, 2001, J VIROL, V75, P215, DOI 10.1128/JVI.75.1.215-225.2001; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; Terradillos O, 2002, ONCOGENE, V21, P377, DOI 10.1038/sj.onc.1205110; Tzeng YJ, 1998, ONCOGENE, V16, P2103, DOI 10.1038/sj.onc.1201733; TZENG YJ, 1993, ONCOGENE, V8, P1965; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; WANG XW, 1995, CANCER RES, V55, P6012	45	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 15	2003	22	19					2910	2919		10.1038/sj.onc.1206539	http://dx.doi.org/10.1038/sj.onc.1206539			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	677TY	12771941				2022-12-17	WOS:000182824800005
J	Mamay, CL; Mingo-Sion, AM; Wolf, DM; Molina, MD; Van Den Berg, CL				Mamay, CL; Mingo-Sion, AM; Wolf, DM; Molina, MD; Van Den Berg, CL			An inhibitory function for JNK in the regulation of IGF-I signaling in breast cancer	ONCOGENE			English	Article						IGF-I; JNK; IRS-1; breast cancer; apoptosis	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; GROWTH-FACTOR; INSULIN-RECEPTOR; CELLULAR STRESSES; MAP KINASE; PHOSPHORYLATION; EXPRESSION; TRANSDUCTION; PATHWAY	Insulin-like growth factor-I receptor (IGF-IR) is frequently overexpressed in a variety of cancer types. Since many breast tumors and cancer cell lines overexpress IGF-IR, we tested IGF-I effects on chemotherapy-treated breast cancer cells. IGF-I protects from chemotherapy-induced apoptosis, suggesting that overlapping signaling pathways modulate IGF-I and chemotherapy treatment outcomes. Taxol and other chemotherapy drugs induce c-Jun N-terminal kinase (JNK), a kinase that conveys cellular stress and death signals. Notably, in this paper we show that IGF-I alone induces a potent JNK response and this activity is reversed by inhibition of phosphatidylinositol 3-kinase (PI3-kinase) with LY294002 in MCF-7 but not T47D cells. Cotreatment of cells with chemotherapy and IGF-I leads to additive JNK responses. Using cells overexpressing Akt, we confirm that IGF-I-mediated survival is Akt dependent. In contrast, overexpression of JNK significantly enhances Taxol-induced apoptosis and inhibits IGF-I survival effects. Further, JNK attenuates anchorage-independent growth of MCF-7 cells. The inhibitory effect of JNK appears to be mediated by serine phosphorylation of IRS-1 (insulin receptor substrate) since both Taxol and IGF-I treatment enhanced Ser(312) IRS-1 phosphorylation, while LY294002 blocked IGF-I-mediated phosphorylation. Taken together, these data provide a mechanism whereby stress or growth factors activate JNK to reduce proliferation and/or survival in breast cancer cells.	Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA; Univ Colorado, Hlth Sci Ctr, Sch Pharm, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Obstet & Gynecol, Denver, CO 80262 USA	University of California System; University of California Davis; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Van Den Berg, CL (corresponding author), Univ Calif Davis, Dept Biol Chem, Davis, CA 95616 USA.	carla.vandenberg@UCHSC.edu			NATIONAL CANCER INSTITUTE [R01CA089288] Funding Source: NIH RePORTER; NCI NIH HHS [CA89288A] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Alblas J, 1998, ONCOGENE, V16, P131, DOI 10.1038/sj.onc.1201485; Bost F, 1997, J BIOL CHEM, V272, P33422, DOI 10.1074/jbc.272.52.33422; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Butler AA, 1998, CANCER RES, V58, P3021; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen NY, 2001, CANCER RES, V61, P3908; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; CULLEN KJ, 1990, CANCER RES, V50, P48; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; Desbois-Mouthon C, 1998, BIOCHEM BIOPH RES CO, V243, P765, DOI 10.1006/bbrc.1998.8181; Dunn SE, 1998, CANCER RES, V58, P3353; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Hemi R, 2002, J BIOL CHEM, V277, P8961, DOI 10.1074/jbc.M109391200; Hermanto U, 2000, CELL GROWTH DIFFER, V11, P655; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Lee AV, 2000, MOL CELL BIOL, V20, P1489, DOI 10.1128/MCB.20.5.1489-1496.2000; Logan SK, 1997, MOL CELL BIOL, V17, P5784, DOI 10.1128/MCB.17.10.5784; LopezIlasaca M, 1997, BIOCHEM BIOPH RES CO, V232, P273, DOI 10.1006/bbrc.1997.6289; Miller BS, 1996, BIOCHEMISTRY-US, V35, P8769, DOI 10.1021/bi952651r; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Monno S, 2000, ENDOCRINOLOGY, V141, P544, DOI 10.1210/en.141.2.544; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PEYRAT JP, 1990, J STEROID BIOCHEM, V37, P823, DOI 10.1016/0960-0760(90)90426-L; Potapova O, 2000, MOL CELL BIOL, V20, P1713, DOI 10.1128/MCB.20.5.1713-1722.2000; Potapova O, 1997, J BIOL CHEM, V272, P14041, DOI 10.1074/jbc.272.22.14041; Resnik JL, 1998, CANCER RES, V58, P1159; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; She QB, 2002, CANCER RES, V62, P1343; SINGER C, 1995, CANCER RES, V55, P2448; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; VandenBerg CL, 1997, EUR J CANCER, V33, P1108, DOI 10.1016/S0959-8049(97)00071-3; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106	48	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					602	614		10.1038/sj.onc.1206186	http://dx.doi.org/10.1038/sj.onc.1206186			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555073				2022-12-17	WOS:000180538200013
J	Vandesompele, J; Edsjo, A; De Preter, K; Axelson, H; Speleman, F; Pahlman, S				Vandesompele, J; Edsjo, A; De Preter, K; Axelson, H; Speleman, F; Pahlman, S			ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value	ONCOGENE			English	Article						ID2; MYC; MYCN; neuroblastoma; prognosis	N-MYC; GENE-EXPRESSION; PROTEINS; CELLS	The MYCN proto-oncogene is frequently amplified in a subgroup of highly aggressive neuroblastomas. The molecular mechanism(s) by which the overexpressed MYCN contributes to an aggressive tumor cell behavior is not well understood. Recently, it was reported that the ID2 gene is a direct target for the MYCN and MYC transcription factors, and that ID2 expression and MYCN amplification correlate positively in neuroblastoma. In addition, ID2 expression was proposed as a negative prognostic parameter. As these results are of potential clinical importance, but not in agreement with our own initial observations, the putative correlation between ID2 and MYC(N) expression in neuroblastoma cell lines and tumors was reinvestigated. We found no correlation between MYCN and ID2 expression in neuroblastoma cell lines or tumor specimens. However, we did find a significant positive correlation between MYC and ID2 expressions in both MYCN-amplified and single-copy tumor specimens, and in MYCN single-copy cell lines. As previously reported, we also found an inverse correlation between MYC and MYCN expressions. Importantly, we could not confirm the reported prognostic power of ID2-expression in neuroblastoma. These data, obtained in two independent laboratories, challenge the previously proposed ID2-MYCN relation.	Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, S-20502 Malmo, Sweden; Ghent Univ Hosp, Ctr Med Genet, B-9000 Ghent, Belgium	Lund University; Skane University Hospital; Ghent University; Ghent University Hospital	Pahlman, S (corresponding author), Lund Univ, Univ Hosp MAS, Dept Lab Med, Div Mol Med, Entrance 78, S-20502 Malmo, Sweden.	sven.pahlman@molmed.mas.lu.se	Edsjö, Anders/AAC-8658-2019; speleman, frank/AAR-5184-2020; De Preter, Katleen/I-7135-2013; Vandesompele, Jo/W-3411-2018	speleman, frank/0000-0002-6628-8559; De Preter, Katleen/0000-0002-7726-5096; Vandesompele, Jo/0000-0001-6274-0184				Bown N, 2001, J CLIN PATHOL, V54, P897, DOI 10.1136/jcp.54.12.897; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; De Preter K, 2002, MODERN PATHOL, V15, P159, DOI 10.1038/modpathol.3880508; Hoehner JC, 1998, LAB INVEST, V78, P29; Hoehner JC, 1996, LAB INVEST, V75, P659; Jogi A, 2002, P NATL ACAD SCI USA, V99, P7021, DOI 10.1073/pnas.102660199; Jogi A, 2002, J BIOL CHEM, V277, P9118, DOI 10.1074/jbc.M107713200; Judware R, 1995, ONCOGENE, V11, P2599; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 2002, CANCER RES, V62, P301; Lasorella A, 2001, ONCOGENE, V20, P8326, DOI 10.1038/sj.onc.1205093; Lutz W, 1996, ONCOGENE, V13, P803; Maris JM, 1999, J CLIN ONCOL, V17, P2264, DOI 10.1200/JCO.1999.17.7.2264; Reiter JL, 1998, GENE CHROMOSOME CANC, V23, P134, DOI 10.1002/(SICI)1098-2264(199810)23:2<134::AID-GCC6>3.0.CO;2-3; SAWAI S, 1993, DEVELOPMENT, V117, P1445; Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wakamatsu Y, 1997, DEVELOPMENT, V124, P1953; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Zebedee Z, 2001, ONCOGENE, V20, P8317, DOI 10.1038/sj.onc.1205092	20	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2003	22	3					456	460		10.1038/sj.onc.1206148	http://dx.doi.org/10.1038/sj.onc.1206148			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545167				2022-12-17	WOS:000180379100015
J	Chen, J; Xiong, JY; Liu, HY; Chernenko, G; Tang, SC				Chen, J; Xiong, JY; Liu, HY; Chernenko, G; Tang, SC			Distinct BAG-1 isoforms have different anti-apoptotic functions in BAG-1-transfected C33A human cervical carcinoma cell line	ONCOGENE			English	Article						BAG-1 isoforms; apoptosis; Bcl-2; Bax; p53; caspase-3	ENHANCED EXPRESSION; ENDOCERVICAL CELLS; CHAPERONE ACTIVITY; PROTEIN BAG-1; RECEPTOR; BCL-2; ACTIVATION; RESISTANCE; GENES; RAP46	BAG-1 protein can be expressed as four isoforms of 50, 46, 33 and 29 kDa with different subcellular localizations, which may have different functions in antiapoptosis, but the exact mechanism remains unclear. We constructed BAG-1 full length and deletion mutated plasmids in a pCR3.1 vector and established stable transfections of BAG-I isoforms in low BAG-1 expressing C33A cells. Treatment of the transfected cells with cisplatin, staurosporine, paclitaxel and doxorubicine showed that BAG-1 p50, p46 and p33 isoforms enhanced the resistance to apoptosis. BAG-I p50, p46 and p33 exhibited different degrees of apoptosis inhibition in the transfected cells and BAG-I p46 isoform had the most pronounced effect on anti-apoptosis. BAG-I p29 failed to protect the transfected cells from apoptosis. Resistance to apoptosis by BAG-1 isoforms was correlated with decreased caspase-3 activation. We also detected the expression of Bax, Bak, p53, Bcl-2, BCl-X-L, AIF and MRP1 by Western blots. Bcl-2 protein expression was significantly increased in p50, p46 and p33 transfected cells, while the expression of Bax, Bak, p53, BCl-X-L and MRP1 was essentially unchanged. These in vitro results suggest that distinct isoforms of BAG-1 have different anti-apoptotic functions and their functions may be correlated to increased Bcl-2 expression.	Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Mem Univ Newfoundland, Fac Med, St John, NF A1B 3V6, Canada	University of Miami; Memorial University Newfoundland	Tang, SC (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, 1475 NW 12th Ave, Miami, FL 33136 USA.	stang@med.miami.edu						Adachi M, 1998, LEUKEMIA LYMPHOMA, V30, P483, DOI 10.3109/10428199809057561; Antoku K, 2001, BIOCHEM BIOPH RES CO, V286, P1003, DOI 10.1006/bbrc.2001.5512; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Crocoll A, 2000, MECH DEVELOP, V91, P355, DOI 10.1016/S0925-4773(99)00284-1; Ding ZH, 2000, BIOCHEM BIOPH RES CO, V270, P415, DOI 10.1006/bbrc.2000.2432; Ding ZH, 2000, INT J CANCER, V87, P818, DOI 10.1002/1097-0215(20000915)87:6<818::AID-IJC10>3.0.CO;2-M; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Niyaz Y, 2001, J CELL SCI, V114, P1839; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; Rorke S, 2001, INT J CANCER, V95, P317, DOI 10.1002/1097-0215(20010920)95:5<317::AID-IJC1055>3.0.CO;2-J; Schneikert J, 1999, J CELL BIOL, V146, P929, DOI 10.1083/jcb.146.5.929; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Takahashi N, 2001, BIOCHEM BIOPH RES CO, V286, P807, DOI 10.1006/bbrc.2001.5473; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tang SC, 1999, J CLIN ONCOL, V17, P1710, DOI 10.1200/JCO.1999.17.6.1710; Terada S, 1997, CYTOTECHNOLOGY, V25, P17, DOI 10.1023/A:1007954103572; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Witcher M, 2001, EXP CELL RES, V265, P167, DOI 10.1006/excr.2001.5176; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Yang XL, 1999, CLIN CANCER RES, V5, P1816; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yang XL, 1998, MOL CARCINOGEN, V22, P95, DOI 10.1002/(SICI)1098-2744(199806)22:2<95::AID-MC4>3.3.CO;2-Y; Yang XL, 1997, J CELL BIOCHEM, V66, P309, DOI 10.1002/(SICI)1097-4644(19970901)66:3<309::AID-JCB4>3.3.CO;2-Y; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	40	35	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7050	7059		10.1038/sj.onc.1205845	http://dx.doi.org/10.1038/sj.onc.1205845			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370827				2022-12-17	WOS:000178424900008
J	Ohno, H; Hirabayashi, S; Iizuka, T; Ohnishi, H; Fujita, T; Hata, Y				Ohno, H; Hirabayashi, S; Iizuka, T; Ohnishi, H; Fujita, T; Hata, Y			Localization of p0071-interacting proteins, plakophilin-related armadillo-repeat protein-interacting protein (PAPIN) and ERBIN, in epithelial cells	ONCOGENE			English	Article						p0071; catenin; ERBIN; ErbB2; PAPIN; PDZ	DOMAIN-CONTAINING PROTEIN; BASOLATERAL PDZ PROTEIN; GUANYLATE KINASE; SCAFFOLDING MOLECULE; BETA-CATENIN; JUNCTIONS; MAGI-1; MEMBER; DENSIN-180; CLONING	PAPIN has six PDZ domains and interacts with p0071, a catenin-related protein. Recent studies have revealed that catenins determine the subcellular localization of some PDZ proteins. We have examined whether the localization of PAPIN is determined by p0071 in epithelial cells. PAPIN was localized not only on the lateral membrane but also on the apical membrane, where p0071 was absent. The targeting to both membranes was mediated by the middle region of PAPIN and did not require the p0071-interacting PDZ domain. In cells that came into contact, PAPIN was diffusely distributed on the plasma membrane, while p0071 was concentrated at immature cell-cell contacts. When epithelial cells were exposed to the low concentration of calcium, p0071 was internalized, whereas PAPIN remained on the plasma membrane. We also confirmed that the interaction with p0071 was not essential for the membrane targeting of ERBIN, a recently identified p0071- and ErbB2-binding protein. PAPIN, p0071, and ERBIN formed a complex in 293T cells. Furthermore, ERBIN and ErbB2 were colocalized with PAPIN on the lateral membrane. These findings suggest that PAPIN, p0071, and ERBIN come to the cell-cell contacts independently and interact with each other on the lateral membrane.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Gastroenterol, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	yuhammch@med.tmd.ac.jp						Apperson ML, 1996, J NEUROSCI, V16, P6839; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Chaib H, 2001, CANCER RES, V61, P2390; Deguchi M, 2000, J BIOL CHEM, V275, P29875, DOI 10.1074/jbc.M005384200; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Hatzfeld M, 1996, J CELL SCI, V109, P2767; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Izawa I, 2002, J BIOL CHEM, V277, P5345, DOI 10.1074/jbc.M110052200; Izawa I, 2002, GENES CELLS, V7, P475, DOI 10.1046/j.1365-2443.2002.00533.x; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Kim HG, 1999, HISTOL HISTOPATHOL, V14, P1175, DOI 10.14670/HH-14.1175; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nishimura W, 2002, J NEUROSCI, V22, P757, DOI 10.1523/JNEUROSCI.22-03-00757.2002; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; Tsukita S, 1996, CELL STRUCT FUNCT, V21, P381, DOI 10.1247/csf.21.381; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	29	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7042	7049		10.1038/sj.onc.1205852	http://dx.doi.org/10.1038/sj.onc.1205852			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370826				2022-12-17	WOS:000178424900007
J	Viniegra, JG; Losa, JH; Sanchez-Arevalo, VJ; Cobo, CP; Soria, VMF; Cajal, SRY; Sanchez-Prieto, R				Viniegra, JG; Losa, JH; Sanchez-Arevalo, VJ; Cobo, CP; Soria, VMF; Cajal, SRY; Sanchez-Prieto, R			Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin	ONCOGENE			English	Article						E1a; PI3k; Akt; downregulation; insulin; cisplatin	PROTEIN-KINASE-B; ADENOVIRUS E1A; OVARIAN-CANCER; CELL-GROWTH; INSULIN; ACTIVATION; EXPRESSION; GENE; PHOSPHORYLATION; SUPPRESSION	In order to investigate the molecular mechanisms implicated in the induction of chemo sensitivity by adenovirus E1a gene expression, we decided to investigate which signal transduction pathways could be affected by the E1a gene in Human Normal Fibroblast (IMR90). No effect was observed in SAPK pathways (p38MAPK and JNK), but E1a was able to affect the Akt activation mediated by insulin. This result was confirmed by transient transfection experiments performed in Cos-7 cells and also observed in other transformed cell lines such as A431. Furthermore, E1a expression induces a decrease in the basal status of Akt activity. Finally we demonstrated that E1a is able to block the Akt activation mediated by cisplatin and correlates with a sensitive phenotype. In summary, our data demonstrate that specific inhibition of the PI3K/Akt pathway mediates some of the biological properties of E1a such as induction of chemosensitivity.	Clin Puerta Hierro, Unidad Patol Mol, Madrid 28035, Spain	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Sanchez-Prieto, R (corresponding author), Clin Puerta Hierro, Unidad Patol Mol, C San Martin de Porres 4, Madrid 28035, Spain.		Sanchez-Prieto, Ricardo/AAY-4271-2021; Ramon y Cajal, Santiago/H-4955-2016; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Javier, Hernandez Losa/C-1173-2008; Prieto, Ricardo/AAZ-7221-2021; Sanchez-Prieto, Ricardo/B-6877-2008; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Ramon y Cajal, Santiago/0000-0002-3867-1390; Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; Javier, Hernandez Losa/0000-0003-1526-3201; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; Fernandez-Soria, Victor Manuel/0000-0002-4225-8697				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Brognard J, 2001, CANCER RES, V61, P3986; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Frisch SM, 2001, ADV CANCER RES, V80, P39, DOI 10.1016/S0065-230X(01)80011-7; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hayakawa J, 2000, CANCER RES, V60, P5988; KIM HS, 1995, MOL ENDOCRINOL, V9, P178, DOI 10.1210/me.9.2.178; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; See RH, 1998, MOL CELL BIOL, V18, P4012, DOI 10.1128/MCB.18.7.4012; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Shao RP, 2001, CANCER RES, V61, P7413; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531; TEODORO JG, 1995, ONCOGENE, V11, P467; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	26	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7131	7136		10.1038/sj.onc.1205934	http://dx.doi.org/10.1038/sj.onc.1205934			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370836				2022-12-17	WOS:000178424900017
J	Kim, BY; Gaynor, RB; Song, K; Dritschilo, A; Jung, M				Kim, BY; Gaynor, RB; Song, K; Dritschilo, A; Jung, M			Constitutive activation of NF-kappa B in Ki-ras-transformed prostate epithelial cells	ONCOGENE			English	Article						Kirsten-ras (Ki-Ras); nuclear factor-kappa B; I-kappa B (I kappa,B); I kappa B kinase (IKK)	KINASE COMPLEX; IKK-ALPHA; TRANSCRIPTIONAL ACTIVITY; INCONTINENTIA PIGMENTI; LIVER DEGENERATION; DEFICIENT MICE; ERK ACTIVITY; BETA; ONCOGENE; PROTEIN	The signaling pathway responsible for the activation of nuclear factor-kappaB (NF-kappaB) by oncogenic forms of Ras remains unclear. Both, the transactivation and DNA binding activities of NF-kappaB, were increased in 267B1 human prostate epithelial cells transformed by viral Kirsten-ras (267B1/Ki-ras cells) compared with those in the parental cells. This increased NF-kappaB activity was attributed to a heterodimeric complex of p50 and p65 subunits. Although the abundance of the inhibitor protein IkappaBbeta was higher in 267B1/Ki-ras cells than in 267B1 cells, an electrophoretic mobility-shift assay suggested that IkappaBalpha is responsible for the activation of NF-kappaB in the former cells. Consistent with this notion, the phosphorylation of IkappaBalpha appeared increased in 267B1/Ki-ras cells, and the proteasome inhibitor I abolished the constitutive activation of NF-kappaB in these cells. The expression of dominant negative mutants of either NIK (NF-kappaB-inducing kinase) or IKKbeta (IkappaB kinase beta) inhibited the activity of NF-kappaB in 267B1/Ki-ras cells. Furthermore, chemical inhibitors specific for Ras activation, sulindac sulfide and farnesytranferase inhibitor 1, markedly reduced IkappaBalpha phosphorylation and NF-kappaB activation in the Ki-ras-transformed cells while transfection of these cells with NIK or IKKbeta counteracted the inhibitory effect on NF-kappaB activation. These results suggest that oncogenic Ki-Ras induces transactivation of NF-kappaB through the NIK-IKKbeta-IkappaBalpha pathway.	Georgetown Univ, Sch Med, Dept Radiat Med, Washington, DC 20007 USA; Univ Texas, SW Med Ctr, Dept Med, Harold Simmons Canc Ctr, Dallas, TX 75235 USA	Georgetown University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Jung, M (corresponding author), Georgetown Univ, Sch Med, Dept Radiat Med, Washington, DC 20007 USA.				NATIONAL CANCER INSTITUTE [R01CA045408, P01CA074175] Funding Source: NIH RePORTER; NCI NIH HHS [CA74175, CA45408] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allgayer H, 1999, BRIT J CANCER, V80, P1884, DOI 10.1038/sj.bjc.6690616; Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0; Caunt CJ, 2001, J BIOL CHEM, V276, P6280, DOI 10.1074/jbc.M006772200; DeLuca C, 1999, J BIOL CHEM, V274, P13010, DOI 10.1074/jbc.274.19.13010; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Janssen YMW, 1999, METHOD ENZYMOL, V300, P363; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kimmelman AC, 2000, ONCOGENE, V19, P2014, DOI 10.1038/sj.onc.1203530; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Lin YB, 1998, INT J COMMUN SYST, V11, P1; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MILLS NE, 1995, CANCER RES, V55, P1444; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MIYAMOTO S, 1994, MOL CELL BIOL, V14, P3276, DOI 10.1128/MCB.14.5.3276; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Ozes ON, 1999, NATURE, V401, P82; PARDA DS, 1993, PROSTATE, V23, P91, DOI 10.1002/pros.2990230202; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; SUKUMAR S, 1991, MOL CARCINOGEN, V4, P362, DOI 10.1002/mc.2940040507; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; UMANOFF H, 1995, P NATL ACAD SCI USA, V92, P1709, DOI 10.1073/pnas.92.5.1709; Wang DZ, 2001, J BIOL CHEM, V276, P3650, DOI 10.1074/jbc.M006115200; Wang WX, 1999, CLIN CANCER RES, V5, P119; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Yamamoto Y, 1999, J BIOL CHEM, V274, P27307, DOI 10.1074/jbc.274.38.27307; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271; Yip-Schneider MT, 2001, BIOCHEM BIOPH RES CO, V280, P992, DOI 10.1006/bbrc.2001.4243; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	48	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2002	21	29					4490	4497		10.1038/sj.onc.1205547	http://dx.doi.org/10.1038/sj.onc.1205547			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	567GH	12085227				2022-12-17	WOS:000176476700003
J	Sers, C; Husmann, K; Nazarenko, I; Reich, S; Wiechen, K; Zhumabayeva, B; Adhikari, P; Schroder, K; Gontarewicz, A; Schafer, R				Sers, C; Husmann, K; Nazarenko, I; Reich, S; Wiechen, K; Zhumabayeva, B; Adhikari, P; Schroder, K; Gontarewicz, A; Schafer, R			The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFN gamma-induced cell death in human ovarian carcinoma cells	ONCOGENE			English	Article						tumour suppressor; H-REV107-1; IRF-1; target gene; IRF gamma; apoptosis	BRCA1 PROMOTER REGION; TRANSCRIPTION FACTOR; LYSYL OXIDASE; DOWN-REGULATION; MESSENGER-RNAS; RETINOIC ACID; EXPRESSION; IRF-1; CANCER; TRANSFORMATION	H-rev107-1 is a growth inhibitory RAS target gene capable of suppressing anchorage independent growth in vitro and in vivo. Using a tumour tissue array with 241 matched tumour and normal tissue cDNA pools, we found down-regulation of H-REV107-1 in 7 out of 14 ovary-derived cDNAs. RT-PCR analysis and immunohistochemical investigation confirmed expression of H-REV107-1 in normal ovarian epithelial cells but down-regulation in high grade ovarian carcinomas. H-REV107-1 is also strongly expressed in immortalized rat and human ovarian epithelial cells in vitro, but suppressed in transformed cells by two different mechanisms. KRAS-transformed rat ovarian cells and PA1 teratocarcinoma cells, reversibly repress H-REV107-1 via MAP/ERK signaling. In contrast, treatment of A27/80 and OVCAR-3 epithelial ovarian cancer cells with IFN-gamma stimulated H-REV107-1 expression. In NIH3T3 cells harbouring an estrogen-inducible IRF-1, H-rev107-1 is directly induced after activation of IRF-1, indicating that H-rev107-1 is a target of IRF-1. Stimulation of H-REV107-1 expression was also observed in ovarian epithelial cells suggesting that IRF-1 is involved in H-REV107-1 regulation in human ovarian epithelium. In the IFNgamma-sensitive cell line A27/80, H-REV107-1 suppresses colony formation. A27/80 and OVCAR-3 cells overexpressing H-REV107-1 protein underwent apoptosis. These results demonstrate down-regulation of the class II tumour suppressor H-REV107-1 in human ovarian carcinomas and suggest an involvement of H-REV107-1 in interferon-dependent cell death.	Univ Hosp Charite, Inst Pathol, D-10117 Berlin, Germany; Natl Res Ctr Biotechnol, Braunschweig, Germany; Clontech Labs, Palo Alto, CA 94303 USA	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Sers, C (corresponding author), Univ Hosp Charite, Inst Pathol, Schumannstr 20-21, D-10117 Berlin, Germany.	christine.sers@charite.de	Nazarenko, Irina/E-5714-2010; Schäfer, Reinhold/AAB-5110-2021; Sers, Christine/B-5438-2010	Nazarenko, Irina/0000-0002-2633-1161; Schafer, Reinhold/0000-0001-7952-2124; Sers, christine/0000-0002-6219-1514				ADAMS AT, 1985, EXP CELL BIOL, V53, P181; Baldwin RL, 2000, CANCER RES, V60, P5329; Bist A, 2000, BIOCHEMISTRY-US, V39, P1966, DOI 10.1021/bi991721h; Burke F, 1999, BRIT J CANCER, V80, P1236, DOI 10.1038/sj.bjc.6690491; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Chelbi-Alix MK, 1999, LEUKEMIA, V13, P1167, DOI 10.1038/sj.leu.2401469; CONTENTE S, 1990, SCIENCE, V249, P796, DOI 10.1126/science.1697103; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Demaeyer E., 1988, INTERFERONS OTHER RE; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Evans TRJ, 1999, BRIT J CANCER, V80, P1, DOI 10.1038/sj.bjc.6690312; Green WB, 1999, LEUKEMIA, V13, P1960, DOI 10.1038/sj.leu.2401596; HAJNAL A, 1993, CANCER RES, V53, P4670; HAJNAL A, 1994, ONCOGENE, V9, P479; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; HARADA H, 1994, ONCOGENE, V9, P3313; Husmann K, 1998, ONCOGENE, V17, P1305, DOI 10.1038/sj.onc.1202060; Jiang Ming-Chung, 2001, Molecular Cell Biology Research Communications, V4, P353, DOI 10.1006/mcbr.2001.0303; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kirchhoff S, 1999, ONCOGENE, V18, P3725, DOI 10.1038/sj.onc.1202704; KIRCHHOFF S, 1995, ONCOGENE, V11, P439; Kondo T, 1997, ONCOGENE, V15, P1275, DOI 10.1038/sj.onc.1201286; Kuchinke W, 1995, NEUROIMMUNOMODULAT, V2, P347, DOI 10.1159/000097214; Momparler RL, 2000, J CELL PHYSIOL, V183, P145, DOI 10.1002/(SICI)1097-4652(200005)183:2<145::AID-JCP1>3.0.CO;2-V; Nozawa H, 1998, INT J CANCER, V77, P522, DOI 10.1002/(SICI)1097-0215(19980812)77:4<522::AID-IJC8>3.0.CO;2-W; OBERHUBER H, 1995, MOL CARCINOGEN, V12, P198, DOI 10.1002/mc.2940120404; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; PALOMBELLA VJ, 1992, MOL CELL BIOL, V12, P3325, DOI 10.1128/MCB.12.8.3325; Patton SE, 1998, CANCER RES, V58, P2253; Rohwedel J, 1999, CELLS TISSUES ORGANS, V165, P190, DOI 10.1159/000016699; RONGLIN X, 2001, J BIOL CHEM, V276, P18624; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Sager R, 1997, P NATL ACAD SCI USA, V94, P952, DOI 10.1073/pnas.94.3.952; SCHAFER R, 1994, REV PHYSIOL BIOCH P, V124, P29, DOI 10.1007/BFb0031031; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sers C, 1997, J CELL BIOL, V136, P935, DOI 10.1083/jcb.136.4.935; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; TAINSKY MA, 1984, SCIENCE, V225, P643, DOI 10.1126/science.6740333; Tamura G, 1996, CANCER RES, V56, P612; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Tan RSP, 1996, CANCER RES, V56, P2417; Tanaka N, 2000, SEMIN CANCER BIOL, V10, P73, DOI 10.1006/scbi.2000.0310; TANAKA N, 1994, CANCER LETT, V83, P191, DOI 10.1016/0304-3835(94)90318-2; TANAKA N, 1994, CELL, V77, P829, DOI 10.1016/0092-8674(94)90132-5; Tchernitsa OI, 1999, ONCOGENE, V18, P5448, DOI 10.1038/sj.onc.1202987; Tnani M, 1999, BBA-MOL CELL RES, V1451, P59, DOI 10.1016/S0167-4889(99)00089-0; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; WILLMAN CL, 1993, SCIENCE, V259, P968, DOI 10.1126/science.8438156; Windbichler GH, 2000, BRIT J CANCER, V82, P1138; Yasukawa H, 2000, ANNU REV IMMUNOL, V18, P143, DOI 10.1146/annurev.immunol.18.1.143; Yip-Schneider MT, 1999, INT J ONCOL, V15, P271; Zhang M, 1997, CELL GROWTH DIFFER, V8, P179; Zhumabayeva B, 2001, BIOTECHNIQUES, V30, P158, DOI 10.2144/01301pf01; ZHUMABAYEVA B, 2001, CLONTECHNIQUES, V16, P27; Zou ZQ, 2000, J BIOL CHEM, V275, P6051, DOI 10.1074/jbc.275.9.6051; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	57	35	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2829	2839		10.1038/sj.onc.1205377	http://dx.doi.org/10.1038/sj.onc.1205377			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973642				2022-12-17	WOS:000175063700007
J	Wang, DG; Patil, S; Li, WH; Humphrey, LE; Brattain, MG; Howell, GM				Wang, DG; Patil, S; Li, WH; Humphrey, LE; Brattain, MG; Howell, GM			Activation of the TGF alpha autocrine loop is downstream of IGF-1 receptor activation during mitogenesis in growth factor dependent human colon carcinoma cells	ONCOGENE			English	Article						colon carcinoma; autocrine transforming growth factor alpha; insulin growth factor-1 receptor; IGF-1R competence factor; growth factor dependence	FACTOR-I RECEPTOR; DIFFERENTIAL REGULATION; GENE-EXPRESSION; TRANSGENIC MICE; EGF RECEPTOR; C-MYC; TRANSCRIPTION; REQUIREMENTS; GLUCOSAMINE; KINASE	The inappropriate expression of TGFalpha in growth arrest contributes to malignant progression in human colon carcinoma cells. Early stage, non-progressed colon tumor cells show a down-regulation of TGFalpha in growth arrest and require both nutrients and growth factors for re-entry into the cell cycle. In contrast, highly progressed cells up-regulate TGFalpha during growth arrest and require only nutrients for re-entry. Given the importance of TGFalpha in malignant progression, this work addressed the regulation of TGFalpha expression in the early stage colon carcinoma cell line, FET. Growth-arrested FET cells down-regulated the expression of TGFalpha, EGFr and, in turn, EGFr activation. These quiescent cells continued to express high levels of IGF-IR protein, but IGF-IR activation was undetectable. Cell cycle re-entry required exogenous growth factor activation of the IGF-IR by insulin or IGF-I. This IGF-IR activation resulted in S phase re-entry and was accompanied by an approximate threefold induction of TGFalpha expression along with EGFr activation at 1 h following release from growth arrest. Activation of IGF-IR occurred within 5 min of cell-cycle re-entry. Previously identified DNA binding proteins which bind to a unique TGFalpha/EGF response element within the TGFalpha promoter were similarly induced following IGF-IR activation. The addition of EGFr neutralizing antibodies abolished the activated IGF-IR stimulated S phase re-entry. Moreover, disruption of the growth arrest associated down-regulation of TGFalpha in FET cells by constitutive TGFalpha expression abrogated the requirement for IGF-IR activation for cell cycle re-entry. Consequently, this study indicates, for the first time, that IGF-IR activation up-regulates components of the TGFalpha autocrine loop resulting in TGFalpha-mediated EGFr activation which was critical for IGF-IR mediated re-entry into the cell cycle from the growth-arrested state.	Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Buffalo, NY 14263 USA; Med Coll Ohio, Dept Biochem & Mol Biol, Toledo, OH 43699 USA	Roswell Park Cancer Institute	Howell, GM (corresponding author), Roswell Pk Canc Inst, Grace Canc Drug Ctr, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.	gillian.howell@roswellpark.org			NCI NIH HHS [CA54870, CA34432] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034432] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1990, ENDOCRINOLOGY, V126, P596, DOI 10.1210/endo-126-1-596; Blakesley VA, 1997, J ENDOCRINOL, V152, P339, DOI 10.1677/joe.0.1520339; BOYD DD, 1988, CANCER RES, V48, P2469; BRATTAIN MG, 1984, CANCER METAST REV, V3, P177, DOI 10.1007/BF00048384; BRATTAIN MG, 1981, ONCODEV BIOL MED, V2, P355; Brattain Michael G., 1994, Current Opinion in Oncology, V6, P77, DOI 10.1097/00001622-199401000-00011; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CAMPOSGONZALEZ R, 1991, CELL REGUL, V2, P663, DOI 10.1091/mbc.2.8.663; CHANTRET I, 1988, CANCER RES, V48, P1936; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1987, CANCER RES, V47, P707; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P707; ENOCH T, 1986, MOL CELL BIOL, V6, P801, DOI 10.1128/MCB.6.3.801; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HOWELL GM, 1995, J CELL PHYSIOL, V162, P256, DOI 10.1002/jcp.1041620211; Howell GM, 1998, MOL CELL BIOL, V18, P303, DOI 10.1128/MCB.18.1.303; HUEBERS HA, 1987, PHYSIOL REV, V67, P520, DOI 10.1152/physrev.1987.67.2.520; Jiang DH, 1998, J BIOL CHEM, V273, P31471, DOI 10.1074/jbc.273.47.31471; KHAZAIE K, 1993, CANCER METAST REV, V12, P255, DOI 10.1007/BF00665957; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MULDER KM, 1991, CANCER RES, V51, P2256; MULDER KM, 1989, MOL ENDOCRINOL, V3, P1215, DOI 10.1210/mend-3-8-1215; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PITTELKOW MR, 1993, CELL GROWTH DIFFER, V4, P513; ROOS MD, 1996, AM J PHYSIOL, V270, P803; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; Sayeski PP, 1996, J BIOL CHEM, V271, P15237, DOI 10.1074/jbc.271.25.15237; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SCHLECHTE W, 1990, CANCER COMMUN, V2, P173; SCHMID C, 1995, CELL BIOL INT, V19, P445, DOI 10.1006/cbir.1995.1088; STEWART AJ, 1990, J BIOL CHEM, V265, P21172; TANAKA S, 1991, AM J PATHOL, V139, P123; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; WU SP, 1992, J CELL BIOL, V116, P187, DOI 10.1083/jcb.116.1.187; Yang HS, 2000, ONCOGENE, V19, P1901, DOI 10.1038/sj.onc.1203513; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	43	35	38	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2785	2796		10.1038/sj.onc.1205375	http://dx.doi.org/10.1038/sj.onc.1205375			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973637				2022-12-17	WOS:000175063700002
J	Gonzales, M; Bowden, GT				Gonzales, M; Bowden, GT			The role of PI 3-kinase in the UVB-induced expression of c-fos	ONCOGENE			English	Article						UVB; c-fos; PI 3-kinase; GSK-3 beta	GLYCOGEN-SYNTHASE KINASE-3; KERATINOCYTE CELL-LINE; P38 MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; AP-1 TRANSACTIVATION; PROTEIN-1 ACTIVATION; BINDING PROTEIN; GENE-EXPRESSION; TRANSGENIC MICE; DNA-SYNTHESIS	The role of the PI 3-kinase signaling pathway in UVB-induced c-fos gene expression was investigated in a human keratinocyte cell line, HaCaT. The enzymatic activity of PI 3-kinase was increased threefold by 250 J/m(2) UVB. Inhibition of PI 3-kinase activity, via expression of a mutant p85 subunit or treatment with wortmannin, resulted in decreased levels of c-fos promoter activity and c-fos protein. Two members of the PI 3-kinase signaling pathway, Akt and GSK-3beta, were also found to affect c-fos transactivation. Expression of dominant negative Akt or wild-type GSK-3beta significantly inhibited UVB-induced c-fos promoter activity. In addition, when GSK-3beta activity was inhibited by lithium chloride, both c-fos promoter activity and protein levels increased. These results demonstrate that both Akt activation and GSK-3beta inactivation are required in the UVB-induction of c-fos. Our results demonstrate for the first time that UVB induction of c-fos is in part mediated by the PI 3-kinase signaling pathway in the HaCaT cell line. By identifying the multiple signaling pathways that are induced by UVB and contribute to the induction of c-fos expression, more drug targets may be identified to aid attempts to prevent and treat skin cancer.	Univ Arizona, Coll Med, Arizona Canc Ctr, Dept Mol & Cellular Biol, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), 1515 N Campbell,Radiat 1,Rm 4999, Tucson, AZ 85724 USA.				NATIONAL CANCER INSTITUTE [P01CA027502] Funding Source: NIH RePORTER; NCI NIH HHS [CA 27502] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Barthelman M, 1998, CANCER RES, V58, P711; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; Chen WX, 1999, MOL CARCINOGEN, V24, P79, DOI 10.1002/(SICI)1098-2744(199902)24:2<79::AID-MC1>3.0.CO;2-E; Chen WX, 1998, J BIOL CHEM, V273, P32176, DOI 10.1074/jbc.273.48.32176; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Funakoshi M, 2001, INT IMMUNOPHARMACOL, V1, P595, DOI 10.1016/S1567-5769(00)00035-7; GREWE M, 1993, J INVEST DERMATOL, V101, P528, DOI 10.1111/1523-1747.ep12365904; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HAYASHI H, 1992, J BIOL CHEM, V267, P22575; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Ibuki Y, 2000, BIOCHEM BIOPH RES CO, V279, P872, DOI 10.1006/bbrc.2000.4018; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; Kabuyama Y, 1998, FEBS LETT, V441, P297, DOI 10.1016/S0014-5793(98)01565-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; MARKS R, 1995, CANCER-AM CANCER SOC, V75, P607, DOI 10.1002/1097-0142(19950115)75:2+<607::AID-CNCR2820751402>3.0.CO;2-8; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; NIKOLAKAKI E, 1993, ONCOGENE, V8, P833; Nomura M, 2001, J BIOL CHEM, V276, P46624, DOI 10.1074/jbc.M107897200; Nomura M, 2001, J BIOL CHEM, V276, P25558, DOI 10.1074/jbc.M101164200; POWIS G, 1994, CANCER RES, V54, P2419; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; RUTHER U, 1989, ONCOGENE, V4, P861; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; Sabbatini P, 1999, J BIOL CHEM, V274, P24263, DOI 10.1074/jbc.274.34.24263; SAEZ E, 1995, CELL, V82, P721, DOI 10.1016/0092-8674(95)90469-7; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Tang QB, 2001, CANCER RES, V61, P4329; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wan YS, 2001, INT J ONCOL, V18, P461; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685	45	35	38	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 18	2002	21	17					2721	2728		10.1038/sj.onc.1205366	http://dx.doi.org/10.1038/sj.onc.1205366			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	541RA	11965545				2022-12-17	WOS:000174996500012
J	Ababou, M; Dumaire, V; Lecluse, Y; Amor-Gueret, M				Ababou, M; Dumaire, V; Lecluse, Y; Amor-Gueret, M			Bloom's syndrome protein response to ultraviolet-C radiation and hydroxyurea-mediated DNA synthesis inhibition	ONCOGENE			English	Article						Bloom's syndrome; UVC radiation; hydroxyurea-mediated DNA synthesis inhibition; cell cycle checkpoints; phosphorylation	SYNDROME GENE-PRODUCT; WERNERS-SYNDROME GENES; SYNDROME FIBROBLASTS; IONIZING-RADIATION; REPLICATION; CELLS; CHECKPOINT; P53; PHOSPHORYLATION; P21(WAF1/CIP1)	Bloom's syndrome (BS) arises through mutations in both copies of the BLM gene that encodes a RecQ 3'-5' DNA helicase. BS patients are predisposed to developing all the cancers that affect the general population, and BS cells exhibit marked genetic instability. We showed recently that BLM protein contributes to the cellular response to ionizing radiation by acting as downstream ATM kinase effector. We now show that following UVC treatment, BLM-deficient cells exhibit a reduction in the number of replicative cells, a partial escape from the G2/M cell cycle checkpoint, and have an altered p21 response. Surprisingly, we found that hydroxyureatreated BLM-deficient cells exhibit an intact S phase arrest, proper recovery from the S phase arrest, and intact p53 and p21 responses. We also show that the level of BLM falls sharply in response to UVC radiation. This UVC-induced reduction in BLM does not require a functional ATM gene and does not result from a subcellular compartment change. Finally, we demonstrate that exposure to UVC and hydroxyurea treatment both induce BLM phosphorylation via an ATM-independent pathway. These results are discussed in the light of their potential physiological significance with regard to the role of BLM in the cellular pathways activated by UVC radiation or HU-mediated inhibition of DNA synthesis.	Inst Gustave Roussy, CNRS, UMR 1598, F-94805 Villejuif, France; Inst Gustave Roussy, Serv Cytometr Flux, IFR 54, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Amor-Gueret, M (corresponding author), Inst Gustave Roussy, CNRS, UMR 1598, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	amor@igr.fr		ababou, mouna/0000-0003-4276-3754				Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Allan LA, 1999, ONCOGENE, V18, P5403, DOI 10.1038/sj.onc.1202931; ANDO T, 2001, J BIOL CHEM, V14, P14; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Barakat A, 2000, Hum Mutat, V15, P584, DOI 10.1002/1098-1004(200006)15:6<584::AID-HUMU28>3.0.CO;2-I; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Collister M, 1998, CARCINOGENESIS, V19, P2115, DOI 10.1093/carcin/19.12.2115; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Davey S, 1998, MOL CELL BIOL, V18, P2721, DOI 10.1128/MCB.18.5.2721; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; Ellis NA, 1996, HUM MOL GENET, V5, P1457, DOI 10.1093/hmg/5.Supplement_1.1457; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Frei C, 2000, GENE DEV, V14, P81; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GIANNELLI F, 1977, NATURE, V265, P466, DOI 10.1038/265466a0; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; GURLEY LR, 1978, EUR J BIOCHEM, V84, P1, DOI 10.1111/j.1432-1033.1978.tb12135.x; HAND R, 1977, HUM GENET, V38, P297, DOI 10.1007/BF00402156; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Karow JK, 2000, CURR OPIN GENET DEV, V10, P32, DOI 10.1016/S0959-437X(99)00039-8; Karow JK, 1997, J BIOL CHEM, V272, P30611, DOI 10.1074/jbc.272.49.30611; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; KURIHARA T, 1987, MUTAT RES, V183, P197, DOI 10.1016/0167-8817(87)90062-9; LEVENSON V, 1993, NUCLEIC ACIDS RES, V21, P3997, DOI 10.1093/nar/21.17.3997; Li L, 1998, MOL GENET METAB, V64, P286, DOI 10.1006/mgme.1998.2733; LONN U, 1990, CANCER RES, V50, P3141; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MAMADA A, 1989, PHOTODERMATOLOGY, V6, P124; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Muchardt C, 1996, EMBO J, V15, P3394, DOI 10.1002/j.1460-2075.1996.tb00705.x; Sauve DM, 1999, J CELL BIOL, V145, P225, DOI 10.1083/jcb.145.2.225; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Wang JA, 1999, INT J RADIAT BIOL, V75, P301, DOI 10.1080/095530099140483; Wang SC, 2001, CANCER RES, V61, P2838; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang Y, 2000, GENE DEV, V14, P927; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu L, 2001, J BIOL CHEM, V276, P19375, DOI 10.1074/jbc.M009471200; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamagata K, 1998, P NATL ACAD SCI USA, V95, P8733, DOI 10.1073/pnas.95.15.8733	43	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	2002	21	13					2079	2088		10.1038/sj.onc.1205246	http://dx.doi.org/10.1038/sj.onc.1205246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	538QR	11960380				2022-12-17	WOS:000174827000014
J	Vortmeyer, A; Huang, SC; Pack, SD; Koch, CA; Lubensky, IA; Oldfield, EH; Zhuang, ZP				Vortmeyer, A; Huang, SC; Pack, SD; Koch, CA; Lubensky, IA; Oldfield, EH; Zhuang, ZP			Somatic point mutation of the wild-type allele detected in tumors of patients with VHL germline deletion	ONCOGENE			English	Article						VHL disease; VHL gene; mutation; deletion	VONHIPPEL-LINDAU DISEASE; SUPPRESSOR GENE; CARCINOMA	The majority of patients with Von Hippel-Lindau (VHL) disease are affected by a VHL germline mutation involving one copy of the VHL gene. Loss of heterozygosity of the second VHL allele can be consistently demonstrated in tumor tissue from these patients, suggesting that allelic deletion is a very early or even initiating event for tumorigenesis. Approximately 20% of VHL disease patients, however, exhibit germline deletion of one entire copy or at least a substantial part of the VHL gene. To investigate the nature of the 'second genetic hit' in this patient population, we analysed two renal cell carcinomas and one CNS hemangioblastoma from three unrelated patients for genetic changes of the second copy of the VHL gene. All three tumors showed retention of one VHL allele by FISH. Single-strand conformation polymorphism and mutation analysis of microdissected tumor DNA revealed somatic point mutations of the wild-type VHL copies in each of the three tumors. The results indicate that the 'two hit model' is equally applicable to patients with VHL germline mutation and VHL germline deletion. In contrast to tumors from patients with VHL germline mutation, however, point mutations of the wild-type allele can be detected in tumors from patients with VHL germline deletion.	NINCDS, Surg Neurol Branch, Mol Pathogenesis Unit, Bethesda, MD 20892 USA; NICHHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Zhuang, ZP (corresponding author), NINCDS, Surg Neurol Branch, Mol Pathogenesis Unit, Bldg 10,Room 5D37, Bethesda, MD 20892 USA.	zhuangp@ninds.nih.gov	Pack, Svetlana D./C-2020-2014; Koch, Christian A/A-4699-2008	Pack, Svetlana D./0000-0003-3256-6626; Koch, Christian A/0000-0003-3127-5739; Koch, Christian/0000-0003-0678-1242				CHOYKE PL, 1995, RADIOLOGY, V194, P629, DOI 10.1148/radiology.194.3.7862955; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gnarra JR, 1997, P NATL ACAD SCI USA, V94, P9102, DOI 10.1073/pnas.94.17.9102; KNUDSON AG, 1985, CANCER RES, V45, P1437; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Maher ER, 1997, MEDICINE, V76, P381, DOI 10.1097/00005792-199711000-00001; Pack SD, 1999, CANCER RES, V59, P5560; SEIZINGER BR, 1988, NATURE, V332, P268, DOI 10.1038/332268a0; Zhuang Z, 1998, Cell Vis, V5, P43	11	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2002	21	8					1167	1170		10.1038/sj.onc.1205121	http://dx.doi.org/10.1038/sj.onc.1205121			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	519ME	11850836				2022-12-17	WOS:000173729400004
J	Gentiletti, F; Mancini, F; D'Angelo, M; Sacchi, A; Pontecorvi, A; Jochemsen, AG; Moretti, F				Gentiletti, F; Mancini, F; D'Angelo, M; Sacchi, A; Pontecorvi, A; Jochemsen, AG; Moretti, F			MDMX stability is regulated by p53-induced caspase cleavage in NIH3T3 mouse fibroblasts	ONCOGENE			English	Article						MDMX; p53; proteolytic degradation; caspase cleavage	DNA-DAMAGE; TUMOR-SUPPRESSOR; P53 PROTEIN; P53-BINDING PROTEIN; ONCOPROTEIN MDM2; PHOSPHORYLATION; DEGRADATION; CELLS; INHIBITION; APOPTOSIS	MDMX is a p53 binding protein, which shares a high degree of homology with MDM2, a negative regulator of the tumor suppressor p53. MDMX has been shown to counteract MDM2-dependent p53 degradation and to stabilize p53 in its inactive form. In this study: we identify two MDMX proteolytic pathways that control its intracellular levels, and show that MDMX post-translational processing may be regulated by p53. Mouse MDMX is cleaved in vitro and in vivo by caspase activity, between aminoacids 358 and 361, producing a p54 minor form. In addition, MDMX is subjected to proteasome-mediated degradation, which concurs to MDMX proteolysis mainly through degradation of p54. A D361A-MDMX mutant, resistant to caspase cleavage, exhibits prolonged intracellular lifetime in comparison to wild-type protein, indicating that caspase cleavage affects stability of MDMX protein probably by modulating its further degradation. Overexpression of exogenous p53 increases the intracellular levels of p54 product. Similarly, activation of endogenous p53 by adriamycin enhances MDMX cleavage and produces a marked decrease of its intracellular levels, while not affecting the D361A-MDMX mutant. In addition, the D361AMDMX mutant lacks the ability to inhibit p53 transactivation in respect to wild-type MDMX, suggesting that MDMX caspase cleavage play an important functional role. In conclusion, our results demonstrate that, in analogy to MDM2, MDMX may be subjected to proteolytic modifications that regulate its intracellular levels. Moreover, decrease of MDMX protein levels following p53 activation suggests a p53-dependent regulatory feedback of MDMX function.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy; Catholic Univ, Med Pathol Inst, I-00100 Rome, Italy; Leiden Univ, Ctr Med, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; CNR, Neurobiol & Mol Med Inst, I-00156 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Leiden University; Leiden University - Excl LUMC; Consiglio Nazionale delle Ricerche (CNR)	Moretti, F (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Via Messi Oro 156, I-00158 Rome, Italy.		Moretti, Fabiola/I-5647-2013; Mancini, Francesca/AAZ-1672-2021; mancini, francesca/K-6062-2016	Moretti, Fabiola/0000-0002-2691-1254; Mancini, Francesca/0000-0002-2459-8815; mancini, francesca/0000-0002-2459-8815				Baek SH, 1997, BIOCHEM J, V325, P325, DOI 10.1042/bj3250325; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chen LH, 1997, J BIOL CHEM, V272, P22966, DOI 10.1074/jbc.272.36.22966; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Freedman DA, 1999, CANCER RES, V59, P1; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; GRAHAM F, 1991, METHOD MOL BIOL, P3587; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; Jackson MW, 2001, J BIOL CHEM, V276, P25336, DOI 10.1074/jbc.M010685200; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; KASTAN MB, 1991, CANCER RES, V51, P6304; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Mayo LD, 1997, CANCER RES, V57, P5013; Mendrysa SM, 2000, MOL CELL BIOL, V20, P2023, DOI 10.1128/MCB.20.6.2023-2030.2000; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moretti F, 1997, ONCOGENE, V14, P729, DOI 10.1038/sj.onc.1200887; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLSON DC, 1993, ONCOGENE, V8, P2353; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Pochampally R, 1999, J BIOL CHEM, V274, P15271, DOI 10.1074/jbc.274.21.15271; Pochampally R, 1998, ONCOGENE, V17, P2629, DOI 10.1038/sj.onc.1202206; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Rallapalli R, 1999, J BIOL CHEM, V274, P8299, DOI 10.1074/jbc.274.12.8299; Ramos YFM, 2001, CANCER RES, V61, P1839; Ratovitski EA, 2001, P NATL ACAD SCI USA, V98, P1817, DOI 10.1073/pnas.98.4.1817; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Shvarts A, 1997, GENOMICS, V43, P34, DOI 10.1006/geno.1997.4775; Sigalas I, 1996, NAT MED, V2, P912, DOI 10.1038/nm0896-912; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Stad R, 2000, J BIOL CHEM, V275, P28039; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	51	35	35	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2002	21	6					867	877		10.1038/sj.onc.1205137	http://dx.doi.org/10.1038/sj.onc.1205137			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	514FC	11840332				2022-12-17	WOS:000173427100002
J	Richie, ER; Schumacher, A; Angel, JM; Holloway, M; Rinchik, EM; Magnuson, T				Richie, ER; Schumacher, A; Angel, JM; Holloway, M; Rinchik, EM; Magnuson, T			The Polycomb-group gene eed regulates thymocyte differentiation and suppresses the development of carcinogen-induced T-cell lymphomas	ONCOGENE			English	Article						lymphomagenesis; Polycom-group gene; eed; thymocyte differentiation	EXTRA SEX COMBS; METHYL-N-NITROSOUREA; MURINE THYMIC LYMPHOMAS; MOUSE CHROMOSOME-7; EVOLUTIONARY CONSERVATION; RAPID DEVELOPMENT; MICE; DROSOPHILA; PROTEIN; EXPRESSION	The mouse Polycomb-group gene, embryonic ectoderm development (eed), appears to regulate cellular growth and differentiation in a developmental and tissue specific manner. During embryogenesis, eed regulates axial patterning, whereas in the adult eed represses proliferation of myeloid and B cell precursors. The present report demonstrates two novel functional activities of eed:alteration of thymocyte maturation and suppression of thymic lymphoma development. Mice that inherit the viable hypomorphic 17Rn5(1989SB) eed allele sustain a partial developmental block at or before the CD4(-)CD8(-)CD44(-) CD25(+) stage of thymocyte differentiation. Furthermore, mice that are homozygous or heterozygous for the hypomorphic eed allele have an increased incidence and decreased latency of N-methyl-N-nitrosourea-induced thymic lymphoma compared to wild-type littermates. These findings support the notion that Polycomb-group genes exert pleiotrophic effects dictated by developmental stage and cellular context.	Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, Smithville, TX 78957 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA; Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA	University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of North Carolina; University of North Carolina Chapel Hill	Richie, ER (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Carcinogenesis, Sci Pk Res Div, POB 389, Smithville, TX 78957 USA.			Richie, Ellen/0000-0003-0786-973X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024462, R37HD024462] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000370] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline; NHGRI NIH HHS [HG00370] Funding Source: Medline; NICHD NIH HHS [HD24462] Funding Source: Medline; NIEHS NIH HHS [ES07784] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akasaka T, 1996, DEVELOPMENT, V122, P1513; Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; ANGEL JM, 1989, J NATL CANCER I, V81, P1652, DOI 10.1093/jnci/81.21.1652; ANGEL JM, 1993, MOL CARCINOGEN, V7, P151, DOI 10.1002/mc.2940070305; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; Denisenko O, 1998, MOL CELL BIOL, V18, P5634, DOI 10.1128/MCB.18.10.5634; Denisenko ON, 1997, MOL CELL BIOL, V17, P4707, DOI 10.1128/MCB.17.8.4707; FAUST C, 1995, DEVELOPMENT, V121, P273; Faust C, 1998, DEVELOPMENT, V125, P4495; Fehling HJ, 1997, CURR OPIN IMMUNOL, V9, P263, DOI 10.1016/S0952-7915(97)80146-X; FREI JV, 1974, CHEM-BIOL INTERACT, V9, P65, DOI 10.1016/0009-2797(74)90068-4; FREI JV, 1980, CARCINOGENESIS, V1, P721, DOI 10.1093/carcin/1.8.721; GODFREY DI, 1994, J IMMUNOL, V152, P4783; GODFREY DI, 1993, J IMMUNOL, V150, P4244; Gomez G, 2000, INT IMMUNOL, V12, P263, DOI 10.1093/intimm/12.3.263; Gunster MJ, 1997, MOL CELL BIOL, V17, P2326, DOI 10.1128/MCB.17.4.2326; GUTJAHR T, 1995, EMBO J, V14, P4296, DOI 10.1002/j.1460-2075.1995.tb00104.x; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kung AL, 2000, GENE DEV, V14, P272; Lessard J, 1999, GENE DEV, V13, P2691, DOI 10.1101/gad.13.20.2691; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; NEWCOMB EW, 1988, CANCER RES, V48, P5514; Ng J, 1997, MOL CELL BIOL, V17, P6663, DOI 10.1128/MCB.17.11.6663; RICHIE ER, 1988, LEUKEMIA RES, V12, P233, DOI 10.1016/0145-2126(88)90141-5; RICHIE ER, 1996, PROGR CLIN BIOL RES, P23; RINCHIK EM, 1993, MAMM GENOME, V4, P349, DOI 10.1007/BF00360583; RINCHIK EM, 1990, P NATL ACAD SCI USA, V87, P896, DOI 10.1073/pnas.87.3.896; Rodewald HR, 1998, ADV IMMUNOL, V69, P1, DOI 10.1016/S0065-2776(08)60606-9; ROMACH E, 1994, CARCINOGENESIS, V15, P2275, DOI 10.1093/carcin/15.10.2275; SATHE SS, 1995, MECH DEVELOP, V52, P77, DOI 10.1016/0925-4773(95)00392-E; Satijn DPE, 1997, MOL CELL BIOL, V17, P4105, DOI 10.1128/MCB.17.7.4105; Schumacher A, 1998, GENOMICS, V54, P79, DOI 10.1006/geno.1998.5509; Schumacher A, 1996, NATURE, V383, P250, DOI 10.1038/383250a0; Sewalt RGAB, 1998, MOL CELL BIOL, V18, P3586, DOI 10.1128/MCB.18.6.3586; SIMON J, 1995, MECH DEVELOP, V53, P197, DOI 10.1016/0925-4773(95)00434-3; SIMON J, 1995, CURR OPIN CELL BIOL, V7, P376, DOI 10.1016/0955-0674(95)80093-X; STETTNER SL, 1991, CANCER RES, V51, P737; STRUHL G, 1982, CELL, V31, P285, DOI 10.1016/0092-8674(82)90428-7; van der Vlag J, 1999, NAT GENET, V23, P474, DOI 10.1038/70602; van Lohuizen M, 1998, MOL CELL BIOL, V18, P3572, DOI 10.1128/MCB.18.6.3572; VANDERLUGT NMT, 1994, GENE DEV, V8, P757, DOI 10.1101/gad.8.7.757; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; ZAIDI NH, 1995, CARCINOGENESIS, V16, P1047, DOI 10.1093/carcin/16.5.1047	45	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 10	2002	21	2					299	306		10.1038/sj.onc.1205051	http://dx.doi.org/10.1038/sj.onc.1205051			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KG	11803473				2022-12-17	WOS:000173026200014
J	Imperiale, MJ				Imperiale, MJ			Oncogenic transformation by the human polyomaviruses	ONCOGENE			English	Review						T antigen; polyomavirus; human cancer; tumor suppressor proteins	LARGE-T-ANTIGEN; JC-VIRUS-DNA; SV40 LARGE T; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; TRANSCRIPTIONAL CONTROL REGION; RETINOBLASTOMA GENE-PRODUCT; HUMAN-BRAIN-TUMORS; PERIPHERAL-BLOOD LEUKOCYTES; EMBRYONIC KIDNEY-CELLS; NONPASSAGED BK VIRUS		Univ Michigan, Sch Med, Dept Microbiol & Immunol, Canc Ctr 6310, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Imperiale, MJ (corresponding author), Univ Michigan, Sch Med, Dept Microbiol & Immunol, Canc Ctr 6310, 1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.							Agostini HT, 1996, J CLIN MICROBIOL, V34, P159, DOI 10.1128/JCM.34.1.159-164.1996; ARTHUR RR, 1994, J NEURO-ONCOL, V20, P55, DOI 10.1007/BF01057961; AULT GS, 1993, J GEN VIROL, V74, P1499, DOI 10.1099/0022-1317-74-8-1499; Barbanti-Brodano G, 1987, Antibiot Chemother (1971), V38, P113; BOLLAG B, 1989, J VIROL, V63, P863, DOI 10.1128/JVI.63.2.863-872.1989; Bollag B, 2000, VIROLOGY, V274, P165, DOI 10.1006/viro.2000.0451; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; BUTEL JS, 1986, CANCER SURV, V5, P343; Campbell KS, 1997, GENE DEV, V11, P1098, DOI 10.1101/gad.11.9.1098; CAPUTO A, 1983, J MED VIROL, V12, P37, DOI 10.1002/jmv.1890120105; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHOO KB, 1993, VIROLOGY, V193, P1042; Ciappi S, 1999, J GEN VIROL, V80, P1017, DOI 10.1099/0022-1317-80-4-1017; Classon M, 2001, EXP CELL RES, V264, P135, DOI 10.1006/excr.2000.5135; COLE CN, 1996, VIROLOGY, P1997; CORALLINI A, 1987, INT J CANCER, V39, P60, DOI 10.1002/ijc.2910390111; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; DALRYMPLE SA, 1990, J VIROL, V64, P1182, DOI 10.1128/JVI.64.3.1182-1191.1990; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEMATTEI M, 1995, INT J CANCER, V61, P756, DOI 10.1002/ijc.2910610603; DEVRIES CR, 1990, J UROLOGY, V143, P1; DORRIES K, 1987, VIROLOGY, V160, P268, DOI 10.1016/0042-6822(87)90071-7; DORRIES K, 1994, VIROLOGY, V198, P59, DOI 10.1006/viro.1994.1008; DYSON N, 1992, J VIROL, V66, P6893, DOI 10.1128/JVI.66.12.6893-6902.1992; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; Elsner C, 1998, J GEN VIROL, V79, P789, DOI 10.1099/0022-1317-79-4-789; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FIORI M, 1976, P NATL ACAD SCI USA, V73, P4662, DOI 10.1073/pnas.73.12.4662; FLAEGSTAD T, 1991, VIROLOGY, V180, P553, DOI 10.1016/0042-6822(91)90069-N; Flaegstad T, 1999, CANCER RES, V59, P1160; Franks RR, 1996, ONCOGENE, V12, P2573; FREUND R, 1992, ONCOGENE, V7, P1979; FRISQUE RJ, 1980, J VIROL, V35, P265, DOI 10.1128/JVI.35.1.265-269.1980; GARDNER SD, 1973, BMJ-BRIT MED J, V1, P77, DOI 10.1136/bmj.1.5845.77; GARDNER SD, 1971, LANCET, V1, P1253; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GOUDSMIT J, 1982, J MED VIROL, V10, P91, DOI 10.1002/jmv.1890100203; GROSSI MP, 1982, J GEN VIROL, V63, P393, DOI 10.1099/0022-1317-63-2-393; Guo J, 1996, J GEN VIROL, V77, P919, DOI 10.1099/0022-1317-77-5-919; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; Harris KF, 1998, MOL CELL BIOL, V18, P1746, DOI 10.1128/MCB.18.3.1746; Harris KF, 1996, J VIROL, V70, P2378, DOI 10.1128/JVI.70.4.2378-2386.1996; Harris KF, 1998, DEV BIOLOGICALS, V94, P81; Howard CM, 1998, J NATL CANCER I, V90, P1451, DOI 10.1093/jnci/90.19.1451; HOWLEY PM, 1980, J VIROL, V36, P878, DOI 10.1128/JVI.36.3.878-882.1980; Imperiale MJ, 2000, VIROLOGY, V267, P1, DOI 10.1006/viro.1999.0092; IWASAKA T, 1993, GYNECOL ONCOL, V48, P104, DOI 10.1006/gyno.1993.1016; KATO K, 1994, JPN J MED SCI BIOL, V47, P167, DOI 10.7883/yoken1952.47.167; Kelley WL, 1997, P NATL ACAD SCI USA, V94, P3679, DOI 10.1073/pnas.94.8.3679; Khalili K, 1999, LANCET, V353, P1152, DOI 10.1016/S0140-6736(99)00357-8; KITAMURA T, 1994, J CLIN MICROBIOL, V32, P2359, DOI 10.1128/JCM.32.10.2359-2363.1994; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 1997, J CELL BIOCHEM, V67, P223, DOI 10.1002/(SICI)1097-4644(19971101)67:2<223::AID-JCB7>3.0.CO;2-Z; KUNITAKE T, 1995, J CLIN MICROBIOL, V33, P1448, DOI 10.1128/JCM.33.6.1448-1451.1995; Laghi L, 1999, P NATL ACAD SCI USA, V96, P7484, DOI 10.1073/pnas.96.13.7484; Lazutka JR, 1996, CANCER LETT, V109, P177, DOI 10.1016/S0304-3835(96)04448-5; LOEBER G, 1988, J VIROL, V62, P1730, DOI 10.1128/JVI.62.5.1730-1735.1988; MARKOWITZ RB, 1991, J VIROL, V65, P4515, DOI 10.1128/JVI.65.8.4515-4519.1991; MARTIN JD, 1985, J VIROL, V53, P306, DOI 10.1128/JVI.53.1.306-311.1985; Monao MCG, 1998, J VIROL, V72, P9918, DOI 10.1128/JVI.72.12.9918-9923.1998; MONINI P, 1995, VIROLOGY, V214, P273, DOI 10.1006/viro.1995.9928; Monini P, 1995, INTERVIROLOGY, V38, P304, DOI 10.1159/000150455; Monini P, 1996, INT J CANCER, V66, P717, DOI 10.1002/(SICI)1097-0215(19960611)66:6<717::AID-IJC1>3.3.CO;2-N; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MUNGRE S, 1994, J VIROL, V68, P1675, DOI 10.1128/JVI.68.3.1675-1681.1994; NEGRINI M, 1990, J GEN VIROL, V71, P2731, DOI 10.1099/0022-1317-71-11-2731; NEGRINI M, 1991, J VIROL, V65, P5092, DOI 10.1128/JVI.65.9.5092-5095.1991; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Newman JT, 1999, J MED VIROL, V58, P79, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;79::AID-JMV13&gt;3.0.CO;2-V; PADGETT BL, 1971, LANCET, V1, P1257; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PATER A, 1986, J VIROL, V58, P680, DOI 10.1128/JVI.58.2.680-683.1986; PATER MM, 1980, VIRUSES NATURALLY OC, P329; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; PORTOLANI M, 1978, J GEN VIROL, V38, P369, DOI 10.1099/0022-1317-38-2-369; PURCHIO AF, 1979, J VIROL, V29, P763, DOI 10.1128/JVI.29.2.763-769.1979; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; Ricciardiello L, 2001, J VIROL, V75, P1996, DOI 10.1128/JVI.75.4.1996-2001.2001; RUBINSTEIN R, 1987, J VIROL, V61, P1747, DOI 10.1128/JVI.61.5.1747-1750.1987; RUBINSTEIN R, 1991, J VIROL, V65, P1600, DOI 10.1128/JVI.65.3.1600-1604.1991; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SHAH KV, 1976, P SOC EXP BIOL MED, V153, P180, DOI 10.3181/00379727-153-39506; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Stubdal H, 1997, MOL CELL BIOL, V17, P4979, DOI 10.1128/MCB.17.9.4979; Sugimoto C, 1997, P NATL ACAD SCI USA, V94, P9191, DOI 10.1073/pnas.94.17.9191; TAGUCHI F, 1982, MICROBIOL IMMUNOL, V26, P1057, DOI 10.1111/j.1348-0421.1982.tb00254.x; TAKEMOTO KK, 1979, J VIROL, V29, P1177, DOI 10.1128/JVI.29.3.1177-1185.1979; TAVIS JE, 1994, VIROLOGY, V199, P384, DOI 10.1006/viro.1994.1136; THEILE M, 1990, ARCH VIROL, V113, P221, DOI 10.1007/BF01316675; Tognon M, 1996, CANCER GENET CYTOGEN, V90, P17, DOI 10.1016/0165-4608(96)00067-2; TOMINAGA T, 1992, VIROLOGY, V186, P736; Trabanelli C, 1998, VIROLOGY, V243, P492, DOI 10.1006/viro.1998.9080; Tretiakova A, 1999, J NEUROSCI RES, V55, P588, DOI 10.1002/(SICI)1097-4547(19990301)55:5<588::AID-JNR6>3.0.CO;2-A; TROWBRIDGE PW, 1995, J NEUROVIROL, V1, P195, DOI 10.3109/13550289509113966; TROWBRIDGE PW, 1993, VIROLOGY, V196, P458, DOI 10.1006/viro.1993.1502; VASAVADA R, 1986, P NATL ACAD SCI USA, V83, P5257, DOI 10.1073/pnas.83.14.5257; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waheed I, 1999, CANCER RES, V59, P6068; WALKER DL, 1973, SCIENCE, V181, P674, DOI 10.1126/science.181.4100.674; WATANABE S, 1985, J VIROL, V55, P823, DOI 10.1128/JVI.55.3.823-825.1985; WATANABE S, 1982, J VIROL, V42, P978, DOI 10.1128/JVI.42.3.978-985.1982; Weber T, 1997, INTERVIROLOGY, V40, P98, DOI 10.1159/000150537; WHITE FA, 1992, J VIROL, V66, P5726, DOI 10.1128/JVI.66.10.5726-5734.1992; YANG SI, 1991, MOL CELL BIOL, V11, P1988, DOI 10.1128/MCB.11.4.1988; YOGO Y, 1991, J CLIN MICROBIOL, V29, P2130, DOI 10.1128/JCM.29.10.2130-2138.1991; YOGO Y, 1994, VIRUS GENES, V8, P99, DOI 10.1007/BF01703608; YOGO Y, 1990, J VIROL, V64, P3139, DOI 10.1128/JVI.64.6.3139-3143.1990; ZERRAHN J, 1993, EMBO J, V12, P4739, DOI 10.1002/j.1460-2075.1993.tb06162.x; ZURHEIN GM, 1983, POLYOMAVIRUSES HUMAN, P205	115	35	35	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	2001	20	54					7917	7923		10.1038/sj.onc.1204916	http://dx.doi.org/10.1038/sj.onc.1204916			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	495JF	11753674				2022-12-17	WOS:000172336500011
J	Karoui, M; Hofmann-Radvanyi, H; Zimmermann, U; Couvelard, A; Degott, C; Faridoni-Laurens, L; Ahomadegbe, JC; Gazzeri, S; Brambilla, E; Clerici, T; Charbonnier, P; Tresallet, C; Mitry, E; Penna, C; Rougier, P; Boileau, C; Thiery, JP; Nordlinger, B; Franc, B; Radvanyi, F				Karoui, M; Hofmann-Radvanyi, H; Zimmermann, U; Couvelard, A; Degott, C; Faridoni-Laurens, L; Ahomadegbe, JC; Gazzeri, S; Brambilla, E; Clerici, T; Charbonnier, P; Tresallet, C; Mitry, E; Penna, C; Rougier, P; Boileau, C; Thiery, JP; Nordlinger, B; Franc, B; Radvanyi, F			No evidence of somatic FGFR3 mutation in various types of carcinoma	ONCOGENE			English	Article						FGFR3; growth factor receptor; carcinoma; oncogene	GROWTH-FACTOR RECEPTOR-3; MULTIPLE-MYELOMA; ACTIVATING MUTATIONS; SKELETAL DISORDERS; FIBROBLAST; GENE; EXPRESSION; DYSPLASIA; BLADDER; CERVIX	Germline specific point mutations in the gene encoding fibroblast growth factor receptor 3 (FGFR3) are associated with autosomal dominant human skeletal dysplasia and craniosynostosis syndromes. Mutations identical to the germinal activating mutations found in severe skeletal dysplasias have been identified in certain types of cancer: at low frequency in multiple myeloma and cervix carcinoma and at high frequency in bladder carcinoma. We analysed, by SSCP and sequencing, the prevalence of FGFR3 mutations in 116 primary tumours of various types (upper aerodigestive tract, oesophagus, stomach, lung and skin). The regions analysed encompassed all FGFR3 point mutations previously described in severe skeletal dysplasia and cancers. No mutations were detected in the tumour types examined, suggesting that FGFR3 mutations are restricted to a few tumour types, the evidence to date suggesting that they are very specific to bladder carcinomas.	Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France; CHU Grenoble, Serv Pathol Cellulaire, F-38700 Grenoble, France; Inst Gustave Roussy, Dept Biol Clin, F-94800 Villejuif, France; Hop Beaujon, Serv Anat & Cytol Pathol, F-92110 Clichy, France; Univ Paris 05, Hop Ambroise Pare, Serv Anat & Cytol Pathol, F-92104 Boulogne, France; Univ Paris 05, Hop Ambroise Pare, Lab Biochim & Genet Mol, F-92104 Boulogne, France; CHRU Lille, Hop Claude Huriez, Serv Chirurg Digest & Transplantat, F-59037 Lille, France; Univ Paris 05, Hop Ambroise Pare, Federat Special Digest, F-92104 Boulogne, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite; Universite de Lille - ISITE; CHU Lille; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; UDICE-French Research Universities; Universite Paris Cite	Thiery, JP (corresponding author), Inst Curie, CNRS, UMR 144, F-75248 Paris 05, France.		boileau, catherine/M-4482-2017; Brambilla, Elisabeth MP/L-8796-2013; gazzeri, sylvie/M-1961-2013; Thiery, Jean Paul/M-9387-2019; gazzeri, sylvie/U-4669-2019; Thiery, Jean Paul/H-1550-2011	boileau, catherine/0000-0002-0371-7539; gazzeri, sylvie/0000-0001-5817-1839; gazzeri, sylvie/0000-0001-5817-1839; Thiery, Jean Paul/0000-0003-0478-5020; Anne, Couvelard/0000-0002-6316-1210; Radvanyi, Francois/0000-0002-5696-6424				Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; COHEN SM, 1992, UROL CLIN N AM, V19, P421; Delezoide AL, 1998, MECH DEVELOP, V77, P19, DOI 10.1016/S0925-4773(98)00133-6; Fracchiolla NS, 1998, BLOOD, V92, P2987, DOI 10.1182/blood.V92.8.2987; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; MURGUE B, 1994, CANCER RES, V54, P5206; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; Richelda R, 1997, BLOOD, V90, P4062, DOI 10.1182/blood.V90.10.4062; Robertson SC, 2000, TRENDS GENET, V16, P265, DOI 10.1016/S0168-9525(00)02021-7; Sibley K, 2001, ONCOGENE, V20, P686, DOI 10.1038/sj.onc.1204110; Tavormina PL, 1999, AM J HUM GENET, V64, P722, DOI 10.1086/302275; van Rhijn BWG, 2001, CANCER RES, V61, P1265; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Wu R, 2000, ONCOGENE, V19, P5543, DOI 10.1038/sj.onc.1203934; Yee CJ, 2000, JNCI-J NATL CANCER I, V92, P1848, DOI 10.1093/jnci/92.22.1848	17	35	38	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 16	2001	20	36					5059	5061		10.1038/sj.onc.1204651	http://dx.doi.org/10.1038/sj.onc.1204651			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	462VE	11526491				2022-12-17	WOS:000170439800016
J	Medh, RD; Wang, AX; Zhou, F; Thompson, EB				Medh, RD; Wang, AX; Zhou, F; Thompson, EB			Constitutive expression of ectopic c-Myc delays glucocorticoid-evoked apoptosis of human leukemic CEM-C7 cells	ONCOGENE			English	Article						cell cycle; caspase 3; TUNEL; Max; p53; p27	MESSENGER-RNA; MEDIATED APOPTOSIS; GENE-TRANSCRIPTION; INDUCED RELEASE; BINDING DOMAIN; GROWTH ARREST; OKADAIC ACID; E-BOX; PROTEIN; CYCLE	Sensitivity to glueocorticoid (GC)-evoked apoptosis in lymphoid cell lines correlates closely with GC-mediated suppression of c-Myc expression. To establish a functional role for c-Myc in GC-mediated apoptosis, we have stably expressed MycER (TM), the human c-Myc protein fused to the modified ligand-binding domain of the murine estrogen receptor a, in GC-sensitive CEM-C7-14 cells. In CEM-C7-14 cells, MycER (TM) constitutively imparts c-Myc functions. Cells expressing MycERT (TM) (C7-MycER (TM)) exhibited a marked reduction in cell death after 72 h in 100 nm dexamethasone (Dex), with 10-20-fold more viable cells when compared to the parental CEM-C7-14 clone. General GC responsiveness was not compromised, as evidenced by Dex-mediated suppression of endogenous c-Mye and cyclin D3, and induction of c-Jun and the glucocorticoid receptor. MycER (TM) also blunted Dex-mediated upregulation of p271(kipI) and suppression of the Myc target p53. In comparison to parental CEM-C7-14 cells, Dex-evoked DNA strand breaks were negligible and caspase activation was delayed, but the extent of GI cell cycle arrest was similar in C7-MycER (TM) cells. Myc-ER (TM) did not result in permanent, complete resistance to GC however, and the GC-treated cells eventually died, indicative of redundant or interactive mechanisms in the GC-evoked lytic response of lymphoid cells. Our results emphasize the importance of c-Myc suppression in GC-evoked apoptosis of CEM-C7-14 cells.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Medh, RD (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.	rmedh@utmb.edu; bthompso@utmb.edu			NATIONAL CANCER INSTITUTE [R01CA041407, R01CA041047] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA041407, R01 CA041407-14, 2RO1 CA41047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Afrakhte M, 1998, CELL GROWTH DIFFER, V9, P983; ASKEW DS, 1991, ONCOGENE, V6, P1915; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Blyth K, 2000, ONCOGENE, V19, P773, DOI 10.1038/sj.onc.1203321; Brunet CL, 1998, CELL DEATH DIFFER, V5, P107, DOI 10.1038/sj.cdd.4400334; BRUNO S, 1992, CANCER RES, V52, P470; Casteels KM, 1998, DIABETES, V47, P1033, DOI 10.2337/diabetes.47.7.1033; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; CHIARUGI V, 1994, CELL MOL BIOL RES, V40, P603; DOWD DR, 1991, J BIOL CHEM, V266, P18423; EASTMANREKS SB, 1986, CANCER RES, V46, P2457; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; Facchini LM, 1998, FASEB J, V12, P633, DOI 10.1096/fasebj.12.9.633; FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO;2-J; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Gaynon PS, 1999, ADV EXP MED BIOL, V457, P593; HARMON JM, 1979, J CELL PHYSIOL, V98, P267, DOI 10.1002/jcp.1040980203; HELMBERG A, 1995, EMBO J, V14, P452, DOI 10.1002/j.1460-2075.1995.tb07021.x; HOMODELARCHE F, 1984, CANCER RES, V44, P431; Jones RM, 1996, MOL CELL BIOL, V16, P4754; KIGUCHI K, 1994, CELL GROWTH DIFFER, V5, P995; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEUNG K, 1975, ENDOCRINOLOGY, V97, P744, DOI 10.1210/endo-97-3-744; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Loffler M, 1999, ONCOGENE, V18, P4626, DOI 10.1038/sj.onc.1202820; Martins TC, 1998, IMMUNOLOGY, V95, P377; Medh RD, 1998, CANCER RES, V58, P3684; Medh RD, 2000, CELL TISSUE RES, V301, P101, DOI 10.1007/s004419900159; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; Montague J W, 1995, Curr Top Microbiol Immunol, V200, P51; Muller D, 1997, ONCOGENE, V15, P2561, DOI 10.1038/sj.onc.1201440; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; PICARD D, 1988, CELL, V54, P1073, DOI 10.1016/0092-8674(88)90122-5; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; REISMAN D, 1993, CELL GROWTH DIFFER, V4, P57; REISMAN D, 1995, MOL ENDOCRINOL, V9, P1500, DOI 10.1210/me.9.11.1500; RHEE K, 1995, CANCER RES, V55, P4188; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Sarin A, 1996, J EXP MED, V184, P2445, DOI 10.1084/jem.184.6.2445; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SPENCER CA, 1991, ADV CANCER RES, V56, P1; SRINIVASAN G, 1994, MOL ENDOCRINOL, V8, P189, DOI 10.1210/me.8.2.189; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; THOMPSON EB, 1995, ANN NY ACAD SCI, V761, P261, DOI 10.1111/j.1749-6632.1995.tb31383.x; Thompson EB, 1999, TRENDS ENDOCRIN MET, V10, P353, DOI 10.1016/S1043-2760(99)00187-3; THULASI R, 1993, J BIOL CHEM, V268, P18306; TOBIAS KE, 1995, ONCOGENE, V11, P1721; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; WAGNER AJ, 1993, MOL CELL BIOL, V13, P2432, DOI 10.1128/MCB.13.4.2432; WOOD KM, 1984, MOL CELL ENDOCRINOL, V37, P169, DOI 10.1016/0303-7207(84)90049-2; Yatouji S, 2000, CELL PROLIFERAT, V33, P51, DOI 10.1046/j.1365-2184.2000.00163.x; Yerly-Motta V, 1999, BIOTECH HISTOCHEM, V74, P119, DOI 10.3109/10520299909047963; YUH YS, 1989, J BIOL CHEM, V264, P10904; Zhou F, 1996, MOL ENDOCRINOL, V10, P306, DOI 10.1210/me.10.3.306	60	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 2	2001	20	34					4629	4639		10.1038/sj.onc.1204680	http://dx.doi.org/10.1038/sj.onc.1204680			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	458RP	11498786	Green Accepted			2022-12-17	WOS:000170208600004
J	Orelli, BJ; Logsdon, JM; Bishop, DK				Orelli, BJ; Logsdon, JM; Bishop, DK			Nine novel conserved motifs in BRCA1 identified by the chicken orthologue	ONCOGENE			English	Article						avian; DT40; breast cancer; BRCA1	DNA-DAMAGE RESPONSE; TRANSCRIPTION-COUPLED REPAIR; SUSCEPTIBILITY GENE BRCA1; BREAST-CANCER; SEQUENCE-ANALYSIS; MEIOTIC CELLS; MOUSE BRCA1; IN-VIVO; PHOSPHORYLATION; AMPLIFICATION	The breast cancer susceptibility gene BRCA1 encodes a multifunctional protein that is mutated in many hereditary breast and ovarian cancers. We have cloned a homologue of the human BRCA1 gene from chicken; the gene encodes a 1749 amino acid protein that is 33% identical to human BRCA1, Phylogenetic analyses of the chicken and mammalian proteins indicate that the chicken gene is a bona fide BRCA1 orthologue, the first to be described from a non-mammal. Most of the chicken protein has diverged considerably from its mammalian orthologues, although the RING and BRCT repeat regions are highly conserved. This marked overall sequence divergence has allowed us to identify nine additional highly-conserved motifs (ranging from 8-56 amino acids in length) which are likely important for BRCA1 function.	Univ Chicago, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	University of Chicago; Emory University	Bishop, DK (corresponding author), Univ Chicago, Dept Radiat & Cellular Oncol, 920 E 58th St, Chicago, IL 60637 USA.		Logsdon, John M/B-7812-2009					ABEL KJ, 1995, HUM MOL GENET, V4, P2265, DOI 10.1093/hmg/4.12.2265; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Bennett LM, 1999, MAMM GENOME, V10, P19, DOI 10.1007/s003359900935; Bhattacharyya A, 2000, J BIOL CHEM, V275, P23899, DOI 10.1074/jbc.C000276200; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen JJ, 1998, MOL CELL, V2, P317, DOI 10.1016/S1097-2765(00)80276-2; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Deng CX, 2000, BIOESSAYS, V22, P728; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Le Page F, 2000, CANCER RES, V60, P5548; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meza JE, 1999, J BIOL CHEM, V274, P5659, DOI 10.1074/jbc.274.9.5659; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; Rose TM, 1998, NUCLEIC ACIDS RES, V26, P1628, DOI 10.1093/nar/26.7.1628; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; SWOFFORD DL, 2001, PAUP PHYLOGENETIC AN; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wang Q, 1998, ONCOGENE, V17, P1939, DOI 10.1038/sj.onc.1202403; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	40	35	38	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 19	2001	20	32					4433	4438		10.1038/sj.onc.1204485	http://dx.doi.org/10.1038/sj.onc.1204485			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	453JK	11466627				2022-12-17	WOS:000169912600020
J	Mattoon, D; Gupta, K; Doyon, J; Loll, PJ; DiMaio, D				Mattoon, D; Gupta, K; Doyon, J; Loll, PJ; DiMaio, D			Identification of the transmembrane dimer interface of the bovine papillomavirus E5 protein	ONCOGENE			English	Article						coiled-coil; papillomavirus; platelet-derived growth factor receptor; transmembrane domain; viral oncogene	FACTOR-BETA RECEPTOR; GROWTH-FACTOR RECEPTOR; TRANSFORMING PROTEIN; TYROSINE KINASE; C127 CELLS; ACTIVATION; DOMAIN; PHOSPHORYLATION; REQUIRES; REVEALS	We have developed a genetic method to determine the active orientation of dimeric transmembrane protein helices, The bovine papillomavirus E5 protein, a 44-amino acid homodimeric protein that appears to traverse membranes as a left-handed foiled-coil, transforms fibroblasts by binding and activating the platelet-derived growth factor (PDCF) beta receptor, A heterologous dimerization domain was used to force E5 monomers to adopt all seven possible symmetric coiled-coil registries relative to one another within the dimer, Focus formation assays demonstrated that dimerization of the E5 protein is required for transformation and identified a single preferred orientation of the monomers, The essential glutamine residue at position 17 resided in the dimer interface in this active orientation, The active chimera formed complexes with the PDGF beta receptor and induced receptor tyrosine phosphorylation, We also identified ES-like structures that underwent non-productive interactions with the receptor.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	Yale University; University of Pennsylvania	DiMaio, D (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.		Gupta, Kushol/GOE-5620-2022	Gupta, Kushol/0000-0002-7006-2667	NATIONAL CANCER INSTITUTE [R01CA037157, R37CA037157] Funding Source: NIH RePORTER; NCI NIH HHS [CA37157] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/s0907444998003254; Burke CL, 1998, MOL CELL BIOL, V18, P5371, DOI 10.1128/MCB.18.9.5371; Burkhard P, 2000, STRUCTURE, V8, P223, DOI 10.1016/S0969-2126(00)00100-3; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; Choma C, 2000, NAT STRUCT BIOL, V7, P161; Cochran AG, 1996, SCIENCE, V271, P1113, DOI 10.1126/science.271.5252.1113; DiMaio D, 2000, CYTOKINE GROWTH F R, V11, P283, DOI 10.1016/S1359-6101(00)00012-5; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; Smith SO, 1996, NAT STRUCT BIOL, V3, P252, DOI 10.1038/nsb0396-252; Sparkowski J, 1996, J VIROL, V70, P2420, DOI 10.1128/JVI.70.4.2420-2430.1996; Surti T, 1998, PROTEINS, V33, P601; Swaminathan K, 1997, NAT STRUCT BIOL, V4, P751, DOI 10.1038/nsb0997-751; WILLIAMS KA, 1991, BIOCHEMISTRY-US, V30, P8919, DOI 10.1021/bi00101a001	25	35	37	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3824	3834		10.1038/sj.onc.1204523	http://dx.doi.org/10.1038/sj.onc.1204523			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439346				2022-12-17	WOS:000169494700008
J	Crostella, L; Lidder, S; Williams, R; Skouteris, GG				Crostella, L; Lidder, S; Williams, R; Skouteris, GG			Hepatocyte Growth Factor/Scatter Factor-induces phosphorylation of cortactin in A431 cells in a Src kinase-independent manner	ONCOGENE			English	Article						tyrosine phosphorylation; MET; F-actin binding proteins	RECEPTOR TYROSINE KINASE; GRB2 BINDING-SITE; SCATTER FACTOR; MET RECEPTOR; C-MET; PHOSPHATIDYLINOSITOL 3-KINASE; EPITHELIAL-CELLS; CARCINOMA-CELLS; V-SRC; MOTILITY	The Hepatocyte Growth Factor receptor transduces proliferating and scattering signals in epithelial and endothelial cells. We have explored potential interactions of the HGF/SF receptor beta-subunit (p145(beta MET)) with F-actin binding partners aiming to identify novel downstream effecters implicated in HGF/SF pluripotent signalling. Cortactin, a p80/85 F-actin binding protein, was found phosphorylated on tyrosine in response to HGF-SF in A431 human epidermoid carcinoma cells, expressing the HGF/SF receptor (c-MET). The HGF/SF receptor was enriched in the detergent-insoluble fraction and was found to co-precipitate with cortactin and to associate in vitro with cortactin, The Grb2 small adapter protein known to associate via its Src homology 2 domain (SH2) with the MET C-terminus, was also associated with cortactin, Transient transfection of A431 cells with dominant-negative Grb2 constructs has revealed that the Grb2-C-SH3 domain possesses central role in cortactin phosphorylation in response to HGF/SF, Finally, tyrosine phosphorylation of cortactin was found uncoupled of endogenous c-Src kinase activity, thus further supporting the hypothesis that cortactin is a direct target of the MET kinase, We propose that cortactin may constitute a docking site for MET-derived signals within the cytoskeleton.	Royal Free & UCL, Sch Med, Dept Med, Inst Hepatol,Lab Cell Biol, London WC1E 6HX, England	University of London; University College London; UCL Medical School	Skouteris, GG (corresponding author), Royal Free & UCL Med Sch, Dept Med, Ctr Hepatol, Lab Cellular & Mol Biol, Upper 3rd Floor,Rowland Hill St,Royal Free Campus, London NW3 2PF, England.	g.skouteris@rfc.ucl.ac.uk						BARDELLI A, 1992, ONCOGENE, V7, P1973; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRAY D, 1986, J CELL SCI, P71; BRUNATI AM, 1995, EUR J BIOCHEM, V229, P164, DOI 10.1111/j.1432-1033.1995.0164l.x; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DOWRICK PG, 1991, CYTOKINE, V3, P299, DOI 10.1016/1043-4666(91)90498-3; DUGINA VB, 1995, J CELL SCI, V108, P1659; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Kim L, 1998, J BIOL CHEM, V273, P23542, DOI 10.1074/jbc.273.36.23542; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; Miyakawa Y, 1997, BLOOD, V89, P2789, DOI 10.1182/blood.V89.8.2789; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Nguyen L, 1997, J BIOL CHEM, V272, P20811, DOI 10.1074/jbc.272.33.20811; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Provenzano C, 1998, EXP CELL RES, V242, P186, DOI 10.1006/excr.1998.4095; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; Rodriguez-Fernandez JL, 1998, J BIOL CHEM, V273, P19321, DOI 10.1074/jbc.273.30.19321; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sabe H, 1997, ONCOGENE, V14, P1779, DOI 10.1038/sj.onc.1201022; Skouteris GG, 1996, J BIOL CHEM, V271, P27266, DOI 10.1074/jbc.271.44.27266; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; TAJIMA H, 1992, EXP CELL RES, V202, P423, DOI 10.1016/0014-4827(92)90095-P; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VANITALLIE CM, 1995, J CELL SCI, V108, P1735; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; Weed SA, 1998, J CELL SCI, V111, P2433; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Yamanashi Y, 1997, J EXP MED, V185, P1387, DOI 10.1084/jem.185.7.1387; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1994, J BIOL CHEM, V269, P20221	50	35	37	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 21	2001	20	28					3735	3745		10.1038/sj.onc.1204474	http://dx.doi.org/10.1038/sj.onc.1204474			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439336				2022-12-17	WOS:000169400200014
J	Liu, BL; Fan, Z				Liu, BL; Fan, Z			The monoclonal antibody 225 activates caspase-8 and induces apoptosis through a tumor necrosis factor receptor family-independent pathway	ONCOGENE			English	Article						apoptosis; caspase; TNF receptor family; EGF receptor; monoclonal antibody	EPIDERMAL GROWTH-FACTOR; FAS-MEDIATED APOPTOSIS; CYTOCHROME-C RELEASE; ANTICANCER DRUGS; CD95 FAS/APO-1; DEATH DOMAIN; CANCER-CELLS; G(1) ARREST; LIGAND; FADD	We previously reported that the anti-epidermal growth factor (EGF) receptor monoclonal antibody (mAb) 225 induces DiFi colon cancer cells to undergo apoptosis, and this apoptosis was accompanied by activation of the two apoptosis initiation caspases, caspase-8 and caspase-9, In the current study, we found that pretreatment of DiFi cells with the caspase-8-specific inhibitor z-IETD-fmk but not pretreatment with the caspase-9-specific inhibitor z-LEHD-fmk inhibited mAb 225-induced apoptosis, indicating that caspase-8 plays an essential role in initiating mAb 225-induced apoptosis, Because caspase-8 is activated primarily by the members of the tumor necrosis factor (TNF) receptor family, such as Fas, TNF receptor-1 (TNFR1), or receptors for TNF-related apoptosis-inducing ligand (TRAIL), we investigated whether mAb 225 activated caspase-8 by regulating one or more of these known pathways, Exposure of DiFi cells to TNF alpha or TRAIL activated caspase-8 and induced apoptosis in the cells. A TNFR1-antagonistic mAb or a TRAIL decoy receptor inhibited the activation of caspase-8 and the subsequent apoptosis induced by TNF alpha or TRAIL, respectively, in the cells. However, neither the TNFR1-antagonistic mAb nor the TRAIL decoy receptor inhibited mAb 225-induced activation of caspase-8 and apoptosis in DiFi cells, DiFi cells express detectable level of Fas but are not sensitive to the treatment by the Fas-agonistic mAb CH-II, A Fas-antagonistic mAb (ZB-4) inhibited the Fas-agonistic mAb CH-ll-induced caspase-8 activation and apoptosis in Jurkat T-leukemic cells (used as positive control), but had no effect on mAb 225-induced activation of caspase-8 and apoptosis in DiFi cells. Taken together, our results suggest that mAb 225 does not interact with or regulate these known death receptor pathways, An exploration is therefore warranted for a novel mechanism by which mAb 225 activates caspase-8 and triggers apoptosis in DiFi cells.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Fan, Z (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 36,1515 Holcombe Blvd, Houston, TX 77030 USA.			Liu, Bolin/0000-0003-0150-8650	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi S, 1997, J BIOL CHEM, V272, P21878, DOI 10.1074/jbc.272.35.21878; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Balachandran S, 2000, J VIROL, V74, P1513, DOI 10.1128/JVI.74.3.1513-1523.2000; Bantel H, 1999, CANCER RES, V59, P2083; Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904; Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BASELGA J, 1993, J NATL CANCER I, V85, P1327, DOI 10.1093/jnci/85.16.1327; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Beltinger C, 1999, P NATL ACAD SCI USA, V96, P8699, DOI 10.1073/pnas.96.15.8699; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795, DOI 10.1074/jbc.270.14.7795; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Ciardiello F, 1999, CLIN CANCER RES, V5, P909; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Fan Z, 1997, CLIN CANCER RES, V3, P1943; FAN Z, 1993, CANCER RES, V53, P4322; FAN Z, 1993, CANCER RES, V53, P4637; FAN Z, 1994, J BIOL CHEM, V269, P27595; Fan Zhen, 1998, Current Opinion in Oncology, V10, P67, DOI 10.1097/00001622-199801000-00011; Fellenberg J, 1997, INT J CANCER, V72, P536, DOI 10.1002/(SICI)1097-0215(19970729)72:3<536::AID-IJC25>3.0.CO;2-8; Gil J, 2000, ONCOGENE, V19, P3665, DOI 10.1038/sj.onc.1203710; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAWAMOTO T, 1983, P NATL ACAD SCI-BIOL, V80, P1337, DOI 10.1073/pnas.80.5.1337; Kharbanda S, 1997, P NATL ACAD SCI USA, V94, P6939, DOI 10.1073/pnas.94.13.6939; Kim CN, 1997, CANCER RES, V57, P3115; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Liu B, 2000, BRIT J CANCER, V82, P1991; Liu BL, 2001, ONCOGENE, V20, P1913, DOI 10.1038/sj.onc.1204277; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MENDELSOHN J, 1999, P AN M AM SOC CLIN, V18, pA389; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Milas L, 2000, CLIN CANCER RES, V6, P701; Muzio M, 1998, J BIOL CHEM, V273, P2926, DOI 10.1074/jbc.273.5.2926; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Peng D, 1996, CANCER RES, V56, P3666; PEREZSOLER R, 1998, P AN M AM SOC CLIN, V17, pA393; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sato J D, 1983, Mol Biol Med, V1, P511; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; Sheikh MS, 1998, ONCOGENE, V17, P2555, DOI 10.1038/sj.onc.1202292; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STAMPFER MR, 1993, EXP CELL RES, V208, P175, DOI 10.1006/excr.1993.1236; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Sun SY, 2001, BIOCHEM BIOPH RES CO, V280, P788, DOI 10.1006/bbrc.2000.4218; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Ungefroren H, 1998, CANCER RES, V58, P1741; VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; WU XP, 1995, J CLIN INVEST, V95, P1897, DOI 10.1172/JCI117871; Wu XP, 1996, ONCOGENE, V12, P1397; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5	63	35	36	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 21	2001	20	28					3726	3734		10.1038/sj.onc.1204490	http://dx.doi.org/10.1038/sj.onc.1204490			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	444LD	11439335				2022-12-17	WOS:000169400200013
J	Bessa, M; Saville, MK; Watson, RJ				Bessa, M; Saville, MK; Watson, RJ			Inhibition of cyclin A/Cdk2 phosphorylation impairs B-Myb transactivation function without affecting interactions with DNA or the CBP coactivator	ONCOGENE			English	Article						B-Myb; cyclin A; phosphorylation; CBP; transcriptional regulation	NEGATIVE REGULATORY DOMAIN; TERMINAL CONSERVED DOMAIN; HUMAN C-MYB; CELL-CYCLE; A-MYB; TRANSCRIPTIONAL COACTIVATOR; HEMATOPOIETIC-CELLS; BINDING ACTIVITY; GENE-PRODUCT; ACTIVATION	Expression of the B-Myb transcription factor is directed by an E2F-dependent transcriptional mechanism to late G1 and S phases of the cell cycle, where its transactivation properties are enhanced post-translationally by cyclin A/Cdk2-mediated phosphorylation, Other experiments have shown that removal of the B-Myb C-terminus constitutively activates both transactivation and DNA-binding activities, suggesting that autoregulation by this inhibitory domain is counteracted by phosphorylation. We report here on further experiments to examine this hypothesis. The importance of this We report here on further experiments to examine this hypothesis. The importance of this modification was first emphasized by showing that co-transfected dominant-negative Cdk2 (Cdk2DN) substantially reduced B-Myb transactivation activity. We then attempted to map the autoregulatory domain by analysing a series of progressively deleted C-terminal B-Myb mutants. Removal of just 29 C-terminal aa increased transactivation appreciably, however, maximal activity required removal of 143 amino acids (as in B-Myb+561). Enhanced B-Myb+561 function correlated with the acquisition of DNA binding activity to a single Myb binding site (MBS) oligonucleotide as determined by bandshift assays, however, further assays showed that even wt B-Myb could bind a DNA fragment containing three MBS. Although transactivation by B-Myb was severely dependent on hyperphosphorylation, neither inhibiting this activity by co-transfecting Cdk2DN nor augmenting it with cyclin A resulted in significant effects on DNA-binding. We also found that B-Myb could synergize with the CBP coactivator and that this cooperativity was cyclin A/Cdk2-dependent. Despite this, the physical association between these proteins was not influenced by the B-Myb phosphorylation status. We discuss these findings in relation to the autoregulation of B-Myb by the C-terminal domain.	Imperial Coll Sch Med, Sect Virol & Cell Biol, London W2 1PG, England; Imperial Coll Sch Med, Ludwig Inst Canc Res, London W2 1PG, England	Imperial College London; Imperial College London; Ludwig Institute for Cancer Research	Watson, RJ (corresponding author), Imperial Coll Sch Med, Sect Virol & Cell Biol, Norfolk Pl,St Marys Campus, London W2 1PG, England.							Ansieau S, 1997, J MOL MED-JMM, V75, P815, DOI 10.1007/s001090050170; ARSURA M, 1992, BLOOD, V79, P2708; Bartsch O, 1999, EUR J BIOCHEM, V260, P384, DOI 10.1046/j.1432-1327.1999.00191.x; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Bies J, 1996, ONCOGENE, V12, P355; Cervellera MN, 2000, J BIOL CHEM, V275, P10692, DOI 10.1074/jbc.275.14.10692; Charrasse S, 2000, ONCOGENE, V19, P2986, DOI 10.1038/sj.onc.1203618; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; De Falco G, 2000, ONCOGENE, V19, P373, DOI 10.1038/sj.onc.1203305; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; GOLAY J, 1991, BLOOD, V77, P149; Horstmann S, 2000, ONCOGENE, V19, P298, DOI 10.1038/sj.onc.1203302; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; HU YL, 1991, ONCOGENE, V6, P1549; Humbert-Lan G, 1999, J BIOL CHEM, V274, P10293, DOI 10.1074/jbc.274.15.10293; Johnson TK, 1999, J BIOL CHEM, V274, P36741, DOI 10.1074/jbc.274.51.36741; KALKBRENNER F, 1990, ONCOGENE, V5, P657; Kamano H, 1995, ONCOGENE, V11, P2575; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; LAM EWF, 1994, EMBO J, V13, P871, DOI 10.1002/j.1460-2075.1994.tb06330.x; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1992, ONCOGENE, V7, P1885; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Miglarese MR, 1996, J BIOL CHEM, V271, P22697, DOI 10.1074/jbc.271.37.22697; Morris L, 2000, NAT CELL BIOL, V2, P232, DOI 10.1038/35008660; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; RAMSAY RG, 1991, ONCOGENE, V6, P1875; RASCHELLA G, 1995, J BIOL CHEM, V270, P8540, DOI 10.1074/jbc.270.15.8540; REISS K, 1991, J CELL PHYSIOL, V148, P338, DOI 10.1002/jcp.1041480303; Robinson C, 1996, ONCOGENE, V12, P1855; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sala A, 1996, J BIOL CHEM, V271, P28738, DOI 10.1074/jbc.271.46.28738; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; Sitzmann J, 1996, ONCOGENE, V12, P1889; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; TASHIRO S, 1995, ONCOGENE, V10, P1699; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; Vorbrueggen G, 1996, BIOL CHEM, V377, P721, DOI 10.1515/bchm3.1996.377.11.721; WATSON RJ, 1993, NUCLEIC ACIDS RES, V21, P267, DOI 10.1093/nar/21.2.267; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282	53	35	35	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 7	2001	20	26					3376	3386		10.1038/sj.onc.1204439	http://dx.doi.org/10.1038/sj.onc.1204439			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	441UW	11423988				2022-12-17	WOS:000169248800008
J	Kim, H; You, SK; Kim, IJ; Foster, LK; Farris, J; Ambady, S; de Leon, FAP; Foster, DN				Kim, H; You, SK; Kim, IJ; Foster, LK; Farris, J; Ambady, S; de Leon, FAP; Foster, DN			Alterations in p53 and E2F-1 function common to immortalized chicken embryo fibroblasts	ONCOGENE			English	Article						chicken embryo fibroblast; immortalization; p53; E2F-1; telomerase	HUMAN-CELLS; SACCHAROMYCES-CEREVISIAE; CELLULAR SENESCENCE; TELOMERASE ACTIVITY; TUMOR-CELLS; GENE; DEGRADATION; EXPRESSION; MECHANISM; PATTERNS	A number of non-virally and non-chemically immortalized chicken embryo fibroblast (CEF) cells have been established recently in continuous cell culture. All immortal CEF cells tested showed common genetic alterations in the expression patterns of p53 and E2F-1 mRNA and protein which were down- and up-regulated, respectively, The biological effects of differentially regulated p53 and E2F-1 were determined by reporter gene transcriptional activity assays, DNA binding assays, and Northern blot analysis of the expression patterns of down-stream genes, In addition, expression of most of the cyclin genes was up-regulated in immortal CEF cells, which may be associated with the rapid cell division rates and serum-independent growth patterns seen in immortal CEF cells. The telomeric lengths and chromosome integrity were maintained in all immortal CEF cell lines without detectable telomerase activity. Although the functional inactivations of the p53 and Rb regulatory pathways are known to be common events for cellular immortalization, the genetic changes leading to alteration of p53 and E2F-1 function through transcriptional and post-transcriptional regulation seem to be unique in immortal CEF cells.	Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA; Seoul Natl Univ, Sch Agr Biotechnol, Suwon 441744, South Korea	University of Minnesota System; University of Minnesota Twin Cities; Seoul National University (SNU)	Foster, DN (corresponding author), 495 AnSci VetMed, 1988 Fitch AVe, St Paul, MN 55108 USA.		Kim, Hyunggee/F-2673-2013; Kang, Phil Jun/F-4716-2013; You, Seungkwon/H-3067-2015	Kim, Hyunggee/0000-0002-4738-0990; Ponce de Leon, Federico/0000-0001-8645-553X				ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; DELEON FAP, 1992, J HERED, V83, P36, DOI 10.1093/oxfordjournals.jhered.a111154; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; Himly M, 1998, VIROLOGY, V248, P295, DOI 10.1006/viro.1998.9290; Jha KK, 1998, EXP CELL RES, V245, P1, DOI 10.1006/excr.1998.4272; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; McEachern MJ, 1996, GENE DEV, V10, P1822, DOI 10.1101/gad.10.14.1822; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; RUBELJ I, 1994, EXP CELL RES, V211, P82, DOI 10.1006/excr.1994.1062; Schaefer-Klein J, 1998, VIROLOGY, V248, P305, DOI 10.1006/viro.1998.9291; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Sedivy JM, 1998, P NATL ACAD SCI USA, V95, P9078, DOI 10.1073/pnas.95.16.9078; SEGAWA K, 1993, ONCOGENE, V8, P543; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Venkatesan RN, 1998, P NATL ACAD SCI USA, V95, P14763, DOI 10.1073/pnas.95.25.14763; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Zhang HS, 1999, CELL, V97, P53, DOI 10.1016/S0092-8674(00)80714-X	36	35	43	0	5	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 10	2001	20	21					2671	2682		10.1038/sj.onc.1204378	http://dx.doi.org/10.1038/sj.onc.1204378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VN	11420679				2022-12-17	WOS:000168652600008
J	McGarvey, TW; Nguyen, T; Tomaszewski, JE; Monson, FC; Malkowicz, SB				McGarvey, TW; Nguyen, T; Tomaszewski, JE; Monson, FC; Malkowicz, SB			Isolation and characterization of the TERE1 gene, a gene down-regulated in transitional cell carcinoma of the bladder	ONCOGENE			English	Article						tumor related gene; bladder neoplasms; TERE1 gene	TUMOR-SUPPRESSOR REGION; CHROMOSOME 1P; GENOMIC INSTABILITY; DELETION; LOCALIZATION; ABERRATIONS; FREQUENT; DNA; HETEROZYGOSITY; METHYLATION	We have identified a novel cDNA product designated transitional epithelial response gene (TERE1), which was localized to chromosome 1p36. The TERE1 transcript (1.5 and 3.5 kb) is present in most normal human tissues including urothelium, but was reduced or absent in the majority of muscle invasive TCC tumors (22 out of 29 cases). The open reading frame encodes a protein of 338 amino acids (MW 36.8 KD). This protein is 57% homologous to a Drosophila protein called heir. We have shown by Western blotting and immuno-histochemistry with a polyclonal antibody to a specific TERE1 peptide, reduced or absent staining in muscle invasive tumors. Transfection of a sense TERE1 construct resulted in an 80-90% inhibition of cellular proliferation in two TCC cell lines and a lack of aneuploidy in the TERE1-transduced J82 cell line, These data suggest a potential role for this gene product in the progression of bladder cancer.	Dept Surg, Div Urol, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Philadelphia, PA 19104 USA; Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania	Malkowicz, SB (corresponding author), Dept Surg, Div Urol, 1 Rhoads,3400 Spruce St, Philadelphia, PA 19104 USA.							*AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN; Ashburner M, 1999, GENETICS, V153, P179; Bieche I, 1998, ONCOL REP, V5, P267; Boni R, 1998, J INVEST DERMATOL, V110, P215, DOI 10.1046/j.1523-1747.1998.00109.x; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Cairns P, 1998, ONCOGENE, V16, P3215, DOI 10.1038/sj.onc.1201855; CAIRNS P, 1991, ONCOGENE, V6, P2305; CHANG WYH, 1995, CANCER RES, V55, P3246; Chen HL, 1996, CANCER GENET CYTOGEN, V86, P102, DOI 10.1016/0165-4608(95)00186-7; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DiSepio D, 1998, P NATL ACAD SCI USA, V95, P14811, DOI 10.1073/pnas.95.25.14811; Ebrahimi SA, 1999, CANCER RES, V59, P311; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gasparian AV, 1998, BRIT J CANCER, V77, P1604, DOI 10.1038/bjc.1998.263; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; Habuchi T, 1998, GENOMICS, V48, P277, DOI 10.1006/geno.1997.5165; Hayashi K, 1991, PCR Methods Appl, V1, P34; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; HONG L, 1998, A DROS RES C, V39, pB373; KNOWLES MA, 1994, CANCER RES, V54, P531; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Malkowicz S B, 1997, Semin Urol Oncol, V15, P169; Martinsson T, 1997, EUR J CANCER, V33, P1997, DOI 10.1016/S0959-8049(97)00278-5; Monteiro ANA, 2000, HISTOL HISTOPATHOL, V15, P299, DOI 10.14670/HH-15.299; NAGAI H, 1995, CANCER RES, V55, P1752; ORLOW I, 1995, J NATL CANCER I, V87, P1524, DOI 10.1093/jnci/87.20.1524; PRAML C, 1995, ONCOGENE, V11, P1357; Reznikoff CA, 1996, SEMIN ONCOL, V23, P571; ROSIN MP, 1995, CANCER RES, V55, P5213; Salem C, 2000, CANCER RES, V60, P2473; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; Sattler HP, 1999, PROSTATE, V39, P79; SHAW ME, 1995, GENE CHROMOSOME CANC, V13, P1, DOI 10.1002/gcc.2870130102; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Simon R, 1998, J PATHOL, V185, P345; SPRUCK CH, 1994, CANCER RES, V54, P784; Steenman M, 1997, CYTOGENET CELL GENET, V77, P296, DOI 10.1159/000134602; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702; Wagner U, 1997, AM J PATHOL, V151, P753; White RWD, 1998, ONCOLOGY-NY, V12, P1717; Williamson C, 1997, J MED GENET, V34, P617, DOI 10.1136/jmg.34.8.617; WILLIAMSON MP, 1994, GENE CHROMOSOME CANC, V9, P108, DOI 10.1002/gcc.2870090206	43	35	42	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 1	2001	20	9					1042	1051		10.1038/sj.onc.1204143	http://dx.doi.org/10.1038/sj.onc.1204143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	406TW	11314041				2022-12-17	WOS:000167232100004
J	Fournes, B; Sadekova, S; Turbide, C; Letourneau, S; Beauchemin, N				Fournes, B; Sadekova, S; Turbide, C; Letourneau, S; Beauchemin, N			The CEACAM1-L Ser503 residue is crucial for inhibition of colon cancer cell tumorigenicity	ONCOGENE			English	Article						CEACAM1; CEA; BGP; CD66a; C-CAM; tumor suppressor; colon cancer; Ser phosphorylation; PMA	HUMAN CARCINOEMBRYONIC ANTIGEN; BILIARY GLYCOPROTEIN CD66A; MOLECULE C-CAM; ADHESION MOLECULE; CYTOPLASMIC DOMAIN; ENDOGENOUS SUBSTRATE; ECTO-ATPASE; NEISSERIA-GONORRHOEAE; TYROSINE KINASE; GENE FAMILY	CEACAM1 (also known as biliary glycoprotein, C-CAM or CD66a) is a cell adhesion molecule of the immunoglobulin family behaving as a tumor inhibitory protein in colon, prostate, liver, endometrial and breast cancers. Inhibition of tumor development is dependent upon the presence of the long 71-73 amino acid cytoplasmic domain of the CEACAM1 protein (CEACAM1-L). We have recently defined a number of cis-acting motifs within the long cytoplasmic domain participating in tumor cell growth inhibition. These are Tyr488, corresponding to an Immunoreceptor Tyrosine-based Inhibition Motif, as web as the three terminal lysine residues of the protein. In this study, we provide evidence that treatment with phorbol esters leads to increased phosphorylation of in vivo P-32-labeled CEACAM1-L in mouse CT51 carcinoma cells, in the mouse 1MEA 7R.1 liver carcinoma cells and in 293 human embryonic kidney cells transfected with the Ceacam1-L cDNA. Basal level Ser phosphorylation was abrogated by treatment with the staurosporine inhibitor, but not by the protein kinase C-specific inhibitor calphostin C or other inhibitors such as H7 or sphingosine. Specific inhibitors of protein kinase A or calmodulin kinase had only minimal effects on the levels of basal or PMA-induced Ser phosphorylation, Furthermore, PMA treatment of the CT51 cells induced cell spreading and cellular relocalization of the CEACAM1-L protein. Since Ser503 has been described as a PMA-induced phosphorylation site in other cell systems, we investigated whether Ser503 was involved in these responses in mouse intestinal cells, No differences were noticed in the basal or the PMA-induced phosphorylation levels, kinase inhibitor sensitivity or the PMA-induced relocalization of the protein between the wild-type and the Ser503Ala mutant CEACAM1-L. However, we provide evidence that Ser503 participates in CEACAM1-L-mediated tumor inhibition as its mutation to an Ala led to in vivo tumor development, contrary to the tumor inhibitory phenotype observed with the wild-type CEACAM1-L protein.	McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Med, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Oncol, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University; McGill University; McGill University	Beauchemin, N (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Promenade Sir William Osier, Montreal, PQ H3G 1Y6, Canada.							Bamberger AM, 1998, AM J PATHOL, V152, P1401; BARNETT TR, 1989, J CELL BIOL, V108, P267, DOI 10.1083/jcb.108.2.267; Beauchemin N, 1998, CELL ADHES COMMUN S, V5, P155; Beauchemin N, 1999, EXP CELL RES, V252, P243; Beauchemin N, 1997, ONCOGENE, V14, P783, DOI 10.1038/sj.onc.1200888; BRUMMER J, 1995, ONCOGENE, V11, P1649; Casnellie J E, 1991, Adv Pharmacol, V22, P167, DOI 10.1016/S1054-3589(08)60035-6; CULIC O, 1992, BIOCHEM J, V285, P47, DOI 10.1042/bj2850047; Danilov V, 1996, RUSS J MATH PHYS, V4, P272; DVEKSLER GS, 1993, P NATL ACAD SCI USA, V90, P1716, DOI 10.1073/pnas.90.5.1716; DVEKSLER GS, 1991, J VIROL, V65, P6881, DOI 10.1128/JVI.65.12.6881-6891.1991; Edlund M, 1998, FEBS LETT, V425, P166, DOI 10.1016/S0014-5793(98)00222-1; Edlund M, 1996, J BIOL CHEM, V271, P1393, DOI 10.1074/jbc.271.3.1393; FORMISANO P, 1995, J BIOL CHEM, V270, P24073, DOI 10.1074/jbc.270.41.24073; FRANGSMYR L, 1995, CANCER RES, V55, P2963; GrayOwen SD, 1997, EMBO J, V16, P3435, DOI 10.1093/emboj/16.12.3435; GSCHWENDT M, 1994, FEBS LETT, V338, P85, DOI 10.1016/0014-5793(94)80121-5; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; HANSSON M, 1989, EXP CELL RES, V181, P63, DOI 10.1016/0014-4827(89)90182-1; Hauck CR, 1998, EMBO J, V17, P443, DOI 10.1093/emboj/17.2.443; HSIEH JT, 1995, CANCER RES, V55, P190; Huang J, 1998, ANTICANCER RES, V18, P3203; Huber M, 1999, J BIOL CHEM, V274, P335, DOI 10.1074/jbc.274.1.335; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Ilantzis C, 1997, LAB INVEST, V76, P703; Imamura H, 1998, MOL BIOL CELL, V9, P2561, DOI 10.1091/mbc.9.9.2561; Izzi L, 1999, ONCOGENE, V18, P5563, DOI 10.1038/sj.onc.1202935; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KLEINERMAN DI, 1995, CANCER RES, V55, P1215; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; Kunath T, 1995, ONCOGENE, V11, P2375; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LIN SH, 1989, J BIOL CHEM, V264, P14408; Luo WP, 1998, ONCOGENE, V16, P1141, DOI 10.1038/sj.onc.1201619; Luo WP, 1997, ONCOGENE, V14, P1697, DOI 10.1038/sj.onc.1200999; MCCUAIG K, 1992, CELL GROWTH DIFFER, V3, P165; MCENTIRE KD, 1989, CANCER RES, V49, P6795; NAJJAR SM, 1995, BIOCHEMISTRY-US, V34, P9341, DOI 10.1021/bi00029a009; NAJJAR SM, 1993, J BIOL CHEM, V268, P1201; NEDELLEC P, 1995, EUR J BIOCHEM, V231, P104, DOI 10.1111/j.1432-1033.1995.tb20676.x; NEUMAIER M, 1993, P NATL ACAD SCI USA, V90, P10744, DOI 10.1073/pnas.90.22.10744; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Nollau P, 1997, CANCER RES, V57, P2354; OCKLIND C, 1982, J BIOL CHEM, V257, P6788; ODIN P, 1986, BIOCHEM J, V236, P559, DOI 10.1042/bj2360559; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; Rojas M, 1996, CELL GROWTH DIFFER, V7, P655; ROJAS M, 1990, CELL GROWTH DIFFER, V1, P527; ROSENBERG M, 1993, CANCER RES, V53, P4938; Sadekova S, 2000, MOL BIOL CELL, V11, P65, DOI 10.1091/mbc.11.1.65; SIPPEL CJ, 1994, J BIOL CHEM, V269, P19539; SOUTHERN PJ, 1982, J MOL APPL GENET, V1, P314; Tanaka K, 1997, INT J CANCER, V74, P15, DOI 10.1002/(SICI)1097-0215(19970220)74:1<15::AID-IJC3>3.0.CO;2-3; Turbide C, 1997, CANCER RES, V57, P2781; VANDERGEER P, 1994, CELL BIOL LAB HDB, P422; Virji M, 1996, MOL MICROBIOL, V22, P941, DOI 10.1046/j.1365-2958.1996.01551.x	58	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 11	2001	20	2					219	230		10.1038/sj.onc.1204058	http://dx.doi.org/10.1038/sj.onc.1204058			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KU	11313949				2022-12-17	WOS:000166410900009
J	Liu, D; Yang, XH; Yang, DL; Zhou, SY				Liu, D; Yang, XH; Yang, DL; Zhou, SY			Genetic screens in mammalian cells by enhanced retroviral mutagens	ONCOGENE			English	Article						genetic screen; retroviral mutagen; oncogene; epitope tagging	EMBRYONIC STEM-CELLS; SIGNAL-TRANSDUCTION PATHWAY; MURINE LEUKEMIA-VIRUS; HOMOLOGOUS RECOMBINATION; PROTEIN-KINASE; V-RAF; CLONING; EXPRESSION; ONCOGENE; ACTIVATION	Genetic approaches such as retrovirus-mediated mutagenesis and cDNA expression libraries have contributed greatly to our understanding of signal transduction in mammalian cells. However, previously described methods for retroviral insertional mutagenesis are hindered by low mutagenesis rates and difficulties in cloning mutated genes. cDNA expression library methods are usually cell-type dependent and bias towards abundant and short messages. With the near completion of the genome projects, alternative genetic methods are needed where large numbers of genes can be more easily isolated and biochemically studied. We have developed a novel retrovirus-mediated genetic screening method in cultured cells. To achieve efficient and regulated mutagenesis, we constructed Enhanced Retroviral Mutagen (ERR I) vectors that contained several engineered sequences (e.g., an ERM Tag and a splice donor) controlled by a tetracycline-responsive promoter. Endogenous genes can thus be randomly activated and tagged in a conditional system. NIH3T3 cells were used to screen for focus-forming genes using the ERM strategy. We showed that these added sequences increased the screening efficiency by >10-fold, and allowed more direct identification of the genes targeted. Sequence analysis of similar to 10% of the >600 focus clones recovered revealed both known oncogenes and novel factors such as protein kinases and GTP/GDP exchange proteins. The ERM strategy should help to facilitate large-scale gene identification in diverse pathways and integrate both genetic (with the completion of the genome projects) and functional information more readily.	Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, Houston, TX 77030 USA	Baylor College of Medicine	Zhou, SY (corresponding author), Baylor Coll Med, Verna & Marrs Mclean Dept Biochem & Mol Biol, 1 Baylor Plaza, Houston, TX 77030 USA.							AHMED NN, 1993, ONCOGENE, V8, P1957; BARBACID M, 1978, J BIOL CHEM, V253, P1408; BARBACID M, 1981, J VIROL, V37, P518, DOI 10.1128/JVI.37.1.518-523.1981; BERNS A, 1988, ARCH VIROL, V102, P1, DOI 10.1007/BF01315558; Brennan J, 1999, METH MOL B, V97, P123, DOI 10.1385/1-59259-270-8:123; BROWN DW, 1988, VIROLOGY, V162, P239, DOI 10.1016/0042-6822(88)90414-X; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; Chiarle R, 1999, CLIN IMMUNOL, V90, P157, DOI 10.1006/clim.1998.4636; CLARK J, 1993, P NATL ACAD SCI USA, V90, P8952, DOI 10.1073/pnas.90.19.8952; COFFIN JM, 1990, RETROVIRIDAE THEIR R; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DANDREA A, 1990, INT J CELL CLONING, V8, P173, DOI 10.1002/stem.5530080716; Darnell RB, 1996, P NATL ACAD SCI USA, V93, P4529, DOI 10.1073/pnas.93.10.4529; DORIN JR, 1989, SCIENCE, V243, P1357; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GONDA MA, 1982, J VIROL, V44, P520, DOI 10.1128/JVI.44.2.520-529.1982; GOSSEN M, 1993, TRENDS BIOCHEM SCI, V18, P471, DOI 10.1016/0968-0004(93)90009-C; GOSSLER A, 1989, SCIENCE, V244, P463, DOI 10.1126/science.2497519; GUNTAKA RV, 1993, MICROBIOL REV, V57, P511, DOI 10.1128/MMBR.57.3.511-521.1993; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; Jaenisch R, 1986, Symp Fundam Cancer Res, V39, P59; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JOHNSON RS, 1989, SCIENCE, V245, P1234, DOI 10.1126/science.2506639; Kawai T, 1999, GENE, V227, P249, DOI 10.1016/S0378-1119(98)00605-2; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Kojima T, 1999, NAT BIOTECHNOL, V17, P487, DOI 10.1038/8666; Kung H J, 1991, Curr Top Microbiol Immunol, V171, P1; Kuwabara PE, 1997, TRENDS GENET, V13, P455, DOI 10.1016/S0168-9525(97)01253-5; Li JY, 1999, NAT GENET, V23, P348, DOI 10.1038/15531; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MUSHINSKI JF, 1983, SCIENCE, V220, P795, DOI 10.1126/science.6687762; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; Norman JC, 1998, J CELL BIOL, V143, P1981, DOI 10.1083/jcb.143.7.1981; Okano HJ, 1999, GENE DEV, V13, P2087, DOI 10.1101/gad.13.16.2087; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; Robinson H L, 1983, Prog Clin Biol Res, V119, P37; Rorth P, 1998, DEVELOPMENT, V125, P1049; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; SCHULTZ A, 1984, VIROLOGY, V133, P431, DOI 10.1016/0042-6822(84)90409-4; SIMON MA, 1992, COLD SPRING HARB SYM, V57, P375, DOI 10.1101/SQB.1992.057.01.042; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Sorensen AB, 1996, J VIROL, V70, P4063; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; STORM S M, 1990, Critical Reviews in Oncogenesis, V2, P1; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tate P, 1998, J CELL SCI, V111, P2575; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; TSICHLIS PN, 1987, ANTICANCER RES, V7, P171; VONMELCHNER H, 1989, J VIROL, V63, P3227, DOI 10.1128/JVI.63.8.3227-3233.1989; WHITEHEAD I, 1995, ONCOGENE, V10, P713; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Whitehead LP, 1999, MOL CELL BIOL, V19, P7759; Wiles MV, 2000, NAT GENET, V24, P13, DOI 10.1038/71622; WONG BY, 1994, J VIROL, V68, P5523, DOI 10.1128/JVI.68.9.5523-5531.1994; YOSHIDA M, 1995, TRANSGENIC RES, V4, P277, DOI 10.1007/BF01969122; Zambrowicz BP, 1998, NATURE, V392, P608, DOI 10.1038/33423	64	35	35	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 7	2000	19	52					5964	5972		10.1038/sj.onc.1203992	http://dx.doi.org/10.1038/sj.onc.1203992			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	382MY	11146547				2022-12-17	WOS:000165827900002
J	Kostic, C; Shaw, PH				Kostic, C; Shaw, PH			Isolation and characterization of sixteen novel p53 response genes	ONCOGENE			English	Article						p53; transcription; inducible; apoptosis	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; PROGRAMMED CELL-DEATH; SUBTRACTIVE HYBRIDIZATION; P53-INDUCIBLE GENE; TYROSINE KINASE; BINDING-PROTEIN; CANCER-CELLS; DNA-BINDING; G(1) ARREST	The EB-1 cell line is a stable transfectant of EB, a p53 null colon carcinoma cell line, with an inducible promoter controlling expression of a wild type p53 cDNA. The induced p53 is transcriptionally active and gives rise to apoptosis in these cells. Using this cellular model for presence or absence of the transcription factor p53 and transactivated genes, the Suppression Subtractive Hybridization (SSH) technique permitted the isolation of 17 mRNA candidates (GIPs-(G) under bar enes (i) under bar nduced by (p) under bar 53), whose expression appears to be p53-dependent. Identity has been established for nine of the 17 isolated candidates. These are HGFL/MSP, Zap-70, APOBEC2, Ponsin/ SH3P12/CAP/FLAF2, CDCreI2b/H5/PrutI2, Igc, lats 2, cytokeratin 15 and PIG-3 (quinone oxidoreductase). The latter gene is the only GIP previously demonstrated to be p53 regulated. Of the eight remaining GIPs, sis correspond to Unigene clusters. One candidate, GIP #1, is significantly homologous (72% identity) to a chicken zinc finger protein, CTCF, which binds to insulator elements and thus attenuates enhancer cross-talk between physically adjacent promoters. The p53-dependent expression of GIPs was confirmed by dependence of expression upon induction of wt p53 expression in the EB-1 cellular model and by up-regulation following activation of an endogenous wt p53 by treatment with adriamycin.	Univ Lausanne, Inst Pathol, Lausanne, Switzerland	University of Lausanne	Shaw, PH (corresponding author), Univ Lausanne, Inst Pathol, Lausanne, Switzerland.			Kostic, Corinne/0000-0003-1006-9733				ALMON E, 1993, DEV BIOL, V156, P107, DOI 10.1006/dbio.1993.1062; ALONIGRINSTEIN R, 1993, ONCOGENE, V8, P3297; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Arah IN, 1998, ANTICANCER RES, V18, P1845; Bacus SS, 1996, ONCOGENE, V12, P2535; Beites CL, 1999, NAT NEUROSCI, V2, P434, DOI 10.1038/8100; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Church DM, 1997, GENOME RES, V7, P787, DOI 10.1101/gr.7.8.787; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Collavin L, 1999, ONCOGENE, V18, P5879, DOI 10.1038/sj.onc.1202970; Comer KA, 1998, ONCOGENE, V16, P1299, DOI 10.1038/sj.onc.1201645; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; Gloushankova N, 1997, ONCOGENE, V15, P2985, DOI 10.1038/sj.onc.1201483; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Han S, 1993, EXS, V65, P81; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HODGSON CP, 1987, NUCLEIC ACIDS RES, V15, P6295, DOI 10.1093/nar/15.15.6295; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOSONO S, 1991, ONCOGENE, V6, P237; ISHIJIMA SA, 1995, CELL IMMUNOL, V165, P278, DOI 10.1006/cimm.1995.1214; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Klotzsche O, 1998, ONCOGENE, V16, P3423, DOI 10.1038/sj.onc.1202155; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LEUBE RE, 1988, J CELL BIOL, V106, P1249, DOI 10.1083/jcb.106.4.1249; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Li S, 1999, J ORTHOP RES, V17, P891, DOI 10.1002/jor.1100170614; Liao W, 1999, BIOCHEM BIOPH RES CO, V260, P398, DOI 10.1006/bbrc.1999.0925; LITTLE JB, 1995, J BIOL CHEM, V270, P11033, DOI 10.1074/jbc.270.19.11033; Maas S, 1997, CURR OPIN CELL BIOL, V9, P343, DOI 10.1016/S0955-0674(97)80006-3; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mehta A, 1996, J BIOL CHEM, V271, P28294, DOI 10.1074/jbc.271.45.28294; MIYASHITA T, 1995, CELL, V80, P293; MUKHOPADHYAY T, 1996, ANTICANCER RES, V16, P99; Nagase T, 1999, DNA Res, V6, P337, DOI 10.1093/dnares/6.5.337; NOBLE JR, 1992, EXP CELL RES, V203, P297, DOI 10.1016/0014-4827(92)90002-P; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Paavola P, 1999, GENOMICS, V55, P122, DOI 10.1006/geno.1998.5612; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Renzing J, 1996, J CELL SCI, V109, P1105; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; Ribon V, 1998, J BIOL CHEM, V273, P4073, DOI 10.1074/jbc.273.7.4073; Rubtsova SN, 1998, FEBS LETT, V430, P353, DOI 10.1016/S0014-5793(98)00692-9; Sambrook J, 1989, MOL CLONING LAB MANU; SHAULSKY G, 1991, P NATL ACAD SCI USA, V88, P8982, DOI 10.1073/pnas.88.20.8982; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; Shaw P, 1996, ONCOGENE, V12, P921; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; St John MAR, 1999, NAT GENET, V21, P182, DOI 10.1038/5965; Stahlhut M, 2000, MOL BIOL CELL, V11, P325, DOI 10.1091/mbc.11.1.325; Take Y, 1996, BIOCHEM BIOPH RES CO, V221, P207, DOI 10.1006/bbrc.1996.0575; Tao WF, 1999, NAT GENET, V21, P177, DOI 10.1038/5960; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; TISHLER RB, 1995, CANCER RES, V55, P6021; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Trepel M, 1998, J NEURO-ONCOL, V39, P19, DOI 10.1023/A:1005910323338; Utrera R, 1998, EMBO J, V17, P5015, DOI 10.1093/emboj/17.17.5015; WALDMAN T, 1995, CANCER RES, V55, P5187; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Xia F, 1997, MUTAT RES-FUND MOL M, V373, P87, DOI 10.1016/S0027-5107(96)00193-5; Xie H, 1999, CELL MOTIL CYTOSKEL, V43, P52, DOI 10.1002/(SICI)1097-0169(1999)43:1<52::AID-CM6>3.0.CO;2-5; XU TA, 1995, DEVELOPMENT, V121, P1053; Yabuta N, 2000, GENOMICS, V63, P263, DOI 10.1006/geno.1999.6065; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3	80	35	39	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 17	2000	19	35					3978	3987		10.1038/sj.onc.1203747	http://dx.doi.org/10.1038/sj.onc.1203747			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962554				2022-12-17	WOS:000088825300003
J	Cristofanelli, B; Valentinis, B; Soddu, S; Rizzo, MG; Marchetti, A; Bossi, G; Morena, AR; Dews, M; Baserga, R; Sacchi, A				Cristofanelli, B; Valentinis, B; Soddu, S; Rizzo, MG; Marchetti, A; Bossi, G; Morena, AR; Dews, M; Baserga, R; Sacchi, A			Cooperative transformation of 32D cells by the combined expression of IRS-1 and V-Ha-Ras	ONCOGENE			English	Article						myelodysplastic syndrome; Shc; PI3-K; MAPK; transformation	GROWTH-FACTOR-I; INSULIN-RECEPTOR SUBSTRATE-1; MULTIPLE SIGNALING PATHWAYS; HEMATOPOIETIC-CELLS; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; PHOSPHATIDYLINOSITOL 3'-KINASE; MATRIX ADHESION; IGF-I; P53; DIFFERENTIATION	32D cells expressing,v-Ha-Ras fail to show a transformed phenotype. Since Ras requires an active IGF-1R for transformation of fibroblasts, we asked whether expression of IRS-1 or Shc (two of the major substrates of the IGF-1R) could co-operate with oncogenic Ras in transforming 32D cells. We find that IRS-1, but not Shc, in combination with v-Ha-Ras generates a fully transformed phenotype in 32D cells, 32D cells expressing both IRS-1 and v-Ha-Ras (32D/IRS1/Ras) survive and proliferate in the absence of IL-3, do not undergo granulocytic differentiation in the presence of G-CSF and form tumors in nu/nu and syngeneic mice, In contrast, 32D cells expressing singly IRS-1 or v-Ha-Ras exhibit only a block in differentiation capacity. Over-expression of Shc proteins, by itself, promotes differentiation of 32D cells. Concomitant expression of IRS-1 and v-Ha-Ras synergistically phosphorylates ERK-1 and ERK-2 whereas a MEK inhibitor rapidly induces death of 32D/IRS1/Ras transformed cells. Furthermore, transformed 32D/IRS1/Ras cells display high levels of PI3-K activation and undergo rapid apoptosis when exposed to PI3-K inhibitors. The data indicate that: (1) a fully transformed phenotype in 32D cells is generated when a block in differentiation (v-Ha-Ras) is coupled with another differentiation block (IRS-1); (2) PI3-K and MAPK activity are required for the survival of transformed cells; (3) the signals generated by IRS-1 and oncogenic Ras converge on ERK and PI3-K resulting in high levels of activation.	Regina Elena Inst Canc Res, CRS, Mol Oncogenesis Lab, I-00158 Rome, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Jefferson University	Sacchi, A (corresponding author), Regina Elena Inst Canc Res, CRS, Mol Oncogenesis Lab, Via Messi Doro 156, I-00158 Rome, Italy.		Marchetti, Alessandra/AAD-5498-2019; Bossi, Gianluca/G-8375-2016; Bossi, Gianluca/B-9394-2017; Soddu, Silvia/ABH-6774-2020; Bossi, Gianluca/ABH-6846-2020; Rizzo, Maria/HGD-6576-2022; Soddu, Silvia/K-2467-2018	Bossi, Gianluca/0000-0002-2947-1063; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; Bossi, Gianluca/0000-0002-2947-1063; Soddu, Silvia/0000-0001-8526-0044; MARCHETTI, ALESSANDRA/0000-0001-9706-848X	NCI NIH HHS [P01 CA 56309, CA 53424] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA056309] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ASKEW DS, 1991, ONCOGENE, V6, P1915; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BOS JL, 1989, CANCER RES, V49, P4682; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CHENG J, 1990, MOL CELL BIOL, V10, P5502, DOI 10.1128/MCB.10.10.5502; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Dews M, 1997, RECEPT SIGNAL TRANS, V7, P231; DEWS M, 2000, IN PRESS ENDOCRINOLO, V141; Engelman JA, 1998, J BIOL CHEM, V273, P32111, DOI 10.1074/jbc.273.48.32111; Fei ZL, 1997, ONCOGENE, V15, P961, DOI 10.1038/sj.onc.1201265; GREENBERGER JS, 1983, FED PROC, V42, P2762; GROOPMAN JE, 1989, NEW ENGL J MED, V321, P1449, DOI 10.1056/NEJM198911233212106; Hugl SR, 1998, J BIOL CHEM, V273, P17771, DOI 10.1074/jbc.273.28.17771; KASTAN MB, 1991, CANCER RES, V51, P4279; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; LANFRANCONE L, 1995, ONCOGENE, V10, P907; MAVILIO F, 1989, ONCOGENE, V4, P301; METCALF D, 1985, BLOOD, V65, P357; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peterson JE, 1996, J BIOL CHEM, V271, P31562, DOI 10.1074/jbc.271.49.31562; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; Soddu S, 1996, MOL CELL BIOL, V16, P487; Soon L, 1999, MOL CELL BIOL, V19, P3816; Tanaka S, 1996, J BIOL CHEM, V271, P14610, DOI 10.1074/jbc.271.24.14610; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Valentinis B, 1999, ONCOGENE, V18, P1827, DOI 10.1038/sj.onc.1202471; Valentinis B, 1999, J BIOL CHEM, V274, P12423, DOI 10.1074/jbc.274.18.12423; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Yenush L, 1996, MOL CELL BIOL, V16, P2509	38	35	36	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2000	19	29					3245	3255		10.1038/sj.onc.1203664	http://dx.doi.org/10.1038/sj.onc.1203664			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	331KY	10918581				2022-12-17	WOS:000088019300003
J	Lassus, P; Roux, P; Zugasti, O; Philips, A; Fort, P; Hibner, U				Lassus, P; Roux, P; Zugasti, O; Philips, A; Fort, P; Hibner, U			Extinction of Rac1 and Cdc42Hs signalling defines a novel p53-dependent apoptotic pathway	ONCOGENE			English	Article						Rac1; Cdc42Hs; adhesion; apoptosis; p53; MAPK	NF-KAPPA-B; WISKOTT-ALDRICH SYNDROME; CELL-DEATH; SIGNALING PATHWAY; ACTIN-CYTOSKELETON; GTPASE CDC42HS; ONCOGENIC RAS; P53; PROTEIN; KINASE	Apoptosis is a normal physiological process which eliminates cells that do not receive adequate extracellular signals. One of the pathways signalling apoptosis is controlled by the small GTPases of the Rho family, also involved in cell proliferation, differentiation and motility, Another major apoptosis signalling pathway involves the p53 tumour suppressor which is activated by a variety of stress and mediates growth arrest or apoptosis in normal cells. We show here that upon detachment from the extracellular matrix, fibroblasts undergo rapid apoptosis that can be rescued by constitutive activation of Rad and Cdc42Hs GTPases, Conversely, inhibition of Rad and Cdc42Hs efficiently triggers apoptosis in adherent cells. Interestingly, apoptosis is not observed in p53(-/-) cells either cultured in suspension or inhibited for Rad and Cdc42Hs activity. Moreover, Rad and Cdc42Hs extinction in normal cells activates endogenous p53, Using specific inhibitors of MAPK pathways, we demonstrate that, in our experimental system, p38 signals survival, while ERK activity is required for apoptosis, Our data constitute the first demonstration that Rad and Cdc42Hs control pathways that require simultaneous signalling through MAPK ERK and p53 to induce apoptosis.	Inst Genet Mol, CNRS, UMR5535, IFR 24, F-34293 Montpellier 5, France; Ctr Rech Biochim Macromol, CNRS, UPR1086, IFR 24, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Hibner, U (corresponding author), Inst Genet Mol, CNRS, UMR5535, IFR 24, 1919 Route Mende, F-34293 Montpellier 5, France.		PHILIPS, Alexandre/AAB-6047-2020; Zugasti, Olivier/P-1352-2017; Roux, Pierre/D-8833-2017; Fort, Philippe/M-9498-2015	Fort, Philippe/0000-0001-5997-8722; Zugasti, Olivier/0000-0002-5616-734X; Lassus, Patrice/0000-0002-2785-7843; Hibner, Urszula/0000-0002-5520-7311				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Donovan FM, 1997, J NEUROSCI, V17, P5316; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Dutartre H, 1996, J CELL SCI, V109, P367; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; Fort P, 1999, Prog Mol Subcell Biol, V22, P159; Franke TF, 1997, NATURE, V390, P116, DOI 10.1038/36442; Franke TF, 1997, CELL, V88, P435, DOI 10.1016/S0092-8674(00)81883-8; Fukasawa K, 1997, MOL CELL BIOL, V17, P506, DOI 10.1128/MCB.17.1.506; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029, DOI 10.1152/ajplung.1997.273.5.L1029; Joneson T, 1999, MOL CELL BIOL, V19, P5892; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lassus P, 1998, NUCLEIC ACIDS RES, V26, P5233, DOI 10.1093/nar/26.22.5233; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moorman JP, 1996, J IMMUNOL, V156, P4146; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; Ozes ON, 1999, NATURE, V401, P82; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	54	35	37	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 11	2000	19	20					2377	2385		10.1038/sj.onc.1203553	http://dx.doi.org/10.1038/sj.onc.1203553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	313UV	10828879				2022-12-17	WOS:000087018400002
J	Huang, S; Stupack, D; Liu, AH; Cheresh, D; Nemerow, GR				Huang, S; Stupack, D; Liu, AH; Cheresh, D; Nemerow, GR			Cell growth and matrix invasion of EBV-immortalized human B lymphocytes is regulated by expression of alpha(v) integrins	ONCOGENE			English	Article						integrins; B lymphocytes; Epstein-Barr virus	VITRONECTIN RECEPTOR; IN-VIVO; FIBRONECTIN; ALPHA-V-BETA-3; MELANOMA; ADHESION; IDENTIFICATION; PURIFICATION; ATTACHMENT; MIGRATION	alpha(v) Integrins have been shown to play an important role in epithelial-derived cell migration, cell growth and tumor invasion/metastasis, however their role on cells of hematopoietic origin is less clear. Epstein-Barr virus (EBV), a human herpesvirus associated with several lymphoproliferative disorders in man, induces expression of alpha(v) integrins on transformed B lymphocytes. In the studies reported here, we show that EBV infection increases alpha(v), beta(3) and beta(5) integrin subunit mRNAs as well as upregulates the expression of the alpha(v)beta(3) integrin protein on human B cells. Among the nine different EBV proteins expressed in latently infected B cells (nuclear and plasma membrane-associated), only LMP1, LMP2A and EBNA2 were shown to selectively transactivate the alpha(v) integrin promoter. Treatment of EBV-transformed B cells with alpha(v) antisense oligonucleotides specifically reduced cell surface expression of alpha(v) integrins, inhibited cell growth in low serum, reduced cell invasion in matrigels and decreased expression of metalloprotease, MMP9, These studies indicate that alpha(v) integrins play a significant role in EBV-induced B-lymphocyte proliferation and invasion. Strategies to interfere with alpha(v) integrin expression and/or function may therefore be of potential value in the treatment of EBV-associated lymphoproliferative disorders.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute	Nemerow, GR (corresponding author), Scripps Res Inst, Dept Immunol, IMM19,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054352] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54352] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1990, CANCER RES, V50, P6757; Brooks PC, 1997, J CLIN INVEST, V99, P1390, DOI 10.1172/JCI119298; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; BUSK M, 1992, J BIOL CHEM, V267, P5790; CHARO IF, 1990, J CELL BIOL, V111, P2795, DOI 10.1083/jcb.111.6.2795; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; DONAHUE JP, 1994, BBA-GENE STRUCT EXPR, V1219, P228, DOI 10.1016/0167-4781(94)90278-X; Eliopoulos AG, 1998, CURR BIOL, V8, pR196, DOI 10.1016/S0960-9822(98)70123-X; EPSTEIN MA, 1973, LANCET, V2, P836; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; HENLE W, 1967, J NATL CANCER I, V43, P1147; Huang S, 1996, J VIROL, V70, P4502, DOI 10.1128/JVI.70.7.4502-4508.1996; Huang S, 1997, P NATL ACAD SCI USA, V94, P8156, DOI 10.1073/pnas.94.15.8156; HUANG SA, 1995, J VIROL, V69, P2257, DOI 10.1128/JVI.69.4.2257-2263.1995; HUANG SA, 1994, J BIOL CHEM, V269, P28764; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Kieff E., 1996, FIELDS VIROLOGY, P2343; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; NIP J, 1995, J CLIN INVEST, V95, P2096, DOI 10.1172/JCI117897; POPE JH, 1967, NATURE, V216, P810, DOI 10.1038/216810a0; PYTELA R, 1985, P NATL ACAD SCI USA, V82, P5766, DOI 10.1073/pnas.82.17.5766; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; SMITH JW, 1990, J BIOL CHEM, V265, P2168; SMITH JW, 1990, J BIOL CHEM, V265, P11008; STUPACK DG, 1991, SCAND J IMMUNOL, V34, P761, DOI 10.1111/j.1365-3083.1991.tb01601.x; STUPACK DG, 1992, EXP CELL RES, V203, P443, DOI 10.1016/0014-4827(92)90019-5; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WILKINS JA, 1983, J IMMUNOL, V131, P298; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Yoshizaki T, 1998, P NATL ACAD SCI USA, V95, P3621, DOI 10.1073/pnas.95.7.3621; ZHANG ZH, 1993, J CELL BIOL, V122, P235, DOI 10.1083/jcb.122.1.235	32	35	37	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2000	19	15					1915	1923		10.1038/sj.onc.1203509	http://dx.doi.org/10.1038/sj.onc.1203509			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	303LX	10773881				2022-12-17	WOS:000086424300007
J	Kashuba, E; Kashuba, V; Pokrovskaja, K; Klein, G; Szekely, L				Kashuba, E; Kashuba, V; Pokrovskaja, K; Klein, G; Szekely, L			Epstein-Barr virus encoded nuclear protein EBNA-3 binds XAP-2, a protein associated with Hepatitis B virus X antigen	ONCOGENE			English	Article						EBNA-3; Xap-2; HBV	ARYL-HYDROCARBON RECEPTOR; RBP-J-KAPPA; GROWTH TRANSFORMATION; BURKITT-LYMPHOMA; EXPRESSION; LYMPHOCYTES; INTERACT; 3A	EBNA-3 (also called EBNA-3A) is one of the EBV encoded nuclear antigens that are necessary for B-cell transformation, EBNA-3 is known to target RBPs, nuclear proteins that also interacts with EBNA-2, EBNA-4 and EBNA-6, In order to identify additional EBNA-3 targets, an EBV-transformed human lymphocyte cDNA library was screened in the yeast two-hybrid system with N-terminus truncated EBNA-3 that cannot interact with RBP-J kappa, A clone, encoding Xap-2 protein, a cellular partner of Hepatitis B virus X-antigen was isolated. This protein is also known as the p38 subunit of the aryl hydrocarbon receptor complex (ARA9), The specific binding to EBNA-3 was confirmed by showing that the GST-Xap-2 precipitated EBNA-3 from CV1 cells that were infected with recombinant vaccinia virus expressing EBNA-3, Deletion of the C-terminus of Xap-2 eliminated the binding. Fusion with green fluorescent protein showed that Xap-2 is preferentially cytoplasmic but translocates to the nucleus upon expression of EBNA-3.	Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Szekely, L (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden.		Kashuba, Elena/Q-4739-2019; Kashuba, Vladimir I/N-3732-2017; Kashuba, Elena/O-5389-2015; Szekely, Laszlo/B-1268-2009; Kashuba, Vladimir/AAO-7742-2020	Kashuba, Elena/0000-0001-7001-4035; Kashuba, Vladimir I/0000-0001-9416-8282; Kashuba, Elena/0000-0001-7001-4035; Pokrovskaja Tamm, Katja/0000-0001-6359-1256; Szekely, Laszlo/0000-0001-6144-6573				ALLDAY MJ, 1993, J GEN VIROL, V74, P361, DOI 10.1099/0022-1317-74-3-361; Carver LA, 1997, J BIOL CHEM, V272, P11452; Carver LA, 1998, J BIOL CHEM, V273, P33580, DOI 10.1074/jbc.273.50.33580; GAVIOLI R, 1992, P NATL ACAD SCI USA, V89, P5862, DOI 10.1073/pnas.89.13.5862; Hahn ME, 1997, P NATL ACAD SCI USA, V94, P13743, DOI 10.1073/pnas.94.25.13743; Johannsen E, 1996, J VIROL, V70, P4179, DOI 10.1128/JVI.70.6.4179-4183.1996; KAISE C, 1994, COLD SPRING HARBOR L, P171; Kashuba E, 1999, J HUMAN VIROL, V2, P33; Kobayashi A, 1997, J BIOCHEM, V122, P703; Krauer KG, 1996, VIROLOGY, V226, P346, DOI 10.1006/viro.1996.0662; Krauer KG, 1998, VIROLOGY, V252, P418, DOI 10.1006/viro.1998.9441; Kuzhandaivelu N, 1996, NUCLEIC ACIDS RES, V24, P4741, DOI 10.1093/nar/24.23.4741; Meyer BK, 1998, MOL CELL BIOL, V18, P978, DOI 10.1128/MCB.18.2.978; Radkov SA, 1997, J VIROL, V71, P8552, DOI 10.1128/JVI.71.11.8552-8562.1997; Robertson ES, 1996, J VIROL, V70, P3068, DOI 10.1128/JVI.70.5.3068-3074.1996; Strobl LJ, 1997, IMMUNOBIOLOGY, V198, P299, DOI 10.1016/S0171-2985(97)80050-2; Szekely L, 1998, J GEN VIROL, V79, P1445, DOI 10.1099/0022-1317-79-6-1445; Szekely L, 1997, CELL GROWTH DIFFER, V8, P599; Szekely L, 1996, J VIROL, V70, P2562, DOI 10.1128/JVI.70.4.2562-2568.1996; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Vaziri C, 1997, J BIOL CHEM, V272, P2762, DOI 10.1074/jbc.272.5.2762; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; Yamaguchi K, 1997, J IMMUNOL, V158, P2165; Zhao B, 1996, J VIROL, V70, P4228, DOI 10.1128/JVI.70.7.4228-4236.1996	24	35	37	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 30	2000	19	14					1801	1806		10.1038/sj.onc.1203501	http://dx.doi.org/10.1038/sj.onc.1203501			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301DG	10777214	Bronze			2022-12-17	WOS:000086292500008
J	Zenklusen, JC; Hodges, LC; LaCava, M; Green, ED; Conti, CJ				Zenklusen, JC; Hodges, LC; LaCava, M; Green, ED; Conti, CJ			Definitive functional evidence for a tumor suppressor gene on human chromosome 7q31.1 neighboring the Fra7G site	ONCOGENE			English	Article						human chromosome 7; prostate carcinoma; tumor suppressor gene; microcell fusion; tumorigenesis	COMMONLY DELETED REGION; PRIMARY BREAST-CANCER; LONG ARM; SQUAMOUS-CELL; FREQUENT LOSS; HETEROZYGOSITY; HUMAN-CHROMOSOME-7; CARCINOMAS; ADENOCARCINOMA; TUMORIGENICITY	We have previously shown that loss of heterozygosity (LOH) on human chromosome (hchr) 7 at q31.1 is common in a variety of tumors of epithelial origin. Frequent LOH of a specific chromosomal marker is indicative of a closely linked tumor suppressor gene (TSG). However, recent reports have also indicated that such a high frequency of LOH could be due to the presence in this region of the second most common aphidicolin-inducible fragile site in the human genome (Fra7G), To address this controversy, we introduced single copies of hchr7 or hchr12 into a highly aggressive human prostate carcinoma cell line (PC3) by microcell-mediated transfer. The tumorigenicity of six clones of PC3/hchr7 hybrids and three clones of PCRhchr12 hybrids, obtained in four separate fusion experiments, were studied in BALB/c nude mice. All but one of the PC3/hchr7 hybrids increased tumor latency by at least twofold, whereas none of the PC3/hchr12 hybrids delayed tumor onset. No differences in the in vitro growth rate Here observed among any of the cell lines assayed (parental and hybrids) suggesting that the observed tumor suppression was due to factors other than cell cycle regulation. Deletion mapping of the PC3/hchr7 tumors obtained after reversion to the malignant phenotype revealed a common region of loss centred around 7q31.1, supporting the TSG hypothesis. The smallest commonly deleted region was similar to 1.5 Mb in size and flanked by the markers D7S486 and D7S655.	Natl Human Genome Res Inst, Genome Technol Branch, NIH, Bethesda, MD 20982 USA; Univ Texas, MD Anderson Canc Ctr, Div Sci Pk Res, Smithville, TX 78957 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Texas System; UTMD Anderson Cancer Center	Zenklusen, JC (corresponding author), Natl Human Genome Res Inst, Genome Technol Branch, NIH, 49 Convent Dr,Room 2C28, Bethesda, MD 20982 USA.							Achille A, 1996, CANCER RES, V56, P3808; BIECHE I, 1992, LANCET, V339, P139, DOI 10.1016/0140-6736(92)90208-K; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cunningham JM, 1996, CANCER RES, V56, P4475; EWING CM, 1995, CANCER RES, V55, P4813; Gupta PK, 1997, CANCER RES, V57, P1188; Huang HJ, 1998, GENE CHROMOSOME CANC, V21, P152, DOI 10.1002/(SICI)1098-2264(199802)21:2<152::AID-GCC11>3.0.CO;2-T; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Huebner K, 1997, BBA-REV CANCER, V1332, pM65, DOI 10.1016/S0304-419X(97)00009-7; Kaighn M E, 1978, Natl Cancer Inst Monogr, P17; Koike M, 1997, GENE CHROMOSOME CANC, V19, P1, DOI 10.1002/(SICI)1098-2264(199705)19:1<1::AID-GCC1>3.0.CO;2-3; KUNIYASU H, 1994, INT J CANCER, V59, P597, DOI 10.1002/ijc.2910590504; Matsuda T, 1997, ONCOGENE, V15, P2773, DOI 10.1038/sj.onc.1201461; NEUMAN WL, 1992, BLOOD, V79, P1501; Nishizuka S, 1997, BRIT J CANCER, V76, P1567, DOI 10.1038/bjc.1997.598; OAKAHASHI S, 1995, CANCER RES, V55, P4114; OGATA T, 1993, MOL CELL BIOL, V13, P6036, DOI 10.1128/MCB.13.10.6036; Sanchez Y, 1996, P NATL ACAD SCI USA, V93, P2551, DOI 10.1073/pnas.93.6.2551; Shridhar V, 1997, ONCOGENE, V15, P2727, DOI 10.1038/sj.onc.1201448; Szeles A, 1997, GENE CHROMOSOME CANC, V20, P329; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Zar JH, 1996, BIOSTAT ANAL, P162; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; Zenklusen JC, 1996, MOL CARCINOGEN, V15, P167; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; ZENKLUSEN JC, 1994, P NATL ACAD SCI USA, V91, P12155, DOI 10.1073/pnas.91.25.12155; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen Jean C., 1999, Neoplasia (New York), V1, P16, DOI 10.1038/sj.neo.7900011	29	35	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 23	2000	19	13					1729	1733		10.1038/sj.onc.1203488	http://dx.doi.org/10.1038/sj.onc.1203488			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	297LG	10763831				2022-12-17	WOS:000086083800014
J	Rose-Hellekant, TA; Sandgren, EP				Rose-Hellekant, TA; Sandgren, EP			Transforming growth factor alpha- and c-myc-induced mammary carcinogenesis in transgenic mice	ONCOGENE			English	Article						c-myc; mammary cancer; transforming growth factor alpha; transgenic mice	ACIDIC PROTEIN GENE; TGF-ALPHA; EPITHELIAL-CELLS; MOUSE MAMMARY; SYNERGISTIC INTERACTION; INDUCED TUMORIGENESIS; HA-RAS; EXPRESSION; GLAND; BREAST	The growth factor transforming growth factor alpha (TGF alpha) and the nuclear transcription factor c-myc often are overexpressed by human breast canter cells. To produce models of breast disease with these etiologies, mice were generated that carried TGF-alpha- or c-myc-encoding transgenes. Transgene targeting employed the whey acidic protein (WAP) gene promoter, which is expressed in pregnant and lactating mammary epithelial cells. Non-virgin WAP-TGF alpha transgenic mice displayed accelerated mammary development during pregnancy, delayed post-parturient mammary involution, a progressive increase in the number of hyperplastic alveolar nodules (HANs), and development of mammary carcinoma with a mean latency of 9 months. Non-virgin WAP-c-myc transgenic mice displayed accelerated mammary gland development during pregnancy and development of mammary carcinomas with a latency of 8 months, Bitransgenic mice carrying both WAP-TGF alpha and WAP-c-myc displayed a dramatic acceleration of tumor development. These models identify the overexpression of TGF alpha or c-myc as etiological factors in the development of mammary neoplasia and demonstrate the increased severity of disease when both molecular alterations are present in the same cell.	Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Sandgren, EP (corresponding author), Univ Wisconsin, Sch Vet Med, Dept Pathobiol Sci, 2015 Linden Dr W, Madison, WI 53706 USA.				NCI NIH HHS [R01-CA64843] Funding Source: Medline; NCRR NIH HHS [K01-RR00145] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064843] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [K01RR000145] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMUNDADOTTIR LT, 1995, CELL GROWTH DIFFER, V6, P737; Amundadottir LT, 1996, ONCOGENE, V13, P757; ANDRES AC, 1988, GENE DEV, V2, P1486, DOI 10.1101/gad.2.11.1486; BAYNA EM, 1990, NUCLEIC ACIDS RES, V18, P2977, DOI 10.1093/nar/18.10.2977; Berns EMJJ, 1996, GENE CHROMOSOME CANC, V16, P170, DOI 10.1002/(SICI)1098-2264(199607)16:3<170::AID-GCC3>3.0.CO;2-W; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Christensen ME, 1996, HISTOCHEM CELL BIOL, V105, P391, DOI 10.1007/BF01463660; Davies BR, 1999, AM J PATHOL, V155, P303, DOI 10.1016/S0002-9440(10)65124-3; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; DERYNCK R, 1992, ADV CANCER RES, V58, P27, DOI 10.1016/S0065-230X(08)60289-4; DUBIK D, 1996, MAMMARY TUMOR CELL C, P171; HALTER SA, 1992, AM J PATHOL, V140, P1131; Jager R, 1997, ONCOGENE, V15, P1787, DOI 10.1038/sj.onc.1201353; JHAPPAN C, 1990, CELL, V61, P1121; KUMAR V, 1995, CELL BIOL INT, V19, P373, DOI 10.1006/cbir.1995.1083; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; Lee D C, 1992, Cancer Treat Res, V63, P233; LEE DC, 1995, PHARMACOL REV, V47, P51; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; McCormack SJ, 1998, ONCOGENE, V16, P2755, DOI 10.1038/sj.onc.1201804; Muller WJ, 1996, MOL CELL BIOL, V16, P5726; Nass SJ, 1997, BREAST CANCER RES TR, V44, P1, DOI 10.1023/A:1005858611585; PITTIUS CW, 1988, MOL ENDOCRINOL, V2, P1027, DOI 10.1210/mend-2-11-1027; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Robinson GW, 1996, DEV DYNAM, V206, P159, DOI 10.1002/(SICI)1097-0177(199606)206:2<159::AID-AJA5>3.0.CO;2-H; Rudland PS, 1995, BIOMED PHARMACOTHER, V49, P389, DOI 10.1016/0753-3322(96)82676-X; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; Santarelli R, 1996, ONCOGENE, V12, P495; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SMITH GH, 1995, AM J PATHOL, V147, P1081; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	34	35	38	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2000	19	8			SI		1092	1096		10.1038/sj.onc.1203350	http://dx.doi.org/10.1038/sj.onc.1203350			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	292LT	10713695				2022-12-17	WOS:000085796400017
J	Ciesielski, MJ; Fenstermaker, RA				Ciesielski, MJ; Fenstermaker, RA			Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function	ONCOGENE			English	Article						epidermal growth factor receptor; glioma; intron; oncogene; phosphorylation; recombination	HUMAN GLIOBLASTOMA CELLS; CONFERS ENHANCED TUMORIGENICITY; EGF-RECEPTOR; TYROSINE KINASE; HUMAN GLIOMAS; MALIGNANT GLIOMAS; FACTOR-ALPHA; EXPRESSION; TRANSFORMATION; AMPLIFICATION	A number of epidermal growth factor receptor (EGFR) deletion mutants have been identified in gliomas, in which the EGFR gene is frequently amplified and rearranged. We have previously characterized the structure of a gene in A-172 human glioma cells that encodes a 190-kDa EGFR mutant with tandem duplication of the tyrosine kinase (TK) and calcium-mediated internalization (CAIN) domains, Here we describe a 185-kDa tandem duplication mutant (TDM) that is expressed in KE and A-1235 glioma cells, along with certain functional characteristics of the mutants. The corresponding transcripts in KE and A-1235 cells contain 1053 additional nucleotides representing an in-frame duplication of exons 18 through 25 which encode the entire TK region and a portion of the CAIN domain. As with duplication of the entire TK/CAIN region (exons 18-26) in A-172 cells, duplication of exons 18-25 is associated with a specific genomic rearrangement between flanking introns, Involved introns contain homology to recombination signal sequence (RSS) heptamers present in the V(D)J region of the T lymphocyte receptor gene. In defined medium, both oncogenic TDM are constitutively autophosphorylated and inefficiently downregulated, High-affinity binding is reduced in EGFR.TDM/18-26, although the t1/2 of receptor internalization is not prolonged.	New York State Dept Hlth, Roswell Pk Canc Inst, Dept Neurosurg, Buffalo, NY 14263 USA; SUNY Buffalo, Dept Neurosurg, Sch Med & Biomed Sci, Buffalo, NY 14260 USA	Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Fenstermaker, RA (corresponding author), New York State Dept Hlth, Roswell Pk Canc Inst, Dept Neurosurg, Elm & Carlton St, Buffalo, NY 14263 USA.				NCI NIH HHS [CA 16056-22] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016056] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; BIGNER SH, 1990, CANCER RES, V50, P8017; BLASBAND AJ, 1990, ONCOGENE, V5, P1213; CALLAGHAN T, 1993, ONCOGENE, V8, P2939; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; Chu CT, 1997, BIOCHEM J, V324, P855, DOI 10.1042/bj3240855; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Etienne MC, 1998, CLIN CANCER RES, V4, P2383; Fenstermaker RA, 1998, ONCOGENE, V16, P3435, DOI 10.1038/sj.onc.1202156; Frisa PS, 1996, CELL GROWTH DIFFER, V7, P223; HALEY JD, 1989, ONCOGENE, V4, P273; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUMPHREY PA, 1990, P NATL ACAD SCI USA, V87, P4207, DOI 10.1073/pnas.87.11.4207; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; HUMPHREY PA, 1988, CANCER RES, V48, P2231; LEHVASLAIHO H, 1989, EMBO J, V8, P159, DOI 10.1002/j.1460-2075.1989.tb03360.x; LIBERMANN TA, 1985, NATURE, V313, P144, DOI 10.1038/313144a0; LUNDJOHANSEN M, 1990, CANCER RES, V50, P6039; MARUNO M, 1991, J NEUROSURG, V75, P97, DOI 10.3171/jns.1991.75.1.0097; Montgomery RB, 1995, J BIOL CHEM, V270, P30562, DOI 10.1074/jbc.270.51.30562; Moscatello DK, 1996, ONCOGENE, V13, P85; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Nagane M, 1996, CANCER RES, V56, P5079; Nagane M, 1998, P NATL ACAD SCI USA, V95, P5724, DOI 10.1073/pnas.95.10.5724; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; ORourke DM, 1997, P NATL ACAD SCI USA, V94, P3250, DOI 10.1073/pnas.94.7.3250; PANNEERSELVAM K, 1995, EUR J BIOCHEM, V230, P951, DOI 10.1111/j.1432-1033.1995.tb20641.x; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; Roth DB, 1998, CELL, V94, P411, DOI 10.1016/S0092-8674(00)81580-9; SCHLEGEL J, 1994, INT J CANCER, V56, P72; STECK PA, 1988, CANCER RES, V48, P5433; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899	37	35	42	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					810	820		10.1038/sj.onc.1203409	http://dx.doi.org/10.1038/sj.onc.1203409			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698499				2022-12-17	WOS:000085192100011
J	Mattot, V; Vercamer, C; Soncin, F; Calmels, T; Huguet, C; Fafeur, V; Vandenbunder, B				Mattot, V; Vercamer, C; Soncin, F; Calmels, T; Huguet, C; Fafeur, V; Vandenbunder, B			Constitutive expression of the DNA-binding domain of Ets1 increases endothelial cell adhesion and stimulates their organization into capillary-like structures	ONCOGENE			English	Article						Ets; transcription factor; endothelial cells; adhesion; angiogenesis	TRANSCRIPTION FACTOR; PLASMINOGEN-ACTIVATOR; CHICK-EMBRYO; INTEGRIN ALPHA(V)BETA(3); EPITHELIAL-CELLS; GENE; DIFFERENTIATION; C-ETS-1; GROWTH; PROMOTER	We previously reported that the Ets1 transcription factor is expressed in endothelial cells during angiogenesis both in normal and pathological development. We analyse here the effects of the stable expression of an Ets transdominant negative mutant (Ets1-DB), consisting in an Ets1 protein lacking its transactivation domain. A retrovirus containing the Ets1-DB sequence fused to an IRES-Neo sequence was designed and used to infect brain capillary (IBE) and aorta (MAE) mouse endothelial cell hues, Cells expressing this Ets1 mutant were examined for proliferation, migration and adhesion, Consistent changes were observed on cell morphology, with increased spreading and modifications in the organization of the cytoskeleton, and increased cell adhesion. We investigated the ability of endothelial cells to organise into capillary-like structures using three-dimensional gels, On Matrigel, all endothelial cell lines formed a cord-like network within 24 h, with an increased ability of Ets1-DB cells to spread on this substrate. In long term cultures, IBE cells expressing Ets1-DB showed a higher capacity to form branched structures; this effect was potentiated by FGF2, These results demonstrate a role of the Ets transcription factors in the regulation of the adhesive and morphogenetic properties of endothelial cells.	Inst Pasteur, CNRS EP560, Inst Biol, F-59021 Lille, France	Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Vandenbunder, B (corresponding author), Inst Pasteur, CNRS EP560, Inst Biol, 1 Rue Calmette, F-59021 Lille, France.		Fafeur, Veronique/L-9072-2018; SONCIN, Fabrice/A-1475-2009	SONCIN, Fabrice/0000-0001-6312-0673				AUERBACH R, 1991, INT J RADIAT BIOL, V60, P1, DOI 10.1080/09553009114551401; Barton K, 1998, IMMUNITY, V9, P555, DOI 10.1016/S1074-7613(00)80638-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; BOLON I, 1995, AM J PATHOL, V147, P1298; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CHEN JH, 1990, ONCOGENE RES, V5, P277; Chen ZQ, 1997, CANCER RES, V57, P2013; CREPIEUX P, 1994, CRIT REV ONCOGENESIS, V5, P615; de Launoit Y, 1998, ONCOGENE, V16, P2065, DOI 10.1038/sj.onc.1201726; Delannoy-Courdent A, 1998, J CELL SCI, V111, P1521; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; Dube A, 1999, CIRC RES, V84, P1177, DOI 10.1161/01.RES.84.10.1177; Fafeur V, 1997, CELL GROWTH DIFFER, V8, P655; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; GHYSDAEL J, 1997, ONCOGENES TRANSCRIPT, P29; Gilles F, 1996, EXP CELL RES, V222, P370, DOI 10.1006/excr.1996.0046; Gory S, 1998, J BIOL CHEM, V273, P6750, DOI 10.1074/jbc.273.12.6750; GREVIN D, 1993, INT J DEV BIOL, V37, P519; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; Hierck BP, 1996, DEV DYNAM, V207, P89; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; KLEINSOYER C, 1986, THROMB HAEMOSTASIS, V56, P232; KRAMER RH, 1990, J CELL BIOL, V111, P1233, DOI 10.1083/jcb.111.3.1233; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Logan SK, 1996, J BIOL CHEM, V271, P774, DOI 10.1074/jbc.271.2.774; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Oda N, 1999, J CELL PHYSIOL, V178, P121, DOI 10.1002/(SICI)1097-4652(199902)178:2<121::AID-JCP1>3.3.CO;2-6; PARDANAUD L, 1993, CELL ADHES COMMUN, V1, P151, DOI 10.3109/15419069309095691; Remy P, 1996, INT J DEV BIOL, V40, P577; SAGE EH, 1991, J BIOL CHEM, V266, P14831; Sapi E, 1998, CANCER RES, V58, P1027; Sieweke MH, 1998, EMBO J, V17, P1728, DOI 10.1093/emboj/17.6.1728; SOUDANT N, 1994, NUCLEIC ACIDS RES, V22, P3871, DOI 10.1093/nar/22.19.3871; VANDENBUNDER B, 1989, DEVELOPMENT, V107, P265; VANDENBUNDER B, 1994, INVAS METAST, V14, P198; Wakiya K, 1996, J BIOL CHEM, V271, P30823, DOI 10.1074/jbc.271.48.30823; WASYLYK C, 1994, ONCOGENE, V9, P3665; WERNERT N, 1994, CANCER RES, V54, P5683; WERNERT N, 1992, AM J PATHOL, V140, P119	51	35	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 10	2000	19	6					762	772		10.1038/sj.onc.1203248	http://dx.doi.org/10.1038/sj.onc.1203248			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	281ZV	10698494				2022-12-17	WOS:000085192100006
J	Riedel, H; Yousaf, N; Zhao, YY; Dai, HP; Deng, YP; Wang, J				Riedel, H; Yousaf, N; Zhao, YY; Dai, HP; Deng, YP; Wang, J			PSM, a mediator of PDGF-BB-, IGF-I-, and insulin-stimulated mitogenesis	ONCOGENE			English	Article						SH2-B; growth factor; receptor tyrosine kinase; adapter; trojan peptide; malignant cell transformation	GROWTH-FACTOR-I; SH2 DOMAIN; PHOSPHATIDYLINOSITOL-3 KINASE; SIGNAL-TRANSDUCTION; TYROSINE KINASE; TRK RECEPTORS; PROTEINS; SYSTEM; CELLS; PHOSPHORYLATION	PSM/SH2-B has been described as a cellular partner of the Fc epsilon RI receptor, insulin receptor (IR), insulin-like growth factor-I (IGF-I) receptor (IGF-IR), and nerve growth factor receptor (TrkA). A function has been proposed in neuronal differentiation and development but its role in other signaling pathways is still unclear. To further elucidate the physiologic role of PSM we have identified additional mitogenic receptor tyrosine kinases as putative PSM partners including platelet-derived growth factor (PDGF) receptor (PDGFR) beta, hepatocyte growth factor receptor (Met), and fibroblast growth factor receptor. We have mapped Y740 as a site of PDGFR beta that is involved in the association with PSM. We have further investigated the putative role of PSM in mitogenesis with three independent experimental strategies and found that all consistently suggested a role as a positive, stimulatory signaling adapter in normal NIH3T3 and baby hamster kidney fibroblasts, (1) PSM expression from cDNA using an ecdysone-regulated transient expression system stimulated PDGF-BB-, IGF-I-, and insulin- but not EGF-induced DNA synthesis in an ecdysone dose-responsive fashion; (2) Microinjection of the (dominant negative) PSM SH2 domain interfered with PDGF-BB- and insulin-induced DNA synthesis; and (3) A peptide mimetic of the PSM Pro-rich putative SH3 domain-binding region interfered with PDGF-BB-, IGF-I-, and insulin- but not with EGF-induced DNA synthesis in NIH3T3 fibroblasts. This experiment was based on cell-permeable fusion peptides with the Drosophila antennapedia homeodomain which effectively traverse the plasma membrane of cultured cells, These experimental strategies independently suggest that PSM functions as a positive, stimulatory, mitogenic signaling mediator in PDGF-BB, IGF-I, and insulin but not in EGF action. This function appears to involve the PSM SH2 domain as well as the Pro-rich putative SH3 domain binding region. Our findings support the model that PSM participates as an adapter in carious mitogenic signaling mechanisms by linking an activated (receptor) phospho-tyrosine to the SH3 domain of an unknown cellular partner.	Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA	Wayne State University	Riedel, H (corresponding author), Wayne State Univ, Dept Biol Sci, 2171 BSB, Detroit, MI 48202 USA.			Deng, Youping/0000-0002-5951-8213	NCI NIH HHS [R01 CA77873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmed Z, 1999, BIOCHEM J, V341, P665, DOI 10.1042/0264-6021:3410665; BASERGA R, 1995, CANCER RES, V55, P249; Blakesley Vicky A., 1996, Cytokine and Growth Factor Reviews, V7, P153, DOI 10.1016/1359-6101(96)00015-9; BROWN SAN, 1993, BIOCHEM BIOPH RES CO, V193, P1116, DOI 10.1006/bbrc.1993.1741; Carter-Su C, 1998, RECENT PROG HORM RES, V53, P61; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; ClaessonWelsh L, 1996, INT J BIOCHEM CELL B, V28, P373, DOI 10.1016/1357-2725(95)00156-5; COOPER J, 1993, BIOL PLATELET DERIVE, P44; DeMali KA, 1997, J BIOL CHEM, V272, P9011; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; Gotoh N, 1995, ONCOGENE, V11, P2525; Hansen H, 1996, J BIOL CHEM, V271, P8882, DOI 10.1074/jbc.271.15.8882; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1993, BIOL PLATELET DERIVE, P1; Higaki M, 1996, J BIOL CHEM, V271, P29342, DOI 10.1074/jbc.271.46.29342; Hughes AD, 1996, GEN PHARMACOL-VASC S, V27, P1079, DOI 10.1016/S0306-3623(96)00060-2; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KAZLAUSKAS A, 1989, CELL, V58, P1121, DOI 10.1016/0092-8674(89)90510-2; Kotani K, 1998, BIOCHEM J, V335, P103, DOI 10.1042/bj3350103; MIURA M, 1995, CANCER RES, V55, P663; MIURA M, 1995, J BIOL CHEM, V270, P22639, DOI 10.1074/jbc.270.38.22639; Moodie SA, 1999, J BIOL CHEM, V274, P11186, DOI 10.1074/jbc.274.16.11186; MURAGAKI Y, 1995, J COMP NEUROL, V356, P387, DOI 10.1002/cne.903560306; MYERS MG, 1991, J BIOL CHEM, V266, P10616; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Northrop JP, 1996, MOL CELL BIOL, V16, P2255; OOI J, 1995, ONCOGENE, V10, P1621; OSBORNE MA, 1995, BIO-TECHNOL, V13, P1474, DOI 10.1038/nbt1295-1474; Prochiantz A, 1996, CURR OPIN NEUROBIOL, V6, P629, DOI 10.1016/S0959-4388(96)80095-X; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; Rankin S, 1996, J BIOL CHEM, V271, P7829, DOI 10.1074/jbc.271.13.7829; Riedel H, 1997, J BIOCHEM-TOKYO, V122, P1105; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; Rui LY, 1999, J BIOL CHEM, V274, P10590, DOI 10.1074/jbc.274.15.10590; Rui LY, 1999, J BIOL CHEM, V274, P26485, DOI 10.1074/jbc.274.37.26485; Rui LY, 1998, J BIOL CHEM, V273, P21239, DOI 10.1074/jbc.273.33.21239; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Rui LY, 1997, MOL CELL BIOL, V17, P6633, DOI 10.1128/MCB.17.11.6633; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wakioka T, 1999, LEUKEMIA, V13, P760, DOI 10.1038/sj.leu.2401397; Wang J, 1999, MOL CELL BIOL, V19, P6217; Wang J, 1998, J BIOL CHEM, V273, P3136, DOI 10.1074/jbc.273.6.3136; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WENNSTROM S, 1994, ONCOGENE, V9, P651; Williams EJ, 1997, J BIOL CHEM, V272, P22349, DOI 10.1074/jbc.272.35.22349; Yokouchi M, 1997, ONCOGENE, V15, P7, DOI 10.1038/sj.onc.1201163; Yokouchi M, 1999, ONCOGENE, V18, P759, DOI 10.1038/sj.onc.1202326; ZVIBEL I, 1985, INT J CANCER, V36, P261, DOI 10.1002/ijc.2910360220	53	35	36	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					39	50		10.1038/sj.onc.1203253	http://dx.doi.org/10.1038/sj.onc.1203253			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644978				2022-12-17	WOS:000084844300005
J	Suhasini, M; Pilz, RB				Suhasini, M; Pilz, RB			Transcriptional elongation of c-myb is regulated by NF-kappa B (p50/RelB)	ONCOGENE			English	Article						c-myb; NF-kappa B; transcriptional regulation; erythroid differentiation; murine erythroleukemia cells	ERYTHROLEUKEMIA CELL-DIFFERENTIATION; MESSENGER-RNA; UP-REGULATION; EXPRESSION; PROMOTER; BINDING; FAMILY; GENE; IDENTIFICATION; ONCOGENE	High levels of c-myb expression are necessary for the proliferation of hematopoietic precursor cells whereas do,vn-regulation of c-myb is required for terminal differentiation; this down-regulation occurs through a conditional block to transcriptional elongation in intron I, We previously observed that cAMP analogs prevented the late down-regulation of c-myb during hexamethylene bisacetamide (HMBA)-induced differentiation of murine erythroleukemia (MEL) cells and blocked differentiation; this correlated with the induction of NF-kappa B (p50/RelB) complexes which were shown to bind to NF-kappa B recognition sites flanking the transcriptional pause site of c-myb. We now selected stably-transfected MEL cells which overexpressed p50, RelB or both at levels similar to those induced by cAMP to determine whether these NF-kappa B proteins regulate c-myb expression in intact cells, We demonstrate that transcriptionally active NF-kappa B (p50/RelB) complexes, but not p50 or RelB alone, prevented the early and late down-regulation of c-myb mRNA and increased c-myb transcriptional elongation in HMBA-induced MEL cells. The increase in c-myb expression was sufficient to block erythroid differentiation and allow continuous proliferation of cells in the presence of HMBA, Steady-state c-myb mRNA levels in untreated cells were not affected by overexpression of NF-kappa B, suggesting that p50/RelB specifically modulated the efficiency of transcriptional attenuation during MEL cell differentiation.	Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA; Univ Calif San Diego, Ctr Canc, La Jolla, CA 92037 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Pilz, RB (corresponding author), Univ Calif San Diego, Dept Med, La Jolla, CA 92037 USA.				NIGMS NIH HHS [R01-GM55586] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055586] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAIL OL, 1993, EMBO J, V12, P5043; BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; CARACCIOLO D, 1990, J CLIN INVEST, V85, P55, DOI 10.1172/JCI114433; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COGSWELL PC, 1993, J IMMUNOL, V150, P2794; COPPOLA JA, 1989, MOL CELL BIOL, V9, P1714, DOI 10.1128/MCB.9.4.1714; DANISH R, 1992, ONCOGENE, V7, P901; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; Dooley S, 1996, LEUKEMIA RES, V20, P429, DOI 10.1016/0145-2126(96)00012-4; Gonda TJ, 1998, INT J BIOCHEM CELL B, V30, P547, DOI 10.1016/S1357-2725(98)00003-X; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; JACOBS SM, 1994, ONCOGENE, V9, P227; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MIYAMOTO S, 1995, ADV CANCER RES, V66, P255, DOI 10.1016/S0065-230X(08)60257-2; MOUNTZ JD, 1993, MOL IMMUNOL, V30, P787, DOI 10.1016/0161-5890(93)90001-R; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NICOLAIDES NC, 1992, J BIOL CHEM, V267, P19665; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Phan SC, 1996, MOL CELL BIOL, V16, P2387; PILZ RB, 1992, J BIOL CHEM, V267, P16161; REDDY CD, 1989, P NATL ACAD SCI USA, V86, P7326, DOI 10.1073/pnas.86.19.7326; RIFKIND RA, 1987, BLOOD CELLS, V13, P277; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Shain KH, 1999, J CELL BIOCHEM, V73, P237, DOI 10.1002/(SICI)1097-4644(19990501)73:2<237::AID-JCB10>3.0.CO;2-H; SOBIESZCZUK PW, 1989, NUCLEIC ACIDS RES, V17, P9593, DOI 10.1093/nar/17.23.9593; Suhasini M, 1997, ONCOGENE, V15, P1859, DOI 10.1038/sj.onc.1201530; Sullivan J, 1997, J BIOL CHEM, V272, P1943, DOI 10.1074/jbc.272.3.1943; TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TOTH CR, 1995, J BIOL CHEM, V270, P7661, DOI 10.1074/jbc.270.13.7661; VALTIERI M, 1991, BLOOD, V77, P1181; WANG LG, 1994, CELL GROWTH DIFFER, V5, P1243; Wang ZB, 1999, EMBO J, V18, P2218, DOI 10.1093/emboj/18.8.2218; WATSON RJ, 1988, ONCOGENE, V2, P267; WATSON RJ, 1988, MOL CELL BIOL, V8, P3938, DOI 10.1128/MCB.8.9.3938; Weih F, 1997, J EXP MED, V185, P1359, DOI 10.1084/jem.185.7.1359; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Zhang MY, 1998, BLOOD, V91, P4136, DOI 10.1182/blood.V91.11.4136.411k26_4136_4144	41	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 2	1999	18	51					7360	7369		10.1038/sj.onc.1203158	http://dx.doi.org/10.1038/sj.onc.1203158			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602492				2022-12-17	WOS:000084119400022
J	Quinlan, MP				Quinlan, MP			Rac regulates the stability of the adherens junction and its components, thus affecting epithelial cell differentiation and transformation	ONCOGENE			English	Article						adhesion; actin; cadherin; catenin; GTPase	ACTIN FILAMENT ORGANIZATION; CADHERIN-CATENIN COMPLEX; SMALL GTPASES; TUMOR PROGRESSION; ALPHA-CATENIN; MDCK CELLS; MOLECULAR-INTERACTIONS; INDEPENDENT PATHWAYS; PROTEIN INTERACTIONS; SIGNAL-TRANSDUCTION	We have previously reported that activated rac (V12rac) can bring about hypertransformation of ras-transformed epithelial cells, which can be suppressed by the dominant negative form of I ac (N17rac). Starting with primary epithelial cells, a series of cell lines expressing wild type (WT) or mutated forms of rns or rac were generated and analysed for their adhesive function and expression and association of adherens junction (AJ) proteins. Normal, primary epithelial cells were self-adhesive and expressed AJs that were very stable. The expression of constitutively active ras resulted in a decrease in, but not loss of, cell-cell adhesion, with concomitantly decreased stability of AJ components. This was extremely exacerbated by the co-expression of constitutively activate rac, but was suppressed by dominant negative rac, which resulted in increased cell-cell adhesion and extremely stable AJs. alpha-catenin also failed to associate,vith E-cadherin-beta-catenin complexes in cells expressing V12rac. Expression of V12rac resulted in the loss of epithelial morphology. The extent of transformation of each cell type corresponded to the stability of the respective AJ complexes. Thus, I ac seems to be involved in regulating the stability of AJs, which promote epithelial cell differentiation, and consequently, modulating tumor progression.	Univ Tennessee, Dept Microbiol & Immunol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Quinlan, MP (corresponding author), Univ Tennessee, Dept Microbiol & Immunol, 858 Madison Ave, Memphis, TN 38163 USA.							Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; BenZeev A, 1997, CURR OPIN CELL BIOL, V9, P99, DOI 10.1016/S0955-0674(97)80158-5; Birchmeier W, 1996, CURR TOP MICROBIOL, V213, P117; BIRCHMEIER W, 1995, CANCER SURV, V24, P129; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; del Peso L, 1997, ONCOGENE, V15, P3047; DOUGLAS JL, 1991, ONCOGENE, V6, P2093; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Fischer RS, 1998, VIROLOGY, V249, P427, DOI 10.1006/viro.1998.9337; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P209; Fischer RS, 1998, CELL GROWTH DIFFER, V9, P905; FRIXEN U, 1991, J CELL BIOL, V111, P173; Geiger B, 1995, ACTA ANAT, V154, P46; GOPALAKRISHNAN S, 1995, CELL GROWTH DIFFER, V6, P985; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hay ED, 1995, ACTA ANAT, V154, P8; HAY ED, 1995, AM J KIDNEY DIS, V26, P678, DOI 10.1016/0272-6386(95)90610-X; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Hynes RO, 1996, DEV BIOL, V180, P402, DOI 10.1006/dbio.1996.0314; Jankowski JA, 1997, J CLIN PATHOL-MOL PA, V50, P289; Janmey PA, 1998, PHYSIOL REV, V78, P763, DOI 10.1152/physrev.1998.78.3.763; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Kobayashi K, 1998, J BIOL CHEM, V273, P291, DOI 10.1074/jbc.273.1.291; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Li ZR, 1998, CANCER RES, V58, P4282; Macara IG, 1996, FASEB J, V10, P625, DOI 10.1096/fasebj.10.5.8621061; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Mareel M, 1997, J CELL PHYSIOL, V173, P271, DOI 10.1002/(SICI)1097-4652(199711)173:2<271::AID-JCP34>3.0.CO;2-G; MAREEL M, 1995, CANCER DETECT PREV, V19, P451; Marrs JA, 1996, INT REV CYTOL, V165, P159, DOI 10.1016/S0074-7696(08)62222-6; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pillay I, 1996, CELL GROWTH DIFFER, V7, P1487; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; QUI RG, 1995, NATURE, V374, P457; QUINLAN MP, 1988, MOL CELL BIOL, V8, P3191, DOI 10.1128/MCB.8.8.3191; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Roux P, 1997, CURR BIOL, V7, P629, DOI 10.1016/S0960-9822(06)00289-2; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Schoenenberger C A, 1991, Trends Cell Biol, V1, P87, DOI 10.1016/0962-8924(91)90035-8; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Steinberg MS, 1996, DEV BIOL, V180, P377, DOI 10.1006/dbio.1996.0312; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tanaka K, 1998, CURR OPIN CELL BIOL, V10, P112, DOI 10.1016/S0955-0674(98)80093-8; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Tsukatani Y, 1997, J CELL PHYSIOL, V173, P54, DOI 10.1002/(SICI)1097-4652(199710)173:1<54::AID-JCP7>3.3.CO;2-G; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vermeulen S, 1996, PATHOL RES PRACT, V192, P694, DOI 10.1016/S0344-0338(96)80091-4; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wittinghofer A, 1998, BIOL CHEM, V379, P933; Wojciak-Stothard B, 1998, J CELL PHYSIOL, V176, P150, DOI 10.1002/(SICI)1097-4652(199807)176:1<150::AID-JCP17>3.0.CO;2-B; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119; YONEMURA S, 1995, J CELL SCI, V108, P127; Zigmond SH, 1996, CURR OPIN CELL BIOL, V8, P66, DOI 10.1016/S0955-0674(96)80050-0; Zohn IM, 1998, ONCOGENE, V17, P1415, DOI 10.1038/sj.onc.1202181	86	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 11	1999	18	47					6434	6442		10.1038/sj.onc.1203026	http://dx.doi.org/10.1038/sj.onc.1203026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	256CW	10597245				2022-12-17	WOS:000083709200005
J	Meyer, KM; Hess, SM; Tlsty, TD; Leadon, SA				Meyer, KM; Hess, SM; Tlsty, TD; Leadon, SA			Human mammary epithelial cells exhibit a differential p53-mediated response following exposure to ionizing radiation or UV light	ONCOGENE			English	Article						p53; p21(WAF1); ionizing radiation; ultraviolet radiation; breast	CELLULAR TUMOR-ANTIGEN; IRRADIATED HUMAN FIBROBLASTS; NUCLEOTIDE EXCISION-REPAIR; CYCLE CHECKPOINT PATHWAY; WILD-TYPE P53; DNA-DAMAGE; ATAXIA-TELANGIECTASIA; PHOSPHORYLATION SITE; GAMMA-RADIATION; G(1) ARREST	The tumor suppressor protein, p53, plays a critical role as a transcriptional activator of downstream target genes involved in the cellular response to DNA damaging agents, We examined the cell cycle checkpoint response of human mammary epithelial cells (HMEC) and their isogenic fibroblast counterparts to ionizing (IR) and ultraviolet (UV) radiation, two genotoxic agents whose DNA damage response pathways involve p53, Using flow cytometric analysis, we found that both mortal and immortalized HMEC, which contain wild-type p53 sequence, do not exhibit a G1 arrest in response to IR, but show an intact G2 checkpoint. Supportive evidence from Western analyses revealed that there was neither an increase in p53 nor one of its downstream targets, p21(WAF1), in HMEC exposed to IR. In contrast, isogenic mammary fibroblasts arrest at the G1 checkpoint and induce the p53 and p21(WAF1) proteins following IR, By comparison, HMEC exposed to UV displayed an S phase arrest and induced the expression of p53 and p21(WAF1). Our results show that the cellular response to DNA damage depends on both the type of damage introduced into the DNA and the specific cell type.	Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Toxicol, Chapel Hill, NC 27599 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of California System; University of California San Francisco	Leadon, SA (corresponding author), Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA040453, R01CA062059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007126] Funding Source: NIH RePORTER; NCI NIH HHS [CA62059, CA40453] Funding Source: Medline; NIEHS NIH HHS [T32 ES07126] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; CANMAN CE, 1994, CANCER RES, V54, P5054; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Cistulli CA, 1998, CANCER RES, V58, P1993; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; FISCELLA M, 1993, ONCOGENE, V8, P1519; Ford JM, 1998, CANCER RES, V58, P599; FORD JM, 1995, P NATL ACAD SCI USA, V92, P8876, DOI 10.1073/pnas.92.19.8876; Gadbois DM, 1997, CANCER RES, V57, P3174; GIRINSKY T, 1995, CANCER RES, V55, P3726; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HARTMANN A, 1995, ONCOGENE, V10, P681; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KAUFMANN WK, 1994, MUTAT RES, V314, P67, DOI 10.1016/0921-8777(94)90062-0; KAUFMANN WK, 1995, CANCER RES, V55, P7; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Ljungman M, 1996, ONCOGENE, V13, P823; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; MCKINNON PJ, 1987, HUM GENET, V75, P197, DOI 10.1007/BF00281059; MEYN MS, 1995, CANCER RES, V55, P5991; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; NAMBA H, 1995, CANCER RES, V55, P2075; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Nigro JM, 1997, CANCER RES, V57, P3635; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666	47	35	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 14	1999	18	42					5795	5805		10.1038/sj.onc.1202977	http://dx.doi.org/10.1038/sj.onc.1202977			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245FG	10523860	Green Published			2022-12-17	WOS:000083095100008
J	Ameyar, M; Shatrov, V; Bouquet, C; Capoulade, C; Cai, ZZ; Stancou, R; Badie, C; Haddada, H; Chouaib, S				Ameyar, M; Shatrov, V; Bouquet, C; Capoulade, C; Cai, ZZ; Stancou, R; Badie, C; Haddada, H; Chouaib, S			Adenovirus-mediated transfer of wild-type p53 gene sensitizes TNF resistant MCF7 derivatives to the cytotoxic effect of this cytokine: relationship with c-myc and Rb	ONCOGENE			English	Article						TNF; p53; c-myc; Rb	TUMOR-NECROSIS-FACTOR; CYCLE CHECKPOINT PATHWAY; BREAST-CARCINOMA CELLS; RETINOBLASTOMA PROTEIN; IN-VIVO; TRANSCRIPTION FACTOR; SUPPRESSOR P53; GROWTH ARREST; FACTOR-ALPHA; BAX GENE	Tumor suppressor p53 is a nuclear transcription factor that blocks cell cycle progression and induces apoptosis, We have previously shown that the MCF7 resistance to the cytotoxic action of TNF correlates with p53 mutations. In the present study, we used a recombinant adenovirus carrying a wild-type p53 gene (Adwtp53) in order to investigate the effect of wt p53 transfer on modulation of cell resistance to the cytotoxic action of TNF. Our data indicate that infection of TNF resistant MCF7 cells (1001 and MCF7/Adr) with Adwtp53 resulted in the restoration of wt p53 expression and function as respectively revealed by the yeast assay and the induction of p53 inducible genes MDM2 and p21, Furthermore, the restoration of p53 function significantly sensitized TNF resistant cells to TNF cytotoxic action. This correlated with a significant don n-regulation of c-myc in both TNF-resistant cell lines and a decrease of Retinoblastoma protein (Rb) in 1001 clone. In contrast, the effect of p53 seems to be independent from Bcl-2 and Bax protein level regulation. The present study suggests that the combination of TNF and Adwtp53 may be a potential strategy to sensitize mutant p53 TNF-resistant tumors to the cytotoxic action of this cytokine.	Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France; Inst Gustave Roussy, INSERM, U362, F-94805 Villejuif, France; Inst Gustave Roussy, UMR 1598, F-94805 Villejuif, France; Inst Gustave Roussy, CNRS, UMR 1772, F-94805 Villejuif, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy	Chouaib, S (corresponding author), Inst Gustave Roussy, INSERM, U487, F-94805 Villejuif, France.		Badie, Christophe/L-5890-2019; Chouaib, Salem/F-7939-2016	Badie, Christophe/0000-0003-4572-5008				ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Cai ZZ, 1997, ONCOGENE, V15, P2817, DOI 10.1038/sj.onc.1201445; Caignard A, 1997, ONCOL REP, V4, P227; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; Chiarugi V, 1996, TUMORI, V82, P205; CHOUAIB S, 1991, IMMUNOL TODAY, V12, P141, DOI 10.1016/0167-5699(91)90076-6; Chouaib S, 1997, IMMUNOL TODAY, V18, P493, DOI 10.1016/S0167-5699(97)01115-8; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; FAIRCHILD CR, 1987, CANCER RES, V47, P5141; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Geley S, 1997, ONCOGENE, V15, P2429, DOI 10.1038/sj.onc.1201399; Gorospe M, 1996, CELL GROWTH DIFFER, V7, P1609; Gottlieb E, 1998, EMBO J, V17, P3587, DOI 10.1093/emboj/17.13.3587; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hainaut P, 1998, NUCLEIC ACIDS RES, V26, P205, DOI 10.1093/nar/26.1.205; HARPER JW, 1993, CELL, V75, P805; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; JAATTELA M, 1995, ONCOGENE, V10, P2297; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; JEOUNG DI, 1995, J BIOL CHEM, V270, P18367, DOI 10.1074/jbc.270.31.18367; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; LEJEUNE F, 1994, CIRC SHOCK, V43, P191; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; LopezMarure R, 1997, BIOCHEM BIOPH RES CO, V236, P819, DOI 10.1006/bbrc.1997.7056; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OPIPARI AW, 1992, J BIOL CHEM, V267, P12424; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Tan XQ, 1997, J BIOL CHEM, V272, P9613; VANHAESEBROECK B, 1993, ONCOGENE, V8, P1075; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989; ZYAD A, 1994, CANCER RES, V54, P825	56	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5464	5472		10.1038/sj.onc.1202919	http://dx.doi.org/10.1038/sj.onc.1202919			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498900				2022-12-17	WOS:000082718600011
J	Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Smulson, ME				Simbulan-Rosenthal, CM; Rosenthal, DS; Luo, RB; Smulson, ME			Poly(ADP-ribose) polymerase upregulates E2F-1 promoter activity and DNA pol alpha expression during early S phase	ONCOGENE			English	Article						PARP; E2F-1; DNA polymerase alpha; DNA replication; promoter activity; gene expression	ANTISENSE RNA EXPRESSION; TRANSCRIPTION FACTOR; CELL-CYCLE; GROWTH-REGULATION; PRIMASE COMPLEX; IN-VITRO; GENE; PROTEIN; REPLICATION; DIFFERENTIATION	E2F-1, a transcription factor implicated in the activation of genes required for S phase such as DNA pol alpha, is regulated by interactions with Rb and by cell-cycle dependent alterations in E2F-1 abundance. We have shown that depletion of poly(ADP-ribose) polymerase (PARP) by antisense RNA expression downregulates pol alpha and E2F-1 expression during early S phase. To examine the role of PARP in the regulation of pol alpha and E2F-1 gene expression, we utilized immortalized mouse fibroblasts derived from wild-type and PARP knockout (PARP-/-) mice as well as PARP-/- cells stably transfected with PARR cDNA [PARP-/-(+PARP)]. After release from serum deprivation, mild-type and PARP-/-(+PARP) cells, but not PARP-/- cells, exhibited a peak of cells in S phase by 16 h and had progressed through the cell cycle by 22 h, Whereas [H-3]thymidine incorporation remained negligible in PARP-/- cells, in vivo DNA replication maximized after 18 h in mild-type and PARP-/-(+PARP) cells, To investigate the effect of PARP on E2F-1 promoter activity, a construct containing the E2F-1 gene promoter fused to a luciferase reporter gene was transiently transfected into these cells, E2F-1 promoter activity in control and PARP-/-(+PARP) cells increased eightfold after 9 h, but not in PARP-/- cells. PARP-/- cells did not show the marked induction of E2F-1 expression during early S phase apparent in control and PARP-/-(+PARP) cells. RT-PCR analysis and pol alpha activity assays revealed the presence of pol alpha transcripts and a sixfold increase in activity in both wildtype and PARP-/- (+PARP) cells after 20 h, but not in PARP-/- cells. These results suggest that PARP plays a role in the induction of E2F-1 promoter activity, which then positively regulates both E2F-1 and pol alpha expression, when quiescent cells reenter the cell cycle upon recovery from aphidicolin exposure or removal of serum.	Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20007 USA	Georgetown University	Smulson, ME (corresponding author), Georgetown Univ, Sch Med, Dept Biochem & Mol Biol, Basic Sci Bldg,Room 351,3900 Reservoir Rd NW, Washington, DC 20007 USA.		Simbulan-Rosenthal, Cynthia M./W-8429-2019; Rosenthal, Dean S/J-2360-2014	Rosenthal, Dean/0000-0002-7624-0209	NCI NIH HHS [P01 CA74175, CA25344] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA074175] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKHATIB HM, 1987, P NATL ACAD SCI USA, V84, P1224, DOI 10.1073/pnas.84.5.1224; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BASERGA R, 1991, J CELL SCI, V98, P433; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; Butler AJ, 1999, MOL CELL BIOL, V19, P296; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; DING RC, 1994, CANCER RES, V54, P4627; DING RC, 1992, J BIOL CHEM, V267, P12804; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; Kannan P, 1999, NUCLEIC ACIDS RES, V27, P866, DOI 10.1093/nar/27.3.866; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; NEUMAN E, 1994, MOL CELL BIOL, V14, P6607, DOI 10.1128/MCB.14.10.6607; NEVINS JR, 1992, SCIENCE, V258, P424; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; Rawling JM, 1997, BIOCHEM J, V324, P249, DOI 10.1042/bj3240249; ROSENTHAL DS, 1995, J INVEST DERMATOL, V105, P38, DOI 10.1111/1523-1747.ep12312525; Shieh WM, 1998, J BIOL CHEM, V273, P30069, DOI 10.1074/jbc.273.46.30069; SIMBULAN CMG, 1993, J BIOL CHEM, V268, P93; Simbulan-Rosenthal CM, 1998, J BIOL CHEM, V273, P13703, DOI 10.1074/jbc.273.22.13703; Simbulan-Rosenthal CM, 1998, BIOCHEMISTRY-US, V37, P9363, DOI 10.1021/bi9731089; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; SMULSON ME, 1995, J BIOL CHEM, V270, P119, DOI 10.1074/jbc.270.1.119; SUKHORUKOV VL, 1994, J MEMBRANE BIOL, V142, P77; Tom TD, 1996, J CELL BIOCHEM, V63, P259, DOI 10.1002/(SICI)1097-4644(19961201)63:3<259::AID-JCB1>3.0.CO;2-W; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WONG SW, 1986, J BIOL CHEM, V261, P7958	35	35	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	1999	18	36					5015	5023		10.1038/sj.onc.1202900	http://dx.doi.org/10.1038/sj.onc.1202900			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	234RA	10490838				2022-12-17	WOS:000082497100001
J	Kurokawa, K; Tanaka, T; Kato, J				Kurokawa, K; Tanaka, T; Kato, J			p19(ARF) prevents G1 cyclin-dependent kinase activation by interacting with MDM2 and activating p53 in mouse fibroblasts	ONCOGENE			English	Article						p19(ARF); G1 cyclin-cdks; G1 arrest; MDM2; p53; p21(Cip1)	CELL-CYCLE; ONCOPROTEIN MDM2; TUMOR-SUPPRESSOR; CDK INHIBITORS; RETINOBLASTOMA PROTEIN; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; MAMMALIAN-CELLS; CANCER; PRODUCT	p19(ARF) encoded by the INK4a tumor suppressor gene locus functions upstream of p53 to induce cell cycle arrest, p19(ARF) can interact with MDM2 and p53 in cells ectopically overexpressing these three components, but the biochemical cascades from p19(ARF) to cell cycle arrest has not been fully elucidated, In this study, we generated stably transfected NIH3T3 cells that express exogenous p19(ARF); under the control of a heavy metal-inducible metalothionine promoter. Cells arrested in G1 by ectopically expressed p19(ARF) contained considerably reduced G1 cyclin dependent kinase (cdk2 and cdk4) activities, The expression of cyclin A (a regulatory subunit of cdk2) markedly decreased, while cyclin D1, the major cdk4 partner in fibroblasts, expressed at a slightly higher level and formed complexes with cdk2 and cdk6 in addition to cdk4. Induction of p19(ARF) activated p53 by increasing its stability; and allowed the expression of p21(Cip1) which bound to all of the cyclin D1-cdk complexes (cyclin D1-cdk2, -cdk4, and -cdk6) thereby inhibiting their kinase activities. p19(ARF) formed complexes with several cellular proteins including mouse MDM2. The majority of MDM2 was found in the complex with p19(ARF), while no p53 was detected in association with p19(ARF). Thus, we propose that p19(ARF) neutralizes MDM2 by sequestration from p53, which results in activation of p53, inhibition of G1 cyclin-cdk activities, and G1 arrest.	Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara 6300101, Japan	Nara Institute of Science & Technology	Kato, J (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, 8916-5 Takayama, Nara 6300101, Japan.		Kurokawa, Kazuo/E-9130-2013; Tanaka, Toshiaki/C-5567-2013; Shingakujyutsu, Kurokawaken/G-1378-2011	Kurokawa, Kazuo/0000-0003-3549-4795; Tanaka, Toshiaki/0000-0002-9448-1452; 				Brown DR, 1998, EMBO J, V17, P2513, DOI 10.1093/emboj/17.9.2513; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cook DM, 1996, ONCOGENE, V13, P1789; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; GOTTLIEB MT, 1996, BIOCHIM BIOPHYS ACTA, V1287, P77; Haber DA, 1997, CELL, V91, P555, DOI 10.1016/S0092-8674(00)80441-9; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LENG P, 1995, INT J ONCOL, V6, P251; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LUNA RMD, 1995, NATURE, V378, P203; MAO L, 1995, CANCER RES, V55, P2995; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEAFF RJ, 1995, CURR BIOL, V5, P28, DOI 10.1016/S0960-9822(95)00009-1; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STONE S, 1995, CANCER RES, V55, P2988; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	41	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 29	1999	18	17					2718	2727		10.1038/sj.onc.1202628	http://dx.doi.org/10.1038/sj.onc.1202628			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	193FH	10348346				2022-12-17	WOS:000080124900007
J	Mayer, T; Meyer, M; Janning, A; Schiedel, AC; Barnekow, A				Mayer, T; Meyer, M; Janning, A; Schiedel, AC; Barnekow, A			A mutant form of the rho protein can restore stress fibers and adhesion plaques in v-src transformed fibroblasts	ONCOGENE			English	Article						rho proteins; transformed fibroblasts; v-src	ROUS-SARCOMA VIRUS; INTRACELLULAR-LOCALIZATION; ACTIN CYTOSKELETON; TYROSINE KINASES; ONCOGENE PRODUCT; CELLS; PHOSPHORYLATION; GTPASES; FAMILY; SIGNAL	The organization of polymerized actin in the mammalian cell is regulated by several members of the rho family. Three rho proteins, cdc42, rac and rho act in a cascade to organize the intracellular actin cytoskeleton. Rho proteins are involved in the formation of actin stress fibers and adhesion plaques in fibroblasts. During transformation of mammalian cells by oncogenes the cytoskeleton is rearranged and stress fibers and adhesion plaques are disintegrated. In this paper we investigate the function of the rho protein in RR1022 rat fibroblasts transformed by the Rous sarcoma virus. Two activated mutants of the rho protein, rho G14V and rho Q63L, and a dominant negative mutant, rho N117I, were stably transfected into RR1022 cells. The resulting cell lines were analysed for the organization of polymerized actin and adhesion plaques. Cells expressing rho Q63L, but not rho wt, rho G14V or rho N117I, showed an altered morphology. These cells displayed a flat, fibroblast like shape when compared with the RR1022 ancestor cells. Immunofluorescence analyses revealed that actin stress fibers and adhesion plaques were rearranged in these cells. We conclude from these data that an active rho protein can restore elements of the actin cytoskeleton in transformed cells by overriding the tyrosine kinase phosphorylation induced by the pp60(v-src).	Muenster Univ, Dept Expt Tumorbiol, D-48149 Muenster, Germany		Mayer, T (corresponding author), Muenster Univ, Dept Expt Tumorbiol, Badestr 9, D-48149 Muenster, Germany.			Mayer, Thomas/0000-0001-6954-2287; Schiedel, Anke/0000-0002-8114-3139				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BARNEKOW A, 1987, COMP BIOCHEM PHYS B, V87, P663, DOI 10.1016/0305-0491(87)90371-3; BARNEKOW A, 1991, BEHRING I MITT, V8, P67; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; DECLUE JE, 1987, MOL CELL BIOL, V7, P371, DOI 10.1128/MCB.7.1.371; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; ERPEL T, 1995, CURR OPIN CELL BIOL, V7, P176, DOI 10.1016/0955-0674(95)80025-5; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FRAME MC, 1994, MOL BIOL CELL, V5, P1177, DOI 10.1091/mbc.5.11.1177; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HALL A, 1992, MOL BIOL CELL, V3, P475, DOI 10.1091/mbc.3.5.475; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HORVATH AR, 1990, ONCOGENE, V5, P1349; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; KELLIE S, 1986, J CELL SCI, V82, P129; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; Leung T, 1996, MOL CELL BIOL, V16, P5313; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; Matsui T, 1996, EMBO J, V15, P2208, DOI 10.1002/j.1460-2075.1996.tb00574.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; PASQUALE EB, 1986, P NATL ACAD SCI USA, V83, P5507, DOI 10.1073/pnas.83.15.5507; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RIDLEY AJ, 1994, EMBO J, V13, P2610; ROHRSCHNEIDER L, 1985, MOL CELL BIOL, V5, P3097, DOI 10.1128/MCB.5.11.3097; SCHIEDEL AC, 1995, FEBS LETT, V376, P113, DOI 10.1016/0014-5793(95)01258-0; Seabra MC, 1996, J BIOL CHEM, V271, P14398, DOI 10.1074/jbc.271.24.14398; SEFTON BM, 1981, CELL, V24, P165, DOI 10.1016/0092-8674(81)90512-2; SETTLEMAN J, 1992, NATURE, V359, P153, DOI 10.1038/359153a0; STOKER AW, 1986, J VIROL, V58, P876, DOI 10.1128/JVI.58.3.876-883.1986; STOSSEL TP, 1989, J BIOL CHEM, V264, P18261; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TROULIARIS S, 1995, J VIROL, V69, P6010, DOI 10.1128/JVI.69.10.6010-6020.1995; TURNER CE, 1991, J CELL BIOL, V115, P201, DOI 10.1083/jcb.115.1.201; WANG HCR, 1992, MOL BIOL CELL, V3, P1329, DOI 10.1091/mbc.3.12.1329; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WYKE AW, 1993, CELL GROWTH DIFFER, V4, P671; WYKE AW, 1995, CELL GROWTH DIFFER, V6, P1225	50	35	36	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 25	1999	18	12					2117	2128		10.1038/sj.onc.1202537	http://dx.doi.org/10.1038/sj.onc.1202537			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	179TX	10321736				2022-12-17	WOS:000079346200009
J	Davis, JN; Williams, BJ; Herron, JT; Galiano, FJ; Meyers, S				Davis, JN; Williams, BJ; Herron, JT; Galiano, FJ; Meyers, S			ETO-2, a new member of the ETO-family of nuclear proteins	ONCOGENE			English	Article						ETO family; MTG8; (8;21) translocation; nuclear; dimerization	ACUTE MYELOID-LEUKEMIA; DROSOPHILA SEGMENTATION GENE; T(8-21) FUSION PROTEIN; CORE-BINDING FACTOR; TRANSCRIPTIONAL REGULATION; MOLECULAR-CLONING; AML1 GENE; CELL-LINE; RUNT; IDENTIFICATION	The t(8;21) is associated with 12-15% of acute myelogenous leukemias of the M2 subtype, the translocation results in the fusion of two genes, AML1 (CBFA2) on chromosome 21 and ETO (MTG8) on chromosome 8, AML1 encodes a DNA binding factor; the ETO protein product is less well characterized, but is thought to be a transcription factor. Here we describe the isolation and characterization of ETO-2, a murine cDNA that encodes a new member of the ETO family of proteins. ETO-2 is 75% identical to murine ETO and shares very high sequence identities over four regions of the protein with ETO (domain I-III and zinc-finger). Northern analysis identifies ETO-2 transcripts in many of the murine tissues analysed and in the developing mouse embryo. ETO-2 is also expressed in myeloid and erythroid cell lines. We confirmed the nuclear localization of ETO-2 and demonstrated that domain III and the zinc-finger region are not required for nuclear localization. We further showed that a region within ETO, containing domain II, mediates dimerization among family members. This region is conserved in the oncoprotein AML-1/ETO. The recent identification of another ETO-like protein, myeloid translocation gene-related protein 1, together with the data presented here, demonstrates that at least three ETO proteins exist with the potential to form dimers in the cell nucleus.	Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Dept Urol, Shreveport, LA 71130 USA; Louisiana State Univ, Med Ctr, Feist Weiller Canc Ctr, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Meyers, S (corresponding author), Louisiana State Univ, Med Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA.				NATIONAL CANCER INSTITUTE [R29CA076186] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA76186] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1993, HEMATOL PATHOL, V7, P1; BAE SC, 1994, MOL CELL BIOL, V14, P3242, DOI 10.1128/MCB.14.5.3242; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DICKSTEIN R, 1996, CELL, V87, P137; ERICKSON P, 1992, BLOOD, V80, P1825; ERICKSON PF, 1994, CANCER RES, V54, P1782; Erickson PF, 1996, BLOOD, V88, P1813; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEINSTEIN PG, 1995, GENETICS, V140, P573; Frank R, 1995, ONCOGENE, V11, P2667; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; Hiebert SW, 1996, CURR TOP MICROBIOL, V211, P253; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; Hwang I, 1997, J IMMUNOL, V158, P1165; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; KAGOSHIMA H, 1993, TRENDS GENET, V9, P338, DOI 10.1016/0168-9525(93)90026-E; KANIA MA, 1990, GENE DEV, V4, P1701, DOI 10.1101/gad.4.10.1701; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; KOZU T, 1993, BLOOD, V82, P1270; Kozu Tomoko, 1997, Leukemia (Basingstoke), V11, P297; LEE JC, 1982, J IMMUNOL, V128, P2393; LENNY N, 1995, ONCOGENE, V11, P1761; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MELNIKOVA IN, 1993, J VIROL, V67, P2408, DOI 10.1128/JVI.67.4.2408-2411.1993; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Meyers S, 1995, CRIT REV EUKAR GENE, V5, P365, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.70; MEYERS S, 1993, MOL CELL BIOL, V13, P6336, DOI 10.1128/MCB.13.10.6336; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; OGAWA E, 1993, P NATL ACAD SCI USA, V90, P6859, DOI 10.1073/pnas.90.14.6859; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; ROWLEY JD, 1984, CANCER RES, V44, P3159; SELLS MA, 1995, GENE, V152, P187, DOI 10.1016/0378-1119(94)00685-L; Speck NA, 1995, CRIT REV EUKAR GENE, V5, P337, DOI 10.1615/CritRevEukarGeneExpr.v5.i3-4.60; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; WANG SW, 1993, MOL CELL BIOL, V13, P3324, DOI 10.1128/MCB.13.6.3324; WANG SW, 1992, MOL CELL BIOL, V12, P89, DOI 10.1128/MCB.12.1.89; WHEELER EF, 1987, MOL CELL BIOL, V7, P1673, DOI 10.1128/MCB.7.5.1673; Zeng CM, 1997, P NATL ACAD SCI USA, V94, P6746, DOI 10.1073/pnas.94.13.6746; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137	44	35	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 11	1999	18	6					1375	1383		10.1038/sj.onc.1202412	http://dx.doi.org/10.1038/sj.onc.1202412			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FW	10022820				2022-12-17	WOS:000078510900014
J	Plaza, S; Aumercier, M; Bailly, M; Dozier, C; Saule, S				Plaza, S; Aumercier, M; Bailly, M; Dozier, C; Saule, S			Involvement of poly(ADP-ribose)-polymerase in the Pax-6 gene regulation in neuroretina	ONCOGENE			English	Article						Pax-6; neuroretina; PARP; enhancer	HOMEOBOX-CONTAINING GENE; DNA-DAMAGE; ALVEOLAR RHABDOMYOSARCOMA; EYELESS GENE; P53 PROTEIN; IN-VITRO; POLYMERASE; QNR; TRANSCRIPTION; EXPRESSION	The quail Pax-6 gene is expressed from two promoters named P0 and P1. P0 promoter is under the control of a neuroretina-specific enhancer (EP), This enhancer activates the P0 promoter specifically in neuroretina cells and in a de developmental stage-dependent manner, The EP enhancer binds efficiently, as revealed by southwestern experiments, to a 110 kDa protein present in neuroretina cells but not in Quail Embryos Cells and Retinal Pigmented Epithelium which do not express the P0-initiated mRNAs, To study the role of p110 in Pax-6 regulation, we have purified the p110 from neuroretina cells extracts. Based on the peptide sequence of the purified protein, we have identified the p110 as the poly(ADP-ribose) polymerase (PARP). Using bandshift experiments and footprinting studies, we present evidence that PARP is a component of protein complexes bound to the EP enhancer that increases the on rate of the protein complex formation to DNA. Using PARP inhibitors (3AB and 6.5 Hphe), we show that these products are able to inhibit EP enhancer activity in neuroretina cells. Finally, we demonstrate that these inhibitors are able to decrease the expression of the P0-initiated mRNA in the MC29-infected RPE cells which, in contrast to the RPE cells, accumulated the PARP in response to v-myc expression, Our results suggest that PARP is involved in the Pax-6 regulation.	Inst Pasteur, Inst Biol, CNRS, F-59021 Lille, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille	Saule, S (corresponding author), Inst Pasteur, Inst Biol, CNRS, EP 560,BP 447,1 Rue Calmette, F-59021 Lille, France.		plaza, serge/F-5290-2015; DOZIER, Christine/P-1539-2014	Aumercier, Marc/0000-0002-0370-3452				BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Bruhn L, 1997, GENE DEV, V11, P640, DOI 10.1101/gad.11.5.640; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Calligaro DO, 1997, BIOORG MED CHEM LETT, V7, P25, DOI 10.1016/S0960-894X(96)00567-7; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHATTERJEE S, 1994, MOL CELL BIOCHEM, V138, P61, DOI 10.1007/BF00928444; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Dahl E, 1997, BIOESSAYS, V19, P755, DOI 10.1002/bies.950190905; DAVIS RJ, 1994, CANCER RES, V54, P2869; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; DEMURCIA G, 1991, BIOESSAYS, V13, P455, DOI 10.1002/bies.950130905; DEMURCIA G, 1994, TRENDS BIOCHEM SCI, V19, P172, DOI 10.1016/0968-0004(94)90280-1; DING RC, 1994, CANCER RES, V54, P4627; DOZIER C, 1993, CELL GROWTH DIFFER, V4, P281; FUJIWARA M, 1994, DIFFERENTIATION, V57, P31, DOI 10.1046/j.1432-0436.1994.5710031.x; GAILLARD C, 1994, SCIENCE, V264, P433, DOI 10.1126/science.8153633; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Glardon S, 1997, DEVELOPMENT, V124, P817; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; ITTEL ME, 1991, GENE, V102, P157, DOI 10.1016/0378-1119(91)90073-K; LARSON CJ, 1992, NUCLEIC ACIDS RES, V20, P3525, DOI 10.1093/nar/20.13.3525; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; MANSOURI A, 1996, CURR OPIN CELL BIOL, V8, P951; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; Meisterernst M, 1997, P NATL ACAD SCI USA, V94, P2261, DOI 10.1073/pnas.94.6.2261; MONCOLLIN V, 1990, NUCLEIC ACIDS RES, V18, P4817, DOI 10.1093/nar/18.16.4817; NESTERENKO MV, 1994, J BIOCHEM BIOPH METH, V28, P239, DOI 10.1016/0165-022X(94)90020-5; Nie J, 1998, FEBS LETT, V424, P27, DOI 10.1016/S0014-5793(98)00131-8; Oei S L, 1997, Rev Physiol Biochem Pharmacol, V131, P127; Oei SL, 1997, BIOCHEM BIOPH RES CO, V240, P108, DOI 10.1006/bbrc.1997.7621; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; PLAZA S, 1995, MOL CELL BIOL, V15, P3344; PLAZA S, 1995, MOL CELL BIOL, V15, P892; Prosser J, 1998, HUM MUTAT, V11, P93, DOI 10.1002/(SICI)1098-1004(1998)11:2<93::AID-HUMU1>3.0.CO;2-M; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; SASTRY SS, 1990, BIOCHEM BIOPH RES CO, V167, P842, DOI 10.1016/0006-291X(90)92102-6; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SMULSON M, 1994, BIOCHEMISTRY-US, V33, P6186, DOI 10.1021/bi00186a018; STEVNSNER T, 1994, NUCLEIC ACIDS RES, V22, P4620, DOI 10.1093/nar/22.22.4620; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Weltin D, 1997, INT J RADIAT BIOL, V72, P685, DOI 10.1080/095530097142843; WesierskaGadek J, 1996, BIOCHEM BIOPH RES CO, V224, P96, DOI 10.1006/bbrc.1996.0990	49	35	35	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 28	1999	18	4					1041	1051		10.1038/sj.onc.1202406	http://dx.doi.org/10.1038/sj.onc.1202406			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	165FT	10023680				2022-12-17	WOS:000078510600021
J	Yan, DH; Wen, Y; Spohn, B; Choubey, D; Gutterman, JU; Hung, MC				Yan, DH; Wen, Y; Spohn, B; Choubey, D; Gutterman, JU; Hung, MC			Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202	ONCOGENE			English	Article						p202; interferon-inducible protein; prostate cancer; PC-3; growth retardation; anchorage-independent growth	TUMOR-NECROSIS-FACTOR; CARCINOMA; TRANSCRIPTION; INHIBITION; EXPRESSION; ALPHA; LINES; GENE; DIFFERENTIATION; INTERLEUKIN-2	Interferons (IFNs) can exert cytostatic and immunomodulatory effects on carcinoma cells. In particular, growth inhibition of human prostate carcinoma by IFNs has been demonstrated both in vitro and in vivo. p202 is a 52 kd nuclear phosphoprotein known to be induced by IFNs. In this report, we showed that the expression of p202 was associated with an anti-proliferative effect on human prostate cancer cells. More importantly, cells that expressed p202 showed reduced ability to grow in soft-agar, indicating a loss of transformation phenotype. Our data suggest that p202 is a growth inhibitor gene in prostate cancer cells and its expression may also suppress transformation phenotype of prostate cancer cells.	Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Surg Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Cancer Ctr, Dept Mol Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Hung, MC (corresponding author), Univ Texas, MD Anderson Cancer Ctr, Dept Tumor Biol, 1515 Holcombe Blvd,Box 79, Houston, TX 77030 USA.		Hung, Mien-Chie/ABD-5911-2021; Choubey, Divaker/A-4771-2008	Hung, Mien-Chie/0000-0003-4317-4740; 	NATIONAL CANCER INSTITUTE [R29CA069031, R01CA058880] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58880, CA69031] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALKWILL FR, 1989, LANCET, V1, P1060; CARRENO V, 1987, LANCET, V2, P1086; Choubey D, 1996, EMBO J, V15, P5668, DOI 10.1002/j.1460-2075.1996.tb00951.x; CHOUBEY D, 1993, J INTERFERON RES, V13, P43, DOI 10.1089/jir.1993.13.43; Choubey D, 1997, ONCOGENE, V15, P291, DOI 10.1038/sj.onc.1201184; CHOUBEY D, 1995, J BIOL CHEM, V270, P6134, DOI 10.1074/jbc.270.11.6134; Choubey D, 1996, BIOCHEM BIOPH RES CO, V221, P396, DOI 10.1006/bbrc.1996.0607; Datta B, 1996, J BIOL CHEM, V271, P27544, DOI 10.1074/jbc.271.44.27544; Datta B, 1998, MOL CELL BIOL, V18, P1074, DOI 10.1128/MCB.18.2.1074; DAWSON MJ, 1995, IMMUNOGENETICS, V41, P40, DOI 10.1007/BF00188431; DeYoung KL, 1997, ONCOGENE, V15, P453, DOI 10.1038/sj.onc.1201206; FIDLER IJ, 1987, CANCER RES, V47, P2020; FIGLIN RA, 1993, SEMIN ONCOL, V20, P11; FRAKER DL, 1994, MELANOMA RES, V4, P27; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; KAIGHN ME, 1979, INVEST UROL, V17, P16; Lembo D, 1995, J BIOL REG HOMEOS AG, V9, P42; Lembo M, 1998, ONCOGENE, V16, P1543, DOI 10.1038/sj.onc.1201677; LENGYEL P, 1995, SEMIN VIROL, V6, P203, DOI 10.1006/smvy.1995.0025; Min W, 1996, MOL CELL BIOL, V16, P359; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.bi.56.070187.003455; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; SEN GC, 1992, J BIOL CHEM, V267, P5017; SICA G, 1989, UROL RES, V17, P111; Sokoloff MH, 1996, CANCER-AM CANCER SOC, V77, P1862; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; TRAPANI JA, 1994, IMMUNOGENETICS, V40, P415; VANMOORSELAAR RJA, 1991, PROSTATE, V18, P331, DOI 10.1002/pros.2990180407; vonEschenbach A, 1997, CA-CANCER J CLIN, V47, P261, DOI 10.3322/canjclin.47.5.261; YU DH, 1993, CANCER RES, V53, P891	30	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 21	1999	18	3					807	811		10.1038/sj.onc.1202369	http://dx.doi.org/10.1038/sj.onc.1202369			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163FW	9989832				2022-12-17	WOS:000078394400027
J	Jeffers, M; Koochekpour, S; Fiscella, M; Sathyanarayana, BK; Vande Woude, GF				Jeffers, M; Koochekpour, S; Fiscella, M; Sathyanarayana, BK; Vande Woude, GF			Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor	ONCOGENE			English	Article						Met; oncogene; signaling	HEPATOCYTE GROWTH-FACTOR; GRB2 BINDING-SITE; SCATTER FACTOR; EPITHELIAL-CELLS; TRANSFORMING ACTIVITY; FACTOR/SCATTER FACTOR; CARBOXY-TERMINUS; PROTOONCOGENE; MUTATIONS; GENE	The Met tyrosine kinase receptor has been implicated in human cancer. Here we have examined the signaling requirements of three oncogenic forms of this molecule: wild type Met in response to ligand/autocrine stimulation, Met which has been mutationally activated, and Tpr-Met (a constitutively active truncated Met fusion protein). Previous studies have demonstrated the importance of a Grb2 binding site, and of specific tyrosine residues (i.e. Y8,9 and Y14,15) for Met function, and we have now explored the relevance of these and other sites for oncogenic Met signaling. Following substitution of various intracellular tyrosines for phenylalanine, we find that the transforming activity of each Met oncogene is dependent upon tyrosines Y8,9 and Y14,15, in addition to two novel tyrosines (Y6 and Y10) not previously implicated in Met signaling. Tyrosines Y6 and Y10 influence a variety of Met-mediated responses both in vitro (transformation, mitogenicity and invasion), and in vivo (tumorigenicity and metastasis). We also show that Tpr-Met is much more dependent on its Grb2 binding site for biological activity than are the other oncogenic forms of the Met receptor. Thus, although the three Met oncogenes examined are similar in their dependency on a number of specific tyrosines for activity, the signaling strategy employed by Tpr-Met can be differentiated from that of the other two.	NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vande Woude, GF (corresponding author), NCI, ABL Basic Res Program, Frederick Canc Res & Dev Ctr, POB B, Ft Detrick, MD 21702 USA.			KOOCHEKPOUR, SHAHRIAR/0000-0001-6649-5788				ALBINI A, 1987, CANCER RES, V47, P3239; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FANTL WJ, 1989, MOL CELL BIOL, V9, P4473, DOI 10.1128/MCB.9.10.4473; FIXMAN ED, 1995, ONCOGENE, V10, P237; Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Fourier TM, 1996, J BIOL CHEM, V271, P22211, DOI 10.1074/jbc.271.36.22211; Giordano S, 1997, P NATL ACAD SCI USA, V94, P13868, DOI 10.1073/pnas.94.25.13868; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; Higashio K, 1993, EXS, V65, P351; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Iwashita T, 1996, ONCOGENE, V12, P481; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, CELL GROWTH DIFFER, V7, P1805; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Jeffers M, 1996, ONCOGENE, V13, P853; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Kamikura DM, 1996, BIOCHEMISTRY-US, V35, P1010, DOI 10.1021/bi9514065; KANDA H, 1993, ONCOGENE, V8, P3047; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Maina F, 1996, CELL, V87, P531, DOI 10.1016/S0092-8674(00)81372-0; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RODRIGUES GA, 1994, ONCOGENE, V9, P2019; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sambrook J, 1989, MOL CLONING LAB MANU; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145	62	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2691	2700		10.1038/sj.onc.1202209	http://dx.doi.org/10.1038/sj.onc.1202209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840933				2022-12-17	WOS:000077146700002
J	Wagner, KU; Dierisseau, P; Rucker, EB; Robinson, GW; Hennighausen, L				Wagner, KU; Dierisseau, P; Rucker, EB; Robinson, GW; Hennighausen, L			Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: Common types of shorter transcripts are true alternative splice variants	ONCOGENE			English	Article						TSG101 protein; mice; human; genomic DNA; pseudogene; mammary gland	HUMAN BREAST-CANCER; MAMMARY-GLAND; PROTEIN; IDENTIFICATION; CHROMOSOME-11; TUMORIGENESIS; FAMILY; INT3	The functional inactivation of the tumor susceptibility gene tsg101 in mouse NIH3T3 cells leads to cell transformation and the formation of metastatic tumors in nude mice. We cloned, mapped and sequenced the mouse tsg101 gene and further identified a processed pseudogene that is 98% identical to the tsg101 cDNA. Based on Northern blot analysis, tsg101 is expressed ubiquitously in mouse tissues. A comparison of the coding region of the mouse tsg101 gene with the human TSG101 cDNA revealed that both the mouse and human gene encode ten additional highly conserved amino acids at the N-terminus. Based on the mouse tsg101 genomic structure, we predicted four additional introns within the human TSG101 gene. Their location was confirmed using PCR and sequencing analysis. The presence of these so far unidentified introns now explains published data on aberrantly spliced mRNA products that were frequently observed in primary breast tumors. We show that a majority of shorter TSG101 transcripts are not the result of aberrant splicing events, but represent a fraction of true alternative splice variants. Finally, we examined tsg101 expression patterns during different stages of mammary gland development and in different transgenic mouse models for breast tumorigenesis.	NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hennighausen, L (corresponding author), NIDDKD, Lab Genet & Physiol, NIH, Bldg 8,Room 101, Bethesda, MD 20892 USA.		Robinson, Gertraud/I-2136-2012; Wagner, Kay-Uwe/B-6044-2009	Wagner, Kay-Uwe/0000-0002-5081-0226; Hennighausen, Lothar/0000-0001-8319-9841	FDA HHS [369VFDK013712] Funding Source: Medline	FDA HHS		Aki T, 1997, J BIOCHEM, V122, P271; ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Gallahan D, 1997, ONCOGENE, V14, P1883, DOI 10.1038/sj.onc.1201035; Gallahan D, 1996, CANCER RES, V56, P1775; Gayther SA, 1997, ONCOGENE, V15, P2119, DOI 10.1038/sj.onc.1201591; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Hampl M, 1998, BIOCHEM BIOPH RES CO, V248, P753, DOI 10.1006/bbrc.1998.9038; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Li ML, 1996, CELL GROWTH DIFFER, V7, P3; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Ozon S, 1997, EUR J BIOCHEM, V248, P794, DOI 10.1111/j.1432-1033.1997.t01-2-00794.x; Ponting CP, 1997, J MOL MED-JMM, V75, P467; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; SANDGREN EP, 1995, CANCER RES, V55, P3915; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Sun ZJ, 1997, ONCOGENE, V15, P3121, DOI 10.1038/sj.onc.1201521; TZENG YJ, 1993, ONCOGENE, V8, P1965; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wang Q, 1998, ONCOGENE, V16, P677, DOI 10.1038/sj.onc.1201563; Watanabe M, 1998, BIOCHEM BIOPH RES CO, V245, P900, DOI 10.1006/bbrc.1998.8547; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Zhong Q, 1997, CANCER RES, V57, P4225	27	35	40	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 26	1998	17	21					2761	2770		10.1038/sj.onc.1202529	http://dx.doi.org/10.1038/sj.onc.1202529			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	141MA	9840940				2022-12-17	WOS:000077146700009
J	Kuo, ML; Shen, SC; Yang, CH; Chuang, SE; Cheng, AL; Huang, TS				Kuo, ML; Shen, SC; Yang, CH; Chuang, SE; Cheng, AL; Huang, TS			Bcl-2 prevents topoisomerase II inhibitor GL331-induced apoptosis is mediated by down-regulation of poly(ADP-ribose)polymerase activity	ONCOGENE			English	Article						Bcl-2; apoptosis; GL331; poly(ADP-ribose)polymerase	NICOTINAMIDE ADENINE-DINUCLEOTIDE; INTERLEUKIN-1-BETA CONVERTING-ENZYME; PROGRAMMED CELL-DEATH; CHINESE-HAMSTER CELLS; LEUKEMIA HL-60 CELLS; MITOCHONDRIAL PERMEABILITY; DNA FRAGMENTATION; ADP-RIBOSYLATION; POLYMERASE; ACTIVATION	Poly (ADP-ribose) polymerase (PARP), a nuclear enzyme responsible for DNA strand breaks, has been recently suggested to be crucial for apoptosis induced by a number chemotherapeutic drugs, In this study, we demonstrated that the PARP activity could be evidently elevated with a peak at 6 h when HL-60 cells were treated with a new anticancer drug GL331, Coincident with the peak of PARP activity, an apparent DNA fragmentation and apoptotic morphology were observed in cells treated with GL331. The subsequent apoptotic DNA fragmentation induced by GL331 could be completely blocked by transfecting cells with anti-sense PARP retroviral vector or by treating cells with PARP inhibitor, 3-aminobenzamide (3-AB). This blocking effect thus suggests that activation of PARP was critically involved in GL331-induced apoptosis, The fact that Bcl-2 has been found to antagonize cell death induced by a wide variety of agents, accounts for why we examined whether if Bcl-2 could antagonize GL331 effects, Interestingly, ectopic overexpression of Bcl-2 in either HL-60 or U937 cells caused in resistance towards GL331-elicited DNA fragmentation and cytotoxic effect. Additionally, Bcl-2 also attenuated the poly(ADP-ribosyl)ation of PARP itself as well as Histone H1 at the early period of drug treatment. However, Bcl-2 did not influence the extent of DNA strand breaks induced by GL331 in either control or Bcl-2-overexpressing cells. In addition, analysis of basal PARP activity in control and several Bcl-2 overexpressing clones revealed that Bcl-2 down-regulated PARP activity under the condition without DNA damages, Above findings suggest that poly(ADP-ribosyl)ation of nuclear targets is important for apoptosis induced by DNA-reactive anticancer drugs.	Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Ctr Canc Res, Dept Oncol, Taipei, Taiwan; Natl Hlth Res Inst, Canc Res Div, Cooperat Lab, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Health Research Institutes - Taiwan	Kuo, ML (corresponding author), Natl Taiwan Univ, Coll Med, Inst Toxicol, Lab Mol & Cellular Toxicol, Taipei, Taiwan.		Huang, Tze-Sing/E-3667-2010; Kuo, Min-Liang/C-4872-2009; Huang, Tze-Sing/C-9361-2013; Chuang, Shuang-En/D-2080-2010	Huang, Tze-Sing/0000-0001-8736-4330; Cheng, Ann-Lii/0000-0002-9152-6512; Yang, James Chih-Hsin/0000-0002-5586-5138; KUO, MIN-LIANG/0000-0002-7139-0144				ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; BENJAMIN RC, 1980, J BIOL CHEM, V255, P493; Bhatia M, 1996, CELL GROWTH DIFFER, V7, P91; CHU G, 1994, J BIOL CHEM, V269, P787; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; ELIOPOULOS AG, 1995, ONCOGENE, V11, P1217; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Eymin B, 1997, CANCER RES, V57, P686; Fabianek RA, 1997, J BIOL CHEM, V272, P4467, DOI 10.1074/jbc.272.7.4467; FAIRBAIRN LJ, 1994, MOL CARCINOGEN, V11, P49, DOI 10.1002/mc.2940110109; FERRO AM, 1984, J BIOL CHEM, V259, P547; FRITZ G, 1994, MUTAT RES, V308, P127, DOI 10.1016/0027-5107(94)90147-3; Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265; GU Y, 1995, J BIOL CHEM, V270, P18715, DOI 10.1074/jbc.270.32.18715; HAHN GM, 1973, RADIAT RES, V55, P280, DOI 10.2307/3573683; Huang TS, 1996, CANCER LETT, V110, P77, DOI 10.1016/S0304-3835(96)04464-3; HUANG TS, 1997, CANCER RES, V57, P2914; Hyde H, 1997, BLOOD, V89, P2453, DOI 10.1182/blood.V89.7.2453; Ibrado AM, 1996, CANCER RES, V56, P4743; IKEJIMA M, 1987, J BIOL CHEM, V262, P17641; Jacobson MD, 1997, CURR BIOL, V7, pR277, DOI 10.1016/S0960-9822(06)00136-9; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kuo ML, 1996, BBA-MOL BASIS DIS, V1317, P95, DOI 10.1016/S0925-4439(96)00032-4; Kyprianou N, 1997, INT J CANCER, V70, P341, DOI 10.1002/(SICI)1097-0215(19970127)70:3<341::AID-IJC16>3.0.CO;2-I; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lopes UG, 1997, J BIOL CHEM, V272, P12893, DOI 10.1074/jbc.272.20.12893; Marchetti P, 1996, J IMMUNOL, V157, P4830; Martins LM, 1997, J BIOL CHEM, V272, P7421, DOI 10.1074/jbc.272.11.7421; MASUTANI M, 1995, BIOCHIMIE, V77, P462, DOI 10.1016/0300-9084(96)88161-2; MEISTERERNST M, 1997, P NATL ACAD SCI USA, V75, P12; MEMON SA, 1995, J IMMUNOL, V155, P4644; MIYASHITA T, 1993, BLOOD, V81, P151; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Paulus W, 1996, J VIROL, V70, P62, DOI 10.1128/JVI.70.1.62-67.1996; SCHRAUFSTATTER IU, 1986, P NATL ACAD SCI USA, V83, P4908, DOI 10.1073/pnas.83.13.4908; SCOVASSI AI, 1984, J BIOL CHEM, V259, P973; Shah GM, 1996, BIOCHEM BIOPH RES CO, V229, P838, DOI 10.1006/bbrc.1996.1889; SimbulanRosenthal CM, 1996, BIOCHEMISTRY-US, V35, P11622, DOI 10.1021/bi953010z; SIMS JL, 1983, BIOCHEMISTRY-US, V22, P5188, DOI 10.1021/bi00291a019; Sokolove PM, 1996, J BIOENERG BIOMEMBR, V28, P199, DOI 10.1007/BF02110651; SOLVEIG WSA, 1984, CARCINGOENESIS, V5, P319; Susin SA, 1997, J EXP MED, V186, P25, DOI 10.1084/jem.186.1.25; Takahashi T, 1996, J BIOCHEM-TOKYO, V119, P256; TANAKA Y, 1994, EXP CELL RES, V213, P242, DOI 10.1006/excr.1994.1196; TANIZAWA A, 1989, EXP CELL RES, V185, P237, DOI 10.1016/0014-4827(89)90052-9; TANUMA SI, 1985, ARCH BIOCHEM BIOPHYS, V237, P38, DOI 10.1016/0003-9861(85)90251-6; TSENG A, 1987, P NATL ACAD SCI USA, V84, P1107, DOI 10.1073/pnas.84.4.1107; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; VAN GL, 1997, EUR J BIOCHEM, V244, P15; Venkatachalam S, 1997, ONCOGENE, V14, P801, DOI 10.1038/sj.onc.1200890; Wang ZQ, 1997, GENE DEV, V11, P2347, DOI 10.1101/gad.11.18.2347; WANG ZQ, 1990, J MED CHEM, V33, P2660, DOI 10.1021/jm00171a050; WHITACRE CM, 1995, CANCER RES, V55, P3697; Wright SC, 1996, J EXP MED, V183, P463, DOI 10.1084/jem.183.2.463; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129; YOSHIHARA K, 1985, BIOCHEM BIOPH RES CO, V128, P61, DOI 10.1016/0006-291X(85)91644-4; ZEREZ CR, 1987, BLOOD, V69, P999	61	35	38	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	1998	17	17					2225	2234		10.1038/sj.onc.1202133	http://dx.doi.org/10.1038/sj.onc.1202133			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	133QX	9811453				2022-12-17	WOS:000076698200008
J	Suzuki, M; Okuyama, S; Okamoto, S; Shirasuna, K; Nakajima, T; Hachiya, T; Nojima, H; Sekiya, S; Oda, K				Suzuki, M; Okuyama, S; Okamoto, S; Shirasuna, K; Nakajima, T; Hachiya, T; Nojima, H; Sekiya, S; Oda, K			A novel E2F binding protein with Myc-type HLH motif stimulates E2F-dependent transcription by forming a heterodimer	ONCOGENE			English	Article						human EC cells; E2F binding protein; E2F-dependent transcription	EMBRYONAL CARCINOMA-CELLS; RETINOBLASTOMA PROTEIN; MAMMALIAN-CELLS; IN-VIVO; FACTOR DRTF1/E2F; CYCLE CONTROL; DP FAMILY; DIFFERENTIATION; CLONING; GENE	The human embryonal carcinoma cells NEC14 can be induced to differentiate morphologically by the addition of 10(-2) M N, N'-hexamethylene-bis-acetamide and cease to grow in several days. Transcription factors of the E2F/DP family have been shown to be closely related to the regulation of cell proliferation. To analyse cellular proteins which interact with E2F in NEC14 cells, cDNA clones encoding E2F binding proteins were isolated from a lambda ZAP II NEC14 cell library with the P-32-labeled GST (Glutathione S-transferase)-E2F-l fusion protein as a probe. One of the clones encodes E2FBP1 which has the helix-loop-helix (HLH) motif, but lacks the basic domain and the zipper structure usually found at N- and C-terminal sides to the HLH motif, respectively, The arrangement of amino acids in the helix 1 and helix 2 regions is quite similar to those of Mxi and Mad, but different from those of E2F-1 and DP-1, Western blot analysis of the immunoprecipitates prepared with anti-E2FBP1 antibody showed that E2FBP1 associates with both E2F-1 and DP-1 in vivo. E2FBP1 alone has no DNA binding activity, but bind to the E2F site through heterodimerization with E2F-1 but not with DP-1, Although E2FBP1 lacks the transactivation domain, it stimulates E2F site-dependent transcription in cooperation with E2F-1.	Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan; MBL Co Ltd, Ina Labs, Nagano 396, Japan; Osaka Univ, Microbial Dis Res Inst, Suita, Osaka 565, Japan; Chiba Univ, Sch Med, Dept Obstet & Gynecol, Chiba 280, Japan	Tokyo University of Science; Osaka University; Chiba University	Oda, K (corresponding author), Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BUCK V, 1995, ONCOGENE, V11, P31; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CORBEIL HB, 1995, ONCOGENE, V11, P909; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DYSON N, 1993, J VIROL, V67, P7641, DOI 10.1128/JVI.67.12.7641-7647.1993; ELIZABETH AK, 1987, J BIOL CHEM, V262, P9136; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HARA E, 1993, ONCOGENE, V8, P1023; HARA E, 1991, NUCLEIC ACIDS RES, V19, P7097, DOI 10.1093/nar/19.25.7097; HARA E, 1995, METH NEUROSCI, V26, P262; HASEGAWA T, 1991, DIFFERENTIATION, V47, P107, DOI 10.1111/j.1432-0436.1991.tb00228.x; HELIN K, 1993, GENE DEV, V7, P1850, DOI 10.1101/gad.7.10.1850; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; Ikeda M, 1996, P NATL ACAD SCI USA, V93, P3215, DOI 10.1073/pnas.93.8.3215; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; NEVINS JR, 1992, SCIENCE, V258, P424; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; PEASON BE, 1991, MOL CELL BIOL, V11, P2081; RASHIDBAIGI A, 1985, J BIOL CHEM, V260, P8514; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SEKIYA S, 1990, GYNECOL ONCOL, V36, P69, DOI 10.1016/0090-8258(90)90111-W; SEKIYA S, 1985, DIFFERENTIATION, V29, P259, DOI 10.1111/j.1432-0436.1985.tb00325.x; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHIN EK, 1995, MOL CELL BIOL, V15, P2252; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WU CL, 1995, MOL CELL BIOL, V15, P2536; XU M, 1994, MOL CELL BIOL, V14, P8420, DOI 10.1128/MCB.14.12.8420; ZAMANIAN M, 1993, MOL CELL BIOL, V13, P389; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG YH, 1995, ONCOGENE, V10, P2085; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	57	35	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 20	1998	17	7					853	865		10.1038/sj.onc.1202163	http://dx.doi.org/10.1038/sj.onc.1202163			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780002				2022-12-17	WOS:000075448800007
J	Karnik, P; Chen, P; Paris, M; Yeger, H; Williams, BRG				Karnik, P; Chen, P; Paris, M; Yeger, H; Williams, BRG			Loss of heterozygosity at chromosome 11p15 in Wilms tumors: identification of two independent regions	ONCOGENE			English	Article						Wilms tumor; tumor suppressor genes; chromosome 11p15; loss of heterozygosity	BECKWITH-WIEDEMANN SYNDROME; LOCUS; GENE; LOCALIZATION; DELETION; TRANSCRIPTS; FRAGMENTS; D11S988	Loss of heterozygosity (LOH) on the short arm of chromosome 11 is the most frequent genetic alteration in Wilms tumors, indicating that one or more tumor suppressor genes that map to this chromosomal region are involved in the development of the disease, The WT1 gene located on 11p13 has been characterized but mutations in this gene occur in only about 10% of Wilms tumors, A second locus (WT2) at chromosome 11p15 has also been described in Wilms tumors but thus far efforts to clone the WT2 gene(s) have been frustrated by the large size (similar to 10 Mb) of this region. Using a high-density marker LOH analysis of 11p15.5-15.4, we have refined the location of a Wilms tumor suppressor gene between the markers D11S1318-D11S1288 (similar to 800 kb) within 11p15.5, We have also identified a second, novel region of LOH that spans the markers D11S1338-D11S1323 (similar to 336 kb) at 11p15.5-p15.4. Thus a second distinct locus, in addition to the previously defined WT2, on chromosome 11p15.5, appears to play a role in the development of Wilms tumors.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Hosp Sick Children, Toronto, ON M5G 1X8, Canada	Cleveland Clinic Foundation; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Karnik, P (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Williams, Bryan R. G./A-5021-2009	Williams, Bryan R. G./0000-0002-4969-1151				ALI IU, 1987, SCIENCE, V238, P185, DOI 10.1126/science.3659909; Baffa R, 1996, CANCER RES, V56, P268; BesnardGuerin C, 1996, HUM GENET, V97, P163, DOI 10.1007/BF02265259; BONETTA L, 1990, SCIENCE, V250, P994, DOI 10.1126/science.2173146; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; COPPES MJ, 1992, GENE CHROMOSOME CANC, V5, P326, DOI 10.1002/gcc.2870050408; FRANCKE U, 1979, CYTOGENET CELL GENET, V24, P185, DOI 10.1159/000131375; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GRUNDY P, 1995, HEMATOL ONCOL CLIN N, V9, P1201, DOI 10.1016/S0889-8588(18)30041-8; Hannigan GE, 1997, GENOMICS, V42, P177, DOI 10.1006/geno.1997.4719; Hoovers JMN, 1995, P NATL ACAD SCI USA, V92, P12456, DOI 10.1073/pnas.92.26.12456; HUANG A, 1990, SCIENCE, V250, P991, DOI 10.1126/science.2173145; JAMES MR, 1994, NAT GENET, V8, P70, DOI 10.1038/ng0994-70; KARNIK P, 1995, HUM MOL GENET, V4, P1889, DOI 10.1093/hmg/4.10.1889; KARNIK P, 1998, IN PRESS HUMAN MOL G; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; PELLETIER J, 1991, NATURE, V353, P431, DOI 10.1038/353431a0; PING AJ, 1989, AM J HUM GENET, V44, P720; Reid LH, 1997, GENOMICS, V43, P366, DOI 10.1006/geno.1997.4826; Reid LH, 1996, HUM MOL GENET, V5, P239, DOI 10.1093/hmg/5.2.239; SAIT SNJ, 1994, GENE CHROMOSOME CANC, V11, P97; Sotelo-Avila C, 1976, Perspect Pediatr Pathol, V3, P255; Tran YK, 1996, CANCER RES, V56, P2916; VARANASI R, 1994, P NATL ACAD SCI USA, V91, P3554, DOI 10.1073/pnas.91.9.3554; VIEL A, 1992, BRIT J CANCER, V66, P1030, DOI 10.1038/bjc.1992.405; WINQVIST R, 1995, CANCER RES, V55, P2660; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C	28	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 16	1998	17	2					237	240		10.1038/sj.onc.1201959	http://dx.doi.org/10.1038/sj.onc.1201959			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZZ211	9674708				2022-12-17	WOS:000074706700012
J	Yue, JB; Buard, A; Mulder, KM				Yue, JB; Buard, A; Mulder, KM			Blockade of TGF beta(3) up-regulation of p27(Kip1) and p21(Cip1) by expression of RasN17 in epithelial cells	ONCOGENE			English	Article						TGF beta; p21(Cip1); P27(Kip1); Ras, cell cycle; intestinal epithelial cells	GROWTH-FACTOR-BETA; CYCLIN-DEPENDENT KINASES; TGF-BETA; CDK; INHIBITOR; ARREST; ACTIVATION; PROTEIN; P21; SENSITIVITY	Our previous data demonstrated that Ras activation is necessary and sufficient for transforming growth factor beta (TGF beta)-mediated Erk1 activation, and is partially required for the inhibition of cyclin-dependent kinase 2 (Cdk2) activity, cyclin A expression and DNA synthesis by TGF beta (KM Mulder and SL Morris, J. Biol. Chem., 267: 5029-5031, 1992; MT Hartsough and KM Mulder, J. Biol. Chem., 270: 7117-7124, 1995; and MT Hartsough et nl., J. Biol. Chem., 271: 22368-22375, 1996). Here, we examined the kinetics and role of Ras in TGF beta(3)-mediated effects on specific G(1) cell cycle components in TGF beta-sensitive (4-1) and TGF beta-resistant (4-6) intestinal epithelial cells (IEC's). Our results indicate that inactivation of Ras by stable, inducible expression of a dominant-negative mutant of Ras (RasN17) completely abrogated the ability of TGF beta(3) to up-regulate both CKI's. In contrast, the ability of TGF beta(3) to up-regulate p27(Kip1) and p21(Cip1) was maintained in ZnCl2-treated control cells. Inactivation of Ras also completely blocked the rapid TGF beta-mediated increase in new synthesis of p27(Kip1) protein. Moreover, up-regulation of p21(Cip1) protein levels and new synthesis of p27(Kip1), as well as the association of these CKI's with Cdk2, preceded the decrease in Cdk2 activity by TGF beta. Collectively, our results suggest that p21(Cip1) and p27(Kip1) are upstream effecters of the TGF beta-mediated inhibition of Cdk2 activity in IEC 4-1 cells, and demonstrate that Ras activation is obligatory for TGF beta-mediated upregulation of these CKIs in untransformed epithelial cells.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Mulder, KM (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Pharmacol, Hershey, PA 17033 USA.		Yue, Jianbo/AAC-4588-2019; Yue, Jianbo/C-4463-2009; Yue, Jianbo/K-8002-2015	Yue, Jianbo/0000-0001-6384-5447	NCI NIH HHS [K04 CA59552, CA54816, CA51452] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA051452, R01CA051452, K04CA059552, R01CA054816] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN RH, 1995, NATURE, V377, P548, DOI 10.1038/377548a0; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; Derynck R, 1996, CURR BIOL, V6, P1226, DOI 10.1016/S0960-9822(96)00702-6; DERYNCK R, 1994, TIBS, V19, P539; ELBENDARY A, 1994, CELL GROWTH DIFFER, V5, P1301; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; Florenes VA, 1996, ONCOGENE, V13, P2447; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; Frey RS, 1997, CANCER RES, V57, P628; GENG Y, 1993, P NATL ACAD SCI USA, V90, P10315, DOI 10.1073/pnas.90.21.10315; HARPER JW, 1993, CELL, V75, P805; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hartsough MT, 1997, PHARMACOL THERAPEUT, V75, P21, DOI 10.1016/S0163-7258(97)00020-X; Iavarone A, 1997, NATURE, V387, P417; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Malliri A, 1996, CELL GROWTH DIFFER, V7, P1291; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MULDER KM, 1993, J CELL PHYSIOL, V154, P162, DOI 10.1002/jcp.1041540120; MULDER KM, 1992, J BIOL CHEM, V267, P5029; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Sgambato A, 1997, CELL GROWTH DIFFER, V8, P393; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SLINGERLAND JM, 1994, MOL CELL BIOL, V14, P3683, DOI 10.1128/MCB.14.6.3683; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Wrana JL, 1996, TRENDS GENET, V12, P493, DOI 10.1016/S0168-9525(96)30109-1	36	35	36	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 9	1998	17	1					47	55		10.1038/sj.onc.1201903	http://dx.doi.org/10.1038/sj.onc.1201903			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZY936	9671313				2022-12-17	WOS:000074677800006
J	Hanford, MG; Rushton, BC; Gowen, LC; Farber, RA				Hanford, MG; Rushton, BC; Gowen, LC; Farber, RA			Microsatellite mutation rates in cancer cell lines deficient or proficient in mismatch repair	ONCOGENE			English	Article						microsatellite instability; mismatch repair; colorectal cancer; fluctuation analysis	NONPOLYPOSIS COLON-CANCER; COLORECTAL-CANCER; GENOMIC INSTABILITY; HOMOLOG; GENE; DNA; HYPERMUTABILITY; SEQUENCES; HMSH2	A selectable system has been used to determine mutation rates within a microsatellite sequence in human cancer cell lines with or without defects in mismatch repair. A sequence consisting of 17 repeats of poly (dC-dA).poly(dT-dG) [abbreviated as (Ca)(17)] was inserted near the 5' end of the bacterial neomycin-resistance gene in a plasmid vector, such that the reading frame of the neo gene is disrupted. This plasmid was introduced into cancer cell lines, where it became integrated into the cellular genome. Clones with insertions or deletions of CA-repeats that restored the normal reading frame of the neo gene were selected in G418, and mutation rates were determined by fluctuation analysis. The rates of reversion in LoVo cells, which are deficient for hMSH2, were about one in a thousand per generation, which is approximately two orders of magnitude higher than in the repair-proficient HT-1080 human fibrosarcoma cell line. The mutation rates in H6 cells, which are derived from the hMLH1-deficient HCT116 line, were more heterogeneous than in LoVo, but all were considerably higher than in the repair-proficient line. Nearly all of the revertants of the repair-deficient lines had deletions of a single CA-repeat from the microsatellite sequence, whereas repair-proficient cells had a broader spectrum of mutations.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Farber, RA (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, CB 7525, Chapel Hill, NC 27599 USA.				NCI NIH HHS [CA63264] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063264] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BRATTAIN MG, 1993, CELL, V75, P1227; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Bubb VJ, 1996, ONCOGENE, V12, P2641; CAPIZZI RL, 1973, MUTAT RES, V17, P147, DOI 10.1016/0027-5107(73)90265-0; DREWINKO B, 1976, CANCER RES, V36, P467; FARBER RA, 1994, HUM MOL GENET, V3, P253, DOI 10.1093/hmg/3.2.253; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HAUGE XY, 1993, HUM MOL GENET, V2, P411, DOI 10.1093/hmg/2.4.411; HONCHEL R, 1995, SEMIN CELL BIOL, V6, P45, DOI 10.1016/1043-4682(95)90014-4; KAHN SM, 1995, CARCINOGENESIS, V16, P1223, DOI 10.1093/carcin/16.5.1223; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lengauer C, 1997, P NATL ACAD SCI USA, V94, P2545, DOI 10.1073/pnas.94.6.2545; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48; LOTHE RA, 1993, CANCER RES, V53, P5849; Luria SE, 1943, GENETICS, V28, P491; Malkhosyan S, 1996, NATURE, V382, P499, DOI 10.1038/382499a0; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; RASHEED S, 1974, CANCER, V33, P1027, DOI 10.1002/1097-0142(197404)33:4<1027::AID-CNCR2820330419>3.0.CO;2-Z; Riedinger KL, 1996, ENVIRON MOL MUTAGEN, V28, P276, DOI 10.1002/(SICI)1098-2280(1996)28:3<276::AID-EM12>3.0.CO;2-C; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Sia EA, 1997, MUTAT RES-DNA REPAIR, V383, P61, DOI 10.1016/S0921-8777(96)00046-8; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; TALBOT CC, 1995, HUM MOL GENET, V4, P1193, DOI 10.1093/hmg/4.7.1193; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; UMAR A, 1994, J BIOL CHEM, V269, P14367	35	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 7	1998	16	18					2389	2393		10.1038/sj.onc.1201751	http://dx.doi.org/10.1038/sj.onc.1201751			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZL389	9620556				2022-12-17	WOS:000073428000011
J	Epstein, CB; Attiyeh, EF; Hobson, DA; Silver, AL; Broach, JR; Levine, AJ				Epstein, CB; Attiyeh, EF; Hobson, DA; Silver, AL; Broach, JR; Levine, AJ			p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors	ONCOGENE			English	Article						p53; yeast; mutations; cancer	WILD-TYPE P53; TEMPERATURE-SENSITIVE MUTANT; CELL-CYCLE ARREST; DNA-BINDING SITE; TERMINAL DOMAIN; SUPPRESSOR GENE; PROTEIN; ACTIVATION; MDM-2; EXPRESSION	p53 is a transcriptional activator that plays a key role in the integration of signals inducing cell division arrest and programed cell death, Moreover, p53 is a tumor suppressor gene, mutations of which are the most commonly detected mutations in diverse malignancies. In order to better understand the significance of p53 mutations to human cancer, me isolated mutant alleles of p53 that had lost transcription factor activity in yeast. These mutant alleles mere evaluated for their precise changes, their activity against three different p53 responsive enhancers and their ability to act in a transdominant fashion to the wild type allele, While many of the mutations isolated in yeast resembled those found in human tumors, consistent with the importance of transcription factor activity for p53 in mammalian cells, the mutational spectrum obtained was dependent upon the p53 enhancer employed for the selection. Some mutations specifically inactivated p53 in yeast for a single enhancer element. Virtually all missense mutations tested had a dominant inhibitory effect on wild type p53 in yeast, Since some of these transdominant mutations are virtually unknown in human tumors me conclude that transdominance, per se, fails to predict which mutations occur frequently in cancer.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Epstein, CB (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol & Oncol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.			Epstein, Charles B./0000-0001-8358-8345; Broach, James/0000-0003-1197-0312				Ausubel FM, 1994, CURRENT PROTOCOLS MO; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; CHEN JY, 1993, ONCOGENE, V8, P2159; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; Freedman DA, 1997, MOL MED, V3, P248, DOI 10.1007/BF03401678; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Levine AJ, 1995, ANN NY ACAD SCI, V768, P111, DOI 10.1111/j.1749-6632.1995.tb12115.x; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; POLAKIS P, 1995, CURR OPIN GENET DEV, V5, P66, DOI 10.1016/S0959-437X(95)90055-1; RIDEOUT WM, 1990, SCIENCE, V249, P1288, DOI 10.1126/science.1697983; ROSE MD, 1990, METHODS YEAST GENETI; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YONISHROUACH F, 1991, NATURE, V32, P345; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x; ZHANG W, 1993, CANCER RES, V53, P4772	53	35	35	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 23	1998	16	16					2115	2122		10.1038/sj.onc.1201734	http://dx.doi.org/10.1038/sj.onc.1201734			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZJ077	9572492				2022-12-17	WOS:000073177200009
J	Gemma, A; Hagiwara, K; Vincent, F; Ke, Y; Hancock, AR; Nagashima, M; Bennett, WP; Harris, CC				Gemma, A; Hagiwara, K; Vincent, F; Ke, Y; Hancock, AR; Nagashima, M; Bennett, WP; Harris, CC			hSmad5 gene, a human hSmad family member: its full length cDNA, genomic structure, promoter region and mutation analysis in human tumors	ONCOGENE			English	Article						transforming growth factor-beta; cDNA; genomic structure; PCR-SSCP	GROWTH-FACTOR-BETA; MAD-RELATED PROTEIN; II RECEPTOR GENE; TGF-BETA; SIGNALING PATHWAYS; CELL-GROWTH; CLONING; CANCER; INHIBITION; KINASE	hSmad (mothers against decapentaplegic)-related proteins are important messengers within the Transforming Growth Factor-beta(1) (TGF-beta(1)) superfamily signal transduction pathways. To further characterize a member of this family, we obtained a full length cDNA of the human hSmad5 (hSmad5) gene by rapid amplification of cDNA ends (RACE) and then determined the genomic structure of the gene. There are eight exons and two alternative transcripts; the shorter transcript lacks exon 2. We identified the hSmad5 promoter region from a human genomic YAC clone by obtaining the nucleotide sequence extending 1235 base pairs upstream of the 5' end of the cDNA. We found a CpG island consistent with a promoter region, and we demonstrated promoter activity in a 1232 bp fragment located upstream of the transcription initiation site. To investigate the frequency of somatic hSmad5 mutations in human cancers, we designed intron-based primers to examine coding regions by polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis. Neither homozygous deletions or point mutations were found in 40 primary gastric tumors and 51 cell lines derived from diverse types of human cancer including 20 cell lines resistant to the growth inhibitory effects of TGF-beta(1). These results suggest that the hSmad5 gene is not commonly mutated and that other genetic alterations mediate the loss of TGF-beta(1) responsiveness in human cancers.	NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; IFREMER, Lab Ecotoxicol, F-44311 Nantes 03, France; Beijing Med Univ, Sch Oncol, Beijing 100034, Peoples R China	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ifremer; Peking University	Harris, CC (corresponding author), NCI, Human Carcinogenesis Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA.			VINCENT-HUBERT, Francoise/0000-0002-2266-9237				ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; FYNAN TM, 1993, CRIT REV ONCOGENESIS, V4, P493; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gemma A, 1997, CANCER RES, V57, P1435; Gemma A, 1996, INT J CANCER, V68, P605, DOI 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2; Hagiwara K, 1996, NUCLEIC ACIDS RES, V24, P2460, DOI 10.1093/nar/24.12.2460; Hahn SA, 1996, SCIENCE, V271, P350, DOI 10.1126/science.271.5247.350; Hayashi H, 1997, CELL, V89, P1165, DOI 10.1016/S0092-8674(00)80303-7; Hoodless PA, 1996, CELL, V85, P489, DOI 10.1016/S0092-8674(00)81250-7; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LECHNER JF, 1983, CANCER RES, V43, P5915; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; Riggins GJ, 1996, NAT GENET, V13, P347, DOI 10.1038/ng0796-347; Riggins GJ, 1997, CANCER RES, V57, P2578; Savage C, 1996, P NATL ACAD SCI USA, V93, P790, DOI 10.1073/pnas.93.2.790; SEKELSKY JJ, 1995, GENETICS, V139, P1347; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; Tamura G, 1996, CANCER RES, V56, P612; VINCENT F, 1997, IN PRESS ONCOGENE; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yingling JM, 1996, P NATL ACAD SCI USA, V93, P8940, DOI 10.1073/pnas.93.17.8940; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	30	35	38	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 19	1998	16	7					951	956		10.1038/sj.onc.1201614	http://dx.doi.org/10.1038/sj.onc.1201614			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX564	9484787				2022-12-17	WOS:000072053200015
J	Joh, T; Yamamoto, K; Kagami, Y; Kakuda, H; Sato, T; Yamamoto, T; Takahashi, T; Ueda, R; Kaibuchi, K; Seto, M				Joh, T; Yamamoto, K; Kagami, Y; Kakuda, H; Sato, T; Yamamoto, T; Takahashi, T; Ueda, R; Kaibuchi, K; Seto, M			Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus	ONCOGENE			English	Article						translocation; 11q23; MLL; AF6; leukemogenesis	11Q23 CHROMOSOMAL TRANSLOCATIONS; ACUTE MYELOID LEUKEMIAS; PROLINE-RICH PROTEIN; DROSOPHILA-TRITHORAX; ALL-1 GENE; CLONING; ABNORMALITIES; EXPRESSION; REARRANGEMENT; HOMOLOG	In infantile leukemias and therapy-related leukemias, the MLL gene is frequently found to be disrupted and fused to various translocation partner genes, such as AF4/FEL, LTG9/AF9 and LTG19/ENL as a result of 11q23 translocations, We previously showed that the N-terminal portion common to various chimeric MLL products, as well as to MLL-LTG9 and MLL-LTG19, localizes in the nuclei, and therefore suggested that it might play an important role in leukemogenesis, In the present study, MLL-AF6 chimeric products found in the t(6;11) (q27;q23) translocation were analysed since AF6, a Ras-binding protein, exhibits a different subcellular localization from that of LTG9/AF9 and LTG19/ENL, Immunofluorescence staining data and cell fractionation analyses demonstrated that MLL-AF6 chimeric products localize in the nuclei despite the fact that AF6 itself localizes in the cytoplasm, confirming the importance of the nuclear localization of chimeric MLL products, The region in the N-terminal portion of MLL responsible for this nuclear localization was examined and found to be a region containing AT-hook motifs.	AICHI CANC CTR,RES INST,LAB CHEMOTHERAPY,NAGOYA,AICHI 464,JAPAN; AICHI CANC CTR,RES INST,IMMUNOL LAB,NAGOYA,AICHI 464,JAPAN; CHIBA UNIV,SCH MED,DEPT PEDIAT,CHIBA 260,JAPAN; NAGOYA CITY UNIV,SCH MED,DEPT INTERNAL MED 2,NAGOYA,AICHI 464,JAPAN; NARA INST SCI & TECHNOL,DIV SIGNAL TRANSDUCT,IKOMA 63001,JAPAN	Aichi Cancer Center; Aichi Cancer Center; Chiba University; Nagoya City University; Nara Institute of Science & Technology								AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; BERNARD OA, 1994, ONCOGENE, V9, P1039; BIRKETT CR, 1985, FEBS LETT, V187, P211, DOI 10.1016/0014-5793(85)81244-8; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; Connelly MA, 1996, GENE, V175, P271, DOI 10.1016/0378-1119(96)00135-7; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; Joh T, 1996, ONCOGENE, V13, P1945; Kakuda H, 1996, BRIT J HAEMATOL, V95, P306, DOI 10.1046/j.1365-2141.1996.d01-1909.x; KANEKO Y, 1986, BLOOD, V67, P484; KURIYAMA M, 1996, J BIOL CHEM, V271, P606; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRASAD R, 1993, CANCER RES, V53, P5624; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TSE W, 1995, BLOOD, V85, P650, DOI 10.1182/blood.V85.3.650.bloodjournal853650; YAMAMOTO K, 1994, BLOOD, V83, P2912, DOI 10.1182/blood.V83.10.2912.2912; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	36	35	40	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 2	1997	15	14					1681	1687		10.1038/sj.onc.1201332	http://dx.doi.org/10.1038/sj.onc.1201332			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349501				2022-12-17	WOS:A1997XY63100007
J	Ma, GZ; Lu, D; Wu, Y; Liu, JX; Arlinghaus, RB				Ma, GZ; Lu, D; Wu, Y; Liu, JX; Arlinghaus, RB			Bcr phosphorylated on tyrosine 177 binds Grb2	ONCOGENE			English	Article						Bcr; Bcr-Abl; tyrosine phosphorylation; Grb2; Ras pathway; Philadelphia chromosome	CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE-ACTIVITY; PHILADELPHIA-CHROMOSOME; GENE ENCODES; ABL PROTEIN; CELL LINE; P160 BCR; K562; ASSOCIATION	We and others have shown that the Bcr-Abl oncoprotein binds activators of the Ras pathway such as Grb2 and She, Grb2 binding is mediated through a phosphorylated tyrosine residue (Y177) located within a consensus Grb2 binding site encoded by the first exon of the BCR gene, Our results indicate that P160 BCR is tyrosine phosphorylated at the same site by Bcr-Abl in kinase assays (Pull ef al., 1994), We performed experiments to determine whether Bcr, which was tyrosine phosphorylated within cells by activated c-Abl, could also bind Grb2, and whether phosphotyrosine 177 was the major binding site. Complexes between Bcr and Abl were detected in a hemopoietic cell line lacking Bcr-Abl and in COS1 cells coexpressing both Bcr and Abl proteins, P160 BCR was tyrosine phosphorylated in COS1 cells coexpressing Abl and Bcr proteins, Similarly, various deletion mutants of Bcr including BCRN553, BCRN413 and BCRN221 were tyrosine phosphorylated by activated c-Abl whereas BCRN159 was not, Wild-type Bcr and Bcr Y177F were examined under these conditions for their ability to co-precipitate with Grb2. The results showed that while wild-type tyrosine phosphorylated Bcr efficiently bound Grb2, tyrosine phosphorylated Bcr Y177F had greatly reduced Grb2-binding ability, Studies with GST-SH2 (Grb2) revealed that tyrosine phosphorylated Bcr was able to bind to GST SH2 (Grb2) but tyrosine phosphorylated Bcr Y177F was deficient in binding, These results indicate that the Bcr protein when phosphorylated at tyrosine 177 binds Grb2, thereby implicating Bcr as a potantial activator of the Ras pathway.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT MOL PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA65611, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA065611] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRASELMANN S, 1995, EMBO J, V14, P4839, DOI 10.1002/j.1460-2075.1995.tb00165.x; CAMPBELL ML, 1990, ONCOGENE, V5, P773; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEIKMANN D, 1991, NATURE, V351, P400; DRUKER B, 1992, BLOOD, V79, P2215; GUO JQ, 1994, BLOOD, V83, P3629; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1987, MOL CELL BIOL, V7, P446; LI WJ, 1989, ONCOGENE, V4, P127; LI WJ, 1988, ONCOGENE, V2, P559; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; MARU Y, 1995, MOL CELL BIOL, V15, P835; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PRIEST JR, 1980, BLOOD, V56, P15; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; REUTHER GW, 1994, SCIENCE, V266, P129, DOI 10.1126/science.7939633; RON D, 1991, NEW BIOL, V3, P372; Sattler M, 1996, ONCOGENE, V12, P839; SHTIVELMAN E, 1987, BLOOD, V69, P971; SHTIVELMAN E, 1986, CELL, V47, P27; SMITH RG, 1981, J IMMUNOL, V126, P596; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; TAUCHI T, 1994, J EXP MED, V179, P165; TENHOEVE J, 1994, MOL CELL BIOL, V9, P1263; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	35	40	1	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 15	1997	14	19					2367	2372		10.1038/sj.onc.1201053	http://dx.doi.org/10.1038/sj.onc.1201053			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WY883	9178913				2022-12-17	WOS:A1997WY88300014
J	Huang, CS; Ma, WY; Dong, ZG				Huang, CS; Ma, WY; Dong, ZG			Signal transduction through atypical PKCs, but not the EGF receptor, is necessary for UVC-induced AP-1 activation in immortal murine cells	ONCOGENE			English	Article						ultraviolet; protein kinase C; AP-1; epidermal growth factor receptor	PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTOR; ESTER TUMOR PROMOTERS; PHORBOL ESTER; EPIDERMAL-CELLS; GENE-EXPRESSION; TYROSINE KINASE; INDUCED TRANSFORMATION; ENHANCER ELEMENT; DELETION MUTANT	The exposure of mammalian cells to ultraviolet (u.v.) irradiation leads to activation of transcription factors, such as AP-1 and NF kappa B. It is postulated that the EGF receptor but not protein kinase C (PKC) is the major membrane mediator in UVC-induced signal transduction. We demonstrate here that the antisense oligonucleotides of PKC zeta and the dominant negative mutant of PKC lambda/iota as well as dominant negative PKC zeta markedly blocked UVC-induced AP-1 activity. In contrast, UVC-induced AP-1 activity in cells devoid of the EGF receptor (B82), is not significantly different from that of the stable transfectants with a kinase-deficient EGF receptor (B82M721), or wild-type EGF receptor (B82L). This was found at all UVC irradiation doses and time courses studied, while high levels of EGF-induced AP-1 activity were observed in B82L cells but not in B82 cells. This evidence strongly suggests that atypical PKCs, but not the EGF receptor, is necessary for UVC-induced AP-1 activation in JB6 and B82 cells.	UNIV MINNESOTA,HORMEL INST,AUSTIN,MN 55912	University of Minnesota System				Huang, Chuanshu/0000-0003-4133-5096				ADLER V, 1995, P NATL ACAD SCI USA, V92, P10585, DOI 10.1073/pnas.92.23.10585; AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1995, INDUCED GENE EXPRESS, P63; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; BORCHERS AH, 1994, EXP CELL RES, V213, P143, DOI 10.1006/excr.1994.1183; BOWDEN GT, 1994, CANCER RES, V54, pS1882; BROWN PH, 1993, ONCOGENE, V8, P877; BUSCHER M, 1988, ONCOGENE, V3, P301; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER G, 1990, J BIOL CHEM, V265, P7709; CHEN HX, 1993, J MED CHEM, V36, P4094, DOI 10.1021/jm00077a014; CHEN WS, 1987, NATURE, V328, P820, DOI 10.1038/328820a0; CHIDA K, 1983, CANCER RES, V43, P3638; COLLINS MKL, 1982, J CELL PHYSIOL, V112, P42, DOI 10.1002/jcp.1041120108; CRESPO P, 1995, BIOCHEM BIOPH RES CO, V213, P266, DOI 10.1006/bbrc.1995.2125; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DHANWADA KR, 1995, ONCOGENE, V11, P1947; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; DOMANN FE, 1994, CELL GROWTH DIFFER, V5, P9; DONG Z, 1994, EARLY DETECTION CANC, P121; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; DONG ZG, 1995, INT J ONCOL, V7, P359; DONG ZG, 1994, P NATL ACAD SCI USA, V91, P609, DOI 10.1073/pnas.91.2.609; ELDREDGE ER, 1994, MOL CELL BIOL, V14, P7527, DOI 10.1128/MCB.14.11.7527; EPSTEIN JH, 1983, J AM ACAD DERMATOL, V9, P487, DOI 10.1016/S0190-9622(83)70160-X; FITZPATRICK TB, 1976, RES PHOTOBIOLOGY, P485; FORBES PD, 1976, RES PHOTOBIOLOGY, P469; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HONEGGER AM, 1987, MOL CELL BIOL, V7, P4568, DOI 10.1128/MCB.7.12.4568; Huang CS, 1996, MOL CELL BIOL, V16, P6427; Huang CS, 1996, INT J ONCOL, V8, P389; HUANG CS, 1996, IN PRESS J BIOL CHEM, V271; KARIN M, 1992, TRENDS BIOCHEM SCI, V17, P418, DOI 10.1016/0968-0004(92)90012-X; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUSEWITT DF, 1993, PHOTOCHEM PHOTOBIOL, V58, P450, DOI 10.1111/j.1751-1097.1993.tb09589.x; Lavrovsky V, 1996, IN VITRO CELL DEV-AN, V32, P234; LEY RD, 1993, P NATL ACAD SCI USA, V90, P4337, DOI 10.1073/pnas.90.10.4337; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LIU M, 1994, CARCINOGENESIS, V15, P1089, DOI 10.1093/carcin/15.6.1089; LIU M, 1995, ONCOGENE, V10, P1955; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MAIHLE N J, 1988, Biochimica et Biophysica Acta, V948, P287; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OHNO Y, 1989, P NATL ACAD SCI USA, V86, P3099; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; Rahmsdorf H., 1992, INDUCED EFFECTS GENO, P141; RONAI Z, 1988, J VIROL, V62, P1067; RONAI ZA, 1990, CELL BIOL TOXICOL, V6, P105, DOI 10.1007/BF00135030; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SCHORPP M, 1984, CELL, V37, P861, DOI 10.1016/0092-8674(84)90421-5; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; SHAH G, 1993, CANCER RES, V53, P38; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P2549, DOI 10.1073/pnas.78.4.2549; SOLANKI V, 1981, P NATL ACAD SCI-BIOL, V78, P1722, DOI 10.1073/pnas.78.3.1722; STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K; STABERG B, 1983, J INVEST DERMATOL, V81, P517, DOI 10.1111/1523-1747.ep12522855; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STRICKLAND PT, 1986, J INVEST DERMATOL, V87, P272, DOI 10.1111/1523-1747.ep12696669; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0	78	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 24	1997	14	16					1945	1954		10.1038/sj.onc.1201056	http://dx.doi.org/10.1038/sj.onc.1201056			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WV804	9150361				2022-12-17	WOS:A1997WV80400007
J	Ookawa, K; Tsuchida, S; Adachi, J; Yokota, J				Ookawa, K; Tsuchida, S; Adachi, J; Yokota, J			Differentiation induced by RB expression and apoptosis induced by p53 expression in an osteosarcoma cell line	ONCOGENE			English	Article						tumor suppressor gene; RB; p53; cell cycle; differentiation; apoptosis	TUMOR-SUPPRESSOR GENES; WILD-TYPE P53; RETINOBLASTOMA-PROTEIN; CYCLE CONTROL; HUMAN BLADDER; HUMAN CANCER; CDK4 AMPLIFICATION; MAMMALIAN-CELLS; CARCINOMA CELLS; LUNG-CARCINOMA	Multiple genetic alterations, including concurrent inactivation of RB and p53, occur frequently in several human cancers. To investigate the biological significance of RB and p53 gene inactivations, a wild-type RB or p53 cDNA expression vector regulated by tetracycline was introduced by stable transfection into an osteosarcoma cell line Saos-2, in which both the RB and p53 genes were inactivated. Induction of introduced RB expression resulted in suppression of cell growth, increased percentage of cells at the G(0)/G(1) phase, and enlargement of the cells. Furthermore, activity of alkaline phosphatase was increased and expression of fibronectin was decreased, suggesting the induction of cell differentiation by RB expression. Induction of p53 expression also resulted in significant suppression of cell growth with slight accumulation of cells at the G(0)/G(1) and G(2)/M phases. The cells mere detached from culture dishes and the dead cell fraction increased. Furthermore, condensation of chromatin and DIVA fragmentation were observed, suggesting the induction of apoptosis by p53. These results suggest that RB and p53 play different roles in carcinogenesis of osteoblast; RB inactivation releases cells from G(0)/G(1) arrest and suppresses cell differentiation while p53 inactivation assists the cells to proliferate by repressing both apoptosis and cell cycle arrest at G(0)/G(1) and G(2)/M.	NATL CANC CTR,RES INST,DIV BIOL,CHUO KU,TOKYO 104,JAPAN; HIROSAKI UNIV,SCH MED,DEPT BIOCHEM 2,HIROSAKI,AOMORI 036,JAPAN	National Cancer Center - Japan; Hirosaki University			Tsuchida, Shigeki/L-3382-2013	Tsuchida, Shigeki/0000-0002-4404-5599				Adachi J, 1996, CELL GROWTH DIFFER, V7, P879; AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; BENEDICT WF, 1990, J CLIN INVEST, V85, P988, DOI 10.1172/JCI114575; BUCKBINDER L, 1994, P NATL ACAD SCI USA, V91, P10640, DOI 10.1073/pnas.91.22.10640; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FUNG YKT, 1993, ONCOGENE, V8, P2659; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIETTING T, 1995, BIOL CHEM HOPPESEYLE, V376, P441; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GOODRICH DW, 1992, NATURE, V360, P177, DOI 10.1038/360177a0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HARPER JW, 1993, CELL, V75, P805; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HE J, 1994, CANCER RES, V54, P5804; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HOLLINGSWORTH RE, 1991, J NATL CANCER I, V83, P91, DOI 10.1093/jnci/83.2.91; HOLLINGSWORTH RE, 1993, CURR OPIN GENET DEV, V3, P55, DOI 10.1016/S0959-437X(05)80341-7; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; ISHIKAWA J, 1991, CANCER RES, V51, P5736; JONES KH, 1985, J HISTOCHEM CYTOCHEM, V33, P77, DOI 10.1177/33.1.2578146; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MURAKAMI Y, 1991, CANCER RES, V51, P5520; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OOKAWA K, 1993, ONCOGENE, V8, P2175; PRESTI JC, 1991, CANCER RES, V51, P5405; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; REIFENBERGER G, 1994, CANCER RES, V54, P4299; RUGGERI B, 1992, ONCOGENE, V7, P1503; Sambrook J, 1989, MOL CLONING LAB MANU; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SCHMIDT EE, 1994, CANCER RES, V54, P6321; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; STEIN GS, 1990, FASEB J, V4, P3111, DOI 10.1096/fasebj.4.13.2210157; STEWART N, 1995, ONCOGENE, V10, P109; STRATTON MR, 1990, ONCOGENE, V5, P1297; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TAKAHASHI R, 1991, P NATL ACAD SCI USA, V88, P5257, DOI 10.1073/pnas.88.12.5257; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; TEMPLETON DJ, 1991, P NATL ACAD SCI USA, V88, P3033, DOI 10.1073/pnas.88.8.3033; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Wyllie A H, 1980, Int Rev Cytol, V68, P251; XU HJ, 1991, CANCER RES, V51, P2735; YAMATO K, 1995, ONCOGENE, V11, P1; YOKOTA J, 1993, FASEB J, V7, P920, DOI 10.1096/fasebj.7.10.8344488; Yonish-Rouach E, 1994, Cell Death Differ, V1, P39; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YONISHROUACH E, 1996, ONCOGENE, V12, P2197; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZHOU YL, 1994, P NATL ACAD SCI USA, V91, P4165, DOI 10.1073/pnas.91.10.4165; ZIEVE GW, 1980, EXP CELL RES, V126, P397, DOI 10.1016/0014-4827(80)90279-7	67	35	42	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR 27	1997	14	12					1389	1396		10.1038/sj.onc.1200976	http://dx.doi.org/10.1038/sj.onc.1200976			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WT584	9136982				2022-12-17	WOS:A1997WT58400001
J	Buettner, VL; Hill, KA; Nishino, H; Schaid, DJ; Frisk, CS; Sommer, SS				Buettner, VL; Hill, KA; Nishino, H; Schaid, DJ; Frisk, CS; Sommer, SS			Increased mutation frequency and altered spectrum in one of four thymic lymphomas derived from tumor prone p53 Big Blue double transgenic mice	ONCOGENE			English	Article						point mutations; Big Blue; mutator phenotype; transitions; deletions with insertions; inversions	NONPOLYPOSIS COLORECTAL-CANCER; MISMATCH REPAIR DEFICIENCY; COLON-CANCER; MICROSATELLITE INSTABILITY; SUPPRESSOR GENE; GASTRIC-CANCER; LACI GENE; HOMOLOG; CARCINOGENESIS; CARCINOMA	p53 (-/-), lacI (+/-) double transgenic (p53/Big Blue(R)) mice provide an opportunity to examine the relationship in vivo between somatic mutation and tumorigenesis, Previously, the frequency and spectra of Cad mutations were found to be similar in normal tissues of 6 week old p53 (-/-) lacI (+/-) and p53 (+/+) lacI (+/-) mice, Herein, p53 (-/-), lacI (+/-) mice were used to examine the frequency and spectrum of spontaneous mutation in thymic lymphomas, Four mice with thymic lymphomas were sacrificed at 2.5, 3, 4 and 4.5 months of age, Normal thymus harvested from two p53 (+/+) lacI (+/-) mice and two p53 (-/-) lacI (+/-) mice served as controls, The mutation frequency in tumor 108 (6.8 x 10(-5)) was elevated 2.3-fold relative to the p53 (-/-) control (P<0.0001; chi(2) test), The mutation spectra were also different (P=0.0009; Fisher exact test); in particular, A:T-->G:C transitions were prominently overrepresented in tumor 108, In addition, there were two examples of unusual deletions with inversions, In tumors 44 and 115, but not 110, there were trends toward increased mutation frequencies and altered spectra, but, within the constraints of present sample sizes, the results are not statistically significant, In conclusion, these findings suggest that altered frequencies and spectra exist in a subset of thymic lymphomas, perhaps due to somatic mutation in one or more DNA repair genes.	MAYO CLIN & MAYO FDN,DEPT BIOCHEM & MOL BIOL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT BIOSTAT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT VET MED,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic								AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHUNG DC, 1995, GASTROENTEROLOGY, V109, P1685, DOI 10.1016/0016-5085(95)90660-6; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower Lawrence A., 1994, Cancer Bulletin (Houston), V46, P161; DOUGLAS GR, 1994, MUTAGENESIS, V9, P451, DOI 10.1093/mutage/9.5.451; DUGGAN BD, 1994, J NATL CANCER I, V86, P1216, DOI 10.1093/jnci/86.16.1216; FARABAUGH PJ, 1978, NATURE, V274, P765, DOI 10.1038/274765a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Gartenhaus R, 1996, BLOOD, V87, P38; GONZALEZZULUETA M, 1993, CANCER RES, V53, P5620; HAN HJ, 1993, CANCER RES, V53, P5087; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; JASS JR, 1994, MUTAT RES-FUND MOL M, V310, P125, DOI 10.1016/0027-5107(94)90016-7; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; LANE DP, 1994, BRIT MED BULL, V50, P582, DOI 10.1093/oxfordjournals.bmb.a072911; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEVINE AJ, 1992, CANCER SURV, V12, P59; LI FP, 1988, CANCER RES, V48, P5358; LOEB LA, 1991, CANCER RES, V51, P3075; Loeb LA, 1996, MUTAT RES-FUND MOL M, V350, P279, DOI 10.1016/0027-5107(95)00117-4; MALKIN D, 1994, BBA-REV CANCER, V1198, P197, DOI 10.1016/0304-419X(94)90014-0; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MIRONOV NM, 1994, CANCER RES, V54, P41; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHINO H, 1995, ONCOGENE, V11, P263; NISHINO H, 1995, BIOTECHNIQUES, V19, P587; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SCHAAPER RM, 1987, P NATL ACAD SCI USA, V84, P6220, DOI 10.1073/pnas.84.17.6220; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z	40	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 5	1996	13	11					2407	2413						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VX108	8957082				2022-12-17	WOS:A1996VX10800013
J	Taki, T; Hayashi, Y; Taniwaki, M; Seto, M; Ueda, R; Hanada, R; Suzukawa, K; Yokota, J; Morishita, K				Taki, T; Hayashi, Y; Taniwaki, M; Seto, M; Ueda, R; Hanada, R; Suzukawa, K; Yokota, J; Morishita, K			Fusion of the MLL gene with two different genes, AF-6 and AF-5 alpha, by a complex translocation involving chromosomes 5, 6, 8 and 11 in infant leukemia	ONCOGENE			English	Article						AF-5 alpha; complex chromosomal translocation; infant leukemia; topoisomerase II recognition site-like sequence	ACUTE LYMPHOBLASTIC-LEUKEMIA; YEAST ARTIFICIAL CHROMOSOME; BREAKPOINT CLUSTER REGION; TUMOR-SUPPRESSOR PROTEIN; ACUTE MYELOID LEUKEMIAS; IN-SITU HYBRIDIZATION; DNA TOPOISOMERASE-II; 11Q23 TRANSLOCATIONS; DROSOPHILA-TRITHORAX; SEPTATE JUNCTIONS	We analysed a complex translocation involving chromosomes 5, 6, 8 and 11 in a case of infant leukemia. Molecular analysis of the MLL gene revealed that MLL was fused with two different genes, AF-6 on chromosome 6q27 and AF-5 alpha. AF-5 alpha, the 11th partner gene fused with MLL, is a novel gene mapped to chromosome 5q12, which encodes a 31 kDa protein of 269 amino acids and contains possible nuclear targeting sequence, potential leucine zipper dimerization motif and an alpha-helical coiled-coil domain. In situ hybridization and molecular cloning analyses demonstrated that two different types of chromosomal recombination had occurred in the cells. One was a three-way translocation among chromosomes 6, 8 and 11, and the other was an insertion of a chromosome 5-derived segment into the breakpoint of chromosomes 8 and 11. Accordingly, the karyotype was defined as del(5)(q11.2q12), der(6)t(6;8) (q27;q11.2), der(8)(8pter-->8q11.2::5q11.2-->5q12::11q23-->11qter), der(11)t(6;11) (q27;q23). Thus, the MLL gene created two different fusion mRNAs, since the chromosome 11 split into two different chromosomes 5 and 6. This is the first report demonstrating fusion of the MLL gene with two different genes by a complex translocation.	NATL CANC CTR, RES INST, DIV BIOL, CHUO KU, TOKYO 104, JAPAN; UNIV TOKYO, FAC MED, DEPT PEDIAT, BUNKYO KU, TOKYO 113, JAPAN; HAMAMATSU UNIV SCH MED, DEPT PEDIAT, HAMAMATSU, SHIZUOKA 43131, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT INTERNAL MED 3, KAMIGYO KU, KYOTO 602, JAPAN; AICHI CANC CTR, RES INST, LAB CHEMOTHERAPY, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; SAITAMA CHILDRENS MED CTR, DIV HEMATOL ONCOL, IWATSUKI, SAITAMA 339, JAPAN	National Cancer Center - Japan; University of Tokyo; Hamamatsu University School of Medicine; Kyoto Prefectural University of Medicine; Aichi Cancer Center; Saitama Children's Medical Center				Suzukawa, Kazumi/0000-0001-9904-3905				BEVERLOO HB, 1995, CANCER RES, V55, P4220; CHEN CS, 1993, BLOOD, V81, P2386; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COLLINS C, 1991, GENOMICS, V11, P997, DOI 10.1016/0888-7543(91)90025-A; DJABALI M, 1992, NAT GENET, V2, P113, DOI 10.1038/ng1092-113; DOMER PH, 1995, LEUKEMIA, V9, P1305; FELIX CA, 1995, CANCER RES, V55, P4287; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; GU Y, 1994, CANCER RES, V54, P2327; GU Y, 1992, P NATL ACAD SCI USA, V89, P10464, DOI 10.1073/pnas.89.21.10464; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HUNGER SP, 1993, BLOOD, V81, P3197; IIDA S, 1993, ONCOGENE, V8, P3085; KEARNEY L, 1992, BLOOD, V80, P1659; KODURU PRK, 1993, ONCOGENE, V8, P3239; Kuriyama M, 1996, J BIOL CHEM, V271, P607, DOI 10.1074/jbc.271.2.607; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCKEITHAN TW, 1992, P NATL ACAD SCI USA, V89, P4923, DOI 10.1073/pnas.89.11.4923; MORISHITA K, 1990, ONCOGENE, V5, P963; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NEGRINI M, 1993, CANCER RES, V53, P4489; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; PRASAD R, 1993, CANCER RES, V53, P5624; PUI CH, 1995, LEUKEMIA, V9, P762; RUBNITZ JE, 1994, BLOOD, V84, P570; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANIWAKI M, 1994, BLOOD, V83, P2962, DOI 10.1182/blood.V83.10.2962.2962; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610; ZIEMINVANDERPOEL S, 1991, P NATL ACAD SCI USA, V88, P10735, DOI 10.1073/pnas.88.23.10735	40	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	1996	13	10					2121	2130						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VV145	8950979				2022-12-17	WOS:A1996VV14500009
J	Joh, T; Kagami, Y; Yamamoto, K; Segawa, T; Takizawa, J; Takahashi, T; Ueda, R; Seto, M				Joh, T; Kagami, Y; Yamamoto, K; Segawa, T; Takizawa, J; Takahashi, T; Ueda, R; Seto, M			Identification of MLL and chimeric MLL gene products involved in 11q23 translocation and possible mechanisms of leukemogenesis by MLL truncation	ONCOGENE			English	Article						translocation; 11q23; MLL; AF9/LTG9; ENL/LTG19; leukemogenesis	ACUTE MYELOID LEUKEMIAS; PROLINE-RICH PROTEIN; CHROMOSOMAL TRANSLOCATIONS; DROSOPHILA-TRITHORAX; ALL-1 GENE; EXPRESSION; CLONING; ABNORMALITIES; CELLS; HRX	11q23 chromosome aberrations are frequently observed in infantile as web as therapy-related leukemias, The target gene at 11q23, MLL, is disrupted by the translocation and becomes fused to various translocation partner genes such as AF4/FEL, LTG9/AF9 and LTG19/ENL, The resulting chimeric mRNAs are fused in frame and have been predicted to encode leukemia-specific chimeric proteins, In the present study, we raised antibodies against MLL, LTG9 and LTG19 and demonstrated that MLL and chimeric MLL-LTG9 and MLL-LTG19 products are synthesized in vivo and are localized in the nuclei, using immunofluorescence and cell fractionation studies, The truncated N-terminal portion of the MLL product common to the various types of 11q23 translocation was also localized in the nuclei in a similar fashion, Murine 32Dc13 cells stably expressing the truncated N-terminal MLL protein exhibited an inhibition of differentiation and a growth advantage following stimulation by granulocyte-colony stimulating factor, although the IL-3 dependency was not significantly changed in comparison to the parental cells, These results suggest that the N-terminal portion common to various MLL-chimeric products plays an important role in leukemogenesis.	AICHI CANC CTR, RES INST, LAB CHEMOTHERAPY, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR, RES INST, IMMUNOL LAB, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN; AICHI CANC CTR HOSP, DEPT HEMATOL & CHEMOTHERAPY, CHIKUSA KU, NAGOYA, AICHI 464, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Aichi Cancer Center								ABE R, 1984, CANCER GENET CYTOGEN, V13, P121, DOI 10.1016/0165-4608(84)90053-0; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BERNARD OA, 1994, ONCOGENE, V9, P1039; CHAPLIN T, 1995, BLOOD, V85, P1435, DOI 10.1182/blood.V85.6.1435.bloodjournal8561435; CORRAL J, 1993, P NATL ACAD SCI USA, V90, P8538, DOI 10.1073/pnas.90.18.8538; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DANIEL MT, 1993, BLOOD, V82, P1858; DENDEREN VJ, 1989, J EXP MED, V169, P87; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; IIDA S, 1993, ONCOGENE, V8, P3085; KANEKO Y, 1986, BLOOD, V67, P484; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; MA Q, 1993, P NATL ACAD SCI USA, V90, P6350, DOI 10.1073/pnas.90.13.6350; MAVILIO F, 1989, ONCOGENE, V4, P301; MITANI K, 1995, BLOOD, V85, P2017, DOI 10.1182/blood.V85.8.2017.bloodjournal8582017; MORRISSEY J, 1993, BLOOD, V81, P1124; NAKAMURA T, 1993, P NATL ACAD SCI USA, V90, P4631, DOI 10.1073/pnas.90.10.4631; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; PRASAD R, 1993, CANCER RES, V53, P5624; PRASAD R, 1994, P NATL ACAD SCI USA, V90, P4631; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; PUI CH, 1991, BLOOD, V77, P440; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; ROVERA G, 1989, ANN NY ACAD SCI, V567, P154, DOI 10.1111/j.1749-6632.1989.tb16467.x; ROWLEY JD, 1990, P NATL ACAD SCI USA, V87, P9358, DOI 10.1073/pnas.87.23.9358; RUBNITZ JE, 1994, BLOOD, V84, P1747; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; THIRMAN MJ, 1994, P NATL ACAD SCI USA, V91, P12110, DOI 10.1073/pnas.91.25.12110; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; TRENT JM, 1989, CYTOGENET CELL GENET, V51, P533, DOI 10.1159/000132807; TSE W, 1995, BLOOD, V85, P650, DOI 10.1182/blood.V85.3.650.bloodjournal853650; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; YAMAMOTO K, 1994, BLOOD, V83, P2912, DOI 10.1182/blood.V83.10.2912.2912; YAMAMOTO K, 1993, ONCOGENE, V8, P479; YAMAMOTO K, 1993, ONCOGENE, V8, P2617; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	37	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	1996	13	9					1945	1953						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934541				2022-12-17	WOS:A1996VR79500014
J	Coppee, F; Gerard, AC; Denef, JF; Ledent, C; Vassart, G; Dumont, JE; Parmentier, M				Coppee, F; Gerard, AC; Denef, JF; Ledent, C; Vassart, G; Dumont, JE; Parmentier, M			Early occurrence of metastatic differentiated thyroid carcinomas in transgenic mice expressing the A2a adenosine receptor gene and the human papillomavirus type 16 E7 oncogene	ONCOGENE			English	Article						thyroid cancer; metastatic tumors; hyperthyroidism; cyclic AMP cascade; E7 oncogene; transgenic model	FIBROBLAST GROWTH-FACTOR; TISSUE-SPECIFIC EXPRESSION; INVASIVE BREAST-CARCINOMA; THYROTROPIN RECEPTOR; TUMOR-GROWTH; THYROGLOBULIN GENE; CELL GROWTH; CYCLIC-AMP; ANGIOGENESIS; MUTATIONS	We report here the characterization of a transgenic mouse model (Tg-A2aR/Tg-E7) resulting from the coexpression of tao oncogenic transgenes in the thyroid, The two transgenes (Tg-A2aR and Tg-E7) were placed under control of the thyroid specific thyroglobulin gene promoter, and directed the expression of either the A2a adenosine receptor that constitutively activates the cAMP pathway, or the E7 protein of the human papillomavirus type 16, that binds and inactivates the retinoblastoma susceptibility gene product (Rbl), Transgenic mice expressing both transgenes were generated by interbreeding the Tg-A2aR and Tg-E7 transgenic lines, generated and characterized previously (Ledent et al., 1992, 1995), These mice develop a larger goiter than that of the two parental lines, and a severe hyperthyroidism comparable to that observed in the Tg-A2aR parental Line, The main feature of the Tg-A2aR/Tg-E7 mice is the rapid occurrence of malignant lesions, and the dissemination of malignant thyroid tissue through the blood stream, generating multiple differentiated and functional metastases in the lung, These metastases appeared as early as 2 months after birth and their frequency increased to 75% over 3 months, They were associated with the presence of large vascular lakes in the thyroid, Electron microscopy of the malignant cells revealed nuclear features similar to those of human thyroid papillary carcinoma, These mice, in which two oncogenes are co-expressed in the thyroid, represent the first genetic animal model developing metastatic differentiated carcinomas of the thyroid with a high frequency.	UNIV CATHOLIQUE LOUVAIN, SERV HISTOL, B-1200 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, SERV GENET MED, B-1070 BRUSSELS, BELGIUM	Universite Catholique Louvain; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Coppee, F (corresponding author), FREE UNIV BRUSSELS, IRIBHN, CAMPUS ERASME, 808 ROUTE LENNIK, B-1070 BRUSSELS, BELGIUM.			Parmentier, Marc/0000-0001-8081-4685				ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ASANO M, 1995, CANCER RES, V55, P5296; BECHTNER G, 1993, ACTA ENDOCRINOL-COP, V129, P458, DOI 10.1530/acta.0.1290458; BERNS A, 1989, INT J CANCER, P22; BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; BOSSI P, 1995, CANCER RES, V55, P5049; BREUER M, 1991, RADIAT ENVIRON BIOPH, V30, P181, DOI 10.1007/BF01226614; CHRISTOPHE D, 1990, TRENDS ENDOCRIN MET, V1, P351, DOI 10.1016/1043-2760(90)90083-F; COLIN IM, 1995, ENDOCRINOLOGY, V136, P5283, DOI 10.1210/en.136.12.5283; DAA T, 1993, ACTA PATHOL JAPON, V43, P582; DENEF JF, 1981, ENDOCRINOLOGY, V108, P2352, DOI 10.1210/endo-108-6-2352; Dumont J E, 1971, Vitam Horm, V29, P287; DUMONT JE, 1992, PHYSIOL REV, V72, P667, DOI 10.1152/physrev.1992.72.3.667; DUPREZ L, 1994, NAT GENET, V7, P396, DOI 10.1038/ng0794-396; EMOTO N, 1991, ENDOCRINOLOGY, V128, P58, DOI 10.1210/endo-128-1-58; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; FEIBERG AP, 1983, ANAL BIOCHEM, V132, P6; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; GERARD CM, 1989, MOL ENDOCRINOL, V3, P2110, DOI 10.1210/mend-3-12-2110; GOLDMAN CK, 1993, MOL BIOL CELL, V4, P121, DOI 10.1091/mbc.4.1.121; GREIL W, 1989, MOL ENDOCRINOL, V3, P858, DOI 10.1210/mend-3-5-858; GRIEP AE, 1993, J VIROL, V67, P1373, DOI 10.1128/JVI.67.3.1373-1384.1993; GUIDI AJ, 1994, J NATL CANCER I, V86, P614, DOI 10.1093/jnci/86.8.614; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; HARVEY M, 1995, CANCER RES, V55, P1146; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; LEDENT C, 1992, EMBO J, V11, P537, DOI 10.1002/j.1460-2075.1992.tb05084.x; LEDENT C, 1991, ENDOCRINOLOGY, V129, P1391, DOI 10.1210/endo-129-3-1391; LEDENT C, 1995, ONCOGENE, V10, P1789; LEDENT C, 1990, P NATL ACAD SCI USA, V87, P6176, DOI 10.1073/pnas.87.16.6176; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MAENHAUT C, 1990, BIOCHEM BIOPH RES CO, V173, P1169, DOI 10.1016/S0006-291X(05)80909-X; MAENHAUT C, 1992, J BIOL CHEM, V267, P3000; NEVINS JR, 1992, SCIENCE, V258, P424; NUNEZ J, 1982, VITAM HORM, V39, P175, DOI 10.1016/S0083-6729(08)61137-1; OSULLIVAN C, 1991, MOL CARCINOGEN, V4, P345, DOI 10.1002/mc.2940040503; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; RANGASWAMY M, 1989, NUCL MED COMMUN, V10, P679, DOI 10.1097/00006231-198909000-00007; ROBBINS J, 1991, ANN INTERN MED, V115, P133, DOI 10.7326/0003-4819-115-2-133; ROGER PP, 1984, MOL CELL ENDOCRINOL, V36, P79, DOI 10.1016/0303-7207(84)90087-X; ROGER PP, 1982, MOL CELL ENDOCRINOL, V26, P165, DOI 10.1016/0303-7207(82)90014-4; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SATO K, 1995, J CLIN INVEST, V96, P1295, DOI 10.1172/JCI118164; SCHERBERG NH, 1981, ENDOCRINOLOGY, V109, P1650, DOI 10.1210/endo-109-5-1650; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SUAREZ HG, 1991, ONCOGENE, V6, P677; THOMAS GA, 1989, AM J PATHOL, V134, P141; THOMAS GA, 1991, BRIT J CANCER, V63, P213, DOI 10.1038/bjc.1991.51; USUKI K, 1989, P NATL ACAD SCI USA, V86, P7427, DOI 10.1073/pnas.86.19.7427; VANHEUVERSWYN B, 1984, P NATL ACAD SCI-BIOL, V81, P5941; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WILLIAMS ED, 1992, TOXICOL LETT, V64-5, P375, DOI 10.1016/0378-4274(92)90210-B; WILLIAMS ED, 1979, CLIN ENDOCRINOL META, V8, P193, DOI 10.1016/S0300-595X(79)80017-1; WOEBER KA, 1991, MED CLIN N AM, V75, P169, DOI 10.1016/S0025-7125(16)30477-1; ZACKSENHAUS E, 1993, ADV CANCER RES, V61, P115, DOI 10.1016/S0065-230X(08)60957-4	65	35	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	1996	13	7					1471	1482						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VL384	8875985				2022-12-17	WOS:A1996VL38400012
J	Baasner, S; vonMelchner, H; Klenner, T; Hilgard, P; Beckers, T				Baasner, S; vonMelchner, H; Klenner, T; Hilgard, P; Beckers, T			Reversible tumorigenesis in mice by conditional expression of the HER2/c-erbB2 receptor tyrosine kinase	ONCOGENE			English	Article						HER2/c-erbB2 receptor tyrosine kinase; tetracycline regulated gene expression; conditional mutant; nude mice xenotransplants; secreted human placental alkaline phosphatase	GROWTH-FACTOR-RECEPTOR; INDUCIBLE GENE-EXPRESSION; HIGHER EUKARYOTIC CELLS; MAMMALIAN-CELLS; NEU-ONCOGENE; TRANSGENIC MICE; REGULATED EXPRESSION; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; HUMAN-BREAST	In the present study we describe the reversible transformation of NIH3T3 fibroblasts by overexpression of the HER2/c-erbB2 receptor tyrosine kinase. Cell lines expressing HER2 under control of a tetracycline-responsive promoter were isolated. Induction of HER2 expression resulted in cellular transformation in vitro as depicted by growth in soft agar and focus formation in tissue culture. Subsequent treatment of these cells with the effector anhydrotetracyline switched-off HER2 expression and induced morphological and functional changes characteristic for non-transformed cells. Subcutaneous transplantation of cells in nude mice resulted in the formation of solid tumors. Interestingly tumor formation was completely suppressed by treatment of the animals with anhydrotetracyline. Our findings indicate that overexpression of HER2 induces the transformed phenotype of NIH3T3 cells and is required for tumor formation and progression in nude mice. By linking the expression of the marker gene secreted placental alkaline phosphatase to the expression of HER2, a sensitive monitoring of tumor development in nude mice was feasible.	ASTA MED AG, DEPT CANC RES, D-60314 FRANKFURT, GERMANY; UNIV FRANKFURT, SCH MED, DEPT HEMATOL, LAB MOL HEMATOL, D-60596 FRANKFURT, GERMANY	Goethe University Frankfurt								ALIMANDI M, 1995, ONCOGENE, V10, P1813; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BECKERS T, 1990, EUR J BIOCHEM, V189, P657, DOI 10.1111/j.1432-1033.1990.tb15534.x; BECKERS T, 1994, BIOTECHNIQUES, V16, P1074; BECKERS T, 1995, EUR J BIOCHEM, V231, P535, DOI 10.1111/j.1432-1033.1995.tb20729.x; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; BLOCHLINGER K, 1984, MOL CELL BIOL, V4, P2929, DOI 10.1128/MCB.4.12.2929; BRANDTRAUF PW, 1994, CRIT REV ONCOGENESIS, V5, P313, DOI 10.1615/CritRevOncog.v5.i2-3.100; BRONSTEIN I, 1994, BIOTECHNIQUES, V17, P172; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DRUCKREY H, 1956, DRUG RES, V6, P539; EFRAT S, 1995, P NATL ACAD SCI USA, V92, P3576, DOI 10.1073/pnas.92.8.3576; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GOSSEN M, 1993, NUCLEIC ACIDS RES, V21, P4411, DOI 10.1093/nar/21.18.4411; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HUNG MC, 1986, P NATL ACAD SCI USA, V83, P261, DOI 10.1073/pnas.83.2.261; HYNES NE, 1993, SEMIN CANCER BIOL, V4, P19; KIM HJ, 1995, J VIROL, V69, P2565, DOI 10.1128/JVI.69.4.2565-2573.1995; KING CR, 1985, SCIENCE, V229, P974, DOI 10.1126/science.2992089; LABOW MA, 1995, METHOD ENZYMOL, V254, P375; LEE J, 1989, EMBO J, V8, P167, DOI 10.1002/j.1460-2075.1989.tb03361.x; LEWIS GD, 1993, CANCER IMMUNOL IMMUN, V37, P255, DOI 10.1007/BF01518520; LONARDO F, 1990, New Biologist, V2, P992; PESCINI R, 1994, BIOCHEM BIOPH RES CO, V202, P1664, DOI 10.1006/bbrc.1994.2125; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RIEDEL H, 1988, P NATL ACAD SCI USA, V85, P1477, DOI 10.1073/pnas.85.5.1477; RODER FT, 1994, MOL GEN GENET, V243, P32, DOI 10.1007/BF00283873; SCAHILL SJ, 1983, P NATL ACAD SCI-BIOL, V80, P4654, DOI 10.1073/pnas.80.15.4654; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SCUDIERO DA, 1988, CANCER RES, V48, P4827; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VARA JA, 1986, NUCLEIC ACIDS RES, V14, P4617, DOI 10.1093/nar/14.11.4617; WALKER AK, 1995, METHOD ENZYMOL, V254, P469; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; WIMMEL A, 1994, ONCOGENE, V9, P995; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yarranton Geoffrey T., 1992, Current Opinion in Biotechnology, V3, P506, DOI 10.1016/0958-1669(92)90078-W	56	35	39	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	1996	13	5					901	911						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VG766	8806679				2022-12-17	WOS:A1996VG76600003
J	Zippel, R; Orecchia, S; Sturani, E; Martegani, E				Zippel, R; Orecchia, S; Sturani, E; Martegani, E			The brain specific ras exchange factor CDC25(Mm): Modulation of its activity through Gi-protein-mediated signals	ONCOGENE			English	Article						Ras; exchange factors; GEF; LPA; Ras-GRF	NUCLEOTIDE-RELEASING FACTOR; GROWTH-FACTOR; RECEPTOR; GRB2; IDENTIFICATION; P21(RAS); FIBROBLASTS; ACTIVATION; EXPRESSION; COMPLEX	CDC25(Mm) is a mouse guanine nucleotide exchange factor specific for Ras, exclusively expressed in the Brain. We used a reporter gene containing a Ras-responsive fos-promoter in order to gain information on the role played by this exchange factor in signal transduction. Transient expression of CDC25(Mm) in CHO cells activates Ras, Moreover serum, but not insulin, can upregulate the response mediated by CDC25(Mm) and this modulation requires that the CDC25(Mm) maintains its N-terminal region, NIH3T3 fibroblasts, stably overexpressing this exchange factor, show a partially transformed phenotype, suggesting that the Ras-dependent pathway is constitutively active. In these cells serum and lysophosphatidic acid (LPA) stimulate Ras activity above the basal level while PDGF does not. Both serum and LPA-induced Ras activations in CDC25(Mm) overexpressing cells can be completely inhibited by pertussis toxin, Moreover, these responses are strongly reduced by coexpression of a truncated version of CDC25(Mm) lacking the C-terminal catalytic portion, This construct behaves in a dominant negative manner suggesting that it may compete with CDC25(Mm) by sequestering in an unproductive way signalling components activated by these factors, The data presented indicate that CDC25(Mm) does not participate in connecting tyrosine, kinase receptors with Ras, while it could mediate Ras activation induced by pertussis toxin sensitive Gi-coupled receptors.			Zippel, R (corresponding author), UNIV MILAN,DEPT GEN PHYSIOL & BIOCHEM,VIA CELORIA 26,I-20133 MILAN,ITALY.			Martegani, Enzo/0000-0001-9196-4224				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1995, NATURE, V376, P727, DOI 10.1038/376727a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FEIG LA, 1994, CURR OPIN CELL BIOL, V6, P204, DOI 10.1016/0955-0674(94)90137-6; FERRARI C, 1994, EXP CELL RES, V210, P353, DOI 10.1006/excr.1994.1048; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HOWE LR, 1993, J BIOL CHEM, V268, P20717; JACQUET E, 1992, J BIOL CHEM, V267, P24181; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARTEGANI E, 1992, EMBO J, V11, P2151, DOI 10.1002/j.1460-2075.1992.tb05274.x; MARTEGANI E, 1993, EUR J HISTHCEM, V37, P73; MEDEMA RH, 1991, MOL CELL BIOL, V11, P5963, DOI 10.1128/MCB.11.12.5963; MOOLENAAR WH, 1995, CURR OPIN CELL BIOL, V7, P203, DOI 10.1016/0955-0674(95)80029-8; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SCHWEIGHOFFER F, 1993, ONCOGENE, V8, P1477; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SHOU CC, 1995, ONCOGENE, V10, P1887; STURANI E, 1989, FEBS LETT, V255, P191, DOI 10.1016/0014-5793(89)81089-0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WEI W, 1994, GENE, V151, P279, DOI 10.1016/0378-1119(94)90671-8; WEI W, 1993, MOL BRAIN RES, V19, P339, DOI 10.1016/0169-328X(93)90136-D; ZIPPEL R, 1986, BIOCHIM BIOPHYS ACTA, V881, P54, DOI 10.1016/0304-4165(86)90096-6; ZIPPEL R, 1994, INT J ONCOL, V4, P175	34	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2697	2703						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700529				2022-12-17	WOS:A1996UW48700024
J	SCALES, JB; WINNING, RS; RENAUD, CS; SHEA, LJ; SARGENT, TD				SCALES, JB; WINNING, RS; RENAUD, CS; SHEA, LJ; SARGENT, TD			NOVEL MEMBERS OF THE EPH RECEPTOR TYROSINE KINASE SUBFAMILY EXPRESSED DURING XENOPUS DEVELOPMENT	ONCOGENE			English	Article						EPH; RECEPTOR TYROSINE KINASE; XENOPUS; CEMENT GLAND	DIFFERENTIAL EXPRESSION; GENE-EXPRESSION; PROTEIN; FAMILY; CLONING; LAEVIS; ELK; IDENTIFICATION; DROSOPHILA; HINDBRAIN	Three cDNAs encoding receptor tyrosine kinases (RTKs) of the eph-subfamily have been identified based on their homology to Pagliaccio (Winning and Sargent, 1994, Mech. Dev. 46:219-229). These have been named TCK, Xelk (Xenopus homologue of elk), and PL7a (pag-like clone 7a). Each of these genes is expressed in a distinctive, tissue specific manner during early development. TCR is expressed in pre-semitic mesoderm, caudal somites, midbrain and cement gland, Xelk is expressed in the brain and spinal cord and in the first and fourth visceral arches. PL7a cDNA is expressed throughout the head and in the tip of the tab. All of the genes are represented in maternal mRNA, and are expressed in adult tissues. The Xelk cDNA encodes a protein which is 94% identical to rat elk and therefore is likely to represent the Xenopus homologue of this gene. TCK and PL7a are less related to previously identified eph-subfamily RTKs. The inability to unambiguously assign TCK and PL7a as Xenopus homologues of any previously identified eph RTK leads us to conclude that these cDNAs represent novel members of this family.	NICHHD,MOLEC GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDRES AC, 1994, ONCOGENE, V9, P1461; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BENNETT BD, 1994, J BIOL CHEM, V269, P14211; BLITZ IL, 1995, DEVELOPMENT, V121, P993; BOHME B, 1993, ONCOGENE, V8, P2857; CHAN J, 1991, ONCOGENE, V6, P1057; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COHN MJ, 1995, CELL, V80, P739, DOI 10.1016/0092-8674(95)90352-6; FOX GM, 1995, ONCOGENE, V10, P897; GILARDIHEBENSTREIT, 1992, ONCOGENE, V7, P2499; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HIRAI H, 1987, SCIENCE, V238, P1717, DOI 10.1126/science.2825356; JAMRICH M, 1989, DEVELOPMENT, V105, P779; JONES TL, 1995, ONCOGENE, V11, P1111; KOBEL HR, 1986, TRENDS GENET, V2, P310, DOI 10.1016/0168-9525(86)90286-6; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LHOTAK V, 1993, MOL CELL BIOL, V13, P7071, DOI 10.1128/MCB.13.11.7071; LINDBERG RA, 1990, MOL CELL BIOL, V10, P6316, DOI 10.1128/MCB.10.12.6316; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATHERS PH, 1995, IN PRESS DEV BIOL; NIETO MA, 1992, DEVELOPMENT, V116, P1137; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; PANNESE M, 1995, DEVELOPMENT, V121, P707; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; RICHTER K, 1988, P NATL ACAD SCI USA, V85, P8086, DOI 10.1073/pnas.85.21.8086; SAJJADI FG, 1993, ONCOGENE, V8, P1807; SARGENT TD, 1986, DEV BIOL, V114, P238, DOI 10.1016/0012-1606(86)90399-4; SCALES JB, 1991, CELL GROWTH DIFFER, V2, P619; TUZI NL, 1994, BRIT J CANCER, V19, P417; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WINNING RS, 1994, MECH DEVELOP, V46, P219, DOI 10.1016/0925-4773(94)90072-8; 1994, WISCONSIN GCG PACKAG	41	35	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	NOV 2	1995	11	9					1745	1752						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TD094	7478602				2022-12-17	WOS:A1995TD09400009
J	KATZAV, S; PACKHAM, G; SUTHERLAND, M; AROCA, P; SANTOS, E; CLEVELAND, JL				KATZAV, S; PACKHAM, G; SUTHERLAND, M; AROCA, P; SANTOS, E; CLEVELAND, JL			VAV AND RAS INDUCE FIBROBLAST TRANSFORMATION BY OVERLAPPING SIGNALING PATHWAYS, WHICH REQUIRE C-MYC FUNCTION	ONCOGENE			English	Article						VAV; VAS; C-MYC; SH2	TYROSINE PHOSPHORYLATION; PROTOONCOGENE PRODUCT; ORNITHINE DECARBOXYLASE; HEMATOPOIETIC-CELLS; TRANSCRIPTIONAL ACTIVATION; NEOPLASTIC TRANSFORMATION; SH2 DOMAIN; PROTEIN; EXPRESSION; KINASE	Recent evidence has suggested that the Vav oncoprotein may function as a hematopoietic-specific GTP exchange factor for the Ras superfamily of proteins, However, transformation of NIH3T3 fibroblast cells by Vav is morphologically distinct from that induced by activated Ras oncogenes, suggesting that the two oncoproteins induce separate signal transduction pathways which promote transformation, To address this issue, the effects of dominant negative mutants of H-ras and proto-Vav (proto-VavR695L, a mutation in the VavSH2 domain) were tested on Vav- and Ras-induced transformation, These mutants partially inhibited both Vav- and Ras-induced transformation, suggesting that they may induce a common downstream signaling pathway which potentiates transformation, As an independent measure of Vav function we also tested the ability of the purified protein encoded by VavSH2 to influence Germinal Vesicle Breakdown (GVBD) during Xenopus oocyte maturation, Microinjection of the VavSH2 protein alone, but not mutant VavR695L SH2 protein, was sufficient to induce GVBD and accelerated maturation induced by normal Ras, suggesting that in this system as well Vav and Ras signals overlap through a common effector, A key target of multiple signalling pathways is c-Myc. Dominant negative versions of c-Myc totally abolished morphologic transformation of NIH3T3 cells by both Vav and Ras oncogenes, These results suggest that distinct, but overlapping, signalling pathways are induced by Vav and Ras and that fibroblast cell transformation by either oncogene requires c-Myc functions.	MCGILL UNIV, DEPT ONCOL, MONTREAL, PQ H3G 1Y6, CANADA; MCGILL UNIV, DEPT MED, MONTREAL, PQ H3G 1Y6, CANADA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; NCI, CELLULAR & MOLEC BIOL LAB, BETHESDA, MD 20892 USA; UNIV TENNESSEE, CTR HLTH SCI, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	McGill University; McGill University; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Tennessee System; University of Tennessee Health Science Center	KATZAV, S (corresponding author), MCGILL UNIV, JEWISH GEN HOSP, LADY DAVIS INST MED RES, TERRY FOX MOLEC ONCOL GRP, MONTREAL, PQ H3T 1E2, CANADA.			Aroca, Pilar/0000-0002-7557-6931	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044158] Funding Source: NIH RePORTER; NCI NIH HHS [P0 CA21765] Funding Source: Medline; NIDDK NIH HHS [DK44158] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADAMS JM, 1992, ONCOGENE, V7, P611; ALAI M, 1992, J BIOL CHEM, V267, P18021; ALITALO K, 1987, BIOCHIM BIOPHYS ACTA, V907, P1, DOI 10.1016/0304-419X(87)90016-3; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; ASKEW DS, 1993, BLOOD, V82, P2079; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BENTINO M, 1991, SCIENCE, V253, P565; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BROUGH DE, 1995, MOL CELL BIOL, V15, P1536; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUSTELO XR, 1994, ONCOGENE, V9, P2405; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; BUSTELO XR, 1992, NATURE, V356, P69; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; COPPOLA J, 1991, CELL GROWTH DIFFER, V2, P95; DANG CV, 1989, NATURE, V337, P664, DOI 10.1038/337664a0; DOSIL M, 1993, MOL CELL BIOL, V13, P6572, DOI 10.1128/MCB.13.10.6572; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS GA, 1993, BIOCHEM J, V294, P339, DOI 10.1042/bj2940339; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GALLAND F, 1992, ONCOGENE, V7, P585; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GULBINS E, 1993, SCIENCE, V260, P822, DOI 10.1126/science.8484124; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; GULBINS E, 1994, J IMMUNOL, V152, P2123; HAKES DJ, 1992, ANAL BIOCHEM, V202, P293, DOI 10.1016/0003-2697(92)90108-J; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HALL A, 1994, SCIENCE, V264, P1413, DOI 10.1126/science.8197454; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; KATZAV S, 1993, ONCOGENE, V8, P1757; KATZAV S, 1994, J BIOL CHEM, V269, P32579; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P2095, DOI 10.1021/bi00007a002; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MIN SY, 1994, CELL GROWTH DIFFER, V5, P563; MIURA O, 1994, BLOOD, V84, P4135, DOI 10.1182/blood.V84.12.4135.bloodjournal84124135; MURKHERJEE B, 1992, GENE DEV, V6, P1480; MUSLIN AJ, 1993, MOL CELL BIOL, V13, P6661, DOI 10.1128/MCB.13.11.6661; NEBREDA AR, 1993, ONCOGENE, V8, P467; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PENA A, 1993, J BIOL CHEM, V268, P27277; PLATANIAS LC, 1994, J BIOL CHEM, V269, P3143; PORRAS A, 1994, J BIOL CHEM, V269, P12741; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PRENDERGAST GC, 1991, CELL, V65, P186; PUIL L, 1992, Current Biology, V2, P275, DOI 10.1016/0960-9822(92)90396-R; RESAR LMS, 1993, MOL CELL BIOL, V13, P1130, DOI 10.1128/MCB.13.2.1130; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SARID J, 1987, P NATL ACAD SCI USA, V84, P170, DOI 10.1073/pnas.84.1.170; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SKLAR MD, 1991, MOL CELL BIOL, V11, P3699, DOI 10.1128/MCB.11.7.3699; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAVIGIAN SV, 1994, MOL CELL BIOL WAGNJ, V5, P375; WAGNER AJ, 1993, CELL GROWTH DIFFER, V4, P879; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629	84	35	35	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1079	1088						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566967				2022-12-17	WOS:A1995RX18000010
J	REZZONICO, R; LOUBAT, A; LALLEMAND, D; PFARR, CM; FAR, DF; PROUDFOOT, A; ROSSI, B; PONZIO, G				REZZONICO, R; LOUBAT, A; LALLEMAND, D; PFARR, CM; FAR, DF; PROUDFOOT, A; ROSSI, B; PONZIO, G			CYCLIC-AMP STIMULATES A JUND/FRA-2 AP-1 COMPLEX AND INHIBITS THE PROLIFERATION OF INTERLEUKIN-6-DEPENDENT CELL-LINES	ONCOGENE			English	Article						ANTIPROLIFERATIVE EFFECT; AP-1; CYCLIC AMP; FRA-2; JUN D; INTERLEUKIN-6	TRANSCRIPTION FACTOR AP-1; DNA-BINDING ACTIVITY; C-JUN; MACROPHAGE DIFFERENTIATION; GENE-TRANSCRIPTION; ENHANCER ACTIVITY; GROWTH-HORMONE; NUCLEAR FACTOR; PHORBOL ESTER; FOS	Interleukin-6 (IL-6) is a proinflammatory cytokine which also acts as a growth factor for some murine hybridomas (7TD1) or human myelomas (U266). We demonstrate that elevation of cAMP cellular content inhibits IL-6-stimulated cell growth, by blocking cells mainly in G1 phase. This inhibition is associated with increased expression of the Fos family protein Fra-2. Treatment of cells with 8Br-cAMP results in increased DNA-binding activity of two distinct AP-1 complexes; JunD/Fra-2 and JunB/Fra-2, and also in elevated AP-1 transactivation. When 8Br-cAMP is withdrawn from the medium, cells enter S phase and Fra-2 protein levels and AP-1 DNA-binding activity decrease to their basal value indicating that a temporally correlation exists between the 8Br-cAMP-mediated induction of JunD/Fra-2 AP-1 complex and the 7TD1 and U266 cell growth inhibition.	FAC MED NICE,INSERM,U364,F-06107 NICE 02,FRANCE; INST PASTEUR,DEPT BIOTECHNOL,ONCOGEN VIRUSES UNIT,F-75724 PARIS 15,FRANCE; GLAXO INST MOLEC BIOL SA,GENEVA,SWITZERLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GlaxoSmithKline			Ponzio, Gilles/Q-1256-2016; Pfarr, Curt/HHD-1410-2022; lallemand, dominique/O-7445-2017; REZZONICO, Roger/N-9626-2016	Ponzio, Gilles/0000-0003-2741-0248; lallemand, dominique/0000-0002-0212-7342; REZZONICO, Roger/0000-0002-8460-1641				ABATE C, 1991, MOL CELL BIOL, V11, P3624, DOI 10.1128/MCB.11.7.3624; ADUNYAH SE, 1991, J BIOL CHEM, V266, P5670; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V129, P1072; BETTS JC, 1993, J BIOL CHEM, V268, P25624; BLOMHOFF HK, 1987, J CELL PHYSIOL, V131, P426, DOI 10.1002/jcp.1041310315; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Distel R J, 1990, Adv Cancer Res, V55, P37, DOI 10.1016/S0065-230X(08)60467-4; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; DOGLIO A, 1986, BIOCHEM J, V238, P123, DOI 10.1042/bj2380123; ELLEDGE SJ, 1994, CURR OPIN CELL BIOL, V6, P847, DOI 10.1016/0955-0674(94)90055-8; GRUDA MC, 1994, ONCOGENE, V9, P2537; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI S-I, 1989, New Biologist, V1, P181; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KAMEDA T, 1993, P NATL ACAD SCI USA, V90, P9369, DOI 10.1073/pnas.90.20.9369; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KIMURA E, 1993, MOL ENDOCRINOL, V7, P1463, DOI 10.1210/me.7.11.1463; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KUMAR G, 1994, J IMMUNOL, V153, P4436; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MASQUILIER D, 1992, J BIOL CHEM, V267, P22460; MATSUI M, 1990, ONCOGENE, V5, P249; MELAMED D, 1993, CELL GROWTH DIFFER, V4, P689; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; NATSUKA S, 1992, BLOOD, V79, P460; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; PROUDFOOT AEI, 1993, J PROTEIN CHEM, V12, P489, DOI 10.1007/BF01025050; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; REZZONICO R, 1995, J BIOL CHEM, V270, P1261, DOI 10.1074/jbc.270.3.1261; ROCK CO, 1992, MOL CELL BIOL, V12, P2351, DOI 10.1128/MCB.12.5.2351; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SCHWAB G, 1991, BLOOD, V77, P587; STANKOVA J, 1992, BIOCHEM J, V282, P625; SUZUKI T, 1991, NUCLEIC ACIDS RES, V19, P5537, DOI 10.1093/nar/19.20.5537; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAMIR A, 1994, J IMMUNOL, V152, P3391; TREJO J, 1992, MOL CELL BIOL, V12, P4742, DOI 10.1128/MCB.12.10.4742; VAIRO G, 1990, J BIOL CHEM, V265, P2692; VANSNICK J, 1986, P NATL ACAD SCI USA, V83, P9676; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGENKA UM, 1994, MOL CELL BIOL, V14, P1386; WILLIAM F, 1990, J BIOL CHEM, V265, P18166; WOLLBERG P, 1994, J BIOL CHEM, V269, P19719; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YOSHIDA T, 1993, NUCLEIC ACIDS RES, V21, P2715, DOI 10.1093/nar/21.11.2715; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	70	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1069	1078						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566966				2022-12-17	WOS:A1995RX18000009
J	CASOLA, S; UNGARO, P; PEDONE, PV; LAZZARO, D; FATTORI, E; CILIBERTO, G; ZARRILLI, R; BRUNI, CB; RICCIO, A				CASOLA, S; UNGARO, P; PEDONE, PV; LAZZARO, D; FATTORI, E; CILIBERTO, G; ZARRILLI, R; BRUNI, CB; RICCIO, A			LOSS OF HETEROZYGOSITY OF IMPRINTED GENES IN SV40 T/T ANTIGEN-INDUCED HEPATOCELLULAR CARCINOMAS	ONCOGENE			English	Article						GENOMIC IMPRINTING; CHROMOSOME IMBALANCES; HEPATOCARCINOGENESIS	GROWTH-FACTOR-II; MOUSE CHROMOSOME-7; TRANSGENIC MICE; WILMS-TUMOR; CANCER; RAT; EXPRESSION; RNA; H19; HEPATOCARCINOGENESIS	Expression of the chromosomally linked Insulin-like Growth Factor II (IGF-II) and H19 genes is regulated by parental imprinting during development, since the maternally inherited IGF-II and the paternally inherited H19 alleles are inactive in fetal tissues. Here we show that expression of IGF-II and H19 genes is activated in transgenic mice during SV40 Tag-induced hepatocarcinogenesis and that imprinting of both genes is conserved in the liver tumors. Allelic imbalances of IGF-II and H19 genes and other chromosome 7 markers were detected in one third (13/39) of the hepatocellular carcinomas analysed. A strong bias on the allele retained in the neoplasms was observed, since underrepresentation or complete loss of maternal chromosome 7 was recognised in 12/13 cases. High levels of IGF-II mRNA were expressed by all carcinomas with relative excess of paternal chromosome 7 alleles and suppressed H19 expression was found in the neoplasms lacking the maternal alleles. Overall the results indicate that expression of imprinted genes is involved in progression of experimental liver tumors and suggest that the murine chromosome 7, whose loss may possibly cause the inactivation of a growth-inhibitory gene, is preferentially retained as paternal copy in the liver tumors because of parental imprinting of IGF-II gene.	UNIV NAPLES FEDERICO II,CTR ENDOCRINOL & ONCOL SPERIMENTALE,CNR,I-80131 NAPLES,ITALY; UNIV NAPLES FEDERICO II,DIPARTIMENTO BIOL & PATOL CELLULARE & MOLEC,I-80131 NAPLES,ITALY; IST RIC BIOL MOLEC P ANGELETTI,DEPT GENET,I-00040 POMEZIA,ITALY	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; University of Naples Federico II			Casola, Stefano/O-3922-2014; Casola, Stefano/AAN-8319-2021; Riccio, Andrea/A-4991-2015; Ciliberto, Gennaro/J-4131-2017; Zarrilli, Raffaele/F-5067-2012; Riccio, Andrea/AAY-7571-2020; Cerrato, Flavia/O-8315-2015	Casola, Stefano/0000-0001-5580-0986; Riccio, Andrea/0000-0001-7990-3576; Ciliberto, Gennaro/0000-0003-2851-8605; Zarrilli, Raffaele/0000-0003-4191-9032; Riccio, Andrea/0000-0001-7990-3576; Cerrato, Flavia/0000-0003-3794-3021; Pedone, Paolo Vincenzo/0000-0002-0828-5843				ALBRECHT S, 1994, CANCER RES, V54, P5041; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; BIRAN H, 1994, TUMOR BIOL, V15, P123, DOI 10.1159/000217882; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; CHIARIOTTI L, 1988, MOL ENDOCRINOL, V2, P1115, DOI 10.1210/mend-2-11-1115; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHRISTOFORI G, 1994, NATURE, V369, P414, DOI 10.1038/369414a0; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK G, 1980, STAINING PROCEDURES; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSONSMITH AC, 1991, NATURE, V351, P667, DOI 10.1038/351667a0; FUJIMORI M, 1991, CANCER RES, V51, P89; HAO Y, 1993, NATURE, V365, P764, DOI 10.1038/365764a0; HELD WA, 1994, CANCER RES, V54, P6489; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; HOLDENER BC, 1993, MAMM GENOME, V4, pS110, DOI 10.1007/BF00360833; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; KONDO M, 1995, ONCOGENE, V10, P1193; LITTLE M, 1991, NATURE, V351, P609, DOI 10.1038/351609a0; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; NORSTEDT G, 1988, CARCINOGENESIS, V9, P209, DOI 10.1093/carcin/9.2.209; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; PACHNIS V, 1988, EMBO J, V7, P673, DOI 10.1002/j.1460-2075.1988.tb02862.x; PACHNIS V, 1984, P NATL ACAD SCI-BIOL, V81, P5523, DOI 10.1073/pnas.81.17.5523; PAL N, 1990, ONCOGENE, V5, P1665; PEDONE PV, 1994, J BIOL CHEM, V269, P23970; PEDONE PV, 1994, HUM MOL GENET, V7, P1117; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; ROGLER CE, 1994, J BIOL CHEM, V269, P13779; Rotwein P, 1991, Growth Factors, V5, P3, DOI 10.3109/08977199109000267; RUTHER U, 1993, ONCOGENE, V8, P87; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIRMACHER P, 1992, CANCER RES, V52, P2549; SCOTT J, 1985, NATURE, V317, P174; SCRABLE H, 1989, P NATL ACAD SCI USA, V86, P7480, DOI 10.1073/pnas.86.19.7480; SEIZINGER BR, 1991, CYTOGENET CELL GENET, V58, P1080, DOI 10.1159/000133722; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; SUNDELIN J, 1985, J BIOL CHEM, V260, P6472; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; UENO T, 1988, CARCINOGENESIS, V9, P1779, DOI 10.1093/carcin/9.10.1779; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WANG HP, 1988, CYTOGENET CELL GENET, V48, P72, DOI 10.1159/000132593; WEKSBERG R, 1993, NAT GENET, V5, P143, DOI 10.1038/ng1093-143; ZARRILLI R, 1992, EUR J BIOCHEM, V209, P445, DOI 10.1111/j.1432-1033.1992.tb17308.x; ZARRILLI R, 1994, MOL CELL ENDOCRINOL, V101, pR1, DOI 10.1016/0303-7207(94)90253-4; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344	56	35	35	0	8	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 17	1995	11	4					711	721						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ469	7651735				2022-12-17	WOS:A1995RQ46900013
J	MARSHALL, GM; CHEUNG, B; STACEY, KP; CAMACHO, ML; SIMPSON, AM; KWAN, E; SMITH, S; HABER, M; NORRIS, MD				MARSHALL, GM; CHEUNG, B; STACEY, KP; CAMACHO, ML; SIMPSON, AM; KWAN, E; SMITH, S; HABER, M; NORRIS, MD			INCREASED RETINOIC ACID RECEPTOR-GAMMA EXPRESSION SUPPRESSES THE MALIGNANT PHENOTYPE AND ALTERS THE DIFFERENTIATION POTENTIAL OF HUMAN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article						DIFFERENTIATION; RETINOIC ACID RECEPTOR GAMMA; NEUROBLASTOMA; RETINOIC ACID	BINDING-PROTEINS; MOUSE; GENE; GROWTH; TRANSCRIPTION; PATTERN; CANCER	Human neuroblastoma (NB) tumor cell lines treated in vitro with the retinoid, all-trans-retinoic acid (aRA), form neurites and undergo growth arrest, Retinoids exert their diverse morphologic effects through a signalling pathway which involves the nuclear retinoid receptors, Defective retinoic acid receptor (RAR) function contributes to the malignant phenotype of several human and experimental tumors. Considerable evidence from gene disruption studies now suggests that one of the RARs, RAR gamma, may directly mediate some retinoid effects on embryonic and malignant cells. We, firstly, examined primary NE tumor tissue for a correlation between endogenous RAR gamma expression and clinical stage of the tumor and secondly, the effects of exogenous overexpression of the RAR gamma gene on a human NE tumor cell line. RAR gamma mRNA expression in 32 primary NE tumor tissue samples were significantly higher in clinically localised tumors compared with advanced or disseminated tumors. The human NE tumor cell line, BE(2)-C, was stably transfected with a mammalian expression (pREP4) over-expressing the human RAR gamma cDNA. Two selected clones over-expressing RAR gamma and 2) exhibited a reduced growth rate compared to control cells, Tumorigenicity was inhibited for BE/G1 cells and there was a delayed onset to tumor formation for BE/G2, cells. aRA caused growth inhibition but not neuritic differentiation of the BE/G clones, while 9-cis-retinoic acid caused both growth arrest and neuritic differentiation. Taken together these results suggest that reduced endogenous RAR gamma expression may contribute to the malignant phenotype of human NE. In NE cells the retinoid signalling pathway for neuritic differentiation may be distinct from that causing growth inhibition.	UNIV NEW S WALES,FAC MED,SCH PAEDIAT,KENSINGTON,NSW 2033,AUSTRALIA; UNIV TECHNOL SYDNEY,DEPT BIOCHEM & PHYSIOL,BROADWAY 2007,AUSTRALIA	University of New South Wales Sydney; University of Technology Sydney	MARSHALL, GM (corresponding author), PRINCE WALES CHILDRENS HOSP,CHILDRENS LEUKAEMIA & CANC RES CTR,HIGH ST,RANDWICK,NSW 2031,AUSTRALIA.		Greenwood, Kathryn/U-6965-2017	Greenwood, Kathryn/0000-0002-1556-0065; Cheung, Belamy/0000-0001-8784-860X; Haber, Michelle/0000-0003-2036-8817; Norris, Murray/0000-0002-0632-4589				ALLENBY G, 1993, P NATL ACAD SCI USA, V90, P30, DOI 10.1073/pnas.90.1.30; AZAR CG, 1990, CELL GROWTH DIFFER, V1, P421; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BASELGA J, 1993, ONCOGENE, V8, P3257; BECKWITH JB, 1963, AM J PATHOL, V43, P1089; BORDOW SB, 1994, CANCER RES, V54, P5036; BOYLAN JF, 1993, P NATL ACAD SCI USA, V90, P9601, DOI 10.1073/pnas.90.20.9601; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; CHAMBON P, 1993, GENE, V135, P223, DOI 10.1016/0378-1119(93)90069-F; CLAGETTDAME M, 1993, ARCH BIOCHEM BIOPHYS, V300, P684, DOI 10.1006/abbi.1993.1095; Cushing H, 1927, AM J PATHOL, V3, P203; DAWSON MI, 1994, BLOOD, V84, P446; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DOLLE P, 1990, DEVELOPMENT, V110, P1133; Evans A E, 1976, Natl Cancer Inst Monogr, V44, P49; EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO;2-G; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HIGUCHI T, 1991, CANCER RES, V51, P3958; ISHIKAWA T, 1990, MOL ENDOCRINOL, V4, P837, DOI 10.1210/mend-4-6-837; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LOHNES D, 1993, CELL, V73, P643, DOI 10.1016/0092-8674(93)90246-M; LUFKIN T, 1993, P NATL ACAD SCI USA, V90, P7225, DOI 10.1073/pnas.90.15.7225; MACMILLAN RW, 1976, J PEDIATR SURG, V11, P461, DOI 10.1016/S0022-3468(76)80204-7; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MARSHALL GM, 1994, ANTICANCER RES, V13, P437; MOASSER MM, 1994, ONCOGENE, V9, P833; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; PAHLMAN S, 1984, CELL DIFFER DEV, V14, P135, DOI 10.1016/0045-6039(84)90038-1; ROCHETTEEGLY C, 1991, J CELL BIOL, V115, P535, DOI 10.1083/jcb.115.2.535; ROUSSELOT P, 1994, ONCOGENE, V9, P545; RUBERTE E, 1990, DEVELOPMENT, V108, P213; RUBERTE E, 1991, DEVELOPMENT, V111, P45; Sambrook J., 1989, MOL CLONING LABOROAT; SIDELL N, 1983, EXP CELL RES, V148, P21, DOI 10.1016/0014-4827(83)90184-2; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; THALLER C, 1990, NATURE, V345, P815, DOI 10.1038/345815a0; WUARIN L, 1994, INT J CANCER, V56, P840, DOI 10.1002/ijc.2910560615; XU XC, 1994, CANCER RES, V54, P3580	42	35	36	0	6	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	AUG 3	1995	11	3					485	491						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN530	7630632				2022-12-17	WOS:A1995RN53000008
J	TSUDA, T; MARINETTI, MR; MASUELLI, L; CUTLER, ML				TSUDA, T; MARINETTI, MR; MASUELLI, L; CUTLER, ML			THE RAS SUPPRESSOR RSU-1 LOCALIZES TO 10P13 AND ITS EXPRESSION IN THE U251 GLIOBLASTOMA CELL-LINE CORRELATES WITH A DECREASE IN GROWTH-RATE AND TUMORIGENIC POTENTIAL	ONCOGENE			English	Note						RSU-1; GLIOBLASTOMA, TUMOR SUPPRESSOR	SACCHAROMYCES-CEREVISIAE; FACTOR RECEPTOR; TYPE-1 NEUROFIBROMATOSIS; ADENYLYL CYCLASE; HUMAN GLIOMAS; BRAIN-TUMORS; GENE; CHROMOSOME-10; HETEROZYGOSITY; MULTIFORME	Rsu-1, which was isolated based on its ability to suppress transformation by v-Ras, is a highly conserved gene which shares homology with yeast adenylyl cyclase in the region required for activation by Ras, Genomic DNA clones of human RSU-1 have been isolated and used as a probe for fluorescence in situ hybridization (FISH) to assign RSU-1 to 10p13, confirming the previous results of somatic cell hybrid mapping localizing RSU-1 to chromosome 10. Screening of more than 20 human tumor cell lines for RSU-1 expression revealed that most cell lines contained abundant RSU-1 RNA and protein. However, the p33 RSU-1 protein was undetectable in the U251 glioblastoma cell line and transfection of a rsu-1 expression vector into U251 cells yielded a cell line in which rsu-1 was under the control of a regulatable metallothionein promoter. Addition of Cd2+ to the U251-Rsu-1 transfectant resulted in transcription of rsu-1 RNA and the accumulation of p33 Rsu-1 protein. Appearance of the Rsu-1 protein correlated with a reduction in growth rate of the U251-Rsu-1 transfectant. In addition, reduction in anchorage independent growth and phenotypic alteration in U251-Rsu-1 transfectant agar colonies was observed. Two U251-Rsu-1 transfectant cell lines were non tumorigenic when injected subcutaneously into athymic nude mice. These results, in conjunction with the frequent deletions observed in chromosome 10 in glioblastomas, suggest that RSU-1 loss of function may play a role in the progression of this disease.	NCI,TUMOR IMMUNOL & BIOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Masuelli, Laura/AGW-4259-2022; Cutler, Mary L/G-5735-2017	Cutler, Mary L/0000-0001-9727-4320; MASUELLI, Laura/0000-0001-8174-8034				AMBROSE D, 1994, J CELL PHYSIOL, V159, P92, DOI 10.1002/jcp.1041590113; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BERKMAN RA, 1992, J NEUROSURG, V77, P432, DOI 10.3171/jns.1992.77.3.0432; BIGNER SH, 1988, CANCER RES, V48, P405; CAVENEE WK, 1992, CANCER, V70, P1788, DOI 10.1002/1097-0142(19920915)70:4+<1788::AID-CNCR2820701621>3.0.CO;2-L; COLICELLI J, 1990, MOL CELL BIOL, V10, P2539, DOI 10.1128/MCB.10.6.2539; CUTLER ML, 1992, MOL CELL BIOL, V12, P3750, DOI 10.1128/MCB.12.9.3750; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FUJIMOTO M, 1989, GENOMICS, V4, P210, DOI 10.1016/0888-7543(89)90302-9; FULTS D, 1993, GENE CHROMOSOME CANC, V7, P173, DOI 10.1002/gcc.2870070311; FULTS D, 1990, CANCER RES, V50, P5784; JAMES CD, 1988, CANCER RES, V48, P5546; JAMES CD, 1990, CANCER SURV, V9, P631; JAROS E, 1992, BRIT J CANCER, V66, P373, DOI 10.1038/bjc.1992.273; JOHNSON MR, 1993, P NATL ACAD SCI USA, V90, P5539, DOI 10.1073/pnas.90.12.5539; JOHNSON MR, 1994, MOL CELL BIOL, V14, P641, DOI 10.1128/MCB.14.1.641; KRANTZ DD, 1991, J BIOL CHEM, V266, P16801; MARK J, 1977, HEREDITAS, V87, P243; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; PERSHOUSE MA, 1993, CANCER RES, V53, P5043; RANSOM DT, 1992, GENE CHROMOSOME CANC, V5, P357, DOI 10.1002/gcc.2870050412; RASHEED BKA, 1992, GENE CHROMOSOME CANC, V5, P75, DOI 10.1002/gcc.2870050111; RESNICOFF M, 1994, CANCER RES, V54, P2218; SHAMAH SM, 1993, MOL CELL BIOL, V13, P7203, DOI 10.1128/MCB.13.12.7203; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; SOLOMON E, 1991, SCIENCE, V254, P1153, DOI 10.1126/science.1957167; SUZUKI N, 1990, P NATL ACAD SCI USA, V87, P8711, DOI 10.1073/pnas.87.22.8711; TROJAN J, 1992, P NATL ACAD SCI USA, V89, P4874, DOI 10.1073/pnas.89.11.4874; TROJAN J, 1993, SCIENCE, V259, P9497; TSUDA T, 1993, GENOMICS, V18, P461, DOI 10.1006/geno.1993.1503; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; VONDEIMLING A, 1992, J NEUROSURG, V77, P295, DOI 10.3171/jns.1992.77.2.0295; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YE Z, 1993, NEUROL RES, V15, P59, DOI 10.1080/01616412.1993.11740109	43	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					397	403						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624154				2022-12-17	WOS:A1995RK95700021
J	WILLIAMS, AC; MILLER, JC; COLLARD, TJ; BRACEY, TS; COSULICH, S; PARASKEVA, C				WILLIAMS, AC; MILLER, JC; COLLARD, TJ; BRACEY, TS; COSULICH, S; PARASKEVA, C			MUTANT P53 IS NOT FULLY DOMINANT OVER ENDOGENOUS WILD-TYPE P53 IN A COLORECTAL ADENOMA CELL-LINE AS DEMONSTRATED BY INDUCTION OF MDM2 PROTEIN AND RETENTION OF A P53 DEPENDENT G1 ARREST AFTER GAMMA-IRRADIATION	ONCOGENE			English	Article						P53; COLON; ADENOMA; MDM2; G1 ARREST; GAMMA IRRADIATION; TGF-BETA	AUTOREGULATORY FEEDBACK LOOP; TUMOR-SUPPRESSOR GENE; BINDING-SITE; CANCER CELLS; MUTATIONS; GROWTH; DNA; TRANSFORMATION; EXPRESSION; APOPTOSIS	To determine whether a single mutational event in one p53 gene is sufficient to confer a significant growth advantage on a colonic epithelial cell, the 143(Ala) p53 mutation was previously expressed in the human colonic adenoma derived cell line AA/C1 (which is wild type for p53) and shown to have no effect on it's in vitro or in vivo growth characteristics. In this investigation, by expressing the 175(His), 248(Trp) or 273(His) mutations in the same AA/C1 cell line, we have shown that this failure to affect the growth of the cells was not mutant specific. We have also demonstrated, using induction of MDM2 protein and the ability of the cells to undergo a p53 dependent G1 arrest, that the 143(Ala), 175(His) or 248(Trp) transfected cells retain functional endogenous wild type p53 activity, and suggest that these p53 mutations would not have a fully dominant negative mode of action in vivo. In contrast, one of the two AA/C1 cell lines transfected with the 273(His) mutation did fail to cell cycle arrest after gamma irradiation, indicating that this mutation can act as a dominant negative. However even loss of wild type p53 function in this fell line was insufficient to directly effect the growth rate of the AA/C1 cells, suggesting that acquisition of the 273(His) mutation may contribute to malignant progression through genomic instability (by inhibiting the G1 arrest) and that other mutations are required before outgrowth of the cell population containing the p53 mutation.	UNIV YORK,DEPT BIOL,JACK BIRCH UNIT ENVIRONM CARCINOGENESIS,YORK YO1 5DD,N YORKSHIRE,ENGLAND	University of York - UK	WILLIAMS, AC (corresponding author), UNIV BRISTOL,DEPT PATHOL & MICROBIOL,CRC,COLORECTAL TUMOUR BIOL RES GRP,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND.			Williams, Ann/0000-0002-6009-7137				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1992, GENE DEV, V6, P1886, DOI 10.1101/gad.6.10.1886; BOND JA, 1994, ONCOGENE, V9, P281; CHEN CY, 1994, P NATL ACAD SCI USA, V91, P2684, DOI 10.1073/pnas.91.7.2684; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; CHIN KV, 1992, SCIENCE, V255, P459, DOI 10.1126/science.1346476; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1994, CANCER RES, V54, P1169; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FEARON ER, 1992, FASEB J, V6, P2783, DOI 10.1096/fasebj.6.10.1321771; FREBOURG T, 1994, CANCER RES, V54, P878; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; ISAACS WB, 1991, CANCER RES, V51, P4716; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVINE AJ, 1992, NEW ENGL J MED, V326, P1350, DOI 10.1056/NEJM199205143262008; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI Y, 1994, ONCOGENE, V9, P2261; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MAITY A, 1994, ONCOL, V31, P1; MANNING AM, 1991, ONCOGENE, V6, P1471; MATOZAKI T, 1992, CANCER RES, V52, P4335; MCILWRATH AJ, 1994, CANCER RES, V54, P3718; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PARK DJ, 1994, ONCOGENE, V9, P1899; PICKSLEY SM, 1993, BIOESSAYS, V15, P689, DOI 10.1002/bies.950151008; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WILLIAMS AC, 1990, CANCER RES, V50, P4724; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; WILLIAMS AC, 1994, ONCOGENE, V9, P1479; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; WYLLIE FS, 1993, MOL CARCINOGEN, V7, P83, DOI 10.1002/mc.2940070205; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	61	35	37	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 6	1995	11	1					141	149						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624121				2022-12-17	WOS:A1995RJ29500017
J	HIRANO, Y; YAMATO, K; TSUCHIDA, N				HIRANO, Y; YAMATO, K; TSUCHIDA, N			A TEMPERATURE-SENSITIVE MUTANT OF THE HUMAN P53, VAL138, ARRESTS RAT-CELL GROWTH WITHOUT INDUCED EXPRESSION OF CIP1/WAF1/SDI1 AFTER TEMPERATURE SHIFT-DOWN	ONCOGENE			English	Article						TEMPERATURE-SENSITIVE MUTANTS; P53; TUMOR SUPPRESSOR GENE; CIP1/WAF1/SDI1	WILD-TYPE P53; MAMMALIAN-CELLS; GENE; PROTEIN; TRANSFORMATION; SUPPRESSOR; DNA; CARCINOMA; ONCOGENE; SEQUENCE	To investigate functions of wild type p53 in human cells, we introduced a (Ala-->Val) mutation at the 138th codon of the human p53 (Val138), which corresponds to the Val135 mutation of the temperature sensitive mouse p53, The human Val138 mutant showed temperature-sensitive transformation of rat embryo fibroblasts (REFs) in collaboration assay with activated vas, and arrested cell proliferation of transformed clones in G1 at 32.5 degrees C. Transient CAT assay for transcriptional activation in human Saos2 cells revealed activity equivalent to that of wild type at 32.5 degrees C but undetectable at 37.5 degrees C. These results suggest that the human Val138 mutant also exhibited the wild type phenotype at the permissive temperature as is for the mouse Val135 mutant, although we observed differences between the two mutants such as in transactivational activities in CV-1 and HeLa cells, Further, the role of cip1/waf1/sdi1 in the cell growth arrest of the Val138/ras-transformed REFs and Val138-introduced Saos2 cells was studied by northern hybridization analysis, Although rapid induction of cip1/waf1/sdi1 mRNA was observed in the Saos2 cells, no detectable induction of mRNAs for cip1/waf1/sdi1 and gadd45 was observed in the transformed REFs upon temperature shift-down, while mdm2 mRNA was enhanced, suggesting that the p53 gene could arrest cell growth by a mechanism other than that,vith induced expression of the gene for p21 cdk-cyclin inhibitor.	TOKYO MED & DENT UNIV,FAC DENT,DEPT MOLEC CELLULAR ONCOL & MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO MED & DENT UNIV,FAC DENT,DEPT ORAL & MAXILLOFACIAL SURG 2,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1994, CANCER RES, V54, P3391; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GEY G, 1952, CANCER RES, V12, P246; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HARPER JW, 1993, CELL, V75, P805; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HIRANO Y, IN PRES ORAL ONCOL E; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IKEDA M, 1989, RECENT PROGR LIFE SC, P119; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P52; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MEDCALF EA, 1992, ONCOGENE, V7, P71; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MOMAND J, 1992, CELL, V69, P1233; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; OTTO A, 1993, ONCOGENE, V8, P2591; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; SAKAI E, 1992, ONCOGENE, V7, P927; Sambrook J., 1989, MOL CLONING LAB MANU; SEHGAL PB, 1993, ONCOGENE, V8, P3417; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; TSUTSUMIISHII Y, 1995, CELL GROWTH DIFFER, V6, P1; VOGELSTEIN B, 1994, NATURE, V370, P174, DOI 10.1038/370174a0; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZHANG W, 1994, EMBO J, V13, P2535, DOI 10.1002/j.1460-2075.1994.tb06543.x	50	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					1879	1885						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761089				2022-12-17	WOS:A1995QZ92600001
J	LINDEMAN, GJ; HARRIS, AW; BATH, ML; EISENMAN, RN; ADAMS, JM				LINDEMAN, GJ; HARRIS, AW; BATH, ML; EISENMAN, RN; ADAMS, JM			OVEREXPRESSED MAX IS NOT ONCOGENIC AND ATTENUATES MYC-INDUCED LYMPHOPROLIFERATION AND LYMPHOMAGENESIS IN TRANSGENIC MICE	ONCOGENE			English	Note						MAX; MYC; TRANSGENIC MICE; LYMPHOMA; LYMPHOID DEVELOPMENT	C-MYC; DNA-BINDING; PROTEIN; GENE; COTRANSFORMATION; TRANSCRIPTION; DIMERIZATION; ACTIVATION; EXPRESSION; LEUKEMIA	The cellular growth promoting function of the Myc oncoprotein requires its heterodimerization with the Max protein, but Max can also form complexes that inhibit Myc action. To determine whether man overexpression in vivo is oncogenic and whether it can modulate the action of Myc, we generated transgenic mice in which the max gene was directed to express in lymphoid cells by a linked immunoglobulin heavy chain enhancer (E mu). Expression of the transgene at substantially higher levels than the endogenous max gene did not perturb lymphoid homeostasis in adult animals nor predispose to lymphomagenesis. The numbers of B-lymphoid cells in very young animals were reduced. Moreover, analysis of bi-transgenic E mu-myc/E mu-max mice revealed that man overexpression attenuated the premalignant B-lymphoproliferative state induced by an Ep-myr: transgene and reduced the rate of lymphoma onset. These results suggest that elevation of Max expression in vivo inhibits the function of Myc.	ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,MELBOURNE,VIC 3050,AUSTRALIA; FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,SEATTLE,WA 98104	Royal Melbourne Hospital; Walter & Eliza Hall Institute; Fred Hutchinson Cancer Center			Adams, Jerry M/E-1199-2013	Adams, Jerry/0000-0002-4360-8628; Lindeman, Geoffrey/0000-0001-9386-2416	NCI NIH HHS [CA57138, CA20525, CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA020525, R01CA020525, R01CA057138, R37CA057138, R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ADAMS JM, 1991, BIOCHIM BIOPHYS ACTA, V1072, P9, DOI 10.1016/0304-419X(91)90004-5; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BERBERICH S, 1992, ONCOGENE, V7, P775; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BODRUG SE, 1994, EMBO J, V13, P2124, DOI 10.1002/j.1460-2075.1994.tb06488.x; EVANS RJ, 1992, J APPROX THEORY, V69, P1, DOI 10.1016/0021-9045(92)90045-P; FISHER F, 1993, EMBO J, V12, P5075, DOI 10.1002/j.1460-2075.1993.tb06201.x; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LEE E T, 1972, Computer Programs in Biomedicine, V2, P315, DOI 10.1016/0010-468X(72)90019-0; LINDEMAN GJ, 1994, IMMUNITY, V1, P517, DOI 10.1016/1074-7613(94)90094-9; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; WAGNER AJ, 1992, P NATL ACAD SCI USA, V89, P3111, DOI 10.1073/pnas.89.7.3111; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	30	35	35	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 2	1995	10	5					1013	1017						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898919				2022-12-17	WOS:A1995QL03800024
J	MANSUR, CP; MARCUS, B; DALAL, S; ANDROPHY, EJ				MANSUR, CP; MARCUS, B; DALAL, S; ANDROPHY, EJ			THE DOMAIN OF P53 REQUIRED FOR BINDING HPV-16 E6 IS SEPARABLE FROM THE DEGRADATION DOMAIN	ONCOGENE			English	Article						PAPILLOMAVIRUS E6 PROTEIN; P53; TRANSCRIPTIONAL ACTIVATION	HUMAN PAPILLOMAVIRUS TYPE-16; SV40 LARGE T; WILD-TYPE; TRANSCRIPTIONAL ACTIVATION; MUTANT P53; DNA-BINDING; PROTEIN; ONCOPROTEIN; TRANSACTIVATION; SEQUENCES	The E6 proteins of specific cancer-associated human papillomaviruses (HPVs) complex with and mediate degradation of the cellular anti-oncogene p53 in vitro. A critical property of p53 is its ability to stimulate transcription from promoters containing its recognition sequence. HPV E6, mutant p53 proteins, and several DNA tumor virus oncogenes inhibit the transcriptional activity of wild-type p53. In this report, the structural requirements for the interaction between HPV 16 E6 and p53 were examined both in vivo and in vitro. p53-stimulated transcription was efficiently inhibited by wild-type HPV 16 E6 and E6 mutants competent for p53 binding and degradation. A series of p53 deletions and hybrid proteins with heterologous DNA binding, dimerization and transactivation domains were analysed for transcriptional interaction with HPV 16 E6 to determine the domains of p53 required for transcriptional inhibition. These chimeric proteins were also analysed for E6 binding and E6-mediated degradation in vitro. In both assays, complex formation with E6 was mediated through the amino-terminal 345 amino acids of p53 without a specific requirement for its C-terminus. Hybrid proteins containing residues 161-345 of p53 also bound E6, but this segment of p53 was not susceptible to E6 induced proteolysis. A second region of p53, within its N-terminal 160 aa, is required for E6 induced degradation of complexed p53. Taken together, these results suggest that the complex formation between E6 and p53 is not mediated through the C-terminus of p53 and that binding and degradation are separable.	TUFTS UNIV, SCH MED, DEPT MOLEC BIOL & MICROBIOL, BOSTON, MA 02111 USA	Tufts University	MANSUR, CP (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DEPT DERMATOL, BOSTON, MA 02111 USA.			Mansur, Claire/0000-0002-2470-3443; Androphy, Elliot/0000-0002-8104-0703	NATIONAL CANCER INSTITUTE [R01CA044174] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA44174] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDROPHY EJ, 1987, NATURE, V325, P70, DOI 10.1038/325070a0; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CROOK T, 1991, CELL, V67, P547, DOI 10.1016/0092-8674(91)90529-8; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; CROOK T, 1994, ONCOGENE, V9, P1225; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DIMAIO D, 1991, ADV CANCER RES, V56, P133; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HERSHKO A, 1988, J BIOL CHEM, V263, P15237; HOPPESEYLER F, 1993, J VIROL, V67, P3111, DOI 10.1128/JVI.67.6.3111-3117.1993; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LAMBERTI C, 1990, EMBO J, V9, P1907, DOI 10.1002/j.1460-2075.1990.tb08317.x; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LECHNER MS, 1994, J VIROL, V68, P4262, DOI 10.1128/JVI.68.7.4262-4273.1994; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAXWELL IH, 1989, BIOTECHNIQUES, V7, P276; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; PRAKASH SS, 1992, GENE DEV, V6, P105, DOI 10.1101/gad.6.1.105; PRIVES C, 1993, GENE DEV, V7, P529, DOI 10.1101/gad.7.4.529; RAGIMOV N, 1993, ONCOGENE, V8, P1183; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; RUPPERT JM, 1993, MOL CELL BIOL, V13, P3811, DOI 10.1128/MCB.13.6.3811; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; SEGAWA K, 1993, ONCOGENE, V8, P543; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	57	35	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	1995	10	3					457	465						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845670				2022-12-17	WOS:A1995QF64800006
J	PLAZA, S; TURQUE, N; DOZIER, C; BAILLY, M; SAULE, S				PLAZA, S; TURQUE, N; DOZIER, C; BAILLY, M; SAULE, S			C-MYB ACTS AS TRANSCRIPTIONAL ACTIVATOR OF THE QUAIL PAX6 (PAX-QNR) PROMOTER THROUGH 2 DIFFERENT MECHANISMS	ONCOGENE			English	Article						C-MYB; PAX-6-REGULATION; NEURORETINA	HOMEOBOX-CONTAINING GENE; DNA-BINDING DOMAIN; AVIAN-MYELOBLASTOSIS VIRUS; V-MYB; MIM-1 GENE; B-MYB; SYNERGISTIC ACTIVATION; FUNCTIONAL DOMAINS; PROTEIN TRUNCATION; ESTROGEN-RECEPTOR	To understand the regulation of the Pax-6 gene, which plays an important role in eye development, we have characterized the promoter region of the quail Pax-6(Pax-QNR) gene. In addition to TATA and CAAT boxes, sequence analysis revealed several putative cis-regulatory elements among which three myb-responsive elements (MRE). C-myb encodes a nuclear, DNA-binding phosphoprotein that functions as transcriptional regulator. Co-transfection in quail embryo cells of the Pax-QNRlpax-6 promoter with a vector expressing the 75 kDa c-myb protein resulted in an increase in Pax-QNR promoter activity. By footprinting experiments we identified multiple binding sites for the myb protein within the promoter region. Protein containing the myb DNA-binding domain fused to the VP16-transactivation domain was fully efficient in Pax-QNR promoter transactivation, demonstrating that myb can transactivate through a direct binding on DNA. However, a myb truncated protein devoid of DNA-binding domain was also able to transactivate the Pax-QNR promoter. These results show that this promoter can be transactivated by the myb protein directly as well as indirectly. Finally we show by in situ hybridization that c-myb is strongly expressed in the developing neuroretina, simultaneously with Pax-QNR. These observations suggest that the c-myb protein may be a regulator of Pax-QNR/pax-6.	INST PASTEUR,DIFFERENCIAT CELLULAIRE & MOLEC LAB,CNRS,EP56,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			DOZIER, Christine/P-1539-2014; plaza, serge/F-5290-2015					AKAM M, 1987, DEVELOPMENT, V101, P1; ANANTHAN J, 1993, MOL CELL BIOL, V13, P1599, DOI 10.1128/MCB.13.3.1599; ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOUWMEESTER T, 1992, MECH DEVELOP, V37, P57, DOI 10.1016/0925-4773(92)90015-C; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; BURK O, 1991, EMBO J, V10, P3713, DOI 10.1002/j.1460-2075.1991.tb04939.x; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; Crepieux Pascale, 1993, Gene Expression, V3, P215; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DOZIER C, 1993, CELL GROWTH DIFFER, V4, P281; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; FOOS G, 1993, ONCOGENE, V8, P1775; FOOS G, 1992, EMBO J, V11, P4619, DOI 10.1002/j.1460-2075.1992.tb05564.x; FRAMPTON J, 1991, PROTEIN ENG, V4, P891, DOI 10.1093/protein/4.8.891; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GARRIDO C, 1992, J VIROL, V66, P160, DOI 10.1128/JVI.66.1.160-166.1992; GARRIDO C, 1992, J VIROL, V66, P6773, DOI 10.1128/JVI.66.11.6773-6776.1992; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; INGHAM PW, 1988, NATURE, V335, P25, DOI 10.1038/335025a0; KESSEL M, 1990, SCIENCE, V249, P374, DOI 10.1126/science.1974085; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; LAM EWF, 1992, ONCOGENE, V7, P1185; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MARTIN P, 1992, ONCOGENE, V7, P1721; MAULBECKER CC, 1993, EMBO J, V12, P2361, DOI 10.1002/j.1460-2075.1993.tb05890.x; MOELLING K, 1984, CELL, V40, P983; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NAKANO T, 1992, ONCOGENE, V7, P527; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; NOMURA T, 1993, J BIOL CHEM, V268, P21914; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; QUEVA C, 1992, DEVELOPMENT, V114, P125; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; STAPLETON P, 1993, NAT GENET, V3, P292, DOI 10.1038/ng0493-292; SUREAU A, 1992, P NATL ACAD SCI USA, V89, P11683, DOI 10.1073/pnas.89.24.11683; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN J, 1991, GENE DEV, V5, P594, DOI 10.1101/gad.5.4.594; WALTHER C, 1991, GENOMICS, V11, P424, DOI 10.1016/0888-7543(91)90151-4; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WESTON K, 1992, NUCLEIC ACIDS RES, V20, P3043, DOI 10.1093/nar/20.12.3043; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	60	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JAN 19	1995	10	2					329	340						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QC624	7838532				2022-12-17	WOS:A1995QC62400012
J	CHOW, LML; DAVIDSON, D; FOURNEL, M; GOSSELIN, P; LEMIEUX, S; LYU, MS; KOZAK, CA; MATIS, LA; VEILLETTE, A				CHOW, LML; DAVIDSON, D; FOURNEL, M; GOSSELIN, P; LEMIEUX, S; LYU, MS; KOZAK, CA; MATIS, LA; VEILLETTE, A			2 DISTINCT PROTEIN ISOFORMS ARE ENCODED BY NTK, A CSK-RELATED TYROSINE PROTEIN-KINASE GENE	ONCOGENE			English	Article							SRC FAMILY KINASES; RECEPTOR; P56LCK; AUTOPHOSPHORYLATION; PHOSPHORYLATES; ASSOCIATION; ACTIVATION; EXPRESSION; P50(CSK); P56(LCK)	Recently, we and others have cloned cDNAs encoding a second member of the Csk family of inhibitory tyrosine protein kinases, which we have termed Ntk. Intriguingly, the mouse ntk cDNA sequences published by two independent groups differed by the presence or absence of a 136 nucleotide-insert near their 5' ends. In this report, we demonstrate that this 136 nucleotide-sequence likely corresponds to a complete exon in the ntk gene (termed exon 2), and that the two types of cDNAs/transcripts are produced by alternative splicing. Using ribonuclease protection assays, it was also established that brain and lymphoid organs, as well as most hemopoietic cells, predominantly expressed ntk transcripts lacking exon 2. In contrast, selected hemopoietic cell lines, such as the immature myeloid cell lines 32D cl3(G) and WEHI-3B, exclusively possessed exon 2-bearing RNAs. Interestingly, exon 2 introduced a novel in-frame upstream AUG in the ntk transcript, which is in the appropriate context for translation initiation. Evidence was obtained that this AUG is utilized in vivo, and that it extends the amino-terminal sequence of Ntk by 40 amino acids. Indeed, while exon 2-deficient ntk RNAs were translated into a 52 kilodalton (kDa) polypeptide (p52(ntk)), those bearing exon 2 produced a 56 kDa protein (p56(ntk)). Furthermore, p56(ntk), but not p52(ntk), was recognized by an antiserum directed against the novel amino-terminal sequence encoded by exon 2. Additional biochemical characterizations showed that p52(ntk) and p56(ntk) were localized to the cytoplasm, and that they partially accumulated in the detergent-insoluble cellular fraction. This last finding suggested that the Ntk proteins can associate with the cytoskeleton. Finally, through linkage analysis of two multilocus crosses, the ntk gene was mapped to Chromosome 10 in the mouse. Taken together, these data showed that ntk, a csk-related tyrosine protein kinase gene, encodes two protein isoforms expressed in distinct cell types. Moreover, they raised the possibility that Ntk may be involved in the regulation of Src-Like enzymes in detergent-insoluble cellular compartments.	MCGILL UNIV,CTR CANC,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT MED,MONTREAL H3G 1Y6,PQ,CANADA; MCGILL UNIV,DEPT ONCOL,MONTREAL H3G 1Y6,PQ,CANADA; UNIV QUEBEC,INST ARMAND FRAPPIER,CTR RECH IMMUNOL,LAVAL H7V 1B7,PQ,CANADA; NIAID,BETHESDA,MD 20892; ALEXION PHARMACEUT INC,NEW HAVEN,CT 06511; MONTREAL GEN HOSP,DEPT MED,MONTREAL H3G 1A4,PQ,CANADA; MONTREAL GEN HOSP,DEPT ONCOL,MONTREAL H3G 1A4,PQ,CANADA	McGill University; McGill University; McGill University; McGill University; University of Quebec; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); McGill University; McGill University				Chow, Lionel/0000-0001-8447-063X				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; BENNETT BD, 1994, J BIOL CHEM, V269, P1068; BERGMAN M, 1992, EMBO J, V11, P2919, DOI 10.1002/j.1460-2075.1992.tb05361.x; BRAUNINGER A, 1993, ONCOGENE, V8, P1365; CARTIER M, 1987, MOL CELL BIOL, V7, P1623, DOI 10.1128/MCB.7.5.1623; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOW LML, 1992, MOL CELL BIOL, V12, P1226, DOI 10.1128/MCB.12.3.1226; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CHOW LML, 1994, P NATL ACAD SCI USA, V91, P4975, DOI 10.1073/pnas.91.11.4975; Coligan JKA, 1991, CURRENT PROTOCOLS IM; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; Gosselin Pierre, 1993, Molecular Immunology, V30, P1185, DOI 10.1016/0161-5890(93)90137-Z; Green EL, 1981, GENETICS PROBABILITY, P77; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HAKE LE, 1994, IN PRESS GENOMICS; IMAMOTO A, 1993, CELL, V73, P1117, DOI 10.1016/0092-8674(93)90641-3; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KOZAK CA, 1990, GENOMICS, V8, P519, DOI 10.1016/0888-7543(90)90039-W; KOZAK M, 1981, NUCLEIC ACIDS RES, V9, P5233, DOI 10.1093/nar/9.20.5233; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LEMIEUX S, 1991, CELL IMMUNOL, V134, P191, DOI 10.1016/0008-8749(91)90342-9; LOUIE RR, 1988, J VIROL, V62, P4673, DOI 10.1128/JVI.62.12.4673-4679.1988; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARTANEN J, 1991, ONCOGENE, V6, P2013; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SAKANO S, 1994, ONCOGENE, V9, P1155; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1988, ONCOGENE RES, V2, P385; VEILLETTE A, 1992, TRENDS GENET, V8, P61, DOI 10.1016/0168-9525(92)90045-6; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	41	35	37	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1994	9	12					3437	3448						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PT392	7970703				2022-12-17	WOS:A1994PT39200005
J	MANO, H; SATO, K; YAZAKI, Y; HIRAI, H				MANO, H; SATO, K; YAZAKI, Y; HIRAI, H			TEC PROTEIN-TYROSINE KINASE DIRECTLY ASSOCIATES WITH LYN PROTEIN-TYROSINE KINASE THROUGH ITS N-TERMINAL UNIQUE DOMAIN	ONCOGENE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; CELL ANTIGEN RECEPTOR; HEMATOPOIETIC-CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; MESSENGER-RNA; GROWTH-FACTOR; SH3 DOMAINS; AMINO-ACIDS; GENE	Most of non-receptor-type protein-tyrosine kinases share common structures, such as N-terminal unique domains, Src homology region (SH)-2 domains, SH-3 domains and kinase domains. Although vast effort has brought some information about the in vivo roles of SH-2, -3 and kinase domains, little is still understood about the function of N-terminal unique domain. By utilizing the glutathione S-transferase (GST)-fusion system, we have investigated the role of N-terminal unique domain of the Tec protein-tyrosine kinase in a mouse IL-3-dependent myeloid cell line. We could reveal that the C-terminal half of the Tec N-terminal unique domain (NTec2 region) can bind to a set of tyrosine-phosphorylated cellular proteins in vitro in an IL-3-dependent manner. Surprisingly, p56/53(Lyn) constitutively binds to the NTec2 region. Among the NTec2-bound Lyn proteins, only-the p56 form seems to be inducibly tyrosine-phosphorylated in response to IL-3. Binding domain of Lyn to the NTec2 region was localized to its SH-3 domain. Tec was also shown to make a stable complex with Lyn in vivo. This is the first report demonstrating the direct association between distinct cytoplasmic protein-tyrosine kinases, especially through N-terminal unique domain.	UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN	University of Tokyo	MANO, H (corresponding author), JICHI MED SCH,DEPT MOLEC BIOL,3311-1 YAKUSHIJI,MINAMI KAWACHI,TOCHIGI 32904,JAPAN.							BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BOLEN JB, 1993, ONCOGENE, V8, P2025; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HARLOW E, 1988, ANTIBODIES LABORATOR; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KATZAV S, 1989, ONCOGENE, V4, P1129; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MACAULEY A, 1993, ONCOGENE, V8, P117; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PRASAD KVS, 1993, P NATL ACAD SCI USA, V90, P7366, DOI 10.1073/pnas.90.15.7366; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; Sambrook J., 1989, MOL CLONING LAB MANU; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TOYOSHIMA H, 1993, P NATL ACAD SCI USA, V90, P5404, DOI 10.1073/pnas.90.12.5404; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YAMANASHI Y, 1991, CELL REGUL, V2, P979, DOI 10.1091/mbc.2.12.979; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391	35	35	38	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1994	9	11					3205	3211						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936643				2022-12-17	WOS:A1994PM65800012
J	SMARDA, J; LIPSICK, JS				SMARDA, J; LIPSICK, JS			C-MYB PREVENTS TPA-INDUCED DIFFERENTIATION AND CELL-DEATH IN V-MYB TRANSFORMED MONOBLASTS	ONCOGENE			English	Article							AVIAN-MYELOBLASTOSIS VIRUS; NORMAL HUMAN-LYMPHOCYTES; HEMATOPOIETIC-CELLS; GENE-EXPRESSION; LEUKEMIA-VIRUS; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATION; TRANS-ACTIVATION; E26; INVITRO	Myelomonocytic cells transformed by v-Myb or altered forms of c-Myb do not contain the full-length c-Myb protein found in most immature hematopoietic cells. To determine if c-Myb was a dominant inhibitor of v-Myb, we have induced the synthesis of full-length c-Myb in monoblasts transformed by v-Myb. We found that although some morphological changes occurred, the presence of both c-Myb and v-Myb was compatible with cell growth. However, the response to phorbol ester (TPA) was significantly altered by c-Myb. Monoblasts transformed by v-Myb can be induced to differentiate into macrophages by treatment with TPA. This process is accompanied by a significant amount of cell death. However, when c-Myb was made TPA-inducible in these cells, TPA-induced differentiation into macrophages was blocked and cell death was prevented. These results demonstrate a significant difference in the biological effects of v-Myb and c-Myb in transformed myelomonocytic cells.	STANFORD UNIV,SCH MED,DEPT PATHOL,STANFORD,CA 94305	Stanford University					NCI NIH HHS [R01-CA43592, K04 CA01457] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K04CA001457, R01CA043592] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALUDA MA, 1961, VIROLOGY, V15, P185, DOI 10.1016/0042-6822(61)90234-3; BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATRON KM, 1992, J IMMUNOL, V148, P934; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUPREY SP, 1985, P NATL ACAD SCI USA, V82, P6937, DOI 10.1073/pnas.82.20.6937; DURBAN EM, 1981, J VIROL, V37, P488, DOI 10.1128/JVI.37.1.488-492.1981; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; GERONDAKIS S, 1986, MOL CELL BIOL, V6, P3677, DOI 10.1128/MCB.6.11.3677; GEWIRTZ AM, 1989, SCIENCE, V245, P180, DOI 10.1126/science.2665077; GEWIRTZ AM, 1988, SCIENCE, V242, P1303, DOI 10.1126/science.2461588; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; HASS R, 1993, CELL GROWTH DIFFER, V4, P159; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; JANG SK, 1989, J VIROL, V63, P1651, DOI 10.1128/JVI.63.4.1651-1660.1989; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KARIN M, 1987, MOL CELL BIOL, V7, P606, DOI 10.1128/MCB.7.2.606; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KU DH, 1993, J BIOL CHEM, V268, P2255; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LIPSICK JS, 1987, J VIROL, V61, P3284, DOI 10.1128/JVI.61.10.3284-3287.1987; LIPSICK JS, 1987, MOL CELL BIOL, V7, P3358, DOI 10.1128/MCB.7.9.3358; LIU JL, 1992, VIROLOGY, V189, P583, DOI 10.1016/0042-6822(92)90581-9; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MOSCOVICI C, 1985, RETROVIRUSES HUMAN P, P177; MOSCOVICI C, 1982, EXPRESSION DIFFERENT, P325; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MOSCOVICI MG, 1983, P NATL ACAD SCI-BIOL, V80, P1421, DOI 10.1073/pnas.80.5.1421; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PESSANO S, 1979, MICROBIOLOGICA, V2, P379; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; REED JC, 1986, P NATL ACAD SCI USA, V83, P3982, DOI 10.1073/pnas.83.11.3982; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SAMBROOK J, 1989, MOL COLONING LABORAT; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SMARDA J, 1993, IN PRESS GENE; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SYMONDS G, 1984, MOL CELL BIOL, V4, P2587, DOI 10.1128/MCB.4.12.2587; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; TODOKORO K, 1988, P NATL ACAD SCI USA, V85, P8900, DOI 10.1073/pnas.85.23.8900; TORELLI G, 1985, MOL CELL BIOL, V5, P2874, DOI 10.1128/MCB.5.10.2874; TRAVALI S, 1991, MOL CELL BIOL, V11, P731, DOI 10.1128/MCB.11.2.731; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	59	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					237	245						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302585				2022-12-17	WOS:A1994MW24700029
J	HOWE, LR; MARSHALL, CJ				HOWE, LR; MARSHALL, CJ			IDENTIFICATION OF AMINO-ACIDS IN P21RAS INVOLVED IN EXCHANGE FACTOR INTERACTION	ONCOGENE			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ACTIVATING PROTEIN GAP; HA-RAS P21; SACCHAROMYCES-CEREVISIAE; GENE-PRODUCT; MONOCLONAL-ANTIBODIES; MOLECULAR MECHANISM; SIGNAL-TRANSDUCTION; TRANSFORMING GENE; VULVAR INDUCTION	Through the genetic analysis of vulva development in C elegans several different sites of mutation have been identified in the let-60 ras protein which have been postulated to affect the function of normal but not oncogenic p21ras (Beitel, G. J., S. G. Clark, and H. R. Horvitz. 1990. Nature 348: 503-509). We have introduced these mutations into mammalian Ha-ras and determined their effect on the function of cellular ras (c-ras), an oncogenically activated variant D12ras and the dominant negative N17ras. From these studies we conclude that two of the mutations S89 --> F89 and DELTA103-108 destabilise ras when it is in the GDP-bound form. However mutations at A66 and G75 lead to stable proteins on which a ras exchange factor SCD25 is unable to promote the formation of ras-GTP. The mutations at A66 show for the first time that helix alpha2 of p21ras is involved in the stimulation of guanine nucleotide exchange by exchange factors.	INST CANC RES,CHESTER BEATTY LABS,237 FULHAM RD,LONDON SW3 6JB,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK				Howe, Louise/0000-0002-1468-7136				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOS JL, 1989, CANCER RES, V49, P4682; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BOYMARCOTTE E, 1989, GENE, V77, P21, DOI 10.1016/0378-1119(89)90355-7; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BUDAY L, 1993, MOL CELL BIOL, V13, P1903, DOI 10.1128/MCB.13.3.1903; BURGERING BMT, 1991, EMBO J, V10, P1103, DOI 10.1002/j.1460-2075.1991.tb08050.x; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CEN H, 1992, EMBO J, V11, P4007, DOI 10.1002/j.1460-2075.1992.tb05494.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FASANO O, 1988, EMBO J, V7, P3375, DOI 10.1002/j.1460-2075.1988.tb03210.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1986, J BIOL CHEM, V261; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1991, GENE DEV, V5, P2188, DOI 10.1101/gad.5.12a.2188; HANCOCK JF, 1988, ONCOGENE, V3, P187; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HUGHES DA, 1990, NATURE, V344, P355, DOI 10.1038/344355a0; KAVOUNIS C, 1991, FEBS LETT, V281, P235, DOI 10.1016/0014-5793(91)80401-N; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; MARSHALL CJ, 1982, NATURE, V299, P171, DOI 10.1038/299171a0; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; REY I, 1991, ONCOGENE, V6, P347; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SHOU C, 1992, NATURE, V358, P351, DOI 10.1038/358351a0; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VERROTTI AC, 1992, EMBO J, V11, P2855, DOI 10.1002/j.1460-2075.1992.tb05353.x; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WILLUMSEN BM, 1991, MOL CELL BIOL, V11, P6026, DOI 10.1128/MCB.11.12.6026; Wittinghofer F, 1992, Semin Cancer Biol, V3, P189; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9	57	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2583	2590						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8361768				2022-12-17	WOS:A1993LT36800032
J	STROBL, LJ; KOHLHUBER, F; MAUTNER, J; POLACK, A; EICK, D				STROBL, LJ; KOHLHUBER, F; MAUTNER, J; POLACK, A; EICK, D			ABSENCE OF A PAUSED TRANSCRIPTION COMPLEX FROM THE C-MYC P2-PROMOTER OF THE TRANSLOCATION CHROMOSOME IN BURKITTS-LYMPHOMA CELLS - IMPLICATION FOR THE C-MYC P1/P2 PROMOTER SHIFT	ONCOGENE			English	Article							RNA-POLYMERASE-II; EPSTEIN-BARR-VIRUS; 1ST EXON; B-CELL; STRUCTURAL ALTERATIONS; VARIANT TRANSLOCATION; CHROMATIN STRUCTURE; SOMATIC MUTATION; HL60 CELLS; GENE	We have shown recently that pausing of RNA polymerase II (pol II) at the transcription start site regulates expression from the P2 promoter of the proto-oncogene c-myc. RNAs initiated at the P2 promoter usually contribute > 80% to steady-state c-myc RNA levels in normal cells. In Burkitt's lymphoma (BL) cells c-myc is chromosomally translocated to an immunoglobulin (1g) gene and preferentially transcribed from the upstream P1 promoter. We have studied the activity of c-myc promoters in two BL cell lines with high expression of P1 RNA. Kinetic nuclear run-on experiments show that the initiation rate at the c-myc P1 promoter in BL2 and BL60 cells is not increased compared with control BJAB cells, whereas the number of paused polymerases at the P2 promoter is greatly diminished. The translocation c-myc gene of BL60 cells was cloned and stably transfected into the BL cell line Raji. The transfected c-myc gene regained the ability to form a paused transcription complex at the c-myc P2 promoter. The data suggest that a paused polymerase at the c-myc P2 promoter impedes transcription from the upstream P1 promoter on a normal c-myc gene. The c-myc gene on the translocation chromosome in BL cells has lost the ability to retain pol II at the P2 promoter, probably by interaction with elements of the adjacent Ig gene locus.	FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INST KLIN MOLEK BIOL & TUMORGENET, MARCHIONINISTR 25, D-81377 MUNICH, GERMANY				Strobl, Lothar J/M-7357-2014	Strobl, Lothar J/0000-0001-8389-1862				ALLEN RW, 1987, J BIOL CHEM, V262, P649; APEL TW, 1992, ONCOGENE, V7, P1267; ASSELIN C, 1989, ONCOGENE, V4, P549; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENGAL E, 1989, J BIOL CHEM, V264, P18926; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BORNKAMM GW, 1988, CELLULAR ONCOGENE AC, P223; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHUNG J, 1987, CELL, V51, P1001, DOI 10.1016/0092-8674(87)90586-1; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DENNY CT, 1985, MOL CELL BIOL, V5, P3199, DOI 10.1128/MCB.5.11.3199; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DYSON PJ, 1985, EMBO J, V4, P2885, DOI 10.1002/j.1460-2075.1985.tb04018.x; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EICK D, 1989, EMBO J, V8, P1965, DOI 10.1002/j.1460-2075.1989.tb03602.x; EICK D, 1985, EMBO J, V4, P3717, DOI 10.1002/j.1460-2075.1985.tb04140.x; EICK D, 1988, ONCOGENE, V3, P397; EICK D, 1990, ONCOGENE, V5, P1397; FLORES O, 1989, J BIOL CHEM, V264, P8913; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALUSKA FG, 1986, NATURE, V324, P158, DOI 10.1038/324158a0; HARTL P, 1987, MOL CELL BIOL, V7, P2037, DOI 10.1128/MCB.7.6.2037; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HENGLEIN B, 1989, MOL CELL BIOL, V9, P2105, DOI 10.1128/MCB.9.5.2105; HOROWITZ H, 1982, NUCLEIC ACIDS RES, V10, P5447, DOI 10.1093/nar/10.18.5447; JOOS S, 1992, HUM MOL GENET, V1, P625, DOI 10.1093/hmg/1.8.625; KEPHART DD, 1992, MOL CELL BIOL, V12, P2067, DOI 10.1128/MCB.12.5.2067; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KOHLHUBER F, 1993, IN PRESS ONCOGENE; KRUGER W, 1987, J MOL BIOL, V195, P31, DOI 10.1016/0022-2836(87)90325-1; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; LACY J, 1987, P NATL ACAD SCI USA, V84, P5838, DOI 10.1073/pnas.84.16.5838; LEE HS, 1992, GENE DEV, V6, P284, DOI 10.1101/gad.6.2.284; Lenoir G M, 1985, IARC Sci Publ, P309; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Magrath I, 1990, Adv Cancer Res, V55, P133, DOI 10.1016/S0065-230X(08)60470-4; MENGLEGAW L, 1987, EMBO J, V6, P1959, DOI 10.1002/j.1460-2075.1987.tb02458.x; MEULIA T, 1992, MOL CELL BIOL, V12, P4590, DOI 10.1128/MCB.12.10.4590; MEYER KB, 1989, EMBO J, V8, P1959, DOI 10.1002/j.1460-2075.1989.tb03601.x; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; NISHIKURA K, 1985, P NATL ACAD SCI USA, V82, P2900, DOI 10.1073/pnas.82.9.2900; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; PLET A, 1992, ONCOGENE, V7, P1847; POLACK A, 1991, ONCOGENE, V6, P2033; POLACK A, 1987, EMBO J, V6, P2959, DOI 10.1002/j.1460-2075.1987.tb02601.x; RABBITTS TH, 1984, NATURE, V309, P592, DOI 10.1038/309592a0; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; REINBERG D, 1987, J BIOL CHEM, V262, P3331; REINES D, 1989, J BIOL CHEM, V264, P10799; RICHMAN A, 1989, MOL CELL BIOL, V9, P4962, DOI 10.1128/MCB.9.11.4962; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; ROBERTS S, 1992, GENE DEV, V6, P1562, DOI 10.1101/gad.6.8.1562; ROBERTS S, 1992, EMBO J, V11, P1085, DOI 10.1002/j.1460-2075.1992.tb05147.x; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; SPENCER CA, 1991, ADV CANCER RES, V56, P1; STEVENS A, 1989, BIOCHEM BIOPH RES CO, V159, P508, DOI 10.1016/0006-291X(89)90022-3; STROBL LJ, 1992, EMBO J, V11, P3307, DOI 10.1002/j.1460-2075.1992.tb05409.x; SUGDEN B, 1985, MOL CELL BIOL, V5, P410, DOI 10.1128/MCB.5.2.410; SUN LK, 1986, NUCLEIC ACIDS RES, V14, P4037, DOI 10.1093/nar/14.10.4037; SUSSMAN DJ, 1991, NUCLEIC ACIDS RES, V19, P5045, DOI 10.1093/nar/19.18.5045; SZAJNERT MF, 1987, NUCLEIC ACIDS RES, V15, P4553, DOI 10.1093/nar/15.11.4553; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; WANG AM, 1985, SCIENCE, V228, P149, DOI 10.1126/science.3856324; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510; ZEIDLER R, 1992, THESIS L MAXIMILIANS; ZIMBERSTROBL U, 1991, J VIROL, V65, P415, DOI 10.1128/JVI.65.1.415-423.1991	82	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1993	8	6					1437	1447						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE064	8502472				2022-12-17	WOS:A1993LE06400006
J	LINDBERG, RA; FISCHER, WH; HUNTER, T				LINDBERG, RA; FISCHER, WH; HUNTER, T			CHARACTERIZATION OF A HUMAN PROTEIN THREONINE KINASE ISOLATED BY SCREENING AN EXPRESSION LIBRARY WITH ANTIBODIES TO PHOSPHOTYROSINE	ONCOGENE			English	Article							TYROSINE KINASE; CONSERVED FEATURES; GENE-PRODUCT; CDNA CLONES; IDENTIFICATION; SERINE; PHOSPHORYLATION; FAMILY; AUTOPHOSPHORYLATION; ACID	We have studied the activity and substrate specificity of the catalytic domain of a protein kinase that was isolated in a screen of a human lambdagt11 fibroblast cDNA library with anti-phosphotyrosine antibodies. The sequence of this protein kinase would predict that it is a protein serine/threonine kinase, which at first seemed incongruent with the cloning method. However, recent reports indicate that some protein kinases can phosphorylate both tyrosine and serine/threonine residues. To determine whether this protein kinase, which we call PYT (for phosphotyrosine picked threonine kinase), was a dual-specificity protein kinase we investigated its substrate specificity when expressed in bacteria. The catalytic domain was active as a protein kinase when expressed from any of several promoters and when expressed as a TrpE fusion protein. All experiments that resulted in an active protein kinase, as judged by incorporation of P-32 by metabolic labeling, also resulted in the generation of proteins that were recognized by anti-phosphotyrosine antibodies. Phosphoamino acid analyses of the metabolically labeled proteins that were recognized by the antibodies consistently yielded large amounts of phosphothreonine and only trace amounts of phosphotyrosine. We mapped the phosphorylation sites in the phosphorylated PYT protein and found only phosphothreonine; 90% of the radioactivity mapped to a threonine in the region autophosphorylated by many protein kinases. These data demonstrate that PYT is primarily a protein threonine kinase, but that it can phosphorylate tyrosine to a small extent, making it a potential dual-specificity protein kinase.	SALK INST, PEPTIDE LAB, SAN DIEGO, CA 92186 USA; UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	Salk Institute; University of California System; University of California San Diego	LINDBERG, RA (corresponding author), SALK INST, MOLEC BIOL & VIROL LAB, POB 85800, SAN DIEGO, CA 92186 USA.				NATIONAL CANCER INSTITUTE [P30CA014195, R35CA039780] Funding Source: NIH RePORTER; NCI NIH HHS [CA-14195, CA-39780] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BENDAVID Y, 1991, EMBO J, V10, P317, DOI 10.1002/j.1460-2075.1991.tb07952.x; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; DOUVILLE EMJ, 1992, MOL CELL BIOL, V12, P2681, DOI 10.1128/MCB.12.6.2681; FEATHERSTONE C, 1991, NATURE, V349, P808, DOI 10.1038/349808a0; FISCHER WH, 1991, METHODS NEUROSCI, V6, P69; FOSTER R, 1989, J BACTERIOL, V171, P272, DOI 10.1128/jb.171.1.272-279.1989; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; ICELY PL, 1991, J BIOL CHEM, V266, P16073; IGARASHI M, 1991, NATURE, V353, P80, DOI 10.1038/353080a0; KAMPS MP, 1988, ONCOGENE, V2, P305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KOZMA LM, 1991, METHOD ENZYMOL, V201, P28; LHOTAK V, 1991, MOL CELL BIOL, V11, P2496, DOI 10.1128/MCB.11.5.2496; LINDBERG RA, 1991, METHOD ENZYMOL, V200, P557; LINDBERG RA, 1988, ONCOGENE, V3, P629; LINDBERG RA, 1992, TRENDS BIOCHEM SCI, V17, P114, DOI 10.1016/0968-0004(92)90248-8; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; PASQUALE EB, 1991, CELL REGUL, V2, P523, DOI 10.1091/mbc.2.7.523; SEGER R, 1991, P NATL ACAD SCI USA, V88, P6142, DOI 10.1073/pnas.88.14.6142; STERN DF, 1991, MOL CELL BIOL, V11, P987, DOI 10.1128/MCB.11.2.987; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WU J, 1991, P NATL ACAD SCI USA, V88, P9508, DOI 10.1073/pnas.88.21.9508; YANSURA DG, 1990, METHOD ENZYMOL, V185, P161	29	35	39	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	1993	8	2					351	359						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	7678926				2022-12-17	WOS:A1993KN00600014
J	MACAULEY, A; OKADA, M; NADA, S; NAKAGAWA, H; COOPER, JA				MACAULEY, A; OKADA, M; NADA, S; NAKAGAWA, H; COOPER, JA			PHOSPHORYLATION OF SRC MUTANTS AT TYR-527 IN FIBROBLASTS DOES NOT CORRELATE WITH INVITRO PHOSPHORYLATION BY CSK	ONCOGENE			English	Article							PROTEIN-TYROSINE KINASE; MIDDLE-T-ANTIGEN; CARBOXY TERMINUS; REGULATORY DOMAIN; PP60C-SRC; ACTIVATION; P60C-SRC; BINDING; TRANSFORMATION; P56LCK	In normal fibroblasts, the product of the cellular src gene, p60c-src or Src, is repressed by phosphorylation at its C-terminal tyrosine residue, Tyr 527. Mutations in Src that prevent phosphorylation cause enzymatic activation and malignant transformation. The tyrosine kinases that phosphorylate Src at Tyr 527 in vivo have not been identified, but a tyrosine kinase known as CSK is an excellent candidate. CSK has the unusual ability to phosphorylate Src in vitro only at Tyr 527. To examine whether CSK has the appropriate sequence specificy to explain the phosphorylation of Src at Tyr 527 in fibroblasts, we have made use of a set of C-terminal substitution mutants of Src. These mutants were previously characterized for their levels of Tyr 527 phosphorylation when expressed in Rat2 fibroblasts. The ability of CSK to phosphorylate selected mutants has now been tested, using both in vitro phosphorylation assays and co-expression of CSK with the Src mutants in a heterologous organism, Saccharomyces cerevisiae. We also tested whether the mutant Src molecules could autophosphorylate at Tyr 527, by examining the phosphorylation state of catalytically active forms expressed in the absence of CSK in yeast cells. The results show that CSK has strict sequence specificity for the normal Src sequence, although it can also phosphorylate the Lck sequence. The other mutant Src molecules tested were not phosphorylated by CSK, even though some of these mutants are highly phosphorylated at Tyr 527 in Rat 2 cells. All the mutants that are phosphorylated at Tyr 527 in Rat2 cells are also able to autophosphorylate at Tyr 527. The results suggest that CSK, autophosphorylation, and phosphorylation by kinases other than CSK, may all contribution to repressing Src catalytic activity in fibroblasts.	OSAKA UNIV,DIV PROT METAB,SUITA,OSAKA 565,JAPAN	Osaka University	COOPER, JA (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.				NATIONAL CANCER INSTITUTE [R37CA041072, R01CA041072] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41072] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; CHENG SH, 1988, MOL CELL BIOL, V8, P1736, DOI 10.1128/MCB.8.4.1736; COBB BS, 1991, MOL CELL BIOL, V11, P5832, DOI 10.1128/MCB.11.12.5832; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; COOPER JA, 1987, ONCOGENE RES, V1, P297; COOPER JA, 1988, P NATL ACAD SCI USA, V85, P4243; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; EISEMAN E, 1990, CANCER CELL-MON REV, V2, P303; HOLTRICH U, 1991, P NATL ACAD SCI USA, V88, P10411, DOI 10.1073/pnas.88.23.10411; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1988, MOL CELL BIOL, V8, P3560, DOI 10.1128/MCB.8.8.3560; MACAULEY A, 1990, New Biologist, V2, P828; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PARTANEN J, 1991, ONCOGENE, V6, P2013; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SABE H, 1992, P NATL ACAD SCI USA, V89, P2190, DOI 10.1073/pnas.89.6.2190; SCHUH SM, 1988, MOL CELL BIOL, V8, P2465, DOI 10.1128/MCB.8.6.2465; THOMAS JE, 1991, SCIENCE, V254, P568, DOI 10.1126/science.1719633; WILKERSON VW, 1985, J VIROL, V55, P314, DOI 10.1128/JVI.55.2.314-321.1985; YACIUK P, 1988, ONCOGENE RES, V3, P207	39	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					117	124						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	7678701				2022-12-17	WOS:A1993KN00500014
J	KESSLER, DJ; SPICER, DB; LAROSA, FA; SONENSHEIN, GE				KESSLER, DJ; SPICER, DB; LAROSA, FA; SONENSHEIN, GE			A NOVEL NF-KB ELEMENT WITHIN EXON-1 OF THE MURINE C-MYC GENE	ONCOGENE			English	Article							TUMOR NECROSIS FACTOR; DNA-BINDING SUBUNIT; EXPRESS CHLORAMPHENICOL ACETYLTRANSFERASE; CELLS INDUCES TRANSCRIPTION; FOS PROTO-ONCOGENE; I-KAPPA-B; MAMMALIAN-CELLS; RECOMBINANT GENOMES; NEGATIVE REGULATOR; FACTOR-ALPHA	We have mapped a site within exon 1 of the murine c-myc gene that forms a variety of complexes with nuclear proteins derived from the murine WEHI 231 B-lymphoma cell line in exponential growth that are altered following treatment with phorbol ester, when transcription of this gene is reduced [Levine, R.A., McCormack, J.E., Buckler, A.J. & Sonenshein, G.E. (1986). Mol. Cell Biol., 6, 4112-4116]. This site, located at +440 to +459 bp relative to the Pl promoter, contains an NK-kappaB-like binding element. The sequence of this element, AGGGAATTTTT, is unusual in that the stretch of pyrimidines is entirely T residues. Binding of NF-kappaB protein was demonstrated by oligonucleotide competition, induction of binding upon 70Z/3 pre-B- to B-cell differentiation, response to GTP in the binding reaction, reduction of binding upon addition of IkappaB protein and uv cross-linking analysis. Functional activity of this internal regulatory element (IRE) was demonstrated in transfection assays using chloramphenicol acetyl transferase (CAT) reporter constructs containing multimerized copies of the IRE driving a heterologous promoter. Mutation of the IRE within the context of the c-myc promoter prevented NF-kappaB-mediated induction of transcription of this oncogene. Thus additional NF-kappaB elements may be defined by this new sequence.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,80 E CONCORD ST,BOSTON,MA 02118	Boston University					NATIONAL CANCER INSTITUTE [R01CA036355] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023454] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36355] Funding Source: Medline; NIAID NIH HHS [AI 23454, AI 07309] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; Bencini DA, 1984, BIOTECHNIQUES, V2, P4; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOHNLEIN E, 1988, CELL, V53, P827, DOI 10.1016/0092-8674(88)90099-2; BOYD AW, 1981, J IMMUNOL, V126, P2466; BUCKLER AJ, 1990, J IMMUNOL, V145, P732; CHANG J, 1991, ONCOGENE, V6, P1979; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DUYAO MP, 1990, P NATL ACAD SCI USA, V87, P4727, DOI 10.1073/pnas.87.12.4727; DUYAO MP, 1992, IN PRESS J BIOL CHEM; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KESSLER DJ, 1992, IN PRESS J EXP MED; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUWABARA MD, 1987, BIOCHEMISTRY-US, V26, P7234, DOI 10.1021/bi00397a006; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVINE RA, 1986, MOL CELL BIOL, V6, P4112, DOI 10.1128/MCB.6.11.4112; LIEBER MR, 1987, GENE DEV, V1, P751, DOI 10.1101/gad.1.8.751; LIN JX, 1987, J BIOL CHEM, V262, P11908; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; LOWENTHAL JW, 1989, P NATL ACAD SCI USA, V86, P2331, DOI 10.1073/pnas.86.7.2331; MECHTI N, 1986, NUCLEIC ACIDS RES, V14, P9653, DOI 10.1093/nar/14.24.9653; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; PRENDERGAST GC, 1989, NATURE, V341, P392, DOI 10.1038/341392a0; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; ZABEL U, 1991, J BIOL CHEM, V266, P252	42	35	35	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2447	2453						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461649				2022-12-17	WOS:A1992KA85600009
J	SAKAMOTO, KM; NIMER, SD; ROSENBLATT, JD; GASSON, JC				SAKAMOTO, KM; NIMER, SD; ROSENBLATT, JD; GASSON, JC			HTLV-I AND HTLV-II TAX TRANSACTIVATE THE HUMAN EGR-1 PROMOTER THROUGH DIFFERENT CIS-ACTING SEQUENCES	ONCOGENE			English	Article							T-CELL LEUKEMIA; HUMAN IMMUNODEFICIENCY VIRUS; PRIMARY HUMAN-LYMPHOCYTES; LONG TERMINAL REPEAT; GENE-EXPRESSION; C-FOS; GROWTH; PROTEIN; TRANSFORMATION; IDENTIFICATION	The immediate-early response gene, EGR-1, encodes a zinc finger-containing transcription factor that is involved in growth and differentiation of a variety of cell types. EGR-1 is induced in normal T cells following mitogenic stimulation and has recently been shown to be constitutively expressed in human T-cell leukemia virus type I (HTLV-I)- and type II (HTLV-II)-transformed T-cell lines. The trans-activating protein of HTLV-I, Tax, has been demonstrated to trans-activate promoters of a number of cellular genes, some of which may be critical in regulating T-cell proliferation. In this study, we examine the effect of Tax on expression of EGR-1 in three T-cell lines and demonstrate that both HTLV-I and -II Tax are capable of trans-activating human EGR-1 recombinant promoter constructs. Interestingly, HTLV-I and -II Tax trans-activate the human EGR-1 promoter through different promoter regions in the Jurkat cell line, suggesting that HTLV-I and -II Tax may lead to constitutive expression of EGR-1 through different signaling pathways. Deregulated expression of EGR-1 may contribute to uncontrolled cell growth and transformation during early stages of T-cell activation in HTLV-I and -II-infected cells.	UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT BIOL CHEM, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, JONSSON COMPREHENS CANC CTR, LOS ANGELES, CA 90024 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles	SAKAMOTO, KM (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT PEDIAT, DIV HEMATOL ONCOL, A2-312, LOS ANGELES, CA 90024 USA.				NATIONAL CANCER INSTITUTE [F32CA008974, K11CA001314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043025] Funding Source: NIH RePORTER; NCI NIH HHS [CA01314, CA08974] Funding Source: Medline; NIDDK NIH HHS [DK43025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDRE C, 1991, ONCOGENE, V6, P543; ALEXANDRE C, 1991, ONCOGENE, V6, P1851; CANN AJ, 1985, NATURE, V318, P571, DOI 10.1038/318571a0; CANN AJ, 1988, ONCOGENE, V3, P123; CHEN ISY, 1983, P NATL ACAD SCI-BIOL, V80, P7006, DOI 10.1073/pnas.80.22.7006; CHEN SJ, 1985, P NATL ACAD SCI USA, V82, P7284, DOI 10.1073/pnas.82.21.7284; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1991, ONCOGENE, V6, P1023; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1989, P NATL ACAD SCI USA, V86, P3351, DOI 10.1073/pnas.86.9.3351; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; KALYANARAMAN VS, 1982, SCIENCE, V218, P571, DOI 10.1126/science.6981847; KUMAR A, 1972, P NATL ACAD SCI USA, V69, P681, DOI 10.1073/pnas.69.3.681; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NIMER SD, 1989, ONCOGENE, V4, P671; PETERLIN BM, 1986, P NATL ACAD SCI USA, V83, P9734, DOI 10.1073/pnas.83.24.9734; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROSENBLATT JD, 1986, NEW ENGL J MED, V315, P372, DOI 10.1056/NEJM198608073150606; ROSENBLATT JD, 1988, BLOOD, V71, P363; SAKAMOTO KM, 1991, ONCOGENE, V6, P867; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; Takatsuki K, 1990, RETROVIRUS BIOL HUMA, P147; TAN TH, 1989, MOL CELL BIOL, V9, P1733, DOI 10.1128/MCB.9.4.1733; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; VARNUM BC, 1989, MOL CELL BIOL, V9, P3580, DOI 10.1128/MCB.9.8.3580; WATERS CM, 1990, ONCOGENE, V5, P669; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	37	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1992	7	11					2125	2130						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1359492				2022-12-17	WOS:A1992JW66500004
J	BIESALSKI, HK; DOEPNER, G; TZIMAS, G; GAMULIN, V; SCHRODER, HC; BATEL, R; NAU, H; MULLER, WEG				BIESALSKI, HK; DOEPNER, G; TZIMAS, G; GAMULIN, V; SCHRODER, HC; BATEL, R; NAU, H; MULLER, WEG			MODULATION OF MYB GENE-EXPRESSION IN SPONGES BY RETINOIC ACID	ONCOGENE			English	Article							HORMONE RESPONSE ELEMENTS; AMINO-TERMINAL REGION; DNA-BINDING DOMAIN; AGGREGATION FACTOR; VITAMIN-A; GEODIA-CYDONIUM; C-MYB; DIFFERENTIAL EXPRESSION; ONCOGENE PRODUCTS; PROTEIN	We demonstrate that the cells of the sponge Geodia cydonium are equipped with the basic elements required for a retinoic acid (RA)-dependent response pathway; RA was identified and quantitated, the cellular RA-binding protein (CRABP) was detected and the nuclear RA receptor (RAR) was found. In the isolated cell system the level of CRABP, but not of RAR, is strongly induced after incubating the cells for 10 h with the homologous aggregation factor. In induced cells incubation with 0.3-mu-M RA results in a strong down-regulation of the c-myb (or c-myb-related) proto-oncogene (M(r) 63 000; mRNA 3.3 kb). We postulate that this pathway is also functionally active and that R.A acts as a natural morphogen.	UNIV MAINZ, INST PHYSIOL CHEM, MOLEK BIOL ABT, DUESBERGWEG 6, W-6500 MAINZ, GERMANY; FREE UNIV BERLIN, INST TOXIKOL & EMBRYONALPHARMAKOL, W-1000 BERLIN 33, GERMANY; RUDJER BOSKOVIC INST, CTR ORGAN CHEM & BIOCHEM, YU-41001 ZAGREB, CROATIA; INST RUDER BOSKOVIC, CTR MARINE RES, YU-552210 ROVINJ, CROATIA	Johannes Gutenberg University of Mainz; Free University of Berlin; Rudjer Boskovic Institute; Rudjer Boskovic Institute			Müller, W. E. G./AAR-8651-2020; Tzimas, Giannis/R-5550-2019	Müller, W. E. G./0000-0002-8223-3689; Tzimas, Giannis/0000-0002-4073-7256; Schroder, Heinz C./0000-0003-0992-6427				Ausubel F.M., 1987, CURRENT PROTOCOLS MO; BACHMANN M, 1986, P NATL ACAD SCI USA, V83, P7770, DOI 10.1073/pnas.83.20.7770; Battey, 1986, BASIC METHODS MOL BI; Biesalski H. K., 1990, METHOD ENZYMOL, V189, P83; BIESALSKI HK, 1990, INT J VITAM NUTR RES, V60, P4; BIESALSKI HK, 1989, J CLIN CHEM CLIN BIO, V27, P65; BIESALSKI HK, 1990, J MICRONUTR ANAL, V7, P97; BIESALSKI HK, 1992, PROGR RETINOIDS; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BOROJEVIC R, 1964, Z ZELLFORSCH MIK ANA, V64, P708, DOI 10.1007/BF01258544; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLE WJ, 1984, P NATL ACAD SCI-BIOL, V81, P4265, DOI 10.1073/pnas.81.14.4265; BOYLE WJ, 1986, P NATL ACAD SCI USA, V83, P4685, DOI 10.1073/pnas.83.13.4685; BROCKES JP, 1989, NEURON, V2, P1285, DOI 10.1016/0896-6273(89)90066-4; CARBALLEIRA NM, 1991, COMP BIOCHEM PHYS B, V100, P489, DOI 10.1016/0305-0491(91)90209-V; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CONRAD J, 1982, J CELL BIOCHEM, V19, P395, DOI 10.1002/jcb.240190408; DESUTTER D, 1977, ROUX ARCH DEV BIOL, V181, P151, DOI 10.1007/BF00848439; DIEHLSEIFERT B, 1989, TISSUE CELL, V21, P25, DOI 10.1016/0040-8166(89)90018-9; DOEPNER G, 1992, IN PRESS DRUG RES; DOLLE P, 1989, NATURE, V342, P702, DOI 10.1038/342702a0; DUNHAM P, 1983, P NATL ACAD SCI-BIOL, V80, P4756, DOI 10.1073/pnas.80.15.4756; ECKHOFF C, 1989, TOXICOL LETT, V48, P171, DOI 10.1016/0378-4274(89)90172-0; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GERLACH T, 1989, AM J CLIN NUTR, V50, P1029, DOI 10.1093/ajcn/50.5.1029; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; Goodwin TW, 1984, BIOCH CAROTENOIDS, VII; GRAMZOW M, 1989, CELL, V59, P939, DOI 10.1016/0092-8674(89)90616-8; GRAMZOW M, 1986, J CELL BIOL, V102, P1344, DOI 10.1083/jcb.102.4.1344; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; HAMADA H, 1988, J BIOL CHEM, V263, P1454; HARLOW E, 1988, ANTIBODIES LABORATOR; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; JANICKBUCKNER D, 1991, FASEB J, V5, P320, DOI 10.1096/fasebj.5.3.2001792; JETTEN AM, 1990, METHOD ENZYMOL, V189, P248; KATZEN AL, 1985, CELL, V41, P449, DOI 10.1016/S0092-8674(85)80018-0; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LITAN R, 1991, IN PRESS BIOMEDICINE; MARTINEZ E, 1991, EMBO J, V10, P263, DOI 10.1002/j.1460-2075.1991.tb07946.x; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MIGITA M, 1990, MICROBIOL IMMUNOL, V34, P937, DOI 10.1111/j.1348-0421.1990.tb01072.x; MILLER WH, 1990, ONCOGENE, V5, P511; MOSCONA AA, 1963, P NATL ACAD SCI USA, V49, P742, DOI 10.1073/pnas.49.5.742; MULLER WEG, 1990, ELECTRON MICROSC REV, V3, P97, DOI 10.1016/0892-0354(90)90016-L; MULLER WEG, 1982, INT REV CYTOL, V77, P129, DOI 10.1016/S0074-7696(08)62466-3; MULLER WEG, 1976, J CELL SCI, V21, P227; MULLER WEG, 1978, DIFFERENTIATION, V10, P45, DOI 10.1111/j.1432-0436.1978.tb00944.x; MULLER WEG, 1987, J BIOL CHEM, V262, P9850; MULLER WEG, 1973, EXP CELL RES, V80, P95, DOI 10.1016/0014-4827(73)90279-6; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; ORO AE, 1988, NATURE, V336, P493, DOI 10.1038/336493a0; ORO AE, 1990, NATURE, V347, P298, DOI 10.1038/347298a0; ORO AE, 1989, DEVELOPMENT, V107, P133; PAZARES J, 1987, EMBO J, V6, P3553, DOI 10.1002/j.1460-2075.1987.tb02684.x; PEARCE JC, 1986, J CHROMATOGR, V353, P371, DOI 10.1016/S0021-9673(01)87107-7; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; ROBITZKI A, 1990, EUR J BIOCHEM, V192, P499, DOI 10.1111/j.1432-1033.1990.tb19253.x; ROSSON D, 1987, ANN NY ACAD SCI, V511, P219, DOI 10.1111/j.1749-6632.1987.tb36250.x; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; ROTTMANN M, 1987, EMBO J, V6, P3939, DOI 10.1002/j.1460-2075.1987.tb02735.x; SCHRODER HC, 1988, BIOCHEM J, V252, P777, DOI 10.1042/bj2520777; SCHRODER HC, 1989, LABORATORY MANUAL; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SUMMERBELL D, 1990, TRENDS NEUROSCI, V13, P142, DOI 10.1016/0166-2236(90)90006-V; TAKENAWA T, 1980, LAB INVEST, V42, P490; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WEIGELE M, 1973, BIOCHEM BIOPH RES CO, V50, P352, DOI 10.1016/0006-291X(73)90847-4; WEINBAUM G, 1973, NATURE, V244, P510, DOI 10.1038/244510a0; WEISSENFELS N, 1985, ZOOMORPHOLOGY, V105, P12, DOI 10.1007/BF00312068; WELLNER U, 1985, LECTURE NOTES MED IN, V25, P579; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WHITE BA, 1982, J BIOL CHEM, V257, P8569; WOLF G, 1991, NUTR REV, V49, P1, DOI 10.1111/j.1753-4887.1991.tb07349.x; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	83	35	35	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	1992	7	9					1765	1774						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323819				2022-12-17	WOS:A1992JJ37600013
J	GODBOUT, R; MIYAKOSHI, J; DOBLER, KD; ANDISON, R; MATSUO, K; ALLALUNISTURNER, MJ; TAKEBE, H; DAY, RS				GODBOUT, R; MIYAKOSHI, J; DOBLER, KD; ANDISON, R; MATSUO, K; ALLALUNISTURNER, MJ; TAKEBE, H; DAY, RS			LACK OF EXPRESSION OF TUMOR-SUPPRESSOR GENES IN HUMAN-MALIGNANT GLIOMA CELL-LINES	ONCOGENE			English	Article							RETINOBLASTOMA-SUSCEPTIBILITY GENE; HUMAN O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; SV40 LARGE-T; SV40-TRANSFORMED CELLS; HUMAN FIBROBLASTS; ESCHERICHIA-COLI; CARCINOMA-CELLS; MESSENGER-RNA; P53 MUTATIONS; RB1 GENE	Human malignant gliomas (glioblastomas and anaplastic astrocytomas) are the most frequent brain tumors and are associated with a variety of genetic alterations including retinoblastoma (RB) and p53 gene mutations, loss of interferon-alpha and beta (IFNA, IFNB) genes and lack of O6-methylguanine-DNA methyltransferase (MGMT) expression. Yet, in the studies performed to date, the relationship between these alterations has not been addressed. In this report, we have studied gene expression in 29 malignant glioma cell lines and have determined that, although loss of the interferon genes and loss of RB, p53 and MGMT mRNAs are frequent events, combinations of genetic alterations involving these four proven or putative tumor-suppressor genes are relatively infrequent. The exception was loss of RB mRNA, which may be associated with lack of MGMT mRNA.	CROSS CANC INST,DEPT MED,MOLEC GENET & CARCINOGENESIS LAB,11560 UNIV AVE,EDMONTON T6G 1Z2,ALBERTA,CANADA; CROSS CANC INST,DEPT RADIAT ONCOL,RADIOBIOL LAB,EDMONTON T6G 1Z2,ALBERTA,CANADA; KYOTO UNIV,FAC MED,DEPT ANGEW PHYS,KYOTO 606,JAPAN	University of Alberta; University of Alberta; Kyoto University			Godbout, Roseline/I-4639-2016	Godbout, Roseline/0000-0002-4779-9265				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BIGNER SH, 1988, CANCER RES, V48, P405; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; DAY RS, 1979, NATURE, V279, P797, DOI 10.1038/279797a0; DAY RS, 1980, NATURE, V288, P724, DOI 10.1038/288724a0; DAY RS, 1974, CANCER RES, V34, P1965; DAY RS, 1991, MUTAT RES, V254, P153, DOI 10.1016/0921-8777(91)90006-B; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FORNACE AJ, 1990, CANCER RES, V50, P7908; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FULTS D, 1989, CANCER RES, V49, P6572; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; GARDNER E, 1991, GENOMICS, V11, P475, DOI 10.1016/0888-7543(91)90162-8; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GODDARD AD, 1988, MOL CELL BIOL, V8, P2082, DOI 10.1128/MCB.8.5.2082; GOEDDEL DV, 1980, NATURE, V287, P411, DOI 10.1038/287411a0; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; JAMES CD, 1988, CANCER RES, V48, P5546; JAMES CD, 1991, CANCER RES, V51, P1684; KIM SJ, 1991, P NATL ACAD SCI USA, V88, P3052, DOI 10.1073/pnas.88.8.3052; KOIKE G, 1990, J BIOL CHEM, V265, P14754; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1988, CANCER RES, V48, P5358; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MINTY AJ, 1981, J BIOL CHEM, V256, P1008; MIYAKOSHI J, 1990, CANCER RES, V50, P278; MIYAKOSHI J, 1991, MUTAT RES, V254, P55, DOI 10.1016/0921-8777(91)90040-V; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PIEPER RO, 1991, CANCER COMMUN, V3, P241, DOI 10.3727/095535491820873092; PIEPER RO, 1990, CANCER COMMUN, V2, P13, DOI 10.3727/095535490820874812; Ponten J, 1975, HUMAN TUMOR CELLS IN, P175, DOI [10.1007/9781-47571647-4_7, DOI 10.1007/9781-47571647-4_7]; RYDBERG B, 1990, J BIOL CHEM, V265, P9563; SARIBAN E, 1987, CANCER RES, V47, P3988; SCUDIERO DA, 1984, CANCER RES, V44, P961; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SHRIVASTAVA S, 1990, NATURE, V348, P747; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TOGUCHIDA J, 1988, CANCER RES, V48, P3939; VENTER DJ, 1991, ONCOGENE, V6, P445; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WAHL GM, 1979, P NATL ACAD SCI USA, V76, P3863; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; YOKOTA J, 1988, ONCOGENE, V3, P471; ZAKUTHOURI R, 1985, EMBO J, V4, P1251, DOI 10.1002/j.1460-2075.1985.tb03768.x	57	35	35	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1879	1884						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501894				2022-12-17	WOS:A1992JJ37600026
J	MORRISON, LE; BOEHMELT, G; ENRIETTO, PJ				MORRISON, LE; BOEHMELT, G; ENRIETTO, PJ			MUTATIONS IN THE REL-HOMOLOGY DOMAIN ALTER THE BIOCHEMICAL-PROPERTIES OF V-REL AND RENDER IT TRANSFORMATION DEFECTIVE IN CHICKEN-EMBRYO FIBROBLASTS	ONCOGENE			English	Article							NF-KAPPA-B; DNA-BINDING SUBUNIT; VIRUS STRAIN-T; RETICULOENDOTHELIOSIS VIRUS; LYMPHOID-CELLS; TRANSCRIPTION FACTOR; PROTO-ONCOGENE; SPLEEN-CELLS; C-REL; ACTIVATION	Sequential deletions of approximately 100 base pairs were made in the rel-homology domain of the viral rel protein. Each deletion mutant was cloned into a replication-competent viral vector and assayed in chicken embryo fibroblasts (CEFs). The deleted v-rel proteins were analysed for localization, complex formation and ability to induce transformation. In vitro-translated mutant proteins were assayed for binding to a NF-kappa-B consensus sequence. All the deletion mutants between nucleotides 37 and 798 in v-rel were transformation defective. Each of the mutants localized predominantly in the cytoplasm, whereas wild-type v-rel localizes predominantly in the nucleus of CEFs. Any disruption of the rel-homology domain reduced binding of the mutant v-rel proteins to the cellular protein, p36, while the requirements for binding to p68c-rel, p115 and p124 appeared to be more complicated. The binding of these three proteins to v-rel appeared to be linked and mediated through c-rel, suggesting that v-rel disrupts normal c-rel function. None of the deletion mutants in this region were able to bind to the NF-kappa-B site. However, mutants which lie outside the rel-homology domain retained the ability to transform CEFs, localize to the nucleus, complex with p36, p115, p124 and p68c-rel and bind to the NK-kappa-B site. These results suggest that transformation by v-rel requires an intact rel-homology domain and that the biochemical properties of v-rel are linked and dependent upon higher order protein structure for full function.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)					NCI NIH HHS [2T32CA09176, R0I CA51792] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176, R01CA051792] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEUG H, 1981, VIROLOGY, V115, P295, DOI 10.1016/0042-6822(81)90112-4; BEUG H, 1979, CELL, V18, P375, DOI 10.1016/0092-8674(79)90057-6; BHAT GV, 1990, ONCOGENE, V5, P625; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN ISY, 1981, J VIROL, V40, P800, DOI 10.1128/JVI.40.3.800-811.1981; COHEN RS, 1981, VIROLOGY, V113, P672, DOI 10.1016/0042-6822(81)90196-3; DAVEY J, 1985, CELL, V40, P667, DOI 10.1016/0092-8674(85)90215-6; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; GARSON K, 1990, VIROLOGY, V177, P106, DOI 10.1016/0042-6822(90)90464-3; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; HANNINK M, 1989, MOL CELL BIOL, V9, P4323, DOI 10.1128/MCB.9.10.4323; HOELZER JD, 1979, VIROLOGY, V93, P20, DOI 10.1016/0042-6822(79)90272-1; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; INOUE J, 1991, P NATL ACAD SCI USA, V88, P3715, DOI 10.1073/pnas.88.9.3715; IP YT, 1991, CELL, V64, P439; KABRUN N, 1991, P NATL ACAD SCI USA, V88, P1783, DOI 10.1073/pnas.88.5.1783; KAMENS J, 1990, MOL CELL BIOL, V10, P2840, DOI 10.1128/MCB.10.6.2840; KERR LD, 1991, GENE DEV, V5, P1464, DOI 10.1101/gad.5.8.1464; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MORRISON LE, 1991, ONCOGENE, V6, P1657; MORRISON LE, 1989, ONCOGENE, V4, P667; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PURCHASE HG, 1975, RETICULOENDOTHELIOSI; RICE NR, 1982, J VIROL, V42, P237, DOI 10.1128/JVI.42.1.237-252.1982; RICHARDSON PM, 1991, IN PRESS J VIROL, V65; SCHWARTZ RC, 1988, VIROLOGY, V165, P182, DOI 10.1016/0042-6822(88)90671-X; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK S, 1988, ONCOGENE RES, V2, P102; STEWARD R, 1987, SCIENCE, V238, P692, DOI 10.1126/science.3118464; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; THISSE C, 1991, CELL, V65, P1191, DOI 10.1016/0092-8674(91)90014-P; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198	44	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1992	7	6					1137	1147						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HU642	1594245				2022-12-17	WOS:A1992HU64200011
J	TRATNER, I; VERMA, IM				TRATNER, I; VERMA, IM			IDENTIFICATION OF A NUCLEAR TARGETING SEQUENCE IN THE FOS PROTEIN	ONCOGENE			English	Article							LEUCINE ZIPPER DOMAIN; JUN INTERACTION; V-FOS; C-FOS; LOCALIZATION; LOCATION; SIGNAL; GENE; EXPRESSION; TRANSPORT	The product of the proto-oncogene fos is a nuclear phosphoprotein. We have investigated if nuclear location of Fos protein is mediated by a nuclear targeting sequence. We show that the cytoplasmic chicken pyruvate kinase protein translocates to the nucleus if fused to the 22 amino acid Fos basic region (amino acids 139-161). However, the nuclear localization of the Fos protein is not affected if the basic region is deleted. We propose that Fos protein contains multiple nuclear targeting sequences which may act independently or in concert with one another.			TRATNER, I (corresponding author), SALK INST,MOLEC BIOL & VIROL LAB,POB 85800,SAN DIEGO,CA 92186, USA.		Tratner, Isabelle/ABD-6361-2021					ADDISON C, 1990, ONCOGENE, V5, P423; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1984, CELL, V36, P259; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, J BIOL CHEM, V264, P18019; DETOGNI P, 1988, MOL CELL BIOL, V8, P2251, DOI 10.1128/MCB.8.5.2251; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KINDY MS, 1990, CELL GROWTH DIFFER, V1, P27; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; MATSUI M, 1990, ONCOGENE, V5, P249; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; PAINE PL, 1972, EXP CELL RES, V74, P81, DOI 10.1016/0014-4827(72)90483-1; PETERS R, 1986, BIOCHIM BIOPHYS ACTA, V864, P305, DOI 10.1016/0304-4157(86)90003-1; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; RANSONE LJ, 1990, P NATL ACAD SCI USA, V87, P3806, DOI 10.1073/pnas.87.10.3806; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; ROBERTS B, 1989, BIOCHIM BIOPHYS ACTA, V1008, P263, DOI 10.1016/0167-4781(89)90016-X; ROBERTS BL, 1987, CELL, V50, P465, DOI 10.1016/0092-8674(87)90500-9; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; STACEY DW, 1984, EXP CELL RES, V154, P283, DOI 10.1016/0014-4827(84)90687-6; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	36	35	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2049	2053						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1945410				2022-12-17	WOS:A1991GX11900016
J	HILLER, S; BREIT, S; WANG, ZQ; WAGNER, EF; SCHWAB, M				HILLER, S; BREIT, S; WANG, ZQ; WAGNER, EF; SCHWAB, M			LOCALIZATION OF REGULATORY ELEMENTS CONTROLLING HUMAN MYCN EXPRESSION	ONCOGENE			English	Article							HUMAN NEURO-BLASTOMA; AVIAN MYELOCYTOMATOSIS VIRUS; RNA POLYMERASE-II; C-MYC; N-MYC; NUCLEOTIDE-SEQUENCE; BURKITT-LYMPHOMA; GENE-EXPRESSION; PROMOTER REGION; PROTO-ONCOGENE	Expression of the cellular oncogene MYCN is restricted to few cell lineages and is highest during development both in mouse and in humans. In pursuit of elucidating the mechanisms underlying MYCN regulation we introduced a human MYCN clone (pNb-9) with approximately 2.5 kbp 5'- and 6 kbp 3'-flanking genomic sequences into different murine and human cell lines as well as into mice. In all cases we found a correlation between the expression of the exogenous and the endogenous MYCN. Among cell lines, only those expressing the endogenous gene also expressed the transfected gene. In the transgenic mice transcripts of the transgene were present in proportion to the transcripts of the endogenous MYCN gene with the highest level in the brain. Therefore, the genetic information necessary for regulated expression of MYCN appears to be contained in pNb-9. To localize the DNA-regions responsible for regulated expression, we generated MYCN/CAT hybrid genes with different portions of the putative MYCN promoter region linked to the reporter gene. Transient transfections into various murine and human cell lines identified three DNA regions apparently involved in the regulation of expression. One region about 200 bp upstream of the transcriptional start sites is responsible for a basal level of MYCN expression. A second region located about 800 bp further upstream appears to be involved in cell type-specific gene activation. The third regulatory element is located at the 3' end of the first exon and/or in the first intron and may mediate tissue-specific down regulation of gene expression.	INST MOLEK PATHOL,A-1030 VIENNA,AUSTRIA	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	HILLER, S (corresponding author), DEUTSCH KREBSFORSCHUNGSZENTRUM,INST EXPTL PATHOL,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY.			Wagner, Erwin F/0000-0001-7872-0196				AGHIB DF, 1990, ONCOGENE, V5, P707; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1986, ADV CANCER RES, V47, P235, DOI 10.1016/S0065-230X(08)60201-8; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AMLER LC, 1989, MOL CELL BIOL, V9, P4903, DOI 10.1128/MCB.9.11.4903; ARRUSHDI A, 1983, SCIENCE, V222, P390, DOI 10.1126/science.6414084; ASKER C, 1989, ONCOGENE, V4, P1523; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Cleveland J L, 1988, Oncogene Res, V3, P357; CLOSE TJ, 1982, GENE, V20, P305, DOI 10.1016/0378-1119(82)90048-8; COLBY WW, 1983, NATURE, V301, P722, DOI 10.1038/301722a0; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GAZIN C, 1984, EMBO J, V3, P383, DOI 10.1002/j.1460-2075.1984.tb01816.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRADY EF, 1987, CANCER RES, V47, P2931; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; Hogan B., 1986, MANIPULATING MOUSE E; IBSON JM, 1988, ONCOGENE, V2, P399; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; JAKOBOVITS A, 1985, NATURE, V318, P188, DOI 10.1038/318188a0; KADDURAHDAOUK R, 1987, GENE DEV, V1, P347, DOI 10.1101/gad.1.4.347; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KAYE F, 1988, MOL CELL BIOL, V8, P186, DOI 10.1128/MCB.8.1.186; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; KUBOTA Y, 1989, BIOCHEM BIOPH RES CO, V162, P991, DOI 10.1016/0006-291X(89)90771-7; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MCGROGAN M, 1985, J BIOL CHEM, V260, P2307; MELTON DW, 1986, CELL, V44, P319, DOI 10.1016/0092-8674(86)90766-X; NEPVEU A, 1987, ONCOGENE, V1, P243; PENN LJZ, 1990, EMBO J, V9, P1113, DOI 10.1002/j.1460-2075.1990.tb08217.x; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; REMMERS EF, 1986, EMBO J, V5, P899, DOI 10.1002/j.1460-2075.1986.tb04301.x; Sambrook J., 1989, MOL CLONING LAB MANU; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1988, ONCOGENE HDB, P381; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SLAMON DJ, 1986, SCIENCE, V232, P768, DOI 10.1126/science.3008339; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SPECTOR DL, 1987, ONCOGENE, V1, P5; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STANTON LW, 1987, MOL CELL BIOL, V7, P4266, DOI 10.1128/MCB.7.12.4266; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; VANLOHUIZEN M, 1989, EMBO J, V8, P133, DOI 10.1002/j.1460-2075.1989.tb03357.x; WRIGHT S, 1989, P NATL ACAD SCI USA, V86, P505, DOI 10.1073/pnas.86.2.505; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x; ZIMMERMAN K, 1990, MOL CELL BIOL, V10, P2096, DOI 10.1128/MCB.10.5.2096; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	64	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					969	977						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	2067849				2022-12-17	WOS:A1991GU62200011
J	HASHIMOTO, T; TAKAHASHI, R; YANDELL, DW; XU, HJ; HU, SX; GUNNELL, S; BENEDICT, WF				HASHIMOTO, T; TAKAHASHI, R; YANDELL, DW; XU, HJ; HU, SX; GUNNELL, S; BENEDICT, WF			CHARACTERIZATION OF INTRAGENIC DELETIONS IN 2 SPORADIC GERMINAL MUTATION CASES OF RETINOBLASTOMA RESULTING IN ABNORMAL GENE-EXPRESSION	ONCOGENE			English	Note							SUSCEPTIBILITY GENE; CELL-CYCLE; GENOMIC ORGANIZATION; PRODUCT; PHOSPHORYLATION; SEQUENCES; PROTEIN; MITOSIS; CANCER	Two gross intragenic deletions of the retinoblastoma (RB) gene from patients with sporadic hereditary disease were analysed in detail. This study was undertaken to determine whether there were common mechanisms for these deletions and whether changes found in the tumors were identical to those found in the constitutional cells. Short repeats at the deletion breakpoints were found in both tumors, one resulting in a 2.0 kb deletion including exons 21 and 22, and the other producing a 3.7 kb deletion including exons 14-17. In addition, the identical sequence changes documented in genomic DNAs and transcripts of these tumors were also observed in the constitutional cells. Both deletions were in-frame and resulted in a truncated transcript and protein identical to the expected size based on the exons deleted. These studies provide further documentation of the events which represent the actual 'two hits' originally hypothesized to be responsible for retinoblastoma development.	BAYLOR UNIV,CTR BIOTECHNOL,4000 RES FOREST DR,THE WOODLANDS,TX 77381; MASSACHUSETTS EYE & EAR HOSP,DEPT OPHTHALMOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Baylor College of Medicine; Baylor University; Harvard University; Harvard Medical School					NATIONAL EYE INSTITUTE [R01EY002715] Funding Source: NIH RePORTER; NEI NIH HHS [EY02715, EY06195] Funding Source: Medline; DRS NIH HHS [BRSG 790G16254] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); DRS NIH HHS		BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; BOOKSTEIN R, 1989, MOL CELL BIOL, V9, P1628, DOI 10.1128/MCB.9.4.1628; BRUNIER D, 1989, EMBO J, V8, P3127, DOI 10.1002/j.1460-2075.1989.tb08465.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CANNING S, 1989, P NATL ACAD SCI USA, V86, P5044, DOI 10.1073/pnas.86.13.5044; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DUNN JM, 1989, MOL CELL BIOL, V9, P4596, DOI 10.1128/MCB.9.11.4596; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; LEE EYHP, 1988, P NATL ACAD SCI USA, V85, P6017, DOI 10.1073/pnas.85.16.6017; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MCGEE TL, 1989, GENE, V80, P119, DOI 10.1016/0378-1119(89)90256-4; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; Shew J.-Y., 1989, ONCOGENE RES, V1, P205; SMITH CL, 1989, J VIROL, V63, P1569, DOI 10.1128/JVI.63.4.1569-1577.1989; TANG A, 1989, ONCOGENE, V4, P401; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WIGGS J, 1988, NEW ENGL J MED, V318, P151, DOI 10.1056/NEJM198801213180305; XU HJ, 1989, ONCOGENE, V4, P807; YANDELL DW, 1989, NEW ENGL J MED, V321, P1689, DOI 10.1056/NEJM198912213212501	27	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					463	469						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	2011402				2022-12-17	WOS:A1991FT34400018
J	STRAUSS, M; HERING, S; LUBBE, L; GRIFFIN, BE				STRAUSS, M; HERING, S; LUBBE, L; GRIFFIN, BE			IMMORTALIZATION AND TRANSFORMATION OF HUMAN FIBROBLASTS BY REGULATED EXPRESSION OF POLYOMA-VIRUS T-ANTIGENS	ONCOGENE			English	Article									ROYAL POSTGRAD MED SCH,DEPT VIROL,DU CANE RD,LONDON W12 0NN,ENGLAND; ACAD SCI GDR,CENT INST MOLEC BIOL,O-1086 BERLIN,GERMANY; CENT INST CANC RES,BERLIN,GERMANY	Imperial College London; German Academy of Sciences at Berlin								BOSHART M, 1985, CELL, V41, P521, DOI 10.1016/S0092-8674(85)80025-8; BRAVO R, 1985, FEBS LETT, V182, P435, DOI 10.1016/0014-5793(85)80349-5; CELIS JE, 1987, FEBS LETT, V220, P1, DOI 10.1016/0014-5793(87)80865-7; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLERTANT P, 1984, NATURE, V311, P276, DOI 10.1038/311276a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GOTOH S, 1979, J GEN VIROL, V42, P409, DOI 10.1099/0022-1317-42-2-409; GRIFFIN BE, 1979, J VIROL, V39, P653; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HUANG AL, 1981, CELL, V27, P245, DOI 10.1016/0092-8674(81)90408-6; HURLIN PJ, 1989, P NATL ACAD SCI USA, V86, P187, DOI 10.1073/pnas.86.1.187; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; KINGSTON RE, 1986, MOL CELL BIOL, V6, P3180, DOI 10.1128/MCB.6.9.3180; KNUDSON AG, 1987, ADV VIRAL ONCOL, V7, P1; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LINZER DIH, 1988, TRENDS GENET, V4, P245, DOI 10.1016/0168-9525(88)90029-7; LOMAX CA, 1978, INTERVIROLOGY, V9, P28, DOI 10.1159/000148918; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; NEWBOLD RF, 1983, NATURE, V304, P648, DOI 10.1038/304648a0; POMERANTZ BJ, 1984, J VIROL, V49, P925, DOI 10.1128/JVI.49.3.925-937.1984; PONTEN J, 1985, IARC SCI PUBL, V58, P171; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RASSOULZADEGAN M, 1983, P NATL ACAD SCI USA, V80, P4345; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SAGER R, 1984, CANCER CELL, V2, P487; SMALL MB, 1982, NATURE, V296, P671, DOI 10.1038/296671a0; SPANDIDOS DA, 1984, NATURE, V310, P469, DOI 10.1038/310469a0; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; STRAUSS M, 1986, GENE, V49, P331, DOI 10.1016/0378-1119(86)90369-0; STRAUSS M, 1989, CURR TOP MICROBIOL, V44, P129; TANG A, 1989, ONCOGENE, V4, P401; TEVETHIA MJ, 1984, VIROLOGY, V137, P414, DOI 10.1016/0042-6822(84)90234-4; Tooze J., 1980, MOL BIOL TUMOR VIR 2; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; VANDOREN K, 1984, MOL CELL BIOL, V4, P1653, DOI 10.1128/MCB.4.8.1653; WEINBERG RA, 1985, SCIENCE, V230, P770, DOI 10.1126/science.2997917; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	45	35	36	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1223	1229						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	1697410				2022-12-17	WOS:A1990DX36100016
J	FERRELL, JE; NOBLE, JA; MARTIN, GS; JACQUES, YV; BAINTON, DF				FERRELL, JE; NOBLE, JA; MARTIN, GS; JACQUES, YV; BAINTON, DF			INTRACELLULAR-LOCALIZATION OF PP60C-SRC IN HUMAN PLATELETS	ONCOGENE			English	Article									UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PATHOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	FERRELL, JE (corresponding author), UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,401 BARKER HALL,BERKELEY,CA 94720, USA.				NCI NIH HHS [CA-17542] Funding Source: Medline; NHLBI NIH HHS [HL-31610] Funding Source: Medline; NIGMS NIH HHS [GM11507] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017542, R37CA017542] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL031610, R01HL031610] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011507] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAINTON DF, 1987, J EXP MED, V166, P1641, DOI 10.1084/jem.166.6.1641; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; COCHET C, 1984, J BIOL CHEM, V259, P2553; CORASH L, 1984, BLOOD, V64, P185; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FERRELL JE, 1988, MOL CELL BIOL, V8, P3603, DOI 10.1128/MCB.8.9.3603; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; HAINFELD JF, 1988, NATURE, V333, P281, DOI 10.1038/333281a0; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PARSONS SJ, 1986, BIOCHEM BIOPH RES CO, V134, P736, DOI 10.1016/S0006-291X(86)80482-X; RADKE K, 1983, J CELL BIOL, V97, P1601, DOI 10.1083/jcb.97.5.1601; RENDU F, 1989, BLOOD, V73, P1545; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SCHLIWA M, 1981, J CELL BIOL, V90, P222, DOI 10.1083/jcb.90.1.222; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; STENBERG PE, 1984, HISTOCHEM J, V16, P983, DOI 10.1007/BF01003853; STENBERG PE, 1984, J CELL BIOL, V98, P748, DOI 10.1083/jcb.98.2.748; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; STENBERG PE, 1986, BIOCH PLATELETS, P257; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; WHITE JG, 1984, BLOOD PLATELET FUNCT, P15	34	35	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1990	5	7					1033	1036						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP415	1695725				2022-12-17	WOS:A1990DP41500011
J	BANKS, L; BARNETT, SC; CROOK, T				BANKS, L; BARNETT, SC; CROOK, T			HPV-16 E7 FUNCTIONS AT THE G1-PHASE TO S-PHASE TRANSITION IN THE CELL-CYCLE	ONCOGENE			English	Article									ST MARYS HOSP,SCH MED,LUDWIG INST CANC RES,LONDON W2 1PG,ENGLAND; LUDWIG INST CANC RES,LONDON W1 P8BT,ENGLAND; UNIV CAMBRIDGE,DEPT PATHOL,IMPERIAL CANC RES FUND TUMOUR VIRUS GRP,CAMBRIDGE CB2 1QP,ENGLAND	Imperial College London; Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; University of Cambridge	BANKS, L (corresponding author), INT CTR GENET ENGN & BIOTECHNOL,PADRICIANO 99,I-34012 TRIESTE,ITALY.							ANDROPHY EJ, 1987, EMBO J, V6, P989, DOI 10.1002/j.1460-2075.1987.tb04849.x; BANKS L, 1987, J GEN VIROL, V68, P1351, DOI 10.1099/0022-1317-68-5-1351; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CROOK T, 1989, EMBO J, V8, P513, DOI 10.1002/j.1460-2075.1989.tb03405.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GISSMANN L, 1983, P NATL ACAD SCI-BIOL, V80, P560, DOI 10.1073/pnas.80.2.560; MATLASHEWSKI G, 1987, EMBO J, V6, P1741, DOI 10.1002/j.1460-2075.1987.tb02426.x; NAKAJIMA T, 1987, MOL CELL BIOL, V7, P3846, DOI 10.1128/MCB.7.10.3846; OLTERSDORF T, 1987, J GEN VIROL, V68, P2933, DOI 10.1099/0022-1317-68-11-2933; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; QUINLAN MP, 1987, J VIROL, V61, P673, DOI 10.1128/JVI.61.3.673-682.1987; SATO H, 1989, VIROLOGY, V168, P195, DOI 10.1016/0042-6822(89)90423-6; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; SMOTKIN D, 1986, P NATL ACAD SCI USA, V83, P4680, DOI 10.1073/pnas.83.13.4680; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPENCE RP, 1988, CANCER RES, V48, P324; STOREY A, 1988, EMBO J, V7, P1815, DOI 10.1002/j.1460-2075.1988.tb03013.x; TAYLOR IW, 1980, J HISTOCHEM CYTOCHEM, V28, P1021, DOI 10.1177/28.9.6157714; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VANDENBRULE AJC, 1989, J MED VIROL, V29, P20, DOI 10.1002/jmv.1890290105; VOUSDEN KH, 1989, ONCOGENE, V4, P153; VOUSDEN KH, 1988, ONCOGENE RES, V3, P167; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; YEE C, 1985, AM J PATHOL, V119, P361; YOUNG LS, 1989, BRIT MED J, V298, P14, DOI 10.1136/bmj.298.6665.14; ZERLER B, 1986, MOL CELL BIOL, V6, P887, DOI 10.1128/MCB.6.3.887	30	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1990	5	6					833	837						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2359620				2022-12-17	WOS:A1990DP55300008
J	KRAISS, S; BARNEKOW, A; MONTENARH, M				KRAISS, S; BARNEKOW, A; MONTENARH, M			PROTEIN-KINASE ACTIVITY ASSOCIATED WITH IMMUNOPURIFIED P53-PROTEIN	ONCOGENE			English	Article									UNIV ULM, DEPT BIOCHEM, POB 4066, W-7900 ULM, GERMANY; INST MED VIROL, W-6300 GIESSEN, GERMANY	Ulm University			Montenarh, Mathias/AAB-6689-2020					ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BAUMANN EA, 1979, P NATL ACAD SCI USA, V76, P3688, DOI 10.1073/pnas.76.8.3688; BIENZ B, 1984, EMBO J, V3, P2179, DOI 10.1002/j.1460-2075.1984.tb02110.x; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADLEY MK, 1982, CELL, V28, P125, DOI 10.1016/0092-8674(82)90382-8; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; CRAWFORD LV, 1981, P NATL ACAD SCI-BIOL, V78, P41, DOI 10.1073/pnas.78.1.41; DELEO AB, 1979, P NATL ACAD SCI USA, V76, P2420, DOI 10.1073/pnas.76.5.2420; DIPPOLD WG, 1981, P NATL ACAD SCI-BIOL, V78, P1695, DOI 10.1073/pnas.78.3.1695; ECKHART W, 1979, CELL, V18, P925, DOI 10.1016/0092-8674(79)90205-8; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FRANSEN L, 1983, J BIOL CHEM, V258, P5276; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GIACHERIO D, 1979, J BIOL CHEM, V254, P8113; GRIFFIN JD, 1979, P NATL ACAD SCI USA, V76, P2610, DOI 10.1073/pnas.76.6.2610; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; JAY G, 1981, P NATL ACAD SCI-BIOL, V78, P2932, DOI 10.1073/pnas.78.5.2932; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KACZMAREK L, 1986, EXP CELL RES, V162, P268, DOI 10.1016/0014-4827(86)90445-3; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LAEMMLI UK, 1970, NATURE, V278, P261; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LASSAM NJ, 1979, NATURE, V277, P241, DOI 10.1038/277241a0; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MCCORMICK F, 1981, NATURE, V292, P63, DOI 10.1038/292063a0; MEEK DW, 1988, MOL CELL BIOL, V8, P461, DOI 10.1128/MCB.8.1.461; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MILLER DW, 1986, GENETIC ENG, V8; MILLER LK, 1987, VECTORS SURVEY MOL C; MILNER J, 1985, VIROLOGY, V147, P206, DOI 10.1016/0042-6822(85)90240-5; MONTENARH M, 1985, EMBO J, V4, P2941, DOI 10.1002/j.1460-2075.1985.tb04027.x; OREILLY DR, 1988, J VIROL, V62, P3109, DOI 10.1128/JVI.62.9.3109-3119.1988; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; PINHASIKIMHI O, 1986, NATURE, V320, P182, DOI 10.1038/320182a0; REICH NC, 1984, NATURE, V308, P199, DOI 10.1038/308199a0; SAMAD A, 1986, P NATL ACAD SCI USA, V83, P897, DOI 10.1073/pnas.83.4.897; SCHAFFHAUSEN BS, 1979, CELL, V18, P935, DOI 10.1016/0092-8674(79)90206-X; SCHERER WF, 1953, J EXP MED, V97, P695, DOI 10.1084/jem.97.5.695; SHIROKI K, 1986, MOL CELL BIOL, V6, P4379, DOI 10.1128/MCB.6.12.4379; SHOHAT O, 1987, ONCOGENE, V1, P277; SMITH AE, 1979, CELL, V18, P915, DOI 10.1016/0092-8674(79)90204-6; STURZBECHER HW, 1987, ONCOGENE, V1, P201; STURZBECHER HW, 1987, VIROLOGY, V160, P445; TJIAN R, 1979, P NATL ACAD SCI USA, V76, P610, DOI 10.1073/pnas.76.2.610; VANROY F, 1984, MOL CELL BIOL, V4, P232, DOI 10.1128/MCB.4.2.232; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213; WALSER A, 1986, EMBO J, V5, P883, DOI 10.1002/j.1460-2075.1986.tb04299.x; YEWDELL JW, 1986, J VIROL, V59, P444, DOI 10.1128/JVI.59.2.444-452.1986	66	35	35	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1990	5	6					845	855						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DP553	2141685				2022-12-17	WOS:A1990DP55300010
J	CAMPBELL, ML; LI, WJ; ARLINGHAUS, RB				CAMPBELL, ML; LI, WJ; ARLINGHAUS, RB			P210 BCR-ABL IS COMPLEXED TO P160 BCR AND PH-P53 PROTEINS IN K562 CELLS	ONCOGENE			English	Note									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT MOLEC PATHOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA47372, CA16672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047372, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COLLINS S, 1987, MOL CELL BIOL, V7, P2870, DOI 10.1128/MCB.7.8.2870; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; KLOETZER W, 1985, VIROLOGY, V140, P230, DOI 10.1016/0042-6822(85)90361-7; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LI WJ, 1989, ONCOGENE, V4, P127; LI WJ, 1988, ONCOGENE, V2, P559; LIFSHITZ B, 1988, ONCOGENE, V2, P112; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MAXWELL SA, 1987, CANCER RES, V47, P1731; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; NOWELL PC, 1960, JNCI-J NATL CANCER I, V25, P85; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079	19	35	36	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1990	5	5					773	776						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DG374	2140598				2022-12-17	WOS:A1990DG37400020
J	ROUSSEL, MF; DOWNING, JR; SHERR, CJ				ROUSSEL, MF; DOWNING, JR; SHERR, CJ			TRANSFORMING ACTIVITIES OF HUMAN CSF-1 RECEPTORS WITH DIFFERENT POINT MUTATIONS AT CODON-301 IN THEIR EXTRACELLULAR DOMAINS	ONCOGENE			English	Article									UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT BIOCHEM, MEMPHIS, TN 38163 USA; ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA	University of Tennessee System; University of Tennessee Health Science Center; St Jude Children's Research Hospital	ROUSSEL, MF (corresponding author), ST JUDE CHILDRENS RES HOSP, HOWARD HUGHES MED INST, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA.		Downing, James R./N-8102-2018; Sherr, Charles J/N-8074-2018; Roussel, Martine F/F-1469-2016	Sherr, Charles J/0000-0002-5516-6206; Roussel, Martine F/0000-0002-1740-8139	NCI NIH HHS [P30-CA21765, R35-CA47064, K08-CA01429] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, R35CA047064, K08CA001429] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; ASHMUN RA, 1989, BLOOD, V73, P827; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BESMER P, 1986, J VIROL, V60, P194, DOI 10.1128/JVI.60.1.194-203.1986; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; BROWNING PJ, 1986, P NATL ACAD SCI USA, V83, P7800, DOI 10.1073/pnas.83.20.7800; COUSSENS L, 1986, NATURE, V320, P277, DOI 10.1038/320277a0; DONNER L, 1982, J VIROL, V41, P489, DOI 10.1128/JVI.41.2.489-500.1982; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; DOWNING JR, 1989, IN PRESS EMBO J; FURMAN WL, 1986, VIROLOGY, V152, P432, DOI 10.1016/0042-6822(86)90145-5; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HARTMANN T, 1989, IN PRESS GROWTH FACT; HEARD JM, 1987, ONCOGENE RES, V1, P423; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; KATO JY, 1989, MOL CELL BIOL, V9, P4069, DOI 10.1128/MCB.9.9.4069; LYMAN SD, 1988, ONCOGENE, V3, P391; MCDONOUGH SK, 1971, CANCER RES, V31, P953; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; RETTENMIER CW, 1987, MOL CELL BIOL, V7, P2378, DOI 10.1128/MCB.7.7.2378; RETTENMIER CW, 1986, J CLIN INVEST, V77, P1740, DOI 10.1172/JCI112496; RETTENMIER CW, 1985, SCIENCE, V228, P320, DOI 10.1126/science.2580348; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SACCA R, 1986, P NATL ACAD SCI USA, V83, P3331, DOI 10.1073/pnas.83.10.3331; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHERR CJ, 1989, BLOOD, V73, P1786; SHERR CJ, 1988, BIOCHIM BIOPHYS ACTA, V948, P225, DOI 10.1016/0304-419X(88)90011-X; SHERR CJ, 1988, COLD SPRING HARB SYM, V53, P521, DOI 10.1101/SQB.1988.053.01.060; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; WOOLFORD J, 1985, MOL CELL BIOL, V5, P3458, DOI 10.1128/MCB.5.12.3458; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	44	35	36	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					25	30						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2157180				2022-12-17	WOS:A1990CM62000004
J	WILLIAMS, BP; SHIPLEY, JP; SPURR, NK; SMITH, DR; HAYMAN, MJ; GOODFELLOW, PN				WILLIAMS, BP; SHIPLEY, JP; SPURR, NK; SMITH, DR; HAYMAN, MJ; GOODFELLOW, PN			A HUMAN SEQUENCE HOMOLOGOUS TO V-SEA MAPS TO CHROMOSOME-11, BAND-Q13	ONCOGENE			English	Note									IMPERIAL CANC RES FUND,HUMAN CYTOGENET LAB,LONDON WC2A 3PX,ENGLAND; IMPERIAL CANC RES FUND,HUMAN GENET RESOURCE FACIL,S MIMMS,HERTS,ENGLAND; COLLABORAT RES INC,DEPT HUMAN GENET,WALTHAM,MA; SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	Cancer Research UK; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	WILLIAMS, BP (corresponding author), IMPERIAL CANC RES FUND,HUMAN MOLEC GENET LAB,POB 123,LINCOLNS INN FIELD,LONDON WC2A 3PX,ENGLAND.			Williams, Brenda Patricia/0000-0003-4690-5932	NCI NIH HHS [CA42573] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1981, SOMAT CELL GENET, V7, P435, DOI 10.1007/BF01542988; BENEDICT SH, 1985, VIROLOGY, V145, P154, DOI 10.1016/0042-6822(85)90210-7; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; CARRITT B, 1979, CYTOGENET CELL GENET, V23, P171, DOI 10.1159/000131323; CARRITT B, 1980, TISSUE CULTURE MED R, V2, P169; CASEY G, 1986, MOL CELL BIOL, V6, P502, DOI 10.1128/MCB.6.2.502; CHAN AML, 1987, ONCOGENE, V1, P229; DEAN M, 1985, NATURE, V318, P285; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EDWARDS YH, 1985, ANN HUM GENET, V49, P101, DOI 10.1111/j.1469-1809.1985.tb01681.x; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOODFELLOW PN, 1982, EUR J IMMUNOL, V12, P659, DOI 10.1002/eji.1830120807; HALL A, 1983, NATURE, V303, P396, DOI 10.1038/303396a0; HARPER ME, 1981, CHROMOSOMA, V83, P431, DOI 10.1007/BF00327364; HARRIS H, 1978, HUMAN GENETICS S; HARRIS H, 1977, HUMAN GENETICS S; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HOBART MJ, 1981, ANN HUM GENET, V45, P331, DOI 10.1111/j.1469-1809.1981.tb00346.x; JONES EA, 1976, SOMAT CELL GENET, V2, P483, DOI 10.1007/BF01542686; KLEIN G, 1985, IMMUNOL TODAY, V6, P208, DOI 10.1016/0167-5699(85)90036-2; LARIZZA L, 1973, CELL BIOL INT REPORT, V7, P325; MANIATIS T, 1982, MOL CLONING LABORATO; NICKAMEYER WS, 1985, J VIROL, V53, P879; POVEY S, 1980, ANN HUM GENET, V43, P241, DOI 10.1111/j.1469-1809.1980.tb01557.x; SHEER D, 1982, SOMAT CELL GENET, V8, P1, DOI 10.1007/BF01538646; SMITH DR, 1988, UNPUB; SOLOMON E, 1976, SOMAT CELL GENET, V2, P125, DOI 10.1007/BF01542626; Stubbs EL, 1935, J EXP MED, V61, P593, DOI 10.1084/jem.61.5.593; SWALLOW DM, 1977, CYTOGENET CELL GENET, V18, P136, DOI 10.1159/000130758; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; TUNNACLIFFE A, 1984, GENETIC ANAL CELL SU, P57; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VANHEYNINGEN V, 1975, ANN HUM GENET, V38, P295; VARMUS HE, 1982, CANCER SURV, V2, P309	35	35	35	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					345	348						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	3205567				2022-12-17	WOS:A1988Q436700015
J	SADOWSKI, I; PAWSON, T				SADOWSKI, I; PAWSON, T			CATALYTIC AND NONCATALYTIC DOMAINS OF THE FUJINAMI SARCOMA-VIRUS P130GAG-FPS PROTEIN-TYROSINE KINASE DISTINGUISHED BY THE EXPRESSION OF V-FPS POLYPEPTIDES IN ESCHERICHIA-COLI	ONCOGENE			English	Article									MT SINAI HOSP,RES INST,DIV MOLEC & DEV BIOL,600 UNIV AVE,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MED GENET,TORONTO M5S 1A1,ONTARIO,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto			Pawson, Tony J/E-4578-2013					BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BUEHNER M, 1974, J MOL BIOL, V90, P25, DOI 10.1016/0022-2836(74)90254-X; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; FOSTER D, 1984, J VIROL, V48, P744; GARBER EA, 1985, MOL CELL BIOL, V5, P2781, DOI 10.1128/MCB.5.10.2781; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; INGMANBAKER J, 1984, J VIROL, V50, P572, DOI 10.1128/JVI.50.2.572-578.1984; JOVE R, 1986, J VIROL, V60, P849, DOI 10.1128/JVI.60.3.849-857.1986; KAMPS MP, 1984, NATURE, V310, P589, DOI 10.1038/310589a0; LEVINSON AD, 1981, P NATL ACAD SCI-BIOL, V78, P1624, DOI 10.1073/pnas.78.3.1624; PAI EF, 1977, J MOL BIOL, V114, P37, DOI 10.1016/0022-2836(77)90281-9; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PRYWES R, 1985, J VIROL, V54, P114, DOI 10.1128/JVI.54.1.114-122.1985; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SCHIEVEN G, 1986, SCIENCE, V231, P390, DOI 10.1126/science.2417318; SHIBUYA M, 1982, CELL, V30, P787, DOI 10.1016/0092-8674(82)90283-5; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SHULZ GE, 1974, NATURE, V250, P120; STERNBERG MJE, 1984, FEBS LETT, V175, P387, DOI 10.1016/0014-5793(84)80774-7; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508; STONE JC, 1985, J VIROL, V55, P721, DOI 10.1128/JVI.55.3.721-727.1985; STONE JC, 1984, CELL, V37, P549, DOI 10.1016/0092-8674(84)90385-4; WANG JYJ, 1982, J BIOL CHEM, V257, P13181; WEINMASTER G, 1984, CELL, V37, P559, DOI 10.1016/0092-8674(84)90386-6; WEINMASTER G, 1986, EMBO J, V5, P69, DOI 10.1002/j.1460-2075.1986.tb04179.x; WEINMASTER G, 1983, J VIROL, V45, P29; YACIUK P, 1986, MOL CELL BIOL, V6, P2807, DOI 10.1128/MCB.6.8.2807; YANOFSKY C, 1981, NUCLEIC ACIDS RES, V9, P6647, DOI 10.1093/nar/9.24.6647	29	35	39	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					181	191						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	2449646				2022-12-17	WOS:A1987J635200011
J	Zeng, Z; Zhao, Y; Chen, QY; Zhu, S; Niu, Y; Ye, Z; Hu, P; Chen, D; Xu, P; Chen, JH; Hu, CJ; Hu, YH; Xu, FY; Tang, J; Wang, F; Han, SB; Huang, MQ; Wang, CY; Zhao, G				Zeng, Zhu; Zhao, Yong; Chen, QingYong; Zhu, Shuai; Niu, Yi; Ye, Zeng; Hu, Ping; Chen, Ding; Xu, Peng; Chen, Jinghuang; Hu, Chaojie; Hu, Yuhang; Xu, Fengyu; Tang, Jiang; Wang, Fan; Han, Shengbo; Huang, Mengqi; Wang, Chunyou; Zhao, Gang			Hypoxic exosomal HIF-1 alpha-stabilizing circZNF91 promotes chemoresistance of normoxic pancreatic cancer cells via enhancing glycolysis	ONCOGENE			English	Article							DRUG-RESISTANCE; INDUCIBLE FACTOR-1-ALPHA; MEDIATED TRANSFER; CHEMOTHERAPY; HIF-1-ALPHA; INHIBITION; RNA	Research has indicated that hypoxia profoundly contributes to chemoresistance of pancreatic cancer (PC), while the precise mechanism has not been fully elucidated. In this study, we report a hypoxic exosomal circular RNA (circRNA)-mediated mechanism of conferred chemoresistance in PC cells. Gemcitabine (GEM) resistance was enhanced in normoxic PC cells incubated with exosomes derived from hypoxic PC cells. CircRNA microarray displayed that circZNF91 was remarkably increased in hypoxic exosomes of PC cells compared with normoxic exosomes. Overexpression of circZNF91 obviously stimulated chemoresistance in PC cells, while knockdown of circZNF91 retarded the hypoxic exosome-transmitted chemoresistance. Mechanistically, the hypoxic-induced exosomal circZNF91 transmitted into normoxic PC cells could competitively bind to miR-23b-3p, which deprives the inhibition of miR-23b-3p on expression of deacetylase Sirtuin1 (SIRT1). Consequently, the upregulated SIRT1 enhanced deacetylation-dependent stability of HIF-1 alpha protein, leading to glycolysis and GEM chemoresistance of recipient PC cells. In addition, we revealed that the increased circZNF91 in hypoxic exosome was attributed to the transcriptional regulation by HIF-1 alpha. Coincidently, transmission of hypoxic exosomes into subcutaneous xenografts in nude mice obviously facilitated the chemoresistance of transplanted PC tumor, which could be reversed by depletion of circZNF91 or upregulation of miR-23b-3p. Furthermore, clinical data showed that circZNF91 was significantly upregulated in PC tissues and correlated with overexpression of glycolytic enzymes and short overall survival time. Collectively, exosomal circZNF91 can function as a cargo mediating the signal transmission between hypoxic and normoxic tumor cells to promote GEM chemoresistance of PC and may potentially serve as a therapeutic target.	[Zeng, Zhu; Zhao, Yong; Chen, QingYong; Zhu, Shuai; Ye, Zeng; Hu, Ping; Chen, Ding; Xu, Peng; Chen, Jinghuang; Hu, Chaojie; Hu, Yuhang; Xu, Fengyu; Tang, Jiang; Wang, Fan; Han, Shengbo; Huang, Mengqi; Zhao, Gang] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Emergency Surg, Wuhan, Peoples R China; [Niu, Yi] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Gastrointestinal Surg, Wuhan, Peoples R China; [Wang, Chunyou] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Pancreat Surg, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zhao, G (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Dept Emergency Surg, Wuhan, Peoples R China.	gangzhao@hust.edu.cn			National Science Foundation Committee of China [81372666, 81672406, 81802450, 81802377]; Clinical Research Physician Program of Tongji Medical College, Huazhong University of Science and Technology	National Science Foundation Committee of China; Clinical Research Physician Program of Tongji Medical College, Huazhong University of Science and Technology	The National Science Foundation Committee of China (Grant Number: 81372666, 81672406 to GZ; 81802450 to SZ; 81802377 to YN); and Clinical Research Physician Program of Tongji Medical College, Huazhong University of Science and Technology to GZ supported this study.	Abraham J, 2015, LEUKEMIA LYMPHOMA, V56, P26, DOI 10.3109/10428194.2014.907890; An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123; Bednar F, 2020, CANCER DISCOV, V10, P762, DOI 10.1158/2159-8290.CD-20-0359; Boeckel JN, 2015, CIRC RES, V117, P884, DOI 10.1161/CIRCRESAHA.115.306319; Borji M, 2019, BIOCHEM GENET, V57, P507, DOI 10.1007/s10528-019-09905-5; Cho HS, 2019, GENES-BASEL, V10, DOI 10.3390/genes10121008; Christenson ES, 2020, LANCET ONCOL, V21, pE135, DOI 10.1016/S1470-2045(19)30795-8; da Costa WL, 2020, JAMA ONCOL, V6, P1163, DOI 10.1001/jamaoncol.2020.0562; Ding CY, 2020, CANCER LETT, V479, P1, DOI 10.1016/j.canlet.2020.03.002; Doktorova H, 2015, BIOMED PAP, V159, P166, DOI 10.5507/bp.2015.025; Dong CJ, 2019, ONCOTARGETS THER, V12, P1947, DOI 10.2147/OTT.S186922; Halbrook CJ, 2019, CELL METAB, V29, P1390, DOI 10.1016/j.cmet.2019.02.001; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hosein AN, 2020, NAT REV GASTRO HEPAT, V17, P487, DOI 10.1038/s41575-020-0300-1; Icard P, 2018, DRUG RESIST UPDATE, V38, P1, DOI 10.1016/j.drup.2018.03.001; Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9; Joo HY, 2015, BIOCHEM BIOPH RES CO, V462, P294, DOI 10.1016/j.bbrc.2015.04.119; Karasic TB, 2019, JAMA ONCOL, V5, P993, DOI 10.1001/jamaoncol.2019.0684; Klotz R, 2020, LANCET ONCOL, V21, pE295, DOI 10.1016/S1470-2045(20)30179-0; Kristensen LS, 2018, RNA BIOL, V15, P280, DOI 10.1080/15476286.2017.1409931; Lane JS, 2020, CANCERS, V12, DOI 10.3390/cancers12061530; Lin SC, 2011, J CLIN INVEST, V121, P1905, DOI 10.1172/JCI44362; Oon CE, 2015, EUR J PHARMACOL, V757, P59, DOI 10.1016/j.ejphar.2015.03.064; Ostrowski M, 2010, NAT CELL BIOL, V12, P19, DOI 10.1038/ncb2000; Paulson AS, 2013, GASTROENTEROLOGY, V144, P1316, DOI 10.1053/j.gastro.2013.01.078; Robey IF, 2005, NEOPLASIA, V7, P324, DOI 10.1593/neo.04430; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004; Siegel RL., 2020, CA-CANCER J CLIN, V70; Takahashi K, 2014, FEBS OPEN BIO, V4, P458, DOI 10.1016/j.fob.2014.04.007; Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124; Wang JP, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.11891; Wang P, 2013, GASTROENTEROLOGY, V145, P1133, DOI 10.1053/j.gastro.2013.07.048; Wang XY, 2020, MOL ONCOL, V14, P539, DOI 10.1002/1878-0261.12629; Warfel NA, 2014, CURR MED CHEM, V21, P3021, DOI 10.2174/0929867321666140414101056; Xu RH, 2005, CANCER RES, V65, P613; Yeo EJ, 2003, J NATL CANCER I, V95, P516, DOI 10.1093/jnci/95.7.516; Yokoi K, 2004, CLIN CANCER RES, V10, P2299, DOI 10.1158/1078-0432.CCR-03-0488; Yoon JH, 2012, METHODS, V58, P81, DOI 10.1016/j.ymeth.2012.07.004; Zeng Z, 2019, THERANOSTICS, V9, P5298, DOI 10.7150/thno.34559; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105; Zhang JG, 2014, CANCER SCI, V105, P445, DOI 10.1111/cas.12364; Zhou WK, 2019, J CELL BIOCHEM, V120, P19635, DOI 10.1002/jcb.29270	44	34	34	4	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 9	2021	40	36					5505	5517		10.1038/s41388-021-01960-w	http://dx.doi.org/10.1038/s41388-021-01960-w		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UO7MC	34294845				2022-12-17	WOS:000678017100002
J	Han, J; Qu, HB; Han, ML; Ding, YC; Xie, MW; Hu, JG; Chen, YW; Dong, HY				Han, Jing; Qu, Hongbo; Han, Mingli; Ding, Yichao; Xie, Mingwei; Hu, Jianguo; Chen, Yuanwen; Dong, Huaying			MSC-induced lncRNA AGAP2-AS1 promotes stemness and trastuzumab resistance through regulating CPT1 expression and fatty acid oxidation in breast cancer	ONCOGENE			English	Article							RNA; METASTASIS; BIOMARKERS; PROLIFERATION; EMTANSINE; LAPATINIB; HER2	Trastuzumab resistance has been becoming a major obstacle for treatment of HER-2-positive breast cancer patients. Increasing evidence suggests that mesenchymal stem cells (MSCs) play critical roles during the formation of drug resistance, however, the underlying mechanism is not well known. In this study, mass spectrometry, RNA pulldown and RNA immunoprecipitation assays were performed to verify the direct interactions among AGAP2-AS1 and other associated targets, such as human antigen R (HuR), miR-15a-5p, and carnitine palmitoyl transferase 1 (CPT1). In vitro and in vivo experimental assays were done to clarify the functional role of AGAP2-AS1 in trastuzumab resistance, stemness, and fatty acid oxidation (FAO). The results showed that MSC co-culture induced trastuzumab resistance. AGAP2-AS1 was upregulated in MSC-cultured cells, and knockdown of AGAP2-AS1 reversed the MSC-mediated trastuzumab resistance. Furthermore, MSC culture-induced AGAP2-AS1 regulates stemness and trastuzumab resistance via activating FAO. Mechanistically, AGAP2-AS1 is associated with HuR, and the AGAP2-AS1-HuR complex could directly bind to the CPT1, increasing its expression via improving RNA stability. In addition, AGAP2-AS1 could serve as ceRNA via sponging miR-15a-5p and releasing CPT1 mRNA. Clinically, increased expression of serum AGAP2-AS1 predicts poor response to trastuzumab treatment in breast cancer patients. In conclusion, MSC culture-induced AGAP2-AS1 caused stemness and trastuzumab resistance via promoting CPT1 expression and inducing FAO. Our results provide new insight of the role of MSCs in trastuzumab resistance and AGAP2-AS1 could be promising predictive biomarker and therapeutic target for HER-2+ breast cancer patients.	[Han, Jing; Ding, Yichao; Xie, Mingwei; Dong, Huaying] Hainan Med Univ, Hainan Affiliated Hosp, Hainan Gen Hosp, Dept Gen Surg, Haikou 570311, Hainan, Peoples R China; [Qu, Hongbo] First Peoples Hosp Chenzhou City, Dept Breast & Thyroid Surg, Chenzhou City 423000, Hunan, Peoples R China; [Han, Mingli] Zhengzhou Univ, Affiliated Hosp 1, Dept Breast Surg, Zhengzhou 450052, Peoples R China; [Hu, Jianguo] Chongqing Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Chongqing 400010, Peoples R China; [Chen, Yuanwen] Univ Chinese Acad Sci, Chongqing Renji Hosp, Dept Gen Surg, Chongqing 400062, Peoples R China	Hainan Medical University; Zhengzhou University; Chongqing Medical University; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Dong, HY (corresponding author), Hainan Med Univ, Hainan Affiliated Hosp, Hainan Gen Hosp, Dept Gen Surg, Haikou 570311, Hainan, Peoples R China.	dr_dhy@163.com		Dong, Huaying/0000-0002-4905-6940	National Natural Science Foundation of China [81960475, 82072932]; "Nanhai series" talent cultivation program of Hainan Province	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); "Nanhai series" talent cultivation program of Hainan Province	This study is supported by National Natural Science Foundation of China (81960475, 82072932) and The "Nanhai series" talent cultivation program of Hainan Province.	Amadori D, 2011, EUR J CANCER, V47, P2091, DOI 10.1016/j.ejca.2011.05.005; Arshi A, 2018, MOL THER-NUCL ACIDS, V12, P751, DOI 10.1016/j.omtn.2018.07.014; Bai Y, 2019, J CELL PHYSIOL, V234, P18837, DOI 10.1002/jcp.28522; Bakheet T, 2018, BBA-GENE REGUL MECH, V1861, P167, DOI 10.1016/j.bbagrm.2017.12.006; Bighin C, 2013, FUTURE ONCOL, V9, P955, DOI [10.2217/fon.13.74, 10.2217/FON.13.74]; Boero S, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0680-0; Borst P, 2012, OPEN BIOL, V2, DOI 10.1098/rsob.120066; Chen RS, 2020, J CELL BIOCHEM, V121, P4043, DOI 10.1002/jcb.29573; Choi HJ, 2020, REDOX BIOL, V36, DOI 10.1016/j.redox.2020.101589; Cuiffo BG, 2014, CELL STEM CELL, V15, P762, DOI 10.1016/j.stem.2014.10.001; Di C, 2015, EXP THER MED, V9, P289, DOI 10.3892/etm.2014.2141; Dong HY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0875-3; Freudenberg JA, 2009, EXP MOL PATHOL, V87, P1, DOI 10.1016/j.yexmp.2009.05.001; Gallardo A, 2012, BRIT J CANCER, V106, P1367, DOI 10.1038/bjc.2012.85; Ghoveud E, 2020, NEUROMOL MED, V22, P111, DOI 10.1007/s12017-019-08570-6; Han ML, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1145-5; He WM, 2019, ONCOGENE, V38, P4637, DOI 10.1038/s41388-019-0747-0; HUANG P, 2018, SCI REP UK, V8; Hui BQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1384-9; Kang M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0845-9; Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248; Li N, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0828-0; Li ZX, 2019, EXP THER MED, V18, P435, DOI 10.3892/etm.2019.7629; Liu ZK, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1188-x; Liu ZX, 2019, ONCOGENE, V38, P88, DOI 10.1038/s41388-018-0407-9; Lorenz R, 2011, ALGORITHM MOL BIOL, V6, DOI 10.1186/1748-7188-6-26; Luo N, 2020, J CELL BIOCHEM, V121, P4176, DOI 10.1002/jcb.29572; Montemurro F, 2014, MOL ONCOL, V8, P20, DOI 10.1016/j.molonc.2013.08.013; Pereira B, 2017, TRENDS CANCER, V3, P506, DOI 10.1016/j.trecan.2017.05.003; PEREZ EA, 2019, BMC CANCER, V19; Pike LS, 2011, BBA-BIOENERGETICS, V1807, P726, DOI 10.1016/j.bbabio.2010.10.022; Ponde N, 2018, BREAST CANCER RES TR, V168, P631, DOI 10.1007/s10549-017-4628-3; Qian C, 2019, J CELL PHYSIOL, V234, P11620, DOI 10.1002/jcp.27819; Rahman M, 2015, METABOLITES, V5, P571, DOI 10.3390/metabo5040571; Seebach C, 2010, INJURY, V41, P731, DOI 10.1016/j.injury.2010.02.017; Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8; Shetty P, 2017, ANN CLIN BIOCHEM, V54, P463, DOI 10.1177/0004563216665867; Shi SJ, 2015, ONCOTARGET, V6, P11652, DOI 10.18632/oncotarget.3457; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Song XY, 2020, J CELL MOL MED, V24, P772, DOI 10.1111/jcmm.14786; Storti CB, 2020, EXP MOL PATHOL, V112, DOI 10.1016/j.yexmp.2019.104354; Tian T, 2018, MOL THER-NUCL ACIDS, V12, P359, DOI 10.1016/j.omtn.2018.05.018; Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124; Wu L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2426-z; Yang XJ, 2020, EXP THER MED, V19, P3097, DOI 10.3892/etm.2020.8558; Zhang JW, 2017, NUCLEIC ACIDS RES, V45, P2849, DOI 10.1093/nar/gkw991; Zhang W, 2018, INT J ONCOL, V53, P527, DOI 10.3892/ijo.2018.4412; Zhu HY, 2018, BIOCHEM BIOPH RES CO, V496, P1308, DOI 10.1016/j.bbrc.2018.02.006	48	34	34	7	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					833	847		10.1038/s41388-020-01574-8	http://dx.doi.org/10.1038/s41388-020-01574-8		DEC 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33273726				2022-12-17	WOS:000599064900002
J	Cheng, R; Billet, S; Liu, CX; Haldar, S; Choudhury, D; Tripathi, M; Hav, M; Merchant, A; Hu, T; Huang, HY; Zhou, HM; Bhowmick, NA				Cheng, Ran; Billet, Sandrine; Liu, Chuanxia; Haldar, Subhash; Choudhury, Diptiman; Tripathi, Manisha; Hav, Monirath; Merchant, Akil; Hu, Tao; Huang, Haiyun; Zhou, Hongmei; Bhowmick, Neil A.			Periodontal inflammation recruits distant metastatic breast cancer cells by increasing myeloid-derived suppressor cells	ONCOGENE			English	Article							T-CELLS; IL-1-BETA; CORRELATE; DISEASE; MICE; IL-1	Periodontal diseases can lead to chronic inflammation affecting the integrity of the tooth supporting tissues. Recently, a striking association has been made between periodontal diseases and primary cancers in the absence of a mechanistic understanding. Here we address the effect of periodontal inflammation (PI) on tumor progression, metastasis, and possible underlining mechanisms. We show that an experimental model of PI in mice can promote lymph node (LN) micrometastasis, as well as head and neck metastasis of 4T1 breast cancer cells, both in early and late stages of cancer progression. The cervical LNs had a greater tumor burden and infiltration of MDSC and M2 macrophages compared with LNs at other sites. Pyroptosis and the resultant IL-1 beta production were detected in patients with PI, mirrored in mouse models. Anakinra, IL-1 receptor antagonist, limited metastasis, and MDSC recruitment at early stages of tumor progression, but failed to reverse established metastatic tumors. PI and the resulting production of IL-1 beta was found to promote CCL5, CXCL12, CCL2, and CXCL5 expression. These chemokines recruit MDSC and macrophages, finally enabling the generation of a premetastatic niche in the inflammatory site. These findings support the idea that periodontal inflammation promotes metastasis of breast cancer by recruiting MDSC in part by pyroptosis-induced IL-1 beta generation and downstream CCL2, CCL5, and CXCL5 signaling in the early steps of metastasis. These studies define the role for IL-1 beta in the metastatic progression of breast cancer and highlight the need to control PI, a pervasive inflammatory condition in older patients.	[Cheng, Ran; Liu, Chuanxia; Zhou, Hongmei] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China; [Cheng, Ran; Billet, Sandrine; Liu, Chuanxia; Haldar, Subhash; Choudhury, Diptiman; Tripathi, Manisha; Hav, Monirath; Merchant, Akil; Bhowmick, Neil A.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Hu, Tao] Sichuan Univ, West China Hosp Stomatol, Dept Prevent Dent, Chengdu, Sichuan, Peoples R China; [Huang, Haiyun] Sichuan Univ, West China Hosp Stomatol, Dept Periodontol, Chengdu, Sichuan, Peoples R China; [Bhowmick, Neil A.] Greater Los Angeles Vet Adm, Dept Res, Los Angeles, CA 90073 USA	Sichuan University; Cedars Sinai Medical Center; Sichuan University; Sichuan University	Zhou, HM (corresponding author), Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu, Sichuan, Peoples R China.; Bhowmick, NA (corresponding author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.; Bhowmick, NA (corresponding author), Greater Los Angeles Vet Adm, Dept Res, Los Angeles, CA 90073 USA.	zhouhm@scu.edu.cn; Neil.Bhowmick@cshs.org		Haldar, Subhash/0000-0002-1230-1770; , Ran/0000-0001-5590-3395; Zhou, Hongmei/0000-0003-2985-3536; Choudhury, Diptiman/0000-0003-1080-4558	National Cancer Institute [R01CA108646, P01CA098912]; Veterans Administration [BX001040]; National Nature Science Foundation of China [81772898, 81272962]	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Administration(US Department of Veterans Affairs); National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Cancer Institute (R01CA108646, P01CA098912) and Veterans Administration (BX001040) to NAB and the National Nature Science Foundation of China (No. 81772898 and 81272962) to HZ.	Abais JM, 2015, ANTIOXID REDOX SIGN, V22, P1111, DOI 10.1089/ars.2014.5994; Achberger S, 2014, MOL IMMUNOL, V58, P182, DOI 10.1016/j.molimm.2013.11.018; Bar D, 2004, FASEB J, V18, P161, DOI 10.1096/fj.03-0483fje; Bode KA, 2009, J IMMUNOL, V182, P2176, DOI 10.4049/jimmunol.0802560; Casella G, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0596-5; Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111; Cheng R, 2018, BBA-MOL BASIS DIS, V1864, P226, DOI 10.1016/j.bbadis.2017.10.025; Cheng R, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00474; Condamine T, 2015, ANNU REV MED, V66, P97, DOI 10.1146/annurev-med-051013-052304; Correa Pelayo, 2011, US Gastroenterol Hepatol Rev, V7, P59; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Gholizadeh P, 2017, BIOMED PHARMACOTHER, V89, P918, DOI 10.1016/j.biopha.2017.02.102; Gomes FIF, 2016, J ORAL MAXILLOFAC RE, V7, pe2; Guo BC, 2016, SCI REP-UK, V6, DOI 10.1038/srep36107; Haldar S, 2016, SCI REP-UK, V6, DOI 10.1038/srep39257; Haldar S, 2015, J BIOL CHEM, V290, P6574, DOI 10.1074/jbc.M114.617886; Han Y W, 2014, Adv Dent Res, V26, P47, DOI 10.1177/0022034514528334; Higgins SC, 2003, J IMMUNOL, V171, P3119, DOI 10.4049/jimmunol.171.6.3119; Huang A, 2013, CANCER IMMUNOL IMMUN, V62, P1439, DOI 10.1007/s00262-013-1450-6; Huang GN, 2017, TOXICOL APPL PHARM, V332, P138, DOI 10.1016/j.taap.2017.04.009; Kaplan RN, 2006, CANCER RES, V66, P11089, DOI 10.1158/0008-5472.CAN-06-2407; Kruger M, 2013, CASE REP DENT, V2013, DOI 10.1155/2013/262410; Kshirsagar AV, 2005, AM J KIDNEY DIS, V45, P650, DOI 10.1053/j.ajkd.2004.12.009; Kumar V, 2016, TRENDS IMMUNOL, V37, P208, DOI 10.1016/j.it.2016.01.004; Linden G, 2007, J CLIN PERIODONTOL, V34, P461, DOI 10.1111/j.1600-051X.2007.01075.x; Lukens JR, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00315; Moergel M, 2013, HEAD FACE MED, V9, DOI 10.1186/1746-160X-9-39; Mora J, 2016, BIOL CHEM, V397, P1125, DOI 10.1515/hsz-2016-0215; Nagy KN, 1998, ORAL ONCOL, V34, P304, DOI 10.1016/S1368-8375(98)80012-2; Pendyala Gowri, 2013, Dent Res J (Isfahan), V10, P704; Ray A, 2013, FRONT CELL INFECT MI, V3, DOI 10.3389/fcimb.2013.00052; Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469; Sampson TR, 2016, CELL, V167, P1469, DOI 10.1016/j.cell.2016.11.018; Schapiro D, 2017, NAT METHODS, V14, P873, DOI [10.1038/nmeth.4391, 10.1038/NMETH.4391]; Schugar RC, 2018, ADIPOCYTE, V7, P49, DOI 10.1080/21623945.2017.1398295; Song XP, 2003, J IMMUNOL, V171, P6448, DOI 10.4049/jimmunol.171.12.6448; Su LK, 2017, INFECT IMMUN, V85, DOI 10.1128/IAI.00213-17; Thi HTH, 2017, J CANCER PREV, V22, P62, DOI 10.15430/JCP.2017.22.2.62; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Yao QW, 2014, TUMOR BIOL, V35, P7073, DOI 10.1007/s13277-014-1951-8; Yokoyama M, 2011, J PERIODONTAL RES, V46, P464, DOI 10.1111/j.1600-0765.2011.01362.x; Youn JI, 2008, J IMMUNOL, V181, P5791, DOI 10.4049/jimmunol.181.8.5791; Yu JP, 2013, J IMMUNOL, V190, P3783, DOI 10.4049/jimmunol.1201449; Zeng XT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079017; Zhang Y, 2013, CELL RES, V23, P394, DOI 10.1038/cr.2012.178	48	34	35	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	7					1543	1556		10.1038/s41388-019-1084-z	http://dx.doi.org/10.1038/s41388-019-1084-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KL2WP	31685946	Green Published, hybrid			2022-12-17	WOS:000513289600011
J	Liu, YT; Mao, C; Wang, M; Liu, N; Ouyang, LL; Liu, SP; Tang, HS; Cao, Y; Liu, S; Wang, X; Xiao, DS; Chen, CS; Shi, Y; Yan, Q; Tao, YG				Liu, Yating; Mao, Chao; Wang, Min; Liu, Na; Ouyang, Lianlian; Liu, Shouping; Tang, Haosheng; Cao, Ya; Liu, Shuang; Wang, Xiang; Xiao, Desheng; Chen, Ceshi; Shi, Ying; Yan, Qin; Tao, Yongguang			Cancer progression is mediated by proline catabolism in non-small cell lung cancer	ONCOGENE			English	Article							NF-KAPPA-B; MITOCHONDRIAL TUMOR-SUPPRESSOR; SUCCINATE-DEHYDROGENASE; METHYLATION PATTERNS; OXIDASE; P53; GENE; EXPRESSION; ALPHA; LSH	Dysregulated metabolism contributes to cancer initiation and progression, but the key drivers of these pathways are just being discovered. Here, we report a critical role for proline catabolism in non-small cell lung cancer (NSCLC). Proline dehydrogenase (PRODH) is activated to reduce proline levels by the chromatin remodeling factor lymphoid-specific helicase (LSH), an epigenetic driver of NSCLC. PRODH promotes NSCLC tumorigenesis by inducing epithelial to mesenchymal transition (EMT) and IKK alpha-dependent inflammatory genes, including CXCL1, LCN2, and IL17C. Consistently, proline addition promotes the expression of these inflammatory genes, as well as EMT, tumor cell proliferation, and migration in vitro and tumor growth in vivo, while the depletion or inhibition of PRODH blocks these phenotypes. In summary, we reveal an essential metabolic pathway amenable to targeting in NSCLC.	[Liu, Yating; Mao, Chao; Wang, Min; Liu, Na; Ouyang, Lianlian; Liu, Shouping; Tang, Haosheng; Cao, Ya; Shi, Ying; Tao, Yongguang] Cent South Univ, Xiangya Hosp, Dept Pathol, Key Lab Carcinogenesis & Canc Invas,Minist Educ, Changsha 410078, Hunan, Peoples R China; [Liu, Yating; Mao, Chao; Wang, Min; Liu, Na; Ouyang, Lianlian; Liu, Shouping; Tang, Haosheng; Shi, Ying; Tao, Yongguang] Cent South Univ, NHC Key Lab Carcinogenesis, Canc Res Inst, Changsha 410078, Hunan, Peoples R China; [Liu, Yating; Mao, Chao; Wang, Min; Liu, Na; Ouyang, Lianlian; Liu, Shouping; Tang, Haosheng; Shi, Ying; Tao, Yongguang] Cent South Univ, Sch Basic Med, Changsha 410078, Hunan, Peoples R China; [Liu, Shuang] Cent South Univ, Xiangya Hosp, Inst Med Sci, Dept Oncol, Changsha 410008, Hunan, Peoples R China; [Wang, Xiang; Tao, Yongguang] Cent South Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha 410011, Hunan, Peoples R China; [Xiao, Desheng] Cent South Univ, Sch Basic Med, Dept Pathol, Changsha 410008, Hunan, Peoples R China; [Xiao, Desheng] Cent South Univ, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China; [Chen, Ceshi] Chinese Acad Sci, Kunming Inst Zool, Collaborat Innovat Ctr Canc Med, Key Lab Anim Models & Human Dis Mech,Chinese Acad, Kunming 650223, Yunnan, Peoples R China; [Yan, Qin] Yale Sch Med, Dept Pathol, New Haven, CT 06520 USA	Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Central South University; Chinese Academy of Sciences; Kunming Institute of Zoology; Yale University	Shi, Y; Tao, YG (corresponding author), Cent South Univ, Xiangya Hosp, Dept Pathol, Key Lab Carcinogenesis & Canc Invas,Minist Educ, Changsha 410078, Hunan, Peoples R China.; Shi, Y; Tao, YG (corresponding author), Cent South Univ, NHC Key Lab Carcinogenesis, Canc Res Inst, Changsha 410078, Hunan, Peoples R China.; Shi, Y; Tao, YG (corresponding author), Cent South Univ, Sch Basic Med, Changsha 410078, Hunan, Peoples R China.; Tao, YG (corresponding author), Cent South Univ, Xiangya Hosp 2, Dept Thorac Surg, Changsha 410011, Hunan, Peoples R China.; Yan, Q (corresponding author), Yale Sch Med, Dept Pathol, New Haven, CT 06520 USA.	yingshi@csu.edu.cn; qin.yan@yale.edu; taoyong@csu.edu.cn	Mao, Chao/AAM-6358-2020	, chao/0000-0002-8685-8539	National Natural Science Foundation of China [81872285, 81728014, 81672787, 81672991, 81874139, 81672308, 81772496]; National Basic Research Program of China [2015CB553903]; Overseas Expertize Introduction Project for Discipline Innovation (111 Project) [111-2-12]; Hunan Provincial Key Area RD Programs [2019SK2253]; Fundamental Research Funds for the Central Universities [1502211723]; Open projects of Key Laboratory of Carcinogenesis and Invasion, Ministry of Education (Central South University) [201805]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Basic Research Program of China(National Basic Research Program of China); Overseas Expertize Introduction Project for Discipline Innovation (111 Project); Hunan Provincial Key Area RD Programs; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Open projects of Key Laboratory of Carcinogenesis and Invasion, Ministry of Education (Central South University)	This work was supported by the National Natural Science Foundation of China [81872285 (YS), 81728014 (YT), 81672787 (YT), 81672991, and 81874139 (SL), 81672308 (XW), 81772496 (DX)]; the National Basic Research Program of China [2015CB553903 (YT)], the Overseas Expertize Introduction Project for Discipline Innovation (111 Project, No. 111-2-12), Hunan Provincial Key Area R&D Programs [2019SK2253 (XW)], the Fundamental Research Funds for the Central Universities [1502211723 (YL)], and Open projects of Key Laboratory of Carcinogenesis and Invasion, Ministry of Education (Central South University) [201805, (CC and YT)].	Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Balgkouranidou I, 2013, BIOMARK MED, V7, P49, DOI [10.2217/BMM.12.111, 10.2217/bmm.12.111]; Bononi A, 2017, CELL DEATH DIFFER, V24, P1694, DOI 10.1038/cdd.2017.95; Carey BW, 2015, NATURE, V518, P413, DOI 10.1038/nature13981; Chen L, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0302-9; Coffelt SB, 2015, NATURE, V522, P345, DOI 10.1038/nature14282; Colak D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063204; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; De Ingeniis J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045190; Diakos CI, 2014, LANCET ONCOL, V15, pE493, DOI 10.1016/S1470-2045(14)70263-3; Donald SP, 2001, CANCER RES, V61, P1810; Elia I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15267; Fan T, 2003, CANCER RES, V63, P4677; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gomez-Chou SB, 2017, CANCER RES, V77, P2647, DOI 10.1158/0008-5472.CAN-16-1986; Govindan R, 2012, CELL, V150, P1121, DOI 10.1016/j.cell.2012.08.024; Gut P, 2013, NATURE, V502, P489, DOI 10.1038/nature12752; Han F, 2015, SCI REP-UK, V5, DOI 10.1038/srep13630; He XZ, 2016, CANCER RES, V76, P5743, DOI 10.1158/0008-5472.CAN-16-0268; He YC, 2019, INT J BIOL SCI, V15, P1187, DOI 10.7150/ijbs.33496; He YC, 2017, BBA-REV CANCER, V1868, P359, DOI 10.1016/j.bbcan.2017.07.002; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Hinz M, 2014, EMBO REP, V15, P46, DOI 10.1002/embr.201337983; Jia JT, 2016, ONCOTARGET, V7, P27280, DOI 10.18632/oncotarget.8465; Jiang YQ, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0248-x; Jiang YQ, 2017, THERANOSTICS, V7, P3293, DOI 10.7150/thno.19988; Jones PA, 2016, NAT REV GENET, V17, P630, DOI 10.1038/nrg.2016.93; Jung M, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf3241; Jungnickel C, 2017, ONCOGENE, V36, P4182, DOI 10.1038/onc.2017.28; Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028; Katada S, 2012, CELL, V148, P24, DOI 10.1016/j.cell.2012.01.001; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Lampropoulou V, 2016, CELL METAB, V24, P158, DOI 10.1016/j.cmet.2016.06.004; Li Q, 2006, J BIOL CHEM, V281, P37566, DOI 10.1074/jbc.M603643200; Liu S, 2014, BBA-GENE REGUL MECH, V1839, P592, DOI 10.1016/j.bbagrm.2014.05.017; Liu W, 2015, SCI REP-UK, V5, DOI 10.1038/srep17206; Liu W, 2012, BIOFACTORS, V38, P398, DOI 10.1002/biof.1036; Liu W, 2012, AUTOPHAGY, V8, P1407, DOI 10.4161/auto.21152; Liu W, 2012, CANCER RES, V72, P3677, DOI 10.1158/0008-5472.CAN-12-0080; Liu W, 2012, P NATL ACAD SCI USA, V109, P8983, DOI 10.1073/pnas.1203244109; Liu Y, 2008, ONCOGENE, V27, P6729, DOI 10.1038/onc.2008.322; Liu YM, 2009, CANCER RES, V69, P6414, DOI 10.1158/0008-5472.CAN-09-1223; Loayza-Puch F, 2016, NATURE, V530, P490, DOI 10.1038/nature16982; Mao C, 2018, AM J CANCER RES, V8, P1214; Mao C, 2018, CANCER RES, V78, P3484, DOI 10.1158/0008-5472.CAN-17-3454; Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P11, DOI 10.1038/nrclinonc.2016.60; McDoniels-Silvers AL, 2002, NEOPLASIA, V4, P141, DOI 10.1038/sj.neo.7900217; Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064; Olivares O, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16031; Pang SS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6048; Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5; Perez-Moreno P, 2012, CLIN CANCER RES, V18, P2443, DOI 10.1158/1078-0432.CCR-11-2370; Phang JM, 2019, ANTIOXID REDOX SIGN, V30, P635, DOI 10.1089/ars.2017.7350; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Raimondi I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069152; Ryu B, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000594; Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403; Shi Y, 2012, CARCINOGENESIS, V33, P1468, DOI 10.1093/carcin/bgs171; Shi Y, 2018, CANCER LETT, V422, P81, DOI 10.1016/j.canlet.2018.02.028; Tang HQ, 2016, CELL REP, V17, P2837, DOI 10.1016/j.celrep.2016.11.038; Tao YG, 2011, P NATL ACAD SCI USA, V108, P5626, DOI 10.1073/pnas.1017000108; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Wang DZ, 2017, CANCER RES, V77, P3655, DOI 10.1158/0008-5472.CAN-16-3199; Willis A, 2004, ONCOGENE, V23, P2330, DOI 10.1038/sj.onc.1207396; Xiao DS, 2017, THERANOSTICS, V7, P132, DOI 10.7150/thno.17032; Xiao DS, 2016, ONCOTARGET, V7, P59049, DOI 10.18632/oncotarget.10011; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0542-9; Yan YT, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0466-z; Yang R, 2019, ONCOGENE, V38, P7133, DOI 10.1038/s41388-019-0909-0; Yang R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1276-y; Yu WS, 2014, GENOME RES, V24, P1613, DOI 10.1101/gr.172015.114; Yu WS, 2014, P NATL ACAD SCI USA, V111, P5890, DOI 10.1073/pnas.1320945111; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhang Y, 2011, CELL RES, V21, P373, DOI 10.1038/cr.2011.33; Zhang ZY, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0074-5; Zhu JJ, 2016, P NATL ACAD SCI USA, V113, P9822, DOI 10.1073/pnas.1610387113	78	34	35	8	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	11					2358	2376		10.1038/s41388-019-1151-5	http://dx.doi.org/10.1038/s41388-019-1151-5		JAN 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KU0ZS	31911619				2022-12-17	WOS:000508154600001
J	Polonen, P; Deen, AJ; Leinonen, HM; Jyrkkanen, HK; Kuosmanen, S; Mononen, M; Jain, A; Tuomainen, T; Pasonen-Seppanen, S; Hartikainen, JM; Mannermaa, A; Nykter, M; Tavi, P; Johansen, T; Heinaniemi, M; Levonen, AL				Polonen, Petri; Deen, Ashik Jawahar; Leinonen, Hanna M.; Jyrkkanen, Henna-Kaisa; Kuosmanen, Suvi; Mononen, Mimmi; Jain, Ashish; Tuomainen, Tomi; Pasonen-Seppanen, Sanna; Hartikainen, Jaana M.; Mannermaa, Arto; Nykter, Matti; Tavi, Pasi; Johansen, Terje; Heinaniemi, Merja; Levonen, Anna-Liisa			Nrf2 and SQSTM1/p62 jointly contribute to mesenchymal transition and invasion in glioblastoma	ONCOGENE			English	Article							TRANSCRIPTION FACTOR NRF2; KEAP1-NRF2 PATHWAY; SIGNALING PATHWAYS; CELL LINE; ACTIVATION; MUTATIONS; GENE; EXPRESSION; P62; ABNORMALITIES	Accumulating evidence suggests that constitutively active Nrf2 has a pivotal role in cancer as it induces pro-survival genes that promote cancer cell proliferation and chemoresistance. The mechanisms of Nrf2 dysregulation and functions in cancer have not been fully characterized. Here, we jointly analyzed the Broad-Novartis Cancer Cell Line Encyclopedia (CCLE) and the Cancer Genome Atlas (TCGA) multi-omics data in order to identify cancer types where Nrf2 activation is present. We found that Nrf2 is hyperactivated in a subset of glioblastoma (GBM) patients, whose tumors display a mesenchymal subtype, and uncover several different mechanisms contributing to increased Nrf2 activity. Importantly, we identified a positive feedback loop between SQSTM1/p62 and Nrf2 as a mechanism for activation of the Nrf2 pathway. We also show that autophagy and serine/threonine signaling regulates p62 mediated Keap1 degradation. Our results in glioma cell lines indicate that both Nrf2 and p62 promote proliferation, invasion and mesenchymal transition. Finally, Nrf2 activity was associated with decreased progression free survival in TCGA GBM patient samples, suggesting that treatments have limited efficacy if this transcription factor is overactivated. Overall, our findings place Nrf2 and p62 as the key components of the mesenchymal subtype network, with implications to tumorigenesis and treatment resistance. Thus, Nrf2 activation could be used as a surrogate prognostic marker in mesenchymal subtype GBMs. Furthermore, strategies aiming at either inhibiting Nrf2 or exploiting Nrf2 hyperactivity for targeted gene therapy may provide novel treatment options for this subset of GBM.	[Polonen, Petri; Pasonen-Seppanen, Sanna; Tavi, Pasi; Heinaniemi, Merja] Univ Eastern Finland, Sch Med, Inst Biomed, POB 1627, FIN-70211 Kuopio, Finland; [Deen, Ashik Jawahar; Leinonen, Hanna M.; Jyrkkanen, Henna-Kaisa; Kuosmanen, Suvi; Mononen, Mimmi; Tuomainen, Tomi; Levonen, Anna-Liisa] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, POB 1627, FIN-70211 Kuopio, Finland; [Jain, Ashish; Johansen, Terje] Univ Tromso, Inst Med Biol, N-9037 Tromso, Norway; [Jain, Ashish] Oslo Univ Hosp, Inst Canc Res, Dept Mol Cell Biol, N-0379 Oslo, Norway; [Jain, Ashish] Univ Oslo, Fac Med, Ctr Canc Biomed, POB 1627, N-0379 Oslo, Norway; [Hartikainen, Jaana M.; Mannermaa, Arto] Univ Eastern Finland, Inst Clin Med, POB 1627, FIN-70211 Kuopio, Finland; [Nykter, Matti] Univ Tampere, Fac Med & Life Sci, POB 100, FIN-33014 Tampere, Finland; [Nykter, Matti] Univ Tampere, BioMediTech Inst, POB 100, FIN-33014 Tampere, Finland	University of Eastern Finland; University of Eastern Finland; UiT The Arctic University of Tromso; University of Oslo; University of Oslo; University of Eastern Finland; Tampere University; Tampere University	Levonen, AL (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Biotechnol & Mol Med, POB 1627, FIN-70211 Kuopio, Finland.	anna-liisa.levonen@uef.fi	Jain, Ashish/H-7356-2017; Johansen, Terje/N-2971-2015; Heinaniemi, Merja/AAS-4530-2020; Hartikainen, Jaana M/E-6256-2015; Linna-Kuosmanen, Suvi/P-4574-2018	Jain, Ashish/0000-0001-6549-2788; Johansen, Terje/0000-0003-1451-9578; Heinaniemi, Merja/0000-0001-6190-3439; Hartikainen, Jaana M/0000-0001-8267-1905; Levonen, Anna-Liisa/0000-0002-6575-2137; Nykter, Matti/0000-0001-6956-2843; Tuomainen, Tomi/0000-0002-2387-6369; Linna-Kuosmanen, Suvi/0000-0002-3278-2727	Finnish Cancer Organizations; Jane and Aatos Erkko Foundation; Sigrid Juselius Foundation; Academy of Finland; Finnish Cultural Foundation; Cancer Society of Finland; North-Savo Regional Cancer Society; Fund of Matti and Vappu Maukonen	Finnish Cancer Organizations; Jane and Aatos Erkko Foundation; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Academy of Finland(Academy of Finland); Finnish Cultural Foundation(Finnish Cultural FoundationFinnish IT center for science); Cancer Society of Finland; North-Savo Regional Cancer Society; Fund of Matti and Vappu Maukonen	This study was supported by the Finnish Cancer Organizations, The Jane and Aatos Erkko Foundation, Sigrid Juselius Foundation, Academy of Finland, Finnish Cultural Foundation, Cancer Society of Finland, North-Savo Regional Cancer Society and Fund of Matti and Vappu Maukonen. Mrs. Arja Korhonen is thanked for her technical assistance. We thank SIBLabs for performing TEM and Dr. Eeva-Liisa Eskelinen, University of Helsinki, for helping with the analysis of TEM pictures.	Agnihotri S, 2016, NEURO-ONCOLOGY, V18, P160, DOI 10.1093/neuonc/nov125; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bouvy-Liivrand M, 2017, NUCLEIC ACIDS RES, V45, P9837, DOI 10.1093/nar/gkx680; Bowman RL, 2017, NEURO-ONCOLOGY, V19, P139, DOI 10.1093/neuonc/now247; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chang JT, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-443; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111; Goldstein LD, 2016, CELL REP, V16, P2605, DOI 10.1016/j.celrep.2016.08.010; Hanzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7; Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Ichimura Y, 2013, MOL CELL, V51, P618, DOI 10.1016/j.molcel.2013.08.003; Inami Y, 2011, J CELL BIOL, V193, P275, DOI 10.1083/jcb.201102031; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jin LT, 2015, CANCER CELL, V27, P257, DOI 10.1016/j.ccell.2014.12.006; Johansen T, 2011, AUTOPHAGY, V7, P279, DOI 10.4161/auto.7.3.14487; Johnson DR, 2012, J NEURO-ONCOL, V107, P359, DOI 10.1007/s11060-011-0749-4; Jyrkkanen HK, 2011, BIOCHEM J, V440, P167, DOI 10.1042/BJ20110526; Kanamori M, 2014, NEURO-ONCOLOGY, V1, P1; Kansanen E, 2012, FREE RADICAL BIO MED, V52, P973, DOI 10.1016/j.freeradbiomed.2011.11.038; Kansanen E, 2011, J BIOL CHEM, V286, P14019, DOI 10.1074/jbc.M110.190710; Kansanen E, 2009, J BIOL CHEM, V284, P33233, DOI 10.1074/jbc.M109.064873; Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Koponen JK, 2007, MOL THER, V15, P2172, DOI 10.1038/sj.mt.6300302; Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10; Leinonen HM, 2014, ADV CANCER RES, V122, P281, DOI 10.1016/B978-0-12-420117-0.00008-6; Leinonen HM, 2012, CANCER RES, V72, P6227, DOI 10.1158/0008-5472.CAN-12-1166; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37; Mitsuishi Y, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00200; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319; Ooi A, 2013, CANCER RES, V73, P2044, DOI 10.1158/0008-5472.CAN-12-3227; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Pajares M, 2016, AUTOPHAGY, V12, P1902, DOI 10.1080/15548627.2016.1208889; Rinaldi M, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17060984; Rokavec M, 2017, SCI REP, V7, P1; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shibata T, 2010, CANCER RES, V70, P9095, DOI 10.1158/0008-5472.CAN-10-0384; Singer E, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.566; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Xie Y, 2015, EBIOMEDICINE, V2, P1351, DOI 10.1016/j.ebiom.2015.08.026; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yoo NJ, 2012, HISTOPATHOLOGY, V60, P943, DOI 10.1111/j.1365-2559.2012.04178.x	53	34	35	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2019	38	50					7473	7490		10.1038/s41388-019-0956-6	http://dx.doi.org/10.1038/s41388-019-0956-6			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JV7GY	31444413	Green Accepted			2022-12-17	WOS:000502530500003
J	Liu, YY; Li, XY; Zhang, YP; Wang, HX; Rong, XM; Peng, JL; He, L; Peng, Y				Liu, Yunyun; Li, Xiaoyu; Zhang, Yuanpei; Wang, Hongxuan; Rong, Xiongming; Peng, Jialing; He, Lei; Peng, Ying			An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme	ONCOGENE			English	Article							CANCER STEM-CELLS; MACROPHAGE POLARIZATION; TGF-BETA; GROWTH; REGULATORS; PREDICTS; AGGRESSIVENESS; PROLIFERATION; INFILTRATION; SUPPRESSES	MicroRNAs (miRNAs) have been shown to be involved in the progression and tumor microenvironment of glioblastoma multiforme (GBM). Our previous research has indicated that miR-340-5p has an antitumor effect in vitro. However, the role of miR-340-5p in GBM has not been fully elucidated. Here, we show that downregulation of miR-340-5p in GBM is correlated with tumor size, recurrence, and poor survival. Moreover, we found that miR-340-5p levels are correlated with the density of tumor-associated macrophages (TAMs) and M2-polarized TAMs in GBM. Biofunctional investigations revealed that downregulation of miR-340-5p promoted TAM recruitment and M2-TAMs polarization in vitro and in vivo. In addition, we found that upregulation of miR-340-5p inhibited tumor growth and was associated with good prognosis in vivo. Through gene expression profiles and bioinformatics analysis, we showed that miR-340-5p directly targets POSTN, which recruited TAMs through integrin alpha v beta 3. Downregulation of miR-340-5p in GBM did not induce the differentiation of TAMs into polarized M2 cells but was able to promote the M2 polarization of TAMs through directly targeting LTBP-1. Furthermore, we found that M2-TAMs promoted tumorigenesis and were associated with a poor prognosis in vivo. In an in vitro study, we demonstrated that M2-TAMs inhibited miR-340-5p expression in GBM cells by upregulation of TGF beta-1, which increased HMGA-2 expression in GBM. A ChIP assay confirmed that HMGA-2 transcriptionally suppressed miR-340-5p expression. Patients with low-miR-340-5p expression, high CD163, high POSTN, high LIBP1 levels, and high HMGA-2 had a poor prognosis with shorter overall survival, confirming data from the TCGA database. These findings suggest that an miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of GBM and may represent a prognostic biomarker and therapeutic strategy for GBM.	[Liu, Yunyun; Li, Xiaoyu; Zhang, Yuanpei; Wang, Hongxuan; Rong, Xiongming; Peng, Jialing; He, Lei; Peng, Ying] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China; [Liu, Yunyun; Li, Xiaoyu; Zhang, Yuanpei; Wang, Hongxuan; Rong, Xiongming; Peng, Jialing; He, Lei; Peng, Ying] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Peng, Y (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Neurol, Guangzhou 510120, Guangdong, Peoples R China.; Peng, Y (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Guangdong, Peoples R China.	docpengy123@163.com			National Natural Science Foundation of China [81572481, 81502167, 81502552]; key point program of Science & Technique plan for production, study, and research of Guangzhou city [201508020058]; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University [KLB09001]; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology [[2013]163]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); key point program of Science & Technique plan for production, study, and research of Guangzhou city; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology	We thank and acknowledge the patients for tumor tissue donation. We also thank SWQ and BH for their scientific support in some experiments. This work was supported by the National Natural Science Foundation of China (No. 81572481 to YP, 81502167 to XMR and 81502552 to LH), the key point program of Science & Technique plan for production, study, and research of Guangzhou city (201508020058). Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes, Sun Yat-sen University and Grant [2013]163 from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology.	Baer C, 2016, NAT CELL BIOL, V18, P790, DOI 10.1038/ncb3371; Chen DG, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03225-9; Chen H, 2017, ONCOGENE, V36, P4415, DOI 10.1038/onc.2017.73; Chen XW, 2017, ONCOGENE, V36, P5045, DOI 10.1038/onc.2017.118; Chi JQ, 2015, VIROLOGY, V476, P72, DOI 10.1016/j.virol.2014.11.027; Chiou GY, 2013, MOL CELL, V52, P693, DOI 10.1016/j.molcel.2013.11.009; Cui TT, 2019, ONCOGENE, V38, P2923, DOI 10.1038/s41388-018-0601-9; Da FA, 2013, CLIN DEV IMMUNOL, V2013; Fabbri M, 2012, P NATL ACAD SCI USA, V109, pE2110, DOI 10.1073/pnas.1209414109; Fernandez S, 2015, ONCOGENE, V34, P3240, DOI 10.1038/onc.2014.267; Fiore D, 2016, ONCOTARGET, V7, P19531, DOI 10.18632/oncotarget.6968; Forstreuter F, 2002, J NEUROIMMUNOL, V132, P93, DOI 10.1016/S0165-5728(02)00315-6; Gargiulo G, 2013, CANCER CELL, V23, P660, DOI 10.1016/j.ccr.2013.03.030; Garris C, 2013, NAT MED, V19, P1207, DOI 10.1038/nm.3355; Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396; Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Held-Feindt J, 2010, EXP CELL RES, V316, P1553, DOI 10.1016/j.yexcr.2010.02.018; Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216; Huang DQ, 2015, ONCOTARGET, V6, P9257, DOI 10.18632/oncotarget.3288; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Komohara Y, 2008, J PATHOL, V216, P15, DOI 10.1002/path.2370; Lathia JD, 2011, CELL STEM CELL, V8, P482, DOI 10.1016/j.stem.2011.04.013; Lee J, 2015, NEURO-ONCOLOGY, V17, P685, DOI 10.1093/neuonc/nou302; Li H, 2006, CELL RES, V16, P169, DOI 10.1038/sj.cr.7310023; Liu B, 2014, HUM PATHOL, V45, P1752, DOI 10.1016/j.humpath.2014.02.028; Luo H, 2015, BRAIN, V138, P3654, DOI 10.1093/brain/awv287; Mellman I, 2011, NATURE, V480, P480, DOI 10.1038/nature10673; Mikheev AM, 2015, NEURO-ONCOLOGY, V17, P372, DOI 10.1093/neuonc/nou161; Ngambenjawong C, 2017, ADV DRUG DELIVER REV, V114, P206, DOI 10.1016/j.addr.2017.04.010; Okada M, 2009, INT J ONCOL, V34, P1621, DOI 10.3892/ijo_00000292; Platten M, 2003, ANN NEUROL, V54, P388, DOI 10.1002/ana.10679; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Qian Y, 2017, ACS NANO, V11, P9536, DOI 10.1021/acsnano.7b05465; Rape A, 2014, ADV DRUG DELIVER REV, V79-80, P172, DOI 10.1016/j.addr.2014.08.012; Rong XM, 2016, ONCOTARGET, V7, P83976, DOI 10.18632/oncotarget.6930; Roth P, 2013, BRAIN, V136, P564, DOI 10.1093/brain/aws351; Saha D, 2017, CANCER CELL, V32, P253, DOI 10.1016/j.ccell.2017.07.006; Schwarm FP, 2016, INT J ONCOL, V48, P1485, DOI 10.3892/ijo.2016.3397; Shi Y, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15080; Simon T, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0878-x; Squadrito ML, 2013, TRENDS IMMUNOL, V34, P350, DOI 10.1016/j.it.2013.02.003; Thuault S, 2006, J CELL BIOL, V174, P175, DOI 10.1083/jcb.200512110; Wang SC, 2012, LAB INVEST, V92, P151, DOI 10.1038/labinvest.2011.128; Wu A, 2010, NEURO-ONCOLOGY, V12, P1113, DOI 10.1093/neuonc/noq082; Wu ZS, 2011, CANCER-AM CANCER SOC, V117, P2842, DOI 10.1002/cncr.25860; Xiong QS, 2017, CELL BIOSCI, V7, DOI 10.1186/s13578-017-0144-8; Yamashita D, 2015, CANCER RES, V75, P1123, DOI 10.1158/0008-5472.CAN-14-0938; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145; Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090; Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613	53	34	34	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2019	38	49					7399	7415		10.1038/s41388-019-0952-x	http://dx.doi.org/10.1038/s41388-019-0952-x			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JT4BN	31427735				2022-12-17	WOS:000500936600003
J	Yang, CX; Cao, ML; Liu, YW; He, YQ; Du, Y; Zhang, GL; Gao, F				Yang, Cuixia; Cao, Manlin; Liu, Yiwen; He, Yiqing; Du, Yan; Zhang, Guoliang; Gao, Feng			Inducible formation of leader cells driven by CD44 switching gives rise to collective invasion and metastases in luminal breast carcinomas	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; CANCER STEM-CELLS; DYNAMIC EQUILIBRIUM; TUMOR-CELLS; MIGRATION; HETEROGENEITY; DISSEMINATION; PLASTICITY; IDENTIFICATION; CONTRIBUTES	Collective invasion into adjacent tissue is a hallmark of luminal breast cancer, and similar to 20% of these cases eventually undergo metastasis. How less aggressive luminal-like breast cancer transitions to invasive cancer remains unclear. Our study revealed that CD44(hi) cancer cells are the leading subpopulation in collectively invading luminal cancer cells and efficiently promote the collective invasion of CD44(lo)/follower cells. The CD44(hi)/leader subpopulation showed a specific gene signature of various hybrid epithelial/mesenchymal genes and key functional coregulators of collective invasion, which was distinct from that of CD44(lo)/follower cells. However, the CD44(hi)/leader cells, which showed a partial epithelial-mesenchymal transition (EMT) phenotype, readily switched to the CD44(lo) phenotype along with collective migration and vice versa; this phenomenon was spontaneous and sensitive to the tumor microenvironment. The CD44(lo)-to-CD44(hi) conversion was accompanied by a shift in CD44s to CD44v but not a conversion of non-cancer stem cells to cancer stem cells (CSCs). Therefore, the CD44(hi) leader cells, as currently identified, are not a stable subpopulation in breast tumors. This plasticity and ability to generate CD44(hi) carcinoma cells with enhanced migratory and invasive behavior might be responsible for the transition from in situ to invasive behavior of luminal-type breast cancer.	[Yang, Cuixia; Liu, Yiwen; He, Yiqing; Du, Yan; Zhang, Guoliang; Gao, Feng] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Mol Biol Lab, Shanghai, Peoples R China; [Yang, Cuixia; Gao, Feng] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Clin Lab, Shanghai, Peoples R China; [Cao, Manlin] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Rehabil Med, Shanghai 200233, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Gao, F (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Mol Biol Lab, Shanghai, Peoples R China.; Gao, F (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Clin Lab, Shanghai, Peoples R China.	gao3507@126.com	liu, yi/GXE-9662-2022		National Natural Science Foundation of China [81672843, 81572821, 81502490, 81502491, 81402419, 81702852, 81872357]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support [20171924]; Shanghai Training and Support Program for Medical Technologist; Natural Science Foundation of Shanghai Municipality [14YF1412200]; Shanghai Shen-Kang Hospital Development Center [SHDC22014004]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support; Shanghai Training and Support Program for Medical Technologist; Natural Science Foundation of Shanghai Municipality(Natural Science Foundation of Shanghai); Shanghai Shen-Kang Hospital Development Center	This work was supported by the National Natural Science Foundation of China (81672843, 81572821, 81502490, 81502491, 81402419, 81702852, 81872357), the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant Support (20171924), the Shanghai Training and Support Program for Medical Technologist (2017), the Natural Science Foundation of Shanghai Municipality (14YF1412200), and the Shanghai Shen-Kang Hospital Development Center (SHDC22014004).	Aceto N, 2014, CELL, V158, P1110, DOI 10.1016/j.cell.2014.07.013; Ahmed M, 2016, CANCER CELL, V30, P432, DOI 10.1016/j.ccell.2016.08.002; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923; Banky B, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-83; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005; Chapnick DA, 2014, MOL BIOL CELL, V25, P1586, DOI 10.1091/mbc.E14-01-0697; Cheung KJ, 2016, P NATL ACAD SCI USA, V113, pE854, DOI 10.1073/pnas.1508541113; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chiasson-MacKenzie C, 2015, J CELL BIOL, V211, P391, DOI 10.1083/jcb.201503081; Corsa CAS, 2016, CELL REP, V15, P2510, DOI 10.1016/j.celrep.2016.05.033; Dang TT, 2011, CANCER RES, V71, P6857, DOI 10.1158/0008-5472.CAN-11-1818; Das T, 2015, NAT CELL BIOL, V17, P276, DOI 10.1038/ncb3115; Donatello S, 2012, AM J PATHOL, V181, P2172, DOI 10.1016/j.ajpath.2012.08.025; Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fortier AM, 2013, J BIOL CHEM, V288, P11555, DOI 10.1074/jbc.M112.428920; Freeman SA, 2018, CELL, V172, P305, DOI 10.1016/j.cell.2017.12.023; Friedl P, 2012, NAT CELL BIOL, V14, P777, DOI 10.1038/ncb2548; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Guo W, 2014, ONCOGENE, V33, P537, DOI 10.1038/onc.2013.260; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ito T, 2015, CLIN BREAST CANCER, V15, pE93, DOI 10.1016/j.clbc.2014.11.002; Kennecke H, 2010, J CLIN ONCOL, V28, P3271, DOI 10.1200/JCO.2009.25.9820; Nguyen-Ngoc KV, 2012, P NATL ACAD SCI USA, V109, pE2595, DOI 10.1073/pnas.1212834109; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Liu LY, 2013, P NATL ACAD SCI USA, V110, P1686, DOI 10.1073/pnas.1221147110; Matak A, 2018, HEPATOLOGY, V68, P933, DOI 10.1002/hep.29679; McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001; Morath I, 2018, ONCOGENE, V37, P1472, DOI 10.1038/s41388-017-0030-1; Park SY, 2010, J CLIN INVEST, V120, P636, DOI 10.1172/JCI40724; Pinto Mauricio P, 2011, Front Endocrinol (Lausanne), V2, P15, DOI 10.3389/fendo.2011.00015; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Preca BT, 2015, INT J CANCER, V137, P2566, DOI 10.1002/ijc.29642; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Reffay M, 2014, NAT CELL BIOL, V16, P217, DOI 10.1038/ncb2917; Ribeiro AS, 2015, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00371; Roswall P, 2018, NAT MED, V24, P463, DOI 10.1038/nm.4494; Shamir ER, 2014, J CELL BIOL, V204, P839, DOI 10.1083/jcb.201306088; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yang CX, 2015, ONCOTARGET, V6, P15283, DOI 10.18632/oncotarget.3681; Yang CX, 2012, J BIOL CHEM, V287, P43094, DOI 10.1074/jbc.M112.349209; Yang G, 2012, BRIT J CANCER, V106, P1512, DOI 10.1038/bjc.2012.126; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Zajac O, 2018, NAT CELL BIOL, V20, P296, DOI 10.1038/s41556-017-0027-6; Zhang GL, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1172154; Zhao S, 2016, CLIN CANCER RES, V22, P5592, DOI 10.1158/1078-0432.CCR-15-3115; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	62	34	34	2	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2019	38	46					7113	7132		10.1038/s41388-019-0899-y	http://dx.doi.org/10.1038/s41388-019-0899-y			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JN5HX	31417182				2022-12-17	WOS:000496930500001
J	Peng, WX; He, RZ; Zhang, ZQ; Yang, L; Mo, YY				Peng, Wan-Xin; He, Rong-Zhang; Zhang, Ziqiang; Yang, Liu; Mo, Yin-Yuan			LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription	ONCOGENE			English	Article							LONG NONCODING RNA; C-MYC; INSIGHTS; GENE; ACTIVATION; EXPRESSION; GENOMICS; PROTEIN; ROLES; CELLS	Although multiple factors are known to contribute to pancreatic ductal adenocarcinoma (PDAC) progression, the role of long non-coding RNAs (lncRNAs) in PDAC remains largely unknown. In this study, we present data that long intergenic noncoding RNA 346 (LINC00346) functions as a promoting factor for PDAC development. We first show that LINC00346 is highly expressed in pancreatic tumor specimens as compared to normal pancreatic tissue based on interrogation of The Cancer Genome Atlas (TCGA) pancreatic adenocarcinoma dataset. Of significance, this upregulation of LINC00346 is associated with overall survival (OS) and disease-free survival (DFS), respectively. We further show that knockout (KO) of LINC00346 impairs pancreatic cancer cell proliferation, tumorigenesis, migration, and invasion ability. Importantly, these phenotypes can be restored by LINC00346 re-expression in KO cells (i.e., rescue experiment). RNA precipitation assays combined with mass spectrometry analysis indicate that LINC00346 interacts with CCCTC-binding factor (CTCF), a known transcriptional repressor of c-Myc. This interaction between LINC00346 and CTCF prevents the binding of CTCF to c-Myc promoter, relieving the CTCF-mediated repression of c-Myc. Thus, LINC00346 functions as a positive transcriptional regulator of c-Myc. Together, these results suggest that LINC00346 contributes to PDAC pathogenesis by activating c-Myc, and as such, LINC00346 may serve as a potential biomarker and therapeutic target for PDAC.	[Peng, Wan-Xin; Yang, Liu] Hangzhou Med Coll, Peoples Hosp, Key Lab Tumor Mol Diag & Individualized Med Zheji, Zhejiang Prov Peoples Hosp, Hangzhou 310014, Zhejiang, Peoples R China; [Peng, Wan-Xin; He, Rong-Zhang; Mo, Yin-Yuan] Univ Mississippi, Med Ctr, Canc Inst, Jackson, MS 39216 USA; [He, Rong-Zhang] First Peoples Hosp Chenzhou, Translat Med Inst, Natl & Local Joint Engn Lab High Through Mol Diag, Chenzhou 423000, Hunan, Peoples R China; [Zhang, Ziqiang] Tongji Univ, Tongji Hosp, Dept Pulm Med, Shanghai 200065, Peoples R China; [Mo, Yin-Yuan] Univ Mississippi, Med Ctr, Dept Pharmacol Toxicol, Jackson, MS 39216 USA	Hangzhou Medical College; Zhejiang Provincial People's Hospital; University of Mississippi; University of Mississippi Medical Center; Tongji University; University of Mississippi; University of Mississippi Medical Center	Yang, L (corresponding author), Hangzhou Med Coll, Peoples Hosp, Key Lab Tumor Mol Diag & Individualized Med Zheji, Zhejiang Prov Peoples Hosp, Hangzhou 310014, Zhejiang, Peoples R China.; Mo, YY (corresponding author), Univ Mississippi, Med Ctr, Canc Inst, Jackson, MS 39216 USA.; Mo, YY (corresponding author), Univ Mississippi, Med Ctr, Dept Pharmacol Toxicol, Jackson, MS 39216 USA.	yangliuqq2003@163.com; ymo@umc.edu	彭, 琬昕/HDN-9075-2022; Peng, Wan-Xin/AAU-1368-2020	彭, 琬昕/0000-0002-2551-8899; 	National Natural Science Foundation of China [81772575]; key project of Health Bureau of Zhejiang Province [2018274734]; NIH [R01 CA154989]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); key project of Health Bureau of Zhejiang Province; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This research was supported by grants from National Natural Science Foundation of China, No. 81772575 (LY) and the key project of Health Bureau of Zhejiang Province, No. 2018274734 (LY), and NIH grant R01 CA154989 (YM).	Birney E, 2007, NATURE, V447, P799, DOI 10.1038/nature05874; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Conacci-Sorrell Maralice, 2014, Cold Spring Harb Perspect Med, V4, pa014357, DOI 10.1101/cshperspect.a014357; Dang CV, 2015, CANCER CELL, V27, P160, DOI 10.1016/j.ccell.2015.01.004; Dunn KL, 2003, BIOCHEM CELL BIOL, V81, P161, DOI 10.1139/o03-052; Fatica A, 2014, NAT REV GENET, V15, P7, DOI 10.1038/nrg3606; Filippova GN, 1996, MOL CELL BIOL, V16, P2802; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975; Gupta SC, 2014, ONCOTARGET, V5, P12070, DOI 10.18632/oncotarget.2514; Guttman M, 2011, NATURE, V477, P295, DOI 10.1038/nature10398; Herold M, 2012, DEVELOPMENT, V139, P1045, DOI 10.1242/dev.065268; Hessmann E, 2016, ONCOGENE, V35, P1609, DOI 10.1038/onc.2015.216; Hu WQ, 2012, EMBO REP, V13, P971, DOI 10.1038/embor.2012.145; Huang JG, 2016, NUCLEIC ACIDS RES, V44, P3059, DOI 10.1093/nar/gkv1353; Hung CL, 2014, P NATL ACAD SCI USA, V111, P18697, DOI 10.1073/pnas.1415669112; Hung T, 2011, NAT GENET, V43, P621, DOI 10.1038/ng.848; Iaccarino I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071497; Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106; Khan MA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040779; Kim J, 2018, NAT GENET, V50, P1705, DOI 10.1038/s41588-018-0252-3; KLENOVA EM, 1993, MOL CELL BIOL, V13, P7612, DOI 10.1128/MCB.13.12.7612; Kung JTY, 2013, GENETICS, V193, P651, DOI 10.1534/genetics.112.146704; Li M, 2015, NAT STRUCT MOL BIOL, V22, P2, DOI 10.1038/nsmb.2946; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; LOBANENKOV VV, 1990, ONCOGENE, V5, P1743; Lu YQ, 2018, CANCER RES, V78, P64, DOI 10.1158/0008-5472.CAN-17-0815; Maldotti M, 2016, BBA-GENE REGUL MECH, V1859, P1322, DOI 10.1016/j.bbagrm.2016.06.010; McMahon SB, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014407; Mercer TR, 2009, NAT REV GENET, V10, P155, DOI 10.1038/nrg2521; Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184; Peng WX, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0727-3; Sachdeva M, 2011, ONCOGENE, V30, P822, DOI 10.1038/onc.2010.463; Schmitt AM, 2016, NAT GENET, V48, P1370, DOI 10.1038/ng.3673; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; Singh R, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.168; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002; Ulitsky I, 2013, CELL, V154, P26, DOI 10.1016/j.cell.2013.06.020; Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018; Wu FT, 2007, MOL CANCER THER, V6, P1823, DOI 10.1158/1535-7163.MCT-06-0771; Xiang JF, 2014, CELL RES, V24, P513, DOI 10.1038/cr.2014.35; Xiao ZD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00902-z; Zetsche B, 2015, CELL, V163, P759, DOI 10.1016/j.cell.2015.09.038; Zhang PF, 2016, EMBO REP, V17, P1204, DOI 10.15252/embr.201642067	48	34	35	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2019	38	41					6770	6780		10.1038/s41388-019-0918-z	http://dx.doi.org/10.1038/s41388-019-0918-z			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC8UZ	31391552				2022-12-17	WOS:000489552900005
J	Chu, Y; Elrod, N; Wang, CJ; Li, L; Chen, T; Routh, A; Xia, Z; Li, W; Wagner, EJ; Ji, P				Chu, Yuan; Elrod, Nathan; Wang, Chaojie; Li, Lei; Chen, Tao; Routh, Andrew; Xia, Zheng; Li, Wei; Wagner, Eric J.; Ji, Ping			Nudt21 regulates the alternative polyadenylation of Pak1 and is predictive in the prognosis of glioblastoma patients	ONCOGENE			English	Article							CLEAVAGE FACTOR IM; BREAST-CANCER; UNTRANSLATED REGIONS; RNA; CELLS; EXPRESSION; GROWTH; ASSOCIATION; RESISTANCE; MELANOMA	Alternative polyadenylation (APA) has emerged as a prevalent feature associated with cancer development and progression. The advantage of APA to tumor progression is to induce oncogenes through 3'-UTR shortening, and to inactivate tumor suppressor genes via the re-routing of microRNA competition. We previously identified the Mammalian Cleavage Factor I-25 (CFIm25) (encoded by Nudt21 gene) as a master APA regulator whose expression levels directly impact the tumorigenicity of glioblastoma (GBM) in vitro and in vivo. Despite its importance, the role of Nudt21 in GBM development is not known and the genes subject to Nudt21 APA regulation that contribute to GBM progression have not been identified. Here, we find that Nudt21 is reduced in low grade glioma (LGG) and all four subtypes of high grade glioma (GBM). Reduced expression of Nudt21 associates with worse survival in TCGA LGG cohorts and two TCGA GBM cohorts. Moreover, although CFIm25 was initially identified as biochemically associated with both CFIm59 and CFIm68, we observed three CFIm distinct subcomplexes exist and CFIm59 protein level is dependent on Nudt21 expression in GBM cells, but CFIm68 is not, and that only CFIm59 predicts prognosis of GBM patients similar to Nudt21. Through the use of Poly(A)-Click-Seq to characterize APA, we define the mRNAs subject to 3'-UTR shortening upon Nudt21 depletion in GBM cells and observed enrichment in genes important in the Ras signaling pathway, including Pak1. Remarkably, we find that Pak1 expression is regulated by Nudt21 through its 3'-UTR APA, and the combination of Pak1 and Nudt21 expression generates an even stronger prognostic indicator of GBM survival versus either value used alone. Collectively, our data uncover Nudt21 and its downstream target Pak1 as a potential "combination biomarker" for predicting prognosis of GBM patients.	[Chu, Yuan; Elrod, Nathan; Routh, Andrew; Wagner, Eric J.; Ji, Ping] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Chu, Yuan; Chen, Tao] Fudan Univ, Zhongshan Hosp, Endoscopy Ctr, Shanghai, Peoples R China; [Chu, Yuan; Chen, Tao] Fudan Univ, Endoscopy Res Inst, Shanghai, Peoples R China; [Wang, Chaojie; Xia, Zheng] OHSU, Dept Mol Microbiol & Immunol, Computat Biol Program, Portland, OR 97273 USA; [Li, Lei; Li, Wei] Baylor Coll Med, Daniel Duncan Canc Ctr, Houston, TX 77030 USA; [Routh, Andrew; Wagner, Eric J.] Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; Fudan University; Fudan University; Oregon Health & Science University; Baylor College of Medicine; University of Texas System; University of Texas Medical Branch Galveston	Wagner, EJ; Ji, P (corresponding author), Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA.; Wagner, EJ (corresponding author), Univ Texas Med Branch, Sealy Ctr Struct Biol & Mol Biophys, Galveston, TX 77555 USA.	ejwagner@utmb.edu; piji@utmb.edu	Elrod, Nathan/N-5956-2016; Routh, Andrew/J-7486-2019; Elrod, Nathan/Q-5610-2019; Wang, Chaojie/AAX-3167-2021; Xia, Zheng/AAC-5360-2022; Li, Lei/S-9028-2016	Elrod, Nathan/0000-0003-1310-6026; Routh, Andrew/0000-0002-2874-5990; Wang, Chaojie/0000-0002-5865-1397; Xia, Zheng/0000-0003-3364-8324; Li, Lei/0000-0003-3924-2544; Ji, Ping/0000-0001-7103-1507	US National Institutes of Health (NIH) [R01CA193466-01]; Cancer Prevention Research Institute of Texas grant [CPRIT RP140800]; NIH [R03 CA223893-01]; NATIONAL CANCER INSTITUTE [R01CA193466, R03CA223893, P30CA016672] Funding Source: NIH RePORTER	US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the US National Institutes of Health (NIH) grants R01CA193466-01 to W.L. and E.J.W., the Cancer Prevention Research Institute of Texas grant CPRIT RP140800 to E.J.W., and NIH R03 CA223893-01 to P.J.	Akman BH, 2012, NUCLEIC ACIDS RES, V40, P10679, DOI 10.1093/nar/gks855; Aoki H, 2007, CLIN CANCER RES, V13, P6603, DOI 10.1158/1078-0432.CCR-07-0145; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brown KM, 2003, MOL CELL, V12, P1467, DOI 10.1016/S1097-2765(03)00453-2; Brumbaugh J, 2018, CELL, V172, P629, DOI 10.1016/j.cell.2017.12.035; Brumbaugh J, 2018, CELL, V172, P106, DOI 10.1016/j.cell.2017.11.023; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cornett AL, 2014, METHODS MOL BIOL, V1125, P157, DOI 10.1007/978-1-62703-971-0_14; Creemers EE, 2016, CIRC RES, V118, P433, DOI 10.1161/CIRCRESAHA.115.307082; Denysenko T, 2010, CELL BIOCHEM FUNCT, V28, P343, DOI 10.1002/cbf.1666; Diederichs S, 2016, EMBO MOL MED, V8, P442, DOI 10.15252/emmm.201506055; Edlinger L, 2017, BRIT J HAEMATOL, V179, P229, DOI 10.1111/bjh.14833; Elkon R, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-7-r59; Fu YG, 2011, GENOME RES, V21, P741, DOI 10.1101/gr.115295.110; Giubellino A, 2008, EXPERT OPIN THER TAR, V12, P1021, DOI [10.1517/14728222.12.8.1021, 10.1517/14728222.12.8.1021 ]; Gruber AR, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6465; Gruber AR, 2012, RNA BIOL, V9, P1405, DOI 10.4161/rna.22570; Han T, 2014, CELL RES, V24, P1023, DOI 10.1038/cr.2014.88; Hardy JG, 2016, BIOCHEM SOC T, V44, P1051, DOI 10.1042/BST20160078; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; JASONNI VM, 1995, ANTICANCER RES, V15, P1327; Ji Z, 2009, P NATL ACAD SCI USA, V106, P7028, DOI 10.1073/pnas.0900028106; Johnson DB, 2014, CLIN CANCER RES, V20, P4186, DOI 10.1158/1078-0432.CCR-13-3270; Kang TW, 2014, SCI REP-UK, V4, DOI 10.1038/srep05546; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Kim S, 2010, GENES CELLS, V15, P1003, DOI 10.1111/j.1365-2443.2010.01436.x; Kumar R, 2006, NAT REV CANCER, V6, P459, DOI 10.1038/nrc1892; Larson KC, 2010, INFLAMM RES, V59, P15, DOI 10.1007/s00011-009-0062-2; Li TF, 2015, ONCOL REP, V34, P2357, DOI 10.3892/or.2015.4226; Masamha CP, 2018, CARCINOGENESIS, V39, P2, DOI 10.1093/carcin/bgx096; Masamha CP, 2016, RNA, V22, P830, DOI 10.1261/rna.055939.116; Masamha CP, 2014, NATURE, V510, P412, DOI 10.1038/nature13261; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Muller S, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau076; Nagarajan P, 2010, J CELL SCI, V123, P3566, DOI 10.1242/jcs.062240; Ozsolak F, 2010, CELL, V143, P1018, DOI 10.1016/j.cell.2010.11.020; Park HJ, 2018, NAT GENET, V50, P783, DOI 10.1038/s41588-018-0118-8; Peng H, 2016, SCI REP-UK, V6, DOI 10.1038/srep22000; Riemann K, 2009, ANTICANCER RES, V29, P1271; Routh A, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx286; Routh A, 2015, J MOL BIOL, V427, P2610, DOI 10.1016/j.jmb.2015.06.011; Ruegsegger U, 1996, J BIOL CHEM, V271, P6107; Shao JF, 2013, OMICS, V17, P136, DOI 10.1089/omi.2012.0098; Singh P, 2009, CANCER RES, V69, P9422, DOI 10.1158/0008-5472.CAN-09-2236; Sowd GA, 2016, P NATL ACAD SCI USA, V113, pE1054, DOI 10.1073/pnas.1524213113; Sun M, 2017, CANCER LETT, V410, P158, DOI 10.1016/j.canlet.2017.09.026; Tian B, 2005, NUCLEIC ACIDS RES, V33, P201, DOI 10.1093/nar/gki158; Tian B, 2017, NAT REV MOL CELL BIO, V18, P18, DOI 10.1038/nrm.2016.116; Wagner EJ, 2002, MOL CELL, V10, P943, DOI 10.1016/S1097-2765(02)00645-7; Walker-Daniels J, 2003, AM J PATHOL, V162, P1037, DOI 10.1016/S0002-9440(10)63899-0; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Xia Z, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6274; Yajima I, 2014, AM J CANCER RES, V4, P182; Yang Q, 2011, STRUCTURE, V19, P368, DOI 10.1016/j.str.2010.12.021; Yang Q, 2010, P NATL ACAD SCI USA, V107, P10062, DOI 10.1073/pnas.1000848107; Zhu Y, 2018, MOL CELL, V69, P62, DOI 10.1016/j.molcel.2017.11.031; Zimmermannova O, 2017, ONCOGENE, V36, P5985, DOI 10.1038/onc.2017.210	60	34	35	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2019	38	21					4154	4168		10.1038/s41388-019-0714-9	http://dx.doi.org/10.1038/s41388-019-0714-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ3HX	30705404	Green Accepted			2022-12-17	WOS:000468740200013
J	Wang, DW; Xu, QQ; Yuan, Q; Jia, MQ; Niu, HM; Liu, XF; Zhang, JS; Young, CY; Yuan, HQ				Wang, Dawei; Xu, Qingqing; Yuan, Quan; Jia, Mengqi; Niu, Huanmin; Liu, Xiaofei; Zhang, Jinsan; Young, Charles Yf; Yuan, Huiqing			Proteasome inhibition boosts autophagic degradation of ubiquitinated-AGR2 and enhances the antitumor efficiency of bevacizumab	ONCOGENE			English	Article							PRO-METASTATIC PROTEIN; ANTERIOR GRADIENT 2; SELECTIVE AUTOPHAGY; CANCER; AGR2; EXPRESSION; BORTEZOMIB; RECEPTOR; GENES; COMBINATION	Anterior gradient 2 (AGR2), a protein belonging to the protein disulfide isomerase (PDI) family, is overexpressed in multiple cancers and promotes angiogenesis to drive cancer progression. The mechanisms controlling AGR2 abundance in cancer remain largely unknown. Here, we observed that AGR2 expression is significantly suppressed by proteasome inhibitor MG132/bortezomib at mRNA and protein levels in lung cancer cells. MG132-mediated repression of AGR2 transcription was independent of ROS generation and ER stress induction, but partially resulted from the downregulated E2F1. Further investigation revealed that MG132 facilitated polyubiquitinated AGR2 degradation through activation of autophagy, as evidenced by predominant restoration of AGR2 level in cells genetic depletion of Atg5 and Atg7, or by autophagy inhibitors. Activation of autophagy by rapamycin noticeably reduced the AGR2 protein in cells and in the mouse tissue samples administrated with bortezomib. We also provided evidence identifying the K48-linked polyubiquitin chains conjugating onto K89 of AGR2 by an E3 ligase UBR5. In addition, an autophagy receptor NBR1 was demonstrated to be important in polyubiquitinated AGR2 clearance in response to MG132 or bortezomib. Importantly, downregulation of AGR2 by proteasome inhibition significantly enhanced antitumor activity of bevacizumab, highlighting the importance of AGR2 as a predictive marker for selection of subgroup patients in chemotherapy.	[Wang, Dawei; Xu, Qingqing; Yuan, Quan; Jia, Mengqi; Niu, Huanmin; Liu, Xiaofei; Yuan, Huiqing] Shandong Univ, Hosp 2, Inst Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan, Shandong, Peoples R China; [Zhang, Jinsan; Young, Charles Yf] Mayo Clin, Coll Med, Dept Urol, Rochester, MN USA	Shandong University; Mayo Clinic	Yuan, HQ (corresponding author), Shandong Univ, Hosp 2, Inst Med Sci, Key Lab Expt Teratol,Minist Educ, Jinan, Shandong, Peoples R China.	lyuanhq@sdu.edu.cn		Xu, Qingqing/0000-0002-7703-5872	973 Program [2013CB910900]; National Natural Science Foundation of China [81473238, 81872896]; Shandong key innovative research program [2018CXGC1216]	973 Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shandong key innovative research program	We would like to thank Professor Srikumar P. Chellappan for kindly providing the plasmid of E2F1, Professor Xuejun Jiang for the gift of GFP-LC3B construct, and Professor Chengjiang Gao for the gift of HA-K48, HA-63, HA-K48R, and HA-63R plasmids (Department of Immunology, School of Medicine of Shandong University, China). This work was supported by 973 Program (2013CB910900), the National Natural Science Foundation of China (81473238, 81872896), and Shandong key innovative research program (2018CXGC1216).	Bu H, 2013, FEBS J, V280, P1249, DOI 10.1111/febs.12118; Chevet E, 2013, ONCOGENE, V32, P2499, DOI 10.1038/onc.2012.346; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chung Kyukwang, 2012, Osaka City Med J, V58, P13; Dasgupta P, 2011, JNCI-J NATL CANCER I, V103, P317, DOI 10.1093/jnci/djq541; Fritzsche FR, 2007, HISTOL HISTOPATHOL, V22, P703, DOI 10.14670/HH-22.703; Gao ZH, 2010, AUTOPHAGY, V6, P126, DOI 10.4161/auto.6.1.10928; Ge PF, 2009, ACTA PHARMACOL SIN, V30, P1046, DOI 10.1038/aps.2009.71; Grice GL, 2016, CELL MOL LIFE SCI, V73, P3497, DOI 10.1007/s00018-016-2255-5; Guo H, 2017, ONCOGENE, V36, P5098, DOI 10.1038/onc.2017.132; Guo YY, 2017, J NEUROSCI, V37, P5978, DOI 10.1523/JNEUROSCI.3148-16.2017; Hengel SM, 2011, J PROTEOME RES, V10, P4567, DOI 10.1021/pr2004117; Hideshima T, 2005, P NATL ACAD SCI USA, V102, P8567, DOI 10.1073/pnas.0503221102; Higa A, 2011, J BIOL CHEM, V286, P44855, DOI 10.1074/jbc.M111.275529; Hrstka R, 2010, ONCOGENE, V29, P4838, DOI 10.1038/onc.2010.228; Hu ZY, 2012, CARCINOGENESIS, V33, P1178, DOI 10.1093/carcin/bgs141; Ichimura Y, 2008, J BIOL CHEM, V283, P22847, DOI 10.1074/jbc.M802182200; Jia MQ, 2018, BBA-MOL BASIS DIS, V1864, P1622, DOI 10.1016/j.bbadis.2018.01.021; Kawaguchi T, 2011, INT J ONCOL, V38, P643, DOI 10.3892/ijo.2010.882; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Khaminets A, 2016, TRENDS CELL BIOL, V26, P6, DOI 10.1016/j.tcb.2015.08.010; Kraft C, 2010, NAT CELL BIOL, V12, P836, DOI 10.1038/ncb0910-836; Krig SR, 2007, J BIOL CHEM, V282, P9703, DOI 10.1074/jbc.M611752200; Li SR, 2012, DEVELOPMENT, V139, P2500, DOI 10.1242/dev.079699; Lim JH, 2004, BIOCHEM BIOPH RES CO, V318, P868, DOI 10.1016/j.bbrc.2004.04.103; Lin HK, 2002, J BIOL CHEM, V277, P36570, DOI 10.1074/jbc.M204751200; Liu ZZ, 2014, CANCER CELL, V26, P106, DOI 10.1016/j.ccr.2014.05.015; Mancias JD, 2016, J MOL BIOL, V428, P1659, DOI 10.1016/j.jmb.2016.02.027; Nakajima S, 2011, FEBS LETT, V585, P2249, DOI 10.1016/j.febslet.2011.05.047; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Piperdi B, 2012, J THORAC ONCOL, V7, P1032, DOI 10.1097/JTO.0b013e31824de2fa; Pohler E, 2004, MOL CELL PROTEOMICS, V3, P534, DOI 10.1074/mcp.M300089-MCP200; Tang CH, 2014, BBA-GENE REGUL MECH, V1839, P425, DOI 10.1016/j.bbagrm.2014.04.017; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Thompson DA, 1998, BIOCHEM BIOPH RES CO, V251, P111, DOI 10.1006/bbrc.1998.9440; Vanderlaag KE, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2586; Wang XJ, 2013, AUTOPHAGY, V9, P1500, DOI 10.4161/auto.25573; Waters S, 2009, FEBS LETT, V583, P1846, DOI 10.1016/j.febslet.2009.04.049; White D, 2013, CANCER-AM CANCER SOC, V119, P339, DOI 10.1002/cncr.27745; Wu WKK, 2008, BIOCHEM BIOPH RES CO, V374, P258, DOI 10.1016/j.bbrc.2008.07.031; Yu HX, 2012, MOL BIOSYST, V8, P2710, DOI 10.1039/c2mb25160d; Yuan C, 2012, J BIOL CHEM, V287, P17006, DOI 10.1074/jbc.M112.341198; Zhao LL, 2009, CANCER RES, V69, P7696, DOI 10.1158/0008-5472.CAN-08-4901; 2014, J BIOL CHEM, V289, P1389, DOI DOI 10.1074/JBC.M114.555441; 2011, J BIOL CHEM, V286, P1830, DOI DOI 10.1074/JBC.M110.215707; 2011, CANCER RES, V71, P7091, DOI DOI 10.1158/0008-5472.CAN-11-1367	46	34	34	3	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3458	3474		10.1038/s41388-019-0675-z	http://dx.doi.org/10.1038/s41388-019-0675-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30647455	hybrid, Green Published			2022-12-17	WOS:000466610000010
J	Iness, AN; Felthousen, J; Ananthapadmanabhan, V; Sesay, F; Saini, S; Guiley, KZ; Rubin, SM; Dozmorov, M; Litovchick, L				Iness, Audra N.; Felthousen, Jessica; Ananthapadmanabhan, Varsha; Sesay, Fatmata; Saini, Siddharth; Guiley, Keelan Z.; Rubin, Seth M.; Dozmorov, Mikhail; Litovchick, Larisa			The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb	ONCOGENE			English	Article							CARCINOMA IN-SITU; GENE-EXPRESSION; TRANSCRIPTION; TARGET; INTEGRATION; ACTIVATION; MECHANISMS; PHASE; FOXM1; LINE	Overexpression of the oncogene MYBL2 (B-Myb) is associated with increased cell proliferation and serves as a marker of poor prognosis in cancer. However, the mechanism by which B-Myb alters the cell cycle is not fully understood. In proliferating cells, B-Myb interacts with the MuvB core complex including LIN9, LIN37, LIN52, RBBP4, and LIN54, forming the MMB (Myb-MuvB) complex, and promotes transcription of genes required for mitosis. Alternatively, the MuvB core interacts with Rb-like protein p130 and E2F4-DP1 to form the DREAM complex that mediates global repression of cell cycle genes in G0/G1, including a subset of MMB target genes. Here, we show that overexpression of B-Myb disrupts the DREAM complex in human cells, and this activity depends on the intact MuvB-binding domain in B-Myb. Furthermore, we found that B-Myb regulates the protein expression levels of the MuvB core subunit LIN52, a key adapter for assembly of both the DREAM and MMB complexes, by a mechanism that requires S28 phosphorylation site in LIN52. Given that high expression of B-Myb correlates with global loss of repression of DREAM target genes in breast and ovarian cancer, our findings offer mechanistic insights for aggressiveness of cancers with MYBL2 amplification, and establish the rationale for targeting B-Myb to restore cell cycle control.	[Iness, Audra N.; Felthousen, Jessica; Ananthapadmanabhan, Varsha; Sesay, Fatmata; Saini, Siddharth; Litovchick, Larisa] Virginia Commonwealth Univ, Div Hematol Oncol & Palliat Care, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Iness, Audra N.; Felthousen, Jessica; Ananthapadmanabhan, Varsha; Sesay, Fatmata; Saini, Siddharth; Litovchick, Larisa] Virginia Commonwealth Univ, Massey Canc Ctr, Med Coll Virginia Campus, Richmond, VA 23298 USA; [Guiley, Keelan Z.; Rubin, Seth M.] Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; [Dozmorov, Mikhail] Virginia Commonwealth Univ, Dept Biostat, Med Coll Virginia Campus, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University; University of California System; University of California Santa Cruz; Virginia Commonwealth University	Litovchick, L (corresponding author), Virginia Commonwealth Univ, Div Hematol Oncol & Palliat Care, Med Coll Virginia Campus, Richmond, VA 23298 USA.; Litovchick, L (corresponding author), Virginia Commonwealth Univ, Massey Canc Ctr, Med Coll Virginia Campus, Richmond, VA 23298 USA.	larisa.litovchick@vcuhealth.org	Iness, Audra Nicole/HDM-4123-2022; Dozmorov, Mikhail/B-1374-2009	Iness, Audra Nicole/0000-0001-5194-1319; Sesay, Fatmata/0000-0002-9973-3639; Dozmorov, Mikhail/0000-0002-0086-8358; Ananthapadmanabhan, Varsha/0000-0002-6909-1460; Litovchick, Larisa/0000-0002-9540-597X; Rubin, Seth/0000-0002-1670-4147	 [R01CA188571];  [R01CA132685];  [R01GM124148];  [F30CA221004]; NATIONAL CANCER INSTITUTE [F30CA221004, R01CA132685, R01CA188571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM124148, R25GM090084] Funding Source: NIH RePORTER	; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank James DeCaprio and Iain Morgan for critically reading the manuscript, and Sophia Gruszecki for technical support. This project was supported in part by R01CA188571 (L.L.), R01CA132685 and R01GM124148 (S.M.R.), and F30CA221004 (A.N.I.).	Allegra CJ, 2010, J NATL CANCER I, V102, P161, DOI 10.1093/jnci/djp485; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Becker W, 2011, FEBS J, V278, P246, DOI 10.1111/j.1742-4658.2010.07956.x; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Chen X, 2013, MOL CELL BIOL, V33, P227, DOI 10.1128/MCB.00881-12; Dedic PN, 2013, MED ONCOL, V30, P523; Fischer M, 2017, CRIT REV BIOCHEM MOL, V52, P638, DOI 10.1080/10409238.2017.1360836; Fischer M, 2016, NUCLEIC ACIDS RES, V44, P6070, DOI 10.1093/nar/gkw523; Forristal C, 2014, MOL CELL BIOL, V34, P2221, DOI 10.1128/MCB.01523-13; Guiley KZ, 2018, P NATL ACAD SCI USA, V115, P10016, DOI 10.1073/pnas.1808136115; Guiley KZ, 2015, GENE DEV, V29, P961, DOI 10.1101/gad.257568.114; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Iltzsche F, 2017, ONCOGENE, V36, P110, DOI 10.1038/onc.2016.181; Inoue Kazushi, 2016, Biomark Cancer, V8, P25, DOI 10.4137/BIC.S38394; Iwahori S, 2017, VIROLOGY, V512, P95, DOI 10.1016/j.virol.2017.09.009; Korenjak M, 2005, CURR OPIN GENET DEV, V15, P520, DOI 10.1016/j.gde.2005.07.001; Korenjak M, 2004, CELL, V119, P181, DOI 10.1016/j.cell.2004.09.034; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; Litovchick L, 2007, MOL CELL, V26, P539, DOI 10.1016/j.molcel.2007.04.015; Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211; Longo PA, 2013, METHOD ENZYMOL, V529, P227, DOI 10.1016/B978-0-12-418687-3.00018-5; LUNDIN A, 1986, METHOD ENZYMOL, V133, P27; Mages CFS, 2017, ELIFE, V6, DOI 10.7554/eLife.26876; Musa J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.244; Ness SA, 2003, BLOOD CELL MOL DIS, V31, P192, DOI 10.1016/S1079-9796(03)00151-7; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Odajima J, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006429; Pilkinton M, 2007, ONCOGENE, V26, P7535, DOI 10.1038/sj.onc.1210562; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Sadasivam S, 2013, NAT REV CANCER, V13, P585, DOI 10.1038/nrc3556; Sadasivam S, 2012, GENE DEV, V26, P474, DOI 10.1101/gad.181933.111; Sala A, 2005, EUR J CANCER, V41, P2479, DOI 10.1016/j.ejca.2005.08.004; Sala A, 1996, J BIOL CHEM, V271, P9363, DOI 10.1074/jbc.271.16.9363; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Schmit F, 2007, CELL CYCLE, V6, P1903, DOI 10.4161/cc.6.15.4512; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Solin LJ, 2013, JNCI-J NATL CANCER I, V105, P701, DOI 10.1093/jnci/djt067; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; STEIN GH, 1979, J CELL PHYSIOL, V99, P43, DOI 10.1002/jcp.1040990107; Tanaka Y, 1999, J BIOL CHEM, V274, P28067, DOI 10.1074/jbc.274.40.28067; Thorner AR, 2009, ONCOGENE, V28, P742, DOI 10.1038/onc.2008.430; Tripathi S, 2015, CELL HOST MICROBE, V18, P723, DOI 10.1016/j.chom.2015.11.002; Ukleja M, 2016, BIOESSAYS, V38, P1048, DOI 10.1002/bies.201600092; Yen HCS, 2008, SCIENCE, V322, P918, DOI 10.1126/science.1160489	44	34	38	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					1080	1092		10.1038/s41388-018-0490-y	http://dx.doi.org/10.1038/s41388-018-0490-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30206359	Green Submitted, Green Accepted			2022-12-17	WOS:000458624900011
J	Szmyd, R; Niska-Blakie, J; Diril, MK; Nunes, PR; Tzelepis, K; Lacroix, A; van Hul, N; Deng, LW; Matos, J; Dreesen, O; Bisteau, X; Kaldis, P				Szmyd, Radoslaw; Niska-Blakie, Joanna; Diril, M. Kasim; Nunes, Patricia Renck; Tzelepis, Konstantinos; Lacroix, Aurelie; van Hul, Noemi; Deng, Lih-Wen; Matos, Joao; Dreesen, Oliver; Bisteau, Xavier; Kaldis, Philipp			Premature activation of Cdk1 leads to mitotic events in S phase and embryonic lethality	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASE; DNA-DAMAGE CHECKPOINT; HOLLIDAY JUNCTION RESOLUTION; INHIBITORY PHOSPHORYLATION; CELL-CYCLE; WEE1 KINASE; NUCLEAR ACCUMULATION; RE-REPLICATION; PROTEIN-KINASE; G2 CHECKPOINT	Cell cycle regulation, especially faithful DNA replication and mitosis, are crucial to maintain genome stability. Cyclin-dependent kinase (CDK)/cyclin complexes drive most processes in cellular proliferation. In response to DNA damage, cell cycle surveillance mechanisms enable normal cells to arrest and undergo repair processes. Perturbations in genomic stability can lead to tumor development and suggest that cell cycle regulators could be effective targets in anticancer therapy. However, many clinical trials ended in failure due to off-target effects of the inhibitors used. Here, we investigate in vivo the importance of WEE1- and MYT1-dependent inhibitory phosphorylation of mammalian CDK1. We generated Cdk1(AF) knockin mice, in which two inhibitory phosphorylation sites are replaced by the non-phosphorylatable amino acids T14A/Y15F. We uncovered that monoallelic expression of CDK1(AF) is early embryonic lethal in mice and induces S phase arrest accompanied by gamma H2AX and DNA damage checkpoint activation in mouse embryonic fibroblasts (MEFs). The chromosomal fragmentation in Cdk1(AF) MEFs does not rely on CDK2 and is partly caused by premature activation of MUS81-SLX4 structure-specific endonuclease complexes, as well as untimely onset of chromosome condensation followed by nuclear lamina disassembly. We provide evidence that tumor development in liver expressing CDK1(AF) is inhibited. Interestingly, the regulatory mechanisms that impede cell proliferation in CDK1(AF) expressing cells differ partially from the actions of the WEE1 inhibitor, MK-1775, with p53 expression determining the sensitivity of cells to the drug response. Thus, our work highlights the importance of improved therapeutic strategies for patients with various cancer types and may explain why some patients respond better to WEE1 inhibitors.	[Szmyd, Radoslaw; Niska-Blakie, Joanna; Diril, M. Kasim; Nunes, Patricia Renck; Tzelepis, Konstantinos; Lacroix, Aurelie; van Hul, Noemi; Bisteau, Xavier; Kaldis, Philipp] ASTAR, IMCB, 61 Biopolis Dr,Proteos 3-09, Singapore 138673, Singapore; [Szmyd, Radoslaw] NUS, NUS Grad Sch Integrat Sci & Engn, Singapore 117597, Singapore; [Niska-Blakie, Joanna] ASTAR, Bioinformat Inst BII, Singapore 138671, Singapore; [Deng, Lih-Wen; Kaldis, Philipp] NUS, Dept Biochem, Singapore 117597, Singapore; [Matos, Joao] Swiss Fed Inst Technol, Dept Biol, Zurich, Switzerland; [Dreesen, Oliver] ASTAR, Inst Med Biol, Singapore 138648, Singapore; [Diril, M. Kasim] Dokuz Eylul Univ, Izmir Biomed & Genome Inst, TR-35340 Izmir, Turkey; [Nunes, Patricia Renck] Ecole Polytech Fed Lausanne, Sch Life Sci, CH-1015 Lausanne, Switzerland; [Tzelepis, Konstantinos] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; [Lacroix, Aurelie] McGill Univ, Dept Chem, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada; [Lacroix, Aurelie] McGill Univ, CSACS, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); National University of Singapore; Swiss Federal Institutes of Technology Domain; ETH Zurich; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Medical Biology (IMB); Dokuz Eylul University; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Wellcome Trust Sanger Institute; McGill University; McGill University	Kaldis, P (corresponding author), ASTAR, IMCB, 61 Biopolis Dr,Proteos 3-09, Singapore 138673, Singapore.; Kaldis, P (corresponding author), NUS, Dept Biochem, Singapore 117597, Singapore.	kaldis@imcb.a-star.edu.sg	Dreesen, Oliver/AAJ-2132-2020; Bisteau, Xavier/Q-7239-2018; Nunes, Patricia Renck/W-8183-2019; Bisteau, Xavier/AAH-6744-2021; Van Hul, Noemi/AAB-7985-2020; Diril, Kasim/GWZ-8547-2022; Kaldis, Philipp/G-2714-2010; Diril, Kasim/Y-1632-2018; Matos, Joao/C-1488-2014	Bisteau, Xavier/0000-0002-8896-5098; Kaldis, Philipp/0000-0002-7247-7591; Renck Nunes, Patricia/0000-0002-9680-0779; Tzelepis, Konstantinos/0000-0002-4865-7648; Van Hul, Noemi/0000-0003-1410-8808; LACROIX, Aurelie/0000-0003-1801-1608; Matos, Joao/0000-0002-3754-3709	Biomedical Research Council of A*STAR (Agency for Science, Technology and Research), Singapore; National Medical Research Council Singapore, NMRC [NMRC/CBRG/0091/2015]	Biomedical Research Council of A*STAR (Agency for Science, Technology and Research), Singapore(Agency for Science Technology & Research (A*STAR)); National Medical Research Council Singapore, NMRC(National Medical Research Council, Singapore)	We thank Zakiah Talib, June Wang, Vithya Anantaraja and Chloe Sim for animal care; and all past and current members of the Kaldis lab for support and discussions. We thank Jos Jonkers and Anton Berns for providing the Rosa26-CreERT2 mice, Andy McMahon for Esr1-Cre mice, T Jake Liang for Alb-Cre mice and Mark Lewandoski for the beta-actin-Cre/Flpe mice. We acknowledge the technical expertise provided by the Advanced Molecular Pathology Laboratory at IMCB. This work was supported by the Biomedical Research Council of A*STAR (Agency for Science, Technology and Research), Singapore and in part by a grant from the National Medical Research Council Singapore, NMRC (NMRC/CBRG/0091/2015) to PK.	Aaltonen K, 2009, BRIT J CANCER, V100, P1055, DOI 10.1038/sj.bjc.6604874; Aarts M, 2012, CANCER DISCOV, V2, P524, DOI 10.1158/2159-8290.CD-11-0320; Abbas T, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012914; Adhikari D, 2016, CELL RES, V26, P1212, DOI 10.1038/cr.2016.119; AJIRO K, 1983, J BIOL CHEM, V258, P4534; Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bayart E, 2004, CANCER RES, V64, P8954, DOI 10.1158/0008-5472.CAN-04-1613; Beck H, 2012, MOL CELL BIOL, V32, P4226, DOI 10.1128/MCB.00412-12; Bell JB, 2007, NAT PROTOC, V2, P3153, DOI 10.1038/nprot.2007.471; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Blasina A, 1997, MOL BIOL CELL, V8, P1013, DOI 10.1091/mbc.8.6.1013; Bonin A, 2000, METH MOL B, V158, P121; Bowers JL, 2004, MOL CELL, V16, P967, DOI 10.1016/j.molcel.2004.11.038; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; Bucher N, 2008, BRIT J CANCER, V98, P523, DOI 10.1038/sj.bjc.6604208; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen T, 2012, DRUG DISCOV TODAY, V17, P194, DOI 10.1016/j.drudis.2011.12.009; Chow JPH, 2013, ONCOGENE, V32, P4778, DOI 10.1038/onc.2012.504; Chow JPH, 2003, MOL BIOL CELL, V14, P3989, DOI 10.1091/mbc.E03-03-0168; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Coulonval K, 2011, MOL BIOL CELL, V22, P3971, DOI 10.1091/mbc.E11-02-0136; Dimitrova N, 2008, NATURE, V456, P524, DOI 10.1038/nature07433; Diril MK, 2012, P NATL ACAD SCI USA, V109, P3826, DOI 10.1073/pnas.1115201109; Dominguez-Kelly R, 2011, J CELL BIOL, V194, P567, DOI 10.1083/jcb.201101047; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Duda H, 2016, DEV CELL, V39, P740, DOI 10.1016/j.devcel.2016.11.017; ENOCH T, 1991, J CELL BIOL, V112, P797, DOI 10.1083/jcb.112.5.797; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Garcia TB, 2018, LEUKEMIA RES, V64, P30, DOI 10.1016/j.leukres.2017.11.004; Garner E, 2013, CELL REP, V5, P207, DOI 10.1016/j.celrep.2013.08.041; GAUTIER J, 1990, CELL, V60, P487, DOI 10.1016/0092-8674(90)90599-A; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; Gupta M, 2007, J BIOL CHEM, V282, P4301, DOI 10.1074/jbc.M607910200; Hanada K, 2007, NAT STRUCT MOL BIOL, V14, P1096, DOI 10.1038/nsmb1313; HARPER JW, 1993, CELL, V75, P805; Hayashi S, 2002, DEV BIOL, V244, P305, DOI 10.1006/dbio.2002.0597; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; Heijink AM, 2015, P NATL ACAD SCI USA, V112, P15160, DOI 10.1073/pnas.1505283112; Hirai H, 2009, MOL CANCER THER, V8, P2992, DOI 10.1158/1535-7163.MCT-09-0463; Ho V, 2015, ONCOTARGET, V6, P27252, DOI 10.18632/oncotarget.4583; Hughes BT, 2013, P NATL ACAD SCI USA, V110, P8954, DOI 10.1073/pnas.1302927110; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Jiang KC, 2003, J BIOL CHEM, V278, P25207, DOI 10.1074/jbc.M300070200; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Johnson N, 2009, MOL CELL, V35, P327, DOI 10.1016/j.molcel.2009.06.036; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kao H, 2001, J EXP MED, V194, P1313, DOI 10.1084/jem.194.9.1313; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Klotz-Noack K, 2012, J CELL SCI, V125, P2436, DOI 10.1242/jcs.100883; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; Krajewska M, 2013, ONCOGENE, V32, P3001, DOI 10.1038/onc.2012.296; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lewandoski M, 1997, COLD SPRING HARB SYM, V62, P159; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Lohka MJ, 1998, BIOL CELL, V90, P591, DOI 10.1016/S0248-4900(99)80017-3; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Matheson CJ, 2016, TRENDS PHARMACOL SCI, V37, P872, DOI 10.1016/j.tips.2016.06.006; Matos J, 2011, CELL, V147, P158, DOI 10.1016/j.cell.2011.08.032; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656; Minemoto Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P13, DOI 10.1016/S0003-9861(03)00010-9; Monaco L, 2005, P NATL ACAD SCI USA, V102, P14244, DOI 10.1073/pnas.0506252102; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Moser R, 2014, CLIN CANCER RES, V20, P4274, DOI 10.1158/1078-0432.CCR-13-2858; Moyer SE, 2006, P NATL ACAD SCI USA, V103, P10236, DOI 10.1073/pnas.0602400103; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nakajo N, 2000, GENE DEV, V14, P328; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; Padmakumar VC, 2009, MOL CELL BIOL, V29, P2582, DOI 10.1128/MCB.00952-08; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; Pfander B, 2017, FEBS LETT, V591, P2048, DOI 10.1002/1873-3468.12727; Pfister SX, 2015, CANCER CELL, V28, P557, DOI 10.1016/j.ccell.2015.09.015; Pomerening JR, 2008, MOL BIOL CELL, V19, P3426, DOI 10.1091/mbc.E08-02-0172; Poon RYC, 1997, CANCER RES, V57, P5168; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Rappold I, 2001, J CELL BIOL, V153, P613, DOI 10.1083/jcb.153.3.613; Rass U, 2010, GENE DEV, V24, P1559, DOI 10.1101/gad.585310; Ross KE, 2000, MOL BIOL CELL, V11, P1597, DOI 10.1091/mbc.11.5.1597; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Sarbajna S, 2014, GENE DEV, V28, P1124, DOI 10.1101/gad.238303.114; Scaffidi P, 2008, NAT CELL BIOL, V10, P452, DOI 10.1038/ncb1708; Schuler M, 2004, GENESIS, V39, P167, DOI 10.1002/gene.20039; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; Tanaka S, 2002, NAT CELL BIOL, V4, P198, DOI 10.1038/ncb757; Tanaka S, 2010, CHROMOSOMA, V119, P565, DOI 10.1007/s00412-010-0291-8; Tominaga Y, 2006, INT J BIOL SCI, V2, P161; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Vincent F, 1999, BIOL CELL, V91, P665; Vooijs M, 2001, EMBO REP, V2, P292, DOI 10.1093/embo-reports/kve064; Vriend LEM, 2013, BBA-REV CANCER, V1836, P227, DOI 10.1016/j.bbcan.2013.05.002; WALDMAN T, 1995, CANCER RES, V55, P5187; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; Wells NJ, 1999, J CELL SCI, V112, P3361; West SC, 2015, COLD SH Q B, V80, P103, DOI 10.1101/sqb.2015.80.027649; Wilkins BJ, 2014, SCIENCE, V343, P77, DOI 10.1126/science.1244508; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Wyatt HDM, 2013, MOL CELL, V52, P234, DOI 10.1016/j.molcel.2013.08.035; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yeeles JTP, 2015, NATURE, V519, P431, DOI 10.1038/nature14285; Zhao H, 2012, MOL CELL BIOL, V32, P1421, DOI 10.1128/MCB.06721-11	121	34	34	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 14	2019	38	7					998	1018		10.1038/s41388-018-0464-0	http://dx.doi.org/10.1038/s41388-018-0464-0			21	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HL3OH	30190546	hybrid, Green Published			2022-12-17	WOS:000458624900006
J	Yang, Y; Wu, XQ; Li, WX; Huang, HM; Li, HD; Pan, XY; Li, XF; Huang, C; Meng, XM; Zhang, L; Lv, XW; Wang, H; Li, J				Yang, Yang; Wu, Xiao-qin; Li, Wan-xia; Huang, Hui-min; Li, Hai-di; Pan, Xue-yin; Li, Xiao-feng; Huang, Cheng; Meng, Xiao-ming; Zhang, Lei; Lv, Xiong-wen; Wang, Hua; Li, Jun			PSTPIP2 connects DNA methylation to macrophage polarization in CCL4-induced mouse model of hepatic fibrosis	ONCOGENE			English	Article							CHRONIC MULTIFOCAL OSTEOMYELITIS; CHRONIC ACTIVE HEPATITIS; AUTOINFLAMMATORY DISEASE; AUTOIMMUNE HEPATITIS; IN-VIVO; HEPATOCELLULAR-CARCINOMA; PSTPIP2-DEFICIENT MICE; CORTICOSTEROID-THERAPY; LIVER FIBROSIS; ACTIVATION	Macrophages play a crucial role in the progression of hepatic fibrosis (HF). In macrophages, epigenetic mechanisms are increasingly being recognized as crucial controllers of their phenotype. However, the functions of macrophage DNA methylation in experimental models of hepatic fibrosis have not been fully addressed. Here, we analyzed isolated hepatic macrophages DNA methylation from CCL4-induced (4 weeks) mice using reduced representation bisulfite sequencing (RRBS). We identified and validated the methylation status of 26 gene promoter regions associated with CpG islands. We further investigated the function of PSTPIP2 in HF by hepatic-adeno-associated virus (AAV9)-PSTPIP2 overexpression. The molecular mechanisms underlying PSTPIPS2-regulated HF were further explored in mice and RAW264.7 cell line. RRBS results show hypermethylation of PSTPIP2 (chr18: 77,843,840-77,843,968) in the 5'-UTR region. PSTPIP2 expression was significantly decreased in isolated hepatic macrophages from CCL4-induced mice. PSTPIP2 hypermethylation is mediated by the methyltransferases DNMT3a and DNMT3b in LPS-induced RAW264.7 cell line. Further investigation indicated that specific overexpression of PSTPIP2 in C57BL/6 mice reduced the inflammatory response and ameliorated liver fibrosis. These data indicated that hypermethylation of PSTPIP2 caused a mixed induction of hepatic classical macrophage (M1) and alternative macrophage (M2) biomarkers in CCL4-induced HF mice. Furthermore, overexpression of PSTPIP2 inhibited the expression of M1 markers by suppressing STAT1 activity, and enhanced the expression of M2 markers by promoting STAT6 activity. In contrast, knockdown of PSTPIP2 promoted M1 polarization and suppressed M2 polarization in vitro. Adding PSTPIP2 expression alleviates liver fibrosis and hepatic inflammation in mice by regulating macrophage polarization.	[Yang, Yang; Wu, Xiao-qin; Li, Wan-xia; Huang, Hui-min; Li, Hai-di; Pan, Xue-yin; Li, Xiao-feng; Huang, Cheng; Meng, Xiao-ming; Zhang, Lei; Lv, Xiong-wen; Wang, Hua; Li, Jun] Anhui Med Univ, Sch Pharm, Anhui Key Lab Bioact Nat Prod, Hefei 230032, Anhui, Peoples R China; [Yang, Yang; Wu, Xiao-qin; Li, Wan-xia; Huang, Hui-min; Li, Hai-di; Pan, Xue-yin; Li, Xiao-feng; Huang, Cheng; Meng, Xiao-ming; Zhang, Lei; Lv, Xiong-wen; Wang, Hua; Li, Jun] Anhui Med Univ, Key Lab Antiinflammatory & Immune Med, Minist Educ, Hefei 230032, Anhui, Peoples R China; [Yang, Yang; Wu, Xiao-qin; Li, Wan-xia; Huang, Hui-min; Li, Hai-di; Pan, Xue-yin; Li, Xiao-feng; Huang, Cheng; Meng, Xiao-ming; Zhang, Lei; Lv, Xiong-wen; Wang, Hua; Li, Jun] Anhui Med Univ, Inst Liver Dis, Hefei 230032, Anhui, Peoples R China; [Yang, Yang; Wu, Xiao-qin; Li, Wan-xia; Huang, Hui-min; Li, Hai-di; Pan, Xue-yin; Li, Xiao-feng; Huang, Cheng; Meng, Xiao-ming; Zhang, Lei; Lv, Xiong-wen; Wang, Hua; Li, Jun] Anhui Med Univ, Anhui Inst Innovat Drugs, Hefei 230032, Anhui, Peoples R China	Anhui Medical University; Anhui Medical University; Anhui Medical University; Anhui Medical University	Li, J (corresponding author), Anhui Med Univ, Sch Pharm, Anhui Key Lab Bioact Nat Prod, Hefei 230032, Anhui, Peoples R China.; Li, J (corresponding author), Anhui Med Univ, Key Lab Antiinflammatory & Immune Med, Minist Educ, Hefei 230032, Anhui, Peoples R China.; Li, J (corresponding author), Anhui Med Univ, Inst Liver Dis, Hefei 230032, Anhui, Peoples R China.; Li, J (corresponding author), Anhui Med Univ, Anhui Inst Innovat Drugs, Hefei 230032, Anhui, Peoples R China.	lj@ahmu.edu.cn	li, xiaofeng/GXF-9442-2022; Yang, Yang/AAB-5926-2021; li, xiao/GSN-6181-2022; lv, xiongwen/ABE-6452-2021	lv, xiongwen/0000-0003-2354-0168; Yang, Yang/0000-0002-0942-1800; Meng, Xiao-ming/0000-0002-1166-561X	National Natural Science Foundation of China [81770609]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by grants from the National Natural Science Foundation of China (81770609).	Amabile G, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8091; Bian EB, 2012, TOXICOL APPL PHARM, V264, P13, DOI 10.1016/j.taap.2012.06.022; Brombacher Frank, 2009, V531, P225, DOI 10.1007/978-1-59745-396-7_15; BYRD L, 1991, GENOMICS, V11, P794, DOI 10.1016/0888-7543(91)90002-V; Calvisi DF, 2011, J HEPATOL, V54, P311, DOI 10.1016/j.jhep.2010.06.036; Cassel SL, 2014, P NATL ACAD SCI USA, V111, P1072, DOI 10.1073/pnas.1318685111; Chen TP, 2004, CURR TOP DEV BIOL, V60, P55; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Cohen-Naftaly Michal, 2011, Therap Adv Gastroenterol, V4, P391, DOI 10.1177/1756283X11413002; Czaja AJ, 2004, HEPATOLOGY, V39, P1631, DOI 10.1002/hep.20235; Czaja AJ, 2004, J HEPATOL, V40, P646, DOI 10.1016/j.jhep.2004.01.009; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dill MT, 2014, J CLIN INVEST, V124, P1568, DOI 10.1172/JCI70408; Drobek A, 2015, J IMMUNOL, V195, P3416, DOI 10.4049/jimmunol.1401494; Ferguson PJ, 2006, BONE, V38, P41, DOI 10.1016/j.bone.2005.07.009; Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003; Fujisaka S, 2009, DIABETES, V58, P2574, DOI 10.2337/db08-1475; Gao GP, 2002, P NATL ACAD SCI USA, V99, P11854, DOI 10.1073/pnas.182412299; Ghiassi-Nejad Zahra, 2008, Expert Rev Gastroenterol Hepatol, V2, P803, DOI 10.1586/17474124.2.6.803; Grosse J, 2006, BLOOD, V107, P3350, DOI 10.1182/blood-2005-09-3556; Gu H, 2010, NAT METHODS, V7, P133, DOI 10.1038/nmeth.1414; Hansen B, 2002, MOL CELL BIOCHEM, V240, P1, DOI 10.1023/A:1020660303855; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Hernandez-Gea V, 2011, ANNU REV PATHOL-MECH, V6, P425, DOI 10.1146/annurev-pathol-011110-130246; Holt MP, 2008, J LEUKOCYTE BIOL, V84, P1410, DOI 10.1189/jlb.0308173; Iredale JP, 2007, J CLIN INVEST, V117, P539, DOI 10.1172/JCI30542; Lee UE, 2011, BEST PRACT RES CL GA, V25, P195, DOI 10.1016/j.bpg.2011.02.005; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Li PP, 2010, J BIOL CHEM, V285, P15333, DOI 10.1074/jbc.M110.100263; Liao HJ, 2015, RHEUMATOLOGY, V54, P1317, DOI 10.1093/rheumatology/keu481; Lippincott J, 2000, MICROSC RES TECHNIQ, V49, P168, DOI 10.1002/(SICI)1097-0029(20000415)49:2<168::AID-JEMT9>3.0.CO;2-T; Luczak MW, 2006, FOLIA HISTOCHEM CYTO, V44, P143; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; McCarty DM, 2003, GENE THER, V10, P2112, DOI 10.1038/sj.gt.3302134; McKenzie GJ, 1998, CURR BIOL, V8, P339, DOI 10.1016/S0960-9822(98)70134-4; McKenzie GJ, 1999, J EXP MED, V189, P1565, DOI 10.1084/jem.189.10.1565; Mouzaki M, 2015, CURR DRUG TARGETS, V16, P1324, DOI 10.2174/1389450116666150416120351; Nakai H, 1999, J VIROL, V73, P5438, DOI 10.1128/JVI.73.7.5438-5447.1999; Nakai H, 2005, J VIROL, V79, P214, DOI 10.1128/JVI.79.1.214-224.2005; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; Ohta M, 2009, GASTROENTEROLOGY, V136, P206, DOI 10.1053/j.gastro.2008.09.063; Ramachandran P, 2012, J HEPATOL, V56, P1417, DOI 10.1016/j.jhep.2011.10.026; Roberts SK, 1996, GASTROENTEROLOGY, V110, P848, DOI 10.1053/gast.1996.v110.pm8608895; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Singal AG, 2010, CLIN GASTROENTEROL H, V8, P280, DOI 10.1016/j.cgh.2009.11.018; Smith ZD, 2009, METHODS, V48, P226, DOI 10.1016/j.ymeth.2009.05.003; Tao H, 2011, TOXICOLOGY, V290, P327, DOI 10.1016/j.tox.2011.10.011; Vento-Tormo R, 2016, J ALLERGY CLIN IMMUN, P202; Villalta SA, 2011, HUM MOL GENET, V20, P790, DOI 10.1093/hmg/ddq523; WANG KK, 1988, HEPATOLOGY, V8, P1679, DOI 10.1002/hep.1840080635; Wang Z, 2003, GENE THER, V10, P2105, DOI 10.1038/sj.gt.3302133; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Yang JJ, 2013, CELL SIGNAL, V25, P1202, DOI 10.1016/j.cellsig.2013.01.005; Yoo J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062152	54	34	36	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 22	2018	37	47					6119	6135		10.1038/s41388-018-0383-0	http://dx.doi.org/10.1038/s41388-018-0383-0			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HB2PG	29993036				2022-12-17	WOS:000450883000002
J	Seo, SU; Woo, SM; Lee, HS; Kim, SH; Min, KJ; Kwon, TK				Seo, Seung Un; Woo, Seon Min; Lee, Hyun-Shik; Kim, Sang Hyun; Min, Kyoung-jin; Kwon, Taeg Kyu			mTORC1/2 inhibitor and curcumin induce apoptosis through lysosomal membrane permeabilization-mediated autophagy	ONCOGENE			English	Article							RENAL-CELL CARCINOMA; BCL-X-L; DOWN-REGULATION; ENDOPLASMIC-RETICULUM; CYTOCHROME-C; MAMMALIAN TARGET; GLIOMA-CELLS; CANCER-CELLS; MOLECULAR-MECHANISMS; SELECTIVE AUTOPHAGY	mTOR is an important regulator of cell growth and forms two complexes, mTORC1/2. In cancer, mTOR signaling is highly activated, and the regulation of this signaling, as an anti-cancer strategy, has been emphasized. However, PP242 (inhibitor of mTORC1 and mTORC2) alone did not induce human renal carcinoma cell death. In this study, we found that PP242 alone did not alter cell viability, but combined curcumin and PP242 treatment induced cell death. Combined PP242 and curcumin treatment induced Bax activation and decreased expression of Mcl-1 and Bcl-2. Furthermore, co-treatment with PP242 and curcumin-induced the downregulation of the Rictor (an mTORC2 complex protein) and Akt protein levels, and ectopic overexpression of Rictor or Akt inhibited PP242 plus curcumin induced cell death. Downregulation of Rictor increased cytosolic Ca2+ release from endoplasmic reticulum, which led to lysosomal damage in PP242 plus curcumin-treated cells. Furthermore, damaged lysosomes induced autophagy. Autophagy inhibitors markedly inhibited cell death. Finally, combined curcumin and PP242 treatment reduced tumor growth and induced cell death in xenograft models. Altogether, our results reveal that combined PP242 and curcumin treatment could induce autophagy-mediated cell death by reducing the expression of Rictor and Akt in renal carcinoma cells.	[Seo, Seung Un; Woo, Seon Min; Min, Kyoung-jin; Kwon, Taeg Kyu] Keimyung Univ, Sch Med, Dept Immunol, 2800 Dalgubeoldaero, Daegu 704701, South Korea; [Lee, Hyun-Shik] KNU, Coll Nat Sci, Plus KNU Creat BioRes Grp BK21, Sch Life Sci,Ctr Nonlinear Dynam, Daegu 41566, South Korea; [Kim, Sang Hyun] Kyungpook Natl Univ, Sch Med, Dept Pharmacol, Daegu 41944, South Korea	Keimyung University; Kyungpook National University	Min, KJ; Kwon, TK (corresponding author), Keimyung Univ, Sch Med, Dept Immunol, 2800 Dalgubeoldaero, Daegu 704701, South Korea.	kyoungjin.min@gmail.com; kwontk@dsmc.or.kr			NRF grant - Korea Government (MSIP) [2014R1A5A2010008, NRF-2016R1A2B2013393, NRF-2016R1D1A1B03933568]	NRF grant - Korea Government (MSIP)	We appreciate critical reading of the manuscript by Jae Man Lee (Kyungpook national university). This work was supported by an NRF grant funded by the Korea Government (MSIP) (2014R1A5A2010008, NRF-2016R1A2B2013393 and NRF-2016R1D1A1B03933568).	Anding AL, 2017, DEV CELL, V41, P10, DOI 10.1016/j.devcel.2017.02.016; Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167; Beevers CS, 2009, CANCER RES, V69, P1000, DOI 10.1158/0008-5472.CAN-08-2367; Betz C, 2013, P NATL ACAD SCI USA, V110, P12526, DOI 10.1073/pnas.1302455110; Boulbes DR, 2011, BIOCHEM BIOPH RES CO, V413, P46, DOI 10.1016/j.bbrc.2011.08.034; Chen H, 1999, ANTICANCER RES, V19, P3675; Copp J, 2009, CANCER RES, V69, P1821, DOI 10.1158/0008-5472.CAN-08-3014; Deeb D, 2003, MOL CANCER THER, V2, P95; Dowling RJO, 2010, BBA-PROTEINS PROTEOM, V1804, P433, DOI 10.1016/j.bbapap.2009.12.001; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Fei Y, 2016, BRAIN RES, V1646, P580, DOI 10.1016/j.brainres.2016.06.046; Fruman DA, 2009, IMMUNOL REV, V228, P253, DOI 10.1111/j.1600-065X.2008.00750.x; Fu ZP, 2015, ONCOTARGET, V6, P19469, DOI 10.18632/oncotarget.3625; Galluzzi L, 2009, NAT REV NEUROSCI, V10, P481, DOI 10.1038/nrn2665; Gao XH, 2005, J EXP THER ONCOL, V5, P39; Go DH, 2017, ONCOTARGET, V8, P58790, DOI 10.18632/oncotarget.17732; Han MA, 2015, CHEM-BIOL INTERACT, V228, P69, DOI 10.1016/j.cbi.2015.01.020; Han SS, 1999, CLIN IMMUNOL, V93, P152, DOI 10.1006/clim.1999.4769; Hoang B, 2012, J BIOL CHEM, V287, P21796, DOI 10.1074/jbc.M111.304626; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Hung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3111; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Jo Y, 2017, BMB REP, V50, P379, DOI 10.5483/BMBRep.2017.50.7.063; Jung EM, 2005, CARCINOGENESIS, V26, P1905, DOI 10.1093/carcin/bgi167; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kunnumakkara AB, 2007, CANCER RES, V67, P3853, DOI 10.1158/0008-5472.CAN-06-4257; Lemasters JJ, 2005, REJUV RES, V8, P3, DOI 10.1089/rej.2005.8.3; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Maejima I, 2013, EMBO J, V32, P2336, DOI 10.1038/emboj.2013.171; Mochida K, 2015, NATURE, V522, P359, DOI 10.1038/nature14506; Moragoda L, 2001, ANTICANCER RES, V21, P873; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531; O'Sullivan-Coyne G, 2009, BRIT J CANCER, V101, P1585, DOI 10.1038/sj.bjc.6605308; OLSSON GM, 1989, VIRCHOWS ARCH B, V56, P263; Ono K, 2003, MOL CELL BIOL, V23, P665, DOI 10.1128/MCB.23.2.665-676.2003; Park YS, 2017, TOX RESEARCH, V33, P211, DOI 10.5487/TR.2017.33.3.211; Peyerl FW, 2007, CELL DEATH DIFFER, V14, P447, DOI 10.1038/sj.cdd.4402025; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schuck S, 2014, J CELL SCI, V127, P4078, DOI 10.1242/jcs.154716; SCUDIERO DA, 1988, CANCER RES, V48, P4827; Seo SU, 2017, REDOX BIOL, V13, P608, DOI 10.1016/j.redox.2017.07.017; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Sirohi VK, 2017, J NUTR BIOCHEM, V44, P60, DOI 10.1016/j.jnutbio.2016.12.021; Soares HP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057289; Szado T, 2008, P NATL ACAD SCI USA, V105, P2427, DOI 10.1073/pnas.0711324105; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Vinod BS, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.26; Wang Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073175; Woo JH, 2003, CARCINOGENESIS, V24, P1199, DOI 10.1093/carcin/bgg082; Woo SM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.472; Woo SM, 2016, ONCOTARGET, V7, P61520, DOI 10.18632/oncotarget.11137; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Zaytseva YY, 2012, CANCER LETT, V319, P1, DOI 10.1016/j.canlet.2012.01.005; Zeng XC, 2004, J CELL SCI, V117, P4991, DOI 10.1242/jcs.01373; Zhang JW, 2015, NAT CELL BIOL, V17, P1259, DOI 10.1038/ncb3230	60	34	39	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 20	2018	37	38					5205	5220		10.1038/s41388-018-0345-6	http://dx.doi.org/10.1038/s41388-018-0345-6			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU2IP	29849119	Green Published, hybrid			2022-12-17	WOS:000445093100005
J	Garg, R; Blando, JM; Perez, CJ; Lal, P; Feldman, MD; Smyth, EM; Ricciotti, E; Grosser, T; Benavides, F; Kazanietz, MG				Garg, Rachana; Blando, Jorge M.; Perez, Carlos J.; Lal, Priti; Feldman, Michael D.; Smyth, Emer M.; Ricciotti, Emanuela; Grosser, Tilo; Benavides, Fernando; Kazanietz, Marcelo G.			COX-2 mediates pro-tumorigenic effects of PKC epsilon in prostate cancer	ONCOGENE			English	Article							PROTEIN-KINASE-C; NF-KAPPA-B; PROSTAGLANDIN RECEPTOR EP2; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; IN-VIVO; COLORECTAL-CANCER; CYCLOOXYGENASE-2 INHIBITORS; TRANSCRIPTION FACTORS; CELL-PROLIFERATION	The pro-oncogenic kinase PKC epsilon is overexpressed in human prostate cancer and cooperates with loss of the tumor suppressor Pten for the development of prostatic adenocarcinoma. However, the effectors driving PKC epsilon-mediated phenotypes remain poorly defined. Here, using cellular and mouse models, we showed that PKC epsilon overexpression acts synergistically with Pten loss to promote NF-kappa B activation and induce cyclooxygenase-2 (COX-2) expression, phenotypic traits which are also observed in human prostate tumors. Targeted disruption of PKC epsilon from prostate cancer cells impaired COX-2 induction and PGE(2) production. Notably, COX-2 inhibitors selectively killed prostate epithelial cells overexpressing PKC epsilon, and this ability was greatly enhanced by Pten loss. Long-term COX-2 inhibition markedly reduced adenocarcinoma formation, as well as angiogenesis in a mouse model of prostate-specific PKC epsilon expression and Pten loss. Overall, our results provide strong evidence for the involvement of the canonical NF-kappa B pathway and its target gene COX2 as PKC epsilon effectors, and highlight the potential of PKC epsilon as a useful biomarker for the use of COX inhibition for chemopreventive and/or chemotherapeutic purposes in prostate cancer.	[Garg, Rachana; Smyth, Emer M.; Ricciotti, Emanuela; Grosser, Tilo; Kazanietz, Marcelo G.] Univ Penn, Dept Syst Pharmacol & Translat Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA; [Blando, Jorge M.] Univ Texas MD Anderson Canc Ctr, Immunopathol Lab, Dept Immunol, Houston, TX 77030 USA; [Perez, Carlos J.; Benavides, Fernando] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Smithville, TX 78957 USA; [Perez, Carlos J.; Benavides, Fernando] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA; [Lal, Priti; Feldman, Michael D.] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Pennsylvania; Pennsylvania Medicine	Kazanietz, MG (corresponding author), Univ Penn, Dept Syst Pharmacol & Translat Therapeut, Perelman Sch Med, Philadelphia, PA 19104 USA.	marcelog@upenn.edu	Ricciotti, Emanuela/AAH-2729-2019; Garg, Rachana/AAQ-9518-2020; Grosser, Tilo/A-1057-2007	Grosser, Tilo/0000-0001-8569-8396; Garg, Rachana/0000-0002-7808-1053	DHHS/NCI Cancer Center Support grant [P30 CA016672];  [R01-CA089202];  [R01-CA189765];  [R01-CA196232 (NIH)];  [PC130641 (DOD)];  [W81XWH-12-1-0009 (DOD)]; NATIONAL CANCER INSTITUTE [R01CA196232, P30CA016672, R01CA089202, R01CA189765] Funding Source: NIH RePORTER	DHHS/NCI Cancer Center Support grant; ; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants R01-CA089202, R01-CA189765, R01-CA196232 (NIH), and PC130641 (DOD) to M.G.K., and W81XWH-12-1-0009 (DOD) to R.G. This study made use of the Research Animal Support Facility at MD Anderson Cancer Center, Smithville, including Laboratory Animal Genetic Services and Mutant Mouse Pathology Services, which are supported by DHHS/NCI Cancer Center Support grant P30 CA016672.	Abedinpour P, 2011, PROSTATE, V71, P813, DOI 10.1002/pros.21297; Adhami VM, 2007, CLIN CANCER RES, V13, P1611, DOI 10.1158/1078-0432.CCR-06-2269; Armstrong AJ, 2012, LANCET ONCOL, V13, P443, DOI 10.1016/S1470-2045(12)70111-0; Aziz MH, 2007, CANCER RES, V67, P8828, DOI 10.1158/0008-5472.CAN-07-1604; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Cai Y, 2008, INT J CANCER, V123, P195, DOI 10.1002/ijc.23481; Caino MC, 2012, ONCOGENE, V31, P2593, DOI 10.1038/onc.2011.428; Caino MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031714; Claudino RF, 2006, J PHARMACOL EXP THER, V318, P611, DOI 10.1124/jpet.106.102806; Dandekar DS, 2005, INT J CANCER, V115, P484, DOI 10.1002/ijc.20878; Denkert C, 2007, PROSTATE, V67, P361, DOI 10.1002/pros.20467; Diaz-Meco MT, 2012, IMMUNOL REV, V246, P154, DOI 10.1111/j.1600-065X.2012.01093.x; Fernandez-Marcos PJ, 2009, P NATL ACAD SCI USA, V106, P12962, DOI 10.1073/pnas.0813055106; Finetti F, 2015, ENDOCR-RELAT CANCER, V22, P665, DOI 10.1530/ERC-15-0277; Fries S, 2006, GASTROENTEROLOGY, V130, P55, DOI 10.1053/j.gastro.2005.10.002; Garcia M, 2014, BJU INT, V113, pE164, DOI 10.1111/bju.12503; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Garg R, 2017, CELL REP, V19, P375, DOI 10.1016/j.celrep.2017.03.042; Garg R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067319; Garg R, 2012, J BIOL CHEM, V287, P37570, DOI 10.1074/jbc.M112.398925; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Gowda R, 2012, CANCER BIOL THER, V13, P756, DOI 10.4161/cbt.20558; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Gupta S, 2004, CANCER RES, V64, P3334, DOI 10.1158/0008-5472.CAN-03-2422; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; Gutierrez-Uzquiza A, 2015, MOL CANCER RES, V13, P1336, DOI 10.1158/1541-7786.MCR-15-0111; Hanaka H, 2009, P NATL ACAD SCI USA, V106, P18757, DOI 10.1073/pnas.0910218106; Harris R. E., 2009, Inflammopharmacology, V17, P55, DOI 10.1007/s10787-009-8049-8; Harris Randall E, 2012, J Exp Pharmacol, V4, P91, DOI 10.2147/JEP.S23826; Henry WS, 2017, CANCER RES, V77, P790, DOI 10.1158/0008-5472.CAN-16-2400; Holden NS, 2008, CELL SIGNAL, V20, P1338, DOI 10.1016/j.cellsig.2008.03.001; Howe LR, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1678; Howe LR, 2003, J MAMMARY GLAND BIOL, V8, P31, DOI 10.1023/A:1025731204719; Hu ZX, 2017, ONCOTARGETS THER, V10, P2893, DOI 10.2147/OTT.S134599; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; Jain K, 2014, CANCERS, V6, P860, DOI 10.3390/cancers6020860; Jain S, 2008, CANCER RES, V68, P7750, DOI 10.1158/0008-5472.CAN-07-6689; Jamal MS, 2011, CANCER RES, V71, DOI 10.1158/1538-7445.AM2011-4204; James ND, 2012, LANCET ONCOL, V13, P549, DOI 10.1016/S1470-2045(12)70088-8; Jiang JX, 2013, TRENDS PHARMACOL SCI, V34, P413, DOI 10.1016/j.tips.2013.05.003; Jiang JX, 2013, J PHARMACOL EXP THER, V344, P360, DOI 10.1124/jpet.112.200444; Jiao J, 2007, CANCER RES, V67, P6083, DOI 10.1158/0008-5472.CAN-06-4202; Kashiwagi E, 2014, PROSTATE CANCER P D, V17, P10, DOI 10.1038/pcan.2013.53; Kashiwagi E, 2013, ENDOCR-RELAT CANCER, V20, P431, DOI 10.1530/ERC-12-0344; Khor LY, 2007, LANCET ONCOL, V8, P912, DOI 10.1016/S1470-2045(07)70280-2; Kim BH, 2011, KOREAN J UROL, V52, P253, DOI 10.4111/kju.2011.52.4.253; Kirschenbaum A, 2000, UROLOGY, V56, P671, DOI 10.1016/S0090-4295(00)00674-9; Lessard L, 2005, BRIT J CANCER, V93, P1019, DOI 10.1038/sj.bjc.6602796; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Lu ZG, 2009, CANCER RES, V69, P5927, DOI 10.1158/0008-5472.CAN-08-4786; Masferrer JL, 2000, CANCER RES, V60, P1306; Mesquita RFDS, 2014, MOL CELL BIOL, V34, P574, DOI 10.1128/MCB.01098-13; Narayanan BA, 2006, PROSTATE, V66, P257, DOI 10.1002/pros.20331; Narayanan BA, 2007, CLIN CANCER RES, V13, P5965, DOI 10.1158/1078-0432.CCR-07-0744; Nirodi CS, 2004, P NATL ACAD SCI USA, V101, P1840, DOI 10.1073/pnas.0303950101; O'Callaghan G, 2015, BRIT J PHARMACOL, V172, P5239, DOI 10.1111/bph.13331; Ogino S, 2008, CLIN CANCER RES, V14, P8221, DOI 10.1158/1078-0432.CCR-08-1841; Pan Q, 2005, CANCER RES, V65, P8366, DOI 10.1158/0008-5472.CAN-05-0553; Richardsen E, 2010, CANCER EPIDEMIOL, V34, P316, DOI 10.1016/j.canep.2010.03.019; Satoh A, 2004, AM J PHYSIOL-GASTR L, V287, pG582, DOI 10.1152/ajpgi.00087.2004; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Terry MB, 2004, JAMA-J AM MED ASSOC, V291, P2433, DOI 10.1001/jama.291.20.2433; Tougeron D, 2014, CLIN CANCER RES, V20, P1087, DOI 10.1158/1078-0432.CCR-13-2563; Turturro SB, 2016, BREAST CANCER RES TR, V156, P33, DOI 10.1007/s10549-016-3729-8; Veitonmaki T, 2013, EUR J CANCER, V49, P938, DOI 10.1016/j.ejca.2012.09.030; Walter B, 2010, WORLD J UROL, V28, P745, DOI 10.1007/s00345-010-0567-x; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang HB, 2014, J BIOL CHEM, V289, P19823, DOI 10.1074/jbc.M114.548446; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wu DQ, 2002, CANCER RES, V62, P2423; Xuan YT, 2005, CIRCULATION, V112, P1971, DOI 10.1161/CIRCULATIONAHA.105.561522; Yoshimura R, 2000, CANCER-AM CANCER SOC, V89, P589, DOI 10.1002/1097-0142(20000801)89:3<589::AID-CNCR14>3.0.CO;2-C; Zheng X, 2010, CANCER PREV RES, V3, P114, DOI 10.1158/1940-6207.CAPR-09-0059	73	34	36	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 23	2018	37	34					4735	4749		10.1038/s41388-018-0318-9	http://dx.doi.org/10.1038/s41388-018-0318-9			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GR3SE	29765153	Green Accepted			2022-12-17	WOS:000442514400008
J	Rademaker, G; Hennequiere, V; Brohee, L; Nokin, MJ; Lovinfosse, P; Durieux, F; Gofflot, S; Bellier, J; Costanza, B; Herfs, M; Peiffer, R; Bettendorff, L; Deroanne, C; Thiry, M; Delvenne, P; Hustinx, R; Bellahcene, A; Castronovo, V; Peulen, O				Rademaker, Gilles; Hennequiere, Vincent; Brohee, Laura; Nokin, Marie-Julie; Lovinfosse, Pierre; Durieux, Florence; Gofflot, Stephanie; Bellier, Justine; Costanza, Brunella; Herfs, Michael; Peiffer, Raphael; Bettendorff, Lucien; Deroanne, Christophe; Thiry, Marc; Delvenne, Philippe; Hustinx, Roland; Bellahcene, Akeila; Castronovo, Vincent; Peulen, Olivier			Myoferlin controls mitochondrial structure and activity in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness	ONCOGENE			English	Article							CANCER-CELLS; DETERMINES; AUTOPHAGY; SURVIVAL; FUSION; PHOSPHORYLATION; HETEROGENEITY; PROGRESSION; METABOLISM; PLASTICITY	Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related death. Therapeutic options remain very limited and are based on classical chemotherapies. Energy metabolism reprogramming appears as an emerging hallmark of cancer and is considered a therapeutic target with considerable potential. Myoferlin, a ferlin family member protein overexpressed in PDAC, is involved in plasma membrane biology and has a tumor-promoting function. In the continuity of our previous studies, we investigated the role of myoferlin in the context of energy metabolism in PDAC. We used selected PDAC tumor samples and PDAC cell lines together with small interfering RNA technology to study the role of myoferlin in energetic metabolism. In PDAC patients, we showed that myoferlin expression is negatively correlated with overall survival and with glycolytic activity evaluated by F-18-deoxyglucose positron emission tomography. We found out that myoferlin is more abundant in lipogenic pancreatic cancer cell lines and is required to maintain a branched mitochondrial structure and a high oxidative phosphorylation activity. The observed mitochondrial fission induced by myoferlin depletion led to a decrease of cell proliferation, ATP production, and autophagy induction, thus indicating an essential role of myoferlin for PDAC cell fitness. The metabolic phenotype switch generated by myoferlin silencing could open up a new perspective in the development of therapeutic strategies, especially in the context of energy metabolism.	[Rademaker, Gilles; Hennequiere, Vincent; Nokin, Marie-Julie; Durieux, Florence; Bellier, Justine; Costanza, Brunella; Peiffer, Raphael; Bellahcene, Akeila; Castronovo, Vincent; Peulen, Olivier] Univ Liege, Metastasis Res Lab, GIGA Canc, Liege, Belgium; [Brohee, Laura; Deroanne, Christophe] Univ Liege, Lab Connect Tissue Biol, GIGA Canc, Liege, Belgium; [Lovinfosse, Pierre; Hustinx, Roland] Univ Liege, Dept Nucl Med & Oncol Imaging, Univ Hosp Ctr, Liege, Belgium; [Gofflot, Stephanie] Univ Liege, Univ Hosp, Tissue Biobank, Liege, Belgium; [Herfs, Michael; Delvenne, Philippe] Univ Liege, Lab Expt Pathol, GIGA Canc, Liege, Belgium; [Bettendorff, Lucien] Univ Liege, Neurophysiol Lab, GIGA Neurosci, Liege, Belgium; [Thiry, Marc] Univ Liege, Lab Cellular & Tissular Biol, GIGA Neurosci, Liege, Belgium	University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege; University of Liege	Peulen, O (corresponding author), Univ Liege, Metastasis Res Lab, GIGA Canc, Liege, Belgium.	olivier.peulen@uliege.be	Costanza, Brunella/AAB-6354-2022; Rademaker, Gilles/X-1386-2019; Peulen, Olivier/C-1250-2018	Rademaker, Gilles/0000-0003-0170-781X; Peulen, Olivier/0000-0002-6933-0134; Brohee, Laura/0000-0001-8498-1579; Peiffer, Raphael/0000-0001-5839-8849; Costanza, Brunella/0000-0001-8279-805X	FNRS Televie grant	FNRS Televie grant(Fonds de la Recherche Scientifique - FNRS)	We acknowledge Dr Chantal Humblet and Mrs Alice Marquet (GIGA-histology platform, ULg), Dr Sandra Ormenese and Dr Jean-Jacques Goval (GIGA-imaging platform, ULg), Dr Emmanuel Di Valentin (GIGA-viral vector platform, ULg), Mrs Patricia Piscicelli (Laboratory of Cellular and Tissular Biology), Mrs Naima Maloujahmoum, and Selina Nuchtern (Metastasis Research Laboratory) for their respective experimental support. We thank Mrs Caroline Ziane for proofreading and English editing. We are also thankful to the institutional Biobank of the University Hospital Liege for providing patient material. The results shown in this work are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/. Akeila Bellahcene and Lucien Bettendorff are Research Directors (FNRS). Christophe Deroanne is a Research Associate (FNRS). Dr Michael Herfs, Dr Marie-Julie Nokin, Dr Brunella Costanza, Mrs Laura Brohee, Mrs Florence Durieux, and Mrs Justine Bellier are supported by an FNRS Televie grant. M. Raphael Peiffer is student-researcher supported by the ULg Medicine Faculty. The sponsor had no other roles in the study.	Alirol E, 2006, ONCOGENE, V25, P4706, DOI 10.1038/sj.onc.1209600; Baek G, 2014, CELL REP, V9, P2233, DOI 10.1016/j.celrep.2014.11.025; Bernatchez PN, 2009, AM J PHYSIOL-CELL PH, V297, pC484, DOI 10.1152/ajpcell.00498.2008; Blomme A, 2016, ONCOGENE, V4, P1151; Blomme A, 2016, ONCOTARGET, V7, P83669, DOI 10.18632/oncotarget.13276; Boudreau A, 2016, NAT CHEM BIOL, V12, P779, DOI 10.1038/nchembio.2143; Cao YL, 2017, NATURE, V542, P372, DOI 10.1038/nature21077; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen HC, 2005, HUM MOL GENET, V14, pR283, DOI 10.1093/hmg/ddi270; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Daemen A, 2015, P NATL ACAD SCI USA, V112, pE4410, DOI 10.1073/pnas.1501605112; Denise C, 2015, ONCOTARGET, V6, P41706, DOI 10.18632/oncotarget.5991; Doherty KR, 2008, J BIOL CHEM, V283, P20252, DOI 10.1074/jbc.M802306200; Doherty KR, 2005, DEVELOPMENT, V132, P5565, DOI 10.1242/dev.02155; ELSASSER HP, 1992, VIRCHOWS ARCH B, V61, P295, DOI 10.1007/BF02890431; Eng CH, 2016, P NATL ACAD SCI USA, V113, P182, DOI 10.1073/pnas.1515617113; Fahmy K, 2016, INT J CANCER, V138, P652, DOI 10.1002/ijc.29820; Gangolf M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013616; Habrook CJ, 2017, CANCER CELL, V31, P5, DOI 10.1016/j.ccell.2016.12.006; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Higashi T, 1997, J NUCL MED, V38, P1337; Hoppins S, 2007, ANNU REV BIOCHEM, V76, P751, DOI 10.1146/annurev.biochem.76.071905.090048; Hyun SH, 2016, EUR J NUCL MED MOL I, V43, P1461, DOI 10.1007/s00259-016-3316-6; Ippolito L, 2016, ONCOTARGET, V7, P61890, DOI 10.18632/oncotarget.11301; Jahani-Asl A, 2007, EMBO REP, V8, P912, DOI 10.1038/sj.embor.7401077; Jones P, 2017, CLIN CANC RES, V23; Kim SE, 2015, BIOCHEM BIOPH RES CO, V463, P205, DOI 10.1016/j.bbrc.2015.05.022; Kosinski M, 2015, RTCGA CANC GENOME AT; Larson Steven M., 1999, Clin Positron Imaging, V2, P159, DOI 10.1016/S1095-0397(99)00016-3; LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039; Lee JW, 2014, J NUCL MED, V55, P898, DOI 10.2967/jnumed.113.131847; Mao K, 2013, CELL CYCLE, V12, P3131, DOI 10.4161/cc.26352; Mishra P, 2016, J CELL BIOL, V212, P379, DOI 10.1083/jcb.201511036; Neuzillet C, 2017, PHARMACOL THERAPEUT, V174, P145, DOI 10.1016/j.pharmthera.2017.02.028; Peixoto P, 2012, CELL DEATH DIFFER, V19, P1239, DOI 10.1038/cdd.2012.3; Protopopova M, 2016, MOL CANCER RES, V14, DOI 10.1158/1557-3125.METCA15-A65; R Core Team, 2019, R LANG ENV STAT COMP; Rosenfeldt MT, 2013, NATURE, V504, P296, DOI 10.1038/nature12865; Ryan DP, 2014, NEW ENGL J MED, V371, P1039, DOI 10.1056/NEJMra1404198; Sancho P, 2015, CELL METAB, V22, P590, DOI 10.1016/j.cmet.2015.08.015; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Turtoi A, 2013, CANCER RES, V73, P5438, DOI 10.1158/0008-5472.CAN-13-1142; Turtoi A, 2011, J PROTEOME RES, V10, P4302, DOI 10.1021/pr200527z; Vander Heiden MG, 2017, CELL, V168, DOI 10.1016/j.cell.2016.12.039; Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611; von der Malsburg K, 2011, DEV CELL, V21, P694, DOI 10.1016/j.devcel.2011.08.026; Yamano K, 2011, NAT CELL BIOL, V13, P1026, DOI 10.1038/ncb2334; Yang A, 2014, CANCER DISCOV, V4, P905, DOI 10.1158/2159-8290.CD-14-0362	51	34	34	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4398	4412		10.1038/s41388-018-0287-z	http://dx.doi.org/10.1038/s41388-018-0287-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29720728	Green Published, hybrid			2022-12-17	WOS:000441144300005
J	Su, TH; Liao, JB; Dai, ZH; Xu, LX; Chen, SL; Wang, YF; Peng, ZW; Zhang, QY; Peng, S; Kuang, M				Su, Tianhong; Liao, Junbin; Dai, Zihao; Xu, Lixia; Chen, Shuling; Wang, Yifei; Peng, Zhenwei; Zhang, Qiuyang; Peng, Sui; Kuang, Ming			Stress-induced phosphoprotein 1 mediates hepatocellular carcinoma metastasis after insufficient radiofrequency ablation	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; PROTEIN 90 HSP90; HEAT-SHOCK; NUCLEAR TRANSLOCATION; SORAFENIB SUPPRESSES; RISK-FACTORS; RECURRENCE; INHIBITORS; MECHANISM; THERAPY	Recent studies indicated that insufficient radiofrequency ablation (RFA) could endow hepatocellular carcinoma (HCC) with higher aggressive potential. Stress-induced phosphoprotein 1 (STIP1), which was found highly expressed in HCC, is a chaperone molecule mediating cell homeostasis under thermal stress. We aimed to explore the role of STIP1 on the metastasis of residual HCC after RFA. Mice model with orthotopic HCC implants or caudal vein injection were employed to assess potential of lung metastasis and/or intrahepatic metastasis (IHM) of HCC cells. Cell culture model was used to determine cell invasion, mesenchymal marker genes expression, and underlying molecular mechanisms. Clinical specimens were collected to analyze the relationship between STIP1 and clinical outcome. We found that insufficient RFA elicited more IHM of HCCLM3 tumors, which could be reduced by silencing STIP1. Knockdown of STIP1 also significantly decreased lung metastatic potential of HCCLM3 cells. In vitro, HCCLM3 and HepG2 displayed a spindle-shaped morphology with upregulation of STIP1 and mesenchymal markers after sublethal heat exposure. Mechanistically, heat exposure induced the formation of STIP1-heat shock protein 90 (HSP90) complex, which could shuttle epithelial transcription repressor Snail1 into nucleus and regulate mesenchymal gene transcription. Blocking the HSP90-STIP1 complex reduced the invasive potential of HCC cells after heat exposure. Using clinical specimen, we found that STIP1 was expressed significantly higher in metastatic tumor tissues and in sera from metastatic HCC patients (p < 0.05). The high expression of STIP1 was significantly linked to shorter recurrence-free survival (p < 0.05). To sum up, our study found that STIP1 is positively associated with the sublethal heat-induced cancer cell metastasis through mediating the mesenchymal gene transcription. Blocking STIP1 activity may suppress HCC cell metastatic potential after RFA.	[Su, Tianhong; Liao, Junbin; Dai, Zihao; Wang, Yifei; Kuang, Ming] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Liver Surg, Guangzhou, Guangdong, Peoples R China; [Xu, Lixia; Peng, Sui] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou, Guangdong, Peoples R China; [Chen, Shuling; Kuang, Ming] Sun Yat Sen Univ, Affiliated Hosp 1, Div Intervent Ultrasound, Guangzhou, Guangdong, Peoples R China; [Peng, Zhenwei; Peng, Sui] Sun Yat Sen Univ, Affiliated Hosp 1, Clin Trials Unit, Guangzhou, Guangdong, Peoples R China; [Zhang, Qiuyang] Baylor Scott & White Res Inst, Ctr Esophageal Res, Dallas, TX USA	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Baylor Health Care System; Baylor University Medical Center	Kuang, M (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Liver Surg, Guangzhou, Guangdong, Peoples R China.; Peng, S (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou, Guangdong, Peoples R China.; Kuang, M (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Div Intervent Ultrasound, Guangzhou, Guangdong, Peoples R China.; Peng, S (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Clin Trials Unit, Guangzhou, Guangdong, Peoples R China.	pengsui@vip.163.com; kuangminda@hotmail.com			National Natural Science Foundation of China [81470817, 81771958]; Guangdong Science and Technology Plan [2016A020215189, 2014A020212396]; National Natural Science Foundation of Guangdong [2015A030311039]; Guangzhou Science and Technology Plan [201704020099]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Science and Technology Plan; National Natural Science Foundation of Guangdong(National Natural Science Foundation of Guangdong Province); Guangzhou Science and Technology Plan	This work was supported by the National Natural Science Foundation of China (81470817, 81771958), the Guangdong Science and Technology Plan (2016A020215189, 2014A020212396), the National Natural Science Foundation of Guangdong (2015A030311039) and the Guangzhou Science and Technology Plan (201704020099).	Chang CH, 2014, MOL PHARMACOL, V85, P849, DOI 10.1124/mol.113.090654; Chen ZB, 2017, BIOCHEM BIOPH RES CO, V493, P365, DOI 10.1016/j.bbrc.2017.09.016; Cikos S, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-113; Daniel S, 2008, BBA-MOL CELL RES, V1783, P1003, DOI 10.1016/j.bbamcr.2008.01.014; Dong SY, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1949-7; Dong SY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-273; Ernst A, 2015, CANCER LETT, V365, P211, DOI 10.1016/j.canlet.2015.05.024; Home T, 2015, CANCER RES, V75, P907, DOI 10.1158/0008-5472.CAN-14-2905; Kang TW, 2017, CLIN MOL HEPATOL, V23, P95, DOI 10.3350/cmh.2017.0006; Kasugai H, 2007, ONCOLOGY-BASEL, V72, P72, DOI 10.1159/000111710; Kim KW, 2011, AM J ROENTGENOL, V196, pW565, DOI 10.2214/AJR.10.5122; Kumalo HM, 2015, CHEM BIOL DRUG DES, V86, P1131, DOI 10.1111/cbdd.12582; Lam VWT, 2008, J AM COLL SURGEONS, V207, P20, DOI 10.1016/j.jamcollsurg.2008.01.020; Lau WY, 2009, ANN SURG, V249, P20, DOI 10.1097/SLA.0b013e31818eec29; Lee HY, 2013, EUR RADIOL, V23, P190, DOI 10.1007/s00330-012-2561-8; Lei W, 2017, J BIOL CHEM, V292, P10414, DOI 10.1074/jbc.M116.769489; Li YY, 2016, METHODS MOL BIOL, V1406, P73, DOI 10.1007/978-1-4939-3444-7_6; Longshaw VM, 2004, J CELL SCI, V117, P701, DOI 10.1242/jcs.00905; Pimienta G, 2011, MOL PHARMACEUT, V8, P2252, DOI 10.1021/mp200346y; Ruzzenente A, 2004, WORLD J GASTROENTERO, V10, P1137; Sadikot T, 2013, ASSAY DRUG DEV TECHN, V11, P478, DOI 10.1089/adt.2012.498; Sala M, 2004, HEPATOLOGY, V40, P1352, DOI 10.1002/hep.20465; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Schulz R, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.508; Smyth T, 2014, MOL CANCER THER, V13, P2793, DOI 10.1158/1535-7163.MCT-14-0452; Takada Yasutsugu, 2003, Int J Clin Oncol, V8, P332, DOI 10.1007/s10147-003-0328-6; Thompson SM, 2016, PLOS ONE, V11; Walsh N, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-140; Wang C, 2016, INT J CANCER, V138, P1824, DOI 10.1002/ijc.29723; Wang TH, 2010, MOL CELL PROTEOMICS, V9, P1873, DOI 10.1074/mcp.M110.000802; Xu M, 2013, ACTA RADIOL, V54, P199, DOI 10.1258/ar.2012.120249; Yoshida S, 2013, HEPATOLOGY, V58, P1667, DOI 10.1002/hep.26526; Zavaglia C, 2008, EUR J GASTROEN HEPAT, V20, P196, DOI 10.1097/MEG.0b013e3282f1cc4a; Zhang WM, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-017-1189-1	34	34	35	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3514	3527		10.1038/s41388-018-0169-4	http://dx.doi.org/10.1038/s41388-018-0169-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29559743				2022-12-17	WOS:000436412500004
J	Wen, JF; Wang, Y; Gao, C; Zhang, GX; You, Q; Zhang, WM; Zhang, ZH; Wang, SL; Peng, GY; Shen, LZ				Wen, Jianfei; Wang, Yao; Gao, Cheng; Zhang, Guoxin; You, Qiang; Zhang, Weiming; Zhang, Zhihong; Wang, Shoulin; Peng, Guangyong; Shen, Lizong			Helicobacter pylori infection promotes Aquaporin 3 expression via the ROS-HIF-1 alpha-AQP3-ROS loop in stomach mucosa: a potential novel mechanism for cancer pathogenesis	ONCOGENE			English	Article							GASTRIC-CANCER; CELLS; INFLAMMATION; HIF-1-ALPHA; MIGRATION; STRESS; ROS	Helicobacter pylori (H. pylori) is the major stomach carcinogen, but the molecular mechanism responsible for the pathogenesis of cancer development mediated by H. pylori infection is still unclear. Aquaporin 3 (AQP3), overexpressed in gastric carcinoma, has a crucial role in gastric carcinogenesis and progression. However, the triggers and precise regulations for AQP3 upregulation during gastric carcinogens also remain unknown. Here we report that H. pylori infection-mediated carcinogenesis may be mechanistically depended on the upregulation of AQP3 expression via reactive oxygen species (ROS) pathway activation in the stomach. The retrospective analyses of clinical samples from patients with gastric carcinoma and other different stages of gastric diseases indicated that AQP3 expression was positively associated with gastric mucosal disease progression and H. pylori infection status as well. Furthermore, H. pylori infection significantly upregulated AQP3 and HIF-1 alpha expression and increased ROS amount in human gastric epithelial AGS and GES-1 cells. Blockage of ROS with inhibitors, NAC and DPI, markedly decreased the expression of AQP3 and HIF-1 alpha in both AGS and GES-1 cells simultaneously. Furthermore, the increased AQP3 in cells was mechanistically due to the transcriptional regulation by HIF-1 alpha. In addition, H. pylori infection exerted production of proinflammatory cytokines IL-6, IL-8, and TNF depending on AQP3 level. Importantly, these in vitro novel findings were further investigated in vivo in a mouse H. pylori infectious model. Our current studies identify the mechanistic link between H. pylori infection and AQP3 upregulation in the pathogenesis of gastric carcinoma, which involves the activation of the ROS-HIF-1 alpha axis and the exacerbated ROS-HIF1 alpha-AQP3-ROS loop.	[Wen, Jianfei; Wang, Yao; Gao, Cheng; Shen, Lizong] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Div Gastrointestinal Surg, Nanjing 210029, Jiangsu, Peoples R China; [Zhang, Guoxin] Nanjing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Nanjing 210029, Jiangsu, Peoples R China; [You, Qiang] Nanjing Med Univ, Affiliated Hosp 2, Dept Geriatr, Nanjing 210003, Jiangsu, Peoples R China; [Zhang, Weiming; Zhang, Zhihong] Nanjing Med Univ, Affiliated Hosp 1, Dept Pathol, Nanjing 210029, Jiangsu, Peoples R China; [Wang, Shoulin] Nanjing Med Univ, Sch Publ Hlth, Nanjing 211166, Jiangsu, Peoples R China; [Peng, Guangyong] St Louis Univ, Sch Med, Dept Internal Med, St Louis, MO 63104 USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Saint Louis University	Shen, LZ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Div Gastrointestinal Surg, Nanjing 210029, Jiangsu, Peoples R China.	shenlz@njmu.edu.cn	CHENG, GAO/AAH-4004-2021	CHENG, GAO/0000-0001-5549-1327	National Natural Science Foundation of China [81272711]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) [JX10231801]; Key Medical Talents Program of Jiangsu Province [ZDRCA2016014]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Key Medical Talents Program of Jiangsu Province	This project was partially supported by the National Natural Science Foundation of China (Grant No. 81272711 to LS, the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD, JX10231801 to LS), and the Key Medical Talents Program of Jiangsu Province (ZDRCA2016014 to LS).	Alzahrani S, 2014, WORLD J GASTROENTERO, V20, P12767, DOI 10.3748/wjg.v20.i36.12767; [Anonymous], 1994, IARC Monogr Eval Carcinog Risks Hum, V61, P1; Backert S, 2016, HELICOBACTER, V21, P19, DOI 10.1111/hel.12335; Bhattacharyya A, 2014, PHYSIOL REV, V94, P329, DOI 10.1152/physrev.00040.2012; Bhattacharyya A, 2010, AM J PHYSIOL-GASTR L, V299, pG1177, DOI 10.1152/ajpgi.00372.2010; Bienert GP, 2014, BBA-GEN SUBJECTS, V1840, P1596, DOI 10.1016/j.bbagen.2013.09.017; Chen J, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-38; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7; Dong Xinhong, 2016, Zhonghua Yi Xue Za Zhi, V96, P265, DOI 10.3760/cma.j.issn.0376-2491.2016.04.007; Dong XQ, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.87; Fichtner-Feigl S, 2015, TRENDS IMMUNOL, V36, P451, DOI 10.1016/j.it.2015.06.007; Gajewski A, 2016, ACTA BIOCHIM POL, V63, P145, DOI 10.18388/abp.2015_1122; Gobert AP, 2017, FREE RADICAL BIO MED, V105, P16, DOI 10.1016/j.freeradbiomed.2016.09.024; Gobert AP, 2017, CURR TOP MICROBIOL, V400, P27, DOI 10.1007/978-3-319-50520-6_2; Grandjean G, 2016, CANCER RES, V76, P4259, DOI 10.1158/0008-5472.CAN-16-0401; Handa O, 2010, INFLAMM RES, V59, P997, DOI 10.1007/s00011-010-0245-x; Hartung ML, 2015, CELL REP, V13, P70, DOI 10.1016/j.celrep.2015.08.074; Huang YM, 2010, CANCER BIOL THER, V9, P1000, DOI 10.4161/cbt.9.12.11705; Kang MJ, 2014, HELICOBACTER, V19, P476, DOI 10.1111/hel.12169; Koeppel M, 2015, CELL REP, V11, P1703, DOI 10.1016/j.celrep.2015.05.030; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Li X, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftu024; Li YN, 2014, TOXICOL LETT, V224, P165, DOI 10.1016/j.toxlet.2013.10.029; Miller EW, 2010, P NATL ACAD SCI USA, V107, P15681, DOI 10.1073/pnas.1005776107; Nakamura J, 2010, INT J CANCER, V127, P1158, DOI 10.1002/ijc.25129; Nam SY, 2011, BRIT J CANCER, V104, P166, DOI 10.1038/sj.bjc.6606020; Nizet V, 2009, NAT REV IMMUNOL, V9, P609, DOI 10.1038/nri2607; Nookaew I, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-41; Park JH, 2003, CLIN CANCER RES, V9, P433; Plummer M, 2015, INT J CANCER, V136, P487, DOI 10.1002/ijc.28999; Satooka H, 2016, MOL CELL BIOL, V36, P1206, DOI 10.1128/MCB.00971-15; Shen LZ, 2010, BIOMED PHARMACOTHER, V64, P313, DOI 10.1016/j.biopha.2009.12.003; Shida M, 2016, INT J ONCOL, V48, P1379, DOI 10.3892/ijo.2016.3359; Shimizu T, 2017, CURR TOP MICROBIOL, V400, P305, DOI 10.1007/978-3-319-50520-6_13; Suarez G, 2015, CANCER RES, V75, P1749, DOI 10.1158/0008-5472.CAN-14-2291; Thiagarajah JR, 2017, P NATL ACAD SCI USA, V114, P568, DOI 10.1073/pnas.1612921114; Thompson PA, 2015, CARCINOGENESIS, V36, pS232, DOI 10.1093/carcin/bgv038; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Verkman AS, 2014, NAT REV DRUG DISCOV, V13, P259, DOI 10.1038/nrd4226; Wan XK, 2016, HELICOBACTER, V21, P554, DOI 10.1111/hel.12311; Wang G, 2012, PLOS ONE, V7; Wang JP, 2012, CANCER LETT, V319, P109, DOI 10.1016/j.canlet.2011.12.040; Yamaguchi N, 2001, LANCET ONCOL, V2, P88, DOI 10.1016/S1470-2045(00)00225-4; Yuan LW, 2016, WORLD J GASTROENTERO, V22, P2046, DOI 10.3748/wjg.v22.i6.2046; Zhao HJ, 2015, ONCOTARGET, V6, P38926, DOI 10.18632/oncotarget.5370; Zhou YC, 2016, ONCOTARGET, V7, P16529, DOI 10.18632/oncotarget.7664	47	34	35	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3549	3561		10.1038/s41388-018-0208-1	http://dx.doi.org/10.1038/s41388-018-0208-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563612				2022-12-17	WOS:000436412500006
J	Peta, E; Sinigaglia, A; Masi, G; Di Camillo, B; Grassi, A; Trevisan, M; Messa, L; Loregian, A; Manfrin, E; Brunelli, M; Martignoni, G; Palu, G; Barzon, L				Peta, Elektra; Sinigaglia, Alessandro; Masi, Giulia; Di Camillo, Barbara; Grassi, Angela; Trevisan, Marta; Messa, Lorenzo; Loregian, Arianna; Manfrin, Erminia; Brunelli, Matteo; Martignoni, Guido; Palu, Giorgio; Barzon, Luisa			HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys	ONCOGENE			English	Article							HUMAN-PAPILLOMAVIRUS; CERVICAL-CANCER; EXPRESSION; MIR-146A; CELLS; CONTRIBUTES; APOPTOSIS; MIR-34A; MICE; DYSREGULATION	Persistent infection by high-risk human papillomaviruses (HPVs) is associated with the development of cervical cancer and a subset of anogenital and head and neck squamous cell carcinomas. Abnormal expression of cellular microRNAs (miRNAs) plays an important role in the development of cancer, including HPV-related tumors. In this study, we demonstrated that miR-146a-5p was down-regulated by E6 and, less efficiently, by E7 of high-risk HPV16 in keratinocytes and the presence of low levels of this miRNA in cervical carcinoma cell lines and in high-risk HPV-positive cervical specimens. Downregulation of miR-146a-5p was mediated at least in part by the transcription repressor c-MYC, through binding sites in the miR-146a promoter. Overexpression of miR-146a-5p significantly inhibited proliferation and migration of keratinocytes and cervical cancer cells. The histone demethylase KDM2B was validated as a new direct target of miR-146a-5p and two putative binding sites for miR-146a-5p were identified in its 3'UTR sequence. Western blot analysis and immunohistochemistry showed that KDM2B was overexpressed in HPV16 E6/E7-positive keratinocytes, in cervical cancer cell lines, and in a subset of invasive cervical carcinomas and HPV-positive laryngeal squamous cell carcinomas. In these tumors, KDM2B overexpression was associated with c-MYC copy number gain. In vitro, silencing of KDM2B inhibited proliferation of cervical cancer cells. In conclusion, this study identified a novel player, the hystone demethylase KDM2B, in HPV-mediated tumorigenesis. E6 and, less efficiently, E7 of high-risk HPV16 up-regulated KDM2B expression in human keratinocytes through a pathway involving overexpression of c-MYC, which in turn downregulated miR-146a-5p.	[Peta, Elektra; Sinigaglia, Alessandro; Masi, Giulia; Trevisan, Marta; Messa, Lorenzo; Loregian, Arianna; Palu, Giorgio; Barzon, Luisa] Univ Padua, Dept Mol Med, Padua, Italy; [Di Camillo, Barbara] Univ Padua, Dept Informat Engn, Padua, Italy; [Grassi, Angela] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy; [Manfrin, Erminia; Brunelli, Matteo; Martignoni, Guido] AOUI Hosp Trust Verona, Dept Diagnost & Publ Hlth, Anat Pathol, Verona, Italy	University of Padua; University of Padua; University of Padua; University of Verona; Azienda Ospedaliera Universitaria Integrata Verona	Barzon, L (corresponding author), Univ Padua, Dept Mol Med, Padua, Italy.	luisa.barzon@unipd.it	Masi, Giulia/K-1577-2016; Grassi, Angela/N-3085-2013; Barzon, Luisa/K-7961-2016; Brunelli, Matteo/AAA-7679-2019; TREVISAN, MARTA/K-6591-2016	Masi, Giulia/0000-0001-9138-9186; Grassi, Angela/0000-0002-8313-8384; Barzon, Luisa/0000-0003-0720-8456; Messa, Lorenzo/0000-0001-6850-0034; TREVISAN, MARTA/0000-0002-3148-7240; sinigaglia, alessandro/0000-0002-2386-1757; BRUNELLI, Matteo/0000-0002-3832-2676; LOREGIAN, ARIANNA/0000-0002-8900-861X	Italian Ministry for Education, University, and Research [2010Z9FLM8]; University of Padova [60A07-3380/10, 60A07-1431/11, 60A07-0183/12, CPDA101217]	Italian Ministry for Education, University, and Research(Ministry of Education, Universities and Research (MIUR)); University of Padova	The authors thank Dr. A Remo (Pathology Unit, Hospital "Mater Salutis" Legnago, Verona, Italy) for providing histological tissue samples. This work was supported by the Italian Ministry for Education, University, and Research (grant 2010Z9FLM8 to G Martignoni and GP); the University of Padova (grants 60A07-3380/10, 1431/11, and 0183/12 to LB; grant CPDA101217 to BD and LB).	Barzon L, 2014, AM J PATHOL, V184, P3376, DOI 10.1016/j.ajpath.2014.08.004; Benetatos L, 2013, CELL MOL LIFE SCI, V70, P795, DOI 10.1007/s00018-012-1080-8; Boldin MP, 2011, J EXP MED, V208, P1189, DOI 10.1084/jem.20101823; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Cameron JE, 2008, J VIROL, V82, P1946, DOI 10.1128/JVI.02136-07; Chang TC, 2008, NAT GENET, V40, P43, DOI 10.1038/ng.2007.30; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016/S1470-2045(10)70230-8; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; Forman D, 2012, VACCINE, V30, pF12, DOI 10.1016/j.vaccine.2012.07.055; Gunasekharan V, 2013, J VIROL, V87, P6037, DOI 10.1128/JVI.00153-13; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; He J, 2011, BLOOD, V117, P3869, DOI 10.1182/blood-2010-10-312736; Honegger A, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004712; Hong XH, 2016, ONCOTARGET, V7, P22092, DOI 10.18632/oncotarget.8020; Hu XX, 2010, CANCER RES, V70, P1441, DOI 10.1158/0008-5472.CAN-09-3289; Kottakis F, 2014, CANCER RES, V74, P3935, DOI 10.1158/0008-5472.CAN-13-2733; Labbaye C, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-13; Lajer CB, 2012, BRIT J CANCER, V106, P1526, DOI 10.1038/bjc.2012.109; Li SH, 2017, NEUROCHEM INT, V107, P156, DOI 10.1016/j.neuint.2017.01.011; Liang GY, 2012, NAT CELL BIOL, V14, P457, DOI 10.1038/ncb2483; Lu LF, 2010, CELL, V142, P914, DOI 10.1016/j.cell.2010.08.012; Lui WO, 2007, CANCER RES, V67, P6031, DOI 10.1158/0008-5472.CAN-06-0561; Martinez I, 2008, ONCOGENE, V27, P2575, DOI 10.1038/sj.onc.1210919; Melar-New M, 2010, J VIROL, V84, P5212, DOI 10.1128/JVI.00078-10; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Peta E, 2017, HUM PATHOL, V61, P33, DOI 10.1016/j.humpath.2016.10.019; Pichler K, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-100; Punj V, 2010, ONCOGENE, V29, P1835, DOI 10.1038/onc.2009.460; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Seitz H, 2004, GENOME RES, V14, P1741, DOI 10.1101/gr.2743304; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tzatsos A, 2013, J CLIN INVEST, V123, P727, DOI 10.1172/JCI64535; Tzatsos A, 2011, J BIOL CHEM, V286, P33061, DOI 10.1074/jbc.M111.257667; Tzatsos A, 2009, P NATL ACAD SCI USA, V106, P2641, DOI 10.1073/pnas.0813139106; VONKNEBEL M, 1992, INT J CANCER, V51, P831, DOI 10.1002/ijc.2910510527; Wang T, 2011, CELL STEM CELL, V9, P575, DOI 10.1016/j.stem.2011.10.005; WANG XH, 2008, PLOS ONE, V3, DOI DOI 10.1371/JOURNAL.PONE.0002557; Wang XH, 2011, INT J CANCER, V129, P1362, DOI 10.1002/ijc.25800; Wang X, 2009, RNA, V15, P637, DOI 10.1261/rna.1442309; Zandberg DP, 2013, CA-CANCER J CLIN, V63, P57, DOI 10.3322/caac.21167; Zhang RY, 2016, INT J CANCER, V138, P1163, DOI 10.1002/ijc.29872; Zhao JL, 2013, ELIFE, V2, DOI 10.7554/eLife.00537; Zhao JL, 2011, P NATL ACAD SCI USA, V108, P9184, DOI 10.1073/pnas.1105398108	50	34	39	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	12					1654	1668		10.1038/s41388-017-0083-1	http://dx.doi.org/10.1038/s41388-017-0083-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GA8YC	29335520				2022-12-17	WOS:000428626700008
J	Tanaka, N; Zhao, M; Tang, L; Patel, AA; Xi, Q; Van, HT; Takahashi, H; Osman, AA; Zhang, JX; Wang, J; Myers, JN; Zhou, G				Tanaka, Noriaki; Zhao, Mei; Tang, Lin; Patel, Ameeta A.; Xi, Qing; Van, Hieu T.; Takahashi, Hideaki; Osman, Abdullah A.; Zhang, Jiexin; Wang, Jing; Myers, Jeffrey N.; Zhou, Ge			Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1	ONCOGENE			English	Article							EVOLUTIONARY ACTION SCORE; BREAST-CANCER; TUMOR-SUPPRESSOR; TP53 MUTATIONS; EXPRESSION; PATHWAY; PROTEINS; SURVIVAL; TUMORIGENESIS; PROGRESSION	Many mutant p53 proteins exert oncogenic gain-of-function (GOF) properties that promote cancer cell invasive growth and metastasis, yet the mechanisms mediating these functions still largely remain elusive. We show here that overexpression of the GOF mutant p53 G245D and other GOF p53 mutants enhances the invasive cell growth of p53-deficient head and neck squamous cell carcinoma (HNSCC) UM-SCC-1 cells both in in vitro three-dimensional culture and in an in vivo orthotopic nude mouse model of HNSCC through a novel transcription-independent mechanism. We demonstrate that the expression of the oncogenic forkhead transcription factor FOXM1 is upregulated by GOF mutant p53s. Moreover, we show that overexpression of GOF mutant p53 G245D decreases the AMP-activated protein kinase (AMPK)-mediated phosphorylation of FOXO3a, a tumor suppressive forkhead transcription factor, leading to its cytoplasmic accumulation. This downregulation of FOXO3a's activity, in turn, leads to de-repression of FOXM1 expression. Importantly, we show that either overexpression of FOXO3a or downregulation of FOXM1 impairs both GOF mutant p53-mediated cell invasion in vitro and pulmonary metastases of UM-SCC-1 cells in vivo. Finally, not only do oral cancer patients with p53 mutations exhibit higher levels of FOXM1 expression than patients with wild-type p53, but also HNSCC patients with TP53 mutations and high levels of FOXM1 expression have the poorest survival outcomes. Given our prior demonstration that GOF mutant p53s inhibit AMPK, our current study, establishes and demonstrates a novel transcription-independent GOF mutant p53-AMPK-FOXO3a-FOXM1 signaling cascade that plays an important role in mediating mutant p53s' gain-of-function activities in HNSCCs.	[Tanaka, Noriaki; Zhao, Mei; Tang, Lin; Patel, Ameeta A.; Xi, Qing; Van, Hieu T.; Takahashi, Hideaki; Osman, Abdullah A.; Myers, Jeffrey N.; Zhou, Ge] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [Zhang, Jiexin; Wang, Jing] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Myers, JN; Zhou, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA.	jmyers@mdanderson.org; gzhou@mdanderson.org	Van, Hieu Thuan/GMX-1075-2022	Takahashi, Hideaki/0000-0003-3783-9961; Van, Hieu Thuan/0000-0002-3328-915X	National Institute of Health [5R01DE014613-13]; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014613] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This study was supported by the National Institute of Health Grant No. 5R01DE014613-13 (J.N.M.).	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Barsotti AM, 2009, ONCOGENE, V28, P4295, DOI 10.1038/onc.2009.282; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Di Agostino S, 2016, EMBO REP, V17, P188, DOI 10.15252/embr.201540488; Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013; Eijkelenboom A, 2013, NAT REV MOL CELL BIO, V14, P83, DOI 10.1038/nrm3507; Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freed-Pastor WA, 2012, CELL, V148, P244, DOI 10.1016/j.cell.2011.12.017; Gemenetzidis E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004849; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Halasi M, 2013, BIOCHEM PHARMACOL, V85, P644, DOI 10.1016/j.bcp.2012.10.013; Ho KK, 2012, J BIOL CHEM, V287, P1545, DOI 10.1074/jbc.M111.284224; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Lam EWF, 2013, NAT REV CANCER, V13, P482, DOI 10.1038/nrc3539; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Mizuno T, 2012, ONCOGENE, V31, P5117, DOI 10.1038/onc.2012.5; Morris BJ, 2015, GERONTOLOGY, V61, P515, DOI 10.1159/000375235; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Myers JN, 2002, CLIN CANCER RES, V8, P293; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Neskey DM, 2015, CANCER RES, V75, P1527, DOI 10.1158/0008-5472.CAN-14-2735; Nho RS, 2014, AM J PHYSIOL-LUNG C, V307, pL632, DOI 10.1152/ajplung.00127.2014; Osman AA, 2015, CANCER RES, V75, P1205, DOI 10.1158/0008-5472.CAN-14-2729; Pandit B, 2009, CELL CYCLE, V8, P3425, DOI 10.4161/cc.8.20.9628; Pfister NT, 2015, GENE DEV, V29, P1298, DOI 10.1101/gad.263202.115; Poeta ML, 2007, NEW ENGL J MED, V357, P2552, DOI 10.1056/NEJMoa073770; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Renault VM, 2011, ONCOGENE, V30, P3207, DOI 10.1038/onc.2011.35; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Senturk S, 2014, P NATL ACAD SCI USA, V111, pE3287, DOI 10.1073/pnas.1321640111; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Walerych D, 2016, NAT CELL BIOL, V18, P897, DOI 10.1038/ncb3380; Wang F, 2008, J MOL BIOL, V384, P590, DOI 10.1016/j.jmb.2008.09.025; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; You H, 2006, P NATL ACAD SCI USA, V103, P9051, DOI 10.1073/pnas.0600889103; Zhao M, 2011, CLIN CANCER RES, V17, P7248, DOI 10.1158/1078-0432.CCR-11-0690; Zhou G, 2016, J CELL BIOCHEM, V117, P2682, DOI 10.1002/jcb.25592; Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	47	34	34	3	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1279	1292		10.1038/s41388-017-0032-z	http://dx.doi.org/10.1038/s41388-017-0032-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29269868	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000427279300002
J	Langer, EM; Kendsersky, ND; Daniel, CJ; Kuziel, GM; Pelz, C; Murphy, KM; Capecchi, MR; Sears, RC				Langer, E. M.; Kendsersky, N. D.; Daniel, C. J.; Kuziel, G. M.; Pelz, C.; Murphy, K. M.; Capecchi, M. R.; Sears, R. C.			ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; MIR-200 FAMILY; ENDOTHELIAL DIFFERENTIATION; PROTEASE NEXIN-1; STEM-CELLS; PDGFR-BETA; EXPRESSION; SERPINE2; ZEB1; ANGIOGENESIS	During normal tumor growth and in response to some therapies, tumor cells experience acute or chronic deprivation of nutrients and oxygen and induce tumor vascularization. While this occurs predominately through sprouting angiogenesis, tumor cells have also been shown to directly contribute to vessel formation through vascular mimicry (VM) and/or endothelial transdifferentiation. The extrinsic and intrinsic mechanisms underlying tumor cell adoption of endothelial phenotypes, however, are not well understood. Here we show that serum withdrawal induces mesenchymal breast cancer cells to undergo VM and that knockdown of the epithelial-to-mesenchymal transition (EMT) regulator, Zinc finger E-box binding homeobox 1 (ZEB1), or overexpression of the ZEB1-repressed microRNAs (miRNAs), miR-200c, miR-183, miR-96 and miR-182 inhibits this process. We find that secreted proteins Fibronectin 1 (FN1) and serine protease inhibitor (serpin) family E member 2 (SERPINE2) are essential for VM in this system. These secreted factors are upregulated in mesenchymal cells in response to serum withdrawal, and overexpression of VM-inhibiting miRNAs abrogates this upregulation. Intriguingly, the receptors for these secreted proteins, low-density lipoprotein receptor-related protein 1 (LRP1) and Integrin beta 1 (ITGB1), are also targets of the VM-inhibiting miRNAs, suggesting that autocrine signaling stimulating VM is regulated by ZEB1-repressed miRNA clusters. Together, these data provide mechanistic insight into the regulation of VM and suggest that miRNAs repressed during EMT, in addition to suppressing migratory and stem-like properties of tumor cells, also inhibit endothelial phenotypes of breast cancer cells adopted in response to a nutrient-deficient microenvironment.	[Langer, E. M.; Kendsersky, N. D.; Daniel, C. J.; Kuziel, G. M.; Sears, R. C.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, 2730 SW Moody Ave, Portland, OR 97201 USA; [Pelz, C.] Oregon Hlth & Sci Univ, Div Bioinformat & Computat Biol, Portland, OR 97201 USA; [Murphy, K. M.; Capecchi, M. R.] Howard Hughes Med Inst, Chevy Chase, MD USA; [Murphy, K. M.] Washington Univ, Dept Pathol & Immunol, St Louis, MO USA; [Capecchi, M. R.] Univ Utah, Dept Human Genet, Salt Lake City, UT USA; [Sears, R. C.] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Howard Hughes Medical Institute; Washington University (WUSTL); Utah System of Higher Education; University of Utah; Oregon Health & Science University	Langer, EM; Sears, RC (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, 2730 SW Moody Ave, Portland, OR 97201 USA.	langere@ohsu.edu; searsr@ohsu.edu			American Cancer Society [118795-PF-10-022-01-CSM]; NCI [CA100855, CA196228]; Knight NCI Cancer Center Support Grant [5P30CA069533]; National Institutes of Health [U54 HG008100]; National Cancer Institute [5P30CA069533]; Susan G Komen Foundation [SAC110]; NATIONAL CANCER INSTITUTE [R01CA100855, R01CA196228, P30CA069533] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [U54HG008100] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Knight NCI Cancer Center Support Grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen Foundation(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This study was supported by a postdoctoral fellowship from the American Cancer Society 118795-PF-10-022-01-CSM (EML), as well as philanthropic gifts from the Colson Family Foundation and the Prospect Creek Foundation, and R01s from the NCI CA100855 and CA196228 (RCS). Flow Cytometry was performed in the Oregon Health & Science University (OHSU) Flow Cytometry Shared Resource, hematoxylin and eosin and PAS staining as well as CD31 IHC was performed by the OHSU Histopathology Shared Resource, and short read sequencing assays (RNA-seq) were performed by the OHSU Massively Parallel Sequencing Shared Resource. These OHSU Shared Resources are supported by the Knight NCI Cancer Center Support Grant 5P30CA069533. We thank Dr Sen Wu for providing the PB-CAG-GFP-iNeo plasmid. We thank Dr Joe Gray for providing cell lines supported by the National Institutes of Health grant U54 HG008100, National Cancer Institute grant 5P30CA069533 and by the Susan G Komen Foundation SAC110. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health nor does it reflect the position or the policy of the Government, and no official endorsement should be inferred.	Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Buchholz M, 2003, CANCER RES, V63, P4945; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Candia BJ, 2006, CANCER CELL INT, V6, DOI 10.1186/1475-2867-6-16; Candiano G, 2004, ELECTROPHORESIS, V25, P1327, DOI 10.1002/elps.200305844; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Chang YS, 2000, P NATL ACAD SCI USA, V97, P14608, DOI 10.1073/pnas.97.26.14608; Choi YC, 2011, MOL CELLS, V32, P77, DOI 10.1007/s10059-011-1042-2; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Cseh B, 2010, J CELL SCI, V123, P3989, DOI 10.1242/jcs.073346; D'Ippolito E, 2016, CANCER RES, V76, P5562, DOI 10.1158/0008-5472.CAN-16-0140; Dyballa Nadine, 2012, Methods Mol Biol, V893, P47, DOI 10.1007/978-1-61779-885-6_4; Fanti Z, 2011, DEV NEUROBIOL, V71, P870, DOI 10.1002/dneu.20866; Fardin P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-185; Farrell AS, 2013, MOL CELL BIOL, V33, P2930, DOI 10.1128/MCB.01455-12; Fayard B, 2009, CANCER RES, V69, P5690, DOI 10.1158/0008-5472.CAN-08-4573; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Francescone RA, 2011, JOVE-J VIS EXP, DOI 10.3791/3040; Francois D, 2014, LAB INVEST, V94, P1237, DOI 10.1038/labinvest.2014.111; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gill JG, 2012, STEM CELLS DEV, V21, P167, DOI 10.1089/scd.2011.0194; Gill JG, 2011, STEM CELLS, V29, P764, DOI 10.1002/stem.628; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Harrell JC, 2014, CLIN EXP METASTAS, V31, P33, DOI 10.1007/s10585-013-9607-4; Heiser LM, 2012, P NATL ACAD SCI USA, V109, P2724, DOI 10.1073/pnas.1018854108; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Jalvy-Delvaille S, 2012, NUCLEIC ACIDS RES, V40, P1356, DOI 10.1093/nar/gkr843; Karroum A, 2012, EUR J PHARMACOL, V685, P1, DOI 10.1016/j.ejphar.2012.04.004; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li GR, 2010, J BIOL CHEM, V285, P5461, DOI 10.1074/jbc.M109.037127; Li XL, 2014, MOL CELL BIOL, V34, P533, DOI 10.1128/MCB.01043-13; Liu TJ, 2013, ONCOGENE, V32, P544, DOI 10.1038/onc.2012.85; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Mense SM, 2006, PHYSIOL GENOMICS, V25, P435, DOI 10.1152/physiolgenomics.00315.2005; Nagahara A, 2010, BIOCHEM BIOPH RES CO, V391, P1641, DOI 10.1016/j.bbrc.2009.12.105; Ong YS, 2010, J CELL BIOL, V190, P331, DOI 10.1083/jcb.201003005; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pecot CV, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3427; Plantamura I, 2014, MOL ONCOL, V8, P968, DOI 10.1016/j.molonc.2014.03.015; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Quesada AR, 2010, CURR PHARM DESIGN, V16, P3932; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Schliekelman MJ, 2011, CANCER RES, V71, P7670, DOI 10.1158/0008-5472.CAN-11-0964; Schoenfeld Jonathan, 2004, Angiogenesis, V7, P143, DOI 10.1007/s10456-004-1677-0; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Soda Y, 2011, P NATL ACAD SCI USA, V108, P4274, DOI 10.1073/pnas.1016030108; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Wagenblast E, 2015, NATURE, V520, P358, DOI 10.1038/nature14403; Wang K, 2015, J CANCER RES CLIN, V141, P805, DOI 10.1007/s00432-014-1858-1; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Wong CM, 2015, ONCOTARGET, V6, P13658, DOI 10.18632/oncotarget.3700; Xu CL, 2017, P NATL ACAD SCI USA, V114, P722, DOI 10.1073/pnas.1615735114; Xu Y, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-16; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Zhang L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-108; Zhou XM, 2008, GENE DEV, V22, P1231, DOI 10.1101/gad.1643308; Zhu M, 2015, SCI REP-UK, V5, DOI 10.1038/srep15471	63	34	35	0	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 22	2018	37	8					1005	1019		10.1038/onc.2017.356	http://dx.doi.org/10.1038/onc.2017.356			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FX2QD	29084210	Green Accepted, Green Published, hybrid			2022-12-17	WOS:000425905700004
